{"doc_key": "354896", "sentences": [["Lidocaine", "-", "induced", "cardiac", "asystole", ".", "Intravenous", "administration", "of", "a", "single", "50", "-", "mg", "bolus", "of", "lidocaine", "in", "a", "67", "-", "year", "-", "old", "man", "resulted", "in", "profound", "depression", "of", "the", "activity", "of", "the", "sinoatrial", "and", "atrioventricular", "nodal", "pacemakers", ".", "The", "patient", "had", "no", "apparent", "associated", "conditions", "which", "might", "have", "predisposed", "him", "to", "the", "development", "of", "bradyarrhythmias", ";", "and", ",", "thus", ",", "this", "probably", "represented", "a", "true", "idiosyncrasy", "to", "lidocaine", "."]], "ner": [[[0, 0, "Chemical"], [16, 16, "Chemical"], [69, 69, "Chemical"], [3, 4, "Disease"], [28, 28, "Disease"], [56, 56, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [16, 16, 3, 4, "CID"], [69, 69, 3, 4, "CID"]]], "clusters": [], "translated": " <0>利多卡因</0> - 诱发<3>心搏停止</3>。一名 67 岁的男性静脉注射单次 50 毫克<1>利多卡因</1>，导致窦房结和房室结起搏器的活动严重<4>抑制</4>。患者没有明显的相关病症，这些病症可能使他易患<5>心动过缓</5>；因此，这可能代表了<2>利多卡因</2>的真正特质。", "revised": true}
{"doc_key": "1967484", "sentences": [["Sulpiride", "-", "induced", "tardive", "dystonia", ".", "Sulpiride", "is", "a", "selective", "D2", "-", "receptor", "antagonist", "with", "antipsychotic", "and", "antidepressant", "properties", ".", "Although", "initially", "thought", "to", "be", "free", "of", "extrapyramidal", "side", "effects", ",", "sulpiride", "-", "induced", "tardive", "dyskinesia", "and", "parkinsonism", "have", "been", "reported", "occasionally", ".", "We", "studied", "a", "37", "-", "year", "-", "old", "man", "who", "developed", "persistent", "segmental", "dystonia", "within", "2", "months", "after", "starting", "sulpiride", "therapy", ".", "We", "could", "not", "find", "any", "previous", "reports", "of", "sulpiride", "-", "induced", "tardive", "dystonia", "."]], "ner": [[[0, 0, "Chemical"], [6, 6, "Chemical"], [31, 31, "Chemical"], [62, 62, "Chemical"], [73, 73, "Chemical"], [3, 4, "Disease"], [56, 56, "Disease"], [76, 77, "Disease"], [34, 35, "Disease"], [37, 37, "Disease"], [17, 17, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 56, 56, "CID"], [0, 0, 76, 77, "CID"], [6, 6, 3, 4, "CID"], [6, 6, 56, 56, "CID"], [6, 6, 76, 77, "CID"], [31, 31, 3, 4, "CID"], [31, 31, 56, 56, "CID"], [31, 31, 76, 77, "CID"], [62, 62, 3, 4, "CID"], [62, 62, 56, 56, "CID"], [62, 62, 76, 77, "CID"], [73, 73, 3, 4, "CID"], [73, 73, 56, 56, "CID"], [73, 73, 76, 77, "CID"]]], "clusters": [], "translated": "<0>舒必利</0> - 诱发 <5>迟发性肌张力障碍</5>。 <1>舒必利</1> 是一种选择性 D2 受体拮抗剂，具有抗精神病和<10>抗抑郁</10> 特性。虽然最初认为没有锥体外系副作用，但偶有报道<2>舒必利</2>诱发的<8>迟发性运动障碍</8>和<9>帕金森症</9>。我们研究了一名 37 岁男性，他在开始<3>舒必利</3>治疗后 2 个月内出现持续性节段性<6>肌张力障碍</6>。我们找不到任何关于<4>舒必利</4> - 诱发 <7>迟发性肌张力障碍</7> 的既往报道。", "revised": true}
{"doc_key": "603022", "sentences": [["Galanthamine", "hydrobromide", ",", "a", "longer", "acting", "anticholinesterase", "drug", ",", "in", "the", "treatment", "of", "the", "central", "effects", "of", "scopolamine", "(", "Hyoscine", ")", ".", "Galanthamine", "hydrobromide", ",", "an", "anticholinesterase", "drug", "capable", "of", "penetrating", "the", "blood", "-", "brain", "barrier", ",", "was", "used", "in", "a", "patient", "demonstrating", "central", "effects", "of", "scopolamine", "(", "hyoscine", ")", "overdosage", ".", "It", "is", "longer", "acting", "than", "physostigmine", "and", "is", "used", "in", "anaesthesia", "to", "reverse", "the", "non", "-", "depolarizing", "neuromuscular", "block", ".", "However", ",", "studies", "into", "the", "dose", "necessary", "to", "combating", "scopolamine", "intoxication", "are", "indicated", "."]], "ner": [[[17, 17, "Chemical"], [19, 19, "Chemical"], [46, 46, "Chemical"], [48, 48, "Chemical"], [81, 81, "Chemical"], [50, 50, "Disease"], [0, 1, "Chemical"], [22, 23, "Chemical"], [57, 57, "Chemical"]]], "relations": [[[17, 17, 50, 50, "CID"], [19, 19, 50, 50, "CID"], [46, 46, 50, 50, "CID"], [48, 48, 50, 50, "CID"], [81, 81, 50, 50, "CID"]]], "clusters": [], "translated": "<6>氢溴酸加兰他敏</6>，一种长效抗胆碱酯酶药，在治疗<0>东莨菪碱</0>（<1>Hyoscine</1>）的中枢作用方面发挥作用。 <7>氢溴酸加兰他敏</7>，一种能够穿透血脑屏障的抗胆碱酯酶药物，被用于一名证实<2>东莨菪碱</2>（<3>Hyoscine</3>）<5>药物过量</5>导致中枢作用的患者。它比<8>毒扁豆碱</8>作用时间更长，在麻醉中用来逆转非去极化神经肌肉阻断。然而需要研究用于对抗<4>东莨菪碱</4>中毒所需的剂量。", "revised": true}
{"doc_key": "1601297", "sentences": [["Electrocardiographic", "evidence", "of", "myocardial", "injury", "in", "psychiatrically", "hospitalized", "cocaine", "abusers", ".", "The", "electrocardiograms", "(", "ECG", ")", "of", "99", "cocaine", "-", "abusing", "patients", "were", "compared", "with", "the", "ECGs", "of", "50", "schizophrenic", "controls", ".", "Eleven", "of", "the", "cocaine", "abusers", "and", "none", "of", "the", "controls", "had", "ECG", "evidence", "of", "significant", "myocardial", "injury", "defined", "as", "myocardial", "infarction", ",", "ischemia", ",", "and", "bundle", "branch", "block", "."]], "ner": [[[8, 8, "Chemical"], [18, 18, "Chemical"], [35, 35, "Chemical"], [51, 52, "Disease"], [57, 59, "Disease"], [3, 4, "Disease"], [47, 48, "Disease"], [29, 29, "Disease"], [54, 54, "Disease"]]], "relations": [[[8, 8, 51, 52, "CID"], [18, 18, 51, 52, "CID"], [35, 35, 51, 52, "CID"], [8, 8, 57, 59, "CID"], [18, 18, 57, 59, "CID"], [35, 35, 57, 59, "CID"]]], "clusters": [], "translated": "精神病住院<0>可卡因</0>滥用者<5>心肌损伤</5>的心电图证据。将99名<1>可卡因</1>滥用患者的心电图 (ECG) 与50名<7>精神分裂症</7>对照者的心电图进行了比较。<2>可卡因</2>滥用者中的 11 人和对照组中没有人有显着<6>心肌损伤</6>的心电图证据，定义为<3>心肌梗塞</3>、<8>缺血</8>和<4>束支阻滞</4>。", "revised": true}
{"doc_key": "2505783", "sentences": [["Chloroacetaldehyde", "and", "its", "contribution", "to", "urotoxicity", "during", "treatment", "with", "cyclophosphamide", "or", "ifosfamide", ".", "An", "experimental", "study", "/", "short", "communication", ".", "Based", "on", "clinical", "data", ",", "indicating", "that", "chloroacetaldehyde", "(", "CAA", ")", "is", "an", "important", "metabolite", "of", "oxazaphosphorine", "cytostatics", ",", "an", "experimental", "study", "was", "carried", "out", "in", "order", "to", "elucidate", "the", "role", "of", "CAA", "in", "the", "development", "of", "hemorrhagic", "cystitis", ".", "The", "data", "demonstrate", "that", "CAA", "after", "i", ".", "v", ".", "administration", "does", "not", "contribute", "to", "bladder", "damage", ".", "When", "instilled", "directly", "into", "the", "bladder", ",", "CAA", "exerts", "urotoxic", "effects", ",", "it", "is", ",", "however", ",", "susceptible", "to", "detoxification", "with", "mesna", "."]], "ner": [[[0, 0, "Chemical"], [27, 27, "Chemical"], [29, 29, "Chemical"], [52, 52, "Chemical"], [64, 64, "Chemical"], [85, 85, "Chemical"], [57, 58, "Disease"], [75, 76, "Disease"], [9, 9, "Chemical"], [11, 11, "Chemical"], [99, 99, "Chemical"]]], "relations": [[[0, 0, 57, 58, "CID"], [27, 27, 57, 58, "CID"], [29, 29, 57, 58, "CID"], [52, 52, 57, 58, "CID"], [64, 64, 57, 58, "CID"], [85, 85, 57, 58, "CID"]]], "clusters": [], "translated": " <0>氯乙醛</0> 及其在<8>环磷酰胺</8>或<9>异环磷酰胺</9>治疗期间对尿毒性的影响。一项实验研究/短沟通。根据临床资料，<1>氯乙醛</1> (<2>CAA</2>)是氧氮杂膦细胞生长抑制剂的重要代谢产物，为阐明<3>CAA</3>在<6>出血性膀胱炎</6>的发展过程中的作用，进行了实验研究。数据表明，<4>CAA</4>在i.v.给药后不会导致<7>膀胱损伤</7>。当直接滴入膀胱时，<5>CAA</5>会产生尿毒作用，但它很容易被<10>美司钠</10>解毒。", "revised": true}
{"doc_key": "3412544", "sentences": [["Does", "paracetamol", "cause", "urothelial", "cancer", "or", "renal", "papillary", "necrosis", "?", "The", "risk", "of", "developing", "renal", "papillary", "necrosis", "or", "cancer", "of", "the", "renal", "pelvis", ",", "ureter", "or", "bladder", "associated", "with", "consumption", "of", "either", "phenacetin", "or", "paracetamol", "was", "calculated", "from", "data", "acquired", "by", "questionnaire", "from", "381", "cases", "and", "808", "controls", ".", "The", "risk", "of", "renal", "papillary", "necrosis", "was", "increased", "nearly", "20", "-", "fold", "by", "consumption", "of", "phenacetin", ",", "which", "also", "increased", "the", "risk", "for", "cancer", "of", "the", "renal", "pelvis", "and", "bladder", "but", "not", "for", "ureteric", "cancer", ".", "By", "contrast", ",", "we", "were", "unable", "to", "substantiate", "an", "increased", "risk", "from", "paracetamol", "consumption", "for", "renal", "papillary", "necrosis", "or", "any", "of", "these", "cancers", "although", "there", "was", "a", "suggestion", "of", "an", "association", "with", "cancer", "of", "the", "ureter", "."]], "ner": [[[32, 32, "Chemical"], [64, 64, "Chemical"], [6, 8, "Disease"], [14, 16, "Disease"], [52, 54, "Disease"], [100, 102, "Disease"], [18, 26, "Disease"], [72, 78, "Disease"], [1, 1, "Chemical"], [34, 34, "Chemical"], [97, 97, "Chemical"], [3, 4, "Disease"], [82, 83, "Disease"], [117, 120, "Disease"], [107, 107, "Disease"]]], "relations": [[[32, 32, 6, 8, "CID"], [32, 32, 14, 16, "CID"], [32, 32, 52, 54, "CID"], [32, 32, 100, 102, "CID"], [64, 64, 6, 8, "CID"], [64, 64, 14, 16, "CID"], [64, 64, 52, 54, "CID"], [64, 64, 100, 102, "CID"], [32, 32, 18, 26, "CID"], [32, 32, 72, 78, "CID"], [64, 64, 18, 26, "CID"], [64, 64, 72, 78, "CID"]]], "clusters": [], "translated": "<8>扑热息痛</8>是否会导致<11>尿路上皮癌</11>或<2>肾乳头坏死</2>？发生<3>肾乳头坏死</3>或<6>肾盂、输尿管或膀胱癌</6>的风险与服用<0>非那西汀</0>或<9>对乙酰氨基酚</9>相关，是根据381名病例和808名对照者的问卷调查数据计算得出。食用<1>非那西汀</1>将使得<4>肾乳头坏死</4>的风险增加近20倍，也增加了<7>肾盂和膀胱癌的风险</7>，但不适用于<12>输尿管癌</12>。相比之下，我们不能证实食用<10>对乙酰氨基酚</10>会增加<5>肾乳头坏死</5>或以上这些<14>癌症</14>的风险，虽然有一种可能与<13>输尿管癌</13>有关。", "revised": true}
{"doc_key": "2385256", "sentences": [["Myasthenia", "gravis", "presenting", "as", "weakness", "after", "magnesium", "administration", ".", "We", "studied", "a", "patient", "with", "no", "prior", "history", "of", "neuromuscular", "disease", "who", "became", "virtually", "quadriplegic", "after", "parenteral", "magnesium", "administration", "for", "preeclampsia", ".", "The", "serum", "magnesium", "concentration", "was", "3", ".", "0", "mEq", "/", "L", ",", "which", "is", "usually", "well", "tolerated", ".", "The", "magnesium", "was", "stopped", "and", "she", "recovered", "over", "a", "few", "days", ".", "While", "she", "was", "weak", ",", "2", "-", "Hz", "repetitive", "stimulation", "revealed", "a", "decrement", "without", "significant", "facilitation", "at", "rapid", "rates", "or", "after", "exercise", ",", "suggesting", "postsynaptic", "neuromuscular", "blockade", ".", "After", "her", "strength", "returned", ",", "repetitive", "stimulation", "was", "normal", ",", "but", "single", "fiber", "EMG", "revealed", "increased", "jitter", "and", "blocking", ".", "Her", "acetylcholine", "receptor", "antibody", "level", "was", "markedly", "elevated", ".", "Although", "paralysis", "after", "magnesium", "administration", "has", "been", "described", "in", "patients", "with", "known", "myasthenia", "gravis", ",", "it", "has", "not", "previously", "been", "reported", "to", "be", "the", "initial", "or", "only", "manifestation", "of", "the", "disease", ".", "Patients", "who", "are", "unusually", "sensitive", "to", "the", "neuromuscular", "effects", "of", "magnesium", "should", "be", "suspected", "of", "having", "an", "underlying", "disorder", "of", "neuromuscular", "transmission", "."]], "ner": [[[6, 6, "Chemical"], [26, 26, "Chemical"], [33, 33, "Chemical"], [50, 50, "Chemical"], [121, 121, "Chemical"], [160, 160, "Chemical"], [0, 1, "Disease"], [130, 131, "Disease"], [110, 110, "Chemical"], [18, 19, "Disease"], [85, 87, "Disease"], [23, 23, "Disease"], [29, 29, "Disease"], [119, 119, "Disease"], [168, 171, "Disease"]]], "relations": [[[6, 6, 0, 1, "CID"], [6, 6, 130, 131, "CID"], [26, 26, 0, 1, "CID"], [26, 26, 130, 131, "CID"], [33, 33, 0, 1, "CID"], [33, 33, 130, 131, "CID"], [50, 50, 0, 1, "CID"], [50, 50, 130, 131, "CID"], [121, 121, 0, 1, "CID"], [121, 121, 130, 131, "CID"], [160, 160, 0, 1, "CID"], [160, 160, 130, 131, "CID"]]], "clusters": [], "translated": " <6>重症肌无力</6>在<0>镁</0>给药后表现为无力。我们研究了一名既往没有<9>神经肌肉疾病</9>病史的患者，该患者在因<12>先兆子痫</12>注射<1>镁</1>后几乎<11>四肢瘫痪</11>。血清<2>镁</2>浓度为3.0 mEq/L，通常耐受性良好。<3>镁</3>停止服用，几天后她就康复了。当她很虚弱时，2赫兹的重复刺激显示在快速或运动后没有显着促进的情况下出现衰减，这表明<10>突触后神经肌肉阻滞</10>。恢复体力后，重复刺激正常，但单纤维肌电图显示抖动和阻滞增加。她的<8>乙酰胆碱</8>受体抗体水平明显升高。尽管已知<7>重症肌无力</7>的患者在服用<4>镁</4>后出现<13>麻痹</13>，但此前并未报道这是重症肌无力的初始表现或唯一表现的病。对<5>镁</5>的神经肌肉作用异常敏感的患者应怀疑有潜在的<14>神经肌肉传递障碍</14>。", "revised": true}
{"doc_key": "3693336", "sentences": [["Triazolam", "-", "induced", "brief", "episodes", "of", "secondary", "mania", "in", "a", "depressed", "patient", ".", "Large", "doses", "of", "triazolam", "repeatedly", "induced", "brief", "episodes", "of", "mania", "in", "a", "depressed", "elderly", "woman", ".", "Features", "of", "organic", "mental", "disorder", "(", "delirium", ")", "were", "not", "present", ".", "Manic", "excitement", "was", "coincident", "with", "the", "duration", "of", "action", "of", "triazolam", ".", "The", "possible", "contribution", "of", "the", "triazolo", "group", "to", "changes", "in", "affective", "status", "is", "discussed", "."]], "ner": [[[0, 0, "Chemical"], [16, 16, "Chemical"], [51, 51, "Chemical"], [58, 58, "Chemical"], [7, 7, "Disease"], [22, 22, "Disease"], [41, 41, "Disease"], [10, 10, "Disease"], [25, 25, "Disease"], [31, 33, "Disease"], [35, 35, "Disease"]]], "relations": [[[0, 0, 7, 7, "CID"], [0, 0, 22, 22, "CID"], [0, 0, 41, 41, "CID"], [16, 16, 7, 7, "CID"], [16, 16, 22, 22, "CID"], [16, 16, 41, 41, "CID"], [51, 51, 7, 7, "CID"], [51, 51, 22, 22, "CID"], [51, 51, 41, 41, "CID"], [58, 58, 7, 7, "CID"], [58, 58, 22, 22, "CID"], [58, 58, 41, 41, "CID"]]], "clusters": [], "translated": " <0>三唑仑</0> - 在<7>抑郁</7>患者中诱发了继发性<4>躁狂</4>的短暂发作。大剂量<1>三唑仑</1>反复诱发一位<8>抑郁症</8>老年妇女的短暂<5>躁狂</5>症。不存在<9>器质性精神障碍</9>（<10>谵妄</10>）的特征。<6>狂躁</6>兴奋与<2>三唑仑</2>的作用持续时间一致。讨论了<3>三唑并</3>组对情感状态变化的可能贡献。", "revised": true}
{"doc_key": "227508", "sentences": [["Naloxone", "reverses", "the", "antihypertensive", "effect", "of", "clonidine", ".", "In", "unanesthetized", ",", "spontaneously", "hypertensive", "rats", "the", "decrease", "in", "blood", "pressure", "and", "heart", "rate", "produced", "by", "intravenous", "clonidine", ",", "5", "to", "20", "micrograms", "/", "kg", ",", "was", "inhibited", "or", "reversed", "by", "nalozone", ",", "0", ".", "2", "to", "2", "mg", "/", "kg", ".", "The", "hypotensive", "effect", "of", "100", "mg", "/", "kg", "alpha", "-", "methyldopa", "was", "also", "partially", "reversed", "by", "naloxone", ".", "Naloxone", "alone", "did", "not", "affect", "either", "blood", "pressure", "or", "heart", "rate", ".", "In", "brain", "membranes", "from", "spontaneously", "hypertensive", "rats", "clonidine", ",", "10", "(", "-", "8", ")", "to", "10", "(", "-", "5", ")", "M", ",", "did", "not", "influence", "stereoselective", "binding", "of", "[", "3H", "]", "-", "naloxone", "(", "8", "nM", ")", ",", "and", "naloxone", ",", "10", "(", "-", "8", ")", "to", "10", "(", "-", "4", ")", "M", ",", "did", "not", "influence", "clonidine", "-", "suppressible", "binding", "of", "[", "3H", "]", "-", "dihydroergocryptine", "(", "1", "nM", ")", ".", "These", "findings", "indicate", "that", "in", "spontaneously", "hypertensive", "rats", "the", "effects", "of", "central", "alpha", "-", "adrenoceptor", "stimulation", "involve", "activation", "of", "opiate", "receptors", ".", "As", "naloxone", "and", "clonidine", "do", "not", "appear", "to", "interact", "with", "the", "same", "receptor", "site", ",", "the", "observed", "functional", "antagonism", "suggests", "the", "release", "of", "an", "endogenous", "opiate", "by", "clonidine", "or", "alpha", "-", "methyldopa", "and", "the", "possible", "role", "of", "the", "opiate", "in", "the", "central", "control", "of", "sympathetic", "tone", "."]], "ner": [[[58, 60, "Chemical"], [203, 205, "Chemical"], [51, 51, "Disease"], [0, 0, "Chemical"], [66, 66, "Chemical"], [68, 68, "Chemical"], [119, 119, "Chemical"], [175, 175, "Chemical"], [12, 12, "Disease"], [85, 85, "Disease"], [158, 158, "Disease"], [6, 6, "Chemical"], [25, 25, "Chemical"], [87, 87, "Chemical"], [137, 137, "Chemical"], [177, 177, "Chemical"], [201, 201, "Chemical"]]], "relations": [[[58, 60, 51, 51, "CID"], [203, 205, 51, 51, "CID"]]], "clusters": [], "translated": "  \n\n<3>纳洛酮</3>可逆转<11>可乐定</11>的降压作用。在未麻醉的自发性<8>高血压</8>大鼠中，静脉注射<12>可乐定</12> 5至20微克/千克可降低血压和心率，而纳洛酮（nalozone）0.2～2毫克/千克。100mg/kg<0>α-甲基多巴</0>的<2>降压</2>作用也被<4>纳洛酮</4>部分逆转。<5>纳洛酮</5>单独使用不会影响血压或心率。在自发性<9>高血压</9>大鼠的脑膜中，<13>可乐定</13>，10(-8)至10(-5) M，则不影响[3H]-纳洛酮(8 nM)的立体选择性结合。而<6>纳洛酮</6>，10(-8)至10(-4) M，则不影响<14>可乐定</14>-[3H]-二氢麦角隐亭(1 nM)的可抑制结合。这些发现表明，在自发性<10>高血压</10>大鼠中，中枢α-肾上腺素能受体的刺激作用涉及阿片受体的活化。由于<7>纳洛酮</7>和<15>可乐定</15>似乎不与同一受体位点相互作用，观察到的功能拮抗作用表明<16>可乐定</16>或<1>α-甲基多巴</1>以及鸦片制剂可能在交感神经紧张的中枢控制中发挥作用。", "revised": true}
{"doc_key": "2234245", "sentences": [["Ocular", "and", "auditory", "toxicity", "in", "hemodialyzed", "patients", "receiving", "desferrioxamine", ".", "During", "an", "18", "-", "month", "period", "of", "study", "41", "hemodialyzed", "patients", "receiving", "desferrioxamine", "(", "10", "-", "40", "mg", "/", "kg", "BW", "/", "3", "times", "weekly", ")", "for", "the", "first", "time", "were", "monitored", "for", "detection", "of", "audiovisual", "toxicity", ".", "6", "patients", "presented", "clinical", "symptoms", "of", "visual", "or", "auditory", "toxicity", ".", "Moreover", ",", "detailed", "ophthalmologic", "and", "audiologic", "studies", "disclosed", "abnormalities", "in", "7", "more", "asymptomatic", "patients", ".", "Visual", "toxicity", "was", "of", "retinal", "origin", "and", "was", "characterized", "by", "a", "tritan", "-", "type", "dyschromatopsy", ",", "sometimes", "associated", "with", "a", "loss", "of", "visual", "acuity", "and", "pigmentary", "retinal", "deposits", ".", "Auditory", "toxicity", "was", "characterized", "by", "a", "mid", "-", "to", "high", "-", "frequency", "neurosensorial", "hearing", "loss", "and", "the", "lesion", "was", "of", "the", "cochlear", "type", ".", "Desferrioxamine", "withdrawal", "resulted", "in", "a", "complete", "recovery", "of", "visual", "function", "in", "1", "patient", "and", "partial", "recovery", "in", "3", ",", "and", "a", "complete", "reversal", "of", "hearing", "loss", "in", "3", "patients", "and", "partial", "recovery", "in", "3", ".", "This", "toxicity", "appeared", "in", "patients", "receiving", "the", "higher", "doses", "of", "desferrioxamine", "or", "coincided", "with", "the", "normalization", "of", "ferritin", "or", "aluminium", "serum", "levels", ".", "The", "data", "indicate", "that", "audiovisual", "toxicity", "is", "not", "an", "infrequent", "complication", "in", "hemodialyzed", "patients", "receiving", "desferrioxamine", ".", "Periodical", "audiovisual", "monitoring", "should", "be", "performed", "on", "hemodialyzed", "patients", "receiving", "the", "drug", "in", "order", "to", "detect", "adverse", "effects", "as", "early", "as", "possible", "."]], "ner": [[[8, 8, "Chemical"], [22, 22, "Chemical"], [127, 127, "Chemical"], [172, 172, "Chemical"], [200, 200, "Chemical"], [0, 3, "Disease"], [45, 46, "Disease"], [54, 57, "Disease"], [74, 75, "Disease"], [93, 97, "Disease"], [189, 190, "Disease"], [99, 101, "Disease"], [115, 117, "Disease"], [103, 104, "Disease"], [151, 152, "Disease"], [163, 163, "Disease"]]], "relations": [[[8, 8, 0, 3, "CID"], [8, 8, 45, 46, "CID"], [8, 8, 54, 57, "CID"], [8, 8, 74, 75, "CID"], [8, 8, 93, 97, "CID"], [8, 8, 189, 190, "CID"], [22, 22, 0, 3, "CID"], [22, 22, 45, 46, "CID"], [22, 22, 54, 57, "CID"], [22, 22, 74, 75, "CID"], [22, 22, 93, 97, "CID"], [22, 22, 189, 190, "CID"], [127, 127, 0, 3, "CID"], [127, 127, 45, 46, "CID"], [127, 127, 54, 57, "CID"], [127, 127, 74, 75, "CID"], [127, 127, 93, 97, "CID"], [127, 127, 189, 190, "CID"], [172, 172, 0, 3, "CID"], [172, 172, 45, 46, "CID"], [172, 172, 54, 57, "CID"], [172, 172, 74, 75, "CID"], [172, 172, 93, 97, "CID"], [172, 172, 189, 190, "CID"], [200, 200, 0, 3, "CID"], [200, 200, 45, 46, "CID"], [200, 200, 54, 57, "CID"], [200, 200, 74, 75, "CID"], [200, 200, 93, 97, "CID"], [200, 200, 189, 190, "CID"], [8, 8, 99, 101, "CID"], [22, 22, 99, 101, "CID"], [127, 127, 99, 101, "CID"], [172, 172, 99, 101, "CID"], [200, 200, 99, 101, "CID"], [8, 8, 115, 117, "CID"], [22, 22, 115, 117, "CID"], [127, 127, 115, 117, "CID"], [172, 172, 115, 117, "CID"], [200, 200, 115, 117, "CID"]]], "clusters": [], "translated": " 接受<0>去铁胺</0>的血液透析患者的<5>眼和听觉毒性</5>。在为期 18 个月的研究期间，对 41 名首次接受<1>去铁胺</1>（10-40 mg/kg BW/每周 3 次）的血液透析患者进行监测，以检测 <6>视听毒性</6>。6 例患者出现了<7>视觉或听觉毒性</7>的临床症状。此外，详细的眼科及听力学研究揭示了另外 7 名无症状患者的异常。 <8>视觉毒性</8> 起源于视网膜，其特征是 tritan 型色素异常，有时与 <9>视力丧失</9>及<11>色素性视网膜沉积</11>相关。 <13>听觉毒性</13> 表现为中高频<12>感觉神经性听力损失</12>，病变为耳蜗型。 <2>去铁胺</2>戒断后，1例患者视觉功能完全恢复，3例患者部分恢复，3例患者<14>听力损失</14>完全逆转，3例患者部分恢复。这种<15>毒性</15>出现在接受较高剂量<3>去铁胺</3>的患者中或者与铁蛋白或铝血清水平正常化同时发生。数据表明，<10>视听毒性</10>在接受<4>去铁胺</4>治疗的血液透析患者中并非罕见的并发症。接受该药物治疗的血液透析患者应该定期进行视听监测，以尽早发现不良反应。", "revised": true}
{"doc_key": "1378968", "sentences": [["Effects", "of", "uninephrectomy", "and", "high", "protein", "feeding", "on", "lithium", "-", "induced", "chronic", "renal", "failure", "in", "rats", ".", "Rats", "with", "lithium", "-", "induced", "nephropathy", "were", "subjected", "to", "high", "protein", "(", "HP", ")", "feeding", ",", "uninephrectomy", "(", "NX", ")", "or", "a", "combination", "of", "these", ",", "in", "an", "attempt", "to", "induce", "glomerular", "hyperfiltration", "and", "further", "progression", "of", "renal", "failure", ".", "Newborn", "female", "Wistar", "rats", "were", "fed", "a", "lithium", "-", "containing", "diet", "(", "50", "mmol", "/", "kg", ")", "for", "8", "weeks", "and", "then", "randomized", "to", "normal", "diet", ",", "HP", "diet", "(", "40", "vs", ".", "19", "%", ")", ",", "NX", "or", "HP", "+", "NX", "for", "another", "8", "weeks", ".", "Corresponding", "non", "-", "lithium", "pretreated", "groups", "were", "generated", ".", "When", "comparing", "all", "lithium", "treated", "versus", "non", "-", "lithium", "-", "treated", "groups", ",", "lithium", "caused", "a", "reduction", "in", "glomerular", "filtration", "rate", "(", "GFR", ")", "without", "significant", "changes", "in", "effective", "renal", "plasma", "flow", "(", "as", "determined", "by", "a", "marker", "secreted", "into", "the", "proximal", "tubules", ")", "or", "lithium", "clearance", ".", "Consequently", ",", "lithium", "pretreatment", "caused", "a", "fall", "in", "filtration", "fraction", "and", "an", "increase", "in", "fractional", "Li", "excretion", ".", "Lithium", "also", "caused", "proteinuria", "and", "systolic", "hypertension", "in", "absence", "of", "glomerulosclerosis", ".", "HP", "failed", "to", "accentuante", "progression", "of", "renal", "failure", "and", "in", "fact", "tended", "to", "increase", "GFR", "and", "decrease", "plasma", "creatinine", "levels", "in", "lithium", "pretreated", "rats", ".", "NX", "caused", "an", "additive", "deterioration", "in", "GFR", "which", ",", "however", ",", "was", "ameliorated", "by", "HP", ".", "NX", "+", "HP", "caused", "a", "further", "rise", "in", "blood", "pressure", "in", "Li", "-", "pretreated", "rats", ".", "The", "results", "indicate", "that", "Li", "-", "induced", "nephropathy", ",", "even", "when", "the", "GFR", "is", "only", "modestly", "reduced", ",", "is", "associated", "with", "proteinuria", "and", "arterial", "systolic", "hypertension", ".", "In", "this", "model", "of", "chronic", "renal", "failure", "the", "decline", "in", "GFR", "is", "not", "accompanied", "by", "a", "corresponding", "fall", "in", "effective", "renal", "plasma", "flow", ",", "which", "may", "be", "the", "functional", "expression", "of", "the", "formation", "of", "nonfiltrating", "atubular", "glomeruli", ".", "The", "fractional", "reabsorption", "of", "tubular", "fluid", "by", "the", "proximal", "tubules", "is", "reduced", ",", "leaving", "the", "distal", "delivery", "unchanged", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[8, 8, "Chemical"], [19, 19, "Chemical"], [64, 64, "Chemical"], [107, 107, "Chemical"], [116, 116, "Chemical"], [121, 121, "Chemical"], [126, 126, "Chemical"], [158, 158, "Chemical"], [163, 163, "Chemical"], [176, 176, "Chemical"], [179, 179, "Chemical"], [212, 212, "Chemical"], [243, 243, "Chemical"], [252, 252, "Chemical"], [11, 13, "Disease"], [279, 281, "Disease"], [182, 182, "Disease"], [269, 269, "Disease"], [185, 185, "Disease"], [273, 273, "Disease"], [22, 22, "Disease"], [255, 255, "Disease"], [54, 55, "Disease"], [197, 198, "Disease"], [189, 189, "Disease"], [209, 209, "Chemical"]]], "relations": [[[8, 8, 11, 13, "CID"], [8, 8, 279, 281, "CID"], [19, 19, 11, 13, "CID"], [19, 19, 279, 281, "CID"], [64, 64, 11, 13, "CID"], [64, 64, 279, 281, "CID"], [107, 107, 11, 13, "CID"], [107, 107, 279, 281, "CID"], [116, 116, 11, 13, "CID"], [116, 116, 279, 281, "CID"], [121, 121, 11, 13, "CID"], [121, 121, 279, 281, "CID"], [126, 126, 11, 13, "CID"], [126, 126, 279, 281, "CID"], [158, 158, 11, 13, "CID"], [158, 158, 279, 281, "CID"], [163, 163, 11, 13, "CID"], [163, 163, 279, 281, "CID"], [176, 176, 11, 13, "CID"], [176, 176, 279, 281, "CID"], [179, 179, 11, 13, "CID"], [179, 179, 279, 281, "CID"], [212, 212, 11, 13, "CID"], [212, 212, 279, 281, "CID"], [243, 243, 11, 13, "CID"], [243, 243, 279, 281, "CID"], [252, 252, 11, 13, "CID"], [252, 252, 279, 281, "CID"], [8, 8, 182, 182, "CID"], [8, 8, 269, 269, "CID"], [19, 19, 182, 182, "CID"], [19, 19, 269, 269, "CID"], [64, 64, 182, 182, "CID"], [64, 64, 269, 269, "CID"], [107, 107, 182, 182, "CID"], [107, 107, 269, 269, "CID"], [116, 116, 182, 182, "CID"], [116, 116, 269, 269, "CID"], [121, 121, 182, 182, "CID"], [121, 121, 269, 269, "CID"], [126, 126, 182, 182, "CID"], [126, 126, 269, 269, "CID"], [158, 158, 182, 182, "CID"], [158, 158, 269, 269, "CID"], [163, 163, 182, 182, "CID"], [163, 163, 269, 269, "CID"], [176, 176, 182, 182, "CID"], [176, 176, 269, 269, "CID"], [179, 179, 182, 182, "CID"], [179, 179, 269, 269, "CID"], [212, 212, 182, 182, "CID"], [212, 212, 269, 269, "CID"], [243, 243, 182, 182, "CID"], [243, 243, 269, 269, "CID"], [252, 252, 182, 182, "CID"], [252, 252, 269, 269, "CID"], [8, 8, 185, 185, "CID"], [8, 8, 273, 273, "CID"], [19, 19, 185, 185, "CID"], [19, 19, 273, 273, "CID"], [64, 64, 185, 185, "CID"], [64, 64, 273, 273, "CID"], [107, 107, 185, 185, "CID"], [107, 107, 273, 273, "CID"], [116, 116, 185, 185, "CID"], [116, 116, 273, 273, "CID"], [121, 121, 185, 185, "CID"], [121, 121, 273, 273, "CID"], [126, 126, 185, 185, "CID"], [126, 126, 273, 273, "CID"], [158, 158, 185, 185, "CID"], [158, 158, 273, 273, "CID"], [163, 163, 185, 185, "CID"], [163, 163, 273, 273, "CID"], [176, 176, 185, 185, "CID"], [176, 176, 273, 273, "CID"], [179, 179, 185, 185, "CID"], [179, 179, 273, 273, "CID"], [212, 212, 185, 185, "CID"], [212, 212, 273, 273, "CID"], [243, 243, 185, 185, "CID"], [243, 243, 273, 273, "CID"], [252, 252, 185, 185, "CID"], [252, 252, 273, 273, "CID"]]], "clusters": [], "translated": "单肾切除术和高蛋白喂养对<0>锂</0>诱导的大鼠<14>慢性肾功能衰竭</14>的影响。对患有<1>锂</1>诱导的<20>肾病</20>的大鼠进行高蛋白（HP）喂养、单肾切除术（NX）或这些方法的组合，以试图诱导肾小球过度滤过和进一步进展<22>肾功能衰竭</22>。新生雌性 Wistar 大鼠被喂食含<2>锂</2>的饮食（50 mmol/kg）8周，然后随机分配到正常饮食、HP饮食（40 vs 19%）、NX或HP+NX中，持续另一个8周。产生相应的非 <3>锂</3>预处理组。当比较所有<4>锂</4>治疗组与非<5>锂</5>治疗组时，<6>锂</6>导致肾小球滤过率（GFR）降低，而有效肾血浆流量（由分泌到近端小管中的标记物确定）或<7>锂</7>清除率。因此，<8>锂</8>预处理导致过滤分数下降和<9>锂</9>排泄分数增加。<10>锂</10>还引起<16>蛋白尿</16>和收缩期<18>高血压</18>，但没有<24>肾小球硬化</24>。 HP未能加重<23>肾功能衰竭</23>的进展，事实上在<11>锂</11>预处理大鼠中倾向于增加GFR并降低血浆<25>肌酐</25>水平。NX导致GFR的附加恶化，然而，HP改善了这种恶化。NX+HP导致<12>Li</12>预处理大鼠的血压进一步升高。结果表明，<13>Li</13> - 诱发的<21>肾病</21>，即使GFR仅适度降低，也与<17>蛋白尿</17>和动脉收缩期<19>高血压</19>有关。在这个<15>慢性肾功能衰竭</15>模型中，GFR的下降并不伴随有效肾血浆流量的相应下降，这可能是非滤过性肾小球形成的功能性表现。近端小管对肾小管液体的部分重吸收减少，远端输送保持不变。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "2632720", "sentences": [["Arterial", "hypertension", "as", "a", "complication", "of", "prolonged", "ketoconazole", "treatment", ".", "Two", "of", "14", "patients", "with", "Cushing", "'s", "syndrome", "treated", "on", "a", "long", "-", "term", "basis", "with", "ketoconazole", "developed", "sustained", "hypertension", ".", "In", "both", "cases", "normal", "plasma", "and", "urinary", "free", "cortisol", "levels", "had", "been", "achieved", "following", "ketoconazole", "therapy", ",", "yet", "continuous", "blood", "pressure", "monitoring", "demonstrated", "hypertension", "31", "(", "patient", "1", ")", "and", "52", "weeks", "(", "patient", "2", ")", "after", "treatment", ".", "In", "patient", "1", ",", "plasma", "levels", "of", "deoxycorticosterone", "and", "11", "-", "deoxycortisol", "were", "elevated", ".", "In", "patient", "2", ",", "in", "addition", "to", "an", "increase", "in", "both", "deoxycorticosterone", "and", "11", "-", "deoxycortisol", "levels", ",", "plasma", "aldosterone", "values", "were", "raised", ",", "with", "a", "concomitant", "suppression", "of", "renin", "levels", ".", "Our", "findings", "show", "that", "long", "-", "term", "treatment", "with", "high", "doses", "of", "ketoconazole", "may", "induce", "enzyme", "blockade", "leading", "to", "mineralocorticoid", "-", "related", "hypertension", "."]], "ner": [[[7, 7, "Chemical"], [26, 26, "Chemical"], [45, 45, "Chemical"], [129, 129, "Chemical"], [1, 1, "Disease"], [29, 29, "Disease"], [54, 54, "Disease"], [139, 139, "Disease"], [39, 39, "Chemical"], [77, 77, "Chemical"], [96, 96, "Chemical"], [79, 81, "Chemical"], [98, 100, "Chemical"], [104, 104, "Chemical"], [15, 17, "Disease"]]], "relations": [[[7, 7, 1, 1, "CID"], [7, 7, 29, 29, "CID"], [7, 7, 54, 54, "CID"], [7, 7, 139, 139, "CID"], [26, 26, 1, 1, "CID"], [26, 26, 29, 29, "CID"], [26, 26, 54, 54, "CID"], [26, 26, 139, 139, "CID"], [45, 45, 1, 1, "CID"], [45, 45, 29, 29, "CID"], [45, 45, 54, 54, "CID"], [45, 45, 139, 139, "CID"], [129, 129, 1, 1, "CID"], [129, 129, 29, 29, "CID"], [129, 129, 54, 54, "CID"], [129, 129, 139, 139, "CID"]]], "clusters": [], "translated": "动脉<4>高血压</4>是长期<0>酮康唑</0>治疗的并发症。在长期接受<1>酮康唑</1>治疗的14名<14>库欣综合征</14>患者中，有两名患者出现了持续性<5>高血压</5>。在这两种情况下，在<2>酮康唑</2>治疗后，血浆和尿游离<8>皮质醇</8>水平均已达到正常水平，但连续血压监测显示<6>高血压</6>31（患者1）和治疗后52周（患者2）。在患者1中，<9>脱氧皮质酮</9>和<11>11-脱氧皮质醇</11>的血浆水平升高。在患者2中，除了<10>脱氧皮质酮</10>和<12>11-脱氧皮质醇</12>水平升高外，血浆<13>醛固酮</13>值升高，同时抑制肾素水平。我们的研究结果表明，长期使用高剂量<3>酮康唑</3>治疗可能会导致酶阻断，导致盐皮质激素相关的<7>高血压</7>。", "revised": true}
{"doc_key": "435349", "sentences": [["Suxamethonium", "infusion", "rate", "and", "observed", "fasciculations", ".", "A", "dose", "-", "response", "study", ".", "Suxamethonium", "chloride", "(", "Sch", ")", "was", "administered", "i", ".", "v", ".", "to", "36", "adult", "males", "at", "six", "rates", ":", "0", ".", "25", "mg", "s", "-", "1", "to", "20", "mg", "s", "-", "1", ".", "The", "infusion", "was", "discontinued", "either", "when", "there", "was", "no", "muscular", "response", "to", "tetanic", "stimulation", "of", "the", "ulnar", "nerve", "or", "when", "Sch", "120", "mg", "was", "exceeded", ".", "Six", "additional", "patients", "received", "a", "30", "-", "mg", "i", ".", "v", ".", "bolus", "dose", ".", "Fasciculations", "in", "six", "areas", "of", "the", "body", "were", "scored", "from", "0", "to", "3", "and", "summated", "as", "a", "total", "fasciculation", "score", ".", "The", "times", "to", "first", "fasciculation", ",", "twitch", "suppression", "and", "tetanus", "suppression", "were", "inversely", "related", "to", "the", "infusion", "rates", ".", "Fasciculations", "in", "the", "six", "areas", "and", "the", "total", "fasciculation", "score", "were", "related", "directly", "to", "the", "rate", "of", "infusion", ".", "Total", "fasciculation", "scores", "in", "the", "30", "-", "mg", "bolus", "group", "and", "the", "5", "-", "mg", "s", "-", "1", "and", "20", "-", "mg", "s", "-", "1", "infusion", "groups", "were", "not", "significantly", "different", "."]], "ner": [[[0, 0, "Chemical"], [13, 14, "Chemical"], [16, 16, "Chemical"], [66, 66, "Chemical"], [5, 5, "Disease"], [87, 87, "Disease"], [105, 105, "Disease"], [112, 112, "Disease"], [127, 127, "Disease"], [135, 135, "Disease"], [147, 147, "Disease"], [58, 58, "Disease"], [114, 114, "Disease"], [117, 117, "Disease"]]], "relations": [[[0, 0, 5, 5, "CID"], [0, 0, 87, 87, "CID"], [0, 0, 105, 105, "CID"], [0, 0, 112, 112, "CID"], [0, 0, 127, 127, "CID"], [0, 0, 135, 135, "CID"], [0, 0, 147, 147, "CID"], [13, 14, 5, 5, "CID"], [13, 14, 87, 87, "CID"], [13, 14, 105, 105, "CID"], [13, 14, 112, 112, "CID"], [13, 14, 127, 127, "CID"], [13, 14, 135, 135, "CID"], [13, 14, 147, 147, "CID"], [16, 16, 5, 5, "CID"], [16, 16, 87, 87, "CID"], [16, 16, 105, 105, "CID"], [16, 16, 112, 112, "CID"], [16, 16, 127, 127, "CID"], [16, 16, 135, 135, "CID"], [16, 16, 147, 147, "CID"], [66, 66, 5, 5, "CID"], [66, 66, 87, 87, "CID"], [66, 66, 105, 105, "CID"], [66, 66, 112, 112, "CID"], [66, 66, 127, 127, "CID"], [66, 66, 135, 135, "CID"], [66, 66, 147, 147, "CID"]]], "clusters": [], "translated": "<0>琥珀胆碱</0><0>输液速度</0>和观察到的<4>肌束震颤</4>。剂量反应研究。<1>氯化琥珀胆碱</1> (<2>Sch</2>) i.v. 给药。以六种比率给36名成年男性：0.25毫克/秒至20毫克/秒。当对尺神经的<11>强直</11>刺激没有肌肉反应或超过<3>Sch</3>120mg时，停止输注。另外六名患者接受了30毫克i.v.推注剂量。<5>身体六个部位的肌束震颤</5>从0到3分，并汇总为<6>肌束震颤</6>总分。首次<7>肌束震颤</7>、<12>抽搐</12>抑制和<13>破伤风</13>抑制的时间与输注速率呈负相关。六个区域的<8>肌束震颤</8>和总的<9>肌束震颤</9>评分与输液速度直接相关。30mg推注组与5mg/秒和20mg/秒输注组的总<10>肌束震颤</10>评分没有显着差异。", "revised": true}
{"doc_key": "3827439", "sentences": [["Recurrent", "reversible", "acute", "renal", "failure", "from", "amphotericin", ".", "A", "patient", "with", "cryptogenic", "cirrhosis", "and", "disseminated", "sporotrichosis", "developed", "acute", "renal", "failure", "immediately", "following", "the", "administration", "of", "amphotericin", "B", "on", "four", "separate", "occasions", ".", "The", "abruptness", "of", "the", "renal", "failure", "and", "its", "reversibility", "within", "days", "suggests", "that", "there", "was", "a", "functional", "component", "to", "the", "renal", "dysfunction", ".", "We", "propose", "that", "amphotericin", ",", "in", "the", "setting", "of", "reduced", "effective", "arterial", "volume", ",", "may", "activate", "tubuloglomerular", "feedback", ",", "thereby", "contributing", "to", "acute", "renal", "failure", "."]], "ner": [[[6, 6, "Chemical"], [25, 26, "Chemical"], [58, 58, "Chemical"], [2, 4, "Disease"], [17, 19, "Disease"], [77, 79, "Disease"], [12, 12, "Disease"], [15, 15, "Disease"], [36, 37, "Disease"], [52, 53, "Disease"]]], "relations": [[[6, 6, 2, 4, "CID"], [6, 6, 17, 19, "CID"], [6, 6, 77, 79, "CID"], [25, 26, 2, 4, "CID"], [25, 26, 17, 19, "CID"], [25, 26, 77, 79, "CID"], [58, 58, 2, 4, "CID"], [58, 58, 17, 19, "CID"], [58, 58, 77, 79, "CID"]]], "clusters": [], "translated": "<0>两性霉素</0>引起的复发性可逆性<3>急性肾功能衰竭</3>。一名患有隐源性<6>肝硬化</6>和播散性<7>孢子丝菌病</7>的患者在接受<1>两性霉素B</1>治疗后立即发生<4>急性肾功能衰竭</4>。肾功能衰竭<8>的突然发生</8>及其在几天内的可逆性表明<9>肾功能障碍</9>存在功能性因素。我们提出，<2>两性霉素</2>在有效动脉容积减少的情况下可能会激活管球反馈，从而导致<5>急性肾功能衰竭</5>。", "revised": true}
{"doc_key": "1420741", "sentences": [["Treatment", "of", "Crohn", "'s", "disease", "with", "fusidic", "acid", ":", "an", "antibiotic", "with", "immunosuppressive", "properties", "similar", "to", "cyclosporin", ".", "Fusidic", "acid", "is", "an", "antibiotic", "with", "T", "-", "cell", "specific", "immunosuppressive", "effects", "similar", "to", "those", "of", "cyclosporin", ".", "Because", "of", "the", "need", "for", "the", "development", "of", "new", "treatments", "for", "Crohn", "'s", "disease", ",", "a", "pilot", "study", "was", "undertaken", "to", "estimate", "the", "pharmacodynamics", "and", "tolerability", "of", "fusidic", "acid", "treatment", "in", "chronic", "active", ",", "therapy", "-", "resistant", "patients", ".", "Eight", "Crohn", "'s", "disease", "patients", "were", "included", ".", "Fusidic", "acid", "was", "administered", "orally", "in", "a", "dose", "of", "500", "mg", "t", ".", "d", ".", "s", ".", "and", "the", "treatment", "was", "planned", "to", "last", "8", "weeks", ".", "The", "disease", "activity", "was", "primarily", "measured", "by", "a", "modified", "individual", "grading", "score", ".", "Five", "of", "8", "patients", "(", "63", "%", ")", "improved", "during", "fusidic", "acid", "treatment", ":", "3", "at", "two", "weeks", "and", "2", "after", "four", "weeks", ".", "There", "were", "no", "serious", "clinical", "side", "effects", ",", "but", "dose", "reduction", "was", "required", "in", "two", "patients", "because", "of", "nausea", ".", "Biochemically", ",", "an", "increase", "in", "alkaline", "phosphatases", "was", "noted", "in", "5", "of", "8", "cases", "(", "63", "%", ")", ",", "and", "the", "greatest", "increases", "were", "seen", "in", "those", "who", "had", "elevated", "levels", "prior", "to", "treatment", ".", "All", "reversed", "to", "pre", "-", "treatment", "levels", "after", "cessation", "of", "treatment", ".", "The", "results", "of", "this", "pilot", "study", "suggest", "that", "fusidic", "acid", "may", "be", "of", "benefit", "in", "selected", "chronic", "active", "Crohn", "'s", "disease", "patients", "in", "whom", "conventional", "treatment", "is", "ineffective", ".", "Because", "there", "seems", "to", "exist", "a", "scientific", "rationale", "for", "the", "use", "of", "fusidic", "acid", "at", "the", "cytokine", "level", "in", "inflammatory", "bowel", "disease", ",", "we", "suggest", "that", "the", "role", "of", "this", "treatment", "should", "be", "further", "investigated", "."]], "ner": [[[6, 7, "Chemical"], [63, 64, "Chemical"], [83, 84, "Chemical"], [133, 134, "Chemical"], [222, 223, "Chemical"], [255, 256, "Chemical"], [165, 165, "Disease"], [2, 4, "Disease"], [47, 49, "Disease"], [76, 78, "Disease"], [232, 234, "Disease"], [16, 16, "Chemical"], [34, 34, "Chemical"], [262, 264, "Disease"]]], "relations": [[[6, 7, 165, 165, "CID"], [63, 64, 165, 165, "CID"], [83, 84, 165, 165, "CID"], [133, 134, 165, 165, "CID"], [222, 223, 165, 165, "CID"], [255, 256, 165, 165, "CID"]]], "clusters": [], "translated": "<0>夫西地酸</0>治疗<7>克罗恩病</7>：一种具有与<11>环孢菌素</11>相似的免疫抑制特性的抗生素。<0>夫西地酸</0>是一种抗生素，具有与<12>环孢菌素</12>相似的T细胞特异性免疫抑制作用。由于需要开发针对<8>克罗恩氏病</8>的新疗法，因此进行了一项初步研究，以评估<1>夫西地酸</1>治疗慢性活性、治疗的药效学和耐受性。八名<9>克罗恩病</9>患者被纳入。 <2>夫西地酸</2>口服给药，剂量为500 mg t . d.small . ，治疗计划持续8周。疾病活动度主要通过修改后的个体分级评分来衡量。八名患者中有五名(63%)在<3>夫西地酸</3>治疗期间有所改善：两名患者治疗两周后，两名患者治疗四周后改善，另一名患者在治疗第5周改善。没有严重的临床副作用，但有两名患者因<6>恶心</6>而需要减少剂量。在生化方面，八个病例中有五个(63%)碱性磷酸酶升高，治疗前水平升高的患者升高幅度最大。停止治疗后，全部恢复到治疗前水平。该初步研究的结果表明，<4>夫西地酸</4>可能对常规治疗无效的特定慢性活动性<10>克罗恩病</10>患者有益。因为在<13>炎症性肠病</13>的细胞因子水平使用<5>夫西地酸</5>似乎存在科学依据，我们建议进一步研究这种治疗的作用。", "revised": true}
{"doc_key": "2572625", "sentences": [["Clotiazepam", "-", "induced", "acute", "hepatitis", ".", "We", "report", "the", "case", "of", "a", "patient", "who", "developed", "acute", "hepatitis", "with", "extensive", "hepatocellular", "necrosis", ",", "7", "months", "after", "the", "onset", "of", "administration", "of", "clotiazepam", ",", "a", "thienodiazepine", "derivative", ".", "Clotiazepam", "withdrawal", "was", "followed", "by", "prompt", "recovery", ".", "The", "administration", "of", "several", "benzodiazepines", ",", "chemically", "related", "to", "clotiazepam", ",", "did", "not", "interfere", "with", "recovery", "and", "did", "not", "induce", "any", "relapse", "of", "hepatitis", ".", "This", "observation", "shows", "that", "clotiazepam", "can", "induce", "acute", "hepatitis", "and", "suggests", "that", "there", "is", "no", "cross", "hepatotoxicity", "between", "clotiazepam", "and", "several", "benzodiazepines", "."]], "ner": [[[0, 0, "Chemical"], [30, 30, "Chemical"], [36, 36, "Chemical"], [53, 53, "Chemical"], [73, 73, "Chemical"], [87, 87, "Chemical"], [4, 4, "Disease"], [16, 16, "Disease"], [67, 67, "Disease"], [77, 77, "Disease"], [85, 85, "Disease"], [18, 20, "Disease"], [33, 33, "Chemical"], [48, 48, "Chemical"], [90, 90, "Chemical"]]], "relations": [[[0, 0, 4, 4, "CID"], [0, 0, 16, 16, "CID"], [0, 0, 67, 67, "CID"], [0, 0, 77, 77, "CID"], [0, 0, 85, 85, "CID"], [30, 30, 4, 4, "CID"], [30, 30, 16, 16, "CID"], [30, 30, 67, 67, "CID"], [30, 30, 77, 77, "CID"], [30, 30, 85, 85, "CID"], [36, 36, 4, 4, "CID"], [36, 36, 16, 16, "CID"], [36, 36, 67, 67, "CID"], [36, 36, 77, 77, "CID"], [36, 36, 85, 85, "CID"], [53, 53, 4, 4, "CID"], [53, 53, 16, 16, "CID"], [53, 53, 67, 67, "CID"], [53, 53, 77, 77, "CID"], [53, 53, 85, 85, "CID"], [73, 73, 4, 4, "CID"], [73, 73, 16, 16, "CID"], [73, 73, 67, 67, "CID"], [73, 73, 77, 77, "CID"], [73, 73, 85, 85, "CID"], [87, 87, 4, 4, "CID"], [87, 87, 16, 16, "CID"], [87, 87, 67, 67, "CID"], [87, 87, 77, 77, "CID"], [87, 87, 85, 85, "CID"]]], "clusters": [], "translated": " <0>氯噻西泮</0>——诱发急性<6>肝炎</6>。我们报告了一名患者发生急性<7>肝炎</7>并伴有<11>广泛肝细胞坏死</11>的病例，在开始服用<1>克硫西泮</1> 7个月后，服用<12>噻吩二氮卓</12>衍生物。停药后<2>氯硫西泮</2>迅速恢复。与<3>氯硬西泮</3>化学相关的几种<13>苯二氮卓类药物</13>的给药不会干扰恢复，也不会引起任何<8>肝炎</8>的复发。该观察表明<4>克硫西泮</4>可诱发急性<9>肝炎</9>，提示<5>克硫西泮</5>与几种<14>苯二氮卓类药物</14>之间没有交叉<10>肝毒性</10>。", "revised": true}
{"doc_key": "3800626", "sentences": [["Compression", "neuropathy", "of", "the", "radial", "nerve", "due", "to", "pentazocine", "-", "induced", "fibrous", "myopathy", ".", "Fibrous", "myopathy", "is", "a", "common", ",", "well", "-", "known", "side", "effect", "of", "repeated", "pentazocine", "injection", ".", "However", ",", "compression", "neuropathy", "due", "to", "fibrotic", "muscle", "affected", "by", "pentazocine", "-", "induced", "myopathy", "has", "not", "previously", "been", "reported", ".", "In", "a", "37", "-", "year", "-", "old", "woman", "with", "documented", "pentazocine", "-", "induced", "fibrous", "myopathy", "of", "triceps", "and", "deltoid", "muscles", "bilaterally", "and", "a", "three", "-", "week", "history", "of", "right", "wrist", "drop", ",", "electrodiagnostic", "examination", "showed", "a", "severe", "but", "partial", "lesion", "of", "the", "right", "radial", "nerve", "distal", "to", "the", "branches", "to", "the", "triceps", ",", "in", "addition", "to", "the", "fibrous", "myopathy", ".", "Surgery", "revealed", "the", "right", "radial", "nerve", "to", "be", "severely", "compressed", "by", "the", "densely", "fibrotic", "lateral", "head", "of", "the", "triceps", ".", "Decompression", "and", "neurolysis", "were", "performed", "with", "good", "subsequent", "recovery", "of", "function", "."]], "ner": [[[8, 8, "Chemical"], [27, 27, "Chemical"], [40, 40, "Chemical"], [60, 60, "Chemical"], [0, 5, "Disease"], [32, 33, "Disease"], [11, 12, "Disease"], [14, 15, "Disease"], [63, 64, "Disease"], [107, 108, "Disease"], [43, 43, "Disease"]]], "relations": [[[8, 8, 0, 5, "CID"], [8, 8, 32, 33, "CID"], [27, 27, 0, 5, "CID"], [27, 27, 32, 33, "CID"], [40, 40, 0, 5, "CID"], [40, 40, 32, 33, "CID"], [60, 60, 0, 5, "CID"], [60, 60, 32, 33, "CID"], [8, 8, 11, 12, "CID"], [8, 8, 14, 15, "CID"], [8, 8, 63, 64, "CID"], [8, 8, 107, 108, "CID"], [27, 27, 11, 12, "CID"], [27, 27, 14, 15, "CID"], [27, 27, 63, 64, "CID"], [27, 27, 107, 108, "CID"], [40, 40, 11, 12, "CID"], [40, 40, 14, 15, "CID"], [40, 40, 63, 64, "CID"], [40, 40, 107, 108, "CID"], [60, 60, 11, 12, "CID"], [60, 60, 14, 15, "CID"], [60, 60, 63, 64, "CID"], [60, 60, 107, 108, "CID"], [8, 8, 43, 43, "CID"], [27, 27, 43, 43, "CID"], [40, 40, 43, 43, "CID"], [60, 60, 43, 43, "CID"]]], "clusters": [], "translated": "<0>喷他佐辛</0>引起的<6>纤维性肌病</6>导致的<4>桡神经压迫性神经病</4>。 <7>纤维性肌病</7>是一种常见、广为人知的反复注射<1>喷他佐辛</1>的副作用。然而，以往尚未报道由<2>喷他佐辛</2>引起的<10>肌病</10>所致的肌肉纤维化导致的<5>神经压迫病</5>。一名37岁女性出现了已记录的<3>喷他佐辛</3>诱导的<8>双侧三头肌和三角肌的纤维性肌病</8>和右手腕下垂三周病史。电生理检查显示右桡神经在三头肌分支远端存在严重而部分性损伤，除<9>纤维性肌病</9>外。手术显示右桡神经被纤维化程度高的三头肌外侧头严重压迫。通过减压和神经松解术治疗，功能得以很好恢复。", "revised": true}
{"doc_key": "2924746", "sentences": [["Chronic", "carbamazepine", "treatment", "in", "the", "rat", ":", "efficacy", ",", "toxicity", ",", "and", "effect", "on", "plasma", "and", "tissue", "folate", "concentrations", ".", "Folate", "depletion", "has", "often", "been", "a", "problem", "in", "chronic", "antiepileptic", "drug", "(", "AED", ")", "therapy", ".", "Carbamazepine", "(", "CBZ", ")", ",", "a", "commonly", "used", "AED", ",", "has", "been", "implicated", "in", "some", "clinical", "studies", ".", "A", "rat", "model", "was", "developed", "to", "examine", "the", "effects", "of", "chronic", "CBZ", "treatment", "on", "folate", "concentrations", "in", "the", "rat", ".", "In", "the", "course", "of", "developing", "this", "model", ",", "a", "common", "vehicle", ",", "propylene", "glycol", ",", "by", "itself", "in", "high", "doses", ",", "was", "found", "to", "exhibit", "protective", "properties", "against", "induced", "seizures", "and", "inhibited", "weight", "gain", ".", "Seizures", "induced", "by", "hexafluorodiethyl", "ether", "(", "HFDE", ")", "were", "also", "found", "to", "be", "a", "more", "sensitive", "measure", "of", "protection", "by", "CBZ", "than", "seizures", "induced", "by", "maximal", "electroshock", "(", "MES", ")", ".", "Oral", "administration", "of", "CBZ", "as", "an", "aqueous", "suspension", "every", "8", "h", "at", "a", "dose", "of", "250", "mg", "/", "kg", "was", "continuously", "protective", "against", "HFDE", "-", "induced", "seizures", "and", "was", "minimally", "toxic", "as", "measured", "by", "weight", "gain", "over", "8", "weeks", "of", "treatment", ".", "The", "CBZ", "levels", "measured", "in", "plasma", "and", "brain", "of", "these", "animals", ",", "however", ",", "were", "below", "those", "normally", "considered", "protective", ".", "This", "treatment", "with", "CBZ", "had", "no", "apparent", "adverse", "effect", "on", "folate", "concentrations", "in", "the", "rat", ",", "and", ",", "indeed", ",", "the", "folate", "concentration", "increased", "in", "liver", "after", "6", "weeks", "of", "treatment", "and", "in", "plasma", "at", "8", "weeks", "of", "treatment", "."]], "ner": [[[112, 113, "Chemical"], [115, 115, "Chemical"], [163, 163, "Chemical"], [103, 103, "Disease"], [109, 109, "Disease"], [131, 131, "Disease"], [166, 166, "Disease"], [1, 1, "Chemical"], [36, 36, "Chemical"], [38, 38, "Chemical"], [65, 65, "Chemical"], [129, 129, "Chemical"], [143, 143, "Chemical"], [183, 183, "Chemical"], [206, 206, "Chemical"], [9, 9, "Disease"], [106, 107, "Disease"], [174, 175, "Disease"], [17, 17, "Chemical"], [20, 20, "Chemical"], [68, 68, "Chemical"], [213, 213, "Chemical"], [224, 224, "Chemical"], [86, 87, "Chemical"]]], "relations": [[[112, 113, 103, 103, "CID"], [112, 113, 109, 109, "CID"], [112, 113, 131, 131, "CID"], [112, 113, 166, 166, "CID"], [115, 115, 103, 103, "CID"], [115, 115, 109, 109, "CID"], [115, 115, 131, 131, "CID"], [115, 115, 166, 166, "CID"], [163, 163, 103, 103, "CID"], [163, 163, 109, 109, "CID"], [163, 163, 131, 131, "CID"], [163, 163, 166, 166, "CID"]]], "clusters": [], "translated": "大鼠慢性<7>卡马西平</7>治疗：疗效、<15>毒性</15>以及对血浆和组织<18>叶酸</18>浓度的影响。<19>叶酸</19>耗竭一直是慢性抗癫痫药物(AED)治疗中的一个问题。 <8>卡马西平</8>（<9> CBZ </9>）是一种常用的抗癫痫药，已被用于一些临床研究。开发大鼠模型以检测长期<10> CBZ </10>治疗对大鼠<20>叶酸</20>浓度的影响。在开发该模型的过程中，发现一种常见的赋形剂<23>丙二醇</23>本身在高剂量下表现出对诱发的<3>癫痫发作</3>和抑制<16>体重增加</16>的保护作用。<0>六氟二乙醚</0>（<1>HFDE</1>）诱导的<4> 癫痫发作</4>也被发现是<11>CBZ</11>比最大电击（MES）诱导的<5>癫痫发作</5>更敏感的保护措施。以 250mg/kg的剂量每8小时口服水性混悬液<12> CBZ </12>持续预防<2> HFDE </2> -诱导的<6>癫痫发作</6>并且在8周的治疗中，通过<17>体重增加</17>衡量毒性最小。然而，在这些动物的血浆和大脑中测得的<13>CBZ</13>水平低于通常认为具有保护作用的水平。这种用<14> CBZ </14>治疗对大鼠体内的<21>叶酸</21>浓度没有明显的不良影响，而且，事实上，治疗6周后肝脏中的<22>叶酸</22>浓度增加，在治疗8周时血浆中的<22>叶酸</22>浓度也增加。", "revised": true}
{"doc_key": "2515254", "sentences": [["Source", "of", "pain", "and", "primitive", "dysfunction", "in", "migraine", ":", "an", "identical", "site", "?", "Twenty", "common", "migraine", "patients", "received", "a", "one", "sided", "frontotemporal", "application", "of", "nitroglycerin", "(", "10", "patients", ")", "or", "placebo", "ointment", "(", "10", "patients", ")", "in", "a", "double", "blind", "study", ".", "Early", "onset", "migraine", "attacks", "were", "induced", "by", "nitroglycerin", "in", "seven", "out", "of", "10", "patients", "versus", "no", "patient", "in", "the", "placebo", "group", ".", "Subsequently", "20", "migraine", "patients", ",", "who", "developed", "an", "early", "onset", "attack", "with", "frontotemporal", "nitroglycerin", ",", "received", "the", "drug", "in", "a", "second", "induction", "test", "at", "other", "body", "areas", ".", "No", "early", "onset", "migraine", "was", "observed", ".", "Thus", "the", "migraine", "-", "inducing", "effect", "of", "nitroglycerin", "seems", "to", "depend", "on", "direct", "stimulation", "of", "the", "habitual", "site", "of", "pain", ",", "suggesting", "that", "the", "frontotemporal", "region", "is", "of", "crucial", "importance", "in", "the", "development", "of", "a", "migraine", "crisis", ".", "This", "is", "not", "consistent", "with", "a", "CNS", "origin", "of", "migraine", "attack", "."]], "ner": [[[24, 24, "Chemical"], [49, 49, "Chemical"], [77, 77, "Chemical"], [106, 106, "Chemical"], [7, 7, "Disease"], [15, 15, "Disease"], [44, 44, "Disease"], [66, 66, "Disease"], [95, 95, "Disease"], [101, 101, "Disease"], [134, 134, "Disease"], [146, 146, "Disease"], [2, 2, "Disease"], [118, 118, "Disease"]]], "relations": [[[24, 24, 7, 7, "CID"], [24, 24, 15, 15, "CID"], [24, 24, 44, 44, "CID"], [24, 24, 66, 66, "CID"], [24, 24, 95, 95, "CID"], [24, 24, 101, 101, "CID"], [24, 24, 134, 134, "CID"], [24, 24, 146, 146, "CID"], [49, 49, 7, 7, "CID"], [49, 49, 15, 15, "CID"], [49, 49, 44, 44, "CID"], [49, 49, 66, 66, "CID"], [49, 49, 95, 95, "CID"], [49, 49, 101, 101, "CID"], [49, 49, 134, 134, "CID"], [49, 49, 146, 146, "CID"], [77, 77, 7, 7, "CID"], [77, 77, 15, 15, "CID"], [77, 77, 44, 44, "CID"], [77, 77, 66, 66, "CID"], [77, 77, 95, 95, "CID"], [77, 77, 101, 101, "CID"], [77, 77, 134, 134, "CID"], [77, 77, 146, 146, "CID"], [106, 106, 7, 7, "CID"], [106, 106, 15, 15, "CID"], [106, 106, 44, 44, "CID"], [106, 106, 66, 66, "CID"], [106, 106, 95, 95, "CID"], [106, 106, 101, 101, "CID"], [106, 106, 134, 134, "CID"], [106, 106, 146, 146, "CID"]]], "clusters": [], "translated": "在<4>偏头痛</4>中<12>疼痛</12>和原始功能障碍的来源：同一部位？在一项双盲研究中，20 名常见的<5>偏头痛</5>患者接受了单侧额颞应用<0>硝酸甘油</0>（10 名患者）或安慰剂软膏（10 名患者）。10 名患者中有 7 名因<1>硝酸甘油</1>而诱发早发性<6>偏头痛</6>发作，而安慰剂组则没有。随后，20 名<7>偏头痛</7>患者因额颞叶<2>硝酸甘油</2>发生早期发作，在身体其他部位进行第二次诱导试验时接受了该药物。未观察到早发性<8>偏头痛</8>。因此,<3>硝酸甘油</3>引起<9>偏头痛</9>的诱发作用似乎取决于对<13>疼痛</13>习惯性部位的直接刺激，这表明额颞区在<10>偏头痛</10>危机发展中具有至关重要的作用，这与<11>偏头痛</11>发作的中枢神经系统起源不一致。", "revised": true}
{"doc_key": "4071154", "sentences": [["Indomethacin", "-", "induced", "renal", "insufficiency", ":", "recurrence", "on", "rechallenge", ".", "We", "have", "reported", "a", "case", "of", "acute", "oliguric", "renal", "failure", "with", "hyperkalemia", "in", "a", "patient", "with", "cirrhosis", ",", "ascites", ",", "and", "cor", "pulmonale", "after", "indomethacin", "therapy", ".", "Prompt", "restoration", "of", "renal", "function", "followed", "drug", "withdrawal", ",", "while", "re", "-", "exposure", "to", "a", "single", "dose", "of", "indomethacin", "caused", "recurrence", "of", "acute", "reversible", "oliguria", ".", "Our", "case", "supports", "the", "hypothesis", "that", "endogenous", "renal", "prostaglandins", "play", "a", "role", "in", "the", "maintenance", "of", "renal", "blood", "flow", "when", "circulating", "plasma", "volume", "is", "diminished", ".", "Since", "nonsteroidal", "anti", "-", "inflammatory", "agents", "interfere", "with", "this", "compensatory", "mechanism", "and", "may", "cause", "acute", "renal", "failure", ",", "they", "should", "be", "used", "with", "caution", "in", "such", "patients", "."]], "ner": [[[0, 0, "Chemical"], [34, 34, "Chemical"], [55, 55, "Chemical"], [21, 21, "Disease"], [26, 26, "Disease"], [28, 28, "Disease"], [31, 32, "Disease"], [61, 61, "Disease"], [103, 105, "Disease"], [3, 4, "Disease"], [18, 19, "Disease"], [71, 71, "Chemical"]]], "relations": [[[0, 0, 21, 21, "CID"], [34, 34, 21, 21, "CID"], [55, 55, 21, 21, "CID"], [0, 0, 26, 26, "CID"], [34, 34, 26, 26, "CID"], [55, 55, 26, 26, "CID"], [0, 0, 28, 28, "CID"], [34, 34, 28, 28, "CID"], [55, 55, 28, 28, "CID"], [0, 0, 31, 32, "CID"], [34, 34, 31, 32, "CID"], [55, 55, 31, 32, "CID"], [0, 0, 61, 61, "CID"], [34, 34, 61, 61, "CID"], [55, 55, 61, 61, "CID"], [0, 0, 103, 105, "CID"], [34, 34, 103, 105, "CID"], [55, 55, 103, 105, "CID"]]], "clusters": [], "translated": " <0>吲哚美辛</0> 引起的<9>肾功能不全</9>：再次用药后复发。我们报道了一例急性<10>肾功能衰竭</10>伴有<3>高钾血症</3>的患者，患者有<4>肝硬化</4>、<5>腹水</5>和<6>肺心病</6>在<1>消炎痛</1>治疗后发生。停药后肾功能迅速恢复，而再次接触单剂量<2>吲哚美辛</2>导致急性可逆性<7>少尿</7>复发。我们的病例支持以下假设：当循环血浆容量减少时，<11>内源性肾前列腺素</11>在维持肾血流方面发挥作用。由于非甾体类抗炎药会干扰这种代偿机制，并可能导致<8>急性肾功能衰竭</8>，因此此类患者应谨慎使用。", "revised": true}
{"doc_key": "6103707", "sentences": [["Comparison", "of", "the", "subjective", "effects", "and", "plasma", "concentrations", "following", "oral", "and", "i", ".", "m", ".", "administration", "of", "flunitrazepam", "in", "volunteers", ".", "Flunitrazepam", "0", ".", "5", ",", "1", ".", "0", "or", "2", ".", "0", "mg", "was", "given", "by", "the", "oral", "or", "i", ".", "m", ".", "routes", "to", "groups", "of", "volunteers", "and", "its", "effects", "compared", ".", "Plasma", "concentrations", "of", "the", "drug", "were", "estimated", "by", "gas", "-", "liquid", "chromatography", ",", "in", "a", "smaller", "number", "of", "the", "subjects", ".", "The", "most", "striking", "effect", "was", "sedation", "which", "increased", "with", "the", "dose", ",", "2", "mg", "producing", "deep", "sleep", "although", "the", "subjects", "could", "still", "be", "aroused", ".", "The", "effects", "of", "i", ".", "m", ".", "administration", "were", "apparent", "earlier", "and", "sometimes", "lasted", "longer", "than", "those", "following", "oral", "administration", ".", "Dizziness", "was", "less", "marked", "than", "sedation", ",", "but", "increased", "with", "the", "dose", ".", "There", "was", "pain", "on", "i", ".", "m", ".", "injection", "of", "flunitrazepam", "significantly", "more", "often", "than", "with", "isotonic", "saline", ".", "Plasma", "concentrations", "varied", "with", "dose", "and", "route", "and", "corresponded", "qualitatively", "with", "the", "subjective", "effects", ".", "The", "drug", "was", "still", "present", "in", "measurable", "quantities", "after", "24", "h", "even", "with", "the", "smallest", "dose", "."]], "ner": [[[17, 17, "Chemical"], [21, 21, "Chemical"], [144, 144, "Chemical"], [121, 121, "Disease"], [136, 136, "Disease"]]], "relations": [[[17, 17, 121, 121, "CID"], [21, 21, 121, 121, "CID"], [144, 144, 121, 121, "CID"], [17, 17, 136, 136, "CID"], [21, 21, 136, 136, "CID"], [144, 144, 136, 136, "CID"]]], "clusters": [], "translated": "比较口服和 i.m.后的主观效果和血浆浓度。<0>氟硝西泮</0>在志愿者中口服或i.m.注射<1>氟硝西泮</1> 0.5、1.0或2.0毫克，并比较其效果。在一些受试者中，通过气液色谱法估计药物的血浆浓度。最显着的效果是随着剂量的增加而增加的镇静作用。2mg的剂量可以产生深度睡眠，尽管受试者仍可被唤醒。i.m.给药的效果比口服更快显现，并有时持续时间更长。 <3>头晕</3>没有镇静那么明显，但是随着剂量的增加而增加。i.m.注射<2>氟硝西泮</2>时，注射部位的<4>疼痛</4>明显高于等渗盐水。血浆浓度随着剂量和途径而变化，并与主观效应定性对应。即使在最小剂量下，24小时后仍可检测到药物存在。", "revised": true}
{"doc_key": "2951327", "sentences": [["Inhibition", "of", "sympathoadrenal", "activity", "by", "atrial", "natriuretic", "factor", "in", "dogs", ".", "In", "six", "conscious", ",", "trained", "dogs", ",", "maintained", "on", "a", "normal", "sodium", "intake", "of", "2", "to", "4", "mEq", "/", "kg", "/", "day", ",", "sympathetic", "activity", "was", "assessed", "as", "the", "release", "rate", "of", "norepinephrine", "and", "epinephrine", "during", "15", "-", "minute", "i", ".", "v", ".", "infusions", "of", "human", "alpha", "-", "atrial", "natriuretic", "factor", ".", "Mean", "arterial", "pressure", "(", "as", "a", "percentage", "of", "control", "+", "/", "-", "SEM", ")", "during", "randomized", "infusions", "of", "0", ".", "03", ",", "0", ".", "1", ",", "0", ".", "3", ",", "or", "1", ".", "0", "microgram", "/", "kg", "/", "min", "was", "99", "+", "/", "-", "1", ",", "95", "+", "/", "-", "1", "(", "p", "less", "than", "0", ".", "05", ")", ",", "93", "+", "/", "-", "1", "(", "p", "less", "than", "0", ".", "01", ")", ",", "or", "79", "+", "/", "-", "6", "%", "(", "p", "less", "than", "0", ".", "001", ")", ",", "respectively", ",", "but", "no", "tachycardia", "and", "no", "augmentation", "of", "the", "norepinephrine", "release", "rate", "(", "up", "to", "0", ".", "3", "microgram", "/", "kg", "/", "min", ")", "were", "observed", ",", "which", "is", "in", "contrast", "to", "comparable", "hypotension", "induced", "by", "hydralazine", "or", "nitroglycerin", ".", "The", "release", "rate", "of", "epinephrine", "(", "control", ",", "6", ".", "7", "+", "/", "-", "0", ".", "6", "ng", "/", "kg", "/", "min", ")", "declined", "immediately", "during", "infusions", "of", "atrial", "natriuretic", "factor", "to", "a", "minimum", "of", "49", "+", "/", "-", "5", "%", "of", "control", "(", "p", "less", "than", "0", ".", "001", ")", "during", "0", ".", "1", "microgram", "/", "kg", "/", "min", "and", "to", "63", "+", "/", "-", "5", "%", "(", "0", ".", "1", "greater", "than", "p", "greater", "than", "0", ".", "05", ")", "or", "95", "+", "/", "-", "13", "%", "(", "not", "significant", ")", "during", "0", ".", "3", "or", "1", ".", "0", "microgram", "/", "kg", "/", "min", ".", "Steady", "state", "arterial", "plasma", "concentrations", "of", "atrial", "natriuretic", "factor", "were", "39", "+", "/", "-", "10", "pg", "/", "ml", "(", "n", "=", "6", ")", "during", "infusions", "of", "saline", "and", "284", "+", "/", "-", "24", "pg", "/", "ml", "(", "n", "=", "6", ")", "and", "1520", "+", "/", "-", "300", "pg", "/", "ml", "(", "n", "=", "9", ")", "during", "0", ".", "03", "and", "0", ".", "1", "microgram", "/", "kg", "/", "min", "infusions", "of", "the", "factor", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[190, 190, "Chemical"], [187, 187, "Disease"], [192, 192, "Chemical"], [22, 22, "Chemical"], [157, 157, "Disease"], [43, 43, "Chemical"], [163, 163, "Chemical"], [45, 45, "Chemical"], [198, 198, "Chemical"]]], "relations": [[[190, 190, 187, 187, "CID"], [192, 192, 187, 187, "CID"]]], "clusters": [], "translated": "犬心房钠尿因子对交感肾上腺活动的抑制作用。在六只清醒、训练有素的狗中，维持正常的<3>钠</3>摄入量2至4mEq/kg/天，交感神经活动被评估为<5>去甲肾上腺素</5>和肾上腺素<7>的释放率</7>在15分钟内i. v. 诉。输注人α-心钠素。随机输注0.03、0.1、0.3或1.0微克/千克/分钟期间的平均动脉压（作为对照的百分比+/-SEM）分别为99+/-1，95+/-1（p小于0.05），93+/-1（p小于0.01），或79+/-6%（p小于0.001），但未观察到<4>心动过速</4>，且未观察到<6>去甲肾上腺素</6>释放率增加（高达0.3微克/千克/分钟），与<0>肼苯哒嗪</0>或<2>硝酸甘油</2>引起的可比较的<1>低血压</1>形成对比。<8>肾上腺素</8>的释放率（对照，6.7+/-0.6ng/kg/min）在输注心钠素期间立即下降至对照的最低49+/-5%（p小于0.001）在0.1微克/千克/分钟和63+/-5%（0.1大于p大于0.05）或95+/-13%（不重要）在0.3或1.0微克/千克/分钟。输注生理盐水期间心钠素的稳态动脉血浆浓度为39+/-10pg/ml（n=6）和284+/-24pg/ml（n=6）和1520+/-300pg/ml（n=9）在0.03和0.1微克/千克/分钟输注该因子。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "3409645", "sentences": [["Sexual", "dysfunction", "among", "patients", "with", "arthritis", ".", "The", "relationship", "of", "arthritis", "and", "sexual", "dysfunction", "was", "investigated", "among", "169", "patients", "with", "rheumatoid", "arthritis", ",", "osteoarthritis", "and", "spondyloarthropathy", ",", "130", "of", "whom", "were", "pair", "-", "matched", "to", "controls", ".", "Assessments", "of", "marital", "happiness", "and", "depressed", "mood", "were", "also", "made", "using", "the", "CES", "-", "D", "and", "the", "Azrin", "Marital", "Happiness", "Scale", "(", "AMHS", ")", ".", "Sexual", "dysfunctions", "were", "found", "to", "be", "common", "among", "patients", "and", "controls", ",", "the", "majority", "in", "both", "groups", "reporting", "one", "or", "more", "dysfunctions", ".", "Impotence", "was", "more", "common", "among", "male", "patients", "than", "controls", "and", "was", "found", "to", "be", "associated", "with", "co", "-", "morbidity", "and", "the", "taking", "of", "methotrexate", ".", "Depressed", "mood", "was", "more", "common", "among", "patients", "and", "was", "associated", "with", "certain", "sexual", "difficulties", ",", "but", "not", "with", "impotence", ".", "Marital", "unhappiness", ",", "as", "indicated", "by", "AMHS", "scores", ",", "was", "not", "associated", "with", "arthritis", "but", "was", "associated", "with", "sexual", "dysfunction", ",", "sexual", "dissatisfaction", "and", "being", "female", "."]], "ner": [[[108, 108, "Chemical"], [85, 85, "Disease"], [128, 128, "Disease"], [0, 1, "Disease"], [12, 13, "Disease"], [62, 63, "Disease"], [148, 149, "Disease"], [5, 5, "Disease"], [10, 10, "Disease"], [143, 143, "Disease"], [20, 21, "Disease"], [23, 23, "Disease"], [25, 25, "Disease"], [42, 43, "Disease"], [110, 111, "Disease"]]], "relations": [[[108, 108, 85, 85, "CID"], [108, 108, 128, 128, "CID"]]], "clusters": [], "translated": "<3>性功能障碍</3>是<7>关节炎</7>患者的一个常见问题。在169例<10>类风湿性关节炎</10>、<11>骨关节炎</11>和<12>脊柱关节病</12>患者中，研究了<8>关节炎</8>和<4>性功能障碍</4>之间的关系，其中130例与对照组进行了匹配。使用 CES-D 和 Azrin 婚姻幸福量表（AMHS）对婚姻幸福感和<13>抑郁情绪</13>进行了评估。患者和对照组中都报告了一种或多种功能障碍，<5>性功能障碍</5>很常见。男性患者中<1>阳痿</1>的发生率比对照组高，与并发症和服用<0>甲氨蝶呤</0>有关。在患者中，<14>情绪低落</14>更为常见，并与一些性困难有关，但与<2>阳痿</2>无关。AMHS评分显示，婚姻不幸福与<9>关节炎</9>无关，但与<6>性功能障碍</6>、性不满和女性身份有关。", "revised": true}
{"doc_key": "3997294", "sentences": [["Pneumonitis", "with", "pleural", "and", "pericardial", "effusion", "and", "neuropathy", "during", "amiodarone", "therapy", ".", "A", "patient", "with", "sinuatrial", "disease", "and", "implanted", "pacemaker", "was", "treated", "with", "amiodarone", "(", "maximum", "dose", "1000", "mg", ",", "maintenance", "dose", "800", "mg", "daily", ")", "for", "10", "months", ",", "for", "control", "of", "supraventricular", "tachyarrhythmias", ".", "He", "developed", "pneumonitis", ",", "pleural", "and", "pericardial", "effusions", ",", "and", "a", "predominantly", "proximal", "motor", "neuropathy", ".", "Immediate", "but", "gradual", "improvement", "followed", "withdrawal", "of", "amiodarone", "and", "treatment", "with", "prednisolone", ".", "Review", "of", "this", "and", "previously", "reported", "cases", "indicates", "the", "need", "for", "early", "diagnosis", "of", "amiodarone", "pneumonitis", ",", "immediate", "withdrawal", "of", "amiodarone", ",", "and", "prompt", "but", "continued", "steroid", "therapy", "to", "ensure", "full", "recovery", "."]], "ner": [[[9, 9, "Chemical"], [23, 23, "Chemical"], [69, 69, "Chemical"], [89, 89, "Chemical"], [95, 95, "Chemical"], [2, 5, "Disease"], [50, 53, "Disease"], [48, 48, "Disease"], [90, 90, "Disease"], [58, 60, "Disease"], [73, 73, "Chemical"], [101, 101, "Chemical"], [7, 7, "Disease"], [15, 16, "Disease"], [43, 44, "Disease"]]], "relations": [[[9, 9, 2, 5, "CID"], [9, 9, 50, 53, "CID"], [23, 23, 2, 5, "CID"], [23, 23, 50, 53, "CID"], [69, 69, 2, 5, "CID"], [69, 69, 50, 53, "CID"], [89, 89, 2, 5, "CID"], [89, 89, 50, 53, "CID"], [95, 95, 2, 5, "CID"], [95, 95, 50, 53, "CID"], [9, 9, 48, 48, "CID"], [9, 9, 90, 90, "CID"], [23, 23, 48, 48, "CID"], [23, 23, 90, 90, "CID"], [69, 69, 48, 48, "CID"], [69, 69, 90, 90, "CID"], [89, 89, 48, 48, "CID"], [89, 89, 90, 90, "CID"], [95, 95, 48, 48, "CID"], [95, 95, 90, 90, "CID"], [9, 9, 58, 60, "CID"], [23, 23, 58, 60, "CID"], [69, 69, 58, 60, "CID"], [89, 89, 58, 60, "CID"], [95, 95, 58, 60, "CID"]]], "clusters": [], "translated": "在 <0>胺碘酮</0> 治疗期间发生<7>肺炎</7>并伴有<5>胸膜和心包积液</5>，以及<12>神经病变</12>。一位患有<13>窦房疾病</13>并植入起搏器的患者接受<1>胺碘酮</1>（最大剂量1000 mg，维持剂量800 mg每天）治疗10个月，以控制<14>室上性快速性心律失常</14>。他出现了<6>胸膜和心包积液</6>，以及主要是<9>近端</9>运动<12>神经病变</12>。在停用<2>胺碘酮</2>和使用<10>泼尼松龙</10>后立即但逐渐改善。回顾这个病例和之前报道的病例表明需要早期诊断<3>胺碘酮</3><8>肺炎</8>，立即停用<4>胺碘酮</4>，并及时但继续<11>类固醇</11>疗法确保完全康复。", "revised": true}
{"doc_key": "2670794", "sentences": [["Effects", "of", "an", "inhibitor", "of", "angiotensin", "converting", "enzyme", "(", "Captopril", ")", "on", "pulmonary", "and", "renal", "insufficiency", "due", "to", "intravascular", "coagulation", "in", "the", "rat", ".", "Induction", "of", "intravascular", "coagulation", "and", "inhibition", "of", "fibrinolysis", "by", "injection", "of", "thrombin", "and", "tranexamic", "acid", "(", "AMCA", ")", "in", "the", "rat", "gives", "rise", "to", "pulmonary", "and", "renal", "insufficiency", "resembling", "that", "occurring", "after", "trauma", "or", "sepsis", "in", "man", ".", "Injection", "of", "Captopril", "(", "1", "mg", "/", "kg", ")", ",", "an", "inhibitor", "of", "angiotensin", "converting", "enzyme", "(", "ACE", ")", ",", "reduced", "both", "pulmonary", "and", "renal", "insufficiency", "in", "this", "rat", "model", ".", "The", "lung", "weights", "were", "lower", "and", "PaO2", "was", "improved", "in", "rats", "given", "this", "enzyme", "-", "blocking", "agent", ".", "The", "contents", "of", "albumin", "in", "the", "lungs", "were", "not", "changed", ",", "indicating", "that", "Captopril", "did", "not", "influence", "the", "extravasation", "of", "protein", ".", "Renal", "damage", "as", "reflected", "by", "an", "increase", "in", "serum", "urea", "and", "in", "kidney", "weight", "was", "prevented", "by", "Captopril", ".", "The", "amount", "of", "fibrin", "in", "the", "kidneys", "was", "also", "considerably", "lower", "than", "in", "animals", "which", "received", "thrombin", "and", "AMCA", "alone", ".", "It", "is", "suggested", "that", "the", "effects", "of", "Captopril", "on", "the", "lungs", "may", "be", "attributable", "to", "a", "vasodilatory", "effect", "due", "to", "a", "reduction", "in", "the", "circulating", "level", "of", "Angiotension", "II", "and", "an", "increase", "in", "prostacyclin", "(", "secondary", "to", "an", "increase", "in", "bradykinin", ")", ".", "Captopril", "may", ",", "by", "the", "same", "mechanism", ",", "reduce", "the", "increase", "in", "glomerular", "filtration", "that", "is", "known", "to", "occur", "after", "an", "injection", "of", "thrombin", ",", "thereby", "diminishing", "the", "aggregation", "of", "fibrin", "monomers", "in", "the", "glomeruli", ",", "with", "the", "result", "that", "less", "fibrin", "will", "be", "deposited", "and", "thus", "less", "kidney", "damage", "will", "be", "produced", "."]], "ner": [[[37, 38, "Chemical"], [40, 40, "Chemical"], [170, 170, "Chemical"], [18, 19, "Disease"], [26, 27, "Disease"], [5, 5, "Chemical"], [75, 75, "Chemical"], [12, 15, "Disease"], [48, 51, "Disease"], [84, 87, "Disease"], [56, 56, "Disease"], [58, 58, "Disease"], [133, 134, "Disease"], [264, 265, "Disease"], [9, 9, "Chemical"], [64, 64, "Chemical"], [124, 124, "Chemical"], [150, 150, "Chemical"], [180, 180, "Chemical"], [216, 216, "Chemical"], [142, 142, "Chemical"], [200, 201, "Chemical"], [206, 206, "Chemical"], [213, 213, "Chemical"]]], "relations": [[[37, 38, 18, 19, "CID"], [37, 38, 26, 27, "CID"], [40, 40, 18, 19, "CID"], [40, 40, 26, 27, "CID"], [170, 170, 18, 19, "CID"], [170, 170, 26, 27, "CID"]]], "clusters": [], "translated": "<5>血管紧张素</5>转化酶抑制剂 (<14>卡托普利</14>) 对 <7>肺和肾功能不全</7> 由于 <3>血管内凝血</3> 的影响鼠。通过在大鼠中注射凝血酶和<0>氨甲环酸</0> (<1>AMCA</1>) 诱导 <4>血管内凝血</4> 和抑制纤维蛋白溶解，引起 <8>肺和肾功能不全</8> 类似于男性 <10>外伤</10> 或 <11>脓毒症</11> 后发生的肾功能不全。注射<15>卡托普利</15>（1 mg/kg），一种 <6>血管紧张素</6>转换酶(ACE)抑制剂，减少了这只大鼠的<9>肺和肾功能不全</9>模型。给予这种酶阻断剂的大鼠肺重量较低，PaO2得到改善。肺内白蛋白含量无变化，说明<16>卡托普利</16>不影响蛋白质的外渗。<12>肾损伤</12> 反映在血清<20>尿素</20>和肾脏重量的增加上，<17>卡托普利</17> 可以预防。肾脏中的纤维蛋白量也明显低于仅接受凝血酶和 <2>AMCA</2> 的动物。提示 <18>卡托普利</18> 对肺的作用可能是由于循环中 <21>血管紧张素 II</21> 水平降低和<22>前列环素</22> 增加而产生的血管舒张作用（继发于<23>缓激肽</23>的增加）。<19>卡托普利</19> 可以通过相同的机制减少已知在注射凝血酶后发生的肾小球滤过的增加，从而减少肾小球中纤维蛋白单体的聚集，结果是更少的纤维蛋白会沉积，从而减少<13>肾脏损害</13> 的产生。", "revised": true}
{"doc_key": "3425586", "sentences": [["Dapsone", "-", "associated", "Heinz", "body", "hemolytic", "anemia", "in", "a", "Cambodian", "woman", "with", "hemoglobin", "E", "trait", ".", "A", "Cambodian", "woman", "with", "hemoglobin", "E", "trait", "(", "AE", ")", "and", "leprosy", "developed", "a", "Heinz", "body", "hemolytic", "anemia", "while", "taking", "a", "dose", "of", "dapsone", "(", "50", "mg", "/", "day", ")", "not", "usually", "associated", "with", "clinical", "hemolysis", ".", "Her", "red", "blood", "cells", "(", "RBCs", ")", "had", "increased", "incubated", "Heinz", "body", "formation", ",", "decreased", "reduced", "glutathione", "(", "GSH", ")", ",", "and", "decreased", "GSH", "stability", ".", "The", "pentose", "phosphate", "shunt", "activity", "of", "the", "dapsone", "-", "exposed", "AE", "RBCs", "was", "increased", "compared", "to", "normal", "RBCs", ".", "Although", "the", "AE", "RBCs", "from", "an", "individual", "not", "taking", "dapsone", "had", "increased", "incubated", "Heinz", "body", "formation", ",", "the", "GSH", "content", "and", "GSH", "stability", "were", "normal", ".", "The", "pentose", "phosphate", "shunt", "activity", "of", "the", "non", "-", "dapsone", "-", "exposed", "AE", "RBCs", "was", "decreased", "compared", "to", "normal", "RBCs", ".", "Thus", ",", "AE", "RBCs", "appear", "to", "have", "an", "increased", "sensitivity", "to", "oxidant", "stress", "both", "in", "vitro", "and", "in", "vivo", ",", "since", "dapsone", "does", "not", "cause", "hemolytic", "anemia", "at", "this", "dose", "in", "hematologically", "normal", "individuals", ".", "Given", "the", "influx", "of", "Southeast", "Asians", "into", "the", "United", "States", ",", "oxidant", "medications", "should", "be", "used", "with", "caution", ",", "especially", "if", "an", "infection", "is", "present", ",", "in", "individuals", "of", "ethnic", "backgrounds", "that", "have", "an", "increased", "prevalence", "of", "hemoglobin", "E", "."]], "ner": [[[0, 0, "Chemical"], [39, 39, "Chemical"], [86, 86, "Chemical"], [107, 107, "Chemical"], [133, 133, "Chemical"], [166, 166, "Chemical"], [5, 6, "Disease"], [32, 33, "Disease"], [170, 171, "Disease"], [27, 27, "Disease"], [51, 51, "Disease"], [202, 202, "Disease"], [69, 69, "Chemical"], [71, 71, "Chemical"], [76, 76, "Chemical"], [116, 116, "Chemical"], [119, 119, "Chemical"], [80, 81, "Chemical"], [125, 126, "Chemical"]]], "relations": [[[0, 0, 5, 6, "CID"], [0, 0, 32, 33, "CID"], [0, 0, 170, 171, "CID"], [39, 39, 5, 6, "CID"], [39, 39, 32, 33, "CID"], [39, 39, 170, 171, "CID"], [86, 86, 5, 6, "CID"], [86, 86, 32, 33, "CID"], [86, 86, 170, 171, "CID"], [107, 107, 5, 6, "CID"], [107, 107, 32, 33, "CID"], [107, 107, 170, 171, "CID"], [133, 133, 5, 6, "CID"], [133, 133, 32, 33, "CID"], [133, 133, 170, 171, "CID"], [166, 166, 5, 6, "CID"], [166, 166, 32, 33, "CID"], [166, 166, 170, 171, "CID"]]], "clusters": [], "translated": " <0>氨苯砜</0> - 与亨氏体<6>溶血性贫血</6>在具有血红蛋白E 特征的柬埔寨妇女中。一名患有血红蛋白E特征(AE)和<9>麻风病</9>的柬埔寨妇女在服用(50 毫克/天)的剂量不通常引起临床<10>溶血</10>的情况下，服用了<1>氨苯砜</1>出现了亨氏体<7>溶血性贫血</7>。她的红细胞(RBCs)在孵育的情况下，增加了亨氏小体形成，<12>谷胱甘肽</12>(<13>GSH</13>) 减少，<14>GSH</14> 的稳定性也下降。与正常的红细胞相比，被<2>氨苯砜</2>暴露的 AE 系的红细胞，其<17>戊糖磷酸</17>分流活性增加。虽然未服用<3>氨苯砜</3>的个体中的 AE 系的红细胞在孵育的情况下，增加了亨氏小体形成，但 <15>GSH</15> 含量和 <16>GSH</16> 的稳定性是正常的。并且与正常红细胞相比，未被<4>氨苯砜</4> 暴露的 AE 系的红细胞其<18>戊糖磷酸</18>分流活性则下降。因此，AE 系的红细胞在体外和体内对氧化应激似乎具有增强的敏感性，因为在血液学正常的个体中，<5>氨苯砜</5> 在该剂量下不会引起<8>溶血性贫血</8>。考虑到东南亚人涌入美国，应谨慎使用氧化剂药物，尤其是在具有血红蛋白 E 特征的种族背景和存在<11>感染</11>的个体中。", "revised": true}
{"doc_key": "6386793", "sentences": [["A", "double", "-", "blind", "study", "of", "the", "efficacy", "and", "safety", "of", "dothiepin", "hydrochloride", "in", "the", "treatment", "of", "major", "depressive", "disorder", ".", "In", "a", "6", "-", "week", "double", "-", "blind", "parallel", "treatment", "study", ",", "dothiepin", "and", "amitriptyline", "were", "compared", "to", "placebo", "in", "the", "treatment", "of", "33", "depressed", "outpatients", ".", "Dothiepin", "and", "amitriptyline", "were", "equally", "effective", "in", "alleviating", "the", "symptoms", "of", "depressive", "illness", ",", "and", "both", "were", "significantly", "superior", "to", "placebo", ".", "The", "overall", "incidence", "of", "side", "effects", "and", "the", "frequency", "and", "severity", "of", "blurred", "vision", ",", "dry", "mouth", ",", "and", "drowsiness", "were", "significantly", "less", "with", "dothiepin", "than", "with", "amitriptyline", ".", "Dothiepin", "also", "produced", "fewer", "CNS", "and", "cardiovascular", "effects", ".", "There", "were", "no", "clinically", "important", "changes", "in", "laboratory", "parameters", ".", "Dothiepin", "thus", "was", "found", "to", "be", "an", "effective", "antidepressant", "drug", "associated", "with", "fewer", "side", "effects", "than", "amitriptyline", "in", "the", "treatment", "of", "depressed", "outpatients", "."]], "ner": [[[35, 35, "Chemical"], [50, 50, "Chemical"], [97, 97, "Chemical"], [134, 134, "Chemical"], [82, 83, "Disease"], [85, 86, "Disease"], [11, 12, "Chemical"], [33, 33, "Chemical"], [48, 48, "Chemical"], [94, 94, "Chemical"], [99, 99, "Chemical"], [118, 118, "Chemical"], [18, 19, "Disease"], [45, 45, "Disease"], [59, 60, "Disease"], [139, 139, "Disease"], [126, 126, "Chemical"]]], "relations": [[[35, 35, 82, 83, "CID"], [50, 50, 82, 83, "CID"], [97, 97, 82, 83, "CID"], [134, 134, 82, 83, "CID"], [35, 35, 85, 86, "CID"], [50, 50, 85, 86, "CID"], [97, 97, 85, 86, "CID"], [134, 134, 85, 86, "CID"]]], "clusters": [], "translated": "<6>盐酸多噻平</6>治疗重度<12>抑郁症</12>有效性和安全性的双盲研究。在一项为期 6 周的双盲平行治疗研究中，比较了 <7>dothiepin</7>和<0>阿米替林</0>与安慰剂对 33 名<13>抑郁症</13>门诊患者的治疗效果。<8>多噻平</8>和<1>阿米替林</1>在缓解<14>抑郁症</14>的症状方面同样有效，并且均明显优于安慰剂。 <9>多噻平</9>的副作用总体发生率以及<4> 视力模糊</4>、<5>口干</5>和嗜睡的频率和严重程度显着低于<2>阿米替林</2>。<10>多噻平</10>对中枢神经系统和心血管的影响也较小。实验室参数没有临床上重要的变化。<11>因此，<6>多噻平</6>被认为是一种有效的<16>抗抑郁药</16>，并且与<3>阿米替林</3>相比，在治疗<15>抑郁症</15>的门诊病人中，其副作用更少。", "revised": true}
{"doc_key": "6286738", "sentences": [["Vitamin", "D3", "toxicity", "in", "dairy", "cows", ".", "Large", "parenteral", "doses", "of", "vitamin", "D3", "(", "15", "to", "17", ".", "5", "x", "10", "(", "6", ")", "IU", "vitamin", "D3", ")", "were", "associated", "with", "prolonged", "hypercalcemia", ",", "hyperphosphatemia", ",", "and", "large", "increases", "of", "vitamin", "D3", "and", "its", "metabolites", "in", "the", "blood", "plasma", "of", "nonlactating", "nonpregnant", "and", "pregnant", "Jersey", "cows", ".", "Calcium", "concentrations", "1", "day", "postpartum", "were", "higher", "in", "cows", "treated", "with", "vitamin", "D3", "about", "32", "days", "prepartum", "(", "8", ".", "8", "mg", "/", "100", "ml", ")", "than", "in", "control", "cows", "(", "5", ".", "5", "mg", "/", "100", "ml", ")", ".", "None", "of", "the", "cows", "treated", "with", "vitamin", "D3", "showed", "signs", "of", "milk", "fever", "during", "the", "peripartal", "period", ";", "however", ",", "22", "%", "of", "the", "control", "cows", "developed", "clinical", "signs", "of", "milk", "fever", "during", "this", "period", ".", "Signs", "of", "vitamin", "D3", "toxicity", "were", "not", "observed", "in", "nonlactating", "nonpregnant", "cows", ";", "however", ",", "pregnant", "cows", "commonly", "developed", "severe", "signs", "of", "vitamin", "D3", "toxicity", "and", "10", "of", "17", "cows", "died", ".", "There", "was", "widespread", "metastatic", "calcification", "in", "the", "cows", "that", "died", ".", "Because", "of", "the", "extreme", "toxicity", "of", "vitamin", "D3", "in", "pregnant", "Jersey", "cows", "and", "the", "low", "margin", "of", "safety", "between", "doses", "of", "vitamin", "D3", "that", "prevent", "milk", "fever", "and", "doses", "that", "induce", "milk", "fever", ",", "we", "concluded", "that", "vitamin", "D3", "can", "not", "be", "used", "practically", "to", "prevent", "milk", "fever", "when", "injected", "several", "weeks", "prepartum", "."]], "ner": [[[0, 1, "Chemical"], [11, 12, "Chemical"], [25, 26, "Chemical"], [40, 41, "Chemical"], [68, 69, "Chemical"], [103, 104, "Chemical"], [135, 136, "Chemical"], [155, 156, "Chemical"], [182, 183, "Chemical"], [197, 198, "Chemical"], [213, 214, "Chemical"], [32, 32, "Disease"], [34, 34, "Disease"], [2, 2, "Disease"], [137, 137, "Disease"], [157, 157, "Disease"], [180, 180, "Disease"], [108, 109, "Disease"], [127, 128, "Disease"], [201, 202, "Disease"], [207, 208, "Disease"], [222, 223, "Disease"], [57, 57, "Chemical"]]], "relations": [[[0, 1, 32, 32, "CID"], [11, 12, 32, 32, "CID"], [25, 26, 32, 32, "CID"], [40, 41, 32, 32, "CID"], [68, 69, 32, 32, "CID"], [103, 104, 32, 32, "CID"], [135, 136, 32, 32, "CID"], [155, 156, 32, 32, "CID"], [182, 183, 32, 32, "CID"], [197, 198, 32, 32, "CID"], [213, 214, 32, 32, "CID"], [0, 1, 34, 34, "CID"], [11, 12, 34, 34, "CID"], [25, 26, 34, 34, "CID"], [40, 41, 34, 34, "CID"], [68, 69, 34, 34, "CID"], [103, 104, 34, 34, "CID"], [135, 136, 34, 34, "CID"], [155, 156, 34, 34, "CID"], [182, 183, 34, 34, "CID"], [197, 198, 34, 34, "CID"], [213, 214, 34, 34, "CID"]]], "clusters": [], "translated": " <0>维生素 D3</0><13>奶牛的毒性</13>。大肠外剂量的<1>维生素 D3</1>（15 至 17.5 x 10(6) IU<2>维生素 D3</2>）与长期<11>高钙血症</11>、<12>高磷酸盐血症</12>，以及<3>维生素 D3</3>及其代谢物在非泌乳非妊娠和妊娠泽西奶牛血浆中的大量增加。<22>钙</22>浓度在产前约32天使用<4>维生素D3</4>处理的奶牛（8.8 mg/100ml）1天产后高于对照奶牛（5.5mg/100ml）。使用<5>维生素 D3</5>治疗的奶牛在围产期没有出现<17>产奶热</17>的迹象；然而，22%的对照奶牛在此期间出现了<18>产奶热</18>的临床症状。<6>维生素 D3</6><14>毒性</14>的迹象未在非泌乳非妊娠奶牛中观察到；然而，妊娠母牛普遍出现<7>维生素 D3</7><15>毒性</15>的严重体征，17头母牛中有10头死亡。死亡的奶牛有广泛的转移性钙化。由于<8>维生素 D3</8>对怀孕的泽西奶牛具有极端的<16>毒性</16>，并且<9>维生素 D3</9>剂量之间的安全边际较低，可防止<19>牛奶发烧</19>和引起<20>乳热</20>的剂量，我们得出结论，当注射数周前 <10>维生素 D3</10>是无法实际预防<21>乳热</21> 的。", "revised": true}
{"doc_key": "3192036", "sentences": [["Death", "from", "chemotherapy", "in", "gestational", "trophoblastic", "disease", ".", "Multiple", "cytotoxic", "drug", "administration", "is", "the", "generally", "accepted", "treatment", "of", "patients", "with", "a", "high", "-", "risk", "stage", "of", "choriocarcinoma", ".", "Based", "on", "this", "principle", "a", "27", "-", "year", "old", "woman", ",", "classified", "as", "being", "in", "the", "high", "-", "risk", "group", "(", "Goldstein", "and", "Berkowitz", "score", ":", "11", ")", ",", "was", "treated", "with", "multiple", "cytotoxic", "drugs", ".", "The", "multiple", "drug", "schema", "consisted", "of", ":", "Etoposide", "16", ".", "213", ",", "Methotrexate", ",", "Cyclophosphamide", ",", "Actomycin", "-", "D", ",", "and", "Cisplatin", ".", "On", "the", "first", "day", "of", "the", "schedule", ",", "moderate", "high", "doses", "of", "Methotrexate", ",", "Etoposide", "and", "Cyclophosphamide", "were", "administered", ".", "Within", "8", "hours", "after", "initiation", "of", "therapy", "the", "patient", "died", "with", "a", "clinical", "picture", "resembling", "massive", "pulmonary", "obstruction", "due", "to", "choriocarcinomic", "tissue", "plugs", ",", "probably", "originating", "from", "the", "uterus", ".", "Formation", "of", "these", "plugs", "was", "probably", "due", "to", "extensive", "tumor", "necrosis", "at", "the", "level", "of", "the", "walls", "of", "the", "major", "uterine", "veins", ",", "which", "resulted", "in", "an", "open", "exchange", "of", "tumor", "plugs", "to", "the", "vascular", "spaces", ";", "decrease", "in", "tumor", "tissue", "coherence", "secondary", "to", "chemotherapy", "may", "have", "further", "contributed", "to", "the", "formation", "of", "tumor", "emboli", ".", "In", "view", "of", "the", "close", "time", "association", "between", "the", "start", "of", "chemotherapy", "and", "the", "acute", "onset", "of", "massive", "embolism", "other", "explanations", ",", "such", "as", "spontaneous", "necrosis", ",", "must", "be", "considered", "less", "likely", ".", "Patients", "with", "large", "pelvic", "tumor", "loads", "are", ",", "according", "to", "existing", "classifications", ",", "at", "high", "risk", "to", "die", "and", "to", "develop", "drug", "resistance", ".", "Notwithstanding", "these", "facts", "our", "findings", "suggest", "that", "these", "patients", "might", "benefit", "from", "relatively", "mild", "initial", "treatment", ",", "especially", "true", "for", "patients", "not", "previously", "exposed", "to", "this", "drug", ".", "Close", "observation", "of", "the", "response", "status", "both", "clinically", "and", "with", "beta", "-", "hCG", "values", "may", "indicate", "whether", "and", "when", "more", "agressive", "combination", "chemotherapy", "should", "be", "started", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[71, 71, "Chemical"], [101, 101, "Chemical"], [123, 124, "Disease"], [76, 76, "Chemical"], [99, 99, "Chemical"], [78, 78, "Chemical"], [103, 103, "Chemical"], [0, 0, "Disease"], [80, 82, "Chemical"], [85, 85, "Chemical"], [4, 6, "Disease"], [26, 26, "Disease"], [146, 146, "Disease"], [167, 167, "Disease"], [176, 176, "Disease"], [190, 190, "Disease"], [147, 147, "Disease"], [218, 218, "Disease"], [211, 211, "Disease"], [229, 230, "Disease"]]], "relations": [[[71, 71, 123, 124, "CID"], [101, 101, 123, 124, "CID"], [76, 76, 123, 124, "CID"], [99, 99, 123, 124, "CID"], [78, 78, 123, 124, "CID"], [103, 103, 123, 124, "CID"]]], "clusters": [], "translated": "因<10>妊娠滋养细胞疾病</10><0>化疗</0>而<7>死亡</7>。多种细胞毒性药物给药是<11>绒毛膜癌</11>高危期患者普遍接受的治疗方法。根据这一原则，一名27岁的女性被归类为高危组（Goldstein和Berkowitz评分：11），接受了多种细胞毒性药物治疗。多种药物方案包括：<0>依托泊苷</0>16.213、<3>甲氨蝶呤</3>、<5>环磷酰胺</5>、<8>放线菌素-D</8>和<9>顺铂</9>。在时间表的第一天，给予中等高剂量的<1>依托泊苷</1>、<4>甲氨蝶呤</4>和<6>环磷酰胺</6>。治疗开始后8小时内，患者因<2>绒毛膜癌</2>组织栓塞（可能起源于子宫）而死亡，临床表现类似于巨大的<18>肺梗阻</18>。这些栓子的形成可能是由于在主要子宫静脉壁水平的广泛<12>肿瘤</12><16>坏死</16>，导致<13>肿瘤</13>栓塞血管间隙；继发于化疗的<14>肿瘤</14>组织连贯性降低可能进一步促成了<15>肿瘤</15>栓塞的形成。鉴于化疗开始与大量<18>栓塞</18>急性发作之间的密切时间关联，其他解释，例如自发性<17>坏死</17>，必须被认为不太可能。根据现有的分类，<19>盆腔肿瘤</19>负荷大的患者死亡和产生耐药性的风险很高。尽管存在这些事实，但我们的研究结果表明，这些患者可能会受益于相对温和的初始治疗，尤其是对于之前未接触过该药物的患者。密切观察临床和 β-hCG 值的反应状态可能表明是否以及何时应该开始更积极的联合化疗。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "6387529", "sentences": [["Behavioral", "effects", "of", "diazepam", "and", "propranolol", "in", "patients", "with", "panic", "disorder", "and", "agoraphobia", ".", "The", "effects", "of", "oral", "doses", "of", "diazepam", "(", "single", "dose", "of", "10", "mg", "and", "a", "median", "dose", "of", "30", "mg", "/", "day", "for", "2", "weeks", ")", "and", "propranolol", "(", "single", "dose", "of", "80", "mg", "and", "a", "median", "dose", "of", "240", "mg", "/", "day", "for", "2", "weeks", ")", "on", "psychological", "performance", "of", "patients", "with", "panic", "disorders", "and", "agoraphobia", "were", "investigated", "in", "a", "double", "-", "blind", ",", "randomized", "and", "crossover", "design", ".", "Both", "drugs", "impaired", "immediate", "free", "recall", "but", "the", "decrease", "was", "greater", "for", "diazepam", "than", "propranolol", ".", "Delayed", "free", "recall", "was", "also", "impaired", "but", "the", "two", "drugs", "did", "not", "differ", ".", "Patients", "tapped", "faster", "after", "propranolol", "than", "diazepam", "and", "they", "were", "more", "sedated", "after", "diazepam", "than", "propranolol", ".", "After", "2", "weeks", "of", "treatment", ",", "patients", "tested", "5", "-", "8", "h", "after", "the", "last", "dose", "of", "medication", "did", "not", "show", "any", "decrement", "of", "performance", ".", "These", "results", "are", "similar", "to", "those", "previously", "found", "in", "healthy", "subjects", ".", "Accumulation", "of", "drugs", "was", "not", "reflected", "in", "prolonged", "behavioral", "impairment", "."]], "ner": [[[3, 3, "Chemical"], [20, 20, "Chemical"], [96, 96, "Chemical"], [120, 120, "Chemical"], [127, 127, "Chemical"], [86, 89, "Disease"], [100, 105, "Disease"], [5, 5, "Chemical"], [41, 41, "Chemical"], [98, 98, "Chemical"], [118, 118, "Chemical"], [129, 129, "Chemical"], [9, 10, "Disease"], [67, 68, "Disease"], [12, 12, "Disease"], [70, 70, "Disease"], [177, 178, "Disease"]]], "relations": [[[3, 3, 86, 89, "CID"], [3, 3, 100, 105, "CID"], [20, 20, 86, 89, "CID"], [20, 20, 100, 105, "CID"], [96, 96, 86, 89, "CID"], [96, 96, 100, 105, "CID"], [120, 120, 86, 89, "CID"], [120, 120, 100, 105, "CID"], [127, 127, 86, 89, "CID"], [127, 127, 100, 105, "CID"], [5, 5, 86, 89, "CID"], [5, 5, 100, 105, "CID"], [41, 41, 86, 89, "CID"], [41, 41, 100, 105, "CID"], [98, 98, 86, 89, "CID"], [98, 98, 100, 105, "CID"], [118, 118, 86, 89, "CID"], [118, 118, 100, 105, "CID"], [129, 129, 86, 89, "CID"], [129, 129, 100, 105, "CID"]]], "clusters": [], "translated": "<0>地西泮</0>和<7>普萘洛尔</7>对<12>恐慌症</12>和<14>广场恐惧症</14>患者的行为影响。口服剂量<1>地西泮</1>（单次剂量 10 mg，中位剂量 30 mg/天，持续 2 周）和<8>普萘洛尔</8>（单次剂量 80 mg，中位剂量 240 mg/天，持续 2 周）的影响在双盲、随机和交叉设计中研究了对<13>恐慌症</13>和<15>广场恐怖症</15>患者心理表现的影响。两种药物<5>都会损害即时自由回忆</5>，但 <2>地西泮</2> 的降低幅度大于<9>普萘洛尔</9>。<6>延迟自由回忆也受损</6>，但两种药物没有区别。<10>普萘洛尔</10>后患者的拍打速度比<3>地西泮</3>快，而<4>地西泮</4>的镇静效果比<11>普萘洛尔</11>更好。治疗两周后，在最后一次服药后5-8小时接受测试的患者没有表现出任何性能下降。这些结果与之前在健康受试者中发现的结果相似。长期的<16>行为障碍</16>并未反映药物的积累。", "revised": true}
{"doc_key": "6287825", "sentences": [["Diseases", "of", "peripheral", "nerves", "as", "seen", "in", "the", "Nigerian", "African", ".", "The", "anatomical", "and", "aetiological", "diagnoses", "of", "peripheral", "nerve", "disease", "excluding", "its", "primary", "benign", "and", "malignant", "disorders", ",", "as", "seen", "in", "358", "Nigerians", "are", "presented", ".", "There", "is", "a", "male", "preponderance", "and", "the", "peak", "incidence", "is", "in", "the", "fourth", "decade", ".", "Sensori", "-", "motor", "neuropathy", "was", "the", "commonest", "presentation", "(", "50", "%", ")", ".", "Guillain", "-", "Barr", "syndrome", "was", "the", "commonest", "identifiable", "cause", "(", "15", ".", "6", "%", ")", ",", "accounting", "for", "half", "of", "the", "cases", "with", "motor", "neuropathy", ".", "Peripheral", "neuropathy", "due", "to", "nutritional", "deficiency", "of", "thiamine", "and", "riboflavin", "was", "common", "(", "10", ".", "1", "%", ")", "and", "presented", "mainly", "as", "sensory", "and", "sensori", "-", "motor", "neuropathy", ".", "Diabetes", "mellitus", "was", "the", "major", "cause", "of", "autonomic", "neuropathy", ".", "Isoniazid", "was", "the", "most", "frequent", "agent", "in", "drug", "-", "induced", "neuropathy", ".", "Migraine", "(", "20", "%", ")", "was", "not", "an", "uncommon", "cause", "of", "cranial", "neuropathy", "although", "malignancies", "arising", "from", "the", "reticuloendothelial", "system", "or", "related", "structures", "of", "the", "head", "and", "neck", "were", "more", "frequent", "(", "26", "%", ")", ".", "In", "26", ".", "5", "%", "of", "all", "the", "cases", ",", "the", "aetiology", "of", "the", "neuropathy", "was", "undetermined", ".", "Heredofamilial", "and", "connective", "tissue", "disorders", "were", "rare", ".", "Some", "of", "the", "factors", "related", "to", "the", "clinical", "presentation", "and", "pathogenesis", "of", "the", "neuropathies", "are", "briefly", "discussed", "."]], "ner": [[[97, 97, "Chemical"], [0, 3, "Disease"], [17, 19, "Disease"], [51, 54, "Disease"], [87, 88, "Disease"], [90, 91, "Disease"], [114, 117, "Disease"], [99, 99, "Chemical"], [129, 129, "Chemical"], [64, 67, "Disease"], [94, 95, "Disease"], [119, 120, "Disease"], [126, 127, "Disease"], [139, 139, "Disease"], [191, 191, "Disease"], [216, 216, "Disease"], [141, 141, "Disease"], [152, 153, "Disease"], [155, 155, "Disease"], [197, 199, "Disease"]]], "relations": [[[97, 97, 0, 3, "CID"], [97, 97, 17, 19, "CID"], [97, 97, 51, 54, "CID"], [97, 97, 87, 88, "CID"], [97, 97, 90, 91, "CID"], [97, 97, 114, 117, "CID"], [99, 99, 0, 3, "CID"], [99, 99, 17, 19, "CID"], [99, 99, 51, 54, "CID"], [99, 99, 87, 88, "CID"], [99, 99, 90, 91, "CID"], [99, 99, 114, 117, "CID"], [129, 129, 0, 3, "CID"], [129, 129, 17, 19, "CID"], [129, 129, 51, 54, "CID"], [129, 129, 87, 88, "CID"], [129, 129, 90, 91, "CID"], [129, 129, 114, 117, "CID"]]], "clusters": [], "translated": "<1>周围神经疾病</1>见于尼日利亚非洲人。介绍了在358名尼日利亚人中观察到的<2>周围神经疾病</2>的解剖学和病因学诊断，不包括其原发性良性和恶性疾病。男性占优势，发病高峰出现在四十多岁。<3>感觉-运动神经病</3>是最常见的表现 (50%)。<9>格林-巴尔综合征</9>是最常见的可识别原因 (15.6%)，占<4>运动神经病</4>病例的一半。<5>周围神经病变</5>由于<0>硫胺素</0>和<7>核黄素</7>的<10>营养缺乏</10>很常见(10.1%)，主要表现为感觉和<6>感觉-运动神经病</6>。<11>糖尿病</11>是<12>自主神经病变</12>的主要原因。<8>异烟肼</8>是药物引起的<13>神经病</13>中最常见的药物。<16>偏头痛</16> (20%)是<17>颅神经病变</17>的常见原因，尽管由网状内皮系统或头颈部相关结构引起的<18>恶性肿瘤</18>更频繁(26%)。在所有病例中有26.5%的<14>神经病变</14>的病因尚未确定。家族遗传和<19>结缔组织疾病</19>很少见。简要讨论了与<15>神经病</15>的临床表现和发病机制相关的一些因素。", "revised": true}
{"doc_key": "6229975", "sentences": [["Changes", "in", "heart", "size", "during", "long", "-", "term", "timolol", "treatment", "after", "myocardial", "infarction", ".", "The", "effect", "of", "long", "-", "term", "timolol", "treatment", "on", "heart", "size", "after", "myocardial", "infarction", "was", "evaluated", "by", "X", "-", "ray", "in", "a", "double", "-", "blind", "study", "including", "241", "patients", "(", "placebo", "126", ",", "timolol", "115", ")", ".", "The", "follow", "-", "up", "period", "was", "12", "months", ".", "The", "timolol", "-", "treated", "patients", "showed", "a", "small", "but", "significant", "increase", "in", "heart", "size", "from", "baseline", "in", "contrast", "to", "a", "decrease", "in", "the", "placebo", "group", ".", "These", "differences", "may", "be", "caused", "by", "timolol", "-", "induced", "bradycardia", "and", "a", "compensatory", "increase", "in", "end", "-", "diastolic", "volume", ".", "The", "timolol", "-", "related", "increase", "in", "heart", "size", "was", "observed", "only", "in", "patients", "with", "normal", "and", "borderline", "heart", "size", ".", "In", "patients", "with", "cardiomegaly", ",", "the", "increase", "in", "heart", "size", "was", "similar", "in", "both", "groups", ".", "After", "re", "-", "infarction", ",", "heart", "size", "increased", "in", "the", "placebo", "group", "and", "remained", "unchanged", "in", "the", "timolol", "group", "."]], "ner": [[[8, 8, "Chemical"], [20, 20, "Chemical"], [47, 47, "Chemical"], [61, 61, "Chemical"], [92, 92, "Chemical"], [107, 107, "Chemical"], [159, 159, "Chemical"], [129, 129, "Disease"], [11, 12, "Disease"], [26, 27, "Disease"], [95, 95, "Disease"], [145, 145, "Disease"]]], "relations": [[[8, 8, 129, 129, "CID"], [20, 20, 129, 129, "CID"], [47, 47, 129, 129, "CID"], [61, 61, 129, 129, "CID"], [92, 92, 129, 129, "CID"], [107, 107, 129, 129, "CID"], [159, 159, 129, 129, "CID"]]], "clusters": [], "translated": "<8>心肌梗塞</8>后长期<0>噻吗洛尔</0>治疗期间心脏大小的变化。长期<1>噻吗洛尔</1>治疗对<9>心肌梗死</9>后心脏大小的影响，在一项包括241名患者的双盲研究中通过X射线评估（安慰剂126名，<2>噻吗洛尔</2>115）。随访期为12个月。 <3>噻吗洛尔</3>-治疗组患者的心脏大小相对于基线有小幅但显着的增加，而安慰剂组则有所减少。这些差异可能是由<4>噻吗洛尔</4>引起的<10>心动过缓</10>和舒张末期容积代偿性增加引起的。 <5>噻吗洛尔</5>-相关的心脏大小增加仅在心脏大小正常和边缘的患者中观察到。在<7>心脏肥大</7>患者中，两组的心脏大小增加相似。再次<11>心肌梗塞</11>后，安慰剂组的心脏体积增大，而<6>噻吗洛尔</6>组则保持不变。", "revised": true}
{"doc_key": "7265370", "sentences": [["Triamterene", "nephrolithiasis", "complicating", "dyazide", "therapy", ".", "A", "case", "of", "triamterene", "nephrolithiasis", "is", "reported", "in", "a", "man", "after", "4", "years", "of", "hydrochlorothiazide", "-", "triamterene", "therapy", "for", "hypertension", ".", "The", "stone", "passed", "spontaneously", "and", "was", "found", "to", "contain", "a", "triamterene", "metabolite", "admixed", "with", "uric", "acid", "salts", ".", "Factors", "affecting", "triamterene", "nephrolithiasis", "are", "discussed", "and", "2", "previously", "reported", "cases", "are", "reviewed", "."]], "ner": [[[0, 0, "Chemical"], [9, 9, "Chemical"], [37, 37, "Chemical"], [47, 47, "Chemical"], [1, 1, "Disease"], [10, 10, "Disease"], [48, 48, "Disease"], [25, 25, "Disease"], [3, 3, "Chemical"], [20, 22, "Chemical"], [41, 43, "Chemical"]]], "relations": [[[0, 0, 1, 1, "CID"], [0, 0, 10, 10, "CID"], [0, 0, 48, 48, "CID"], [9, 9, 1, 1, "CID"], [9, 9, 10, 10, "CID"], [9, 9, 48, 48, "CID"], [37, 37, 1, 1, "CID"], [37, 37, 10, 10, "CID"], [37, 37, 48, 48, "CID"], [47, 47, 1, 1, "CID"], [47, 47, 10, 10, "CID"], [47, 47, 48, 48, "CID"]]], "clusters": [], "translated": " <0>氨苯蝶啶</0> <4>肾结石</4> 使<8>联肼</8>治疗复杂化。一例男性在<9>氢氯噻嗪-氨苯蝶啶</9>治疗<7>高血压</7>4年后发生<1>氨苯蝶啶</1><5>肾结石</5>。结石自发排出，并被发现含有混合有<10>尿酸盐</10>的<2>氨苯蝶啶</2>代谢物。讨论影响<3>氨苯蝶啶</3><6>肾结石</6>的因素，并回顾2例先前报道的病例。", "revised": true}
{"doc_key": "3437726", "sentences": [["Severe", "complications", "of", "antianginal", "drug", "therapy", "in", "a", "patient", "identified", "as", "a", "poor", "metabolizer", "of", "metoprolol", ",", "propafenone", ",", "diltiazem", ",", "and", "sparteine", ".", "A", "47", "-", "year", "-", "old", "patient", "suffering", "from", "coronary", "artery", "disease", "was", "admitted", "to", "the", "CCU", "in", "shock", "with", "III", ".", "AV", "block", ",", "severe", "hypotension", ",", "and", "impairment", "of", "ventricular", "function", ".", "One", "week", "prior", "to", "admission", "a", "therapy", "with", "standard", "doses", "of", "metoprolol", "(", "100", "mg", "t", ".", "i", ".", "d", ".", "and", "then", "100", "mg", "b", ".", "i", ".", "d", ".", ")", "had", "been", "initiated", ".", "Two", "days", "before", "admission", "diltiazem", "(", "60", "mg", "b", ".", "i", ".", "d", ".", ")", "was", "prescribed", "in", "addition", ".", "Analyses", "of", "a", "blood", "sample", "revealed", "unusually", "high", "plasma", "concentrations", "of", "metoprolol", "(", "greater", "than", "3000", "ng", "/", "ml", ")", "and", "diltiazem", "(", "526", "ng", "/", "ml", ")", ".", "The", "patient", "recovered", "within", "1", "week", "following", "discontinuation", "of", "antianginal", "therapy", ".", "Three", "months", "later", "the", "patient", "was", "exposed", "to", "a", "single", "dose", "of", "metoprolol", ",", "diltiazem", ",", "propafenone", "(", "since", "he", "had", "received", "this", "drug", "in", "the", "past", ")", ",", "and", "sparteine", "(", "as", "a", "probe", "for", "the", "debrisoquine", "/", "sparteine", "type", "polymorphism", "of", "oxidative", "drug", "metabolism", ")", ".", "It", "was", "found", "that", "he", "was", "a", "poor", "metabolizer", "of", "all", "four", "drugs", ",", "indicating", "that", "their", "metabolism", "is", "under", "the", "same", "genetic", "control", ".", "Therefore", ",", "patients", "belonging", "to", "the", "poor", "-", "metabolizer", "phenotype", "of", "sparteine", "/", "debrisoquine", "polymorphism", "in", "drug", "metabolism", ",", "which", "constitutes", "6", ".", "4", "%", "of", "the", "German", "population", ",", "may", "experience", "adverse", "drug", "reactions", "when", "treated", "with", "standard", "doses", "of", "one", "of", "these", "drugs", "alone", ".", "Moreover", ",", "the", "coadministration", "of", "these", "frequently", "used", "drugs", "is", "expected", "to", "be", "especially", "harmful", "in", "this", "subgroup", "of", "patients", "."]], "ner": [[[15, 15, "Chemical"], [69, 69, "Chemical"], [125, 125, "Chemical"], [167, 167, "Chemical"], [46, 47, "Disease"], [50, 50, "Disease"], [53, 56, "Disease"], [19, 19, "Chemical"], [98, 98, "Chemical"], [135, 135, "Chemical"], [169, 169, "Chemical"], [33, 35, "Disease"], [42, 42, "Disease"], [260, 262, "Disease"], [17, 17, "Chemical"], [171, 171, "Chemical"], [22, 22, "Chemical"], [185, 185, "Chemical"], [194, 194, "Chemical"], [239, 239, "Chemical"], [192, 192, "Chemical"], [241, 241, "Chemical"]]], "relations": [[[15, 15, 46, 47, "CID"], [69, 69, 46, 47, "CID"], [125, 125, 46, 47, "CID"], [167, 167, 46, 47, "CID"], [15, 15, 50, 50, "CID"], [69, 69, 50, 50, "CID"], [125, 125, 50, 50, "CID"], [167, 167, 50, 50, "CID"], [15, 15, 53, 56, "CID"], [69, 69, 53, 56, "CID"], [125, 125, 53, 56, "CID"], [167, 167, 53, 56, "CID"], [19, 19, 46, 47, "CID"], [98, 98, 46, 47, "CID"], [135, 135, 46, 47, "CID"], [169, 169, 46, 47, "CID"], [19, 19, 50, 50, "CID"], [98, 98, 50, 50, "CID"], [135, 135, 50, 50, "CID"], [169, 169, 50, 50, "CID"], [19, 19, 53, 56, "CID"], [98, 98, 53, 56, "CID"], [135, 135, 53, 56, "CID"], [169, 169, 53, 56, "CID"]]], "clusters": [], "translated": "患者抗心绞痛药物治疗的严重并发症被确定为<0>美托洛尔</0>、<14>普罗帕酮</14>、<7>地尔硫卓</7>和<16>斯帕特因</16>的弱代谢者。一名患有<11>冠状动脉疾病</11>的47岁患者因<12>休克</12>III.被送入CCU。<4>房室传导阻滞</4>、严重<5>低血压</5>、<6>心室功能障碍</6>。入院前一周开始使用标准剂量的<1>美托洛尔</1>（100mg t.i.d.，然后100mg b.i.d.）治疗。入院前两天，还开了<8>地尔硫卓</8>（60mg b.i.d.）。血样分析显示<2>美托洛尔</2>（大于3000ng/mL）和<9>地尔硫卓</9>（526ng/mL）的血浆浓度异常高。患者在停止抗心绞痛治疗后1周内康复。三个月后，患者接受了单剂量的<3>美托洛尔</3>、<10>地尔硫卓</10>、<15>普罗帕酮</15>（因为他过去接受过这种药物），<17>斯帕特因</17>（作为<20>异喹啉</20>/<18>斯帕特因</18>型氧化药物代谢多态性的探针）。结果发现，他是所有四种药物的弱代谢者，表明它们的代谢受同一基因控制。因此，属于弱代谢表型的患者<19>斯帕特因</19>/<21>异喹啉</21>药物代谢多态性，构成6.4%的德国人在单独使用标准剂量的其中一种药物时可能会出现<13>药物不良反应</13>。此外，这些常用药物的共同给药预计对这一亚组患者尤其有害。", "revised": true}
{"doc_key": "7834920", "sentences": [["Crescentic", "fibrillary", "glomerulonephritis", "associated", "with", "intermittent", "rifampin", "therapy", "for", "pulmonary", "tuberculosis", ".", "This", "case", "study", "reveals", "an", "unusual", "finding", "of", "rapidly", "proliferative", "crescentic", "glomerulonephritis", "in", "a", "patient", "treated", "with", "rifampin", "who", "had", "no", "other", "identifiable", "causes", "for", "developing", "this", "disease", ".", "This", "patient", "underwent", "a", "10", "-", "month", "regimen", "of", "rifampin", "and", "isoniazid", "for", "pulmonary", "tuberculosis", "and", "was", "discovered", "to", "have", "developed", "signs", "of", "severe", "renal", "failure", "five", "weeks", "after", "completion", "of", "therapy", ".", "Renal", "biopsy", "revealed", "severe", "glomerulonephritis", "with", "crescents", ",", "electron", "dense", "fibrillar", "deposits", "and", "moderate", "lymphocytic", "interstitial", "infiltrate", ".", "Other", "possible", "causes", "of", "rapidly", "progressive", "glomerulonephritis", "were", "investigated", "and", "ruled", "out", ".", "This", "report", "documents", "the", "unusual", "occurrence", "of", "rapidly", "progressive", "glomerulonephritis", "with", "crescents", "and", "fibrillar", "glomerulonephritis", "in", "a", "patient", "treated", "with", "rifampin", "."]], "ner": [[[6, 6, "Chemical"], [29, 29, "Chemical"], [50, 50, "Chemical"], [125, 125, "Chemical"], [2, 2, "Disease"], [23, 23, "Disease"], [78, 78, "Disease"], [98, 98, "Disease"], [114, 114, "Disease"], [119, 119, "Disease"], [65, 66, "Disease"], [52, 52, "Chemical"], [9, 10, "Disease"], [54, 55, "Disease"]]], "relations": [[[6, 6, 2, 2, "CID"], [6, 6, 23, 23, "CID"], [6, 6, 78, 78, "CID"], [6, 6, 98, 98, "CID"], [6, 6, 114, 114, "CID"], [6, 6, 119, 119, "CID"], [29, 29, 2, 2, "CID"], [29, 29, 23, 23, "CID"], [29, 29, 78, 78, "CID"], [29, 29, 98, 98, "CID"], [29, 29, 114, 114, "CID"], [29, 29, 119, 119, "CID"], [50, 50, 2, 2, "CID"], [50, 50, 23, 23, "CID"], [50, 50, 78, 78, "CID"], [50, 50, 98, 98, "CID"], [50, 50, 114, 114, "CID"], [50, 50, 119, 119, "CID"], [125, 125, 2, 2, "CID"], [125, 125, 23, 23, "CID"], [125, 125, 78, 78, "CID"], [125, 125, 98, 98, "CID"], [125, 125, 114, 114, "CID"], [125, 125, 119, 119, "CID"], [6, 6, 65, 66, "CID"], [29, 29, 65, 66, "CID"], [50, 50, 65, 66, "CID"], [125, 125, 65, 66, "CID"]]], "clusters": [], "translated": "新月体纤维性<4>肾小球肾炎</4>与间歇性<0>利福平</0>治疗<12>肺结核</12>相关。本案例研究揭示了一名接受<1>利福平</1>治疗的患者出现快速增殖性新月体性<5>肾小球肾炎</5>的异常发现，该患者没有其他可确定的发病原因。该患者接受了为期10个月的<2>利福平</2>和<11>异烟肼</11>治疗<13>肺结核</13>的治疗方案，并被发现出现了严重<10>肾功能衰竭的迹象</10>，完成治疗后五周。肾活检显示重度<6>肾小球肾炎</6>伴新月体、电子致密纤维状沉积物和中度淋巴细胞间质浸润。调查并排除了导致快速进展的<7>肾小球肾炎</7>的其他可能原因。该报告记录了一名接受<3>利福平</3>治疗的患者异常发生快速进展性<8>肾小球肾炎</8>并伴有新月体和纤维状<9>肾小球肾炎</9>。", "revised": true}
{"doc_key": "7444978", "sentences": [["Age", "-", "dependent", "sensitivity", "of", "the", "rat", "to", "neurotoxic", "effects", "of", "streptomycin", ".", "Streptomycin", "sulfate", "(", "300", "mg", "/", "kg", "s", ".", "c", ".", ")", "was", "injected", "for", "various", "periods", "into", "preweanling", "rats", "and", "for", "3", "weeks", "into", "weanling", "rats", ".", "Beginning", "at", "8", "days", "of", "age", ",", "body", "movement", "and", "hearing", "were", "examined", "for", "6", "and", "up", "to", "17", "weeks", ",", "respectively", ".", "Abnormal", "movements", "and", "deafness", "occurred", "only", "in", "rats", "treated", "during", "the", "preweaning", "period", ";", "within", "this", "period", "the", "greatest", "sensitivities", "for", "these", "abnormalities", "occurred", "from", "2", "to", "11", "-", "17", "and", "5", "to", "11", "days", "of", "age", ",", "respectively", ",", "indicating", "that", "the", "cochlea", "is", "more", "sensitive", "to", "streptomycin", "than", "the", "site", "(", "vestibular", "or", "central", ")", "responsible", "for", "the", "dyskinesias", "."]], "ner": [[[11, 11, "Chemical"], [13, 13, "Chemical"], [112, 112, "Chemical"], [64, 65, "Disease"], [124, 124, "Disease"], [67, 67, "Disease"], [8, 8, "Disease"]]], "relations": [[[11, 11, 64, 65, "CID"], [11, 11, 124, 124, "CID"], [13, 13, 64, 65, "CID"], [13, 13, 124, 124, "CID"], [112, 112, 64, 65, "CID"], [112, 112, 124, 124, "CID"], [11, 11, 67, 67, "CID"], [13, 13, 67, 67, "CID"], [112, 112, 67, 67, "CID"]]], "clusters": [], "translated": "大鼠对<0>链霉素</0>的<6>神经毒性</6>作用的年龄依赖性敏感性。 <1>链霉素</1>硫酸盐 (300 mg/kg s.c.)注射到断奶前大鼠的不同时期和3周内注射到断奶大鼠体内。从8日龄开始，分别在6周和17周内检查身体运动和听力。<3>异常运动</3>和<5>耳聋</5>仅发生在断奶前处理的大鼠；在此期间，这些异常的最大敏感性分别发生在2到11-17日龄和5到11日龄，这表明耳蜗对<2>链霉素</2>比部位（前庭或中枢）更敏感，负责<4>运动障碍</4>。", "revised": true}
{"doc_key": "8682684", "sentences": [["Acetaminophen", "-", "induced", "hypotension", ".", "Through", "30", "years", "of", "widespread", "use", ",", "acetaminophen", "has", "been", "shown", "to", "be", "a", "remarkably", "safe", "medication", "in", "therapeutic", "dosages", ".", "The", "potential", "for", "acetaminophen", "to", "produce", "cardiovascular", "toxicities", "is", "very", "low", ".", "However", ",", "acetaminophen", "has", "been", "demonstrated", "to", "produce", "symptoms", "of", "anaphylaxis", ",", "including", "hypotension", ",", "in", "sensitive", "individuals", ".", "This", "article", "describes", "two", "critically", "ill", "patients", "in", "whom", "transient", "episodes", "of", "hypotension", "reproducibly", "developed", "after", "administration", "of", "acetaminophen", ".", "Other", "symptoms", "of", "allergic", "reactions", "were", "not", "clinically", "detectable", ".", "The", "hypotensive", "episodes", "were", "severe", "enough", "to", "require", "vasopressor", "administration", ".", "The", "reports", "illustrate", "the", "need", "for", "clinicians", "to", "consider", "acetaminophen", "in", "patients", "with", "hypotension", "of", "unknown", "origin", "."]], "ner": [[[0, 0, "Chemical"], [12, 12, "Chemical"], [29, 29, "Chemical"], [40, 40, "Chemical"], [75, 75, "Chemical"], [107, 107, "Chemical"], [3, 3, "Disease"], [51, 51, "Disease"], [69, 69, "Disease"], [88, 88, "Disease"], [111, 111, "Disease"], [32, 33, "Disease"], [48, 48, "Disease"], [61, 62, "Disease"], [80, 81, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 51, 51, "CID"], [0, 0, 69, 69, "CID"], [0, 0, 88, 88, "CID"], [0, 0, 111, 111, "CID"], [12, 12, 3, 3, "CID"], [12, 12, 51, 51, "CID"], [12, 12, 69, 69, "CID"], [12, 12, 88, 88, "CID"], [12, 12, 111, 111, "CID"], [29, 29, 3, 3, "CID"], [29, 29, 51, 51, "CID"], [29, 29, 69, 69, "CID"], [29, 29, 88, 88, "CID"], [29, 29, 111, 111, "CID"], [40, 40, 3, 3, "CID"], [40, 40, 51, 51, "CID"], [40, 40, 69, 69, "CID"], [40, 40, 88, 88, "CID"], [40, 40, 111, 111, "CID"], [75, 75, 3, 3, "CID"], [75, 75, 51, 51, "CID"], [75, 75, 69, 69, "CID"], [75, 75, 88, 88, "CID"], [75, 75, 111, 111, "CID"], [107, 107, 3, 3, "CID"], [107, 107, 51, 51, "CID"], [107, 107, 69, 69, "CID"], [107, 107, 88, 88, "CID"], [107, 107, 111, 111, "CID"]]], "clusters": [], "translated": " \n\n<0>对乙酰氨基酚</0> - 引起的<6>低血压</6>。经过30年的广泛使用，<1>对乙酰氨基酚</1>已被证明是治疗剂量非常安全的药物。<2>对乙酰氨基酚</2>产生<11>心血管毒性</11>的可能性非常低。然而，<3>对乙酰氨基酚</3>已被证明会在敏感个体中产生<12>过敏反应</12>的症状，包括<7>低血压</7>。本文介绍了两名<13>危重症</13>患者，他们在服用<4>对乙酰氨基酚</4>后反复出现短暂的<8>低血压</8>发作。<14>过敏反应</14>的其他症状在临床上无法检测到。<9>低血压</9>发作严重到需要使用升压药。这些报告表明临床医生需要考虑使用<5>对乙酰氨基酚</5>治疗不明原因的<10>低血压</10>患者。", "revised": true}
{"doc_key": "7881871", "sentences": [["Time", "course", "of", "lipid", "peroxidation", "in", "puromycin", "aminonucleoside", "-", "induced", "nephropathy", ".", "Reactive", "oxygen", "species", "have", "been", "implicated", "in", "the", "pathogenesis", "of", "acute", "puromycin", "aminonucleoside", "(", "PAN", ")", "-", "induced", "nephropathy", ",", "with", "antioxidants", "significantly", "reducing", "the", "proteinuria", ".", "The", "temporal", "relationship", "between", "lipid", "peroxidation", "in", "the", "kidney", "and", "proteinuria", "was", "examined", "in", "this", "study", ".", "Rats", "were", "treated", "with", "a", "single", "IV", "injection", "of", "puromycin", "aminonucleoside", ",", "(", "PAN", ",", "7", ".", "5", "mg", "/", "kg", ")", "and", "24", "hour", "urine", "samples", "were", "obtained", "prior", "to", "sacrifice", "on", "days", "3", ",", "5", ",", "7", ",", "10", ",", "17", ",", "27", ",", "41", "(", "N", "=", "5", "-", "10", "per", "group", ")", ".", "The", "kidneys", "were", "removed", ",", "flushed", "with", "ice", "cold", "TRIS", "buffer", ".", "Kidney", "cortices", "from", "each", "animal", "were", "used", "to", "prepare", "homogenates", ".", "Tissue", "lipid", "peroxidation", "was", "measured", "in", "whole", "homogenates", "as", "well", "as", "in", "lipid", "extracts", "from", "homogenates", "as", "thiobarbituric", "acid", "reactive", "substances", ".", "Proteinuria", "was", "evident", "at", "day", "5", ",", "peaked", "at", "day", "7", "and", "persisted", "to", "day", "27", ".", "Lipid", "peroxidation", "in", "homogenates", "was", "maximal", "at", "day", "3", "and", "declined", "rapidly", "to", "control", "levels", "by", "day", "17", ".", "This", "study", "supports", "the", "role", "of", "lipid", "peroxidation", "in", "mediating", "the", "proteinuric", "injury", "in", "PAN", "nephropathy", "."]], "ner": [[[6, 7, "Chemical"], [23, 24, "Chemical"], [26, 26, "Chemical"], [65, 66, "Chemical"], [69, 69, "Chemical"], [208, 208, "Chemical"], [10, 10, "Disease"], [30, 30, "Disease"], [209, 209, "Disease"], [37, 37, "Disease"], [49, 49, "Disease"], [158, 158, "Disease"], [205, 206, "Disease"], [13, 13, "Chemical"], [153, 154, "Chemical"]]], "relations": [[[6, 7, 10, 10, "CID"], [6, 7, 30, 30, "CID"], [6, 7, 209, 209, "CID"], [23, 24, 10, 10, "CID"], [23, 24, 30, 30, "CID"], [23, 24, 209, 209, "CID"], [26, 26, 10, 10, "CID"], [26, 26, 30, 30, "CID"], [26, 26, 209, 209, "CID"], [65, 66, 10, 10, "CID"], [65, 66, 30, 30, "CID"], [65, 66, 209, 209, "CID"], [69, 69, 10, 10, "CID"], [69, 69, 30, 30, "CID"], [69, 69, 209, 209, "CID"], [208, 208, 10, 10, "CID"], [208, 208, 30, 30, "CID"], [208, 208, 209, 209, "CID"], [6, 7, 37, 37, "CID"], [6, 7, 49, 49, "CID"], [6, 7, 158, 158, "CID"], [6, 7, 205, 206, "CID"], [23, 24, 37, 37, "CID"], [23, 24, 49, 49, "CID"], [23, 24, 158, 158, "CID"], [23, 24, 205, 206, "CID"], [26, 26, 37, 37, "CID"], [26, 26, 49, 49, "CID"], [26, 26, 158, 158, "CID"], [26, 26, 205, 206, "CID"], [65, 66, 37, 37, "CID"], [65, 66, 49, 49, "CID"], [65, 66, 158, 158, "CID"], [65, 66, 205, 206, "CID"], [69, 69, 37, 37, "CID"], [69, 69, 49, 49, "CID"], [69, 69, 158, 158, "CID"], [69, 69, 205, 206, "CID"], [208, 208, 37, 37, "CID"], [208, 208, 49, 49, "CID"], [208, 208, 158, 158, "CID"], [208, 208, 205, 206, "CID"]]], "clusters": [], "translated": "<0>嘌呤霉素氨基核苷</0><6>肾病</6>脂质过氧化反应的时程。活性<13>氧</13>物种与急性<1>嘌呤霉素氨基核苷</1>（<2>PAN</2>）诱导的<7>肾病</7>的发病机制有关，具有抗氧化剂显着降低<9>蛋白尿</9>。本研究考察了肾脏中脂质过氧化与<10>蛋白尿</10>之间的时间关系。大鼠单次静脉注射<3>嘌呤霉素氨基核苷</3>（<4>PAN</4>，7.5 mg/kg）并在第3天处死前采集24小时尿样，5、7、10、17、27、41（每组N=5-10）。取出肾脏，用冰冷的TRIS缓冲液冲洗。来自每只动物的肾皮质用于制备匀浆。作为<14>硫代巴比妥酸</14>活性物质，组织脂质过氧化在整个匀浆以及来自匀浆的脂质提取物中被测量。<11>蛋白尿</11>在第5天明显，在第7天达到高峰并持续到第27天。匀浆中的脂质过氧化作用在第3天达到最大，并在第17天迅速下降至对照水平。本研究支持脂质过氧化介导<12>蛋白尿损伤</12>在<5>PAN</5><8>肾病</8>中的作用。", "revised": true}
{"doc_key": "8410052", "sentences": [["Immunohistochemical", "studies", "with", "antibodies", "to", "neurofilament", "proteins", "on", "axonal", "damage", "in", "experimental", "focal", "lesions", "in", "rat", ".", "Immunohistochemistry", "with", "monoclonal", "antibodies", "against", "neurofilament", "(", "NF", ")", "proteins", "of", "middle", "and", "high", "molecular", "weight", "class", ",", "NF", "-", "M", "and", "NF", "-", "H", ",", "was", "used", "to", "study", "axonal", "injury", "in", "the", "borderzone", "of", "focal", "lesions", "in", "rats", ".", "Focal", "injury", "in", "the", "cortex", "was", "produced", "by", "infusion", "of", "lactate", "at", "acid", "pH", "or", "by", "stab", "caused", "by", "needle", "insertion", ".", "Infarcts", "in", "substantia", "nigra", "pars", "reticulata", "were", "evoked", "by", "prolonged", "pilocarpine", "-", "induced", "status", "epilepticus", ".", "Immunohistochemical", "staining", "for", "NFs", "showed", "characteristic", "terminal", "clubs", "of", "axons", "in", "the", "borderzone", "of", "lesions", ".", "Differences", "in", "the", "labelling", "pattern", "occurred", "with", "different", "antibodies", "which", "apparently", "depended", "on", "molecular", "weight", "class", "of", "NFs", "and", "phosphorylation", "state", ".", "These", "immunohistochemical", "changes", "of", "NFs", "can", "serve", "as", "a", "marker", "for", "axonal", "damage", "in", "various", "experimental", "traumatic", "or", "ischemic", "lesions", "."]], "ner": [[[90, 90, "Chemical"], [8, 9, "Disease"], [47, 48, "Disease"], [59, 62, "Disease"], [145, 146, "Disease"], [80, 85, "Disease"], [93, 94, "Disease"], [68, 68, "Chemical"], [150, 150, "Disease"]]], "relations": [[[90, 90, 8, 9, "CID"], [90, 90, 47, 48, "CID"], [90, 90, 59, 62, "CID"], [90, 90, 145, 146, "CID"], [90, 90, 80, 85, "CID"], [90, 90, 93, 94, "CID"]]], "clusters": [], "translated": "神经丝蛋白抗体对大鼠实验性局灶性损伤<1>轴突损伤</1>的免疫组织化学研究。利用抗中高分子量神经丝(NF)蛋白NF-M和NF-H的单克隆抗体进行免疫组织化学研究，研究了大鼠局灶性损伤边界区的<2>轴突损伤</2>。皮质中的局灶性<3>损伤</3>是由在酸性pH下输注<7>乳酸</7>或由针插入引起的<3>刺伤</3>引起的。<5>黑质网状部梗死</5>由长期<0>毛果芸香碱</0>诱导的<6>癫痫持续状态</6>诱发。NFs的免疫组织化学染色显示病变边界区有特征性的轴突末端俱乐部。不同抗体的标记模式存在差异，这显然取决于NF的分子量类别和磷酸化状态。NF的这些免疫组织化学变化可作为各种实验性<8>创伤性</8>或缺血性病变中<4>轴突损伤</4>的标志物。", "revised": true}
{"doc_key": "7423039", "sentences": [["Metabolic", "involvement", "in", "adriamycin", "cardiotoxicity", ".", "The", "cardiotoxic", "effects", "of", "adriamycin", "were", "studied", "in", "mammalian", "myocardial", "cells", "in", "culture", "as", "a", "model", "system", ".", "Adriamycin", "inhibited", "cell", "growth", "and", "the", "rhythmic", "contractions", "characteristic", "of", "myocardial", "cells", "in", "culture", ".", "A", "possible", "involvement", "of", "energy", "metabolism", "was", "suggested", "previously", ",", "and", "in", "this", "study", "the", "adenylate", "energy", "charge", "and", "phosphorylcreatine", "mole", "fraction", "were", "determined", "in", "the", "adriamycin", "-", "treated", "cells", ".", "The", "adenylate", "energy", "charge", "was", "found", "to", "be", "significantly", "decreased", ",", "while", "the", "phophorylcreatine", "mole", "fraction", "was", "unchanged", ".", "Such", "disparity", "suggests", "an", "inhibition", "of", "creatine", "phosphokinase", ".", "The", "addition", "of", "1", "mM", "adenosine", "to", "the", "myocardial", "cell", "cultures", "markedly", "increases", "the", "ATP", "concentration", "through", "a", "pathway", "reportedly", "leading", "to", "a", "compartmentalized", "ATP", "pool", ".", "In", "the", "adriamycin", "-", "treated", "cells", ",", "the", "addition", "of", "adenosine", "increased", "the", "adenylate", "charge", "and", ",", "concomitant", "with", "this", "inrcease", ",", "the", "cells", "'", "functional", "integrity", ",", "in", "terms", "of", "percentage", "of", "beating", "cells", "and", "rate", "of", "contractions", ",", "was", "maintained", "."]], "ner": [[[3, 3, "Chemical"], [10, 10, "Chemical"], [24, 24, "Chemical"], [65, 65, "Chemical"], [127, 127, "Chemical"], [4, 4, "Disease"], [7, 7, "Disease"], [58, 58, "Chemical"], [83, 83, "Chemical"], [95, 95, "Chemical"], [103, 103, "Chemical"], [135, 135, "Chemical"], [112, 112, "Chemical"], [122, 122, "Chemical"]]], "relations": [[[3, 3, 4, 4, "CID"], [3, 3, 7, 7, "CID"], [10, 10, 4, 4, "CID"], [10, 10, 7, 7, "CID"], [24, 24, 4, 4, "CID"], [24, 24, 7, 7, "CID"], [65, 65, 4, 4, "CID"], [65, 65, 7, 7, "CID"], [127, 127, 4, 4, "CID"], [127, 127, 7, 7, "CID"]]], "clusters": [], "translated": "代谢参与<0>阿霉素</0> <5>心脏毒性</5>。以培养的哺乳动物心肌细胞为模型系统，研究了<1>阿霉素</1>的<6>心脏毒性</6>作用。<2>阿霉素</2>抑制培养物中心肌细胞的细胞生长和节律性收缩特征。先前提出可能涉及能量代谢，在本研究中，测定了<3>阿霉素</3>处理的细胞中的腺苷酸能荷和<7>磷酸肌酸</7>摩尔分数。发现腺苷酸能量电荷显着降低，而<8>磷酸肌酸</8>摩尔分数没有变化。这种差异表明<9>肌酸磷酸激酶</9>受到抑制。向心肌细胞培养物中添加1 mM<10>腺苷</10>会显着增加<12>ATP</12>浓度，据报道，该途径会导致区域化的<13>ATP</13>池。在<4>阿霉素</4>处理的细胞中，添加<11>腺苷</11>增加了腺苷酸电荷，伴随着这种增加，细胞的功能完整性，以跳动细胞的百分比和宫缩率，维持不变。", "revised": true}
{"doc_key": "11419773", "sentences": [["Caffeine", "-", "induced", "cardiac", "arrhythmia", ":", "an", "unrecognised", "danger", "of", "healthfood", "products", ".", "We", "describe", "a", "25", "-", "year", "-", "old", "woman", "with", "pre", "-", "existing", "mitral", "valve", "prolapse", "who", "developed", "intractable", "ventricular", "fibrillation", "after", "consuming", "a", "\"", "natural", "energy", "\"", "guarana", "health", "drink", "containing", "a", "high", "concentration", "of", "caffeine", ".", "This", "case", "highlights", "the", "need", "for", "adequate", "labelling", "and", "regulation", "of", "such", "products", "."]], "ner": [[[0, 0, "Chemical"], [49, 49, "Chemical"], [32, 33, "Disease"], [3, 4, "Disease"], [26, 28, "Disease"]]], "relations": [[[0, 0, 32, 33, "CID"], [49, 49, 32, 33, "CID"]]], "clusters": [], "translated": "<0>咖啡因</0>引起的<3>心律失常</3>：健康食品的一种未被认识的危险。我们描述了一名患有<4>二尖瓣脱垂</4>的25岁女性，她在饮用一种含有高浓度<1>咖啡因</1>的 \"天然能量\"瓜拉纳（一种含咖啡因的饮料）饮品后，发展出顽固的<2>室颤</2>。该案例凸显了对此类产品进行适当标识和监管的必要性。", "revised": true}
{"doc_key": "7930386", "sentences": [["Clomipramine", "-", "induced", "sleep", "disturbance", "does", "not", "impair", "its", "prolactin", "-", "releasing", "action", ".", "The", "present", "study", "was", "undertaken", "to", "examine", "the", "role", "of", "sleep", "disturbance", ",", "induced", "by", "clomipramine", "administration", ",", "on", "the", "secretory", "rate", "of", "prolactin", "(", "PRL", ")", "in", "addition", "to", "the", "direct", "drug", "effect", ".", "Two", "groups", "of", "supine", "subjects", "were", "studied", "under", "placebo", "-", "controlled", "conditions", ",", "one", "during", "the", "night", ",", "when", "sleeping", "(", "n", "=", "7", ")", "and", "the", "other", "at", "daytime", ",", "when", "awake", "(", "n", "=", "6", ")", ".", "Each", "subject", "received", "a", "single", "50", "mg", "dose", "of", "clomipramine", "given", "orally", "2", "hours", "before", "blood", "collection", ".", "Plasma", "PRL", "concentrations", "were", "analysed", "at", "10", "min", "intervals", "and", "underlying", "secretory", "rates", "calculated", "by", "a", "deconvolution", "procedure", ".", "For", "both", "experiments", "the", "drug", "intake", "led", "to", "significant", "increases", "in", "PRL", "secretion", ",", "acting", "preferentially", "on", "tonic", "secretion", "as", "pulse", "amplitude", "and", "frequency", "did", "not", "differ", "significantly", "from", "corresponding", "control", "values", ".", "During", "the", "night", "clomipramine", "ingestion", "altered", "the", "complete", "sleep", "architecture", "in", "that", "it", "suppressed", "REM", "sleep", "and", "the", "sleep", "cycles", "and", "induced", "increased", "wakefulness", ".", "As", "the", "relative", "increase", "in", "PRL", "secretion", "expressed", "as", "a", "percentage", "of", "the", "mean", "did", "not", "significantly", "differ", "between", "the", "night", "and", "day", "time", "studies", "(", "46", "+", "/", "-", "19", "%", "vs", "34", "+", "/", "-", "10", "%", ")", ",", "it", "can", "be", "concluded", "that", "the", "observed", "sleep", "disturbance", "did", "not", "interfere", "with", "the", "drug", "action", "per", "se", ".", "The", "presence", "of", "REM", "sleep", "was", "shown", "not", "to", "be", "a", "determining", "factor", "either", "for", "secretory", "pulse", "amplitude", "and", "frequency", ",", "as", ",", "for", "both", ",", "mean", "nocturnal", "values", "were", "similar", "with", "and", "without", "prior", "clomipramine", "ingestion", "."]], "ner": [[[0, 0, "Chemical"], [29, 29, "Chemical"], [97, 97, "Chemical"], [161, 161, "Chemical"], [278, 278, "Chemical"], [3, 4, "Disease"], [24, 25, "Disease"], [231, 232, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 24, 25, "CID"], [0, 0, 231, 232, "CID"], [29, 29, 3, 4, "CID"], [29, 29, 24, 25, "CID"], [29, 29, 231, 232, "CID"], [97, 97, 3, 4, "CID"], [97, 97, 24, 25, "CID"], [97, 97, 231, 232, "CID"], [161, 161, 3, 4, "CID"], [161, 161, 24, 25, "CID"], [161, 161, 231, 232, "CID"], [278, 278, 3, 4, "CID"], [278, 278, 24, 25, "CID"], [278, 278, 231, 232, "CID"]]], "clusters": [], "translated": " <0>氯米帕明</0>引起的<5>睡眠障碍</5>不会影响其催乳素释放作用。本研究旨在检验<6>睡眠障碍</6>，由<1>氯米帕明</1> 给药引起的，对催乳素 (PRL) 分泌率的影响，除直接药物作用外。两组仰卧受试者在安慰剂对照条件下进行研究，一组在夜间睡觉时(n = 7)，另一组在白天清醒时(n = 6)。每名受试者在采血前2小时接受单次50 mg 剂量的<2>氯米帕明</2>口服给药。每隔10分钟分析一次血浆PRL浓度，并通过去卷积程序计算潜在的分泌率。对于这两个实验，药物摄入导致PRL分泌显着增加，优先作用于强直分泌，因为脉冲幅度和频率与相应的对照值没有显着差异。在夜间<3>氯米帕明</3>摄入改变了完整的睡眠结构，因为它抑制了REM 睡眠和睡眠周期，并导致觉醒增加。由于以平均值百分比表示的PRL分泌的相对增加在夜间和白天时间研究之间没有显着差异（46 + / - 19 %对比 34 + / - 10%），可以得出结论，观察到的<7>睡眠障碍</7>本身不干扰药物作用。事实证明，REM睡眠的存在不是分泌脉冲幅度和频率的决定性因素，因为对于两者而言，无论是否服用过<4>氯米帕明</4>，夜间的平均值都相似。", "revised": true}
{"doc_key": "9766615", "sentences": [["Adverse", "effects", "of", "the", "atypical", "antipsychotics", ".", "Collaborative", "Working", "Group", "on", "Clinical", "Trial", "Evaluations", ".", "Adverse", "effects", "of", "antipsychotics", "often", "lead", "to", "noncompliance", ".", "Thus", ",", "clinicians", "should", "address", "patients", "'", "concerns", "about", "adverse", "effects", "and", "attempt", "to", "choose", "medications", "that", "will", "improve", "their", "patients", "'", "quality", "of", "life", "as", "well", "as", "overall", "health", ".", "The", "side", "effect", "profiles", "of", "the", "atypical", "antipsychotics", "are", "more", "advantageous", "than", "those", "of", "the", "conventional", "neuroleptics", ".", "Conventional", "agents", "are", "associated", "with", "unwanted", "central", "nervous", "system", "effects", ",", "including", "extrapyramidal", "symptoms", "(", "EPS", ")", ",", "tardive", "dyskinesia", ",", "sedation", ",", "and", "possible", "impairment", "of", "some", "cognitive", "measures", ",", "as", "well", "as", "cardiac", "effects", ",", "orthostatic", "hypotension", ",", "hepatic", "changes", ",", "anticholinergic", "side", "effects", ",", "sexual", "dysfunction", ",", "and", "weight", "gain", ".", "The", "newer", "atypical", "agents", "have", "a", "lower", "risk", "of", "EPS", ",", "but", "are", "associated", "in", "varying", "degrees", "with", "sedation", ",", "cardiovascular", "effects", ",", "anticholinergic", "effects", ",", "weight", "gain", ",", "sexual", "dysfunction", ",", "hepatic", "effects", ",", "lowered", "seizure", "threshold", "(", "primarily", "clozapine", ")", ",", "and", "agranulocytosis", "(", "clozapine", "only", ")", ".", "Since", "the", "incidence", "and", "severity", "of", "specific", "adverse", "effects", "differ", "among", "the", "various", "atypicals", ",", "the", "clinician", "should", "carefully", "consider", "which", "side", "effects", "are", "most", "likely", "to", "lead", "to", "the", "individual", "'s", "dissatisfaction", "and", "noncompliance", "before", "choosing", "an", "antipsychotic", "for", "a", "particular", "patient", "."]], "ner": [[[167, 167, "Chemical"], [173, 173, "Chemical"], [171, 171, "Disease"], [85, 86, "Disease"], [88, 88, "Disease"], [136, 136, "Disease"], [91, 92, "Disease"], [110, 111, "Disease"], [120, 121, "Disease"], [156, 157, "Disease"], [124, 125, "Disease"], [153, 154, "Disease"], [163, 163, "Disease"]]], "relations": [[[167, 167, 171, 171, "CID"], [173, 173, 171, 171, "CID"]]], "clusters": [], "translated": "非典型抗精神病药的副作用。临床试验评估合作工作组。抗精神病药的副作用常常导致不依从。因此，临床医生应该解决患者对不良反应的担忧，并尝试选择能够改善患者生活质量和整体健康的药物。非典型抗精神病药物的副作用特征比常规抗精神病药物的副作用特征更有利。常规药物与不良的中枢神经系统影响相关，包括<3>锥体外系症状</3>（<4>EPS</4>）、<6>迟发性运动障碍</6>、镇静和某些认知能力可能受损措施，以及心脏影响、<7>体位性低血压</7>、肝脏变化、抗胆碱能副作用、<8>性功能障碍</8>和<10>体重增加</10>。较新的非典型药物具有较低的<5>EPS</5>风险，但在不同程度上与镇静、心血管作用、抗胆碱能作用、<11>体重增加</11>、<9>性功能障碍</9>、肝效应、降低<12>癫痫发作阈值</12>（主要是<0>氯氮平</0>）和<2>粒细胞缺乏症</2>（仅<1>氯氮平</1>）。由于各种非典型药物的特定不良反应的发生率和严重程度各不相同，临床医生在为特定患者选择抗精神病药之前应仔细考虑哪些副作用最有可能导致个体的不满和不依从。", "revised": true}
{"doc_key": "7988234", "sentences": [["Angioedema", "following", "the", "intravenous", "administration", "of", "metoprolol", ".", "A", "72", "-", "year", "-", "old", "woman", "was", "admitted", "to", "the", "hospital", "with", "\"", "flash", "\"", "pulmonary", "edema", ",", "preceded", "by", "chest", "pain", ",", "requiring", "intubation", ".", "Her", "medical", "history", "included", "coronary", "artery", "disease", "with", "previous", "myocardial", "infarctions", ",", "hypertension", ",", "and", "diabetes", "mellitus", ".", "A", "history", "of", "angioedema", "secondary", "to", "lisinopril", "therapy", "was", "elicited", ".", "Current", "medications", "did", "not", "include", "angiotensin", "-", "converting", "enzyme", "inhibitors", "or", "beta", "-", "blockers", ".", "She", "had", "no", "previous", "beta", "-", "blocking", "drug", "exposure", ".", "During", "the", "first", "day", "of", "hospitalization", "(", "while", "intubated", ")", ",", "intravenous", "metoprolol", "was", "given", ",", "resulting", "in", "severe", "angioedema", ".", "The", "angioedema", "resolved", "after", "therapy", "with", "intravenous", "steroids", "and", "diphenhydramine", "hydrochloride", "."]], "ner": [[[6, 6, "Chemical"], [101, 101, "Chemical"], [0, 0, "Disease"], [56, 56, "Disease"], [108, 108, "Disease"], [111, 111, "Disease"], [59, 59, "Chemical"], [69, 69, "Chemical"], [117, 117, "Chemical"], [119, 119, "Chemical"], [24, 25, "Disease"], [29, 30, "Disease"], [39, 41, "Disease"], [44, 45, "Disease"], [47, 47, "Disease"], [50, 51, "Disease"]]], "relations": [[[6, 6, 0, 0, "CID"], [6, 6, 56, 56, "CID"], [6, 6, 108, 108, "CID"], [6, 6, 111, 111, "CID"], [101, 101, 0, 0, "CID"], [101, 101, 56, 56, "CID"], [101, 101, 108, 108, "CID"], [101, 101, 111, 111, "CID"], [59, 59, 0, 0, "CID"], [59, 59, 56, 56, "CID"], [59, 59, 108, 108, "CID"], [59, 59, 111, 111, "CID"]]], "clusters": [], "translated": " <2>血管性水肿</2> 静脉注射<0>美托洛尔</0>后。一名72岁的女性因“闪现”<10>肺水肿</10>入院，随后出现<11>胸痛</11>，需要插管。她的病史包括<12>冠状动脉疾病</12>和既往<13>心肌梗塞</13>、<14>高血压</14>和<15>糖尿病</15>。<3>血管性水肿</3>继发于<6>赖诺普利</6>治疗的病史。目前的药物不包括<7>血管紧张素</7>-转换酶抑制剂或β-受体阻滞剂。她以前没有接触过β受体阻滞剂。在住院的第一天（插管期间），静脉注射<1>美托洛尔</1>，导致严重的<4>血管性水肿</4>。<5>血管性水肿</5>在静脉<8>类固醇</8>和<9>苯海拉明</9>盐酸盐治疗后消退。", "revised": true}
{"doc_key": "6692345", "sentences": [["Effect", "of", "aspirin", "on", "N", "-", "[", "4", "-", "(", "5", "-", "nitro", "-", "2", "-", "furyl", ")", "-", "2", "-", "thiazolyl", "]", "-", "formamide", "-", "induced", "epithelial", "proliferation", "in", "the", "urinary", "bladder", "and", "forestomach", "of", "the", "rat", ".", "The", "co", "-", "administration", "of", "aspirin", "with", "N", "-", "[", "4", "-", "(", "5", "-", "nitro", "-", "2", "-", "furyl", ")", "-", "2", "-", "thiazolyl", "]", "-", "formamide", "(", "FANFT", ")", "to", "rats", "resulted", "in", "a", "reduced", "incidence", "of", "FANFT", "-", "induced", "bladder", "carcinomas", "but", "a", "concomitant", "induction", "of", "forestomach", "tumors", ".", "An", "autoradiographic", "study", "was", "performed", "on", "male", "F", "-", "344", "rats", "fed", "diet", "containing", "FANFT", "at", "a", "level", "of", "0", ".", "2", "%", "and", "/", "or", "aspirin", "at", "a", "level", "of", "0", ".", "5", "%", "to", "evaluate", "the", "effect", "of", "aspirin", "on", "the", "increased", "cell", "proliferation", "induced", "by", "FANFT", "in", "the", "forestomach", "and", "bladder", ".", "FANFT", "-", "induced", "cell", "proliferation", "in", "the", "bladder", "was", "significantly", "suppressed", "by", "aspirin", "co", "-", "administration", "after", "4", "weeks", "but", "not", "after", "12", "weeks", ".", "In", "the", "forestomach", ",", "and", "also", "in", "the", "liver", ",", "aspirin", "did", "not", "affect", "the", "FANFT", "-", "induced", "increase", "in", "labeling", "index", ".", "The", "present", "results", "are", "consistent", "with", "the", "carcinogenicity", "experiment", "suggesting", "that", "different", "mechanisms", "are", "involved", "in", "FANFT", "carcinogenesis", "in", "the", "bladder", "and", "forestomach", ",", "and", "that", "aspirin", "'s", "effect", "on", "FANFT", "in", "the", "forestomach", "is", "not", "due", "to", "an", "irritant", "effect", "associated", "with", "increased", "cell", "proliferation", ".", "Also", ",", "there", "appears", "to", "be", "an", "adaptation", "by", "the", "rats", "to", "the", "chronic", "ingestion", "of", "aspirin", "."]], "ner": [[[4, 24, "Chemical"], [46, 66, "Chemical"], [68, 68, "Chemical"], [78, 78, "Chemical"], [105, 105, "Chemical"], [139, 139, "Chemical"], [146, 146, "Chemical"], [186, 186, "Chemical"], [210, 210, "Chemical"], [224, 224, "Chemical"], [81, 82, "Disease"], [88, 89, "Disease"], [2, 2, "Chemical"], [44, 44, "Chemical"], [117, 117, "Chemical"], [131, 131, "Chemical"], [158, 158, "Chemical"], [181, 181, "Chemical"], [220, 220, "Chemical"], [257, 257, "Chemical"], [211, 211, "Disease"]]], "relations": [[[4, 24, 81, 82, "CID"], [46, 66, 81, 82, "CID"], [68, 68, 81, 82, "CID"], [78, 78, 81, 82, "CID"], [105, 105, 81, 82, "CID"], [139, 139, 81, 82, "CID"], [146, 146, 81, 82, "CID"], [186, 186, 81, 82, "CID"], [210, 210, 81, 82, "CID"], [224, 224, 81, 82, "CID"], [4, 24, 88, 89, "CID"], [46, 66, 88, 89, "CID"], [68, 68, 88, 89, "CID"], [78, 78, 88, 89, "CID"], [105, 105, 88, 89, "CID"], [139, 139, 88, 89, "CID"], [146, 146, 88, 89, "CID"], [186, 186, 88, 89, "CID"], [210, 210, 88, 89, "CID"], [224, 224, 88, 89, "CID"]]], "clusters": [], "translated": "<12>阿司匹林</12>对<0>N-[4-(5-硝基-2-呋喃基)-2-噻唑基]-甲酰胺</0>诱导的膀胱和前胃上皮增生的影响。 <13>阿司匹林</13>与<1>N-[4-(5-硝基-2-呋喃基)-2-噻唑基]-甲酰胺</1>（<2>FANFT</2>）合用于大鼠，可减少<3> FANFT </3>诱发的<10> 膀胱癌 </10>的发病率，但同时诱发<11>前胃肿瘤</11>。对喂食含有水平为0.2%的<4>FANFT</4>和/或0.5%的<14>阿司匹林</14>的雄性F-344大鼠进行放射自显影研究，评估<15>阿司匹林</15>对<5>FANFT</5>在前胃和膀胱诱导的细胞增殖的影响。<6> FANFT </6>诱导的膀胱细胞增殖在4周后被<16> 阿司匹林 </16>合用显着抑制，但在12周后没有。而在前胃和肝脏中，<17>阿司匹林</17>不影响<7>FANFT</7>诱导的标记指数的增加。目前的结果与致癌性实验一致，表明不同的机制参与了膀胱和前胃的<8> FANFT </8><20>致癌作用</20>，并且<18>阿司匹林</18>对前胃<9>FANFT</9>的影响不是由于与细胞增殖的增加相关的刺激作用。此外，看起来老鼠对长期服用<19>阿司匹林</19>已有适应。", "revised": true}
{"doc_key": "8423889", "sentences": [["Increase", "of", "Parkinson", "disability", "after", "fluoxetine", "medication", ".", "Depression", "is", "a", "major", "clinical", "feature", "of", "Parkinson", "'s", "disease", ".", "We", "report", "the", "increased", "amount", "of", "motor", "disability", "in", "four", "patients", "with", "idiopathic", "Parkinson", "'s", "disease", "after", "exposure", "to", "the", "antidepressant", "fluoxetine", ".", "The", "possibility", "of", "a", "clinically", "relevant", "dopamine", "-", "antagonistic", "capacity", "of", "fluoxetine", "in", "Parkinson", "'s", "disease", "patients", "must", "be", "considered", "."]], "ner": [[[5, 5, "Chemical"], [40, 40, "Chemical"], [53, 53, "Chemical"], [2, 3, "Disease"], [25, 26, "Disease"], [39, 39, "Chemical"], [48, 48, "Chemical"], [8, 8, "Disease"], [15, 17, "Disease"], [31, 34, "Disease"], [55, 57, "Disease"]]], "relations": [[[5, 5, 2, 3, "CID"], [5, 5, 25, 26, "CID"], [40, 40, 2, 3, "CID"], [40, 40, 25, 26, "CID"], [53, 53, 2, 3, "CID"], [53, 53, 25, 26, "CID"]]], "clusters": [], "translated": "<0>氟西汀</0>药物治疗后<3>帕金森功能障碍</3>的增加。 <7>抑郁</7>是<8>帕金森病</8>的主要临床特征。我们报告了四名患有<9>特发性帕金森病</9>的患者，接触 <5>抗抑郁药</5><1>氟西汀</1>后<4>运动障碍</4>的增加。必须考虑 <10>帕金森病</10>患者<2>氟西汀</2>的临床相关<6>多巴胺</6>拮抗能力的可能性。", "revised": true}
{"doc_key": "10193204", "sentences": [["Effects", "of", "tetrandrine", "and", "fangchinoline", "on", "experimental", "thrombosis", "in", "mice", "and", "human", "platelet", "aggregation", ".", "Tetrandrine", "(", "TET", ")", "and", "fangchinoline", "(", "FAN", ")", "are", "two", "naturally", "occurring", "analogues", "with", "a", "bisbenzylisoquinoline", "structure", ".", "The", "present", "study", "was", "undertaken", "to", "investigate", "the", "effects", "of", "TET", "and", "FAN", "on", "the", "experimental", "thrombosis", "induced", "by", "collagen", "plus", "epinephrine", "(", "EP", ")", "in", "mice", ",", "and", "platelet", "aggregation", "and", "blood", "coagulation", "in", "vitro", ".", "In", "the", "in", "vivo", "study", ",", "the", "administration", "(", "50", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", "of", "TET", "and", "FAN", "in", "mice", "showed", "the", "inhibition", "of", "thrombosis", "by", "55", "%", "and", "35", "%", ",", "respectively", ",", "while", "acetylsalicylic", "acid", "(", "ASA", ",", "50", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", ",", "a", "positive", "control", ",", "showed", "only", "30", "%", "inhibition", ".", "In", "the", "vitro", "human", "platelet", "aggregations", "induced", "by", "the", "agonists", "used", "in", "tests", ",", "TET", "and", "FAN", "showed", "the", "inhibitions", "dose", "dependently", ".", "In", "addition", ",", "neither", "TET", "nor", "FAN", "showed", "any", "anticoagulation", "activities", "in", "the", "measurement", "of", "the", "activated", "partial", "thromboplastin", "time", "(", "APTT", ")", ",", "prothrombin", "time", "(", "PT", ")", "and", "thrombin", "time", "(", "TT", ")", "using", "human", "-", "citrated", "plasma", ".", "These", "results", "suggest", "that", "antithrombosis", "of", "TET", "and", "FAN", "in", "mice", "may", "be", "mainly", "related", "to", "the", "antiplatelet", "aggregation", "activities", "."]], "ner": [[[55, 55, "Chemical"], [57, 57, "Chemical"], [7, 7, "Disease"], [50, 50, "Disease"], [100, 100, "Disease"], [2, 2, "Chemical"], [15, 15, "Chemical"], [17, 17, "Chemical"], [44, 44, "Chemical"], [91, 91, "Chemical"], [151, 151, "Chemical"], [164, 164, "Chemical"], [207, 207, "Chemical"], [12, 13, "Disease"], [63, 64, "Disease"], [141, 142, "Disease"], [66, 67, "Disease"], [4, 4, "Chemical"], [20, 20, "Chemical"], [22, 22, "Chemical"], [46, 46, "Chemical"], [93, 93, "Chemical"], [153, 153, "Chemical"], [166, 166, "Chemical"], [209, 209, "Chemical"], [31, 31, "Chemical"], [111, 112, "Chemical"], [114, 114, "Chemical"]]], "relations": [[[55, 55, 7, 7, "CID"], [55, 55, 50, 50, "CID"], [55, 55, 100, 100, "CID"], [57, 57, 7, 7, "CID"], [57, 57, 50, 50, "CID"], [57, 57, 100, 100, "CID"]]], "clusters": [], "translated": "<5>粉防己碱</5>和<17>防己啉</17>对小鼠实验性<2>血栓形成</2>和人<13>血小板聚集</13>的影响。 <6>粉防己碱</6>（<7>TET</7>）和<18>防己啉</18>（<19>FAN</19>）是两种天然存在的类似物，具有<25>双苄基异喹啉</25>结构。本研究旨在研究<8>TET</8>和<20>FAN</20>对胶原加<0>肾上腺素</0>（<1>EP</1>）诱导的实验性<3>血栓形成</3>在小鼠体内的影响，以及在体外模型中对<14>血小板聚集</14>和<16>血液凝固</16>的影响。在小鼠体内给药（50mg/kg，i.p.）<9>TET</9>和<21>FAN</21>分别显示出55％和35％的抑制<4>血栓形成</4>，而阳性对照<26>乙酰水杨酸</26>（<27>ASA</27>，50mg / kg，i.p.）仅显示了30％的抑制。在体外对试验中使用的激动剂诱导的人<15>血小板聚集</15>中，<10>TET</10>和<22>FAN</22>表示剂量依赖性抑制。此外，在血浆中使用活化部分凝血活酶时间（APTT），凝血酶原时间（PT）和凝血酶时间（TT）进行测量时，<11>TET</11>和<23>FAN</23>均未显示任何抗凝活性。这些结果表明<12>TET</12>和<24>FAN</24>在小鼠体内的抗血栓作用可能主要与抗血小板聚集活性有关。", "revised": true}
{"doc_key": "9625142", "sentences": [["Acute", "hepatitis", ",", "autoimmune", "hemolytic", "anemia", ",", "and", "erythroblastocytopenia", "induced", "by", "ceftriaxone", ".", "An", "80", "-", "yr", "-", "old", "man", "developed", "acute", "hepatitis", "shortly", "after", "ingesting", "oral", "ceftriaxone", ".", "Although", "the", "transaminases", "gradually", "returned", "to", "baseline", "after", "withholding", "the", "beta", "lactam", "antibiotic", ",", "there", "was", "a", "gradual", "increase", "in", "serum", "bilirubin", "and", "a", "decrease", "in", "hemoglobin", "concentration", "caused", "by", "an", "autoimmune", "hemolytic", "anemia", "and", "erythroblastocytopenia", ".", "These", "responded", "to", "systemic", "steroids", "and", "immunoglobulins", ".", "Despite", "the", "widespread", "use", "of", "these", "agents", "this", "triad", "of", "side", "effects", "has", "not", "previously", "been", "reported", "in", "connection", "with", "beta", "lactam", "antibiotics", "."]], "ner": [[[11, 11, "Chemical"], [27, 27, "Chemical"], [1, 1, "Disease"], [22, 22, "Disease"], [3, 5, "Disease"], [60, 62, "Disease"], [39, 40, "Chemical"], [94, 95, "Chemical"], [50, 50, "Chemical"], [70, 70, "Chemical"]]], "relations": [[[11, 11, 1, 1, "CID"], [11, 11, 22, 22, "CID"], [27, 27, 1, 1, "CID"], [27, 27, 22, 22, "CID"], [11, 11, 3, 5, "CID"], [11, 11, 60, 62, "CID"], [27, 27, 3, 5, "CID"], [27, 27, 60, 62, "CID"]]], "clusters": [], "translated": "<0>头孢曲松</0>引起的急性<2>肝炎</2>、<4>自身免疫性溶血性贫血</4>和红细胞减少症。一名80岁的男性在口服<1>头孢曲松</1>后不久患上了急性<3>肝炎</3>。虽然停用<6>β内酰胺</6>抗生素后转氨酶逐渐恢复到基线水平，但由于<5>自身免疫性溶血性贫血</5>和红细胞减少症导致血清<8>胆红素</8>逐渐升高和血红蛋白浓度降低。这些对全身性<9>类固醇</9>和免疫球蛋白有反应。尽管这些药物被广泛使用，但以前尚未报道与<7>β内酰胺</7>抗生素有关的这三联副作用。", "revised": true}
{"doc_key": "11581460", "sentences": [["Bladder", "retention", "of", "urine", "as", "a", "result", "of", "continuous", "intravenous", "infusion", "of", "fentanyl", ":", "2", "case", "reports", ".", "Sedation", "has", "been", "commonly", "used", "in", "the", "neonate", "to", "decrease", "the", "stress", "and", "pain", "from", "the", "noxious", "stimuli", "and", "invasive", "procedures", "in", "the", "neonatal", "intensive", "care", "unit", ",", "as", "well", "as", "to", "facilitate", "synchrony", "between", "ventilator", "and", "spontaneous", "breaths", ".", "Fentanyl", ",", "an", "opioid", "analgesic", ",", "is", "frequently", "used", "in", "the", "neonatal", "intensive", "care", "unit", "setting", "for", "these", "very", "purposes", ".", "Various", "reported", "side", "effects", "of", "fentanyl", "administration", "include", "chest", "wall", "rigidity", ",", "hypotension", ",", "respiratory", "depression", ",", "and", "bradycardia", ".", "Here", ",", "2", "cases", "of", "urinary", "bladder", "retention", "leading", "to", "renal", "pelvocalyceal", "dilatation", "mimicking", "hydronephrosis", "as", "a", "result", "of", "continuous", "infusion", "of", "fentanyl", "are", "reported", "."]], "ner": [[[12, 12, "Chemical"], [58, 58, "Chemical"], [84, 84, "Chemical"], [121, 121, "Chemical"], [1, 3, "Disease"], [91, 91, "Disease"], [93, 94, "Disease"], [97, 97, "Disease"], [104, 106, "Disease"], [31, 31, "Disease"], [87, 89, "Disease"], [113, 113, "Disease"]]], "relations": [[[12, 12, 1, 3, "CID"], [58, 58, 1, 3, "CID"], [84, 84, 1, 3, "CID"], [121, 121, 1, 3, "CID"], [12, 12, 91, 91, "CID"], [58, 58, 91, 91, "CID"], [84, 84, 91, 91, "CID"], [121, 121, 91, 91, "CID"], [12, 12, 93, 94, "CID"], [58, 58, 93, 94, "CID"], [84, 84, 93, 94, "CID"], [121, 121, 93, 94, "CID"], [12, 12, 97, 97, "CID"], [58, 58, 97, 97, "CID"], [84, 84, 97, 97, "CID"], [121, 121, 97, 97, "CID"], [12, 12, 104, 106, "CID"], [58, 58, 104, 106, "CID"], [84, 84, 104, 106, "CID"], [121, 121, 104, 106, "CID"]]], "clusters": [], "translated": "连续静脉滴注<0>芬太尼</0>致膀胱<4>尿潴留</4>2例。镇静剂常用于新生儿，以减轻新生儿重症监护病房中伤害性刺激和侵入性操作引起的压力和<9>疼痛</9>，以及促进呼吸机和自主呼吸之间的同步。<1>芬太尼</1>是一种阿片类镇痛剂，在新生儿重症监护病房中经常用于这些目的。芬太尼<2>给药</2>的各种副作用包括<10>胸壁僵硬</10>、<5>低血压</5>、<6>呼吸抑制</6>和<7>心动过缓</7>。在此，报告了2例<8>膀胱潴留</8>导致肾盂扩张类似<11>肾积水</11>的病例，其原因是连续输注<3>芬太尼</3>。", "revised": true}
{"doc_key": "11379838", "sentences": [["Antidepressant", "-", "induced", "mania", "in", "bipolar", "patients", ":", "identification", "of", "risk", "factors", ".", "BACKGROUND", ":", "Concerns", "about", "possible", "risks", "of", "switching", "to", "mania", "associated", "with", "antidepressants", "continue", "to", "interfere", "with", "the", "establishment", "of", "an", "optimal", "treatment", "paradigm", "for", "bipolar", "depression", ".", "METHOD", ":", "The", "response", "of", "44", "patients", "meeting", "DSM", "-", "IV", "criteria", "for", "bipolar", "disorder", "to", "naturalistic", "treatment", "was", "assessed", "for", "at", "least", "6", "weeks", "using", "the", "Montgomery", "-", "Asberg", "Depression", "Rating", "Scale", "and", "the", "Bech", "-", "Rafaelson", "Mania", "Rating", "Scale", ".", "Patients", "who", "experienced", "a", "manic", "or", "hypomanic", "switch", "were", "compared", "with", "those", "who", "did", "not", "on", "several", "variables", "including", "age", ",", "sex", ",", "diagnosis", "(", "DSM", "-", "IV", "bipolar", "I", "vs", ".", "bipolar", "II", ")", ",", "number", "of", "previous", "manic", "episodes", ",", "type", "of", "antidepressant", "therapy", "used", "(", "electroconvulsive", "therapy", "vs", ".", "antidepressant", "drugs", "and", ",", "more", "particularly", ",", "selective", "serotonin", "reuptake", "inhibitors", "[", "SSRIs", "]", ")", ",", "use", "and", "type", "of", "mood", "stabilizers", "(", "lithium", "vs", ".", "anticonvulsants", ")", ",", "and", "temperament", "of", "the", "patient", ",", "assessed", "during", "a", "normothymic", "period", "using", "the", "hyperthymia", "component", "of", "the", "Semi", "-", "structured", "Affective", "Temperament", "Interview", ".", "RESULTS", ":", "Switches", "to", "hypomania", "or", "mania", "occurred", "in", "27", "%", "of", "all", "patients", "(", "N", "=", "12", ")", "(", "and", "in", "24", "%", "of", "the", "subgroup", "of", "patients", "treated", "with", "SSRIs", "[", "8", "/", "33", "]", ")", ";", "16", "%", "(", "N", "=", "7", ")", "experienced", "manic", "episodes", ",", "and", "11", "%", "(", "N", "=", "5", ")", "experienced", "hypomanic", "episodes", ".", "Sex", ",", "age", ",", "diagnosis", "(", "bipolar", "I", "vs", ".", "bipolar", "II", ")", ",", "and", "additional", "treatment", "did", "not", "affect", "the", "risk", "of", "switching", ".", "The", "incidence", "of", "mood", "switches", "seemed", "not", "to", "differ", "between", "patients", "receiving", "an", "anticonvulsant", "and", "those", "receiving", "no", "mood", "stabilizer", ".", "In", "contrast", ",", "mood", "switches", "were", "less", "frequent", "in", "patients", "receiving", "lithium", "(", "15", "%", ",", "4", "/", "26", ")", "than", "in", "patients", "not", "treated", "with", "lithium", "(", "44", "%", ",", "8", "/", "18", ";", "p", "=", ".", "04", ")", ".", "The", "number", "of", "previous", "manic", "episodes", "did", "not", "affect", "the", "probability", "of", "switching", ",", "whereas", "a", "high", "score", "on", "the", "hyperthymia", "component", "of", "the", "Semistructured", "Affective", "Temperament", "Interview", "was", "associated", "with", "a", "greater", "risk", "of", "switching", "(", "p", "=", ".", "008", ")", ".", "CONCLUSION", ":", "The", "frequency", "of", "mood", "switching", "associated", "with", "acute", "antidepressant", "therapy", "may", "be", "reduced", "by", "lithium", "treatment", ".", "Particular", "attention", "should", "be", "paid", "to", "patients", "with", "a", "hyperthymic", "temperament", ",", "who", "have", "a", "greater", "risk", "of", "mood", "switches", "."]], "ner": [[[0, 0, "Chemical"], [25, 25, "Chemical"], [127, 127, "Chemical"], [135, 135, "Chemical"], [390, 390, "Chemical"], [3, 3, "Disease"], [5, 5, "Disease"], [22, 22, "Disease"], [38, 39, "Disease"], [54, 55, "Disease"], [87, 87, "Disease"], [89, 89, "Disease"], [108, 112, "Disease"], [115, 116, "Disease"], [122, 122, "Disease"], [192, 192, "Disease"], [194, 194, "Disease"], [235, 235, "Disease"], [247, 247, "Disease"], [256, 257, "Disease"], [260, 261, "Disease"], [341, 341, "Disease"], [143, 145, "Chemical"], [147, 147, "Chemical"], [219, 219, "Chemical"], [158, 158, "Chemical"], [307, 307, "Chemical"], [322, 322, "Chemical"], [396, 396, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 5, 5, "CID"], [0, 0, 22, 22, "CID"], [0, 0, 38, 39, "CID"], [0, 0, 54, 55, "CID"], [0, 0, 87, 87, "CID"], [0, 0, 89, 89, "CID"], [0, 0, 108, 112, "CID"], [0, 0, 115, 116, "CID"], [0, 0, 122, 122, "CID"], [0, 0, 192, 192, "CID"], [0, 0, 194, 194, "CID"], [0, 0, 235, 235, "CID"], [0, 0, 247, 247, "CID"], [0, 0, 256, 257, "CID"], [0, 0, 260, 261, "CID"], [0, 0, 341, 341, "CID"], [25, 25, 3, 3, "CID"], [25, 25, 5, 5, "CID"], [25, 25, 22, 22, "CID"], [25, 25, 38, 39, "CID"], [25, 25, 54, 55, "CID"], [25, 25, 87, 87, "CID"], [25, 25, 89, 89, "CID"], [25, 25, 108, 112, "CID"], [25, 25, 115, 116, "CID"], [25, 25, 122, 122, "CID"], [25, 25, 192, 192, "CID"], [25, 25, 194, 194, "CID"], [25, 25, 235, 235, "CID"], [25, 25, 247, 247, "CID"], [25, 25, 256, 257, "CID"], [25, 25, 260, 261, "CID"], [25, 25, 341, 341, "CID"], [127, 127, 3, 3, "CID"], [127, 127, 5, 5, "CID"], [127, 127, 22, 22, "CID"], [127, 127, 38, 39, "CID"], [127, 127, 54, 55, "CID"], [127, 127, 87, 87, "CID"], [127, 127, 89, 89, "CID"], [127, 127, 108, 112, "CID"], [127, 127, 115, 116, "CID"], [127, 127, 122, 122, "CID"], [127, 127, 192, 192, "CID"], [127, 127, 194, 194, "CID"], [127, 127, 235, 235, "CID"], [127, 127, 247, 247, "CID"], [127, 127, 256, 257, "CID"], [127, 127, 260, 261, "CID"], [127, 127, 341, 341, "CID"], [135, 135, 3, 3, "CID"], [135, 135, 5, 5, "CID"], [135, 135, 22, 22, "CID"], [135, 135, 38, 39, "CID"], [135, 135, 54, 55, "CID"], [135, 135, 87, 87, "CID"], [135, 135, 89, 89, "CID"], [135, 135, 108, 112, "CID"], [135, 135, 115, 116, "CID"], [135, 135, 122, 122, "CID"], [135, 135, 192, 192, "CID"], [135, 135, 194, 194, "CID"], [135, 135, 235, 235, "CID"], [135, 135, 247, 247, "CID"], [135, 135, 256, 257, "CID"], [135, 135, 260, 261, "CID"], [135, 135, 341, 341, "CID"], [390, 390, 3, 3, "CID"], [390, 390, 5, 5, "CID"], [390, 390, 22, 22, "CID"], [390, 390, 38, 39, "CID"], [390, 390, 54, 55, "CID"], [390, 390, 87, 87, "CID"], [390, 390, 89, 89, "CID"], [390, 390, 108, 112, "CID"], [390, 390, 115, 116, "CID"], [390, 390, 122, 122, "CID"], [390, 390, 192, 192, "CID"], [390, 390, 194, 194, "CID"], [390, 390, 235, 235, "CID"], [390, 390, 247, 247, "CID"], [390, 390, 256, 257, "CID"], [390, 390, 260, 261, "CID"], [390, 390, 341, 341, "CID"], [143, 145, 3, 3, "CID"], [143, 145, 5, 5, "CID"], [143, 145, 22, 22, "CID"], [143, 145, 38, 39, "CID"], [143, 145, 54, 55, "CID"], [143, 145, 87, 87, "CID"], [143, 145, 89, 89, "CID"], [143, 145, 108, 112, "CID"], [143, 145, 115, 116, "CID"], [143, 145, 122, 122, "CID"], [143, 145, 192, 192, "CID"], [143, 145, 194, 194, "CID"], [143, 145, 235, 235, "CID"], [143, 145, 247, 247, "CID"], [143, 145, 256, 257, "CID"], [143, 145, 260, 261, "CID"], [143, 145, 341, 341, "CID"], [147, 147, 3, 3, "CID"], [147, 147, 5, 5, "CID"], [147, 147, 22, 22, "CID"], [147, 147, 38, 39, "CID"], [147, 147, 54, 55, "CID"], [147, 147, 87, 87, "CID"], [147, 147, 89, 89, "CID"], [147, 147, 108, 112, "CID"], [147, 147, 115, 116, "CID"], [147, 147, 122, 122, "CID"], [147, 147, 192, 192, "CID"], [147, 147, 194, 194, "CID"], [147, 147, 235, 235, "CID"], [147, 147, 247, 247, "CID"], [147, 147, 256, 257, "CID"], [147, 147, 260, 261, "CID"], [147, 147, 341, 341, "CID"], [219, 219, 3, 3, "CID"], [219, 219, 5, 5, "CID"], [219, 219, 22, 22, "CID"], [219, 219, 38, 39, "CID"], [219, 219, 54, 55, "CID"], [219, 219, 87, 87, "CID"], [219, 219, 89, 89, "CID"], [219, 219, 108, 112, "CID"], [219, 219, 115, 116, "CID"], [219, 219, 122, 122, "CID"], [219, 219, 192, 192, "CID"], [219, 219, 194, 194, "CID"], [219, 219, 235, 235, "CID"], [219, 219, 247, 247, "CID"], [219, 219, 256, 257, "CID"], [219, 219, 260, 261, "CID"], [219, 219, 341, 341, "CID"]]], "clusters": [], "translated": " <0>抗抑郁药</0>引起的<6>躁郁症</6>患者<5>躁狂</5>：危险因素的识别。背景：对与<1>抗抑郁药</1>相关的转为<7>躁狂症</7>的可能风险的担忧继续干扰<8>双相抑郁症</8>最佳治疗范例的建立。方法：使用 Montgomery-Asberg 抑郁量表和 Bech-Rafaelson 躁狂量表评估 44 名符合 DSM-IV 标准的<9>双相情感障碍</9>患者对自然疗法至少 6 周的反应。将经历过<10>躁狂</10>或<11>轻躁狂</11>转变的患者与未经历过年龄、性别、诊断（<12>DSM-IV双相I</12>对比<13>双相II</13>）、之前的<14>躁狂</14>发作次数、使用的<2>抗抑郁药</2>治疗类型（电休克疗法对比<3>抗抑郁药</3>药物，更具体地说，选择性<22>5-羟色胺再摄取抑制剂</22>[<23> SSRIs</23>]），情绪稳定剂的使用和类型（<25>锂</25>与抗惊厥药）和患者的气质，在正常情绪期间使用半结构化情感气质访谈的情绪亢进成分进行评估。结果：所有患者（N=44）中有27% 发生了向<15>轻躁狂</15>或<16>躁狂</16>的转变（以及接受<24>SSRIs</24>[8/33]）；16%（N=7）经历过<17>躁狂</17>发作，11%（N=5）经历过<18>轻躁狂</18>发作。性别、年龄、诊断（<19>双相Ⅰ型</19>与<20>双相Ⅱ型</20>）和额外治疗不影响转换的风险。情绪转换的发生率在接受抗惊厥药和未接受情绪稳定剂的患者之间似乎没有差异。相比之下，接受<26>锂</26>（15%，4/26）的患者的情绪转换频率低于未接受<27>锂</27>治疗的患者（44%，8/18；p=.04）。之前<21>躁狂</21>发作的次数不影响转换的可能性，而半结构化情感气质访谈中情绪亢进成分的高分与转换的风险较高有关(p=.008)。结论：<28>锂</28>治疗可降低与急性<4>抗抑郁药</4>治疗相关的情绪转换频率。应特别注意气质亢进的患者，他们情绪转换的风险更大。", "revised": true}
{"doc_key": "16274958", "sentences": [["Recurrent", "dysphonia", "and", "acitretin", ".", "We", "report", "the", "case", "of", "a", "woman", "complaining", "of", "dysphonia", "while", "she", "was", "treated", "by", "acitretin", ".", "Her", "symptoms", "totally", "regressed", "after", "drug", "withdrawal", "and", "reappeared", "when", "acitretin", "was", "reintroduced", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "of", "acitretin", "-", "induced", "dysphonia", ".", "This", "effect", "may", "be", "related", "to", "the", "pharmacological", "effect", "of", "this", "drug", "on", "mucous", "membranes", "."]], "ner": [[[3, 3, "Chemical"], [20, 20, "Chemical"], [32, 32, "Chemical"], [46, 46, "Chemical"], [1, 1, "Disease"], [14, 14, "Disease"], [49, 49, "Disease"]]], "relations": [[[3, 3, 1, 1, "CID"], [3, 3, 14, 14, "CID"], [3, 3, 49, 49, "CID"], [20, 20, 1, 1, "CID"], [20, 20, 14, 14, "CID"], [20, 20, 49, 49, "CID"], [32, 32, 1, 1, "CID"], [32, 32, 14, 14, "CID"], [32, 32, 49, 49, "CID"], [46, 46, 1, 1, "CID"], [46, 46, 14, 14, "CID"], [46, 46, 49, 49, "CID"]]], "clusters": [], "translated": "反复出现<4>发音困难</4>和<0>阿维A</0>。我们报告了一名女性在接受<1>阿维A</1>治疗期间抱怨<5>发音困难</5>的病例。她的症状在停药后完全消退，并在重新服用<2>阿维A</2>后再次出现。据了解，这是首例<3>阿维A</3>诱发<6>发音困难</6>的病例。这种作用可能与本药对粘膜的药理作用有关。", "revised": true}
{"doc_key": "6888657", "sentences": [["Characterization", "of", "estrogen", "-", "induced", "adenohypophyseal", "tumors", "in", "the", "Fischer", "344", "rat", ".", "Pituitary", "tumors", "were", "induced", "in", "F344", "female", "rats", "by", "chronic", "treatment", "with", "diethylstilbestrol", "(", "DES", ",", "8", "-", "10", "mg", ")", "implanted", "subcutaneously", "in", "silastic", "capsules", ".", "Over", "a", "range", "of", "1", "-", "150", "days", "of", "DES", "treatment", ",", "pairs", "of", "control", "and", "DES", "-", "treated", "rats", "were", "sacrificed", ",", "and", "their", "pituitaries", "dissociated", "enzymatically", "into", "single", "-", "cell", "preparations", ".", "The", "cell", "populations", "were", "examined", "regarding", "total", "cell", "recovery", "correlated", "with", "gland", "weight", ",", "intracellular", "prolactin", "(", "PRL", ")", "content", "and", "subsequent", "release", "in", "primary", "culture", ",", "immunocytochemical", "PRL", "staining", ",", "density", "and", "/", "or", "size", "alterations", "via", "separation", "on", "Ficoll", "-", "Hypaque", "and", "by", "unit", "gravity", "sedimentation", ",", "and", "cell", "cycle", "analysis", ",", "after", "acriflavine", "DNA", "staining", ",", "by", "laser", "flow", "cytometry", ".", "Total", "cell", "yields", "from", "DES", "-", "treated", "pituitaries", "increased", "from", "1", ".", "3", "times", "control", "yields", "at", "8", "days", "of", "treatment", "to", "58", ".", "9", "times", "control", "values", "by", "day", "150", ".", "Intracellular", "PRL", "content", "ranged", "from", "1", ".", "9", "to", "9", ".", "4", "times", "control", "levels", ",", "and", "PRL", "release", "in", "vitro", "was", "significantly", "and", "consistently", "higher", "than", "controls", ",", "after", "at", "least", "8", "days", "of", "DES", "exposure", ".", "Beyond", "8", "days", "of", "DES", "exposure", ",", "the", "immunochemically", "PRL", "-", "positive", "proportion", "of", "cells", "increased", "to", "over", "50", "%", "of", "the", "total", "population", ".", "Increased", "density", "and", "/", "or", "size", "and", "PRL", "content", "were", "indicated", "for", "the", "majority", "of", "the", "PRL", "cell", "population", "in", "both", "types", "of", "separation", "protocols", ".", "All", "these", "effects", "of", "DES", "were", "more", "pronounced", "among", "previously", "ovariectomized", "animals", ".", "The", "data", "extend", "the", "findings", "of", "other", "investigators", ",", "further", "establishing", "the", "DES", "-", "induced", "tumor", "as", "a", "model", "for", "study", "of", "PRL", "cellular", "control", "mechanisms", "."]], "ner": [[[25, 25, "Chemical"], [27, 27, "Chemical"], [49, 49, "Chemical"], [56, 56, "Chemical"], [142, 142, "Chemical"], [205, 205, "Chemical"], [212, 212, "Chemical"], [263, 263, "Chemical"], [284, 284, "Chemical"], [5, 6, "Disease"], [13, 14, "Disease"], [2, 2, "Chemical"], [287, 287, "Disease"], [129, 129, "Chemical"]]], "relations": [[[25, 25, 5, 6, "CID"], [25, 25, 13, 14, "CID"], [27, 27, 5, 6, "CID"], [27, 27, 13, 14, "CID"], [49, 49, 5, 6, "CID"], [49, 49, 13, 14, "CID"], [56, 56, 5, 6, "CID"], [56, 56, 13, 14, "CID"], [142, 142, 5, 6, "CID"], [142, 142, 13, 14, "CID"], [205, 205, 5, 6, "CID"], [205, 205, 13, 14, "CID"], [212, 212, 5, 6, "CID"], [212, 212, 13, 14, "CID"], [263, 263, 5, 6, "CID"], [263, 263, 13, 14, "CID"], [284, 284, 5, 6, "CID"], [284, 284, 13, 14, "CID"]]], "clusters": [], "translated": "Fischer 344 大鼠<11>雌激素</11>诱导的<9>腺垂体肿瘤</9>的特征。将<0>己烯雌酚</0>（<1>DES</1>，8-10mg）植入硅橡胶胶囊皮下长期治疗F344雌性大鼠<10>垂体瘤</10>。在<2>DES</2>处理1-150天的范围内，将成对的对照组和 <3>DES</3>处理的大鼠处死，它们的垂体通过酶促解离成单细胞制剂。检查细胞群的总细胞恢复情况与腺体重量、细胞内催乳素（PRL）含量和原代培养中的后续释放、免疫细胞化学PRL染色、通过 Ficoll-Hypaque 分离和单位重力沉降的密度和/或大小改变，以及细胞周期分析，<13>吖啶黄</13>DNA染色后，激光流式细胞术。 <4>DES</4>处理的垂体的总细胞产量从1.3倍控制产量治疗8天起增加到天150为58.9倍控制产量。细胞内PRL含量范围为1.9到9.4倍控制水平，且PRL的体外释放在<5>DES</5>暴露至少8天后显著且始终高于对照。在<6>DES</6>暴露超过8天后，免疫化学PRL阳性的细胞比例增加到总细胞群的50%以上。在两种类型的分离方案中，大多数PRL细胞群的密度和/或大小和PRL含量都增加了。上述<7>DES</7>所有这些影响在先前切除卵巢的动物中更为明显。该数据扩展了其他研究者的发现，进一步建立了<8>DES</8>诱导的<12>肿瘤</12>作为研究PRL细胞控制机制的模型。", "revised": true}
{"doc_key": "11706060", "sentences": [["Combined", "antiretroviral", "therapy", "causes", "cardiomyopathy", "and", "elevates", "plasma", "lactate", "in", "transgenic", "AIDS", "mice", ".", "Highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", "is", "implicated", "in", "cardiomyopathy", "(", "CM", ")", "and", "in", "elevated", "plasma", "lactate", "(", "LA", ")", "in", "AIDS", "through", "mechanisms", "of", "mitochondrial", "dysfunction", ".", "To", "determine", "mitochondrial", "events", "from", "HAART", "in", "vivo", ",", "8", "-", "week", "-", "old", "hemizygous", "transgenic", "AIDS", "mice", "(", "NL4", "-", "3Delta", "gag", "/", "pol", ";", "TG", ")", "and", "wild", "-", "type", "FVB", "/", "n", "littermates", "were", "treated", "with", "the", "HAART", "combination", "of", "zidovudine", ",", "lamivudine", ",", "and", "indinavir", "or", "vehicle", "control", "for", "10", "days", "or", "35", "days", ".", "At", "termination", "of", "the", "experiments", ",", "mice", "underwent", "echocardiography", ",", "quantitation", "of", "abundance", "of", "molecular", "markers", "of", "CM", "(", "ventricular", "mRNA", "encoding", "atrial", "natriuretic", "factor", "[", "ANF", "]", "and", "sarcoplasmic", "calcium", "ATPase", "[", "SERCA2", "]", ")", ",", "and", "determination", "of", "plasma", "LA", ".", "Myocardial", "histologic", "features", "were", "analyzed", "semiquantitatively", "and", "results", "were", "confirmed", "by", "transmission", "electron", "microscopy", ".", "After", "35", "days", "in", "the", "TG", "+", "HAART", "cohort", ",", "left", "ventricular", "mass", "increased", "160", "%", "by", "echocardiography", ".", "Molecularly", ",", "ANF", "mRNA", "increased", "250", "%", "and", "SERCA2", "mRNA", "decreased", "57", "%", ".", "Biochemically", ",", "LA", "was", "elevated", "(", "8", ".", "5", "+", "/", "-", "2", ".", "0", "mM", ")", ".", "Pathologically", ",", "granular", "cytoplasmic", "changes", "were", "found", "in", "cardiac", "myocytes", ",", "indicating", "enlarged", ",", "damaged", "mitochondria", ".", "Findings", "were", "confirmed", "ultrastructurally", ".", "No", "changes", "were", "found", "in", "other", "cohorts", ".", "After", "10", "days", ",", "only", "ANF", "was", "elevated", ",", "and", "only", "in", "the", "TG", "+", "HAART", "cohort", ".", "Results", "show", "that", "cumulative", "HAART", "caused", "mitochondrial", "CM", "with", "elevated", "LA", "in", "AIDS", "transgenic", "mice", "."]], "ner": [[[87, 87, "Chemical"], [4, 4, "Disease"], [24, 24, "Disease"], [26, 26, "Disease"], [120, 120, "Disease"], [267, 267, "Disease"], [89, 89, "Chemical"], [92, 92, "Chemical"], [8, 8, "Chemical"], [32, 32, "Chemical"], [34, 34, "Chemical"], [144, 144, "Chemical"], [196, 196, "Chemical"], [270, 270, "Chemical"], [133, 133, "Chemical"], [11, 11, "Disease"], [37, 37, "Disease"], [60, 60, "Disease"], [272, 272, "Disease"], [41, 42, "Disease"]]], "relations": [[[87, 87, 4, 4, "CID"], [87, 87, 24, 24, "CID"], [87, 87, 26, 26, "CID"], [87, 87, 120, 120, "CID"], [87, 87, 267, 267, "CID"], [89, 89, 4, 4, "CID"], [89, 89, 24, 24, "CID"], [89, 89, 26, 26, "CID"], [89, 89, 120, 120, "CID"], [89, 89, 267, 267, "CID"], [92, 92, 4, 4, "CID"], [92, 92, 24, 24, "CID"], [92, 92, 26, 26, "CID"], [92, 92, 120, 120, "CID"], [92, 92, 267, 267, "CID"]]], "clusters": [], "translated": "联合抗逆转录病毒疗法导致<1>心肌病</1>并升高转基因<15>AIDS</15>小鼠的血浆<8>乳酸</8>。高效抗逆转录病毒疗法 (HAART) 与<2>心肌病</2> (<3>CM</3>)和升高的血浆<9>乳酸</9> (<10>LA</10>)有关，在<16>AIDS</16>中通过<19>线粒体功能障碍</19>的机制。为了确定体内 HAART 引起的线粒体事件，8 周龄半合子转基因<17>AIDS</17>小鼠(NL4-3Delta gag/pol;TG)和野生型FVB/n同窝小鼠接受HAART联合治疗<0>齐多夫定</0>、<6>拉米夫定</6>和<7>茚地那韦</7>或载体对照10天或35天。在实验结束时，对小鼠进行超声心动图，<4>CM</4>分子标记丰度的定量(心室mRNA编码心钠素[ANF]和肌浆<14>钙</14>ATP酶[SERCA2])，以及血浆<11>乳酸</11>的测定。对心肌组织学特征进行半定量分析，结果经透射电镜证实。在TG+HAART队列中35天后，超声心动图显示左心室质量增加了160%。分子结构上，ANF mRNA增加了250%，SERCA2 mRNA减少了57%。在生化方面，<12>乳酸</12>升高(8.5+/-2.0 mM)。病理上，在心肌细胞中发现颗粒状细胞质变化，表明线粒体增大、受损。结果在超微结构上得到证实。其他队列未发现变化。10天后，只有ANF升高，并且仅在TG+HAART队列中。结果表明，在<18>AIDS</18>转基因小鼠中累积的HAART导致线粒体<5>心肌病</5>和<13>乳酸</13>升高。", "revised": true}
{"doc_key": "6773726", "sentences": [["Provocation", "of", "postural", "hypotension", "by", "nitroglycerin", "in", "diabetic", "autonomic", "neuropathy", "?", "The", "effect", "of", "nitroglycerin", "on", "heart", "rate", "and", "systolic", "blood", "pressure", "was", "compared", "in", "5", "normal", "subjects", ",", "12", "diabetic", "subjects", "without", "autonomic", "neuropathy", ",", "and", "5", "diabetic", "subjects", "with", "autonomic", "neuropathy", ".", "The", "magnitude", "and", "time", "course", "of", "the", "increase", "in", "heart", "rate", "and", "the", "decrease", "in", "systolic", "blood", "pressure", "after", "nitroglycerin", "were", "similar", "in", "the", "normal", "and", "diabetic", "subjects", "without", "autonomic", "neuropathy", ",", "whereas", "a", "lesser", "increase", "in", "heart", "rate", "and", "a", "greater", "decrease", "in", "systolic", "blood", "pressure", "occurred", "in", "the", "diabetic", "subjects", "with", "autonomic", "neuropathy", ".", "It", "is", "therefore", "suggested", "that", "caution", "should", "be", "exercised", "when", "prescribing", "vasodilator", "drugs", "in", "diabetic", "patients", ",", "particularly", "those", "with", "autonomic", "neuropathy", "."]], "ner": [[[5, 5, "Chemical"], [14, 14, "Chemical"], [63, 63, "Chemical"], [3, 3, "Disease"], [7, 9, "Disease"], [30, 30, "Disease"], [38, 38, "Disease"], [70, 70, "Disease"], [94, 94, "Disease"], [114, 114, "Disease"], [33, 34, "Disease"], [41, 42, "Disease"], [73, 74, "Disease"], [97, 98, "Disease"], [120, 121, "Disease"]]], "relations": [[[5, 5, 3, 3, "CID"], [14, 14, 3, 3, "CID"], [63, 63, 3, 3, "CID"]]], "clusters": [], "translated": "<4>糖尿病自主神经病变</4>中用<0>硝酸甘油</0>诱发体位性<3>低血压</3>？对于5名正常受试者、12名<5>糖尿病</5>无<10>自主神经病变</10>的受试者和5名<6>糖尿病</6>患者 <11>自主神经病变</11> 进行了<1>硝酸甘油</1>的心率和收缩压影响对比。在正常和<7>糖尿病</7>没有<12>自主神经病变</12>的受试者中，<2>硝酸甘油</2>后心率增加和收缩压下降的幅度和时间过程是相似的，而<8>糖尿病</8>患者中<13>自主神经病变</13>的心率增加较小，收缩压下降较大。因此，建议谨慎为<9>糖尿病</9>患者，尤其是<14>自主神经病变</14>患者开具血管扩张药处方。", "revised": true}
{"doc_key": "8073369", "sentences": [["Effect", "of", "coniine", "on", "the", "developing", "chick", "embryo", ".", "Coniine", ",", "an", "alkaloid", "from", "Conium", "maculatum", "(", "poison", "hemlock", ")", ",", "has", "been", "shown", "to", "be", "teratogenic", "in", "livestock", ".", "The", "major", "teratogenic", "outcome", "is", "arthrogryposis", ",", "presumably", "due", "to", "nicotinic", "receptor", "blockade", ".", "However", ",", "coniine", "has", "failed", "to", "produce", "arthrogryposis", "in", "rats", "or", "mice", "and", "is", "only", "weakly", "teratogenic", "in", "rabbits", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "and", "compare", "the", "effects", "of", "coniine", "and", "nicotine", "in", "the", "developing", "chick", ".", "Concentrations", "of", "coniine", "and", "nicotine", "sulfate", "were", "0", ".", "015", "%", ",", "0", ".", "03", "%", ",", "0", ".", "075", "%", ",", "0", ".", "15", "%", ",", "0", ".", "75", "%", ",", "1", ".", "5", "%", ",", "3", "%", ",", "and", "6", "%", "and", "1", "%", ",", "5", "%", ",", "and", "10", "%", ",", "respectively", ".", "Both", "compounds", "caused", "deformations", "and", "lethality", "in", "a", "dose", "-", "dependent", "manner", ".", "All", "concentrations", "of", "nicotine", "sulfate", "caused", "some", "lethality", "but", "a", "no", "effect", "level", "for", "coniine", "lethality", "was", "0", ".", "75", "%", ".", "The", "deformations", "caused", "by", "both", "coniine", "and", "nicotine", "sulfate", "were", "excessive", "flexion", "or", "extension", "of", "one", "or", "more", "toes", ".", "No", "histopathological", "alterations", "or", "differences", "in", "bone", "formation", "were", "seen", "in", "the", "limbs", "or", "toes", "of", "any", "chicks", "from", "any", "group", ";", "however", ",", "extensive", "cranial", "hemorrhage", "occurred", "in", "all", "nicotine", "sulfate", "-", "treated", "chicks", ".", "There", "was", "a", "statistically", "significant", "(", "P", "<", "or", "=", "0", ".", "01", ")", "decrease", "in", "movement", "in", "coniine", "and", "nicotine", "sulfate", "treated", "chicks", "as", "determined", "by", "ultrasound", ".", "Control", "chicks", "were", "in", "motion", "an", "average", "of", "33", ".", "67", "%", "of", "the", "time", ",", "while", "coniine", "-", "treated", "chicks", "were", "only", "moving", "8", ".", "95", "%", "of", "a", "5", "-", "min", "interval", ",", "and", "no", "movement", "was", "observed", "for", "nicotine", "sulfate", "treated", "chicks", ".", "In", "summary", ",", "the", "chick", "embryo", "provides", "a", "reliable", "and", "simple", "experimental", "animal", "model", "of", "coniine", "-", "induced", "arthrogryposis", ".", "Data", "from", "this", "model", "support", "a", "mechanism", "involving", "nicotinic", "receptor", "blockade", "with", "subsequent", "decreased", "fetal", "movement", "."]], "ner": [[[2, 2, "Chemical"], [9, 9, "Chemical"], [46, 46, "Chemical"], [77, 77, "Chemical"], [87, 87, "Chemical"], [168, 168, "Chemical"], [181, 181, "Chemical"], [250, 250, "Chemical"], [278, 278, "Chemical"], [322, 322, "Chemical"], [35, 35, "Disease"], [51, 51, "Disease"], [325, 325, "Disease"], [79, 79, "Chemical"], [89, 89, "Chemical"], [157, 157, "Chemical"], [183, 183, "Chemical"], [226, 226, "Chemical"], [252, 252, "Chemical"], [302, 302, "Chemical"], [221, 222, "Disease"], [144, 144, "Disease"], [177, 177, "Disease"], [186, 194, "Disease"]]], "relations": [[[2, 2, 35, 35, "CID"], [2, 2, 51, 51, "CID"], [2, 2, 325, 325, "CID"], [9, 9, 35, 35, "CID"], [9, 9, 51, 51, "CID"], [9, 9, 325, 325, "CID"], [46, 46, 35, 35, "CID"], [46, 46, 51, 51, "CID"], [46, 46, 325, 325, "CID"], [77, 77, 35, 35, "CID"], [77, 77, 51, 51, "CID"], [77, 77, 325, 325, "CID"], [87, 87, 35, 35, "CID"], [87, 87, 51, 51, "CID"], [87, 87, 325, 325, "CID"], [168, 168, 35, 35, "CID"], [168, 168, 51, 51, "CID"], [168, 168, 325, 325, "CID"], [181, 181, 35, 35, "CID"], [181, 181, 51, 51, "CID"], [181, 181, 325, 325, "CID"], [250, 250, 35, 35, "CID"], [250, 250, 51, 51, "CID"], [250, 250, 325, 325, "CID"], [278, 278, 35, 35, "CID"], [278, 278, 51, 51, "CID"], [278, 278, 325, 325, "CID"], [322, 322, 35, 35, "CID"], [322, 322, 51, 51, "CID"], [322, 322, 325, 325, "CID"], [79, 79, 35, 35, "CID"], [79, 79, 51, 51, "CID"], [79, 79, 325, 325, "CID"], [89, 89, 35, 35, "CID"], [89, 89, 51, 51, "CID"], [89, 89, 325, 325, "CID"], [157, 157, 35, 35, "CID"], [157, 157, 51, 51, "CID"], [157, 157, 325, 325, "CID"], [183, 183, 35, 35, "CID"], [183, 183, 51, 51, "CID"], [183, 183, 325, 325, "CID"], [226, 226, 35, 35, "CID"], [226, 226, 51, 51, "CID"], [226, 226, 325, 325, "CID"], [252, 252, 35, 35, "CID"], [252, 252, 51, 51, "CID"], [252, 252, 325, 325, "CID"], [302, 302, 35, 35, "CID"], [302, 302, 51, 51, "CID"], [302, 302, 325, 325, "CID"], [79, 79, 221, 222, "CID"], [89, 89, 221, 222, "CID"], [157, 157, 221, 222, "CID"], [183, 183, 221, 222, "CID"], [226, 226, 221, 222, "CID"], [252, 252, 221, 222, "CID"], [302, 302, 221, 222, "CID"]]], "clusters": [], "translated": "<0>可尼碱</0>对发育鸡胚的影响。<1>Coniine</1>是一种来自Conium maculatum（毒芹）的生物碱，已被证明对家畜具有致畸作用。主要的致畸结果是<10>关节弯曲</10>，可能是由于烟碱样受体阻滞所致。然而，<2>可尼碱</2>未能在大鼠或小鼠中产生<11>关节弯曲</11>，对家兔仅有微弱的致畸作用。本研究的目的是评估和比较<3>可尼碱</3>和<13>尼古丁</13>对发育中的小鸡的影响。<4>可尼碱</4>和<14>尼古丁</14>硫酸盐的浓度分别为0.015%、0.03%、0.075%、0.15%、0.75%、1.5%、3%和6%，以及1%、5%和10%。这两种化合物都以剂量依赖的方式引起<21>变形</21>和致死率。所有浓度的<15>尼古丁</15>硫酸盐都会引起一定程度的致死率，但对<5>可尼碱</5>致死率的无影响水平为0.75%。由<6>可尼碱</6>和<16>尼古丁</16>硫酸盐引起的<22>变形</22>为<23>一只或多只脚趾过度屈伸</23>。在任何组的任何小鸡的四肢或脚趾中均未观察到组织病理学改变或骨形成差异；然而，所有<17>尼古丁</17>硫酸盐治疗的小鸡都发生了广泛的<20>颅内出血</20>。超声确定<7>可尼碱</7>和<18>尼古丁</18>硫酸盐处理的小鸡的运动量有统计学意义(P <或= 0.01)。对照小鸡平均运动33.67%的时间，而<8>可尼碱</8>处理的小鸡仅移动8.95%的5分钟间隔，并且没有观察到<19>尼古丁</19>硫酸盐处理的小鸡的运动。综上所述，鸡胚为<9>可尼碱</9>诱导的<12>关节挛缩</12>提供了可靠、简单的实验动物模型。来自该模型的数据支持一种机制，该机制涉及烟碱受体阻滞以及随后的胎动减少。", "revised": true}
{"doc_key": "15804801", "sentences": [["Coronary", "aneurysm", "after", "implantation", "of", "a", "paclitaxel", "-", "eluting", "stent", ".", "Formation", "of", "coronary", "aneurysm", "is", "a", "rare", "complication", "of", "stenting", "with", "bare", "metal", "stents", ",", "but", "based", "on", "experimental", "studies", "drug", "-", "eluting", "stents", "may", "induce", "toxic", "effects", "on", "the", "vessel", "wall", "with", "incomplete", "stent", "apposition", ",", "aneurysm", "formation", "and", "with", "the", "potential", "of", "stent", "thrombosis", "or", "vessel", "rupture", ".", "We", "present", "a", "43", "-", "year", "-", "old", "man", "who", "developed", "a", "coronary", "aneurysm", "in", "the", "right", "coronary", "artery", "6", "months", "after", "receiving", "a", "paclitaxel", "-", "eluting", "stent", ".", "The", "patient", "was", "asymptomatic", "and", "the", "aneurysm", "was", "detected", "in", "a", "routine", "control", ".", "Angiography", "and", "intracoronary", "ultrasound", "demonstrated", "lack", "of", "contact", "between", "stent", "and", "vessel", "wall", "in", "a", "15", "-", "mm", "long", "segment", "with", "maximal", "aneurysm", "diameter", "of", "6", ".", "0", "mm", ".", "The", "patient", "was", "successfully", "treated", "with", "a", "graft", "stent", "."]], "ner": [[[6, 6, "Chemical"], [85, 85, "Chemical"], [0, 1, "Disease"], [13, 14, "Disease"], [73, 74, "Disease"], [48, 48, "Disease"], [96, 96, "Disease"], [126, 126, "Disease"], [56, 56, "Disease"]]], "relations": [[[6, 6, 0, 1, "CID"], [6, 6, 13, 14, "CID"], [6, 6, 73, 74, "CID"], [85, 85, 0, 1, "CID"], [85, 85, 13, 14, "CID"], [85, 85, 73, 74, "CID"]]], "clusters": [], "translated": "<2>冠状动脉瘤</2>植入<0>紫杉醇</0>洗脱支架后。<3>冠状动脉瘤</3>的形成是裸金属支架置入术的罕见并发症，但根据实验研究，药物洗脱支架可能会对血管壁产生毒性作用，支架并置不完全，<5>动脉瘤</5>形成并具有支架<8>血栓形成</8>或血管破裂的潜能。我们介绍了一名43岁的男性，他在接受<1>紫杉醇</1>洗脱支架后6个月在右冠状动脉中发生了<4>冠状动脉瘤</4>。患者无症状，<6>动脉瘤</6>在常规检查中被检测到。血管造影和冠状动脉内超声显示在一个15毫米长的节段中，支架和血管壁之间缺乏接触，最大<7>动脉瘤</7>直径为6.0毫米。患者成功地接受了移植支架治疗。", "revised": true}
{"doc_key": "12653683", "sentences": [["Epithelial", "sodium", "channel", "(", "ENaC", ")", "subunit", "mRNA", "and", "protein", "expression", "in", "rats", "with", "puromycin", "aminonucleoside", "-", "induced", "nephrotic", "syndrome", ".", "In", "experimental", "nephrotic", "syndrome", ",", "urinary", "sodium", "excretion", "is", "decreased", "during", "the", "early", "phase", "of", "the", "disease", ".", "The", "molecular", "mechanism", "(", "s", ")", "leading", "to", "salt", "retention", "has", "not", "been", "completely", "elucidated", ".", "The", "rate", "-", "limiting", "constituent", "of", "collecting", "duct", "sodium", "transport", "is", "the", "epithelial", "sodium", "channel", "(", "ENaC", ")", ".", "We", "examined", "the", "abundance", "of", "ENaC", "subunit", "mRNAs", "and", "proteins", "in", "puromycin", "aminonucleoside", "(", "PAN", ")", "-", "induced", "nephrotic", "syndrome", ".", "The", "time", "courses", "of", "urinary", "sodium", "excretion", ",", "plasma", "aldosterone", "concentration", "and", "proteinuria", "were", "studied", "in", "male", "Sprague", "-", "Dawley", "rats", "treated", "with", "a", "single", "dose", "of", "either", "PAN", "or", "vehicle", ".", "The", "relative", "amounts", "of", "alphaENaC", ",", "betaENaC", "and", "gammaENaC", "mRNAs", "were", "determined", "in", "kidneys", "from", "these", "rats", "by", "real", "-", "time", "quantitative", "TaqMan", "PCR", ",", "and", "the", "amounts", "of", "proteins", "by", "Western", "blot", ".", "The", "kinetics", "of", "urinary", "sodium", "excretion", "and", "the", "appearance", "of", "proteinuria", "were", "comparable", "with", "those", "reported", "previously", ".", "Sodium", "retention", "occurred", "on", "days", "2", ",", "3", "and", "6", "after", "PAN", "injection", ".", "A", "significant", "up", "-", "regulation", "of", "alphaENaC", "and", "betaENaC", "mRNA", "abundance", "on", "days", "1", "and", "2", "preceded", "sodium", "retention", "on", "days", "2", "and", "3", ".", "Conversely", ",", "down", "-", "regulation", "of", "alphaENaC", ",", "betaENaC", "and", "gammaENaC", "mRNA", "expression", "on", "day", "3", "occurred", "in", "the", "presence", "of", "high", "aldosterone", "concentrations", ",", "and", "was", "followed", "by", "a", "return", "of", "sodium", "excretion", "to", "control", "values", ".", "The", "amounts", "of", "alphaENaC", ",", "betaENaC", "and", "gammaENaC", "proteins", "were", "not", "increased", "during", "PAN", "-", "induced", "sodium", "retention", ".", "In", "conclusion", ",", "ENaC", "mRNA", "expression", ",", "especially", "alphaENaC", ",", "is", "increased", "in", "the", "very", "early", "phase", "of", "the", "experimental", "model", "of", "PAN", "-", "induced", "nephrotic", "syndrome", "in", "rats", ",", "but", "appears", "to", "escape", "from", "the", "regulation", "by", "aldosterone", "after", "day", "3", "."]], "ner": [[[14, 15, "Chemical"], [85, 86, "Chemical"], [88, 88, "Chemical"], [123, 123, "Chemical"], [190, 190, "Chemical"], [269, 269, "Chemical"], [297, 297, "Chemical"], [18, 19, "Disease"], [23, 24, "Disease"], [92, 93, "Disease"], [300, 301, "Disease"], [107, 107, "Disease"], [171, 171, "Disease"], [1, 1, "Chemical"], [27, 27, "Chemical"], [63, 63, "Chemical"], [68, 68, "Chemical"], [100, 100, "Chemical"], [165, 165, "Chemical"], [179, 179, "Chemical"], [210, 210, "Chemical"], [250, 250, "Chemical"], [272, 272, "Chemical"], [104, 104, "Chemical"], [240, 240, "Chemical"], [313, 313, "Chemical"]]], "relations": [[[14, 15, 18, 19, "CID"], [14, 15, 23, 24, "CID"], [14, 15, 92, 93, "CID"], [14, 15, 300, 301, "CID"], [85, 86, 18, 19, "CID"], [85, 86, 23, 24, "CID"], [85, 86, 92, 93, "CID"], [85, 86, 300, 301, "CID"], [88, 88, 18, 19, "CID"], [88, 88, 23, 24, "CID"], [88, 88, 92, 93, "CID"], [88, 88, 300, 301, "CID"], [123, 123, 18, 19, "CID"], [123, 123, 23, 24, "CID"], [123, 123, 92, 93, "CID"], [123, 123, 300, 301, "CID"], [190, 190, 18, 19, "CID"], [190, 190, 23, 24, "CID"], [190, 190, 92, 93, "CID"], [190, 190, 300, 301, "CID"], [269, 269, 18, 19, "CID"], [269, 269, 23, 24, "CID"], [269, 269, 92, 93, "CID"], [269, 269, 300, 301, "CID"], [297, 297, 18, 19, "CID"], [297, 297, 23, 24, "CID"], [297, 297, 92, 93, "CID"], [297, 297, 300, 301, "CID"], [14, 15, 107, 107, "CID"], [14, 15, 171, 171, "CID"], [85, 86, 107, 107, "CID"], [85, 86, 171, 171, "CID"], [88, 88, 107, 107, "CID"], [88, 88, 171, 171, "CID"], [123, 123, 107, 107, "CID"], [123, 123, 171, 171, "CID"], [190, 190, 107, 107, "CID"], [190, 190, 171, 171, "CID"], [269, 269, 107, 107, "CID"], [269, 269, 171, 171, "CID"], [297, 297, 107, 107, "CID"], [297, 297, 171, 171, "CID"]]], "clusters": [], "translated": "<0>嘌呤霉素氨基核苷</0>致<7>肾病综合征</7>大鼠上皮<13>钠</13>通道 (ENaC) 亚基 mRNA 和蛋白表达。在实验性<8>肾病综合征</8>中，疾病早期尿<14>钠</14>排泄减少。导致盐滞留的分子机制尚未完全阐明。集合管<15>钠</15>转运的限速成分是上皮<16>钠</16>通道 (ENaC)。我们检测了<1>嘌呤霉素氨基核苷</1> (<2>PAN</2>) 诱导的<9>肾病综合征</9>中 ENaC 亚基 mRNA 和蛋白质的丰度。在雄性 Sprague-Dawley 大鼠中研究了单剂量<3>PAN</3>或车辆后的时间进程，包括尿<17>钠</17>排泄、血浆<23>醛固酮</23>浓度和<11>蛋白尿</11>。通过实时定量TaqMan PCR测定这些大鼠肾脏中alphaENaC、betaENaC和gammaENaC mRNA的相对量，并通过蛋白质印迹法测定蛋白质的量。尿<18>钠</18>排泄动力学和<12>蛋白尿</12>的表现与之前报道的相当。<4>PAN</4>注射后第2、3、6天出现<19>钠</19>潴留。第1天和第2天alphaENaC和betaENaC mRNA丰度的显着上调先于第2天和第3天的<20>钠</20>滞留。相反，第3天alphaENaC、betaENaC和gammaENaC mRNA表达的下调发生在高<24>醛固酮</24>浓度的情况下，随后<21>钠</21>排泄恢复到控制水平价值观。在<5>PAN</5>诱导的<22>钠</22>滞留期间，alphaENaC、betaENaC和gammaENaC蛋白的数量没有增加。总之，ENaC mRNA 表达，尤其是 alphaENaC，在<6>PAN</6>诱导的大鼠<10>肾病综合征</10>实验模型的极早期增加，但似乎逃脱了第3天后由<25>醛固酮</25>调节。", "revised": true}
{"doc_key": "16160878", "sentences": [["Behavioral", "effects", "of", "urotensin", "-", "II", "centrally", "administered", "in", "mice", ".", "Urotensin", "-", "II", "(", "U", "-", "II", ")", "receptors", "are", "widely", "distributed", "in", "the", "central", "nervous", "system", ".", "Intracerebroventricular", "(", "i", ".", "c", ".", "v", ".", ")", "injection", "of", "U", "-", "II", "causes", "hypertension", "and", "bradycardia", "and", "stimulates", "prolactin", "and", "thyrotropin", "secretion", ".", "However", ",", "the", "behavioral", "effects", "of", "centrally", "administered", "U", "-", "II", "have", "received", "little", "attention", ".", "In", "the", "present", "study", ",", "we", "tested", "the", "effects", "of", "i", ".", "c", ".", "v", ".", "injections", "of", "U", "-", "II", "on", "behavioral", ",", "metabolic", ",", "and", "endocrine", "responses", "in", "mice", ".", "Administration", "of", "graded", "doses", "of", "U", "-", "II", "(", "1", "-", "10", ",", "000", "ng", "/", "mouse", ")", "provoked", ":", "(", "1", ")", "a", "dose", "-", "dependent", "reduction", "in", "the", "number", "of", "head", "dips", "in", "the", "hole", "-", "board", "test", ";", "(", "2", ")", "a", "dose", "-", "dependent", "reduction", "in", "the", "number", "of", "entries", "in", "the", "white", "chamber", "in", "the", "black", "-", "and", "-", "white", "compartment", "test", ",", "and", "in", "the", "number", "of", "entries", "in", "the", "central", "platform", "and", "open", "arms", "in", "the", "plus", "-", "maze", "test", ";", "and", "(", "3", ")", "a", "dose", "-", "dependent", "increase", "in", "the", "duration", "of", "immobility", "in", "the", "forced", "-", "swimming", "test", "and", "tail", "suspension", "test", ".", "Intracerebroventricular", "injection", "of", "U", "-", "II", "also", "caused", "an", "increase", "in", ":", "food", "intake", "at", "doses", "of", "100", "and", "1", ",", "000", "ng", "/", "mouse", ",", "water", "intake", "at", "doses", "of", "100", "-", "10", ",", "000", "ng", "/", "mouse", ",", "and", "horizontal", "locomotion", "activity", "at", "a", "dose", "of", "10", ",", "000", "ng", "/", "mouse", ".", "Whatever", "was", "the", "dose", ",", "the", "central", "administration", "of", "U", "-", "II", "had", "no", "effect", "on", "body", "temperature", ",", "nociception", ",", "apomorphine", "-", "induced", "penile", "erection", "and", "climbing", "behavior", ",", "and", "stress", "-", "induced", "plasma", "corticosterone", "level", ".", "Taken", "together", ",", "the", "present", "study", "demonstrates", "that", "the", "central", "injection", "of", "U", "-", "II", "at", "doses", "of", "1", "-", "10", ",", "000", "ng", "/", "mouse", "induces", "anxiogenic", "-", "and", "depressant", "-", "like", "effects", "in", "mouse", ".", "These", "data", "suggest", "that", "U", "-", "II", "may", "be", "involved", "in", "some", "aspects", "of", "psychiatric", "disorders", "."]], "ner": [[[291, 291, "Chemical"], [294, 295, "Disease"], [3, 5, "Chemical"], [11, 13, "Chemical"], [15, 17, "Chemical"], [40, 42, "Chemical"], [62, 64, "Chemical"], [88, 90, "Chemical"], [107, 109, "Chemical"], [218, 220, "Chemical"], [279, 281, "Chemical"], [320, 322, "Chemical"], [349, 351, "Chemical"], [44, 44, "Disease"], [46, 46, "Disease"], [359, 360, "Disease"], [305, 305, "Chemical"]]], "relations": [[[291, 291, 294, 295, "CID"]]], "clusters": [], "translated": "<2>urotensin-II</2>对小鼠集中给药的行为影响。<3>Urotensin-II</3>（<4>U-II</4>）受体广泛分布于中枢神经系统。侧脑室（i.c.v.）注射<5>U-II</5>会导致<13>高血压</13>和<14>心动过缓</14>，并刺激催乳素和促甲状腺激素的分泌。然而，集中管理的<6>U-II</6>的行为影响却很少受到关注。在本研究中，我们测试了i.c.v.注射<7>U-II</7>对小鼠行为、代谢和内分泌反应的影响。分级剂量的<8>U-II</8>（1-10,000 ng/小鼠）给药引起：（1）孔板试验中头部浸入次数的剂量依赖性减少；（2）剂量依赖性减少黑白室试验中白色室的入口数量，以及加号迷宫试验中中央平台和张开双臂的入口数量；（3）强迫游泳试验和悬尾试验中不动持续时间的剂量依赖性增加。<9>U-II</9>的侧脑室注射也引起以下方面的增加：100和1,000 ng/小鼠的食物摄入量，100-10,000 ng/小鼠的饮水量和水平运动活性剂量为10,000 ng/小鼠。无论剂量是多少，<10>U-II</10>的中枢给药对体温、伤害感受、<0>阿药吗啡</0>诱导的<1>阴茎勃起</1>和攀爬行为没有影响，和应激诱导的血浆<16>皮质酮</16>水平。综上所述，本研究表明，以1-10,000 ng/小鼠的剂量中枢注射<11>U-II</11>可在小鼠中诱导产生焦虑和抑制样作用。这些数据表明<12>U-II</12>可能参与了<15>精神障碍</15>的某些方面。", "revised": true}
{"doc_key": "18417364", "sentences": [["Nicotine", "-", "induced", "nystagmus", "correlates", "with", "midpontine", "activation", ".", "The", "pathomechanism", "of", "nicotine", "-", "induced", "nystagmus", "(", "NIN", ")", "is", "unknown", ".", "The", "aim", "of", "this", "study", "was", "to", "delineate", "brain", "structures", "that", "are", "involved", "in", "NIN", "generation", ".", "Eight", "healthy", "volunteers", "inhaled", "nicotine", "in", "darkness", "during", "a", "functional", "magnetic", "resonance", "imaging", "(", "fMRI", ")", "experiment", ";", "eye", "movements", "were", "registered", "using", "video", "-", "oculography", ".", "NIN", "correlated", "with", "blood", "oxygen", "level", "-", "dependent", "(", "BOLD", ")", "activity", "levels", "in", "a", "midpontine", "site", "in", "the", "posterior", "basis", "pontis", ".", "NIN", "-", "induced", "midpontine", "activation", "may", "correspond", "to", "activation", "of", "the", "dorsomedial", "pontine", "nuclei", "and", "the", "nucleus", "reticularis", "tegmenti", "pontis", ",", "structures", "known", "to", "participate", "in", "the", "generation", "of", "multidirectional", "saccades", "and", "smooth", "pursuit", "eye", "movements", "."]], "ner": [[[0, 0, "Chemical"], [12, 12, "Chemical"], [43, 43, "Chemical"], [3, 3, "Disease"], [15, 15, "Disease"], [17, 17, "Disease"], [36, 36, "Disease"], [66, 66, "Disease"], [89, 89, "Disease"], [70, 70, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 15, 15, "CID"], [0, 0, 17, 17, "CID"], [0, 0, 36, 36, "CID"], [0, 0, 66, 66, "CID"], [0, 0, 89, 89, "CID"], [12, 12, 3, 3, "CID"], [12, 12, 15, 15, "CID"], [12, 12, 17, 17, "CID"], [12, 12, 36, 36, "CID"], [12, 12, 66, 66, "CID"], [12, 12, 89, 89, "CID"], [43, 43, 3, 3, "CID"], [43, 43, 15, 15, "CID"], [43, 43, 17, 17, "CID"], [43, 43, 36, 36, "CID"], [43, 43, 66, 66, "CID"], [43, 43, 89, 89, "CID"]]], "clusters": [], "translated": " <0>尼古丁</0>诱发的<3>眼球震颤</3>与脑桥中部激活相关。 <1>尼古丁</1> -诱发的<4>眼球震颤</4>（<5>NIN</5>）的发病机制尚不清楚。这项研究的目的是描绘参与 <6>NIN</6> 生成的大脑结构。八名健康志愿者在功能磁共振成像（fMRI）实验中在黑暗中吸入<2>尼古丁</2>，眼球运动使用视频眼动仪记录。 <7>NIN</7>与脑桥后基部的脑桥中部活性水平依赖于血液<9>氧</9>含量（BOLD）。诱导 <8>NIN</8> 的脑桥中部激活可能对应于脑桥背内侧核和网状被盖核的激活，这些结构已知参与多向扫视和平稳追踪眼球运动的产生。", "revised": true}
{"doc_key": "10526274", "sentences": [["Gemcitabine", "plus", "vinorelbine", "in", "nonsmall", "cell", "lung", "carcinoma", "patients", "age", "70", "years", "or", "older", "or", "patients", "who", "can", "not", "receive", "cisplatin", ".", "Oncopaz", "Cooperative", "Group", ".", "BACKGROUND", ":", "Although", "the", "prevalence", "of", "nonsmall", "cell", "lung", "carcinoma", "(", "NSCLC", ")", "is", "high", "among", "elderly", "patients", ",", "few", "data", "are", "available", "regarding", "the", "efficacy", "and", "toxicity", "of", "chemotherapy", "in", "this", "group", "of", "patients", ".", "Recent", "reports", "indicate", "that", "single", "agent", "therapy", "with", "vinorelbine", "(", "VNB", ")", "or", "gemcitabine", "(", "GEM", ")", "may", "obtain", "a", "response", "rate", "of", "20", "-", "30", "%", "in", "elderly", "patients", ",", "with", "acceptable", "toxicity", "and", "improvement", "in", "symptoms", "and", "quality", "of", "life", ".", "In", "the", "current", "study", "the", "efficacy", "and", "toxicity", "of", "the", "combination", "of", "GEM", "and", "VNB", "in", "elderly", "patients", "with", "advanced", "NSCLC", "or", "those", "with", "some", "contraindication", "to", "receiving", "cisplatin", "were", "assessed", ".", "METHODS", ":", "Forty", "-", "nine", "patients", "with", "advanced", "NSCLC", "were", "included", ",", "38", "of", "whom", "were", "age", ">", "/", "=", "70", "years", "and", "11", "were", "age", "<", "70", "years", "but", "who", "had", "some", "contraindication", "to", "receiving", "cisplatin", ".", "All", "patients", "were", "evaluable", "for", "response", "and", "toxicity", ".", "Treatment", "was", "comprised", "of", "VNB", ",", "25", "mg", "/", "m", "(", "2", ")", ",", "plus", "GEM", ",", "1000", "mg", "/", "m", "(", "2", ")", ",", "both", "on", "Days", "1", ",", "8", ",", "and", "15", "every", "28", "days", ".", "Patients", "received", "a", "minimum", "of", "three", "courses", "unless", "progressive", "disease", "was", "detected", ".", "RESULTS", ":", "One", "hundred", "sixty", "-", "five", "courses", "were", "administered", ",", "with", "a", "median", "of", "3", ".", "6", "courses", "per", "patient", ".", "The", "overall", "response", "rate", "was", "26", "%", "(", "95", "%", "confidence", "interval", ",", "15", "-", "41", "%", ")", ".", "Two", "patients", "attained", "a", "complete", "response", "(", "4", "%", ")", "and", "11", "patients", "(", "22", "%", ")", "achieved", "a", "partial", "response", ".", "Eastern", "Cooperative", "Oncology", "Group", "performance", "status", "improved", "in", "35", "%", "of", "those", "patients", "with", "an", "initial", "value", ">", "0", ",", "whereas", "relief", "of", "at", "least", "1", "symptom", "without", "worsening", "of", "other", "symptoms", "was", "noted", "in", "27", "patients", "(", "55", "%", ")", ".", "The", "median", "time", "to", "progression", "was", "16", "weeks", "and", "the", "1", "-", "year", "survival", "rate", "was", "33", "%", ".", "Toxicity", "was", "mild", ".", "Six", "patients", "(", "12", "%", ")", "had", "World", "Health", "Organization", "Grade", "3", "-", "4", "neutropenia", ",", "2", "patients", "(", "4", "%", ")", "had", "Grade", "3", "-", "4", "thrombocytopenia", ",", "and", "2", "patients", "(", "4", "%", ")", "had", "Grade", "3", "neurotoxicity", ".", "Three", "patients", "with", "severe", "neutropenia", "(", "6", "%", ")", "died", "of", "sepsis", ".", "The", "median", "age", "of", "those", "patients", "developing", "Grade", "3", "-", "4", "neutropenia", "was", "significantly", "higher", "than", "that", "of", "the", "remaining", "patients", "(", "75", "years", "vs", ".", "72", "years", ";", "P", "=", "0", ".", "047", ")", ".", "CONCLUSIONS", ":", "The", "combination", "of", "GEM", "and", "VNB", "is", "moderately", "active", "and", "well", "tolerated", "except", "in", "patients", "age", ">", "/", "=", "75", "years", ".", "This", "age", "group", "had", "an", "increased", "risk", "of", "myelosuppression", ".", "Therefore", "the", "prophylactic", "use", "of", "granulocyte", "-", "colony", "stimulating", "factor", "should", "be", "considered", "with", "this", "treatment", ".", "New", "chemotherapy", "combinations", "with", "higher", "activity", "and", "lower", "toxicity", "are", "needed", "for", "elderly", "patients", "with", "advanced", "NSCLC", "."]], "ner": [[[0, 0, "Chemical"], [75, 75, "Chemical"], [77, 77, "Chemical"], [117, 117, "Chemical"], [199, 199, "Chemical"], [458, 458, "Chemical"], [377, 377, "Disease"], [408, 408, "Disease"], [428, 428, "Disease"], [390, 390, "Disease"], [402, 402, "Disease"], [2, 2, "Chemical"], [70, 70, "Chemical"], [72, 72, "Chemical"], [119, 119, "Chemical"], [188, 188, "Chemical"], [460, 460, "Chemical"], [4, 7, "Disease"], [32, 35, "Disease"], [37, 37, "Disease"], [125, 125, "Disease"], [145, 145, "Disease"], [520, 520, "Disease"], [53, 53, "Disease"], [95, 95, "Disease"], [112, 112, "Disease"], [182, 182, "Disease"], [359, 359, "Disease"], [512, 512, "Disease"], [415, 415, "Disease"], [485, 485, "Disease"], [20, 20, "Chemical"], [133, 133, "Chemical"], [173, 173, "Chemical"]]], "relations": [[[0, 0, 377, 377, "CID"], [0, 0, 408, 408, "CID"], [0, 0, 428, 428, "CID"], [75, 75, 377, 377, "CID"], [75, 75, 408, 408, "CID"], [75, 75, 428, 428, "CID"], [77, 77, 377, 377, "CID"], [77, 77, 408, 408, "CID"], [77, 77, 428, 428, "CID"], [117, 117, 377, 377, "CID"], [117, 117, 408, 408, "CID"], [117, 117, 428, 428, "CID"], [199, 199, 377, 377, "CID"], [199, 199, 408, 408, "CID"], [199, 199, 428, 428, "CID"], [458, 458, 377, 377, "CID"], [458, 458, 408, 408, "CID"], [458, 458, 428, 428, "CID"], [0, 0, 390, 390, "CID"], [75, 75, 390, 390, "CID"], [77, 77, 390, 390, "CID"], [117, 117, 390, 390, "CID"], [199, 199, 390, 390, "CID"], [458, 458, 390, 390, "CID"], [0, 0, 402, 402, "CID"], [75, 75, 402, 402, "CID"], [77, 77, 402, 402, "CID"], [117, 117, 402, 402, "CID"], [199, 199, 402, 402, "CID"], [458, 458, 402, 402, "CID"], [2, 2, 377, 377, "CID"], [2, 2, 408, 408, "CID"], [2, 2, 428, 428, "CID"], [70, 70, 377, 377, "CID"], [70, 70, 408, 408, "CID"], [70, 70, 428, 428, "CID"], [72, 72, 377, 377, "CID"], [72, 72, 408, 408, "CID"], [72, 72, 428, 428, "CID"], [119, 119, 377, 377, "CID"], [119, 119, 408, 408, "CID"], [119, 119, 428, 428, "CID"], [188, 188, 377, 377, "CID"], [188, 188, 408, 408, "CID"], [188, 188, 428, 428, "CID"], [460, 460, 377, 377, "CID"], [460, 460, 408, 408, "CID"], [460, 460, 428, 428, "CID"], [2, 2, 390, 390, "CID"], [70, 70, 390, 390, "CID"], [72, 72, 390, 390, "CID"], [119, 119, 390, 390, "CID"], [188, 188, 390, 390, "CID"], [460, 460, 390, 390, "CID"], [2, 2, 402, 402, "CID"], [70, 70, 402, 402, "CID"], [72, 72, 402, 402, "CID"], [119, 119, 402, 402, "CID"], [188, 188, 402, 402, "CID"], [460, 460, 402, 402, "CID"]]], "clusters": [], "translated": "<0>吉西他滨</0>加<11>长春瑞滨</11>治疗<17>非小细胞肺癌</17>患者70岁或以上或不能接受<31>顺铂</31>的患者。 Oncopaz 合作组。背景：虽然<18>非小细胞肺癌</18>（<19>NSCLC</19>）在老年患者中的患病率很高，但关于其疗效和<23>毒性</23>的数据很少。最近的报告表明，使用<12>长春瑞滨</12>（<13>VNB</13>）或<1>吉西他滨</1>（<2>GEM</2>）的单药治疗可能获得缓解率20-30%的老年患者，具有可接受的<24>毒性</24>和改善症状和生活质量。在本研究中，评估了使用<3>GEM</3>和<14>VNB</14>的联合治疗老年晚期<20>NSCLC</20>或对那些有接受<32>顺铂</32>禁忌症的患者的疗效和<25>毒性</25>。方法：纳入49例晚期<21>NSCLC</21>患者，其中38例年龄>/=70岁，11例年龄<70岁但有接受<33>顺铂</33>治疗的禁忌证。所有患者都可评估反应和<26>毒性</26>。治疗包括<15>VNB</15>25 mg/m(2)加上<4>GEM</4>1000 mg/m(2)，在第1天、第8天和第15天每28天一次。除非检测到疾病进展，否则患者至少接受三个疗程。结果：共开设165个课程，中位数为3.6个疗程/患。总体反应率为26 %（95%置信区间，15-41%）。两名患者获得完全缓解(4%)，11名患者(22%)获得部分缓解。Eastern Cooperative Oncology Group的体能状态在初始值>0的患者中有35%有所改善，而在27名患者(55%)中注意到至少1种症状得到缓解而其他症状没有恶化。中位进展时间为16周，1年生存率为33%。<27>毒性</27>是轻微的。6名患者(12%)患有世界卫生组织3-4级<6>中性粒细胞减少症</6>，2名患者(4%)患有3-4级<9>血小板减少症</9>，2名患者(4%)具有3级<10>神经毒性</10>。3例发生严重<7>中性粒细胞减少</7>的患者(6%)死于<29>败血症</29>。发生3-4级<8>中性粒细胞减少症</8>的患者的中位年龄显著高于其余患者(75岁对72岁;P=0.047)。结论：<5>GEM</5>和<16>VNB</16>的联合使用具有中等活性且耐受良好，但对于年龄>/=75岁的患者需要谨慎，可能存在<30>骨髓抑制</30>的风险，因此应该考虑本治疗的预防性使用粒细胞集落刺激因子。老年晚期<22>NSCLC</22>患者需要具有更高活性和更低<28>毒性</28>的新型化疗组合。", "revised": true}
{"doc_key": "18343374", "sentences": [["Central", "retinal", "vein", "occlusion", "associated", "with", "clomiphene", "-", "induced", "ovulation", ".", "OBJECTIVE", ":", "To", "report", "a", "case", "of", "central", "retinal", "vein", "occlusion", "associated", "with", "clomiphene", "citrate", "(", "CC", ")", ".", "DESIGN", ":", "Case", "study", ".", "SETTING", ":", "Ophthalmology", "clinic", "of", "an", "academic", "hospital", ".", "PATIENT", "(", "S", ")", ":", "A", "36", "-", "year", "-", "old", "woman", "referred", "from", "the", "infertility", "clinic", "for", "blurred", "vision", ".", "INTERVENTION", "(", "S", ")", ":", "Ophthalmic", "examination", "after", "CC", "therapy", ".", "MAIN", "OUTCOME", "MEASURE", "(", "S", ")", ":", "Central", "retinal", "vein", "occlusion", "after", "ovulation", "induction", "with", "CC", ".", "RESULT", "(", "S", ")", ":", "A", "36", "-", "year", "-", "old", "Chinese", "woman", "developed", "central", "retinal", "vein", "occlusion", "after", "eight", "courses", "of", "CC", ".", "A", "search", "of", "the", "literature", "on", "the", "thromboembolic", "complications", "of", "CC", "does", "not", "include", "this", "severe", "ophthalmic", "complication", ",", "although", "mild", "visual", "disturbance", "after", "CC", "intake", "is", "not", "uncommon", ".", "CONCLUSION", "(", "S", ")", ":", "This", "is", "the", "first", "reported", "case", "of", "central", "retinal", "vein", "occlusion", "after", "treatment", "with", "CC", ".", "Extra", "caution", "is", "warranted", "in", "treating", "infertility", "patients", "with", "CC", ",", "and", "patients", "should", "be", "well", "informed", "of", "this", "side", "effect", "before", "commencement", "of", "therapy", "."]], "ner": [[[6, 6, "Chemical"], [24, 25, "Chemical"], [27, 27, "Chemical"], [73, 73, "Chemical"], [91, 91, "Chemical"], [115, 115, "Chemical"], [127, 127, "Chemical"], [141, 141, "Chemical"], [166, 166, "Chemical"], [177, 177, "Chemical"], [1, 3, "Disease"], [19, 21, "Disease"], [84, 86, "Disease"], [108, 110, "Disease"], [160, 162, "Disease"], [62, 63, "Disease"], [138, 139, "Disease"], [59, 59, "Disease"], [174, 174, "Disease"], [124, 124, "Disease"]]], "relations": [[[6, 6, 1, 3, "CID"], [6, 6, 19, 21, "CID"], [6, 6, 84, 86, "CID"], [6, 6, 108, 110, "CID"], [6, 6, 160, 162, "CID"], [24, 25, 1, 3, "CID"], [24, 25, 19, 21, "CID"], [24, 25, 84, 86, "CID"], [24, 25, 108, 110, "CID"], [24, 25, 160, 162, "CID"], [27, 27, 1, 3, "CID"], [27, 27, 19, 21, "CID"], [27, 27, 84, 86, "CID"], [27, 27, 108, 110, "CID"], [27, 27, 160, 162, "CID"], [73, 73, 1, 3, "CID"], [73, 73, 19, 21, "CID"], [73, 73, 84, 86, "CID"], [73, 73, 108, 110, "CID"], [73, 73, 160, 162, "CID"], [91, 91, 1, 3, "CID"], [91, 91, 19, 21, "CID"], [91, 91, 84, 86, "CID"], [91, 91, 108, 110, "CID"], [91, 91, 160, 162, "CID"], [115, 115, 1, 3, "CID"], [115, 115, 19, 21, "CID"], [115, 115, 84, 86, "CID"], [115, 115, 108, 110, "CID"], [115, 115, 160, 162, "CID"], [127, 127, 1, 3, "CID"], [127, 127, 19, 21, "CID"], [127, 127, 84, 86, "CID"], [127, 127, 108, 110, "CID"], [127, 127, 160, 162, "CID"], [141, 141, 1, 3, "CID"], [141, 141, 19, 21, "CID"], [141, 141, 84, 86, "CID"], [141, 141, 108, 110, "CID"], [141, 141, 160, 162, "CID"], [166, 166, 1, 3, "CID"], [166, 166, 19, 21, "CID"], [166, 166, 84, 86, "CID"], [166, 166, 108, 110, "CID"], [166, 166, 160, 162, "CID"], [177, 177, 1, 3, "CID"], [177, 177, 19, 21, "CID"], [177, 177, 84, 86, "CID"], [177, 177, 108, 110, "CID"], [177, 177, 160, 162, "CID"], [6, 6, 62, 63, "CID"], [6, 6, 138, 139, "CID"], [24, 25, 62, 63, "CID"], [24, 25, 138, 139, "CID"], [27, 27, 62, 63, "CID"], [27, 27, 138, 139, "CID"], [73, 73, 62, 63, "CID"], [73, 73, 138, 139, "CID"], [91, 91, 62, 63, "CID"], [91, 91, 138, 139, "CID"], [115, 115, 62, 63, "CID"], [115, 115, 138, 139, "CID"], [127, 127, 62, 63, "CID"], [127, 127, 138, 139, "CID"], [141, 141, 62, 63, "CID"], [141, 141, 138, 139, "CID"], [166, 166, 62, 63, "CID"], [166, 166, 138, 139, "CID"], [177, 177, 62, 63, "CID"], [177, 177, 138, 139, "CID"]]], "clusters": [], "translated": "中央 <10>视网膜静脉阻塞</10> 与 <0>克罗米芬</0> 诱导的排卵有关。目的：报告1例<1>克罗米芬</1>引起<11>视网膜中央静脉阻塞</11>（<2>CC</2>）。设计：案例研究。地点：一家学术医院的眼科门诊。患者 (S)：一名36岁的女性，因<15>视力模糊</15>从<17>不孕症</17>诊所转诊。干预 (S)：<3>CC</3>治疗后的眼科检查。主要结果测量 (S)： <4>CC</4> 诱导排卵后中央<12>视网膜静脉阻塞</12>。结果(S)：一名36岁的中国女性在<5>CC</5> 8个疗程后发生<13>视网膜中央静脉阻塞</13>。搜索关于<6>CC</6>的<19>血栓栓塞</19>并发症的文献不包括这种严重的眼科并发症，尽管<7>CC</7>摄入量后轻度<16>视力障碍</16>并不少见。结论(S)：这是首例<8>CC</8>治疗后发生<14>视网膜中央静脉阻塞</14>的病例。治疗<18>不孕症</18>患有<9>CC</9>的患者需要格外小心，并且在开始治疗前应充分告知患者这种副作用。", "revised": true}
{"doc_key": "11752354", "sentences": [["Oral", "contraceptives", "and", "the", "risk", "of", "myocardial", "infarction", ".", "BACKGROUND", ":", "An", "association", "between", "the", "use", "of", "oral", "contraceptives", "and", "the", "risk", "of", "myocardial", "infarction", "has", "been", "found", "in", "some", ",", "but", "not", "all", ",", "studies", ".", "We", "investigated", "this", "association", ",", "according", "to", "the", "type", "of", "progestagen", "included", "in", "third", "-", "generation", "(", "i", ".", "e", ".", ",", "desogestrel", "or", "gestodene", ")", "and", "second", "-", "generation", "(", "i", ".", "e", ".", ",", "levonorgestrel", ")", "oral", "contraceptives", ",", "the", "dose", "of", "estrogen", ",", "and", "the", "presence", "or", "absence", "of", "prothrombotic", "mutations", "METHODS", ":", "In", "a", "nationwide", ",", "population", "-", "based", ",", "case", "-", "control", "study", ",", "we", "identified", "and", "enrolled", "248", "women", "18", "through", "49", "years", "of", "age", "who", "had", "had", "a", "first", "myocardial", "infarction", "between", "1990", "and", "1995", "and", "925", "control", "women", "who", "had", "not", "had", "a", "myocardial", "infarction", "and", "who", "were", "matched", "for", "age", ",", "calendar", "year", "of", "the", "index", "event", ",", "and", "area", "of", "residence", ".", "Subjects", "supplied", "information", "on", "oral", "-", "contraceptive", "use", "and", "major", "cardiovascular", "risk", "factors", ".", "An", "analysis", "for", "factor", "V", "Leiden", "and", "the", "G20210A", "mutation", "in", "the", "prothrombin", "gene", "was", "conducted", "in", "217", "patients", "and", "763", "controls", "RESULTS", ":", "The", "odds", "ratio", "for", "myocardial", "infarction", "among", "women", "who", "used", "any", "type", "of", "combined", "oral", "contraceptive", ",", "as", "compared", "with", "nonusers", ",", "was", "2", ".", "0", "(", "95", "percent", "confidence", "interval", ",", "1", ".", "5", "to", "2", ".", "8", ")", ".", "The", "adjusted", "odds", "ratio", "was", "2", ".", "5", "(", "95", "percent", "confidence", "interval", ",", "1", ".", "5", "to", "4", ".", "1", ")", "among", "women", "who", "used", "second", "-", "generation", "oral", "contraceptives", "and", "1", ".", "3", "(", "95", "percent", "confidence", "interval", ",", "0", ".", "7", "to", "2", ".", "5", ")", "among", "those", "who", "used", "third", "-", "generation", "oral", "contraceptives", ".", "Among", "women", "who", "used", "oral", "contraceptives", ",", "the", "odds", "ratio", "was", "2", ".", "1", "(", "95", "percent", "confidence", "interval", ",", "1", ".", "5", "to", "3", ".", "0", ")", "for", "those", "without", "a", "prothrombotic", "mutation", "and", "1", ".", "9", "(", "95", "percent", "confidence", "interval", ",", "0", ".", "6", "to", "5", ".", "5", ")", "for", "those", "with", "a", "mutation", "CONCLUSIONS", ":", "The", "risk", "of", "myocardial", "infarction", "was", "increased", "among", "women", "who", "used", "second", "-", "generation", "oral", "contraceptives", ".", "The", "results", "with", "respect", "to", "the", "use", "of", "third", "-", "generation", "oral", "contraceptives", "were", "inconclusive", "but", "suggested", "that", "the", "risk", "was", "lower", "than", "the", "risk", "associated", "with", "second", "-", "generation", "oral", "contraceptives", ".", "The", "risk", "of", "myocardial", "infarction", "was", "similar", "among", "women", "who", "used", "oral", "contraceptives", "whether", "or", "not", "they", "had", "a", "prothrombotic", "mutation", "."]], "ner": [[[0, 1, "Chemical"], [17, 18, "Chemical"], [75, 76, "Chemical"], [163, 165, "Chemical"], [211, 212, "Chemical"], [267, 268, "Chemical"], [294, 295, "Chemical"], [301, 302, "Chemical"], [370, 371, "Chemical"], [384, 385, "Chemical"], [403, 404, "Chemical"], [417, 418, "Chemical"], [6, 7, "Disease"], [23, 24, "Disease"], [123, 124, "Disease"], [138, 139, "Disease"], [201, 202, "Disease"], [359, 360, "Disease"], [409, 410, "Disease"], [47, 47, "Chemical"], [59, 59, "Chemical"], [61, 61, "Chemical"], [73, 73, "Chemical"], [81, 81, "Chemical"]]], "relations": [[[0, 1, 6, 7, "CID"], [0, 1, 23, 24, "CID"], [0, 1, 123, 124, "CID"], [0, 1, 138, 139, "CID"], [0, 1, 201, 202, "CID"], [0, 1, 359, 360, "CID"], [0, 1, 409, 410, "CID"], [17, 18, 6, 7, "CID"], [17, 18, 23, 24, "CID"], [17, 18, 123, 124, "CID"], [17, 18, 138, 139, "CID"], [17, 18, 201, 202, "CID"], [17, 18, 359, 360, "CID"], [17, 18, 409, 410, "CID"], [75, 76, 6, 7, "CID"], [75, 76, 23, 24, "CID"], [75, 76, 123, 124, "CID"], [75, 76, 138, 139, "CID"], [75, 76, 201, 202, "CID"], [75, 76, 359, 360, "CID"], [75, 76, 409, 410, "CID"], [163, 165, 6, 7, "CID"], [163, 165, 23, 24, "CID"], [163, 165, 123, 124, "CID"], [163, 165, 138, 139, "CID"], [163, 165, 201, 202, "CID"], [163, 165, 359, 360, "CID"], [163, 165, 409, 410, "CID"], [211, 212, 6, 7, "CID"], [211, 212, 23, 24, "CID"], [211, 212, 123, 124, "CID"], [211, 212, 138, 139, "CID"], [211, 212, 201, 202, "CID"], [211, 212, 359, 360, "CID"], [211, 212, 409, 410, "CID"], [267, 268, 6, 7, "CID"], [267, 268, 23, 24, "CID"], [267, 268, 123, 124, "CID"], [267, 268, 138, 139, "CID"], [267, 268, 201, 202, "CID"], [267, 268, 359, 360, "CID"], [267, 268, 409, 410, "CID"], [294, 295, 6, 7, "CID"], [294, 295, 23, 24, "CID"], [294, 295, 123, 124, "CID"], [294, 295, 138, 139, "CID"], [294, 295, 201, 202, "CID"], [294, 295, 359, 360, "CID"], [294, 295, 409, 410, "CID"], [301, 302, 6, 7, "CID"], [301, 302, 23, 24, "CID"], [301, 302, 123, 124, "CID"], [301, 302, 138, 139, "CID"], [301, 302, 201, 202, "CID"], [301, 302, 359, 360, "CID"], [301, 302, 409, 410, "CID"], [370, 371, 6, 7, "CID"], [370, 371, 23, 24, "CID"], [370, 371, 123, 124, "CID"], [370, 371, 138, 139, "CID"], [370, 371, 201, 202, "CID"], [370, 371, 359, 360, "CID"], [370, 371, 409, 410, "CID"], [384, 385, 6, 7, "CID"], [384, 385, 23, 24, "CID"], [384, 385, 123, 124, "CID"], [384, 385, 138, 139, "CID"], [384, 385, 201, 202, "CID"], [384, 385, 359, 360, "CID"], [384, 385, 409, 410, "CID"], [403, 404, 6, 7, "CID"], [403, 404, 23, 24, "CID"], [403, 404, 123, 124, "CID"], [403, 404, 138, 139, "CID"], [403, 404, 201, 202, "CID"], [403, 404, 359, 360, "CID"], [403, 404, 409, 410, "CID"], [417, 418, 6, 7, "CID"], [417, 418, 23, 24, "CID"], [417, 418, 123, 124, "CID"], [417, 418, 138, 139, "CID"], [417, 418, 201, 202, "CID"], [417, 418, 359, 360, "CID"], [417, 418, 409, 410, "CID"]]], "clusters": [], "translated": " <0>口服避孕药</0>和<12>心肌梗塞</12>的风险。背景：一些（但不是所有）研究发现使用<1>口服避孕药</1>与<13>心肌梗死</13>的风险之间存在关联。我们根据第三代（即<20>去氧孕烯</20>或<21>孕二烯酮</21>）和第二代中包含的<19>孕激素</19>的类型调查了这种关联 -代（即<22>左炔诺孕酮</22>)，<2>口服避孕药</2>，<23>雌激素</23>的剂量，以及是否存在促血栓形成突变。 方法：在一个在全国范围内，基于人群的病例对照研究，我们确定并招募了248名18至49岁的女性，她们在1990年至1995年间首次发生过<14>心肌梗死</14>，以及925名未发生过<15>心肌梗死</15>的对照女性并且年龄、指数事件发生的日历年和居住地区相匹配。受试者提供有关<3>口服避孕药</3>使用和主要心血管危险因素的信息。对217名患者和763名对照者进行了因子V Leiden和凝血酶原基因G20210A突变的分析。 结果：在使用任何类型的复方<4>口服避孕药</4>的女性中，与非用户相比，<16>心肌梗死</16>的比值比为2.0（95%置信区间，1.5至2.8）。调整后的比值比为2.5（95%置信区间，1.5至4.1）在使用第二代<5>口服避孕药</5>和1.3(95%置信区间，0.7至2.5)在使用第三代<6>口服避孕药</6>的人群中。在使用<7>口服避孕药</7>的女性中，比值比为2.1(95%置信区间，1.5至3.0)对于那些没有促血栓突变的人和1.9(95%置信区间，0.6至5.5)对于那些有突变的人。 结论：<17>心肌梗死</17>的风险在使用第二代<8>口服避孕药的女性中增加</8>。关于使用第三代<9>口服避孕药</9>的结果尚无定论，但表明该风险低于与第二代<10>口服避孕药</10>相关的风险。<18>心肌梗死</18>的风险在使用<11>口服避孕药</11>的女性中是相似的，无论她们是否有促血栓形成突变。", "revised": true}
{"doc_key": "17244258", "sentences": [["In", "vitro", "characterization", "of", "parasympathetic", "and", "sympathetic", "responses", "in", "cyclophosphamide", "-", "induced", "cystitis", "in", "the", "rat", ".", "In", "cyclophosphamide", "-", "induced", "cystitis", "in", "the", "rat", ",", "detrusor", "function", "is", "impaired", "and", "the", "expression", "and", "effects", "of", "muscarinic", "receptors", "altered", ".", "Whether", "or", "not", "the", "neuronal", "transmission", "may", "be", "affected", "by", "cystitis", "was", "presently", "investigated", ".", "Responses", "of", "urinary", "strip", "preparations", "from", "control", "and", "cyclophosphamide", "-", "pretreated", "rats", "to", "electrical", "field", "stimulation", "and", "to", "agonists", "were", "assessed", "in", "the", "absence", "and", "presence", "of", "muscarinic", ",", "adrenergic", "and", "purinergic", "receptor", "antagonists", ".", "Generally", ",", "atropine", "reduced", "contractions", ",", "but", "in", "contrast", "to", "controls", ",", "it", "also", "reduced", "responses", "to", "low", "electrical", "field", "stimulation", "intensity", "(", "1", "-", "5", "Hz", ")", "in", "inflamed", "preparations", ".", "In", "both", "types", ",", "purinoceptor", "desensitization", "with", "alpha", ",", "beta", "-", "methylene", "adenosine", "-", "5", "'", "-", "triphosphate", "(", "alpha", ",", "beta", "-", "meATP", ")", "caused", "further", "reductions", "at", "low", "frequencies", "(", "<", "10", "Hz", ")", ".", "The", "muscarinic", "receptor", "antagonists", "atropine", ",", "4", "-", "diphenylacetoxy", "-", "N", "-", "methylpiperidine", "(", "4", "-", "DAMP", ")", "(", "'", "M", "(", "1", ")", "/", "M", "(", "3", ")", "/", "M", "(", "5", ")", "-", "selective", "'", ")", ",", "methoctramine", "(", "'", "M", "(", "2", ")", "-", "selective", "'", ")", "and", "pirenzepine", "(", "'", "M", "(", "1", ")", "-", "selective", "'", ")", "antagonized", "the", "tonic", "component", "of", "the", "electrical", "field", "stimulation", "-", "evoked", "contractile", "response", "more", "potently", "than", "the", "phasic", "component", ".", "4", "-", "DAMP", "inhibited", "the", "tonic", "contractions", "in", "controls", "more", "potently", "than", "methoctramine", "and", "pirenzepine", ".", "In", "inflamed", "preparations", ",", "the", "muscarinic", "receptor", "antagonism", "on", "the", "phasic", "component", "of", "the", "electrical", "field", "stimulation", "-", "evoked", "contraction", "was", "decreased", "and", "the", "pirenzepine", "and", "4", "-", "DAMP", "antagonism", "on", "the", "tonic", "component", "was", "much", "less", "efficient", "than", "in", "controls", ".", "In", "contrast", "to", "controls", ",", "methoctramine", "increased", "-", "-", "instead", "of", "decreased", "-", "-", "the", "tonic", "responses", "at", "high", "frequencies", ".", "While", "contractions", "to", "carbachol", "and", "ATP", "were", "the", "same", "in", "inflamed", "and", "in", "control", "strips", "when", "related", "to", "a", "reference", "potassium", "response", ",", "isoprenaline", "-", "induced", "relaxations", "were", "smaller", "in", "inflamed", "strips", ".", "Thus", ",", "in", "cystitis", "substantial", "changes", "of", "the", "efferent", "functional", "responses", "occur", ".", "While", "postjunctional", "beta", "-", "adrenoceptor", "-", "mediated", "relaxations", "are", "reduced", ",", "effects", "by", "prejunctional", "inhibitory", "muscarinic", "receptors", "may", "be", "increased", "."]], "ner": [[[9, 9, "Chemical"], [18, 18, "Chemical"], [63, 63, "Chemical"], [12, 12, "Disease"], [21, 21, "Disease"], [50, 50, "Disease"], [356, 356, "Disease"], [92, 92, "Chemical"], [163, 163, "Chemical"], [129, 139, "Chemical"], [141, 145, "Chemical"], [165, 171, "Chemical"], [173, 175, "Chemical"], [241, 243, "Chemical"], [283, 285, "Chemical"], [198, 198, "Chemical"], [253, 253, "Chemical"], [304, 304, "Chemical"], [210, 210, "Chemical"], [255, 255, "Chemical"], [281, 281, "Chemical"], [323, 323, "Chemical"], [325, 325, "Chemical"], [340, 340, "Chemical"], [343, 343, "Chemical"]]], "relations": [[[9, 9, 12, 12, "CID"], [9, 9, 21, 21, "CID"], [9, 9, 50, 50, "CID"], [9, 9, 356, 356, "CID"], [18, 18, 12, 12, "CID"], [18, 18, 21, 21, "CID"], [18, 18, 50, 50, "CID"], [18, 18, 356, 356, "CID"], [63, 63, 12, 12, "CID"], [63, 63, 21, 21, "CID"], [63, 63, 50, 50, "CID"], [63, 63, 356, 356, "CID"]]], "clusters": [], "translated": "<0>环磷酰胺</0>诱导的大鼠<3>膀胱炎</3>中副交感神经和交感神经反应的体外表征。在<1>环磷酰胺</1>诱导的大鼠<4>膀胱炎</4>中，逼尿肌功能受损，毒蕈碱受体的表达和作用发生改变。目前正在研究神经元传递是否受<5>膀胱炎</5>的影响。在毒蕈碱、肾上腺素能和嘌呤能受体拮抗剂存在和不存在的情况下，评估来自对照和<2>环磷酰胺</2>预处理大鼠的尿带制剂对电场刺激和激动剂的反应。一般来说，<7>阿托品</7>会减少收缩，但与对照组相比，它还会减少发炎制剂对低电场刺激强度（1-5 Hz）的反应。在这两种类型中，嘌呤受体脱敏通过使用<9>α，β-亚甲基腺苷-5'三磷酸</9>（<10>α，β-meATP</10>）引起低频（<10 Hz）的进一步降低。在响应中，毒蕈碱受体拮抗剂<8>阿托品</8>、<11>4-二苯基乙酰氧基-N-甲基哌啶</11>（<12>4-DAMP</12>）（“M（1）/M（3）/M（5）-选择性”）、<15>甲氧西林</15>（“M（2）-选择性”）和<18>哌仑西平</18>（“M（1）-选择性”）比相位成分更有效地拮抗补药电场刺激的成分——诱发的收缩反应。在对照组中，<13>4-DAMP</13>比<16>美索曲明</16>和<19>哌仑西平</19>更有效地抑制强直性收缩。在发炎制剂中，与电场刺激诱发收缩的相位成分相比，毒蕈碱受体的拮抗作用减弱，<20>哌仑西平</20>和<14>4-DAMP</14>对强直成分的拮抗作用明显增强，但效率低于对照组。而在高频时，<17>甲氧西林</17> 与对照组相比，增加而不是减少了强直反应。与参考<23>钾</23>反应相关时，在发炎和对照条带中，<21>卡巴胆碱</21>和<22>ATP</22>的收缩是相同的，但<24>异丙肾上腺素</24> -诱导的松弛在发炎条带中较小。因此，在<6>膀胱炎</6>中，传出功能反应发生了实质性变化。当连接后β-肾上腺素能受体介导的松弛减少时，连接前抑制性毒蕈碱受体的作用可能会增加。", "revised": true}
{"doc_key": "10669626", "sentences": [["Warfarin", "-", "induced", "artery", "calcification", "is", "accelerated", "by", "growth", "and", "vitamin", "D", ".", "The", "present", "studies", "demonstrate", "that", "growth", "and", "vitamin", "D", "treatment", "enhance", "the", "extent", "of", "artery", "calcification", "in", "rats", "given", "sufficient", "doses", "of", "Warfarin", "to", "inhibit", "gamma", "-", "carboxylation", "of", "matrix", "Gla", "protein", ",", "a", "calcification", "inhibitor", "known", "to", "be", "expressed", "by", "smooth", "muscle", "cells", "and", "macrophages", "in", "the", "artery", "wall", ".", "The", "first", "series", "of", "experiments", "examined", "the", "influence", "of", "age", "and", "growth", "status", "on", "artery", "calcification", "in", "Warfarin", "-", "treated", "rats", ".", "Treatment", "for", "2", "weeks", "with", "Warfarin", "caused", "massive", "focal", "calcification", "of", "the", "artery", "media", "in", "20", "-", "day", "-", "old", "rats", "and", "less", "extensive", "focal", "calcification", "in", "42", "-", "day", "-", "old", "rats", ".", "In", "contrast", ",", "no", "artery", "calcification", "could", "be", "detected", "in", "10", "-", "month", "-", "old", "adult", "rats", "even", "after", "4", "weeks", "of", "Warfarin", "treatment", ".", "To", "directly", "examine", "the", "importance", "of", "growth", "to", "Warfarin", "-", "induced", "artery", "calcification", "in", "animals", "of", "the", "same", "age", ",", "20", "-", "day", "-", "old", "rats", "were", "fed", "for", "2", "weeks", "either", "an", "ad", "libitum", "diet", "or", "a", "6", "-", "g", "/", "d", "restricted", "diet", "that", "maintains", "weight", "but", "prevents", "growth", ".", "Concurrent", "treatment", "of", "both", "dietary", "groups", "with", "Warfarin", "produced", "massive", "focal", "calcification", "of", "the", "artery", "media", "in", "the", "ad", "libitum", "-", "fed", "rats", "but", "no", "detectable", "artery", "calcification", "in", "the", "restricted", "-", "diet", ",", "growth", "-", "inhibited", "group", ".", "Although", "the", "explanation", "for", "the", "association", "between", "artery", "calcification", "and", "growth", "status", "can", "not", "be", "determined", "from", "the", "present", "study", ",", "there", "was", "a", "relationship", "between", "higher", "serum", "phosphate", "and", "susceptibility", "to", "artery", "calcification", ",", "with", "30", "%", "higher", "levels", "of", "serum", "phosphate", "in", "young", ",", "ad", "libitum", "-", "fed", "rats", "compared", "with", "either", "of", "the", "groups", "that", "was", "resistant", "to", "Warfarin", "-", "induced", "artery", "calcification", ",", "ie", ",", "the", "10", "-", "month", "-", "old", "rats", "and", "the", "restricted", "-", "diet", ",", "growth", "-", "inhibited", "young", "rats", ".", "This", "observation", "suggests", "that", "increased", "susceptibility", "to", "Warfarin", "-", "induced", "artery", "calcification", "could", "be", "related", "to", "higher", "serum", "phosphate", "levels", ".", "The", "second", "set", "of", "experiments", "examined", "the", "possible", "synergy", "between", "vitamin", "D", "and", "Warfarin", "in", "artery", "calcification", ".", "High", "doses", "of", "vitamin", "D", "are", "known", "to", "cause", "calcification", "of", "the", "artery", "media", "in", "as", "little", "as", "3", "to", "4", "days", ".", "High", "doses", "of", "the", "vitamin", "K", "antagonist", "Warfarin", "are", "also", "known", "to", "cause", "calcification", "of", "the", "artery", "media", ",", "but", "at", "treatment", "times", "of", "2", "weeks", "or", "longer", "yet", "not", "at", "1", "week", ".", "In", "the", "current", "study", ",", "we", "investigated", "the", "synergy", "between", "these", "2", "treatments", "and", "found", "that", "concurrent", "Warfarin", "administration", "dramatically", "increased", "the", "extent", "of", "calcification", "in", "the", "media", "of", "vitamin", "D", "-", "treated", "rats", "at", "3", "and", "4", "days", ".", "There", "was", "a", "close", "parallel", "between", "the", "effect", "of", "vitamin", "D", "dose", "on", "artery", "calcification", "and", "the", "effect", "of", "vitamin", "D", "dose", "on", "the", "elevation", "of", "serum", "calcium", ",", "which", "suggests", "that", "vitamin", "D", "may", "induce", "artery", "calcification", "through", "its", "effect", "on", "serum", "calcium", ".", "Because", "Warfarin", "treatment", "had", "no", "effect", "on", "the", "elevation", "in", "serum", "calcium", "produced", "by", "vitamin", "D", ",", "the", "synergy", "between", "Warfarin", "and", "vitamin", "D", "is", "probably", "best", "explained", "by", "the", "hypothesis", "that", "Warfarin", "inhibits", "the", "activity", "of", "matrix", "Gla", "protein", "as", "a", "calcification", "inhibitor", ".", "High", "levels", "of", "matrix", "Gla", "protein", "are", "found", "at", "sites", "of", "artery", "calcification", "in", "rats", "treated", "with", "vitamin", "D", "plus", "Warfarin", ",", "and", "chemical", "analysis", "showed", "that", "the", "protein", "that", "accumulated", "was", "indeed", "not", "gamma", "-", "carboxylated", ".", "These", "observations", "indicate", "that", "although", "the", "gamma", "-", "carboxyglutamate", "residues", "of", "matrix", "Gla", "protein", "are", "apparently", "required", "for", "its", "function", "as", "a", "calcification", "inhibitor", ",", "they", "are", "not", "required", "for", "its", "accumulation", "at", "calcification", "sites", "."]], "ner": [[[0, 0, "Chemical"], [35, 35, "Chemical"], [81, 81, "Chemical"], [91, 91, "Chemical"], [142, 142, "Chemical"], [153, 153, "Chemical"], [204, 204, "Chemical"], [297, 297, "Chemical"], [331, 331, "Chemical"], [358, 358, "Chemical"], [393, 393, "Chemical"], [437, 437, "Chemical"], [506, 506, "Chemical"], [525, 525, "Chemical"], [537, 537, "Chemical"], [570, 570, "Chemical"], [3, 4, "Disease"], [27, 28, "Disease"], [78, 79, "Disease"], [95, 98, "Disease"], [124, 125, "Disease"], [156, 157, "Disease"], [208, 211, "Disease"], [223, 224, "Disease"], [243, 244, "Disease"], [268, 269, "Disease"], [300, 301, "Disease"], [334, 335, "Disease"], [360, 361, "Disease"], [372, 375, "Disease"], [399, 402, "Disease"], [473, 474, "Disease"], [496, 497, "Disease"], [561, 562, "Disease"], [47, 47, "Disease"], [111, 111, "Disease"], [444, 444, "Disease"], [547, 547, "Disease"], [610, 610, "Disease"], [621, 621, "Disease"], [10, 11, "Chemical"], [20, 21, "Chemical"], [355, 356, "Chemical"], [366, 367, "Chemical"], [449, 450, "Chemical"], [469, 470, "Chemical"], [479, 480, "Chemical"], [492, 493, "Chemical"], [519, 520, "Chemical"], [527, 528, "Chemical"], [567, 568, "Chemical"], [264, 264, "Chemical"], [278, 278, "Chemical"], [342, 342, "Chemical"], [390, 391, "Chemical"], [487, 487, "Chemical"], [503, 503, "Chemical"], [516, 516, "Chemical"], [584, 586, "Chemical"], [594, 596, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 27, 28, "CID"], [0, 0, 78, 79, "CID"], [0, 0, 95, 98, "CID"], [0, 0, 124, 125, "CID"], [0, 0, 156, 157, "CID"], [0, 0, 208, 211, "CID"], [0, 0, 223, 224, "CID"], [0, 0, 243, 244, "CID"], [0, 0, 268, 269, "CID"], [0, 0, 300, 301, "CID"], [0, 0, 334, 335, "CID"], [0, 0, 360, 361, "CID"], [0, 0, 372, 375, "CID"], [0, 0, 399, 402, "CID"], [0, 0, 473, 474, "CID"], [0, 0, 496, 497, "CID"], [0, 0, 561, 562, "CID"], [35, 35, 3, 4, "CID"], [35, 35, 27, 28, "CID"], [35, 35, 78, 79, "CID"], [35, 35, 95, 98, "CID"], [35, 35, 124, 125, "CID"], [35, 35, 156, 157, "CID"], [35, 35, 208, 211, "CID"], [35, 35, 223, 224, "CID"], [35, 35, 243, 244, "CID"], [35, 35, 268, 269, "CID"], [35, 35, 300, 301, "CID"], [35, 35, 334, 335, "CID"], [35, 35, 360, 361, "CID"], [35, 35, 372, 375, "CID"], [35, 35, 399, 402, "CID"], [35, 35, 473, 474, "CID"], [35, 35, 496, 497, "CID"], [35, 35, 561, 562, "CID"], [81, 81, 3, 4, "CID"], [81, 81, 27, 28, "CID"], [81, 81, 78, 79, "CID"], [81, 81, 95, 98, "CID"], [81, 81, 124, 125, "CID"], [81, 81, 156, 157, "CID"], [81, 81, 208, 211, "CID"], [81, 81, 223, 224, "CID"], [81, 81, 243, 244, "CID"], [81, 81, 268, 269, "CID"], [81, 81, 300, 301, "CID"], [81, 81, 334, 335, "CID"], [81, 81, 360, 361, "CID"], [81, 81, 372, 375, "CID"], [81, 81, 399, 402, "CID"], [81, 81, 473, 474, "CID"], [81, 81, 496, 497, "CID"], [81, 81, 561, 562, "CID"], [91, 91, 3, 4, "CID"], [91, 91, 27, 28, "CID"], [91, 91, 78, 79, "CID"], [91, 91, 95, 98, "CID"], [91, 91, 124, 125, "CID"], [91, 91, 156, 157, "CID"], [91, 91, 208, 211, "CID"], [91, 91, 223, 224, "CID"], [91, 91, 243, 244, "CID"], [91, 91, 268, 269, "CID"], [91, 91, 300, 301, "CID"], [91, 91, 334, 335, "CID"], [91, 91, 360, 361, "CID"], [91, 91, 372, 375, "CID"], [91, 91, 399, 402, "CID"], [91, 91, 473, 474, "CID"], [91, 91, 496, 497, "CID"], [91, 91, 561, 562, "CID"], [142, 142, 3, 4, "CID"], [142, 142, 27, 28, "CID"], [142, 142, 78, 79, "CID"], [142, 142, 95, 98, "CID"], [142, 142, 124, 125, "CID"], [142, 142, 156, 157, "CID"], [142, 142, 208, 211, "CID"], [142, 142, 223, 224, "CID"], [142, 142, 243, 244, "CID"], [142, 142, 268, 269, "CID"], [142, 142, 300, 301, "CID"], [142, 142, 334, 335, "CID"], [142, 142, 360, 361, "CID"], [142, 142, 372, 375, "CID"], [142, 142, 399, 402, "CID"], [142, 142, 473, 474, "CID"], [142, 142, 496, 497, "CID"], [142, 142, 561, 562, "CID"], [153, 153, 3, 4, "CID"], [153, 153, 27, 28, "CID"], [153, 153, 78, 79, "CID"], [153, 153, 95, 98, "CID"], [153, 153, 124, 125, "CID"], [153, 153, 156, 157, "CID"], [153, 153, 208, 211, "CID"], [153, 153, 223, 224, "CID"], [153, 153, 243, 244, "CID"], [153, 153, 268, 269, "CID"], [153, 153, 300, 301, "CID"], [153, 153, 334, 335, "CID"], [153, 153, 360, 361, "CID"], [153, 153, 372, 375, "CID"], [153, 153, 399, 402, "CID"], [153, 153, 473, 474, "CID"], [153, 153, 496, 497, "CID"], [153, 153, 561, 562, "CID"], [204, 204, 3, 4, "CID"], [204, 204, 27, 28, "CID"], [204, 204, 78, 79, "CID"], [204, 204, 95, 98, "CID"], [204, 204, 124, 125, "CID"], [204, 204, 156, 157, "CID"], [204, 204, 208, 211, "CID"], [204, 204, 223, 224, "CID"], [204, 204, 243, 244, "CID"], [204, 204, 268, 269, "CID"], [204, 204, 300, 301, "CID"], [204, 204, 334, 335, "CID"], [204, 204, 360, 361, "CID"], [204, 204, 372, 375, "CID"], [204, 204, 399, 402, "CID"], [204, 204, 473, 474, "CID"], [204, 204, 496, 497, "CID"], [204, 204, 561, 562, "CID"], [297, 297, 3, 4, "CID"], [297, 297, 27, 28, "CID"], [297, 297, 78, 79, "CID"], [297, 297, 95, 98, "CID"], [297, 297, 124, 125, "CID"], [297, 297, 156, 157, "CID"], [297, 297, 208, 211, "CID"], [297, 297, 223, 224, "CID"], [297, 297, 243, 244, "CID"], [297, 297, 268, 269, "CID"], [297, 297, 300, 301, "CID"], [297, 297, 334, 335, "CID"], [297, 297, 360, 361, "CID"], [297, 297, 372, 375, "CID"], [297, 297, 399, 402, "CID"], [297, 297, 473, 474, "CID"], [297, 297, 496, 497, "CID"], [297, 297, 561, 562, "CID"], [331, 331, 3, 4, "CID"], [331, 331, 27, 28, "CID"], [331, 331, 78, 79, "CID"], [331, 331, 95, 98, "CID"], [331, 331, 124, 125, "CID"], [331, 331, 156, 157, "CID"], [331, 331, 208, 211, "CID"], [331, 331, 223, 224, "CID"], [331, 331, 243, 244, "CID"], [331, 331, 268, 269, "CID"], [331, 331, 300, 301, "CID"], [331, 331, 334, 335, "CID"], [331, 331, 360, 361, "CID"], [331, 331, 372, 375, "CID"], [331, 331, 399, 402, "CID"], [331, 331, 473, 474, "CID"], [331, 331, 496, 497, "CID"], [331, 331, 561, 562, "CID"], [358, 358, 3, 4, "CID"], [358, 358, 27, 28, "CID"], [358, 358, 78, 79, "CID"], [358, 358, 95, 98, "CID"], [358, 358, 124, 125, "CID"], [358, 358, 156, 157, "CID"], [358, 358, 208, 211, "CID"], [358, 358, 223, 224, "CID"], [358, 358, 243, 244, "CID"], [358, 358, 268, 269, "CID"], [358, 358, 300, 301, "CID"], [358, 358, 334, 335, "CID"], [358, 358, 360, 361, "CID"], [358, 358, 372, 375, "CID"], [358, 358, 399, 402, "CID"], [358, 358, 473, 474, "CID"], [358, 358, 496, 497, "CID"], [358, 358, 561, 562, "CID"], [393, 393, 3, 4, "CID"], [393, 393, 27, 28, "CID"], [393, 393, 78, 79, "CID"], [393, 393, 95, 98, "CID"], [393, 393, 124, 125, "CID"], [393, 393, 156, 157, "CID"], [393, 393, 208, 211, "CID"], [393, 393, 223, 224, "CID"], [393, 393, 243, 244, "CID"], [393, 393, 268, 269, "CID"], [393, 393, 300, 301, "CID"], [393, 393, 334, 335, "CID"], [393, 393, 360, 361, "CID"], [393, 393, 372, 375, "CID"], [393, 393, 399, 402, "CID"], [393, 393, 473, 474, "CID"], [393, 393, 496, 497, "CID"], [393, 393, 561, 562, "CID"], [437, 437, 3, 4, "CID"], [437, 437, 27, 28, "CID"], [437, 437, 78, 79, "CID"], [437, 437, 95, 98, "CID"], [437, 437, 124, 125, "CID"], [437, 437, 156, 157, "CID"], [437, 437, 208, 211, "CID"], [437, 437, 223, 224, "CID"], [437, 437, 243, 244, "CID"], [437, 437, 268, 269, "CID"], [437, 437, 300, 301, "CID"], [437, 437, 334, 335, "CID"], [437, 437, 360, 361, "CID"], [437, 437, 372, 375, "CID"], [437, 437, 399, 402, "CID"], [437, 437, 473, 474, "CID"], [437, 437, 496, 497, "CID"], [437, 437, 561, 562, "CID"], [506, 506, 3, 4, "CID"], [506, 506, 27, 28, "CID"], [506, 506, 78, 79, "CID"], [506, 506, 95, 98, "CID"], [506, 506, 124, 125, "CID"], [506, 506, 156, 157, "CID"], [506, 506, 208, 211, "CID"], [506, 506, 223, 224, "CID"], [506, 506, 243, 244, "CID"], [506, 506, 268, 269, "CID"], [506, 506, 300, 301, "CID"], [506, 506, 334, 335, "CID"], [506, 506, 360, 361, "CID"], [506, 506, 372, 375, "CID"], [506, 506, 399, 402, "CID"], [506, 506, 473, 474, "CID"], [506, 506, 496, 497, "CID"], [506, 506, 561, 562, "CID"], [525, 525, 3, 4, "CID"], [525, 525, 27, 28, "CID"], [525, 525, 78, 79, "CID"], [525, 525, 95, 98, "CID"], [525, 525, 124, 125, "CID"], [525, 525, 156, 157, "CID"], [525, 525, 208, 211, "CID"], [525, 525, 223, 224, "CID"], [525, 525, 243, 244, "CID"], [525, 525, 268, 269, "CID"], [525, 525, 300, 301, "CID"], [525, 525, 334, 335, "CID"], [525, 525, 360, 361, "CID"], [525, 525, 372, 375, "CID"], [525, 525, 399, 402, "CID"], [525, 525, 473, 474, "CID"], [525, 525, 496, 497, "CID"], [525, 525, 561, 562, "CID"], [537, 537, 3, 4, "CID"], [537, 537, 27, 28, "CID"], [537, 537, 78, 79, "CID"], [537, 537, 95, 98, "CID"], [537, 537, 124, 125, "CID"], [537, 537, 156, 157, "CID"], [537, 537, 208, 211, "CID"], [537, 537, 223, 224, "CID"], [537, 537, 243, 244, "CID"], [537, 537, 268, 269, "CID"], [537, 537, 300, 301, "CID"], [537, 537, 334, 335, "CID"], [537, 537, 360, 361, "CID"], [537, 537, 372, 375, "CID"], [537, 537, 399, 402, "CID"], [537, 537, 473, 474, "CID"], [537, 537, 496, 497, "CID"], [537, 537, 561, 562, "CID"], [570, 570, 3, 4, "CID"], [570, 570, 27, 28, "CID"], [570, 570, 78, 79, "CID"], [570, 570, 95, 98, "CID"], [570, 570, 124, 125, "CID"], [570, 570, 156, 157, "CID"], [570, 570, 208, 211, "CID"], [570, 570, 223, 224, "CID"], [570, 570, 243, 244, "CID"], [570, 570, 268, 269, "CID"], [570, 570, 300, 301, "CID"], [570, 570, 334, 335, "CID"], [570, 570, 360, 361, "CID"], [570, 570, 372, 375, "CID"], [570, 570, 399, 402, "CID"], [570, 570, 473, 474, "CID"], [570, 570, 496, 497, "CID"], [570, 570, 561, 562, "CID"]]], "clusters": [], "translated": " <0>华法林</0>诱导的<16>动脉钙化</16>被生长和<40>维生素 D </40>加速。目前的研究表明，生长和<41>维生素 D </41>治疗可增强大鼠<17>动脉钙化</17>的程度，给予足够剂量的<1>华法林</1>以抑制基质 Gla 蛋白，一种<34>钙化</34>抑制剂，已知由动脉壁中的平滑肌细胞和巨噬细胞表达。第一个系列的实验检查了年龄和生长状态对<2>华法林</2>治疗的大鼠<18>动脉钙化</18>的影响。用<3>华法林</3>治疗 2 周导致20日龄大鼠的动脉中层大量局灶性<19>钙化</19>，而42-大天的老鼠则产生了较少的局灶性<35>钙化</35>。相比之下，10个月大的成年大鼠即使经过4周的<4>华法林</4>治疗也未发现<20>动脉钙化</20>。为了直接检验生长对<5>华法林</5>诱导的同龄动物<21>动脉钙化</21>的重要性，20天大的大鼠被随意喂食2周或6克/天的限制饮食，可保持体重但会阻止生长。用<6>华法林</6>同时治疗两个饮食组，在随意喂养的大鼠中产生大量局灶性动脉<22>钙化</22>，但在限制饮食、生长抑制组中则未检测到<23> 动脉钙化</23>。虽然目前的研究无法解释<24>动脉钙化</24>与生长状态之间的关联，但较高的血清<51>磷酸盐</51>与<25>动脉易感性</25>之间存在相关性，30%的血清<52>磷酸盐</52>水平比那些对<7>华法林</7>诱导的<26>动脉钙化</26>具有耐受性的组，即10月龄大鼠和限制饮食、生长抑制的幼鼠，都要高。这一观察表明，对<8>华法林</8>诱导的<27>动脉钙化</27>的易感性增加可能与较高的血清<53>磷酸盐</53>水平有关。第二组实验检查了<42>维生素 D </42>和<9>华法林</9>在<28>动脉钙化</28>中可能的协同作用。众所周知，高剂量的<43>维生素 D </43>会在短短3至4天内引起<29>动脉中膜钙化</29>。高剂量的<54>维生素 K </54>拮抗剂<10>华法林</10>也已知会导致<30>动脉钙化</30>中层，但治疗时间为2周或更长时间，而不是在1周。在当前的研究中，我们调查了这两种治疗之间的协同作用，发现同时服用<11>华法林</11>可显着增加<44>维生素 D </44>治疗的大鼠介质中的<36> 钙化</36>程度，在第3天和第4天治疗的大鼠。 <45> 维生素 D </45>剂量对<31>动脉钙化</31>的影响与<46>维生素 D </46>剂量对血清<55>钙</55>升高的影响有很好的平行关系，这提示<47>维生素 D </47>可能诱导<32>动脉钙化</32>，是通过其对血清<56>钙</56>的升高作用。因为<12>华法林</12>治疗对<48>维生素 D</48>产生的血清<57>钙</57>升高没有影响，因此，<13>华法林</13>和<49>维生素 D </49>之间的协同作用最好通过<14>华法林</14>抑制作为<37>钙化</37>抑制剂的基质Gla蛋白的活性来解释。在用<50>维生素D</50>加<15>华法林</15>治疗的大鼠中，在<33>动脉钙化</33>部位发现高水平的基质Gla蛋白，化学分析表明该蛋白积累的确实不是<58>伽马-羧化</58>。这些观察结果表明，虽然基质Gla蛋白的<59>γ-羧基谷氨酸</59>残基显然是其作为<38>钙化</38>抑制剂的功能所必需的，但它们在<39>钙化</39>部位的积累并不是必须的。", "revised": true}
{"doc_key": "16330766", "sentences": [["Pharmacological", "modulation", "of", "pain", "-", "related", "brain", "activity", "during", "normal", "and", "central", "sensitization", "states", "in", "humans", ".", "Abnormal", "processing", "of", "somatosensory", "inputs", "in", "the", "central", "nervous", "system", "(", "central", "sensitization", ")", "is", "the", "mechanism", "accounting", "for", "the", "enhanced", "pain", "sensitivity", "in", "the", "skin", "surrounding", "tissue", "injury", "(", "secondary", "hyperalgesia", ")", ".", "Secondary", "hyperalgesia", "shares", "clinical", "characteristics", "with", "neurogenic", "hyperalgesia", "in", "patients", "with", "neuropathic", "pain", ".", "Abnormal", "brain", "responses", "to", "somatosensory", "stimuli", "have", "been", "found", "in", "patients", "with", "hyperalgesia", "as", "well", "as", "in", "normal", "subjects", "during", "experimental", "central", "sensitization", ".", "The", "aim", "of", "this", "study", "was", "to", "assess", "the", "effects", "of", "gabapentin", ",", "a", "drug", "effective", "in", "neuropathic", "pain", "patients", ",", "on", "brain", "processing", "of", "nociceptive", "information", "in", "normal", "and", "central", "sensitization", "states", ".", "Using", "functional", "magnetic", "resonance", "imaging", "(", "fMRI", ")", "in", "normal", "volunteers", ",", "we", "studied", "the", "gabapentin", "-", "induced", "modulation", "of", "brain", "activity", "in", "response", "to", "nociceptive", "mechanical", "stimulation", "of", "normal", "skin", "and", "capsaicin", "-", "induced", "secondary", "hyperalgesia", ".", "The", "dose", "of", "gabapentin", "was", "1", ",", "800", "mg", "per", "os", ",", "in", "a", "single", "administration", ".", "We", "found", "that", "(", "i", ")", "gabapentin", "reduced", "the", "activations", "in", "the", "bilateral", "operculoinsular", "cortex", ",", "independently", "of", "the", "presence", "of", "central", "sensitization", ";", "(", "ii", ")", "gabapentin", "reduced", "the", "activation", "in", "the", "brainstem", ",", "only", "during", "central", "sensitization", ";", "(", "iii", ")", "gabapentin", "suppressed", "stimulus", "-", "induced", "deactivations", ",", "only", "during", "central", "sensitization", ";", "this", "effect", "was", "more", "robust", "than", "the", "effect", "on", "brain", "activation", ".", "The", "observed", "drug", "-", "induced", "effects", "were", "not", "due", "to", "changes", "in", "the", "baseline", "fMRI", "signal", ".", "These", "findings", "indicate", "that", "gabapentin", "has", "a", "measurable", "antinociceptive", "effect", "and", "a", "stronger", "antihyperalgesic", "effect", "most", "evident", "in", "the", "brain", "areas", "undergoing", "deactivation", ",", "thus", "supporting", "the", "concept", "that", "gabapentin", "is", "more", "effective", "in", "modulating", "nociceptive", "transmission", "when", "central", "sensitization", "is", "present", "."]], "ner": [[[155, 155, "Chemical"], [47, 48, "Disease"], [51, 52, "Disease"], [57, 58, "Disease"], [77, 77, "Disease"], [158, 159, "Disease"], [100, 100, "Chemical"], [138, 138, "Chemical"], [164, 164, "Chemical"], [184, 184, "Chemical"], [205, 205, "Chemical"], [221, 221, "Chemical"], [266, 266, "Chemical"], [291, 291, "Chemical"], [3, 3, "Disease"], [38, 38, "Disease"], [44, 45, "Disease"], [62, 63, "Disease"], [106, 107, "Disease"]]], "relations": [[[155, 155, 47, 48, "CID"], [155, 155, 51, 52, "CID"], [155, 155, 57, 58, "CID"], [155, 155, 77, 77, "CID"], [155, 155, 158, 159, "CID"]]], "clusters": [], "translated": "<14>疼痛</14>的药理学调节 - 在人类正常和中枢敏化状态下与大脑活动相关。中枢神经系统中体感输入的异常处理（中枢敏化）是导致<16>组织损伤</16>周围皮肤<15>疼痛</15>敏感性增强的机制（<1>继发性痛觉过敏</1> ) 。<2>继发性痛觉过敏</2>与<3>神经源性痛觉过敏</3>在<17>神经性疼痛</17>患者中具有相同的临床特征。在实验性中枢敏化过程中，<4>痛觉过敏</4>患者以及正常受试者均发现大脑对体感刺激的异常反应。本研究的目的是评估<6>加巴喷丁</6>（一种对<18>神经性疼痛</18>患者有效的药物）对正常和中枢致敏状态下大脑处理伤害性信息的影响。在正常志愿者身上使用功能磁共振成像 (fMRI)，我们研究了<7>加巴喷丁</7>诱导的大脑活动调节，以响应正常皮肤的伤害性机械刺激和<0>辣椒素</0>诱导的<5>继发性痛觉过敏</5>。 <8>加巴喷丁</8> 的剂量为 1,800 mg，口服，单次给药。我们发现(i)<9>加巴喷丁</9>减少双侧岛盖皮层的激活，与是否存在中枢致敏无关；(ii)<10>加巴喷丁</10>仅在中枢敏化期间减少脑干中的激活；(iii)<11>加巴喷丁</11>仅在中枢敏化期间抑制刺激诱导的失活；这种影响比对大脑激活的影响更强大。观察到的药物诱导效应不是由于基线fMRI信号的变化。这些发现表明<12>加巴喷丁</12>具有可测量的镇痛作用和更强的抗痛觉过敏作用，这在正在失活的大脑区域最为明显，从而支持了<13>加巴喷丁</13>在调节伤害感受方面更有效的概念存在中枢敏化时的传播。", "revised": true}
{"doc_key": "16574712", "sentences": [["MDMA", "polydrug", "users", "show", "process", "-", "specific", "central", "executive", "impairments", "coupled", "with", "impaired", "social", "and", "emotional", "judgement", "processes", ".", "In", "recent", "years", "working", "memory", "deficits", "have", "been", "reported", "in", "users", "of", "MDMA", "(", "3", ",", "4", "-", "methylenedioxymethamphetamine", ",", "ecstasy", ")", ".", "The", "current", "study", "aimed", "to", "assess", "the", "impact", "of", "MDMA", "use", "on", "three", "separate", "central", "executive", "processes", "(", "set", "shifting", ",", "inhibition", "and", "memory", "updating", ")", "and", "also", "on", "\"", "prefrontal", "\"", "mediated", "social", "and", "emotional", "judgement", "processes", ".", "Fifteen", "polydrug", "ecstasy", "users", "and", "15", "polydrug", "non", "-", "ecstasy", "user", "controls", "completed", "a", "general", "drug", "use", "questionnaire", ",", "the", "Brixton", "Spatial", "Anticipation", "task", "(", "set", "shifting", ")", ",", "Backward", "Digit", "Span", "procedure", "(", "memory", "updating", ")", ",", "Inhibition", "of", "Return", "(", "inhibition", ")", ",", "an", "emotional", "intelligence", "scale", ",", "the", "Tromso", "Social", "Intelligence", "Scale", "and", "the", "Dysexecutive", "Questionnaire", "(", "DEX", ")", ".", "Compared", "with", "MDMA", "-", "free", "polydrug", "controls", ",", "MDMA", "polydrug", "users", "showed", "impairments", "in", "set", "shifting", "and", "memory", "updating", ",", "and", "also", "in", "social", "and", "emotional", "judgement", "processes", ".", "The", "latter", "two", "deficits", "remained", "significant", "after", "controlling", "for", "other", "drug", "use", ".", "These", "data", "lend", "further", "support", "to", "the", "proposal", "that", "cognitive", "processes", "mediated", "by", "the", "prefrontal", "cortex", "may", "be", "impaired", "by", "recreational", "ecstasy", "use", "."]], "ner": [[[0, 0, "Chemical"], [31, 31, "Chemical"], [33, 37, "Chemical"], [39, 39, "Chemical"], [51, 51, "Chemical"], [83, 83, "Chemical"], [90, 90, "Chemical"], [146, 146, "Chemical"], [152, 152, "Chemical"], [207, 207, "Chemical"], [12, 17, "Disease"], [23, 24, "Disease"]]], "relations": [[[0, 0, 12, 17, "CID"], [31, 31, 12, 17, "CID"], [33, 37, 12, 17, "CID"], [39, 39, 12, 17, "CID"], [51, 51, 12, 17, "CID"], [83, 83, 12, 17, "CID"], [90, 90, 12, 17, "CID"], [146, 146, 12, 17, "CID"], [152, 152, 12, 17, "CID"], [207, 207, 12, 17, "CID"]]], "clusters": [], "translated": " <0>摇头丸</0>吸毒者表现出特定过程的中央执行障碍以及<10>受损的社交和情感判断过程</10>。近年来，使用<1>MDMA</1>（<2>3, 4-亚甲二氧基甲基苯丙胺</2>，<3>摇头丸</3>）的人报告了工作<11>记忆缺陷</11>。目前的研究旨在评估<4>MDMA</4>使用对三个独立的中央执行过程（定势转换、抑制和记忆更新）以及对“前额叶”介导的社会和情绪判断过程的影响。15名多药<5>摇头丸</5>使用者和15名多药非<6>摇头丸</6>使用者控制组完成了一般药物使用问卷、Brixton空间预测任务（设置转换）、向后数字跨度程序（记忆更新）、抑制回归（抑制）、情商量表、特罗姆瑟社会智力量表和执行障碍问卷（DEX）。与未使用<7>MDMA</7>的多药对照组相比，使用<8>MDMA</8>的多药使用者在定型转换和记忆更新以及社交和情绪判断过程中表现出障碍。后两项障碍在控制了其他药物使用后仍然显著。这些数据进一步支持了由前额叶皮质介导的认知过程可能会因娱乐性<9>摇头丸</9>使用而受损的提议。", "revised": true}
{"doc_key": "18020536", "sentences": [["Associations", "between", "use", "of", "benzodiazepines", "or", "related", "drugs", "and", "health", ",", "physical", "abilities", "and", "cognitive", "function", ":", "a", "non", "-", "randomised", "clinical", "study", "in", "the", "elderly", ".", "OBJECTIVE", ":", "To", "describe", "associations", "between", "the", "use", "of", "benzodiazepines", "or", "related", "drugs", "(", "BZDs", "/", "RDs", ")", "and", "health", ",", "functional", "abilities", "and", "cognitive", "function", "in", "the", "elderly", ".", "METHODS", ":", "A", "non", "-", "randomised", "clinical", "study", "of", "patients", "aged", ">", "or", "=", "65", "years", "admitted", "to", "acute", "hospital", "wards", "during", "1", "month", ".", "164", "patients", "(", "mean", "age", "+", "/", "-", "standard", "deviation", "[", "SD", "]", "81", ".", "6", "+", "/", "-", "6", ".", "8", "years", ")", "were", "admitted", ".", "Of", "these", ",", "nearly", "half", "(", "n", "=", "78", ")", "had", "used", "BZDs", "/", "RDs", "before", "admission", ",", "and", "the", "remainder", "(", "n", "=", "86", ")", "were", "non", "-", "users", ".", "Cognitive", "ability", "was", "assessed", "by", "the", "Mini", "-", "Mental", "State", "Examination", "(", "MMSE", ")", ".", "Patients", "scoring", ">", "or", "=", "20", "MMSE", "sum", "points", "were", "interviewed", "(", "n", "=", "79", ")", "and", "questioned", "regarding", "symptoms", "and", "functional", "abilities", "during", "the", "week", "prior", "to", "admission", ".", "Data", "on", "use", "of", "BZDs", "/", "RDs", "before", "admission", ",", "current", "medications", "and", "discharge", "diagnoses", "were", "collected", "from", "medical", "records", ".", "Health", ",", "physical", "abilities", "and", "cognitive", "function", "were", "compared", "between", "BZD", "/", "RD", "users", "and", "non", "-", "users", ",", "and", "adjustments", "were", "made", "for", "confounding", "variables", ".", "The", "residual", "serum", "concentrations", "of", "oxazepam", ",", "temazepam", "and", "zopiclone", "were", "analysed", ".", "RESULTS", ":", "The", "mean", "+", "/", "-", "SD", "duration", "of", "BZD", "/", "RD", "use", "was", "7", "+", "/", "-", "7", "years", "(", "range", "1", "-", "31", ")", ".", "Two", "or", "three", "BZDs", "/", "RDs", "were", "concomitantly", "taken", "by", "26", "%", "of", "users", "(", "n", "=", "20", ")", ".", "Long", "-", "term", "use", "of", "these", "drugs", "was", "associated", "with", "female", "sex", "and", "use", "of", "a", "higher", "number", "of", "drugs", "with", "effects", "on", "the", "CNS", ",", "which", "tended", "to", "be", "related", "to", "diagnosed", "dementia", ".", "After", "adjustment", "for", "these", "variables", "as", "confounders", ",", "use", "of", "BZDs", "/", "RDs", "was", "not", "associated", "with", "cognitive", "function", "as", "measured", "by", "the", "MMSE", ".", "However", ",", "use", "of", "BZDs", "/", "RDs", "was", "associated", "with", "dizziness", ",", "inability", "to", "sleep", "after", "awaking", "at", "night", "and", "tiredness", "in", "the", "mornings", "during", "the", "week", "prior", "to", "admission", "and", "with", "stronger", "depressive", "symptoms", "measured", "at", "the", "beginning", "of", "the", "hospital", "stay", ".", "Use", "of", "BZDs", "/", "RDs", "tended", "to", "be", "associated", "with", "a", "reduced", "ability", "to", "walk", "and", "shorter", "night", "-", "time", "sleep", "during", "the", "week", "prior", "to", "admission", ".", "A", "higher", "residual", "serum", "concentration", "of", "temazepam", "correlated", "with", "a", "lower", "MMSE", "sum", "score", "after", "adjustment", "for", "confounding", "variables", ".", "CONCLUSIONS", ":", "Long", "-", "term", "use", "and", "concomitant", "use", "of", "more", "than", "one", "BZD", "/", "RD", "were", "common", "in", "elderly", "patients", "hospitalised", "because", "of", "acute", "illnesses", ".", "Long", "-", "term", "use", "was", "associated", "with", "daytime", "and", "night", "-", "time", "symptoms", "indicative", "of", "poorer", "health", "and", "potentially", "caused", "by", "the", "adverse", "effects", "of", "these", "drugs", "."]], "ner": [[[4, 4, "Chemical"], [36, 36, "Chemical"], [41, 41, "Chemical"], [121, 121, "Chemical"], [189, 189, "Chemical"], [277, 277, "Chemical"], [339, 339, "Chemical"], [358, 358, "Chemical"], [400, 400, "Chemical"], [364, 364, "Disease"], [366, 368, "Disease"], [374, 374, "Disease"], [387, 388, "Disease"], [327, 327, "Disease"], [238, 238, "Chemical"], [240, 240, "Chemical"], [432, 432, "Chemical"], [242, 242, "Chemical"]]], "relations": [[[4, 4, 364, 364, "CID"], [36, 36, 364, 364, "CID"], [41, 41, 364, 364, "CID"], [121, 121, 364, 364, "CID"], [189, 189, 364, 364, "CID"], [277, 277, 364, 364, "CID"], [339, 339, 364, 364, "CID"], [358, 358, 364, 364, "CID"], [400, 400, 364, 364, "CID"], [4, 4, 366, 368, "CID"], [36, 36, 366, 368, "CID"], [41, 41, 366, 368, "CID"], [121, 121, 366, 368, "CID"], [189, 189, 366, 368, "CID"], [277, 277, 366, 368, "CID"], [339, 339, 366, 368, "CID"], [358, 358, 366, 368, "CID"], [400, 400, 366, 368, "CID"], [4, 4, 374, 374, "CID"], [36, 36, 374, 374, "CID"], [41, 41, 374, 374, "CID"], [121, 121, 374, 374, "CID"], [189, 189, 374, 374, "CID"], [277, 277, 374, 374, "CID"], [339, 339, 374, 374, "CID"], [358, 358, 374, 374, "CID"], [400, 400, 374, 374, "CID"], [4, 4, 387, 388, "CID"], [36, 36, 387, 388, "CID"], [41, 41, 387, 388, "CID"], [121, 121, 387, 388, "CID"], [189, 189, 387, 388, "CID"], [277, 277, 387, 388, "CID"], [339, 339, 387, 388, "CID"], [358, 358, 387, 388, "CID"], [400, 400, 387, 388, "CID"]]], "clusters": [], "translated": "使用<0>苯二氮卓类药物</0>或相关药物与健康、身体能力和认知功能之间的关联：一项针对老年人的非随机临床研究。目的：描述老年人使用<1>苯二氮卓类</1>或相关药物(<2>BZDs</2>/RDs)与健康、功能能力和认知功能之间的关联。方法：对1个月内入住急症医院病房的年龄>或= 65 岁的患者进行的一项非随机临床研究。164名患者（平均年龄+/-标准差[SD] 81.6+/-6.8岁）被收治。其中，将近一半(n=78)在入院前使用过<3>BZD</3>/RD，其余(n=86)未使用。认知能力通过简易精神状态检查（MMSE）进行评估。在入院前一周内，对MMSE总分得分>或=20的患者进行了访谈(n=79)，并询问了有关症状和功能能力的问题。从医疗记录中收集入院前<4>BZDs</4>/RDs的使用情况、当前药物治疗和出院诊断的数据。比较了BZD/RD使用者和非使用者之间的健康、身体能力和认知功能，并对混杂变量进行了调整。分析了<14>奥沙西泮</14>、<15>替马西泮</15>和<17>佐匹克隆</17>的血清残留浓度。 结果：BZD/RD使用的平均+/-SD持续时间为7+/-7年（范围1-31）。26%的用户(n=20)同时服用了两个或三个<5>BZD</5>/RD。长期使用这些药物与女性相关，并且使用更多对中枢神经系统有影响的药物，这往往与确诊的<13>痴呆</13>有关。将这些变量作为混杂因素进行调整后，<6>BZDs</6>/RDs的使用与MMSE测量的认知功能无关。然而，<7>BZDs</7>/RDs的使用与<9>头晕</9>、夜间醒来后<10>无法入睡</10>和<11>疲倦</11>有关入院前一周的早晨，以及在住院开始时测量到的<12>抑郁症状</12>更强烈。<8>BZDs</8>/RDs的使用往往与入院前一周行走能力下降和夜间睡眠时间缩短有关。校正混杂变量后，<16>替马西泮</16>的较高残留血清浓度与较低的MMSE总分相关。结论：长期使用和同时使用一种以上的BZD/RD在因急性疾病住院的老年患者中很常见。长期使用与表明健康状况较差的白天和夜间症状有关，并可能由这些药物的副作用引起。", "revised": true}
{"doc_key": "20470218", "sentences": [["Central", "nervous", "system", "complications", "during", "treatment", "of", "acute", "lymphoblastic", "leukemia", "in", "a", "single", "pediatric", "institution", ".", "Central", "nervous", "system", "(", "CNS", ")", "complications", "during", "treatment", "of", "childhood", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "remain", "a", "challenging", "clinical", "problem", ".", "Outcome", "improvement", "with", "more", "intensive", "chemotherapy", "has", "significantly", "increased", "the", "incidence", "and", "severity", "of", "adverse", "events", ".", "This", "study", "analyzed", "the", "incidence", "of", "neurological", "complications", "during", "ALL", "treatment", "in", "a", "single", "pediatric", "institution", ",", "focusing", "on", "clinical", ",", "radiological", ",", "and", "electrophysiological", "findings", ".", "Exclusion", "criteria", "included", "CNS", "leukemic", "infiltration", "at", "diagnosis", ",", "therapy", "-", "related", "peripheral", "neuropathy", ",", "late", "-", "onset", "encephalopathy", ",", "or", "long", "-", "term", "neurocognitive", "defects", ".", "During", "a", "9", "-", "year", "period", ",", "we", "retrospectively", "collected", "27", "neurological", "events", "(", "11", "%", ")", "in", "as", "many", "patients", ",", "from", "253", "children", "enrolled", "in", "the", "ALL", "front", "-", "line", "protocol", ".", "CNS", "complications", "included", "posterior", "reversible", "leukoencephalopathy", "syndrome", "(", "n", "=", "10", ")", ",", "stroke", "(", "n", "=", "5", ")", ",", "temporal", "lobe", "epilepsy", "(", "n", "=", "2", ")", ",", "high", "-", "dose", "methotrexate", "toxicity", "(", "n", "=", "2", ")", ",", "syndrome", "of", "inappropriate", "antidiuretic", "hormone", "secretion", "(", "n", "=", "1", ")", ",", "and", "other", "unclassified", "events", "(", "n", "=", "7", ")", ".", "In", "conclusion", ",", "CNS", "complications", "are", "frequent", "events", "during", "ALL", "therapy", ",", "and", "require", "rapid", "detection", "and", "prompt", "treatment", "to", "limit", "permanent", "damage", "."]], "ner": [[[176, 176, "Chemical"], [0, 3, "Disease"], [16, 22, "Disease"], [62, 63, "Disease"], [107, 108, "Disease"], [7, 9, "Disease"], [27, 29, "Disease"], [31, 31, "Disease"], [65, 65, "Disease"], [138, 138, "Disease"], [215, 215, "Disease"], [87, 88, "Disease"], [95, 96, "Disease"], [101, 101, "Disease"], [149, 149, "Disease"], [157, 157, "Disease"], [164, 166, "Disease"], [177, 177, "Disease"], [186, 189, "Disease"]]], "relations": [[[176, 176, 0, 3, "CID"], [176, 176, 16, 22, "CID"], [176, 176, 62, 63, "CID"], [176, 176, 107, 108, "CID"]]], "clusters": [], "translated": " <1>中枢神经系统并发症</1>在单一儿科机构治疗<5>急性淋巴细胞白血病</5>期间。儿童<6>急性淋巴细胞白血病</6>（<7>ALL</7>）治疗过程中的<2>中枢神经系统（CNS）并发症</2>仍然是一个具有挑战性的临床问题。更强化化疗的结果改善显着增加了不良事件的发生率和严重性。本研究分析了单个儿科机构<8>ALL</8>治疗期间<3>神经系统并发症</3>的发生率，重点关注临床、放射学和电生理学结果。排除标准包括诊断时CNS<11>白血病浸润</11>、治疗相关<12>周围神经病变</12>、迟发性<13>脑病</13>或长期<4>神经认知缺陷</4>。在9年时间里，我们回顾性地收集了27例神经系统事件 (11%)，涉及参与<9>ALL</9>一线方案的253名儿童。CNS并发症包括后部可逆性<14>白质脑病</14>综合征 (n=10)，<15>中风</15> (n=5)，<16>颞叶癫痫</16> (n=2)，高剂量<0>甲氨蝶呤</0> <17>毒性</17> (n=2)，<18>抗利尿激素分泌异常</18>综合征 (n=1)，和其他未分类事件 (n=7)。总之，CNS并发症是<10>ALL</10>治疗期间的常见事件，需要快速检测和及时治疗以减少永久性损害。", "revised": true}
{"doc_key": "18023325", "sentences": [["Acute", "vocal", "fold", "palsy", "after", "acute", "disulfiram", "intoxication", ".", "Acute", "peripheral", "neuropathy", "caused", "by", "a", "disulfiram", "overdose", "is", "very", "rare", "and", "there", "is", "no", "report", "of", "it", "leading", "to", "vocal", "fold", "palsy", ".", "A", "49", "-", "year", "-", "old", "woman", "was", "transferred", "to", "our", "department", "because", "of", "quadriparesis", ",", "lancinating", "pain", ",", "sensory", "loss", ",", "and", "paresthesia", "of", "the", "distal", "limbs", ".", "One", "month", "previously", ",", "she", "had", "taken", "a", "single", "high", "dose", "of", "disulfiram", "(", "130", "tablets", "of", "ALCOHOL", "STOP", "TAB", ",", "Shin", "-", "Poong", "Pharm", ".", "Co", ".", ",", "Ansan", ",", "Korea", ")", "in", "a", "suicide", "attempt", ".", "She", "was", "not", "an", "alcoholic", ".", "For", "the", "first", "few", "days", "after", "ingestion", ",", "she", "was", "in", "a", "confused", "state", "and", "had", "mild", "to", "moderate", "ataxia", "and", "giddiness", ".", "She", "noticed", "hoarseness", "and", "distally", "accentuated", "motor", "and", "sensory", "dysfunction", "after", "she", "had", "recovered", "from", "this", "state", ".", "A", "nerve", "conduction", "study", "was", "consistent", "with", "severe", "sensorimotor", "axonal", "polyneuropathy", ".", "Laryngeal", "electromyography", "(", "thyroarytenoid", "muscle", ")", "showed", "ample", "denervation", "potentials", ".", "Laryngoscopy", "revealed", "asymmetric", "vocal", "fold", "movements", "during", "phonation", ".", "Her", "vocal", "change", "and", "weakness", "began", "to", "improve", "spontaneously", "about", "3", "weeks", "after", "transfer", ".", "This", "was", "a", "case", "of", "acute", "palsy", "of", "the", "recurrent", "laryngeal", "nerve", "and", "superimposed", "severe", "acute", "sensorimotor", "axonal", "polyneuropathy", "caused", "by", "high", "-", "dose", "disulfiram", "intoxication", "."]], "ner": [[[6, 6, "Chemical"], [15, 15, "Chemical"], [74, 74, "Chemical"], [218, 218, "Chemical"], [1, 3, "Disease"], [29, 31, "Disease"], [10, 11, "Disease"], [47, 47, "Disease"], [50, 50, "Disease"], [56, 56, "Disease"], [125, 125, "Disease"], [79, 79, "Chemical"], [16, 16, "Disease"], [52, 53, "Disease"], [127, 127, "Disease"], [131, 131, "Disease"], [157, 157, "Disease"], [212, 212, "Disease"], [200, 200, "Disease"]]], "relations": [[[6, 6, 1, 3, "CID"], [6, 6, 29, 31, "CID"], [15, 15, 1, 3, "CID"], [15, 15, 29, 31, "CID"], [74, 74, 1, 3, "CID"], [74, 74, 29, 31, "CID"], [218, 218, 1, 3, "CID"], [218, 218, 29, 31, "CID"], [6, 6, 10, 11, "CID"], [15, 15, 10, 11, "CID"], [74, 74, 10, 11, "CID"], [218, 218, 10, 11, "CID"], [6, 6, 47, 47, "CID"], [15, 15, 47, 47, "CID"], [74, 74, 47, 47, "CID"], [218, 218, 47, 47, "CID"], [6, 6, 50, 50, "CID"], [15, 15, 50, 50, "CID"], [74, 74, 50, 50, "CID"], [218, 218, 50, 50, "CID"], [6, 6, 56, 56, "CID"], [15, 15, 56, 56, "CID"], [74, 74, 56, 56, "CID"], [218, 218, 56, 56, "CID"], [6, 6, 125, 125, "CID"], [15, 15, 125, 125, "CID"], [74, 74, 125, 125, "CID"], [218, 218, 125, 125, "CID"]]], "clusters": [], "translated": "急性<0>双硫仑</0>中毒后出现急性<4>声带麻痹</4>。<1>双硫仑</1><12>过量</12>引起的急性<6>周围神经病变</6>非常罕见，也没有导致<5>声带麻痹</5>的报道。一名49岁女性因<7>四肢瘫痪</7>、刀割样<8>痛</8>、<13>感觉丧失</13>和<9>感觉异常</9>肢体远端。一个月前，她服用了单次高剂量的<2>双硫仑</2>（130片<11>ALCOHOL</11>STOP TAB，Shin-Poong Pharm. Co.，韩国安山）自杀。她不是酒鬼。摄入后的最初几天，她处于意识模糊状态，并有轻度至中度<10>共济失调</10>和<14>头晕</14>。从这种状态恢复后，她注意到<15>声音嘶哑</15>和远端加重的运动和感觉功能障碍。神经传导研究与严重的感觉运动轴突<16>多发性神经病</16>一致。喉肌电图（甲杓肌）显示充足的去神经支配电位。喉镜检查显示发声过程中声带运动不对称。转移后约3周，她的声音变化和虚弱开始自发改善。这是一例由大剂量<3>双硫仑</3>中毒引起的喉返神经急性<18>麻痹</18>并叠加严重的急性感觉运动性轴突<17>多发性神经病</17>。", "revised": true}
{"doc_key": "17111419", "sentences": [["Severe", "citrate", "toxicity", "complicating", "volunteer", "apheresis", "platelet", "donation", ".", "We", "report", "a", "case", "of", "severe", "citrate", "toxicity", "during", "volunteer", "donor", "apheresis", "platelet", "collection", ".", "The", "donor", "was", "a", "40", "-", "year", "-", "old", "female", ",", "first", "-", "time", "apheresis", "platelet", "donor", ".", "Past", "medical", "history", "was", "remarkable", "for", "hypertension", ",", "hyperlipidemia", ",", "and", "depression", ".", "Reported", "medications", "included", "bumetanide", ",", "pravastatin", ",", "and", "paroxetine", ".", "Thirty", "minutes", "from", "the", "start", "of", "the", "procedure", ",", "the", "donor", "noted", "tingling", "around", "the", "mouth", ",", "hands", ",", "and", "feet", ".", "She", "then", "very", "rapidly", "developed", "acute", "onset", "of", "severe", "facial", "and", "extremity", "tetany", ".", "Empirical", "treatment", "with", "intravenous", "calcium", "gluconate", "was", "initiated", ",", "and", "muscle", "contractions", "slowly", "subsided", "over", "approximately", "10", "to", "15", "minutes", ".", "The", "events", "are", "consistent", "with", "a", "severe", "reaction", "to", "calcium", "chelation", "by", "sodium", "citrate", "anticoagulant", "resulting", "in", "symptomatic", "systemic", "hypocalcemia", ".", "Upon", "additional", "retrospective", "analysis", ",", "it", "was", "noted", "that", "bumetanide", "is", "a", "loop", "diuretic", "that", "may", "cause", "significant", "hypocalcemia", ".", "We", "conclude", "that", "careful", "screening", "for", "medications", "and", "underlying", "conditions", "predisposing", "to", "hypocalcemia", "is", "recommended", "to", "help", "prevent", "severe", "reactions", "due", "to", "citrate", "toxicity", ".", "Laboratory", "measurement", "of", "pre", "-", "procedure", "serum", "calcium", "levels", "in", "selected", "donors", "may", "identify", "cases", "requiring", "heightened", "vigilance", ".", "The", "case", "also", "illustrates", "the", "importance", "of", "maintaining", "preparedness", "for", "managing", "rare", "but", "serious", "reactions", "in", "volunteer", "apheresis", "blood", "donors", "."]], "ner": [[[1, 1, "Chemical"], [15, 15, "Chemical"], [134, 135, "Chemical"], [185, 185, "Chemical"], [141, 141, "Disease"], [161, 161, "Disease"], [175, 175, "Disease"], [2, 2, "Disease"], [16, 16, "Disease"], [186, 186, "Disease"], [48, 48, "Disease"], [50, 50, "Disease"], [53, 53, "Disease"], [99, 99, "Disease"], [111, 112, "Disease"], [58, 58, "Chemical"], [152, 152, "Chemical"], [60, 60, "Chemical"], [63, 63, "Chemical"], [105, 106, "Chemical"], [131, 131, "Chemical"], [195, 195, "Chemical"], [155, 156, "Chemical"]]], "relations": [[[1, 1, 141, 141, "CID"], [1, 1, 161, 161, "CID"], [1, 1, 175, 175, "CID"], [15, 15, 141, 141, "CID"], [15, 15, 161, 161, "CID"], [15, 15, 175, 175, "CID"], [134, 135, 141, 141, "CID"], [134, 135, 161, 161, "CID"], [134, 135, 175, 175, "CID"], [185, 185, 141, 141, "CID"], [185, 185, 161, 161, "CID"], [185, 185, 175, 175, "CID"]]], "clusters": [], "translated": "严重的<0>柠檬酸盐</0><7>毒性</7>使志愿者单采血小板捐赠复杂化。我们报告了一例严重<1>柠檬酸盐</1><8>毒性</8>的病例，该病例在志愿者单采血小板采集过程中发生。捐献者是一位40岁的女性，首次单采血小板捐献者。既往病史有<10>高血压</10>、<11>高脂血症</11>和<12>抑郁症</12>。报告的药物包括<15>布美他尼</15>、<17>普伐他汀</17>和<18>帕罗西汀</18>。手术开始后30分钟，捐献者注意到嘴巴、手和脚周围有刺痛感。然后，她很快出现严重的面部和肢体<13>手足搐搦症</13>的急性发作。开始使用静脉注射<19>葡萄糖酸钙</19>进行经验性治疗，<14>肌肉收缩</14>在大约10到15分钟内缓慢消退。这些事件与<2>柠檬酸钠</2>抗凝剂对<20>钙</20>螯合的严重反应一致，导致有症状的全身性<4>低钙血症</4>。进一步的回顾性分析表明，<16>布美他尼</16>是一种<22>袢利尿剂</22>，可能导致显着的<5>低钙血症</5>。我们得出结论，建议仔细筛查易导致<6>低钙血症</6>的药物和潜在病症，以帮助预防因<3>柠檬酸盐</3><9>毒性</9>引起的严重反应。对选定供体进行术前血清<21>钙</21>水平的实验室测量可能会发现需要提高警惕的病例。该案例还说明了保持准备的重要性，以应对自愿单采献血者罕见但严重的反应。", "revised": true}
{"doc_key": "12639165", "sentences": [["Ticlopidine", "-", "induced", "cholestatic", "hepatitis", ".", "OBJECTIVE", ":", "To", "report", "2", "cases", "of", "ticlopidine", "-", "induced", "cholestatic", "hepatitis", ",", "investigate", "its", "mechanism", ",", "and", "compare", "the", "observed", "main", "characteristics", "with", "those", "of", "the", "published", "cases", ".", "CASE", "SUMMARIES", ":", "Two", "patients", "developed", "prolonged", "cholestatic", "hepatitis", "after", "receiving", "ticlopidine", "following", "percutaneous", "coronary", "angioplasty", ",", "with", "complete", "remission", "during", "the", "follow", "-", "up", "period", ".", "T", "-", "cell", "stimulation", "by", "therapeutic", "concentration", "of", "ticlopidine", "was", "demonstrated", "in", "vitro", "in", "the", "patients", ",", "but", "not", "in", "healthy", "controls", ".", "DISCUSSION", ":", "Cholestatic", "hepatitis", "is", "a", "rare", "complication", "of", "the", "antiplatelet", "agent", "ticlopidine", ";", "several", "cases", "have", "been", "reported", "but", "few", "in", "the", "English", "literature", ".", "Our", "patients", "developed", "jaundice", "following", "treatment", "with", "ticlopidine", "and", "showed", "the", "clinical", "and", "laboratory", "characteristics", "of", "cholestatic", "hepatitis", ",", "which", "resolved", "after", "discontinuation", "of", "the", "drug", ".", "Hepatitis", "may", "develop", "weeks", "after", "discontinuation", "of", "the", "drug", "and", "may", "run", "a", "prolonged", "course", ",", "but", "complete", "remission", "was", "observed", "in", "all", "reported", "cases", ".", "An", "objective", "causality", "assessment", "revealed", "that", "the", "adverse", "drug", "event", "was", "probably", "related", "to", "the", "use", "of", "ticlopidine", ".", "The", "mechanisms", "of", "this", "ticlopidine", "-", "induced", "cholestasis", "are", "unclear", ".", "Immune", "mechanisms", "may", "be", "involved", "in", "the", "drug", "'s", "hepatotoxicity", ",", "as", "suggested", "by", "the", "T", "-", "cell", "stimulation", "study", "reported", "here", ".", "CONCLUSIONS", ":", "Cholestatic", "hepatitis", "is", "a", "rare", "adverse", "effect", "of", "ticlopidine", "that", "may", "be", "immune", "mediated", ".", "Patients", "receiving", "the", "drug", "should", "be", "monitored", "with", "liver", "function", "tests", "along", "with", "complete", "blood", "cell", "counts", ".", "This", "complication", "will", "be", "observed", "even", "less", "often", "in", "the", "future", "as", "ticlopidine", "is", "being", "replaced", "by", "the", "newer", "antiplatelet", "agent", "clopidogrel", "."]], "ner": [[[0, 0, "Chemical"], [13, 13, "Chemical"], [47, 47, "Chemical"], [71, 71, "Chemical"], [98, 98, "Chemical"], [119, 119, "Chemical"], [182, 182, "Chemical"], [188, 188, "Chemical"], [228, 228, "Chemical"], [265, 265, "Chemical"], [3, 4, "Disease"], [16, 17, "Disease"], [43, 44, "Disease"], [88, 89, "Disease"], [128, 129, "Disease"], [191, 191, "Disease"], [220, 221, "Disease"], [139, 139, "Disease"], [204, 204, "Disease"], [115, 115, "Disease"], [274, 274, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 16, 17, "CID"], [0, 0, 43, 44, "CID"], [0, 0, 88, 89, "CID"], [0, 0, 128, 129, "CID"], [0, 0, 191, 191, "CID"], [0, 0, 220, 221, "CID"], [13, 13, 3, 4, "CID"], [13, 13, 16, 17, "CID"], [13, 13, 43, 44, "CID"], [13, 13, 88, 89, "CID"], [13, 13, 128, 129, "CID"], [13, 13, 191, 191, "CID"], [13, 13, 220, 221, "CID"], [47, 47, 3, 4, "CID"], [47, 47, 16, 17, "CID"], [47, 47, 43, 44, "CID"], [47, 47, 88, 89, "CID"], [47, 47, 128, 129, "CID"], [47, 47, 191, 191, "CID"], [47, 47, 220, 221, "CID"], [71, 71, 3, 4, "CID"], [71, 71, 16, 17, "CID"], [71, 71, 43, 44, "CID"], [71, 71, 88, 89, "CID"], [71, 71, 128, 129, "CID"], [71, 71, 191, 191, "CID"], [71, 71, 220, 221, "CID"], [98, 98, 3, 4, "CID"], [98, 98, 16, 17, "CID"], [98, 98, 43, 44, "CID"], [98, 98, 88, 89, "CID"], [98, 98, 128, 129, "CID"], [98, 98, 191, 191, "CID"], [98, 98, 220, 221, "CID"], [119, 119, 3, 4, "CID"], [119, 119, 16, 17, "CID"], [119, 119, 43, 44, "CID"], [119, 119, 88, 89, "CID"], [119, 119, 128, 129, "CID"], [119, 119, 191, 191, "CID"], [119, 119, 220, 221, "CID"], [182, 182, 3, 4, "CID"], [182, 182, 16, 17, "CID"], [182, 182, 43, 44, "CID"], [182, 182, 88, 89, "CID"], [182, 182, 128, 129, "CID"], [182, 182, 191, 191, "CID"], [182, 182, 220, 221, "CID"], [188, 188, 3, 4, "CID"], [188, 188, 16, 17, "CID"], [188, 188, 43, 44, "CID"], [188, 188, 88, 89, "CID"], [188, 188, 128, 129, "CID"], [188, 188, 191, 191, "CID"], [188, 188, 220, 221, "CID"], [228, 228, 3, 4, "CID"], [228, 228, 16, 17, "CID"], [228, 228, 43, 44, "CID"], [228, 228, 88, 89, "CID"], [228, 228, 128, 129, "CID"], [228, 228, 191, 191, "CID"], [228, 228, 220, 221, "CID"], [265, 265, 3, 4, "CID"], [265, 265, 16, 17, "CID"], [265, 265, 43, 44, "CID"], [265, 265, 88, 89, "CID"], [265, 265, 128, 129, "CID"], [265, 265, 191, 191, "CID"], [265, 265, 220, 221, "CID"], [0, 0, 139, 139, "CID"], [0, 0, 204, 204, "CID"], [13, 13, 139, 139, "CID"], [13, 13, 204, 204, "CID"], [47, 47, 139, 139, "CID"], [47, 47, 204, 204, "CID"], [71, 71, 139, 139, "CID"], [71, 71, 204, 204, "CID"], [98, 98, 139, 139, "CID"], [98, 98, 204, 204, "CID"], [119, 119, 139, 139, "CID"], [119, 119, 204, 204, "CID"], [182, 182, 139, 139, "CID"], [182, 182, 204, 204, "CID"], [188, 188, 139, 139, "CID"], [188, 188, 204, 204, "CID"], [228, 228, 139, 139, "CID"], [228, 228, 204, 204, "CID"], [265, 265, 139, 139, "CID"], [265, 265, 204, 204, "CID"], [0, 0, 115, 115, "CID"], [13, 13, 115, 115, "CID"], [47, 47, 115, 115, "CID"], [71, 71, 115, 115, "CID"], [98, 98, 115, 115, "CID"], [119, 119, 115, 115, "CID"], [182, 182, 115, 115, "CID"], [188, 188, 115, 115, "CID"], [228, 228, 115, 115, "CID"], [265, 265, 115, 115, "CID"]]], "clusters": [], "translated": "<0>噻氯匹定</0>诱发的<10>胆汁淤积性肝炎</10>。目的：报道2例<1>噻氯匹定</1>所致<11>胆汁淤积性肝炎</11>，探讨其发生机制，并将观察到的主要特征与已发表病例进行比较。病例概要：2例经皮冠状动脉成形术后接受<2>噻氯匹定</2>治疗后出现长期<12>胆汁淤积性肝炎</12>，随访期间完全缓解。治疗浓度的<3>噻氯匹定</3>对T细胞的刺激作用在体外实验中得到证实，但在健康对照中则不然。讨论：<13>胆汁淤积性肝炎</13>是抗血小板药物<4>噻氯匹定</4>的罕见并发症；已经报道了几个案例，但在英文文献中很少见。我们的患者在使用<5>噻氯匹定</5>治疗后出现<19>黄疸</19>，并表现出<14>胆汁淤积性肝炎</14>的临床和实验室特征，停药后症状消失。 <17>肝炎</17>可能会在停药数周后发生，并且病程可能会延长，但在所有报告的病例中均观察到完全缓解。客观的因果关系评估显示，不良药物事件可能与使用<6>噻氯匹定</6>有关。这种<7>噻氯匹定</7>诱导的<15>胆汁淤积</15>的机制尚不清楚。免疫机制可能与药物的<18>肝毒性</18>有关，正如此处报道的T细胞刺激研究所表明的那样。结论：<16>胆汁淤积性肝炎</16>是<8>噻氯匹定</8>的罕见不良反应，可能是免疫介导的。接受药物治疗的患者应接受肝功能检查和全血细胞计数监测。随着<9>噻氯匹定</9>被更新的抗血小板药物<20>氯吡格雷</20>取代，这种并发症在未来会更少出现。", "revised": true}
{"doc_key": "14659530", "sentences": [["NO", "-", "induced", "migraine", "attack", ":", "strong", "increase", "in", "plasma", "calcitonin", "gene", "-", "related", "peptide", "(", "CGRP", ")", "concentration", "and", "negative", "correlation", "with", "platelet", "serotonin", "release", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "investigate", "changes", "in", "the", "plasma", "calcitonin", "gene", "-", "related", "peptide", "(", "CGRP", ")", "concentration", "and", "platelet", "serotonin", "(", "5", "-", "hydroxytriptamine", ",", "5", "-", "HT", ")", "content", "during", "the", "immediate", "headache", "and", "the", "delayed", "genuine", "migraine", "attack", "provoked", "by", "nitroglycerin", ".", "Fifteen", "female", "migraineurs", "(", "without", "aura", ")", "and", "eight", "controls", "participated", "in", "the", "study", ".", "Sublingual", "nitroglycerin", "(", "0", ".", "5", "mg", ")", "was", "administered", ".", "Blood", "was", "collected", "from", "the", "antecubital", "vein", "four", "times", ":", "60", "min", "before", "and", "after", "the", "nitroglycerin", "application", ",", "and", "60", "and", "120", "min", "after", "the", "beginning", "of", "the", "migraine", "attack", "(", "mean", "344", "and", "404", "min", ";", "12", "subjects", ")", ".", "In", "those", "subjects", "who", "had", "no", "migraine", "attack", "(", "11", "subjects", ")", "a", "similar", "time", "schedule", "was", "used", ".", "Plasma", "CGRP", "concentration", "increased", "significantly", "(", "P", "<", "0", ".", "01", ")", "during", "the", "migraine", "attack", "and", "returned", "to", "baseline", "after", "the", "cessation", "of", "the", "migraine", ".", "In", "addition", ",", "both", "change", "and", "peak", ",", "showed", "significant", "positive", "correlations", "with", "migraine", "headache", "intensity", "(", "P", "<", "0", ".", "001", ")", ".", "However", ",", "plasma", "CGRP", "concentrations", "failed", "to", "change", "during", "immediate", "headache", "and", "in", "the", "subjects", "with", "no", "migraine", "attack", ".", "Basal", "CGRP", "concentration", "was", "significantly", "higher", "and", "platelet", "5", "-", "HT", "content", "tended", "to", "be", "lower", "in", "subjects", "who", "experienced", "a", "migraine", "attack", ".", "Platelet", "serotonin", "content", "decreased", "significantly", "(", "P", "<", "0", ".", "01", ")", "after", "nitroglycerin", "in", "subjects", "with", "no", "migraine", "attack", "but", "no", "consistent", "change", "was", "observed", "in", "patients", "with", "migraine", "attack", ".", "In", "conclusion", ",", "the", "fact", "that", "plasma", "CGRP", "concentration", "correlates", "with", "the", "timing", "and", "severity", "of", "a", "migraine", "headache", "suggests", "a", "direct", "relationship", "between", "CGRP", "and", "migraine", ".", "In", "contrast", ",", "serotonin", "release", "from", "platelets", "does", "not", "provoke", "migraine", ",", "it", "may", "even", "counteract", "the", "headache", "and", "the", "concomitant", "CGRP", "release", "in", "this", "model", "."]], "ner": [[[0, 0, "Chemical"], [78, 82, "Disease"], [74, 74, "Chemical"], [92, 92, "Chemical"], [118, 118, "Chemical"], [271, 271, "Chemical"], [3, 3, "Disease"], [70, 70, "Disease"], [131, 131, "Disease"], [150, 150, "Disease"], [177, 177, "Disease"], [188, 188, "Disease"], [203, 203, "Disease"], [231, 231, "Disease"], [255, 255, "Disease"], [276, 276, "Disease"], [287, 287, "Disease"], [307, 307, "Disease"], [316, 316, "Disease"], [328, 328, "Disease"], [65, 65, "Disease"], [204, 204, "Disease"], [224, 224, "Disease"], [308, 308, "Disease"], [335, 335, "Disease"], [10, 14, "Chemical"], [16, 16, "Chemical"], [40, 44, "Chemical"], [46, 46, "Chemical"], [164, 164, "Chemical"], [217, 217, "Chemical"], [235, 235, "Chemical"], [297, 297, "Chemical"], [314, 314, "Chemical"], [339, 339, "Chemical"], [24, 24, "Chemical"], [51, 51, "Chemical"], [53, 55, "Chemical"], [57, 59, "Chemical"], [242, 244, "Chemical"], [259, 259, "Chemical"], [321, 321, "Chemical"]]], "relations": [[[0, 0, 78, 82, "CID"], [74, 74, 78, 82, "CID"], [92, 92, 78, 82, "CID"], [118, 118, 78, 82, "CID"], [271, 271, 78, 82, "CID"]]], "clusters": [], "translated": "<0>NO</0>-诱发<6>偏头痛</6>发作：血浆<25>降钙素基因相关肽</25>（<26>CGRP</26>）浓度强烈升高，呈负相关随着血小板<35>血清素</35>的释放。本研究的目的是研究血浆<27>降钙素基因相关肽</27>（<28>CGRP</28>）浓度和血小板<36>血清素</36>（<37>5-羟曲他明</37>，<38>5-HT</38>）在 <2>硝酸甘油</2>引起的即刻<20>头痛</20>和迟发性真正的<7>偏头痛</7>发作期间的含量。十五名女性<1>偏头痛患者（无先兆）</1>和八名对照组参与了这项研究。给予舌下<3>硝酸甘油</3>（0.5mg）。从肘前静脉采集血液四次：<4>硝酸甘油</4>应用前后60分钟，<8>偏头痛</8>发作开始后60和120分钟（平均344和404分钟；12名受试者）。在那些没有<9>偏头痛</9>发作的受试者（11名受试者）中，使用了类似的时间表。血浆<29>CGRP</29>浓度在<10>偏头痛</10>发作期间显着增加(P < 0.01)，并在<11>偏头痛</11>停止后恢复到基线水平。此外，变化和峰值均与<12>偏头痛</12><21>头痛</21>强度呈显着正相关(P < 0.001)。然而，血浆<30>CGRP</30>浓度在即刻<22>头痛</22>期间和没有<13>偏头痛</13>发作的受试者中没有变化。在经历过<14>偏头痛</14>发作的受试者中，基础<31>CGRP</31>浓度显着升高，血小板<39>5-HT</39>含量趋于降低。在<5>硝酸甘油</5>后没有<15>偏头痛</15>发作的受试者中，血小板<40>血清素</40>含量显着降低(P < 0.01)，但在偏头痛患者中未观察到一致的变化<16>偏头痛</16>发作。总之，血浆<32>CGRP</32>浓度与<17>偏头痛</17><23>头痛</23>的时间和严重程度相关的事实表明<33>CGRP</33>和<18>偏头痛</18>。相比之下，血小板释放的<41>血清素</41>不会引起<19>偏头痛</19>，它甚至可以抵消<24>头痛</24>和伴随的<34>CGRP</34>在此模型中发布。", "revised": true}
{"doc_key": "20003049", "sentences": [["Prolonged", "elevation", "of", "plasma", "argatroban", "in", "a", "cardiac", "transplant", "patient", "with", "a", "suspected", "history", "of", "heparin", "-", "induced", "thrombocytopenia", "with", "thrombosis", ".", "BACKGROUND", ":", "Direct", "thrombin", "inhibitors", "(", "DTIs", ")", "provide", "an", "alternative", "method", "of", "anticoagulation", "for", "patients", "with", "a", "history", "of", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "or", "HIT", "with", "thrombosis", "(", "HITT", ")", "undergoing", "cardiopulmonary", "bypass", "(", "CPB", ")", ".", "In", "the", "following", "report", ",", "a", "65", "-", "year", "-", "old", "critically", "ill", "patient", "with", "a", "suspected", "history", "of", "HITT", "was", "administered", "argatroban", "for", "anticoagulation", "on", "bypass", "during", "heart", "transplantation", ".", "The", "patient", "required", "massive", "transfusion", "support", "(", "55", "units", "of", "red", "blood", "cells", ",", "42", "units", "of", "fresh", "-", "frozen", "plasma", ",", "40", "units", "of", "cryoprecipitate", ",", "40", "units", "of", "platelets", ",", "and", "three", "doses", "of", "recombinant", "Factor", "VIIa", ")", "for", "severe", "intraoperative", "and", "postoperative", "bleeding", ".", "STUDY", "DESIGN", "AND", "METHODS", ":", "Plasma", "samples", "from", "before", "and", "after", "CPB", "were", "analyzed", "postoperatively", "for", "argatroban", "concentration", "using", "a", "modified", "ecarin", "clotting", "time", "(", "ECT", ")", "assay", ".", "RESULTS", ":", "Unexpectedly", "high", "concentrations", "of", "argatroban", "were", "measured", "in", "these", "samples", "(", "range", ",", "0", "-", "32", "microg", "/", "mL", ")", ",", "and", "a", "prolonged", "plasma", "argatroban", "half", "life", "(", "t", "(", "1", "/", "2", ")", ")", "of", "514", "minutes", "was", "observed", "(", "published", "elimination", "t", "(", "1", "/", "2", ")", "is", "39", "-", "51", "minutes", "[", "<", "or", "=", "181", "minutes", "with", "hepatic", "impairment", "]", ")", ".", "CONCLUSIONS", ":", "Correlation", "of", "plasma", "argatroban", "concentration", "versus", "the", "patient", "'s", "coagulation", "variables", "and", "clinical", "course", "suggest", "that", "prolonged", "elevated", "levels", "of", "plasma", "argatroban", "may", "have", "contributed", "to", "the", "patient", "'s", "extended", "coagulopathy", ".", "Because", "DTIs", "do", "not", "have", "reversal", "agents", ",", "surgical", "teams", "and", "transfusion", "services", "should", "remain", "aware", "of", "the", "possibility", "of", "massive", "transfusion", "events", "during", "anticoagulation", "with", "these", "agents", ".", "This", "is", "the", "first", "report", "to", "measure", "plasma", "argatroban", "concentration", "in", "the", "context", "of", "CPB", "and", "extended", "coagulopathy", "."]], "ner": [[[4, 4, "Chemical"], [85, 85, "Chemical"], [157, 157, "Chemical"], [176, 176, "Chemical"], [197, 197, "Chemical"], [244, 244, "Chemical"], [262, 262, "Chemical"], [310, 310, "Chemical"], [136, 139, "Disease"], [18, 18, "Disease"], [45, 45, "Disease"], [47, 47, "Disease"], [50, 50, "Disease"], [54, 54, "Disease"], [82, 82, "Disease"], [20, 20, "Disease"], [52, 52, "Disease"], [74, 75, "Disease"], [234, 235, "Disease"], [271, 271, "Disease"], [319, 319, "Disease"], [15, 15, "Chemical"], [42, 42, "Chemical"]]], "relations": [[[4, 4, 136, 139, "CID"], [85, 85, 136, 139, "CID"], [157, 157, 136, 139, "CID"], [176, 176, 136, 139, "CID"], [197, 197, 136, 139, "CID"], [244, 244, 136, 139, "CID"], [262, 262, 136, 139, "CID"], [310, 310, 136, 139, "CID"]]], "clusters": [], "translated": "疑似 <21>肝素</21> 诱发的 <9>血小板减少症</9> 并伴有 <15>血栓形成</15> 的心脏移植患者血浆 <0>阿加曲班</0> 长期升高。背景：直接凝血酶抑制剂 (DTI) 为有<22>肝素</22> 诱发的 <10>血小板减少症</10> (<11>HIT</11>)或 <12>HIT</12> 伴有 <16>血栓</16> (<13>HITT</13>)正在接受体外循环 (CPB) 。在下面的报告中，一位 65 岁的 <17>危重症</17> 疑似 <14>HITT</14> 患者接受了 <1>阿加曲班</1> 心脏移植手术中的抗凝治疗。患者需要大量输血支持 (55 单位红细胞，42 单位新鲜冰冻血浆，40 单位冷沉淀，40 单位血小板和三剂重组因子 VIIa) 用于严重的<8>术中和术后出血</8> 。研究设计和方法：采用改良的蛇蝎血凝血时间 (ECT) 测定法，对 CPB 前后的血浆样本进行术后<2>阿加曲班</2>浓度分析。结果：在这些样品中检测到出乎意料的高浓度<3>阿加曲班</3>（范围，0-32 微克/毫升），以及延长的血浆<4>阿加曲班</4>半衰期 (t (1 / 2) ) 观察到 514 分钟 (公布的消除时间 t (1 / 2) 为 39-51 分钟 [<或=181 分钟与<18>肝损伤</18>])。结论：血浆<5>阿加曲班</5>浓度与患者凝血变量和临床病程的相关性表明，持续升高的血浆<6>阿加曲班</6>水平可能导致患者<19>凝血异常</19>的延长。因为DTIs没有逆转剂，外科团队和输血服务部门应该意识到在使用这些药物进行抗凝治疗期间可能发生大量输血事件。这是第一份在 CPB 和长期<20>凝血异常</20> 情况下测量血浆<7>阿加曲班</7>浓度的报告。", "revised": true}
{"doc_key": "1987816", "sentences": [["Less", "frequent", "lithium", "administration", "and", "lower", "urine", "volume", ".", "OBJECTIVE", ":", "This", "study", "was", "designed", "to", "determine", "whether", "patients", "maintained", "on", "a", "regimen", "of", "lithium", "on", "a", "once", "-", "per", "-", "day", "schedule", "have", "lower", "urine", "volumes", "than", "do", "patients", "receiving", "multiple", "doses", "per", "day", ".", "METHOD", ":", "This", "was", "a", "cross", "-", "sectional", "study", "of", "85", "patients", "from", "a", "lithium", "clinic", "who", "received", "different", "dose", "schedules", ".", "Patients", "were", "admitted", "to", "the", "hospital", "for", "measurement", "of", "lithium", "level", ",", "creatinine", "clearance", ",", "urine", "volume", ",", "and", "maximum", "osmolality", ".", "RESULTS", ":", "Multiple", "daily", "doses", "of", "lithium", "were", "associated", "with", "higher", "urine", "volumes", ".", "The", "dosing", "schedule", ",", "duration", "of", "lithium", "treatment", ",", "and", "daily", "dose", "of", "lithium", "did", "not", "affect", "maximum", "osmolality", "or", "creatinine", "clearance", ".", "CONCLUSIONS", ":", "Urine", "volume", "can", "be", "reduced", "by", "giving", "lithium", "once", "daily", "and", "/", "or", "by", "lowering", "the", "total", "daily", "dose", ".", "Lithium", "-", "induced", "polyuria", "seems", "to", "be", "related", "to", "extrarenal", "as", "well", "as", "to", "renal", "effects", "."]], "ner": [[[2, 2, "Chemical"], [24, 24, "Chemical"], [60, 60, "Chemical"], [77, 77, "Chemical"], [96, 96, "Chemical"], [110, 110, "Chemical"], [117, 117, "Chemical"], [136, 136, "Chemical"], [149, 149, "Chemical"], [152, 152, "Disease"], [80, 80, "Chemical"], [124, 124, "Chemical"]]], "relations": [[[2, 2, 152, 152, "CID"], [24, 24, 152, 152, "CID"], [60, 60, 152, 152, "CID"], [77, 77, 152, 152, "CID"], [96, 96, 152, 152, "CID"], [110, 110, 152, 152, "CID"], [117, 117, 152, 152, "CID"], [136, 136, 152, 152, "CID"], [149, 149, 152, 152, "CID"]]], "clusters": [], "translated": "降低<0>锂</0>给药频率并降低尿量。目的：本研究旨在确定每天服用一次<1>锂</1>方案的患者的尿量是否低于每天服用多次剂量的患者。方法：这是一项横断面研究，纳入了来自<2>锂</2>诊所的85名接受不同剂量方案的患者。患者入院进行<3>锂</3>水平、<10>肌酐</10>清除率、尿量和最大渗透压的测量。结果：每日多次服用<4>锂</4>与较高的尿量有关。给药方案、<5>锂</5>治疗持续时间和<6>锂</6>日剂量不影响最大渗透压或<11>肌酐</11>清除率。结论：每天一次服用<7>锂</7>和/或降低每日总剂量可以减少尿量。<8>锂</8>引起的<9>多尿</9>似乎与肾外和肾脏效应有关。", "revised": true}
{"doc_key": "869641", "sentences": [["Mediation", "of", "enhanced", "reflex", "vagal", "bradycardia", "by", "L", "-", "dopa", "via", "central", "dopamine", "formation", "in", "dogs", ".", "L", "-", "Dopa", "(", "5", "mg", "/", "kg", "i", ".", "v", ".", ")", "decreased", "blood", "pressure", "and", "heart", "rate", "after", "extracerebral", "decarboxylase", "inhibition", "with", "MK", "-", "486", "(", "25", "mg", "/", "kg", "i", ".", "v", ".", ")", "in", "anesthetize", "MAO", "-", "inhibited", "dogs", ".", "In", "addition", ",", "reflex", "bradycardia", "caused", "by", "injected", "norepinephrine", "was", "significantly", "enhanced", "by", "L", "-", "dopa", ",", "DL", "-", "Threo", "-", "dihydroxyphenylserine", "had", "no", "effect", "on", "blood", "pressure", ",", "heart", "rate", "or", "reflex", "responses", "to", "norepinephrine", ".", "FLA", "-", "63", ",", "a", "dopamine", "-", "beta", "-", "oxidase", "inhibitor", ",", "did", "not", "have", "any", "effect", "on", "the", "hypotension", ",", "bradycardia", "or", "reflex", "-", "enhancing", "effect", "of", "L", "-", "dopa", ".", "Pimozide", "did", "not", "affect", "the", "actions", "of", "L", "-", "dopa", "on", "blood", "pressure", "and", "heart", "rate", "but", "completely", "blocked", "the", "enhancement", "of", "reflexes", ".", "Removal", "of", "the", "carotid", "sinuses", "caused", "an", "elevation", "blood", "pressure", "and", "heart", "rate", "and", "abolished", "the", "negative", "chronotropic", "effect", "of", "norepinephrine", ".", "However", ",", "L", "-", "dopa", "restored", "the", "bradycardia", "caused", "by", "norepinephrine", "in", "addition", "to", "decreasing", "blood", "pressure", "and", "heart", "rate", ".", "5", "-", "HTP", "(", "5", "mg", "/", "kg", "i", ".", "v", ".", ")", "decreased", "blood", "pressure", "and", "heart", "rate", "and", "decreased", "the", "reflex", "bradycardia", "to", "norepinephrine", ".", "It", "is", "concluded", "that", "L", "-", "dopa", "enhances", "reflex", "bradycardia", "through", "central", "alpha", "-", "receptor", "stimulation", ".", "Furthermore", ",", "the", "effects", "are", "mediated", "through", "dopamine", "rather", "than", "norepinephrine", "and", "do", "not", "require", "the", "carotid", "sinus", "baroreceptors", "."]], "ner": [[[69, 69, "Chemical"], [96, 96, "Chemical"], [174, 174, "Chemical"], [186, 186, "Chemical"], [222, 222, "Chemical"], [251, 251, "Chemical"], [5, 5, "Disease"], [65, 65, "Disease"], [119, 119, "Disease"], [183, 183, "Disease"], [220, 220, "Disease"], [233, 233, "Disease"], [7, 9, "Chemical"], [17, 19, "Chemical"], [74, 76, "Chemical"], [126, 128, "Chemical"], [137, 139, "Chemical"], [178, 180, "Chemical"], [228, 230, "Chemical"], [12, 12, "Chemical"], [103, 103, "Chemical"], [248, 248, "Chemical"], [41, 43, "Chemical"], [56, 56, "Chemical"], [78, 82, "Chemical"], [98, 100, "Chemical"], [130, 130, "Chemical"], [197, 199, "Chemical"], [117, 117, "Disease"]]], "relations": [[[69, 69, 5, 5, "CID"], [69, 69, 65, 65, "CID"], [69, 69, 119, 119, "CID"], [69, 69, 183, 183, "CID"], [69, 69, 220, 220, "CID"], [69, 69, 233, 233, "CID"], [96, 96, 5, 5, "CID"], [96, 96, 65, 65, "CID"], [96, 96, 119, 119, "CID"], [96, 96, 183, 183, "CID"], [96, 96, 220, 220, "CID"], [96, 96, 233, 233, "CID"], [174, 174, 5, 5, "CID"], [174, 174, 65, 65, "CID"], [174, 174, 119, 119, "CID"], [174, 174, 183, 183, "CID"], [174, 174, 220, 220, "CID"], [174, 174, 233, 233, "CID"], [186, 186, 5, 5, "CID"], [186, 186, 65, 65, "CID"], [186, 186, 119, 119, "CID"], [186, 186, 183, 183, "CID"], [186, 186, 220, 220, "CID"], [186, 186, 233, 233, "CID"], [222, 222, 5, 5, "CID"], [222, 222, 65, 65, "CID"], [222, 222, 119, 119, "CID"], [222, 222, 183, 183, "CID"], [222, 222, 220, 220, "CID"], [222, 222, 233, 233, "CID"], [251, 251, 5, 5, "CID"], [251, 251, 65, 65, "CID"], [251, 251, 119, 119, "CID"], [251, 251, 183, 183, "CID"], [251, 251, 220, 220, "CID"], [251, 251, 233, 233, "CID"]]], "clusters": [], "translated": "<12>左旋多巴</12> 通过犬中枢<19>多巴胺</19> 形成增强反射性迷走神经<6>心动过缓</6>的调解。 <13>L-Dopa</13> (5 mg/kg i. v.) 用<22>MK-486</22> (25 mg/kg i. v.) 抑制脑外脱羧酶后 (<23>MAO</23>-抑制狗) 血压和心率降低。此外，注射<0>去甲肾上腺素</0>引起的反射性<7>心动过缓</7>被<14>左旋多巴</14>显着增强，<24> DL-苏-二羟苯丝氨酸</24>对血压、心率或对<1>去甲肾上腺素</1>的反射反应没有影响。<25>FLA-63</25>，一种<20>多巴胺</20>-β-氧化酶抑制剂，对<28>低血压</28>、<8>心动过缓</8>或<15>左旋多巴</15>的反射增强作用没有影响。<26>匹莫齐特</26> 不影响<16>左旋多巴</16>对血压和心率的作用，但完全阻断反射的增强。颈动脉窦的切除导致血压和心率升高，并消除了<2>去甲肾上腺素</2>的负性变时作用。然而，<17>左旋多巴</17>除了降低血压和心率外，还恢复了由<3>去甲肾上腺素</3>引起的<9>心动过缓</9>。 <27> 5-HTP </27> (5 mg/kg i. v.) 降低血压和心率，并降低对<4>去甲肾上腺素</4>的反射<10>心动过缓</10>。结论是<18>左旋多巴</18>通过刺激中枢α-受体增强反射性<11>心动过缓</11>。此外，这些作用是通过<21>多巴胺</21>而不是<5>去甲肾上腺素</5>介导的，并且不需要颈动脉窦压力感受器。", "revised": true}
{"doc_key": "19631624", "sentences": [["Learning", "and", "memory", "deficits", "in", "ecstasy", "users", "and", "their", "neural", "correlates", "during", "a", "face", "-", "learning", "task", ".", "It", "has", "been", "consistently", "shown", "that", "ecstasy", "users", "display", "impairments", "in", "learning", "and", "memory", "performance", ".", "In", "addition", ",", "working", "memory", "processing", "in", "ecstasy", "users", "has", "been", "shown", "to", "be", "associated", "with", "neural", "alterations", "in", "hippocampal", "and", "/", "or", "cortical", "regions", "as", "measured", "by", "functional", "magnetic", "resonance", "imaging", "(", "fMRI", ")", ".", "Using", "functional", "imaging", "and", "a", "face", "-", "learning", "task", ",", "we", "investigated", "neural", "correlates", "of", "encoding", "and", "recalling", "face", "-", "name", "associations", "in", "20", "recreational", "drug", "users", "whose", "predominant", "drug", "use", "was", "ecstasy", "and", "20", "controls", ".", "To", "address", "the", "potential", "confounding", "effects", "of", "the", "cannabis", "use", "of", "the", "ecstasy", "using", "group", ",", "a", "second", "analysis", "included", "14", "previously", "tested", "cannabis", "users", "(", "Nestor", ",", "L", ".", ",", "Roberts", ",", "G", ".", ",", "Garavan", ",", "H", ".", ",", "Hester", ",", "R", ".", ",", "2008", ".", "Deficits", "in", "learning", "and", "memory", ":", "parahippocampal", "hyperactivity", "and", "frontocortical", "hypoactivity", "in", "cannabis", "users", ".", "Neuroimage", "40", ",", "1328", "-", "1339", ")", ".", "Ecstasy", "users", "performed", "significantly", "worse", "in", "learning", "and", "memory", "compared", "to", "controls", "and", "cannabis", "users", ".", "A", "conjunction", "analysis", "of", "the", "encode", "and", "recall", "phases", "of", "the", "task", "revealed", "ecstasy", "-", "specific", "hyperactivity", "in", "bilateral", "frontal", "regions", ",", "left", "temporal", ",", "right", "parietal", ",", "bilateral", "temporal", ",", "and", "bilateral", "occipital", "brain", "regions", ".", "Ecstasy", "-", "specific", "hypoactivity", "was", "evident", "in", "the", "right", "dorsal", "anterior", "cingulated", "cortex", "(", "ACC", ")", "and", "left", "posterior", "cingulated", "cortex", ".", "In", "both", "ecstasy", "and", "cannabis", "groups", "brain", "activation", "was", "decreased", "in", "the", "right", "medial", "frontal", "gyrus", ",", "left", "parahippocampal", "gyrus", ",", "left", "dorsal", "cingulate", "gyrus", ",", "and", "left", "caudate", ".", "These", "results", "elucidated", "ecstasy", "-", "related", "deficits", ",", "only", "some", "of", "which", "might", "be", "attributed", "to", "cannabis", "use", ".", "These", "ecstasy", "-", "specific", "effects", "may", "be", "related", "to", "the", "vulnerability", "of", "isocortical", "and", "allocortical", "regions", "to", "the", "neurotoxic", "effects", "of", "ecstasy", "."]], "ner": [[[5, 5, "Chemical"], [24, 24, "Chemical"], [41, 41, "Chemical"], [102, 102, "Chemical"], [119, 119, "Chemical"], [178, 178, "Chemical"], [207, 207, "Chemical"], [231, 231, "Chemical"], [255, 255, "Chemical"], [286, 286, "Chemical"], [303, 303, "Chemical"], [323, 323, "Chemical"], [0, 3, "Disease"], [27, 31, "Disease"], [155, 159, "Disease"], [115, 115, "Chemical"], [130, 130, "Chemical"], [167, 167, "Chemical"], [191, 191, "Chemical"], [257, 257, "Chemical"], [299, 299, "Chemical"], [162, 162, "Disease"], [210, 210, "Disease"], [320, 320, "Disease"]]], "relations": [[[5, 5, 0, 3, "CID"], [5, 5, 27, 31, "CID"], [5, 5, 155, 159, "CID"], [24, 24, 0, 3, "CID"], [24, 24, 27, 31, "CID"], [24, 24, 155, 159, "CID"], [41, 41, 0, 3, "CID"], [41, 41, 27, 31, "CID"], [41, 41, 155, 159, "CID"], [102, 102, 0, 3, "CID"], [102, 102, 27, 31, "CID"], [102, 102, 155, 159, "CID"], [119, 119, 0, 3, "CID"], [119, 119, 27, 31, "CID"], [119, 119, 155, 159, "CID"], [178, 178, 0, 3, "CID"], [178, 178, 27, 31, "CID"], [178, 178, 155, 159, "CID"], [207, 207, 0, 3, "CID"], [207, 207, 27, 31, "CID"], [207, 207, 155, 159, "CID"], [231, 231, 0, 3, "CID"], [231, 231, 27, 31, "CID"], [231, 231, 155, 159, "CID"], [255, 255, 0, 3, "CID"], [255, 255, 27, 31, "CID"], [255, 255, 155, 159, "CID"], [286, 286, 0, 3, "CID"], [286, 286, 27, 31, "CID"], [286, 286, 155, 159, "CID"], [303, 303, 0, 3, "CID"], [303, 303, 27, 31, "CID"], [303, 303, 155, 159, "CID"], [323, 323, 0, 3, "CID"], [323, 323, 27, 31, "CID"], [323, 323, 155, 159, "CID"]]], "clusters": [], "translated": " <12> 学习和记忆缺陷 </12> <0> 摇头丸 </0> 用户及其在面部学习任务中的神经关联。一致表明，<1> 摇头丸 </1> 使用者会表现出 <13> 学习和记忆障碍 </13> 表现。此外，通过功能磁共振成像 (fMRI) 测量，<2> 摇头丸 </2> 使用者的工作记忆处理已被证明与海马体和/或皮层区域的神经改变有关。我们使用功能成像和面部学习任务，研究了 20 名主要使用 <3> 摇头丸 </3> 的消遣性吸毒者和 20 名对照组的编码和回忆面部名称关联的神经相关性。为了解决 <15> 大麻 </15> 使用的 <4> 摇头丸 </4> 使用组的潜在混杂影响，第二项分析包括 14 名先前测试过的 <16> 大麻 </16> 使用者（内斯特，L., Roberts,G.., Garavan,H.., Hester,R.., 2008. <14> 学习和记忆缺陷 </14> ：海马旁 <21> 活动过度 </21> 和 <17> 大麻中的额皮质活动减退</17> 用户. Neuroimage 40, 1328 - 1339).与对照组和 <18> 大麻 </18> 使用者相比，<5> 摇头丸 </5> 使用者在学习和记忆方面的表现明显更差。对任务的编码和回忆阶段的结合分析显示，<6> 摇头丸 </6> - 双侧额叶区域、左侧颞叶、右侧顶叶、双侧颞叶和双侧枕叶脑区的特异性 <22> 活动过度 </22> 。<7> 摇头丸 </7> - 特异性活动减退在右侧背前扣带皮层 (ACC) 和左侧后扣带皮层。在 <8> 摇头丸 </8> 和 <19> 大麻 </19> 组中，右侧内侧前额回、左侧海马旁回、左侧背扣带回和左侧尾状核的大脑活动均减少。这些结果阐明了与 <9> 摇头丸 </9> 相关的缺陷，其中只有一部分可能归因于<20>大麻</20>的使用。这些 <10> 摇头丸 </10> 的特异性作用可能与同皮质和异皮质区域对 <11> 摇头丸 </11> 的 <23> 神经毒性 </23> 的作用的脆弱性有关。", "revised": true}
{"doc_key": "1749407", "sentences": [["Cocaine", "-", "induced", "myocardial", "infarction", ":", "clinical", "observations", "and", "pathogenetic", "considerations", ".", "Clinical", "and", "experimental", "data", "published", "to", "date", "suggest", "several", "possible", "mechanisms", "by", "which", "cocaine", "may", "result", "in", "acute", "myocardial", "infarction", ".", "In", "individuals", "with", "preexisting", ",", "high", "-", "grade", "coronary", "arterial", "narrowing", ",", "acute", "myocardial", "infarction", "may", "result", "from", "an", "increase", "in", "myocardial", "oxygen", "demand", "associated", "with", "cocaine", "-", "induced", "increase", "in", "rate", "-", "pressure", "product", ".", "In", "other", "individuals", "with", "no", "underlying", "atherosclerotic", "obstruction", ",", "coronary", "occlusion", "may", "be", "due", "to", "spasm", ",", "thrombus", ",", "or", "both", ".", "With", "regard", "to", "spasm", ",", "the", "clinical", "findings", "are", "largely", "circumstantial", ",", "and", "the", "locus", "of", "cocaine", "-", "induced", "vasoconstriction", "remains", "speculative", ".", "Although", "certain", "clinical", "and", "experimental", "findings", "support", "the", "hypothesis", "that", "spasm", "involves", "the", "epicardial", ",", "medium", "-", "size", "vessels", ",", "other", "data", "suggest", "intramural", "vasoconstriction", ".", "Diffuse", "intramural", "vasoconstriction", "is", "not", "consistent", "with", "reports", "of", "segmental", ",", "discrete", "infarction", ".", "Whereas", "certain", "in", "vivo", "data", "suggest", "that", "these", "effects", "are", "alpha", "-", "mediated", ",", "other", "in", "vitro", "data", "suggest", "the", "opposite", ".", "The", "finding", "of", "cocaine", "-", "induced", "vasoconstriction", "in", "segments", "of", "(", "noninnervated", ")", "human", "umbilical", "artery", "suggests", "that", "the", "presence", "or", "absence", "of", "intact", "innervation", "is", "not", "sufficient", "to", "explain", "the", "discrepant", "data", "involving", "the", "possibility", "of", "alpha", "-", "mediated", "effects", ".", "Finally", ",", "the", "contribution", "of", "a", "primary", ",", "thrombotic", "effect", "of", "cocaine", "has", "not", "been", "excluded", "."]], "ner": [[[0, 0, "Chemical"], [25, 25, "Chemical"], [59, 59, "Chemical"], [107, 107, "Chemical"], [179, 179, "Chemical"], [229, 229, "Chemical"], [3, 4, "Disease"], [29, 31, "Disease"], [45, 47, "Disease"], [75, 76, "Disease"], [78, 79, "Disease"], [84, 84, "Disease"], [94, 94, "Disease"], [124, 124, "Disease"], [86, 86, "Disease"], [226, 226, "Disease"], [152, 152, "Disease"], [55, 55, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 29, 31, "CID"], [0, 0, 45, 47, "CID"], [25, 25, 3, 4, "CID"], [25, 25, 29, 31, "CID"], [25, 25, 45, 47, "CID"], [59, 59, 3, 4, "CID"], [59, 59, 29, 31, "CID"], [59, 59, 45, 47, "CID"], [107, 107, 3, 4, "CID"], [107, 107, 29, 31, "CID"], [107, 107, 45, 47, "CID"], [179, 179, 3, 4, "CID"], [179, 179, 29, 31, "CID"], [179, 179, 45, 47, "CID"], [229, 229, 3, 4, "CID"], [229, 229, 29, 31, "CID"], [229, 229, 45, 47, "CID"]]], "clusters": [], "translated": "<0>可卡因</0>诱发的<6>心肌梗死</6>：临床观察和发病机制考虑。迄今为止发表的临床和实验数据表明，<1>可卡因</1>可能导致<7>急性心肌梗死</7>的几种可能机制。在先前存在严重冠状动脉狭窄的个体中，<8>急性心肌梗死</8>可能是由于与<2>可卡因</2>相关的心肌<17>氧气</17>需求增加所致-增加速率-压力产物。在其他没有潜在的<9>动脉粥样硬化阻塞</9>的个体中，<10>冠状动脉闭塞</10>可能是由于<11>痉挛</11>、<14>血栓</14>或两者兼而有之。关于<12>痉挛</12>，临床发现主要是间接的，<3>可卡因</3>引起的血管收缩的位置仍然是推测性的。尽管某些临床和实验结果支持<13>痉挛</13>涉及心外膜中等大小血管的假说，但其他数据表明壁内血管收缩。弥漫性壁内血管收缩与段状、离散性<16>梗塞</16>的报道不一致。虽然某些体内数据表明这些影响是α介导的，但其他体外数据表明相反。在（非神经支配的）人脐动脉段中发现<4>可卡因</4>诱导的血管收缩，表明存在或不存在完整的神经支配不足以解释涉及α介导效应的可能性的不一致数据。最后，<5>可卡因</5>的主要的<15>血栓形成</15>作用的贡献并未被排除。", "revised": true}
{"doc_key": "19308880", "sentences": [["Confusion", ",", "a", "rather", "serious", "adverse", "drug", "reaction", "with", "valproic", "acid", ":", "a", "review", "of", "the", "French", "Pharmacovigilance", "database", ".", "INTRODUCTION", ":", "Confusion", "is", "an", "adverse", "drug", "reaction", "frequently", "observed", "with", "valproic", "acid", ".", "Some", "case", "reports", "are", "published", "in", "the", "literature", "but", "no", "systematic", "study", "from", "a", "sample", "of", "patients", "has", "been", "published", ".", "We", "performed", "this", "study", "in", "order", "to", "describe", "the", "main", "characteristics", "of", "this", "adverse", "drug", "reaction", ".", "METHODS", ":", "Using", "the", "French", "Pharmacovigilance", "database", ",", "we", "selected", "the", "cases", "of", "confusion", "reported", "since", "1985", "with", "valproic", "acid", ".", "RESULTS", ":", "272", "cases", "of", "confusion", "were", "reported", "with", "valproic", "acid", ":", "153", "women", "and", "119", "men", ".", "Confusion", "mostly", "occurred", "during", "the", "two", "first", "weeks", "following", "valproic", "acid", "exposure", "(", "39", ".", "7", "%", ")", ".", "It", "was", "\"", "serious", "\"", "for", "almost", "2", "/", "3", "of", "the", "patients", "(", "62", ".", "5", "%", ")", "and", "its", "outcome", "favourable", "in", "most", "of", "the", "cases", "(", "82", "%", ")", ".", "The", "occurrence", "of", "this", "ADR", "was", "more", "frequent", "in", "patients", "aged", "between", "61", "and", "80", "years", ".", "CONCLUSION", ":", "This", "work", "shows", "that", "confusion", "with", "valproic", "acid", "is", "a", "serious", ",", "rather", "frequent", "but", "reversible", "adverse", "drug", "reaction", ".", "It", "occurs", "especially", "in", "older", "patients", "and", "during", "the", "first", "two", "weeks", "of", "treatment", "."]], "ner": [[[9, 10, "Chemical"], [31, 32, "Chemical"], [90, 91, "Chemical"], [102, 103, "Chemical"], [120, 121, "Chemical"], [188, 189, "Chemical"], [0, 0, "Disease"], [22, 22, "Disease"], [85, 85, "Disease"], [98, 98, "Disease"], [111, 111, "Disease"], [186, 186, "Disease"]]], "relations": [[[9, 10, 0, 0, "CID"], [9, 10, 22, 22, "CID"], [9, 10, 85, 85, "CID"], [9, 10, 98, 98, "CID"], [9, 10, 111, 111, "CID"], [9, 10, 186, 186, "CID"], [31, 32, 0, 0, "CID"], [31, 32, 22, 22, "CID"], [31, 32, 85, 85, "CID"], [31, 32, 98, 98, "CID"], [31, 32, 111, 111, "CID"], [31, 32, 186, 186, "CID"], [90, 91, 0, 0, "CID"], [90, 91, 22, 22, "CID"], [90, 91, 85, 85, "CID"], [90, 91, 98, 98, "CID"], [90, 91, 111, 111, "CID"], [90, 91, 186, 186, "CID"], [102, 103, 0, 0, "CID"], [102, 103, 22, 22, "CID"], [102, 103, 85, 85, "CID"], [102, 103, 98, 98, "CID"], [102, 103, 111, 111, "CID"], [102, 103, 186, 186, "CID"], [120, 121, 0, 0, "CID"], [120, 121, 22, 22, "CID"], [120, 121, 85, 85, "CID"], [120, 121, 98, 98, "CID"], [120, 121, 111, 111, "CID"], [120, 121, 186, 186, "CID"], [188, 189, 0, 0, "CID"], [188, 189, 22, 22, "CID"], [188, 189, 85, 85, "CID"], [188, 189, 98, 98, "CID"], [188, 189, 111, 111, "CID"], [188, 189, 186, 186, "CID"]]], "clusters": [], "translated": "<6>混淆</6>，<0>丙戊酸</0>的相当严重的药物不良反应：对法国药物警戒数据库的回顾。简介：<7>混淆</7>是<1>丙戊酸</1>时常见的药物不良反应。一些病例报告已在文献中发表，但尚未发表对患者样本进行的系统研究。我们进行这项研究是为了描述这种药物不良反应的主要特征。方法：利用法国药物警戒数据库，我们选取自1985年以来报告的使用<2>丙戊酸</2>出现<8>混淆</8>的病例。结果：272例<9>意识模糊</9>与<3>丙戊酸</3>有关：153名女性和119名男性。<10>混淆</10>主要发生在<4>丙戊酸</4>暴露后的前两周内(39.7%)。对于将近三分之二的患者(62.5%)来说这是“严重的”，而且大多数病例(82%)的结果是有利的。这种不良反应在61至80岁的患者中更常见。结论：这项工作表明<11>混淆</11>与<5>丙戊酸</5>是一种严重的、相当频繁但可逆的药物不良反应。它尤其发生在老年患者和治疗的前两周。", "revised": true}
{"doc_key": "2304736", "sentences": [["Prazosin", "-", "induced", "stress", "incontinence", ".", "A", "case", "of", "genuine", "stress", "incontinence", "due", "to", "prazosin", ",", "a", "common", "antihypertensive", "drug", ",", "is", "presented", ".", "Prazosin", "exerts", "its", "antihypertensive", "effects", "through", "vasodilatation", "caused", "by", "selective", "blockade", "of", "postsynaptic", "alpha", "-", "1", "adrenergic", "receptors", ".", "As", "an", "alpha", "-", "blocker", ",", "it", "also", "exerts", "a", "significant", "relaxant", "effect", "on", "the", "bladder", "neck", "and", "urethra", ".", "The", "patient", "'s", "clinical", "course", "is", "described", "and", "correlated", "with", "initial", "urodynamic", "studies", "while", "on", "prazosin", "and", "subsequent", "studies", "while", "taking", "verapamil", ".", "Her", "incontinence", "resolved", "with", "the", "change", "of", "medication", ".", "The", "restoration", "of", "continence", "was", "accompanied", "by", "a", "substantial", "rise", "in", "maximum", "urethral", "pressure", ",", "maximum", "urethral", "closure", "pressure", ",", "and", "functional", "urethral", "length", ".", "Patients", "who", "present", "with", "stress", "incontinence", "while", "taking", "prazosin", "should", "change", "their", "antihypertensive", "medication", "before", "considering", "surgery", ",", "because", "their", "incontinence", "may", "resolve", "spontaneously", "with", "a", "change", "in", "drug", "therapy", "."]], "ner": [[[0, 0, "Chemical"], [14, 14, "Chemical"], [24, 24, "Chemical"], [78, 78, "Chemical"], [128, 128, "Chemical"], [3, 4, "Disease"], [10, 11, "Disease"], [124, 125, "Disease"], [87, 87, "Disease"], [140, 140, "Disease"], [84, 84, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 10, 11, "CID"], [0, 0, 124, 125, "CID"], [14, 14, 3, 4, "CID"], [14, 14, 10, 11, "CID"], [14, 14, 124, 125, "CID"], [24, 24, 3, 4, "CID"], [24, 24, 10, 11, "CID"], [24, 24, 124, 125, "CID"], [78, 78, 3, 4, "CID"], [78, 78, 10, 11, "CID"], [78, 78, 124, 125, "CID"], [128, 128, 3, 4, "CID"], [128, 128, 10, 11, "CID"], [128, 128, 124, 125, "CID"]]], "clusters": [], "translated": " <0>哌唑嗪</0> - 诱发<5>压力性尿失禁</5>。介绍了一例由<1>哌唑嗪</1>（一种常见的抗高血压药物）引起的真正<6>压力性尿失禁</6>。<2>哌唑嗪</2>通过选择性阻断突触后α-1肾上腺素能受体引起的血管舒张作用发挥降压作用。作为α受体阻滞剂，它对膀胱颈和尿道也有显着的松弛作用。描述了患者的临床病程，并与初始尿动力学研究时服用<3>哌唑嗪</3>以及后续服用<10>维拉帕米</10>的研究结果做出了相关性解释。她的<8>尿失禁</8>随着药物的改变而得到解决。失禁的恢复伴随着最大尿道压力、最大尿道闭合压力和功能性尿道长度的显着增加。服用<4>哌唑嗪</4>时出现<7>压力性尿失禁</7>的患者应在考虑手术前更换降压药，因为他们的<9>尿失禁</9>可能会随着药物的改变而自发消退治疗。", "revised": true}
{"doc_key": "1786266", "sentences": [["Rabbit", "syndrome", ",", "antidepressant", "use", ",", "and", "cerebral", "perfusion", "SPECT", "scan", "findings", ".", "The", "rabbit", "syndrome", "is", "an", "extrapyramidal", "side", "effect", "associated", "with", "chronic", "neuroleptic", "therapy", ".", "Its", "occurrence", "in", "a", "patient", "being", "treated", "with", "imipramine", "is", "described", ",", "representing", "the", "first", "reported", "case", "of", "this", "syndrome", "in", "conjunction", "with", "antidepressants", ".", "Repeated", "cerebral", "perfusion", "SPECT", "scans", "revealed", "decreased", "basal", "ganglia", "perfusion", "while", "the", "movement", "disorder", "was", "present", ",", "and", "a", "return", "to", "normal", "perfusion", "when", "the", "rabbit", "syndrome", "resolved", "."]], "ner": [[[35, 35, "Chemical"], [0, 1, "Disease"], [14, 15, "Disease"], [58, 61, "Disease"], [77, 78, "Disease"], [3, 3, "Chemical"], [50, 50, "Chemical"], [64, 65, "Disease"]]], "relations": [[[35, 35, 0, 1, "CID"], [35, 35, 14, 15, "CID"], [35, 35, 58, 61, "CID"], [35, 35, 77, 78, "CID"]]], "clusters": [], "translated": "<1>兔综合征</1>，<5>抗抑郁药</5>的使用，以及脑灌注SPECT扫描所见。<2>兔综合征</2>是一种与慢性抗精神病药治疗相关的锥体外系副作用。描述了它在接受<0>丙咪嗪</0>治疗的患者中的发生，代表了该综合征与<6>抗抑郁药</6>联合使用的首例报道。重复脑灌注SPECT扫描显示<3>基底神经节灌注减少</3>，而<7>运动障碍</7>存在，当<4>兔综合征</4>消退时恢复正常灌注。", "revised": true}
{"doc_key": "20882060", "sentences": [["Effects", "of", "pallidal", "neurotensin", "on", "haloperidol", "-", "induced", "parkinsonian", "catalepsy", ":", "behavioral", "and", "electrophysiological", "studies", ".", "OBJECTIVE", ":", "The", "globus", "pallidus", "plays", "a", "critical", "role", "in", "movement", "regulation", ".", "Previous", "studies", "have", "indicated", "that", "the", "globus", "pallidus", "receives", "neurotensinergic", "innervation", "from", "the", "striatum", ",", "and", "systemic", "administration", "of", "a", "neurotensin", "analog", "could", "produce", "antiparkinsonian", "effects", ".", "The", "present", "study", "aimed", "to", "investigate", "the", "effects", "of", "pallidal", "neurotensin", "on", "haloperidol", "-", "induced", "parkinsonian", "symptoms", ".", "METHODS", ":", "Behavioral", "experiments", "and", "electrophysiological", "recordings", "were", "performed", "in", "the", "present", "study", ".", "RESULTS", ":", "Bilateral", "infusions", "of", "neurotensin", "into", "the", "globus", "pallidus", "reversed", "haloperidol", "-", "induced", "parkinsonian", "catalepsy", "in", "rats", ".", "Electrophysiological", "recordings", "showed", "that", "microinjection", "of", "neurotensin", "induced", "excitation", "of", "pallidal", "neurons", "in", "the", "presence", "of", "systemic", "haloperidol", "administration", ".", "The", "neurotensin", "type", "-", "1", "receptor", "antagonist", "SR48692", "blocked", "both", "the", "behavioral", "and", "the", "electrophysiological", "effects", "induced", "by", "neurotensin", ".", "CONCLUSION", ":", "Activation", "of", "pallidal", "neurotensin", "receptors", "may", "be", "involved", "in", "neurotensin", "-", "induced", "antiparkinsonian", "effects", "."]], "ner": [[[5, 5, "Chemical"], [68, 68, "Chemical"], [99, 99, "Chemical"], [124, 124, "Chemical"], [8, 9, "Disease"], [102, 103, "Disease"], [3, 3, "Chemical"], [49, 49, "Chemical"], [66, 66, "Chemical"], [93, 93, "Chemical"], [113, 113, "Chemical"], [145, 145, "Chemical"], [152, 152, "Chemical"], [158, 158, "Chemical"], [71, 72, "Disease"], [128, 133, "Chemical"], [134, 134, "Chemical"]]], "relations": [[[5, 5, 8, 9, "CID"], [5, 5, 102, 103, "CID"], [68, 68, 8, 9, "CID"], [68, 68, 102, 103, "CID"], [99, 99, 8, 9, "CID"], [99, 99, 102, 103, "CID"], [124, 124, 8, 9, "CID"], [124, 124, 102, 103, "CID"]]], "clusters": [], "translated": "苍白球<6>神经降压素</6><0>氟哌啶醇</0>诱发的<4>帕金森强直症</4>的影响：行为和电生理学研究。目的：苍白球在运动调节中起着关键作用。先前的研究表明，苍白球接受来自纹状体的神经降压素能神经支配，<7>神经降压素</7>类似物的全身给药可产生抗帕金森病作用。本研究旨在探讨苍白球<8>神经降压素</8>对<1>氟哌啶醇</1>诱发的<14>帕金森症状</14>的影响。方法：在本研究中进行了行为实验和电生理记录。结果：双侧输注<9>神经降压素</9>到苍白球可逆转<2>氟哌啶醇</2>诱导的<5>帕金森强直性昏厥</5>。电生理记录显示，在全身性<3>氟哌啶醇</3>给药的情况下，显微注射<10>神经降压素</10>可诱导苍白球神经元兴奋。<15>神经降压素1型受体拮抗剂</15><16>SR48692</16>可阻断<11>神经降压素</11>诱导的行为和电生理效应。结论：苍白球<12>神经降压素</12>受体的激活可能参与了<13>神经降压素</13>诱导的抗帕金森病作用。", "revised": true}
{"doc_key": "322550", "sentences": [["Pulmonary", "shunt", "and", "cardiovascular", "responses", "to", "CPAP", "during", "nitroprusside", "-", "induced", "hypotension", ".", "The", "effects", "of", "continuous", "positive", "airway", "pressure", "(", "CPAP", ")", "on", "cardiovascular", "dynamics", "and", "pulmonary", "shunt", "(", "QS", "/", "QT", ")", "were", "investigated", "in", "12", "dogs", "before", "and", "during", "sodium", "nitroprusside", "infusion", "that", "decreased", "mean", "arterial", "blood", "pressure", "40", "-", "50", "per", "cent", ".", "Before", "nitroprusside", "infusion", ",", "5", "cm", "H2O", "CPAP", "significantly", ",", "P", "less", "than", ".", "05", ",", "decreased", "arterial", "blood", "pressure", ",", "but", "did", "not", "significantly", "alter", "heart", "rate", ",", "cardiac", "output", ",", "systemic", "vascular", "resistance", ",", "or", "QS", "/", "QT", ".", "Ten", "cm", "H2O", "CPAP", "before", "nitroprusside", "infusion", "produced", "a", "further", "decrease", "in", "arterial", "blood", "pressure", "and", "significantly", "increased", "heart", "rate", "and", "decreased", "cardiac", "output", "and", "QS", "/", "QT", ".", "Nitroprusside", "caused", "significant", "decreases", "in", "arterial", "blood", "pressure", "and", "systemic", "vascular", "resistance", "and", "increases", "in", "heart", "rate", ",", "but", "did", "not", "change", "cardiac", "output", "or", "QS", "/", "QT", ".", "Five", "cm", "H2O", "CPAP", "during", "nitroprusside", "did", "not", "further", "alter", "any", "of", "the", "above", "-", "mentioned", "variables", ".", "However", ",", "10", "cm", "H2O", "CPAP", "decreased", "arterial", "blood", "pressure", ",", "cardiac", "output", ",", "and", "QS", "/", "QT", ".", "These", "data", "indicate", "that", "nitroprusside", "infusion", "rates", "that", "decrease", "mean", "arterial", "blood", "pressure", "by", "40", "-", "50", "per", "cent", "do", "not", "change", "cardiac", "output", "or", "QS", "/", "QT", ".", "During", "nitroprusside", "infusion", "low", "levels", "of", "CPAP", "do", "not", "markedly", "alter", "cardiovascular", "dynamics", ",", "but", "high", "levels", "of", "CPAP", "(", "10", "cm", "H2O", ")", ",", "while", "decreasing", "QS", "/", "QT", ",", "produce", "marked", "decreases", "in", "arterial", "blood", "pressure", "and", "cardiac", "output", "."]], "ner": [[[8, 8, "Chemical"], [42, 43, "Chemical"], [58, 58, "Chemical"], [103, 103, "Chemical"], [127, 127, "Chemical"], [161, 161, "Chemical"], [197, 197, "Chemical"], [223, 223, "Chemical"], [11, 11, "Disease"], [108, 112, "Disease"], [130, 134, "Disease"], [255, 262, "Disease"], [119, 121, "Disease"], [63, 63, "Chemical"], [100, 100, "Chemical"], [158, 158, "Chemical"], [178, 178, "Chemical"], [244, 244, "Chemical"]]], "relations": [[[8, 8, 11, 11, "CID"], [8, 8, 108, 112, "CID"], [8, 8, 130, 134, "CID"], [8, 8, 255, 262, "CID"], [42, 43, 11, 11, "CID"], [42, 43, 108, 112, "CID"], [42, 43, 130, 134, "CID"], [42, 43, 255, 262, "CID"], [58, 58, 11, 11, "CID"], [58, 58, 108, 112, "CID"], [58, 58, 130, 134, "CID"], [58, 58, 255, 262, "CID"], [103, 103, 11, 11, "CID"], [103, 103, 108, 112, "CID"], [103, 103, 130, 134, "CID"], [103, 103, 255, 262, "CID"], [127, 127, 11, 11, "CID"], [127, 127, 108, 112, "CID"], [127, 127, 130, 134, "CID"], [127, 127, 255, 262, "CID"], [161, 161, 11, 11, "CID"], [161, 161, 108, 112, "CID"], [161, 161, 130, 134, "CID"], [161, 161, 255, 262, "CID"], [197, 197, 11, 11, "CID"], [197, 197, 108, 112, "CID"], [197, 197, 130, 134, "CID"], [197, 197, 255, 262, "CID"], [223, 223, 11, 11, "CID"], [223, 223, 108, 112, "CID"], [223, 223, 130, 134, "CID"], [223, 223, 255, 262, "CID"]]], "clusters": [], "translated": "<0>硝普钠</0>引起的<8>低血压</8>期间肺分流和对 CPAP 的心血管反应。持续气道正压通气 (CPAP) 对心血管动力学和肺分流 (QS/QT) 的影响在<1>硝普钠</1>输注前和输注期间对12只狗进行了研究，该输注使平均动脉血压降低了40-50%。<2>硝普钠</2>滴注前，5 cm <13>H2O</13> CPAP 明显，P 小于0.05，降低动脉血压，但没有显着改变心率、心输出量、全身血管阻力或 QS/QT。10 cm <14>H2O</14> CPAP 在<3>硝普钠</3>输注前进一步<9>降低动脉血压</9>，并显着增加心率和<12>降低心输出量</12>和 QS/QT。<4>硝普钠</4>引起显着<10>动脉血压降低</10>和全身血管阻力以及心率增加，但不改变心输出量或 QS/QT。5 cm<15>H2O</15> CPAP在<5>硝普钠</5>期间没有进一步改变任何上述变量。然而，10 cm <16>H2O</16> CPAP 降低动脉血压、心输出量和 QS/QT。这些数据表明，可将平均动脉血压降低40-50%的<6>硝普钠</6>输注率不会改变心输出量或 QS/QT。在<7>硝普钠</7>输注期间，低水平的CPAP不会显着改变心血管动力学，但高水平的 CPAP（10 cm <17>H2O</17>）在降低 QS/QT 的同时，会产生显着的<11>动脉血压和心输出量下降</11>。", "revised": true}
{"doc_key": "12369736", "sentences": [["Effects", "of", "5", "-", "HT1B", "receptor", "ligands", "microinjected", "into", "the", "accumbal", "shell", "or", "core", "on", "the", "cocaine", "-", "induced", "locomotor", "hyperactivity", "in", "rats", ".", "The", "present", "study", "was", "designed", "to", "examine", "the", "effect", "of", "5", "-", "HT1B", "receptor", "ligands", "microinjected", "into", "the", "subregions", "of", "the", "nucleus", "accumbens", "(", "the", "shell", "and", "the", "core", ")", "on", "the", "locomotor", "hyperactivity", "induced", "by", "cocaine", "in", "rats", ".", "Male", "Wistar", "rats", "were", "implanted", "bilaterally", "with", "cannulae", "into", "the", "accumbens", "shell", "or", "core", ",", "and", "then", "were", "locally", "injected", "with", "GR", "55562", "(", "an", "antagonist", "of", "5", "-", "HT1B", "receptors", ")", "or", "CP", "93129", "(", "an", "agonist", "of", "5", "-", "HT1B", "receptors", ")", ".", "Given", "alone", "to", "any", "accumbal", "subregion", ",", "GR", "55562", "(", "0", ".", "1", "-", "10", "microg", "/", "side", ")", "or", "CP", "93129", "(", "0", ".", "1", "-", "10", "microg", "/", "side", ")", "did", "not", "change", "basal", "locomotor", "activity", ".", "Systemic", "cocaine", "(", "10", "mg", "/", "kg", ")", "significantly", "increased", "the", "locomotor", "activity", "of", "rats", ".", "GR", "55562", "(", "0", ".", "1", "-", "10", "microg", "/", "side", ")", ",", "administered", "intra", "-", "accumbens", "shell", "prior", "to", "cocaine", ",", "dose", "-", "dependently", "attenuated", "the", "psychostimulant", "-", "induced", "locomotor", "hyperactivity", ".", "Such", "attenuation", "was", "not", "found", "in", "animals", "which", "had", "been", "injected", "with", "GR", "55562", "into", "the", "accumbens", "core", ".", "When", "injected", "into", "the", "accumbens", "shell", "(", "but", "not", "the", "core", ")", "before", "cocaine", ",", "CP", "93129", "(", "0", ".", "1", "-", "10", "microg", "/", "side", ")", "enhanced", "the", "locomotor", "response", "to", "cocaine", ";", "the", "maximum", "effect", "being", "observed", "after", "10", "microg", "/", "side", "of", "the", "agonist", ".", "The", "later", "enhancement", "was", "attenuated", "after", "intra", "-", "accumbens", "shell", "treatment", "with", "GR", "55562", "(", "1", "microg", "/", "side", ")", ".", "Our", "findings", "indicate", "that", "cocaine", "induced", "hyperlocomotion", "is", "modified", "by", "5", "-", "HT1B", "receptor", "ligands", "microinjected", "into", "the", "accumbens", "shell", ",", "but", "not", "core", ",", "this", "modification", "consisting", "in", "inhibitory", "and", "facilitatory", "effects", "of", "the", "5", "-", "HT1B", "receptor", "antagonist", "(", "GR", "55562", ")", "and", "agonist", "(", "CP", "93129", ")", ",", "respectively", ".", "In", "other", "words", ",", "the", "present", "results", "suggest", "that", "the", "accumbal", "shell", "5", "-", "HT1B", "receptors", "play", "a", "permissive", "role", "in", "the", "behavioural", "response", "to", "the", "psychostimulant", "."]], "ner": [[[16, 16, "Chemical"], [60, 60, "Chemical"], [149, 149, "Chemical"], [184, 184, "Chemical"], [229, 229, "Chemical"], [248, 248, "Chemical"], [289, 289, "Chemical"], [19, 20, "Disease"], [56, 57, "Disease"], [194, 195, "Disease"], [291, 291, "Disease"], [97, 98, "Chemical"], [129, 130, "Chemical"], [231, 232, "Chemical"], [332, 333, "Chemical"], [85, 86, "Chemical"], [116, 117, "Chemical"], [164, 165, "Chemical"], [209, 210, "Chemical"], [276, 277, "Chemical"], [326, 327, "Chemical"]]], "relations": [[[16, 16, 19, 20, "CID"], [16, 16, 56, 57, "CID"], [16, 16, 194, 195, "CID"], [16, 16, 291, 291, "CID"], [60, 60, 19, 20, "CID"], [60, 60, 56, 57, "CID"], [60, 60, 194, 195, "CID"], [60, 60, 291, 291, "CID"], [149, 149, 19, 20, "CID"], [149, 149, 56, 57, "CID"], [149, 149, 194, 195, "CID"], [149, 149, 291, 291, "CID"], [184, 184, 19, 20, "CID"], [184, 184, 56, 57, "CID"], [184, 184, 194, 195, "CID"], [184, 184, 291, 291, "CID"], [229, 229, 19, 20, "CID"], [229, 229, 56, 57, "CID"], [229, 229, 194, 195, "CID"], [229, 229, 291, 291, "CID"], [248, 248, 19, 20, "CID"], [248, 248, 56, 57, "CID"], [248, 248, 194, 195, "CID"], [248, 248, 291, 291, "CID"], [289, 289, 19, 20, "CID"], [289, 289, 56, 57, "CID"], [289, 289, 194, 195, "CID"], [289, 289, 291, 291, "CID"], [97, 98, 19, 20, "CID"], [97, 98, 56, 57, "CID"], [97, 98, 194, 195, "CID"], [97, 98, 291, 291, "CID"], [129, 130, 19, 20, "CID"], [129, 130, 56, 57, "CID"], [129, 130, 194, 195, "CID"], [129, 130, 291, 291, "CID"], [231, 232, 19, 20, "CID"], [231, 232, 56, 57, "CID"], [231, 232, 194, 195, "CID"], [231, 232, 291, 291, "CID"], [332, 333, 19, 20, "CID"], [332, 333, 56, 57, "CID"], [332, 333, 194, 195, "CID"], [332, 333, 291, 291, "CID"]]], "clusters": [], "translated": "5-HT1B 受体配体显微注射到伏核壳或核中对<0>可卡因</0>诱导的大鼠<7>运动机能亢进</7>的影响。本研究旨在检测显微注射到伏隔核（核壳和核）亚区的 5-HT1B 受体配体对<1>可卡因</1>诱导的<8>运动机能亢进</8>的影响。雄性Wistar大鼠双侧插管植入伏核壳或核，然后局部注射<15>GR 55562</15>（5-HT1B受体拮抗剂）或<11>CP 93129</11>（5-HT1B受体的激动剂）。\n\n给任一伏隔的分区单独给药，<16>GR 55562</16>(0.1-10微克/侧)或<12>CP 93129</12>(0.1-10微克/侧)未改变基础运动活动。系统地给予<2>可卡因</2>(10 mg/kg)显着增加大鼠的运动能力。<17>GR 55562</17> (0.1-10 微克/侧)，在给予<3>可卡因</3>之前在伏隔壳内给药，剂量依赖性地减弱了精神兴奋剂引起的<9>运动机能亢进</9>。这样的衰减在被注射<18>GR 55562</18>到伏隔核的动物中未被发现。当在给予<4>可卡因</4>之前注射到伏隔壳（而不是核心），<13>CP 93129</13>(0.1-10微克/侧)增强了对<5>可卡因</5>的运动反应。最大效果在给予10微克/侧的激动剂后观察到。后续的增强在在注射<19>GR 55562</19>(1微克/侧)到伏隔内壳后被减弱。\n\n我们的研究结果表明，<6>可卡因</6>诱导的<10>过度运动</10>被5-HT1B受体配体显微注射到伏核壳而不是核中进行修正。这种修正包括 5-HT1B受体拮抗剂(<20>GR 55562</20>)和激动剂(<14>CP 93129</14>)的抑制和促进作用。换句话说，目前的结果表明，累积壳5-HT1B受体在精神兴奋剂的行为反应中起着许可作用。", "revised": true}
{"doc_key": "2312209", "sentences": [["Myocardial", "infarction", "following", "sublingual", "administration", "of", "isosorbide", "dinitrate", ".", "A", "78", "-", "year", "-", "old", "with", "healed", "septal", "necrosis", "suffered", "a", "recurrent", "myocardial", "infarction", "of", "the", "anterior", "wall", "following", "the", "administration", "of", "isosorbide", "dinitrate", "5", "mg", "sublingually", ".", "After", "detailing", "the", "course", "of", "events", ",", "we", "discuss", "the", "role", "of", "paradoxical", "coronary", "spasm", "and", "hypotension", "-", "mediated", "myocardial", "ischemia", "occurring", "downstream", "to", "significant", "coronary", "arterial", "stenosis", "in", "the", "pathophysiology", "of", "acute", "coronary", "insufficiency", "."]], "ner": [[[6, 7, "Chemical"], [32, 33, "Chemical"], [0, 1, "Disease"], [22, 23, "Disease"], [18, 18, "Disease"], [52, 52, "Disease"], [54, 54, "Disease"], [57, 58, "Disease"], [63, 65, "Disease"], [70, 72, "Disease"]]], "relations": [[[6, 7, 0, 1, "CID"], [6, 7, 22, 23, "CID"], [32, 33, 0, 1, "CID"], [32, 33, 22, 23, "CID"]]], "clusters": [], "translated": "<2>心肌梗死</2>在舌下含服<0>硝酸异山梨酯</0>后发生。一位78岁的室间隔<4>坏死</4>患者在给予舌下<1>硝酸异山梨酯</1> 5mg后再次发生前壁<3>心肌梗塞</3>。在详细说明事件过程之后，我们探讨了矛盾性冠状动脉<5>痉挛</5>和<6>低血压</6>-介导的<7>心肌缺血</7>，这些现象发生在显着的冠状动脉<8>狭窄</8>的下游，对于<9>急性冠状动脉供血不足</9>的病理生理学有着重要作用。", "revised": true}
{"doc_key": "1919871", "sentences": [["Irreversible", "damage", "to", "the", "medullary", "interstitium", "in", "experimental", "analgesic", "nephropathy", "in", "F344", "rats", ".", "Renal", "papillary", "necrosis", "(", "RPN", ")", "and", "a", "decreased", "urinary", "concentrating", "ability", "developed", "during", "continuous", "long", "-", "term", "treatment", "with", "aspirin", "and", "paracetamol", "in", "female", "Fischer", "344", "rats", ".", "Renal", "structure", "and", "concentrating", "ability", "were", "examined", "after", "a", "recovery", "period", "of", "up", "to", "18", "weeks", ",", "when", "no", "analgesics", "were", "given", ",", "to", "investigate", "whether", "the", "analgesic", "-", "induced", "changes", "were", "reversible", ".", "There", "was", "no", "evidence", "of", "repair", "to", "the", "damaged", "medullary", "interstitial", "matrix", ",", "or", "proliferation", "of", "remaining", "undamaged", "type", "1", "medullary", "interstitial", "cells", "after", "the", "recovery", "period", "following", "analgesic", "treatment", ".", "The", "recovery", "of", "urinary", "concentrating", "ability", "was", "related", "to", "the", "length", "of", "analgesic", "treatment", "and", "the", "extent", "of", "the", "resulting", "inner", "medullary", "structural", "damage", ".", "During", "the", "early", "stages", "of", "analgesic", "treatment", ",", "the", "changes", "in", "urinary", "concentrating", "ability", "were", "reversible", ",", "but", "after", "prolonged", "analgesic", "treatment", ",", "maximum", "urinary", "concentrating", "ability", "failed", "to", "recover", ".", "This", "study", "shows", "that", "prolonged", "analgesic", "treatment", "in", "Fischer", "344", "rats", "causes", "progressive", "and", "irreversible", "damage", "to", "the", "interstitial", "matrix", "and", "type", "1", "interstitial", "cells", "leading", "to", "RPN", ".", "The", "associated", "urinary", "concentrating", "defect", "is", "reversible", "only", "during", "the", "early", "stages", "of", "structural", "damage", "to", "the", "inner", "medulla", "."]], "ner": [[[34, 34, "Chemical"], [14, 16, "Disease"], [18, 18, "Disease"], [191, 191, "Disease"], [36, 36, "Chemical"], [9, 9, "Disease"]]], "relations": [[[34, 34, 14, 16, "CID"], [34, 34, 18, 18, "CID"], [34, 34, 191, 191, "CID"], [36, 36, 14, 16, "CID"], [36, 36, 18, 18, "CID"], [36, 36, 191, 191, "CID"]]], "clusters": [], "translated": "F344大鼠实验性镇痛<5>肾病</5>对髓质间质的不可逆损伤。<1>肾乳头坏死</1> (<2>RPN</2>)和尿浓缩能力下降在连续长期使用<0>阿司匹林</0>和<4>扑热息痛</4>在雌性Fischer 344大鼠中。在长达18周的恢复期（未给予镇痛药）后检查肾脏结构和浓缩能力，以研究镇痛药引起的变化是否可逆。在镇痛治疗后的恢复期后，没有证据表明受损的髓质间质基质得到修复，或剩余未受损的1型髓质间质细胞增殖。尿浓缩能力的恢复与镇痛治疗时间的长短及由此引起的髓内结构损伤程度有关。镇痛治疗初期，尿浓缩能力的改变是可逆的，但长时间镇痛治疗后，最大尿浓缩能力未能恢复。这项研究表明，Fischer 344大鼠的长期镇痛治疗会对间质基质和1型间质细胞造成进行性和不可逆的损伤，从而导致<3>RPN</3>。相关的尿液浓缩缺陷仅在内部髓质结构损伤的早期阶段是可逆的。", "revised": true}
{"doc_key": "26094", "sentences": [["Antihypertensive", "drugs", "and", "depression", ":", "a", "reappraisal", ".", "Eighty", "-", "nine", "new", "referral", "hypertensive", "out", "-", "patients", "and", "46", "new", "referral", "non", "-", "hypertensive", "chronically", "physically", "ill", "out", "-", "patients", "completed", "a", "mood", "rating", "scale", "at", "regular", "intervals", "for", "one", "year", ".", "The", "results", "showed", "a", "high", "prevalence", "of", "depression", "in", "both", "groups", "of", "patients", ",", "with", "no", "preponderance", "in", "the", "hypertensive", "group", ".", "Hypertensive", "patients", "with", "psychiatric", "histories", "had", "a", "higher", "prevalence", "of", "depression", "than", "the", "comparison", "patients", ".", "This", "was", "accounted", "for", "by", "a", "significant", "number", "of", "depressions", "occurring", "in", "methyl", "dopa", "treated", "patients", "with", "psychiatric", "histories", "."]], "ner": [[[92, 93, "Chemical"], [3, 3, "Disease"], [49, 49, "Disease"], [74, 74, "Disease"], [89, 89, "Disease"], [13, 13, "Disease"], [23, 23, "Disease"], [61, 61, "Disease"], [64, 64, "Disease"], [67, 67, "Disease"], [97, 97, "Disease"]]], "relations": [[[92, 93, 3, 3, "CID"], [92, 93, 49, 49, "CID"], [92, 93, 74, 74, "CID"], [92, 93, 89, 89, "CID"]]], "clusters": [], "translated": "抗高血压药物和<1>抑郁症</1>：重新评估。89名新转诊的<5>高血压</5>门诊患者和46名新转诊的非<6>高血压</6>慢性身体疾病门诊患者在一年内定期完成情绪评定量表。结果显示，两组患者<2>抑郁症</2>的患病率都很高，<7>高血压</7>组的患病率不高。有<9>精神病</9>病史的<8>高血压</8>患者<3>抑郁症</3>的患病率高于对照患者。这是由<0>甲基多巴</0>治疗的有<10>精神病</10>病史的患者中发生的大量<4>抑郁症</4>造成的。", "revised": true}
{"doc_key": "20196116", "sentences": [["Antituberculosis", "therapy", "-", "induced", "acute", "liver", "failure", ":", "magnitude", ",", "profile", ",", "prognosis", ",", "and", "predictors", "of", "outcome", ".", "Antituberculosis", "therapy", "(", "ATT", ")", "-", "associated", "acute", "liver", "failure", "(", "ATT", "-", "ALF", ")", "is", "the", "commonest", "drug", "-", "induced", "ALF", "in", "South", "Asia", ".", "Prospective", "studies", "on", "ATT", "-", "ALF", "are", "lacking", ".", "The", "current", "study", "prospectively", "evaluated", "the", "magnitude", ",", "clinical", "course", ",", "outcome", ",", "and", "prognostic", "factors", "in", "ATT", "-", "ALF", ".", "From", "January", "1986", "to", "January", "2009", ",", "1223", "consecutive", "ALF", "patients", "were", "evaluated", ":", "ATT", "alone", "was", "the", "cause", "in", "70", "(", "5", ".", "7", "%", ")", "patients", ".", "Another", "15", "(", "1", ".", "2", "%", ")", "had", "ATT", "and", "simultaneous", "hepatitis", "virus", "infection", ".", "In", "44", "(", "62", ".", "8", "%", ")", "patients", ",", "ATT", "was", "prescribed", "empirically", "without", "definitive", "evidence", "of", "tuberculosis", ".", "ATT", "-", "ALF", "patients", "were", "younger", "(", "32", ".", "87", "[", "+", "/", "-", "15", ".", "8", "]", "years", ")", ",", "and", "49", "(", "70", "%", ")", "of", "them", "were", "women", ".", "Most", "had", "hyperacute", "presentation", ";", "the", "median", "icterus", "encephalopathy", "interval", "was", "4", ".", "5", "(", "0", "-", "30", ")", "days", ".", "The", "median", "duration", "of", "ATT", "before", "ALF", "was", "30", "(", "7", "-", "350", ")", "days", ".", "At", "presentation", ",", "advanced", "encephalopathy", "and", "cerebral", "edema", "were", "present", "in", "51", "(", "76", "%", ")", "and", "29", "(", "41", ".", "4", "%", ")", "patients", ",", "respectively", ".", "Gastrointestinal", "bleed", ",", "seizures", ",", "infection", ",", "and", "acute", "renal", "failure", "were", "documented", "in", "seven", "(", "10", "%", ")", ",", "five", "(", "7", ".", "1", "%", ")", ",", "26", "(", "37", ".", "1", "%", ")", ",", "and", "seven", "(", "10", "%", ")", "patients", ",", "respectively", ".", "Compared", "with", "hepatitis", "E", "virus", "(", "HEV", ")", "and", "non", "-", "A", "non", "-", "E", "-", "induced", "ALF", ",", "ATT", "-", "ALF", "patients", "had", "nearly", "similar", "presentations", "except", "for", "older", "age", "and", "less", "elevation", "of", "liver", "enzymes", ".", "The", "mortality", "rate", "among", "patients", "with", "ATT", "-", "ALF", "was", "high", "(", "67", ".", "1", "%", ",", "n", "=", "47", ")", ",", "and", "only", "23", "(", "32", ".", "9", "%", ")", "patients", "recovered", "with", "medical", "treatment", ".", "In", "multivariate", "analysis", ",", "three", "factors", "independently", "predicted", "mortality", ":", "serum", "bilirubin", "(", ">", "or", "=", "10", ".", "8", "mg", "/", "dL", ")", ",", "prothrombin", "time", "(", "PT", ")", "prolongation", "(", ">", "or", "=", "26", "seconds", ")", ",", "and", "grade", "III", "/", "IV", "encephalopathy", "at", "presentation", ".", "CONCLUSION", ":", "ATT", "-", "ALF", "constituted", "5", ".", "7", "%", "of", "ALF", "at", "our", "center", "and", "had", "a", "high", "mortality", "rate", ".", "Because", "the", "mortality", "rate", "is", "so", "high", ",", "determining", "which", "factors", "are", "predictors", "is", "less", "important", ".", "A", "high", "proportion", "of", "patients", "had", "consumed", "ATT", "empirically", ",", "which", "could", "have", "been", "prevented", "."]], "ner": [[[0, 0, "Chemical"], [19, 19, "Chemical"], [4, 6, "Disease"], [26, 28, "Disease"], [32, 32, "Disease"], [40, 40, "Disease"], [50, 50, "Disease"], [73, 73, "Disease"], [84, 84, "Disease"], [142, 142, "Disease"], [199, 199, "Disease"], [300, 300, "Disease"], [304, 304, "Disease"], [329, 329, "Disease"], [409, 409, "Disease"], [416, 416, "Disease"], [116, 118, "Disease"], [138, 138, "Disease"], [179, 179, "Disease"], [180, 180, "Disease"], [213, 213, "Disease"], [401, 401, "Disease"], [215, 216, "Disease"], [237, 238, "Disease"], [240, 240, "Disease"], [242, 242, "Disease"], [245, 247, "Disease"], [285, 286, "Disease"], [369, 369, "Chemical"]]], "relations": [[[0, 0, 4, 6, "CID"], [0, 0, 26, 28, "CID"], [0, 0, 32, 32, "CID"], [0, 0, 40, 40, "CID"], [0, 0, 50, 50, "CID"], [0, 0, 73, 73, "CID"], [0, 0, 84, 84, "CID"], [0, 0, 142, 142, "CID"], [0, 0, 199, 199, "CID"], [0, 0, 300, 300, "CID"], [0, 0, 304, 304, "CID"], [0, 0, 329, 329, "CID"], [0, 0, 409, 409, "CID"], [0, 0, 416, 416, "CID"], [19, 19, 4, 6, "CID"], [19, 19, 26, 28, "CID"], [19, 19, 32, 32, "CID"], [19, 19, 40, 40, "CID"], [19, 19, 50, 50, "CID"], [19, 19, 73, 73, "CID"], [19, 19, 84, 84, "CID"], [19, 19, 142, 142, "CID"], [19, 19, 199, 199, "CID"], [19, 19, 300, 300, "CID"], [19, 19, 304, 304, "CID"], [19, 19, 329, 329, "CID"], [19, 19, 409, 409, "CID"], [19, 19, 416, 416, "CID"]]], "clusters": [], "translated": "<0>抗结核</0>治疗引起的<2>急性肝功能衰竭</2>：严重程度、概况、预后和结果预测因子。<1>抗结核</1>疗法（ATT）-相关的<3>急性肝衰竭</3>（ATT-<4>ALF</4>）是最常见的药物性<5>ALF</5>在南亚。缺乏对 ATT-<6>ALF</6> 的前瞻性研究。目前的研究前瞻性地评估了 ATT-<7>ALF</7> 的严重程度、临床过程、结果和预后因素。从1986年1月到2009年1月，对1223名连续的<8>ALF</8>患者进行了评估：ATT单独是70名（5.7%）患者的病因。另有15人（1.2%）患有ATT并同时感染<16>肝炎病毒</16>。在44名（62.8%）患者中，ATT是根据经验开具的处方，没有<17>结核病</17>的明确证据。ATT-<9>ALF</9>患者年龄较小（32.87[+/-15.8]岁），其中49名（70%）为女性。大多数有超急性表现；<18>黄疸</18> <19>脑病</19>间隔的中位数为4.5（0-30）天。<10>ALF</10>前ATT的中位持续时间为30（7-350）天。就诊时，分别有51例（76%）和29例（41.4%）患者出现晚期<20>脑病</20>和<22>脑水肿</22>。<23>胃肠道出血</23>、<24>癫痫发作</24>、<25>感染</25>和<26>急性肾功能衰竭</26>记录在七（10%）、五（7.1%）、26（37.1%）和7（10%）名患者。与<27>戊型肝炎</27>病毒（HEV）和非A非E型<11>ALF</11>相比，ATT-<12>ALF</12>患者的表现几乎相似，除了年龄越大肝酶升高越少。ATT-<13>ALF</13>患者病死率高（67.1%，n=47），经药物治疗痊愈者仅23例（32.9%）。在多变量分析中，三个独立预测死亡率的因素：血清<28>胆红素</28>（>或=10.8mg/dL）、凝血酶原时间（PT）延长（>或=26秒），以及III / IV级<21>脑病</21>就诊时。结论：ATT-<14>ALF</14>构成5.7%的<15>ALF</15>在我们中心，死亡率很高。由于死亡率如此之高，确定哪些因素是预测因素就不那么重要了。很大一部分患者凭经验服用了ATT，这本来是可以避免的。", "revised": true}
{"doc_key": "2549018", "sentences": [["Fluoxetine", "-", "induced", "akathisia", ":", "clinical", "and", "theoretical", "implications", ".", "Five", "patients", "receiving", "fluoxetine", "for", "the", "treatment", "of", "obsessive", "compulsive", "disorder", "or", "major", "depression", "developed", "akathisia", ".", "The", "typical", "fluoxetine", "-", "induced", "symptoms", "of", "restlessness", ",", "constant", "pacing", ",", "purposeless", "movements", "of", "the", "feet", "and", "legs", ",", "and", "marked", "anxiety", "were", "indistinguishable", "from", "those", "of", "neuroleptic", "-", "induced", "akathisia", ".", "Three", "patients", "who", "had", "experienced", "neuroleptic", "-", "induced", "akathisia", "in", "the", "past", "reported", "that", "the", "symptoms", "of", "fluoxetine", "-", "induced", "akathisia", "were", "identical", ",", "although", "somewhat", "milder", ".", "Akathisia", "appeared", "to", "be", "a", "common", "side", "effect", "of", "fluoxetine", "and", "generally", "responded", "well", "to", "treatment", "with", "the", "beta", "-", "adrenergic", "antagonist", "propranolol", ",", "dose", "reduction", ",", "or", "both", ".", "The", "authors", "suggest", "that", "fluoxetine", "-", "induced", "akathisia", "may", "be", "caused", "by", "serotonergically", "mediated", "inhibition", "of", "dopaminergic", "neurotransmission", "and", "that", "the", "pathophysiology", "of", "fluoxetine", "-", "induced", "akathisia", "and", "tricyclic", "antidepressant", "-", "induced", "\"", "jitteriness", "\"", "may", "be", "identical", "."]], "ner": [[[0, 0, "Chemical"], [13, 13, "Chemical"], [29, 29, "Chemical"], [77, 77, "Chemical"], [97, 97, "Chemical"], [122, 122, "Chemical"], [141, 141, "Chemical"], [3, 3, "Disease"], [25, 25, "Disease"], [58, 58, "Disease"], [68, 68, "Disease"], [80, 80, "Disease"], [88, 88, "Disease"], [125, 125, "Disease"], [144, 144, "Disease"], [18, 20, "Disease"], [22, 23, "Disease"], [49, 49, "Disease"], [110, 110, "Chemical"], [147, 147, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 25, 25, "CID"], [0, 0, 58, 58, "CID"], [0, 0, 68, 68, "CID"], [0, 0, 80, 80, "CID"], [0, 0, 88, 88, "CID"], [0, 0, 125, 125, "CID"], [0, 0, 144, 144, "CID"], [13, 13, 3, 3, "CID"], [13, 13, 25, 25, "CID"], [13, 13, 58, 58, "CID"], [13, 13, 68, 68, "CID"], [13, 13, 80, 80, "CID"], [13, 13, 88, 88, "CID"], [13, 13, 125, 125, "CID"], [13, 13, 144, 144, "CID"], [29, 29, 3, 3, "CID"], [29, 29, 25, 25, "CID"], [29, 29, 58, 58, "CID"], [29, 29, 68, 68, "CID"], [29, 29, 80, 80, "CID"], [29, 29, 88, 88, "CID"], [29, 29, 125, 125, "CID"], [29, 29, 144, 144, "CID"], [77, 77, 3, 3, "CID"], [77, 77, 25, 25, "CID"], [77, 77, 58, 58, "CID"], [77, 77, 68, 68, "CID"], [77, 77, 80, 80, "CID"], [77, 77, 88, 88, "CID"], [77, 77, 125, 125, "CID"], [77, 77, 144, 144, "CID"], [97, 97, 3, 3, "CID"], [97, 97, 25, 25, "CID"], [97, 97, 58, 58, "CID"], [97, 97, 68, 68, "CID"], [97, 97, 80, 80, "CID"], [97, 97, 88, 88, "CID"], [97, 97, 125, 125, "CID"], [97, 97, 144, 144, "CID"], [122, 122, 3, 3, "CID"], [122, 122, 25, 25, "CID"], [122, 122, 58, 58, "CID"], [122, 122, 68, 68, "CID"], [122, 122, 80, 80, "CID"], [122, 122, 88, 88, "CID"], [122, 122, 125, 125, "CID"], [122, 122, 144, 144, "CID"], [141, 141, 3, 3, "CID"], [141, 141, 25, 25, "CID"], [141, 141, 58, 58, "CID"], [141, 141, 68, 68, "CID"], [141, 141, 80, 80, "CID"], [141, 141, 88, 88, "CID"], [141, 141, 125, 125, "CID"], [141, 141, 144, 144, "CID"]]], "clusters": [], "translated": "<0>氟西汀</0>诱导的<7>静坐不能</7>：临床和理论意义。五名接受<1>氟西汀</1>治疗<15>强迫症</15>或<16>重度抑郁症</16>的患者出现了<8>静坐不能</8>。典型的<2>氟西汀</2>引起的烦躁不安、不停地走动、脚和腿的无目的运动以及明显的<17>焦虑</17>症状与抗精神病药物引起的<9>静坐不能</9>无法区分。过去经历过抗精神病药引起的<10>静坐不能</10>的三名患者报告说，<11>氟西汀</11>引起的<3>静坐不能</3>的症状是相同的，尽管稍微轻一些。 <12>静坐不能</12>似乎是<4>氟西汀</4>的常见副作用，通常对使用β-肾上腺素能拮抗剂<18>普萘洛尔</18>和/或减量治疗反应良好。作者认为<5>氟西汀</5>-诱导的<13>静坐不能</13>可能是由血清素介导的多巴胺能神经传递抑制引起的，并且<6>氟西汀</6>-诱导的<14>静坐不能</14>和三环类<19>抗抑郁药</19>引起的“神经过敏”可能是相同的。", "revised": true}
{"doc_key": "20722491", "sentences": [["Safety", "of", "capecitabine", ":", "a", "review", ".", "IMPORTANCE", "OF", "THE", "FIELD", ":", "Fluoropyrimidines", ",", "in", "particular", "5", "-", "fluorouracil", "(", "5", "-", "FU", ")", ",", "have", "been", "the", "mainstay", "of", "treatment", "for", "several", "solid", "tumors", ",", "including", "colorectal", ",", "breast", "and", "head", "and", "neck", "cancers", ",", "for", ">", "40", "years", ".", "AREAS", "COVERED", "IN", "THIS", "REVIEW", ":", "This", "article", "reviews", "the", "pharmacology", "and", "efficacy", "of", "capecitabine", "with", "a", "special", "emphasis", "on", "its", "safety", ".", "WHAT", "THE", "READER", "WILL", "GAIN", ":", "The", "reader", "will", "gain", "better", "insight", "into", "the", "safety", "of", "capecitabine", "in", "special", "populations", "such", "as", "patients", "with", "advanced", "age", ",", "renal", "and", "kidney", "disease", ".", "We", "also", "explore", "different", "dosing", "and", "schedules", "of", "capecitabine", "administration", ".", "TAKE", "HOME", "MESSAGE", ":", "Capecitabine", "is", "an", "oral", "prodrug", "of", "5", "-", "FU", "and", "was", "developed", "to", "fulfill", "the", "need", "for", "a", "more", "convenient", "therapy", "and", "provide", "an", "improved", "safety", "/", "efficacy", "profile", ".", "It", "has", "shown", "promising", "results", "alone", "or", "in", "combination", "with", "other", "chemotherapeutic", "agents", "in", "colorectal", ",", "breast", ",", "pancreaticobiliary", ",", "gastric", ",", "renal", "cell", "and", "head", "and", "neck", "cancers", ".", "The", "most", "commonly", "reported", "toxic", "effects", "of", "capecitabine", "are", "diarrhea", ",", "nausea", ",", "vomiting", ",", "stomatitis", "and", "hand", "-", "foot", "syndrome", ".", "Capecitabine", "has", "a", "well", "-", "established", "safety", "profile", "and", "can", "be", "given", "safely", "to", "patients", "with", "advanced", "age", ",", "hepatic", "and", "renal", "dysfunctions", "."]], "ner": [[[2, 2, "Chemical"], [65, 65, "Chemical"], [90, 90, "Chemical"], [114, 114, "Chemical"], [121, 121, "Chemical"], [188, 188, "Chemical"], [203, 203, "Chemical"], [190, 190, "Disease"], [192, 192, "Disease"], [194, 194, "Disease"], [196, 196, "Disease"], [198, 201, "Disease"], [34, 34, "Disease"], [37, 44, "Disease"], [165, 179, "Disease"], [101, 104, "Disease"], [222, 225, "Disease"], [16, 18, "Chemical"], [20, 22, "Chemical"], [127, 129, "Chemical"]]], "relations": [[[2, 2, 190, 190, "CID"], [65, 65, 190, 190, "CID"], [90, 90, 190, 190, "CID"], [114, 114, 190, 190, "CID"], [121, 121, 190, 190, "CID"], [188, 188, 190, 190, "CID"], [203, 203, 190, 190, "CID"], [2, 2, 192, 192, "CID"], [65, 65, 192, 192, "CID"], [90, 90, 192, 192, "CID"], [114, 114, 192, 192, "CID"], [121, 121, 192, 192, "CID"], [188, 188, 192, 192, "CID"], [203, 203, 192, 192, "CID"], [2, 2, 194, 194, "CID"], [65, 65, 194, 194, "CID"], [90, 90, 194, 194, "CID"], [114, 114, 194, 194, "CID"], [121, 121, 194, 194, "CID"], [188, 188, 194, 194, "CID"], [203, 203, 194, 194, "CID"], [2, 2, 196, 196, "CID"], [65, 65, 196, 196, "CID"], [90, 90, 196, 196, "CID"], [114, 114, 196, 196, "CID"], [121, 121, 196, 196, "CID"], [188, 188, 196, 196, "CID"], [203, 203, 196, 196, "CID"], [2, 2, 198, 201, "CID"], [65, 65, 198, 201, "CID"], [90, 90, 198, 201, "CID"], [114, 114, 198, 201, "CID"], [121, 121, 198, 201, "CID"], [188, 188, 198, 201, "CID"], [203, 203, 198, 201, "CID"]]], "clusters": [], "translated": "<0>卡培他滨</0>的安全性：综述。领域的重要性：氟嘧啶，特别是<17>5-氟尿嘧啶</17>（<18>5-FU</18>），已成为多种实体<12>肿瘤</12>的主要治疗药物，包括<13>结直肠癌、乳腺癌和头颈癌</13>，治疗时间>40年。本综述涵盖的领域：本文综述了<1>卡培他滨</1>的药理学和疗效，特别强调了其安全性。读者将获得什么：读者将更好地了解<2>卡培他滨</2>在特殊人群中的安全性，例如高龄患者、<15>肾脏和肾脏疾病</15>。我们还探讨了<3>卡培他滨</3>给药的不同剂量和时间表。重要信息：<4>卡培他滨</4>是口服前体药物<19>5-FU</19>，其开发旨在满足对更方便的治疗的需求，并提供更高的安全性/有效性。它在<14>结直肠癌、乳腺癌、胰胆管癌、胃癌、肾细胞癌和头颈癌</14>中单独或与其他化疗药物联合使用时显示出可喜的结果。最常报告的<5>卡培他滨</5>毒性作用是<7>腹泻</7>、<8>恶心</8>、<9>呕吐</9>、<10>口腔炎</10>和<11>手足综合症</11>。<6>卡培他滨</6>具有公认的安全性，可安全地用于<16>肝肾功能不全</16>的患者。", "revised": true}
{"doc_key": "18208574", "sentences": [["Higher", "optical", "density", "of", "an", "antigen", "assay", "predicts", "thrombosis", "in", "patients", "with", "heparin", "-", "induced", "thrombocytopenia", ".", "OBJECTIVES", ":", "To", "correlate", "optical", "density", "and", "percent", "inhibition", "of", "a", "two", "-", "step", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "antigen", "assay", "with", "thrombosis", ";", "the", "assay", "utilizes", "reaction", "inhibition", "characteristics", "of", "a", "high", "heparin", "concentration", ".", "PATIENTS", "AND", "METHODS", ":", "Patients", "with", "more", "than", "50", "%", "decrease", "in", "platelet", "count", "or", "thrombocytopenia", "(", "<", "150", "x", "10", "(", "9", ")", "/", "L", ")", "after", "exposure", "to", "heparin", ",", "who", "had", "a", "positive", "two", "-", "step", "antigen", "assay", "[", "optical", "density", "(", "OD", ")", ">", "0", ".", "4", "and", ">", "50", "inhibition", "with", "high", "concentration", "of", "heparin", "]", "were", "included", "in", "the", "study", ".", "RESULTS", ":", "Forty", "of", "94", "HIT", "patients", "had", "thrombosis", "at", "diagnosis", ";", "54", "/", "94", "had", "isolated", "-", "HIT", "without", "thrombosis", ".", "Eight", "of", "the", "isolated", "-", "HIT", "patients", "developed", "thrombosis", "within", "the", "next", "30", "d", ";", "thus", ",", "a", "total", "of", "48", "patients", "had", "thrombosis", "at", "day", "30", ".", "At", "diagnosis", "there", "was", "no", "significant", "difference", "in", "OD", "between", "HIT", "patients", "with", "thrombosis", "and", "those", "with", "isolated", "-", "HIT", ".", "However", ",", "OD", "was", "significantly", "higher", "in", "all", "patients", "with", "thrombosis", "(", "n", "=", "48", ",", "1", ".", "34", "+", "/", "-", "0", ".", "89", ")", ",", "including", "isolated", "-", "HIT", "patients", "who", "later", "developed", "thrombosis", "within", "30", "d", "(", "n", "=", "8", ",", "1", ".", "84", "+", "/", "-", "0", ".", "64", ")", "as", "compared", "to", "isolated", "-", "HIT", "patients", "who", "did", "not", "develop", "thrombosis", "(", "0", ".", "96", "+", "/", "-", "0", ".", "75", ";", "P", "=", "0", ".", "011", "and", "P", "=", "0", ".", "008", ")", ".", "The", "Receiver", "Operative", "Characteristic", "Curve", "showed", "that", "OD", ">", "1", ".", "27", "in", "the", "isolated", "-", "HIT", "group", "had", "a", "significantly", "higher", "chance", "of", "developing", "thrombosis", "by", "day", "30", ".", "None", "of", "these", "groups", "showed", "significant", "difference", "in", "percent", "inhibition", ".", "Multivariate", "analysis", "showed", "a", "2", ".", "8", "-", "fold", "increased", "risk", "of", "thrombosis", "in", "females", ".", "Similarly", ",", "thrombotic", "risk", "increased", "with", "age", "and", "OD", "values", ".", "CONCLUSION", ":", "Higher", "OD", "is", "associated", "with", "significant", "risk", "of", "subsequent", "thrombosis", "in", "patients", "with", "isolated", "-", "HIT", ";", "percent", "inhibition", ",", "however", ",", "was", "not", "predictive", "."]], "ner": [[[12, 12, "Chemical"], [31, 31, "Chemical"], [52, 52, "Chemical"], [85, 85, "Chemical"], [114, 114, "Chemical"], [8, 8, "Disease"], [41, 41, "Disease"], [130, 130, "Disease"], [142, 142, "Disease"], [152, 152, "Disease"], [167, 167, "Disease"], [185, 185, "Disease"], [203, 203, "Disease"], [228, 228, "Disease"], [258, 258, "Disease"], [308, 308, "Disease"], [336, 336, "Disease"], [342, 342, "Disease"], [362, 362, "Disease"], [15, 15, "Disease"], [34, 34, "Disease"], [36, 36, "Disease"], [70, 70, "Disease"], [127, 127, "Disease"], [140, 140, "Disease"], [149, 149, "Disease"], [182, 182, "Disease"], [191, 191, "Disease"], [223, 223, "Disease"], [252, 252, "Disease"], [299, 299, "Disease"], [368, 368, "Disease"]]], "relations": [[[12, 12, 8, 8, "CID"], [12, 12, 41, 41, "CID"], [12, 12, 130, 130, "CID"], [12, 12, 142, 142, "CID"], [12, 12, 152, 152, "CID"], [12, 12, 167, 167, "CID"], [12, 12, 185, 185, "CID"], [12, 12, 203, 203, "CID"], [12, 12, 228, 228, "CID"], [12, 12, 258, 258, "CID"], [12, 12, 308, 308, "CID"], [12, 12, 336, 336, "CID"], [12, 12, 342, 342, "CID"], [12, 12, 362, 362, "CID"], [31, 31, 8, 8, "CID"], [31, 31, 41, 41, "CID"], [31, 31, 130, 130, "CID"], [31, 31, 142, 142, "CID"], [31, 31, 152, 152, "CID"], [31, 31, 167, 167, "CID"], [31, 31, 185, 185, "CID"], [31, 31, 203, 203, "CID"], [31, 31, 228, 228, "CID"], [31, 31, 258, 258, "CID"], [31, 31, 308, 308, "CID"], [31, 31, 336, 336, "CID"], [31, 31, 342, 342, "CID"], [31, 31, 362, 362, "CID"], [52, 52, 8, 8, "CID"], [52, 52, 41, 41, "CID"], [52, 52, 130, 130, "CID"], [52, 52, 142, 142, "CID"], [52, 52, 152, 152, "CID"], [52, 52, 167, 167, "CID"], [52, 52, 185, 185, "CID"], [52, 52, 203, 203, "CID"], [52, 52, 228, 228, "CID"], [52, 52, 258, 258, "CID"], [52, 52, 308, 308, "CID"], [52, 52, 336, 336, "CID"], [52, 52, 342, 342, "CID"], [52, 52, 362, 362, "CID"], [85, 85, 8, 8, "CID"], [85, 85, 41, 41, "CID"], [85, 85, 130, 130, "CID"], [85, 85, 142, 142, "CID"], [85, 85, 152, 152, "CID"], [85, 85, 167, 167, "CID"], [85, 85, 185, 185, "CID"], [85, 85, 203, 203, "CID"], [85, 85, 228, 228, "CID"], [85, 85, 258, 258, "CID"], [85, 85, 308, 308, "CID"], [85, 85, 336, 336, "CID"], [85, 85, 342, 342, "CID"], [85, 85, 362, 362, "CID"], [114, 114, 8, 8, "CID"], [114, 114, 41, 41, "CID"], [114, 114, 130, 130, "CID"], [114, 114, 142, 142, "CID"], [114, 114, 152, 152, "CID"], [114, 114, 167, 167, "CID"], [114, 114, 185, 185, "CID"], [114, 114, 203, 203, "CID"], [114, 114, 228, 228, "CID"], [114, 114, 258, 258, "CID"], [114, 114, 308, 308, "CID"], [114, 114, 336, 336, "CID"], [114, 114, 342, 342, "CID"], [114, 114, 362, 362, "CID"], [12, 12, 15, 15, "CID"], [12, 12, 34, 34, "CID"], [12, 12, 36, 36, "CID"], [12, 12, 70, 70, "CID"], [12, 12, 127, 127, "CID"], [12, 12, 140, 140, "CID"], [12, 12, 149, 149, "CID"], [12, 12, 182, 182, "CID"], [12, 12, 191, 191, "CID"], [12, 12, 223, 223, "CID"], [12, 12, 252, 252, "CID"], [12, 12, 299, 299, "CID"], [12, 12, 368, 368, "CID"], [31, 31, 15, 15, "CID"], [31, 31, 34, 34, "CID"], [31, 31, 36, 36, "CID"], [31, 31, 70, 70, "CID"], [31, 31, 127, 127, "CID"], [31, 31, 140, 140, "CID"], [31, 31, 149, 149, "CID"], [31, 31, 182, 182, "CID"], [31, 31, 191, 191, "CID"], [31, 31, 223, 223, "CID"], [31, 31, 252, 252, "CID"], [31, 31, 299, 299, "CID"], [31, 31, 368, 368, "CID"], [52, 52, 15, 15, "CID"], [52, 52, 34, 34, "CID"], [52, 52, 36, 36, "CID"], [52, 52, 70, 70, "CID"], [52, 52, 127, 127, "CID"], [52, 52, 140, 140, "CID"], [52, 52, 149, 149, "CID"], [52, 52, 182, 182, "CID"], [52, 52, 191, 191, "CID"], [52, 52, 223, 223, "CID"], [52, 52, 252, 252, "CID"], [52, 52, 299, 299, "CID"], [52, 52, 368, 368, "CID"], [85, 85, 15, 15, "CID"], [85, 85, 34, 34, "CID"], [85, 85, 36, 36, "CID"], [85, 85, 70, 70, "CID"], [85, 85, 127, 127, "CID"], [85, 85, 140, 140, "CID"], [85, 85, 149, 149, "CID"], [85, 85, 182, 182, "CID"], [85, 85, 191, 191, "CID"], [85, 85, 223, 223, "CID"], [85, 85, 252, 252, "CID"], [85, 85, 299, 299, "CID"], [85, 85, 368, 368, "CID"], [114, 114, 15, 15, "CID"], [114, 114, 34, 34, "CID"], [114, 114, 36, 36, "CID"], [114, 114, 70, 70, "CID"], [114, 114, 127, 127, "CID"], [114, 114, 140, 140, "CID"], [114, 114, 149, 149, "CID"], [114, 114, 182, 182, "CID"], [114, 114, 191, 191, "CID"], [114, 114, 223, 223, "CID"], [114, 114, 252, 252, "CID"], [114, 114, 299, 299, "CID"], [114, 114, 368, 368, "CID"]]], "clusters": [], "translated": "抗原测定的较高光密度可预测<0>肝素</0>诱导的<19>血小板减少症</19>患者的<5>血栓形成</5>。目的：将两步<1>肝素</1>诱导的<20>血小板减少症</20>（<21>HIT</21>）抗原测定与<6>血栓</6>；该测定利用了高浓度<2>肝素</2>的反应抑制特性。患者和方法：在接触<3>肝素</3>后血小板计数减少超过50%或<22>血小板减少症</22>（<150 x 10(9)/L）的患者，其具有阳性两步抗原测定[光密度(OD)>0.4和> 50抑制与高浓度<4>肝素</4>]被纳入研究。结果：94例<23>HIT</23>患者中有40例诊断时有<7>血栓形成</7>；54/94有孤立的-<24>HIT</24>没有<8>血栓形成</8>。8名孤立的-<25>HIT</25>患者在接下来的30天内发生了<9>血栓形成</9>；因此，共有48名患者在第30天发生了<10>血栓形成</10>。诊断时，<26>HIT</26> <11>血栓形成</11>患者与单纯<27>HIT</27>患者的OD无显着差异。然而，所有<12>血栓形成</12>患者（n = 48，1.34 + /- 0.89），包括孤立的-<28>HIT</28>患者，他们后来发展为<13>血栓形成</13>在30天内(n = 8，1.84 + /- 0.64)与孤立的-<29>HIT</29>未发生<14>血栓形成</14>的患者相比(0.96+/-0.75; P = 0.011和P = 0.008)。接受者操作特征曲线显示OD > 1.27在第30天时，<30>HIT</30>组发生<15>血栓形成</15>的机会显着增加。这些组都没有显示抑制百分比的显着差异。多变量分析显示2.女性<16>血栓形成</16>的风险增加8倍。同样，<17>血栓形成</17>的风险随着年龄和OD值的增加而增加。结论：对于<31>HIT</31>患者，较高的OD与后续<18>血栓形成</18>的显着风险相关；然而，抑制百分比并不是预测性的。", "revised": true}
{"doc_key": "2611118", "sentences": [["Chronic", "active", "hepatitis", "associated", "with", "diclofenac", "sodium", "therapy", ".", "Diclofenac", "sodium", "(", "Voltarol", ",", "Geigy", "Pharmaceuticals", ")", "is", "a", "non", "-", "steroidal", "anti", "-", "inflammatory", "derivative", "of", "phenylacetic", "acid", ".", "Although", "generally", "well", "-", "tolerated", ",", "asymptomatic", "abnormalities", "of", "liver", "function", "have", "been", "recorded", "and", ",", "less", "commonly", ",", "severe", "hepatitis", "induced", "by", "diclofenac", ".", "The", "patient", "described", "developed", "chronic", "active", "hepatitis", "after", "six", "months", "therapy", "with", "diclofenac", "sodium", "which", "progressed", "despite", "the", "withdrawal", "of", "the", "drug", ",", "a", "finding", "not", "previously", "reported", "."]], "ner": [[[5, 6, "Chemical"], [9, 10, "Chemical"], [12, 12, "Chemical"], [53, 53, "Chemical"], [67, 68, "Chemical"], [37, 40, "Disease"], [50, 50, "Disease"], [0, 2, "Disease"], [59, 61, "Disease"], [27, 28, "Chemical"]]], "relations": [[[5, 6, 37, 40, "CID"], [5, 6, 50, 50, "CID"], [9, 10, 37, 40, "CID"], [9, 10, 50, 50, "CID"], [12, 12, 37, 40, "CID"], [12, 12, 50, 50, "CID"], [53, 53, 37, 40, "CID"], [53, 53, 50, 50, "CID"], [67, 68, 37, 40, "CID"], [67, 68, 50, 50, "CID"]]], "clusters": [], "translated": "与<0>双氯芬酸钠</0>治疗相关的<7>慢性活动性肝炎</7>。 <1>双氯芬酸钠</1>（<2>Voltarol</2>，Geigy Pharmaceuticals）是<9>苯乙酸</9>的非甾体抗炎衍生物。虽然通常耐受性良好，但已记录到无症状的<5>肝功能异常</5>，并且不太常见由<3>双氯芬酸</3>引起的严重<6>肝炎</6>。患者描述在使用<4>双氯芬酸钠</4>治疗六个月后发展为<8>慢性活动性肝炎</8>，尽管停药后仍继续发展，这一发现以前没有报道过。", "revised": true}
{"doc_key": "1835291", "sentences": [["Acute", "bronchodilating", "effects", "of", "ipratropium", "bromide", "and", "theophylline", "in", "chronic", "obstructive", "pulmonary", "disease", ".", "The", "bronchodilator", "effects", "of", "a", "single", "dose", "of", "ipratropium", "bromide", "aerosol", "(", "36", "micrograms", ")", "and", "short", "-", "acting", "theophylline", "tablets", "(", "dose", "titrated", "to", "produce", "serum", "levels", "of", "10", "-", "20", "micrograms", "/", "mL", ")", "were", "compared", "in", "a", "double", "-", "blind", ",", "placebo", "-", "controlled", "crossover", "study", "in", "21", "patients", "with", "stable", ",", "chronic", "obstructive", "pulmonary", "disease", ".", "Mean", "peak", "forced", "expiratory", "volume", "in", "1", "second", "(", "FEV1", ")", "increases", "over", "baseline", "and", "the", "proportion", "of", "patients", "attaining", "at", "least", "a", "15", "%", "increase", "in", "the", "FEV1", "(", "responders", ")", "were", "31", "%", "and", "90", "%", ",", "respectively", ",", "for", "ipratropium", "and", "17", "%", "and", "50", "%", ",", "respectively", ",", "for", "theophylline", ".", "The", "average", "FEV1", "increases", "during", "the", "6", "-", "hour", "observation", "period", "were", "18", "%", "for", "ipratropium", "and", "8", "%", "for", "theophylline", ".", "The", "mean", "duration", "of", "action", "was", "3", ".", "8", "hours", "with", "ipratropium", "and", "2", ".", "4", "hours", "with", "theophylline", ".", "While", "side", "effects", "were", "rare", ",", "those", "experienced", "after", "theophylline", "use", "did", "involve", "the", "cardiovascular", "and", "gastrointestinal", "systems", ".", "These", "results", "show", "that", "ipratropium", "is", "a", "more", "potent", "bronchodilator", "than", "oral", "theophylline", "in", "patients", "with", "chronic", "airflow", "obstruction", "."]], "ner": [[[7, 7, "Chemical"], [33, 33, "Chemical"], [127, 127, "Chemical"], [149, 149, "Chemical"], [169, 169, "Chemical"], [180, 180, "Chemical"], [202, 202, "Chemical"], [185, 188, "Disease"], [4, 5, "Chemical"], [22, 23, "Chemical"], [116, 116, "Chemical"], [144, 144, "Chemical"], [162, 162, "Chemical"], [194, 194, "Chemical"], [9, 12, "Disease"], [69, 72, "Disease"], [206, 208, "Disease"]]], "relations": [[[7, 7, 185, 188, "CID"], [33, 33, 185, 188, "CID"], [127, 127, 185, 188, "CID"], [149, 149, 185, 188, "CID"], [169, 169, 185, 188, "CID"], [180, 180, 185, 188, "CID"], [202, 202, 185, 188, "CID"]]], "clusters": [], "translated": "<8>异丙托溴铵</8>和<0>茶碱</0>对<14>慢性阻塞性肺疾病</14>的急性支气管扩张作用。单剂量<9>异丙托溴铵</9>气雾剂（36微克）和短效<1>茶碱</1>片剂（滴定剂量以产生10-20微克/毫升的血清水平）的支气管扩张作用在一项双盲、安慰剂对照交叉研究中对21名稳定的<15>慢性阻塞性肺疾病</15>患者进行了比较。对于<10>异丙托溴铵</10>，第一秒用力最大呼气量(FEV1)的平均峰值比基线增加，FEV1增加至少15%的患者比例（有反应者）分别为31%和90%；<2>茶碱</2>分别为17%和50%。在6小时观察期内，<11>异丙托溴铵</11>和<3>茶碱</3>的平均FEV1增加分别为18%和8%。平均作用持续时间为3.8小时与<12>异丙托溴铵</12>和2.4小时使用<4>茶碱</4>。虽然副作用很少见，但<5>茶碱</5>使用后出现的副作用确实涉及<7>心血管和胃肠系统</7>。这些结果表明，对于<16>慢性气流阻塞</16>患者，<13>异丙托溴铵</13>是一种比口服<6>茶碱</6>更有效的支气管扩张剂。", "revised": true}
{"doc_key": "17175308", "sentences": [["Proteinuria", "after", "conversion", "to", "sirolimus", "in", "renal", "transplant", "recipients", ".", "Sirolimus", "(", "SRL", ")", "is", "a", "new", ",", "potent", "immunosuppressive", "agent", ".", "More", "recently", ",", "proteinuria", "has", "been", "reported", "as", "a", "consequence", "of", "sirolimus", "therapy", ",", "although", "the", "mechanism", "has", "remained", "unclear", ".", "We", "retrospectively", "examined", "the", "records", "of", "25", "renal", "transplant", "patients", ",", "who", "developed", "or", "displayed", "increased", "proteinuria", "after", "SRL", "conversion", ".", "The", "patient", "cohort", "(", "14", "men", ",", "11", "women", ")", "was", "treated", "with", "SRL", "as", "conversion", "therapy", ",", "due", "to", "chronic", "allograft", "nephropathy", "(", "CAN", ")", "(", "n", "=", "15", ")", "neoplasia", "(", "n", "=", "8", ")", ";", "Kaposi", "'s", "sarcoma", ",", "Four", "skin", "cancers", ",", "One", "intestinal", "tumors", ",", "One", "renal", "cell", "carsinom", ")", "or", "BK", "virus", "nephropathy", "(", "n", "=", "2", ")", ".", "SRL", "was", "started", "at", "a", "mean", "of", "78", "+", "/", "-", "42", "(", "15", "to", "163", ")", "months", "after", "transplantation", ".", "Mean", "follow", "-", "up", "on", "SRL", "therapy", "was", "20", "+", "/", "-", "12", "(", "6", "to", "43", ")", "months", ".", "Proteinuria", "increased", "from", "0", ".", "445", "(", "0", "to", "1", ".", "5", ")", "g", "/", "d", "before", "conversion", "to", "3", ".", "2", "g", "/", "dL", "(", "0", ".", "2", "to", "12", ")", "after", "conversion", "(", "P", "=", "0", ".", "001", ")", ".", "Before", "conversion", "8", "(", "32", "%", ")", "patients", "had", "no", "proteinuria", ",", "whereas", "afterwards", "all", "patients", "had", "proteinuria", ".", "In", "28", "%", "of", "patients", "proteinuria", "remained", "unchanged", ",", "whereas", "it", "increased", "in", "68", "%", "of", "patients", ".", "In", "40", "%", "it", "increased", "by", "more", "than", "100", "%", ".", "Twenty", "-", "eight", "percent", "of", "patients", "showed", "increased", "proteinuria", "to", "the", "nephrotic", "range", ".", "Biopsies", "performed", "in", "five", "patients", "revealed", "new", "pathological", "changes", ":", "One", "membranoproliferative", "glomerulopathy", "and", "interstitial", "nephritis", ".", "These", "patients", "showed", "persistently", "good", "graft", "function", ".", "Serum", "creatinine", "values", "did", "not", "change", "significantly", ":", "1", ".", "98", "+", "/", "-", "0", ".", "8", "mg", "/", "dL", "before", "SRL", "therapy", "and", "2", ".", "53", "+", "/", "-", "1", ".", "9", "mg", "/", "dL", "at", "last", "follow", "-", "up", "(", "P", "=", ".", "14", ")", ".", "Five", "grafts", "were", "lost", "and", "the", "patients", "returned", "to", "dialysis", ".", "Five", "patients", "displayed", "CAN", "and", "Kaposi", "'s", "sarcoma", ".", "Mean", "urinary", "protein", "of", "patients", "who", "returned", "to", "dialysis", "was", "1", ".", "26", "(", "0", ".", "5", "to", "3", ".", "5", ")", "g", "/", "d", "before", "and", "4", ".", "7", "(", "3", "to", "12", ")", "g", "/", "d", "after", "conversion", "(", "P", "=", ".", "01", ")", ".", "Mean", "serum", "creatinine", "level", "before", "conversion", "was", "2", ".", "21", "mg", "/", "dL", "and", "thereafter", ",", "4", ".", "93", "mg", "/", "dL", "(", "P", "=", ".", "02", ")", ".", "Heavy", "proteinuria", "was", "common", "after", "the", "use", "of", "SRL", "as", "rescue", "therapy", "for", "renal", "transplantation", ".", "Therefore", ",", "conversion", "should", "be", "considered", "for", "patients", "who", "have", "not", "developed", "advanced", "CAN", "and", "proteinuria", ".", "The", "possibility", "of", "de", "novo", "glomerular", "pathology", "under", "SRL", "treatment", "requires", "further", "investigation", "by", "renal", "biopsy", "."]], "ner": [[[4, 4, "Chemical"], [10, 10, "Chemical"], [12, 12, "Chemical"], [33, 33, "Chemical"], [61, 61, "Chemical"], [77, 77, "Chemical"], [129, 129, "Chemical"], [155, 155, "Chemical"], [320, 320, "Chemical"], [451, 451, "Chemical"], [484, 484, "Chemical"], [0, 0, "Disease"], [25, 25, "Disease"], [59, 59, "Disease"], [170, 170, "Disease"], [222, 222, "Disease"], [229, 229, "Disease"], [236, 236, "Disease"], [268, 268, "Disease"], [444, 444, "Disease"], [474, 474, "Disease"], [300, 300, "Chemical"], [416, 416, "Chemical"], [84, 86, "Disease"], [88, 88, "Disease"], [122, 122, "Disease"], [361, 361, "Disease"], [472, 472, "Disease"], [95, 95, "Disease"], [102, 104, "Disease"], [363, 365, "Disease"], [107, 108, "Disease"], [111, 112, "Disease"], [115, 117, "Disease"], [271, 271, "Disease"], [285, 286, "Disease"], [288, 289, "Disease"]]], "relations": [[[4, 4, 0, 0, "CID"], [4, 4, 25, 25, "CID"], [4, 4, 59, 59, "CID"], [4, 4, 170, 170, "CID"], [4, 4, 222, 222, "CID"], [4, 4, 229, 229, "CID"], [4, 4, 236, 236, "CID"], [4, 4, 268, 268, "CID"], [4, 4, 444, 444, "CID"], [4, 4, 474, 474, "CID"], [10, 10, 0, 0, "CID"], [10, 10, 25, 25, "CID"], [10, 10, 59, 59, "CID"], [10, 10, 170, 170, "CID"], [10, 10, 222, 222, "CID"], [10, 10, 229, 229, "CID"], [10, 10, 236, 236, "CID"], [10, 10, 268, 268, "CID"], [10, 10, 444, 444, "CID"], [10, 10, 474, 474, "CID"], [12, 12, 0, 0, "CID"], [12, 12, 25, 25, "CID"], [12, 12, 59, 59, "CID"], [12, 12, 170, 170, "CID"], [12, 12, 222, 222, "CID"], [12, 12, 229, 229, "CID"], [12, 12, 236, 236, "CID"], [12, 12, 268, 268, "CID"], [12, 12, 444, 444, "CID"], [12, 12, 474, 474, "CID"], [33, 33, 0, 0, "CID"], [33, 33, 25, 25, "CID"], [33, 33, 59, 59, "CID"], [33, 33, 170, 170, "CID"], [33, 33, 222, 222, "CID"], [33, 33, 229, 229, "CID"], [33, 33, 236, 236, "CID"], [33, 33, 268, 268, "CID"], [33, 33, 444, 444, "CID"], [33, 33, 474, 474, "CID"], [61, 61, 0, 0, "CID"], [61, 61, 25, 25, "CID"], [61, 61, 59, 59, "CID"], [61, 61, 170, 170, "CID"], [61, 61, 222, 222, "CID"], [61, 61, 229, 229, "CID"], [61, 61, 236, 236, "CID"], [61, 61, 268, 268, "CID"], [61, 61, 444, 444, "CID"], [61, 61, 474, 474, "CID"], [77, 77, 0, 0, "CID"], [77, 77, 25, 25, "CID"], [77, 77, 59, 59, "CID"], [77, 77, 170, 170, "CID"], [77, 77, 222, 222, "CID"], [77, 77, 229, 229, "CID"], [77, 77, 236, 236, "CID"], [77, 77, 268, 268, "CID"], [77, 77, 444, 444, "CID"], [77, 77, 474, 474, "CID"], [129, 129, 0, 0, "CID"], [129, 129, 25, 25, "CID"], [129, 129, 59, 59, "CID"], [129, 129, 170, 170, "CID"], [129, 129, 222, 222, "CID"], [129, 129, 229, 229, "CID"], [129, 129, 236, 236, "CID"], [129, 129, 268, 268, "CID"], [129, 129, 444, 444, "CID"], [129, 129, 474, 474, "CID"], [155, 155, 0, 0, "CID"], [155, 155, 25, 25, "CID"], [155, 155, 59, 59, "CID"], [155, 155, 170, 170, "CID"], [155, 155, 222, 222, "CID"], [155, 155, 229, 229, "CID"], [155, 155, 236, 236, "CID"], [155, 155, 268, 268, "CID"], [155, 155, 444, 444, "CID"], [155, 155, 474, 474, "CID"], [320, 320, 0, 0, "CID"], [320, 320, 25, 25, "CID"], [320, 320, 59, 59, "CID"], [320, 320, 170, 170, "CID"], [320, 320, 222, 222, "CID"], [320, 320, 229, 229, "CID"], [320, 320, 236, 236, "CID"], [320, 320, 268, 268, "CID"], [320, 320, 444, 444, "CID"], [320, 320, 474, 474, "CID"], [451, 451, 0, 0, "CID"], [451, 451, 25, 25, "CID"], [451, 451, 59, 59, "CID"], [451, 451, 170, 170, "CID"], [451, 451, 222, 222, "CID"], [451, 451, 229, 229, "CID"], [451, 451, 236, 236, "CID"], [451, 451, 268, 268, "CID"], [451, 451, 444, 444, "CID"], [451, 451, 474, 474, "CID"], [484, 484, 0, 0, "CID"], [484, 484, 25, 25, "CID"], [484, 484, 59, 59, "CID"], [484, 484, 170, 170, "CID"], [484, 484, 222, 222, "CID"], [484, 484, 229, 229, "CID"], [484, 484, 236, 236, "CID"], [484, 484, 268, 268, "CID"], [484, 484, 444, 444, "CID"], [484, 484, 474, 474, "CID"]]], "clusters": [], "translated": "<11>蛋白尿</11>在肾移植受者转换为<0>西罗莫司</0>后。 <1>西罗莫司</1>（<2>SRL</2>）是一种新型的强效免疫抑制剂。最近，<12>蛋白尿</12>作为<3>西罗莫司</3>治疗的结果已被报道，虽然机制仍不清楚。我们回顾性地检查了25位肾移植患者的记录，这些患者在<4>SRL</4>转换后出现或表现出增加的<13>蛋白尿</13>。患者队列（14男，11女）接受了<5>SRL</5>作为转换治疗，原因是由于<23>慢性移植物肾病</23>（<24>CAN</24>）（n=15）<28>肿瘤</28>（n=8）；<29>卡波氏肉瘤</29>，四个<31>皮肤癌</31>、一个<32>结肠癌</32>、一个<33>肾细胞癌</33>）或BK病毒<25>肾病</25>（n=2）。<6>SRL</6>开始于移植后平均78 +/- 42（15至163）个月。在<7>SRL</7>治疗期间的平均随访时间为20 +/- 12（6至43）个月。<14>蛋白尿</14>从0增加。445（0至1.5）克/天转变为3.2克/天（0.2至12）（P=0.001）。转化前有8名（32%）患者没有<15>蛋白尿</15>，而转化后所有患者都有<16>蛋白尿</16>。28%的患者<17>蛋白尿</17>保持不变，而68%的患者蛋白尿增加。在40%中，它增加了100% 以上。28%的患者显示<18>蛋白尿</18>增加到<34>肾病</34>范围。对五名患者进行的活检显示了新的病理变化：一例<35>膜增生性肾小球肾炎</35>和<36>间质性肾炎</36>。这些患者表现出持续良好的移植功能。血清<21>肌酐</21>值无明显变化：1.98 +/- 0.8 mg/dL（<8>SRL</8>治疗前）和2.53 +/- 1.9 mg/dL（在最后一次随访时）（P=.14）。五个移植物丢失，患者回到透析状态。五名患者表现出<26>CAN</26>和<30>卡波西肉瘤</30>。返回透析的患者的平均尿蛋白水平为1.26（0.5至3.5）克/天，在转换后为4.7（3至12）克/天（P=.01）。转换前的平均血清<22>肌酐</22>水平为2.21毫克/分升，在此之后为4.93毫克/分升（P=.02）。在肾移植的抢救治疗中，使用<9>SRL</9>后重度<19>蛋白尿</19>是常见的。因此，对于未发展为晚期<27>CAN</27>和<20>蛋白尿</20>的患者，应考虑转换。对于在<10>SRL</10>治疗下新发生的肾小球病理学，需要进一步通过肾活检进行调查。", "revised": true}
{"doc_key": "3107448", "sentences": [["Glyburide", "-", "induced", "hepatitis", ".", "Drug", "-", "induced", "hepatotoxicity", ",", "although", "common", ",", "has", "been", "reported", "only", "infrequently", "with", "sulfonylureas", ".", "For", "glyburide", ",", "a", "second", "-", "generation", "sulfonylurea", ",", "only", "two", "brief", "reports", "of", "hepatotoxicity", "exist", ".", "Two", "patients", "with", "type", "II", "diabetes", "mellitus", "developed", "an", "acute", "hepatitis", "-", "like", "syndrome", "soon", "after", "initiation", "of", "glyburide", "therapy", ".", "There", "was", "no", "serologic", "evidence", "of", "viral", "infection", ",", "and", "a", "liver", "biopsy", "sample", "showed", "a", "histologic", "pattern", "consistent", "with", "drug", "-", "induced", "hepatitis", ".", "Both", "patients", "recovered", "quickly", "after", "stopping", "glyburide", "therapy", "and", "have", "remained", "well", "for", "a", "follow", "-", "up", "period", "of", "1", "year", ".", "Glyburide", "can", "produce", "an", "acute", "hepatitis", "-", "like", "illness", "in", "some", "persons", "."]], "ner": [[[0, 0, "Chemical"], [22, 22, "Chemical"], [56, 56, "Chemical"], [90, 90, "Chemical"], [106, 106, "Chemical"], [3, 3, "Disease"], [8, 8, "Disease"], [35, 35, "Disease"], [47, 51, "Disease"], [79, 82, "Disease"], [110, 114, "Disease"], [41, 44, "Disease"], [65, 66, "Disease"], [19, 19, "Chemical"], [28, 28, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 8, 8, "CID"], [0, 0, 35, 35, "CID"], [0, 0, 47, 51, "CID"], [0, 0, 79, 82, "CID"], [0, 0, 110, 114, "CID"], [22, 22, 3, 3, "CID"], [22, 22, 8, 8, "CID"], [22, 22, 35, 35, "CID"], [22, 22, 47, 51, "CID"], [22, 22, 79, 82, "CID"], [22, 22, 110, 114, "CID"], [56, 56, 3, 3, "CID"], [56, 56, 8, 8, "CID"], [56, 56, 35, 35, "CID"], [56, 56, 47, 51, "CID"], [56, 56, 79, 82, "CID"], [56, 56, 110, 114, "CID"], [90, 90, 3, 3, "CID"], [90, 90, 8, 8, "CID"], [90, 90, 35, 35, "CID"], [90, 90, 47, 51, "CID"], [90, 90, 79, 82, "CID"], [90, 90, 110, 114, "CID"], [106, 106, 3, 3, "CID"], [106, 106, 8, 8, "CID"], [106, 106, 35, 35, "CID"], [106, 106, 47, 51, "CID"], [106, 106, 79, 82, "CID"], [106, 106, 110, 114, "CID"]]], "clusters": [], "translated": " <0>格列本脲</0>诱发<5>肝炎</5>。药物引起的<6>肝毒性</6>虽然很常见，但很少见于<13>磺脲类药物</13>。对于<1>格列本脲</1>，第二代<14>磺酰脲</14>，只有两份关于<7>肝毒性</7>的简短报道。两名<11>II型糖尿病</11>患者在<2>格列本脲</2>治疗开始后不久就出现了<8>急性肝炎-样综合征</8>。没有<12>病毒感染</12>的血清学证据，肝活检标本显示与<9>药物性肝炎</9>一致的组织学模式。两名患者在停止<3>格列本脲</3>治疗后均恢复得很快，并且在1年的随访期内均保持良好状态。<4>格列本脲</4>可在某些人身上引起<10>急性肝炎-样疾病</10>。", "revised": true}
{"doc_key": "3719553", "sentences": [["Allergic", "reaction", "to", "5", "-", "fluorouracil", "infusion", ".", "An", "allergic", "reaction", "consisting", "of", "angioneurotic", "edema", "secondary", "to", "continuous", "infusion", "5", "-", "fluorouracil", "occurred", "in", "a", "patient", "with", "recurrent", "carcinoma", "of", "the", "oral", "cavity", ",", "cirrhosis", ",", "and", "cisplatin", "-", "induced", "impaired", "renal", "function", ".", "This", "reaction", "occurred", "during", "the", "sixth", "and", "seventh", "courses", "of", "infusional", "chemotherapy", ".", "Oral", "diphenhydramine", "and", "prednisone", "were", "ineffective", "in", "preventing", "the", "recurrence", "of", "the", "allergic", "reaction", ".", "Discontinuance", "of", "effective", "chemotherapy", "in", "this", "patient", "during", "partial", "remission", "resulted", "in", "fatal", "disease", "progression", "."]], "ner": [[[3, 5, "Chemical"], [19, 21, "Chemical"], [13, 14, "Disease"], [0, 1, "Disease"], [9, 10, "Disease"], [69, 70, "Disease"], [37, 37, "Chemical"], [58, 58, "Chemical"], [60, 60, "Chemical"], [28, 32, "Disease"], [34, 34, "Disease"], [40, 42, "Disease"]]], "relations": [[[3, 5, 13, 14, "CID"], [19, 21, 13, 14, "CID"]]], "clusters": [], "translated": "对<0>5-氟尿嘧啶</0>输液的<3>过敏反应</3>。由于持续输注 <1>5-氟尿嘧啶</1>，患有复发性 <9>口腔癌</9>、<10>肝硬化</10>和<6>顺铂</6>诱导的<11>肾功能受损</11>病人出现了由<2>血管神经性水肿</2>组成的<4>过敏反应</4>。该反应发生在输注化疗的第六和第七个疗程期间。口服<7>苯海拉明</7>和<8>泼尼松</8>对预防<5>过敏反应</5>的复发无效。该患者在部分缓解期间停止有效的化疗导致致命的疾病进展。", "revised": true}
{"doc_key": "6503301", "sentences": [["Veno", "-", "occlusive", "liver", "disease", "after", "dacarbazine", "therapy", "(", "DTIC", ")", "for", "melanoma", ".", "A", "case", "of", "veno", "-", "occlusive", "disease", "of", "the", "liver", "with", "fatal", "outcome", "after", "dacarbazine", "(", "DTIC", ")", "therapy", "for", "melanoma", "is", "reported", ".", "There", "was", "a", "fulminant", "clinical", "course", "from", "start", "of", "symptoms", "until", "death", ".", "At", "autopsy", "the", "liver", "was", "enlarged", "and", "firm", "with", "signs", "of", "venous", "congestion", ".", "Small", "-", "and", "medium", "-", "sized", "hepatic", "veins", "were", "blocked", "by", "thrombosis", ".", "Eosinophilic", "infiltrations", "were", "found", "around", "the", "vessels", ".", "Published", "cases", "from", "the", "literature", "are", "reviewed", "and", "pertinent", "features", "discussed", "."]], "ner": [[[6, 6, "Chemical"], [9, 9, "Chemical"], [28, 28, "Chemical"], [30, 30, "Chemical"], [0, 4, "Disease"], [17, 23, "Disease"], [12, 12, "Disease"], [34, 34, "Disease"], [49, 49, "Disease"], [62, 63, "Disease"], [76, 76, "Disease"]]], "relations": [[[6, 6, 0, 4, "CID"], [6, 6, 17, 23, "CID"], [9, 9, 0, 4, "CID"], [9, 9, 17, 23, "CID"], [28, 28, 0, 4, "CID"], [28, 28, 17, 23, "CID"], [30, 30, 0, 4, "CID"], [30, 30, 17, 23, "CID"]]], "clusters": [], "translated": "<6>黑色素瘤</6><0>达卡巴嗪</0>治疗(<1>DTIC</1>)后<4>静脉闭塞性肝病</4>。一例<5>静脉闭塞性肝病</5>在<2>达卡巴嗪</2>(<3>DTIC</3>)治疗<7>黑色素瘤</7>后出现致命结局是报道。从出现症状到<8>死亡</8>有一个暴发性临床过程。尸检时，肝脏肿大变硬，有<9>静脉充血</9>的迹象。中小肝静脉因<10>血栓形成</10>而阻塞。血管周围发现嗜酸性粒细胞浸润。对文献中已发表的案例进行了回顾，并讨论了相关特征。", "revised": true}
{"doc_key": "7083920", "sentences": [["Further", "observations", "on", "the", "electrophysiologic", "effects", "of", "oral", "amiodarone", "therapy", ".", "A", "case", "is", "presented", "of", "a", "reversible", "intra", "-", "Hisian", "block", "occurring", "under", "amiodarone", "treatment", "for", "atrial", "tachycardia", "in", "a", "patient", "without", "clear", "intraventricular", "conduction", "abnormalities", ".", "His", "bundle", "recordings", "showed", "an", "atrial", "tachycardia", "with", "intermittent", "exit", "block", "and", "greatly", "prolonged", "BH", "and", "HV", "intervals", "(", "40", "and", "100", "msec", ",", "respectively", ")", ".", "Thirty", "days", "after", "amiodarone", "discontinuation", ",", "His", "bundle", "electrograms", "showed", "atrial", "flutter", "without", "intra", "-", "Hisian", "or", "infra", "-", "Hisian", "delay", ".", "Amiodarone", "should", "be", "used", "with", "caution", "during", "long", "-", "term", "oral", "therapy", "in", "patients", "with", "or", "without", "clear", "intraventricular", "conduction", "defects", "."]], "ner": [[[8, 8, "Chemical"], [24, 24, "Chemical"], [68, 68, "Chemical"], [87, 87, "Chemical"], [18, 21, "Disease"], [27, 28, "Disease"], [43, 44, "Disease"], [34, 36, "Disease"], [75, 76, "Disease"]]], "relations": [[[8, 8, 18, 21, "CID"], [24, 24, 18, 21, "CID"], [68, 68, 18, 21, "CID"], [87, 87, 18, 21, "CID"]]], "clusters": [], "translated": "口服<0>胺碘酮</0>治疗电生理效应的进一步观察。一例发生在<1>胺碘酮</1>治疗<5>房性心动过速</5>的可逆性<4>希氏内阻滞</4>患者没有明显的<7>室内传导异常</7>。他的束记录显示<6>房性心动过速</6>伴有间歇性出口传导阻滞和 BH 和 HV 间期大大延长（分别为40和100毫秒）。<2>胺碘酮</2>停药30天后，希氏束电图显示<8>心房扑动</8>，无希氏内或希氏下延迟。<3>胺碘酮</3>在有或没有明显的<7>室内传导缺陷</7>的患者长期口服治疗时应慎用。", "revised": true}
{"doc_key": "4008111", "sentences": [["Amiodarone", "-", "induced", "sinoatrial", "block", ".", "We", "observed", "sinoatrial", "block", "due", "to", "chronic", "amiodarone", "administration", "in", "a", "5", "-", "year", "-", "old", "boy", "with", "primary", "cardiomyopathy", ",", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "and", "supraventricular", "tachycardia", ".", "Reduction", "in", "the", "dosage", "of", "amiodarone", "resulted", "in", "the", "disappearance", "of", "the", "sinoatrial", "block", "and", "the", "persistence", "of", "asymptomatic", "sinus", "bradycardia", "."]], "ner": [[[0, 0, "Chemical"], [13, 13, "Chemical"], [42, 42, "Chemical"], [3, 4, "Disease"], [8, 9, "Disease"], [49, 50, "Disease"], [24, 25, "Disease"], [27, 32, "Disease"], [34, 35, "Disease"], [56, 57, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 8, 9, "CID"], [0, 0, 49, 50, "CID"], [13, 13, 3, 4, "CID"], [13, 13, 8, 9, "CID"], [13, 13, 49, 50, "CID"], [42, 42, 3, 4, "CID"], [42, 42, 8, 9, "CID"], [42, 42, 49, 50, "CID"]]], "clusters": [], "translated": " <0>胺碘酮</0> - 诱发<3>窦房传导阻滞</3>。我们在一名患有<6>原发性心肌病</6>、<7>Wolff-Parkinson-White综合征</7>和<8>室上性心动过速</8>的5岁男孩中观察到由于慢性<1>胺碘酮</1>给药，<4>窦房传导阻滞</4>发生。减少<2>胺碘酮</2>的剂量导致<5>窦房传导阻滞</5>消失和<9>窦性心动过缓</9>持续存在但无症状。", "revised": true}
{"doc_key": "7269015", "sentences": [["Busulfan", "-", "induced", "hemorrhagic", "cystitis", ".", "A", "case", "of", "a", "busulfan", "-", "induced", "hemorrhage", "cystitis", "is", "reported", ".", "Spontaneous", "resolution", "occurred", "following", "cessation", "of", "the", "drug", ".", "The", "similarity", "between", "the", "histologic", "appearances", "of", "busulfan", "cystitis", "and", "both", "radiation", "and", "cyclophosphamide", "-", "induced", "cystitis", "is", "discussed", "and", "the", "world", "literature", "reviewed", ".", "In", "view", "of", "the", "known", "tendency", "of", "busulfan", "to", "induce", "cellular", "atypia", "and", "carcinoma", "in", "other", "sites", ",", "periodic", "urinary", "cytology", "is", "suggested", "in", "patients", "on", "long", "-", "term", "therapy", "."]], "ner": [[[0, 0, "Chemical"], [10, 10, "Chemical"], [34, 34, "Chemical"], [59, 59, "Chemical"], [3, 4, "Disease"], [13, 14, "Disease"], [35, 35, "Disease"], [43, 43, "Disease"], [65, 65, "Disease"], [40, 40, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 13, 14, "CID"], [10, 10, 3, 4, "CID"], [10, 10, 13, 14, "CID"], [34, 34, 3, 4, "CID"], [34, 34, 13, 14, "CID"], [59, 59, 3, 4, "CID"], [59, 59, 13, 14, "CID"], [0, 0, 35, 35, "CID"], [0, 0, 43, 43, "CID"], [10, 10, 35, 35, "CID"], [10, 10, 43, 43, "CID"], [34, 34, 35, 35, "CID"], [34, 34, 43, 43, "CID"], [59, 59, 35, 35, "CID"], [59, 59, 43, 43, "CID"]]], "clusters": [], "translated": "<0>白消安</0>诱发<4>出血性膀胱炎</4>。报道了一例<1>白消安</1>诱发的<5>出血性膀胱炎</5>。停药后自发消退。讨论了<2>白消安</2> <6>膀胱炎</6>与辐射和<9>环磷酰胺</9>诱发的<7>膀胱炎</7>组织学表现的相似性，文献综述。鉴于已知<3>白消安</3>可在其他部位诱发细胞异型和<8>癌</8>，建议对长期治疗的患者定期进行尿液细胞学检查。", "revised": true}
{"doc_key": "3564823", "sentences": [["Drug", "-", "induced", "arterial", "spasm", "relieved", "by", "lidocaine", ".", "Case", "report", ".", "Following", "major", "intracranial", "surgery", "in", "a", "35", "-", "year", "-", "old", "man", ",", "sodium", "pentothal", "was", "intravenously", "infused", "to", "minimize", "cerebral", "ischaemia", ".", "Intense", "vasospasm", "with", "threatened", "gangrene", "arose", "in", "the", "arm", "used", "for", "the", "infusion", ".", "Since", "the", "cranial", "condition", "precluded", "use", "of", "more", "usual", "methods", ",", "lidocaine", "was", "given", "intra", "-", "arterially", ",", "with", "careful", "cardiovascular", "monitoring", ",", "to", "counteract", "the", "vasospasm", ".", "The", "treatment", "was", "rapidly", "successful", "."]], "ner": [[[25, 26, "Chemical"], [4, 4, "Disease"], [7, 7, "Chemical"], [60, 60, "Chemical"], [32, 33, "Disease"], [36, 36, "Disease"], [75, 75, "Disease"], [39, 39, "Disease"]]], "relations": [[[25, 26, 4, 4, "CID"]]], "clusters": [], "translated": "药物引起的动脉<1>痉挛</1>被<2>利多卡因</2>缓解。案例报告。一名35岁男性在接受大型颅内手术后，静脉输注了<0>喷妥索钠</0>以尽量减少<4>脑缺血</4>。用于输液的手臂出现了严重的<5>血管痉挛</5>和<7>坏疽</7>。由于颅骨状况无法使用更常用的方法，<3>利多卡因</3>经动脉内给药，同时仔细监测心血管，以抵消<6>血管痉挛</6>。治疗很快就成功了。", "revised": true}
{"doc_key": "2696505", "sentences": [["A", "randomized", "comparison", "of", "labetalol", "and", "nitroprusside", "for", "induced", "hypotension", ".", "In", "a", "randomized", "study", ",", "labetalol", "-", "induced", "hypotension", "and", "nitroprusside", "-", "induced", "hypotension", "were", "compared", "in", "20", "patients", "(", "10", "in", "each", "group", ")", "scheduled", "for", "major", "orthopedic", "procedures", ".", "Each", "patient", "was", "subjected", "to", "an", "identical", "anesthetic", "protocol", "and", "similar", "drug", "-", "induced", "reductions", "in", "mean", "arterial", "blood", "pressure", "(", "BP", ")", "(", "50", "to", "55", "mmHg", ")", ".", "Nitroprusside", "infusion", "was", "associated", "with", "a", "significant", "(", "p", "less", "than", "0", ".", "05", ")", "increase", "in", "heart", "rate", "and", "cardiac", "output", ";", "rebound", "hypertension", "was", "observed", "in", "three", "patients", "after", "discontinuation", "of", "nitroprusside", ".", "Labetalol", "administration", "was", "not", "associated", "with", "any", "of", "these", "findings", ".", "Arterial", "PO2", "decreased", "in", "both", "groups", ".", "It", "was", "concluded", "that", "labetalol", "offers", "advantages", "over", "nitroprusside", "."]], "ner": [[[4, 4, "Chemical"], [16, 16, "Chemical"], [107, 107, "Chemical"], [129, 129, "Chemical"], [9, 9, "Disease"], [19, 19, "Disease"], [24, 24, "Disease"], [56, 61, "Disease"], [6, 6, "Chemical"], [21, 21, "Chemical"], [105, 105, "Chemical"], [133, 133, "Chemical"], [87, 93, "Disease"], [96, 96, "Disease"], [119, 119, "Chemical"]]], "relations": [[[4, 4, 9, 9, "CID"], [4, 4, 19, 19, "CID"], [4, 4, 24, 24, "CID"], [4, 4, 56, 61, "CID"], [16, 16, 9, 9, "CID"], [16, 16, 19, 19, "CID"], [16, 16, 24, 24, "CID"], [16, 16, 56, 61, "CID"], [107, 107, 9, 9, "CID"], [107, 107, 19, 19, "CID"], [107, 107, 24, 24, "CID"], [107, 107, 56, 61, "CID"], [129, 129, 9, 9, "CID"], [129, 129, 19, 19, "CID"], [129, 129, 24, 24, "CID"], [129, 129, 56, 61, "CID"], [6, 6, 9, 9, "CID"], [6, 6, 19, 19, "CID"], [6, 6, 24, 24, "CID"], [6, 6, 56, 61, "CID"], [21, 21, 9, 9, "CID"], [21, 21, 19, 19, "CID"], [21, 21, 24, 24, "CID"], [21, 21, 56, 61, "CID"], [105, 105, 9, 9, "CID"], [105, 105, 19, 19, "CID"], [105, 105, 24, 24, "CID"], [105, 105, 56, 61, "CID"], [133, 133, 9, 9, "CID"], [133, 133, 19, 19, "CID"], [133, 133, 24, 24, "CID"], [133, 133, 56, 61, "CID"], [6, 6, 87, 93, "CID"], [21, 21, 87, 93, "CID"], [105, 105, 87, 93, "CID"], [133, 133, 87, 93, "CID"]]], "clusters": [], "translated": "<0>拉贝洛尔</0>和<8>硝普钠</8>对诱导性<4>低血压</4>的随机比较。在一项随机研究中，比较了20名患者（10每组）预定进行主要骨科手术。每位患者都接受了相同的麻醉方案和类似的药物诱导的<7>平均动脉血压降低</7>（BP）（50至55毫米汞柱）。<9>硝普钠</9>-诱导的<6>低血压</6>和<1>拉贝洛尔</1>-诱导的<5>低血压</5>进行了比较。硝普钠输注与显着（p小于0.05）<12>心率和心输出量增加</12>相关；在停用<10>硝普钠</10>后，观察到三名患者存在反跳性<13>高血压</13>。给药<2>拉贝洛尔</2>与这些发现均无关。两组的<14>动脉PO2</14>均降低。得出的结论是，<3>拉贝洛尔</3>优于<11>硝普钠</11>。", "revised": true}
{"doc_key": "3341566", "sentences": [["Systolic", "pressure", "variation", "is", "greater", "during", "hemorrhage", "than", "during", "sodium", "nitroprusside", "-", "induced", "hypotension", "in", "ventilated", "dogs", ".", "The", "systolic", "pressure", "variation", "(", "SPV", ")", ",", "which", "is", "the", "difference", "between", "the", "maximal", "and", "minimal", "values", "of", "the", "systolic", "blood", "pressure", "(", "SBP", ")", "after", "one", "positive", "-", "pressure", "breath", ",", "was", "studied", "in", "ventilated", "dogs", "subjected", "to", "hypotension", ".", "Mean", "arterial", "pressure", "was", "decreased", "to", "50", "mm", "Hg", "for", "30", "minutes", "either", "by", "hemorrhage", "(", "HEM", ",", "n", "=", "7", ")", "or", "by", "continuous", "infusion", "of", "sodium", "nitroprusside", "(", "SNP", ",", "n", "=", "7", ")", ".", "During", "HEM", "-", "induced", "hypotension", "the", "cardiac", "output", "was", "significantly", "lower", "and", "systemic", "vascular", "resistance", "higher", "compared", "with", "that", "in", "the", "SNP", "group", ".", "The", "systemic", ",", "central", "venous", ",", "pulmonary", "capillary", "wedge", "pressures", ",", "and", "heart", "rates", ",", "were", "similar", "in", "the", "two", "groups", ".", "Analysis", "of", "the", "respiratory", "changes", "in", "the", "arterial", "pressure", "waveform", "enabled", "differentiation", "between", "the", "two", "groups", ".", "The", "SPV", "during", "hypotension", "was", "15", ".", "7", "+", "/", "-", "6", ".", "7", "mm", "Hg", "in", "the", "HEM", "group", ",", "compared", "with", "9", ".", "1", "+", "/", "-", "2", ".", "0", "mm", "Hg", "in", "the", "SNP", "group", "(", "P", "less", "than", "0", ".", "02", ")", ".", "The", "delta", "down", ",", "which", "is", "the", "measure", "of", "decrease", "of", "SBP", "after", "a", "mechanical", "breath", ",", "was", "20", ".", "3", "+", "/", "-", "8", ".", "4", "and", "10", ".", "1", "+", "/", "-", "3", ".", "8", "mm", "Hg", "in", "the", "HEM", "and", "SNP", "groups", ",", "respectively", ",", "during", "hypotension", "(", "P", "less", "than", "0", ".", "02", ")", ".", "It", "is", "concluded", "that", "increases", "in", "the", "SPV", "and", "the", "delta", "down", "are", "characteristic", "of", "a", "hypotensive", "state", "due", "to", "a", "predominant", "decrease", "in", "preload", ".", "They", "are", "thus", "more", "important", "during", "absolute", "hypovolemia", "than", "during", "deliberate", "hypotension", "."]], "ner": [[[9, 10, "Chemical"], [87, 88, "Chemical"], [90, 90, "Chemical"], [118, 118, "Chemical"], [196, 196, "Chemical"], [250, 250, "Chemical"], [13, 13, "Disease"], [58, 58, "Disease"], [101, 101, "Disease"], [163, 163, "Disease"], [256, 256, "Disease"], [282, 282, "Disease"], [303, 303, "Disease"], [6, 6, "Disease"], [74, 74, "Disease"], [76, 76, "Disease"], [98, 98, "Disease"], [178, 178, "Disease"], [248, 248, "Disease"], [299, 299, "Disease"]]], "relations": [[[9, 10, 13, 13, "CID"], [9, 10, 58, 58, "CID"], [9, 10, 101, 101, "CID"], [9, 10, 163, 163, "CID"], [9, 10, 256, 256, "CID"], [9, 10, 282, 282, "CID"], [9, 10, 303, 303, "CID"], [87, 88, 13, 13, "CID"], [87, 88, 58, 58, "CID"], [87, 88, 101, 101, "CID"], [87, 88, 163, 163, "CID"], [87, 88, 256, 256, "CID"], [87, 88, 282, 282, "CID"], [87, 88, 303, 303, "CID"], [90, 90, 13, 13, "CID"], [90, 90, 58, 58, "CID"], [90, 90, 101, 101, "CID"], [90, 90, 163, 163, "CID"], [90, 90, 256, 256, "CID"], [90, 90, 282, 282, "CID"], [90, 90, 303, 303, "CID"], [118, 118, 13, 13, "CID"], [118, 118, 58, 58, "CID"], [118, 118, 101, 101, "CID"], [118, 118, 163, 163, "CID"], [118, 118, 256, 256, "CID"], [118, 118, 282, 282, "CID"], [118, 118, 303, 303, "CID"], [196, 196, 13, 13, "CID"], [196, 196, 58, 58, "CID"], [196, 196, 101, 101, "CID"], [196, 196, 163, 163, "CID"], [196, 196, 256, 256, "CID"], [196, 196, 282, 282, "CID"], [196, 196, 303, 303, "CID"], [250, 250, 13, 13, "CID"], [250, 250, 58, 58, "CID"], [250, 250, 101, 101, "CID"], [250, 250, 163, 163, "CID"], [250, 250, 256, 256, "CID"], [250, 250, 282, 282, "CID"], [250, 250, 303, 303, "CID"]]], "clusters": [], "translated": "在通气犬中，<13>出血</13>期间的收缩压变化大于<0>硝普钠</0> 引起的<6>低血压</6>期间的收缩压变化。收缩压变异 (SPV)，即一次正压呼吸后收缩压 (SBP)的最大值和最小值之间的差值，在受到<7>低血压</7> 的通气狗身上进行了研究。平均动脉压降低至50 mmHg，持续30分钟，采用两种方法：一是通过<14>出血</14>（<15>HEM</15>，n=7），二是用<1>硝普钠</1>连续输注（<2>SNP</2>，n=7）。与<3>SNP</3>组相比，采用<16>HEM</16>时，引起的<8>低血压</8>心输出量显著降低，全身血管阻力显著升高。两组的全身、中心静脉、肺毛细血管楔压和心率相似。通过分析动脉压波形中的呼吸变化，可以区分两组。在<9>低血压</9>期间，<17>HEM</17>组的SPV为15.7 +/- 6.7 mmHg，而<4>SNP</4>组为9.1 +/- 2.0 mmHg（P小于0.02）。在<10>低血压</10>期间，<18>HEM</18>组和<5>SNP</5>组的Delta Down分别为20.3 +/- 8.4和10.1 +/- 3.8 mmHg （P小于0.02）。结果表明，由于前负荷的显着降低，SPV和Delta Down的增加是由于占据主导地位的一种<11>低血压 </11>状态。因此，与故意<12>低血压 </12>状态相比，在绝对<19>低血容量 </19>期间它们更为重要。", "revised": true}
{"doc_key": "2673163", "sentences": [["Stroke", "associated", "with", "cocaine", "use", ".", "We", "describe", "eight", "patients", "in", "whom", "cocaine", "use", "was", "related", "to", "stroke", "and", "review", "39", "cases", "from", "the", "literature", ".", "Among", "these", "47", "patients", "the", "mean", "(", "+", "/", "-", "SD", ")", "age", "was", "32", ".", "5", "+", "/", "-", "12", ".", "1", "years", ";", "76", "%", "(", "34", "/", "45", ")", "were", "men", ".", "Stroke", "followed", "cocaine", "use", "by", "inhalation", ",", "intranasal", ",", "intravenous", ",", "and", "intramuscular", "routes", ".", "Intracranial", "aneurysms", "or", "arteriovenous", "malformations", "were", "present", "in", "17", "of", "32", "patients", "studied", "angiographically", "or", "at", "autopsy", ";", "cerebral", "vasculitis", "was", "present", "in", "two", "patients", ".", "Cerebral", "infarction", "occurred", "in", "10", "patients", "(", "22", "%", ")", ",", "intracerebral", "hemorrhage", "in", "22", "(", "49", "%", ")", ",", "and", "subarachnoid", "hemorrhage", "in", "13", "(", "29", "%", ")", ".", "These", "data", "indicate", "that", "(", "1", ")", "the", "apparent", "incidence", "of", "stroke", "related", "to", "cocaine", "use", "is", "increasing", ";", "(", "2", ")", "cocaine", "-", "associated", "stroke", "occurs", "primarily", "in", "young", "adults", ";", "(", "3", ")", "stroke", "may", "follow", "any", "route", "of", "cocaine", "administration", ";", "(", "4", ")", "stroke", "after", "cocaine", "use", "is", "frequently", "associated", "with", "intracranial", "aneurysms", "and", "arteriovenous", "malformations", ";", "and", "(", "5", ")", "in", "cocaine", "-", "associated", "stroke", ",", "the", "frequency", "of", "intracranial", "hemorrhage", "exceeds", "that", "of", "cerebral", "infarction", "."]], "ner": [[[3, 3, "Chemical"], [12, 12, "Chemical"], [63, 63, "Chemical"], [146, 146, "Chemical"], [154, 154, "Chemical"], [173, 173, "Chemical"], [181, 181, "Chemical"], [198, 198, "Chemical"], [102, 103, "Disease"], [211, 212, "Disease"], [113, 114, "Disease"], [123, 124, "Disease"], [0, 0, "Disease"], [17, 17, "Disease"], [61, 61, "Disease"], [143, 143, "Disease"], [157, 157, "Disease"], [167, 167, "Disease"], [179, 179, "Disease"], [201, 201, "Disease"], [76, 77, "Disease"], [187, 188, "Disease"], [79, 80, "Disease"], [190, 191, "Disease"], [94, 95, "Disease"], [206, 207, "Disease"]]], "relations": [[[3, 3, 102, 103, "CID"], [3, 3, 211, 212, "CID"], [12, 12, 102, 103, "CID"], [12, 12, 211, 212, "CID"], [63, 63, 102, 103, "CID"], [63, 63, 211, 212, "CID"], [146, 146, 102, 103, "CID"], [146, 146, 211, 212, "CID"], [154, 154, 102, 103, "CID"], [154, 154, 211, 212, "CID"], [173, 173, 102, 103, "CID"], [173, 173, 211, 212, "CID"], [181, 181, 102, 103, "CID"], [181, 181, 211, 212, "CID"], [198, 198, 102, 103, "CID"], [198, 198, 211, 212, "CID"], [3, 3, 113, 114, "CID"], [12, 12, 113, 114, "CID"], [63, 63, 113, 114, "CID"], [146, 146, 113, 114, "CID"], [154, 154, 113, 114, "CID"], [173, 173, 113, 114, "CID"], [181, 181, 113, 114, "CID"], [198, 198, 113, 114, "CID"], [3, 3, 123, 124, "CID"], [12, 12, 123, 124, "CID"], [63, 63, 123, 124, "CID"], [146, 146, 123, 124, "CID"], [154, 154, 123, 124, "CID"], [173, 173, 123, 124, "CID"], [181, 181, 123, 124, "CID"], [198, 198, 123, 124, "CID"]]], "clusters": [], "translated": " <12>中风</12>与<0>可卡因</0>使用有关。我们描述了8例，在这些患者中<1>可卡因</1>使用与<13>中风</13>相关，另外回顾了文献中的39例。在这47名患者中，平均年龄（+/-SD）为32.5+/-12.1岁，其中76%（34/45）为男性。继<2>可卡因</2>吸入、鼻内、静脉内和肌肉内途径使用后，<14>中风</14>发生了。32例血管造影或尸检研究的患者中，17例存在<20>颅内动脉瘤</20>或<22>动静脉畸形</22>；2例患者存在<24>脑血管炎</24>。10例（22%）患者出现<8>脑梗死</8>，22例（49%）出现<10>脑出血</10>，13例（29%）出现<11>蛛网膜下腔出血</11>。这些数据表明：（1）与<3>可卡因</3>使用相关的<15>中风</15>表观发病率正在增加；（2）<4>可卡因</4>-相关<16>中风</16>发生在年轻成年人 ; (3) <17>中风</17>可能发生在任何<5>可卡因</5>给药途径之后；（4）<6>可卡因</6>使用后的<18>中风</18>常常与<21>颅内动脉瘤</21>和<23>动静脉畸形</23>有关；（5）在<7>可卡因</7>-相关<19>中风</19>中，<25>颅内出血</25>的发生频率超过<9>脑梗塞</9>。", "revised": true}
{"doc_key": "7862923", "sentences": [["Effect", "of", "switching", "carbamazepine", "to", "oxcarbazepine", "on", "the", "plasma", "levels", "of", "neuroleptics", ".", "A", "case", "report", ".", "Carbamazepine", "was", "switched", "to", "its", "10", "-", "keto", "analogue", "oxcarbazepine", "among", "six", "difficult", "-", "to", "-", "treat", "schizophrenic", "or", "organic", "psychotic", "patients", "using", "concomitantly", "haloperidol", ",", "chlorpromazine", "or", "clozapine", ".", "This", "change", "resulted", "within", "2", "-", "4", "weeks", "in", "the", "50", "-", "200", "%", "increase", "in", "the", "plasma", "levels", "of", "these", "neuroleptics", "and", "the", "appearance", "of", "extrapyramidal", "symptoms", ".", "None", "of", "the", "patients", "showed", "any", "clinical", "deteriotation", "during", "the", "following", "3", "-", "6", "months", ".", "The", "results", "of", "this", "case", "report", "support", "the", "idea", "that", "in", "contrast", "with", "carbamazepine", "oxcarbazepine", "does", "not", "induce", "the", "hepatic", "microsomal", "enzyme", "systems", "regulating", "the", "inactivation", "of", "antipsychotic", "drugs", "."]], "ner": [[[5, 5, "Chemical"], [26, 26, "Chemical"], [106, 106, "Chemical"], [73, 74, "Disease"], [41, 41, "Chemical"], [43, 43, "Chemical"], [45, 45, "Chemical"], [3, 3, "Chemical"], [17, 17, "Chemical"], [105, 105, "Chemical"], [34, 34, "Disease"], [36, 37, "Disease"]]], "relations": [[[5, 5, 73, 74, "CID"], [26, 26, 73, 74, "CID"], [106, 106, 73, 74, "CID"], [41, 41, 73, 74, "CID"], [43, 43, 73, 74, "CID"], [45, 45, 73, 74, "CID"]]], "clusters": [], "translated": "将<7>卡马西平</7><0>转换为奥卡西平</0>对抗精神病药血浆水平的影响。个案报告。<8>卡马西平</8>在6名难以治疗的<10>精神分裂症</10>或<11>器质性精神病</11>患者中被转换为它的10-酮类似物<1>奥卡西平</1>，同时使用<4>氟哌啶醇</4>、<5>氯丙嗪</5>或<6>氯氮平</6>。这种变化在2-4周内导致这些精神安定药的血浆水平增加50-200%，并出现<3>锥体外系症状</3>。在接下来的3-6个月内，没有患者出现任何临床恶化。本病例报告的结果支持这样的观点，即与<9>卡马西平</9>相比，<2>奥卡西平</2>不会诱导调节抗精神病药物失活的肝微粒体酶系统。", "revised": true}
{"doc_key": "7352670", "sentences": [["Rebound", "hypertensive", "after", "sodium", "nitroprusside", "prevented", "by", "saralasin", "in", "rats", ".", "The", "role", "of", "the", "renin", "-", "-", "angiotensin", "system", "in", "the", "maintenance", "of", "blood", "pressure", "during", "halothane", "anesthesia", "and", "sodium", "nitroprusside", "(", "SNP", ")", "-", "induced", "hypotension", "was", "evaluated", ".", "Control", "rats", "received", "halothane", "anesthesia", "(", "1", "MAC", ")", "for", "one", "hour", ",", "followed", "by", "SNP", "infusion", ",", "40", "microgram", "/", "kg", "/", "min", ",", "for", "30", "min", ",", "followed", "by", "a", "30", "-", "min", "recovery", "period", ".", "A", "second", "group", "of", "rats", "was", "treated", "identically", "and", ",", "in", "addition", ",", "received", "an", "infusion", "of", "saralasin", "(", "a", "competitive", "inhibitor", "of", "angiotensin", "II", ")", "throughout", "the", "experimental", "period", ".", "In", "each", "group", ",", "SNP", "infusion", "resulted", "in", "an", "initial", "decrease", "in", "blood", "pressure", "from", "86", "torr", "and", "83", "torr", ",", "respectively", ",", "to", "48", "torr", ".", "During", "the", "SNP", "infusion", "the", "control", "animals", "demonstrated", "a", "progressive", "increase", "in", "blood", "pressure", "to", "61", "torr", ",", "whereas", "the", "saralasin", "-", "treated", "animals", "showed", "no", "change", ".", "Following", "discontinuation", "of", "SNP", ",", "blood", "pressure", "in", "the", "control", "animals", "rebounded", "to", "94", "torr", ",", "as", "compared", "with", "78", "torr", "in", "the", "saralasin", "-", "treated", "rats", ".", "This", "study", "indicates", "that", "with", "stable", "halothane", "anesthesia", ",", "the", "partial", "recovery", "of", "blood", "pressure", "during", "SNP", "infusion", "and", "the", "post", "-", "SNP", "rebound", "of", "blood", "pressure", "can", "be", "completely", "blocked", "by", "saralasin", ".", "This", "demonstrates", "the", "participation", "of", "the", "renin", "-", "-", "angiotensin", "system", "in", "antagonizing", "the", "combined", "hypotensive", "effects", "of", "halothane", "and", "SNP", "."]], "ner": [[[3, 4, "Chemical"], [30, 31, "Chemical"], [33, 33, "Chemical"], [56, 56, "Chemical"], [114, 114, "Chemical"], [139, 139, "Chemical"], [168, 168, "Chemical"], [209, 209, "Chemical"], [215, 215, "Chemical"], [247, 247, "Chemical"], [37, 37, "Disease"], [242, 242, "Disease"], [27, 27, "Chemical"], [44, 44, "Chemical"], [199, 199, "Chemical"], [245, 245, "Chemical"], [1, 1, "Disease"], [147, 150, "Disease"], [7, 7, "Chemical"], [96, 96, "Chemical"], [157, 157, "Chemical"], [188, 188, "Chemical"], [225, 225, "Chemical"], [18, 18, "Chemical"], [236, 236, "Chemical"], [102, 103, "Chemical"]]], "relations": [[[3, 4, 37, 37, "CID"], [3, 4, 242, 242, "CID"], [30, 31, 37, 37, "CID"], [30, 31, 242, 242, "CID"], [33, 33, 37, 37, "CID"], [33, 33, 242, 242, "CID"], [56, 56, 37, 37, "CID"], [56, 56, 242, 242, "CID"], [114, 114, 37, 37, "CID"], [114, 114, 242, 242, "CID"], [139, 139, 37, 37, "CID"], [139, 139, 242, 242, "CID"], [168, 168, 37, 37, "CID"], [168, 168, 242, 242, "CID"], [209, 209, 37, 37, "CID"], [209, 209, 242, 242, "CID"], [215, 215, 37, 37, "CID"], [215, 215, 242, 242, "CID"], [247, 247, 37, 37, "CID"], [247, 247, 242, 242, "CID"], [27, 27, 37, 37, "CID"], [27, 27, 242, 242, "CID"], [44, 44, 37, 37, "CID"], [44, 44, 242, 242, "CID"], [199, 199, 37, 37, "CID"], [199, 199, 242, 242, "CID"], [245, 245, 37, 37, "CID"], [245, 245, 242, 242, "CID"]]], "clusters": [], "translated": "大鼠<18> saralasin </18>预防<0>硝普钠</0>后<16>高血压</16>反弹。肾素--<23>血管紧张素</23>系统在<12>氟烷</12>麻醉和<1>硝普钠</1>（<2>SNP</2>）-诱导的<10>低血压</10>维持血压中的作用进行了评估。对照大鼠接受<13>氟烷</13>麻醉（1 MAC）一小时，然后<3>SNP</3>输注，40微克/公斤/分钟，持续30分钟，然后恢复30分钟时期。第二组大鼠接受相同的治疗，此外，在整个实验期间还接受了<19> saralasin </19>（<25>血管紧张素 II</25>的竞争性抑制剂）的输注。在每组中，<4>SNP</4>输注导致初始血压分别从86托和83托降至48托。在<5>SNP</5>输注过程中，对照动物表现出进行性<17>血压升高</17>至61托，而<20>saralasin</20>处理的动物没有表现出任何变化。停止使用<6> SNP </6>后，对照组动物的血压回升至94托，而<21>saralasin</21>治疗大鼠的血压为78托。本研究表明，在稳定的<14>氟烷</14>麻醉下，<7>SNP</7> 输注期间血压的部分恢复和<8>SNP</8>后血压反弹可以被<22> saralasin </22>完全阻断。这表明肾素--<24>血管紧张素</24>系统参与拮抗<15>氟烷</15>和<9>SNP</9>的联合<11>降压</11>作用。", "revised": true}
{"doc_key": "7919560", "sentences": [["Erythema", "multiforme", "and", "hypersensitivity", "myocarditis", "caused", "by", "ampicillin", ".", "OBJECTIVE", ":", "To", "report", "a", "case", "of", "erythema", "multiforme", "and", "hypersensitivity", "myocarditis", "caused", "by", "ampicillin", ".", "CASE", "SUMMARY", ":", "A", "13", "-", "year", "-", "old", "boy", "was", "treated", "with", "ampicillin", "and", "gentamicin", "because", "of", "suspected", "septicemia", ".", "Medications", "were", "discontinued", "when", "erythema", "multiforme", "and", "congestive", "heart", "failure", "caused", "by", "myocarditis", "occurred", ".", "The", "patient", "was", "treated", "with", "methylprednisolone", "and", "gradually", "improved", ".", "Macrophage", "-", "migration", "inhibition", "(", "MIF", ")", "test", "with", "ampicillin", "was", "positive", ".", "DISCUSSION", ":", "After", "most", "infections", "causing", "erythema", "multiforme", "and", "myocarditis", "were", "ruled", "out", ",", "a", "drug", "-", "induced", "allergic", "reaction", "was", "suspected", ".", "Positive", "MIF", "test", "for", "ampicillin", "showed", "sensitization", "of", "the", "patient", "'s", "lymphocytes", "to", "ampicillin", ".", "CONCLUSIONS", ":", "Hypersensitivity", "myocarditis", "is", "a", "rare", "and", "dangerous", "manifestation", "of", "allergy", "to", "penicillins", "."]], "ner": [[[7, 7, "Chemical"], [23, 23, "Chemical"], [38, 38, "Chemical"], [80, 80, "Chemical"], [111, 111, "Chemical"], [120, 120, "Chemical"], [0, 1, "Disease"], [16, 17, "Disease"], [50, 51, "Disease"], [90, 91, "Disease"], [3, 4, "Disease"], [19, 20, "Disease"], [58, 58, "Disease"], [93, 93, "Disease"], [124, 125, "Disease"], [99, 103, "Disease"], [133, 133, "Disease"], [40, 40, "Chemical"], [66, 66, "Chemical"], [135, 135, "Chemical"], [44, 44, "Disease"], [53, 55, "Disease"], [88, 88, "Disease"]]], "relations": [[[7, 7, 0, 1, "CID"], [7, 7, 16, 17, "CID"], [7, 7, 50, 51, "CID"], [7, 7, 90, 91, "CID"], [23, 23, 0, 1, "CID"], [23, 23, 16, 17, "CID"], [23, 23, 50, 51, "CID"], [23, 23, 90, 91, "CID"], [38, 38, 0, 1, "CID"], [38, 38, 16, 17, "CID"], [38, 38, 50, 51, "CID"], [38, 38, 90, 91, "CID"], [80, 80, 0, 1, "CID"], [80, 80, 16, 17, "CID"], [80, 80, 50, 51, "CID"], [80, 80, 90, 91, "CID"], [111, 111, 0, 1, "CID"], [111, 111, 16, 17, "CID"], [111, 111, 50, 51, "CID"], [111, 111, 90, 91, "CID"], [120, 120, 0, 1, "CID"], [120, 120, 16, 17, "CID"], [120, 120, 50, 51, "CID"], [120, 120, 90, 91, "CID"], [7, 7, 3, 4, "CID"], [7, 7, 19, 20, "CID"], [7, 7, 58, 58, "CID"], [7, 7, 93, 93, "CID"], [7, 7, 124, 125, "CID"], [23, 23, 3, 4, "CID"], [23, 23, 19, 20, "CID"], [23, 23, 58, 58, "CID"], [23, 23, 93, 93, "CID"], [23, 23, 124, 125, "CID"], [38, 38, 3, 4, "CID"], [38, 38, 19, 20, "CID"], [38, 38, 58, 58, "CID"], [38, 38, 93, 93, "CID"], [38, 38, 124, 125, "CID"], [80, 80, 3, 4, "CID"], [80, 80, 19, 20, "CID"], [80, 80, 58, 58, "CID"], [80, 80, 93, 93, "CID"], [80, 80, 124, 125, "CID"], [111, 111, 3, 4, "CID"], [111, 111, 19, 20, "CID"], [111, 111, 58, 58, "CID"], [111, 111, 93, 93, "CID"], [111, 111, 124, 125, "CID"], [120, 120, 3, 4, "CID"], [120, 120, 19, 20, "CID"], [120, 120, 58, 58, "CID"], [120, 120, 93, 93, "CID"], [120, 120, 124, 125, "CID"], [7, 7, 99, 103, "CID"], [7, 7, 133, 133, "CID"], [23, 23, 99, 103, "CID"], [23, 23, 133, 133, "CID"], [38, 38, 99, 103, "CID"], [38, 38, 133, 133, "CID"], [80, 80, 99, 103, "CID"], [80, 80, 133, 133, "CID"], [111, 111, 99, 103, "CID"], [111, 111, 133, 133, "CID"], [120, 120, 99, 103, "CID"], [120, 120, 133, 133, "CID"]]], "clusters": [], "translated": " <6>多形性红斑</6>和<10>过敏性心肌炎</10>由<0>氨苄青霉素</0>引起。目的：报告1例<1>氨苄青霉素</1>致<7>多形性红斑</7>和<11>过敏性心肌炎</11>病例。病例概要：一名13岁男孩因疑似<20>败血症</20>接受<2>氨苄青霉素</2>和<17>庆大霉素</17>治疗。因<12>心肌炎</12>引起<8>多形性红斑</8>和<21>充血性心力衰竭</21>时停药。患者给予<18>甲泼尼龙</18>治疗，逐渐好转。<3>氨苄青霉素</3>巨噬细胞迁移抑制(MIF)试验阳性。讨论：排除了导致<9>多形性红斑</9>和<13>心肌炎</13>的大多数<22>感染</22>后，怀疑是<15>药物引起的过敏反应</15>。阳性的<4>MIF试验</4>表明患者的淋巴细胞对<5>氨苄青霉素</5>敏感。结论：<14>过敏性心肌炎</14>是对<19>青霉素</19><16>过敏</16>的一种罕见且危险的表现。", "revised": true}
{"doc_key": "7504976", "sentences": [["Toxic", "hepatitis", "induced", "by", "antithyroid", "drugs", ":", "four", "cases", "including", "one", "with", "cross", "-", "reactivity", "between", "carbimazole", "and", "benzylthiouracil", ".", "OBJECTIVE", ":", "This", "study", "was", "conducted", "to", "assess", "the", "occurrence", "of", "hepatic", "adverse", "effects", "encountered", "with", "antithyroid", "drugs", ".", "METHODS", ":", "Retrospective", "review", "of", "medical", "records", "of", "236", "patients", "with", "hyperthyroidism", "admitted", "in", "our", "department", "(", "in", "-", "or", "out", "-", "patients", ")", "from", "1986", "to", "1992", ".", "RESULTS", ":", "Four", "patients", "(", "1", ".", "7", "%", ")", "were", "identified", "with", "toxic", "hepatitis", "which", "could", "reasonably", "be", "attributed", "to", "the", "use", "of", "antithyroid", "agent", ".", "Two", "patients", "had", "a", "cholestatic", "hepatitis", "induced", "by", "carbimazole", "(", "N", "omercazole", ")", ".", "Two", "others", "had", "a", "mixed", "(", "cholestatic", "and", "cytolytic", ")", "hepatitis", "following", "carbimazole", ".", "One", "of", "the", "latter", "two", "patients", "further", "experienced", "a", "cytolytic", "hepatitis", "which", "appeared", "after", "Benzylthiouracil", "(", "Basd", "ne", ")", "had", "replaced", "carbimazole", ".", "Biological", "features", "of", "hepatitis", "disappeared", "in", "all", "cases", "after", "cessation", "of", "the", "incriminated", "drug", ",", "while", "biliary", ",", "viral", "and", "immunological", "searches", "were", "negative", ".", "Only", "2", "patients", "of", "our", "retrospective", "study", "experienced", "a", "mild", "or", "severe", "neutropenia", ".", "CONCLUSION", ":", "Toxic", "hepatitis", "is", "a", "potential", "adverse", "effect", "of", "antithyroid", "drugs", "which", "warrants", ",", "as", "for", "haematological", "disturbances", ",", "a", "pre", "-", "therapeutic", "determination", "and", "a", "careful", "follow", "-", "up", "of", "relevant", "biological", "markers", ".", "Moreover", ",", "hepatotoxicity", "may", "not", "be", "restricted", "to", "one", "class", "of", "antithyroid", "agents", "."]], "ner": [[[16, 16, "Chemical"], [103, 103, "Chemical"], [105, 106, "Chemical"], [121, 121, "Chemical"], [144, 144, "Chemical"], [0, 1, "Disease"], [31, 33, "Disease"], [81, 82, "Disease"], [99, 100, "Disease"], [119, 119, "Disease"], [133, 133, "Disease"], [149, 149, "Disease"], [187, 188, "Disease"], [223, 223, "Disease"], [115, 115, "Disease"], [18, 18, "Chemical"], [137, 137, "Chemical"], [139, 140, "Chemical"], [50, 50, "Disease"], [183, 183, "Disease"]]], "relations": [[[16, 16, 0, 1, "CID"], [16, 16, 31, 33, "CID"], [16, 16, 81, 82, "CID"], [16, 16, 99, 100, "CID"], [16, 16, 119, 119, "CID"], [16, 16, 133, 133, "CID"], [16, 16, 149, 149, "CID"], [16, 16, 187, 188, "CID"], [16, 16, 223, 223, "CID"], [103, 103, 0, 1, "CID"], [103, 103, 31, 33, "CID"], [103, 103, 81, 82, "CID"], [103, 103, 99, 100, "CID"], [103, 103, 119, 119, "CID"], [103, 103, 133, 133, "CID"], [103, 103, 149, 149, "CID"], [103, 103, 187, 188, "CID"], [103, 103, 223, 223, "CID"], [105, 106, 0, 1, "CID"], [105, 106, 31, 33, "CID"], [105, 106, 81, 82, "CID"], [105, 106, 99, 100, "CID"], [105, 106, 119, 119, "CID"], [105, 106, 133, 133, "CID"], [105, 106, 149, 149, "CID"], [105, 106, 187, 188, "CID"], [105, 106, 223, 223, "CID"], [121, 121, 0, 1, "CID"], [121, 121, 31, 33, "CID"], [121, 121, 81, 82, "CID"], [121, 121, 99, 100, "CID"], [121, 121, 119, 119, "CID"], [121, 121, 133, 133, "CID"], [121, 121, 149, 149, "CID"], [121, 121, 187, 188, "CID"], [121, 121, 223, 223, "CID"], [144, 144, 0, 1, "CID"], [144, 144, 31, 33, "CID"], [144, 144, 81, 82, "CID"], [144, 144, 99, 100, "CID"], [144, 144, 119, 119, "CID"], [144, 144, 133, 133, "CID"], [144, 144, 149, 149, "CID"], [144, 144, 187, 188, "CID"], [144, 144, 223, 223, "CID"], [16, 16, 115, 115, "CID"], [103, 103, 115, 115, "CID"], [105, 106, 115, 115, "CID"], [121, 121, 115, 115, "CID"], [144, 144, 115, 115, "CID"]]], "clusters": [], "translated": " <5>抗甲状腺药物致中毒性肝炎</5>：4例，其中1例与<0>卡比马唑</0>和<15>苄基硫氧嘧啶</15>有交叉反应。目的：本研究旨在评估抗甲状腺药物<6>肝脏不良反应</6>的发生率。方法：回顾性分析1986年至1992年我科收治的236例<18>甲状腺功能亢进</18>患者（住院或门诊）的病历资料。结果：4名患者（1.7%）被诊断为<7>中毒性肝炎</7>，这可以合理地归因于抗甲状腺药物的使用。2例因<1>卡比马唑</1>（<2>N奥美唑</2>）致<8>胆汁淤积性肝炎</8>。另外两名患者在用<3>卡比马唑</3>后出现混合性（<14>胆汁淤积性</14>和细胞溶解性）<9>肝炎</9>。其中，有一名患者在用<16>苄基硫氧嘧啶</16>（<17>Basdne</17>）代替<4>卡比马唑</4>后出现溶细胞性<10>肝炎</10>。停用有关药物后<11>肝炎</11>的生物学特征在所有病例中消失，而胆道、病毒学和免疫学的检查均为阴性。在我们的回顾性研究中，只有 2 名患者出现轻度或重度<19>中性粒细胞减少症</19>。结论：<12>中毒性肝炎</12>是抗甲状腺药物的潜在不良反应，对于血液学异常，治疗前应确定并密切随访相关生物标志物。此外，<13>肝毒性</13>可能不仅限于一类抗甲状腺药物。", "revised": true}
{"doc_key": "7858459", "sentences": [["Acute", "confusion", "induced", "by", "a", "high", "-", "dose", "infusion", "of", "5", "-", "fluorouracil", "and", "folinic", "acid", ".", "A", "61", "-", "year", "-", "old", "man", "was", "treated", "with", "combination", "chemotherapy", "incorporating", "cisplatinum", ",", "etoposide", ",", "high", "-", "dose", "5", "-", "fluorouracil", "(", "2", ",", "250", "mg", "/", "m2", "/", "24", "hours", ")", "and", "folinic", "acid", "for", "an", "inoperable", "gastric", "adenocarcinoma", ".", "He", "developed", "acute", "neurologic", "symptoms", "of", "mental", "confusion", ",", "disorientation", "and", "irritability", ",", "and", "then", "lapsed", "into", "a", "deep", "coma", ",", "lasting", "for", "approximately", "40", "hours", "during", "the", "first", "dose", "(", "day", "2", ")", "of", "5", "-", "fluorouracil", "and", "folinic", "acid", "infusion", ".", "This", "complication", "reappeared", "on", "day", "25", "during", "the", "second", "dose", "of", "5", "-", "fluorouracil", "and", "folinic", "acid", ",", "which", "were", "then", "the", "only", "drugs", "given", ".", "Because", "folinic", "acid", "was", "unlikely", "to", "be", "associated", "with", "this", "condition", ",", "neurotoxicity", "due", "to", "high", "-", "dose", "5", "-", "fluorouracil", "was", "highly", "suspected", ".", "The", "pathogenesis", "of", "5", "-", "fluorouracil", "neurotoxicity", "may", "be", "due", "to", "a", "Krebs", "cycle", "blockade", "by", "fluoroacetate", "and", "fluorocitrate", ",", "thiamine", "deficiency", ",", "or", "dihydrouracil", "dehydrogenase", "deficiency", ".", "High", "-", "dose", "5", "-", "fluorouracil", "/", "folinic", "acid", "infusion", "therapy", "has", "recently", "become", "a", "popular", "regimen", "for", "various", "cancers", ".", "It", "is", "necessary", "that", "both", "oncologists", "and", "neurologists", "be", "fully", "aware", "of", "this", "unusual", "complication", "."]], "ner": [[[10, 12, "Chemical"], [37, 39, "Chemical"], [95, 97, "Chemical"], [114, 116, "Chemical"], [147, 149, "Chemical"], [157, 159, "Chemical"], [185, 187, "Chemical"], [1, 1, "Disease"], [67, 67, "Disease"], [69, 69, "Disease"], [14, 15, "Chemical"], [52, 53, "Chemical"], [99, 100, "Chemical"], [118, 119, "Chemical"], [130, 131, "Chemical"], [189, 190, "Chemical"], [79, 79, "Disease"], [30, 30, "Chemical"], [32, 32, "Chemical"], [170, 170, "Chemical"], [172, 172, "Chemical"], [174, 174, "Chemical"], [178, 178, "Chemical"], [57, 58, "Disease"], [71, 71, "Disease"], [141, 141, "Disease"], [160, 160, "Disease"], [201, 201, "Disease"]]], "relations": [[[10, 12, 1, 1, "CID"], [10, 12, 67, 67, "CID"], [10, 12, 69, 69, "CID"], [37, 39, 1, 1, "CID"], [37, 39, 67, 67, "CID"], [37, 39, 69, 69, "CID"], [95, 97, 1, 1, "CID"], [95, 97, 67, 67, "CID"], [95, 97, 69, 69, "CID"], [114, 116, 1, 1, "CID"], [114, 116, 67, 67, "CID"], [114, 116, 69, 69, "CID"], [147, 149, 1, 1, "CID"], [147, 149, 67, 67, "CID"], [147, 149, 69, 69, "CID"], [157, 159, 1, 1, "CID"], [157, 159, 67, 67, "CID"], [157, 159, 69, 69, "CID"], [185, 187, 1, 1, "CID"], [185, 187, 67, 67, "CID"], [185, 187, 69, 69, "CID"], [14, 15, 1, 1, "CID"], [14, 15, 67, 67, "CID"], [14, 15, 69, 69, "CID"], [52, 53, 1, 1, "CID"], [52, 53, 67, 67, "CID"], [52, 53, 69, 69, "CID"], [99, 100, 1, 1, "CID"], [99, 100, 67, 67, "CID"], [99, 100, 69, 69, "CID"], [118, 119, 1, 1, "CID"], [118, 119, 67, 67, "CID"], [118, 119, 69, 69, "CID"], [130, 131, 1, 1, "CID"], [130, 131, 67, 67, "CID"], [130, 131, 69, 69, "CID"], [189, 190, 1, 1, "CID"], [189, 190, 67, 67, "CID"], [189, 190, 69, 69, "CID"], [10, 12, 79, 79, "CID"], [37, 39, 79, 79, "CID"], [95, 97, 79, 79, "CID"], [114, 116, 79, 79, "CID"], [147, 149, 79, 79, "CID"], [157, 159, 79, 79, "CID"], [185, 187, 79, 79, "CID"], [14, 15, 79, 79, "CID"], [52, 53, 79, 79, "CID"], [99, 100, 79, 79, "CID"], [118, 119, 79, 79, "CID"], [130, 131, 79, 79, "CID"], [189, 190, 79, 79, "CID"]]], "clusters": [], "translated": "由高剂量输注<0>5-氟尿嘧啶</0>和<10>亚叶酸</10>引起的急性<7>意识模糊</7>。一名 61 岁男性接受了联合化疗，包括<17>顺铂</17>、<18>依托泊苷</18>、高剂量<1>5-氟尿嘧啶</1>（2,250 mg/m2/24小时）和<11>亚叶酸</11>用于不能手术的<23>胃腺癌</23>。他出现精神<8>意识模糊</8>、<9>定向障碍</9>和<24>易怒</24>的急性神经系统症状，然后陷入深度<16>昏迷</16>，持续在第一剂（第2天）<2>5-氟尿嘧啶</2>和<12>亚叶酸</12>输注期间持续约40小时。该并发症在第25天第二次服用<3>5-氟尿嘧啶</3>和<13>亚叶酸</13>期间再次出现，这也是当时唯一给予的药物。由于<14>亚叶酸</14>不太可能与该病症相关，因此高度怀疑<25>神经毒性</25>由于高剂量<4>5-氟尿嘧啶</4>。 <5>5-氟尿嘧啶</5><26>神经毒性</26>的发病机制可能是由于<19>氟乙酸</19>和<20>氟柠檬酸盐</20>、<21>硫胺素</21>缺乏症对克雷布斯循环的阻断、或<22>二氢尿嘧啶</22>脱氢酶缺乏症。高剂量<6>5-氟尿嘧啶</6>/<15>亚叶酸</15>输注疗法最近已成为各种<27>癌症</27>的流行疗法。肿瘤学家和神经学家都必须充分意识到这种不寻常的并发症。", "revised": true}
{"doc_key": "8638206", "sentences": [["Persistent", "paralysis", "after", "prolonged", "use", "of", "atracurium", "in", "the", "absence", "of", "corticosteroids", ".", "Neuromuscular", "blocking", "agents", "(", "NMBAs", ")", "are", "often", "used", "for", "patients", "requiring", "prolonged", "mechanical", "ventilation", ".", "Reports", "of", "persistent", "paralysis", "after", "the", "discontinuance", "of", "these", "drugs", "have", "most", "often", "involved", "aminosteroid", "-", "based", "NMBAs", "such", "as", "vecuronium", "bromide", ",", "especially", "when", "used", "in", "conjunction", "with", "corticosteroids", ".", "Atracurium", "besylate", ",", "a", "short", "-", "acting", "benzylisoquinolinium", "NMBA", "that", "is", "eliminated", "independently", "of", "renal", "or", "hepatic", "function", ",", "has", "also", "been", "associated", "with", "persistent", "paralysis", ",", "but", "only", "when", "used", "with", "corticosteroids", ".", "We", "report", "a", "case", "of", "atracurium", "-", "related", "paralysis", "persisting", "for", "approximately", "50", "hours", "in", "a", "patient", "who", "was", "not", "treated", "with", "corticosteroids", "."]], "ner": [[[6, 6, "Chemical"], [60, 61, "Chemical"], [99, 99, "Chemical"], [1, 1, "Disease"], [32, 32, "Disease"], [85, 85, "Disease"], [102, 102, "Disease"], [49, 50, "Chemical"]]], "relations": [[[6, 6, 1, 1, "CID"], [6, 6, 32, 32, "CID"], [6, 6, 85, 85, "CID"], [6, 6, 102, 102, "CID"], [60, 61, 1, 1, "CID"], [60, 61, 32, 32, "CID"], [60, 61, 85, 85, "CID"], [60, 61, 102, 102, "CID"], [99, 99, 1, 1, "CID"], [99, 99, 32, 32, "CID"], [99, 99, 85, 85, "CID"], [99, 99, 102, 102, "CID"], [49, 50, 1, 1, "CID"], [49, 50, 32, 32, "CID"], [49, 50, 85, 85, "CID"], [49, 50, 102, 102, "CID"]]], "clusters": [], "translated": "在没有皮质类固醇的情况下长期使用<0>阿曲库铵</0>后持续<3>瘫痪</3>。神经肌肉阻滞剂 (NMBA) 通常用于需要长时间机械通气的患者。停用这些药物后出现持续性<4>麻痹</4>的报告最常涉及基于氨基类固醇的 NMBA，例如<7>维库溴铵</7>，尤其是与皮质类固醇联合使用时。<1>阿曲库铵</1>是一种短效苄基异喹啉 NMBA，其清除与肾功能或肝功能无关，并且只有在与皮质类固醇一起使用时才会导致持续性<5>麻痹</5>。我们报告了一例与<2>阿曲库铵</2>相关的<6>麻痹</6>，在未接受皮质类固醇治疗的患者中持续约50小时。", "revised": true}
{"doc_key": "2054792", "sentences": [["Effect", "of", "adriamycin", "combined", "with", "whole", "body", "hyperthermia", "on", "tumor", "and", "normal", "tissues", ".", "Thermal", "enhancement", "of", "Adriamycin", "-", "mediated", "antitumor", "activity", "and", "normal", "tissue", "toxicities", "by", "whole", "body", "hyperthermia", "were", "compared", "using", "a", "F344", "rat", "model", ".", "Antitumor", "activity", "was", "studied", "using", "a", "tumor", "growth", "delay", "assay", ".", "Acute", "normal", "tissue", "toxicities", "(", "i", ".", "e", ".", ",", "leukopenia", "and", "thrombocytopenia", ")", "and", "late", "normal", "tissue", "toxicities", "(", "i", ".", "e", ".", ",", "myocardial", "and", "kidney", "injury", ")", "were", "evaluated", "by", "functional", "/", "physiological", "assays", "and", "by", "morphological", "techniques", ".", "Whole", "body", "hyperthermia", "(", "120", "min", "at", "41", ".", "5", "degrees", "C", ")", "enhanced", "both", "Adriamycin", "-", "mediated", "antitumor", "activity", "and", "toxic", "side", "effects", ".", "The", "thermal", "enhancement", "ratio", "calculated", "for", "antitumor", "activity", "was", "1", ".", "6", ".", "Thermal", "enhancement", "ratios", "estimated", "for", "\"", "acute", "\"", "hematological", "changes", "were", "1", ".", "3", ",", "whereas", "those", "estimated", "for", "\"", "late", "\"", "damage", "(", "based", "on", "morphological", "cardiac", "and", "renal", "lesions", ")", "varied", "between", "2", ".", "4", "and", "4", ".", "3", ".", "Thus", ",", "while", "whole", "body", "hyperthermia", "enhances", "Adriamycin", "-", "mediated", "antitumor", "effect", ",", "normal", "tissue", "toxicity", "is", "also", "increased", ",", "and", "the", "potential", "therapeutic", "gain", "of", "the", "combined", "modality", "treatment", "is", "eroded", "."]], "ner": [[[2, 2, "Chemical"], [17, 17, "Chemical"], [106, 106, "Chemical"], [178, 178, "Chemical"], [74, 77, "Disease"], [156, 159, "Disease"], [7, 7, "Disease"], [29, 29, "Disease"], [93, 93, "Disease"], [176, 176, "Disease"], [9, 9, "Disease"], [44, 44, "Disease"], [25, 25, "Disease"], [52, 52, "Disease"], [67, 67, "Disease"], [186, 186, "Disease"], [59, 59, "Disease"], [61, 61, "Disease"]]], "relations": [[[2, 2, 74, 77, "CID"], [2, 2, 156, 159, "CID"], [17, 17, 74, 77, "CID"], [17, 17, 156, 159, "CID"], [106, 106, 74, 77, "CID"], [106, 106, 156, 159, "CID"], [178, 178, 74, 77, "CID"], [178, 178, 156, 159, "CID"]]], "clusters": [], "translated": "<0>阿霉素</0>联合全身<6>热疗</6>对<10>肿瘤</10>和正常组织的影响。使用F344大鼠模型比较了全身<7>热疗</7>对<1>阿霉素</1>介导的抗肿瘤活性和正常组织<12>毒性</12>的热增强作用。使用<11>肿瘤</11>生长延迟试验研究了抗肿瘤活性。急性正常组织<13>毒性</13>（即<16>白细胞减少</16>和<17>血小板减少</17>）和晚期正常组织<14>毒性</14>（即<4>心肌和肾脏损伤</4>）通过功能/生理分析和形态学技术进行评估。全身<8>热疗</8>（120分钟，41.5摄氏度）增强了<2>阿霉素</2>介导的抗肿瘤活性和毒副作用。抗肿瘤活性计算的热增强比为1.6。估计“急性”血液学变化的热增强比为1.3，而那些估计的“晚期”损伤（基于形态学<5>心脏和肾脏损伤</5>）在2.4和4.3之间变化。因此，虽然全身<9>热疗</9>增强了<3>阿霉素</3>介导的抗肿瘤作用，但正常组织的<15>毒性</15>也增加了，联合疗法的潜在治疗收益被侵蚀。", "revised": true}
{"doc_key": "6133211", "sentences": [["Possible", "teratogenicity", "of", "sulphasalazine", ".", "Three", "infants", ",", "born", "of", "two", "mothers", "with", "inflammatory", "bowel", "disease", "who", "received", "treatment", "with", "sulphasalazine", "throughout", "pregnancy", ",", "were", "found", "to", "have", "major", "congenital", "anomalies", ".", "In", "the", "singleton", "pregnancy", ",", "the", "mother", "had", "ulcerative", "colitis", ",", "and", "the", "infant", ",", "a", "male", ",", "had", "coarctation", "of", "the", "aorta", "and", "a", "ventricular", "septal", "defect", ".", "In", "the", "twin", "pregnancy", ",", "the", "mother", "had", "Crohn", "'s", "disease", ".", "The", "first", "twin", ",", "a", "female", ",", "had", "a", "left", "Potter", "-", "type", "IIa", "polycystic", "kidney", "and", "a", "rudimentary", "left", "uterine", "cornu", ".", "The", "second", "twin", ",", "a", "male", ",", "had", "some", "features", "of", "Potter", "'s", "facies", ",", "hypoplastic", "lungs", ",", "absent", "kidneys", "and", "ureters", ",", "and", "talipes", "equinovarus", ".", "Despite", "reports", "to", "the", "contrary", ",", "it", "is", "suggested", "that", "sulphasalazine", "may", "be", "teratogenic", "."]], "ner": [[[3, 3, "Chemical"], [20, 20, "Chemical"], [133, 133, "Chemical"], [51, 54, "Disease"], [57, 59, "Disease"], [83, 88, "Disease"], [120, 121, "Disease"], [13, 15, "Disease"], [29, 30, "Disease"], [40, 41, "Disease"], [69, 71, "Disease"]]], "relations": [[[3, 3, 51, 54, "CID"], [20, 20, 51, 54, "CID"], [133, 133, 51, 54, "CID"], [3, 3, 57, 59, "CID"], [20, 20, 57, 59, "CID"], [133, 133, 57, 59, "CID"], [3, 3, 83, 88, "CID"], [20, 20, 83, 88, "CID"], [133, 133, 83, 88, "CID"], [3, 3, 120, 121, "CID"], [20, 20, 120, 121, "CID"], [133, 133, 120, 121, "CID"]]], "clusters": [], "translated": "<0>柳氮磺胺吡啶</0>可能致畸。两名患有<7>炎症性肠病</7>的母亲在整个怀孕期间接受<1>柳氮磺胺吡啶</1>治疗，他们所生的三名婴儿被发现有严重的<8>先天性异常</8>。单胎妊娠，母亲<9>溃疡性结肠炎</9>，男婴有<3>主动脉缩窄</3>和<4>室间隔缺损</4>。在双胞胎妊娠中，母亲患有<10>克罗恩病</10>。第一个双胞胎是女性，有一个左侧<5>Potter IIa型多囊肾</5>和一个发育不全的左侧子宫角。第二对双胞胎是男性，具有波特的面容、肺部发育不全、肾脏和输尿管缺失以及<6>马蹄足</6>的某些特征。尽管有相反的报道，但提示<2>柳氮磺胺吡啶</2>可能具有致畸作用。", "revised": true}
{"doc_key": "10342929", "sentences": [["Angioedema", "due", "to", "ACE", "inhibitors", ":", "common", "and", "inadequately", "diagnosed", ".", "The", "estimated", "incidence", "of", "angioedema", "during", "angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "inhibitor", "treatment", "is", "between", "1", "and", "7", "per", "thousand", "patients", ".", "This", "potentially", "serious", "adverse", "effect", "is", "often", "preceded", "by", "minor", "manifestations", "that", "may", "serve", "as", "a", "warning", "."]], "ner": [[[3, 4, "Chemical"], [17, 24, "Chemical"], [0, 0, "Disease"], [15, 15, "Disease"]]], "relations": [[[3, 4, 0, 0, "CID"], [3, 4, 15, 15, "CID"], [17, 24, 0, 0, "CID"], [17, 24, 15, 15, "CID"]]], "clusters": [], "translated": "<2>血管性水肿</2> 由于<0>ACE抑制剂</0>：常见且诊断不充分。<1>血管紧张素转换酶(ACE)抑制剂</1>治疗期间<3>血管性水肿</3>的估计发生率为千分之1到7。这种潜在的严重不良反应之前通常会出现可作为警告的轻微表现。", "revised": true}
{"doc_key": "7628595", "sentences": [["Study", "of", "the", "role", "of", "vitamin", "B12", "and", "folinic", "acid", "supplementation", "in", "preventing", "hematologic", "toxicity", "of", "zidovudine", ".", "A", "prospective", ",", "randomized", "study", "was", "conducted", "to", "evaluate", "the", "role", "of", "vitamin", "B12", "and", "folinic", "acid", "supplementation", "in", "preventing", "zidovudine", "(", "ZDV", ")", "-", "induced", "bone", "marrow", "suppression", ".", "Seventy", "-", "five", "human", "immunodeficiency", "virus", "(", "HIV", ")", "-", "infected", "patients", "with", "CD4", "+", "cell", "counts", "<", "500", "/", "mm3", "were", "randomized", "to", "receive", "either", "ZDV", "(", "500", "mg", "daily", ")", "alone", "(", "group", "I", ",", "n", "=", "38", ")", "or", "in", "combination", "with", "folinic", "acid", "(", "15", "mg", "daily", ")", "and", "intramascular", "vitamin", "B12", "(", "1000", "micrograms", "monthly", ")", "(", "group", "II", ",", "n", "=", "37", ")", ".", "Finally", ",", "15", "patients", "were", "excluded", "from", "the", "study", "(", "noncompliance", "14", ",", "death", "1", ")", ";", "thus", ",", "60", "patients", "(", "31", "in", "group", "I", "and", "29", "in", "group", "II", ")", "were", "eligible", "for", "analysis", ".", "No", "significant", "differences", "between", "groups", "were", "found", "at", "enrollment", ".", "During", "the", "study", ",", "vitamin", "B12", "and", "folate", "levels", "were", "significantly", "higher", "in", "group", "II", "patients", ";", "however", ",", "no", "differences", "in", "hemoglobin", ",", "hematocrit", ",", "mean", "corpuscular", "volume", ",", "and", "white", "-", "cell", ",", "neutrophil", "and", "platelet", "counts", "were", "observed", "between", "groups", "at", "3", ",", "6", ",", "9", "and", "12", "months", ".", "Severe", "hematologic", "toxicity", "(", "neutrophil", "count", "<", "1000", "/", "mm3", "and", "/", "or", "hemoglobin", "<", "8", "g", "/", "dl", ")", "occurred", "in", "4", "patients", "assigned", "to", "group", "I", "and", "7", "assigned", "to", "group", "II", ".", "There", "was", "no", "correlation", "between", "vitamin", "B12", "or", "folate", "levels", "and", "development", "of", "myelosuppression", ".", "Vitamin", "B12", "and", "folinic", "acid", "supplementation", "of", "ZDV", "therapy", "does", "not", "seem", "useful", "in", "preventing", "or", "reducing", "ZDV", "-", "induced", "myelotoxicity", "in", "the", "overall", "treated", "population", ",", "although", "a", "beneficial", "effect", "in", "certain", "subgroups", "of", "patients", "can", "not", "be", "excluded", "."]], "ner": [[[16, 16, "Chemical"], [38, 38, "Chemical"], [40, 40, "Chemical"], [74, 74, "Chemical"], [275, 275, "Chemical"], [285, 285, "Chemical"], [44, 46, "Disease"], [266, 266, "Disease"], [288, 288, "Disease"], [5, 6, "Chemical"], [30, 31, "Chemical"], [102, 103, "Chemical"], [169, 170, "Chemical"], [258, 259, "Chemical"], [268, 269, "Chemical"], [14, 14, "Disease"], [220, 220, "Disease"], [51, 58, "Disease"], [131, 131, "Disease"], [8, 9, "Chemical"], [33, 34, "Chemical"], [93, 94, "Chemical"], [271, 272, "Chemical"], [172, 172, "Chemical"], [261, 261, "Chemical"]]], "relations": [[[16, 16, 44, 46, "CID"], [16, 16, 266, 266, "CID"], [16, 16, 288, 288, "CID"], [38, 38, 44, 46, "CID"], [38, 38, 266, 266, "CID"], [38, 38, 288, 288, "CID"], [40, 40, 44, 46, "CID"], [40, 40, 266, 266, "CID"], [40, 40, 288, 288, "CID"], [74, 74, 44, 46, "CID"], [74, 74, 266, 266, "CID"], [74, 74, 288, 288, "CID"], [275, 275, 44, 46, "CID"], [275, 275, 266, 266, "CID"], [275, 275, 288, 288, "CID"], [285, 285, 44, 46, "CID"], [285, 285, 266, 266, "CID"], [285, 285, 288, 288, "CID"]]], "clusters": [], "translated": "<9>维生素B12</9>和<19>亚叶酸</19>补充剂在预防<0>齐多夫定</0><15>血液学毒性</15>中的作用研究。进行了一项前瞻性随机研究，以评估<10>维生素B12</10>和<20>亚叶酸</20>补充剂在预防<1>齐多夫定</1>（<2>ZDV</2>）-诱导<6>骨髓抑制</6>。75例<17>HIV 感染</17>CD4+细胞计数<500/mm3>的患者随机接受<3>ZDV</3> (每天500毫克)单独治疗(第I组，n=38)或与<21>亚叶酸</21>(每天15毫克)和肌肉注射<11>维生素B12</11>(每月1000微克)联合使用（第 II 组，n=37)。最后，15名患者被排除在研究之外（不依从14名，<18>1名死亡</18>)；因此，60名患者（I组31名，II组29名）符合分析条件。入组时未发现组间有显着差异。在研究期间，II组患者的<12>维生素B12</12>和<23>叶酸</23>水平显着升高；然而，在第3、6、9和12个月时，各组之间的血红蛋白、血细胞比容、平均红细胞体积以及白细胞、中性粒细胞和血小板计数没有差异。分配到I组的4名患者和分配到II组的7名患者发生了严重的<16>血液学毒性</16>（中性粒细胞计数<1000/mm3>和/或血红蛋白<8g/dl>）。<13>维生素B12</13>或<24>叶酸</24>水平与<7>骨髓抑制</7>的发展之间没有相关性。<14>维生素B12</14>和<22>亚叶酸</22>补充<4>ZDV</4>疗法似乎对预防或减少<5>ZDV</5>-诱导的<8>骨髓毒性</8>没有用，在整个治疗人群中，尽管不能排除对某些亚组患者的有益作用。", "revised": true}
{"doc_key": "8669433", "sentences": [["Habitual", "use", "of", "acetaminophen", "as", "a", "risk", "factor", "for", "chronic", "renal", "failure", ":", "a", "comparison", "with", "phenacetin", ".", "Six", "epidemiologic", "studies", "in", "the", "United", "States", "and", "Europe", "indicate", "that", "habitual", "use", "of", "phenacetin", "is", "associated", "with", "the", "development", "of", "chronic", "renal", "failure", "and", "end", "-", "stage", "renal", "disease", "(", "ESRD", ")", ",", "with", "a", "relative", "risk", "in", "the", "range", "of", "4", "to", "19", ".", "As", "a", "result", "of", "these", "and", "other", "studies", ",", "phenacetin", "has", "now", "been", "withdrawn", "from", "the", "market", "in", "most", "countries", ".", "However", ",", "three", "case", "control", "studies", ",", "one", "each", "in", "North", "Carolina", ",", "northern", "Maryland", ",", "and", "West", "Berlin", ",", "Germany", ",", "showed", "that", "habitual", "use", "of", "acetaminophen", "is", "also", "associated", "with", "chronic", "renal", "failure", "and", "ESRD", ",", "with", "a", "relative", "risk", "in", "the", "range", "of", "2", "to", "4", ".", "These", "studies", "suggest", "that", "both", "phenacetin", "and", "acetaminophen", "may", "contribute", "to", "the", "burden", "of", "ESRD", ",", "with", "the", "risk", "of", "the", "latter", "being", "somewhat", "less", "than", "that", "of", "the", "former", ".", "This", "apparent", "difference", "in", "risk", "may", "not", "be", "due", "to", "differences", "in", "nephrotoxic", "potential", "of", "the", "drugs", "themselves", ".", "A", "lower", "relative", "risk", "would", "be", "expected", "for", "acetaminophen", "if", "the", "risk", "of", "both", "drugs", "in", "combination", "with", "other", "analgesics", "was", "higher", "than", "the", "risk", "of", "either", "agent", "alone", ".", "Thus", ",", "acetaminophen", "has", "been", "used", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "analgesics", ",", "whereas", "phenacetin", "was", "available", "only", "in", "combinations", ".", "The", "possibility", "that", "habitual", "use", "of", "acetaminophen", "alone", "increases", "the", "risk", "of", "ESRD", "has", "not", "been", "clearly", "demonstrated", ",", "but", "can", "not", "be", "dismissed", "."]], "ner": [[[16, 16, "Chemical"], [32, 32, "Chemical"], [73, 73, "Chemical"], [140, 140, "Chemical"], [234, 234, "Chemical"], [9, 11, "Disease"], [39, 41, "Disease"], [43, 47, "Disease"], [49, 49, "Disease"], [117, 119, "Disease"], [121, 121, "Disease"], [149, 149, "Disease"], [253, 253, "Disease"], [3, 3, "Chemical"], [112, 112, "Chemical"], [142, 142, "Chemical"], [193, 193, "Chemical"], [217, 217, "Chemical"], [247, 247, "Chemical"], [178, 178, "Disease"]]], "relations": [[[16, 16, 9, 11, "CID"], [16, 16, 39, 41, "CID"], [16, 16, 43, 47, "CID"], [16, 16, 49, 49, "CID"], [16, 16, 117, 119, "CID"], [16, 16, 121, 121, "CID"], [16, 16, 149, 149, "CID"], [16, 16, 253, 253, "CID"], [32, 32, 9, 11, "CID"], [32, 32, 39, 41, "CID"], [32, 32, 43, 47, "CID"], [32, 32, 49, 49, "CID"], [32, 32, 117, 119, "CID"], [32, 32, 121, 121, "CID"], [32, 32, 149, 149, "CID"], [32, 32, 253, 253, "CID"], [73, 73, 9, 11, "CID"], [73, 73, 39, 41, "CID"], [73, 73, 43, 47, "CID"], [73, 73, 49, 49, "CID"], [73, 73, 117, 119, "CID"], [73, 73, 121, 121, "CID"], [73, 73, 149, 149, "CID"], [73, 73, 253, 253, "CID"], [140, 140, 9, 11, "CID"], [140, 140, 39, 41, "CID"], [140, 140, 43, 47, "CID"], [140, 140, 49, 49, "CID"], [140, 140, 117, 119, "CID"], [140, 140, 121, 121, "CID"], [140, 140, 149, 149, "CID"], [140, 140, 253, 253, "CID"], [234, 234, 9, 11, "CID"], [234, 234, 39, 41, "CID"], [234, 234, 43, 47, "CID"], [234, 234, 49, 49, "CID"], [234, 234, 117, 119, "CID"], [234, 234, 121, 121, "CID"], [234, 234, 149, 149, "CID"], [234, 234, 253, 253, "CID"]]], "clusters": [], "translated": "习惯性使用<13>对乙酰氨基酚</13>作为<5>慢性肾功能衰竭</5>的危险因素：与<0>非那西汀</0>的比较。美国和欧洲的六项流行病学研究表明，习惯性使用<1>非那西丁</1>与<6>慢性肾功能衰竭</6>和<7>终末期肾病</7>（<8>ESRD</8>），相对风险在4到19之间。由于这些和其他研究，<2>非那西汀</2>现已从大多数国家/地区的市场撤出。然而，三项病例对照研究（北卡罗来纳州、北马里兰州和德国西柏林各一项）表明，习惯性使用<14>对乙酰氨基酚</14>也与<9>慢性肾功能衰竭</9>和<10>终末期肾病</10>（<10>ESRD</10>），相对风险范围为2至4。这些研究表明，<3>非那西汀</3>和<15>对乙酰氨基酚</15>都可能导致<11>终末期肾病</11>的负担，后者的风险略低于前者。这种明显的风险差异可能不是由于药物本身的<19>肾毒性</19>潜力差异所致。如果两种药物与其他镇痛药联合使用的风险高于单独使用任何一种药物的风险，则<16>对乙酰氨基酚</16>的相对风险预计较低。因此，<17>对乙酰氨基酚</17>既可作为单一药物使用，也可与其他镇痛药联合使用，而<4>非那西汀</4>只能以联合药物的形式使用。单独使用<18>对乙酰氨基酚</18>会增加<12>终末期肾病</12>的风险的可能性尚未得到明确证实，但不能排除。", "revised": true}
{"doc_key": "8752018", "sentences": [["Lithium", "-", "associated", "cognitive", "and", "functional", "deficits", "reduced", "by", "a", "switch", "to", "divalproex", "sodium", ":", "a", "case", "series", ".", "BACKGROUND", ":", "Lithium", "remains", "a", "first", "-", "line", "treatment", "for", "the", "acute", "and", "maintenance", "treatment", "of", "bipolar", "disorder", ".", "Although", "much", "has", "been", "written", "about", "the", "management", "of", "the", "more", "common", "adverse", "effects", "of", "lithium", ",", "such", "as", "polyuria", "and", "tremor", ",", "more", "subtle", "lithium", "side", "effects", "such", "as", "cognitive", "deficits", ",", "loss", "of", "creativity", ",", "and", "functional", "impairments", "remain", "understudied", ".", "This", "report", "summarizes", "our", "experience", "in", "switching", "bipolar", "patients", "from", "lithium", "to", "divalproex", "sodium", "to", "alleviate", "such", "cognitive", "and", "functional", "impairments", ".", "METHOD", ":", "Open", ",", "case", "series", "design", ".", "RESULTS", ":", "We", "report", "seven", "cases", "where", "substitution", "of", "lithium", ",", "either", "fully", "or", "partially", ",", "with", "divalproex", "sodium", "was", "extremely", "helpful", "in", "reducing", "the", "cognitive", ",", "motivational", ",", "or", "creative", "deficits", "attributed", "to", "lithium", "in", "our", "bipolar", "patients", ".", "CONCLUSION", ":", "In", "this", "preliminary", "report", ",", "divalproex", "sodium", "was", "a", "superior", "alternative", "to", "lithium", "in", "bipolar", "patients", "experiencing", "cognitive", "deficits", ",", "loss", "of", "creativity", ",", "and", "functional", "impairments", "."]], "ner": [[[0, 0, "Chemical"], [21, 21, "Chemical"], [53, 53, "Chemical"], [63, 63, "Chemical"], [91, 91, "Chemical"], [120, 120, "Chemical"], [145, 145, "Chemical"], [165, 165, "Chemical"], [3, 6, "Disease"], [68, 69, "Disease"], [71, 73, "Disease"], [76, 77, "Disease"], [98, 101, "Disease"], [136, 142, "Disease"], [170, 171, "Disease"], [173, 175, "Disease"], [178, 179, "Disease"], [35, 36, "Disease"], [88, 88, "Disease"], [148, 148, "Disease"], [167, 167, "Disease"], [57, 57, "Disease"], [59, 59, "Disease"], [12, 13, "Chemical"], [93, 94, "Chemical"], [128, 129, "Chemical"], [158, 159, "Chemical"]]], "relations": [[[0, 0, 3, 6, "CID"], [0, 0, 68, 69, "CID"], [0, 0, 71, 73, "CID"], [0, 0, 76, 77, "CID"], [0, 0, 98, 101, "CID"], [0, 0, 136, 142, "CID"], [0, 0, 170, 171, "CID"], [0, 0, 173, 175, "CID"], [0, 0, 178, 179, "CID"], [21, 21, 3, 6, "CID"], [21, 21, 68, 69, "CID"], [21, 21, 71, 73, "CID"], [21, 21, 76, 77, "CID"], [21, 21, 98, 101, "CID"], [21, 21, 136, 142, "CID"], [21, 21, 170, 171, "CID"], [21, 21, 173, 175, "CID"], [21, 21, 178, 179, "CID"], [53, 53, 3, 6, "CID"], [53, 53, 68, 69, "CID"], [53, 53, 71, 73, "CID"], [53, 53, 76, 77, "CID"], [53, 53, 98, 101, "CID"], [53, 53, 136, 142, "CID"], [53, 53, 170, 171, "CID"], [53, 53, 173, 175, "CID"], [53, 53, 178, 179, "CID"], [63, 63, 3, 6, "CID"], [63, 63, 68, 69, "CID"], [63, 63, 71, 73, "CID"], [63, 63, 76, 77, "CID"], [63, 63, 98, 101, "CID"], [63, 63, 136, 142, "CID"], [63, 63, 170, 171, "CID"], [63, 63, 173, 175, "CID"], [63, 63, 178, 179, "CID"], [91, 91, 3, 6, "CID"], [91, 91, 68, 69, "CID"], [91, 91, 71, 73, "CID"], [91, 91, 76, 77, "CID"], [91, 91, 98, 101, "CID"], [91, 91, 136, 142, "CID"], [91, 91, 170, 171, "CID"], [91, 91, 173, 175, "CID"], [91, 91, 178, 179, "CID"], [120, 120, 3, 6, "CID"], [120, 120, 68, 69, "CID"], [120, 120, 71, 73, "CID"], [120, 120, 76, 77, "CID"], [120, 120, 98, 101, "CID"], [120, 120, 136, 142, "CID"], [120, 120, 170, 171, "CID"], [120, 120, 173, 175, "CID"], [120, 120, 178, 179, "CID"], [145, 145, 3, 6, "CID"], [145, 145, 68, 69, "CID"], [145, 145, 71, 73, "CID"], [145, 145, 76, 77, "CID"], [145, 145, 98, 101, "CID"], [145, 145, 136, 142, "CID"], [145, 145, 170, 171, "CID"], [145, 145, 173, 175, "CID"], [145, 145, 178, 179, "CID"], [165, 165, 3, 6, "CID"], [165, 165, 68, 69, "CID"], [165, 165, 71, 73, "CID"], [165, 165, 76, 77, "CID"], [165, 165, 98, 101, "CID"], [165, 165, 136, 142, "CID"], [165, 165, 170, 171, "CID"], [165, 165, 173, 175, "CID"], [165, 165, 178, 179, "CID"]]], "clusters": [], "translated": " <0>锂</0>相关的<8>认知和功能缺陷</8>通过改用<23>双丙戊酸钠</23>而减少：病例系列。背景：<1>锂</1>仍然是<17>双相情感障碍</17>急性期和维持治疗的一线药物。虽然已经写了很多关于<2>锂</2>更常见不良反应的管理，例如<21>多尿</21>和<22>震颤</22>，但更微妙的<3>锂</3>副作用，例如<9>认知缺陷</9>，<10>创造力丧失</10>和<11>功能障碍</11>仍未得到充分研究。本报告总结了我们将<18>双相</18>患者从<4>锂</4>转换为<24>双丙戊酸钠</24>以减轻此类<12>认知和功能障碍</12>的经验。方法：打开，案例系列设计。结果：我们报告了7个案例，其中用<25>双丙戊酸钠</25>完全或部分替代 <5>锂</5>对减少归因于<6>锂</6>的<13>认知、动机或创造力缺陷</13>的<19>双极</19>患者非常有帮助。结论：在这份初步报告中，<26>双丙戊酸钠</26>是对<20>双相</20>患者经历的<14>认知缺陷</14>、<15>创造力丧失</15>和<16>功能障碍</16>的优于<7>锂</7>的替代品。", "revised": true}
{"doc_key": "6727060", "sentences": [["A", "case", "of", "tardive", "dyskinesia", "caused", "by", "metoclopramide", ".", "Abnormal", "involuntary", "movements", "appeared", "in", "the", "mouth", ",", "tongue", ",", "neck", "and", "abdomen", "of", "a", "64", "-", "year", "-", "old", "male", "patient", "after", "he", "took", "metoclopramide", "for", "gastrointestinal", "disorder", "in", "a", "regimen", "of", "30", "mg", "per", "day", "for", "a", "total", "of", "about", "260", "days", ".", "The", "symptoms", "exacerbated", "to", "a", "maximum", "in", "a", "month", ".", "When", "the", "metoclopramide", "administration", "was", "discontinued", ",", "the", "abnormal", "movements", "gradually", "improved", "to", "a", "considerable", "extent", ".", "Attention", "to", "the", "possible", "induction", "of", "specific", "tardive", "dyskinesia", "is", "called", "for", "in", "the", "use", "of", "this", "drug", "."]], "ner": [[[7, 7, "Chemical"], [34, 34, "Chemical"], [66, 66, "Chemical"], [3, 4, "Disease"], [9, 11, "Disease"], [72, 73, "Disease"], [88, 89, "Disease"], [36, 37, "Disease"]]], "relations": [[[7, 7, 3, 4, "CID"], [7, 7, 9, 11, "CID"], [7, 7, 72, 73, "CID"], [7, 7, 88, 89, "CID"], [34, 34, 3, 4, "CID"], [34, 34, 9, 11, "CID"], [34, 34, 72, 73, "CID"], [34, 34, 88, 89, "CID"], [66, 66, 3, 4, "CID"], [66, 66, 9, 11, "CID"], [66, 66, 72, 73, "CID"], [66, 66, 88, 89, "CID"]]], "clusters": [], "translated": "<0>甲氧氯普胺</0>致<3>迟发性运动障碍</3>一例。64岁男性患者因<7>胃肠功能紊乱</7>服用每天30毫克，总共服用260天的<1>甲氧氯普胺</1>后出现口、舌、颈、腹部<4>异常的不自主运动</4>。症状在一个月内加重到最大。停用<2>甲氧氯普胺</2>后<5>异常动作</5>逐渐得到相当程度的改善。应注意该药可能诱发特异性<6>迟发性运动障碍</6>。", "revised": true}
{"doc_key": "9698967", "sentences": [["An", "unusual", "toxic", "reaction", "to", "axillary", "block", "by", "mepivacaine", "with", "adrenaline", ".", "An", "increase", "in", "blood", "pressure", ",", "accompanied", "by", "atrial", "fibrillation", ",", "agitation", ",", "incomprehensible", "shouts", "and", "loss", "of", "consciousness", ",", "was", "observed", "in", "an", "elderly", ",", "ASA", "classification", "group", "II", ",", "cardiovascularly", "medicated", "male", ",", "12", "min", "after", "performance", "of", "axillary", "block", "with", "mepivacaine", "850", "mg", "containing", "adrenaline", "0", ".", "225", "mg", ",", "for", "correction", "of", "Dupuytren", "'s", "contracture", ".", "After", "intravenous", "administration", "of", "labetalol", ",", "metoprolol", "and", "midazolam", "the", "patient", "'s", "condition", "improved", ",", "and", "15", "min", "later", "he", "woke", "up", ".", "The", "block", "was", "successful", "and", "surgery", "was", "conducted", "as", "scheduled", "despite", "persisting", "atrial", "fibrillation", ".", "Postoperatively", ",", "the", "patient", "refused", "DC", "cardioversion", "and", "was", "treated", "medically", ".", "Both", "the", "temporal", "relationship", "of", "events", "and", "the", "response", "to", "treatment", "suggest", "that", "a", "rapid", "systemic", "absorption", "of", "mepivacaine", "with", "adrenaline", "and", "/", "or", "interaction", "of", "these", "drugs", "with", "the", "patient", "'s", "cardiovascular", "medications", "were", "responsible", "for", "the", "perioperative", "complications", "."]], "ner": [[[8, 8, "Chemical"], [55, 55, "Chemical"], [140, 140, "Chemical"], [13, 16, "Disease"], [20, 21, "Disease"], [107, 108, "Disease"], [10, 10, "Chemical"], [59, 59, "Chemical"], [142, 142, "Chemical"], [23, 23, "Disease"], [25, 26, "Disease"], [28, 30, "Disease"], [68, 70, "Disease"], [76, 76, "Chemical"], [78, 78, "Chemical"], [80, 80, "Chemical"]]], "relations": [[[8, 8, 13, 16, "CID"], [55, 55, 13, 16, "CID"], [140, 140, 13, 16, "CID"], [8, 8, 20, 21, "CID"], [8, 8, 107, 108, "CID"], [55, 55, 20, 21, "CID"], [55, 55, 107, 108, "CID"], [140, 140, 20, 21, "CID"], [140, 140, 107, 108, "CID"], [10, 10, 13, 16, "CID"], [59, 59, 13, 16, "CID"], [142, 142, 13, 16, "CID"], [10, 10, 20, 21, "CID"], [10, 10, 107, 108, "CID"], [59, 59, 20, 21, "CID"], [59, 59, 107, 108, "CID"], [142, 142, 20, 21, "CID"], [142, 142, 107, 108, "CID"]]], "clusters": [], "translated": "<0>甲哌卡因</0>和<6>肾上腺素</6>对腋窝阻滞的异常毒性反应。<3>血压升高</3>，伴有<4>心房颤动</4>，<9>激动</9>，<10>难以理解的叫喊</10>和<11>意识丧失</11>，在老年、ASA 分类组 II、心血管药物治疗男性中观察到，在用<1>甲哌卡因</1> 850 mg 含<7>肾上腺素</7> 0.225 mg，用于矫正<12>Dupuytren挛缩</12>的腋窝阻滞后12分钟。静脉给予<13>拉贝洛尔</13>、<14>美托洛尔</14>和<15>咪达唑仑</15>后，患者病情好转，15分钟后苏醒。尽管<5>心房颤动持续存在</5>，阻滞还是成功的，手术也如期进行。术后，患者拒绝直流电复律，接受药物治疗。事件的时间关系和对治疗的反应表明，<2>甲哌卡因</2>和<8>肾上腺素</8>的快速全身吸收和/或这些药物与患者心血管药物的相互作用是负责围手术期的并发症。", "revised": true}
{"doc_key": "10739826", "sentences": [["Recurrent", "use", "of", "newer", "oral", "contraceptives", "and", "the", "risk", "of", "venous", "thromboembolism", ".", "The", "epidemiological", "studies", "that", "assessed", "the", "risk", "of", "venous", "thromboembolism", "(", "VTE", ")", "associated", "with", "newer", "oral", "contraceptives", "(", "OC", ")", "did", "not", "distinguish", "between", "patterns", "of", "OC", "use", ",", "namely", "first", "-", "time", "users", ",", "repeaters", "and", "switchers", ".", "Data", "from", "a", "Transnational", "case", "-", "control", "study", "were", "used", "to", "assess", "the", "risk", "of", "VTE", "for", "the", "latter", "patterns", "of", "use", ",", "while", "accounting", "for", "duration", "of", "use", ".", "Over", "the", "period", "1993", "-", "1996", ",", "551", "cases", "of", "VTE", "were", "identified", "in", "Germany", "and", "the", "UK", "along", "with", "2066", "controls", ".", "Totals", "of", "128", "cases", "and", "650", "controls", "were", "analysed", "for", "repeat", "use", "and", "135", "cases", "and", "622", "controls", "for", "switching", "patterns", ".", "The", "adjusted", "rate", "ratio", "of", "VTE", "for", "repeat", "users", "of", "third", "generation", "OC", "was", "0", ".", "6", "(", "95", "%", "CI", ":", "0", ".", "3", "-", "1", ".", "2", ")", "relative", "to", "repeat", "users", "of", "second", "generation", "pills", ",", "whereas", "it", "was", "1", ".", "3", "(", "95", "%", "CI", ":", "0", ".", "7", "-", "2", ".", "4", ")", "for", "switchers", "from", "second", "to", "third", "generation", "pills", "relative", "to", "switchers", "from", "third", "to", "second", "generation", "pills", ".", "We", "conclude", "that", "second", "and", "third", "generation", "agents", "are", "associated", "with", "equivalent", "risks", "of", "VTE", "when", "the", "same", "agent", "is", "used", "repeatedly", "after", "interruption", "periods", "or", "when", "users", "are", "switched", "between", "the", "two", "generations", "of", "pills", ".", "These", "analyses", "suggest", "that", "the", "higher", "risk", "observed", "for", "the", "newer", "OC", "in", "other", "studies", "may", "be", "the", "result", "of", "inadequate", "comparisons", "of", "pill", "users", "with", "different", "patterns", "of", "pill", "use", "."]], "ner": [[[4, 5, "Chemical"], [29, 30, "Chemical"], [32, 32, "Chemical"], [40, 40, "Chemical"], [140, 140, "Chemical"], [252, 252, "Chemical"], [10, 11, "Disease"], [21, 22, "Disease"], [24, 24, "Disease"], [68, 68, "Disease"], [93, 93, "Disease"], [133, 133, "Disease"], [218, 218, "Disease"]]], "relations": [[[4, 5, 10, 11, "CID"], [4, 5, 21, 22, "CID"], [4, 5, 24, 24, "CID"], [4, 5, 68, 68, "CID"], [4, 5, 93, 93, "CID"], [4, 5, 133, 133, "CID"], [4, 5, 218, 218, "CID"], [29, 30, 10, 11, "CID"], [29, 30, 21, 22, "CID"], [29, 30, 24, 24, "CID"], [29, 30, 68, 68, "CID"], [29, 30, 93, 93, "CID"], [29, 30, 133, 133, "CID"], [29, 30, 218, 218, "CID"], [32, 32, 10, 11, "CID"], [32, 32, 21, 22, "CID"], [32, 32, 24, 24, "CID"], [32, 32, 68, 68, "CID"], [32, 32, 93, 93, "CID"], [32, 32, 133, 133, "CID"], [32, 32, 218, 218, "CID"], [40, 40, 10, 11, "CID"], [40, 40, 21, 22, "CID"], [40, 40, 24, 24, "CID"], [40, 40, 68, 68, "CID"], [40, 40, 93, 93, "CID"], [40, 40, 133, 133, "CID"], [40, 40, 218, 218, "CID"], [140, 140, 10, 11, "CID"], [140, 140, 21, 22, "CID"], [140, 140, 24, 24, "CID"], [140, 140, 68, 68, "CID"], [140, 140, 93, 93, "CID"], [140, 140, 133, 133, "CID"], [140, 140, 218, 218, "CID"], [252, 252, 10, 11, "CID"], [252, 252, 21, 22, "CID"], [252, 252, 24, 24, "CID"], [252, 252, 68, 68, "CID"], [252, 252, 93, 93, "CID"], [252, 252, 133, 133, "CID"], [252, 252, 218, 218, "CID"]]], "clusters": [], "translated": "反复使用较新的<0>口服避孕药</0>和<6>静脉血栓栓塞</6>的风险。评估<7>静脉血栓栓塞症</7> (<8>VTE</8>)与较新的<1>口服避孕药</1> (<2>OC</2>) 相关风险的流行病学研究表明不区分<3>OC</3>使用模式，即初次使用者、中继者和切换者。来自跨国病例对照研究的数据用于评估后一种使用模式的<9>VTE</9>风险，同时考虑使用持续时间。在 1993 年至 1996 年期间，德国和英国确定了551例<10>VTE</10>病例以及2066例对照病例。总共分析了128个重复使用的病例和650个对照的病例，以及135个转换模式的病例和622个对照病例。第三代<4>OC</4>重复用户<11>VTE</11>调整后的比率为0.6 (95% CI: 0.3-1.2) 相对于第二代药丸的重复使用者，而它是1.3 (95% CI: 0.7-2.4) 对于从第二代到第三代药丸的转换者相对于从第三代到第二代药丸的转换者。我们得出结论，当在中断期后重复使用同一种药物或当用户在两代药物之间切换时，第二代和第三代药物与<12>VTE</12>的等效风险相关。这些分析表明，在其他研究中观察到较新的<5>OC</5>的风险较高，这可能是由于对具有不同药丸使用模式的药丸使用者进行了不充分的比较。", "revised": true}
{"doc_key": "9587734", "sentences": [["Suxamethonium", "-", "induced", "cardiac", "arrest", "and", "death", "following", "5", "days", "of", "immobilization", ".", "The", "present", "report", "describes", "a", "case", "of", "cardiac", "arrest", "and", "subsequent", "death", "as", "a", "result", "of", "hyperkalaemia", "following", "the", "use", "of", "suxamethonium", "in", "a", "23", "-", "year", "-", "old", "Malawian", "woman", ".", "Five", "days", "after", "the", "onset", "of", "the", "symptoms", "of", "meningitis", ",", "the", "patient", "aspirated", "stomach", "contents", "and", "needed", "endotracheal", "intubation", ".", "Forty", "seconds", "after", "injection", "of", "suxamethonium", ",", "bradycardia", "and", "cardiac", "arrest", "occurred", ".", "Attempts", "to", "resuscitate", "the", "patient", "were", "not", "successful", ".", "The", "serum", "level", "of", "potassium", "was", "observed", "to", "be", "8", ".", "4", "mequiv", "L", "-", "1", ".", "Apart", "from", "the", "reduction", "in", "the", "patient", "'s", "level", "of", "consciousness", ",", "there", "were", "no", "signs", "of", "motor", "neurone", "damage", "or", "of", "any", "of", "the", "other", "known", "predisposing", "conditions", "for", "hyperkalaemia", "following", "the", "administration", "of", "suxamethonium", ".", "It", "is", "postulated", "that", "her", "death", "was", "caused", "by", "hypersensitivity", "to", "suxamethonium", ",", "associated", "with", "her", "5", "-", "day", "immobilization", "."]], "ner": [[[0, 0, "Chemical"], [34, 34, "Chemical"], [71, 71, "Chemical"], [140, 140, "Chemical"], [153, 153, "Chemical"], [3, 4, "Disease"], [20, 21, "Disease"], [75, 76, "Disease"], [29, 29, "Disease"], [135, 135, "Disease"], [73, 73, "Disease"], [151, 151, "Disease"], [6, 6, "Disease"], [24, 24, "Disease"], [147, 147, "Disease"], [54, 54, "Disease"], [92, 92, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 20, 21, "CID"], [0, 0, 75, 76, "CID"], [34, 34, 3, 4, "CID"], [34, 34, 20, 21, "CID"], [34, 34, 75, 76, "CID"], [71, 71, 3, 4, "CID"], [71, 71, 20, 21, "CID"], [71, 71, 75, 76, "CID"], [140, 140, 3, 4, "CID"], [140, 140, 20, 21, "CID"], [140, 140, 75, 76, "CID"], [153, 153, 3, 4, "CID"], [153, 153, 20, 21, "CID"], [153, 153, 75, 76, "CID"], [0, 0, 29, 29, "CID"], [0, 0, 135, 135, "CID"], [34, 34, 29, 29, "CID"], [34, 34, 135, 135, "CID"], [71, 71, 29, 29, "CID"], [71, 71, 135, 135, "CID"], [140, 140, 29, 29, "CID"], [140, 140, 135, 135, "CID"], [153, 153, 29, 29, "CID"], [153, 153, 135, 135, "CID"], [0, 0, 73, 73, "CID"], [34, 34, 73, 73, "CID"], [71, 71, 73, 73, "CID"], [140, 140, 73, 73, "CID"], [153, 153, 73, 73, "CID"], [0, 0, 151, 151, "CID"], [34, 34, 151, 151, "CID"], [71, 71, 151, 151, "CID"], [140, 140, 151, 151, "CID"], [153, 153, 151, 151, "CID"]]], "clusters": [], "translated": "固定5天后，<0>琥珀胆碱</0>诱发<5>心脏骤停</5>和<12>死亡</12>。本报告描述了一例23岁的马拉维女子，使用<1>琥珀胆碱</1>后因<8>高钾血症</8>导致<6>心脏骤停</6>和随后的<13>死亡</13>。在出现<15>脑膜炎</15>症状5天后，患者误吸胃内容物，需要气管插管。在注射<2>琥珀胆碱</2>40秒后，发生<10>心动过缓</10>和<7>心脏骤停</7>。尝试使病人复苏没有成功。观察到血清<16>钾</16>水平为8.4 mequiv/L-1。除了患者意识水平的降低，在使用<3>琥珀胆碱</3>后，没有出现运动神经元损伤或任何其他已知诱发<9>高钾血症</9>条件的迹象。据推测，她的<14>死亡</14>是由于她在5天内制动所引起的对<4>琥珀胆碱</4>的<11>过敏</11>。", "revised": true}
{"doc_key": "8739323", "sentences": [["Effect", "of", "some", "anticancer", "drugs", "and", "combined", "chemotherapy", "on", "renal", "toxicity", ".", "The", "nephrotoxic", "action", "of", "anticancer", "drugs", "such", "as", "nitrogranulogen", "(", "NG", ")", ",", "methotrexate", "(", "MTX", ")", ",", "5", "-", "fluorouracil", "(", "5", "-", "FU", ")", "and", "cyclophosphamide", "(", "CY", ")", "administered", "alone", "or", "in", "combination", "[", "MTX", "+", "5", "-", "FU", "+", "CY", "(", "CMF", ")", "]", "was", "evaluated", "in", "experiments", "on", "Wistar", "rats", ".", "After", "drug", "administration", ",", "creatinine", "concentrations", "in", "the", "plasma", "and", "in", "the", "urine", "of", "the", "rats", "were", "determined", ",", "as", "well", "as", "creatinine", "clearance", ".", "Histopathologic", "evaluation", "of", "the", "kidneys", "was", "also", "performed", ".", "After", "MTX", "administration", "a", "significant", "increase", "(", "p", "=", "0", ".", "0228", ")", "in", "the", "plasma", "creatinine", "concentration", "and", "a", "significant", "(", "p", "=", "0", ".", "0001", ")", "decrease", "in", "creatinine", "clearance", "was", "noted", "compared", "to", "controls", ".", "After", "the", "administration", "of", "NG", ",", "5", "-", "FU", "and", "CY", "neither", "a", "statistically", "significant", "increase", "in", "creatinine", "concentration", "nor", "an", "increase", "in", "creatinine", "clearance", "was", "observed", "compared", "to", "the", "group", "receiving", "no", "cytostatics", ".", "Following", "polytherapy", "according", "to", "the", "CMF", "regimen", ",", "a", "statistically", "significant", "decrease", "(", "p", "=", "0", ".", "0343", ")", "in", "creatinine", "clearance", "was", "found", ",", "but", "creatinine", "concentration", "did", "not", "increase", "significantly", "compared", "to", "controls", ".", "CY", "caused", "hemorrhagic", "cystitis", "in", "40", "%", "of", "rats", ",", "but", "it", "did", "not", "cause", "this", "complication", "when", "combined", "with", "5", "-", "FU", "and", "MTX", ".", "Histologic", "changes", "were", "found", "in", "rat", "kidneys", "after", "administration", "of", "MTX", ",", "CY", "and", "NG", ",", "while", "no", "such", "change", "was", "observed", "after", "5", "-", "FU", "and", "joint", "administration", "of", "MTX", "+", "5", "-", "FU", "+", "CY", "compared", "to", "controls", ".", "Our", "studies", "indicate", "that", "nephrotoxicity", "of", "MTX", "+", "5", "-", "FU", "+", "CY", "administered", "jointly", "is", "lower", "than", "in", "monotherapy", "."]], "ner": [[[39, 39, "Chemical"], [41, 41, "Chemical"], [55, 55, "Chemical"], [150, 150, "Chemical"], [211, 211, "Chemical"], [249, 249, "Chemical"], [273, 273, "Chemical"], [290, 290, "Chemical"], [213, 214, "Disease"], [20, 20, "Chemical"], [22, 22, "Chemical"], [144, 144, "Chemical"], [251, 251, "Chemical"], [9, 10, "Disease"], [13, 13, "Disease"], [282, 282, "Disease"], [25, 25, "Chemical"], [27, 27, "Chemical"], [49, 49, "Chemical"], [103, 103, "Chemical"], [235, 235, "Chemical"], [247, 247, "Chemical"], [267, 267, "Chemical"], [284, 284, "Chemical"], [30, 32, "Chemical"], [34, 36, "Chemical"], [51, 53, "Chemical"], [146, 148, "Chemical"], [231, 233, "Chemical"], [260, 262, "Chemical"], [269, 271, "Chemical"], [286, 288, "Chemical"], [72, 72, "Chemical"], [90, 90, "Chemical"], [118, 118, "Chemical"], [132, 132, "Chemical"], [157, 157, "Chemical"], [163, 163, "Chemical"], [195, 195, "Chemical"], [201, 201, "Chemical"]]], "relations": [[[39, 39, 213, 214, "CID"], [41, 41, 213, 214, "CID"], [55, 55, 213, 214, "CID"], [150, 150, 213, 214, "CID"], [211, 211, 213, 214, "CID"], [249, 249, 213, 214, "CID"], [273, 273, 213, 214, "CID"], [290, 290, 213, 214, "CID"]]], "clusters": [], "translated": "部分抗癌药物与联合化疗对<13>肾毒性</13>的影响。<9>硝基颗粒剂</9>（<10>NG</10>）、<16>甲氨蝶呤</16>（<17>MTX</17>）等抗癌药物的<14>肾毒性</14>作用，<24>5-氟尿嘧啶</24>（<25>5-FU</25>）和<0> 环磷酰胺</0>（<1>CY</1>）单独或联合给药[<18>MTX</18>+<26>5-FU</26>+<2>CY</2> (CMF)]在 Wistar 大鼠实验中进行了评价。给药后，测定大鼠血浆和尿液中的<32>肌酐 </32>浓度，以及<33>肌酐</33>清除率。还对肾脏进行了组织病理学评估。<19>MTX</19> 给药后，血浆<34>肌酐</34>浓度显着增加（p = 0.0228），<35>肌酐</35>清除率显着降低（p = 0.0001）与对照相比。 <11>NG</11>、<27>5-FU</27>和<3>CY</3>给药后，<36>肌酐</36>浓度既没有统计学显着增加，也没有增加与未接受细胞抑制剂的组相比，观察到<37>肌酐</37>清除率。根据CMF方案进行综合治疗后，<38>肌酐</38>清除率显着降低（p = 0.0343），但与对照组相比，<39>肌酐</39>浓度没有显着增加。<4>CY</4>引起40%大鼠<8>出血性膀胱炎</8>，但与<28>5-FU</28>和<20>MTX</20>联用不引起此并发症。 <21>MTX</21>、<5>CY</5>和<12>NG</12>大鼠肾脏组织学改变，<29>5-FU</29>无组织学改变，<22>MTX</22>+<30>5-FU</30>+<6>CY</6>联合给药与对照组相比。我们的研究表明，<23>MTX</23>+<31>5-FU</31>+<7>CY</7>联合用药的<15>肾毒性</15>低于单药治疗。", "revised": true}
{"doc_key": "9869257", "sentences": [["Memory", "facilitation", "and", "stimulation", "of", "endogenous", "nerve", "growth", "factor", "synthesis", "by", "the", "acetylcholine", "releaser", "PG", "-", "9", ".", "The", "effects", "of", "PG", "-", "9", "(", "3alpha", "-", "tropyl", "2", "-", "(", "p", "-", "bromophenyl", ")", "propionate", ")", ",", "the", "acetylcholine", "releaser", ",", "on", "memory", "processes", "and", "nerve", "growth", "factor", "(", "NGF", ")", "synthesis", "were", "evaluated", ".", "In", "the", "mouse", "passive", "-", "avoidance", "test", ",", "PG", "-", "9", "(", "10", "-", "30", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", ",", "administered", "20", "min", "before", "the", "training", "session", ",", "prevented", "amnesia", "induced", "by", "both", "the", "non", "selective", "antimuscarinic", "drug", "scopolamine", "and", "the", "M1", "-", "selective", "antagonist", "S", "-", "(", "-", ")", "-", "ET", "-", "126", ".", "In", "the", "same", "experimental", "conditions", ",", "PG", "-", "9", "(", "5", "-", "20", "microg", "per", "mouse", ",", "i", ".", "c", ".", "v", ".", ")", "was", "also", "able", "to", "prevent", "antimuscarine", "-", "induced", "amnesia", ",", "demonstrating", "a", "central", "localization", "of", "the", "activity", ".", "At", "the", "highest", "effective", "doses", ",", "PG", "-", "9", "did", "not", "produce", "any", "collateral", "symptoms", "as", "revealed", "by", "the", "Irwin", "test", ",", "and", "it", "did", "not", "modify", "spontaneous", "motility", "and", "inspection", "activity", ",", "as", "revealed", "by", "the", "hole", "-", "board", "test", ".", "PG", "-", "9", "was", "also", "able", "to", "increase", "the", "amount", "of", "NGF", "secreted", "in", "vitro", "by", "astrocytes", "in", "a", "dose", "-", "dependent", "manner", ".", "The", "maximal", "NGF", "contents", "obtained", "by", "PG", "-", "9", "were", "17", ".", "6", "-", "fold", "of", "the", "control", "value", ".", "During", "culture", ",", "no", "morphological", "changes", "were", "found", "at", "effective", "concentrations", "of", "PG", "-", "9", ".", "The", "current", "work", "indicates", "the", "ability", "of", "PG", "-", "9", "to", "induce", "beneficial", "effects", "on", "cognitive", "processes", "and", "stimulate", "activity", "of", "NGF", "synthesis", "in", "astroglial", "cells", ".", "Therefore", ",", "PG", "-", "9", "could", "represent", "a", "potential", "useful", "drug", "able", "to", "improve", "the", "function", "of", "impaired", "cognitive", "processes", "."]], "ner": [[[99, 99, "Chemical"], [90, 90, "Disease"], [148, 148, "Disease"], [106, 114, "Chemical"], [12, 12, "Chemical"], [39, 39, "Chemical"], [14, 16, "Chemical"], [21, 23, "Chemical"], [25, 35, "Chemical"], [64, 66, "Chemical"], [122, 124, "Chemical"], [164, 166, "Chemical"], [200, 202, "Chemical"], [230, 232, "Chemical"], [256, 258, "Chemical"], [267, 269, "Chemical"], [289, 291, "Chemical"]]], "relations": [[[99, 99, 90, 90, "CID"], [99, 99, 148, 148, "CID"], [106, 114, 90, 90, "CID"], [106, 114, 148, 148, "CID"]]], "clusters": [], "translated": " <4>乙酰胆碱</4>释放剂<6>PG-9</6>对内源性神经生长因子合成的记忆促进和刺激作用。<7><6>PG - 9</6></7> (<8>3alpha - tropyl 2 - (p - bromophenyl) propionate</8>)，<5>乙酰胆碱</5>释放剂，对记忆过程和神经生长因子 (NGF) 的合成进行了评估。在小鼠被动回避试验中，<9>PG - 9</9> (10-30 mg/kg，i.p.)，在训练前 20 分钟给药，可预防<1>健忘症</1>引起的由非选择性抗毒蕈碱药物<0>东莨菪碱</0>和 M1-选择性拮抗剂<3>S-(-)-ET-126</3> 共同作用。在相同的实验条件下，<10>PG - 9</10> (每只小鼠 5-20 微克，i.c.v.) 也能够预防抗毒蕈碱引起的<2>健忘症</2>，证明活性的中央定位。在最高有效剂量下，<11>PG - 9</11> 没有产生欧文试验所揭示的任何附带症状，并且它没有改变自发运动和检查活动，如孔板试验所揭示的那样。<12>PG-9</12>还能够以剂量依赖的方式增加星形胶质细胞体外分泌的 NGF 的量。<13>PG-9</13> 得到的最大 NGF 含量为 17。对照值的 6 倍。培养过程中，在有效浓度下未观察到<14>PG-9</14>形态学的变化。目前的工作表明<15>PG-9</15> 能够对认知过程产生有益影响并刺激星形胶质细胞中 NGF 合成的活性。因此，<16>PG-9</16> 可能是一种潜在的有用药物，能够改善受损认知过程的功能。", "revised": true}
{"doc_key": "10457883", "sentences": [["Recurarization", "in", "the", "recovery", "room", ".", "A", "case", "of", "recurarization", "in", "the", "recovery", "room", "is", "reported", ".", "Accumulation", "of", "atracurium", "in", "the", "intravenous", "line", "led", "to", "recurarization", "after", "flushing", "the", "line", "in", "the", "recovery", "room", ".", "A", "respiratory", "arrest", "with", "severe", "desaturation", "and", "bradycardia", "occurred", ".", "Circumstances", "leading", "to", "this", "event", "and", "the", "mechanisms", "enabling", "a", "neuromuscular", "blockade", "to", "occur", ",", "following", "the", "administration", "of", "a", "small", "dose", "of", "relaxant", ",", "are", "discussed", "."]], "ner": [[[19, 19, "Chemical"], [37, 38, "Disease"], [41, 41, "Disease"], [43, 43, "Disease"], [56, 57, "Disease"]]], "relations": [[[19, 19, 37, 38, "CID"], [19, 19, 41, 41, "CID"], [19, 19, 43, 43, "CID"]]], "clusters": [], "translated": "在回收室进行再次肌肉松弛。报告了一例在回收室发生的再次肌肉松弛。静脉输液管路中的<0>阿曲库铵</0>积累，在回收室冲洗管路后导致肌肉再次松弛。出现了<1>呼吸骤停</1>，伴有严重的<2>氧饱和度降低</2>和<3>心动过缓</3>。讨论了导致该事件的情况以及在小剂量松弛剂注射后，能够发生<4>神经肌肉阻滞</4>的机制。", "revised": true}
{"doc_key": "9390208", "sentences": [["Treatment", "of", "previously", "treated", "metastatic", "breast", "cancer", "by", "mitoxantrone", "and", "48", "-", "hour", "continuous", "infusion", "of", "high", "-", "dose", "5", "-", "FU", "and", "leucovorin", "(", "MFL", ")", ":", "low", "palliative", "benefit", "and", "high", "treatment", "-", "related", "toxicity", ".", "For", "previously", "treated", "advanced", "breast", "cancer", ",", "there", "is", "no", "standard", "second", "-", "line", "therapy", ".", "Combination", "chemotherapy", "with", "mitoxantrone", ",", "high", "-", "dose", "5", "-", "fluorouracil", "(", "5", "-", "FU", ")", "and", "leucovorin", "(", "MFL", "regimen", ")", "had", "been", "reported", "as", "an", "effective", "and", "well", "tolerated", "regimen", ".", "From", "October", "1993", "to", "November", "1995", ",", "we", "treated", "13", "patients", "with", "previously", "chemotherapy", "-", "treated", "metastatic", "breast", "cancer", "by", "mitoxantrone", ",", "12", "mg", "/", "m2", ",", "on", "day", "1", "and", "continuous", "infusion", "of", "5", "-", "FU", ",", "3000", "mg", "/", "m2", ",", "together", "with", "leucovorin", ",", "300", "mg", "/", "m2", ",", "for", "48", "h", "from", "day", "1", "to", "2", ".", "Each", "course", "of", "chemotherapy", "was", "given", "every", "4", "weeks", ".", "Most", "of", "these", "patients", "had", "more", "than", "two", "metastatic", "sites", ",", "with", "lung", "metastasis", "predominant", ".", "Seven", "patients", "had", "been", "treated", "with", "anthracycline", ".", "Seven", "patients", "had", "previously", "received", "radiotherapy", "and", "seven", "had", "received", "hormone", "therapy", ".", "Median", "number", "of", "courses", "of", "MFL", "regimen", "given", "was", "six", "and", "the", "median", "cumulative", "dose", "of", "mitoxantrone", "was", "68", ".", "35", "mg", "/", "m2", ".", "One", "patient", "had", "complete", "response", ",", "seven", "had", "stable", "disease", ",", "none", "had", "partial", "response", "and", "five", "had", "progressive", "disease", ".", "The", "overall", "objective", "response", "rate", "was", "7", ".", "6", "%", ".", "The", "median", "follow", "-", "up", "period", "was", "14", "months", ".", "Median", "survival", "was", "16", "months", ".", "Median", "progression", "-", "free", "survival", "was", "5", "months", ".", "A", "complete", "responder", "had", "relapse", "-", "free", "survival", "up", "to", "17", "months", ".", "Major", "toxicities", "were", "cardiotoxicity", "and", "leukopenia", ".", "Eight", "patients", "were", "dead", "in", "the", "last", "follow", "-", "up", ";", "two", "of", "them", "died", "of", "treatment", "-", "related", "toxicity", ".", "The", "MFL", "regimen", "achieves", "little", "palliative", "benefit", "and", "induces", "severe", "toxicity", "at", "a", "fairly", "high", "rate", ".", "Administration", "of", "this", "regimen", "to", "breast", "cancer", "patients", "who", "have", "been", "treated", "by", "chemotherapy", "and", "those", "with", "impaired", "heart", "function", "requires", "careful", "attention", "."]], "ner": [[[25, 25, "Chemical"], [73, 74, "Chemical"], [200, 201, "Chemical"], [319, 320, "Chemical"], [295, 295, "Disease"], [352, 354, "Disease"], [8, 8, "Chemical"], [57, 57, "Chemical"], [107, 107, "Chemical"], [211, 211, "Chemical"], [5, 6, "Disease"], [42, 43, "Disease"], [104, 105, "Disease"], [340, 341, "Disease"], [19, 21, "Chemical"], [62, 64, "Chemical"], [66, 68, "Chemical"], [121, 123, "Chemical"], [23, 23, "Chemical"], [71, 71, "Chemical"], [132, 132, "Chemical"], [180, 180, "Chemical"], [36, 36, "Disease"], [291, 291, "Disease"], [316, 316, "Disease"], [328, 328, "Disease"], [293, 293, "Disease"]]], "relations": [[[25, 25, 295, 295, "CID"], [73, 74, 295, 295, "CID"], [200, 201, 295, 295, "CID"], [319, 320, 295, 295, "CID"], [25, 25, 352, 354, "CID"], [73, 74, 352, 354, "CID"], [200, 201, 352, 354, "CID"], [319, 320, 352, 354, "CID"]]], "clusters": [], "translated": "<6>米托蒽醌</6>和高剂量<14>5-FU</14>和<18>亚叶酸</18>（<0>MFL</0>）连续输注48小时治疗既往治疗过的转移性<10>乳腺癌</10>：低姑息性益处和高治疗相关<22>毒性</22>。对于既往接受过治疗的晚期<11>乳腺癌</11>，没有标准的二线治疗。与<7>米托蒽醌</7>、高剂量<15>5-氟尿嘧啶</15>（<16>5-FU</16>）和<19>亚叶酸</19>（<1>MFL 方案</1>）已被报道为一种有效且耐受性良好的方案。从 1993 年 10 月到 1995 年 11 月，我们使用<8>米托蒽醌</8>治疗了 13 名既往接受过化疗的转移性<12>乳腺癌</12>患者，第1天 12 mg/m2 并持续输注<17>5-FU</17>，3000 mg/m2，与<20>亚叶酸</20>，300 mg/m2，第 1 天至第 2 天 48 小时。每个疗程的化疗每 4 周进行一次。大多数这些患者有两个以上的转移部位，肺转移占主导地位。7 例患者接受过<21>蒽环类药物</21>治疗。七名患者之前接受过放疗，七名患者接受过激素治疗。<2>MFL 方案</2>的中位疗程数为 6，<9>米托蒽醌</9>的中位累积剂量为 68.35 毫克/平方米。1 名患者完全缓解，7 名患者疾病稳定，没有患者部分缓解，5 名患者疾病进展。总体客观缓解率为 7.6%。中位随访期为 14 个月。中位生存期为 16 个月。中位无进展生存期为 5 个月。完全缓解者的无复发生存期可达 17 个月。主要<23>毒性</23>是<4>白细胞减少</4>和<26>心脏毒性</26>。末次随访时死亡 8 例；其中两人死于治疗相关的<24>毒性</24>。<3>MFL方案</3>几乎没有缓解作用，并以相当高的比率诱发严重的<25>毒性</25>。对<13>乳腺癌</13>接受过化疗的患者和<5>心功能受损</5>的患者使用该方案需要特别注意。", "revised": true}
{"doc_key": "10791295", "sentences": [["Development", "of", "apomorphine", "-", "induced", "aggressive", "behavior", ":", "comparison", "of", "adult", "male", "and", "female", "Wistar", "rats", ".", "The", "development", "of", "apomorphine", "-", "induced", "(", "1", ".", "0", "mg", "/", "kg", "s", ".", "c", ".", "once", "daily", ")", "aggressive", "behavior", "of", "adult", "male", "and", "female", "Wistar", "rats", "obtained", "from", "the", "same", "breeder", "was", "studied", "in", "two", "consecutive", "sets", ".", "In", "male", "animals", ",", "repeated", "apomorphine", "treatment", "induced", "a", "gradual", "development", "of", "aggressive", "behavior", "as", "evidenced", "by", "the", "increased", "intensity", "of", "aggressiveness", "and", "shortened", "latency", "before", "the", "first", "attack", "toward", "the", "opponent", ".", "In", "female", "rats", ",", "only", "a", "weak", "tendency", "toward", "aggressiveness", "was", "found", ".", "In", "conclusion", ",", "the", "present", "study", "demonstrates", "gender", "differences", "in", "the", "development", "of", "the", "apomorphine", "-", "induced", "aggressive", "behavior", "and", "indicates", "that", "the", "female", "rats", "do", "not", "fill", "the", "validation", "criteria", "for", "use", "in", "this", "method", "."]], "ner": [[[2, 2, "Chemical"], [20, 20, "Chemical"], [63, 63, "Chemical"], [118, 118, "Chemical"], [5, 6, "Disease"], [37, 38, "Disease"], [70, 71, "Disease"], [79, 79, "Disease"], [100, 100, "Disease"], [121, 122, "Disease"]]], "relations": [[[2, 2, 5, 6, "CID"], [2, 2, 37, 38, "CID"], [2, 2, 70, 71, "CID"], [2, 2, 79, 79, "CID"], [2, 2, 100, 100, "CID"], [2, 2, 121, 122, "CID"], [20, 20, 5, 6, "CID"], [20, 20, 37, 38, "CID"], [20, 20, 70, 71, "CID"], [20, 20, 79, 79, "CID"], [20, 20, 100, 100, "CID"], [20, 20, 121, 122, "CID"], [63, 63, 5, 6, "CID"], [63, 63, 37, 38, "CID"], [63, 63, 70, 71, "CID"], [63, 63, 79, 79, "CID"], [63, 63, 100, 100, "CID"], [63, 63, 121, 122, "CID"], [118, 118, 5, 6, "CID"], [118, 118, 37, 38, "CID"], [118, 118, 70, 71, "CID"], [118, 118, 79, 79, "CID"], [118, 118, 100, 100, "CID"], [118, 118, 121, 122, "CID"]]], "clusters": [], "translated": "<0>阿扑吗啡</0>诱导的<4>攻击行为</4>的发展：成年雄性和雌性 Wistar 大鼠的比较。研究了<1>阿扑吗啡</1>诱导的（1.0 mg/kg s.c.每天一次）<5>攻击行为</5>的发展，从同一饲养员获得的成年雄性和雌性 Wistar 大鼠的发展在两个连续的集合中。在雄性动物中，重复<2>阿扑吗啡</2>治疗诱导了<6>攻击行为</6>的逐渐发展，这体现在朝着对手发起第一次攻击的潜伏期缩短和<7>攻击性</7>强度增加。在雌性大鼠中，仅发现<8>攻击性</8>的弱倾向。总之，本研究表明在<3>阿扑吗啡</3>诱导的<9>攻击行为</9>的发展过程中存在性别差异，并表明雌性大鼠不符合该方法使用的验证标准。", "revised": true}
{"doc_key": "18442015", "sentences": [["Protective", "effect", "of", "verapamil", "on", "gastric", "hemorrhagic", "ulcers", "in", "severe", "atherosclerotic", "rats", ".", "Studies", "concerning", "with", "pathogenesis", "of", "gastric", "hemorrhage", "and", "mucosal", "ulceration", "produced", "in", "atherosclerotic", "rats", "are", "lacking", ".", "The", "aim", "of", "this", "study", "is", "to", "examine", "the", "role", "of", "gastric", "acid", "back", "-", "diffusion", ",", "mast", "cell", "histamine", "release", ",", "lipid", "peroxide", "(", "LPO", ")", "generation", "and", "mucosal", "microvascular", "permeability", "in", "modulating", "gastric", "hemorrhage", "and", "ulcer", "in", "rats", "with", "atherosclerosis", "induced", "by", "coadministration", "of", "vitamin", "D2", "and", "cholesterol", ".", "Additionally", ",", "the", "protective", "effect", "of", "verapamil", "on", "this", "ulcer", "model", "was", "evaluated", ".", "Male", "Wistar", "rats", "were", "challenged", "intragastrically", "once", "daily", "for", "9", "days", "with", "1", ".", "0", "ml", "/", "kg", "of", "corn", "oil", "containing", "vitamin", "D2", "and", "cholesterol", "to", "induce", "atherosclerosis", ".", "Control", "rats", "received", "corn", "oil", "only", ".", "After", "gastric", "surgery", ",", "rat", "stomachs", "were", "irrigated", "for", "3", "h", "with", "either", "simulated", "gastric", "juice", "or", "normal", "saline", ".", "Gastric", "acid", "back", "-", "diffusion", ",", "mucosal", "LPO", "generation", ",", "histamine", "concentration", ",", "microvascular", "permeability", ",", "luminal", "hemoglobin", "content", "and", "ulcer", "areas", "were", "determined", ".", "Elevated", "atherosclerotic", "parameters", ",", "such", "as", "serum", "calcium", ",", "total", "cholesterol", "and", "low", "-", "density", "lipoprotein", "concentration", "were", "obtained", "in", "atherosclerotic", "rats", ".", "Severe", "gastric", "ulcers", "accompanied", "with", "increased", "ulcerogenic", "factors", ",", "including", "gastric", "acid", "back", "-", "diffusion", ",", "histamine", "release", ",", "LPO", "generation", "and", "luminal", "hemoglobin", "content", "were", "also", "observed", "in", "these", "rats", ".", "Moreover", ",", "a", "positive", "correlation", "of", "histamine", "to", "gastric", "hemorrhage", "and", "to", "ulcer", "was", "found", "in", "those", "atherosclerotic", "rats", ".", "This", "hemorrhagic", "ulcer", "and", "various", "ulcerogenic", "parameters", "were", "dose", "-", "dependently", "ameliorated", "by", "daily", "intragastric", "verapamil", ".", "Atherosclerosis", "could", "produce", "gastric", "hemorrhagic", "ulcer", "via", "aggravation", "of", "gastric", "acid", "back", "-", "diffusion", ",", "LPO", "generation", ",", "histamine", "release", "and", "microvascular", "permeability", "that", "could", "be", "ameliorated", "by", "verapamil", "in", "rats", "."]], "ner": [[[76, 77, "Chemical"], [117, 118, "Chemical"], [5, 6, "Disease"], [18, 19, "Disease"], [64, 65, "Disease"], [240, 241, "Disease"], [253, 253, "Disease"], [272, 273, "Disease"], [79, 79, "Chemical"], [120, 120, "Chemical"], [187, 187, "Chemical"], [7, 7, "Disease"], [67, 67, "Disease"], [90, 90, "Disease"], [172, 172, "Disease"], [202, 202, "Disease"], [244, 244, "Disease"], [254, 254, "Disease"], [274, 274, "Disease"], [10, 10, "Disease"], [25, 25, "Disease"], [71, 71, "Disease"], [123, 123, "Disease"], [178, 178, "Disease"], [197, 197, "Disease"], [249, 249, "Disease"], [269, 269, "Disease"], [3, 3, "Chemical"], [87, 87, "Chemical"], [267, 267, "Chemical"], [297, 297, "Chemical"], [49, 49, "Chemical"], [162, 162, "Chemical"], [216, 216, "Chemical"], [238, 238, "Chemical"], [287, 287, "Chemical"], [168, 168, "Chemical"], [222, 222, "Chemical"], [184, 184, "Chemical"]]], "relations": [[[76, 77, 5, 6, "CID"], [76, 77, 18, 19, "CID"], [76, 77, 64, 65, "CID"], [76, 77, 240, 241, "CID"], [76, 77, 253, 253, "CID"], [76, 77, 272, 273, "CID"], [117, 118, 5, 6, "CID"], [117, 118, 18, 19, "CID"], [117, 118, 64, 65, "CID"], [117, 118, 240, 241, "CID"], [117, 118, 253, 253, "CID"], [117, 118, 272, 273, "CID"], [79, 79, 5, 6, "CID"], [79, 79, 18, 19, "CID"], [79, 79, 64, 65, "CID"], [79, 79, 240, 241, "CID"], [79, 79, 253, 253, "CID"], [79, 79, 272, 273, "CID"], [120, 120, 5, 6, "CID"], [120, 120, 18, 19, "CID"], [120, 120, 64, 65, "CID"], [120, 120, 240, 241, "CID"], [120, 120, 253, 253, "CID"], [120, 120, 272, 273, "CID"], [187, 187, 5, 6, "CID"], [187, 187, 18, 19, "CID"], [187, 187, 64, 65, "CID"], [187, 187, 240, 241, "CID"], [187, 187, 253, 253, "CID"], [187, 187, 272, 273, "CID"], [76, 77, 7, 7, "CID"], [76, 77, 67, 67, "CID"], [76, 77, 90, 90, "CID"], [76, 77, 172, 172, "CID"], [76, 77, 202, 202, "CID"], [76, 77, 244, 244, "CID"], [76, 77, 254, 254, "CID"], [76, 77, 274, 274, "CID"], [117, 118, 7, 7, "CID"], [117, 118, 67, 67, "CID"], [117, 118, 90, 90, "CID"], [117, 118, 172, 172, "CID"], [117, 118, 202, 202, "CID"], [117, 118, 244, 244, "CID"], [117, 118, 254, 254, "CID"], [117, 118, 274, 274, "CID"], [79, 79, 7, 7, "CID"], [79, 79, 67, 67, "CID"], [79, 79, 90, 90, "CID"], [79, 79, 172, 172, "CID"], [79, 79, 202, 202, "CID"], [79, 79, 244, 244, "CID"], [79, 79, 254, 254, "CID"], [79, 79, 274, 274, "CID"], [120, 120, 7, 7, "CID"], [120, 120, 67, 67, "CID"], [120, 120, 90, 90, "CID"], [120, 120, 172, 172, "CID"], [120, 120, 202, 202, "CID"], [120, 120, 244, 244, "CID"], [120, 120, 254, 254, "CID"], [120, 120, 274, 274, "CID"], [187, 187, 7, 7, "CID"], [187, 187, 67, 67, "CID"], [187, 187, 90, 90, "CID"], [187, 187, 172, 172, "CID"], [187, 187, 202, 202, "CID"], [187, 187, 244, 244, "CID"], [187, 187, 254, 254, "CID"], [187, 187, 274, 274, "CID"], [76, 77, 10, 10, "CID"], [76, 77, 25, 25, "CID"], [76, 77, 71, 71, "CID"], [76, 77, 123, 123, "CID"], [76, 77, 178, 178, "CID"], [76, 77, 197, 197, "CID"], [76, 77, 249, 249, "CID"], [76, 77, 269, 269, "CID"], [117, 118, 10, 10, "CID"], [117, 118, 25, 25, "CID"], [117, 118, 71, 71, "CID"], [117, 118, 123, 123, "CID"], [117, 118, 178, 178, "CID"], [117, 118, 197, 197, "CID"], [117, 118, 249, 249, "CID"], [117, 118, 269, 269, "CID"], [79, 79, 10, 10, "CID"], [79, 79, 25, 25, "CID"], [79, 79, 71, 71, "CID"], [79, 79, 123, 123, "CID"], [79, 79, 178, 178, "CID"], [79, 79, 197, 197, "CID"], [79, 79, 249, 249, "CID"], [79, 79, 269, 269, "CID"], [120, 120, 10, 10, "CID"], [120, 120, 25, 25, "CID"], [120, 120, 71, 71, "CID"], [120, 120, 123, 123, "CID"], [120, 120, 178, 178, "CID"], [120, 120, 197, 197, "CID"], [120, 120, 249, 249, "CID"], [120, 120, 269, 269, "CID"], [187, 187, 10, 10, "CID"], [187, 187, 25, 25, "CID"], [187, 187, 71, 71, "CID"], [187, 187, 123, 123, "CID"], [187, 187, 178, 178, "CID"], [187, 187, 197, 197, "CID"], [187, 187, 249, 249, "CID"], [187, 187, 269, 269, "CID"]]], "clusters": [], "translated": "<27>维拉帕米</27>对严重<19>动脉粥样硬化</19>大鼠<2>胃出血</2><11>溃疡</11>的保护作用。对<3>胃出血</3>和<20>动脉粥样硬化</20>大鼠粘膜溃疡的发病机制研究尚缺乏。本研究的目的是检查胃酸反扩散、肥大细胞<31>组胺</31>释放、脂质过氧化物 (LPO) 生成和粘膜微血管通透性在调节<4>胃出血</4>和<12>溃疡</12>中的作用，<0>维生素D2</0>和<8>胆固醇</8>共同给药引起大鼠<21>动脉粥样硬化</21>。此外，还评估了<28>维拉帕米</28>对该<13>溃疡</13>模型的保护作用。雄性Wistar大鼠用1.0毫升/千克的玉米油含有<1>维生素D2</1>和<9>胆固醇</9>，可诱发<22>动脉粥样硬化</22>。对照大鼠只接受玉米油。胃手术后，用模拟胃液或生理盐水冲洗大鼠胃3小时。测定胃酸反扩散、粘膜LPO生成、<32>组胺</32>浓度、微血管通透性、<36>管腔</36>血红蛋白含量和<14>溃疡</14>面积。在<24>动脉粥样硬化</24>大鼠中获得升高的<23>动脉粥样硬化</23>参数，例如血清<38>钙</38>、总<10>胆固醇</10>和低密度脂蛋白浓度。这些大鼠伴有严重胃<15>溃疡</15>，并伴随着胃酸反扩散、<33>组胺</33>释放、LPO生成和<37>腔内</37>血红蛋白含量增加等溃疡发生因素。此外，在<25>动脉粥样硬化</25>大鼠中发现<34>组胺</34>与<5>胃出血</5>和<16>溃疡</16>呈正相关。这种<6>出血性</6><17>溃疡</17>和各种溃疡性参数通过每日胃内<29>维拉帕米</29>剂量依赖性得到改善。<26>动脉粥样硬化</26>通过加重胃酸反扩散、LPO生成、<35>组胺</35>释放和微血管通透性造成<7>胃出血</7>和<18>溃疡</18>，而用<30>维拉帕米</30>可改善大鼠的通透性。", "revised": true}
{"doc_key": "11587867", "sentences": [["Fatal", "myeloencephalopathy", "due", "to", "accidental", "intrathecal", "vincristin", "administration", ":", "a", "report", "of", "two", "cases", ".", "We", "report", "on", "two", "fatal", "cases", "of", "accidental", "intrathecal", "vincristine", "instillation", "in", "a", "5", "-", "year", "old", "girl", "with", "recurrent", "acute", "lymphoblastic", "leucemia", "and", "a", "57", "-", "year", "old", "man", "with", "lymphoblastic", "lymphoma", ".", "The", "girl", "died", "seven", "days", ",", "the", "man", "four", "weeks", "after", "intrathecal", "injection", "of", "vincristine", ".", "Clinically", ",", "the", "onset", "was", "characterized", "by", "the", "signs", "of", "opistothonus", ",", "sensory", "and", "motor", "dysfunction", "and", "ascending", "paralysis", ".", "Histological", "and", "immunohistochemical", "investigations", "(", "HE", "-", "LFB", ",", "CD", "-", "68", ",", "Neurofilament", ")", "revealed", "degeneration", "of", "myelin", "and", "axons", "as", "well", "as", "pseudocystic", "transformation", "in", "areas", "exposed", "to", "vincristine", ",", "accompanied", "by", "secondary", "changes", "with", "numerous", "prominent", "macrophages", ".", "The", "clinical", "course", "and", "histopathological", "results", "of", "the", "two", "cases", "are", "presented", ".", "A", "review", "of", "all", "reported", "cases", "in", "the", "literature", "is", "given", ".", "A", "better", "controlled", "regimen", "for", "administering", "vincristine", "and", "intrathecal", "chemotherapy", "is", "recommended", "."]], "ner": [[[6, 6, "Chemical"], [24, 24, "Chemical"], [63, 63, "Chemical"], [115, 115, "Chemical"], [157, 157, "Chemical"], [75, 80, "Disease"], [101, 105, "Disease"], [1, 1, "Disease"], [35, 37, "Disease"], [46, 47, "Disease"], [83, 83, "Disease"]]], "relations": [[[6, 6, 75, 80, "CID"], [24, 24, 75, 80, "CID"], [63, 63, 75, 80, "CID"], [115, 115, 75, 80, "CID"], [157, 157, 75, 80, "CID"], [6, 6, 101, 105, "CID"], [24, 24, 101, 105, "CID"], [63, 63, 101, 105, "CID"], [115, 115, 101, 105, "CID"], [157, 157, 101, 105, "CID"]]], "clusters": [], "translated": "因意外鞘内注射<0>长春新碱</0>致死性<7>脊髓脑病</7>：两例报告。我们报告了两例意外鞘内注射<1>长春新碱</1>致死病例，一名5岁女孩患有复发性<8>急性淋巴细胞白血病</8>，另一名57岁男子患有<9>淋巴细胞淋巴瘤</9>。女孩在鞘内注射<2>长春新碱</2>后第7天死去，男子在鞘内注射后4周死亡。临床上，以<5>角弓反张、感觉和运动功能障碍</5>和上行<10>麻痹</10>体征起病。组织学和免疫组织化学研究（HE-LFB，CD-68，Neurofilament）显示<6>髓鞘和轴突退化</6>以及暴露于<3>长春新碱</3>区域的假囊性转化，并伴有有数突出的巨噬细胞的继发性变化。介绍了这两个病例的临床过程和组织病理学结果。对文献中所有报道的病例进行了回顾。推荐使用更好的控制方案来施用<4>长春新碱</4>和鞘内化疗。", "revised": true}
{"doc_key": "8302922", "sentences": [["Epidural", "blood", "flow", "during", "prostaglandin", "E1", "or", "trimethaphan", "induced", "hypotension", ".", "To", "evaluate", "the", "effect", "of", "prostaglandin", "E1", "(", "PGE1", ")", "or", "trimethaphan", "(", "TMP", ")", "induced", "hypotension", "on", "epidural", "blood", "flow", "(", "EBF", ")", "during", "spinal", "surgery", ",", "EBF", "was", "measured", "using", "the", "heat", "clearance", "method", "in", "30", "patients", "who", "underwent", "postero", "-", "lateral", "interbody", "fusion", "under", "isoflurane", "anaesthesia", ".", "An", "initial", "dose", "of", "0", ".", "1", "microgram", ".", "kg", "-", "1", ".", "min", "-", "1", "of", "PGE1", "(", "15", "patients", ")", ",", "or", "10", "micrograms", ".", "kg", "-", "1", ".", "min", "-", "1", "of", "TMP", "(", "15", "patients", ")", "was", "administered", "intravenously", "after", "the", "dural", "opening", "and", "the", "dose", "was", "adjusted", "to", "maintain", "the", "mean", "arterial", "blood", "pressure", "(", "MAP", ")", "at", "about", "60", "mmHg", ".", "The", "hypotensive", "drug", "was", "discontinued", "at", "the", "completion", "of", "the", "operative", "procedure", ".", "After", "starting", "PGE1", "or", "TMP", ",", "MAP", "and", "rate", "pressure", "product", "(", "RPP", ")", "decreased", "significantly", "compared", "with", "preinfusion", "values", "(", "P", "<", "0", ".", "01", ")", ",", "and", "the", "degree", "of", "hypotension", "due", "to", "PGE1", "remained", "constant", "until", "60", "min", "after", "its", "discontinuation", ".", "Heart", "rate", "(", "HR", ")", "did", "not", "change", "in", "either", "group", ".", "EBFF", "did", "not", "change", "during", "PGE1", "infusion", "whereas", "in", "the", "TMP", "group", ",", "EBF", "decreased", "significantly", "at", "30", "and", "60", "min", "after", "the", "start", "of", "TMP", "(", "preinfusion", ":", "45", ".", "9", "+", "/", "-", "13", ".", "9", "ml", "/", "100g", "/", "min", ".", "30", "min", ":", "32", ".", "3", "+", "/", "-", "9", ".", "9", "ml", "/", "100", "g", "/", "min", "(", "P", "<", "0", ".", "05", ")", ".", "60", "min", ":", "30", "+", "/", "-", "7", ".", "5", "ml", "/", "100", "g", "/", "min", "(", "P", "<", "0", ".", "05", ")", ")", ".", "These", "results", "suggest", "that", "PGE1", "may", "be", "preferable", "to", "TMP", "for", "hypotensive", "anaesthesia", "in", "spinal", "surgery", "because", "TMP", "decreased", "EBF", "."]], "ner": [[[4, 5, "Chemical"], [16, 17, "Chemical"], [19, 19, "Chemical"], [78, 78, "Chemical"], [143, 143, "Chemical"], [176, 176, "Chemical"], [203, 203, "Chemical"], [297, 297, "Chemical"], [9, 9, "Disease"], [27, 27, "Disease"], [129, 129, "Disease"], [173, 173, "Disease"], [304, 304, "Disease"], [7, 7, "Chemical"], [22, 22, "Chemical"], [24, 24, "Chemical"], [96, 96, "Chemical"], [145, 145, "Chemical"], [208, 208, "Chemical"], [223, 223, "Chemical"], [302, 302, "Chemical"], [310, 310, "Chemical"], [58, 58, "Chemical"]]], "relations": [[[4, 5, 9, 9, "CID"], [4, 5, 27, 27, "CID"], [4, 5, 129, 129, "CID"], [4, 5, 173, 173, "CID"], [4, 5, 304, 304, "CID"], [16, 17, 9, 9, "CID"], [16, 17, 27, 27, "CID"], [16, 17, 129, 129, "CID"], [16, 17, 173, 173, "CID"], [16, 17, 304, 304, "CID"], [19, 19, 9, 9, "CID"], [19, 19, 27, 27, "CID"], [19, 19, 129, 129, "CID"], [19, 19, 173, 173, "CID"], [19, 19, 304, 304, "CID"], [78, 78, 9, 9, "CID"], [78, 78, 27, 27, "CID"], [78, 78, 129, 129, "CID"], [78, 78, 173, 173, "CID"], [78, 78, 304, 304, "CID"], [143, 143, 9, 9, "CID"], [143, 143, 27, 27, "CID"], [143, 143, 129, 129, "CID"], [143, 143, 173, 173, "CID"], [143, 143, 304, 304, "CID"], [176, 176, 9, 9, "CID"], [176, 176, 27, 27, "CID"], [176, 176, 129, 129, "CID"], [176, 176, 173, 173, "CID"], [176, 176, 304, 304, "CID"], [203, 203, 9, 9, "CID"], [203, 203, 27, 27, "CID"], [203, 203, 129, 129, "CID"], [203, 203, 173, 173, "CID"], [203, 203, 304, 304, "CID"], [297, 297, 9, 9, "CID"], [297, 297, 27, 27, "CID"], [297, 297, 129, 129, "CID"], [297, 297, 173, 173, "CID"], [297, 297, 304, 304, "CID"], [7, 7, 9, 9, "CID"], [7, 7, 27, 27, "CID"], [7, 7, 129, 129, "CID"], [7, 7, 173, 173, "CID"], [7, 7, 304, 304, "CID"], [22, 22, 9, 9, "CID"], [22, 22, 27, 27, "CID"], [22, 22, 129, 129, "CID"], [22, 22, 173, 173, "CID"], [22, 22, 304, 304, "CID"], [24, 24, 9, 9, "CID"], [24, 24, 27, 27, "CID"], [24, 24, 129, 129, "CID"], [24, 24, 173, 173, "CID"], [24, 24, 304, 304, "CID"], [96, 96, 9, 9, "CID"], [96, 96, 27, 27, "CID"], [96, 96, 129, 129, "CID"], [96, 96, 173, 173, "CID"], [96, 96, 304, 304, "CID"], [145, 145, 9, 9, "CID"], [145, 145, 27, 27, "CID"], [145, 145, 129, 129, "CID"], [145, 145, 173, 173, "CID"], [145, 145, 304, 304, "CID"], [208, 208, 9, 9, "CID"], [208, 208, 27, 27, "CID"], [208, 208, 129, 129, "CID"], [208, 208, 173, 173, "CID"], [208, 208, 304, 304, "CID"], [223, 223, 9, 9, "CID"], [223, 223, 27, 27, "CID"], [223, 223, 129, 129, "CID"], [223, 223, 173, 173, "CID"], [223, 223, 304, 304, "CID"], [302, 302, 9, 9, "CID"], [302, 302, 27, 27, "CID"], [302, 302, 129, 129, "CID"], [302, 302, 173, 173, "CID"], [302, 302, 304, 304, "CID"], [310, 310, 9, 9, "CID"], [310, 310, 27, 27, "CID"], [310, 310, 129, 129, "CID"], [310, 310, 173, 173, "CID"], [310, 310, 304, 304, "CID"]]], "clusters": [], "translated": "<0>前列腺素E1</0>或<13>三美沙芬</13>引起的<8>低血压</8>时硬膜外血流。评价<1>前列腺素E1</1>（<2>PGE1</2>）或<14>三美沙芬</14>（<15>TMP</15>）对<9>低血压</9>，关于脊柱手术硬膜外血流(EBF)的研究，采用热清除法对30例<22>异氟烷</22>麻醉下后外侧椎间融合术患者的EBF进行了测量。初始剂量为 0.1 微克/公斤.min-1的<3>PGE1</3>（15名患者），或 10 微克/公斤.min-1的<16>TMP</16>（15例）在硬脑膜切开后静脉给药，调整剂量以维持平均动脉血压(MAP)在60mmHg左右。 <10>降压</10>药物在手术过程结束时停用。开始<4>PGE1</4>或<17>TMP</17>后，MAP和速率压力乘积(RPP)较输注前显著下降(P<0 .01)，由于<5>PGE1</5>，<11>低血压程度</11>在停药后60分钟内保持不变。两组的心率(HR)都没有变化。EBF在<6>PGE1</6>输注期间没有变化，而在<18>TMP</18>组中，EBF在<19>TMP</19>开始后30和60分钟显著下降（输注前：45.9+/-13.9毫升/100克/分钟，30分钟：32.3+/-9.9毫升/100克/分钟(P<0.05)，60分钟：30+/-7.5毫升/100克/分钟(P<0.05)）。这些结果表明，对于脊柱手术中的<12>低血压</12>麻醉，<7>PGE1</7>可能优于<20>TMP</20>，因为<21>TMP</21>降低了EBF。", "revised": true}
{"doc_key": "3676049", "sentences": [["Cerebral", "blood", "flow", "and", "metabolism", "during", "isoflurane", "-", "induced", "hypotension", "in", "patients", "subjected", "to", "surgery", "for", "cerebral", "aneurysms", ".", "Cerebral", "blood", "flow", "and", "cerebral", "metabolic", "rate", "for", "oxygen", "were", "measured", "during", "isoflurane", "-", "induced", "hypotension", "in", "10", "patients", "subjected", "to", "craniotomy", "for", "clipping", "of", "a", "cerebral", "aneurysm", ".", "Flow", "and", "metabolism", "were", "measured", "5", "-", "13", "days", "after", "the", "subarachnoid", "haemorrhage", "by", "a", "modification", "of", "the", "classical", "Kety", "-", "Schmidt", "technique", "using", "xenon", "-", "133", "i", ".", "v", ".", "Anaesthesia", "was", "maintained", "with", "an", "inspired", "isoflurane", "concentration", "of", "0", ".", "75", "%", "(", "plus", "67", "%", "nitrous", "oxide", "in", "oxygen", ")", ",", "during", "which", "CBF", "and", "CMRO2", "were", "34", ".", "3", "+", "/", "-", "2", ".", "1", "ml", "/", "100", "g", "min", "-", "1", "and", "2", ".", "32", "+", "/", "-", "0", ".", "16", "ml", "/", "100", "g", "min", "-", "1", "at", "PaCO2", "4", ".", "1", "+", "/", "-", "0", ".", "1", "kPa", "(", "mean", "+", "/", "-", "SEM", ")", ".", "Controlled", "hypotension", "to", "an", "average", "MAP", "of", "50", "-", "55", "mm", "Hg", "was", "induced", "by", "increasing", "the", "dose", "of", "isoflurane", ",", "and", "maintained", "at", "an", "inspired", "concentration", "of", "2", ".", "2", "+", "/", "-", "0", ".", "2", "%", ".", "This", "resulted", "in", "a", "significant", "decrease", "in", "CMRO2", "(", "to", "1", ".", "73", "+", "/", "-", "0", ".", "16", "ml", "/", "100", "g", "min", "-", "1", ")", ",", "while", "CBF", "was", "unchanged", ".", "After", "the", "clipping", "of", "the", "aneurysm", "the", "isoflurane", "concentration", "was", "reduced", "to", "0", ".", "75", "%", ".", "There", "was", "a", "significant", "increase", "in", "CBF", ",", "although", "CMRO2", "was", "unchanged", ",", "compared", "with", "pre", "-", "hypotensive", "values", ".", "These", "changes", "might", "offer", "protection", "to", "brain", "tissue", "during", "periods", "of", "induced", "hypotension", "."]], "ner": [[[6, 6, "Chemical"], [31, 31, "Chemical"], [85, 85, "Chemical"], [180, 180, "Chemical"], [240, 240, "Chemical"], [9, 9, "Disease"], [34, 34, "Disease"], [162, 162, "Disease"], [267, 267, "Disease"], [282, 282, "Disease"], [16, 17, "Disease"], [45, 46, "Disease"], [59, 60, "Disease"], [238, 238, "Disease"], [27, 27, "Chemical"], [99, 99, "Chemical"], [72, 72, "Chemical"], [96, 97, "Chemical"], [172, 172, "Chemical"]]], "relations": [[[6, 6, 9, 9, "CID"], [6, 6, 34, 34, "CID"], [6, 6, 162, 162, "CID"], [6, 6, 267, 267, "CID"], [6, 6, 282, 282, "CID"], [31, 31, 9, 9, "CID"], [31, 31, 34, 34, "CID"], [31, 31, 162, 162, "CID"], [31, 31, 267, 267, "CID"], [31, 31, 282, 282, "CID"], [85, 85, 9, 9, "CID"], [85, 85, 34, 34, "CID"], [85, 85, 162, 162, "CID"], [85, 85, 267, 267, "CID"], [85, 85, 282, 282, "CID"], [180, 180, 9, 9, "CID"], [180, 180, 34, 34, "CID"], [180, 180, 162, 162, "CID"], [180, 180, 267, 267, "CID"], [180, 180, 282, 282, "CID"], [240, 240, 9, 9, "CID"], [240, 240, 34, 34, "CID"], [240, 240, 162, 162, "CID"], [240, 240, 267, 267, "CID"], [240, 240, 282, 282, "CID"]]], "clusters": [], "translated": "接受<10>脑动脉瘤</10>手术的患者在<0>异氟烷</0>引起的<5>低血压</5>期间的脑血流量和代谢。在<1>异氟醚</1>引起的<6>低血压</6>过程中测量了<14>氧气</14>的脑血流量和脑代谢率，10名接受开颅手术以夹闭<11>脑动脉瘤</11>的患者。在<12>蛛网膜下腔出血</12>后5-13天，通过使用经典Kety-Schmidt技术的改进（使用<16>氙气</16>-133 i.v.）来测量流量和代谢。维持麻醉，吸入浓度为0.75%的<2>异氟醚</2>（加入67%的<17>氧化亚氮</17>和<15>氧气</15>）。此时，CBF和CMRO2值分别为34.3+/-2.1毫升/100克分钟-1和2.32+/-0.16毫升/100克分钟-1，PaCO2为4.1+/-0.1 kPa（平均值+/- SEM）。通过增加<3>异氟醚</3>的剂量诱导<7>控制性的低血压</7>，平均MAP达到50-55 mm<Hg><18></18>，并维持吸入浓度为2.2+/-0.2%。这导致CMRO2显着降低（至1.73+/-0.16毫升/100克分钟-1），但CBF没有变化。夹闭了<13>动脉瘤</13>后，<4>异氟醚</4>浓度降至0.75%。与<8>控制性的低血压</8>前相比，尽管CMRO2没有变化，但CBF显着提高。这些变化可能使脑组织在诱导的<9>低血压</9>期间得到保护。", "revised": true}
{"doc_key": "9855119", "sentences": [["Clinical", "and", "histopathologic", "examination", "of", "renal", "allografts", "treated", "with", "tacrolimus", "(", "FK506", ")", "for", "at", "least", "one", "year", ".", "BACKGROUND", ":", "We", "clinically", "and", "pathologically", "analyzed", "renal", "allografts", "from", "1", "9", "renal", "transplant", "patients", "treated", "with", "tacrolimus", "(", "FK506", ")", "for", "more", "than", "1", "year", ".", "METHODS", ":", "Twenty", "-", "six", "renal", "allograft", "biopsy", "specimens", "from", "1", "9", "renal", "transplant", "patients", "who", "underwent", "transplantations", "between", "1991", "and", "1993", "were", "evaluated", ".", "Thirteen", "biopsies", "were", "performed", "from", "stable", "functioning", "renal", "allografts", "with", "informed", "consent", "(", "nonepisode", "biopsy", ")", "and", "the", "other", "13", "were", "from", "dysfunctional", "renal", "allografts", "with", "a", "clinical", "indication", "for", "biopsy", "(", "episode", "biopsy", ")", ".", "RESULTS", ":", "The", "main", "pathologic", "diagnoses", "(", "some", "overlap", ")", "were", "acute", "rejection", "(", "AR", ";", "n", "=", "4", ")", ",", "chronic", "rejection", "(", "CR", ";", "n", "=", "5", ")", ",", "AR", "+", "CR", "(", "n", "=", "4", ")", ",", "recurrent", "IgA", "nephropathy", "(", "n", "=", "5", ")", ",", "normal", "findings", "(", "n", "=", "2", ")", ",", "minimal", "-", "type", "chronic", "FK506", "nephropathy", "(", "n", "=", "9", ")", ",", "and", "mild", "-", "type", "FK506", "nephropathy", "(", "n", "=", "11", ")", ".", "Of", "the", "nonepisode", "biopsies", ",", "7", "and", "4", "biopsies", "showed", "minimal", "-", "type", "and", "mild", "-", "type", "chronic", "FK506", "nephropathy", ",", "respectively", ".", "Chronic", "FK506", "nephropathy", "consisted", "of", "rough", "and", "foamy", "tubular", "vacuolization", "(", "5", "biopsies", ")", ",", "arteriolopathy", "(", "angiodegeneration", "of", "the", "arteriolar", "wall", ";", "20", "biopsies", ")", ",", "focal", "segmental", "glomerulosclerosis", "(", "4", "biopsies", ")", "and", "the", "striped", "form", "of", "interstitial", "fibrosis", "(", "11", "biopsies", ")", ".", "The", "serum", "creatinine", "levels", "of", "patients", "in", "the", "mild", "-", "type", "chronic", "FK506", "nephropathy", "group", ",", "which", "included", "7", "episode", "biopsies", ",", "were", "statistically", "higher", "than", "those", "in", "the", "minimum", "-", "type", "chronic", "FK506", "-", "nephropathy", "group", "(", "P", "<", "0", ".", "001", ")", ".", "CONCLUSIONS", ":", "This", "study", "demonstrates", "that", "chronic", "FK506", "nephropathy", "consists", "primarily", "of", "arteriolopathy", "manifesting", "as", "insudative", "hyalinosis", "of", "the", "arteriolar", "wall", ",", "and", "suggests", "that", "mild", "-", "type", "chronic", "FK506", "nephropathy", "is", "a", "condition", "which", "may", "lead", "to", "deterioration", "of", "renal", "allograft", "function", "."]], "ner": [[[9, 9, "Chemical"], [11, 11, "Chemical"], [36, 36, "Chemical"], [38, 38, "Chemical"], [168, 168, "Chemical"], [180, 180, "Chemical"], [206, 206, "Chemical"], [212, 212, "Chemical"], [269, 269, "Chemical"], [290, 290, "Chemical"], [309, 309, "Chemical"], [331, 331, "Chemical"], [238, 240, "Disease"], [148, 149, "Disease"], [169, 169, "Disease"], [181, 181, "Disease"], [207, 207, "Disease"], [213, 213, "Disease"], [270, 270, "Disease"], [292, 292, "Disease"], [310, 310, "Disease"], [332, 332, "Disease"], [250, 251, "Disease"], [259, 259, "Chemical"]]], "relations": [[[9, 9, 238, 240, "CID"], [11, 11, 238, 240, "CID"], [36, 36, 238, 240, "CID"], [38, 38, 238, 240, "CID"], [168, 168, 238, 240, "CID"], [180, 180, 238, 240, "CID"], [206, 206, 238, 240, "CID"], [212, 212, 238, 240, "CID"], [269, 269, 238, 240, "CID"], [290, 290, 238, 240, "CID"], [309, 309, 238, 240, "CID"], [331, 331, 238, 240, "CID"]]], "clusters": [], "translated": "用<0>他克莫司</0>（<1>FK506</1>）治疗至少一年的肾同种异体移植物的临床和组织病理学检查。背景：我们对19例接受<2>他克莫司</2>（<3>FK506</3>）治疗1年以上的肾移植患者进行了临床和病理学分析。方法：对1991年至1993年间接受移植的19名肾移植患者的26份肾同种异体移植活检标本进行了评估。13例活检是在知情同意的情况下从功能稳定的同种异体肾移植物中进行的（非发作性活检），另外13例是来自具有活检临床指征的功能失调性肾同种异体移植物（发作性活检）。\n结果：主要病理诊断（部分重叠）为急性排斥反应（AR；n=4）、慢性排斥反应（CR；n=5）、AR+CR（n=4）、复发性<13>IgA肾病</13>（n=5）、正常检查结果（n=2）、轻微型慢性<4>FK506</4><14>肾病</14>（n=9）和轻型<5>FK506</5><15>肾病</15>（n=11）。在非发作性活检中，7例和4例活检分别显示轻型和轻型慢性<6>FK506</6><16>肾病</16>。慢性<7>FK506</7><17>肾病</17>包括粗糙和泡沫状肾小管空泡化（5次活检）、小动脉病（小动脉壁血管变性；20次活检）、<12>局灶性节段性肾小球硬化</12>（4例活检）和条纹状<22>间质纤维化</22>（11例活检）。轻型慢性<8>FK506</8><18>肾病</18>组7例活检患者血清<23>肌酐</23>水平显着高于对照组最小型慢性<9>FK506</9>-<19>肾病</19>组（P<0.001）。\n结论：本研究表明，慢性<10>FK506</10><20>肾病</20>主要表现为小动脉病变，即小动脉壁浸润性玻璃样变，并提示轻型慢性<11>FK506</11><21>肾病</21>是一种可能导致同种异体移植肾功能恶化的病症。", "revised": true}
{"doc_key": "11147747", "sentences": [["Serotonergic", "antidepressants", "and", "urinary", "incontinence", ".", "Many", "new", "serotonergic", "antidepressants", "have", "been", "introduced", "over", "the", "past", "decade", ".", "Although", "urinary", "incontinence", "is", "listed", "as", "one", "side", "effect", "of", "these", "drugs", "in", "their", "package", "inserts", "there", "is", "only", "one", "report", "in", "the", "literature", ".", "This", "concerns", "2", "male", "patients", "who", "experienced", "incontinence", "while", "taking", "venlafaxine", ".", "In", "the", "present", "paper", "the", "authors", "describe", "2", "female", "patients", "who", "developed", "incontinence", "secondary", "to", "the", "selective", "serotonin", "reuptake", "inhibitors", "paroxetine", "and", "sertraline", ",", "as", "well", "as", "a", "third", "who", "developed", "this", "side", "effect", "on", "venlafaxine", ".", "In", "2", "of", "the", "3", "cases", "the", "patients", "were", "also", "taking", "lithium", "carbonate", "and", "beta", "-", "blockers", ",", "both", "of", "which", "could", "have", "contributed", "to", "the", "incontinence", ".", "Animal", "studies", "suggest", "that", "incontinence", "secondary", "to", "serotonergic", "antidepressants", "could", "be", "mediated", "by", "the", "5HT4", "receptors", "found", "on", "the", "bladder", ".", "Further", "research", "is", "needed", "to", "delineate", "the", "frequency", "of", "this", "troubling", "side", "effect", "and", "how", "best", "to", "treat", "it", "."]], "ner": [[[0, 1, "Chemical"], [8, 9, "Chemical"], [127, 128, "Chemical"], [3, 4, "Disease"], [19, 20, "Disease"], [50, 50, "Disease"], [67, 67, "Disease"], [118, 118, "Disease"], [124, 124, "Disease"], [53, 53, "Chemical"], [90, 90, "Chemical"], [75, 75, "Chemical"], [77, 77, "Chemical"], [103, 104, "Chemical"], [72, 72, "Chemical"]]], "relations": [[[0, 1, 3, 4, "CID"], [0, 1, 19, 20, "CID"], [0, 1, 50, 50, "CID"], [0, 1, 67, 67, "CID"], [0, 1, 118, 118, "CID"], [0, 1, 124, 124, "CID"], [8, 9, 3, 4, "CID"], [8, 9, 19, 20, "CID"], [8, 9, 50, 50, "CID"], [8, 9, 67, 67, "CID"], [8, 9, 118, 118, "CID"], [8, 9, 124, 124, "CID"], [127, 128, 3, 4, "CID"], [127, 128, 19, 20, "CID"], [127, 128, 50, 50, "CID"], [127, 128, 67, 67, "CID"], [127, 128, 118, 118, "CID"], [127, 128, 124, 124, "CID"], [53, 53, 3, 4, "CID"], [53, 53, 19, 20, "CID"], [53, 53, 50, 50, "CID"], [53, 53, 67, 67, "CID"], [53, 53, 118, 118, "CID"], [53, 53, 124, 124, "CID"], [90, 90, 3, 4, "CID"], [90, 90, 19, 20, "CID"], [90, 90, 50, 50, "CID"], [90, 90, 67, 67, "CID"], [90, 90, 118, 118, "CID"], [90, 90, 124, 124, "CID"], [75, 75, 3, 4, "CID"], [75, 75, 19, 20, "CID"], [75, 75, 50, 50, "CID"], [75, 75, 67, 67, "CID"], [75, 75, 118, 118, "CID"], [75, 75, 124, 124, "CID"], [77, 77, 3, 4, "CID"], [77, 77, 19, 20, "CID"], [77, 77, 50, 50, "CID"], [77, 77, 67, 67, "CID"], [77, 77, 118, 118, "CID"], [77, 77, 124, 124, "CID"], [103, 104, 3, 4, "CID"], [103, 104, 19, 20, "CID"], [103, 104, 50, 50, "CID"], [103, 104, 67, 67, "CID"], [103, 104, 118, 118, "CID"], [103, 104, 124, 124, "CID"]]], "clusters": [], "translated": " <0>5-羟色胺能抗抑郁药</0>和<3>尿失禁</3>。在过去十年中，引入了许多新的<1>血清素抗抑郁药</1>。虽然<4>尿失禁</4>被列为这些药物的包装说明书中的一种副作用，但文献中只有一份报告。这涉及2名男性患者，他们在服用<9>文拉法辛</9>时出现了<5>尿失禁</5>。在本文中，作者描述了2名女性患者，她们继发于选择性<14>5-羟色胺</14>再摄取抑制剂<11>帕罗西汀</11>和<12>舍曲林</12> 分别出现<6>失禁</6>的情况，并有第三名患者在服用<10>文拉法辛</10>时出现这种副作用。在3例中，有2例患者还服用了<13>碳酸锂</13>和β受体阻滞剂，这两种药物都可能导致<7>尿失禁</7>。动物研究表明， <2>血清素抗抑郁药</2>引起的<8>尿失禁</8>可能是由于膀胱上发现的5-HT4受体介导的。需要进一步的研究来描述这种令人不安的副作用的频率以及如何最好地治疗它。", "revised": true}
{"doc_key": "12574103", "sentences": [["Prenatal", "dexamethasone", "programs", "hypertension", "and", "renal", "injury", "in", "the", "rat", ".", "Dexamethasone", "is", "frequently", "administered", "to", "the", "developing", "fetus", "to", "accelerate", "pulmonary", "development", ".", "The", "purpose", "of", "the", "present", "study", "was", "to", "determine", "if", "prenatal", "dexamethasone", "programmed", "a", "progressive", "increase", "in", "blood", "pressure", "and", "renal", "injury", "in", "rats", ".", "Pregnant", "rats", "were", "given", "either", "vehicle", "or", "2", "daily", "intraperitoneal", "injections", "of", "dexamethasone", "(", "0", ".", "2", "mg", "/", "kg", "body", "weight", ")", "on", "gestational", "days", "11", "and", "12", ",", "13", "and", "14", ",", "15", "and", "16", ",", "17", "and", "18", ",", "or", "19", "and", "20", ".", "Offspring", "of", "rats", "administered", "dexamethasone", "on", "days", "15", "and", "16", "gestation", "had", "a", "20", "%", "reduction", "in", "glomerular", "number", "compared", "with", "control", "at", "6", "to", "9", "months", "of", "age", "(", "22", "527", "+", "/", "-", "509", "versus", "28", "050", "+", "/", "-", "561", ",", "P", "<", "0", ".", "05", ")", ",", "which", "was", "comparable", "to", "the", "percent", "reduction", "in", "glomeruli", "measured", "at", "3", "weeks", "of", "age", ".", "Six", "-", "to", "9", "-", "month", "old", "rats", "receiving", "prenatal", "dexamethasone", "on", "days", "17", "and", "18", "of", "gestation", "had", "a", "17", "%", "reduction", "in", "glomeruli", "(", "23", "380", "+", "/", "-", "587", ")", "compared", "with", "control", "rats", "(", "P", "<", "0", ".", "05", ")", ".", "Male", "rats", "that", "received", "prenatal", "dexamethasone", "on", "days", "15", "and", "16", ",", "17", "and", "18", ",", "and", "13", "and", "14", "of", "gestation", "had", "elevated", "blood", "pressures", "at", "6", "months", "of", "age", ";", "the", "latter", "group", "did", "not", "have", "a", "reduction", "in", "glomerular", "number", ".", "Adult", "rats", "given", "dexamethasone", "on", "days", "15", "and", "16", "of", "gestation", "had", "more", "glomeruli", "with", "glomerulosclerosis", "than", "control", "rats", ".", "This", "study", "shows", "that", "prenatal", "dexamethasone", "in", "rats", "results", "in", "a", "reduction", "in", "glomerular", "number", ",", "glomerulosclerosis", ",", "and", "hypertension", "when", "administered", "at", "specific", "points", "during", "gestation", ".", "Hypertension", "was", "observed", "in", "animals", "that", "had", "a", "reduction", "in", "glomeruli", "as", "well", "as", "in", "a", "group", "that", "did", "not", "have", "a", "reduction", "in", "glomerular", "number", ",", "suggesting", "that", "a", "reduction", "in", "glomerular", "number", "is", "not", "the", "sole", "cause", "for", "the", "development", "of", "hypertension", "."]], "ner": [[[1, 1, "Chemical"], [35, 35, "Chemical"], [61, 61, "Chemical"], [100, 100, "Chemical"], [173, 173, "Chemical"], [213, 213, "Chemical"], [255, 255, "Chemical"], [277, 277, "Chemical"], [3, 3, "Disease"], [39, 42, "Disease"], [231, 233, "Disease"], [291, 291, "Disease"], [300, 300, "Disease"], [343, 343, "Disease"], [5, 6, "Disease"], [44, 45, "Disease"], [111, 114, "Disease"], [247, 250, "Disease"], [283, 286, "Disease"], [322, 325, "Disease"], [330, 333, "Disease"], [267, 267, "Disease"], [288, 288, "Disease"]]], "relations": [[[1, 1, 3, 3, "CID"], [1, 1, 39, 42, "CID"], [1, 1, 231, 233, "CID"], [1, 1, 291, 291, "CID"], [1, 1, 300, 300, "CID"], [1, 1, 343, 343, "CID"], [35, 35, 3, 3, "CID"], [35, 35, 39, 42, "CID"], [35, 35, 231, 233, "CID"], [35, 35, 291, 291, "CID"], [35, 35, 300, 300, "CID"], [35, 35, 343, 343, "CID"], [61, 61, 3, 3, "CID"], [61, 61, 39, 42, "CID"], [61, 61, 231, 233, "CID"], [61, 61, 291, 291, "CID"], [61, 61, 300, 300, "CID"], [61, 61, 343, 343, "CID"], [100, 100, 3, 3, "CID"], [100, 100, 39, 42, "CID"], [100, 100, 231, 233, "CID"], [100, 100, 291, 291, "CID"], [100, 100, 300, 300, "CID"], [100, 100, 343, 343, "CID"], [173, 173, 3, 3, "CID"], [173, 173, 39, 42, "CID"], [173, 173, 231, 233, "CID"], [173, 173, 291, 291, "CID"], [173, 173, 300, 300, "CID"], [173, 173, 343, 343, "CID"], [213, 213, 3, 3, "CID"], [213, 213, 39, 42, "CID"], [213, 213, 231, 233, "CID"], [213, 213, 291, 291, "CID"], [213, 213, 300, 300, "CID"], [213, 213, 343, 343, "CID"], [255, 255, 3, 3, "CID"], [255, 255, 39, 42, "CID"], [255, 255, 231, 233, "CID"], [255, 255, 291, 291, "CID"], [255, 255, 300, 300, "CID"], [255, 255, 343, 343, "CID"], [277, 277, 3, 3, "CID"], [277, 277, 39, 42, "CID"], [277, 277, 231, 233, "CID"], [277, 277, 291, 291, "CID"], [277, 277, 300, 300, "CID"], [277, 277, 343, 343, "CID"], [1, 1, 5, 6, "CID"], [1, 1, 44, 45, "CID"], [1, 1, 111, 114, "CID"], [1, 1, 247, 250, "CID"], [1, 1, 283, 286, "CID"], [1, 1, 322, 325, "CID"], [1, 1, 330, 333, "CID"], [35, 35, 5, 6, "CID"], [35, 35, 44, 45, "CID"], [35, 35, 111, 114, "CID"], [35, 35, 247, 250, "CID"], [35, 35, 283, 286, "CID"], [35, 35, 322, 325, "CID"], [35, 35, 330, 333, "CID"], [61, 61, 5, 6, "CID"], [61, 61, 44, 45, "CID"], [61, 61, 111, 114, "CID"], [61, 61, 247, 250, "CID"], [61, 61, 283, 286, "CID"], [61, 61, 322, 325, "CID"], [61, 61, 330, 333, "CID"], [100, 100, 5, 6, "CID"], [100, 100, 44, 45, "CID"], [100, 100, 111, 114, "CID"], [100, 100, 247, 250, "CID"], [100, 100, 283, 286, "CID"], [100, 100, 322, 325, "CID"], [100, 100, 330, 333, "CID"], [173, 173, 5, 6, "CID"], [173, 173, 44, 45, "CID"], [173, 173, 111, 114, "CID"], [173, 173, 247, 250, "CID"], [173, 173, 283, 286, "CID"], [173, 173, 322, 325, "CID"], [173, 173, 330, 333, "CID"], [213, 213, 5, 6, "CID"], [213, 213, 44, 45, "CID"], [213, 213, 111, 114, "CID"], [213, 213, 247, 250, "CID"], [213, 213, 283, 286, "CID"], [213, 213, 322, 325, "CID"], [213, 213, 330, 333, "CID"], [255, 255, 5, 6, "CID"], [255, 255, 44, 45, "CID"], [255, 255, 111, 114, "CID"], [255, 255, 247, 250, "CID"], [255, 255, 283, 286, "CID"], [255, 255, 322, 325, "CID"], [255, 255, 330, 333, "CID"], [277, 277, 5, 6, "CID"], [277, 277, 44, 45, "CID"], [277, 277, 111, 114, "CID"], [277, 277, 247, 250, "CID"], [277, 277, 283, 286, "CID"], [277, 277, 322, 325, "CID"], [277, 277, 330, 333, "CID"]]], "clusters": [], "translated": "产前<0>地塞米松</0>程序<8>高血压</8>和<14>肾损伤</14>的大鼠。地塞米松经常用于发育中的胎儿以加速肺部发育。本研究的目的是确定产前<1>地塞米松</1>是否会导致大鼠进行性<9>血压升高</9>和<15>肾损伤</15>。妊娠大鼠在妊娠第11和12、13和14、15和16、17和18天或第19和20天腹腔注射<2>地塞米松</2>（0.2 mg/kg体重）。在妊娠第15天和第16天给予<3>地塞米松</3>的大鼠后代在6至9个月大时与对照组相比<16>肾小球数量减少</16>20%（22 527 + /- 509与28 050 + /- 561相比，P < 0.05），这与3周龄时测量的肾小球百分数减少相当。在妊娠第17天和第18天接受产前<4>地塞米松</4>的6至9个月大的大鼠肾小球减少了17%（23 380 + /- 587）（P < 0.05），与对照大鼠相比。在妊娠第15天和第16天、第17天和第18天以及第13天和第14天接受产前<5>地塞米松</5>的雄性大鼠在6个月大时出现<10>血压升高</10>；后一组没有<17>肾小球数量减少</17>。在妊娠第15天和第16天给予<6>地塞米松</6>的成年大鼠比对照大鼠有更多的肾小球<21>肾小球硬化</21>。这项研究表明，产前<7>地塞米松</7>导致<18>肾小球数量减少</18>、<22>肾小球硬化</22>和<11>高血压</11>的大鼠在妊娠期间的特定时间点。在<12>高血压</12>的动物中观察到肾小球减少以及没有<19>肾小球数量减少</19> 的动物，这表明<20>肾小球减少数字</20>并不是<13>高血压</13>发展的唯一原因。", "revised": true}
{"doc_key": "12041669", "sentences": [["Antithymocyte", "globulin", "in", "the", "treatment", "of", "D", "-", "penicillamine", "-", "induced", "aplastic", "anemia", ".", "A", "patient", "who", "received", "antithymocyte", "globulin", "therapy", "for", "aplastic", "anemia", "due", "to", "D", "-", "penicillamine", "therapy", "is", "described", ".", "Bone", "marrow", "recovery", "and", "peripheral", "blood", "recovery", "were", "complete", "1", "month", "and", "3", "months", ",", "respectively", ",", "after", "treatment", ",", "and", "blood", "transfusion", "or", "other", "therapies", "were", "not", "necessary", "in", "a", "follow", "-", "up", "period", "of", "more", "than", "2", "years", ".", "Use", "of", "antithymocyte", "globulin", "may", "be", "the", "optimal", "treatment", "of", "D", "-", "penicillamine", "-", "induced", "aplastic", "anemia", "."]], "ner": [[[6, 8, "Chemical"], [26, 28, "Chemical"], [84, 86, "Chemical"], [11, 12, "Disease"], [22, 23, "Disease"], [89, 90, "Disease"], [0, 1, "Chemical"], [18, 19, "Chemical"], [76, 77, "Chemical"]]], "relations": [[[6, 8, 11, 12, "CID"], [6, 8, 22, 23, "CID"], [6, 8, 89, 90, "CID"], [26, 28, 11, 12, "CID"], [26, 28, 22, 23, "CID"], [26, 28, 89, 90, "CID"], [84, 86, 11, 12, "CID"], [84, 86, 22, 23, "CID"], [84, 86, 89, 90, "CID"]]], "clusters": [], "translated": "<6>抗胸腺细胞球蛋白</6>治疗<0>D-青霉胺</0><5>所致</5>的<3>再生障碍性贫血</3>。描述了因<1>D-青霉胺</1>治疗<4>再生障碍性贫血</4>而接受<7>抗胸腺细胞球蛋白</7>治疗的患者。骨髓恢复和外周血恢复分别在治疗后1个月和3个月完成，随访2年以上均无需输血或其他治疗。使用<8>抗胸腺细胞球蛋白</8>可能是治疗<2>D-青霉胺</2><5>所致</5>的<3>再生障碍性贫血</3>的最佳选择。", "revised": true}
{"doc_key": "11391224", "sentences": [["Peritubular", "capillary", "basement", "membrane", "reduplication", "in", "allografts", "and", "native", "kidney", "disease", ":", "a", "clinicopathologic", "study", "of", "278", "consecutive", "renal", "specimens", ".", "BACKGROUND", ":", "An", "association", "has", "been", "found", "between", "transplant", "glomerulopathy", "(", "TG", ")", "and", "reduplication", "of", "peritubular", "capillary", "basement", "membranes", "(", "PTCR", ")", ".", "Although", "such", "an", "association", "is", "of", "practical", "and", "theoretical", "importance", ",", "only", "one", "prospective", "study", "has", "tried", "to", "confirm", "it", ".", "METHODS", ":", "We", "examined", "278", "consecutive", "renal", "specimens", "(", "from", "135", "transplants", "and", "143", "native", "kidneys", ")", "for", "ultrastructural", "evidence", "of", "PTCR", ".", "In", "addition", "to", "renal", "allografts", "with", "TG", ",", "we", "also", "examined", "grafts", "with", "acute", "rejection", ",", "recurrent", "glomerulonephritis", ",", "chronic", "allograft", "nephropathy", "and", "stable", "grafts", "(", "\"", "protocol", "biopsies", "\"", ")", ".", "Native", "kidney", "specimens", "included", "a", "wide", "range", "of", "glomerulopathies", "as", "well", "as", "cases", "of", "thrombotic", "microangiopathy", ",", "malignant", "hypertension", ",", "acute", "interstitial", "nephritis", ",", "and", "acute", "tubular", "necrosis", ".", "RESULTS", ":", "We", "found", "PTCR", "in", "14", "of", "15", "cases", "of", "TG", ",", "in", "7", "transplant", "biopsy", "specimens", "without", "TG", ",", "and", "in", "13", "of", "143", "native", "kidney", "biopsy", "specimens", ".", "These", "13", "included", "cases", "of", "malignant", "hypertension", ",", "thrombotic", "microangiopathy", ",", "lupus", "nephritis", ",", "Henoch", "-", "Schonlein", "nephritis", ",", "crescentic", "glomerulonephritis", ",", "and", "cocaine", "-", "related", "acute", "renal", "failure", ".", "Mild", "PTCR", "in", "allografts", "without", "TG", "did", "not", "predict", "renal", "failure", "or", "significant", "proteinuria", "after", "follow", "-", "up", "periods", "of", "between", "3", "months", "and", "1", "year", ".", "CONCLUSIONS", ":", "We", "conclude", "that", "in", "transplants", ",", "there", "is", "a", "strong", "association", "between", "well", "-", "developed", "PTCR", "and", "TG", ",", "while", "the", "significance", "of", "mild", "PTCR", "and", "its", "predictive", "value", "in", "the", "absence", "of", "TG", "is", "unclear", ".", "PTCR", "also", "occurs", "in", "certain", "native", "kidney", "diseases", ",", "though", "the", "association", "is", "not", "as", "strong", "as", "that", "for", "TG", ".", "We", "suggest", "that", "repeated", "endothelial", "injury", ",", "including", "immunologic", "injury", ",", "may", "be", "the", "cause", "of", "this", "lesion", "both", "in", "allografts", "and", "native", "kidneys", "."]], "ner": [[[204, 204, "Chemical"], [207, 209, "Disease"], [9, 10, "Disease"], [29, 30, "Disease"], [32, 32, "Disease"], [95, 95, "Disease"], [129, 129, "Disease"], [161, 161, "Disease"], [169, 169, "Disease"], [216, 216, "Disease"], [257, 257, "Disease"], [273, 273, "Disease"], [283, 284, "Disease"], [296, 296, "Disease"], [106, 106, "Disease"], [201, 201, "Disease"], [108, 110, "Disease"], [135, 136, "Disease"], [189, 190, "Disease"], [138, 139, "Disease"], [186, 187, "Disease"], [142, 143, "Disease"], [146, 148, "Disease"], [192, 193, "Disease"], [195, 198, "Disease"], [220, 221, "Disease"], [224, 224, "Disease"], [302, 303, "Disease"], [306, 307, "Disease"]]], "relations": [[[204, 204, 207, 209, "CID"]]], "clusters": [], "translated": "同种异体移植物和天然<2>肾脏疾病</2>中的管周毛细血管基底膜重复：278个连续肾脏标本的临床病理学研究。背景：已发现<3>移植肾小球病</3>（<4>TG</4>）与肾小管周围毛细血管基底膜（PTCR）重复之间存在关联。尽管这种关联具有实践和理论重要性，但只有一项前瞻性研究试图证实这一点。方法：我们检查了278个连续的肾脏标本（来自135个移植肾和143个天然肾脏）以寻找PTCR的超微结构证据。除了具有<5>TG</5>的肾同种异体移植物外，我们还检查了具有急性排斥反应、复发性<14>肾小球肾炎</14>、<16>慢性同种异体移植肾病</16>和稳定移植物的移植物（“方案活检”）。本机肾脏标本包括范围广泛的<6>肾小球病</6>，以及<17>血栓性微血管病</17>、<19>恶性高血压</19>、急性<21>间质性肾炎</21>和<22>急性肾小管坏死</22>。结果：我们在15例<7>TG</7>病例中的14例、7例无<8>TG</8>的移植活检标本和143例自体肾活检标本中的13例中发现了PTCR。这13例包括<20>恶性高血压</20>、<18>血栓性微血管病</18>、<23>狼疮性肾炎</23>、<24>Henoch-Schonlein肾炎</24>、新月体<15>肾小球肾炎</15>和<0>可卡因</0>-相关的<1>急性肾功能衰竭</1>。在3个月至1年的随访期后，没有<9>TG</9>的同种异体移植物中的轻度PTCR不能预测<25>肾功能衰竭</25>或明显的<26>蛋白尿</26>。结论：我们得出结论，在移植中，发育良好的PTCR与<10>TG</10>之间存在很强的相关性，而轻度PTCR的重要性及其在没有<11>TG</11>的情况下的预测价值不清楚。PTCR也发生在某些本地<12>肾脏疾病</12>中，尽管这种关联不如<13>TG</13>强。我们认为，重复的<27>内皮细胞损伤</27>，包括<28>免疫损伤</28>，可能是同种异体移植物和天然肾脏中这种损伤的原因。", "revised": true}
{"doc_key": "14765563", "sentences": [["Risks", "of", "the", "consumption", "of", "beverages", "containing", "quinine", ".", "Although", "the", "United", "States", "Food", "and", "Drug", "Administration", "banned", "its", "use", "for", "nocturnal", "leg", "cramps", "due", "to", "lack", "of", "safety", "and", "efficacy", ",", "quinine", "is", "widely", "available", "in", "beverages", "including", "tonic", "water", "and", "bitter", "lemon", ".", "Numerous", "anecdotal", "reports", "suggest", "that", "products", "containing", "quinine", "may", "produce", "neurological", "complications", ",", "including", "confusion", ",", "altered", "mental", "status", ",", "seizures", ",", "and", "coma", ",", "particularly", "in", "older", "women", ".", "Psychologists", "need", "to", "inquire", "about", "consumption", "of", "quinine", "-", "containing", "beverages", "as", "part", "of", "an", "evaluation", "process", "."]], "ner": [[[7, 7, "Chemical"], [32, 32, "Chemical"], [52, 52, "Chemical"], [82, 82, "Chemical"], [59, 59, "Disease"], [65, 65, "Disease"], [68, 68, "Disease"], [21, 23, "Disease"], [55, 56, "Disease"]]], "relations": [[[7, 7, 59, 59, "CID"], [32, 32, 59, 59, "CID"], [52, 52, 59, 59, "CID"], [82, 82, 59, 59, "CID"], [7, 7, 65, 65, "CID"], [32, 32, 65, 65, "CID"], [52, 52, 65, 65, "CID"], [82, 82, 65, 65, "CID"], [7, 7, 68, 68, "CID"], [32, 32, 68, 68, "CID"], [52, 52, 68, 68, "CID"], [82, 82, 68, 68, "CID"]]], "clusters": [], "translated": "饮用含<0>奎宁</0>的饮料的风险。尽管美国食品和药物管理局因缺乏安全性和有效性而禁止将其用于<7>夜间腿部抽筋</7>，但<1>奎宁</1>广泛用于包括滋补水和苦柠檬在内的饮料中。许多轶事报告表明，含有<2>奎宁</2>的产品可能会产生<8>神经系统并发症</8>，包括<4>意识模糊</4>、<5>癫痫发作</5>、<6>昏迷</6>，尤其是老年妇女。作为评估过程的一部分，心理学家需要询问含<3>奎宁</3>的饮料的消费情况。", "revised": true}
{"doc_key": "11426838", "sentences": [["Conformationally", "restricted", "analogs", "of", "BD1008", "and", "an", "antisense", "oligodeoxynucleotide", "targeting", "sigma1", "receptors", "produce", "anti", "-", "cocaine", "effects", "in", "mice", ".", "Cocaine", "'s", "ability", "to", "interact", "with", "sigma", "receptors", "suggests", "that", "these", "proteins", "mediate", "some", "of", "its", "behavioral", "effects", ".", "Therefore", ",", "three", "novel", "sigma", "receptor", "ligands", "with", "antagonist", "activity", "were", "evaluated", "in", "Swiss", "Webster", "mice", ":", "BD1018", "(", "3S", "-", "1", "-", "[", "2", "-", "(", "3", ",", "4", "-", "dichlorophenyl", ")", "ethyl", "]", "-", "1", ",", "4", "-", "diazabicyclo", "[", "4", ".", "3", ".", "0", "]", "nonane", ")", ",", "BD1063", "(", "1", "-", "[", "2", "-", "(", "3", ",", "4", "-", "dichlorophenyl", ")", "ethyl", "]", "-", "4", "-", "methylpiperazine", ")", ",", "and", "LR132", "(", "1R", ",", "2S", "-", "(", "+", ")", "-", "cis", "-", "N", "-", "[", "2", "-", "(", "3", ",", "4", "-", "dichlorophenyl", ")", "ethyl", "]", "-", "2", "-", "(", "1", "-", "pyrrolidinyl", ")", "cyclohexylamine", ")", ".", "Competition", "binding", "assays", "demonstrated", "that", "all", "three", "compounds", "have", "high", "affinities", "for", "sigma1", "receptors", ".", "The", "three", "compounds", "vary", "in", "their", "affinities", "for", "sigma2", "receptors", "and", "exhibit", "negligible", "affinities", "for", "dopamine", ",", "opioid", ",", "GABA", "(", "A", ")", "and", "NMDA", "receptors", ".", "In", "behavioral", "studies", ",", "pre", "-", "treatment", "of", "mice", "with", "BD1018", ",", "BD1063", ",", "or", "LR132", "significantly", "attenuated", "cocaine", "-", "induced", "convulsions", "and", "lethality", ".", "Moreover", ",", "post", "-", "treatment", "with", "LR132", "prevented", "cocaine", "-", "induced", "lethality", "in", "a", "significant", "proportion", "of", "animals", ".", "In", "contrast", "to", "the", "protection", "provided", "by", "the", "putative", "antagonists", ",", "the", "well", "-", "characterized", "sigma", "receptor", "agonist", "di", "-", "o", "-", "tolylguanidine", "(", "DTG", ")", "and", "the", "novel", "sigma", "receptor", "agonist", "BD1031", "(", "3R", "-", "1", "-", "[", "2", "-", "(", "3", ",", "4", "-", "dichlorophenyl", ")", "ethyl", "]", "-", "1", ",", "4", "-", "diazabicyclo", "[", "4", ".", "3", ".", "0", "]", "nonane", ")", "each", "worsened", "the", "behavioral", "toxicity", "of", "cocaine", ".", "At", "doses", "where", "alone", ",", "they", "produced", "no", "significant", "effects", "on", "locomotion", ",", "BD1018", ",", "BD1063", "and", "LR132", "significantly", "attenuated", "the", "locomotor", "stimulatory", "effects", "of", "cocaine", ".", "To", "further", "validate", "the", "hypothesis", "that", "the", "anti", "-", "cocaine", "effects", "of", "the", "novel", "ligands", "involved", "antagonism", "of", "sigma", "receptors", ",", "an", "antisense", "oligodeoxynucleotide", "against", "sigma1", "receptors", "was", "also", "shown", "to", "significantly", "attenuate", "the", "convulsive", "and", "locomotor", "stimulatory", "effects", "of", "cocaine", ".", "Together", ",", "the", "data", "suggests", "that", "functional", "antagonism", "of", "sigma", "receptors", "is", "capable", "of", "attenuating", "a", "number", "of", "cocaine", "-", "induced", "behaviors", "."]], "ner": [[[15, 15, "Chemical"], [20, 20, "Chemical"], [210, 210, "Chemical"], [225, 225, "Chemical"], [307, 307, "Chemical"], [334, 334, "Chemical"], [345, 345, "Chemical"], [376, 376, "Chemical"], [396, 396, "Chemical"], [213, 213, "Disease"], [370, 370, "Disease"], [4, 4, "Chemical"], [305, 305, "Disease"], [8, 8, "Chemical"], [359, 359, "Chemical"], [90, 90, "Chemical"], [92, 109, "Chemical"], [204, 204, "Chemical"], [324, 324, "Chemical"], [180, 180, "Chemical"], [184, 184, "Chemical"], [189, 189, "Chemical"], [254, 258, "Chemical"], [260, 260, "Chemical"]]], "relations": [[[15, 15, 213, 213, "CID"], [15, 15, 370, 370, "CID"], [20, 20, 213, 213, "CID"], [20, 20, 370, 370, "CID"], [210, 210, 213, 213, "CID"], [210, 210, 370, 370, "CID"], [225, 225, 213, 213, "CID"], [225, 225, 370, 370, "CID"], [307, 307, 213, 213, "CID"], [307, 307, 370, 370, "CID"], [334, 334, 213, 213, "CID"], [334, 334, 370, 370, "CID"], [345, 345, 213, 213, "CID"], [345, 345, 370, 370, "CID"], [376, 376, 213, 213, "CID"], [376, 376, 370, 370, "CID"], [396, 396, 213, 213, "CID"], [396, 396, 370, 370, "CID"]]], "clusters": [], "translated": "<11>BD1008</11> 的构象限制类似物和靶向 sigma1 受体的反义<13>寡脱氧核苷酸</13>在小鼠体内产生抗<0>可卡因</0>作用。<1>可卡因</1>的能够与σ 受体相互作用表明这些受体介导了它的某些行为影响。因此，在 Swiss Webster 小鼠中评估了三种具有拮抗活性的新型 sigma 受体配体：BD1018（3S-1-[2-(3,4-二氯苯基)乙基]-1,4-二氮杂双环[4.3.0]壬烷）、<15>BD1063</15>（<16>1-[2-(3,4-二氯苯基)乙基]-4-甲基哌嗪</16>）和LR132（1R,2S-(+)-cis-N-[2-(3,4-二氯苯基)乙基]-2-(1-吡咯基)环己胺）。竞争结合实验证明，所有三种化合物都对 sigma1 受体具有高亲和力。这三种化合物对 sigma2 受体的亲和力不同，对<19>多巴胺</19>、阿片类药物、<20>GABA</20>(A)和<21>NMDA</21>受体的亲和力可以忽略不计。在行为研究中，用BD1018、<17>BD1063</17>或LR132对小鼠进行预处理可显着减轻<2>可卡因</2>引起的<9>抽搐</9>和致死率。此外，后处理用LR132可在相当大比例的动物中防止<3>可卡因</3>引起的致死率。与推定的拮抗剂提供的保护相反，充分表征的 sigma 受体激动剂<22>二-o-甲苯基胍</22>（<23>DTG</23>）和新型 sigma 受体激动剂BD1031（3R-1-[2-(3,4-二氯苯基)乙基]-1,4-二氮杂双环[4.3.0]壬烷）各自加重了<12>可卡因</12>的行为<4>毒性</4>。在单独剂量下，它们对运动没有产生显着影响，BD1018、<18>BD1063</18>和LR132显着减弱了<5>可卡因</5>的运动刺激作用。为了进一步验证新配体的抗<6>可卡因</6>作用涉及sigma受体拮抗作用的假设，针对sigma1受体的反义<14>寡脱氧核苷酸</14>也显示显着减弱<10>抽搐</10>和<7>可卡因</7>的运动刺激作用。总之，数据表明sigma受体的功能性拮抗作用能够减弱许多<8>可卡因</8>诱导的行为。", "revised": true}
{"doc_key": "11198499", "sentences": [["Hypotension", "following", "the", "initiation", "of", "tizanidine", "in", "a", "patient", "treated", "with", "an", "angiotensin", "converting", "enzyme", "inhibitor", "for", "chronic", "hypertension", ".", "Centrally", "acting", "alpha", "-", "2", "adrenergic", "agonists", "are", "one", "of", "several", "pharmacologic", "agents", "used", "in", "the", "treatment", "of", "spasticity", "related", "to", "disorders", "of", "the", "central", "nervous", "system", ".", "In", "addition", "to", "their", "effects", "on", "spasticity", ",", "certain", "adverse", "cardiorespiratory", "effects", "have", "been", "reported", ".", "Adults", "chronically", "treated", "with", "angiotensin", "converting", "enzyme", "inhibitors", "may", "have", "a", "limited", "ability", "to", "respond", "to", "hypotension", "when", "the", "sympathetic", "response", "is", "simultaneously", "blocked", ".", "The", "authors", "present", "a", "10", "-", "year", "-", "old", "boy", "chronically", "treated", "with", "lisinopril", ",", "an", "angiotensin", "converting", "enzyme", "inhibitor", ",", "to", "control", "hypertension", "who", "developed", "hypotension", "following", "the", "addition", "of", "tizanidine", ",", "an", "alpha", "-", "2", "agonist", ",", "for", "the", "treatment", "of", "spasticity", ".", "The", "possible", "interaction", "of", "tizanidine", "and", "other", "antihypertensive", "agents", "should", "be", "kept", "in", "mind", "when", "prescribing", "therapy", "to", "treat", "either", "hypertension", "or", "spasticity", "in", "such", "patients", "."]], "ner": [[[5, 5, "Chemical"], [120, 120, "Chemical"], [138, 138, "Chemical"], [0, 0, "Disease"], [80, 80, "Disease"], [115, 115, "Disease"], [102, 102, "Chemical"], [12, 12, "Chemical"], [68, 68, "Chemical"], [105, 105, "Chemical"], [18, 18, "Disease"], [112, 112, "Disease"], [154, 154, "Disease"], [38, 38, "Disease"], [54, 54, "Disease"], [132, 132, "Disease"], [156, 156, "Disease"], [41, 46, "Disease"]]], "relations": [[[5, 5, 0, 0, "CID"], [5, 5, 80, 80, "CID"], [5, 5, 115, 115, "CID"], [120, 120, 0, 0, "CID"], [120, 120, 80, 80, "CID"], [120, 120, 115, 115, "CID"], [138, 138, 0, 0, "CID"], [138, 138, 80, 80, "CID"], [138, 138, 115, 115, "CID"], [102, 102, 0, 0, "CID"], [102, 102, 80, 80, "CID"], [102, 102, 115, 115, "CID"]]], "clusters": [], "translated": " <3>低血压</3>  <0>替扎尼定</0> 治疗患者长期接受 <7>血管紧张素</7> 转换酶抑制剂治疗慢性<10>高血压</10> 后的<3>低血压</3>。中枢作用的α-2肾上腺素能激动剂是用于治疗与<17>中枢神经系统疾病</17>相关的<13>痉挛状态</13>的几种药物之一。除了它们对<14>痉挛状态</14>的影响外，还报道了某些不良的心肺功能。长期接受<8>血管紧张素</8>转换酶抑制剂治疗的成人可能对当交感神经反应同时被阻断时的<4>低血压</4>的反应能力受到限制。作者介绍了一名10岁男孩长期接受<6>赖诺普利</6>治疗，这是一种<9>血管紧张素</9>转化酶抑制剂，以控制<11>高血压</11>，他在加入<1>替扎尼定</1>后出现<5>低血压</5>，这是一种α-2激动剂，用于治疗<15>痉挛状态</15>。在为此类患者开处方治疗<12>高血压</12>或<16>痉挛</16>时，应牢记<2>替扎尼定</2>与其他抗高血压药物可能存在的相互作用。", "revised": true}
{"doc_key": "11569530", "sentences": [["Pharmacokinetic", "/", "pharmacodynamic", "assessment", "of", "the", "effects", "of", "E4031", ",", "cisapride", ",", "terfenadine", "and", "terodiline", "on", "monophasic", "action", "potential", "duration", "in", "dog", ".", "1", ".", "Torsades", "de", "pointes", "(", "TDP", ")", "is", "a", "potentially", "fatal", "ventricular", "tachycardia", "associated", "with", "increases", "in", "QT", "interval", "and", "monophasic", "action", "potential", "duration", "(", "MAPD", ")", ".", "TDP", "is", "a", "side", "-", "effect", "that", "has", "led", "to", "withdrawal", "of", "several", "drugs", "from", "the", "market", "(", "e", ".", "g", ".", "terfenadine", "and", "terodiline", ")", ".", "2", ".", "The", "potential", "of", "compounds", "to", "cause", "TDP", "was", "evaluated", "by", "monitoring", "their", "effects", "on", "MAPD", "in", "dog", ".", "Four", "compounds", "known", "to", "increase", "QT", "interval", "and", "cause", "TDP", "were", "investigated", ":", "terfenadine", ",", "terodiline", ",", "cisapride", "and", "E4031", ".", "On", "the", "basis", "that", "only", "free", "drug", "in", "the", "systemic", "circulation", "will", "elicit", "a", "pharmacological", "response", "target", ",", "free", "concentrations", "in", "plasma", "were", "selected", "to", "mimic", "the", "free", "drug", "exposures", "in", "man", ".", "Infusion", "regimens", "were", "designed", "that", "rapidly", "achieved", "and", "maintained", "target", "-", "free", "concentrations", "of", "these", "drugs", "in", "plasma", "and", "data", "on", "the", "relationship", "between", "free", "concentration", "and", "changes", "in", "MAPD", "were", "obtained", "for", "these", "compounds", ".", "3", ".", "These", "data", "indicate", "that", "the", "free", "ED50", "in", "plasma", "for", "terfenadine", "(", "1", ".", "9", "nM", ")", ",", "terodiline", "(", "76", "nM", ")", ",", "cisapride", "(", "11", "nM", ")", "and", "E4031", "(", "1", ".", "9", "nM", ")", "closely", "correlate", "with", "the", "free", "concentration", "in", "man", "causing", "QT", "effects", ".", "For", "compounds", "that", "have", "shown", "TDP", "in", "the", "clinic", "(", "terfenadine", ",", "terodiline", ",", "cisapride", ")", "there", "is", "little", "differentiation", "between", "the", "dog", "ED50", "and", "the", "efficacious", "free", "plasma", "concentrations", "in", "man", "(", "<", "10", "-", "fold", ")", "reflecting", "their", "limited", "safety", "margins", ".", "These", "data", "underline", "the", "need", "to", "maximize", "the", "therapeutic", "ratio", "with", "respect", "to", "TDP", "in", "potential", "development", "candidates", "and", "the", "importance", "of", "using", "free", "drug", "concentrations", "in", "pharmacokinetic", "/", "pharmacodynamic", "studies", "."]], "ner": [[[10, 10, "Chemical"], [116, 116, "Chemical"], [215, 215, "Chemical"], [254, 254, "Chemical"], [25, 27, "Disease"], [29, 29, "Disease"], [52, 52, "Disease"], [87, 87, "Disease"], [108, 108, "Disease"], [245, 245, "Disease"], [297, 297, "Disease"], [12, 12, "Chemical"], [74, 74, "Chemical"], [112, 112, "Chemical"], [201, 201, "Chemical"], [250, 250, "Chemical"], [14, 14, "Chemical"], [76, 76, "Chemical"], [114, 114, "Chemical"], [209, 209, "Chemical"], [252, 252, "Chemical"], [8, 8, "Chemical"], [118, 118, "Chemical"], [221, 221, "Chemical"], [35, 36, "Disease"]]], "relations": [[[10, 10, 25, 27, "CID"], [10, 10, 29, 29, "CID"], [10, 10, 52, 52, "CID"], [10, 10, 87, 87, "CID"], [10, 10, 108, 108, "CID"], [10, 10, 245, 245, "CID"], [10, 10, 297, 297, "CID"], [116, 116, 25, 27, "CID"], [116, 116, 29, 29, "CID"], [116, 116, 52, 52, "CID"], [116, 116, 87, 87, "CID"], [116, 116, 108, 108, "CID"], [116, 116, 245, 245, "CID"], [116, 116, 297, 297, "CID"], [215, 215, 25, 27, "CID"], [215, 215, 29, 29, "CID"], [215, 215, 52, 52, "CID"], [215, 215, 87, 87, "CID"], [215, 215, 108, 108, "CID"], [215, 215, 245, 245, "CID"], [215, 215, 297, 297, "CID"], [254, 254, 25, 27, "CID"], [254, 254, 29, 29, "CID"], [254, 254, 52, 52, "CID"], [254, 254, 87, 87, "CID"], [254, 254, 108, 108, "CID"], [254, 254, 245, 245, "CID"], [254, 254, 297, 297, "CID"], [12, 12, 25, 27, "CID"], [12, 12, 29, 29, "CID"], [12, 12, 52, 52, "CID"], [12, 12, 87, 87, "CID"], [12, 12, 108, 108, "CID"], [12, 12, 245, 245, "CID"], [12, 12, 297, 297, "CID"], [74, 74, 25, 27, "CID"], [74, 74, 29, 29, "CID"], [74, 74, 52, 52, "CID"], [74, 74, 87, 87, "CID"], [74, 74, 108, 108, "CID"], [74, 74, 245, 245, "CID"], [74, 74, 297, 297, "CID"], [112, 112, 25, 27, "CID"], [112, 112, 29, 29, "CID"], [112, 112, 52, 52, "CID"], [112, 112, 87, 87, "CID"], [112, 112, 108, 108, "CID"], [112, 112, 245, 245, "CID"], [112, 112, 297, 297, "CID"], [201, 201, 25, 27, "CID"], [201, 201, 29, 29, "CID"], [201, 201, 52, 52, "CID"], [201, 201, 87, 87, "CID"], [201, 201, 108, 108, "CID"], [201, 201, 245, 245, "CID"], [201, 201, 297, 297, "CID"], [250, 250, 25, 27, "CID"], [250, 250, 29, 29, "CID"], [250, 250, 52, 52, "CID"], [250, 250, 87, 87, "CID"], [250, 250, 108, 108, "CID"], [250, 250, 245, 245, "CID"], [250, 250, 297, 297, "CID"], [14, 14, 25, 27, "CID"], [14, 14, 29, 29, "CID"], [14, 14, 52, 52, "CID"], [14, 14, 87, 87, "CID"], [14, 14, 108, 108, "CID"], [14, 14, 245, 245, "CID"], [14, 14, 297, 297, "CID"], [76, 76, 25, 27, "CID"], [76, 76, 29, 29, "CID"], [76, 76, 52, 52, "CID"], [76, 76, 87, 87, "CID"], [76, 76, 108, 108, "CID"], [76, 76, 245, 245, "CID"], [76, 76, 297, 297, "CID"], [114, 114, 25, 27, "CID"], [114, 114, 29, 29, "CID"], [114, 114, 52, 52, "CID"], [114, 114, 87, 87, "CID"], [114, 114, 108, 108, "CID"], [114, 114, 245, 245, "CID"], [114, 114, 297, 297, "CID"], [209, 209, 25, 27, "CID"], [209, 209, 29, 29, "CID"], [209, 209, 52, 52, "CID"], [209, 209, 87, 87, "CID"], [209, 209, 108, 108, "CID"], [209, 209, 245, 245, "CID"], [209, 209, 297, 297, "CID"], [252, 252, 25, 27, "CID"], [252, 252, 29, 29, "CID"], [252, 252, 52, 52, "CID"], [252, 252, 87, 87, "CID"], [252, 252, 108, 108, "CID"], [252, 252, 245, 245, "CID"], [252, 252, 297, 297, "CID"]]], "clusters": [], "translated": "<21>E4031</21>、<0>西沙必利</0>、<11>特非那定</11>和<16>特罗地林</16>对犬单相动作电位持续时间影响的药代动力学/药效学评价。1. <4>尖端扭转型室性心动过速</4>（<5>TDP</5>）是一种可能致命的<24>室性心动过速</24>，与QT间期和单相动作电位时程（MAPD）的增加有关。 <6>TDP</6>是一种副作用，已导致几种药物从市场上撤下（例如<12>特非那定</12>和<17>特罗地林</17>）。2.化合物引起<7>TDP</7>的可能性是通过监测它们对狗的MAPD的影响来评估的。研究了四种已知会增加QT间期并导致<8>TDP</8>的化合物：<13>特非那定</13>、<18>特罗地林</18>、<1>西沙必利</1>和<22>E4031</22>。基于只有体循环中的游离药物才会引起药理反应靶点，选择血浆中的游离浓度来模拟人体的游离药物暴露。设计的输注方案可快速达到并维持这些药物在血浆中的无靶标浓度，并获得了这些化合物的游离浓度与MAPD变化之间关系的数据。3.这些数据表明，<14>特非那定</14>（1.9 nM）、<19>特罗地林</19>（76 nM）、<2>西沙必利</2>（11 nM）和<23>E4031</23>（1.9 nM）在血浆中的游离ED50和引起QT效应的游离浓度密切相关。对于在临床上显示<9>TDP</9>的化合物（<15>特非那定</15>、<20>特罗地林</20>、<3>西沙必利</3>），两者之间几乎没有区别，狗的ED50和人的有效游离血浆浓度（<10倍）反映了它们有限的安全范围。这些数据强调了在潜在开发候选药物中最大化<10>TDP</10>治疗比的必要性，以及在药代动力学/药效学研究中使用游离药物浓度的重要性。", "revised": true}
{"doc_key": "12789195", "sentences": [["Pseudoacromegaly", "induced", "by", "the", "long", "-", "term", "use", "of", "minoxidil", ".", "Acromegaly", "is", "an", "endocrine", "disorder", "caused", "by", "chronic", "excessive", "growth", "hormone", "secretion", "from", "the", "anterior", "pituitary", "gland", ".", "Significant", "disfiguring", "changes", "occur", "as", "a", "result", "of", "bone", ",", "cartilage", ",", "and", "soft", "tissue", "hypertrophy", ",", "including", "the", "thickening", "of", "the", "skin", ",", "coarsening", "of", "facial", "features", ",", "and", "cutis", "verticis", "gyrata", ".", "Pseudoacromegaly", ",", "on", "the", "other", "hand", ",", "is", "the", "presence", "of", "similar", "acromegaloid", "features", "in", "the", "absence", "of", "elevated", "growth", "hormone", "or", "insulin", "-", "like", "growth", "factor", "levels", ".", "We", "present", "a", "patient", "with", "pseudoacromegaly", "that", "resulted", "from", "the", "long", "-", "term", "use", "of", "minoxidil", "at", "an", "unusually", "high", "dose", ".", "This", "is", "the", "first", "case", "report", "of", "pseudoacromegaly", "as", "a", "side", "effect", "of", "minoxidil", "use", "."]], "ner": [[[9, 9, "Chemical"], [107, 107, "Chemical"], [127, 127, "Chemical"], [11, 11, "Disease"], [0, 0, "Disease"], [63, 63, "Disease"], [97, 97, "Disease"], [121, 121, "Disease"], [14, 15, "Disease"], [44, 44, "Disease"], [59, 61, "Disease"]]], "relations": [[[9, 9, 11, 11, "CID"], [107, 107, 11, 11, "CID"], [127, 127, 11, 11, "CID"]]], "clusters": [], "translated": "<4>假性肢端肥大症</4> 长期服用<0>米诺地尔</0>所致。 <3>肢端肥大症</3>是一种<8>内分泌失调</8>，由脑垂体前叶长期过度分泌生长激素所致。骨骼、软骨和软组织<9>肥大</9>会导致显着的毁容性变化，包括皮肤增厚、面部特征变粗和<10>皮脂瘤</10>。 <5>假性肢端肥大症</5>，另一方面，是在没有升高的生长激素或胰岛素样生长因子水平的情况下存在类似的肢端肥大样特征。我们介绍了一名患有<6>假性肢端肥大症</6>的患者，该患者因长期使用异常高剂量的<1>米诺地尔</1>而导致。这是第一例<7>假性肢端肥大症</7>作为<2>米诺地尔</2>使用的副作用的病例报告。", "revised": true}
{"doc_key": "12198388", "sentences": [["The", "relationship", "between", "hippocampal", "acetylcholine", "release", "and", "cholinergic", "convulsant", "sensitivity", "in", "withdrawal", "seizure", "-", "prone", "and", "withdrawal", "seizure", "-", "resistant", "selected", "mouse", "lines", ".", "BACKGROUND", ":", "The", "septo", "-", "hippocampal", "cholinergic", "pathway", "has", "been", "implicated", "in", "epileptogenesis", ",", "and", "genetic", "factors", "influence", "the", "response", "to", "cholinergic", "agents", ",", "but", "limited", "data", "are", "available", "on", "cholinergic", "involvement", "in", "alcohol", "withdrawal", "severity", ".", "Thus", ",", "the", "relationship", "between", "cholinergic", "activity", "and", "responsiveness", "and", "alcohol", "withdrawal", "was", "investigated", "in", "a", "genetic", "animal", "model", "of", "ethanol", "withdrawal", "severity", ".", "METHODS", ":", "Cholinergic", "convulsant", "sensitivity", "was", "examined", "in", "alcohol", "-", "na", "ve", "Withdrawal", "Seizure", "-", "Prone", "(", "WSP", ")", "and", "-", "Resistant", "(", "WSR", ")", "mice", ".", "Animals", "were", "administered", "nicotine", ",", "carbachol", ",", "or", "neostigmine", "via", "timed", "tail", "vein", "infusion", ",", "and", "the", "latencies", "to", "onset", "of", "tremor", "and", "clonus", "were", "recorded", "and", "converted", "to", "threshold", "dose", ".", "We", "also", "used", "microdialysis", "to", "measure", "basal", "and", "potassium", "-", "stimulated", "acetylcholine", "(", "ACh", ")", "release", "in", "the", "CA1", "region", "of", "the", "hippocampus", ".", "Potassium", "was", "applied", "by", "reverse", "dialysis", "twice", ",", "separated", "by", "75", "min", ".", "Hippocampal", "ACh", "also", "was", "measured", "during", "testing", "for", "handling", "-", "induced", "convulsions", ".", "RESULTS", ":", "Sensitivity", "to", "several", "convulsion", "endpoints", "induced", "by", "nicotine", ",", "carbachol", ",", "and", "neostigmine", "were", "significantly", "greater", "in", "WSR", "versus", "WSP", "mice", ".", "In", "microdialysis", "experiments", ",", "the", "lines", "did", "not", "differ", "in", "basal", "release", "of", "ACh", ",", "and", "50", "mM", "KCl", "increased", "ACh", "output", "in", "both", "lines", "of", "mice", ".", "However", ",", "the", "increase", "in", "release", "of", "ACh", "produced", "by", "the", "first", "application", "of", "KCl", "was", "2", "-", "fold", "higher", "in", "WSP", "versus", "WSR", "mice", ".", "When", "hippocampal", "ACh", "was", "measured", "during", "testing", "for", "handling", "-", "induced", "convulsions", ",", "extracellular", "ACh", "was", "significantly", "elevated", "(", "192", "%", ")", "in", "WSP", "mice", ",", "but", "was", "nonsignificantly", "elevated", "(", "59", "%", ")", "in", "WSR", "mice", ".", "CONCLUSIONS", ":", "These", "results", "suggest", "that", "differences", "in", "cholinergic", "activity", "and", "postsynaptic", "sensitivity", "to", "cholinergic", "convulsants", "may", "be", "associated", "with", "ethanol", "withdrawal", "severity", "and", "implicate", "cholinergic", "mechanisms", "in", "alcohol", "withdrawal", ".", "Specifically", ",", "WSP", "mice", "may", "have", "lower", "sensitivity", "to", "cholinergic", "convulsants", "compared", "with", "WSR", "because", "of", "postsynaptic", "receptor", "desensitization", "brought", "on", "by", "higher", "activity", "of", "cholinergic", "neurons", "."]], "ner": [[[115, 115, "Chemical"], [203, 203, "Chemical"], [12, 12, "Disease"], [17, 17, "Disease"], [98, 98, "Disease"], [192, 192, "Disease"], [199, 199, "Disease"], [283, 283, "Disease"], [325, 325, "Disease"], [351, 351, "Disease"], [117, 117, "Chemical"], [205, 205, "Chemical"], [120, 120, "Chemical"], [208, 208, "Chemical"], [4, 4, "Chemical"], [155, 155, "Chemical"], [157, 157, "Chemical"], [182, 182, "Chemical"], [231, 231, "Chemical"], [238, 238, "Chemical"], [253, 253, "Chemical"], [274, 274, "Chemical"], [286, 286, "Chemical"], [133, 133, "Disease"], [57, 57, "Chemical"], [71, 71, "Chemical"], [81, 81, "Chemical"], [93, 93, "Chemical"], [330, 330, "Chemical"], [338, 338, "Chemical"], [152, 152, "Chemical"], [168, 168, "Chemical"], [236, 236, "Chemical"], [260, 260, "Chemical"]]], "relations": [[[115, 115, 12, 12, "CID"], [115, 115, 17, 17, "CID"], [115, 115, 98, 98, "CID"], [115, 115, 192, 192, "CID"], [115, 115, 199, 199, "CID"], [115, 115, 283, 283, "CID"], [115, 115, 325, 325, "CID"], [115, 115, 351, 351, "CID"], [203, 203, 12, 12, "CID"], [203, 203, 17, 17, "CID"], [203, 203, 98, 98, "CID"], [203, 203, 192, 192, "CID"], [203, 203, 199, 199, "CID"], [203, 203, 283, 283, "CID"], [203, 203, 325, 325, "CID"], [203, 203, 351, 351, "CID"], [117, 117, 12, 12, "CID"], [117, 117, 17, 17, "CID"], [117, 117, 98, 98, "CID"], [117, 117, 192, 192, "CID"], [117, 117, 199, 199, "CID"], [117, 117, 283, 283, "CID"], [117, 117, 325, 325, "CID"], [117, 117, 351, 351, "CID"], [205, 205, 12, 12, "CID"], [205, 205, 17, 17, "CID"], [205, 205, 98, 98, "CID"], [205, 205, 192, 192, "CID"], [205, 205, 199, 199, "CID"], [205, 205, 283, 283, "CID"], [205, 205, 325, 325, "CID"], [205, 205, 351, 351, "CID"], [120, 120, 12, 12, "CID"], [120, 120, 17, 17, "CID"], [120, 120, 98, 98, "CID"], [120, 120, 192, 192, "CID"], [120, 120, 199, 199, "CID"], [120, 120, 283, 283, "CID"], [120, 120, 325, 325, "CID"], [120, 120, 351, 351, "CID"], [208, 208, 12, 12, "CID"], [208, 208, 17, 17, "CID"], [208, 208, 98, 98, "CID"], [208, 208, 192, 192, "CID"], [208, 208, 199, 199, "CID"], [208, 208, 283, 283, "CID"], [208, 208, 325, 325, "CID"], [208, 208, 351, 351, "CID"]]], "clusters": [], "translated": "海马<14>乙酰胆碱</14>释放与胆碱能惊厥敏感性之间的关系，在戒断<2>癫痫发作</2>倾向和戒断<3>癫痫发作</3>抵抗选择小鼠品系。背景：隔海马胆碱能通路与癫痫发生有关，遗传因素影响对胆碱能药物的反应，但关于胆碱能参与<24>酒精</24>戒断严重程度的数据有限。因此，在<26>乙醇</26>戒断严重程度的遗传动物模型中研究了胆碱能活性和反应性与<25>酒精</25>戒断之间的关系。方法：在<27>酒精</27>-初始戒断<4>癫痫</4>-易发（WSP）和抗性（WSR）小鼠中检测胆碱能惊厥敏感性。通过定时尾静脉输注给动物<0>尼古丁</0>、<10>卡巴胆碱</10>或<12>新斯的明</12>，以及<23>震颤</23>发作的潜伏期和阵挛被记录并转换为阈值剂量。我们还使用微透析法测量海马体CA1区的基础释放和<30>钾</30>刺激的<15>乙酰胆碱</15> (<16>ACh</16>)释放。 <31>钾</31>反透析两次，间隔75 min。海马<17>ACh</17>还在测试过程中测量了处理引起的<5>抽搐</5>。结果：WSR与WSP相比，<1>尼古丁</1>、<11>卡巴胆碱</11>和<13>新斯的明</13>对几个<6>惊厥</6>终点的敏感性显着更高。在微透析实验中，两种小鼠品系的<18>ACh</18>基础释放没有差异，50 mM<32>KCl</32>增加了<19>ACh</19>输出。然而，WSP小鼠与WSR小鼠相比，首次应用<33>KCl</33>产生的<20>ACh</20>释放增加了2倍。当海马体<21>ACh</21>在测试处理引起的<7>抽搐</7>时，WSP小鼠的细胞外<22>ACh</22>显着升高（192%），但没有显着性在WSR小鼠中升高（59%）。结论：这些结果表明，胆碱能活性和对胆碱能<8>惊厥药</8>的突触后敏感性的差异可能与<28>乙醇</28>戒断严重程度相关，并暗示了<29>酒精</29>中的胆碱能机制退出。具体而言，与WSR相比，WSP小鼠对胆碱能<9>惊厥</9>的敏感性可能较低，这是因为胆碱能神经元的较高活性导致突触后受体脱敏。", "revised": true}
{"doc_key": "14657095", "sentences": [["Reversible", "dilated", "cardiomyopathy", "related", "to", "amphotericin", "B", "therapy", ".", "We", "describe", "a", "patient", "who", "developed", "dilated", "cardiomyopathy", "and", "clinical", "congestive", "heart", "failure", "after", "2", "months", "of", "therapy", "with", "amphotericin", "B", "(", "AmB", ")", "for", "disseminated", "coccidioidomycosis", ".", "His", "echocardiographic", "abnormalities", "and", "heart", "failure", "resolved", "after", "posaconazole", "was", "substituted", "for", "AmB", ".", "It", "is", "important", "to", "recognize", "the", "rare", "and", "potentially", "reversible", "toxicity", "of", "AmB", "."]], "ner": [[[5, 6, "Chemical"], [28, 29, "Chemical"], [31, 31, "Chemical"], [49, 49, "Chemical"], [63, 63, "Chemical"], [1, 2, "Disease"], [15, 16, "Disease"], [20, 21, "Disease"], [41, 42, "Disease"], [45, 45, "Chemical"], [35, 35, "Disease"], [61, 61, "Disease"]]], "relations": [[[5, 6, 1, 2, "CID"], [5, 6, 15, 16, "CID"], [28, 29, 1, 2, "CID"], [28, 29, 15, 16, "CID"], [31, 31, 1, 2, "CID"], [31, 31, 15, 16, "CID"], [49, 49, 1, 2, "CID"], [49, 49, 15, 16, "CID"], [63, 63, 1, 2, "CID"], [63, 63, 15, 16, "CID"], [5, 6, 20, 21, "CID"], [5, 6, 41, 42, "CID"], [28, 29, 20, 21, "CID"], [28, 29, 41, 42, "CID"], [31, 31, 20, 21, "CID"], [31, 31, 41, 42, "CID"], [49, 49, 20, 21, "CID"], [49, 49, 41, 42, "CID"], [63, 63, 20, 21, "CID"], [63, 63, 41, 42, "CID"]]], "clusters": [], "translated": "与<0>两性霉素B</0>治疗相关的可逆性<5>扩张型心肌病</5>。我们描述了一名患者，在使用<1>两性霉素B</1> (<2>AmB</2>) 用于播散性<10>球孢子菌病</10> 2 个月后，出现临床性充血性<7>心力衰竭</7>和<6>扩张型心肌病</6>。在用<9>泊沙康唑</9>替代<3>AmB</3>后，他的心脏超声图异常和<8>心力衰竭</8>得到解决。重要的是要认识到<4>AmB</4>的罕见且可能可逆的<11>毒性</11>。", "revised": true}
{"doc_key": "8690168", "sentences": [["Reduction", "of", "heparan", "sulphate", "-", "associated", "anionic", "sites", "in", "the", "glomerular", "basement", "membrane", "of", "rats", "with", "streptozotocin", "-", "induced", "diabetic", "nephropathy", ".", "Heparan", "sulphate", "-", "associated", "anionic", "sites", "in", "the", "glomerular", "basement", "membrane", "were", "studied", "in", "rats", "8", "months", "after", "induction", "of", "diabetes", "by", "streptozotocin", "and", "in", "age", "-", "adn", "sex", "-", "matched", "control", "rats", ",", "employing", "the", "cationic", "dye", "cuprolinic", "blue", ".", "Morphometric", "analysis", "at", "the", "ultrastructural", "level", "was", "performed", "using", "a", "computerized", "image", "processor", ".", "The", "heparan", "sulphate", "specificity", "of", "the", "cuprolinic", "blue", "staining", "was", "demonstrated", "by", "glycosaminoglycan", "-", "degrading", "enzymes", ",", "showing", "that", "pretreatment", "of", "the", "sections", "with", "heparitinase", "abolished", "all", "staining", ",", "whereas", "chondroitinase", "ABC", "had", "no", "effect", ".", "The", "majority", "of", "anionic", "sites", "(", "74", "%", "in", "diabetic", "and", "81", "%", "in", "control", "rats", ")", "were", "found", "within", "the", "lamina", "rara", "externa", "of", "the", "glomerular", "basement", "membrane", ".", "A", "minority", "of", "anionic", "sites", "were", "scattered", "throughout", "the", "lamina", "densa", "and", "lamina", "rara", "interna", ",", "and", "were", "significantly", "smaller", "than", "those", "in", "the", "lamina", "rara", "externa", "of", "the", "glomerular", "basement", "membrane", "(", "p", "<", "0", ".", "001", "and", "p", "<", "0", ".", "01", "for", "diabetic", "and", "control", "rats", ",", "respectively", ")", ".", "Diabetic", "rats", "progressively", "developed", "albuminuria", "reaching", "40", ".", "3", "(", "32", ".", "2", "-", "62", ".", "0", ")", "mg", "/", "24", "h", "after", "8", "months", "in", "contrast", "to", "the", "control", "animals", "(", "0", ".", "8", "(", "0", ".", "2", "-", "0", ".", "9", ")", "mg", "/", "24", "h", ",", "p", "<", "0", ".", "002", ")", ".", "At", "the", "same", "time", ",", "the", "number", "of", "heparan", "sulphate", "anionic", "sites", "and", "the", "total", "anionic", "site", "surface", "(", "number", "of", "anionic", "sites", "x", "mean", "anionic", "site", "surface", ")", "in", "the", "lamina", "rara", "externa", "of", "the", "glomerular", "basement", "membrane", "was", "reduced", "by", "19", "%", "(", "p", "<", "0", ".", "021", ")", "and", "by", "26", "%", "(", "p", "<", "0", ".", "02", ")", ",", "respectively", ".", "Number", "and", "total", "anionic", "site", "surface", "in", "the", "remaining", "part", "of", "the", "glomerular", "basement", "membrane", "(", "lamina", "densa", "and", "lamina", "rara", "interna", ")", "were", "not", "significantly", "changed", ".", "We", "conclude", "that", "in", "streptozotocin", "-", "diabetic", "rats", "with", "an", "increased", "urinary", "albumin", "excretion", ",", "a", "reduced", "heparan", "sulphate", "charge", "barrier", "/", "density", "is", "found", "at", "the", "lamina", "rara", "externa", "of", "the", "glomerular", "basement", "membrane", "."]], "ner": [[[16, 16, "Chemical"], [44, 44, "Chemical"], [349, 349, "Chemical"], [19, 20, "Disease"], [2, 3, "Chemical"], [22, 23, "Chemical"], [78, 79, "Chemical"], [260, 261, "Chemical"], [362, 363, "Chemical"], [42, 42, "Disease"], [122, 122, "Disease"], [188, 188, "Disease"], [196, 196, "Disease"], [351, 351, "Disease"], [200, 200, "Disease"], [60, 61, "Chemical"], [83, 84, "Chemical"], [89, 89, "Chemical"]]], "relations": [[[16, 16, 19, 20, "CID"], [44, 44, 19, 20, "CID"], [349, 349, 19, 20, "CID"]]], "clusters": [], "translated": "减少<4>硫酸乙酰肝素</4>-<0>链脲佐菌素</0>诱导的<3>糖尿病肾病</3>大鼠肾小球基底膜中的阴离子位点。<5>硫酸乙酰肝素</5>- 在<1>链脲佐菌素</1>诱导<9>糖尿病</9>后8个月以及年龄和性别匹配的对照大鼠中研究了肾小球基底膜中相关的阴离子位点，使用阳离子染料<15>铜氨蓝</15>。使用计算机图像处理器进行超微结构水平的形态学分析。 <6>硫酸乙酰肝素</6><16>铜氨蓝</16> 染色的特异性由<17>糖胺聚糖</17>降解酶证实，表明用肝素酶预处理切片可消除所有染色，而软骨素酶ABC没有效果。大多数阴离子位点（<10>糖尿病</10>大鼠中为74%，对照组大鼠中为81%）位于肾小球基底膜稀薄外侧层。少数阴离子位点散布在整个致密层和内稀层，并且明显小于肾小球基底膜稀薄外侧层中的阴离子位点(p<0.001和p<0.01<11>糖尿病</11>和对照大鼠，分别)。 <12>糖尿病</12>大鼠逐渐出现<14>白蛋白尿</14>，达到40.3 (32.2-62.0)毫克/24小时，与对照动物相比(0.8 (0.2-0.9)毫克/24小时，p<0.002)。同时，肾小球基底膜外稀层的<7>硫酸乙酰肝素</7>阴离子位点数和总阴离子位点表面积(阴离子位点数x平均阴离子位点表面积)减少了19% (p<0.021)和26% (p<0.02)。肾小球基底膜其余部分(致密层和内稀层)的数量和总阴离子位点表面没有明显变化。我们得出结论，在<2>链脲佐菌素</2>-<13>糖尿病</13> 大鼠中，尿白蛋白排泄增加，位于肾小球基底膜的稀薄外侧层的<8>硫酸乙酰肝素</8>电荷屏障/密度降低。", "revised": true}
{"doc_key": "12615818", "sentences": [["The", "risk", "of", "venous", "thromboembolism", "in", "women", "prescribed", "cyproterone", "acetate", "in", "combination", "with", "ethinyl", "estradiol", ":", "a", "nested", "cohort", "analysis", "and", "case", "-", "control", "study", ".", "BACKGROUND", ":", "Cyproterone", "acetate", "combined", "with", "ethinyl", "estradiol", "(", "CPA", "/", "EE", ")", "is", "licensed", "in", "the", "UK", "for", "the", "treatment", "of", "women", "with", "acne", "and", "hirsutism", "and", "is", "also", "a", "treatment", "option", "for", "polycystic", "ovary", "syndrome", "(", "PCOS", ")", ".", "Previous", "studies", "have", "demonstrated", "an", "increased", "risk", "of", "venous", "thromboembolism", "(", "VTE", ")", "associated", "with", "CPA", "/", "EE", "compared", "with", "conventional", "combined", "oral", "contraceptives", "(", "COCs", ")", ".", "We", "believe", "the", "results", "of", "those", "studies", "may", "have", "been", "affected", "by", "residual", "confounding", ".", "METHODS", ":", "Using", "the", "General", "Practice", "Research", "Database", "we", "conducted", "a", "cohort", "analysis", "and", "case", "-", "control", "study", "nested", "within", "a", "population", "of", "women", "aged", "between", "15", "and", "39", "years", "with", "acne", ",", "hirsutism", "or", "PCOS", "to", "estimate", "the", "risk", "of", "VTE", "associated", "with", "CPA", "/", "EE", ".", "RESULTS", ":", "The", "age", "-", "adjusted", "incidence", "rate", "ratio", "for", "CPA", "/", "EE", "versus", "conventional", "COCs", "was", "2", ".", "20", "[", "95", "%", "confidence", "interval", "(", "CI", ")", "1", ".", "35", "-", "3", ".", "58", "]", ".", "Using", "as", "the", "reference", "group", "women", "who", "were", "not", "using", "oral", "contraception", ",", "had", "no", "recent", "pregnancy", "or", "menopausal", "symptoms", ",", "the", "case", "-", "control", "analysis", "gave", "an", "adjusted", "odds", "ratio", "(", "OR", "(", "adj", ")", ")", "of", "7", ".", "44", "(", "95", "%", "CI", "3", ".", "67", "-", "15", ".", "08", ")", "for", "CPA", "/", "EE", "use", "compared", "with", "an", "OR", "(", "adj", ")", "of", "2", ".", "58", "(", "95", "%", "CI", "1", ".", "60", "-", "4", ".", "18", ")", "for", "use", "of", "conventional", "COCs", ".", "CONCLUSIONS", ":", "We", "have", "demonstrated", "an", "increased", "risk", "of", "VTE", "associated", "with", "the", "use", "of", "CPA", "/", "EE", "in", "women", "with", "acne", ",", "hirsutism", "or", "PCOS", "although", "residual", "confounding", "by", "indication", "can", "not", "be", "excluded", "."]], "ner": [[[8, 9, "Chemical"], [28, 29, "Chemical"], [35, 35, "Chemical"], [82, 82, "Chemical"], [154, 154, "Chemical"], [168, 168, "Chemical"], [249, 249, "Chemical"], [297, 297, "Chemical"], [3, 4, "Disease"], [75, 76, "Disease"], [78, 78, "Disease"], [151, 151, "Disease"], [291, 291, "Disease"], [13, 14, "Chemical"], [32, 33, "Chemical"], [37, 37, "Chemical"], [84, 84, "Chemical"], [156, 156, "Chemical"], [170, 170, "Chemical"], [251, 251, "Chemical"], [299, 299, "Chemical"], [89, 90, "Chemical"], [50, 50, "Disease"], [141, 141, "Disease"], [303, 303, "Disease"], [52, 52, "Disease"], [143, 143, "Disease"], [305, 305, "Disease"], [60, 62, "Disease"], [64, 64, "Disease"], [145, 145, "Disease"], [307, 307, "Disease"]]], "relations": [[[8, 9, 3, 4, "CID"], [8, 9, 75, 76, "CID"], [8, 9, 78, 78, "CID"], [8, 9, 151, 151, "CID"], [8, 9, 291, 291, "CID"], [28, 29, 3, 4, "CID"], [28, 29, 75, 76, "CID"], [28, 29, 78, 78, "CID"], [28, 29, 151, 151, "CID"], [28, 29, 291, 291, "CID"], [35, 35, 3, 4, "CID"], [35, 35, 75, 76, "CID"], [35, 35, 78, 78, "CID"], [35, 35, 151, 151, "CID"], [35, 35, 291, 291, "CID"], [82, 82, 3, 4, "CID"], [82, 82, 75, 76, "CID"], [82, 82, 78, 78, "CID"], [82, 82, 151, 151, "CID"], [82, 82, 291, 291, "CID"], [154, 154, 3, 4, "CID"], [154, 154, 75, 76, "CID"], [154, 154, 78, 78, "CID"], [154, 154, 151, 151, "CID"], [154, 154, 291, 291, "CID"], [168, 168, 3, 4, "CID"], [168, 168, 75, 76, "CID"], [168, 168, 78, 78, "CID"], [168, 168, 151, 151, "CID"], [168, 168, 291, 291, "CID"], [249, 249, 3, 4, "CID"], [249, 249, 75, 76, "CID"], [249, 249, 78, 78, "CID"], [249, 249, 151, 151, "CID"], [249, 249, 291, 291, "CID"], [297, 297, 3, 4, "CID"], [297, 297, 75, 76, "CID"], [297, 297, 78, 78, "CID"], [297, 297, 151, 151, "CID"], [297, 297, 291, 291, "CID"], [13, 14, 3, 4, "CID"], [13, 14, 75, 76, "CID"], [13, 14, 78, 78, "CID"], [13, 14, 151, 151, "CID"], [13, 14, 291, 291, "CID"], [32, 33, 3, 4, "CID"], [32, 33, 75, 76, "CID"], [32, 33, 78, 78, "CID"], [32, 33, 151, 151, "CID"], [32, 33, 291, 291, "CID"], [37, 37, 3, 4, "CID"], [37, 37, 75, 76, "CID"], [37, 37, 78, 78, "CID"], [37, 37, 151, 151, "CID"], [37, 37, 291, 291, "CID"], [84, 84, 3, 4, "CID"], [84, 84, 75, 76, "CID"], [84, 84, 78, 78, "CID"], [84, 84, 151, 151, "CID"], [84, 84, 291, 291, "CID"], [156, 156, 3, 4, "CID"], [156, 156, 75, 76, "CID"], [156, 156, 78, 78, "CID"], [156, 156, 151, 151, "CID"], [156, 156, 291, 291, "CID"], [170, 170, 3, 4, "CID"], [170, 170, 75, 76, "CID"], [170, 170, 78, 78, "CID"], [170, 170, 151, 151, "CID"], [170, 170, 291, 291, "CID"], [251, 251, 3, 4, "CID"], [251, 251, 75, 76, "CID"], [251, 251, 78, 78, "CID"], [251, 251, 151, 151, "CID"], [251, 251, 291, 291, "CID"], [299, 299, 3, 4, "CID"], [299, 299, 75, 76, "CID"], [299, 299, 78, 78, "CID"], [299, 299, 151, 151, "CID"], [299, 299, 291, 291, "CID"]]], "clusters": [], "translated": "服用<0>醋酸环丙孕酮</0>和<13>乙炔雌二醇</13>的女性发生<8>静脉血栓栓塞</8>的风险：巢式队列分析和病例对照研究。背景：<1>醋酸环丙孕酮</1>联合<14>炔雌醇</14>（<2>CPA</2>/<15>EE</15>）在英国获得许可用于治疗患有<22>痤疮</22>和<25>多毛症</25>的女性，也是<28>多囊卵巢综合征</28>（<29>PCOS</29>）的治疗选择。先前的研究表明，与传统联合治疗相比，<3>醋酸环丙孕酮</3>/<16>乙炔雌二醇</16> 相关的<9>静脉血栓栓塞症</9> (<10>VTE</10>)的风险增加，即<21>口服避孕药</21>（COCs）。我们认为这些研究的结果可能受到残余混杂的影响。\n\n方法：在患有<23>痤疮</23>、<26>多毛症</26>或<30>多囊卵巢综合征</30> ( <31> PCOS </31> ) 的年龄在 15 至 39 岁之间的女性人群中使用全科医疗研究数据库进行嵌套队列分析和病例对照研究，以评估与<4>醋酸环丙孕酮</4>/<17>乙炔雌二醇</17>相关的<11>VTE</11>风险。\n\n结果：与传统 COC 相比，<5>醋酸环丙孕酮</5>/<18>乙炔雌二醇</18> 的年龄校正发病率比为 2.20 [95% 置信区间 (CI) 1.35-3.58]。将未使用口服避孕药、最近未怀孕或无更年期症状的女性作为参考组，病例对照分析显示，使用<6>醋酸环丙孕酮</6>/<19>乙炔雌二醇</19>的调整后比值比 (OR (adj)) 为 7.44 (95% CI 3.67-15.08)，而使用传统 COC 的 OR (adj) 为 2.58 (95% CI 1.60-4.18)。\n\n结论：我们已经证明在患有<24>痤疮</24>、<27>多毛症</27>或<31>多囊卵巢综合征</31>的女性中使用<7>醋酸环丙孕酮</7>/<20>乙炔雌二醇</20>会增加<12>VTE</12>的风险，尽管不能排除因适应症引起的残留混杂。", "revised": true}
{"doc_key": "11679859", "sentences": [["Intravenous", "administration", "of", "prochlorperazine", "by", "15", "-", "minute", "infusion", "versus", "2", "-", "minute", "bolus", "does", "not", "affect", "the", "incidence", "of", "akathisia", ":", "a", "prospective", ",", "randomized", ",", "controlled", "trial", ".", "STUDY", "OBJECTIVE", ":", "We", "sought", "to", "compare", "the", "rate", "of", "akathisia", "after", "administration", "of", "intravenous", "prochlorperazine", "as", "a", "2", "-", "minute", "bolus", "or", "15", "-", "minute", "infusion", ".", "METHODS", ":", "We", "conducted", "a", "prospective", ",", "randomized", ",", "double", "-", "blind", "study", "in", "the", "emergency", "department", "of", "a", "central", "-", "city", "teaching", "hospital", ".", "Patients", "aged", "18", "years", "or", "older", "treated", "with", "prochlorperazine", "for", "headache", ",", "nausea", ",", "or", "vomiting", "were", "eligible", "for", "inclusion", ".", "Study", "participants", "were", "randomized", "to", "receive", "10", "mg", "of", "prochlorperazine", "administered", "intravenously", "by", "means", "of", "2", "-", "minute", "push", "(", "bolus", "group", ")", "or", "10", "mg", "diluted", "in", "50", "mL", "of", "normal", "saline", "solution", "administered", "by", "means", "of", "intravenous", "infusion", "during", "a", "15", "-", "minute", "period", "(", "infusion", "group", ")", ".", "The", "main", "outcome", "was", "the", "number", "of", "study", "participants", "experiencing", "akathisia", "within", "60", "minutes", "of", "administration", ".", "Akathisia", "was", "defined", "as", "either", "a", "spontaneous", "report", "of", "restlessness", "or", "agitation", "or", "a", "change", "of", "2", "or", "more", "in", "the", "patient", "-", "reported", "akathisia", "rating", "scale", "and", "a", "change", "of", "at", "least", "1", "in", "the", "investigator", "-", "observed", "akathisia", "rating", "scale", ".", "The", "intensity", "of", "headache", "and", "nausea", "was", "measured", "with", "a", "100", "-", "mm", "visual", "analog", "scale", ".", "RESULTS", ":", "One", "hundred", "patients", "were", "enrolled", ".", "One", "study", "participant", "was", "excluded", "after", "protocol", "violation", ".", "Seventy", "-", "three", "percent", "(", "73", "/", "99", ")", "of", "the", "study", "participants", "were", "treated", "for", "headache", "and", "70", "%", "(", "70", "/", "99", ")", "for", "nausea", ".", "In", "the", "bolus", "group", ",", "26", ".", "0", "%", "(", "13", "/", "50", ")", "had", "akathisia", "compared", "with", "32", ".", "7", "%", "(", "16", "/", "49", ")", "in", "the", "infusion", "group", "(", "Delta", "=", "-", "6", ".", "7", "%", ";", "95", "%", "confidence", "interval", "[", "CI", "]", "-", "24", ".", "6", "%", "to", "11", ".", "2", "%", ")", ".", "The", "difference", "between", "the", "bolus", "and", "infusion", "groups", "in", "the", "percentage", "of", "participants", "who", "saw", "a", "50", "%", "reduction", "in", "their", "headache", "intensity", "within", "30", "minutes", "was", "11", ".", "8", "%", "(", "95", "%", "CI", "-", "9", ".", "6", "%", "to", "33", ".", "3", "%", ")", ".", "The", "difference", "in", "the", "percentage", "of", "patients", "with", "a", "50", "%", "reduction", "in", "their", "nausea", "was", "12", ".", "6", "%", "(", "95", "%", "CI", "-", "4", ".", "6", "%", "to", "29", ".", "8", "%", ")", ".", "CONCLUSION", ":", "A", "50", "%", "reduction", "in", "the", "incidence", "of", "akathisia", "when", "prochlorperazine", "was", "administered", "by", "means", "of", "15", "-", "minute", "intravenous", "infusion", "versus", "a", "2", "-", "minute", "intravenous", "push", "was", "not", "detected", ".", "The", "efficacy", "of", "prochlorperazine", "in", "the", "treatment", "of", "headache", "and", "nausea", "likewise", "did", "not", "appear", "to", "be", "affected", "by", "the", "rate", "of", "administration", ",", "although", "no", "formal", "statistical", "comparisons", "were", "made", "."]], "ner": [[[3, 3, "Chemical"], [45, 45, "Chemical"], [91, 91, "Chemical"], [113, 113, "Chemical"], [431, 431, "Chemical"], [456, 456, "Chemical"], [20, 20, "Disease"], [40, 40, "Disease"], [165, 165, "Disease"], [196, 196, "Disease"], [211, 211, "Disease"], [292, 292, "Disease"], [429, 429, "Disease"], [93, 93, "Disease"], [218, 218, "Disease"], [265, 265, "Disease"], [357, 357, "Disease"], [461, 461, "Disease"], [95, 95, "Disease"], [220, 220, "Disease"], [275, 275, "Disease"], [397, 397, "Disease"], [463, 463, "Disease"], [98, 98, "Disease"], [183, 183, "Disease"]]], "relations": [[[3, 3, 20, 20, "CID"], [3, 3, 40, 40, "CID"], [3, 3, 165, 165, "CID"], [3, 3, 196, 196, "CID"], [3, 3, 211, 211, "CID"], [3, 3, 292, 292, "CID"], [3, 3, 429, 429, "CID"], [45, 45, 20, 20, "CID"], [45, 45, 40, 40, "CID"], [45, 45, 165, 165, "CID"], [45, 45, 196, 196, "CID"], [45, 45, 211, 211, "CID"], [45, 45, 292, 292, "CID"], [45, 45, 429, 429, "CID"], [91, 91, 20, 20, "CID"], [91, 91, 40, 40, "CID"], [91, 91, 165, 165, "CID"], [91, 91, 196, 196, "CID"], [91, 91, 211, 211, "CID"], [91, 91, 292, 292, "CID"], [91, 91, 429, 429, "CID"], [113, 113, 20, 20, "CID"], [113, 113, 40, 40, "CID"], [113, 113, 165, 165, "CID"], [113, 113, 196, 196, "CID"], [113, 113, 211, 211, "CID"], [113, 113, 292, 292, "CID"], [113, 113, 429, 429, "CID"], [431, 431, 20, 20, "CID"], [431, 431, 40, 40, "CID"], [431, 431, 165, 165, "CID"], [431, 431, 196, 196, "CID"], [431, 431, 211, 211, "CID"], [431, 431, 292, 292, "CID"], [431, 431, 429, 429, "CID"], [456, 456, 20, 20, "CID"], [456, 456, 40, 40, "CID"], [456, 456, 165, 165, "CID"], [456, 456, 196, 196, "CID"], [456, 456, 211, 211, "CID"], [456, 456, 292, 292, "CID"], [456, 456, 429, 429, "CID"]]], "clusters": [], "translated": "通过 15 分钟输注与 2 分钟推注相比，<0>丙氯拉嗪</0>静脉内给药不会影响<6>静坐不能</6>的发生率：一项前瞻性、随机、对照试验。研究目的：我们试图比较以 2 分钟推注或 15 分钟输注静脉注射<1>丙氯拉嗪</1>后的<7>静坐不能</7>发生率。方法：我们在中心城市教学医院的急诊科进行了一项前瞻性、随机、双盲研究。因<13>头痛</13>、<18>恶心</18>或<23>呕吐</23>而接受<2>丙氯拉嗪</2>治疗的 18 岁或以上患者符合纳入条件。研究参与者被随机分配接受 10 mg <3>丙氯拉嗪</3> 通过 2 分钟推注（<3>推注组</3>）静脉内给药或在 15 分钟内通过静脉输注在 50 mL 生理盐水中稀释 10 mg 分期（<3>输液组</3>）。主要结果是在给药后 60 分钟内出现<8>静坐不能</8>的研究参与者人数。静坐不能被定义为自发报告坐立不安或<24>激越</24>，或者患者报告的<9>静坐不能</9>评分量表变化至少为1，并且至少有1的变化调查员观察到的<10>静坐不能</10>评定量表。<14>头痛</14>和<19>恶心</19>的强度用100毫米视觉模拟量表测量。结果：100名患者入选。一名研究参与者在违反协议后被排除在外。百分之七十三 (73 / 99) 的研究参与者接受了<15>头痛</15>的治疗，70% (70 / 99) 的参与者接受了<20>恶心</20>的治疗。在<3>推注组</3>中，26.0% (13 / 50) 有<11>静坐不能</11>，与输液组相比，输液组有32.7% (16 / 49)（Delta = -6.7%; 95%置信区间[CI] -24.6%至11.2%）。推注组和输液组在 30 分钟内<16>头痛</16>强度降低50% 的参与者百分比之间的差异为11.8%（95% CI-9.6%至33.3%）。 <21>恶心</21>减少50% 的患者百分比差异为12.6%（95% CI-4.6%至29.8%）。结论：<4>丙氯拉嗪</4>通过 15 分钟静脉输注与 2 分钟静脉推注相比，<12>静坐不能</12>的发生率降低了50%。<5>丙氯拉嗪</5>治疗<17>头痛</17>和<22>恶心</22>的疗效似乎也不受给药速率的影响，尽管没有正式的统计比较被制成。", "revised": true}
{"doc_key": "15737522", "sentences": [["Ceftriaxone", "-", "associated", "biliary", "pseudolithiasis", "in", "paediatric", "surgical", "patients", ".", "It", "is", "well", "known", "that", "ceftriaxone", "leads", "to", "pseudolithiasis", "in", "some", "patients", ".", "Clinical", "and", "experimental", "studies", "also", "suggest", "that", "situations", "causing", "gallbladder", "dysfunction", ",", "such", "as", "fasting", ",", "may", "have", "a", "role", "for", "the", "development", "of", "pseudolithiasis", ".", "In", "this", "study", ",", "we", "prospectively", "evaluated", "the", "incidence", "and", "clinical", "importance", "of", "pseudolithiasis", "in", "paediatric", "surgical", "patients", "receiving", "ceftriaxone", "treatment", ",", "who", "often", "had", "to", "fast", "in", "the", "post", "-", "operative", "period", ".", "Fifty", "children", "who", "were", "given", "ceftriaxone", "were", "evaluated", "by", "serial", "abdominal", "sonograms", ".", "Of", "those", ",", "13", "(", "26", "%", ")", "developed", "biliary", "pathology", ".", "Comparison", "of", "the", "patients", "with", "or", "without", "pseudolithiasis", "revealed", "no", "significant", "difference", "with", "respect", "to", "age", ",", "sex", ",", "duration", "of", "the", "treatment", "and", "starvation", "variables", ".", "After", "cessation", "of", "the", "treatment", ",", "pseudolithiasis", "resolved", "spontaneously", "within", "a", "short", "period", ".", "The", "incidence", "of", "pseudolithiasis", "is", "not", "affected", "by", "fasting", "."]], "ner": [[[0, 0, "Chemical"], [15, 15, "Chemical"], [68, 68, "Chemical"], [88, 88, "Chemical"], [3, 4, "Disease"], [18, 18, "Disease"], [47, 47, "Disease"], [62, 62, "Disease"], [115, 115, "Disease"], [141, 141, "Disease"], [152, 152, "Disease"], [32, 33, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 18, 18, "CID"], [0, 0, 47, 47, "CID"], [0, 0, 62, 62, "CID"], [0, 0, 115, 115, "CID"], [0, 0, 141, 141, "CID"], [0, 0, 152, 152, "CID"], [15, 15, 3, 4, "CID"], [15, 15, 18, 18, "CID"], [15, 15, 47, 47, "CID"], [15, 15, 62, 62, "CID"], [15, 15, 115, 115, "CID"], [15, 15, 141, 141, "CID"], [15, 15, 152, 152, "CID"], [68, 68, 3, 4, "CID"], [68, 68, 18, 18, "CID"], [68, 68, 47, 47, "CID"], [68, 68, 62, 62, "CID"], [68, 68, 115, 115, "CID"], [68, 68, 141, 141, "CID"], [68, 68, 152, 152, "CID"], [88, 88, 3, 4, "CID"], [88, 88, 18, 18, "CID"], [88, 88, 47, 47, "CID"], [88, 88, 62, 62, "CID"], [88, 88, 115, 115, "CID"], [88, 88, 141, 141, "CID"], [88, 88, 152, 152, "CID"]]], "clusters": [], "translated": " <0>头孢曲松</0> - 相关<4>胆道假性结石症</4>儿科手术患者。众所周知，<1>头孢曲松</1>在一些患者中会导致<5>假性结石症</5>。临床和实验研究还表明，导致<11>胆囊功能障碍</11>的情况，例如禁食，可能对<6>假性结石症</6>的发展有影响。在这项研究中，我们前瞻性地评估了接受<2>头孢曲松</2>治疗的小儿外科患者中<7>假性结石症</7>的发生率和临床重要性，这些患者在术后期间经常需要禁食。给予<3>头孢曲松</3>的50名儿童通过连续腹部超声检查进行了评估，其中13人(26%)出现胆道病变。比较有或没有<8>假性结石症</8>的患者，发现在年龄、性别、治疗持续时间和饥饿变量方面没有显着差异。停止治疗后，<9>假性结石症</9>在短期内自行消退。<10>假性结石症</10>的发病率不受禁食的影响。", "revised": true}
{"doc_key": "12820454", "sentences": [["Combined", "androgen", "blockade", "-", "induced", "anemia", "in", "prostate", "cancer", "patients", "without", "bone", "involvement", ".", "BACKGROUND", ":", "To", "determine", "the", "onset", "and", "extent", "of", "combined", "androgen", "blockade", "(", "CAB", ")", "-", "induced", "anemia", "in", "prostate", "cancer", "patients", "without", "bone", "involvement", ".", "PATIENTS", "AND", "METHODS", ":", "Forty", "-", "two", "patients", "with", "biopsy", "-", "proven", "prostatic", "adenocarcinoma", "[", "26", "with", "stage", "C", "(", "T3N0M0", ")", "and", "16", "with", "stage", "D1", "(", "T3N1M0", ")", "]", "were", "included", "in", "this", "study", ".", "All", "patients", "received", "CAB", "[", "leuprolide", "acetate", "(", "LHRH", "-", "A", ")", "3", ".", "75", "mg", ",", "intramuscularly", ",", "every", "28", "days", "plus", "250", "mg", "flutamide", ",", "tid", ",", "per", "Os", "]", "and", "were", "evaluated", "for", "anemia", "by", "physical", "examination", "and", "laboratory", "tests", "at", "baseline", "and", "4", "subsequent", "intervals", "(", "1", ",", "2", ",", "3", "and", "6", "months", "post", "-", "CAB", ")", ".", "Hb", ",", "PSA", "and", "Testosterone", "measurements", "were", "recorded", ".", "Patients", "with", "stage", "D2", "-", "3", "disease", ",", "abnormal", "hemoglobin", "level", "or", "renal", "and", "liver", "function", "tests", "that", "were", "higher", "than", "the", "upper", "limits", "were", "excluded", "from", "the", "study", ".", "The", "duration", "of", "the", "study", "was", "six", "months", ".", "RESULTS", ":", "The", "mean", "hemoglobin", "(", "Hb", ")", "levels", "were", "significantly", "declined", "in", "all", "patients", "from", "baseline", "of", "14", ".", "2", "g", "/", "dl", "to", "14", ".", "0", "g", "/", "dl", ",", "13", ".", "5", "g", "/", "dl", ",", "13", ".", "2", "g", "/", "dl", "and", "12", ".", "7", "g", "/", "dl", "at", "1", ",", "2", ",", "3", "and", "6", "months", "post", "-", "CAB", ",", "respectively", ".", "Severe", "and", "clinically", "evident", "anemia", "of", "Hb", "<", "11", "g", "/", "dl", "with", "clinical", "symptoms", "was", "detected", "in", "6", "patients", "(", "14", ".", "3", "%", ")", ".", "This", "CAB", "-", "induced", "anemia", "was", "normochromic", "and", "normocytic", ".", "At", "six", "months", "post", "-", "CAB", ",", "patients", "with", "severe", "anemia", "had", "a", "Hb", "mean", "value", "of", "10", ".", "2", "+", "/", "-", "0", ".", "1", "g", "/", "dl", "(", "X", "+", "/", "-", "SE", ")", ",", "whereas", "the", "other", "patients", "had", "mild", "anemia", "with", "Hb", "mean", "value", "of", "13", ".", "2", "+", "/", "-", "0", ".", "17", "(", "X", "+", "/", "-", "SE", ")", ".", "The", "development", "of", "severe", "anemia", "at", "6", "months", "post", "-", "CAB", "was", "predictable", "by", "the", "reduction", "of", "Hb", "baseline", "value", "of", "more", "than", "2", ".", "5", "g", "/", "dl", "after", "3", "months", "of", "CAB", "(", "p", "=", "0", ".", "01", ")", ".", "The", "development", "of", "severe", "CAB", "-", "induced", "anemia", "in", "prostate", "cancer", "patients", "did", "not", "correlate", "with", "T", "baseline", "values", "(", "T", "<", "3", "ng", "/", "ml", "versus", "T", ">", "or", "=", "3", "ng", "/", "ml", ")", ",", "with", "age", "(", "<", "76", "yrs", "versus", ">", "or", "=", "76", "yrs", ")", ",", "and", "clinical", "stage", "(", "stage", "C", "versus", "stage", "D1", ")", ".", "Severe", "and", "clinically", "evident", "anemia", "was", "easily", "corrected", "by", "subcutaneous", "injections", "(", "3", "times", "/", "week", "for", "1", "month", ")", "of", "recombinant", "erythropoietin", "(", "rHuEPO", "-", "beta", ")", ".", "CONCLUSION", ":", "Our", "data", "suggest", "that", "rHuEPO", "-", "beta", "correctable", "CAB", "-", "induced", "anemia", "occurs", "in", "14", ".", "3", "%", "of", "prostate", "cancer", "patients", "after", "6", "months", "of", "therapy", "."]], "ner": [[[82, 83, "Chemical"], [85, 87, "Chemical"], [5, 5, "Disease"], [31, 31, "Disease"], [113, 113, "Disease"], [259, 259, "Disease"], [286, 286, "Disease"], [302, 302, "Disease"], [335, 335, "Disease"], [362, 362, "Disease"], [407, 407, "Disease"], [466, 466, "Disease"], [504, 504, "Disease"], [102, 102, "Chemical"], [144, 144, "Chemical"], [7, 8, "Disease"], [33, 34, "Disease"], [409, 410, "Disease"], [512, 513, "Disease"], [52, 53, "Disease"]]], "relations": [[[82, 83, 5, 5, "CID"], [82, 83, 31, 31, "CID"], [82, 83, 113, 113, "CID"], [82, 83, 259, 259, "CID"], [82, 83, 286, 286, "CID"], [82, 83, 302, 302, "CID"], [82, 83, 335, 335, "CID"], [82, 83, 362, 362, "CID"], [82, 83, 407, 407, "CID"], [82, 83, 466, 466, "CID"], [82, 83, 504, 504, "CID"], [85, 87, 5, 5, "CID"], [85, 87, 31, 31, "CID"], [85, 87, 113, 113, "CID"], [85, 87, 259, 259, "CID"], [85, 87, 286, 286, "CID"], [85, 87, 302, 302, "CID"], [85, 87, 335, 335, "CID"], [85, 87, 362, 362, "CID"], [85, 87, 407, 407, "CID"], [85, 87, 466, 466, "CID"], [85, 87, 504, 504, "CID"], [102, 102, 5, 5, "CID"], [102, 102, 31, 31, "CID"], [102, 102, 113, 113, "CID"], [102, 102, 259, 259, "CID"], [102, 102, 286, 286, "CID"], [102, 102, 302, 302, "CID"], [102, 102, 335, 335, "CID"], [102, 102, 362, 362, "CID"], [102, 102, 407, 407, "CID"], [102, 102, 466, 466, "CID"], [102, 102, 504, 504, "CID"]]], "clusters": [], "translated": "联合雄激素阻断引起的<2>贫血</2>在<15>前列腺癌</15>没有骨骼受累的患者中。背景：确定无骨骼受累的<16>前列腺癌</16>患者联合雄激素阻断(CAB)诱导的<3>贫血</3>的发生和程度。患者和方法：42名活检证实为<19>前列腺腺癌</19>的患者[26名C期(T3N0M0)和16名D1期(T3N1M0)]被纳入本研究。所有患者均接受CAB[<0>醋酸亮丙瑞林</0>(<1>LHRH-A</1>) 3.75mg，肌肉注射，每28天加上250mg<13>氟他胺</13>，tid，每Os]并在基线和随后的4个间隔时通过体格检查和实验室测试评估<4>贫血</4>(CAB后1、2、3和6个月)。记录Hb、PSA和<14>睾酮</14>测量值。患有D2-3期疾病、血红蛋白水平异常或肝肾功能检查高于上限的患者被排除在研究之外。研究持续时间为六个月。结果：所有患者的平均血红蛋白(Hb)水平均较基线14显着下降。2克/分升至14.0克/分升，13.5克/分升，13.2克/分升和12.7克/分升<CAB后1、2、3和6个月>。6例(14.3%)患者出现严重且临床明显的<5>贫血</5>，Hb<11 g/dl，伴有临床症状。这种CAB诱发的<6>贫血</6>呈正色素性和正细胞性。在CAB后六个月，患有严重<7>贫血</7>的患者的Hb平均值为10.2+/-0.1g/dl(X+/-SE)，而其他患者有轻度<8>贫血</8>，Hb平均值为13.2+/-0.17(X+/-SE)。<9>CAB后6个月</9>时严重<9>贫血</9>的发展可通过Hb基线值降低超过2.5 g/dl后3个月的CAB来预测(p=0.01)。<17>前列腺癌</17>患者中严重CAB诱发的<10>贫血</10>的发展与T基线值无关(T<3 ng/ml对比T>=3 ng/ml)、年龄(<76岁对>=76岁)和临床分期(C期对D1期)。通过皮下注射(每周3次，持续1个月)重组促红细胞生成素(rHuEPO-beta)，可以轻松纠正临床上明显的严重<11>贫血</11>。结论：我们的数据表明rHuEPO-beta可校正CAB诱导的<12>贫血</12>发生在14.3% 的<18>前列腺癌</18>患者在治疗6个月后。", "revised": true}
{"doc_key": "16403073", "sentences": [["Ketoconazole", "induced", "torsades", "de", "pointes", "without", "concomitant", "use", "of", "QT", "interval", "-", "prolonging", "drug", ".", "Ketoconazole", "is", "not", "known", "to", "be", "proarrhythmic", "without", "concomitant", "use", "of", "QT", "interval", "-", "prolonging", "drugs", ".", "We", "report", "a", "woman", "with", "coronary", "artery", "disease", "who", "developed", "a", "markedly", "prolonged", "QT", "interval", "and", "torsades", "de", "pointes", "(", "TdP", ")", "after", "taking", "ketoconazole", "for", "treatment", "of", "fungal", "infection", ".", "Her", "QT", "interval", "returned", "to", "normal", "upon", "withdrawal", "of", "ketoconazole", ".", "Genetic", "study", "did", "not", "find", "any", "mutation", "in", "her", "genes", "that", "encode", "cardiac", "IKr", "channel", "proteins", ".", "We", "postulate", "that", "by", "virtue", "of", "its", "direct", "blocking", "action", "on", "IKr", ",", "ketoconazole", "alone", "may", "prolong", "QT", "interval", "and", "induce", "TdP", ".", "This", "calls", "for", "attention", "when", "ketoconazole", "is", "administered", "to", "patients", "with", "risk", "factors", "for", "acquired", "long", "QT", "syndrome", "."]], "ner": [[[0, 0, "Chemical"], [15, 15, "Chemical"], [56, 56, "Chemical"], [72, 72, "Chemical"], [104, 104, "Chemical"], [119, 119, "Chemical"], [2, 4, "Disease"], [48, 50, "Disease"], [52, 52, "Disease"], [112, 112, "Disease"], [44, 46, "Disease"], [129, 131, "Disease"], [37, 39, "Disease"], [60, 61, "Disease"]]], "relations": [[[0, 0, 2, 4, "CID"], [0, 0, 48, 50, "CID"], [0, 0, 52, 52, "CID"], [0, 0, 112, 112, "CID"], [15, 15, 2, 4, "CID"], [15, 15, 48, 50, "CID"], [15, 15, 52, 52, "CID"], [15, 15, 112, 112, "CID"], [56, 56, 2, 4, "CID"], [56, 56, 48, 50, "CID"], [56, 56, 52, 52, "CID"], [56, 56, 112, 112, "CID"], [72, 72, 2, 4, "CID"], [72, 72, 48, 50, "CID"], [72, 72, 52, 52, "CID"], [72, 72, 112, 112, "CID"], [104, 104, 2, 4, "CID"], [104, 104, 48, 50, "CID"], [104, 104, 52, 52, "CID"], [104, 104, 112, 112, "CID"], [119, 119, 2, 4, "CID"], [119, 119, 48, 50, "CID"], [119, 119, 52, 52, "CID"], [119, 119, 112, 112, "CID"], [0, 0, 44, 46, "CID"], [0, 0, 129, 131, "CID"], [15, 15, 44, 46, "CID"], [15, 15, 129, 131, "CID"], [56, 56, 44, 46, "CID"], [56, 56, 129, 131, "CID"], [72, 72, 44, 46, "CID"], [72, 72, 129, 131, "CID"], [104, 104, 44, 46, "CID"], [104, 104, 129, 131, "CID"], [119, 119, 44, 46, "CID"], [119, 119, 129, 131, "CID"]]], "clusters": [], "translated": " <0>酮康唑</0> 诱发<6>尖端扭转型室速</6>而无需同时使用 QT 间期延长药物。<1>酮康唑</1>在不同时使用QT 间期延长药物的情况下未知是否会导致心律失常。我们报告了一名患有<12>冠状动脉疾病</12>的女性，她服用<2>酮康唑</2>治疗<13>真菌感染</13>后出现了显着的<10>QT间期延长</10>和<7>尖端扭转型室速</7> (<8>TdP</8>)。停用<3>酮康唑</3>后，她的QT间期恢复正常。基因研究没有发现她编码心脏 IKr 通道蛋白的基因有任何突变。我们假设，由于其对IKr的直接阻断作用，单独使用<4>酮康唑</4>可能会延长QT间期并诱发<9>TdP</9>。当<5>酮康唑</5>用于具有获得性<11>长QT综合征</11>危险因素的患者时，需要注意这一点。", "revised": true}
{"doc_key": "16005948", "sentences": [["Evaluation", "of", "the", "anticocaine", "monoclonal", "antibody", "GNC92H2", "as", "an", "immunotherapy", "for", "cocaine", "overdose", ".", "The", "illicit", "use", "of", "cocaine", "continues", "in", "epidemic", "proportions", "and", "treatment", "for", "cocaine", "overdose", "remains", "elusive", ".", "Current", "protein", "-", "based", "technology", "offers", "a", "new", "therapeutic", "venue", "by", "which", "antibodies", "bind", "the", "drug", "in", "the", "blood", "stream", ",", "inactivating", "its", "toxic", "effects", ".", "The", "therapeutic", "potential", "of", "the", "anticocaine", "antibody", "GNC92H2", "was", "examined", "using", "a", "model", "of", "cocaine", "overdose", ".", "Swiss", "albino", "mice", "prepared", "with", "intrajugular", "catheters", "were", "tested", "in", "photocell", "cages", "after", "administration", "of", "93", "mg", "/", "kg", "(", "LD50", ")", "of", "cocaine", "and", "GNC92H2", "infusions", "ranging", "from", "30", "to", "190", "mg", "/", "kg", ".", "GNC92H2", "was", "delivered", "30", "min", "before", ",", "concomitantly", "or", "3", "min", "after", "cocaine", "treatment", ".", "Significant", "blockade", "of", "cocaine", "toxicity", "was", "observed", "with", "the", "higher", "dose", "of", "GNC92H2", "(", "190", "mg", "/", "kg", ")", ",", "where", "premorbid", "behaviors", "were", "reduced", "up", "to", "40", "%", ",", "seizures", "up", "to", "77", "%", "and", "death", "by", "72", "%", ".", "Importantly", ",", "GNC92H2", "prevented", "death", "even", "post", "-", "cocaine", "injection", ".", "The", "results", "support", "the", "important", "potential", "of", "GNC92H2", "as", "a", "therapeutic", "tool", "against", "cocaine", "overdose", "."]], "ner": [[[18, 18, "Chemical"], [97, 97, "Chemical"], [122, 122, "Chemical"], [128, 128, "Chemical"], [174, 174, "Chemical"], [155, 155, "Disease"], [11, 12, "Disease"], [26, 27, "Disease"], [71, 72, "Disease"], [190, 191, "Disease"], [129, 129, "Disease"], [161, 161, "Disease"], [170, 170, "Disease"]]], "relations": [[[18, 18, 155, 155, "CID"], [97, 97, 155, 155, "CID"], [122, 122, 155, 155, "CID"], [128, 128, 155, 155, "CID"], [174, 174, 155, 155, "CID"]]], "clusters": [], "translated": "评估抗可卡因单克隆抗体 GNC92H2 作为 <6>可卡因过量服用的免疫疗法</6>。<0>可卡因</0>的非法使用继续流行，治疗<7>可卡因过量</7>仍然难以捉摸。目前基于蛋白质的技术提供了一个新的治疗场所，抗体通过该场所结合血流中的药物，使其毒性作用失活。使用 <8>可卡因过量</8>模型检查了抗可卡因抗体 GNC92H2 的治疗潜力。在给予 93 mg/kg (LD50) 的<1>可卡因</1>和 30 至 190 mg/kg 的 GNC92H2 输注后，使用颈内导管制备的瑞士白化小鼠在光电池笼中进行了测试。GNC92H2 在<2>可卡因</2>治疗前 30 分钟、同时或 3 分钟后给药。使用较高剂量的 GNC92H2 (190 mg/kg) 观察到显着阻断<3>可卡因</3><10>毒性</10>，其中病前行为减少高达 40%，<5>癫痫发作</5> 达 77% 和 <11>死亡</11> 达 72%。重要的是，GNC92H2 甚至在<4>可卡因</4>注射后也能防止<12>死亡</12>。结果支持 GNC92H2 作为治疗<9>可卡因过量</9>的治疗工具的重要潜力。", "revised": true}
{"doc_key": "15145918", "sentences": [["Differential", "modulation", "by", "estrogen", "of", "alpha2", "-", "adrenergic", "and", "I1", "-", "imidazoline", "receptor", "-", "mediated", "hypotension", "in", "female", "rats", ".", "We", "have", "recently", "shown", "that", "estrogen", "negatively", "modulates", "the", "hypotensive", "effect", "of", "clonidine", "(", "mixed", "alpha2", "-", "/", "I1", "-", "receptor", "agonist", ")", "in", "female", "rats", "and", "implicates", "the", "cardiovascular", "autonomic", "control", "in", "this", "interaction", ".", "The", "present", "study", "investigated", "whether", "this", "effect", "of", "estrogen", "involves", "interaction", "with", "alpha2", "-", "and", "/", "or", "I1", "-", "receptors", ".", "Changes", "evoked", "by", "a", "single", "intraperitoneal", "injection", "of", "rilmenidine", "(", "600", "microg", "/", "kg", ")", "or", "alpha", "-", "methyldopa", "(", "100", "mg", "/", "kg", ")", ",", "selective", "I1", "-", "and", "alpha2", "-", "receptor", "agonists", ",", "respectively", ",", "in", "blood", "pressure", ",", "hemodynamic", "variability", ",", "and", "locomotor", "activity", "were", "assessed", "in", "radiotelemetered", "sham", "-", "operated", "and", "ovariectomized", "(", "Ovx", ")", "Sprague", "-", "Dawley", "female", "rats", "with", "or", "without", "12", "-", "wk", "estrogen", "replacement", ".", "Three", "time", "domain", "indexes", "of", "hemodynamic", "variability", "were", "employed", ":", "the", "standard", "deviation", "of", "mean", "arterial", "pressure", "as", "a", "measure", "of", "blood", "pressure", "variability", "and", "the", "standard", "deviation", "of", "beat", "-", "to", "-", "beat", "intervals", "(", "SDRR", ")", "and", "the", "root", "mean", "square", "of", "successive", "differences", "in", "R", "-", "wave", "-", "to", "-", "R", "-", "wave", "intervals", "as", "measures", "of", "heart", "rate", "variability", ".", "In", "sham", "-", "operated", "rats", ",", "rilmenidine", "or", "alpha", "-", "methyldopa", "elicited", "similar", "hypotension", "that", "lasted", "at", "least", "5", "h", "and", "was", "associated", "with", "reductions", "in", "standard", "deviation", "of", "mean", "arterial", "pressure", ".", "SDRR", "was", "reduced", "only", "by", "alpha", "-", "methyldopa", ".", "Ovx", "significantly", "enhanced", "the", "hypotensive", "response", "to", "alpha", "-", "methyldopa", ",", "in", "contrast", "to", "no", "effect", "on", "rilmenidine", "hypotension", ".", "The", "enhanced", "alpha", "-", "methyldopa", "hypotension", "in", "Ovx", "rats", "was", "paralleled", "with", "further", "reduction", "in", "SDRR", "and", "a", "reduced", "locomotor", "activity", ".", "Estrogen", "replacement", "(", "17beta", "-", "estradiol", "subcutaneous", "pellet", ",", "14", ".", "2", "microg", "/", "day", ",", "12", "wk", ")", "of", "Ovx", "rats", "restored", "the", "hemodynamic", "and", "locomotor", "effects", "of", "alpha", "-", "methyldopa", "to", "sham", "-", "operated", "levels", ".", "These", "findings", "suggest", "that", "estrogen", "downregulates", "alpha2", "-", "but", "not", "I1", "-", "receptor", "-", "mediated", "hypotension", "and", "highlight", "a", "role", "for", "the", "cardiac", "autonomic", "control", "in", "alpha", "-", "methyldopa", "-", "estrogen", "interaction", "."]], "ner": [[[85, 85, "Chemical"], [220, 220, "Chemical"], [273, 273, "Chemical"], [15, 15, "Disease"], [29, 29, "Disease"], [227, 227, "Disease"], [260, 260, "Disease"], [274, 274, "Disease"], [281, 281, "Disease"], [351, 351, "Disease"], [93, 95, "Chemical"], [222, 224, "Chemical"], [252, 254, "Chemical"], [263, 265, "Chemical"], [278, 280, "Chemical"], [327, 329, "Chemical"], [362, 364, "Chemical"], [3, 3, "Chemical"], [25, 25, "Chemical"], [64, 64, "Chemical"], [147, 147, "Chemical"], [340, 340, "Chemical"], [366, 366, "Chemical"], [293, 296, "Disease"], [11, 11, "Chemical"], [32, 32, "Chemical"], [301, 303, "Chemical"]]], "relations": [[[85, 85, 15, 15, "CID"], [85, 85, 29, 29, "CID"], [85, 85, 227, 227, "CID"], [85, 85, 260, 260, "CID"], [85, 85, 274, 274, "CID"], [85, 85, 281, 281, "CID"], [85, 85, 351, 351, "CID"], [220, 220, 15, 15, "CID"], [220, 220, 29, 29, "CID"], [220, 220, 227, 227, "CID"], [220, 220, 260, 260, "CID"], [220, 220, 274, 274, "CID"], [220, 220, 281, 281, "CID"], [220, 220, 351, 351, "CID"], [273, 273, 15, 15, "CID"], [273, 273, 29, 29, "CID"], [273, 273, 227, 227, "CID"], [273, 273, 260, 260, "CID"], [273, 273, 274, 274, "CID"], [273, 273, 281, 281, "CID"], [273, 273, 351, 351, "CID"], [93, 95, 15, 15, "CID"], [93, 95, 29, 29, "CID"], [93, 95, 227, 227, "CID"], [93, 95, 260, 260, "CID"], [93, 95, 274, 274, "CID"], [93, 95, 281, 281, "CID"], [93, 95, 351, 351, "CID"], [222, 224, 15, 15, "CID"], [222, 224, 29, 29, "CID"], [222, 224, 227, 227, "CID"], [222, 224, 260, 260, "CID"], [222, 224, 274, 274, "CID"], [222, 224, 281, 281, "CID"], [222, 224, 351, 351, "CID"], [252, 254, 15, 15, "CID"], [252, 254, 29, 29, "CID"], [252, 254, 227, 227, "CID"], [252, 254, 260, 260, "CID"], [252, 254, 274, 274, "CID"], [252, 254, 281, 281, "CID"], [252, 254, 351, 351, "CID"], [263, 265, 15, 15, "CID"], [263, 265, 29, 29, "CID"], [263, 265, 227, 227, "CID"], [263, 265, 260, 260, "CID"], [263, 265, 274, 274, "CID"], [263, 265, 281, 281, "CID"], [263, 265, 351, 351, "CID"], [278, 280, 15, 15, "CID"], [278, 280, 29, 29, "CID"], [278, 280, 227, 227, "CID"], [278, 280, 260, 260, "CID"], [278, 280, 274, 274, "CID"], [278, 280, 281, 281, "CID"], [278, 280, 351, 351, "CID"], [327, 329, 15, 15, "CID"], [327, 329, 29, 29, "CID"], [327, 329, 227, 227, "CID"], [327, 329, 260, 260, "CID"], [327, 329, 274, 274, "CID"], [327, 329, 281, 281, "CID"], [327, 329, 351, 351, "CID"], [362, 364, 15, 15, "CID"], [362, 364, 29, 29, "CID"], [362, 364, 227, 227, "CID"], [362, 364, 260, 260, "CID"], [362, 364, 274, 274, "CID"], [362, 364, 281, 281, "CID"], [362, 364, 351, 351, "CID"]]], "clusters": [], "translated": " <17>雌激素</17>对雌性大鼠α2-肾上腺素能和I1-<24>咪唑啉</24>受体介导的<3>低血压</3>的差异调节。我们最近表明，<18>雌激素</18>负向调节<25>可乐定</25>（混合alpha2-/I1-受体激动剂）对雌性大鼠的<4> 降压</4>作用，并暗示心血管自主神经控制在此相互作用。本研究调查了<19>雌激素 </19>的这种作用是否涉及与alpha2-和/或I1-受体的相互作用。单次腹膜内注射<0>利美尼定</0>（600微克/千克）或<10>α-甲基多巴</10> （100毫克/千克）引起的变化，在接受或不接受12周<20> 雌激素</20>替代的radiotelemetered假手术和卵巢切除（Ovx）Sprague-Dawley雌性大鼠中评估了血压、血液动力学变异性和运动活动。血液动力学变异性的三个时域指标被采用：作为血压变异性度量的平均动脉压的标准差和心跳间期（SDRR）的标准差和R波间隔连续差值的均方根。在假手术大鼠中，<1>利美尼定</1>或<11>α-甲基多巴</11>引起类似的<5>低血压</5>，持续至少5小时，并且与标准差削减相伴。SDRR仅被<12>α-甲基多巴</12>降低。Ovx显着增强了对<13>α-甲基多巴</13>的<6>降压</6>反应，而对<2>利美尼定</2>的<7>降压</7>没有影响。 Ovx大鼠中<14>α-甲基多巴</14><8>低血压</8>的增强伴随着SDRR的进一步降低和<23>运动活动的降低</23>。Ovx大鼠的雌激素替代（<26>17beta-雌二醇</26>皮下微丸，14.2微克/天，12周）恢复了<15>α-甲基多巴</15>对假手术的血流动力学和运动效应水平。这些发现表明<21>雌激素</21>下调alpha2-但不是I1-受体介导的<9>低血压</9>并强调心脏自主控制在<16>α-甲基多巴</16>-<22>雌激素</22>相互作用中的作用。", "revised": true}
{"doc_key": "15233872", "sentences": [["Cardioprotective", "effect", "of", "tincture", "of", "Crataegus", "on", "isoproterenol", "-", "induced", "myocardial", "infarction", "in", "rats", ".", "Tincture", "of", "Crataegus", "(", "TCR", ")", ",", "an", "alcoholic", "extract", "of", "the", "berries", "of", "hawthorn", "(", "Crataegus", "oxycantha", ")", ",", "is", "used", "in", "herbal", "and", "homeopathic", "medicine", ".", "The", "present", "study", "was", "done", "to", "investigate", "the", "protective", "effect", "of", "TCR", "on", "experimentally", "induced", "myocardial", "infarction", "in", "rats", ".", "Pretreatment", "of", "TCR", ",", "at", "a", "dose", "of", "0", ".", "5", "mL", "/", "100", "g", "bodyweight", "per", "day", ",", "orally", "for", "30", "days", ",", "prevented", "the", "increase", "in", "lipid", "peroxidation", "and", "activity", "of", "marker", "enzymes", "observed", "in", "isoproterenol", "-", "induced", "rats", "(", "85", "mg", "kg", "(", "-", "1", ")", "s", ".", "c", ".", "for", "2", "days", "at", "an", "interval", "of", "24", "h", ")", ".", "TCR", "prevented", "the", "isoproterenol", "-", "induced", "decrease", "in", "antioxidant", "enzymes", "in", "the", "heart", "and", "increased", "the", "rate", "of", "ADP", "-", "stimulated", "oxygen", "uptake", "and", "respiratory", "coupling", "ratio", ".", "TCR", "protected", "against", "pathological", "changes", "induced", "by", "isoproterenol", "in", "rat", "heart", ".", "The", "results", "show", "that", "pretreatment", "with", "TCR", "may", "be", "useful", "in", "preventing", "the", "damage", "induced", "by", "isoproterenol", "in", "rat", "heart", "."]], "ner": [[[7, 7, "Chemical"], [100, 100, "Chemical"], [130, 130, "Chemical"], [162, 162, "Chemical"], [183, 183, "Chemical"], [10, 11, "Disease"], [58, 59, "Disease"], [3, 5, "Chemical"], [15, 17, "Chemical"], [19, 19, "Chemical"], [23, 29, "Chemical"], [31, 32, "Chemical"], [54, 54, "Chemical"], [65, 65, "Chemical"], [127, 127, "Chemical"], [155, 155, "Chemical"], [173, 173, "Chemical"], [145, 145, "Chemical"], [148, 148, "Chemical"]]], "relations": [[[7, 7, 10, 11, "CID"], [7, 7, 58, 59, "CID"], [100, 100, 10, 11, "CID"], [100, 100, 58, 59, "CID"], [130, 130, 10, 11, "CID"], [130, 130, 58, 59, "CID"], [162, 162, 10, 11, "CID"], [162, 162, 58, 59, "CID"], [183, 183, 10, 11, "CID"], [183, 183, 58, 59, "CID"]]], "clusters": [], "translated": "<7>山楂酊</7>对<0>异丙肾上腺素</0>所致大鼠<5>心肌梗死</5>的心脏保护作用。 <8>山楂酊</8> (<9>TCR</9>)，<10>山楂浆果</10> (<11>Crataegus oxycantha</11>) 的酒精提取物，用于在草药和顺势疗法中。本研究旨在探讨 <12>TCR</12> 对大鼠实验性<6>心肌梗死</6>的保护作用。 <13>TCR</13> 预处理，剂量为 0.5 mL/100g 体重每天口服 30 天，可防止在<1>异丙肾上腺素</1>诱导的大鼠中观察到的脂质过氧化和标志酶活性的增加 (85 mg/kg(-1) s.c.连续 2 天，间隔 24 小时)。<14>TCR</14>阻止了<2>异丙肾上腺素</2>-诱导心脏抗氧化酶的减少并增加了<17>ADP</17>的速率-刺激了<18>氧气</18>摄取和呼吸耦合比。<15>TCR</15>对<3>异丙肾上腺素</3>引起的大鼠心脏病理变化具有保护作用。结果表明，<16>TCR</16>预处理可有效预防<4>异丙肾上腺素</4>对大鼠心脏的损伤。", "revised": true}
{"doc_key": "16938416", "sentences": [["High", "-", "dose", "testosterone", "is", "associated", "with", "atherosclerosis", "in", "postmenopausal", "women", ".", "OBJECTIVES", ":", "To", "study", "the", "long", "-", "term", "effects", "of", "androgen", "treatment", "on", "atherosclerosis", "in", "postmenopausal", "women", ".", "METHODS", ":", "In", "a", "population", "-", "based", "study", "in", "513", "naturally", "postmenopausal", "women", "aged", "54", "-", "67", "years", ",", "we", "studied", "the", "association", "between", "self", "-", "reported", "intramuscularly", "administered", "high", "-", "dose", "estrogen", "-", "testosterone", "therapy", "(", "estradiol", "-", "and", "testosterone", "esters", ")", "and", "aortic", "atherosclerosis", ".", "Aortic", "atherosclerosis", "was", "diagnosed", "by", "radiographic", "detection", "of", "calcified", "deposits", "in", "the", "abdominal", "aorta", ",", "which", "have", "been", "shown", "to", "reflect", "intima", "atherosclerosis", ".", "Hormone", "therapy", "users", "were", "compared", "with", "never", "users", ".", "RESULTS", ":", "Intramuscular", "hormone", "therapy", "use", "for", "1", "year", "or", "longer", "was", "reported", "by", "25", "women", ".", "In", "almost", "half", "of", "these", "women", "severe", "atherosclerosis", "of", "the", "aorta", "was", "present", "(", "n", "=", "11", ")", ",", "while", "in", "women", "without", "hormone", "use", "severe", "atherosclerosis", "of", "the", "aorta", "was", "present", "in", "less", "than", "20", "%", "(", "OR", "3", ".", "1", ";", "95", "%", "CI", ",", "1", ".", "1", "-", "8", ".", "5", ",", "adjusted", "for", "age", ",", "years", "since", "menopause", ",", "smoking", ",", "and", "body", "mass", "index", ")", ".", "The", "association", "remained", "after", "additional", "adjustment", "for", "diabetes", ",", "cholesterol", "level", ",", "systolic", "blood", "pressure", ",", "or", "alcohol", "use", ".", "No", "association", "was", "found", "for", "hormone", "use", "less", "than", "1", "year", ".", "CONCLUSION", ":", "Our", "results", "suggest", "that", "high", "-", "dose", "testosterone", "therapy", "may", "adversely", "affect", "atherosclerosis", "in", "postmenopausal", "women", "and", "indicate", "that", "androgen", "replacement", "in", "these", "women", "may", "not", "be", "harmless", "."]], "ner": [[[3, 3, "Chemical"], [64, 64, "Chemical"], [239, 239, "Chemical"], [7, 7, "Disease"], [25, 25, "Disease"], [75, 75, "Disease"], [78, 78, "Disease"], [99, 99, "Disease"], [134, 134, "Disease"], [153, 153, "Disease"], [244, 244, "Disease"], [205, 205, "Disease"], [62, 62, "Chemical"], [67, 71, "Chemical"], [207, 207, "Chemical"], [215, 215, "Chemical"]]], "relations": [[[3, 3, 7, 7, "CID"], [3, 3, 25, 25, "CID"], [3, 3, 75, 75, "CID"], [3, 3, 78, 78, "CID"], [3, 3, 99, 99, "CID"], [3, 3, 134, 134, "CID"], [3, 3, 153, 153, "CID"], [3, 3, 244, 244, "CID"], [64, 64, 7, 7, "CID"], [64, 64, 25, 25, "CID"], [64, 64, 75, 75, "CID"], [64, 64, 78, 78, "CID"], [64, 64, 99, 99, "CID"], [64, 64, 134, 134, "CID"], [64, 64, 153, 153, "CID"], [64, 64, 244, 244, "CID"], [239, 239, 7, 7, "CID"], [239, 239, 25, 25, "CID"], [239, 239, 75, 75, "CID"], [239, 239, 78, 78, "CID"], [239, 239, 99, 99, "CID"], [239, 239, 134, 134, "CID"], [239, 239, 153, 153, "CID"], [239, 239, 244, 244, "CID"]]], "clusters": [], "translated": "高剂量<0>睾酮</0>与绝经后妇女的<3>动脉粥样硬化</3>有关。目的：研究雄激素治疗对绝经后妇女<4>动脉粥样硬化</4>的长期影响。方法：在一项针对 513 名年龄在 54 - 67 岁的自然绝经后女性的基于人群的研究中，我们研究了自我报告的肌肉注射高剂量<12>雌激素</12>-<1>睾酮</1>治疗（<13>雌二醇和睾酮酯</13>）与主动脉<5>动脉粥样硬化</5>之间的关联。主动脉<6>动脉粥样硬化</6>是通过射线照相检测腹主动脉中的钙化沉积物来诊断的，这已被证明可以反映内膜<7>动脉粥样硬化</7>。激素疗法使用者与从未使用者进行了比较。结果：25名女性报告使用肌内激素治疗1年或更长时间。这些女性中几乎有一半存在严重的<8>动脉粥样硬化</8>主动脉(n = 11)，而在未使用激素的女性中，只有不到20%存在严重的<9>动脉粥样硬化</9>（OR 3.1；95% CI，1.1-8.5，根据年龄、绝经后年数、吸烟和体重指数进行调整）。在对<11>糖尿病</11>、<14>胆固醇</14>水平、收缩压或<15>酒精</15>使用进行额外调整后，该关联仍然存在。未发现激素使用少于1年有关联。结论：我们的结果表明，高剂量<2>睾酮</2>治疗可能对绝经后妇女的<10>动脉粥样硬化</10>产生不利影响，并表明对这些妇女进行雄激素替代治疗可能并非无害。", "revised": true}
{"doc_key": "15036754", "sentences": [["Organophosphate", "-", "induced", "convulsions", "and", "prevention", "of", "neuropathological", "damages", ".", "Such", "organophosphorus", "(", "OP", ")", "compounds", "as", "diisopropylfluorophosphate", "(", "DFP", ")", ",", "sarin", "and", "soman", "are", "potent", "inhibitors", "of", "acetylcholinesterases", "(", "AChEs", ")", "and", "butyrylcholinesterases", "(", "BChEs", ")", ".", "The", "acute", "toxicity", "of", "OPs", "is", "the", "result", "of", "their", "irreversible", "binding", "with", "AChEs", "in", "the", "central", "nervous", "system", "(", "CNS", ")", ",", "which", "elevates", "acetylcholine", "(", "ACh", ")", "levels", ".", "The", "protective", "action", "of", "subcutaneously", "(", "SC", ")", "administered", "antidotes", "or", "their", "combinations", "in", "DFP", "(", "2", ".", "0", "mg", "/", "kg", "BW", ")", "intoxication", "was", "studied", "in", "9", "-", "10", "-", "weeks", "-", "old", "Han", "-", "Wistar", "male", "rats", ".", "The", "rats", "received", "AChE", "reactivator", "pralidoxime", "-", "2", "-", "chloride", "(", "2PAM", ")", "(", "30", ".", "0", "mg", "/", "kg", "BW", ")", ",", "anticonvulsant", "diazepam", "(", "2", ".", "0", "mg", "/", "kg", "BW", ")", ",", "A", "(", "1", ")", "-", "adenosine", "receptor", "agonist", "N", "(", "6", ")", "-", "cyclopentyl", "adenosine", "(", "CPA", ")", "(", "2", ".", "0", "mg", "/", "kg", "BW", ")", ",", "NMDA", "-", "receptor", "antagonist", "dizocilpine", "maleate", "(", "+", "-", "MK801", "hydrogen", "maleate", ")", "(", "2", ".", "0", "mg", "/", "kg", "BW", ")", "or", "their", "combinations", "with", "cholinolytic", "drug", "atropine", "sulfate", "(", "50", ".", "0", "mg", "/", "kg", "BW", ")", "immediately", "or", "30", "min", "after", "the", "single", "SC", "injection", "of", "DFP", ".", "The", "control", "rats", "received", "atropine", "sulfate", ",", "but", "also", "saline", "and", "olive", "oil", "instead", "of", "other", "antidotes", "and", "DFP", ",", "respectively", ".", "All", "rats", "were", "terminated", "either", "24", "h", "or", "3", "weeks", "after", "the", "DFP", "injection", ".", "The", "rats", "treated", "with", "DFP", "-", "atropine", "showed", "severe", "typical", "OP", "-", "induced", "toxicity", "signs", ".", "When", "CPA", ",", "diazepam", "or", "2PAM", "was", "given", "immediately", "after", "DFP", "-", "atropine", ",", "these", "treatments", "prevented", ",", "delayed", "or", "shortened", "the", "occurrence", "of", "serious", "signs", "of", "poisoning", ".", "Atropine", "-", "MK801", "did", "not", "offer", "any", "additional", "protection", "against", "DFP", "toxicity", ".", "In", "conclusion", ",", "CPA", ",", "diazepam", "and", "2PAM", "in", "combination", "with", "atropine", "prevented", "the", "occurrence", "of", "serious", "signs", "of", "poisoning", "and", "thus", "reduced", "the", "toxicity", "of", "DFP", "in", "rat", "."]], "ner": [[[17, 17, "Chemical"], [19, 19, "Chemical"], [84, 84, "Chemical"], [223, 223, "Chemical"], [243, 243, "Chemical"], [259, 259, "Chemical"], [266, 266, "Chemical"], [288, 288, "Chemical"], [317, 317, "Chemical"], [346, 346, "Chemical"], [3, 3, "Disease"], [0, 0, "Chemical"], [11, 11, "Chemical"], [13, 13, "Chemical"], [43, 43, "Chemical"], [272, 272, "Chemical"], [7, 8, "Disease"], [41, 41, "Disease"], [275, 275, "Disease"], [318, 318, "Disease"], [344, 344, "Disease"], [305, 305, "Disease"], [339, 339, "Disease"], [22, 22, "Chemical"], [24, 24, "Chemical"], [64, 64, "Chemical"], [66, 66, "Chemical"], [116, 120, "Chemical"], [122, 122, "Chemical"], [283, 283, "Chemical"], [327, 327, "Chemical"], [135, 135, "Chemical"], [281, 281, "Chemical"], [325, 325, "Chemical"], [151, 151, "Chemical"], [154, 160, "Chemical"], [162, 162, "Chemical"], [279, 279, "Chemical"], [323, 323, "Chemical"], [174, 174, "Chemical"], [178, 179, "Chemical"], [309, 309, "Chemical"], [202, 203, "Chemical"], [229, 230, "Chemical"], [268, 268, "Chemical"], [290, 290, "Chemical"], [307, 307, "Chemical"], [331, 331, "Chemical"]]], "relations": [[[17, 17, 3, 3, "CID"], [19, 19, 3, 3, "CID"], [84, 84, 3, 3, "CID"], [223, 223, 3, 3, "CID"], [243, 243, 3, 3, "CID"], [259, 259, 3, 3, "CID"], [266, 266, 3, 3, "CID"], [288, 288, 3, 3, "CID"], [317, 317, 3, 3, "CID"], [346, 346, 3, 3, "CID"]]], "clusters": [], "translated": "<11>有机磷</11> - 诱发<10>惊厥</10>和预防<16>神经病理学损伤</16>。 <12>有机磷</12>（<13>OP</13>）化合物如<0>二异丙基氟磷酸盐</0>（<1>DFP</1>）、<23>沙林</23>和<24>梭曼</24>是乙酰胆碱酯酶（AChEs）和丁酰胆碱酯酶（BChEs）的有效抑制剂。 <14>OPs</14>的急性<17>毒性</17>是它们与中枢神经系统（CNS）中的AChEs不可逆结合的结果，这会升高<25>乙酰胆碱</25>（<26>ACh</26>）水平。在9-10周龄的Han-Wistar雄性大鼠中研究了皮下（SC）给予解毒剂或其组合对<2>DFP</2>（2.0 mg / kg BW）中毒的保护作用。大鼠接受乙酰胆碱酯酶活化剂<27>解磷定-2-氯</27>（<28>2PAM</28>）（30.0 mg / kg BW）、抗惊厥药<31>地西泮</31>（2.0 mg / kg BW）、A（1）-<34>腺苷</34> 受体激动剂<35>N（6）-环戊基腺苷</35>（<36>CPA</36>）（2.0mg/kg BW），<39>NMDA</39> - 受体拮抗剂<40>马来酸地佐西平</40>（+-MK801 马来酸氢盐）(2.0 mg/kg BW)或其与胆碱溶解药物的组合<42>硫酸阿托品</42>（50.0mg/kg BW）立即或单次皮下注射<3>DFP</3>后30分钟。对照大鼠接受<43>硫酸阿托品</43>，但也分别接受生理盐水和橄榄油代替其他解毒剂和<4>DFP</4>，在<5>DFP</5>注射后24小时或3周处死所有大鼠。 <6>DFP</6>-<44>阿托品</44>处理的大鼠表现出严重的典型<15>OP</15>诱导的<18>毒性</18>体征。当<37>CPA</37>、<32>地西泮</32>或<29>2PAM</29>在<7>DFP</7>-<45>阿托品</45>后立即给予时，这些治疗可预防、延迟或缩短严重中毒的<21>症状</21>的发生。 <46>阿托品</46>-<41>MK801</41>没有提供任何额外保护对抗<8>DFP</8><19>毒性</19>。总之，<38>CPA</38>、<33>地西泮</33>和<30>2PAM</30>与<47>阿托品</47>联合使用可预防严重中毒<22>症状的发生</22>，从而降低了<9>DFP</9>对大鼠的<20>毒性</20>。", "revised": true}
{"doc_key": "17612891", "sentences": [["Acute", "myocarditis", "associated", "with", "clozapine", ".", "OBJECTIVE", ":", "A", "case", "of", "acute", "myocarditis", "associated", "with", "the", "commencement", "of", "clozapine", "is", "described", ",", "highlighting", "the", "onset", ",", "course", "and", "possible", "contributing", "factors", ".", "There", "is", "an", "urgent", "need", "to", "raise", "awareness", "about", "this", "potentially", "fatal", "complication", "of", "clozapine", "use", ".", "RESULTS", ":", "A", "20", "-", "year", "-", "old", "male", "with", "schizophrenia", "developed", "a", "sudden", "onset", "of", "myocarditis", "after", "commencement", "of", "clozapine", ".", "The", "patient", "recovered", "with", "intensive", "medical", "support", ".", "The", "symptoms", "occurred", "around", "2", "weeks", "after", "starting", "clozapine", "in", "an", "inpatient", "setting", ".", "Possible", "contributing", "factors", "may", "have", "been", "concomitant", "antidepressant", "use", "and", "unaccustomed", "physical", "activity", ".", "CONCLUSIONS", ":", "Myocarditis", "is", "an", "increasingly", "recognized", "complication", "associated", "with", "the", "use", "of", "clozapine", ".", "It", "can", "be", "fatal", "if", "not", "recognized", "and", "treated", "early", ".", "Considering", "that", "clozapine", "remains", "the", "gold", "standard", "in", "treatment", "of", "resistant", "psychosis", ",", "there", "is", "an", "urgent", "need", "to", "raise", "awareness", "among", "medical", "and", "paramedical", "staff", "involved", "in", "the", "care", "of", "these", "patients", ".", "There", "are", "also", "implications", "for", "recommendations", "and", "regulations", "regarding", "the", "use", "of", "clozapine", "."]], "ner": [[[4, 4, "Chemical"], [18, 18, "Chemical"], [46, 46, "Chemical"], [69, 69, "Chemical"], [87, 87, "Chemical"], [120, 120, "Chemical"], [135, 135, "Chemical"], [179, 179, "Chemical"], [1, 1, "Disease"], [12, 12, "Disease"], [65, 65, "Disease"], [109, 109, "Disease"], [100, 100, "Chemical"], [59, 59, "Disease"], [144, 144, "Disease"]]], "relations": [[[4, 4, 1, 1, "CID"], [4, 4, 12, 12, "CID"], [4, 4, 65, 65, "CID"], [4, 4, 109, 109, "CID"], [18, 18, 1, 1, "CID"], [18, 18, 12, 12, "CID"], [18, 18, 65, 65, "CID"], [18, 18, 109, 109, "CID"], [46, 46, 1, 1, "CID"], [46, 46, 12, 12, "CID"], [46, 46, 65, 65, "CID"], [46, 46, 109, 109, "CID"], [69, 69, 1, 1, "CID"], [69, 69, 12, 12, "CID"], [69, 69, 65, 65, "CID"], [69, 69, 109, 109, "CID"], [87, 87, 1, 1, "CID"], [87, 87, 12, 12, "CID"], [87, 87, 65, 65, "CID"], [87, 87, 109, 109, "CID"], [120, 120, 1, 1, "CID"], [120, 120, 12, 12, "CID"], [120, 120, 65, 65, "CID"], [120, 120, 109, 109, "CID"], [135, 135, 1, 1, "CID"], [135, 135, 12, 12, "CID"], [135, 135, 65, 65, "CID"], [135, 135, 109, 109, "CID"], [179, 179, 1, 1, "CID"], [179, 179, 12, 12, "CID"], [179, 179, 65, 65, "CID"], [179, 179, 109, 109, "CID"], [100, 100, 1, 1, "CID"], [100, 100, 12, 12, "CID"], [100, 100, 65, 65, "CID"], [100, 100, 109, 109, "CID"]]], "clusters": [], "translated": "急性<8>心肌炎</8>与<0>氯氮平</0>有关。目的：描述一例与开始使用<1>氯氮平</1>相关的急性<9>心肌炎</9>，重点介绍发病、病程和可能的影响因素。迫切需要提高对<2>氯氮平</2>使用的这种潜在致命并发症的认识。结果：一名患有<13>精神分裂症</13>的20岁男性在开始使用<3>氯氮平</3>治疗后突然发作<10>心肌炎</10>。病人在密集的医疗支持下康复。这些症状是在住院期间开始<4>氯氮平</4>治疗后约2周出现的。可能的促成因素可能是同时使用<12>抗抑郁药</12>和不习惯的身体活动。结论：<11>心肌炎</11>是与使用<5>氯氮平</5>相关的越来越多的并发症。如果不及早识别和治疗，它可能是致命的。考虑到<6>氯氮平</6>仍然是治疗顽固性<14>精神病</14>的金标准，因此迫切需要提高参与这些患者护理的医疗和辅助医疗人员的意识。关于<7>氯氮平</7>的使用的建议和法规也有影响。", "revised": true}
{"doc_key": "17343925", "sentences": [["Influence", "of", "smoking", "on", "developing", "cochlea", ".", "Does", "smoking", "during", "pregnancy", "affect", "the", "amplitudes", "of", "transient", "evoked", "otoacoustic", "emissions", "in", "newborns", "?", "OBJECTIVE", ":", "Maternal", "tobacco", "smoking", "has", "negative", "effects", "on", "fetal", "growth", ".", "The", "influence", "of", "smoking", "during", "pregnancy", "on", "the", "developing", "cochlea", "has", "not", "been", "estimated", ",", "although", "smoking", "has", "been", "positively", "associated", "with", "hearing", "loss", "in", "adults", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "the", "effects", "of", "maternal", "smoking", "on", "transient", "evoked", "otoacoustic", "emissions", "(", "TEOAEs", ")", "of", "healthy", "neonates", ".", "METHODS", ":", "This", "study", "was", "undertaken", "as", "part", "of", "neonatal", "screening", "for", "hearing", "impairment", "and", "involved", "both", "ears", "of", "200", "newborns", ".", "Newborns", "whose", "mothers", "reported", "smoking", "during", "pregnancy", "(", "n", "=", "200", "ears", ")", "were", "compared", "to", "a", "control", "group", "of", "newborns", "(", "n", "=", "200", "ears", ")", ",", "whose", "mothers", "were", "non", "-", "smokers", ".", "Exposure", "to", "tobacco", "was", "characterized", "as", "low", "(", "<", "5", "cigarettes", "per", "day", ",", "n", "=", "88", "ears", ")", ",", "moderate", "(", "5", "<", "or", "=", "cigarettes", "per", "day", "<", "10", ",", "n", "=", "76", ")", "or", "high", "(", ">", "or", "=", "10", "cigarettes", "per", "day", ",", "n", "=", "36", ")", ".", "RESULTS", ":", "In", "exposed", "neonates", ",", "TEOAEs", "mean", "response", "(", "across", "frequency", ")", "and", "mean", "amplitude", "at", "4000Hz", "was", "significantly", "lower", "than", "in", "non", "-", "exposed", "neonates", ".", "Comparisons", "between", "exposed", "newborns", "'", "subgroups", "revealed", "no", "significant", "differences", ".", "However", ",", "by", "comparing", "each", "subgroup", "to", "control", "group", ",", "we", "found", "statistically", "significant", "decreases", "of", "TEOAEs", "amplitudes", "at", "4000Hz", "for", "all", "three", "groups", ".", "Mean", "TEOAEs", "responses", "of", "highly", "exposed", "newborns", "were", "also", "significantly", "lower", "in", "comparison", "to", "our", "control", "group", ".", "CONCLUSION", ":", "In", "utero", ",", "exposure", "to", "tobacco", "smoking", "seems", "to", "have", "a", "small", "impact", "on", "outer", "hair", "cells", ".", "These", "effects", "seem", "to", "be", "equally", "true", "for", "all", "exposed", "newborns", ",", "regardless", "of", "the", "degree", "of", "exposure", ".", "Further", "studies", "are", "needed", "in", "order", "to", "establish", "a", "potential", "negative", "effect", "of", "maternal", "smoking", "on", "the", "neonate", "'s", "hearing", "acuity", "."]], "ner": [[[2, 2, "Chemical"], [8, 8, "Chemical"], [26, 26, "Chemical"], [37, 37, "Chemical"], [50, 50, "Chemical"], [73, 73, "Chemical"], [112, 112, "Chemical"], [285, 285, "Chemical"], [330, 330, "Chemical"], [56, 57, "Disease"], [98, 99, "Disease"]]], "relations": [[[2, 2, 56, 57, "CID"], [2, 2, 98, 99, "CID"], [8, 8, 56, 57, "CID"], [8, 8, 98, 99, "CID"], [26, 26, 56, 57, "CID"], [26, 26, 98, 99, "CID"], [37, 37, 56, 57, "CID"], [37, 37, 98, 99, "CID"], [50, 50, 56, 57, "CID"], [50, 50, 98, 99, "CID"], [73, 73, 56, 57, "CID"], [73, 73, 98, 99, "CID"], [112, 112, 56, 57, "CID"], [112, 112, 98, 99, "CID"], [285, 285, 56, 57, "CID"], [285, 285, 98, 99, "CID"], [330, 330, 56, 57, "CID"], [330, 330, 98, 99, "CID"]]], "clusters": [], "translated": "在怀孕期间，<1>吸烟</1>是否会影响新生儿瞬态诱发耳声发射的振幅？<0>吸烟</0>对耳蜗发育的影响。目的：母亲烟草<2>吸烟</2>对胎儿生长有负面影响。尽管<4>吸烟</4>与成人<9>听力损失</9>呈正相关，但怀孕期间<3>吸烟</3>对发育中的耳蜗的影响尚未得到估计。本研究的目的是确定母亲<5>吸烟</5>对健康新生儿瞬态诱发耳声发射（TEOAE）的影响。方法：这项研究是作为<10>听力障碍</10>新生儿筛查的一部分进行的，涉及200名新生儿的双耳。母亲报告在怀孕期间<6>吸烟</6>的新生儿（n = 200 只耳朵）与母亲为非吸烟者的新生儿对照组（n = 200 只耳朵）进行了比较。接触烟草的特征为低度（每天<5支香烟，n = 88耳）、中度（每天5<或=香烟<10支，n = 76）或高度（>或=每天10支香烟，n = 36）。结果：在暴露的新生儿中，TEOAE的平均响应（跨频率）和4000Hz的平均振幅明显低于未暴露的新生儿。暴露的新生儿亚组之间的比较显示没有显着差异。然而，通过将每个子组与对照组进行比较，我们发现所有三个组在4000Hz时的TEOAE振幅均有统计学意义的降低。与我们的对照组相比，高度暴露新生儿的平均TEOAE反应也显着降低。结论：在子宫内，接触烟草<7>吸烟</7>似乎对外毛细胞有很小的影响。这些影响似乎对所有暴露的新生儿都同样适用，无论暴露程度如何。需要进一步研究以确定母亲<8>吸烟</8>对新生儿听力的潜在负面影响。", "revised": true}
{"doc_key": "3780846", "sentences": [["On", "the", "mechanisms", "of", "the", "development", "of", "tolerance", "to", "the", "muscular", "rigidity", "produced", "by", "morphine", "in", "rats", ".", "The", "development", "of", "tolerance", "to", "the", "muscular", "rigidity", "produced", "by", "morphine", "was", "studied", "in", "rats", ".", "Saline", "-", "pretreated", "controls", "given", "a", "test", "dose", "of", "morphine", "(", "20", "mg", "/", "kg", "i", ".", "p", ".", ")", "showed", "a", "pronounced", "rigidity", "recorded", "as", "tonic", "activity", "in", "the", "electromyogram", ".", "Rats", "treated", "for", "11", "days", "with", "morphine", "and", "withdrawn", "for", "36", "-", "40", "h", "showed", "differences", "in", "the", "development", "of", "tolerance", ":", "about", "half", "of", "the", "animals", "showed", "a", "rigidity", "after", "the", "test", "dose", "of", "morphine", "that", "was", "not", "significantly", "less", "than", "in", "the", "controls", "and", "were", "akinetic", "(", "A", "group", ")", ".", "The", "other", "rats", "showed", "a", "strong", "decrease", "in", "the", "rigidity", "and", "the", "occurrence", "of", "stereotyped", "(", "S", ")", "licking", "and", "/", "or", "gnawing", "in", "presence", "of", "akinetic", "or", "hyperkinetic", "(", "K", ")", "behaviour", "(", "AS", "/", "KS", "group", ")", ",", "suggesting", "signs", "of", "dopaminergic", "activation", ".", "The", "rigidity", "was", "considerably", "decreased", "in", "both", "groups", "after", "20", "days", "'", "treatment", ".", "In", "a", "further", "series", "of", "experiments", ",", "haloperidol", "(", "0", ".", "2", "mg", "/", "kg", "i", ".", "p", ".", ")", "was", "used", "in", "order", "to", "block", "the", "dopaminergic", "activation", "and", "to", "estimate", "the", "real", "degree", "of", "the", "tolerance", "to", "the", "rigidity", "without", "any", "dopaminergic", "interference", ".", "Haloperidol", "enhanced", "the", "rigidity", "in", "the", "A", "group", ".", "However", ",", "the", "level", "in", "the", "AS", "/", "KS", "group", "remained", "considerably", "lower", "than", "in", "the", "A", "group", ".", "The", "results", "suggest", "that", "rigidity", ",", "which", "is", "assumed", "to", "be", "due", "to", "an", "action", "of", "morphine", "in", "the", "striatum", ",", "can", "be", "antagonized", "by", "another", "process", "leading", "to", "dopaminergic", "activation", "in", "the", "striatum", ".", "Nevertheless", ",", "there", "occurs", "some", "real", "tolerance", "to", "this", "effect", ".", "The", "rapid", "alternations", "of", "rigidity", "and", "the", "signs", "of", "dopaminergic", "activation", "observed", "in", "the", "animals", "of", "the", "AS", "/", "KS", "group", "might", "be", "due", "to", "rapid", "shifts", "in", "the", "predominance", "of", "various", "DA", "-", "innervated", "structures", "."]], "ner": [[[14, 14, "Chemical"], [28, 28, "Chemical"], [43, 43, "Chemical"], [72, 72, "Chemical"], [101, 101, "Chemical"], [269, 269, "Chemical"], [10, 11, "Disease"], [24, 25, "Disease"], [57, 57, "Disease"], [95, 95, "Disease"], [128, 128, "Disease"], [166, 166, "Disease"], [219, 219, "Disease"], [228, 228, "Disease"], [257, 257, "Disease"], [303, 303, "Disease"], [186, 186, "Chemical"], [225, 225, "Chemical"], [113, 113, "Disease"], [145, 145, "Disease"], [147, 147, "Disease"]]], "relations": [[[14, 14, 10, 11, "CID"], [14, 14, 24, 25, "CID"], [14, 14, 57, 57, "CID"], [14, 14, 95, 95, "CID"], [14, 14, 128, 128, "CID"], [14, 14, 166, 166, "CID"], [14, 14, 219, 219, "CID"], [14, 14, 228, 228, "CID"], [14, 14, 257, 257, "CID"], [14, 14, 303, 303, "CID"], [28, 28, 10, 11, "CID"], [28, 28, 24, 25, "CID"], [28, 28, 57, 57, "CID"], [28, 28, 95, 95, "CID"], [28, 28, 128, 128, "CID"], [28, 28, 166, 166, "CID"], [28, 28, 219, 219, "CID"], [28, 28, 228, 228, "CID"], [28, 28, 257, 257, "CID"], [28, 28, 303, 303, "CID"], [43, 43, 10, 11, "CID"], [43, 43, 24, 25, "CID"], [43, 43, 57, 57, "CID"], [43, 43, 95, 95, "CID"], [43, 43, 128, 128, "CID"], [43, 43, 166, 166, "CID"], [43, 43, 219, 219, "CID"], [43, 43, 228, 228, "CID"], [43, 43, 257, 257, "CID"], [43, 43, 303, 303, "CID"], [72, 72, 10, 11, "CID"], [72, 72, 24, 25, "CID"], [72, 72, 57, 57, "CID"], [72, 72, 95, 95, "CID"], [72, 72, 128, 128, "CID"], [72, 72, 166, 166, "CID"], [72, 72, 219, 219, "CID"], [72, 72, 228, 228, "CID"], [72, 72, 257, 257, "CID"], [72, 72, 303, 303, "CID"], [101, 101, 10, 11, "CID"], [101, 101, 24, 25, "CID"], [101, 101, 57, 57, "CID"], [101, 101, 95, 95, "CID"], [101, 101, 128, 128, "CID"], [101, 101, 166, 166, "CID"], [101, 101, 219, 219, "CID"], [101, 101, 228, 228, "CID"], [101, 101, 257, 257, "CID"], [101, 101, 303, 303, "CID"], [269, 269, 10, 11, "CID"], [269, 269, 24, 25, "CID"], [269, 269, 57, 57, "CID"], [269, 269, 95, 95, "CID"], [269, 269, 128, 128, "CID"], [269, 269, 166, 166, "CID"], [269, 269, 219, 219, "CID"], [269, 269, 228, 228, "CID"], [269, 269, 257, 257, "CID"], [269, 269, 303, 303, "CID"], [186, 186, 10, 11, "CID"], [186, 186, 24, 25, "CID"], [186, 186, 57, 57, "CID"], [186, 186, 95, 95, "CID"], [186, 186, 128, 128, "CID"], [186, 186, 166, 166, "CID"], [186, 186, 219, 219, "CID"], [186, 186, 228, 228, "CID"], [186, 186, 257, 257, "CID"], [186, 186, 303, 303, "CID"], [225, 225, 10, 11, "CID"], [225, 225, 24, 25, "CID"], [225, 225, 57, 57, "CID"], [225, 225, 95, 95, "CID"], [225, 225, 128, 128, "CID"], [225, 225, 166, 166, "CID"], [225, 225, 219, 219, "CID"], [225, 225, 228, 228, "CID"], [225, 225, 257, 257, "CID"], [225, 225, 303, 303, "CID"], [14, 14, 113, 113, "CID"], [14, 14, 145, 145, "CID"], [28, 28, 113, 113, "CID"], [28, 28, 145, 145, "CID"], [43, 43, 113, 113, "CID"], [43, 43, 145, 145, "CID"], [72, 72, 113, 113, "CID"], [72, 72, 145, 145, "CID"], [101, 101, 113, 113, "CID"], [101, 101, 145, 145, "CID"], [269, 269, 113, 113, "CID"], [269, 269, 145, 145, "CID"], [14, 14, 147, 147, "CID"], [28, 28, 147, 147, "CID"], [43, 43, 147, 147, "CID"], [72, 72, 147, 147, "CID"], [101, 101, 147, 147, "CID"], [269, 269, 147, 147, "CID"]]], "clusters": [], "translated": "大鼠对<0>吗啡</0>产生的<6>肌肉强直</6>产生耐受的机制研究。在大鼠中研究了对<1>吗啡</1>产生的<7>肌肉僵硬</7>耐受性的发展。给予测试剂量<2>吗啡</2>（20 mg/kg i.p.）的生理盐水预处理对照组显示出明显的<8>强直</8>，在肌电图中记录为强直活动。用<3>吗啡</3>治疗11天并停药36-40小时的大鼠表现出耐受性发展的差异：大约一半的动物在试验剂量<4>吗啡</4>后表现出<9>僵硬</9>，这并不显著低于对照组，并且是<18>无活动能力</18>（a组）。其他大鼠在<10>肌肉僵硬</10>和刻板(S)舔和/或啃存在<19>运动不足</19>或<20>运动过度</20>方面表现出强烈的下降(K)行为（AS/KS组），提示多巴胺能激活的迹象。治疗20天后，两组<11>肌肉僵硬</11>均明显下降。在进一步的一系列实验中，使用<16>氟哌啶醇</16>（0.2 mg/kg i.p.）来阻断多巴胺能激活并评估对<12>肌肉僵硬</12>的真实耐受程度，没有任何多巴胺能干扰。<17>氟哌啶醇</17>增强了A组的<13>肌肉僵硬</13>。然而，AS/KS组的水平仍远低于A组。结果表明，<14>肌肉强直</14>被认为是由于纹状体中<5>吗啡</5>的作用所致，可被另一种导致纹状体多巴胺能激活的过程所拮抗。然而，对这种影响确实存在一定的容忍度。在AS/KS组动物中观察到的<15>肌肉僵硬</15>和多巴胺能激活迹象的快速变化可能是由于各种DA神经支配结构的优势快速转变所致。", "revised": true}
{"doc_key": "18081909", "sentences": [["Encephalopathy", "induced", "by", "levetiracetam", "added", "to", "valproate", ".", "BACKGROUND", ":", "We", "report", "on", "the", "manifestation", "of", "a", "levetiracetam", "(", "LEV", ")", "-", "induced", "encephalopathy", ".", "FINDINGS", ":", "A", "28", "-", "year", "-", "old", "man", "suffering", "from", "idiopathic", "epilepsy", "with", "generalized", "seizures", "was", "treated", "with", "LEV", "(", "3000", "mg", ")", "added", "to", "valproate", "(", "VPA", ")", "(", "2000", "mg", ")", ".", "Frequency", "of", "generalized", "tonic", "-", "clonic", "seizures", "increased", "from", "one", "per", "6", "months", "to", "two", "per", "month", ".", "Neuropsychological", "testing", "showed", "impaired", "word", "fluency", ",", "psychomotor", "speed", "and", "working", "memory", ".", "The", "interictal", "electroencephalogram", "(", "EEG", ")", "showed", "a", "generalized", "slowing", "to", "5", "per", "second", "theta", "rhythms", "with", "bilateral", "generalized", "high", "-", "amplitude", "discharges", ".", "OUTCOME", ":", "Following", "discontinuation", "of", "LEV", ",", "EEG", "and", "neuropsychological", "findings", "improved", "and", "seizure", "frequency", "decreased", "."]], "ner": [[[3, 3, "Chemical"], [17, 17, "Chemical"], [19, 19, "Chemical"], [44, 44, "Chemical"], [120, 120, "Chemical"], [0, 0, "Disease"], [23, 23, "Disease"], [6, 6, "Chemical"], [51, 51, "Chemical"], [53, 53, "Chemical"], [63, 66, "Disease"], [81, 89, "Disease"], [36, 37, "Disease"], [40, 40, "Disease"], [128, 128, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 23, 23, "CID"], [17, 17, 0, 0, "CID"], [17, 17, 23, 23, "CID"], [19, 19, 0, 0, "CID"], [19, 19, 23, 23, "CID"], [44, 44, 0, 0, "CID"], [44, 44, 23, 23, "CID"], [120, 120, 0, 0, "CID"], [120, 120, 23, 23, "CID"], [6, 6, 0, 0, "CID"], [6, 6, 23, 23, "CID"], [51, 51, 0, 0, "CID"], [51, 51, 23, 23, "CID"], [53, 53, 0, 0, "CID"], [53, 53, 23, 23, "CID"], [3, 3, 63, 66, "CID"], [17, 17, 63, 66, "CID"], [19, 19, 63, 66, "CID"], [44, 44, 63, 66, "CID"], [120, 120, 63, 66, "CID"], [3, 3, 81, 89, "CID"], [17, 17, 81, 89, "CID"], [19, 19, 81, 89, "CID"], [44, 44, 81, 89, "CID"], [120, 120, 81, 89, "CID"], [6, 6, 63, 66, "CID"], [51, 51, 63, 66, "CID"], [53, 53, 63, 66, "CID"], [6, 6, 81, 89, "CID"], [51, 51, 81, 89, "CID"], [53, 53, 81, 89, "CID"]]], "clusters": [], "translated": " <5>脑病</5> 由 <0>左乙拉西坦</0> 加入 <7>丙戊酸盐</7> 所致。背景：我们报告了 <1>左乙拉西坦</1> （<2>LEV</2>）诱发的<6>脑病</6> 的表现。调查结果：一名患有<12>特发性癫痫</12>并伴有全身性<13>癫痫发作</13>的28岁男性，在<8>丙戊酸盐</8>（<9>VPA</9>）（2000毫克）中加入<3>LEV</3>（3000毫克）进行治疗。全身性<10>强直阵挛发作</10>的频率从每六个月一次增加到每月两次。神经心理学测试显示<11>单词流畅性、心理运动速度和工作记忆受损</11>。发作间期脑电图（EEG）显示全身性减慢至每秒5次theta节律，双侧全身性高振幅放电。结果：停止<4>LEV</4> 后，EEG和神经心理学结果得到改善，<14>癫痫发作</14> 频率降低。", "revised": true}
{"doc_key": "18996674", "sentences": [["Intracavernous", "epinephrine", ":", "a", "minimally", "invasive", "treatment", "for", "priapism", "in", "the", "emergency", "department", ".", "Priapism", "is", "the", "prolonged", "erection", "of", "the", "penis", "in", "the", "absence", "of", "sexual", "arousal", ".", "A", "45", "-", "year", "-", "old", "man", ",", "an", "admitted", "frequent", "cocaine", "user", ",", "presented", "to", "the", "Emergency", "Department", "(", "ED", ")", "on", "two", "separate", "occasions", "with", "a", "history", "of", "priapism", "after", "cocaine", "use", ".", "The", "management", "options", "in", "the", "ED", ",", "as", "exemplified", "by", "four", "individual", "case", "reports", ",", "in", "particular", "the", "use", "of", "a", "minimally", "invasive", "method", "of", "intracorporal", "epinephrine", "instillation", ",", "are", "discussed", "."]], "ner": [[[40, 40, "Chemical"], [61, 61, "Chemical"], [8, 8, "Disease"], [14, 14, "Disease"], [59, 59, "Disease"], [1, 1, "Chemical"], [90, 90, "Chemical"]]], "relations": [[[40, 40, 8, 8, "CID"], [40, 40, 14, 14, "CID"], [40, 40, 59, 59, "CID"], [61, 61, 8, 8, "CID"], [61, 61, 14, 14, "CID"], [61, 61, 59, 59, "CID"]]], "clusters": [], "translated": "海绵体内<5>肾上腺素</5>：<2>阴茎异常勃起</2>的微创治疗。 <3>阴茎异常勃起</3>是指在没有性唤起的情况下阴茎长时间勃起。一名45岁的男性，入院时经常吸食<0>可卡因</0>，曾两次因使用<1>可卡因</1>后出现<4>阴茎异常勃起</4>到急诊室 (ED) 就诊。讨论了 ED 中的管理选项，以四个个案报告为例，特别是使用体内<6>肾上腺素</6>滴注的微创方法。", "revised": true}
{"doc_key": "8092427", "sentences": [["Immediate", "allergic", "reactions", "to", "amoxicillin", ".", "A", "large", "group", "of", "patients", "with", "suspected", "allergic", "reactions", "to", "beta", "-", "lactam", "antibiotics", "was", "evaluated", ".", "A", "detailed", "clinical", "history", ",", "together", "with", "skin", "tests", ",", "RAST", "(", "radioallergosorbent", "test", ")", ",", "and", "controlled", "challenge", "tests", ",", "was", "used", "to", "establish", "whether", "patients", "allergic", "to", "beta", "-", "lactam", "antibiotics", "had", "selective", "immediate", "allergic", "responses", "to", "amoxicillin", "(", "AX", ")", "or", "were", "cross", "-", "reacting", "with", "other", "penicillin", "derivatives", ".", "Skin", "tests", "were", "performed", "with", "benzylpenicilloyl", "-", "poly", "-", "L", "-", "lysine", "(", "BPO", "-", "PLL", ")", ",", "benzylpenicilloate", ",", "benzylpenicillin", "(", "PG", ")", ",", "ampicillin", "(", "AMP", ")", ",", "and", "AX", ".", "RAST", "for", "BPO", "-", "PLL", "and", "AX", "-", "PLL", "was", "done", ".", "When", "both", "skin", "test", "and", "RAST", "for", "BPO", "were", "negative", ",", "single", "-", "blind", ",", "placebo", "-", "controlled", "challenge", "tests", "were", "done", "to", "ensure", "tolerance", "of", "PG", "or", "sensitivity", "to", "AX", ".", "A", "total", "of", "177", "patients", "were", "diagnosed", "as", "allergic", "to", "beta", "-", "lactam", "antibiotics", ".", "We", "selected", "the", "54", "(", "30", ".", "5", "%", ")", "cases", "of", "immediate", "AX", "allergy", "with", "good", "tolerance", "of", "PG", ".", "Anaphylaxis", "was", "seen", "in", "37", "patients", "(", "69", "%", ")", ",", "the", "other", "17", "(", "31", "%", ")", "having", "urticaria", "and", "/", "or", "angioedema", ".", "All", "the", "patients", "were", "skin", "test", "negative", "to", "BPO", ";", "49", "of", "51", "(", "96", "%", ")", "were", "also", "negative", "to", "MDM", ",", "and", "44", "of", "46", "(", "96", "%", ")", "to", "PG", ".", "Skin", "tests", "with", "AX", "were", "positive", "in", "34", "(", "63", "%", ")", "patients", ".", "RAST", "was", "positive", "for", "AX", "in", "22", "patients", "(", "41", "%", ")", "and", "to", "BPO", "in", "just", "5", "(", "9", "%", ")", ".", "None", "of", "the", "sera", "with", "negative", "RAST", "for", "AX", "were", "positive", "to", "BPO", ".", "Challenge", "tests", "with", "AX", "were", "performed", "in", "23", "subjects", "(", "43", "%", ")", "to", "establish", "the", "diagnosis", "of", "immediate", "allergic", "reaction", "to", "AX", ",", "and", "in", "15", "cases", "(", "28", "%", ")", "both", "skin", "test", "and", "RAST", "for", "AX", "were", "negative", ".", "PG", "was", "well", "tolerated", "by", "all", "54", "patients", ".", "We", "describe", "the", "largest", "group", "of", "AX", "-", "allergic", "patients", "who", "have", "tolerated", "PG", "reported", "so", "far", ".", "Diagnosis", "of", "these", "patients", "can", "be", "achieved", "only", "if", "specific", "AX", "-", "related", "reagents", "are", "employed", ".", "Further", "studies", "are", "necessary", "to", "determine", "the", "exact", "extent", "of", "this", "problem", "and", "to", "improve", "the", "efficacy", "of", "diagnostic", "methods", "."]], "ner": [[[4, 4, "Chemical"], [62, 62, "Chemical"], [64, 64, "Chemical"], [107, 107, "Chemical"], [115, 115, "Chemical"], [151, 151, "Chemical"], [181, 181, "Chemical"], [251, 251, "Chemical"], [266, 266, "Chemical"], [293, 293, "Chemical"], [302, 302, "Chemical"], [321, 321, "Chemical"], [337, 337, "Chemical"], [356, 356, "Chemical"], [378, 378, "Chemical"], [1, 2, "Disease"], [13, 14, "Disease"], [50, 50, "Disease"], [59, 59, "Disease"], [161, 161, "Disease"], [182, 182, "Disease"], [318, 319, "Disease"], [358, 358, "Disease"], [189, 189, "Disease"], [212, 212, "Disease"], [16, 18, "Chemical"], [52, 54, "Chemical"], [163, 165, "Chemical"], [73, 73, "Chemical"], [96, 96, "Chemical"], [98, 98, "Chemical"], [147, 147, "Chemical"], [187, 187, "Chemical"], [246, 246, "Chemical"], [341, 341, "Chemical"], [363, 363, "Chemical"], [101, 101, "Chemical"], [103, 103, "Chemical"], [208, 208, "Disease"], [235, 235, "Disease"]]], "relations": [[[4, 4, 1, 2, "CID"], [4, 4, 13, 14, "CID"], [4, 4, 50, 50, "CID"], [4, 4, 59, 59, "CID"], [4, 4, 161, 161, "CID"], [4, 4, 182, 182, "CID"], [4, 4, 318, 319, "CID"], [4, 4, 358, 358, "CID"], [62, 62, 1, 2, "CID"], [62, 62, 13, 14, "CID"], [62, 62, 50, 50, "CID"], [62, 62, 59, 59, "CID"], [62, 62, 161, 161, "CID"], [62, 62, 182, 182, "CID"], [62, 62, 318, 319, "CID"], [62, 62, 358, 358, "CID"], [64, 64, 1, 2, "CID"], [64, 64, 13, 14, "CID"], [64, 64, 50, 50, "CID"], [64, 64, 59, 59, "CID"], [64, 64, 161, 161, "CID"], [64, 64, 182, 182, "CID"], [64, 64, 318, 319, "CID"], [64, 64, 358, 358, "CID"], [107, 107, 1, 2, "CID"], [107, 107, 13, 14, "CID"], [107, 107, 50, 50, "CID"], [107, 107, 59, 59, "CID"], [107, 107, 161, 161, "CID"], [107, 107, 182, 182, "CID"], [107, 107, 318, 319, "CID"], [107, 107, 358, 358, "CID"], [115, 115, 1, 2, "CID"], [115, 115, 13, 14, "CID"], [115, 115, 50, 50, "CID"], [115, 115, 59, 59, "CID"], [115, 115, 161, 161, "CID"], [115, 115, 182, 182, "CID"], [115, 115, 318, 319, "CID"], [115, 115, 358, 358, "CID"], [151, 151, 1, 2, "CID"], [151, 151, 13, 14, "CID"], [151, 151, 50, 50, "CID"], [151, 151, 59, 59, "CID"], [151, 151, 161, 161, "CID"], [151, 151, 182, 182, "CID"], [151, 151, 318, 319, "CID"], [151, 151, 358, 358, "CID"], [181, 181, 1, 2, "CID"], [181, 181, 13, 14, "CID"], [181, 181, 50, 50, "CID"], [181, 181, 59, 59, "CID"], [181, 181, 161, 161, "CID"], [181, 181, 182, 182, "CID"], [181, 181, 318, 319, "CID"], [181, 181, 358, 358, "CID"], [251, 251, 1, 2, "CID"], [251, 251, 13, 14, "CID"], [251, 251, 50, 50, "CID"], [251, 251, 59, 59, "CID"], [251, 251, 161, 161, "CID"], [251, 251, 182, 182, "CID"], [251, 251, 318, 319, "CID"], [251, 251, 358, 358, "CID"], [266, 266, 1, 2, "CID"], [266, 266, 13, 14, "CID"], [266, 266, 50, 50, "CID"], [266, 266, 59, 59, "CID"], [266, 266, 161, 161, "CID"], [266, 266, 182, 182, "CID"], [266, 266, 318, 319, "CID"], [266, 266, 358, 358, "CID"], [293, 293, 1, 2, "CID"], [293, 293, 13, 14, "CID"], [293, 293, 50, 50, "CID"], [293, 293, 59, 59, "CID"], [293, 293, 161, 161, "CID"], [293, 293, 182, 182, "CID"], [293, 293, 318, 319, "CID"], [293, 293, 358, 358, "CID"], [302, 302, 1, 2, "CID"], [302, 302, 13, 14, "CID"], [302, 302, 50, 50, "CID"], [302, 302, 59, 59, "CID"], [302, 302, 161, 161, "CID"], [302, 302, 182, 182, "CID"], [302, 302, 318, 319, "CID"], [302, 302, 358, 358, "CID"], [321, 321, 1, 2, "CID"], [321, 321, 13, 14, "CID"], [321, 321, 50, 50, "CID"], [321, 321, 59, 59, "CID"], [321, 321, 161, 161, "CID"], [321, 321, 182, 182, "CID"], [321, 321, 318, 319, "CID"], [321, 321, 358, 358, "CID"], [337, 337, 1, 2, "CID"], [337, 337, 13, 14, "CID"], [337, 337, 50, 50, "CID"], [337, 337, 59, 59, "CID"], [337, 337, 161, 161, "CID"], [337, 337, 182, 182, "CID"], [337, 337, 318, 319, "CID"], [337, 337, 358, 358, "CID"], [356, 356, 1, 2, "CID"], [356, 356, 13, 14, "CID"], [356, 356, 50, 50, "CID"], [356, 356, 59, 59, "CID"], [356, 356, 161, 161, "CID"], [356, 356, 182, 182, "CID"], [356, 356, 318, 319, "CID"], [356, 356, 358, 358, "CID"], [378, 378, 1, 2, "CID"], [378, 378, 13, 14, "CID"], [378, 378, 50, 50, "CID"], [378, 378, 59, 59, "CID"], [378, 378, 161, 161, "CID"], [378, 378, 182, 182, "CID"], [378, 378, 318, 319, "CID"], [378, 378, 358, 358, "CID"], [4, 4, 189, 189, "CID"], [62, 62, 189, 189, "CID"], [64, 64, 189, 189, "CID"], [107, 107, 189, 189, "CID"], [115, 115, 189, 189, "CID"], [151, 151, 189, 189, "CID"], [181, 181, 189, 189, "CID"], [251, 251, 189, 189, "CID"], [266, 266, 189, 189, "CID"], [293, 293, 189, 189, "CID"], [302, 302, 189, 189, "CID"], [321, 321, 189, 189, "CID"], [337, 337, 189, 189, "CID"], [356, 356, 189, 189, "CID"], [378, 378, 189, 189, "CID"], [4, 4, 212, 212, "CID"], [62, 62, 212, 212, "CID"], [64, 64, 212, 212, "CID"], [107, 107, 212, 212, "CID"], [115, 115, 212, 212, "CID"], [151, 151, 212, 212, "CID"], [181, 181, 212, 212, "CID"], [251, 251, 212, 212, "CID"], [266, 266, 212, 212, "CID"], [293, 293, 212, 212, "CID"], [302, 302, 212, 212, "CID"], [321, 321, 212, 212, "CID"], [337, 337, 212, 212, "CID"], [356, 356, 212, 212, "CID"], [378, 378, 212, 212, "CID"]]], "clusters": [], "translated": "对<0>阿莫西林</0>的立即<15>过敏反应</15>。对疑似对<25>β-内酰胺</25>抗生素有<16>过敏反应</16>的一大批患者进行了评估。详细的临床病史，连同皮肤试验、RAST（放射性过敏吸附剂试验）和受控激发试验，被用于确定对<26>β-内酰胺</26>抗生素<17>过敏</17>的患者是否有选择性立即使用对<1>阿莫西林</1>（<2>AX</2>）有<18>过敏</18>反应，或与其他<28>青霉素</28>衍生物发生交叉反应。皮肤试验分别采用苄基青霉素-聚-L-赖氨酸（BPO-PLL）、青霉素酸苄酯、<29>苄青霉素</29>（<30>PG</30>）、<36>氨苄青霉素</36>（<37>AMP</37>）和<3>AX</3>。RAST分别检测BPO-PLL和<4>AX</4>-PLL。当BPO的皮肤试验和RAST均为阴性时，进行单盲、安慰剂对照的激发试验以确保对<31>PG</31>的耐受性或对<5>AX</5>的敏感性。共有177例患者被诊断为对<27>β-内酰胺</27>类抗生素<19>过敏</19>。选取对<32>PG</32>耐受性良好的54例（30.5%）即刻<6>AX</6><20>过敏</20>例。37名患者（69%）出现了<23>过敏反应</23>，其余17名（31%）出现了<38>荨麻疹</38>和/或<24>血管性水肿</24>。所有患者BPO皮试均为阴性；51人中有49人（96%）对<39>MDM</39>也呈阴性，46人中有44人（96%）对<33>PG</33>也呈阴性。34名（63%）患者的<7>AX</7>皮肤试验呈阳性。22名患者（41%）的RAST对<8>AX</8>呈阳性，仅5名（9%）的BPO呈阳性。<9>AX</9>RAST阴性的血清均未呈BPO阳性。对23名受试者（43%）进行了<10>AX</10>激发试验，以确定对<11>AX</11>的即刻<21>过敏反应</21>诊断，并在15例（28%）<12>AX</12>的皮试和RAST均为阴性。对所有54名患者，<34>PG</34>的耐受性良好。我们描述了迄今为止报道过的最大的<13>AX</13>-<22>过敏</22>患者组，这些患者已耐受<35>PG</35>。只有使用特定的<14>AX</14>相关试剂才能对这些患者进行诊断。需要进一步的研究来确定这个问题的确切程度并提高诊断方法的有效性。", "revised": true}
{"doc_key": "17241784", "sentences": [["Progressive", "myopathy", "with", "up", "-", "regulation", "of", "MHC", "-", "I", "associated", "with", "statin", "therapy", ".", "Statins", "can", "cause", "a", "necrotizing", "myopathy", "and", "hyperCKaemia", "which", "is", "reversible", "on", "cessation", "of", "the", "drug", ".", "What", "is", "less", "well", "known", "is", "a", "phenomenon", "whereby", "statins", "may", "induce", "a", "myopathy", ",", "which", "persists", "or", "may", "progress", "after", "stopping", "the", "drug", ".", "We", "investigated", "the", "muscle", "pathology", "in", "8", "such", "cases", ".", "All", "had", "myofibre", "necrosis", "but", "only", "3", "had", "an", "inflammatory", "infiltrate", ".", "In", "all", "cases", "there", "was", "diffuse", "or", "multifocal", "up", "-", "regulation", "of", "MHC", "-", "I", "expression", "even", "in", "non", "-", "necrotic", "fibres", ".", "Progressive", "improvement", "occurred", "in", "7", "cases", "after", "commencement", "of", "prednisolone", "and", "methotrexate", ",", "and", "in", "one", "case", "spontaneously", ".", "These", "observations", "suggest", "that", "statins", "may", "initiate", "an", "immune", "-", "mediated", "myopathy", "that", "persists", "after", "withdrawal", "of", "the", "drug", "and", "responds", "to", "immunosuppressive", "therapy", ".", "The", "mechanism", "of", "this", "myopathy", "is", "uncertain", "but", "may", "involve", "the", "induction", "by", "statins", "of", "an", "endoplasmic", "reticulum", "stress", "response", "with", "associated", "up", "-", "regulation", "of", "MHC", "-", "I", "expression", "and", "antigen", "presentation", "by", "muscle", "fibres", "."]], "ner": [[[12, 12, "Chemical"], [15, 15, "Chemical"], [41, 41, "Chemical"], [125, 125, "Chemical"], [159, 159, "Chemical"], [1, 1, "Disease"], [20, 20, "Disease"], [45, 45, "Disease"], [132, 132, "Disease"], [150, 150, "Disease"], [70, 70, "Disease"], [99, 99, "Disease"], [111, 111, "Chemical"], [113, 113, "Chemical"]]], "relations": [[[12, 12, 1, 1, "CID"], [12, 12, 20, 20, "CID"], [12, 12, 45, 45, "CID"], [12, 12, 132, 132, "CID"], [12, 12, 150, 150, "CID"], [15, 15, 1, 1, "CID"], [15, 15, 20, 20, "CID"], [15, 15, 45, 45, "CID"], [15, 15, 132, 132, "CID"], [15, 15, 150, 150, "CID"], [41, 41, 1, 1, "CID"], [41, 41, 20, 20, "CID"], [41, 41, 45, 45, "CID"], [41, 41, 132, 132, "CID"], [41, 41, 150, 150, "CID"], [125, 125, 1, 1, "CID"], [125, 125, 20, 20, "CID"], [125, 125, 45, 45, "CID"], [125, 125, 132, 132, "CID"], [125, 125, 150, 150, "CID"], [159, 159, 1, 1, "CID"], [159, 159, 20, 20, "CID"], [159, 159, 45, 45, "CID"], [159, 159, 132, 132, "CID"], [159, 159, 150, 150, "CID"], [12, 12, 70, 70, "CID"], [12, 12, 99, 99, "CID"], [15, 15, 70, 70, "CID"], [15, 15, 99, 99, "CID"], [41, 41, 70, 70, "CID"], [41, 41, 99, 99, "CID"], [125, 125, 70, 70, "CID"], [125, 125, 99, 99, "CID"], [159, 159, 70, 70, "CID"], [159, 159, 99, 99, "CID"]]], "clusters": [], "translated": "进行性<5>肌病</5>伴有 MHC-I 上调与<0>他汀类药物</0>治疗相关。<1>他汀类药物</1>可引起坏死性<6>肌病</6>和停药后可逆的高血钾症。鲜为人知的是<2>他汀类药物</2>可能诱发<7>肌病</7>的现象，这种现象在停药后持续存在或可能进展。我们调查了8例此类病例的肌肉病理学。所有人都有肌纤维<10>坏死</10>，但只有3人有炎症浸润。在所有情况下，即使在非<11>坏死</11>纤维中，MHC-I表达也存在弥漫性或多灶性上调。在<12>泼尼松龙</12>和<13>甲氨蝶呤</13>开始后，7例出现了渐进性改善，1例自发改善。这些观察结果表明，<3>他汀类药物</3>可能引发免疫介导的<8>肌病</8>，这种病在停药后仍持续存在，并且对免疫抑制治疗有反应。这种<9>肌病</9>的机制尚不确定，但可能涉及<4>他汀类药物</4>诱导内质网应激反应，同时上调MHC-I表达和肌纤维抗原呈递。", "revised": true}
{"doc_key": "17400887", "sentences": [["Neuroinflammation", "and", "behavioral", "abnormalities", "after", "neonatal", "terbutaline", "treatment", "in", "rats", ":", "implications", "for", "autism", ".", "Autism", "is", "a", "neurodevelopmental", "disorder", "presenting", "before", "3", "years", "of", "age", "with", "deficits", "in", "communication", "and", "social", "skills", "and", "repetitive", "behaviors", ".", "In", "addition", "to", "genetic", "influences", ",", "recent", "studies", "suggest", "that", "prenatal", "drug", "or", "chemical", "exposures", "are", "risk", "factors", "for", "autism", ".", "Terbutaline", ",", "a", "beta2", "-", "adrenoceptor", "agonist", "used", "to", "arrest", "preterm", "labor", ",", "has", "been", "associated", "with", "increased", "concordance", "for", "autism", "in", "dizygotic", "twins", ".", "We", "studied", "the", "effects", "of", "terbutaline", "on", "microglial", "activation", "in", "different", "brain", "regions", "and", "behavioral", "outcomes", "in", "developing", "rats", ".", "Newborn", "rats", "were", "given", "terbutaline", "(", "10", "mg", "/", "kg", ")", "daily", "on", "postnatal", "days", "(", "PN", ")", "2", "to", "5", "or", "PN", "11", "to", "14", "and", "examined", "24", "h", "after", "the", "last", "dose", "and", "at", "PN", "30", ".", "Immunohistochemical", "studies", "showed", "that", "administration", "of", "terbutaline", "on", "PN", "2", "to", "5", "produced", "a", "robust", "increase", "in", "microglial", "activation", "on", "PN", "30", "in", "the", "cerebral", "cortex", ",", "as", "well", "as", "in", "cerebellar", "and", "cerebrocortical", "white", "matter", ".", "None", "of", "these", "effects", "occurred", "in", "animals", "given", "terbutaline", "on", "PN", "11", "to", "14", ".", "In", "behavioral", "tests", ",", "animals", "treated", "with", "terbutaline", "on", "PN", "2", "to", "5", "showed", "consistent", "patterns", "of", "hyper", "-", "reactivity", "to", "novelty", "and", "aversive", "stimuli", "when", "assessed", "in", "a", "novel", "open", "field", ",", "as", "well", "as", "in", "the", "acoustic", "startle", "response", "test", ".", "Our", "findings", "indicate", "that", "beta2", "-", "adrenoceptor", "overstimulation", "during", "an", "early", "critical", "period", "results", "in", "microglial", "activation", "associated", "with", "innate", "neuroinflammatory", "pathways", "and", "behavioral", "abnormalities", ",", "similar", "to", "those", "described", "in", "autism", ".", "This", "study", "provides", "a", "useful", "animal", "model", "for", "understanding", "the", "neuropathological", "processes", "underlying", "autism", "spectrum", "disorders", "."]], "ner": [[[6, 6, "Chemical"], [58, 58, "Chemical"], [88, 88, "Chemical"], [107, 107, "Chemical"], [148, 148, "Chemical"], [187, 187, "Chemical"], [201, 201, "Chemical"], [13, 13, "Disease"], [15, 15, "Disease"], [56, 56, "Disease"], [78, 78, "Disease"], [268, 268, "Disease"], [0, 0, "Disease"], [2, 3, "Disease"], [34, 35, "Disease"], [260, 261, "Disease"], [18, 19, "Disease"], [27, 32, "Disease"], [68, 69, "Disease"], [283, 285, "Disease"]]], "relations": [[[6, 6, 13, 13, "CID"], [6, 6, 15, 15, "CID"], [6, 6, 56, 56, "CID"], [6, 6, 78, 78, "CID"], [6, 6, 268, 268, "CID"], [58, 58, 13, 13, "CID"], [58, 58, 15, 15, "CID"], [58, 58, 56, 56, "CID"], [58, 58, 78, 78, "CID"], [58, 58, 268, 268, "CID"], [88, 88, 13, 13, "CID"], [88, 88, 15, 15, "CID"], [88, 88, 56, 56, "CID"], [88, 88, 78, 78, "CID"], [88, 88, 268, 268, "CID"], [107, 107, 13, 13, "CID"], [107, 107, 15, 15, "CID"], [107, 107, 56, 56, "CID"], [107, 107, 78, 78, "CID"], [107, 107, 268, 268, "CID"], [148, 148, 13, 13, "CID"], [148, 148, 15, 15, "CID"], [148, 148, 56, 56, "CID"], [148, 148, 78, 78, "CID"], [148, 148, 268, 268, "CID"], [187, 187, 13, 13, "CID"], [187, 187, 15, 15, "CID"], [187, 187, 56, 56, "CID"], [187, 187, 78, 78, "CID"], [187, 187, 268, 268, "CID"], [201, 201, 13, 13, "CID"], [201, 201, 15, 15, "CID"], [201, 201, 56, 56, "CID"], [201, 201, 78, 78, "CID"], [201, 201, 268, 268, "CID"]]], "clusters": [], "translated": " <12>神经炎症</12> 和<13>行为异常</13>在新生大鼠中的发生与<0>特布他林</0>的治疗有关：对<7>自闭症</7>的影响。 <8> 自闭症</8> 是一种 <16>神经发育障碍</16> ，在 3 岁之前出现，具有<17>沟通和社交技能缺陷</17>和<14>重复行为</14> 。除了遗传影响外，最近的研究表明，产前接触药物或化学品是<9>自闭症</9>的危险因素。 <1>特布他林</1>是一种用于抑制<18>早产</18>的β2肾上腺素受体激动剂，它与异卵双胞胎中<10>自闭症</10>的一致性增加有关。我们研究了<2>特布他林</2>对发育中大鼠不同脑部区域小胶质细胞激活和行为结果的影响。新生大鼠在出生后第2至5天或第11至14天每天给予<3>特布他林</3>（10 mg/kg），并在最后一次给药后24小时和PN 30时进行检查。免疫组织化学研究表明，在PN 2至5期间给予<4>特布他林</4>会导致PN 30时大脑皮层，小脑和脑皮质白质区域小胶质细胞激活明显增加。在PN 11到14期间给予<5>特布他林</5>的动物没有出现这些影响。在行为测试中，接受<6>特布他林</6>治疗的动物在PN 2至5期间表现出对新颖和厌恶刺激的过度反应模式，在开放领域测试和听觉惊跳反应测试中均有体现。我们的研究结果表明，在早期关键时期，过度激活β2肾上腺素受体将引起小胶质细胞激活，从而引发内在神经炎症通路和<15>行为异常</15>，这与发生在<11>自闭症</11>中的类似。该研究为理解<19>自闭症谱系障碍</19>的神经病理过程提供了一个有用的动物模型。", "revised": true}
{"doc_key": "15458908", "sentences": [["Safety", "and", "adverse", "effects", "associated", "with", "raloxifene", ":", "multiple", "outcomes", "of", "raloxifene", "evaluation", ".", "OBJECTIVE", ":", "To", "examine", "the", "effect", "of", "raloxifene", "on", "major", "adverse", "events", "that", "occur", "with", "postmenopausal", "estrogen", "therapy", "or", "tamoxifen", ".", "METHODS", ":", "The", "Multiple", "Outcomes", "of", "Raloxifene", "Evaluation", ",", "a", "multicenter", ",", "randomized", ",", "double", "-", "blind", "trial", ",", "enrolled", "7", ",", "705", "postmenopausal", "women", "with", "osteoporosis", ".", "Women", "were", "randomly", "assigned", "to", "raloxifene", "60", "mg", "/", "d", "or", "120", "mg", "/", "d", "or", "placebo", ".", "Outcomes", "included", "venous", "thromboembolism", ",", "cataracts", ",", "gallbladder", "disease", ",", "and", "endometrial", "hyperplasia", "or", "cancer", ".", "RESULTS", ":", "During", "a", "mean", "follow", "-", "up", "of", "3", ".", "3", "years", ",", "raloxifene", "was", "associated", "with", "an", "increased", "risk", "for", "venous", "thromboembolism", "(", "relative", "risk", "[", "RR", "]", "2", ".", "1", ";", "95", "%", "confidence", "interval", "[", "CI", "]", "1", ".", "2", "-", "3", ".", "8", ")", ".", "The", "excess", "event", "rate", "was", "1", ".", "8", "per", "1", ",", "000", "woman", "-", "years", "(", "95", "%", "CI", "-", "0", ".", "5", "-", "4", ".", "1", ")", ",", "and", "the", "number", "needed", "to", "treat", "to", "cause", "1", "event", "was", "170", "(", "95", "%", "CI", "100", "-", "582", ")", "over", "3", ".", "3", "years", ".", "Risk", "in", "the", "raloxifene", "group", "was", "higher", "than", "in", "the", "placebo", "group", "for", "the", "first", "2", "years", ",", "but", "decreased", "to", "about", "the", "same", "rate", "as", "in", "the", "placebo", "group", "thereafter", ".", "Raloxifene", "did", "not", "increase", "risk", "for", "cataracts", "(", "RR", "0", ".", "9", ";", "95", "%", "CI", "0", ".", "8", "-", "1", ".", "1", ")", ",", "gallbladder", "disease", "(", "RR", "1", ".", "0", ";", "95", "%", "CI", "0", ".", "7", "-", "1", ".", "3", ")", ",", "endometrial", "hyperplasia", "(", "RR", "1", ".", "3", ";", "95", "%", "CI", "0", ".", "4", "-", "5", ".", "1", ")", ",", "or", "endometrial", "cancer", "(", "RR", "0", ".", "9", ";", "95", "%", "CI", "0", ".", "3", "-", "2", ".", "7", ")", ".", "CONCLUSION", ":", "Raloxifene", "was", "associated", "with", "an", "increased", "risk", "for", "venous", "thromboembolism", ",", "but", "there", "was", "no", "increased", "risk", "for", "cataracts", ",", "gallbladder", "disease", ",", "endometrial", "hyperplasia", ",", "or", "endometrial", "cancer", ".", "LEVEL", "OF", "EVIDENCE", ":", "I"]], "ner": [[[6, 6, "Chemical"], [11, 11, "Chemical"], [21, 21, "Chemical"], [41, 41, "Chemical"], [68, 68, "Chemical"], [111, 111, "Chemical"], [205, 205, "Chemical"], [234, 234, "Chemical"], [322, 322, "Chemical"], [83, 84, "Disease"], [119, 120, "Disease"], [330, 331, "Disease"], [61, 61, "Disease"], [86, 86, "Disease"], [240, 240, "Disease"], [340, 340, "Disease"], [88, 89, "Disease"], [259, 260, "Disease"], [342, 343, "Disease"], [92, 95, "Disease"], [279, 280, "Disease"], [345, 346, "Disease"], [300, 301, "Disease"], [349, 350, "Disease"], [30, 30, "Chemical"], [33, 33, "Chemical"]]], "relations": [[[6, 6, 83, 84, "CID"], [6, 6, 119, 120, "CID"], [6, 6, 330, 331, "CID"], [11, 11, 83, 84, "CID"], [11, 11, 119, 120, "CID"], [11, 11, 330, 331, "CID"], [21, 21, 83, 84, "CID"], [21, 21, 119, 120, "CID"], [21, 21, 330, 331, "CID"], [41, 41, 83, 84, "CID"], [41, 41, 119, 120, "CID"], [41, 41, 330, 331, "CID"], [68, 68, 83, 84, "CID"], [68, 68, 119, 120, "CID"], [68, 68, 330, 331, "CID"], [111, 111, 83, 84, "CID"], [111, 111, 119, 120, "CID"], [111, 111, 330, 331, "CID"], [205, 205, 83, 84, "CID"], [205, 205, 119, 120, "CID"], [205, 205, 330, 331, "CID"], [234, 234, 83, 84, "CID"], [234, 234, 119, 120, "CID"], [234, 234, 330, 331, "CID"], [322, 322, 83, 84, "CID"], [322, 322, 119, 120, "CID"], [322, 322, 330, 331, "CID"]]], "clusters": [], "translated": "与<0>雷洛昔芬</0>相关的安全性和不良反应：<1>雷洛昔芬</1>评估的多项结果。目的：研究<2>雷洛昔芬</2>对绝经后<24>雌激素</24>治疗或<25>他莫昔芬</25>发生的主要不良事件的影响。方法：<3>雷洛昔芬</3>评估的多项结果，一项多中心、随机、双盲试验，招募了7,705名患有<12>骨质疏松症</12>的绝经后妇女。女性被随机分配到<4>雷洛昔芬</4> 60 mg/d或120 mg/d或安慰剂组。结果包括<9>静脉血栓栓塞</9>、<13>白内障</13>、<16>胆囊疾病</16>和<19>子宫内膜增生或癌症</19>。结果：平均随访时间为3.3年，<5>雷洛昔芬</5>与<10>静脉血栓栓塞症</10>风险增加相关（相对风险[RR]2.1；95%置信区间[CI]1.2-3.8）。超额事件率为每1,000名女性年8次（95% CI-0.5-4.1），导致1次事件需要治疗的人数为170（95% CI 100-582）超过3.3年。<6>雷洛昔芬</6>组的风险在前2年高于安慰剂组，但此后下降至与安慰剂组大致相同的比率。<7>雷洛昔芬</7>不会增加<14>白内障</14>（RR 0.9；95% CI 0.8-1.1）、<17>胆囊疾病</17>（RR 1.0；95% CI 0.7-1.3）、<20>子宫内膜增生</20>（RR 1.3；95% CI 0.4-5.1）或<22>子宫内膜癌</22>（RR 0.9；95% CI 0.3-2.7）。结论：<8>雷洛昔芬</8>与<11>静脉血栓栓塞</11>的风险增加相关，但未增加<15>白内障</15>、<18>胆囊疾病</18>、<21>子宫内膜增生</21>或<23>子宫内膜癌</23>的风险。证据等级：I", "revised": true}
{"doc_key": "16167916", "sentences": [["The", "effects", "of", "short", "-", "term", "raloxifene", "therapy", "on", "fibrinolysis", "markers", ":", "TAFI", ",", "tPA", ",", "and", "PAI", "-", "1", ".", "BACKGROUND", ":", "Markers", "of", "fibrinolysis", ",", "thrombin", "-", "activatable", "fibrinolysis", "inhibitor", "(", "TAFI", ")", ",", "tissue", "-", "type", "plasminogen", "activator", "(", "tPA", ")", ",", "and", "plasminogen", "activator", "inhibitor", "-", "1", "(", "PAI", "-", "1", ")", "levels", "were", "studied", "for", "the", "evaluation", "of", "short", "-", "term", "effects", "of", "raloxifene", "administration", "in", "postmenopausal", "women", ".", "METHODS", ":", "Thirty", "-", "nine", "postmenopausal", "women", "with", "osteopenia", "or", "osteoporosis", "were", "included", "in", "this", "prospective", ",", "controlled", "clinical", "study", ".", "Twenty", "-", "five", "women", "were", "given", "raloxifene", "hydrochloride", "(", "60", "mg", "/", "day", ")", "plus", "calcium", "(", "500", "mg", "/", "day", ")", ".", "Age", "-", "matched", "controls", "(", "n", "=", "14", ")", "were", "given", "only", "calcium", ".", "Plasma", "TAFI", ",", "tPA", ",", "and", "PAI", "-", "1", "antigen", "levels", "were", "measured", "at", "baseline", "and", "after", "3", "months", "of", "treatment", "by", "commercially", "available", "ELISA", "kits", ".", "Variations", "of", "individuals", "were", "assessed", "by", "Wilcoxon", "'s", "test", ".", "Relationship", "between", "those", "markers", "and", "demographic", "characteristics", "were", "investigated", ".", "RESULTS", ":", "Three", "months", "of", "raloxifene", "treatment", "was", "associated", "with", "a", "significant", "decrease", "in", "the", "plasma", "TAFI", "antigen", "concentrations", "(", "16", "%", "change", ",", "P", "<", "0", ".", "01", ")", ",", "and", "a", "significant", "increase", "in", "tPA", "antigen", "concentrations", "(", "25", "%", "change", ",", "P", "<", "0", ".", "05", ")", ".", "A", "significant", "correlation", "was", "found", "between", "baseline", "TAFI", "antigen", "concentrations", "and", "the", "duration", "of", "amenorrhea", "(", "P", "<", "0", ".", "05", ";", "r", "=", "0", ".", "33", ")", ".", "CONCLUSION", ":", "We", "suggest", "that", "the", "increased", "risk", "of", "venous", "thromboembolism", "due", "to", "raloxifene", "treatment", "may", "be", "related", "to", "increased", "tPA", "levels", ",", "but", "not", "TAFI", "levels", "."]], "ner": [[[6, 6, "Chemical"], [68, 68, "Chemical"], [101, 102, "Chemical"], [184, 184, "Chemical"], [272, 272, "Chemical"], [268, 269, "Disease"], [82, 82, "Disease"], [84, 84, "Disease"], [244, 244, "Disease"], [110, 110, "Chemical"], [130, 130, "Chemical"]]], "relations": [[[6, 6, 268, 269, "CID"], [68, 68, 268, 269, "CID"], [101, 102, 268, 269, "CID"], [184, 184, 268, 269, "CID"], [272, 272, 268, 269, "CID"]]], "clusters": [], "translated": "短期<0>雷洛昔芬</0>治疗对纤维蛋白溶解标志物的影响：TAFI、tPA 和 PAI-1。背景：研究了纤维蛋白溶解的标志物，凝血酶激活的纤维蛋白溶解抑制剂（<1> TAFI </1>），组织型纤溶酶原激活物（<3> tPA </3>）和纤溶酶原激活物抑制物 - 1（<2> PAI - 1 </2>）水平，以评估短期<0>雷洛昔芬</0> 给药的效果。方法：39 名患有<6>骨质减少</6>或<7>骨质疏松症</7>的绝经后妇女被纳入这项前瞻性对照临床研究。25 名女性服用<2>盐酸雷洛昔芬</2>（60 毫克/天）加<9>钙</9>（500 毫克/天）。年龄匹配的对照组 (n = 14) 仅给予<10>钙</10>。血浆<1> TAFI </1>、<3> tPA </3> 和<2> PAI-1 </2> 抗原水平在基线和治疗 3 个月后通过市售 ELISA 试剂盒进行测量。个体差异通过 Wilcoxon 检验进行评估。调查了这些标记与人口统计特征之间的关系。结果：三个月的<0>雷洛昔芬</0> 治疗与血浆<1> TAFI </1> 抗原浓度显着降低（16% 变化，P<0.01）和<3> tPA </3>抗原浓度显着升高（25% 变化，P<0.05）相关。基线<1> TAFI </1> 抗原浓度与<8>闭经</8>持续时间之间存在显着相关性（P<0.05; r=0.33）。结论：我们认为<4>雷洛昔芬</4>治疗导致<5>静脉血栓栓塞</5>风险增加可能与<3> tPA </3>水平升高有关，但与<1> TAFI </1>水平无关。", "revised": true}
{"doc_key": "17261653", "sentences": [["Direct", "inhibition", "of", "cardiac", "hyperpolarization", "-", "activated", "cyclic", "nucleotide", "-", "gated", "pacemaker", "channels", "by", "clonidine", ".", "BACKGROUND", ":", "Inhibition", "of", "cardiac", "sympathetic", "tone", "represents", "an", "important", "strategy", "for", "treatment", "of", "cardiovascular", "disease", ",", "including", "arrhythmia", ",", "coronary", "heart", "disease", ",", "and", "chronic", "heart", "failure", ".", "Activation", "of", "presynaptic", "alpha2", "-", "adrenoceptors", "is", "the", "most", "widely", "accepted", "mechanism", "of", "action", "of", "the", "antisympathetic", "drug", "clonidine", ";", "however", ",", "other", "target", "proteins", "have", "been", "postulated", "to", "contribute", "to", "the", "in", "vivo", "actions", "of", "clonidine", ".", "METHODS", "AND", "RESULTS", ":", "To", "test", "whether", "clonidine", "elicits", "pharmacological", "effects", "independent", "of", "alpha2", "-", "adrenoceptors", ",", "we", "have", "generated", "mice", "with", "a", "targeted", "deletion", "of", "all", "3", "alpha2", "-", "adrenoceptor", "subtypes", "(", "alpha2ABC", "-", "/", "-", ")", ".", "Alpha2ABC", "-", "/", "-", "mice", "were", "completely", "unresponsive", "to", "the", "analgesic", "and", "hypnotic", "effects", "of", "clonidine", ";", "however", ",", "clonidine", "significantly", "lowered", "heart", "rate", "in", "alpha2ABC", "-", "/", "-", "mice", "by", "up", "to", "150", "bpm", ".", "Clonidine", "-", "induced", "bradycardia", "in", "conscious", "alpha2ABC", "-", "/", "-", "mice", "was", "32", ".", "3", "%", "(", "10", "microg", "/", "kg", ")", "and", "26", ".", "6", "%", "(", "100", "microg", "/", "kg", ")", "of", "the", "effect", "in", "wild", "-", "type", "mice", ".", "A", "similar", "bradycardic", "effect", "of", "clonidine", "was", "observed", "in", "isolated", "spontaneously", "beating", "right", "atria", "from", "alpha2ABC", "-", "knockout", "and", "wild", "-", "type", "mice", ".", "Clonidine", "inhibited", "the", "native", "pacemaker", "current", "(", "I", "(", "f", ")", ")", "in", "isolated", "sinoatrial", "node", "pacemaker", "cells", "and", "the", "I", "(", "f", ")", "-", "generating", "hyperpolarization", "-", "activated", "cyclic", "nucleotide", "-", "gated", "(", "HCN", ")", "2", "and", "HCN4", "channels", "in", "transfected", "HEK293", "cells", ".", "As", "a", "consequence", "of", "blocking", "I", "(", "f", ")", ",", "clonidine", "reduced", "the", "slope", "of", "the", "diastolic", "depolarization", "and", "the", "frequency", "of", "pacemaker", "potentials", "in", "sinoatrial", "node", "cells", "from", "wild", "-", "type", "and", "alpha2ABC", "-", "knockout", "mice", ".", "CONCLUSIONS", ":", "Direct", "inhibition", "of", "cardiac", "HCN", "pacemaker", "channels", "contributes", "to", "the", "bradycardic", "effects", "of", "clonidine", "gene", "-", "targeted", "mice", "in", "vivo", ",", "and", "thus", ",", "clonidine", "-", "like", "drugs", "represent", "novel", "structures", "for", "future", "HCN", "channel", "inhibitors", "."]], "ner": [[[14, 14, "Chemical"], [63, 63, "Chemical"], [81, 81, "Chemical"], [90, 90, "Chemical"], [137, 137, "Chemical"], [141, 141, "Chemical"], [158, 158, "Chemical"], [205, 205, "Chemical"], [224, 224, "Chemical"], [279, 279, "Chemical"], [322, 322, "Chemical"], [333, 333, "Chemical"], [161, 161, "Disease"], [7, 8, "Chemical"], [253, 254, "Chemical"], [30, 31, "Disease"], [34, 34, "Disease"], [36, 38, "Disease"], [42, 43, "Disease"]]], "relations": [[[14, 14, 161, 161, "CID"], [63, 63, 161, 161, "CID"], [81, 81, 161, 161, "CID"], [90, 90, 161, 161, "CID"], [137, 137, 161, 161, "CID"], [141, 141, 161, 161, "CID"], [158, 158, 161, 161, "CID"], [205, 205, 161, 161, "CID"], [224, 224, 161, 161, "CID"], [279, 279, 161, 161, "CID"], [322, 322, 161, 161, "CID"], [333, 333, 161, 161, "CID"]]], "clusters": [], "translated": "<0>可乐定</0>直接抑制心脏超极化-激活<13>环核苷酸</13>-门控起搏器通道。背景：抑制心脏交感神经张力是治疗<15>心血管疾病</15>的重要策略，包括<16>心律失常</16>、<17>冠心病</17>和慢性<18>心力衰竭</18>。突触前 alpha2-肾上腺素能受体的激活是抗交感神经药物<1>可乐定</1>最广泛接受的作用机制；然而，其他靶蛋白已被假定有助于<2>可乐定</2>的体内作用。 \n方法和结果：为了测试<3>可乐定</3>是否会产生独立于alpha2-肾上腺素能受体的药理作用，我们培育了靶向缺失所有3种alpha2-肾上腺素能受体亚型(alpha2ABC-/-)的小鼠。Alpha2ABC-/-小鼠对<4>可乐定</4>的镇痛催眠作用完全无反应；然而，<5>可乐定</5>可显着降低alpha2ABC-/-小鼠的心率，最高可达150 bpm。<6>可乐定</6>诱导的<12>心动过缓</12>在有意识的alpha2ABC-/-小鼠中为32.3%（10微克/千克）和26.6%（100微克/千克）对野生型小鼠的影响。在来自alpha2ABC敲除小鼠和野生型小鼠的分离的自发搏动右心房中观察到<7>可乐定</7>的类似心动过缓作用。<8>可乐定</8>抑制分离的窦房结起搏器细胞中的天然起搏器电流(I(f))和I(f)-产生超极化-激活<14>环核苷酸</14>-门控(HCN)转染的HEK293细胞中的2和HCN4通道。作为阻断I(f)的结果，<9>可乐定</9>降低了野生型和alpha2ABC敲除小鼠的窦房结细胞中舒张期去极化的斜率和起搏器电位的频率。 \n结论：直接抑制心脏HCN起搏器通道有助于<10>可乐定</10>基因靶向小鼠体内的心动过缓效应，因此，<11>可乐定</11>类药物代表未来HCN的新结构通道抑制剂。", "revised": true}
{"doc_key": "18083142", "sentences": [["Norepinephrine", "signaling", "through", "beta", "-", "adrenergic", "receptors", "is", "critical", "for", "expression", "of", "cocaine", "-", "induced", "anxiety", ".", "BACKGROUND", ":", "Cocaine", "is", "a", "widely", "abused", "psychostimulant", "that", "has", "both", "rewarding", "and", "aversive", "properties", ".", "While", "the", "mechanisms", "underlying", "cocaine", "'s", "rewarding", "effects", "have", "been", "studied", "extensively", ",", "less", "attention", "has", "been", "paid", "to", "the", "unpleasant", "behavioral", "states", "induced", "by", "cocaine", ",", "such", "as", "anxiety", ".", "METHODS", ":", "In", "this", "study", ",", "we", "evaluated", "the", "performance", "of", "dopamine", "beta", "-", "hydroxylase", "knockout", "(", "Dbh", "-", "/", "-", ")", "mice", ",", "which", "lack", "norepinephrine", "(", "NE", ")", ",", "in", "the", "elevated", "plus", "maze", "(", "EPM", ")", "to", "examine", "the", "contribution", "of", "noradrenergic", "signaling", "to", "cocaine", "-", "induced", "anxiety", ".", "RESULTS", ":", "We", "found", "that", "cocaine", "dose", "-", "dependently", "increased", "anxiety", "-", "like", "behavior", "in", "control", "(", "Dbh", "+", "/", "-", ")", "mice", ",", "as", "measured", "by", "a", "decrease", "in", "open", "arm", "exploration", ".", "The", "Dbh", "-", "/", "-", "mice", "had", "normal", "baseline", "performance", "in", "the", "EPM", "but", "were", "completely", "resistant", "to", "the", "anxiogenic", "effects", "of", "cocaine", ".", "Cocaine", "-", "induced", "anxiety", "was", "also", "attenuated", "in", "Dbh", "+", "/", "-", "mice", "following", "administration", "of", "disulfiram", ",", "a", "dopamine", "beta", "-", "hydroxylase", "(", "DBH", ")", "inhibitor", ".", "In", "experiments", "using", "specific", "adrenergic", "antagonists", ",", "we", "found", "that", "pretreatment", "with", "the", "beta", "-", "adrenergic", "receptor", "antagonist", "propranolol", "blocked", "cocaine", "-", "induced", "anxiety", "-", "like", "behavior", "in", "Dbh", "+", "/", "-", "and", "wild", "-", "type", "C57BL6", "/", "J", "mice", ",", "while", "the", "alpha", "(", "1", ")", "antagonist", "prazosin", "and", "the", "alpha", "(", "2", ")", "antagonist", "yohimbine", "had", "no", "effect", ".", "CONCLUSIONS", ":", "These", "results", "indicate", "that", "noradrenergic", "signaling", "via", "beta", "-", "adrenergic", "receptors", "is", "required", "for", "cocaine", "-", "induced", "anxiety", "in", "mice", "."]], "ner": [[[12, 12, "Chemical"], [19, 19, "Chemical"], [37, 37, "Chemical"], [58, 58, "Chemical"], [111, 111, "Chemical"], [121, 121, "Chemical"], [172, 172, "Chemical"], [174, 174, "Chemical"], [222, 222, "Chemical"], [279, 279, "Chemical"], [15, 15, "Disease"], [62, 62, "Disease"], [114, 114, "Disease"], [126, 126, "Disease"], [177, 177, "Disease"], [225, 225, "Disease"], [282, 282, "Disease"], [0, 0, "Chemical"], [90, 90, "Chemical"], [92, 92, "Chemical"], [75, 75, "Chemical"], [193, 193, "Chemical"], [190, 190, "Chemical"], [220, 220, "Chemical"], [250, 250, "Chemical"], [258, 258, "Chemical"]]], "relations": [[[12, 12, 15, 15, "CID"], [12, 12, 62, 62, "CID"], [12, 12, 114, 114, "CID"], [12, 12, 126, 126, "CID"], [12, 12, 177, 177, "CID"], [12, 12, 225, 225, "CID"], [12, 12, 282, 282, "CID"], [19, 19, 15, 15, "CID"], [19, 19, 62, 62, "CID"], [19, 19, 114, 114, "CID"], [19, 19, 126, 126, "CID"], [19, 19, 177, 177, "CID"], [19, 19, 225, 225, "CID"], [19, 19, 282, 282, "CID"], [37, 37, 15, 15, "CID"], [37, 37, 62, 62, "CID"], [37, 37, 114, 114, "CID"], [37, 37, 126, 126, "CID"], [37, 37, 177, 177, "CID"], [37, 37, 225, 225, "CID"], [37, 37, 282, 282, "CID"], [58, 58, 15, 15, "CID"], [58, 58, 62, 62, "CID"], [58, 58, 114, 114, "CID"], [58, 58, 126, 126, "CID"], [58, 58, 177, 177, "CID"], [58, 58, 225, 225, "CID"], [58, 58, 282, 282, "CID"], [111, 111, 15, 15, "CID"], [111, 111, 62, 62, "CID"], [111, 111, 114, 114, "CID"], [111, 111, 126, 126, "CID"], [111, 111, 177, 177, "CID"], [111, 111, 225, 225, "CID"], [111, 111, 282, 282, "CID"], [121, 121, 15, 15, "CID"], [121, 121, 62, 62, "CID"], [121, 121, 114, 114, "CID"], [121, 121, 126, 126, "CID"], [121, 121, 177, 177, "CID"], [121, 121, 225, 225, "CID"], [121, 121, 282, 282, "CID"], [172, 172, 15, 15, "CID"], [172, 172, 62, 62, "CID"], [172, 172, 114, 114, "CID"], [172, 172, 126, 126, "CID"], [172, 172, 177, 177, "CID"], [172, 172, 225, 225, "CID"], [172, 172, 282, 282, "CID"], [174, 174, 15, 15, "CID"], [174, 174, 62, 62, "CID"], [174, 174, 114, 114, "CID"], [174, 174, 126, 126, "CID"], [174, 174, 177, 177, "CID"], [174, 174, 225, 225, "CID"], [174, 174, 282, 282, "CID"], [222, 222, 15, 15, "CID"], [222, 222, 62, 62, "CID"], [222, 222, 114, 114, "CID"], [222, 222, 126, 126, "CID"], [222, 222, 177, 177, "CID"], [222, 222, 225, 225, "CID"], [222, 222, 282, 282, "CID"], [279, 279, 15, 15, "CID"], [279, 279, 62, 62, "CID"], [279, 279, 114, 114, "CID"], [279, 279, 126, 126, "CID"], [279, 279, 177, 177, "CID"], [279, 279, 225, 225, "CID"], [279, 279, 282, 282, "CID"]]], "clusters": [], "translated": "<17>去甲肾上腺素</17>通过β-肾上腺素能受体的信号传导对于<0>可卡因</0>的表达至关重要-诱导<10>焦虑</10>。背景：<1>可卡因</1>是一种被广泛滥用的精神兴奋剂，具有有益和厌恶的特性。虽然对<2>可卡因</2>奖赏效应的机制进行了广泛研究，但很少有人关注<3>可卡因</3>引起的不愉快行为状态，例如<11>焦虑</11>。方法：在这项研究中，我们对缺乏<18>去甲肾上腺素</18> (<19>NE</19>)的<20>多巴胺</20>β-羟化酶敲除 (Dbh-/-) 小鼠的表现进行了评估，在高架十字迷宫 (EPM) 中检查去甲肾上腺素能信号对<4>可卡因</4>诱导的<12>焦虑</12>的贡献。结果：我们发现，<5>可卡因</5>剂量依赖性地增加了对照 (Dbh+/-) 小鼠的<13>焦虑</13>样行为，这是通过张开的开臂探索途径的减少来衡量的。Dbh-/-小鼠在EPM中具有正常的基线表现，但对<6>可卡因</6>的焦虑作用完全有抵抗力。<7>可卡因</7>-诱导的<14>焦虑</14>在Dbh+/-小鼠中也减弱了，随着<21>多巴胺</21>β-羟化酶(DBH)抑制剂<22>双硫仑</22>的治疗。在使用特定肾上腺素能拮抗剂的实验中，我们发现预先使用β-肾上腺素能受体拮抗剂<23>普萘洛尔</23>可以防止<8>可卡因</8>诱导的<15>焦虑</15>-Dbh+/-和野生型C57BL6/J小鼠中出现的样行为，而α(1)拮抗剂<24>哌唑嗪</24>和α(2)拮抗剂<25>育亨宾</25>则无作用。结论：这些结果表明，<9>可卡因</9>诱导的小鼠<16>焦虑</16>需要通过β-肾上腺素能受体的去甲肾上腺素能信号传导。", "revised": true}
{"doc_key": "19058010", "sentences": [["Effect", "of", "green", "tea", "and", "vitamin", "E", "combination", "in", "isoproterenol", "induced", "myocardial", "infarction", "in", "rats", ".", "The", "present", "study", "was", "aimed", "to", "investigate", "the", "combined", "effects", "of", "green", "tea", "and", "vitamin", "E", "on", "heart", "weight", ",", "body", "weight", ",", "serum", "marker", "enzymes", ",", "lipid", "peroxidation", ",", "endogenous", "antioxidants", "and", "membrane", "bound", "ATPases", "in", "isoproterenol", "(", "ISO", ")", "-", "induced", "myocardial", "infarction", "in", "rats", ".", "Adult", "male", "albino", "rats", ",", "treated", "with", "ISO", "(", "200", "mg", "/", "kg", ",", "s", ".", "c", ".", ")", "for", "2", "days", "at", "an", "interval", "of", "24", "h", "caused", "a", "significant", "(", "P", "<", "0", ".", "05", ")", "elevation", "of", "heart", "weight", ",", "serum", "marker", "enzymes", ",", "lipid", "peroxidation", "and", "Ca", "+", "2", "ATPase", "level", "whereas", "there", "was", "a", "significant", "(", "P", "<", "0", ".", "05", ")", "decrease", "in", "body", "weight", ",", "endogenous", "antioxidants", ",", "Na", "+", "/", "K", "+", "ATPase", "and", "Mg", "+", "2", "ATPase", "levels", ".", "Administration", "of", "green", "tea", "(", "100", "mg", "/", "kg", "/", "day", ",", "p", ".", "o", ".", ")", "and", "vitamin", "E", "(", "100", "mg", "/", "kg", "/", "day", ",", "p", ".", "o", ".", ")", "together", "for", "30", "consecutive", "days", "and", "challenged", "with", "ISO", "on", "the", "day", "29th", "and", "30th", ",", "showed", "a", "significant", "(", "P", "<", "0", ".", "05", ")", "decrease", "in", "heart", "weight", ",", "serum", "marker", "enzymes", ",", "lipid", "peroxidation", ",", "Ca", "+", "2", "ATPase", "and", "a", "significant", "increase", "in", "the", "body", "weight", ",", "endogenous", "antioxidants", ",", "Na", "+", "/", "K", "+", "ATPase", "and", "Mg", "+", "2", "ATPase", "when", "compared", "with", "ISO", "treated", "group", "and", "green", "tea", "or", "vitamin", "E", "alone", "treated", "groups", ".", "These", "findings", "indicate", "the", "synergistic", "protective", "effect", "of", "green", "tea", "and", "vitamin", "E", "during", "ISO", "induced", "myocardial", "infarction", "in", "rats", "."]], "ner": [[[9, 9, "Chemical"], [53, 53, "Chemical"], [55, 55, "Chemical"], [71, 71, "Chemical"], [193, 193, "Chemical"], [253, 253, "Chemical"], [280, 280, "Chemical"], [11, 12, "Disease"], [59, 60, "Disease"], [282, 283, "Disease"], [2, 3, "Chemical"], [27, 28, "Chemical"], [154, 155, "Chemical"], [257, 258, "Chemical"], [274, 275, "Chemical"], [5, 6, "Chemical"], [30, 31, "Chemical"], [170, 171, "Chemical"], [260, 261, "Chemical"], [277, 278, "Chemical"], [114, 114, "Chemical"], [223, 223, "Chemical"], [139, 139, "Chemical"], [239, 239, "Chemical"], [142, 142, "Chemical"], [242, 242, "Chemical"], [146, 146, "Chemical"], [246, 246, "Chemical"]]], "relations": [[[9, 9, 11, 12, "CID"], [9, 9, 59, 60, "CID"], [9, 9, 282, 283, "CID"], [53, 53, 11, 12, "CID"], [53, 53, 59, 60, "CID"], [53, 53, 282, 283, "CID"], [55, 55, 11, 12, "CID"], [55, 55, 59, 60, "CID"], [55, 55, 282, 283, "CID"], [71, 71, 11, 12, "CID"], [71, 71, 59, 60, "CID"], [71, 71, 282, 283, "CID"], [193, 193, 11, 12, "CID"], [193, 193, 59, 60, "CID"], [193, 193, 282, 283, "CID"], [253, 253, 11, 12, "CID"], [253, 253, 59, 60, "CID"], [253, 253, 282, 283, "CID"], [280, 280, 11, 12, "CID"], [280, 280, 59, 60, "CID"], [280, 280, 282, 283, "CID"]]], "clusters": [], "translated": " <10>绿茶</10>与<15>维生素E</15>合用对<0>异丙肾上腺素</0>诱导的大鼠<7>心肌梗死</7>的影响。本研究旨在探讨<11>绿茶</11>和<16>维生素E</16>对心脏重量、体重、血清标记酶、脂质过氧化、内源性抗氧化剂和膜结合ATP酶的综合影响在<1>异丙肾上腺素</1> (<2>ISO</2>)诱导的大鼠<8>心肌梗死</8>中。成年雄性白化大鼠，用<3>ISO</3> (200 mg/kg, s.c.)处理2天，间隔24小时，引起显着（P<0.05）的心脏重量升高，血清标记酶、脂质过氧化和 <20>Ca</20>+2 ATPase水平，而体重、内源性抗氧化剂、<22>Na</22>+/<24>K</24>+ ATPase和<26>Mg</26>+2 ATPase 水平显着（ P < 0.05）降低。用<12>绿茶</12>（100 mg/kg/天，p.o.）和<17>维生素E</17>（100 mg/kg/天，p.o.）一起服用30连续天数，并在第29和第30天挑战用<4>ISO</4>，结果显示心脏重量、血清标记酶、脂质过氧化、<21>Ca</21>+2ATPase 显着(P<0.05)降低，而体重显着增加，内源性抗氧化剂<23>Na</23>+/<25>K</25>+ATPase和<27>Mg</27>+2 ATPase 显着（ P < 0.05）增加，与<5>ISO</5>治疗组以及仅用<13>绿茶</13>或仅用<18>维生素E</18>治疗组相比。这些发现表明<14>绿茶</14>和<19>维生素E</19>在<6>ISO</6>诱导的大鼠<9>心肌梗死</9>过程中具有协同保护作用。", "revised": true}
{"doc_key": "17147461", "sentences": [["Sirolimus", "-", "associated", "proteinuria", "and", "renal", "dysfunction", ".", "Sirolimus", "is", "a", "novel", "immunosuppressant", "with", "potent", "antiproliferative", "actions", "through", "its", "ability", "to", "inhibit", "the", "raptor", "-", "containing", "mammalian", "target", "of", "rapamycin", "protein", "kinase", ".", "Sirolimus", "represents", "a", "major", "therapeutic", "advance", "in", "the", "prevention", "of", "acute", "renal", "allograft", "rejection", "and", "chronic", "allograft", "nephropathy", ".", "Its", "role", "in", "the", "therapy", "of", "glomerulonephritis", ",", "autoimmunity", ",", "cystic", "renal", "diseases", "and", "renal", "cancer", "is", "under", "investigation", ".", "Because", "sirolimus", "does", "not", "share", "the", "vasomotor", "renal", "adverse", "effects", "exhibited", "by", "calcineurin", "inhibitors", ",", "it", "has", "been", "designated", "a", "'", "non", "-", "nephrotoxic", "drug", "'", ".", "However", ",", "clinical", "reports", "suggest", "that", ",", "under", "some", "circumstances", ",", "sirolimus", "is", "associated", "with", "proteinuria", "and", "acute", "renal", "dysfunction", ".", "A", "common", "risk", "factor", "appears", "to", "be", "presence", "of", "pre", "-", "existing", "chronic", "renal", "damage", ".", "The", "mechanisms", "of", "sirolimus", "-", "associated", "proteinuria", "are", "multifactorial", "and", "may", "be", "due", "to", "an", "increase", "in", "glomerular", "capillary", "pressure", "following", "calcineurin", "inhibitor", "withdrawal", ".", "It", "has", "also", "been", "suggested", "that", "sirolimus", "directly", "causes", "increased", "glomerular", "permeability", "/", "injury", ",", "but", "evidence", "for", "this", "mechanism", "is", "currently", "inconclusive", ".", "The", "acute", "renal", "dysfunction", "associated", "with", "sirolimus", "(", "such", "as", "in", "delayed", "graft", "function", ")", "may", "be", "due", "to", "suppression", "of", "compensatory", "renal", "cell", "proliferation", "and", "survival", "/", "repair", "processes", ".", "Although", "these", "adverse", "effects", "occur", "in", "some", "patients", ",", "their", "occurrence", "could", "be", "minimised", "by", "knowledge", "of", "the", "molecular", "effects", "of", "sirolimus", "on", "the", "kidney", ",", "the", "use", "of", "sirolimus", "in", "appropriate", "patient", "populations", ",", "close", "monitoring", "of", "proteinuria", "and", "renal", "function", ",", "use", "of", "angiotensin", "-", "converting", "enzyme", "inhibitors", "or", "angiotensin", "II", "receptor", "blockers", "if", "proteinuria", "occurs", "and", "withdrawal", "if", "needed", ".", "Further", "long", "-", "term", "analysis", "of", "renal", "allograft", "studies", "using", "sirolimus", "as", "de", "novo", "immunosuppression", "along", "with", "clinical", "and", "laboratory", "studies", "will", "refine", "these", "issues", "in", "the", "future", "."]], "ner": [[[0, 0, "Chemical"], [8, 8, "Chemical"], [29, 29, "Chemical"], [33, 33, "Chemical"], [73, 73, "Chemical"], [110, 110, "Chemical"], [139, 139, "Chemical"], [167, 167, "Chemical"], [191, 191, "Chemical"], [237, 237, "Chemical"], [245, 245, "Chemical"], [289, 289, "Chemical"], [3, 3, "Disease"], [114, 114, "Disease"], [142, 142, "Disease"], [254, 254, "Disease"], [272, 272, "Disease"], [5, 6, "Disease"], [50, 50, "Disease"], [95, 95, "Disease"], [58, 58, "Disease"], [60, 60, "Disease"], [62, 64, "Disease"], [66, 67, "Disease"], [116, 118, "Disease"], [186, 188, "Disease"], [132, 134, "Disease"], [261, 261, "Chemical"], [267, 268, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 114, 114, "CID"], [0, 0, 142, 142, "CID"], [0, 0, 254, 254, "CID"], [0, 0, 272, 272, "CID"], [8, 8, 3, 3, "CID"], [8, 8, 114, 114, "CID"], [8, 8, 142, 142, "CID"], [8, 8, 254, 254, "CID"], [8, 8, 272, 272, "CID"], [29, 29, 3, 3, "CID"], [29, 29, 114, 114, "CID"], [29, 29, 142, 142, "CID"], [29, 29, 254, 254, "CID"], [29, 29, 272, 272, "CID"], [33, 33, 3, 3, "CID"], [33, 33, 114, 114, "CID"], [33, 33, 142, 142, "CID"], [33, 33, 254, 254, "CID"], [33, 33, 272, 272, "CID"], [73, 73, 3, 3, "CID"], [73, 73, 114, 114, "CID"], [73, 73, 142, 142, "CID"], [73, 73, 254, 254, "CID"], [73, 73, 272, 272, "CID"], [110, 110, 3, 3, "CID"], [110, 110, 114, 114, "CID"], [110, 110, 142, 142, "CID"], [110, 110, 254, 254, "CID"], [110, 110, 272, 272, "CID"], [139, 139, 3, 3, "CID"], [139, 139, 114, 114, "CID"], [139, 139, 142, 142, "CID"], [139, 139, 254, 254, "CID"], [139, 139, 272, 272, "CID"], [167, 167, 3, 3, "CID"], [167, 167, 114, 114, "CID"], [167, 167, 142, 142, "CID"], [167, 167, 254, 254, "CID"], [167, 167, 272, 272, "CID"], [191, 191, 3, 3, "CID"], [191, 191, 114, 114, "CID"], [191, 191, 142, 142, "CID"], [191, 191, 254, 254, "CID"], [191, 191, 272, 272, "CID"], [237, 237, 3, 3, "CID"], [237, 237, 114, 114, "CID"], [237, 237, 142, 142, "CID"], [237, 237, 254, 254, "CID"], [237, 237, 272, 272, "CID"], [245, 245, 3, 3, "CID"], [245, 245, 114, 114, "CID"], [245, 245, 142, 142, "CID"], [245, 245, 254, 254, "CID"], [245, 245, 272, 272, "CID"], [289, 289, 3, 3, "CID"], [289, 289, 114, 114, "CID"], [289, 289, 142, 142, "CID"], [289, 289, 254, 254, "CID"], [289, 289, 272, 272, "CID"], [0, 0, 5, 6, "CID"], [0, 0, 50, 50, "CID"], [0, 0, 95, 95, "CID"], [8, 8, 5, 6, "CID"], [8, 8, 50, 50, "CID"], [8, 8, 95, 95, "CID"], [29, 29, 5, 6, "CID"], [29, 29, 50, 50, "CID"], [29, 29, 95, 95, "CID"], [33, 33, 5, 6, "CID"], [33, 33, 50, 50, "CID"], [33, 33, 95, 95, "CID"], [73, 73, 5, 6, "CID"], [73, 73, 50, 50, "CID"], [73, 73, 95, 95, "CID"], [110, 110, 5, 6, "CID"], [110, 110, 50, 50, "CID"], [110, 110, 95, 95, "CID"], [139, 139, 5, 6, "CID"], [139, 139, 50, 50, "CID"], [139, 139, 95, 95, "CID"], [167, 167, 5, 6, "CID"], [167, 167, 50, 50, "CID"], [167, 167, 95, 95, "CID"], [191, 191, 5, 6, "CID"], [191, 191, 50, 50, "CID"], [191, 191, 95, 95, "CID"], [237, 237, 5, 6, "CID"], [237, 237, 50, 50, "CID"], [237, 237, 95, 95, "CID"], [245, 245, 5, 6, "CID"], [245, 245, 50, 50, "CID"], [245, 245, 95, 95, "CID"], [289, 289, 5, 6, "CID"], [289, 289, 50, 50, "CID"], [289, 289, 95, 95, "CID"]]], "clusters": [], "translated": "<0>西罗莫司</0> - 相关<12>蛋白尿</12>和<17>肾功能不全</17>。<1>西罗莫司</1>是一种新型免疫抑制剂，通过抑制含有<2>猛禽</2>的雷帕霉素蛋白激酶靶标，具有有效的抗增殖作用。<3>西罗莫司</3>代表了预防急性肾同种异体移植物排斥反应和慢性同种异体移植物<18>肾病</18>的重大治疗进展。它在<20>肾小球肾炎</20>、<21>自身免疫</21>、<22>囊性肾病</22>和<23>肾癌</23>治疗中的作用正在研究中。因为<4>西罗莫司</4>不具有<19>钙调神经磷酸酶抑制剂</19>所表现出的血管舒缩肾不良反应，所以它已被指定为“非<19>肾毒性</19>药物”。然而，临床报告表明，在某些情况下，<5>西罗莫司</5>与<13>蛋白尿</13>和<24>急性肾功能不全</24>有关。一个常见的危险因素似乎是预先存在的<26>慢性肾损伤</26>。<6>西罗莫司</6>相关的<14>蛋白尿</14>的机制是多因素的，可能是由于<11>钙调神经磷酸酶抑制剂</11>停用后肾小球毛细血管压力增加所致。也有人提出，<7>西罗莫司</7>直接导致肾小球通透性增加/损伤，但这种机制的证据目前还不确定。与<8>西罗莫司</8>相关的<25>急性肾功能障碍</25>（如移植物功能延迟）可能是由于代偿性肾细胞增殖和存活/修复过程受到抑制。尽管这些不良反应发生在一些患者身上，但可以通过了解<9>西罗莫司</9>对肾脏的分子效应、在适当的患者人群中使用<10>西罗莫司</10>来最大限度地减少它们的发生，关闭监测<15>蛋白尿</15>和肾功能，使用<27>血管紧张素</27>-转换酶抑制剂或<28>血管紧张素II</28>受体阻滞剂，如果<16>蛋白尿</16>发生则使用。在需要时退出。使用<11>西罗莫司</11>作为从头免疫抑制的肾同种异体移植研究的进一步长期分析以及临床和实验室研究将在未来完善这些问题。", "revised": true}
{"doc_key": "983936", "sentences": [["Effects", "of", "acetylsalicylic", "acid", ",", "dipyridamole", ",", "and", "hydrocortisone", "on", "epinephrine", "-", "induced", "myocardial", "injury", "in", "dogs", ".", "A", "reproducible", "model", "for", "producing", "diffuse", "myocardial", "injury", "(", "epinephrine", "infusion", ")", "has", "been", "developed", "to", "study", "the", "cardioprotective", "effects", "of", "agents", "or", "maneuvers", "which", "might", "alter", "the", "evolution", "of", "acute", "myocardial", "infarction", ".", "Infusions", "of", "epinephrine", "(", "4", "mug", "per", "kilogram", "per", "minute", "for", "6", "hours", ")", "increased", "radiocalcium", "uptakes", "into", "intact", "myocardium", "and", "each", "of", "its", "subcellular", "components", "with", "the", "mitochondrial", "fraction", "showing", "the", "most", "consistent", "changes", "when", "compared", "to", "saline", "-", "infused", "control", "animals", "(", "4", ",", "957", "vs", ".", "827", "counts", "per", "minute", "per", "gram", "of", "dried", "tissue", "or", "fraction", ")", ".", "Myocardial", "concentrations", "of", "calcium", "also", "increased", "significantly", "(", "12", ".", "0", "vs", ".", "5", ".", "0", "mg", ".", "per", "100", "Gm", ".", "of", "fat", "-", "free", "dry", "weight", ")", ".", "Infusions", "of", "calcium", "chloride", "sufficient", "to", "raise", "serum", "calcium", "concentrations", "2", "mEq", ".", "per", "liter", "failed", "to", "increase", "calcium", "influx", "into", "the", "myocardial", "cell", ".", "Mitochondrial", "radiocalcium", "uptakes", "were", "significantly", "decreased", "in", "animals", "pretreated", "with", "acetylsalicylic", "acid", "or", "dipyridamole", "or", "when", "hydrocortisone", "was", "added", "to", "the", "epinephrine", "infusion", "(", "2", ",", "682", ",", "2", ",", "803", ",", "and", "3", ",", "424", "counts", "per", "minute", "per", "gram", "of", "dried", "fraction", ",", "respectively", ")", ".", "Myocardial", "calcium", "concentrations", "also", "were", "decreased", "(", "11", ".", "2", ",", "8", ".", "3", ",", "and", "8", ".", "9", "mg", ".", "per", "100", "Gm", ".", "of", "fat", "-", "free", "dry", "weight", ",", "respectively", ")", "in", "the", "three", "treatment", "groups", ",", "being", "significantly", "decreased", "only", "in", "the", "last", "two", ".", "Evidence", "of", "microscopic", "damage", "was", "graded", "as", "less", "severe", "in", "the", "three", "treatment", "groups", ".", "Acetylsalicylic", "acid", ",", "dipyridamole", ",", "and", "hydrocortisone", "all", "appear", "to", "have", "cardioprotective", "effects", "when", "tested", "in", "this", "model", "."]], "ner": [[[10, 10, "Chemical"], [27, 27, "Chemical"], [54, 54, "Chemical"], [190, 190, "Chemical"], [13, 14, "Disease"], [24, 25, "Disease"], [2, 3, "Chemical"], [179, 180, "Chemical"], [281, 282, "Chemical"], [49, 50, "Disease"], [5, 5, "Chemical"], [182, 182, "Chemical"], [284, 284, "Chemical"], [8, 8, "Chemical"], [185, 185, "Chemical"], [287, 287, "Chemical"], [67, 67, "Chemical"], [170, 170, "Chemical"], [117, 117, "Chemical"], [152, 152, "Chemical"], [162, 162, "Chemical"], [218, 218, "Chemical"], [146, 147, "Chemical"]]], "relations": [[[10, 10, 13, 14, "CID"], [10, 10, 24, 25, "CID"], [27, 27, 13, 14, "CID"], [27, 27, 24, 25, "CID"], [54, 54, 13, 14, "CID"], [54, 54, 24, 25, "CID"], [190, 190, 13, 14, "CID"], [190, 190, 24, 25, "CID"]]], "clusters": [], "translated": "<6>乙酰水杨酸</6>、<10>双嘧达莫</10>、<13>氢化可的松</13>对<0>肾上腺素</0>所致的<4>心肌损伤</4>的影响在狗身上。已开发出可产生弥漫性<5>心肌损伤</5>（<1>肾上腺素</1>输注）的可重复模型，以研究可能改变急性<9>心肌梗死演变的药物或操作的心脏保护作用</9>。输注<2>肾上腺素</2>（每分钟4ug/kg，持续6小时）增加了<16>放射性钙</16>摄取到完整心肌及其每个亚细胞成分中，线粒体部分显示出最一致的变化，与注入盐水的对照动物相比（每克干燥组织或部分每分钟4,957次计数与827次计数）。<18>钙</18>的心肌浓度也显著增加（12.0 vs 5.0mg/100g脂肪酸-自由干重）。输注足以将血清<19>钙</19>浓度提高2mEq的<22>氯化钙</22>。每升未能增加<20>钙</20>流入心肌细胞。在用<7>乙酰水杨酸</7>或<11>双嘧达莫</11>或<14>氢化可的松</14>添加到<3>肾上腺素</3>输注时，线粒体<17>放射性钙</17>摄取显著降低（每克干燥组织或部分每分钟分别为2,682、2,803和3,424计数），心肌<21>钙</21>浓度也有所降低（分别为11.2、8.3和8.9mg/100g脂肪酸-自由干重），在三个治疗组中显著降低只在最后两个。微观损伤的证据在三个治疗组中被分级为不太严重。<8>乙酰水杨酸</8>、<12>双嘧达莫</12>和<15>氢化可的松</15>在该模型中测试时均显示出心脏保护作用。", "revised": true}
{"doc_key": "19581773", "sentences": [["Development", "of", "ocular", "myasthenia", "during", "pegylated", "interferon", "and", "ribavirin", "treatment", "for", "chronic", "hepatitis", "C", ".", "A", "63", "-", "year", "-", "old", "male", "experienced", "sudden", "diplopia", "after", "9", "weeks", "of", "administration", "of", "pegylated", "interferon", "(", "IFN", ")", "alpha", "-", "2b", "and", "ribavirin", "for", "chronic", "hepatitis", "C", "(", "CHC", ")", ".", "Ophthalmologic", "examinations", "showed", "ptosis", "on", "the", "right", "upper", "lid", "and", "restricted", "right", "eye", "movement", "without", "any", "other", "neurological", "signs", ".", "A", "brain", "imaging", "study", "and", "repetitive", "nerve", "stimulation", "test", "indicated", "no", "abnormality", ".", "The", "acetylcholine", "receptor", "antibody", "titer", "and", "response", "to", "acetylcholinesterase", "inhibitors", "were", "negative", ",", "and", "the", "results", "of", "thyroid", "function", "tests", "were", "normal", ".", "The", "patient", "'s", "ophthalmological", "symptoms", "improved", "rapidly", "3", "weeks", "after", "discontinuation", "of", "pegylated", "IFN", "alpha", "-", "2b", "and", "ribavirin", ".", "The", "ocular", "myasthenia", "associated", "with", "combination", "therapy", "of", "pegylated", "IFN", "alpha", "-", "2b", "and", "ribavirin", "for", "CHC", "is", "very", "rarely", "reported", ";", "therefore", ",", "we", "present", "this", "case", "with", "a", "review", "of", "the", "various", "eye", "complications", "of", "IFN", "therapy", "."]], "ner": [[[5, 6, "Chemical"], [31, 38, "Chemical"], [117, 121, "Chemical"], [133, 137, "Chemical"], [162, 162, "Chemical"], [2, 3, "Disease"], [126, 127, "Disease"], [8, 8, "Chemical"], [40, 40, "Chemical"], [123, 123, "Chemical"], [139, 139, "Chemical"], [52, 57, "Disease"], [59, 62, "Disease"], [83, 83, "Chemical"], [11, 13, "Disease"], [42, 44, "Disease"], [46, 46, "Disease"], [141, 141, "Disease"], [24, 24, "Disease"]]], "relations": [[[5, 6, 2, 3, "CID"], [5, 6, 126, 127, "CID"], [31, 38, 2, 3, "CID"], [31, 38, 126, 127, "CID"], [117, 121, 2, 3, "CID"], [117, 121, 126, 127, "CID"], [133, 137, 2, 3, "CID"], [133, 137, 126, 127, "CID"], [162, 162, 2, 3, "CID"], [162, 162, 126, 127, "CID"], [8, 8, 2, 3, "CID"], [8, 8, 126, 127, "CID"], [40, 40, 2, 3, "CID"], [40, 40, 126, 127, "CID"], [123, 123, 2, 3, "CID"], [123, 123, 126, 127, "CID"], [139, 139, 2, 3, "CID"], [139, 139, 126, 127, "CID"], [5, 6, 52, 57, "CID"], [31, 38, 52, 57, "CID"], [117, 121, 52, 57, "CID"], [133, 137, 52, 57, "CID"], [162, 162, 52, 57, "CID"], [5, 6, 59, 62, "CID"], [31, 38, 59, 62, "CID"], [117, 121, 59, 62, "CID"], [133, 137, 59, 62, "CID"], [162, 162, 59, 62, "CID"], [8, 8, 52, 57, "CID"], [40, 40, 52, 57, "CID"], [123, 123, 52, 57, "CID"], [139, 139, 52, 57, "CID"], [8, 8, 59, 62, "CID"], [40, 40, 59, 62, "CID"], [123, 123, 59, 62, "CID"], [139, 139, 59, 62, "CID"]]], "clusters": [], "translated": "<0>聚乙二醇干扰素</0>和<7>利巴韦林</7>治疗<14>慢性丙型肝炎</14>期间发生<5>眼部肌无力</5>。一名63岁男性在服用<1>聚乙二醇干扰素（IFN）α-2b</1>和<8>利巴韦林</8>治疗<15>慢性丙型肝炎</15> (<16>CHC</16>) 9周后突然出现<18>复视</18>。眼科检查显示<11>右上眼睑下垂</11>和<12>右眼运动受限</12>，无任何其他神经体征。脑成像研究和重复神经刺激试验表明没有异常。<13>乙酰胆碱</13>受体抗体滴度和对乙酰胆碱酯酶抑制剂的反应均为阴性，甲状腺功能检查结果正常。停用<2>聚乙二醇干扰素α-2b</2>和<9>利巴韦林</9>后3周，患者的眼科症状迅速好转。<6>眼部肌无力</6>与<3>聚乙二醇干扰素α-2b</3>和<10>利巴韦林</10>联合治疗<17>慢性丙型肝炎</17>相关的报道非常罕见；因此，我们通过对<4>IFN</4>治疗的各种眼部并发症的回顾来呈现该病例。", "revised": true}
{"doc_key": "1428568", "sentences": [["Changes", "in", "depressive", "status", "associated", "with", "topical", "beta", "-", "blockers", ".", "Depression", "and", "sexual", "dysfunction", "have", "been", "related", "to", "side", "effects", "of", "topical", "beta", "-", "blockers", ".", "We", "performed", "a", "preliminary", "study", "in", "order", "to", "determine", "any", "difference", "between", "a", "non", "selective", "beta", "-", "blocker", "(", "timolol", ")", "and", "a", "selective", "beta", "-", "blocker", "(", "betaxolol", ")", "regarding", "CNS", "side", "effects", ".", "Eight", "glaucomatous", "patients", "chronically", "treated", "with", "timolol", "0", ".", "5", "%", "/", "12h", ",", "suffering", "from", "depression", "diagnosed", "through", "DMS", "-", "III", "-", "R", "criteria", ",", "were", "included", "in", "the", "study", ".", "During", "the", "six", "-", "month", "follow", "up", ",", "depression", "was", "quantified", "through", "the", "Beck", "and", "Zung", "-", "Conde", "scales", "every", "two", "months", ".", "In", "a", "double", "blind", "cross", "-", "over", "study", "with", "control", "group", ",", "the", "patients", "under", "timolol", "treatment", "presented", "higher", "depression", "values", "measured", "through", "the", "Beck", "and", "the", "Zung", "-", "Conde", "scales", "(", "p", "<", "0", ".", "001", "vs", "control", ")", ".", "These", "results", "suggest", "that", "betaxolol", "could", "be", "less", "of", "a", "depression", "-", "inducer", "than", "timolol", "in", "predisposed", "patients", "."]], "ner": [[[46, 46, "Chemical"], [68, 68, "Chemical"], [132, 132, "Chemical"], [172, 172, "Chemical"], [2, 2, "Disease"], [11, 11, "Disease"], [78, 78, "Disease"], [102, 102, "Disease"], [136, 136, "Disease"], [168, 168, "Disease"], [55, 55, "Chemical"], [162, 162, "Chemical"], [13, 14, "Disease"], [63, 63, "Disease"]]], "relations": [[[46, 46, 2, 2, "CID"], [46, 46, 11, 11, "CID"], [46, 46, 78, 78, "CID"], [46, 46, 102, 102, "CID"], [46, 46, 136, 136, "CID"], [46, 46, 168, 168, "CID"], [68, 68, 2, 2, "CID"], [68, 68, 11, 11, "CID"], [68, 68, 78, 78, "CID"], [68, 68, 102, 102, "CID"], [68, 68, 136, 136, "CID"], [68, 68, 168, 168, "CID"], [132, 132, 2, 2, "CID"], [132, 132, 11, 11, "CID"], [132, 132, 78, 78, "CID"], [132, 132, 102, 102, "CID"], [132, 132, 136, 136, "CID"], [132, 132, 168, 168, "CID"], [172, 172, 2, 2, "CID"], [172, 172, 11, 11, "CID"], [172, 172, 78, 78, "CID"], [172, 172, 102, 102, "CID"], [172, 172, 136, 136, "CID"], [172, 172, 168, 168, "CID"]]], "clusters": [], "translated": " <4>抑郁</4>状态的变化与外用β受体阻滞剂有关。<5>抑郁症</5>和<12>性功能障碍</12>与外用β受体阻滞剂的副作用有关。我们进行了一项初步研究，以确定非选择性β受体阻滞剂(<0>噻吗洛尔</0>)和选择性β受体阻滞剂(<10>倍他洛尔</10>)在CNS副作用方面的差异。八名<13>青光眼</13>患者长期接受0.5%/12h的<1>噻吗洛尔</1>治疗，且通过DMS-III-R标准诊断患有<6>抑郁症</6>，纳入研究。在六个月的随访期间，通过Beck和Zung-Conde量表每两个月量化<7>抑郁症</7>。在与对照组进行的双盲交叉研究中，接受<2>噻吗洛尔</2>治疗的患者表现出更高的<8>抑郁</8>值，通过Beck和Zung-Conde量表测量(p < 0.001 对控制)。这些结果表明，<11>倍他洛尔</11>对易感患者的<9>抑郁症</9>诱导作用低于<3>噻吗洛尔</3>。", "revised": true}
{"doc_key": "20619828", "sentences": [["A", "novel", ",", "multiple", "symptom", "model", "of", "obsessive", "-", "compulsive", "-", "like", "behaviors", "in", "animals", ".", "BACKGROUND", ":", "Current", "animal", "models", "of", "obsessive", "-", "compulsive", "disorder", "(", "OCD", ")", "typically", "involve", "acute", ",", "drug", "-", "induced", "symptom", "provocation", "or", "a", "genetic", "association", "with", "stereotypies", "or", "anxiety", ".", "None", "of", "these", "current", "models", "demonstrate", "multiple", "OCD", "-", "like", "behaviors", ".", "METHODS", ":", "Neonatal", "rats", "were", "treated", "with", "the", "tricyclic", "antidepressant", "clomipramine", "or", "vehicle", "between", "days", "9", "and", "16", "twice", "daily", "and", "behaviorally", "tested", "in", "adulthood", ".", "RESULTS", ":", "Clomipramine", "exposure", "in", "immature", "rats", "produced", "significant", "behavioral", "and", "biochemical", "changes", "that", "include", "enhanced", "anxiety", "(", "elevated", "plus", "maze", "and", "marble", "burying", ")", ",", "behavioral", "inflexibility", "(", "perseveration", "in", "the", "spontaneous", "alternation", "task", "and", "impaired", "reversal", "learning", ")", ",", "working", "memory", "impairment", "(", "e", ".", "g", ".", ",", "win", "-", "shift", "paradigm", ")", ",", "hoarding", ",", "and", "corticostriatal", "dysfunction", ".", "Dopamine", "D2", "receptors", "were", "elevated", "in", "the", "striatum", ",", "whereas", "serotonin", "2C", ",", "but", "not", "serotonin", "1A", ",", "receptors", "were", "elevated", "in", "the", "orbital", "frontal", "cortex", ".", "CONCLUSIONS", ":", "This", "is", "the", "first", "demonstration", "of", "multiple", "symptoms", "consistent", "with", "an", "OCD", "-", "like", "profile", "in", "animals", ".", "Moreover", ",", "these", "behaviors", "are", "accompanied", "by", "biochemical", "changes", "in", "brain", "regions", "previously", "identified", "as", "relevant", "to", "OCD", ".", "This", "novel", "model", "of", "OCD", "demonstrates", "that", "drug", "exposure", "during", "a", "sensitive", "period", "can", "program", "disease", "-", "like", "systems", "permanently", ",", "which", "could", "have", "implications", "for", "current", "and", "future", "therapeutic", "strategies", "for", "this", "and", "other", "psychiatric", "disorders", "."]], "ner": [[[69, 69, "Chemical"], [87, 87, "Chemical"], [45, 45, "Disease"], [101, 101, "Disease"], [127, 128, "Disease"], [141, 141, "Disease"], [68, 68, "Chemical"], [7, 12, "Disease"], [22, 25, "Disease"], [27, 27, "Disease"], [54, 54, "Disease"], [187, 187, "Disease"], [211, 211, "Disease"], [217, 217, "Disease"], [147, 147, "Chemical"], [157, 157, "Chemical"], [162, 162, "Chemical"], [248, 249, "Disease"]]], "relations": [[[69, 69, 45, 45, "CID"], [69, 69, 101, 101, "CID"], [87, 87, 45, 45, "CID"], [87, 87, 101, 101, "CID"], [69, 69, 127, 128, "CID"], [87, 87, 127, 128, "CID"], [69, 69, 141, 141, "CID"], [87, 87, 141, 141, "CID"]]], "clusters": [], "translated": "动物<7>强迫症样行为</7>的新颖多症状模型。背景：当前的<8>强迫症</8> (<9>OCD</9>)动物模型通常涉及急性、药物诱发的症状激发或与刻板印象或<2>焦虑</2>的遗传关联。这些当前模型中没有一个表现出多种<10>强迫症</10>-样行为。方法：新生大鼠在第9天和第16天每天两次接受三环类<6>抗抑郁药</6><0>氯米帕明</0>或赋形剂治疗，并在成年期进行行为测试。结果：<1>氯米帕明</1>对未成熟大鼠的暴露产生了显着的行为和生化变化，包括增强的<3>焦虑</3>（高架十字迷宫和大理石掩埋），行为不灵活（坚持自发交替任务和逆向学习受损）、工作<4>记忆障碍</4>（例如，win-shift范式）、<5>囤积</5>和皮质纹状体功能障碍。<14>多巴胺</14>D2受体在纹状体中升高，而<15>5-羟色胺</15>2C而非<16>5-羟色胺</16>1A受体在眶额皮质中升高。结论：这是动物身上首次出现符合<11>强迫症</11>样特征的多种症状。此外，这些行为伴随着先前被确定为与<12>强迫症</12>相关的大脑区域的生化变化。<13>OCD</13>的新模型表明，在敏感时期接触药物可以永久性地对疾病样系统进行编程，这可能对当前和未来针对这种和其他<17>精神疾病</17>的治疗策略产生影响。", "revised": true}
{"doc_key": "19957053", "sentences": [["Phenylephrine", "but", "not", "ephedrine", "reduces", "frontal", "lobe", "oxygenation", "following", "anesthesia", "-", "induced", "hypotension", ".", "BACKGROUND", ":", "Vasopressor", "agents", "are", "used", "to", "correct", "anesthesia", "-", "induced", "hypotension", ".", "We", "describe", "the", "effect", "of", "phenylephrine", "and", "ephedrine", "on", "frontal", "lobe", "oxygenation", "(", "S", "(", "c", ")", "O", "(", "2", ")", ")", "following", "anesthesia", "-", "induced", "hypotension", ".", "METHODS", ":", "Following", "induction", "of", "anesthesia", "by", "fentanyl", "(", "0", ".", "15", "mg", "kg", "(", "-", "1", ")", ")", "and", "propofol", "(", "2", ".", "0", "mg", "kg", "(", "-", "1", ")", ")", ",", "13", "patients", "received", "phenylephrine", "(", "0", ".", "1", "mg", "iv", ")", "and", "12", "patients", "received", "ephedrine", "(", "10", "mg", "iv", ")", "to", "restore", "mean", "arterial", "pressure", "(", "MAP", ")", ".", "Heart", "rate", "(", "HR", ")", ",", "MAP", ",", "stroke", "volume", "(", "SV", ")", ",", "cardiac", "output", "(", "CO", ")", ",", "and", "frontal", "lobe", "oxygenation", "(", "S", "(", "c", ")", "O", "(", "2", ")", ")", "were", "registered", ".", "RESULTS", ":", "Induction", "of", "anesthesia", "was", "followed", "by", "a", "decrease", "in", "MAP", ",", "HR", ",", "SV", ",", "and", "CO", "concomitant", "with", "an", "elevation", "in", "S", "(", "c", ")", "O", "(", "2", ")", ".", "After", "administration", "of", "phenylephrine", ",", "MAP", "increased", "(", "51", "+", "/", "-", "12", "to", "81", "+", "/", "-", "13", "mmHg", ";", "P", "<", "0", ".", "001", ";", "mean", "+", "/", "-", "SD", ")", ".", "However", ",", "a", "14", "%", "(", "from", "70", "+", "/", "-", "8", "%", "to", "60", "+", "/", "-", "7", "%", ")", "reduction", "in", "S", "(", "c", ")", "O", "(", "2", ")", "(", "P", "<", "0", ".", "05", ")", "followed", "with", "no", "change", "in", "CO", "(", "3", ".", "7", "+", "/", "-", "1", ".", "1", "to", "3", ".", "4", "+", "/", "-", "0", ".", "9", "l", "min", "(", "-", "1", ")", ")", ".", "The", "administration", "of", "ephedrine", "led", "to", "a", "similar", "increase", "in", "MAP", "(", "53", "+", "/", "-", "9", "to", "79", "+", "/", "-", "8", "mmHg", ";", "P", "<", "0", ".", "001", ")", ",", "restored", "CO", "(", "3", ".", "2", "+", "/", "-", "1", ".", "2", "to", "5", ".", "0", "+", "/", "-", "1", ".", "3", "l", "min", "(", "-", "1", ")", ")", ",", "and", "preserved", "S", "(", "c", ")", "O", "(", "2", ")", ".", "CONCLUSIONS", ":", "The", "utilization", "of", "phenylephrine", "to", "correct", "hypotension", "induced", "by", "anesthesia", "has", "a", "negative", "impact", "on", "S", "(", "c", ")", "O", "(", "2", ")", "while", "ephedrine", "maintains", "frontal", "lobe", "oxygenation", "potentially", "related", "to", "an", "increase", "in", "CO", "."]], "ner": [[[0, 0, "Chemical"], [32, 32, "Chemical"], [91, 91, "Chemical"], [191, 191, "Chemical"], [372, 372, "Chemical"], [4, 7, "Disease"], [62, 62, "Chemical"], [12, 12, "Disease"], [25, 25, "Disease"], [53, 53, "Disease"], [163, 173, "Disease"], [375, 375, "Disease"], [75, 75, "Chemical"], [126, 126, "Disease"], [3, 3, "Chemical"], [34, 34, "Chemical"], [103, 103, "Chemical"], [297, 297, "Chemical"], [393, 393, "Chemical"]]], "relations": [[[0, 0, 4, 7, "CID"], [32, 32, 4, 7, "CID"], [91, 91, 4, 7, "CID"], [191, 191, 4, 7, "CID"], [372, 372, 4, 7, "CID"], [62, 62, 12, 12, "CID"], [62, 62, 25, 25, "CID"], [62, 62, 53, 53, "CID"], [62, 62, 163, 173, "CID"], [62, 62, 375, 375, "CID"], [75, 75, 12, 12, "CID"], [75, 75, 25, 25, "CID"], [75, 75, 53, 53, "CID"], [75, 75, 163, 173, "CID"], [75, 75, 375, 375, "CID"]]], "clusters": [], "translated": " <0>去氧肾上腺素</0>而非<14>麻黄碱</14> 减少麻醉引起的<7>低血压</7><5>后额叶氧合作用</5>。背景：血管升压药用于纠正麻醉引起的<8>低血压</8>。我们描述了<1>去氧肾上腺素</1>和<15>麻黄碱</15>对麻醉引起的<9>低血压</9>后额叶氧合(S(c)O(2))的影响。方法：13例患者经<6>芬太尼</6>(0.15 mg kg(-1))和<12>异丙酚</12>(2.0 mg kg(-1))诱导麻醉。<2>去氧肾上腺素</2>(0.1 mg iv)和12名患者接受<16>麻黄碱</16>(10 mg iv)以恢复平均动脉压(MAP)。记录了心率(HR)、MAP、<13>每搏</13>容积(SV)、心输出量(CO)和额叶氧合(S(c)O(2))。结果：麻醉诱导后<10>MAP、HR、SV和CO降低</10>，同时S(c)O(2)升高。服用<3>去氧肾上腺素</3>后，MAP升高(51+/-12至81+/-13mmHg；P<0.001；平均值+/-SD)。然而，S(c)O(2)减少了14%（从70+/-8%到60+/-7%），而CO(3.7+/-1.1至3.4+/-0.9l分钟(-1))。<17>麻黄碱</17>的给药导致MAP的类似增加(53+/-9至79+/-8mmHg；P<0.001)，CO恢复(3.2+/-1.2至5.0+/-1.3l分钟(-1))，并保留S(c)O(2)。结论：使用<4>去氧肾上腺素</4>纠正麻醉引起的<11>低血压</11>对S(c)O(2)有负面影响，而<18>麻黄碱</18>维持额叶氧合可能与CO增加有关。", "revised": true}
{"doc_key": "1867351", "sentences": [["Neuropsychiatric", "side", "effects", "after", "the", "use", "of", "mefloquine", ".", "This", "study", "describes", "neuropsychiatric", "side", "effects", "in", "patients", "after", "treatment", "with", "mefloquine", ".", "Reactions", "consisted", "mainly", "of", "seizures", ",", "acute", "psychoses", ",", "anxiety", "neurosis", ",", "and", "major", "disturbances", "of", "sleep", "-", "wake", "rhythm", ".", "Side", "effects", "occurred", "after", "both", "therapeutic", "and", "prophylactic", "intake", "and", "were", "graded", "from", "moderate", "to", "severe", ".", "In", "a", "risk", "analysis", "of", "neuropsychiatric", "side", "effects", "in", "Germany", ",", "it", "is", "estimated", "that", "one", "of", "8", ",", "000", "mefloquine", "users", "suffers", "from", "such", "reactions", ".", "The", "incidence", "calculation", "revealed", "that", "one", "of", "215", "therapeutic", "users", "had", "reactions", ",", "compared", "with", "one", "of", "13", ",", "000", "in", "the", "prophylaxis", "group", ",", "making", "the", "risk", "of", "neuropsychiatric", "reactions", "after", "mefloquine", "treatment", "60", "times", "higher", "than", "after", "prophylaxis", ".", "Therefore", ",", "certain", "limitations", "for", "malaria", "prophylaxis", "and", "treatment", "with", "mefloquine", "are", "recommended", "."]], "ner": [[[7, 7, "Chemical"], [20, 20, "Chemical"], [80, 80, "Chemical"], [119, 119, "Chemical"], [138, 138, "Chemical"], [26, 26, "Disease"], [29, 29, "Disease"], [31, 32, "Disease"], [36, 41, "Disease"], [133, 133, "Disease"]]], "relations": [[[7, 7, 26, 26, "CID"], [20, 20, 26, 26, "CID"], [80, 80, 26, 26, "CID"], [119, 119, 26, 26, "CID"], [138, 138, 26, 26, "CID"], [7, 7, 29, 29, "CID"], [20, 20, 29, 29, "CID"], [80, 80, 29, 29, "CID"], [119, 119, 29, 29, "CID"], [138, 138, 29, 29, "CID"], [7, 7, 31, 32, "CID"], [20, 20, 31, 32, "CID"], [80, 80, 31, 32, "CID"], [119, 119, 31, 32, "CID"], [138, 138, 31, 32, "CID"], [7, 7, 36, 41, "CID"], [20, 20, 36, 41, "CID"], [80, 80, 36, 41, "CID"], [119, 119, 36, 41, "CID"], [138, 138, 36, 41, "CID"]]], "clusters": [], "translated": "使用<0>甲氟喹</0>后的神经精神副作用。本研究描述了接受<1>甲氟喹</1>治疗后患者的神经精神副作用。反应主要包括<5>癫痫发作</5>、急性<6>精神病</6>、<7>焦虑性神经症</7>和主要<8>睡眠-觉醒节律紊乱</8>。副作用发生在治疗性和预防性摄入后，并从中度到重度分级。在德国的一项神经精神副作用风险分析中，估计每8,000名<2>甲氟喹</2>使用者中就有一人出现此类反应。发生率计算显示，215名治疗使用者中有1人出现反应，而预防组为13,000人中有1人出现反应，这使得<3>甲氟喹</3>治疗后发生神经精神反应的风险比预防后高60倍。因此，推荐使用<4>甲氟喹</4>预防和治疗<9>疟疾</9>的某些限制。", "revised": true}
{"doc_key": "16904497", "sentences": [["Cauda", "equina", "syndrome", "after", "epidural", "steroid", "injection", ":", "a", "case", "report", ".", "OBJECTIVE", ":", "Conventional", "treatment", "methods", "of", "lumbusacral", "radiculopathy", "are", "physical", "therapy", ",", "epidural", "steroid", "injections", ",", "oral", "medications", ",", "and", "spinal", "manipulative", "therapy", ".", "Cauda", "equina", "syndrome", "is", "a", "rare", "complication", "of", "epidural", "anesthesia", ".", "The", "following", "case", "is", "a", "report", "of", "cauda", "equina", "syndrome", "possibly", "caused", "by", "epidural", "injection", "of", "triamcinolone", "and", "bupivacaine", ".", "CLINICAL", "FEATURES", ":", "A", "50", "-", "year", "-", "old", "woman", "with", "low", "back", "and", "right", "leg", "pain", "was", "scheduled", "for", "epidural", "steroid", "injection", ".", "INTERVENTION", "AND", "OUTCOME", ":", "An", "18", "-", "gauge", "Touhy", "needle", "was", "inserted", "until", "loss", "of", "resistance", "occurred", "at", "the", "L4", "-", "5", "level", ".", "Spread", "of", "the", "contrast", "medium", "within", "the", "epidural", "space", "was", "determined", "by", "radiographic", "imaging", ".", "After", "verifying", "the", "epidural", "space", ",", "bupivacaine", "and", "triamcinolone", "diacetate", "were", "injected", ".", "After", "the", "injection", ",", "there", "was", "a", "reduction", "in", "radicular", "symptoms", ".", "Three", "hours", "later", ",", "she", "complained", "of", "perineal", "numbness", "and", "lower", "extremity", "weakness", ".", "The", "neurologic", "evaluation", "revealed", "loss", "of", "sensation", "in", "the", "saddle", "area", "and", "medial", "aspect", "of", "her", "right", "leg", ".", "There", "was", "a", "decrease", "in", "the", "perception", "of", "pinprick", "test", ".", "Deep", "-", "tendon", "reflexes", "were", "decreased", "especially", "in", "the", "right", "leg", ".", "She", "was", "unable", "to", "urinate", ".", "The", "patient", "'s", "symptoms", "improved", "slightly", "over", "the", "next", "few", "hours", ".", "She", "had", "a", "gradual", "return", "of", "motor", "function", "and", "ability", "of", "feeling", "Foley", "catheter", ".", "All", "of", "the", "symptoms", "were", "completely", "resolved", "over", "the", "next", "8", "hours", ".", "CONCLUSION", ":", "Complications", "associated", "with", "epidural", "steroid", "injections", "are", "rare", ".", "Clinical", "examination", "and", "continued", "vigilance", "for", "neurologic", "deterioration", "after", "epidural", "steroid", "injections", "is", "important", "."]], "ner": [[[65, 65, "Chemical"], [136, 136, "Chemical"], [0, 2, "Disease"], [36, 38, "Disease"], [54, 56, "Disease"], [138, 139, "Chemical"], [5, 5, "Chemical"], [25, 25, "Chemical"], [88, 88, "Chemical"], [263, 263, "Chemical"], [278, 278, "Chemical"], [63, 63, "Chemical"], [19, 19, "Disease"], [78, 83, "Disease"], [163, 163, "Disease"], [173, 175, "Disease"], [165, 167, "Disease"], [274, 275, "Disease"]]], "relations": [[[65, 65, 0, 2, "CID"], [65, 65, 36, 38, "CID"], [65, 65, 54, 56, "CID"], [136, 136, 0, 2, "CID"], [136, 136, 36, 38, "CID"], [136, 136, 54, 56, "CID"], [138, 139, 0, 2, "CID"], [138, 139, 36, 38, "CID"], [138, 139, 54, 56, "CID"]]], "clusters": [], "translated": "硬膜外<6>类固醇</6>注射后的<2>马尾综合征</2>一例。目的：腰骶<12>神经根病</12>的常规治疗方法有物理治疗、硬膜外<7>类固醇</7>注射、口服药物治疗和脊柱手法治疗等。<3>马尾综合征</3>是硬膜外麻醉的一种罕见并发症。以下病例报告<4>马尾综合征</4>，可能由<11>去炎松</11>和<0>布比卡因</0>硬膜外注射所致。临床特征：一名50岁的女性因<13>低背部和右腿疼痛</13>计划接受硬膜外<8>类固醇</8>注射。干预和结果：插入一根18号Touhy针，直到L4-5水平失去阻力。通过放射成像确定注射物在硬膜外间隙内的扩散情况。确认硬膜外间隙后，注射<1>布比卡因</1>和<5>双乙酸去炎松</5>。注射后，神经根的症状有所减轻。三个小时后，她抱怨骨盆区<14>感觉异常</14>和<16>下肢无力</16>。神经系统评估显示她的右腿坐骑区和内踝区域<15>感觉消失</15>。针刺试验的敏感度有所下降。特别是患者右侧深腱反射减退。她无法排尿。患者的症状逐渐好转，并逐渐恢复了运动功能和感知Foley导管的能力。所有症状都在接下来的8小时内完全消失。结论：硬膜外<9>类固醇</9>注射引起并发症十分罕见。硬膜外<10>类固醇</10>注射后的临床检查和持续警惕<17>神经功能恶化</17>非常重要。", "revised": true}
{"doc_key": "2950248", "sentences": [["Dipyridamole", "-", "induced", "myocardial", "ischemia", ".", "Angina", "and", "ischemic", "electrocardiographic", "changes", "occurred", "after", "administration", "of", "oral", "dipyridamole", "in", "four", "patients", "awaiting", "urgent", "myocardial", "revascularization", "procedures", ".", "To", "our", "knowledge", ",", "this", "has", "not", "previously", "been", "reported", "as", "a", "side", "effect", "of", "preoperative", "dipyridamole", "therapy", ",", "although", "dipyridamole", "-", "induced", "myocardial", "ischemia", "has", "been", "demonstrated", "to", "occur", "in", "animals", "and", "humans", "with", "coronary", "artery", "disease", ".", "Epicardial", "coronary", "collateral", "vessels", "were", "demonstrated", "in", "all", "four", "patients", ";", "a", "coronary", "\"", "steal", "\"", "phenomenon", "may", "be", "the", "mechanism", "of", "the", "dipyridamole", "-", "induced", "ischemia", "observed", "."]], "ner": [[[0, 0, "Chemical"], [16, 16, "Chemical"], [42, 42, "Chemical"], [46, 46, "Chemical"], [88, 88, "Chemical"], [6, 6, "Disease"], [3, 4, "Disease"], [49, 50, "Disease"], [61, 63, "Disease"], [91, 91, "Disease"]]], "relations": [[[0, 0, 6, 6, "CID"], [16, 16, 6, 6, "CID"], [42, 42, 6, 6, "CID"], [46, 46, 6, 6, "CID"], [88, 88, 6, 6, "CID"]]], "clusters": [], "translated": " <0>双嘧达莫</0>-诱发<6>心肌缺血</6>。 <5>心绞痛</5>和缺血性心电图变化发生在四名等待紧急心肌血运重建手术的患者口服<1>双嘧达莫</1>后。据我们所知，<3>虽然诱导的</3> <7>心肌缺血</7>已被证明发生在患有<8>冠状动脉疾病</8>的动物和人类身上，但这尚不被作为术前<2>双嘧达莫</2>治疗的副作用。所有四名患者均显示心外膜冠状动脉侧支血管；冠状动脉“偷血”现象可能是观察到<4>双嘧达莫</4>诱发的<9>缺血</9>的机制。", "revised": true}
{"doc_key": "2070391", "sentences": [["Reduction", "in", "injection", "pain", "using", "buffered", "lidocaine", "as", "a", "local", "anesthetic", "before", "cardiac", "catheterization", ".", "Previous", "reports", "have", "suggested", "that", "pain", "associated", "with", "the", "injection", "of", "lidocaine", "is", "related", "to", "the", "acidic", "pH", "of", "the", "solution", ".", "To", "determine", "if", "the", "addition", "of", "a", "buffering", "solution", "to", "adjust", "the", "pH", "of", "lidocaine", "into", "the", "physiologic", "range", "would", "reduce", "pain", "during", "injection", ",", "we", "performed", "a", "blinded", "randomized", "study", "in", "patients", "undergoing", "cardiac", "catheterization", ".", "Twenty", "patients", "were", "asked", "to", "quantify", "the", "severity", "of", "pain", "after", "receiving", "standard", "lidocaine", "in", "one", "femoral", "area", "and", "buffered", "lidocaine", "in", "the", "opposite", "femoral", "area", ".", "The", "mean", "pain", "score", "for", "buffered", "lidocaine", "was", "significantly", "lower", "than", "the", "mean", "score", "for", "standard", "lidocaine", "(", "2", ".", "7", "+", "/", "-", "1", ".", "9", "vs", ".", "3", ".", "8", "+", "/", "-", "2", ".", "2", ",", "P", "=", "0", ".", "03", ")", ".", "The", "pH", "adjustment", "of", "standard", "lidocaine", "can", "be", "accomplished", "easily", "in", "the", "catheterization", "laboratory", "before", "injection", "and", "results", "in", "a", "reduction", "of", "the", "pain", "occurring", "during", "the", "infiltration", "of", "tissues", "."]], "ner": [[[6, 6, "Chemical"], [26, 26, "Chemical"], [51, 51, "Chemical"], [87, 87, "Chemical"], [94, 94, "Chemical"], [107, 107, "Chemical"], [117, 117, "Chemical"], [152, 152, "Chemical"], [3, 3, "Disease"], [20, 20, "Disease"], [58, 58, "Disease"], [83, 83, "Disease"], [103, 103, "Disease"], [170, 170, "Disease"]]], "relations": [[[6, 6, 3, 3, "CID"], [6, 6, 20, 20, "CID"], [6, 6, 58, 58, "CID"], [6, 6, 83, 83, "CID"], [6, 6, 103, 103, "CID"], [6, 6, 170, 170, "CID"], [26, 26, 3, 3, "CID"], [26, 26, 20, 20, "CID"], [26, 26, 58, 58, "CID"], [26, 26, 83, 83, "CID"], [26, 26, 103, 103, "CID"], [26, 26, 170, 170, "CID"], [51, 51, 3, 3, "CID"], [51, 51, 20, 20, "CID"], [51, 51, 58, 58, "CID"], [51, 51, 83, 83, "CID"], [51, 51, 103, 103, "CID"], [51, 51, 170, 170, "CID"], [87, 87, 3, 3, "CID"], [87, 87, 20, 20, "CID"], [87, 87, 58, 58, "CID"], [87, 87, 83, 83, "CID"], [87, 87, 103, 103, "CID"], [87, 87, 170, 170, "CID"], [94, 94, 3, 3, "CID"], [94, 94, 20, 20, "CID"], [94, 94, 58, 58, "CID"], [94, 94, 83, 83, "CID"], [94, 94, 103, 103, "CID"], [94, 94, 170, 170, "CID"], [107, 107, 3, 3, "CID"], [107, 107, 20, 20, "CID"], [107, 107, 58, 58, "CID"], [107, 107, 83, 83, "CID"], [107, 107, 103, 103, "CID"], [107, 107, 170, 170, "CID"], [117, 117, 3, 3, "CID"], [117, 117, 20, 20, "CID"], [117, 117, 58, 58, "CID"], [117, 117, 83, 83, "CID"], [117, 117, 103, 103, "CID"], [117, 117, 170, 170, "CID"], [152, 152, 3, 3, "CID"], [152, 152, 20, 20, "CID"], [152, 152, 58, 58, "CID"], [152, 152, 83, 83, "CID"], [152, 152, 103, 103, "CID"], [152, 152, 170, 170, "CID"]]], "clusters": [], "translated": "在心导管术前使用缓冲的<0>利多卡因</0>作为局部麻醉剂减少注射<8>疼痛</8>。以前的报告表明，与注射<1>利多卡因</1>相关的<9>疼痛</9>与溶液的酸性pH值有关。为了确定添加缓冲溶液以将<2>利多卡因</2>的pH值调整到生理范围内是否会减少注射过程中的<10>疼痛</10>，我们对接受心导管插入术的患者进行了一项随机盲法研究。在一个股骨区域接受标准<3>利多卡因</3>并在对侧股骨区域接受缓冲<4>利多卡因</4>后，要求20名患者量化<11>疼痛</11>的严重程度。缓冲<5>利多卡因</5>的平均<12>疼痛</12>评分显着低于标准<6>利多卡因</6>的平均评分（2.7 +/- 1.9 vs. 3.8 +/- 2.2, P=0.03）。标准<7>利多卡因</7>的pH值调整可以在注射前在导管实验室轻松完成，从而减少组织浸润期间发生的<13>疼痛</13>。", "revised": true}
{"doc_key": "3560095", "sentences": [["Flurbiprofen", "in", "the", "treatment", "of", "juvenile", "rheumatoid", "arthritis", ".", "Thirty", "-", "four", "patients", "with", "juvenile", "rheumatoid", "arthritis", ",", "who", "were", "treated", "with", "flurbiprofen", "at", "a", "maximum", "dose", "of", "4", "mg", "/", "kg", "/", "day", ",", "had", "statistically", "significant", "decreases", "from", "baseline", "in", "6", "arthritis", "indices", "after", "12", "weeks", "of", "treatment", ".", "Improvements", "were", "seen", "in", "the", "number", "of", "tender", "joints", ",", "the", "severity", "of", "swelling", "and", "tenderness", ",", "the", "time", "of", "walk", "50", "feet", ",", "the", "duration", "of", "morning", "stiffness", "and", "the", "circumference", "of", "the", "left", "knee", ".", "The", "most", "frequently", "observed", "side", "effect", "was", "fecal", "occult", "blood", "(", "25", "%", "of", "patients", ")", ";", "however", ",", "there", "was", "no", "other", "evidence", "of", "gastrointestinal", "(", "GI", ")", "bleeding", "in", "these", "patients", ".", "One", "patient", "was", "prematurely", "discontinued", "from", "the", "study", "for", "severe", "headache", "and", "abdominal", "pain", ".", "Most", "side", "effects", "were", "mild", "and", "related", "to", "the", "GI", "tract", "."]], "ner": [[[0, 0, "Chemical"], [22, 22, "Chemical"], [113, 117, "Disease"], [132, 132, "Disease"], [134, 135, "Disease"], [5, 7, "Disease"], [14, 16, "Disease"], [43, 43, "Disease"], [64, 64, "Disease"]]], "relations": [[[0, 0, 113, 117, "CID"], [22, 22, 113, 117, "CID"], [0, 0, 132, 132, "CID"], [22, 22, 132, 132, "CID"], [0, 0, 134, 135, "CID"], [22, 22, 134, 135, "CID"]]], "clusters": [], "translated": "<0>氟比洛芬</0>治疗<5>幼年类风湿性关节炎</5>。34名<6>幼年类风湿性关节炎</6>患者接受了最大剂量4mg/kg/天的<1>氟比洛芬</1>治疗，其中6<7>关节炎</7>指数在治疗12周后有显著下降。压痛关节的数量、<8>肿胀</8>和压痛的严重程度、步行50英尺的时间、晨僵持续时间和左膝周长均有改善。最常观察到的副作用是粪便潜血（25%的患者）；然而，在这些患者中没有其他<2>胃肠道(GI)出血</2>的证据。一名患者因严重<3>头痛</3>和<4>腹痛</4>提前退出研究。大多数副作用是轻微的并且与胃肠道有关。", "revised": true}
{"doc_key": "2445283", "sentences": [["Tolerance", "and", "antiviral", "effect", "of", "ribavirin", "in", "patients", "with", "Argentine", "hemorrhagic", "fever", ".", "Tolerance", "and", "antiviral", "effect", "of", "ribavirin", "was", "studied", "in", "6", "patients", "with", "Argentine", "hemorrhagic", "fever", "(", "AHF", ")", "of", "more", "than", "8", "days", "of", "evolution", ".", "Administration", "of", "ribavirin", "resulted", "in", "a", "neutralization", "of", "viremia", "and", "a", "drop", "of", "endogenous", "interferon", "titers", ".", "The", "average", "time", "of", "death", "was", "delayed", ".", "A", "reversible", "anemia", "was", "the", "only", "adverse", "effect", "observed", ".", "From", "these", "results", ",", "we", "conclude", "that", "ribavirin", "has", "an", "antiviral", "effect", "in", "advanced", "cases", "of", "AHF", ",", "and", "that", "anemia", ",", "the", "only", "secondary", "reaction", "observed", ",", "can", "be", "easily", "managed", ".", "The", "possible", "beneficial", "effect", "of", "ribavirin", "during", "the", "initial", "days", "of", "AHF", "is", "discussed", "."]], "ner": [[[5, 5, "Chemical"], [18, 18, "Chemical"], [41, 41, "Chemical"], [81, 81, "Chemical"], [112, 112, "Chemical"], [66, 66, "Disease"], [94, 94, "Disease"], [9, 11, "Disease"], [25, 27, "Disease"], [29, 29, "Disease"], [90, 90, "Disease"], [118, 118, "Disease"], [47, 47, "Disease"], [60, 60, "Disease"]]], "relations": [[[5, 5, 66, 66, "CID"], [5, 5, 94, 94, "CID"], [18, 18, 66, 66, "CID"], [18, 18, 94, 94, "CID"], [41, 41, 66, 66, "CID"], [41, 41, 94, 94, "CID"], [81, 81, 66, 66, "CID"], [81, 81, 94, 94, "CID"], [112, 112, 66, 66, "CID"], [112, 112, 94, 94, "CID"]]], "clusters": [], "translated": "<0>利巴韦林</0>对<7>阿根廷出血热</7>患者的耐受性和抗病毒作用。对6例发病时间超过8天的<8>阿根廷出血热</8>（<9>急性心力衰竭</9>）患者，研究了<1>利巴韦林</1>的耐受性和抗病毒作用。给药后发现：<2>利巴韦林</2>导致<12>病毒血症</12>的中和和内源性干扰素滴度的下降。可逆性<5>贫血</5>是观察到的唯一不良反应。平均<13>死亡</13>时间被推迟。从这些结果中，我们得出结论，<3>利巴韦林</3>对晚期<10>AHF</10>病例具有抗病毒作用，唯一观察到的继发反应是<6>贫血</6>，可以易于管理。我们还讨论了<4>利巴韦林</4>在<11>AHF</11>最初几天可能产生的有益作用。", "revised": true}
{"doc_key": "1833784", "sentences": [["Evidence", "for", "an", "involvement", "of", "D1", "and", "D2", "dopamine", "receptors", "in", "mediating", "nicotine", "-", "induced", "hyperactivity", "in", "rats", ".", "Previous", "studies", "have", "suggested", "that", "repeated", "exposure", "of", "rats", "to", "the", "drug", "or", "to", "the", "experimental", "environment", "is", "necessary", "to", "observe", "nicotine", "-", "induced", "locomotor", "stimulation", ".", "In", "the", "present", "study", "the", "role", "of", "habituation", "to", "the", "experimental", "environment", "on", "the", "stimulant", "effect", "of", "nicotine", "in", "rats", "was", "examined", ".", "In", "addition", ",", "the", "role", "of", "dopamine", "receptors", "in", "mediating", "nicotine", "-", "induced", "locomotor", "stimulation", "was", "investigated", "by", "examining", "the", "effects", "of", "selective", "D1", "and", "D2", "dopamine", "receptor", "antagonists", "on", "activity", "induced", "by", "nicotine", ".", "Locomotor", "activity", "was", "assessed", "in", "male", "Sprague", "-", "Dawley", "rats", "tested", "in", "photocell", "cages", ".", "Nicotine", "(", "1", ".", "0", "mg", "/", "kg", ")", "caused", "a", "significant", "increase", "in", "locomotor", "activity", "in", "rats", "that", "were", "habituated", "to", "the", "test", "environment", ",", "but", "had", "only", "a", "weak", "and", "delayed", "stimulant", "action", "in", "rats", "that", "were", "unfamiliar", "with", "the", "test", "environment", ".", "The", "stimulant", "action", "of", "nicotine", "was", "blocked", "by", "the", "central", "nicotinic", "antagonist", "mecamylamine", "but", "not", "by", "the", "peripheral", "nicotinic", "blocker", "hexamethonium", ",", "indicating", "that", "the", "response", "is", "probably", "mediated", "by", "central", "nicotinic", "receptors", ".", "Nicotine", "-", "induced", "hyperactivity", "was", "blocked", "by", "the", "selective", "D1", "antagonist", "SCH", "23390", ",", "the", "selective", "D2", "antagonist", "raclopride", "and", "the", "D1", "/", "D2", "antagonist", "fluphenazine", ".", "Pretreatment", "with", "the", "D2", "agonist", "PHNO", "enhanced", "nicotine", "-", "induced", "hyperactivity", ",", "whereas", "the", "D1", "agonist", "SKF", "38393", "had", "no", "effect", ".", "The", "results", "indicate", "that", "acute", "nicotine", "injection", "induces", "a", "pronounced", "hyperactivity", "in", "rats", "habituated", "to", "the", "test", "environment", ".", "The", "effect", "appears", "to", "be", "mediated", "by", "central", "nicotine", "receptors", ",", "possibly", "located", "on", "dopaminergic", "neurons", ",", "and", "also", "requires", "the", "activation", "of", "both", "D1", "and", "D2", "dopamine", "receptors", "."]], "ner": [[[12, 12, "Chemical"], [40, 40, "Chemical"], [63, 63, "Chemical"], [79, 79, "Chemical"], [102, 102, "Chemical"], [119, 119, "Chemical"], [168, 168, "Chemical"], [198, 198, "Chemical"], [232, 232, "Chemical"], [252, 252, "Chemical"], [274, 274, "Chemical"], [15, 15, "Disease"], [131, 134, "Disease"], [201, 201, "Disease"], [235, 235, "Disease"], [257, 257, "Disease"], [8, 8, "Chemical"], [75, 75, "Chemical"], [95, 95, "Chemical"], [293, 293, "Chemical"], [176, 176, "Chemical"], [184, 184, "Chemical"], [209, 210, "Chemical"], [216, 216, "Chemical"], [223, 223, "Chemical"], [241, 242, "Chemical"]]], "relations": [[[12, 12, 15, 15, "CID"], [12, 12, 131, 134, "CID"], [12, 12, 201, 201, "CID"], [12, 12, 235, 235, "CID"], [12, 12, 257, 257, "CID"], [40, 40, 15, 15, "CID"], [40, 40, 131, 134, "CID"], [40, 40, 201, 201, "CID"], [40, 40, 235, 235, "CID"], [40, 40, 257, 257, "CID"], [63, 63, 15, 15, "CID"], [63, 63, 131, 134, "CID"], [63, 63, 201, 201, "CID"], [63, 63, 235, 235, "CID"], [63, 63, 257, 257, "CID"], [79, 79, 15, 15, "CID"], [79, 79, 131, 134, "CID"], [79, 79, 201, 201, "CID"], [79, 79, 235, 235, "CID"], [79, 79, 257, 257, "CID"], [102, 102, 15, 15, "CID"], [102, 102, 131, 134, "CID"], [102, 102, 201, 201, "CID"], [102, 102, 235, 235, "CID"], [102, 102, 257, 257, "CID"], [119, 119, 15, 15, "CID"], [119, 119, 131, 134, "CID"], [119, 119, 201, 201, "CID"], [119, 119, 235, 235, "CID"], [119, 119, 257, 257, "CID"], [168, 168, 15, 15, "CID"], [168, 168, 131, 134, "CID"], [168, 168, 201, 201, "CID"], [168, 168, 235, 235, "CID"], [168, 168, 257, 257, "CID"], [198, 198, 15, 15, "CID"], [198, 198, 131, 134, "CID"], [198, 198, 201, 201, "CID"], [198, 198, 235, 235, "CID"], [198, 198, 257, 257, "CID"], [232, 232, 15, 15, "CID"], [232, 232, 131, 134, "CID"], [232, 232, 201, 201, "CID"], [232, 232, 235, 235, "CID"], [232, 232, 257, 257, "CID"], [252, 252, 15, 15, "CID"], [252, 252, 131, 134, "CID"], [252, 252, 201, 201, "CID"], [252, 252, 235, 235, "CID"], [252, 252, 257, 257, "CID"], [274, 274, 15, 15, "CID"], [274, 274, 131, 134, "CID"], [274, 274, 201, 201, "CID"], [274, 274, 235, 235, "CID"], [274, 274, 257, 257, "CID"]]], "clusters": [], "translated": "D1 和 D2 <16> 多巴胺 </16> 受体参与介导 <0> 尼古丁 </0> -诱导的<11>多动症</11> 的证据。以往的研究表明，大鼠反复接触药物或实验环境对于观察 <1> 尼古丁 </1> -诱导的运动刺激是必要的。在本研究中，研究了实验环境的习惯对大鼠 <2> 尼古丁 </2> 的兴奋作用的作用。此外，通过检测选择性 D1 和 D2 <18> 多巴胺 </18> 受体拮抗剂的作用，研究了 <17> 多巴胺 </17> 受体在介导 <3> 尼古丁 </3> 诱导的运动刺激中的作用<4>尼古丁</4>诱导的活性。对在光电池笼中测试的雄性 Sprague-Dawley 大鼠的运动活动进行了评估。 <5> 尼古丁 </5> (1.0 mg/kg) 使习惯了试验环境的大鼠显着 <12> 增加运动活动 </12>，但对于不熟悉测试环境的大鼠只具有微弱和延迟的刺激作用。 <6> 尼古丁 </6> 的兴奋作用被中枢烟碱受体拮抗剂 <20> 美卡拉明 </20> 阻断，但不被外周烟碱受体阻滞剂 <21> 六甲铵 </21> 阻断，表明该反应可能是介导的通过中枢烟碱受体。 <7> 尼古丁 </7> -诱导的 <13>活动过度</13> 被选择性 D1 受体拮抗剂 <22> SCH 23390 </22> 、选择性 D2 受体拮抗剂 <23> raclopride </23> 和 D1/D2 受体拮抗剂 <24>氟奋乃静</24> 阻断。用 D2 激动剂 PHNO 预处理可增强 <8> 尼古丁 </8> -诱导的<14>活动过度</14>，而 D1 激动剂 <25> SKF 38393 </25> 则没有效果。结果表明，急性 <9> 尼古丁 </9> 注射会在习惯于测试环境的大鼠中引起明显的 <15> 多动症 </15>。该效应似乎是由中枢 <10> 尼古丁 </10> 受体介导的，可能位于多巴胺能神经元上，并且还需要同时激活 D1 和 D2 <19> 多巴胺 </19> 受体。", "revised": true}
{"doc_key": "6534871", "sentences": [["Effects", "of", "training", "on", "the", "extent", "of", "experimental", "myocardial", "infarction", "in", "aging", "rats", ".", "The", "effects", "of", "exercise", "on", "the", "severity", "of", "isoproterenol", "-", "induced", "myocardial", "infarction", "were", "studied", "in", "female", "albino", "rats", "of", "20", ",", "40", ",", "60", "and", "80", "weeks", "of", "age", ".", "The", "rats", "were", "trained", "to", "swim", "for", "a", "specific", "duration", "and", "for", "a", "particular", "period", ".", "The", "occurrence", "of", "infarcts", "were", "confirmed", "by", "histological", "methods", ".", "Elevations", "in", "the", "serum", "GOT", "and", "GPT", "were", "maximum", "in", "the", "sedentary", "-", "isoproterenols", "and", "minimum", "in", "the", "exercise", "-", "controls", ".", "These", "changes", "in", "the", "serum", "transaminases", "were", "associated", "with", "corresponding", "depletions", "in", "the", "cardiac", "GOT", "and", "GPT", ".", "However", ",", "age", "was", "seen", "to", "interfere", "with", "the", "responses", "exhibited", "by", "the", "young", "and", "old", "rats", ".", "Studies", "dealing", "with", "myocardial", "infarction", "are", "more", "informative", "when", "dealt", "with", "age", "."]], "ner": [[[22, 22, "Chemical"], [84, 84, "Chemical"], [8, 9, "Disease"], [25, 26, "Disease"], [132, 133, "Disease"], [64, 64, "Disease"]]], "relations": [[[22, 22, 8, 9, "CID"], [22, 22, 25, 26, "CID"], [22, 22, 132, 133, "CID"], [84, 84, 8, 9, "CID"], [84, 84, 25, 26, "CID"], [84, 84, 132, 133, "CID"]]], "clusters": [], "translated": "训练对老龄大鼠实验性<2>心肌梗死</2>程度的影响。在20、40、60和80周龄的雌性白化大鼠中研究了运动对<0>异丙肾上腺素</0>诱发的<3>心肌梗死</3>严重程度的影响。这些老鼠被训练在特定的持续时间和特定的时间段内游泳。组织学方法证实了<5>梗死</5>的发生。血清GOT和GPT的升高在久坐-<1>异丙肾上腺素</1>组中最高，在运动组中最低。血清转氨酶的这些变化与心脏GOT和GPT的相应消耗有关。然而，年龄会干扰年轻和老年老鼠的反应。处理<4>心肌梗死</4>的研究在涉及年龄时更有意义。", "revised": true}
{"doc_key": "3031535", "sentences": [["Noradrenergic", "involvement", "in", "catalepsy", "induced", "by", "delta", "9", "-", "tetrahydrocannabinol", ".", "In", "order", "to", "elucidate", "the", "role", "of", "the", "catecholaminergic", "system", "in", "the", "cataleptogenic", "effect", "of", "delta", "9", "-", "tetrahydrocannabinol", "(", "THC", ")", ",", "the", "effect", "of", "pretreatment", "with", "6", "-", "hydroxydopamine", "(", "6", "-", "OHDA", ")", "or", "with", "desipramine", "and", "6", "-", "OHDA", "and", "lesions", "of", "the", "locus", "coeruleus", "were", "investigated", "in", "rats", ".", "The", "cataleptogenic", "effect", "of", "THC", "was", "significantly", "reduced", "in", "rats", "treated", "with", "6", "-", "OHDA", "and", "in", "rats", "with", "lesions", "of", "the", "locus", "coeruleus", "but", "not", "in", "rats", "treated", "with", "desipramine", "and", "6", "-", "OHDA", ",", "as", "compared", "with", "control", "rats", ".", "On", "the", "contrary", ",", "the", "cataleptogenic", "effect", "of", "haloperidol", "was", "significantly", "reduced", "in", "rats", "treated", "with", "desipramine", "and", "6", "-", "OHDA", "but", "not", "in", "rats", "treated", "with", "6", "-", "OHDA", "or", "in", "rats", "with", "lesions", "of", "the", "locus", "coeruleus", ".", "These", "results", "indicate", "that", "noradrenergic", "neurons", "have", "an", "important", "role", "in", "the", "manifestation", "of", "catalepsy", "induced", "by", "THC", ",", "whereas", "dopaminergic", "neurons", "are", "important", "in", "catalepsy", "induced", "by", "haloperidol", "."]], "ner": [[[6, 9, "Chemical"], [26, 29, "Chemical"], [31, 31, "Chemical"], [69, 69, "Chemical"], [164, 164, "Chemical"], [3, 3, "Disease"], [161, 161, "Disease"], [172, 172, "Disease"], [115, 115, "Chemical"], [175, 175, "Chemical"], [39, 41, "Chemical"], [43, 45, "Chemical"], [51, 53, "Chemical"], [77, 79, "Chemical"], [97, 99, "Chemical"], [125, 127, "Chemical"], [134, 136, "Chemical"], [49, 49, "Chemical"], [95, 95, "Chemical"], [123, 123, "Chemical"]]], "relations": [[[6, 9, 3, 3, "CID"], [6, 9, 161, 161, "CID"], [6, 9, 172, 172, "CID"], [26, 29, 3, 3, "CID"], [26, 29, 161, 161, "CID"], [26, 29, 172, 172, "CID"], [31, 31, 3, 3, "CID"], [31, 31, 161, 161, "CID"], [31, 31, 172, 172, "CID"], [69, 69, 3, 3, "CID"], [69, 69, 161, 161, "CID"], [69, 69, 172, 172, "CID"], [164, 164, 3, 3, "CID"], [164, 164, 161, 161, "CID"], [164, 164, 172, 172, "CID"], [115, 115, 3, 3, "CID"], [115, 115, 161, 161, "CID"], [115, 115, 172, 172, "CID"], [175, 175, 3, 3, "CID"], [175, 175, 161, 161, "CID"], [175, 175, 172, 172, "CID"]]], "clusters": [], "translated": "去甲肾上腺素能参与<5>强直性昏厥</5>由<0>delta 9 - 四氢大麻酚</0>诱导。为了阐明儿茶酚胺能系统在<1>δ9-四氢大麻酚</1> (<2>THC</2>)致强直作用中的作用，研究了预处理<10>6-羟基多巴胺</10> (<11>6-OHDA</11>)或<17>地昔帕明</17> 和<12>6-OHDA</12>对大鼠的蓝斑损伤。用<13>6-OHDA</13>治疗的大鼠和有蓝斑损伤的大鼠中，<3>THC</3>的强直作用显着降低，但是，在用<18>地昔帕明</18>和<14>6-OHDA</14>治疗的大鼠中没有降低，与对照大鼠相比。相反，在<19>地昔帕明</19>和<15>6-OHDA</15>治疗的大鼠中，<8>氟哌啶醇</8>的强直作用显着降低，但在用<16>6-OHDA</16>治疗的大鼠或有蓝斑病变的大鼠中没有。这些结果表明，去甲肾上腺素能神经元在<4>THC</4>诱发的<6>强直性昏厥</6>表现中具有重要作用，而多巴胺能神经元在<9>氟哌啶醇</9>诱发的<7>强直性昏厥</7>中具有重要作用。", "revised": true}
{"doc_key": "3828020", "sentences": [["Cerebral", "infarction", "with", "a", "single", "oral", "dose", "of", "phenylpropanolamine", ".", "Phenylpropanolamine", "(", "PPA", ")", ",", "a", "synthetic", "sympathomimetic", "that", "is", "structurally", "similar", "to", "amphetamine", ",", "is", "available", "over", "the", "counter", "in", "anorectics", ",", "nasal", "congestants", ",", "and", "cold", "preparations", ".", "Its", "prolonged", "use", "or", "overuse", "has", "been", "associated", "with", "seizures", ",", "intracerebral", "hemorrhage", ",", "neuropsychiatric", "symptoms", ",", "and", "nonhemorrhagic", "cerebral", "infarction", ".", "We", "report", "the", "case", "of", "a", "young", "woman", "who", "suffered", "a", "cerebral", "infarction", "after", "taking", "a", "single", "oral", "dose", "of", "PPA", "."]], "ner": [[[8, 8, "Chemical"], [10, 10, "Chemical"], [12, 12, "Chemical"], [82, 82, "Chemical"], [0, 1, "Disease"], [59, 60, "Disease"], [73, 74, "Disease"], [49, 49, "Disease"], [51, 52, "Disease"], [54, 55, "Disease"], [23, 23, "Chemical"]]], "relations": [[[8, 8, 0, 1, "CID"], [8, 8, 59, 60, "CID"], [8, 8, 73, 74, "CID"], [10, 10, 0, 1, "CID"], [10, 10, 59, 60, "CID"], [10, 10, 73, 74, "CID"], [12, 12, 0, 1, "CID"], [12, 12, 59, 60, "CID"], [12, 12, 73, 74, "CID"], [82, 82, 0, 1, "CID"], [82, 82, 59, 60, "CID"], [82, 82, 73, 74, "CID"], [8, 8, 49, 49, "CID"], [10, 10, 49, 49, "CID"], [12, 12, 49, 49, "CID"], [82, 82, 49, 49, "CID"], [8, 8, 51, 52, "CID"], [10, 10, 51, 52, "CID"], [12, 12, 51, 52, "CID"], [82, 82, 51, 52, "CID"], [8, 8, 54, 55, "CID"], [10, 10, 54, 55, "CID"], [12, 12, 54, 55, "CID"], [82, 82, 54, 55, "CID"]]], "clusters": [], "translated": "<4>脑梗死</4> with a single oral dose of <0>苯丙醇胺</0>。 <1>苯丙醇胺</1> (<2>PPA</2>) 是一种合成的拟交感神经药，其结构类似于<10>苯丙胺</10>，可在柜台购买，用于厌食药、鼻充血剂和感冒药。其长期使用或过度使用与<7>癫痫发作</7>、<8>脑出血</8>、<9>神经精神症状</9>和非出血性<5>脑梗塞</5>有关。我们报告了一名年轻女性在单次口服剂量<3>PPA</3>后发生<6>脑梗塞</6>的病例。", "revised": true}
{"doc_key": "3187073", "sentences": [["Adverse", "cardiac", "effects", "during", "induction", "chemotherapy", "treatment", "with", "cis", "-", "platin", "and", "5", "-", "fluorouracil", ".", "Survival", "for", "patients", "with", "advanced", "head", "and", "neck", "carcinoma", "and", "esophageal", "carcinoma", "is", "poor", "with", "radiotherapy", "and", "/", "or", "surgery", ".", "Obviously", ",", "there", "is", "a", "need", "for", "effective", "chemotherapy", ".", "In", "the", "present", "study", ",", "cis", "-", "platin", "(", "80", "-", "120", "mg", "/", "m2BSA", ")", "and", "5", "-", "FU", "(", "1000", "mg", "/", "m2BSA", "daily", "as", "a", "continuous", "infusion", "during", "5", "days", ")", "were", "given", "to", "76", "patients", "before", "radiotherapy", "and", "surgery", ".", "The", "aim", "of", "the", "study", "was", "to", "clarify", "the", "incidence", "and", "severity", "of", "adverse", "cardiac", "effects", "to", "this", "treatment", ".", "Before", "treatment", "all", "patients", "had", "a", "cardiac", "evaluation", "and", "during", "treatment", "serial", "ECG", "recordings", "were", "performed", ".", "In", "the", "pre", "-", "treatment", "evaluation", ",", "signs", "of", "cardiovascular", "disease", "were", "found", "in", "33", "patients", "(", "43", "%", ")", ".", "During", "treatment", ",", "adverse", "cardiac", "effects", "were", "observed", "in", "14", "patients", "(", "18", "%", ")", ".", "The", "mean", "age", "of", "these", "patients", "was", "the", "same", "as", "for", "the", "entire", "group", ",", "64", "years", ".", "The", "incidence", "of", "cardiotoxicity", "was", "not", "higher", "in", "patients", "with", "signs", "of", "cardiovascular", "disease", "than", "in", "those", "without", "in", "the", "pre", "-", "treatment", "evaluation", ".", "The", "most", "common", "signs", "of", "cardiotoxicity", "were", "chest", "pain", ",", "ST", "-", "T", "wave", "changes", "and", "atrial", "fibrillation", ".", "This", "was", "followed", "by", "ventricular", "fibrillation", "in", "one", "patient", "and", "sudden", "death", "in", "another", ".", "It", "is", "concluded", "that", "patients", "on", "5", "-", "FU", "treatment", "should", "be", "under", "close", "supervision", "and", "that", "the", "treatment", "should", "be", "discontinued", "if", "chest", "pain", "or", "tachyarrhythmia", "is", "observed", "."]], "ner": [[[8, 10, "Chemical"], [52, 54, "Chemical"], [137, 138, "Disease"], [195, 196, "Disease"], [215, 216, "Disease"], [265, 266, "Disease"], [224, 225, "Disease"], [231, 232, "Disease"], [12, 14, "Chemical"], [64, 66, "Chemical"], [248, 250, "Chemical"], [21, 24, "Disease"], [26, 27, "Disease"], [186, 186, "Disease"], [213, 213, "Disease"], [237, 238, "Disease"], [268, 268, "Disease"]]], "relations": [[[8, 10, 137, 138, "CID"], [8, 10, 195, 196, "CID"], [52, 54, 137, 138, "CID"], [52, 54, 195, 196, "CID"], [8, 10, 215, 216, "CID"], [8, 10, 265, 266, "CID"], [52, 54, 215, 216, "CID"], [52, 54, 265, 266, "CID"], [8, 10, 224, 225, "CID"], [52, 54, 224, 225, "CID"], [8, 10, 231, 232, "CID"], [52, 54, 231, 232, "CID"], [12, 14, 137, 138, "CID"], [12, 14, 195, 196, "CID"], [64, 66, 137, 138, "CID"], [64, 66, 195, 196, "CID"], [248, 250, 137, 138, "CID"], [248, 250, 195, 196, "CID"], [12, 14, 215, 216, "CID"], [12, 14, 265, 266, "CID"], [64, 66, 215, 216, "CID"], [64, 66, 265, 266, "CID"], [248, 250, 215, 216, "CID"], [248, 250, 265, 266, "CID"], [12, 14, 224, 225, "CID"], [64, 66, 224, 225, "CID"], [248, 250, 224, 225, "CID"], [12, 14, 231, 232, "CID"], [64, 66, 231, 232, "CID"], [248, 250, 231, 232, "CID"]]], "clusters": [], "translated": " <0>顺铂</0> 和 <8>5-氟尿嘧啶</8> 诱导化疗期间的心脏不良反应。晚期<11>头颈癌</11>和<12>食管癌</12>患者接受放疗和/或手术后的生存率很低。显然，需要有效的化疗。在本研究中，<1>顺铂</1>（80-120 mg/m2BSA）和<9>5-FU</9>（每天1000 mg/m2BSA连续输注5天）对76名患者进行放疗和手术前。该研究的目的是阐明这种治疗对心脏产生不良影响的发生率和严重程度。在治疗之前，所有患者都进行了心脏评估，并在治疗期间进行了一系列心电图记录。在治疗前的评估中，33名患者（43%）发现了<2>心血管疾病</2>的体征。在治疗期间，观察到14名患者(18%)出现了<13>心脏毒性</13>。这些患者的平均年龄与整个组相同，均为64岁。在治疗前评估中，有 <3>心血管疾病</3>体征的患者的<13>心脏毒性</13>发生率并不高于没有心血管疾病体征的患者。最常见的<14>心脏毒性</14>表现为<4>胸痛</4>、ST-T 波改变和<6>心房颤动</6>。随后一位患者出现 <7>心室颤动</7>，另一名患者出现 <15>猝死</15>。得出结论：接受<10> 5-FU </10>治疗的患者应该受到密切监督，如果观察到<5>胸痛</5>或<16>快速性心律失常</16>，则应立即停止治疗。", "revised": true}
{"doc_key": "3015567", "sentences": [["Inhibition", "of", "immunoreactive", "corticotropin", "-", "releasing", "factor", "secretion", "into", "the", "hypophysial", "-", "portal", "circulation", "by", "delayed", "glucocorticoid", "feedback", ".", "Nitroprusside", "-", "induced", "hypotension", "evokes", "ACTH", "secretion", "which", "is", "primarily", "mediated", "by", "enhanced", "secretion", "of", "immunoreactive", "corticotropin", "-", "releasing", "factor", "(", "irCRF", ")", "into", "the", "hypophysial", "-", "portal", "circulation", ".", "Portal", "plasma", "concentrations", "of", "neither", "arginine", "vasopressin", "nor", "oxytocin", "are", "significantly", "altered", "in", "this", "paradigm", ".", "Application", "of", "a", "delayed", "feedback", "signal", ",", "in", "the", "form", "of", "a", "2", "-", "h", "systemic", "corticosterone", "infusion", "in", "urethane", "-", "anesthetized", "rats", "with", "pharmacological", "blockade", "of", "glucocorticoid", "synthesis", ",", "is", "without", "effect", "on", "the", "resting", "secretion", "of", "arginine", "vasopressin", "and", "oxytocin", "at", "any", "corticosterone", "feedback", "dose", "tested", ".", "Resting", "irCRF", "levels", "are", "suppressed", "only", "at", "the", "highest", "corticosterone", "infusion", "rate", ",", "which", "resulted", "in", "systemic", "corticosterone", "levels", "of", "40", "micrograms", "/", "dl", ".", "Suppression", "of", "irCRF", "secretion", "in", "response", "to", "nitroprusside", "-", "induced", "hypotension", "is", "observed", "and", "occurs", "at", "a", "plasma", "corticosterone", "level", "between", "8", "-", "12", "micrograms", "/", "dl", ".", "These", "studies", "provide", "further", "evidence", "for", "a", "strong", "central", "component", "of", "the", "delayed", "feedback", "process", "which", "is", "mediated", "by", "modulation", "of", "irCRF", "release", "."]], "ner": [[[19, 19, "Chemical"], [146, 146, "Chemical"], [22, 22, "Disease"], [149, 149, "Disease"], [54, 55, "Chemical"], [103, 104, "Chemical"], [57, 57, "Chemical"], [106, 106, "Chemical"], [81, 81, "Chemical"], [109, 109, "Chemical"], [123, 123, "Chemical"], [131, 131, "Chemical"], [157, 157, "Chemical"], [84, 84, "Chemical"]]], "relations": [[[19, 19, 22, 22, "CID"], [19, 19, 149, 149, "CID"], [146, 146, 22, 22, "CID"], [146, 146, 149, 149, "CID"]]], "clusters": [], "translated": "通过延迟糖皮质激素反馈抑制免疫反应性促肾上腺皮质激素释放因子分泌到垂体门静脉循环中。 <0>硝普钠</0>诱导的<2>低血压</2>引起 ACTH 分泌，这主要是由免疫反应性促肾上腺皮质激素释放因子 (irCRF) 分泌增加到垂体-门脉循环中介导的。未观察到这种模型下门脉血<4>精氨酸加压素</4>和<6>催产素</6>浓度的显著改变。在药理学抑制糖皮质激素合成后的2小时中，给予<13>氨甲酸乙酯麻醉</13>大鼠全身性<8>皮质酮</8>输注的延迟反馈信号对于静息时<5>精氨酸加压素</5>和<7>催产素</7>的释放在任何剂量<9>皮质酮</9>反馈下均不产生影响。只有在最高的<10>皮质酮</10>输注速率下，静息的 irCRF 水平受到抑制，其导致全身水平的<11>皮质酮</11>为40微克/dL。在<1>硝普钠</1>诱导的<3>低血压</3>的反应中，仅在血浆<12>皮质酮</12>水平为8-12微克/dL时出现了对irCRF分泌的抑制，这表明一个重要的中枢成分构成了延迟反馈过程，这是由irCRF释放调控介导的。", "revised": true}
{"doc_key": "1720453", "sentences": [["Long", "-", "term", "follow", "-", "up", "of", "ifosfamide", "renal", "toxicity", "in", "children", "treated", "for", "malignant", "mesenchymal", "tumors", ":", "an", "International", "Society", "of", "Pediatric", "Oncology", "report", ".", "The", "renal", "function", "of", "74", "children", "with", "malignant", "mesenchymal", "tumors", "in", "complete", "remission", "and", "who", "have", "received", "the", "same", "ifosfamide", "chemotherapy", "protocol", "(", "International", "Society", "of", "Pediatric", "Oncology", "Malignant", "Mesenchymal", "Tumor", "Study", "84", "[", "SIOP", "MMT", "84", "]", ")", "were", "studied", "1", "year", "after", "the", "completion", "of", "treatment", ".", "Total", "cumulative", "doses", "were", "36", "or", "60", "g", "/", "m2", "of", "ifosfamide", "(", "six", "or", "10", "cycles", "of", "ifosfamide", ",", "vincristine", ",", "and", "dactinomycin", "[", "IVA", "]", ")", ".", "None", "of", "them", "had", "received", "cisplatin", "chemotherapy", ".", "Ages", "ranged", "from", "4", "months", "to", "17", "years", ";", "58", "patients", "were", "males", "and", "42", "females", ".", "The", "most", "common", "primary", "tumor", "site", "was", "the", "head", "and", "neck", ".", "Renal", "function", "was", "investigated", "by", "measuring", "plasma", "and", "urinary", "electrolytes", ",", "glucosuria", ",", "proteinuria", ",", "aminoaciduria", ",", "urinary", "pH", ",", "osmolarity", ",", "creatinine", "clearance", ",", "phosphate", "tubular", "reabsorption", ",", "beta", "2", "microglobulinuria", ",", "and", "lysozymuria", ".", "Fifty", "-", "eight", "patients", "(", "78", "%", ")", "had", "normal", "renal", "tests", ",", "whereas", "16", "patients", "(", "22", "%", ")", "had", "renal", "abnormalities", ".", "Two", "subsets", "of", "patients", "were", "identified", "from", "this", "latter", "group", ":", "the", "first", "included", "four", "patients", "(", "5", "%", "of", "the", "total", "population", ")", "who", "developed", "major", "toxicity", "resulting", "in", "Fanconi", "'s", "syndrome", "(", "TDFS", ")", ";", "and", "the", "second", "group", "included", "five", "patients", "with", "elevated", "beta", "2", "microglobulinuria", "and", "low", "phosphate", "reabsorption", ".", "The", "remaining", "seven", "patients", "had", "isolated", "beta", "2", "microglobulinuria", ".", "Severe", "toxicity", "was", "correlated", "with", "the", "higher", "cumulative", "dose", "of", "60", "g", "/", "m2", "of", "ifosfamide", ",", "a", "younger", "age", "(", "less", "than", "2", "1", "/", "2", "years", "old", ")", ",", "and", "a", "predominance", "of", "vesicoprostatic", "tumor", "involvement", ".", "This", "low", "percentage", "(", "5", "%", ")", "of", "TDFS", "must", "be", "evaluated", "with", "respect", "to", "the", "efficacy", "of", "ifosfamide", "in", "the", "treatment", "of", "mesenchymal", "tumors", "in", "children", "."]], "ner": [[[7, 7, "Chemical"], [45, 45, "Chemical"], [86, 86, "Chemical"], [280, 280, "Chemical"], [322, 322, "Chemical"], [8, 9, "Disease"], [198, 199, "Disease"], [231, 233, "Disease"], [235, 235, "Disease"], [14, 16, "Disease"], [33, 35, "Disease"], [54, 56, "Disease"], [327, 328, "Disease"], [133, 133, "Disease"], [301, 301, "Disease"], [152, 152, "Disease"], [154, 154, "Disease"], [156, 156, "Disease"], [228, 228, "Disease"], [266, 266, "Disease"], [93, 98, "Chemical"], [100, 100, "Chemical"], [109, 109, "Chemical"], [163, 163, "Chemical"], [166, 166, "Chemical"], [252, 252, "Chemical"]]], "relations": [[[7, 7, 8, 9, "CID"], [7, 7, 198, 199, "CID"], [45, 45, 8, 9, "CID"], [45, 45, 198, 199, "CID"], [86, 86, 8, 9, "CID"], [86, 86, 198, 199, "CID"], [280, 280, 8, 9, "CID"], [280, 280, 198, 199, "CID"], [322, 322, 8, 9, "CID"], [322, 322, 198, 199, "CID"], [7, 7, 231, 233, "CID"], [7, 7, 235, 235, "CID"], [45, 45, 231, 233, "CID"], [45, 45, 235, 235, "CID"], [86, 86, 231, 233, "CID"], [86, 86, 235, 235, "CID"], [280, 280, 231, 233, "CID"], [280, 280, 235, 235, "CID"], [322, 322, 231, 233, "CID"], [322, 322, 235, 235, "CID"]]], "clusters": [], "translated": "<0>异环磷酰胺</0> <5>肾毒性</5>治疗<9>恶性间充质肿瘤</9>儿童的长期随访：国际儿科肿瘤学会报告。74例<10>恶性间叶性肿瘤</10>完全缓解且接受相同<1>异环磷酰胺</1>化疗方案的患儿的肾功能（国际儿科肿瘤学会<11>恶性间叶性肿瘤</11>研究84[SIOP MMT 84]）在完成治疗1年后进行了研究。<2>异环磷酰胺</2>的总累积剂量为36或60g/m2（<20>异环磷酰胺、长春新碱和更生霉素</20>[<21>IVA</21>]6或10个周期）。均未接受<22>顺铂</22>化疗。年龄从4个月到17岁不等；男58例，女42例。最常见的原发性<13>肿瘤</13>部位是头颈部。通过测量血浆和尿液电解质、<15>尿糖</15>、<16>蛋白尿</16>、<17>氨基酸尿</17>、尿液pH值、渗透压、<23>肌酐</23>清除率、<24>磷酸盐</24>肾小管重吸收、β2微球蛋白尿和溶菌尿来研究肾功能。58名患者（78%）的肾脏检查正常，而16名患者（22%）有<6>肾脏异常</6>。从后一组中确定了两个患者子集：第一个包括四名患者（占总人口的5%），他们出现了严重的<18>毒性</18>导致<7>范可尼综合征</7>（<8>TDFS</8>）；第二组包括5名患有升高的β2微球蛋白尿和低<25>磷酸盐</25>重吸收的患者。其余7名患者患有孤立性β2微球蛋白尿。严重<19>毒性</19>与60g/m2的较高累积剂量<3>异环磷酰胺</3>、较年轻的年龄（小于21/2岁）和膀胱前列腺素占优势相关的<14>肿瘤</14>受累。必须根据<4>异环磷酰胺</4>治疗儿童<12>间充质肿瘤</12>的疗效对TDFS的这种低百分比（5%）进行评估。", "revised": true}
{"doc_key": "6538499", "sentences": [["Effect", "of", "polyethylene", "glycol", "400", "on", "adriamycin", "toxicity", "in", "mice", ".", "The", "effect", "of", "a", "widely", "used", "organic", "solvent", ",", "polyethylene", "glycol", "400", "(", "PEG", "400", ")", ",", "on", "the", "toxic", "action", "of", "an", "acute", "or", "chronic", "treatment", "with", "adriamycin", "(", "ADR", ")", "was", "evaluated", "in", "mice", ".", "PEG", "400", "impressively", "decreased", "both", "acute", "high", "-", "dose", "and", "chronic", "low", "-", "dose", "-", "ADR", "-", "associated", "lethality", ".", "Light", "microscopic", "analysis", "showed", "a", "significant", "protection", "against", "ADR", "-", "induced", "cardiac", "morphological", "alterations", ".", "Such", "treatment", "did", "not", "diminish", "the", "ADR", "antitumor", "activity", "in", "L1210", "leukemia", "and", "in", "Ehrlich", "ascites", "tumor", "."]], "ner": [[[6, 6, "Chemical"], [39, 39, "Chemical"], [41, 41, "Chemical"], [63, 63, "Chemical"], [76, 76, "Chemical"], [89, 89, "Chemical"], [79, 81, "Disease"], [2, 4, "Chemical"], [20, 22, "Chemical"], [24, 25, "Chemical"], [48, 49, "Chemical"], [7, 7, "Disease"], [93, 94, "Disease"], [97, 99, "Disease"]]], "relations": [[[6, 6, 79, 81, "CID"], [39, 39, 79, 81, "CID"], [41, 41, 79, 81, "CID"], [63, 63, 79, 81, "CID"], [76, 76, 79, 81, "CID"], [89, 89, 79, 81, "CID"]]], "clusters": [], "translated": "<7>聚乙二醇400</7>对小鼠<0>阿霉素</0><11>毒性</11>的影响。广泛使用的有机溶剂<8>聚乙二醇400</8> (<9>PEG 400</9>)对<1>阿霉素</1> (<2>ADR</2>) 急性或慢性治疗的毒性作用的影响在小鼠中进行了评估。<10>PEG 400</10>显着降低了急性高剂量和慢性低剂量-<3>ADR</3>-相关的致死率。光学显微镜分析显示对<4>ADR</4> 诱导的<6>心脏形态学改变</6>具有显着保护作用。这种治疗不会降低<5>ADR</5>在<12>L1210白血病</12>和<13>艾氏腹水瘤</13>中的抗肿瘤活性。", "revised": true}
{"doc_key": "2266990", "sentences": [["Randomized", ",", "double", "-", "blind", "trial", "of", "mazindol", "in", "Duchenne", "dystrophy", ".", "There", "is", "evidence", "that", "growth", "hormone", "may", "be", "related", "to", "the", "progression", "of", "weakness", "in", "Duchenne", "dystrophy", ".", "We", "conducted", "a", "12", "-", "month", "controlled", "trial", "of", "mazindol", ",", "a", "putative", "growth", "hormone", "secretion", "inhibitor", ",", "in", "83", "boys", "with", "Duchenne", "dystrophy", ".", "Muscle", "strength", ",", "contractures", ",", "functional", "ability", "and", "pulmonary", "function", "were", "tested", "at", "baseline", ",", "and", "6", "and", "12", "months", "after", "treatment", "with", "mazindol", "(", "3", "mg", "/", "d", ")", "or", "placebo", ".", "The", "study", "was", "designed", "to", "have", "a", "power", "of", "greater", "than", "0", ".", "90", "to", "detect", "a", "slowing", "to", "25", "%", "of", "the", "expected", "rate", "of", "progression", "of", "weakness", "at", "P", "less", "than", "0", ".", "05", ".", "Mazindol", "did", "not", "benefit", "strength", "at", "any", "point", "in", "the", "study", ".", "Side", "effects", "attributable", "to", "mazindol", "included", "decreased", "appetite", "(", "36", "%", ")", ",", "dry", "mouth", "(", "10", "%", ")", ",", "behavioral", "change", "(", "22", "%", ")", ",", "and", "gastrointestinal", "symptoms", "(", "18", "%", ")", ";", "mazindol", "dosage", "was", "reduced", "in", "43", "%", "of", "patients", ".", "The", "effect", "of", "mazindol", "on", "GH", "secretion", "was", "estimated", "indirectly", "by", "comparing", "the", "postabsorptive", "IGF", "-", "I", "levels", "obtained", "following", "3", ",", "6", ",", "9", ",", "and", "12", "months", "in", "the", "mazindol", "treated", "to", "those", "in", "the", "placebo", "groups", ".", "Although", "mazindol", "-", "treated", "patients", "gained", "less", "weight", "and", "height", "than", "placebo", "-", "treated", "patients", ",", "no", "significant", "effect", "on", "IGF", "-", "I", "levels", "was", "observed", ".", "Mazindol", "doses", "not", "slow", "the", "progression", "of", "weakness", "in", "Duchenne", "dystrophy", "."]], "ner": [[[7, 7, "Chemical"], [39, 39, "Chemical"], [78, 78, "Chemical"], [125, 125, "Chemical"], [141, 141, "Chemical"], [172, 172, "Chemical"], [185, 185, "Chemical"], [213, 213, "Chemical"], [223, 223, "Chemical"], [249, 249, "Chemical"], [143, 144, "Disease"], [150, 151, "Disease"], [165, 166, "Disease"], [9, 10, "Disease"], [27, 28, "Disease"], [52, 53, "Disease"], [258, 259, "Disease"], [25, 25, "Disease"], [116, 116, "Disease"], [256, 256, "Disease"]]], "relations": [[[7, 7, 143, 144, "CID"], [39, 39, 143, 144, "CID"], [78, 78, 143, 144, "CID"], [125, 125, 143, 144, "CID"], [141, 141, 143, 144, "CID"], [172, 172, 143, 144, "CID"], [185, 185, 143, 144, "CID"], [213, 213, 143, 144, "CID"], [223, 223, 143, 144, "CID"], [249, 249, 143, 144, "CID"], [7, 7, 150, 151, "CID"], [39, 39, 150, 151, "CID"], [78, 78, 150, 151, "CID"], [125, 125, 150, 151, "CID"], [141, 141, 150, 151, "CID"], [172, 172, 150, 151, "CID"], [185, 185, 150, 151, "CID"], [213, 213, 150, 151, "CID"], [223, 223, 150, 151, "CID"], [249, 249, 150, 151, "CID"], [7, 7, 165, 166, "CID"], [39, 39, 165, 166, "CID"], [78, 78, 165, 166, "CID"], [125, 125, 165, 166, "CID"], [141, 141, 165, 166, "CID"], [172, 172, 165, 166, "CID"], [185, 185, 165, 166, "CID"], [213, 213, 165, 166, "CID"], [223, 223, 165, 166, "CID"], [249, 249, 165, 166, "CID"]]], "clusters": [], "translated": " <0>马吲哚</0>在<13>杜氏营养不良症</13>中的随机双盲试验。有证据表明，生长激素可能与<17>无力</17>的进展在<14>杜氏营养不良症</14>中有关。我们对83名患有<15>杜氏营养不良症</15>的男孩进行了为期12个月的<1>马吲哚</1>对照试验，这是一种推定的生长激素分泌抑制剂。在使用<2>马吲哚</2> (3 mg/d) 或安慰剂治疗后，在基线、6个月和12个月时测试了肌肉力量、挛缩、功能能力和肺功能。该研究被设计为具有功效大于0.90以检测P小于0.05时<18>无力</18>的预期进展速度减慢到25%的效果。在研究的任何时候，<3>马吲哚</3>都没有提高强度。 <4>马吲哚</4>引起的副作用包括<10>食欲下降</10> (36%)，<11>口干</11> (10%)，行为改变 (22%)，和<12>胃肠道症状</12>（18%）；<5>马吲哚</5>的剂量在43%的患者中被减少。通过比较治疗组和安慰剂组，间接估计了<6>马吲哚</6>对GH分泌的影响，在接受<7>马吲哚</7>治疗后3、6、9和12个月后，采用吸收后IGF-I水平来进行估计。尽管<8>马吲哚</8>治疗的患者体重和身高的增加低于安慰剂治疗的患者，但没有观察到对IGF-I水平的显着影响。<9>马吲哚</9>的剂量不会减缓<16>杜兴氏营养不良症</16>中<19>虚弱</19>的进展。", "revised": true}
{"doc_key": "3371379", "sentences": [["Verapamil", "-", "induced", "carbamazepine", "neurotoxicity", ".", "A", "report", "of", "two", "cases", ".", "Two", "patients", "with", "signs", "of", "carbamazepine", "neurotoxicity", "after", "combined", "treatment", "with", "verapamil", "showed", "complete", "recovery", "after", "discontinuation", "of", "the", "calcium", "entry", "blocker", ".", "Use", "of", "verapamil", "in", "combination", "with", "carbamazepine", "should", "either", "be", "avoided", "or", "prescribed", "only", "with", "appropriate", "adjustment", "of", "the", "carbamazepine", "dose", "(", "usually", "reduction", "of", "the", "carbamazepine", "dose", "by", "one", "half", ")", "."]], "ner": [[[0, 0, "Chemical"], [23, 23, "Chemical"], [37, 37, "Chemical"], [4, 4, "Disease"], [18, 18, "Disease"], [3, 3, "Chemical"], [17, 17, "Chemical"], [41, 41, "Chemical"], [54, 54, "Chemical"], [61, 61, "Chemical"], [31, 31, "Chemical"]]], "relations": [[[0, 0, 4, 4, "CID"], [0, 0, 18, 18, "CID"], [23, 23, 4, 4, "CID"], [23, 23, 18, 18, "CID"], [37, 37, 4, 4, "CID"], [37, 37, 18, 18, "CID"], [3, 3, 4, 4, "CID"], [3, 3, 18, 18, "CID"], [17, 17, 4, 4, "CID"], [17, 17, 18, 18, "CID"], [41, 41, 4, 4, "CID"], [41, 41, 18, 18, "CID"], [54, 54, 4, 4, "CID"], [54, 54, 18, 18, "CID"], [61, 61, 4, 4, "CID"], [61, 61, 18, 18, "CID"]]], "clusters": [], "translated": " <0>维拉帕米</0> -诱导的<5>卡马西平</5><3>神经毒性</3>。两例报告。两名患者在与<1>维拉帕米</1>联合治疗后出现<6>卡马西平</6><4>神经毒性</4>症状，停用<10>钙</10>进入阻滞剂后完全恢复。应避免使用<2>维拉帕米</2>与<7>卡马西平</7>或仅在适当调整<8>卡马西平</8>剂量（通常减少<9>卡马西平</9>剂量减半）。", "revised": true}
{"doc_key": "3125768", "sentences": [["Intracranial", "pressure", "increases", "during", "alfentanil", "-", "induced", "rigidity", ".", "Intracranial", "pressure", "(", "ICP", ")", "was", "measured", "during", "alfentanil", "-", "induced", "rigidity", "in", "rats", ".", "Ten", "rats", "had", "arterial", ",", "central", "venous", "(", "CVP", ")", ",", "and", "subdural", "cannulae", "inserted", "under", "halothane", "anesthesia", ".", "The", "animals", "were", "mechanically", "ventilated", "to", "achieve", "normocarbia", "(", "PCO2", "=", "42", "+", "/", "-", "1", "mmHg", ",", "mean", "+", "/", "-", "SE", ")", ".", "Following", "instrumentation", ",", "halothane", "was", "discontinued", "and", "alfentanil", "(", "125", "mu", "/", "kg", ")", "administered", "iv", "during", "emergence", "from", "halothane", "anesthesia", ".", "In", "the", "five", "rats", "that", "developed", "somatic", "rigidity", ",", "ICP", "and", "CVP", "increased", "significantly", "above", "baseline", "(", "delta", "ICP", "7", ".", "5", "+", "/", "-", "1", ".", "0", "mmHg", ",", "delta", "CVP", "5", ".", "9", "+", "/", "-", "1", ".", "3", "mmHg", ")", ".", "These", "variables", "returned", "to", "baseline", "when", "rigidity", "was", "abolished", "with", "metocurine", ".", "In", "five", "rats", "that", "did", "not", "become", "rigid", ",", "ICP", "and", "CVP", "did", "not", "change", "following", "alfentanil", ".", "These", "observations", "suggest", "that", "rigidity", "should", "be", "prevented", "when", "alfentanil", ",", "and", ",", "presumably", ",", "other", "opiates", ",", "are", "used", "in", "the", "anesthetic", "management", "of", "patients", "with", "ICP", "problems", "."]], "ner": [[[4, 4, "Chemical"], [17, 17, "Chemical"], [75, 75, "Chemical"], [162, 162, "Chemical"], [173, 173, "Chemical"], [7, 7, "Disease"], [20, 20, "Disease"], [96, 97, "Disease"], [140, 140, "Disease"], [168, 168, "Disease"], [40, 40, "Chemical"], [71, 71, "Chemical"], [87, 87, "Chemical"], [144, 144, "Chemical"]]], "relations": [[[4, 4, 7, 7, "CID"], [4, 4, 20, 20, "CID"], [4, 4, 96, 97, "CID"], [4, 4, 140, 140, "CID"], [4, 4, 168, 168, "CID"], [17, 17, 7, 7, "CID"], [17, 17, 20, 20, "CID"], [17, 17, 96, 97, "CID"], [17, 17, 140, 140, "CID"], [17, 17, 168, 168, "CID"], [75, 75, 7, 7, "CID"], [75, 75, 20, 20, "CID"], [75, 75, 96, 97, "CID"], [75, 75, 140, 140, "CID"], [75, 75, 168, 168, "CID"], [162, 162, 7, 7, "CID"], [162, 162, 20, 20, "CID"], [162, 162, 96, 97, "CID"], [162, 162, 140, 140, "CID"], [162, 162, 168, 168, "CID"], [173, 173, 7, 7, "CID"], [173, 173, 20, 20, "CID"], [173, 173, 96, 97, "CID"], [173, 173, 140, 140, "CID"], [173, 173, 168, 168, "CID"]]], "clusters": [], "translated": "<0>阿芬太尼</0>引起的<5>强直</5>期间颅内压升高。在大鼠<1>阿芬太尼</1>诱导的<6>强直</6>期间测量颅内压（ICP ）。10只大鼠在<10>氟烷</10>麻醉下插入动脉、中央静脉 (CVP)和硬膜下插管。对动物进行机械通气以达到正常碳酸水平（PCO2 = 42 +/- 1 mmHg，平均值+/- SE）。器械操作后，停止使用<11>氟烷</11>，并在<12>氟烷</12>麻醉苏醒期间静脉注射<2>阿芬太尼</2>（125 μ/kg）。在发生<7>躯体僵硬</7>的五只大鼠中，ICP 和 CVP 显着高于基线（delta ICP 7.5+/-1.0 mmHg，delta CVP 5.9+/-1.3 mmHg）。当消除<8>强直</8>用<13>美托库仑</13>时，这些变量恢复到基线。在5只没有变得僵硬的大鼠中，ICP和CVP在<3>阿芬太尼</3>后没有变化。这些观察结果表明，在应用<4>阿芬太尼</4>和可能的其他阿片类药物的ICP问题患者的麻醉管理时，应避免<9>强直</9>。", "revised": true}
{"doc_key": "7053303", "sentences": [["Age", "and", "renal", "clearance", "of", "cimetidine", ".", "In", "35", "patients", "(", "ages", "20", "to", "86", "yr", ")", "receiving", "cimetidine", "therapeutically", "two", "serum", "samples", "and", "all", "urine", "formed", "in", "the", "interim", "were", "collected", "for", "analysis", "of", "cimetidine", "by", "high", "-", "pressure", "liquid", "chromatography", "and", "for", "creatinine", ".", "Cimetidine", "clearance", "decreased", "with", "age", ".", "The", "extrapolated", "6", "-", "hr", "serum", "concentration", "of", "cimetidine", "per", "unit", "dose", ",", "after", "intravenous", "cimetidine", ",", "increased", "with", "age", "of", "the", "patients", ".", "The", "ratio", "of", "cimetidine", "clearance", "to", "creatinine", "clearance", "(", "Rc", ")", "averaged", "4", ".", "8", "+", "/", "-", "2", ".", "0", ",", "indicating", "net", "tubular", "secretion", "for", "cimetidine", ".", "Rc", "seemed", "to", "be", "independent", "of", "age", "and", "decreased", "with", "increasing", "serum", "concentration", "of", "cimetidine", ",", "suggesting", "that", "secretion", "of", "cimetidine", "is", "a", "saturable", "process", ".", "There", "was", "only", "one", "case", "of", "dementia", "possibly", "due", "to", "cimetidine", "(", "with", "a", "drug", "level", "of", "1", ".", "9", "microgram", "/", "ml", "6", "hr", "after", "a", "dose", ")", "in", "a", "group", "of", "13", "patients", "without", "liver", "or", "kidney", "disease", "who", "had", "cimetidine", "levels", "above", "1", ".", "25", "microgram", "/", "ml", ".", "Thus", ",", "high", "cimetidine", "levels", "alone", "do", "not", "always", "induce", "dementia", "."]], "ner": [[[5, 5, "Chemical"], [18, 18, "Chemical"], [35, 35, "Chemical"], [46, 46, "Chemical"], [60, 60, "Chemical"], [67, 67, "Chemical"], [79, 79, "Chemical"], [103, 103, "Chemical"], [119, 119, "Chemical"], [125, 125, "Chemical"], [141, 141, "Chemical"], [173, 173, "Chemical"], [186, 186, "Chemical"], [137, 137, "Disease"], [193, 193, "Disease"], [167, 170, "Disease"], [44, 44, "Chemical"], [82, 82, "Chemical"]]], "relations": [[[5, 5, 137, 137, "CID"], [5, 5, 193, 193, "CID"], [18, 18, 137, 137, "CID"], [18, 18, 193, 193, "CID"], [35, 35, 137, 137, "CID"], [35, 35, 193, 193, "CID"], [46, 46, 137, 137, "CID"], [46, 46, 193, 193, "CID"], [60, 60, 137, 137, "CID"], [60, 60, 193, 193, "CID"], [67, 67, 137, 137, "CID"], [67, 67, 193, 193, "CID"], [79, 79, 137, 137, "CID"], [79, 79, 193, 193, "CID"], [103, 103, 137, 137, "CID"], [103, 103, 193, 193, "CID"], [119, 119, 137, 137, "CID"], [119, 119, 193, 193, "CID"], [125, 125, 137, 137, "CID"], [125, 125, 193, 193, "CID"], [141, 141, 137, 137, "CID"], [141, 141, 193, 193, "CID"], [173, 173, 137, 137, "CID"], [173, 173, 193, 193, "CID"], [186, 186, 137, 137, "CID"], [186, 186, 193, 193, "CID"]]], "clusters": [], "translated": "<0>西咪替丁</0>的年龄和肾脏清除率。在接受<1>西咪替丁</1>治疗的35名患者（年龄20至86岁）中，收集了两份血清样本和在此期间形成的所有尿液，用于通过高压液相色谱法分析<2>西咪替丁</2>和<16>肌酐</16>。<3>西咪替丁</3>清除率随年龄增长而降低。静脉注射<5>西咪替丁</5>后，每单位剂量<4>西咪替丁</4>外推的6小时血清浓度随着患者年龄的增长而增加。<6>西咪替丁</6>清除率与<17>肌酐</17>清除率（Rc）的比值平均为4.8+/-2.0，表示<7>西咪替丁</7>的净肾小管分泌。Rc似乎与年龄无关，随着<8>西咪替丁</8>血清浓度的升高而降低，表明<9>西咪替丁</9>的分泌是一个饱和过程。在一组13名未有<15>肝脏或肾脏疾病</15>的患者中，只有一例<13>痴呆</13>可能是由于<10>西咪替丁</10>（给药后6小时药物浓度为1.9微克/毫升）引起的，<11>西咪替丁</11>水平高于1.25微克/毫升。因此，单独高水平的<12>西咪替丁</12>并不总能诱发<14>痴呆</14>。", "revised": true}
{"doc_key": "6861444", "sentences": [["Blood", "pressure", "response", "to", "chronic", "low", "-", "dose", "intrarenal", "noradrenaline", "infusion", "in", "conscious", "rats", ".", "Sodium", "chloride", "solution", "(", "0", ".", "9", "%", ")", "or", "noradrenaline", "in", "doses", "of", "4", ",", "12", "and", "36", "micrograms", "h", "-", "1", "kg", "-", "1", "was", "infused", "for", "five", "consecutive", "days", ",", "either", "intrarenally", "(", "by", "a", "new", "technique", ")", "or", "intravenously", "into", "rats", "with", "one", "kidney", "removed", ".", "Intrarenal", "infusion", "of", "noradrenaline", "caused", "hypertension", "at", "doses", "which", "did", "not", "do", "so", "when", "infused", "intravenously", ".", "Intrarenal", "compared", "with", "intravenous", "infusion", "of", "noradrenaline", "caused", "higher", "plasma", "noradrenaline", "concentrations", "and", "a", "shift", "of", "the", "plasma", "noradrenaline", "concentration", "-", "blood", "pressure", "effect", "curve", "towards", "lower", "plasma", "noradrenaline", "levels", ".", "These", "results", "suggest", "that", "hypertension", "after", "chronic", "intrarenal", "noradrenaline", "infusion", "is", "produced", "by", "relatively", "higher", "levels", "of", "circulating", "noradrenaline", "and", "by", "triggering", "of", "an", "additional", "intrarenal", "pressor", "mechanism", "."]], "ner": [[[9, 9, "Chemical"], [25, 25, "Chemical"], [68, 68, "Chemical"], [88, 88, "Chemical"], [92, 92, "Chemical"], [100, 100, "Chemical"], [110, 110, "Chemical"], [121, 121, "Chemical"], [131, 131, "Chemical"], [70, 70, "Disease"], [117, 117, "Disease"], [15, 16, "Chemical"]]], "relations": [[[9, 9, 70, 70, "CID"], [9, 9, 117, 117, "CID"], [25, 25, 70, 70, "CID"], [25, 25, 117, 117, "CID"], [68, 68, 70, 70, "CID"], [68, 68, 117, 117, "CID"], [88, 88, 70, 70, "CID"], [88, 88, 117, 117, "CID"], [92, 92, 70, 70, "CID"], [92, 92, 117, 117, "CID"], [100, 100, 70, 70, "CID"], [100, 100, 117, 117, "CID"], [110, 110, 70, 70, "CID"], [110, 110, 117, 117, "CID"], [121, 121, 70, 70, "CID"], [121, 121, 117, 117, "CID"], [131, 131, 70, 70, "CID"], [131, 131, 117, 117, "CID"]]], "clusters": [], "translated": "清醒大鼠慢性低剂量肾内<0>去甲肾上腺素</0>输注的血压反应。<11>氯化钠</11>溶液 (0.9%) 或以4, 12和36微克h-1kg-1的剂量连续输注五天,<1>去甲肾上腺素</1>或者肾内 (通过一种新技术)或静脉注射到去除一个肾脏的大鼠体内。肾内输注<2>去甲肾上腺素</2>会导致<9>高血压</9>，而静脉输注时不会引起高血压。与静脉输注<3>去甲肾上腺素</3>相比，肾内输注引起更高的血浆<4>去甲肾上腺素</4>浓度和血浆<5>去甲肾上腺素</5>浓度-血压效应曲线向较低血浆<6>去甲肾上腺素</6>水平。这些结果表明，慢性肾内<7>去甲肾上腺素</7>输注后的<10>高血压</10>是由相对较高水平的循环<8>去甲肾上腺素</8>和触发额外的肾内升压机制引起的。", "revised": true}
{"doc_key": "891050", "sentences": [["Late", "recovery", "of", "renal", "function", "in", "a", "woman", "with", "the", "hemolytic", "uremic", "syndrome", ".", "A", "case", "is", "reported", "of", "the", "hemolytic", "uremic", "syndrome", "(", "HUS", ")", "in", "a", "woman", "taking", "oral", "contraceptives", ".", "She", "was", "treated", "with", "heparin", ",", "dipyridamole", "and", "hemodialysis", ";", "and", "after", "more", "than", "three", "months", ",", "her", "urinary", "output", "rose", "above", "500", "ml", ";", "and", "six", "months", "after", "the", "onset", "of", "anuria", ",", "dialysis", "treatment", "was", "stopped", ".", "This", "case", "emphasizes", "the", "possibility", "that", "HUS", "in", "adults", "is", "not", "invariably", "irreversible", "and", "that", ",", "despite", "prolonged", "oliguria", ",", "recovery", "of", "renal", "function", "can", "be", "obtained", ".", "Therefore", ",", "in", "adult", "patients", "affected", "by", "HUS", ",", "dialysis", "should", "not", "be", "discontinued", "prematurely", ";", "moreover", ",", "bilateral", "nephrectomy", ",", "for", "treatment", "of", "severe", "hypertension", "and", "microangiopathic", "hemolytic", "anemia", ",", "should", "be", "performed", "with", "caution", "."]], "ner": [[[30, 31, "Chemical"], [10, 12, "Disease"], [20, 22, "Disease"], [24, 24, "Disease"], [78, 78, "Disease"], [107, 107, "Disease"], [37, 37, "Chemical"], [39, 39, "Chemical"], [65, 65, "Disease"], [90, 90, "Disease"], [125, 125, "Disease"], [127, 129, "Disease"]]], "relations": [[[30, 31, 10, 12, "CID"], [30, 31, 20, 22, "CID"], [30, 31, 24, 24, "CID"], [30, 31, 78, 78, "CID"], [30, 31, 107, 107, "CID"]]], "clusters": [], "translated": "患有<1>溶血性尿毒症综合征</1>的女性肾功能恢复较晚。据报道，一名服用<0>口服避孕药</0>的妇女发生了<2>溶血性尿毒症综合征</2> (<3>HUS</3>)。接受了<6>肝素</6>、<7>双嘧达莫</7>和血液透析治疗；三个多月后，她的尿量上升到500毫升以上；<8>无尿</8>发作六个月后，停止透析治疗。该病例强调了成人<4>HUS</4>并非总是不可逆的可能性，并且尽管<9>少尿</9>时间延长，肾功能仍可恢复。因此，在受<5>HUS</5>影响的成年患者中，不应过早停止透析；此外，双侧肾切除术，用于治疗严重<10>高血压</10>和<11>微血管病性溶血性贫血</11>，应谨慎进行。", "revised": true}
{"doc_key": "8319760", "sentences": [["Dup", "753", "prevents", "the", "development", "of", "puromycin", "aminonucleoside", "-", "induced", "nephrosis", ".", "The", "appearance", "of", "nephrotic", "syndromes", "such", "as", "proteinuria", ",", "hypoalbuminemia", ",", "hypercholesterolemia", "and", "increase", "in", "blood", "nitrogen", "urea", ",", "induced", "in", "rats", "by", "injection", "of", "puromycin", "aminonucleoside", "was", "markedly", "inhibited", "by", "oral", "administration", "of", "Dup", "753", "(", "losartan", ")", ",", "a", "novel", "angiotensin", "II", "receptor", "antagonist", ",", "at", "a", "dose", "of", "1", "or", "2", "mg", "/", "kg", "per", "day", ".", "The", "results", "suggest", "a", "possible", "involvement", "of", "the", "renin", "-", "angiotensin", "system", "in", "the", "development", "of", "puromycin", "aminonucleoside", "-", "induced", "nephrosis", "."]], "ner": [[[6, 7, "Chemical"], [37, 38, "Chemical"], [88, 89, "Chemical"], [15, 16, "Disease"], [19, 19, "Disease"], [21, 21, "Disease"], [23, 23, "Disease"], [0, 1, "Chemical"], [46, 47, "Chemical"], [49, 49, "Chemical"], [10, 10, "Disease"], [92, 92, "Disease"], [27, 29, "Chemical"], [54, 55, "Chemical"], [82, 82, "Chemical"]]], "relations": [[[6, 7, 15, 16, "CID"], [37, 38, 15, 16, "CID"], [88, 89, 15, 16, "CID"], [6, 7, 19, 19, "CID"], [37, 38, 19, 19, "CID"], [88, 89, 19, 19, "CID"], [6, 7, 21, 21, "CID"], [37, 38, 21, 21, "CID"], [88, 89, 21, 21, "CID"], [6, 7, 23, 23, "CID"], [37, 38, 23, 23, "CID"], [88, 89, 23, 23, "CID"]]], "clusters": [], "translated": "<7> Dup 753 </7> 可防止 <0> 嘌呤霉素氨基核苷 </0> 诱导的<10>肾病</10>的发展。出现<3>肾病综合征</3>，如<4>蛋白尿</4>、<5>低白蛋白血症</5>、<6>高胆固醇血症</6>和<12>血氮素升高</12>，在大鼠中注射<1>嘌呤霉素氨基核苷</1>可明显抑制口服<8> Dup 753 </8>(<9>洛卡新</9> )，一种新的<13>血管紧张素II</13>受体拮抗剂，剂量为每天1或2mg/kg。结果表明，肾素-<14>血管紧张素</14>系统可能参与<2>嘌呤霉素氨基核苷</2>诱导的<11>肾病</11>的发展。", "revised": true}
{"doc_key": "7453952", "sentences": [["Attenuation", "of", "the", "lithium", "-", "induced", "diabetes", "-", "insipidus", "-", "like", "syndrome", "by", "amiloride", "in", "rats", ".", "The", "effect", "of", "amiloride", "on", "lithium", "-", "induced", "polydipsia", "and", "polyuria", "and", "on", "the", "lithium", "concentration", "in", "the", "plasma", ",", "brain", ",", "kidney", ",", "thyroid", "and", "red", "blood", "cells", "was", "investigated", "in", "rats", ",", "chronically", "treated", "with", "LiCl", ".", "Amiloride", "reduced", "the", "drinking", "and", "urine", "volume", "of", "rats", "in", "an", "acute", "(", "6", "or", "12", "h", ")", "and", "a", "subacute", "(", "3", "days", ")", "experiment", ".", "6", "h", "after", "the", "administration", "of", "amiloride", ",", "a", "reduction", "was", "observed", "in", "the", "lithium", "content", "of", "the", "renal", "medulla", "but", "not", "in", "the", "other", "organs", "studied", ".", "At", "12", "h", ",", "all", "the", "tissues", "showed", "a", "slight", "increase", "in", "lithium", "levels", ".", "After", "3", "days", "of", "combined", "treatment", ",", "a", "marked", "elevation", "in", "plasma", "and", "tissue", "lithium", "levels", "accompanied", "a", "reduction", "in", "water", "intake", ".", "In", "all", "the", "experiments", ",", "the", "attenuation", "of", "the", "lithium", "-", "induced", "diabetes", "-", "insipidus", "-", "like", "syndrome", "by", "amiloride", "was", "accompanied", "by", "a", "reduction", "of", "the", "ratio", "between", "the", "lithium", "concentration", "in", "the", "renal", "medulla", "and", "its", "levels", "in", "the", "blood", "and", "an", "elevation", "in", "the", "plasma", "potassium", "level", ".", "It", "is", "concluded", "that", "acute", "amiloride", "administration", "to", "lithium", "-", "treated", "patients", "suffering", "from", "polydipsia", "and", "polyuria", "might", "relieve", "these", "patients", "but", "prolonged", "amiloride", "supplementation", "would", "result", "in", "elevated", "lithium", "levels", "and", "might", "be", "hazardous", "."]], "ner": [[[3, 3, "Chemical"], [22, 22, "Chemical"], [31, 31, "Chemical"], [97, 97, "Chemical"], [123, 123, "Chemical"], [140, 140, "Chemical"], [158, 158, "Chemical"], [179, 179, "Chemical"], [208, 208, "Chemical"], [229, 229, "Chemical"], [6, 11, "Disease"], [161, 166, "Disease"], [25, 25, "Disease"], [214, 214, "Disease"], [27, 27, "Disease"], [216, 216, "Disease"], [13, 13, "Chemical"], [20, 20, "Chemical"], [56, 56, "Chemical"], [89, 89, "Chemical"], [168, 168, "Chemical"], [205, 205, "Chemical"], [223, 223, "Chemical"], [54, 54, "Chemical"], [197, 197, "Chemical"]]], "relations": [[[3, 3, 6, 11, "CID"], [3, 3, 161, 166, "CID"], [22, 22, 6, 11, "CID"], [22, 22, 161, 166, "CID"], [31, 31, 6, 11, "CID"], [31, 31, 161, 166, "CID"], [97, 97, 6, 11, "CID"], [97, 97, 161, 166, "CID"], [123, 123, 6, 11, "CID"], [123, 123, 161, 166, "CID"], [140, 140, 6, 11, "CID"], [140, 140, 161, 166, "CID"], [158, 158, 6, 11, "CID"], [158, 158, 161, 166, "CID"], [179, 179, 6, 11, "CID"], [179, 179, 161, 166, "CID"], [208, 208, 6, 11, "CID"], [208, 208, 161, 166, "CID"], [229, 229, 6, 11, "CID"], [229, 229, 161, 166, "CID"]]], "clusters": [], "translated": "<16>阿米洛利</16>对大鼠<0>锂</0>诱导的<10>尿崩症样综合征</10>的减弱作用。<17>阿米洛利</17>对<1>锂</1>诱发的<12>烦渴</12>和<14>多尿</14>以及<2>锂</2>的影响在用<23>LiCl</23>长期治疗的大鼠中研究了血浆、脑、肾、甲状腺和红细胞中的浓度。<18>阿米洛利</18>在急性（6或12小时）和亚急性（3天）实验中减少大鼠的饮水量和尿量。服用<19>阿米洛利</19> 6小时后，观察到<3>肾髓质</3>的<4>锂</4>含量减少，但在其他研究器官中没有观察到。12小时后，所有组织的<4>锂</4>水平均略有升高。联合治疗3天后，血浆和组织<5>锂</5>水平显着升高，同时水摄入量减少。在所有实验中，<20>阿米洛利</20>对<6>锂</6>诱导的<11>尿崩症样综合征</11>的减弱伴随着两者之间比率的降低，<7>肾髓质</7>中的<3>锂</3>浓度及其在血液中的水平以及血浆中<24>钾</24>水平的升高。得出的结论是，急性<21>阿米洛利</21>给予<8>锂</8>-治疗患有<13>烦渴</13>和<15>多尿</15>的患者可能会缓解这些症状，但长期补充<22>阿米洛利</22>会导致<9>锂</9>水平升高，并且可能是危险的。", "revised": true}
{"doc_key": "7088431", "sentences": [["Development", "of", "clear", "cell", "adenocarcinoma", "in", "DES", "-", "exposed", "offspring", "under", "observation", ".", "Two", "cases", "of", "clear", "cell", "adenocarcinoma", "of", "the", "vagina", "detected", "at", "follow", "-", "up", "in", "young", "women", "exposed", "in", "utero", "to", "diethylstilbestrol", "are", "reported", ".", "One", "patient", ",", "aged", "23", ",", "had", "been", "followed", "for", "2", "years", "before", "carcinoma", "was", "diagnosed", ";", "the", "second", "patient", ",", "aged", "22", ",", "had", "been", "seen", "on", "a", "regular", "basis", "for", "5", "years", ",", "8", "months", ".", "In", "both", "instances", ",", "suspicion", "of", "the", "presence", "of", "carcinoma", "was", "aroused", "by", "the", "palpation", "of", "a", "small", "nodule", "in", "the", "vaginal", "fornix", ".", "Hysterosalpingography", "was", "performed", "on", "both", "patients", "and", ",", "in", "1", "instance", ",", "an", "abnormal", "x", "-", "ray", "film", "was", "reflected", "by", "the", "gross", "appearance", "of", "the", "uterine", "cavity", "found", "in", "the", "surgical", "specimen", "."]], "ner": [[[6, 6, "Chemical"], [34, 34, "Chemical"], [2, 4, "Disease"], [16, 21, "Disease"], [51, 51, "Disease"], [85, 85, "Disease"]]], "relations": [[[6, 6, 2, 4, "CID"], [6, 6, 16, 21, "CID"], [34, 34, 2, 4, "CID"], [34, 34, 16, 21, "CID"]]], "clusters": [], "translated": "<0>DES</0>暴露后代发生<2>透明细胞腺癌</2>的观察。据报道，在子宫内暴露于<1> 己烯雌酚</1>的年轻女性中，有两例<3>阴道透明细胞腺癌</3>的随访发现。1例患者，23岁，随访2年，确诊<4>癌</4>；第二位患者，22岁，已定期就诊5年零8个月。在这两种情况下，都怀疑存在<5>癌</5>，原因是触诊阴道穹隆处有一个小结节。对这两名患者均进行了子宫输卵管造影术，在1例患者中，异常的X射线胶片反映在手术标本中子宫腔的大体外观上。", "revised": true}
{"doc_key": "2355241", "sentences": [["Cause", "of", "death", "among", "patients", "with", "Parkinson", "'s", "disease", ":", "a", "rare", "mortality", "due", "to", "cerebral", "haemorrhage", ".", "Causes", "of", "death", ",", "with", "special", "reference", "to", "cerebral", "haemorrhage", ",", "among", "240", "patients", "with", "pathologically", "verified", "Parkinson", "'s", "disease", "were", "investigated", "using", "the", "Annuals", "of", "the", "Pathological", "Autopsy", "Cases", "in", "Japan", "from", "1981", "to", "1985", ".", "The", "leading", "causes", "of", "death", "were", "pneumonia", "and", "bronchitis", "(", "44", ".", "1", "%", ")", ",", "malignant", "neoplasms", "(", "11", ".", "6", "%", ")", ",", "heart", "diseases", "(", "4", ".", "1", "%", ")", ",", "cerebral", "infarction", "(", "3", ".", "7", "%", ")", "and", "septicaemia", "(", "3", ".", "3", "%", ")", ".", "Cerebral", "haemorrhage", "was", "the", "11th", "most", "frequent", "cause", "of", "death", ",", "accounting", "for", "only", "0", ".", "8", "%", "of", "deaths", "among", "the", "patients", ",", "whereas", "it", "was", "the", "5th", "most", "common", "cause", "of", "death", "among", "the", "Japanese", "general", "population", "in", "1985", ".", "The", "low", "incidence", "of", "cerebral", "haemorrhage", "as", "a", "cause", "of", "death", "in", "patients", "with", "Parkinson", "'s", "disease", "may", "reflect", "the", "hypotensive", "effect", "of", "levodopa", "and", "a", "hypotensive", "mechanism", "due", "to", "reduced", "noradrenaline", "levels", "in", "the", "parkinsonian", "brain", "."]], "ner": [[[171, 171, "Chemical"], [168, 168, "Disease"], [174, 174, "Disease"], [2, 2, "Disease"], [20, 20, "Disease"], [59, 59, "Disease"], [115, 115, "Disease"], [125, 125, "Disease"], [139, 139, "Disease"], [158, 158, "Disease"], [179, 179, "Chemical"], [6, 8, "Disease"], [35, 37, "Disease"], [162, 164, "Disease"], [183, 183, "Disease"], [15, 16, "Disease"], [26, 27, "Disease"], [106, 107, "Disease"], [152, 153, "Disease"], [61, 61, "Disease"], [63, 63, "Disease"], [72, 72, "Disease"], [80, 81, "Disease"], [89, 90, "Disease"], [98, 98, "Disease"]]], "relations": [[[171, 171, 168, 168, "CID"], [171, 171, 174, 174, "CID"]]], "clusters": [], "translated": "<11>帕金森病</11>患者<3>死亡</3>的原因：<15>脑出血</15>引起的罕见死亡。<4>死亡</4>的原因，特别是<16>脑出血</16>，在 240 名经病理学证实为<12>帕金森氏病</12>的患者中，使用1981年至1985年的《日本病理尸检年鉴》进行了调查。 <5>死亡</5> 的主要原因是 <19>肺炎</19> 和 <20>支气管炎</20>（44.1%），恶性<21>肿瘤</21>（11.6%）、<22>心脏病</22>（4.1%）、<23>脑梗塞</23>（3.7%）和<24>败血症</24>（3.3%）。<17>脑出血</17>是<6>死亡</6>的第 11 位最常见原因，仅占 0.8% 的<7>患者死亡</7>，而在1985年，它是日本普通人群中<8>死亡</8>的第 5 大最常见原因。<18>脑出血</18>作为<13>帕金森病</13>患者<9>死亡</9>的低发生率可能反映了<0>左旋多巴</0>的<1>降压</1>作用和由于<14>帕金森病</14>大脑中<10>去甲肾上腺素</10>水平降低的<2>低血压</2>机制。", "revised": true}
{"doc_key": "8649546", "sentences": [["Improvement", "of", "levodopa", "-", "induced", "dyskinesia", "by", "propranolol", "in", "Parkinson", "'s", "disease", ".", "Seven", "patients", "suffering", "from", "Parkinson", "'s", "disease", "(", "PD", ")", "with", "severely", "disabling", "dyskinesia", "received", "low", "-", "dose", "propranolol", "as", "an", "adjunct", "to", "the", "currently", "used", "medical", "treatment", ".", "There", "was", "a", "significant", "40", "%", "improvement", "in", "the", "dyskinesia", "score", "without", "increase", "of", "parkinsonian", "motor", "disability", ".", "Ballistic", "and", "choreic", "dyskinesia", "were", "markedly", "ameliorated", ",", "whereas", "dystonia", "was", "not", ".", "This", "study", "suggests", "that", "administration", "of", "low", "doses", "of", "beta", "-", "blockers", "may", "improve", "levodopa", "-", "induced", "ballistic", "and", "choreic", "dyskinesia", "in", "PD", "."]], "ner": [[[2, 2, "Chemical"], [87, 87, "Chemical"], [5, 5, "Disease"], [26, 26, "Disease"], [51, 51, "Disease"], [63, 63, "Disease"], [93, 93, "Disease"], [9, 11, "Disease"], [17, 19, "Disease"], [21, 21, "Disease"], [56, 56, "Disease"], [95, 95, "Disease"], [57, 58, "Disease"], [69, 69, "Disease"], [7, 7, "Chemical"], [31, 31, "Chemical"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 26, 26, "CID"], [2, 2, 51, 51, "CID"], [2, 2, 63, 63, "CID"], [2, 2, 93, 93, "CID"], [87, 87, 5, 5, "CID"], [87, 87, 26, 26, "CID"], [87, 87, 51, 51, "CID"], [87, 87, 63, 63, "CID"], [87, 87, 93, 93, "CID"]]], "clusters": [], "translated": "<7>帕金森病</7><14>普萘洛尔</14>改善<0>左旋多巴</0>引起的<2>运动障碍</2>。七名患有<8>帕金森氏病</8> (<9>PD</9>) 并伴有严重致残性<3>运动障碍</3>的患者接受低剂量<15>普萘洛尔</15>作为辅助目前使用的药物治疗。<4>运动障碍</4>评分有40%的显着改善，而<10>帕金森病</10><12>运动障碍</12>没有增加。弹道性和舞蹈症<5>运动障碍</5>得到显着改善，而<13>肌张力障碍</13>则没有。该研究表明，给予低剂量的β受体阻滞剂可能会改善<1>左旋多巴</1>诱发的弹道和舞蹈病<6>运动障碍</6>。<11>PD</11>。", "revised": true}
{"doc_key": "7802851", "sentences": [["Safety", "and", "side", "-", "effects", "of", "alprazolam", ".", "Controlled", "study", "in", "agoraphobia", "with", "panic", "disorder", ".", "BACKGROUND", ":", "The", "widespread", "use", "of", "benzodiazepines", "has", "led", "to", "increasing", "recognition", "of", "their", "unwanted", "effects", ".", "The", "efficacy", "of", "alprazolam", "and", "placebo", "in", "panic", "disorder", "with", "agoraphobia", ",", "and", "the", "side", "-", "effect", "and", "adverse", "effect", "profiles", "of", "both", "drug", "groups", "were", "measured", ".", "METHOD", ":", "In", "London", "and", "Toronto", "154", "patients", "who", "met", "DSM", "-", "III", "criteria", "for", "panic", "disorder", "with", "agoraphobia", "were", "randomised", "to", "alprazolam", "or", "placebo", ".", "Subjects", "in", "each", "drug", "group", "also", "received", "either", "exposure", "or", "relaxation", ".", "Treatment", "was", "from", "weeks", "0", "to", "8", "and", "was", "then", "tapered", "from", "weeks", "8", "to", "16", ".", "RESULTS", ":", "Mean", "alprazolam", "dose", "was", "5", "mg", "daily", ".", "Compared", "with", "placebo", "subjects", ",", "alprazolam", "patients", "developed", "more", "adverse", "reactions", "(", "21", "%", "v", ".", "0", "%", ")", "of", "depression", ",", "enuresis", ",", "disinhibition", "and", "aggression", ";", "and", "more", "side", "-", "effects", ",", "particularly", "sedation", ",", "irritability", ",", "impaired", "memory", ",", "weight", "loss", "and", "ataxia", ".", "Side", "-", "effects", "tended", "to", "diminish", "during", "treatment", "but", "remained", "significant", "at", "week", "8", ".", "Despite", "this", ",", "the", "drop", "-", "out", "rate", "was", "low", ".", "CONCLUSIONS", ":", "Alprazolam", "caused", "side", "-", "effects", "and", "adverse", "effects", "during", "treatment", "but", "many", "patients", "were", "willing", "to", "accept", "these", "."]], "ner": [[[6, 6, "Chemical"], [36, 36, "Chemical"], [83, 83, "Chemical"], [119, 119, "Chemical"], [131, 131, "Chemical"], [201, 201, "Chemical"], [146, 146, "Disease"], [148, 148, "Disease"], [165, 166, "Disease"], [168, 169, "Disease"], [171, 171, "Disease"], [11, 11, "Disease"], [43, 43, "Disease"], [79, 79, "Disease"], [13, 14, "Disease"], [40, 41, "Disease"], [76, 77, "Disease"], [152, 152, "Disease"], [163, 163, "Disease"], [22, 22, "Chemical"]]], "relations": [[[6, 6, 146, 146, "CID"], [36, 36, 146, 146, "CID"], [83, 83, 146, 146, "CID"], [119, 119, 146, 146, "CID"], [131, 131, 146, 146, "CID"], [201, 201, 146, 146, "CID"], [6, 6, 148, 148, "CID"], [36, 36, 148, 148, "CID"], [83, 83, 148, 148, "CID"], [119, 119, 148, 148, "CID"], [131, 131, 148, 148, "CID"], [201, 201, 148, 148, "CID"], [6, 6, 165, 166, "CID"], [36, 36, 165, 166, "CID"], [83, 83, 165, 166, "CID"], [119, 119, 165, 166, "CID"], [131, 131, 165, 166, "CID"], [201, 201, 165, 166, "CID"], [6, 6, 168, 169, "CID"], [36, 36, 168, 169, "CID"], [83, 83, 168, 169, "CID"], [119, 119, 168, 169, "CID"], [131, 131, 168, 169, "CID"], [201, 201, 168, 169, "CID"], [6, 6, 171, 171, "CID"], [36, 36, 171, 171, "CID"], [83, 83, 171, 171, "CID"], [119, 119, 171, 171, "CID"], [131, 131, 171, 171, "CID"], [201, 201, 171, 171, "CID"]]], "clusters": [], "translated": "<0>阿普唑仑</0>的安全性和副作用。<11>广场恐惧症</11>伴有<14>恐慌症</14>的对照研究。背景：<19>苯二氮卓类药物</19>的广泛使用导致人们越来越多地认识到它们的副作用。在<15>恐慌症</15>伴有<12>广场恐惧症</12>方面，<1>阿普唑仑</1>和安慰剂的疗效，以及两个药物组的副作用和不良反应概况进行了测量。方法：在伦敦和多伦多，154名符合 DSM - III 标准的<16>恐慌症</16>伴有<13>广场恐惧症</13>的患者被随机分配到<2>阿普唑仑</2>或安慰剂组。每个药物组的受试者也接受了暴露或放松。治疗从第0周到第8周，然后从第8周到第16周逐渐减量。结果：<3>阿普唑仑</3>的平均剂量为每天5毫克。与安慰剂组相比，使用<4>阿普唑仑</4>的患者出现更多的不良反应（21%对0%）， 包括<6>抑郁</6>、<7>遗尿</7>、脱抑制和<17>侵略</17>等; 以及更多的副作用，特别是镇静，<18>易怒</18>、<8>记忆力减退</8>、<9>体重减轻</9>和<10>共济失调</10>。在治疗期间，副作用趋于减少，但在第8周仍然很明显。尽管如此，辍学率是很低的。结论：在治疗过程中，<5>阿普唑仑</5>会产生副作用和不良反应，但很多患者愿意接受这种情况。", "revised": true}
{"doc_key": "6747681", "sentences": [["Intra", "-", "arterial", "BCNU", "chemotherapy", "for", "treatment", "of", "malignant", "gliomas", "of", "the", "central", "nervous", "system", ".", "Because", "of", "the", "rapid", "systemic", "clearance", "of", "BCNU", "(", "1", ",", "3", "-", "bis", "-", "(", "2", "-", "chloroethyl", ")", "-", "1", "-", "nitrosourea", ")", ",", "intra", "-", "arterial", "administration", "should", "provide", "a", "substantial", "advantage", "over", "intravenous", "administration", "for", "the", "treatment", "of", "malignant", "gliomas", ".", "Thirty", "-", "six", "patients", "were", "treated", "with", "BCNU", "every", "6", "to", "8", "weeks", ",", "either", "by", "transfemoral", "catheterization", "of", "the", "internal", "carotid", "or", "vertebral", "artery", "or", "through", "a", "fully", "implantable", "intracarotid", "drug", "delivery", "system", ",", "beginning", "with", "a", "dose", "of", "200", "mg", "/", "sq", "m", "body", "surface", "area", ".", "Twelve", "patients", "with", "Grade", "III", "or", "IV", "astrocytomas", "were", "treated", "after", "partial", "resection", "of", "the", "tumor", "without", "prior", "radiation", "therapy", ".", "After", "two", "to", "seven", "cycles", "of", "chemotherapy", ",", "nine", "patients", "showed", "a", "decrease", "in", "tumor", "size", "and", "surrounding", "edema", "on", "contrast", "-", "enhanced", "computerized", "tomography", "scans", ".", "In", "the", "nine", "responders", ",", "median", "duration", "of", "chemotherapy", "response", "from", "the", "time", "of", "operation", "was", "25", "weeks", "(", "range", "12", "to", "more", "than", "91", "weeks", ")", ".", "The", "median", "duration", "of", "survival", "in", "the", "12", "patients", "was", "54", "weeks", "(", "range", "21", "to", "more", "than", "156", "weeks", ")", ",", "with", "an", "18", "-", "month", "survival", "rate", "of", "42", "%", ".", "Twenty", "-", "four", "patients", "with", "recurrent", "Grade", "I", "to", "IV", "astrocytomas", ",", "whose", "resection", "and", "irradiation", "therapy", "had", "failed", ",", "received", "two", "to", "eight", "courses", "of", "intra", "-", "arterial", "BCNU", "therapy", ".", "Seventeen", "of", "these", "had", "a", "response", "or", "were", "stable", "for", "a", "median", "of", "20", "weeks", "(", "range", "6", "to", "more", "than", "66", "weeks", ")", ".", "The", "catheterization", "procedure", "is", "safe", ",", "with", "no", "immediate", "complication", "in", "111", "infusions", "of", "BCNU", ".", "A", "delayed", "complication", "in", "nine", "patients", "has", "been", "unilateral", "loss", "of", "vision", "secondary", "to", "a", "retinal", "vasculitis", ".", "The", "frequency", "of", "visual", "loss", "decreased", "after", "the", "concentration", "of", "the", "ethanol", "diluent", "was", "lowered", "."]], "ner": [[[3, 3, "Chemical"], [23, 23, "Chemical"], [25, 39, "Chemical"], [68, 68, "Chemical"], [248, 248, "Chemical"], [290, 290, "Chemical"], [307, 308, "Disease"], [8, 9, "Disease"], [58, 59, "Disease"], [117, 117, "Disease"], [229, 229, "Disease"], [125, 125, "Disease"], [145, 145, "Disease"], [149, 149, "Disease"], [301, 303, "Disease"], [313, 314, "Disease"], [321, 321, "Chemical"]]], "relations": [[[3, 3, 307, 308, "CID"], [23, 23, 307, 308, "CID"], [25, 39, 307, 308, "CID"], [68, 68, 307, 308, "CID"], [248, 248, 307, 308, "CID"], [290, 290, 307, 308, "CID"]]], "clusters": [], "translated": "动脉内<0>BCNU</0>化疗治疗中枢神经系统<7>恶性胶质瘤</7>。由于<1>BCNU</1>（<2>1,3-双（2-氯乙基）-1-亚硝基脲</2>）的快速全身清除，动脉内给药应提供显着优势，用于治疗<8>恶性胶质瘤</8>。36名患者每6至8周接受<3>BCNU</3>治疗，通过经股动脉经颈内动脉或椎动脉插管或通过完全可植入的颈内动脉给药系统，起始剂量为200 mg/平方米体表面积。12名患有III级或IV级<9>星形细胞瘤</9>的患者在部分切除<11>肿瘤</11>后接受了治疗，之前未接受过放射治疗。在2到7个化疗周期后，9名患者在增强计算机断层扫描中显示<12>肿瘤</12>的大小和周围<13>水肿</13>缩小。在9名反应者中，从手术开始化疗反应的中位持续时间为25周（范围从12到超过91周）。12名患者的中位生存期为54周（范围为21周至超过156周），18个月生存率为42%。24例复发的I-IV级<10>星形细胞瘤</10>患者，其切除和放疗均失败，接受了2-8个疗程的动脉内<4>BCNU</4>治疗。其中17个有反应或在中位数20周（范围6到超过66周）内保持稳定。插管过程安全，<5>BCNU</5> 111次输注无即刻并发症。9名患者的迟发并发症是继发于<6>视网膜血管炎</6>的单侧<14>视力丧失</14>。降低<16>乙醇</16>稀释剂的浓度后，<15>视力丧失</15>的频率降低。", "revised": true}
{"doc_key": "8386779", "sentences": [["Sodium", "bicarbonate", "alleviates", "penile", "pain", "induced", "by", "intracavernous", "injections", "for", "erectile", "dysfunction", ".", "In", "an", "attempt", "to", "determine", "whether", "penile", "pain", "associated", "with", "intracorporeal", "injections", "could", "be", "due", "to", "the", "acidity", "of", "the", "medication", ",", "we", "performed", "a", "randomized", "study", "comparing", "the", "incidence", "of", "penile", "pain", "following", "intracorporeal", "injections", "with", "or", "without", "the", "addition", "of", "sodium", "bicarbonate", "to", "the", "intracorporeal", "medications", ".", "A", "total", "of", "38", "consecutive", "patients", "who", "presented", "to", "our", "clinic", "with", "impotence", "received", "0", ".", "2", "ml", ".", "of", "a", "combination", "of", "3", "drugs", ":", "6", "mg", ".", "papaverine", ",", "100", "micrograms", ".", "phentolamine", "and", "10", "micrograms", ".", "prostaglandin", "E1", "with", "(", "pH", "7", ".", "05", ")", "or", "without", "(", "pH", "4", ".", "17", ")", "the", "addition", "of", "sodium", "bicarbonate", "(", "0", ".", "03", "mEq", ".", ")", ".", "Of", "the", "19", "patients", "without", "sodium", "bicarbonate", "added", "to", "the", "medication", "11", "(", "58", "%", ")", "complained", "of", "penile", "pain", "due", "to", "the", "medication", ",", "while", "only", "1", "of", "the", "19", "men", "(", "5", "%", ")", "who", "received", "sodium", "bicarbonate", "complained", "of", "penile", "pain", ".", "From", "these", "data", "we", "conclude", "that", "the", "penile", "pain", "following", "intracorporeal", "injections", "is", "most", "likely", "due", "to", "the", "acidity", "of", "the", "medication", ",", "which", "can", "be", "overcome", "by", "elevating", "the", "pH", "to", "a", "neutral", "level", "."]], "ner": [[[96, 96, "Chemical"], [3, 4, "Disease"], [19, 20, "Disease"], [44, 45, "Disease"], [149, 150, "Disease"], [173, 174, "Disease"], [183, 184, "Disease"], [101, 102, "Chemical"], [0, 1, "Chemical"], [55, 56, "Chemical"], [121, 122, "Chemical"], [136, 137, "Chemical"], [169, 170, "Chemical"], [10, 11, "Disease"], [74, 74, "Disease"], [91, 91, "Chemical"]]], "relations": [[[96, 96, 3, 4, "CID"], [96, 96, 19, 20, "CID"], [96, 96, 44, 45, "CID"], [96, 96, 149, 150, "CID"], [96, 96, 173, 174, "CID"], [96, 96, 183, 184, "CID"], [101, 102, 3, 4, "CID"], [101, 102, 19, 20, "CID"], [101, 102, 44, 45, "CID"], [101, 102, 149, 150, "CID"], [101, 102, 173, 174, "CID"], [101, 102, 183, 184, "CID"]]], "clusters": [], "translated": " <8>碳酸氢钠</8>减轻因<13>勃起功能障碍</13>海绵体内注射引起的<1>阴茎疼痛</1>。为了确定与体内注射相关的<2>阴茎疼痛</2>是否是由药物的酸度引起的，我们进行了一项随机研究，比较了体内注射后<3>阴茎疼痛</3>的发生率在体内药物中添加或不添加<9>碳酸氢钠</9>。共有38名因<14>阳痿</14>就诊于我们诊所的连续患者接受了0.2毫升。3种药物的组合：6毫克。<15>罂粟碱</15>，100微克。<0>酚妥拉明</0>和10微克。<7>前列腺素E1</7> 添加（pH 7.05）或不添加（pH 4.17）<10>碳酸氢钠</10>（0.03 mEq.）。未在药物中添加<11>碳酸氢钠</11>的19名患者中，有11名（58%）主诉因药物引起的<4>阴茎疼痛</4>，而19名男性中只有1名（5%）接受<12>碳酸氢钠</12>治疗的患者抱怨<5>阴茎疼痛</5>。根据这些数据，我们得出结论，体内注射后的<6>阴茎疼痛</6>很可能是由于药物的酸度所致，这可以通过将pH值升高至中性水平来克服。", "revised": true}
{"doc_key": "7248170", "sentences": [["Phenobarbitone", "-", "induced", "enlargement", "of", "the", "liver", "in", "the", "rat", ":", "its", "relationship", "to", "carbon", "tetrachloride", "-", "induced", "cirrhosis", ".", "The", "yield", "of", "severe", "cirrhosis", "of", "the", "liver", "(", "defined", "as", "a", "shrunken", "finely", "nodular", "liver", "with", "micronodular", "histology", ",", "ascites", "greater", "than", "30", "ml", ",", "plasma", "albumin", "less", "than", "2", ".", "2", "g", "/", "dl", ",", "splenomegaly", "2", "-", "3", "times", "normal", ",", "and", "testicular", "atrophy", "approximately", "half", "normal", "weight", ")", "after", "12", "doses", "of", "carbon", "tetrachloride", "given", "intragastrically", "in", "the", "phenobarbitone", "-", "primed", "rat", "was", "increased", "from", "25", "%", "to", "56", "%", "by", "giving", "the", "initial", "\"", "calibrating", "\"", "dose", "of", "carbon", "tetrachloride", "at", "the", "peak", "of", "the", "phenobarbitone", "-", "induced", "enlargement", "of", "the", "liver", ".", "At", "this", "point", "it", "was", "assumed", "that", "the", "cytochrome", "P450", "/", "CCl4", "toxic", "state", "was", "both", "maximal", "and", "stable", ".", "The", "optimal", "rat", "size", "to", "begin", "phenobarbitone", "was", "determined", "as", "100", "g", ",", "and", "this", "size", "as", "a", "group", "had", "a", "mean", "maximum", "relative", "liver", "weight", "increase", "47", "%", "greater", "than", "normal", "rats", "of", "the", "same", "body", "weight", ".", "The", "optimal", "time", "for", "the", "initial", "dose", "of", "carbon", "tetrachloride", "was", "after", "14", "days", "on", "phenobarbitone", "."]], "ner": [[[0, 0, "Chemical"], [82, 82, "Chemical"], [110, 110, "Chemical"], [144, 144, "Chemical"], [192, 192, "Chemical"], [3, 6, "Disease"], [113, 116, "Disease"], [24, 27, "Disease"], [14, 15, "Chemical"], [76, 77, "Chemical"], [103, 104, "Chemical"], [129, 129, "Chemical"], [185, 186, "Chemical"], [18, 18, "Disease"], [40, 40, "Disease"], [57, 57, "Disease"], [66, 66, "Disease"]]], "relations": [[[0, 0, 3, 6, "CID"], [0, 0, 113, 116, "CID"], [82, 82, 3, 6, "CID"], [82, 82, 113, 116, "CID"], [110, 110, 3, 6, "CID"], [110, 110, 113, 116, "CID"], [144, 144, 3, 6, "CID"], [144, 144, 113, 116, "CID"], [192, 192, 3, 6, "CID"], [192, 192, 113, 116, "CID"], [0, 0, 24, 27, "CID"], [82, 82, 24, 27, "CID"], [110, 110, 24, 27, "CID"], [144, 144, 24, 27, "CID"], [192, 192, 24, 27, "CID"], [14, 15, 24, 27, "CID"], [76, 77, 24, 27, "CID"], [103, 104, 24, 27, "CID"], [129, 129, 24, 27, "CID"], [185, 186, 24, 27, "CID"]]], "clusters": [], "translated": "<0>苯巴比妥</0>引起的大鼠<5>肝脏肿大</5>：与<8>四氯化碳</8>引起的<13>肝硬化</13>的关系。严重<7>肝硬化</7>的产量（定义为一个肝脏缩小、质地细小颗粒、<14>腹水</14>大于30ml、<15>脾肿大</15>2-3倍于正常、血浆白蛋白低于2.2g/dl、<16>睾丸萎缩</16>大约是正常重量的一半）在100g的<1>苯巴比妥</1>预处理的大鼠中，在经历了<2>苯巴比妥</2>引起的<6>肝脏肿大</6>的巅峰后，通过在第一次 '标定' 剂量的<10>四氯化碳</10>注入后的增加，由于在这个时候细胞色素 P450 / <11> CCl4</11> 的毒性状态是最大的，相对于只服用<9>四氯化碳</9>的大鼠，增加了从25%到56%（给予12剂<9>四氯化碳</9>）。最佳<3>苯巴比妥</3>初次剂量应在服用<4>苯巴比妥</4>14天后进行注入。<12>四氯化碳</12>的最好剂量是在 <4>苯巴比妥</4> 接种14天后。", "revised": true}
{"doc_key": "9199746", "sentences": [["Macula", "toxicity", "after", "intravitreal", "amikacin", ".", "BACKGROUND", ":", "Although", "intravitreal", "aminoglycosides", "have", "substantially", "improved", "visual", "prognosis", "in", "endophthalmitis", ",", "macular", "infarction", "may", "impair", "full", "visual", "recovery", ".", "METHODS", ":", "We", "present", "a", "case", "of", "presumed", "amikacin", "retinal", "toxicity", "following", "treatment", "with", "amikacin", "and", "vancomycin", "for", "alpha", "-", "haemolytic", "streptococcal", "endophthalmitis", ".", "RESULTS", ":", "Endophthalmitis", "resolved", "with", "improvement", "in", "visual", "acuity", "to", "6", "/", "24", "at", "three", "months", ".", "Fundus", "fluorescein", "angiography", "confirmed", "macular", "capillary", "closure", "and", "telangiectasis", ".", "CONCLUSIONS", ":", "Currently", "accepted", "intravitreal", "antibiotic", "regimens", "may", "cause", "retinal", "toxicity", "and", "macular", "ischaemia", ".", "Treatment", "strategies", "aimed", "at", "avoiding", "retinal", "toxicity", "are", "discussed", "."]], "ner": [[[4, 4, "Chemical"], [35, 35, "Chemical"], [41, 41, "Chemical"], [36, 37, "Disease"], [87, 88, "Disease"], [98, 99, "Disease"], [91, 91, "Disease"], [1, 1, "Disease"], [10, 10, "Chemical"], [43, 43, "Chemical"], [69, 69, "Chemical"], [17, 17, "Disease"], [53, 53, "Disease"], [20, 20, "Disease"], [48, 49, "Disease"], [76, 76, "Disease"]]], "relations": [[[4, 4, 36, 37, "CID"], [4, 4, 87, 88, "CID"], [4, 4, 98, 99, "CID"], [35, 35, 36, 37, "CID"], [35, 35, 87, 88, "CID"], [35, 35, 98, 99, "CID"], [41, 41, 36, 37, "CID"], [41, 41, 87, 88, "CID"], [41, 41, 98, 99, "CID"], [4, 4, 91, 91, "CID"], [35, 35, 91, 91, "CID"], [41, 41, 91, 91, "CID"]]], "clusters": [], "translated": "玻璃体内注射<0>阿米卡星</0>后的黄斑<7>毒性</7>。背景：虽然玻璃体内注射<8>氨基糖苷类药物</8>可显着改善<11>眼内炎</11>患者的视力预后，但黄斑<13>梗死</13>可能会影响视力的完全恢复。方法：我们提出了一个假定<1>阿米卡星</1><3>视网膜毒性</3>的病例，该病例在使用<2>阿米卡星</2>和<9>万古霉素</9>治疗α- 溶血<14>链球菌性眼内炎</14>。结果：<12>眼内炎</12>随着视力在三个月时提高到6/24而得到解决。眼底<10>荧光素</10>血管造影证实黄斑毛细血管闭合和<15>毛细血管扩张</15>。结论：目前公认的玻璃体内抗生素治疗方案可能引起<4>视网膜毒性</4>和黄斑部<6>缺血</6>。讨论了旨在避免<5>视网膜毒性</5>的治疗策略。", "revised": true}
{"doc_key": "8421099", "sentences": [["Prospective", "study", "of", "the", "long", "-", "term", "effects", "of", "somatostatin", "analog", "(", "octreotide", ")", "on", "gallbladder", "function", "and", "gallstone", "formation", "in", "Chinese", "acromegalic", "patients", ".", "This", "article", "reports", "the", "changes", "in", "gallbladder", "function", "examined", "by", "ultrasonography", "in", "20", "Chinese", "patients", "with", "active", "acromegaly", "treated", "with", "sc", "injection", "of", "the", "somatostatin", "analog", "octreotide", "in", "dosages", "of", "300", "-", "1500", "micrograms", "/", "day", "for", "a", "mean", "of", "24", ".", "2", "+", "/", "-", "13", ".", "9", "months", ".", "During", "treatment", "with", "octreotide", ",", "17", "patients", "developed", "sludge", ",", "10", "had", "gallstones", ",", "and", "1", "developed", "acute", "cholecystitis", "requiring", "surgery", ".", "In", "all", "of", "7", "patients", "examined", "acutely", ",", "gallbladder", "contractility", "was", "inhibited", "after", "a", "single", "100", "-", "micrograms", "injection", ".", "In", "8", "patients", "followed", "for", "24", "weeks", ",", "gallbladder", "contractility", "remained", "depressed", "throughout", "therapy", ".", "After", "withdrawal", "of", "octreotide", "in", "10", "patients", "without", "gallstones", ",", "8", "patients", "assessed", "had", "return", "of", "normal", "gallbladder", "contractility", "within", "1", "month", ".", "In", "8", "of", "the", "remaining", "10", "patients", "who", "developed", "gallstones", "during", "treatment", ",", "gallbladder", "contractility", "normalized", "in", "5", "patients", "(", "3", "of", "whom", "has", "disappearance", "of", "their", "stones", "within", "3", "weeks", ")", ",", "and", "remained", "depressed", "in", "3", "(", "2", "of", "whom", "had", "stones", "present", "at", "6", "months", ")", ".", "Our", "results", "suggest", "that", "the", "suppression", "of", "gallbladder", "contractility", "is", "the", "cause", "of", "the", "successive", "formation", "of", "bile", "sludge", ",", "gallstones", ",", "and", "cholecystitis", "during", "octreotide", "therapy", "in", "Chinese", "acromegalic", "patients", ".", "It", "is", "therefore", "very", "important", "to", "follow", "the", "changes", "of", "gallbladder", "function", "during", "long", "-", "term", "octreotide", "therapy", "of", "acromegalic", "patients", "."]], "ner": [[[12, 12, "Chemical"], [51, 51, "Chemical"], [79, 79, "Chemical"], [136, 136, "Chemical"], [231, 231, "Chemical"], [254, 254, "Chemical"], [18, 18, "Disease"], [88, 88, "Disease"], [141, 141, "Disease"], [165, 165, "Disease"], [226, 226, "Disease"], [93, 94, "Disease"], [22, 22, "Disease"], [42, 42, "Disease"], [235, 235, "Disease"], [257, 257, "Disease"], [129, 129, "Disease"], [191, 191, "Disease"], [229, 229, "Disease"]]], "relations": [[[12, 12, 18, 18, "CID"], [12, 12, 88, 88, "CID"], [12, 12, 141, 141, "CID"], [12, 12, 165, 165, "CID"], [12, 12, 226, 226, "CID"], [51, 51, 18, 18, "CID"], [51, 51, 88, 88, "CID"], [51, 51, 141, 141, "CID"], [51, 51, 165, 165, "CID"], [51, 51, 226, 226, "CID"], [79, 79, 18, 18, "CID"], [79, 79, 88, 88, "CID"], [79, 79, 141, 141, "CID"], [79, 79, 165, 165, "CID"], [79, 79, 226, 226, "CID"], [136, 136, 18, 18, "CID"], [136, 136, 88, 88, "CID"], [136, 136, 141, 141, "CID"], [136, 136, 165, 165, "CID"], [136, 136, 226, 226, "CID"], [231, 231, 18, 18, "CID"], [231, 231, 88, 88, "CID"], [231, 231, 141, 141, "CID"], [231, 231, 165, 165, "CID"], [231, 231, 226, 226, "CID"], [254, 254, 18, 18, "CID"], [254, 254, 88, 88, "CID"], [254, 254, 141, 141, "CID"], [254, 254, 165, 165, "CID"], [254, 254, 226, 226, "CID"], [12, 12, 93, 94, "CID"], [51, 51, 93, 94, "CID"], [79, 79, 93, 94, "CID"], [136, 136, 93, 94, "CID"], [231, 231, 93, 94, "CID"], [254, 254, 93, 94, "CID"]]], "clusters": [], "translated": "生长抑素类似物(<0>奥曲肽</0>)对中国<12>肢端肥大症</12>患者胆囊功能和<6>胆结石</6>形成长期影响的前瞻性研究。本文报道了20例中国活动性<13>肢端肥大症</13>患者皮下注射生长抑素类似物<1>奥曲肽</1>剂量为300-1500微克/天时超声检查胆囊功能的变化，平均为24.2+/-13.9个月。在<2>奥曲肽</2>治疗期间，17例患者出现胆汁淤积（sludge），10例出现<7>胆结石</7>，1例出现<11>急性胆囊炎</11>需要手术治疗。在所有7名接受急性检查的患者中，单次注射100微克后胆囊收缩受到抑制。在随访24周的8名患者中，胆囊收缩力在整个治疗过程中一直<16>抑制</16>。在10名没有<8>胆结石</8>的患者停用<3>奥曲肽</3>后，评估的8名患者在1个月内恢复了正常的胆囊收缩力。在治疗期间发生<9>胆结石</9>的其余10名患者中，有8名患者的胆囊收缩力恢复正常（其中3名患者的结石在3周内消失），并保持<17>抑郁</17>3人（其中2人在6个月时出现结石）。我们的研究结果表明，胆囊收缩力的抑制是胆泥、<10>胆结石</10>和<18>胆囊炎</18>在<4>奥曲肽</4>治疗期间相继形成的原因。<14>肢端肥大症</14>患者。因此，在长期<5>奥曲肽</5>治疗过程中，跟踪<15>肢端肥大症</15>患者胆囊功能的变化非常重要。", "revised": true}
{"doc_key": "10365197", "sentences": [["Cocaine", "-", "induced", "mood", "disorder", ":", "prevalence", "rates", "and", "psychiatric", "symptoms", "in", "an", "outpatient", "cocaine", "-", "dependent", "sample", ".", "This", "paper", "attempts", "to", "examine", "and", "compare", "prevalence", "rates", "and", "symptom", "patterns", "of", "DSM", "substance", "-", "induced", "and", "other", "mood", "disorders", ".", "243", "cocaine", "-", "dependent", "outpatients", "with", "cocaine", "-", "induced", "mood", "disorder", "(", "CIMD", ")", ",", "other", "mood", "disorders", ",", "or", "no", "mood", "disorder", "were", "compared", "on", "measures", "of", "psychiatric", "symptoms", ".", "The", "prevalence", "rate", "for", "CIMD", "was", "12", "%", "at", "baseline", ".", "Introduction", "of", "the", "DSM", "-", "IV", "diagnosis", "of", "CIMD", "did", "not", "substantially", "affect", "rates", "of", "the", "other", "depressive", "disorders", ".", "Patients", "with", "CIMD", "had", "symptom", "severity", "levels", "between", "those", "of", "patients", "with", "and", "without", "a", "mood", "disorder", ".", "These", "findings", "suggest", "some", "validity", "for", "the", "new", "DSM", "-", "IV", "diagnosis", "of", "CIMD", ",", "but", "also", "suggest", "that", "it", "requires", "further", "specification", "and", "replication", "."]], "ner": [[[0, 0, "Chemical"], [14, 14, "Chemical"], [42, 42, "Chemical"], [47, 47, "Chemical"], [3, 4, "Disease"], [38, 39, "Disease"], [50, 51, "Disease"], [57, 58, "Disease"], [62, 63, "Disease"], [118, 119, "Disease"], [9, 9, "Disease"], [69, 69, "Disease"], [53, 53, "Disease"], [76, 76, "Disease"], [91, 91, "Disease"], [105, 105, "Disease"], [134, 134, "Disease"], [100, 101, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 38, 39, "CID"], [0, 0, 50, 51, "CID"], [0, 0, 57, 58, "CID"], [0, 0, 62, 63, "CID"], [0, 0, 118, 119, "CID"], [14, 14, 3, 4, "CID"], [14, 14, 38, 39, "CID"], [14, 14, 50, 51, "CID"], [14, 14, 57, 58, "CID"], [14, 14, 62, 63, "CID"], [14, 14, 118, 119, "CID"], [42, 42, 3, 4, "CID"], [42, 42, 38, 39, "CID"], [42, 42, 50, 51, "CID"], [42, 42, 57, 58, "CID"], [42, 42, 62, 63, "CID"], [42, 42, 118, 119, "CID"], [47, 47, 3, 4, "CID"], [47, 47, 38, 39, "CID"], [47, 47, 50, 51, "CID"], [47, 47, 57, 58, "CID"], [47, 47, 62, 63, "CID"], [47, 47, 118, 119, "CID"]]], "clusters": [], "translated": "<0>可卡因</0>诱发的<4>情绪障碍</4>：<1>门诊</1><2>可卡因</2>依赖样本的患病率和<10>精神病学</10>症状。本文试图检查和比较 DSM 物质引起的和其他<5>情绪障碍</5>的患病率和症状模式。243<2>可卡因</2>依赖门诊患者中，有<3>可卡因</3>诱发<6>情绪障碍</6>（<12>CIMD</12>），还有其他的<7>情绪障碍</7>或没有<8>情绪障碍</8>。这些患者在<11>精神症状</11>的测量上进行了比较。 <13>CIMD</13> 的患病率为基线时的12%。引入 DSM-IV 诊断的<14>CIMD</14> 并未显著影响其他<17>抑郁症</17>的发病率。患有<15>CIMD</15>的患者症状的严重程度介于<9>有情绪障碍</9>和<9>没有情绪障碍</9>的患者之间。这些发现表明新的 DSM-IV 诊断<16>CIMD</16> 具有一定有效性，但也表明它需要进一步的规范和复制。", "revised": true}
{"doc_key": "18217897", "sentences": [["Thalidomide", "has", "limited", "single", "-", "agent", "activity", "in", "relapsed", "or", "refractory", "indolent", "non", "-", "Hodgkin", "lymphomas", ":", "a", "phase", "II", "trial", "of", "the", "Cancer", "and", "Leukemia", "Group", "B", ".", "Thalidomide", "is", "an", "immunomodulatory", "agent", "with", "demonstrated", "activity", "in", "multiple", "myeloma", ",", "mantle", "cell", "lymphoma", "and", "lymphoplasmacytic", "lymphoma", ".", "Its", "activity", "is", "believed", "to", "be", "due", "modulation", "of", "the", "tumour", "milieu", ",", "including", "downregulation", "of", "angiogenesis", "and", "inflammatory", "cytokines", ".", "Between", "July", "2001", "and", "April", "2004", ",", "24", "patients", "with", "relapsed", "/", "refractory", "indolent", "lymphomas", "received", "thalidomide", "200", "mg", "daily", "with", "escalation", "by", "100", "mg", "daily", "every", "1", "-", "2", "weeks", "as", "tolerated", ",", "up", "to", "a", "maximum", "of", "800", "mg", "daily", ".", "Patients", "had", "received", "a", "median", "of", "2", "(", "range", ",", "1", "-", "4", ")", "prior", "regimens", ".", "Of", "24", "evaluable", "patients", ",", "two", "achieved", "a", "complete", "remission", "and", "one", "achieved", "a", "partial", "remission", "for", "an", "overall", "response", "rate", "of", "12", ".", "5", "%", "(", "95", "%", "confidence", "interval", ":", "2", ".", "6", "-", "32", ".", "4", "%", ")", ".", "Eleven", "patients", "progressed", "during", "therapy", ".", "Grade", "3", "-", "4", "adverse", "effects", "included", "myelosuppression", ",", "fatigue", ",", "somnolence", "/", "depressed", "mood", ",", "neuropathy", "and", "dyspnea", ".", "Of", "concern", "was", "the", "occurrence", "of", "four", "thromboembolic", "events", ".", "Our", "results", "failed", "to", "demonstrate", "an", "important", "response", "rate", "to", "single", "agent", "thalidomide", "in", "indolent", "lymphomas", "and", "contrast", "with", "the", "higher", "activity", "level", "reported", "with", "the", "second", "generation", "immunomodulatory", "agent", ",", "lenalidomide", "."]], "ner": [[[0, 0, "Chemical"], [29, 29, "Chemical"], [85, 85, "Chemical"], [219, 219, "Chemical"], [204, 204, "Disease"], [12, 15, "Disease"], [23, 23, "Disease"], [58, 58, "Disease"], [25, 25, "Disease"], [38, 39, "Disease"], [41, 43, "Disease"], [45, 46, "Disease"], [83, 83, "Disease"], [222, 222, "Disease"], [184, 184, "Disease"], [186, 186, "Disease"], [188, 188, "Disease"], [190, 191, "Disease"], [193, 193, "Disease"], [195, 195, "Disease"], [238, 238, "Chemical"]]], "relations": [[[0, 0, 204, 204, "CID"], [29, 29, 204, 204, "CID"], [85, 85, 204, 204, "CID"], [219, 219, 204, 204, "CID"]]], "clusters": [], "translated": "<0>沙利度胺</0>在复发或难治性惰性<5>非霍奇金淋巴瘤</5>中具有有限的单药活性：<6>癌症</6>和<8>白血病的II期试验</8>组B。 <1>沙利度胺</1>是一种免疫调节剂，在<9>多发性骨髓瘤</9>、<10>套细胞淋巴瘤</10>和<11>淋巴浆细胞淋巴瘤</11>中显示出活性。它的活性被认为是由于<7>肿瘤</7>环境的调节，包括下调血管生成和炎性细胞因子。2001年7月至2004年4月期间，24名患有复发/难治性惰性<12>淋巴瘤</12>的患者每天接受<2>沙利度胺</2> 200mg治疗，并在耐受情况下每1-2周每天增加100mg，最高可达每天最多800毫克。患者接受过中位数为2（范围1-4）的既往治疗方案。在24名可评估的患者中，两名达到完全缓解，一名达到部分缓解，总反应率为12.5%（95%置信区间：2.6-32.4%）。11名患者在治疗期间出现进展。3-4级不良反应包括<14>骨髓抑制</14>、<15>疲劳</15>、<16>嗜睡</16>/<17>情绪低落</17>、<18>神经病变</18>和<19>呼吸困难</19>。值得关注的是发生了四次<4>血栓栓塞</4>事件。我们的结果未能证明单药<3>沙利度胺</3>在惰性<13>淋巴瘤</13>中的重要反应率，并且与第二代免疫调节剂<20>来那度胺</20>报告的更高活性水平形成对比。", "revised": true}
{"doc_key": "8919272", "sentences": [["Morphological", "features", "of", "encephalopathy", "after", "chronic", "administration", "of", "the", "antiepileptic", "drug", "valproate", "to", "rats", ".", "A", "transmission", "electron", "microscopic", "study", "of", "capillaries", "in", "the", "cerebellar", "cortex", ".", "Long", "-", "term", "intragastric", "application", "of", "the", "antiepileptic", "drug", "sodium", "valproate", "(", "Vupral", "\"", "Polfa", "\"", ")", "at", "the", "effective", "dose", "of", "200", "mg", "/", "kg", "b", ".", "w", ".", "once", "daily", "to", "rats", "for", "1", ",", "3", ",", "6", ",", "9", "and", "12", "months", "revealed", "neurological", "disorders", "indicating", "cerebellum", "damage", "(", "\"", "valproate", "encephalopathy", "\"", ")", ".", "The", "first", "ultrastructural", "changes", "in", "structural", "elements", "of", "the", "blood", "-", "brain", "-", "barrier", "(", "BBB", ")", "in", "the", "cerebellar", "cortex", "were", "detectable", "after", "3", "months", "of", "the", "experiment", ".", "They", "became", "more", "severe", "in", "the", "later", "months", "of", "the", "experiment", ",", "and", "were", "most", "severe", "after", "12", "months", ",", "located", "mainly", "in", "the", "molecular", "layer", "of", "the", "cerebellar", "cortex", ".", "Lesions", "of", "the", "capillary", "included", "necrosis", "of", "endothelial", "cells", ".", "Organelles", "of", "these", "cells", ",", "in", "particular", "the", "mitochondria", "(", "increased", "number", "and", "size", ",", "distinct", "degeneration", "of", "their", "matrix", "and", "cristae", ")", "and", "Golgi", "apparatus", "were", "altered", ".", "Reduced", "size", "of", "capillary", "lumen", "and", "occlusion", "were", "caused", "by", "swollen", "endothelial", "cells", "which", "had", "luminal", "protrusions", "and", "swollen", "microvilli", ".", "Pressure", "on", "the", "vessel", "wall", "was", "produced", "by", "enlarged", "perivascular", "astrocytic", "processes", ".", "Fragments", "of", "necrotic", "endothelial", "cells", "were", "in", "the", "vascular", "lumens", "and", "in", "these", "there", "was", "loosening", "and", "breaking", "of", "tight", "cellular", "junctions", ".", "Damage", "to", "the", "vascular", "basement", "lamina", "was", "also", "observed", ".", "Damage", "to", "the", "capillary", "was", "accompanied", "by", "marked", "damage", "to", "neuroglial", "cells", ",", "mainly", "to", "perivascular", "processes", "of", "astrocytes", ".", "The", "proliferation", "of", "astrocytes", "(", "Bergmann", "'s", "in", "particular", ")", "and", "occasionally", "of", "oligodendrocytes", "was", "found", ".", "Alterations", "in", "the", "structural", "elements", "of", "the", "BBB", "coexisted", "with", "marked", "lesions", "of", "neurons", "of", "the", "cerebellum", "(", "Purkinje", "cells", "are", "earliest", ")", ".", "In", "electron", "micrographs", "both", "luminal", "and", "antiluminal", "sides", "of", "the", "BBB", "of", "the", "cerebellar", "cortex", "had", "similar", "lesions", ".", "The", "possible", "influence", "of", "the", "hepatic", "damage", ",", "mainly", "hyperammonemia", ",", "upon", "the", "development", "of", "valproate", "encephalopathy", "is", "discussed", "."]], "ner": [[[11, 11, "Chemical"], [36, 37, "Chemical"], [80, 80, "Chemical"], [347, 347, "Chemical"], [3, 3, "Disease"], [81, 81, "Disease"], [348, 348, "Disease"], [200, 200, "Chemical"], [317, 317, "Chemical"], [73, 74, "Disease"], [76, 77, "Disease"], [151, 151, "Disease"], [221, 221, "Disease"], [337, 338, "Disease"], [341, 341, "Disease"]]], "relations": [[[11, 11, 3, 3, "CID"], [11, 11, 81, 81, "CID"], [11, 11, 348, 348, "CID"], [36, 37, 3, 3, "CID"], [36, 37, 81, 81, "CID"], [36, 37, 348, 348, "CID"], [80, 80, 3, 3, "CID"], [80, 80, 81, 81, "CID"], [80, 80, 348, 348, "CID"], [347, 347, 3, 3, "CID"], [347, 347, 81, 81, "CID"], [347, 347, 348, 348, "CID"]]], "clusters": [], "translated": "大鼠长期服用抗癫痫药物<0>丙戊酸盐</0>后<4>脑病</4>的形态学特征。小脑皮层毛细血管的透射电子显微镜研究。抗癫痫药<1>丙戊酸钠</1>（Vupral“Polfa”）长期灌胃，有效剂量为200mg/kg b.w.，大鼠每天一次，持续1、3、6、9和12个月显示<9>神经障碍</9>，表明<10>小脑损伤</10>（\"<2>丙戊酸钠</2><5>脑病</5>\"）。实验3个月后，可检测到小脑皮层血脑屏障 (BBB) 结构元素的第一个超微结构变化。它们在实验的最后几个月变得更加严重，并且在12个月后最为严重，主要位于小脑皮层的分子层。毛细血管病变包括内皮细胞<11>坏死</11>。这些细胞的细胞器，特别是线粒体（数量和大小增加，基质和嵴明显退化）和高尔基体发生了改变。毛细血管腔缩小和闭塞是由肿胀的内皮细胞引起的，内皮细胞有<7>管腔</7>突起和肿胀的微绒毛。血管周围星形胶质细胞突起扩大，压迫血管壁。碎片的<12>坏死</12>内皮细胞位于血管腔内，在这些腔内，紧密的细胞连接发生松动和断裂。还观察到血管基底层的损伤。毛细血管的损伤伴随着神经胶质细胞的明显损伤，主要是星形胶质细胞的血管周围突。发现了星形胶质细胞（特别是Bergmann 胶质细胞）和偶尔有些丝状胶质细胞的增殖。 BBB 结构元素的改变与小脑神经元的明显损伤共存（浦肯野细胞最早）。在电子显微照片中，小脑皮质 BBB 的<8>管腔</8>和反管腔侧均有相似的病变。讨论了<13>肝损伤</13>，主要是<14>高氨血症</14>，对<3>丙戊酸盐</3><6>脑病</6>的可能影响。", "revised": true}
{"doc_key": "9522152", "sentences": [["A", "transient", "neurological", "deficit", "following", "intrathecal", "injection", "of", "1", "%", "hyperbaric", "bupivacaine", "for", "unilateral", "spinal", "anaesthesia", ".", "We", "describe", "a", "case", "of", "transient", "neurological", "deficit", "that", "occurred", "after", "unilateral", "spinal", "anaesthesia", "with", "8", "mg", "of", "1", "%", "hyperbaric", "bupivacaine", "slowly", "injected", "through", "a", "25", "-", "gauge", "pencil", "-", "point", "spinal", "needle", ".", "The", "surgery", "and", "anaesthesia", "were", "uneventful", ",", "but", "3", "days", "after", "surgery", ",", "the", "patient", "reported", "an", "area", "of", "hypoaesthesia", "over", "L3", "-", "L4", "dermatomes", "of", "the", "leg", "which", "had", "been", "operated", "on", "(", "loss", "of", "pinprick", "sensation", ")", "without", "reduction", "in", "muscular", "strength", ".", "Sensation", "in", "this", "area", "returned", "to", "normal", "over", "the", "following", "2", "weeks", ".", "Prospective", "multicentre", "studies", "with", "a", "large", "population", "and", "a", "long", "follow", "-", "up", "should", "be", "performed", "in", "order", "to", "evaluate", "the", "incidence", "of", "this", "unusual", "side", "effect", ".", "However", ",", "we", "suggest", "that", "a", "low", "solution", "concentration", "should", "be", "preferred", "for", "unilateral", "spinal", "anaesthesia", "with", "a", "hyperbaric", "anaesthetic", "solution", "(", "if", "pencil", "-", "point", "needle", "and", "slow", "injection", "rate", "are", "employed", ")", ",", "in", "order", "to", "minimize", "the", "risk", "of", "a", "localized", "high", "peak", "anaesthetic", "concentration", ",", "which", "might", "lead", "to", "a", "transient", "neurological", "deficit", "."]], "ner": [[[11, 11, "Chemical"], [38, 38, "Chemical"], [86, 89, "Disease"], [2, 3, "Disease"], [23, 24, "Disease"], [193, 194, "Disease"]]], "relations": [[[11, 11, 86, 89, "CID"], [38, 38, 86, 89, "CID"]]], "clusters": [], "translated": "鞘内注射 1% 高压 <0>布比卡因</0> 进行单侧脊髓麻醉后出现短暂的<3>神经功能缺损</3>。我们描述了一例短暂性<4>神经功能缺损</4>发生在单侧脊髓麻醉后，通过 25 号铅笔尖脊髓针缓慢注射 8 毫克 1% 高压<1>布比卡因</1>。手术和麻醉都很顺利，但手术后 3 天，患者报告手术后腿部 L3-L4 皮节区域出现感觉减退（<2>针刺感丧失</2>），但肌肉无减少力量。在接下来的 2 周内，该区域的感觉恢复正常。应进行具有大量人群和长期随访的前瞻性多中心研究，以评估这种不寻常副作用的发生率。然而，我们建议在使用高压麻醉溶液进行单侧脊髓麻醉时（如果使用铅笔尖针和缓慢的注射速度），应首选低溶液浓度，以尽量减少局部高峰值麻醉浓度的风险，这可能导致短暂的<5>神经功能缺损</5>。", "revised": true}
{"doc_key": "9754849", "sentences": [["Choreoathetoid", "movements", "associated", "with", "rapid", "adjustment", "to", "methadone", ".", "Choreatiform", "hyperkinesias", "are", "known", "to", "be", "occasional", "movement", "abnormalities", "during", "intoxications", "with", "cocaine", "but", "not", "opiates", ".", "This", "is", "a", "case", "report", "of", "euphoria", "and", "choreoathetoid", "movements", "both", "transiently", "induced", "by", "rapid", "adjustment", "to", "the", "selective", "mu", "-", "opioid", "receptor", "agonist", "methadone", "in", "an", "inpatient", "previously", "abusing", "heroine", "and", "cocaine", ".", "In", "addition", ",", "minor", "EEG", "abnormalities", "occurred", ".", "Possible", "underlying", "neurobiological", "phenomena", "are", "discussed", "."]], "ner": [[[7, 7, "Chemical"], [50, 50, "Chemical"], [0, 1, "Disease"], [9, 10, "Disease"], [34, 35, "Disease"], [21, 21, "Chemical"], [58, 58, "Chemical"], [56, 56, "Chemical"], [16, 17, "Disease"]]], "relations": [[[7, 7, 0, 1, "CID"], [7, 7, 9, 10, "CID"], [7, 7, 34, 35, "CID"], [50, 50, 0, 1, "CID"], [50, 50, 9, 10, "CID"], [50, 50, 34, 35, "CID"], [21, 21, 0, 1, "CID"], [21, 21, 9, 10, "CID"], [21, 21, 34, 35, "CID"], [58, 58, 0, 1, "CID"], [58, 58, 9, 10, "CID"], [58, 58, 34, 35, "CID"]]], "clusters": [], "translated": "<2> 手足徐动症运动 </2> 与<0>美沙酮</0>的快速调整有关。 <3>舞蹈样运动亢进</3> 已知是在<5>可卡因</5>而不是阿片类药物中毒期间偶尔出现的<8>运动异常</8>。这是一例欣快感和<4>舞蹈手足徐动样运动</4>的病例报告，这两种情况均由快速调整选择性μ-阿片受体激动剂<1>美沙酮</1>引起，该住院患者之前曾滥用<7>海洛因</7>和<6>可卡因</6>。此外，还出现了轻微的脑电图异常。讨论了可能的潜在神经生物学现象。", "revised": true}
{"doc_key": "9721172", "sentences": [["Drug", "-", "associated", "acute", "-", "onset", "vanishing", "bile", "duct", "and", "Stevens", "-", "Johnson", "syndromes", "in", "a", "child", ".", "Acute", "vanishing", "bile", "duct", "syndrome", "is", "a", "rare", "but", "established", "cause", "of", "progressive", "cholestasis", "in", "adults", ",", "is", "most", "often", "drug", "or", "toxin", "related", ",", "and", "is", "of", "unknown", "pathogenesis", ".", "It", "has", "not", "been", "reported", "previously", "in", "children", ".", "Stevens", "-", "Johnson", "syndrome", "is", "a", "well", "-", "recognized", "immune", "complex", "-", "mediated", "hypersensitivity", "reaction", "that", "affects", "all", "age", "groups", ",", "is", "drug", "or", "infection", "induced", ",", "and", "has", "classic", "systemic", ",", "mucosal", ",", "and", "dermatologic", "manifestations", ".", "A", "previously", "healthy", "child", "who", "developed", "acute", ",", "severe", ",", "rapidly", "progressive", "vanishing", "bile", "duct", "syndrome", "shortly", "after", "Stevens", "-", "Johnson", "syndrome", "is", "described", ";", "this", "was", "temporally", "associated", "with", "ibuprofen", "use", ".", "Despite", "therapy", "with", "ursodeoxycholic", "acid", ",", "prednisone", ",", "and", "then", "tacrolimus", ",", "her", "cholestatic", "disease", "was", "unrelenting", ",", "with", "cirrhosis", "shown", "by", "biopsy", "6", "months", "after", "presentation", ".", "This", "case", "documents", "acute", "drug", "-", "related", "vanishing", "bile", "duct", "syndrome", "in", "the", "pediatric", "age", "group", "and", "suggests", "shared", "immune", "mechanisms", "in", "the", "pathogenesis", "of", "both", "Stevens", "-", "Johnson", "syndrome", "and", "vanishing", "bile", "duct", "syndrome", "."]], "ner": [[[126, 126, "Chemical"], [10, 13, "Disease"], [58, 61, "Disease"], [114, 117, "Disease"], [183, 186, "Disease"], [31, 31, "Disease"], [142, 143, "Disease"], [6, 8, "Disease"], [19, 21, "Disease"], [108, 111, "Disease"], [164, 167, "Disease"], [188, 191, "Disease"], [132, 133, "Chemical"], [135, 135, "Chemical"], [139, 139, "Chemical"], [71, 71, "Disease"], [82, 82, "Disease"], [148, 148, "Disease"]]], "relations": [[[126, 126, 10, 13, "CID"], [126, 126, 58, 61, "CID"], [126, 126, 114, 117, "CID"], [126, 126, 183, 186, "CID"], [126, 126, 31, 31, "CID"], [126, 126, 142, 143, "CID"]]], "clusters": [], "translated": "一名儿童出现与药物相关的急性发作 <7>胆管消失</7> 和<1>史蒂文斯-约翰逊综合征</1>。急性<8>胆管消失</8>综合征是一种罕见但已确定的成人进行性<5>胆汁淤积</5>的病因，通常与药物或毒素有关，发病机制未知。以前在儿童中没有报道过。<2>史蒂文斯-约翰逊综合征</2>是一种公认的免疫复合物介导的<15>超敏反应</15>，影响所有年龄组，由药物或<16>感染</16>引起，并且具有典型的全身、粘膜和皮肤病学表现。一名既往健康的儿童，在<3>史蒂文斯-约翰逊综合征</3>后不久发展为急性、严重、快速进展的<9>胆管消失综合征</9>；这暂时与<0>布洛芬</0>使用有关。尽管用<12>熊去氧胆酸</12>、<13>泼尼松</13>和<14>他克莫司</14>进行治疗，她的<6>胆汁淤积症</6>仍未缓解，<17>就诊后6个月活检显示肝硬化</17>。该病例记录了儿科年龄组的急性药物相关<10>胆管消失综合征</10>，并表明<4>史蒂文斯-约翰逊综合征</4>和<11>胆管消失的发病机制中存在共同的免疫机制</11>。", "revised": true}
{"doc_key": "10737864", "sentences": [["A", "developmental", "analysis", "of", "clonidine", "'s", "effects", "on", "cardiac", "rate", "and", "ultrasound", "production", "in", "infant", "rats", ".", "Under", "controlled", "conditions", ",", "infant", "rats", "emit", "ultrasonic", "vocalizations", "during", "extreme", "cold", "exposure", "and", "after", "administration", "of", "the", "alpha", "(", "2", ")", "adrenoceptor", "agonist", ",", "clonidine", ".", "Previous", "investigations", "have", "determined", "that", ",", "in", "response", "to", "clonidine", ",", "ultrasound", "production", "increases", "through", "the", "2nd", "-", "week", "postpartum", "and", "decreases", "thereafter", ".", "Given", "that", "sympathetic", "neural", "dominance", "exhibits", "a", "similar", "developmental", "pattern", ",", "and", "given", "that", "clonidine", "induces", "sympathetic", "withdrawal", "and", "bradycardia", ",", "we", "hypothesized", "that", "clonidine", "'s", "developmental", "effects", "on", "cardiac", "rate", "and", "ultrasound", "production", "would", "mirror", "each", "other", ".", "Therefore", ",", "in", "the", "present", "experiment", ",", "the", "effects", "of", "clonidine", "administration", "(", "0", ".", "5", "mg", "/", "kg", ")", "on", "cardiac", "rate", "and", "ultrasound", "production", "were", "examined", "in", "2", "-", ",", "8", "-", ",", "15", "-", ",", "and", "20", "-", "day", "-", "old", "rats", ".", "Age", "-", "related", "changes", "in", "ultrasound", "production", "corresponded", "with", "changes", "in", "cardiovascular", "variables", ",", "including", "baseline", "cardiac", "rate", "and", "clonidine", "-", "induced", "bradycardia", ".", "This", "experiment", "is", "discussed", "with", "regard", "to", "the", "hypothesis", "that", "ultrasound", "production", "is", "the", "acoustic", "by", "-", "product", "of", "a", "physiological", "maneuver", "that", "compensates", "for", "clonidine", "'s", "detrimental", "effects", "on", "cardiovascular", "function", "."]], "ner": [[[4, 4, "Chemical"], [42, 42, "Chemical"], [53, 53, "Chemical"], [82, 82, "Chemical"], [92, 92, "Chemical"], [117, 117, "Chemical"], [172, 172, "Chemical"], [202, 202, "Chemical"], [87, 87, "Disease"], [175, 175, "Disease"]]], "relations": [[[4, 4, 87, 87, "CID"], [4, 4, 175, 175, "CID"], [42, 42, 87, 87, "CID"], [42, 42, 175, 175, "CID"], [53, 53, 87, 87, "CID"], [53, 53, 175, 175, "CID"], [82, 82, 87, 87, "CID"], [82, 82, 175, 175, "CID"], [92, 92, 87, 87, "CID"], [92, 92, 175, 175, "CID"], [117, 117, 87, 87, "CID"], [117, 117, 175, 175, "CID"], [172, 172, 87, 87, "CID"], [172, 172, 175, 175, "CID"], [202, 202, 87, 87, "CID"], [202, 202, 175, 175, "CID"]]], "clusters": [], "translated": "<0>可乐定</0>的对幼鼠心率和超声产生影响的发育分析。在受控条件下，幼鼠在极度寒冷的环境中和服用 α (2) 肾上腺素能受体激动剂<1>可乐定</1>后会发出超声波。以前的研究已经确定，作为对<2>可乐定</2>的反应，超声产生在产后第2周增加，此后减少。鉴于交感神经优势表现出相似的发育模式，并且鉴于<3>可乐定</3>引起交感神经退缩和<8>心动过缓</8>，我们假设<4>可乐定</4>的发育影响心率和超声产生会相互反映。因此，在本实验中，在第2天、第8天、第15天和第20天检查了<5>可乐定</5>给药（0.5 mg/kg）对心率和超声产生的影响。年龄相关的超声产生变化与心血管变量的变化相对应，包括基线心率和<6>可乐定</6>诱发的<9>心动过缓</9>。这个实验是根据以下假设进行讨论的：超声波的产生是补偿<7>可乐定</7>对心血管功能的不利影响的生理操作的声学副产品。", "revised": true}
{"doc_key": "9284778", "sentences": [["Epidemic", "of", "liver", "disease", "caused", "by", "hydrochlorofluorocarbons", "used", "as", "ozone", "-", "sparing", "substitutes", "of", "chlorofluorocarbons", ".", "BACKGROUND", ":", "Hydrochlorofluorocarbons", "(", "HCFCs", ")", "are", "used", "increasingly", "in", "industry", "as", "substitutes", "for", "ozone", "-", "depleting", "chlorofluorocarbons", "(", "CFCs", ")", ".", "Limited", "studies", "in", "animals", "indicate", "potential", "hepatotoxicity", "of", "some", "of", "these", "compounds", ".", "We", "investigated", "an", "epidemic", "of", "liver", "disease", "in", "nine", "industrial", "workers", "who", "had", "had", "repeated", "accidental", "exposure", "to", "a", "mixture", "of", "1", ",", "1", "-", "dichloro", "-", "2", ",", "2", ",", "2", "-", "trifluoroethane", "(", "HCFC", "123", ")", "and", "1", "-", "chloro", "-", "1", ",", "2", ",", "2", ",", "2", "-", "tetrafluoroethane", "(", "HCFC", "124", ")", ".", "All", "nine", "exposed", "workers", "were", "affected", "to", "various", "degrees", ".", "Both", "compounds", "are", "metabolised", "in", "the", "same", "way", "as", "1", "-", "bromo", "-", "1", "-", "chloro", "-", "2", ",", "2", ",", "2", "-", "trifluoroethane", "(", "halothane", ")", "to", "form", "reactive", "trifluoroacetyl", "halide", "intermediates", ",", "which", "have", "been", "implicated", "in", "the", "hepatotoxicity", "of", "halothane", ".", "We", "aimed", "to", "test", "whether", "HCFCs", "123", "and", "124", "can", "result", "in", "serious", "liver", "disease", ".", "METHODS", ":", "For", "one", "severely", "affected", "worker", "liver", "biopsy", "and", "immunohistochemical", "stainings", "for", "the", "presence", "of", "trifluoroacetyl", "protein", "adducts", "were", "done", ".", "The", "serum", "of", "six", "affected", "workers", "and", "five", "controls", "was", "tested", "for", "autoantibodies", "that", "react", "with", "human", "liver", "cytochrome", "-", "P450", "2E1", "(", "P450", "2E1", ")", "and", "P58", "protein", "disulphide", "isomerase", "isoform", "(", "P58", ")", ".", "FINDINGS", ":", "The", "liver", "biopsy", "sample", "showed", "hepatocellular", "necrosis", "which", "was", "prominent", "in", "perivenular", "zone", "three", "and", "extended", "focally", "from", "portal", "tracts", "to", "portal", "tracts", "and", "centrilobular", "areas", "(", "bridging", "necrosis", ")", ".", "Trifluoroacetyl", "-", "adducted", "proteins", "were", "detected", "in", "surviving", "hepatocytes", ".", "Autoantibodies", "against", "P450", "2E1", "or", "P58", ",", "previously", "associated", "with", "halothane", "hepatitis", ",", "were", "detected", "in", "the", "serum", "of", "five", "affected", "workers", ".", "INTERPRETATION", ":", "Repeated", "exposure", "of", "human", "beings", "to", "HCFCs", "123", "and", "124", "can", "result", "in", "serious", "liver", "injury", "in", "a", "large", "proportion", "of", "the", "exposed", "population", ".", "Although", "the", "exact", "mechanism", "of", "hepatotoxicity", "of", "these", "agents", "is", "not", "known", ",", "the", "results", "suggest", "that", "trifluoroacetyl", "-", "altered", "liver", "proteins", "are", "involved", ".", "In", "view", "of", "the", "potentially", "widespread", "use", "of", "these", "compounds", ",", "there", "is", "an", "urgent", "need", "to", "develop", "safer", "alternatives", "."]], "ner": [[[72, 84, "Chemical"], [86, 87, "Chemical"], [167, 170, "Chemical"], [310, 313, "Chemical"], [2, 3, "Disease"], [56, 57, "Disease"], [175, 176, "Disease"], [90, 102, "Chemical"], [104, 105, "Chemical"], [9, 9, "Chemical"], [30, 30, "Chemical"], [14, 14, "Chemical"], [33, 33, "Chemical"], [35, 35, "Chemical"], [127, 141, "Chemical"], [143, 143, "Chemical"], [160, 160, "Chemical"], [148, 148, "Chemical"], [194, 194, "Chemical"], [269, 269, "Chemical"], [346, 346, "Chemical"], [44, 44, "Disease"], [158, 158, "Disease"], [318, 319, "Disease"], [334, 334, "Disease"], [244, 244, "Disease"], [266, 266, "Disease"], [289, 290, "Disease"]]], "relations": [[[72, 84, 2, 3, "CID"], [72, 84, 56, 57, "CID"], [72, 84, 175, 176, "CID"], [86, 87, 2, 3, "CID"], [86, 87, 56, 57, "CID"], [86, 87, 175, 176, "CID"], [167, 170, 2, 3, "CID"], [167, 170, 56, 57, "CID"], [167, 170, 175, 176, "CID"], [310, 313, 2, 3, "CID"], [310, 313, 56, 57, "CID"], [310, 313, 175, 176, "CID"], [90, 102, 2, 3, "CID"], [90, 102, 56, 57, "CID"], [90, 102, 175, 176, "CID"], [104, 105, 2, 3, "CID"], [104, 105, 56, 57, "CID"], [104, 105, 175, 176, "CID"]]], "clusters": [], "translated": "用作<9>臭氧</9>的氢氯氟烃引起的<4>肝病</4>流行 - <11>氯氟烃</11>的替代品。背景：氢氯氟烃 (HCFC) 在工业中越来越多地用作<10>臭氧</10>的替代品-消耗<12>氯氟烃</12>（<13>CFC</13>）。有限的动物研究表明其中一些化合物具有潜在的<21>肝毒性</21>。我们调查了9名工业工人的<5>肝病</5>流行病，这些工人曾多次意外接触<0>1,1-二氯-2,2,2-三氟乙烷</0>（<1>HCFC 123</1>）和<7>1-氯-1,2,2,2-四氟乙烷</7>（<8>HCFC 124</8>）。九名接触工人均受到不同程度的影响。这两种化合物的代谢方式与<14>1-溴-1-氯-2,2,2-三氟乙烷</14>（<15>氟烷</15>）相同，形成反应性的<17>三氟乙酰基</17>卤化物中间体，与<16>氟烷</16>的<22>肝毒性</22>有关。我们的目的是测试<2>HCFC 123和124</2>是否会导致严重的<6>肝脏疾病</6>。方法：对一名受重伤的工人进行肝脏活检和免疫组织化学染色，以确定是否存在<18>三氟乙酰</18>蛋白加合物。检测了6名受影响工人和5名对照者的血清中与人肝细胞色素-P450 2E1 (P450 2E1)和P58蛋白二硫化物异构酶亚型 (P58)发生反应的自身抗体。发现：肝活检标本显示肝细胞<25>坏死</25>，在静脉周三区明显，并从汇管束局灶性延伸至汇管束和小叶中心区（桥接的<26>坏死</26>）。<19>三氟乙酰</19>-加合物在存活的肝细胞中被检测到。在5名受影响的工人的血清中检测到先前与<27>氟烷</27>肝炎有关的针对P450 2E1或P58的自身抗体。解释：人类反复接触<3>HCFCs 123和124</3>会导致大部分接触人群发生严重的<23>肝损伤</23>。虽然这些药物<24>肝毒性</24>的确切机制尚不清楚，但结果表明，<20>三氟乙酰</20>-改变的肝蛋白参与其中。鉴于这些化合物可能广泛使用，迫切需要开发更安全的替代品。", "revised": true}
{"doc_key": "11642480", "sentences": [["Palpebral", "twitching", "in", "a", "depressed", "adolescent", "on", "citalopram", ".", "Current", "estimates", "suggest", "that", "between", "0", ".", "4", "%", "and", "8", ".", "3", "%", "of", "children", "and", "adolescents", "are", "affected", "by", "major", "depression", ".", "We", "report", "a", "favorable", "response", "to", "treatment", "with", "citalopram", "by", "a", "15", "-", "year", "-", "old", "boy", "with", "major", "depression", "who", "exhibited", "palpebral", "twitching", "during", "his", "first", "2", "weeks", "of", "treatment", ".", "This", "may", "have", "been", "a", "side", "effect", "of", "citalopram", "as", "it", "remitted", "with", "redistribution", "of", "doses", "."]], "ner": [[[7, 7, "Chemical"], [41, 41, "Chemical"], [73, 73, "Chemical"], [0, 1, "Disease"], [55, 56, "Disease"], [4, 4, "Disease"], [30, 31, "Disease"], [51, 52, "Disease"]]], "relations": [[[7, 7, 0, 1, "CID"], [7, 7, 55, 56, "CID"], [41, 41, 0, 1, "CID"], [41, 41, 55, 56, "CID"], [73, 73, 0, 1, "CID"], [73, 73, 55, 56, "CID"]]], "clusters": [], "translated": "服用 <0> 西酞普兰 </0> 的<5> 抑郁症 </5>青少年的<3>眼睑抽搐</3>。目前的估计表明在 0.4% 和 8.3% 的儿童和青少年患有<6>重度抑郁症</6>。我们报告了一名患有<7>重度抑郁症</7>的 15 岁男孩，对治疗 <1>西酞普兰</1>有良好反应，他在头两周的治疗中出现了 <4>眼睑抽搐</4>。这可能是由于<2>西酞普兰</2>的副作用，因为在重新分配药量后症状缓解了。", "revised": true}
{"doc_key": "6518066", "sentences": [["Maternal", "lithium", "and", "neonatal", "Ebstein", "'s", "anomaly", ":", "evaluation", "with", "cross", "-", "sectional", "echocardiography", ".", "Cross", "-", "sectional", "echocardiography", "was", "used", "to", "evaluate", "two", "neonates", "whose", "mothers", "ingested", "lithium", "during", "pregnancy", ".", "In", "one", "infant", ",", "Ebstein", "'s", "anomaly", "of", "the", "tricuspid", "valve", "was", "identified", ".", "In", "the", "other", "infant", "cross", "-", "sectional", "echocardiography", "provided", "reassurance", "that", "the", "infant", "did", "not", "have", "Ebstein", "'s", "anomaly", ".", "Cross", "-", "sectional", "echocardiographic", "screening", "of", "newborns", "exposed", "to", "lithium", "during", "gestation", "can", "provide", "highly", "accurate", ",", "noninvasive", "assessment", "of", "the", "presence", "or", "absence", "of", "lithium", "-", "induced", "cardiac", "malformations", "."]], "ner": [[[1, 1, "Chemical"], [28, 28, "Chemical"], [75, 75, "Chemical"], [91, 91, "Chemical"], [4, 6, "Disease"], [36, 38, "Disease"], [62, 64, "Disease"], [94, 95, "Disease"]]], "relations": [[[1, 1, 4, 6, "CID"], [1, 1, 36, 38, "CID"], [1, 1, 62, 64, "CID"], [28, 28, 4, 6, "CID"], [28, 28, 36, 38, "CID"], [28, 28, 62, 64, "CID"], [75, 75, 4, 6, "CID"], [75, 75, 36, 38, "CID"], [75, 75, 62, 64, "CID"], [91, 91, 4, 6, "CID"], [91, 91, 36, 38, "CID"], [91, 91, 62, 64, "CID"]]], "clusters": [], "translated": "产妇<0>锂</0>和新生儿<4>Ebstein异常</4>：横断面超声心动图评估。使用横断面超声心动图评估了两个新生儿，其母亲在怀孕期间摄入了<1>锂</1>。在一名婴儿中，确定了<5>三尖瓣的Ebstein畸形</5>。在另一例婴儿中，横断面超声心动图证实该婴儿没有<6>埃布斯坦畸形</6>。对<2>妊娠期间暴露于锂的</2>新生儿进行横断面超声心动图筛查，可提供高度准确、无创的评估是否存在<3>锂诱发的</3><7>心脏畸形</7>。", "revised": true}
{"doc_key": "10743446", "sentences": [["Differential", "effects", "of", "systemically", "administered", "ketamine", "and", "lidocaine", "on", "dynamic", "and", "static", "hyperalgesia", "induced", "by", "intradermal", "capsaicin", "in", "humans", ".", "We", "have", "examined", "the", "effect", "of", "systemic", "administration", "of", "ketamine", "and", "lidocaine", "on", "brush", "-", "evoked", "(", "dynamic", ")", "pain", "and", "punctate", "-", "evoked", "(", "static", ")", "hyperalgesia", "induced", "by", "capsaicin", ".", "In", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "crossover", "study", ",", "we", "studied", "12", "volunteers", "in", "three", "experiments", ".", "Capsaicin", "100", "micrograms", "was", "injected", "intradermally", "on", "the", "volar", "forearm", "followed", "by", "an", "i", ".", "v", ".", "infusion", "of", "ketamine", "(", "bolus", "0", ".", "1", "mg", "kg", "-", "1", "over", "10", "min", "followed", "by", "infusion", "of", "7", "micrograms", "kg", "-", "1", "min", "-", "1", ")", ",", "lidocaine", "5", "mg", "kg", "-", "1", "or", "saline", "for", "50", "min", ".", "Infusion", "started", "15", "min", "after", "injection", "of", "capsaicin", ".", "The", "following", "were", "measured", ":", "spontaneous", "pain", ",", "pain", "evoked", "by", "punctate", "and", "brush", "stimuli", "(", "VAS", ")", ",", "and", "areas", "of", "brush", "-", "evoked", "and", "punctate", "-", "evoked", "hyperalgesia", ".", "Ketamine", "reduced", "both", "the", "area", "of", "brush", "-", "evoked", "and", "punctate", "-", "evoked", "hyperalgesia", "significantly", "and", "it", "tended", "to", "reduce", "brush", "-", "evoked", "pain", ".", "Lidocaine", "reduced", "the", "area", "of", "punctate", "-", "evoked", "hyperalgesia", "significantly", ".", "It", "tended", "to", "reduce", "VAS", "scores", "of", "spontaneous", "pain", "but", "had", "no", "effect", "on", "evoked", "pain", ".", "The", "differential", "effects", "of", "ketamine", "and", "lidocaine", "on", "static", "and", "dynamic", "hyperalgesia", "suggest", "that", "the", "two", "types", "of", "hyperalgesia", "are", "mediated", "by", "separate", "mechanisms", "and", "have", "a", "distinct", "pharmacology", "."]], "ner": [[[16, 16, "Chemical"], [50, 50, "Chemical"], [75, 75, "Chemical"], [140, 140, "Chemical"], [12, 12, "Disease"], [47, 47, "Disease"], [171, 171, "Disease"], [186, 186, "Disease"], [206, 206, "Disease"], [237, 237, "Disease"], [244, 244, "Disease"], [39, 39, "Disease"], [148, 148, "Disease"], [150, 150, "Disease"], [196, 196, "Disease"], [217, 217, "Disease"], [224, 224, "Disease"], [5, 5, "Chemical"], [29, 29, "Chemical"], [94, 94, "Chemical"], [173, 173, "Chemical"], [230, 230, "Chemical"], [7, 7, "Chemical"], [31, 31, "Chemical"], [121, 121, "Chemical"], [198, 198, "Chemical"], [232, 232, "Chemical"]]], "relations": [[[16, 16, 12, 12, "CID"], [16, 16, 47, 47, "CID"], [16, 16, 171, 171, "CID"], [16, 16, 186, 186, "CID"], [16, 16, 206, 206, "CID"], [16, 16, 237, 237, "CID"], [16, 16, 244, 244, "CID"], [50, 50, 12, 12, "CID"], [50, 50, 47, 47, "CID"], [50, 50, 171, 171, "CID"], [50, 50, 186, 186, "CID"], [50, 50, 206, 206, "CID"], [50, 50, 237, 237, "CID"], [50, 50, 244, 244, "CID"], [75, 75, 12, 12, "CID"], [75, 75, 47, 47, "CID"], [75, 75, 171, 171, "CID"], [75, 75, 186, 186, "CID"], [75, 75, 206, 206, "CID"], [75, 75, 237, 237, "CID"], [75, 75, 244, 244, "CID"], [140, 140, 12, 12, "CID"], [140, 140, 47, 47, "CID"], [140, 140, 171, 171, "CID"], [140, 140, 186, 186, "CID"], [140, 140, 206, 206, "CID"], [140, 140, 237, 237, "CID"], [140, 140, 244, 244, "CID"], [16, 16, 39, 39, "CID"], [16, 16, 148, 148, "CID"], [16, 16, 150, 150, "CID"], [16, 16, 196, 196, "CID"], [16, 16, 217, 217, "CID"], [16, 16, 224, 224, "CID"], [50, 50, 39, 39, "CID"], [50, 50, 148, 148, "CID"], [50, 50, 150, 150, "CID"], [50, 50, 196, 196, "CID"], [50, 50, 217, 217, "CID"], [50, 50, 224, 224, "CID"], [75, 75, 39, 39, "CID"], [75, 75, 148, 148, "CID"], [75, 75, 150, 150, "CID"], [75, 75, 196, 196, "CID"], [75, 75, 217, 217, "CID"], [75, 75, 224, 224, "CID"], [140, 140, 39, 39, "CID"], [140, 140, 148, 148, "CID"], [140, 140, 150, 150, "CID"], [140, 140, 196, 196, "CID"], [140, 140, 217, 217, "CID"], [140, 140, 224, 224, "CID"]]], "clusters": [], "translated": "全身给药<17>氯胺酮</17>和<22>利多卡因</22>对人体皮内<0>辣椒素</0>诱导的动态和静态<4>痛觉过敏</4>的不同影响。我们检查了全身给药 <18>氯胺酮</18> 和 <23>利多卡因</23> 对刷状诱发（动态）<11>疼痛</11> 和点状诱发（静态）<5>痛觉过敏</5>由<1>辣椒素</1>引起的影响。在一项随机、双盲、安慰剂对照、交叉研究中，我们在三个实验中研究了12名志愿者。 <2>辣椒素</2>100微克被皮内注射在前臂掌侧，然后i. v.输注 <19>氯胺酮</19>（推注0.1 mg kg-1超过10分钟，然后输注7微克kg-1分钟-1），<24>利多卡因</24> 5mgkg-1或生理盐水50分钟。输注在<3>辣椒素</3>注射后15分钟开始。测量了以下内容：自发性<12>疼痛</12>，由点状和刷刺激（VAS）诱发的<13>疼痛</13>，以及刷诱发和点状诱发的<6>痛觉过敏</6>区域。<20>氯胺酮</20>显着减少了刷子诱发和点状诱发的<7>痛觉过敏</7>的面积，并且它倾向于减少刷子诱发的<14>疼痛</14>。 <25>利多卡因</25>显着减少了点状诱发的<8>痛觉过敏</8>的面积。它倾向于降低自发性<15>疼痛</15>的VAS评分，但对诱发的<16>疼痛</16>没有影响。<21>氯胺酮</21>和<26>利多卡因</26>对静态和动态<9>痛觉过敏</9>的不同影响表明，这两种类型的<10>痛觉过敏</10>是由独立的机制介导并具有鲜明的药理学。", "revised": true}
{"doc_key": "11256525", "sentences": [["Repeated", "transient", "anuria", "following", "losartan", "administration", "in", "a", "patient", "with", "a", "solitary", "kidney", ".", "We", "report", "the", "case", "of", "a", "70", "-", "year", "-", "old", "hypertensive", "man", "with", "a", "solitary", "kidney", "and", "chronic", "renal", "insufficiency", "who", "developed", "two", "episodes", "of", "transient", "anuria", "after", "losartan", "administration", ".", "He", "was", "hospitalized", "for", "a", "myocardial", "infarction", "with", "pulmonary", "edema", ",", "treated", "with", "high", "-", "dose", "diuretics", ".", "Due", "to", "severe", "systolic", "dysfunction", "losartan", "was", "prescribed", ".", "Surprisingly", ",", "the", "first", "dose", "of", "50", "mg", "of", "losartan", "resulted", "in", "a", "sudden", "anuria", ",", "which", "lasted", "eight", "hours", "despite", "high", "-", "dose", "furosemide", "and", "amine", "infusion", ".", "One", "week", "later", ",", "by", "mistake", ",", "losartan", "was", "prescribed", "again", "and", "after", "the", "second", "dose", "of", "50", "mg", ",", "the", "patient", "developed", "a", "second", "episode", "of", "transient", "anuria", "lasting", "10", "hours", ".", "During", "these", "two", "episodes", ",", "his", "blood", "pressure", "diminished", "but", "no", "severe", "hypotension", "was", "noted", ".", "Ultimately", ",", "an", "arteriography", "showed", "a", "70", "-", "80", "%", "renal", "artery", "stenosis", ".", "In", "this", "patient", ",", "renal", "artery", "stenosis", "combined", "with", "heart", "failure", "and", "diuretic", "therapy", "certainly", "resulted", "in", "a", "strong", "activation", "of", "the", "renin", "-", "angiotensin", "system", "(", "RAS", ")", ".", "Under", "such", "conditions", ",", "angiotensin", "II", "receptor", "blockade", "by", "losartan", "probably", "induced", "a", "critical", "fall", "in", "glomerular", "filtration", "pressure", ".", "This", "case", "report", "highlights", "the", "fact", "that", "the", "angiotensin", "II", "receptor", "antagonist", "losartan", "can", "cause", "serious", "unexpected", "complications", "in", "patients", "with", "renovascular", "disease", "and", "should", "be", "used", "with", "extreme", "caution", "in", "this", "setting", "."]], "ner": [[[4, 4, "Chemical"], [43, 43, "Chemical"], [69, 69, "Chemical"], [82, 82, "Chemical"], [109, 109, "Chemical"], [204, 204, "Chemical"], [227, 227, "Chemical"], [2, 2, "Disease"], [41, 41, "Disease"], [87, 87, "Disease"], [130, 130, "Disease"], [97, 97, "Chemical"], [99, 99, "Chemical"], [189, 189, "Chemical"], [199, 200, "Chemical"], [223, 224, "Chemical"], [25, 25, "Disease"], [32, 34, "Disease"], [51, 52, "Disease"], [54, 55, "Disease"], [67, 68, "Disease"], [147, 147, "Disease"], [161, 163, "Disease"], [169, 171, "Disease"], [174, 175, "Disease"], [236, 237, "Disease"]]], "relations": [[[4, 4, 2, 2, "CID"], [4, 4, 41, 41, "CID"], [4, 4, 87, 87, "CID"], [4, 4, 130, 130, "CID"], [43, 43, 2, 2, "CID"], [43, 43, 41, 41, "CID"], [43, 43, 87, 87, "CID"], [43, 43, 130, 130, "CID"], [69, 69, 2, 2, "CID"], [69, 69, 41, 41, "CID"], [69, 69, 87, 87, "CID"], [69, 69, 130, 130, "CID"], [82, 82, 2, 2, "CID"], [82, 82, 41, 41, "CID"], [82, 82, 87, 87, "CID"], [82, 82, 130, 130, "CID"], [109, 109, 2, 2, "CID"], [109, 109, 41, 41, "CID"], [109, 109, 87, 87, "CID"], [109, 109, 130, 130, "CID"], [204, 204, 2, 2, "CID"], [204, 204, 41, 41, "CID"], [204, 204, 87, 87, "CID"], [204, 204, 130, 130, "CID"], [227, 227, 2, 2, "CID"], [227, 227, 41, 41, "CID"], [227, 227, 87, 87, "CID"], [227, 227, 130, 130, "CID"]]], "clusters": [], "translated": "<0>氯沙坦</0> 给药后，单肾患者反复出现短暂性<7>无尿</7>。我们报告了一名 70 岁的<16>高血压</16> 男性，他患有孤立肾和<17>慢性肾功能不全</17>，他在治疗后出现两次短暂性<8>无尿</8><1>氯沙坦</1>给药。他因<18>心肌梗塞</18>和<19>肺水肿</19>住院，接受大剂量利尿剂治疗。由于严重的<20>收缩功能障碍</20><2>氯沙坦</2>被规定。令人惊讶的是，首次服用 50mg 的<3>氯沙坦</3>导致了突然的<9>无尿</9>，尽管使用了高剂量的<11>呋塞米</11>和<12>胺</12>输液仍持续了八个小时。一周后，由于失误，再次开了<4>氯沙坦</4>，在第二次服用50mg 后，患者出现了第二次持续10小时的短暂性<10>无尿</10>。在这两次发作期间，他的血压有所下降，但未发现严重的<21>低血压</21>。最终，动脉造影显示 70-80%<22>肾动脉狭窄</22>。在该患者中，<23>肾动脉狭窄</23>合并<24>心力衰竭</24>和利尿剂治疗肯定会导致肾素-<13>血管紧张素</13>系统(RAS)的强烈激活。在这种情况下，<5>氯沙坦</5>对<14>血管紧张素II</14>受体的阻断作用可能导致肾小球滤过压急剧下降。本病例报告强调了这样一个事实，即<15>血管紧张素II</15>受体拮抗剂<6>氯沙坦</6>可在<25>肾血管疾病</25>患者中引起严重的意外并发症，应在极端情况下谨慎使用此设置。", "revised": true}
{"doc_key": "4812392", "sentences": [["Treatment", "of", "psoriasis", "with", "azathioprine", ".", "Azathioprine", "treatment", "benefited", "19", "(", "66", "%", ")", "out", "of", "29", "patients", "suffering", "from", "severe", "psoriasis", ".", "Haematological", "complications", "were", "not", "troublesome", "and", "results", "of", "biochemical", "liver", "function", "tests", "remained", "normal", ".", "Minimal", "cholestasis", "was", "seen", "in", "two", "cases", "and", "portal", "fibrosis", "of", "a", "reversible", "degree", "in", "eight", ".", "Liver", "biopsies", "should", "be", "undertaken", "at", "regular", "intervals", "if", "azathioprine", "therapy", "is", "continued", "so", "that", "structural", "liver", "damage", "may", "be", "detected", "at", "an", "early", "and", "reversible", "stage", "."]], "ner": [[[4, 4, "Chemical"], [6, 6, "Chemical"], [64, 64, "Chemical"], [39, 39, "Disease"], [47, 47, "Disease"], [2, 2, "Disease"], [21, 21, "Disease"], [71, 72, "Disease"]]], "relations": [[[4, 4, 39, 39, "CID"], [6, 6, 39, 39, "CID"], [64, 64, 39, 39, "CID"], [4, 4, 47, 47, "CID"], [6, 6, 47, 47, "CID"], [64, 64, 47, 47, "CID"]]], "clusters": [], "translated": "用<0>硫唑嘌呤</0>治疗<5>银屑病</5>。 <1>硫唑嘌呤</1>治疗使29名患有严重<6>银屑病</6>的患者中的19名（66%）受益。血液学并发症并不麻烦，生化肝功能检查结果保持正常。2例出现轻微<3>胆汁淤积</3>，8例出现可逆程度的<4>门脉纤维化</4>。如果继续<2>硫唑嘌呤</2>治疗，应定期进行肝活检，以便在早期和可逆阶段检测到<7>结构性肝损伤</7>。", "revised": true}
{"doc_key": "10721819", "sentences": [["Effects", "of", "long", "-", "term", "pretreatment", "with", "isoproterenol", "on", "bromocriptine", "-", "induced", "tachycardia", "in", "conscious", "rats", ".", "It", "has", "been", "shown", "that", "bromocriptine", "-", "induced", "tachycardia", ",", "which", "persisted", "after", "adrenalectomy", ",", "is", "(", "i", ")", "mediated", "by", "central", "dopamine", "D2", "receptor", "activation", "and", "(", "ii", ")", "reduced", "by", "5", "-", "day", "isoproterenol", "pretreatment", ",", "supporting", "therefore", "the", "hypothesis", "that", "this", "effect", "is", "dependent", "on", "sympathetic", "outflow", "to", "the", "heart", ".", "This", "study", "was", "conducted", "to", "examine", "whether", "prolonged", "pretreatment", "with", "isoproterenol", "could", "abolish", "bromocriptine", "-", "induced", "tachycardia", "in", "conscious", "rats", ".", "Isoproterenol", "pretreatment", "for", "15", "days", "caused", "cardiac", "hypertrophy", "without", "affecting", "baseline", "blood", "pressure", "and", "heart", "rate", ".", "In", "control", "rats", ",", "intravenous", "bromocriptine", "(", "150", "microg", "/", "kg", ")", "induced", "significant", "hypotension", "and", "tachycardia", ".", "Bromocriptine", "-", "induced", "hypotension", "was", "unaffected", "by", "isoproterenol", "pretreatment", ",", "while", "tachycardia", "was", "reversed", "to", "significant", "bradycardia", ",", "an", "effect", "that", "was", "partly", "reduced", "by", "i", ".", "v", ".", "domperidone", "(", "0", ".", "5", "mg", "/", "kg", ")", ".", "Neither", "cardiac", "vagal", "nor", "sympathetic", "tone", "was", "altered", "by", "isoproterenol", "pretreatment", ".", "In", "isolated", "perfused", "heart", "preparations", "from", "isoproterenol", "-", "pretreated", "rats", ",", "the", "isoproterenol", "-", "induced", "maximal", "increase", "in", "left", "ventricular", "systolic", "pressure", "was", "significantly", "reduced", ",", "compared", "with", "saline", "-", "pretreated", "rats", "(", "the", "EC50", "of", "the", "isoproterenol", "-", "induced", "increase", "in", "left", "ventricular", "systolic", "pressure", "was", "enhanced", "approximately", "22", "-", "fold", ")", ".", "These", "results", "show", "that", "15", "-", "day", "isoproterenol", "pretreatment", "not", "only", "abolished", "but", "reversed", "bromocriptine", "-", "induced", "tachycardia", "to", "bradycardia", ",", "an", "effect", "that", "is", "mainly", "related", "to", "further", "cardiac", "beta", "-", "adrenoceptor", "desensitization", "rather", "than", "to", "impairment", "of", "autonomic", "regulation", "of", "the", "heart", ".", "They", "suggest", "that", ",", "in", "normal", "conscious", "rats", ",", "the", "central", "tachycardia", "of", "bromocriptine", "appears", "to", "predominate", "and", "to", "mask", "the", "bradycardia", "of", "this", "agonist", "at", "peripheral", "dopamine", "D2", "receptors", "."]], "ner": [[[7, 7, "Chemical"], [52, 52, "Chemical"], [81, 81, "Chemical"], [92, 92, "Chemical"], [134, 134, "Chemical"], [175, 175, "Chemical"], [184, 184, "Chemical"], [190, 190, "Chemical"], [215, 215, "Chemical"], [239, 239, "Chemical"], [98, 99, "Disease"], [143, 143, "Disease"], [251, 251, "Disease"], [298, 298, "Disease"], [9, 9, "Chemical"], [22, 22, "Chemical"], [84, 84, "Chemical"], [114, 114, "Chemical"], [127, 127, "Chemical"], [246, 246, "Chemical"], [290, 290, "Chemical"], [12, 12, "Disease"], [25, 25, "Disease"], [87, 87, "Disease"], [125, 125, "Disease"], [138, 138, "Disease"], [249, 249, "Disease"], [288, 288, "Disease"], [123, 123, "Disease"], [130, 130, "Disease"], [156, 156, "Chemical"], [39, 39, "Chemical"], [304, 304, "Chemical"]]], "relations": [[[7, 7, 98, 99, "CID"], [52, 52, 98, 99, "CID"], [81, 81, 98, 99, "CID"], [92, 92, 98, 99, "CID"], [134, 134, 98, 99, "CID"], [175, 175, 98, 99, "CID"], [184, 184, 98, 99, "CID"], [190, 190, 98, 99, "CID"], [215, 215, 98, 99, "CID"], [239, 239, 98, 99, "CID"], [7, 7, 143, 143, "CID"], [7, 7, 251, 251, "CID"], [7, 7, 298, 298, "CID"], [52, 52, 143, 143, "CID"], [52, 52, 251, 251, "CID"], [52, 52, 298, 298, "CID"], [81, 81, 143, 143, "CID"], [81, 81, 251, 251, "CID"], [81, 81, 298, 298, "CID"], [92, 92, 143, 143, "CID"], [92, 92, 251, 251, "CID"], [92, 92, 298, 298, "CID"], [134, 134, 143, 143, "CID"], [134, 134, 251, 251, "CID"], [134, 134, 298, 298, "CID"], [175, 175, 143, 143, "CID"], [175, 175, 251, 251, "CID"], [175, 175, 298, 298, "CID"], [184, 184, 143, 143, "CID"], [184, 184, 251, 251, "CID"], [184, 184, 298, 298, "CID"], [190, 190, 143, 143, "CID"], [190, 190, 251, 251, "CID"], [190, 190, 298, 298, "CID"], [215, 215, 143, 143, "CID"], [215, 215, 251, 251, "CID"], [215, 215, 298, 298, "CID"], [239, 239, 143, 143, "CID"], [239, 239, 251, 251, "CID"], [239, 239, 298, 298, "CID"], [9, 9, 12, 12, "CID"], [9, 9, 25, 25, "CID"], [9, 9, 87, 87, "CID"], [9, 9, 125, 125, "CID"], [9, 9, 138, 138, "CID"], [9, 9, 249, 249, "CID"], [9, 9, 288, 288, "CID"], [22, 22, 12, 12, "CID"], [22, 22, 25, 25, "CID"], [22, 22, 87, 87, "CID"], [22, 22, 125, 125, "CID"], [22, 22, 138, 138, "CID"], [22, 22, 249, 249, "CID"], [22, 22, 288, 288, "CID"], [84, 84, 12, 12, "CID"], [84, 84, 25, 25, "CID"], [84, 84, 87, 87, "CID"], [84, 84, 125, 125, "CID"], [84, 84, 138, 138, "CID"], [84, 84, 249, 249, "CID"], [84, 84, 288, 288, "CID"], [114, 114, 12, 12, "CID"], [114, 114, 25, 25, "CID"], [114, 114, 87, 87, "CID"], [114, 114, 125, 125, "CID"], [114, 114, 138, 138, "CID"], [114, 114, 249, 249, "CID"], [114, 114, 288, 288, "CID"], [127, 127, 12, 12, "CID"], [127, 127, 25, 25, "CID"], [127, 127, 87, 87, "CID"], [127, 127, 125, 125, "CID"], [127, 127, 138, 138, "CID"], [127, 127, 249, 249, "CID"], [127, 127, 288, 288, "CID"], [246, 246, 12, 12, "CID"], [246, 246, 25, 25, "CID"], [246, 246, 87, 87, "CID"], [246, 246, 125, 125, "CID"], [246, 246, 138, 138, "CID"], [246, 246, 249, 249, "CID"], [246, 246, 288, 288, "CID"], [290, 290, 12, 12, "CID"], [290, 290, 25, 25, "CID"], [290, 290, 87, 87, "CID"], [290, 290, 125, 125, "CID"], [290, 290, 138, 138, "CID"], [290, 290, 249, 249, "CID"], [290, 290, 288, 288, "CID"], [9, 9, 123, 123, "CID"], [9, 9, 130, 130, "CID"], [22, 22, 123, 123, "CID"], [22, 22, 130, 130, "CID"], [84, 84, 123, 123, "CID"], [84, 84, 130, 130, "CID"], [114, 114, 123, 123, "CID"], [114, 114, 130, 130, "CID"], [127, 127, 123, 123, "CID"], [127, 127, 130, 130, "CID"], [246, 246, 123, 123, "CID"], [246, 246, 130, 130, "CID"], [290, 290, 123, 123, "CID"], [290, 290, 130, 130, "CID"], [156, 156, 143, 143, "CID"], [156, 156, 251, 251, "CID"], [156, 156, 298, 298, "CID"]]], "clusters": [], "translated": "<0>异丙肾上腺素</0>长期预处理对<14>溴隐亭</14>诱发的清醒大鼠<21>心动过速</21>的影响。已经表明，<15>溴隐亭</15>诱导的<22>心动过速</22>在肾上腺切除术后持续存在，是 (i) 由中枢<31>多巴胺</31>D2受体激活和 (ii) 减少了5天的<1>异丙肾上腺素</1>预处理，因此支持这种效应依赖于心脏交感神经流出的假设。进行这项研究是为了检查用<2>异丙肾上腺素</2>延长预处理是否可以消除<16>溴隐亭</16>诱导的有意识大鼠的<23>心动过速</23>。 <3>异丙肾上腺素</3>预处理15天引起<10>心脏肥大</10>，但不影响基线血压和心率。在对照大鼠中，静脉注射<17>溴隐亭</17>（150微克/千克）可引起显着的<24>心动过速</24>和<28>低血压</28>。 <18>溴隐亭</18>引起的<29>低血压</29>不受<4>异丙肾上腺素</4>预处理的影响，而<25>心动过速</25>逆转为明显的<11>心动过缓</11>，部分被i.v.<30>多潘立酮</30> (0.5 mg/kg)降低的效果。 <5>异丙肾上腺素</5>预处理后，心脏迷走神经和交感神经张力均未改变。在来自<6>异丙肾上腺素</6>预处理大鼠的离体灌注心脏制剂中，<7>异丙肾上腺素</7>诱导的左心室收缩压的最大增加与盐水预处理大鼠相比显着降低（<8>异丙肾上腺素</8>引起的左心室收缩压增加的EC50大约提高了22倍）。这些结果表明，15天<9>异丙肾上腺素</9> 预处理不仅消除，而且逆转了<19>溴隐亭</19>诱导的<26>心动过速</26> 至<12>心动过缓</12>，这种影响主要与心脏β-肾上腺素能受体进一步脱敏有关，而不是与心脏自主调节受损有关。他们表明，在正常清醒的大鼠中，<20>溴隐亭</20>的中枢性<27>心动过速</27>似乎占主导地位，并掩盖了外周<32>多巴胺</32>D2受体这种激动剂的<13>心动过缓</13>。", "revised": true}
{"doc_key": "9522143", "sentences": [["The", "effect", "of", "different", "anaesthetic", "agents", "in", "hearing", "loss", "following", "spinal", "anaesthesia", ".", "The", "cause", "of", "hearing", "loss", "after", "spinal", "anaesthesia", "is", "unknown", ".", "Up", "until", "now", ",", "the", "only", "factor", "studied", "has", "been", "the", "effect", "of", "the", "diameter", "of", "the", "spinal", "needle", "on", "post", "-", "operative", "sensorineural", "hearing", "loss", ".", "The", "aim", "of", "this", "study", "was", "to", "describe", "this", "hearing", "loss", "and", "to", "investigate", "other", "factors", "influencing", "the", "degree", "of", "hearing", "loss", ".", "Two", "groups", "of", "22", "similar", "patients", "were", "studied", ":", "one", "group", "received", "6", "mL", "prilocaine", "2", "%", ";", "and", "the", "other", "received", "3", "mL", "bupivacaine", "0", ".", "5", "%", ".", "Patients", "given", "prilocaine", "were", "more", "likely", "to", "develop", "hearing", "loss", "(", "10", "out", "of", "22", ")", "than", "those", "given", "bupivacaine", "(", "4", "out", "of", "22", ")", "(", "P", "<", "0", ".", "05", ")", ".", "The", "average", "hearing", "loss", "for", "speech", "frequencies", "was", "about", "10", "dB", "after", "prilocaine", "and", "15", "dB", "after", "bupivacaine", ".", "None", "of", "the", "patients", "complained", "of", "subjective", "hearing", "loss", ".", "Long", "-", "term", "follow", "-", "up", "of", "the", "patients", "was", "not", "possible", "."]], "ner": [[[88, 88, "Chemical"], [106, 106, "Chemical"], [150, 150, "Chemical"], [7, 8, "Disease"], [16, 17, "Disease"], [60, 61, "Disease"], [71, 72, "Disease"], [112, 113, "Disease"], [140, 141, "Disease"], [164, 165, "Disease"], [98, 98, "Chemical"], [123, 123, "Chemical"], [155, 155, "Chemical"], [47, 49, "Disease"]]], "relations": [[[88, 88, 7, 8, "CID"], [88, 88, 16, 17, "CID"], [88, 88, 60, 61, "CID"], [88, 88, 71, 72, "CID"], [88, 88, 112, 113, "CID"], [88, 88, 140, 141, "CID"], [88, 88, 164, 165, "CID"], [106, 106, 7, 8, "CID"], [106, 106, 16, 17, "CID"], [106, 106, 60, 61, "CID"], [106, 106, 71, 72, "CID"], [106, 106, 112, 113, "CID"], [106, 106, 140, 141, "CID"], [106, 106, 164, 165, "CID"], [150, 150, 7, 8, "CID"], [150, 150, 16, 17, "CID"], [150, 150, 60, 61, "CID"], [150, 150, 71, 72, "CID"], [150, 150, 112, 113, "CID"], [150, 150, 140, 141, "CID"], [150, 150, 164, 165, "CID"], [98, 98, 7, 8, "CID"], [98, 98, 16, 17, "CID"], [98, 98, 60, 61, "CID"], [98, 98, 71, 72, "CID"], [98, 98, 112, 113, "CID"], [98, 98, 140, 141, "CID"], [98, 98, 164, 165, "CID"], [123, 123, 7, 8, "CID"], [123, 123, 16, 17, "CID"], [123, 123, 60, 61, "CID"], [123, 123, 71, 72, "CID"], [123, 123, 112, 113, "CID"], [123, 123, 140, 141, "CID"], [123, 123, 164, 165, "CID"], [155, 155, 7, 8, "CID"], [155, 155, 16, 17, "CID"], [155, 155, 60, 61, "CID"], [155, 155, 71, 72, "CID"], [155, 155, 112, 113, "CID"], [155, 155, 140, 141, "CID"], [155, 155, 164, 165, "CID"]]], "clusters": [], "translated": "不同麻醉剂对腰麻后<3>听力损失</3>的影响。腰麻后<4>听力下降</4>的原因不明。到目前为止，唯一研究的因素是脊髓穿刺针的直径对术后<13>感音神经性听力损失</13>的影响。本研究的目的是描述这种<5>听力损失</5>并调查影响<6>听力损失</6>程度的其他因素。研究了两组 22 名相似的患者：一组接受 6 mL <0>丙胺卡因</0> 2%；另一个接受 3 mL <10>布比卡因</10> 0.5%。接受<1>丙胺卡因</1>的患者比接受<11>布比卡因</11>的患者（22 人中有 4 人）更容易发生<7>听力损失</7>（22 人中有 10 人）（P < 0.05）。<2>丙胺卡因</2>后，语音频率的平均<8>听力损失</8>约为 10 dB，<12>布比卡因</12>后约为 15 dB。没有患者主诉有主观<9>听力下降</9>。不可能对患者进行长期随访。", "revised": true}
{"doc_key": "9249847", "sentences": [["Iatrogenically", "induced", "intractable", "atrioventricular", "reentrant", "tachycardia", "after", "verapamil", "and", "catheter", "ablation", "in", "a", "patient", "with", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "and", "idiopathic", "dilated", "cardiomyopathy", ".", "In", "a", "patient", "with", "WPW", "syndrome", "and", "idiopathic", "dilated", "cardiomyopathy", ",", "intractable", "atrioventricular", "reentrant", "tachycardia", "(", "AVRT", ")", "was", "iatrogenically", "induced", ".", "QRS", "without", "preexcitation", ",", "caused", "by", "junctional", "escape", "beats", "after", "verapamil", "or", "unidirectional", "antegrade", "block", "of", "accessory", "pathway", "after", "catheter", "ablation", ",", "established", "frequent", "AVRT", "attack", "."]], "ner": [[[7, 7, "Chemical"], [58, 58, "Chemical"], [3, 5, "Disease"], [38, 40, "Disease"], [42, 42, "Disease"], [72, 72, "Disease"], [15, 20, "Disease"], [30, 31, "Disease"], [22, 24, "Disease"], [33, 35, "Disease"]]], "relations": [[[7, 7, 3, 5, "CID"], [7, 7, 38, 40, "CID"], [7, 7, 42, 42, "CID"], [7, 7, 72, 72, "CID"], [58, 58, 3, 5, "CID"], [58, 58, 38, 40, "CID"], [58, 58, 42, 42, "CID"], [58, 58, 72, 72, "CID"]]], "clusters": [], "translated": "一名患有<6>沃尔夫-帕金森-怀特综合征</6>和<8>特发性扩张型心肌病</8>的患者，在<0>维拉帕米</0>和导管消融后，医源性诱发了难治性<2>房室折返性心动过速</2>（<4>AVRT</4>）。患者患有<7>WPW综合征</7>和<9>特发性扩张型心肌病</9>，医源性诱发了难治性<3>房室折返性心动过速</3>（<5>AVRT</5>）。无预激的QRS，在<1>维拉帕米</1>后发生交界性逸搏或导管消融后，旁路单向顺行阻滞引起频繁的<5>AVRT</5>发作。", "revised": true}
{"doc_key": "19759529", "sentences": [["The", "glycine", "transporter", "-", "1", "inhibitor", "SSR103800", "displays", "a", "selective", "and", "specific", "antipsychotic", "-", "like", "profile", "in", "normal", "and", "transgenic", "mice", ".", "Schizophrenia", "has", "been", "initially", "associated", "with", "dysfunction", "in", "dopamine", "neurotransmission", ".", "However", ",", "the", "observation", "that", "antagonists", "of", "the", "glutamate", "N", "-", "methyl", "-", "D", "-", "aspartate", "(", "NMDA", ")", "receptor", "produce", "schizophrenic", "-", "like", "symptoms", "in", "humans", "has", "led", "to", "the", "idea", "of", "a", "dysfunctioning", "of", "the", "glutamatergic", "system", "via", "its", "NMDA", "receptor", ".", "As", "a", "result", ",", "there", "is", "a", "growing", "interest", "in", "the", "development", "of", "pharmacological", "agents", "with", "potential", "antipsychotic", "properties", "that", "enhance", "the", "activity", "of", "the", "glutamatergic", "system", "via", "a", "modulation", "of", "the", "NMDA", "receptor", ".", "Among", "them", "are", "glycine", "transporter", "-", "1", "(", "GlyT1", ")", "inhibitors", "such", "as", "SSR103800", ",", "which", "indirectly", "enhance", "NMDA", "receptor", "function", "by", "increasing", "the", "glycine", "(", "a", "co", "-", "agonist", "for", "the", "NMDA", "receptor", ")", "levels", "in", "the", "synapse", ".", "This", "study", "aimed", "at", "investigating", "the", "potential", "antipsychotic", "-", "like", "properties", "of", "SSR103800", ",", "with", "a", "particular", "focus", "on", "models", "of", "hyperactivity", ",", "involving", "either", "drug", "challenge", "(", "ie", ",", "amphetamine", "and", "MK", "-", "801", ")", "or", "transgenic", "mice", "(", "ie", ",", "NMDA", "Nr1", "(", "neo", "-", "/", "-", ")", "and", "DAT", "(", "-", "/", "-", ")", ")", ".", "Results", "showed", "that", "SSR103800", "(", "10", "-", "30", "mg", "/", "kg", "p", ".", "o", ".", ")", "blocked", "hyperactivity", "induced", "by", "the", "non", "-", "competitive", "NMDA", "receptor", "antagonist", ",", "MK", "-", "801", "and", "partially", "reversed", "spontaneous", "hyperactivity", "of", "NMDA", "Nr1", "(", "neo", "-", "/", "-", ")", "mice", ".", "In", "contrast", ",", "SSR103800", "failed", "to", "affect", "hyperactivity", "induced", "by", "amphetamine", "or", "naturally", "observed", "in", "dopamine", "transporter", "(", "DAT", "(", "-", "/", "-", ")", ")", "knockout", "mice", "(", "10", "-", "30", "mg", "/", "kg", "p", ".", "o", ".", ")", ".", "Importantly", ",", "both", "classical", "(", "haloperidol", ")", "and", "atypical", "(", "olanzapine", ",", "clozapine", "and", "aripiprazole", ")", "antipsychotics", "were", "effective", "in", "all", "these", "models", "of", "hyperactivity", ".", "However", ",", "unlike", "these", "latter", ",", "SSR103800", "did", "not", "produce", "catalepsy", "(", "retention", "on", "the", "bar", "test", ")", "up", "to", "30", "mg", "/", "kg", "p", ".", "o", ".", "Together", "these", "findings", "show", "that", "the", "GlyT1", "inhibitor", ",", "SSR103800", ",", "produces", "antipsychotic", "-", "like", "effects", ",", "which", "differ", "from", "those", "observed", "with", "compounds", "primarily", "targeting", "the", "dopaminergic", "system", ",", "and", "has", "a", "reduced", "side", "-", "effect", "potential", "as", "compared", "with", "these", "latter", "drugs", "."]], "ner": [[[182, 182, "Chemical"], [268, 268, "Chemical"], [173, 173, "Disease"], [228, 228, "Disease"], [246, 246, "Disease"], [265, 265, "Disease"], [322, 322, "Disease"], [184, 186, "Chemical"], [239, 241, "Chemical"], [303, 303, "Chemical"], [334, 334, "Disease"], [308, 308, "Chemical"], [310, 310, "Chemical"], [312, 312, "Chemical"], [1, 1, "Chemical"], [115, 115, "Chemical"], [136, 136, "Chemical"], [22, 22, "Disease"], [54, 54, "Disease"], [30, 30, "Chemical"], [273, 273, "Chemical"], [41, 41, "Chemical"], [42, 48, "Chemical"], [50, 50, "Chemical"], [74, 74, "Chemical"], [109, 109, "Chemical"], [130, 130, "Chemical"], [144, 144, "Chemical"], [194, 194, "Chemical"], [235, 235, "Chemical"], [248, 248, "Chemical"]]], "relations": [[[182, 182, 173, 173, "CID"], [182, 182, 228, 228, "CID"], [182, 182, 246, 246, "CID"], [182, 182, 265, 265, "CID"], [182, 182, 322, 322, "CID"], [268, 268, 173, 173, "CID"], [268, 268, 228, 228, "CID"], [268, 268, 246, 246, "CID"], [268, 268, 265, 265, "CID"], [268, 268, 322, 322, "CID"], [184, 186, 173, 173, "CID"], [184, 186, 228, 228, "CID"], [184, 186, 246, 246, "CID"], [184, 186, 265, 265, "CID"], [184, 186, 322, 322, "CID"], [239, 241, 173, 173, "CID"], [239, 241, 228, 228, "CID"], [239, 241, 246, 246, "CID"], [239, 241, 265, 265, "CID"], [239, 241, 322, 322, "CID"], [303, 303, 334, 334, "CID"], [308, 308, 334, 334, "CID"], [310, 310, 334, 334, "CID"], [312, 312, 334, 334, "CID"]]], "clusters": [], "translated": "<14>甘氨酸</14>转运蛋白-1抑制剂SSR103800在正常和转基因小鼠中表现出选择性和特异性抗精神病药样特征。<17>精神分裂症</17>最初与<19>多巴胺</19>神经传递功能障碍有关。然而，观察到<21>谷氨酸</21><22>N-甲基-D-天冬氨酸</22>(<23>NMDA</23>)受体拮抗剂产生<18>精神分裂症</18>-人类的类似症状导致了谷氨酸能系统通过其<24>NMDA</24>受体功能障碍的想法。因此，人们越来越关注开发具有潜在抗精神病特性的药物，这些药物通过调节<25>NMDA</25>受体来增强谷氨酸能系统的活性。其中有<15>甘氨酸</15>转运蛋白-1(GlyT1)抑制剂，如SSR103800，通过增加<16>甘氨酸</16>(一种辅酶-<27>NMDA</27>受体的激动剂)在突触中的水平，间接增强了<26>NMDA</26>受体功能。本研究旨在研究SSR103800的潜在抗精神病药样特性，特别关注<2>多动症</2>模型，涉及药物挑战(即<0>苯丙胺</0>和<7>MK-801</7>)或转基因小鼠(即<28>NMDA</28>Nr1(neo-/-)和DAT(-/-))。结果表明，SSR103800(10-30mg/kgp.o.)可阻断由非竞争性<29>NMDA</29>受体拮抗剂<8>MK-801</8>诱导的<3>活动过度</3>并部分逆转了<30>NMDA</30>Nr1(neo-/-)小鼠的自发性<4>活动过度</4>。相比之下，SSR103800未能影响<1>苯丙胺</1>诱导的<5>活动过度</5>或在<20>多巴胺</20>转运蛋白(DAT(-/-))敲除小鼠中自然观察到的(10-30毫克/公斤p.o.)。重要的是，经典(<9>氟哌啶醇</9>)和非典型(<11>奥氮平</11>，<12>氯氮平</12>和<13>阿立哌唑</13>)抗精神病药物对所有这些都有效<6>多动症</6>模型。然而，与后者不同的是，SSR103800在高达30mg/kgp时不会产生<10>强直性昏厥</10>（在棒测试中的滞留）。这些发现共同表明，GlyT1抑制剂SSR103800可产生类似抗精神病药的作用，这与主要针对多巴胺能系统的化合物所观察到的作用不同，并且与后两种药物相比，潜在的副作用较小。", "revised": true}
{"doc_key": "12684739", "sentences": [["Sub", "-", "chronic", "low", "dose", "gamma", "-", "vinyl", "GABA", "(", "vigabatrin", ")", "inhibits", "cocaine", "-", "induced", "increases", "in", "nucleus", "accumbens", "dopamine", ".", "RATIONALE", ":", "gamma", "-", "Vinyl", "GABA", "(", "GVG", ")", "irreversibly", "inhibits", "GABA", "-", "transaminase", ".", "This", "non", "-", "receptor", "mediated", "inhibition", "requires", "de", "novo", "synthesis", "for", "restoration", "of", "functional", "GABA", "catabolism", ".", "OBJECTIVES", ":", "Given", "its", "preclinical", "success", "for", "treating", "substance", "abuse", "and", "the", "increased", "risk", "of", "visual", "field", "defects", "(", "VFD", ")", "associated", "with", "cumulative", "lifetime", "exposure", ",", "we", "explored", "the", "effects", "of", "sub", "-", "chronic", "low", "dose", "GVG", "on", "cocaine", "-", "induced", "increases", "in", "nucleus", "accumbens", "(", "NAcc", ")", "dopamine", "(", "DA", ")", ".", "METHODS", ":", "Using", "in", "vivo", "microdialysis", ",", "we", "compared", "acute", "exposure", "(", "450", "mg", "/", "kg", ")", "to", "an", "identical", "sub", "-", "chronic", "exposure", "(", "150", "mg", "/", "kg", "per", "day", "for", "3", "days", ")", ",", "followed", "by", "1", "-", "or", "3", "-", "day", "washout", ".", "Finally", ",", "we", "examined", "the", "low", "dose", "of", "150", "mg", "/", "kg", "(", "50", "mg", "/", "kg", "per", "day", ")", "using", "a", "similar", "washout", "period", ".", "RESULTS", ":", "Sub", "-", "chronic", "GVG", "exposure", "inhibited", "the", "effect", "of", "cocaine", "for", "3", "days", ",", "which", "exceeded", "in", "magnitude", "and", "duration", "the", "identical", "acute", "dose", ".", "CONCLUSIONS", ":", "Sub", "-", "chronic", "low", "dose", "GVG", "potentiates", "and", "extends", "the", "inhibition", "of", "cocaine", "-", "induced", "increases", "in", "dopamine", ",", "effectively", "reducing", "cumulative", "exposures", "and", "the", "risk", "for", "VFDS", "."]], "ner": [[[5, 8, "Chemical"], [10, 10, "Chemical"], [24, 27, "Chemical"], [29, 29, "Chemical"], [91, 91, "Chemical"], [185, 185, "Chemical"], [214, 214, "Chemical"], [69, 71, "Disease"], [73, 73, "Disease"], [62, 63, "Disease"], [13, 13, "Chemical"], [93, 93, "Chemical"], [191, 191, "Chemical"], [221, 221, "Chemical"], [20, 20, "Chemical"], [103, 103, "Chemical"], [105, 105, "Chemical"], [226, 226, "Chemical"], [33, 33, "Chemical"], [51, 51, "Chemical"]]], "relations": [[[5, 8, 69, 71, "CID"], [5, 8, 73, 73, "CID"], [10, 10, 69, 71, "CID"], [10, 10, 73, 73, "CID"], [24, 27, 69, 71, "CID"], [24, 27, 73, 73, "CID"], [29, 29, 69, 71, "CID"], [29, 29, 73, 73, "CID"], [91, 91, 69, 71, "CID"], [91, 91, 73, 73, "CID"], [185, 185, 69, 71, "CID"], [185, 185, 73, 73, "CID"], [214, 214, 69, 71, "CID"], [214, 214, 73, 73, "CID"]]], "clusters": [], "translated": "亚慢性低剂量<0>γ-乙烯基 GABA</0>（<1>氨己烯酸</1>）抑制<10>可卡因</10>诱导的伏隔核<14>多巴胺</14>增加。基本原理：<2>γ-乙烯基 GABA</2> (<3>GVG</3>) 不可逆地抑制<18>GABA</18>-转氨酶。这种非受体介导的抑制需要从头合成以恢复功能性<19>GABA</19>分解代谢。目的：鉴于其在治疗<9>药物滥用</9>方面的临床前成功以及与累积终生暴露相关的<7>视野缺损</7>（<8>VFD</8>）风险增加，我们探索了亚慢性低剂量<4>GVG</4>对<11>可卡因</11>诱导的伏隔核 (NAcc)<15>多巴胺</15>（<16>DA</16>）的影响。方法：使用体内微透析，我们比较了急性暴露（450 mg/kg）和相同的亚慢性暴露（每天150 mg/kg，持续3天），然后进行1或3天的清除。最后，我们使用类似的清除期检查了150 mg/kg（每天50 mg/kg）的低剂量。结果：亚慢性<5>GVG</5>暴露抑制<12>可卡因</12>的作用达3天，其幅度和持续时间超过相同的急性剂量。结论：亚慢性低剂量<6>GVG</6>增强并延长了对<13>可卡因</13>诱导的<17>多巴胺</17>增加的抑制作用，有效降低了累积暴露和<8>VFD</8>。", "revised": true}
{"doc_key": "12757899", "sentences": [["Estradiol", "reduces", "seizure", "-", "induced", "hippocampal", "injury", "in", "ovariectomized", "female", "but", "not", "in", "male", "rats", ".", "Estrogens", "protect", "ovariectomized", "rats", "from", "hippocampal", "injury", "induced", "by", "kainic", "acid", "-", "induced", "status", "epilepticus", "(", "SE", ")", ".", "We", "compared", "the", "effects", "of", "17beta", "-", "estradiol", "in", "adult", "male", "and", "ovariectomized", "female", "rats", "subjected", "to", "lithium", "-", "pilocarpine", "-", "induced", "SE", ".", "Rats", "received", "subcutaneous", "injections", "of", "17beta", "-", "estradiol", "(", "2", "microg", "/", "rat", ")", "or", "oil", "once", "daily", "for", "four", "consecutive", "days", ".", "SE", "was", "induced", "20", "h", "following", "the", "second", "injection", "and", "terminated", "3", "h", "later", ".", "The", "extent", "of", "silver", "-", "stained", "CA3", "and", "CA1", "hippocampal", "neurons", "was", "evaluated", "2", "days", "after", "SE", ".", "17beta", "-", "Estradiol", "did", "not", "alter", "the", "onset", "of", "first", "clonus", "in", "ovariectomized", "rats", "but", "accelerated", "it", "in", "males", ".", "17beta", "-", "Estradiol", "reduced", "the", "argyrophilic", "neurons", "in", "the", "CA1", "and", "CA3", "-", "C", "sectors", "of", "ovariectomized", "rats", ".", "In", "males", ",", "estradiol", "increased", "the", "total", "damage", "score", ".", "These", "findings", "suggest", "that", "the", "effects", "of", "estradiol", "on", "seizure", "threshold", "and", "damage", "may", "be", "altered", "by", "sex", "-", "related", "differences", "in", "the", "hormonal", "environment", "."]], "ner": [[[52, 52, "Chemical"], [5, 6, "Disease"], [21, 22, "Disease"], [54, 54, "Chemical"], [29, 30, "Disease"], [32, 32, "Disease"], [57, 57, "Disease"], [82, 82, "Disease"], [113, 113, "Disease"], [0, 0, "Chemical"], [40, 42, "Chemical"], [64, 66, "Chemical"], [115, 117, "Chemical"], [135, 137, "Chemical"], [157, 157, "Chemical"], [171, 171, "Chemical"], [2, 2, "Disease"], [173, 173, "Disease"], [25, 26, "Chemical"], [100, 100, "Chemical"]]], "relations": [[[52, 52, 5, 6, "CID"], [52, 52, 21, 22, "CID"], [54, 54, 5, 6, "CID"], [54, 54, 21, 22, "CID"], [52, 52, 29, 30, "CID"], [52, 52, 32, 32, "CID"], [52, 52, 57, 57, "CID"], [52, 52, 82, 82, "CID"], [52, 52, 113, 113, "CID"], [54, 54, 29, 30, "CID"], [54, 54, 32, 32, "CID"], [54, 54, 57, 57, "CID"], [54, 54, 82, 82, "CID"], [54, 54, 113, 113, "CID"]]], "clusters": [], "translated": "<9>雌二醇</9> 减少了 <16>癫痫发作</16> - 诱导的 <1>海马损伤</1> 在卵巢切除的雌性大鼠中，但在雄性大鼠中没有。雌激素对<18>红藻酸</18>诱发的<4>癫痫持续状态</4>（<5>SE</5>）引起的<2>海马损伤</2>具有保护作用。我们比较了成年雄性和切除卵巢的雌性大鼠在<0>锂</0> - <3>毛果芸香碱</3> - 诱导的<6>SE</6>下，<10>17beta - 雌二醇</10>的影响。大鼠每天皮下注射<11>17beta - 雌二醇</11>（2微克/大鼠）或油，连续四天。第二次注射后20小时诱导<7>SE</7>，3小时后终止。在<8>SE</8>后2天评估<19>银</19>染色的CA3和CA1海马神经元的范围。 <12> 17beta-雌二醇 </12>不改变卵巢切除大鼠第一次阵挛的发作，但在雄性中加速。在去卵巢大鼠中，<13>17beta-雌二醇</13>减少了CA1和CA3-C区的嗜银神经元。在雄性中，<14>雌二醇</14>增加了总损伤评分。这些发现表明，<15>雌二醇</15>对<17>癫痫发作</17> 阈值和损伤的影响可能会因荷尔蒙环境中与性别相关的差异而改变。", "revised": true}
{"doc_key": "9672936", "sentences": [["Pethidine", "-", "associated", "seizure", "in", "a", "healthy", "adolescent", "receiving", "pethidine", "for", "postoperative", "pain", "control", ".", "A", "healthy", "17", "-", "year", "-", "old", "male", "received", "standard", "intermittent", "doses", "of", "pethidine", "via", "a", "patient", "-", "controlled", "analgesia", "(", "PCA", ")", "pump", "for", "management", "of", "postoperative", "pain", "control", ".", "Twenty", "-", "three", "h", "postoperatively", "he", "developed", "a", "brief", "self", "-", "limited", "seizure", ".", "Both", "plasma", "pethidine", "and", "norpethidine", "were", "elevated", "in", "the", "range", "associated", "with", "clinical", "manifestations", "of", "central", "nervous", "system", "excitation", ".", "No", "other", "risk", "factors", "for", "CNS", "toxicity", "were", "identified", ".", "This", "method", "allowed", "frequent", "self", "-", "dosing", "of", "pethidine", "at", "short", "time", "intervals", "and", "rapid", "accumulation", "of", "pethidine", "and", "norpethidine", ".", "The", "routine", "use", "of", "pethidine", "via", "PCA", "even", "for", "a", "brief", "postoperative", "analgesia", "should", "be", "reconsidered", "."]], "ner": [[[0, 0, "Chemical"], [9, 9, "Chemical"], [28, 28, "Chemical"], [62, 62, "Chemical"], [98, 98, "Chemical"], [107, 107, "Chemical"], [115, 115, "Chemical"], [3, 3, "Disease"], [58, 58, "Disease"], [11, 12, "Disease"], [42, 43, "Disease"], [86, 86, "Disease"], [64, 64, "Chemical"], [109, 109, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 58, 58, "CID"], [9, 9, 3, 3, "CID"], [9, 9, 58, 58, "CID"], [28, 28, 3, 3, "CID"], [28, 28, 58, 58, "CID"], [62, 62, 3, 3, "CID"], [62, 62, 58, 58, "CID"], [98, 98, 3, 3, "CID"], [98, 98, 58, 58, "CID"], [107, 107, 3, 3, "CID"], [107, 107, 58, 58, "CID"], [115, 115, 3, 3, "CID"], [115, 115, 58, 58, "CID"]]], "clusters": [], "translated": "<0>哌替啶</0> - 与<7>癫痫发作</7>相关的健康青少年接受<1>哌替啶</1>以控制<9>术后疼痛</9>。一名健康的17岁男性通过患者自控镇痛 (PCA) 泵接受 标准间歇剂量 的<2>哌替啶</2>，以控制<10>术后疼痛</10>。术后23小时，他出现了短暂的自限性<8>癫痫发作</8>。血浆<3>哌替啶</3>和<12>去甲哌替啶</12>均在与中枢神经系统兴奋的临床表现相关的范围内升高。未发现其他导致 CNS<11> 毒性</11>的危险因素。这种方法允许在短时间间隔内频繁地自我给药<4>哌替啶</4>，并快速积累<5>哌替啶</5>和<13>去甲哌替啶</13>。应重新考虑通过PCA常规使用<6>哌替啶</6>，即使是短暂的术后镇痛。", "revised": true}
{"doc_key": "18619688", "sentences": [["Adriamycin", "-", "induced", "autophagic", "cardiomyocyte", "death", "plays", "a", "pathogenic", "role", "in", "a", "rat", "model", "of", "heart", "failure", ".", "BACKGROUND", ":", "The", "mechanisms", "underlying", "heart", "failure", "induced", "by", "adriamycin", "are", "very", "complicated", "and", "still", "unclear", ".", "The", "aim", "of", "this", "study", "was", "to", "investigate", "whether", "autophagy", "was", "involved", "in", "the", "progression", "of", "heart", "failure", "induced", "by", "adriamycin", ",", "so", "that", "we", "can", "develop", "a", "novel", "treatment", "strategy", "for", "heart", "failure", ".", "METHODS", ":", "3", "-", "methyladenine", "(", "3MA", ")", ",", "a", "specific", "inhibitor", "on", "autophagy", "was", "used", "in", "a", "heart", "failure", "model", "of", "rats", "induced", "by", "adriamycin", ".", "Neonatal", "cardiomyocytes", "were", "isolated", "from", "Sprague", "-", "Dawley", "rat", "hearts", "and", "randomly", "divided", "into", "controls", ",", "an", "adriamycin", "-", "treated", "group", ",", "and", "a", "3MA", "plus", "adriamycin", "-", "treated", "group", ".", "We", "then", "examined", "the", "morphology", ",", "expression", "of", "beclin", "1", "gene", ",", "mitochondrial", "permeability", "transition", "(", "MPT", ")", ",", "and", "Na", "+", "-", "K", "+", "ATPase", "activity", "in", "vivo", ".", "We", "also", "assessed", "cell", "viability", ",", "mitochondrial", "membrane", "potential", "changes", "and", "counted", "autophagic", "vacuoles", "in", "cultured", "cardiomyocytes", ".", "In", "addition", ",", "we", "analyzed", "the", "expression", "of", "autophagy", "associated", "gene", ",", "beclin", "1", "using", "RT", "-", "PCR", "and", "Western", "blotting", "in", "an", "animal", "model", ".", "RESULTS", ":", "3MA", "significantly", "improved", "cardiac", "function", "and", "reduced", "mitochondrial", "injury", ".", "Furthermore", ",", "adriamycin", "induced", "the", "formation", "of", "autophagic", "vacuoles", ",", "and", "3MA", "strongly", "downregulated", "the", "expression", "of", "beclin", "1", "in", "adriamycin", "-", "induced", "failing", "heart", "and", "inhibited", "the", "formation", "of", "autophagic", "vacuoles", ".", "CONCLUSION", ":", "Autophagic", "cardiomyocyte", "death", "plays", "an", "important", "role", "in", "the", "pathogenesis", "of", "heart", "failure", "in", "rats", "induced", "by", "adriamycin", ".", "Mitochondrial", "injury", "may", "be", "involved", "in", "the", "progression", "of", "heart", "failure", "caused", "by", "adriamycin", "via", "the", "autophagy", "pathway", "."]], "ner": [[[0, 0, "Chemical"], [27, 27, "Chemical"], [55, 55, "Chemical"], [95, 95, "Chemical"], [114, 114, "Chemical"], [123, 123, "Chemical"], [216, 216, "Chemical"], [234, 234, "Chemical"], [266, 266, "Chemical"], [281, 281, "Chemical"], [15, 16, "Disease"], [23, 24, "Disease"], [51, 52, "Disease"], [67, 68, "Disease"], [88, 89, "Disease"], [260, 261, "Disease"], [277, 278, "Disease"], [5, 5, "Disease"], [251, 251, "Disease"], [72, 74, "Chemical"], [76, 76, "Chemical"], [121, 121, "Chemical"], [204, 204, "Chemical"], [225, 225, "Chemical"], [151, 151, "Chemical"]]], "relations": [[[0, 0, 15, 16, "CID"], [0, 0, 23, 24, "CID"], [0, 0, 51, 52, "CID"], [0, 0, 67, 68, "CID"], [0, 0, 88, 89, "CID"], [0, 0, 260, 261, "CID"], [0, 0, 277, 278, "CID"], [27, 27, 15, 16, "CID"], [27, 27, 23, 24, "CID"], [27, 27, 51, 52, "CID"], [27, 27, 67, 68, "CID"], [27, 27, 88, 89, "CID"], [27, 27, 260, 261, "CID"], [27, 27, 277, 278, "CID"], [55, 55, 15, 16, "CID"], [55, 55, 23, 24, "CID"], [55, 55, 51, 52, "CID"], [55, 55, 67, 68, "CID"], [55, 55, 88, 89, "CID"], [55, 55, 260, 261, "CID"], [55, 55, 277, 278, "CID"], [95, 95, 15, 16, "CID"], [95, 95, 23, 24, "CID"], [95, 95, 51, 52, "CID"], [95, 95, 67, 68, "CID"], [95, 95, 88, 89, "CID"], [95, 95, 260, 261, "CID"], [95, 95, 277, 278, "CID"], [114, 114, 15, 16, "CID"], [114, 114, 23, 24, "CID"], [114, 114, 51, 52, "CID"], [114, 114, 67, 68, "CID"], [114, 114, 88, 89, "CID"], [114, 114, 260, 261, "CID"], [114, 114, 277, 278, "CID"], [123, 123, 15, 16, "CID"], [123, 123, 23, 24, "CID"], [123, 123, 51, 52, "CID"], [123, 123, 67, 68, "CID"], [123, 123, 88, 89, "CID"], [123, 123, 260, 261, "CID"], [123, 123, 277, 278, "CID"], [216, 216, 15, 16, "CID"], [216, 216, 23, 24, "CID"], [216, 216, 51, 52, "CID"], [216, 216, 67, 68, "CID"], [216, 216, 88, 89, "CID"], [216, 216, 260, 261, "CID"], [216, 216, 277, 278, "CID"], [234, 234, 15, 16, "CID"], [234, 234, 23, 24, "CID"], [234, 234, 51, 52, "CID"], [234, 234, 67, 68, "CID"], [234, 234, 88, 89, "CID"], [234, 234, 260, 261, "CID"], [234, 234, 277, 278, "CID"], [266, 266, 15, 16, "CID"], [266, 266, 23, 24, "CID"], [266, 266, 51, 52, "CID"], [266, 266, 67, 68, "CID"], [266, 266, 88, 89, "CID"], [266, 266, 260, 261, "CID"], [266, 266, 277, 278, "CID"], [281, 281, 15, 16, "CID"], [281, 281, 23, 24, "CID"], [281, 281, 51, 52, "CID"], [281, 281, 67, 68, "CID"], [281, 281, 88, 89, "CID"], [281, 281, 260, 261, "CID"], [281, 281, 277, 278, "CID"]]], "clusters": [], "translated": " <0>阿霉素</0> -诱导的自噬性心肌细胞<17>死亡</17>在大鼠<10>心力衰竭</10>模型中起致病作用。背景：引起<11>心力衰竭</11>的机制十分复杂，而<1>阿霉素</1>致病的机制目前仍不清楚。本研究旨在探讨自噬是否参与<2>阿霉素</2>所致<12>心力衰竭</12>的进展，从而制定新的<13>心力衰竭</13> 治疗策略。方法：在<3>阿霉素</3>诱导的<14>心力衰竭</14>模型大鼠中，使用特异性自噬抑制剂<19>3-甲基腺嘌呤</19>（<20>3MA</20>）。从Sprague-Dawley大鼠心脏中分离新生心肌细胞，并随机分成对照组、<4>阿霉素</4>处理组和加<21>3MA</21>的<5>阿霉素</5>处理组。我们检测了体内的形态学、beclin1基因的表达、线粒体通透性转换（MPT）和Na+ -<24>K+</24> ATP酶活性，并在培养的心肌细胞中评估了细胞活力、线粒体膜电位变化并计算自噬泡的数量。此外，在动物模型中，我们通过RT-PCR和Western blotting分析了自噬相关基因beclin1的表达情况。结果：自噬抑制剂<22>3MA</22>显著改善了心功能，并减轻了线粒体损伤。此外，<6>阿霉素</6>诱导出自噬泡的生成，而自噬泡的形成受<23>3MA</23>的显著抑制，起到了调节<7>阿霉素</7>诱导的自噬泡中beclin1的表达，阻断了自噬泡形成的作用。结论：自噬性心肌细胞<18>死亡</18>在<8>阿霉素</8>致大鼠 <15> 心力衰竭 </15>的发病机制中起重要作用。线粒体受损可能是<9>阿霉素</9>所致<16>心力衰竭</16>进展的一个自噬途径。", "revised": true}
{"doc_key": "10704919", "sentences": [["Hemolysis", "of", "human", "erythrocytes", "induced", "by", "tamoxifen", "is", "related", "to", "disruption", "of", "membrane", "structure", ".", "Tamoxifen", "(", "TAM", ")", ",", "the", "antiestrogenic", "drug", "most", "widely", "prescribed", "in", "the", "chemotherapy", "of", "breast", "cancer", ",", "induces", "changes", "in", "normal", "discoid", "shape", "of", "erythrocytes", "and", "hemolytic", "anemia", ".", "This", "work", "evaluates", "the", "effects", "of", "TAM", "on", "isolated", "human", "erythrocytes", ",", "attempting", "to", "identify", "the", "underlying", "mechanisms", "on", "TAM", "-", "induced", "hemolytic", "anemia", "and", "the", "involvement", "of", "biomembranes", "in", "its", "cytostatic", "action", "mechanisms", ".", "TAM", "induces", "hemolysis", "of", "erythrocytes", "as", "a", "function", "of", "concentration", ".", "The", "extension", "of", "hemolysis", "is", "variable", "with", "erythrocyte", "samples", ",", "but", "12", ".", "5", "microM", "TAM", "induces", "total", "hemolysis", "of", "all", "tested", "suspensions", ".", "Despite", "inducing", "extensive", "erythrocyte", "lysis", ",", "TAM", "does", "not", "shift", "the", "osmotic", "fragility", "curves", "of", "erythrocytes", ".", "The", "hemolytic", "effect", "of", "TAM", "is", "prevented", "by", "low", "concentrations", "of", "alpha", "-", "tocopherol", "(", "alpha", "-", "T", ")", "and", "alpha", "-", "tocopherol", "acetate", "(", "alpha", "-", "TAc", ")", "(", "inactivated", "functional", "hydroxyl", ")", "indicating", "that", "TAM", "-", "induced", "hemolysis", "is", "not", "related", "to", "oxidative", "membrane", "damage", ".", "This", "was", "further", "evidenced", "by", "absence", "of", "oxygen", "consumption", "and", "hemoglobin", "oxidation", "both", "determined", "in", "parallel", "with", "TAM", "-", "induced", "hemolysis", ".", "Furthermore", ",", "it", "was", "observed", "that", "TAM", "inhibits", "the", "peroxidation", "of", "human", "erythrocytes", "induced", "by", "AAPH", ",", "thus", "ruling", "out", "TAM", "-", "induced", "cell", "oxidative", "stress", ".", "Hemolysis", "caused", "by", "TAM", "was", "not", "preceded", "by", "the", "leakage", "of", "K", "(", "+", ")", "from", "the", "cells", ",", "also", "excluding", "a", "colloid", "-", "osmotic", "type", "mechanism", "of", "hemolysis", ",", "according", "to", "the", "effects", "on", "osmotic", "fragility", "curves", ".", "However", ",", "TAM", "induces", "release", "of", "peripheral", "proteins", "of", "membrane", "-", "cytoskeleton", "and", "cytosol", "proteins", "essentially", "bound", "to", "band", "3", ".", "Either", "alpha", "-", "T", "or", "alpha", "-", "TAc", "increases", "membrane", "packing", "and", "prevents", "TAM", "partition", "into", "model", "membranes", ".", "These", "effects", "suggest", "that", "the", "protection", "from", "hemolysis", "by", "tocopherols", "is", "related", "to", "a", "decreased", "TAM", "incorporation", "in", "condensed", "membranes", "and", "the", "structural", "damage", "of", "the", "erythrocyte", "membrane", "is", "consequently", "avoided", ".", "Therefore", ",", "TAM", "-", "induced", "hemolysis", "results", "from", "a", "structural", "perturbation", "of", "red", "cell", "membrane", ",", "leading", "to", "changes", "in", "the", "framework", "of", "the", "erythrocyte", "membrane", "and", "its", "cytoskeleton", "caused", "by", "its", "high", "partition", "in", "the", "membrane", ".", "These", "defects", "explain", "the", "abnormal", "erythrocyte", "shape", "and", "decreased", "mechanical", "stability", "promoted", "by", "TAM", ",", "resulting", "in", "hemolytic", "anemia", ".", "Additionally", ",", "since", "membrane", "leakage", "is", "a", "final", "stage", "of", "cytotoxicity", ",", "the", "disruption", "of", "the", "structural", "characteristics", "of", "biomembranes", "by", "TAM", "may", "contribute", "to", "the", "multiple", "mechanisms", "of", "its", "anticancer", "action", "."]], "ner": [[[6, 6, "Chemical"], [15, 15, "Chemical"], [17, 17, "Chemical"], [51, 51, "Chemical"], [64, 64, "Chemical"], [80, 80, "Chemical"], [106, 106, "Chemical"], [121, 121, "Chemical"], [136, 136, "Chemical"], [168, 168, "Chemical"], [197, 197, "Chemical"], [208, 208, "Chemical"], [222, 222, "Chemical"], [232, 232, "Chemical"], [270, 270, "Chemical"], [302, 302, "Chemical"], [323, 323, "Chemical"], [342, 342, "Chemical"], [391, 391, "Chemical"], [419, 419, "Chemical"], [0, 0, "Disease"], [82, 82, "Disease"], [94, 94, "Disease"], [109, 109, "Disease"], [133, 133, "Disease"], [171, 171, "Disease"], [200, 200, "Disease"], [229, 229, "Disease"], [257, 257, "Disease"], [315, 315, "Disease"], [345, 345, "Disease"], [42, 43, "Disease"], [67, 68, "Disease"], [395, 396, "Disease"], [143, 145, "Chemical"], [147, 149, "Chemical"], [152, 155, "Chemical"], [157, 159, "Chemical"], [290, 292, "Chemical"], [294, 296, "Chemical"], [164, 164, "Chemical"], [187, 187, "Chemical"], [217, 217, "Chemical"], [240, 240, "Chemical"], [317, 317, "Chemical"], [30, 31, "Disease"]]], "relations": [[[6, 6, 0, 0, "CID"], [6, 6, 82, 82, "CID"], [6, 6, 94, 94, "CID"], [6, 6, 109, 109, "CID"], [6, 6, 133, 133, "CID"], [6, 6, 171, 171, "CID"], [6, 6, 200, 200, "CID"], [6, 6, 229, 229, "CID"], [6, 6, 257, 257, "CID"], [6, 6, 315, 315, "CID"], [6, 6, 345, 345, "CID"], [15, 15, 0, 0, "CID"], [15, 15, 82, 82, "CID"], [15, 15, 94, 94, "CID"], [15, 15, 109, 109, "CID"], [15, 15, 133, 133, "CID"], [15, 15, 171, 171, "CID"], [15, 15, 200, 200, "CID"], [15, 15, 229, 229, "CID"], [15, 15, 257, 257, "CID"], [15, 15, 315, 315, "CID"], [15, 15, 345, 345, "CID"], [17, 17, 0, 0, "CID"], [17, 17, 82, 82, "CID"], [17, 17, 94, 94, "CID"], [17, 17, 109, 109, "CID"], [17, 17, 133, 133, "CID"], [17, 17, 171, 171, "CID"], [17, 17, 200, 200, "CID"], [17, 17, 229, 229, "CID"], [17, 17, 257, 257, "CID"], [17, 17, 315, 315, "CID"], [17, 17, 345, 345, "CID"], [51, 51, 0, 0, "CID"], [51, 51, 82, 82, "CID"], [51, 51, 94, 94, "CID"], [51, 51, 109, 109, "CID"], [51, 51, 133, 133, "CID"], [51, 51, 171, 171, "CID"], [51, 51, 200, 200, "CID"], [51, 51, 229, 229, "CID"], [51, 51, 257, 257, "CID"], [51, 51, 315, 315, "CID"], [51, 51, 345, 345, "CID"], [64, 64, 0, 0, "CID"], [64, 64, 82, 82, "CID"], [64, 64, 94, 94, "CID"], [64, 64, 109, 109, "CID"], [64, 64, 133, 133, "CID"], [64, 64, 171, 171, "CID"], [64, 64, 200, 200, "CID"], [64, 64, 229, 229, "CID"], [64, 64, 257, 257, "CID"], [64, 64, 315, 315, "CID"], [64, 64, 345, 345, "CID"], [80, 80, 0, 0, "CID"], [80, 80, 82, 82, "CID"], [80, 80, 94, 94, "CID"], [80, 80, 109, 109, "CID"], [80, 80, 133, 133, "CID"], [80, 80, 171, 171, "CID"], [80, 80, 200, 200, "CID"], [80, 80, 229, 229, "CID"], [80, 80, 257, 257, "CID"], [80, 80, 315, 315, "CID"], [80, 80, 345, 345, "CID"], [106, 106, 0, 0, "CID"], [106, 106, 82, 82, "CID"], [106, 106, 94, 94, "CID"], [106, 106, 109, 109, "CID"], [106, 106, 133, 133, "CID"], [106, 106, 171, 171, "CID"], [106, 106, 200, 200, "CID"], [106, 106, 229, 229, "CID"], [106, 106, 257, 257, "CID"], [106, 106, 315, 315, "CID"], [106, 106, 345, 345, "CID"], [121, 121, 0, 0, "CID"], [121, 121, 82, 82, "CID"], [121, 121, 94, 94, "CID"], [121, 121, 109, 109, "CID"], [121, 121, 133, 133, "CID"], [121, 121, 171, 171, "CID"], [121, 121, 200, 200, "CID"], [121, 121, 229, 229, "CID"], [121, 121, 257, 257, "CID"], [121, 121, 315, 315, "CID"], [121, 121, 345, 345, "CID"], [136, 136, 0, 0, "CID"], [136, 136, 82, 82, "CID"], [136, 136, 94, 94, "CID"], [136, 136, 109, 109, "CID"], [136, 136, 133, 133, "CID"], [136, 136, 171, 171, "CID"], [136, 136, 200, 200, "CID"], [136, 136, 229, 229, "CID"], [136, 136, 257, 257, "CID"], [136, 136, 315, 315, "CID"], [136, 136, 345, 345, "CID"], [168, 168, 0, 0, "CID"], [168, 168, 82, 82, "CID"], [168, 168, 94, 94, "CID"], [168, 168, 109, 109, "CID"], [168, 168, 133, 133, "CID"], [168, 168, 171, 171, "CID"], [168, 168, 200, 200, "CID"], [168, 168, 229, 229, "CID"], [168, 168, 257, 257, "CID"], [168, 168, 315, 315, "CID"], [168, 168, 345, 345, "CID"], [197, 197, 0, 0, "CID"], [197, 197, 82, 82, "CID"], [197, 197, 94, 94, "CID"], [197, 197, 109, 109, "CID"], [197, 197, 133, 133, "CID"], [197, 197, 171, 171, "CID"], [197, 197, 200, 200, "CID"], [197, 197, 229, 229, "CID"], [197, 197, 257, 257, "CID"], [197, 197, 315, 315, "CID"], [197, 197, 345, 345, "CID"], [208, 208, 0, 0, "CID"], [208, 208, 82, 82, "CID"], [208, 208, 94, 94, "CID"], [208, 208, 109, 109, "CID"], [208, 208, 133, 133, "CID"], [208, 208, 171, 171, "CID"], [208, 208, 200, 200, "CID"], [208, 208, 229, 229, "CID"], [208, 208, 257, 257, "CID"], [208, 208, 315, 315, "CID"], [208, 208, 345, 345, "CID"], [222, 222, 0, 0, "CID"], [222, 222, 82, 82, "CID"], [222, 222, 94, 94, "CID"], [222, 222, 109, 109, "CID"], [222, 222, 133, 133, "CID"], [222, 222, 171, 171, "CID"], [222, 222, 200, 200, "CID"], [222, 222, 229, 229, "CID"], [222, 222, 257, 257, "CID"], [222, 222, 315, 315, "CID"], [222, 222, 345, 345, "CID"], [232, 232, 0, 0, "CID"], [232, 232, 82, 82, "CID"], [232, 232, 94, 94, "CID"], [232, 232, 109, 109, "CID"], [232, 232, 133, 133, "CID"], [232, 232, 171, 171, "CID"], [232, 232, 200, 200, "CID"], [232, 232, 229, 229, "CID"], [232, 232, 257, 257, "CID"], [232, 232, 315, 315, "CID"], [232, 232, 345, 345, "CID"], [270, 270, 0, 0, "CID"], [270, 270, 82, 82, "CID"], [270, 270, 94, 94, "CID"], [270, 270, 109, 109, "CID"], [270, 270, 133, 133, "CID"], [270, 270, 171, 171, "CID"], [270, 270, 200, 200, "CID"], [270, 270, 229, 229, "CID"], [270, 270, 257, 257, "CID"], [270, 270, 315, 315, "CID"], [270, 270, 345, 345, "CID"], [302, 302, 0, 0, "CID"], [302, 302, 82, 82, "CID"], [302, 302, 94, 94, "CID"], [302, 302, 109, 109, "CID"], [302, 302, 133, 133, "CID"], [302, 302, 171, 171, "CID"], [302, 302, 200, 200, "CID"], [302, 302, 229, 229, "CID"], [302, 302, 257, 257, "CID"], [302, 302, 315, 315, "CID"], [302, 302, 345, 345, "CID"], [323, 323, 0, 0, "CID"], [323, 323, 82, 82, "CID"], [323, 323, 94, 94, "CID"], [323, 323, 109, 109, "CID"], [323, 323, 133, 133, "CID"], [323, 323, 171, 171, "CID"], [323, 323, 200, 200, "CID"], [323, 323, 229, 229, "CID"], [323, 323, 257, 257, "CID"], [323, 323, 315, 315, "CID"], [323, 323, 345, 345, "CID"], [342, 342, 0, 0, "CID"], [342, 342, 82, 82, "CID"], [342, 342, 94, 94, "CID"], [342, 342, 109, 109, "CID"], [342, 342, 133, 133, "CID"], [342, 342, 171, 171, "CID"], [342, 342, 200, 200, "CID"], [342, 342, 229, 229, "CID"], [342, 342, 257, 257, "CID"], [342, 342, 315, 315, "CID"], [342, 342, 345, 345, "CID"], [391, 391, 0, 0, "CID"], [391, 391, 82, 82, "CID"], [391, 391, 94, 94, "CID"], [391, 391, 109, 109, "CID"], [391, 391, 133, 133, "CID"], [391, 391, 171, 171, "CID"], [391, 391, 200, 200, "CID"], [391, 391, 229, 229, "CID"], [391, 391, 257, 257, "CID"], [391, 391, 315, 315, "CID"], [391, 391, 345, 345, "CID"], [419, 419, 0, 0, "CID"], [419, 419, 82, 82, "CID"], [419, 419, 94, 94, "CID"], [419, 419, 109, 109, "CID"], [419, 419, 133, 133, "CID"], [419, 419, 171, 171, "CID"], [419, 419, 200, 200, "CID"], [419, 419, 229, 229, "CID"], [419, 419, 257, 257, "CID"], [419, 419, 315, 315, "CID"], [419, 419, 345, 345, "CID"], [6, 6, 42, 43, "CID"], [6, 6, 67, 68, "CID"], [6, 6, 395, 396, "CID"], [15, 15, 42, 43, "CID"], [15, 15, 67, 68, "CID"], [15, 15, 395, 396, "CID"], [17, 17, 42, 43, "CID"], [17, 17, 67, 68, "CID"], [17, 17, 395, 396, "CID"], [51, 51, 42, 43, "CID"], [51, 51, 67, 68, "CID"], [51, 51, 395, 396, "CID"], [64, 64, 42, 43, "CID"], [64, 64, 67, 68, "CID"], [64, 64, 395, 396, "CID"], [80, 80, 42, 43, "CID"], [80, 80, 67, 68, "CID"], [80, 80, 395, 396, "CID"], [106, 106, 42, 43, "CID"], [106, 106, 67, 68, "CID"], [106, 106, 395, 396, "CID"], [121, 121, 42, 43, "CID"], [121, 121, 67, 68, "CID"], [121, 121, 395, 396, "CID"], [136, 136, 42, 43, "CID"], [136, 136, 67, 68, "CID"], [136, 136, 395, 396, "CID"], [168, 168, 42, 43, "CID"], [168, 168, 67, 68, "CID"], [168, 168, 395, 396, "CID"], [197, 197, 42, 43, "CID"], [197, 197, 67, 68, "CID"], [197, 197, 395, 396, "CID"], [208, 208, 42, 43, "CID"], [208, 208, 67, 68, "CID"], [208, 208, 395, 396, "CID"], [222, 222, 42, 43, "CID"], [222, 222, 67, 68, "CID"], [222, 222, 395, 396, "CID"], [232, 232, 42, 43, "CID"], [232, 232, 67, 68, "CID"], [232, 232, 395, 396, "CID"], [270, 270, 42, 43, "CID"], [270, 270, 67, 68, "CID"], [270, 270, 395, 396, "CID"], [302, 302, 42, 43, "CID"], [302, 302, 67, 68, "CID"], [302, 302, 395, 396, "CID"], [323, 323, 42, 43, "CID"], [323, 323, 67, 68, "CID"], [323, 323, 395, 396, "CID"], [342, 342, 42, 43, "CID"], [342, 342, 67, 68, "CID"], [342, 342, 395, 396, "CID"], [391, 391, 42, 43, "CID"], [391, 391, 67, 68, "CID"], [391, 391, 395, 396, "CID"], [419, 419, 42, 43, "CID"], [419, 419, 67, 68, "CID"], [419, 419, 395, 396, "CID"]]], "clusters": [], "translated": "<0>他莫昔芬</0>引起的人红细胞<20>溶血</20>与膜结构破坏有关。<1>他莫昔芬</1>（<2>TAM</2>）是在<45>乳腺癌</45>化疗中最广泛使用的抗雌激素药物，可诱导红细胞正常盘状形状的变化和<31>溶血性贫血</31>。这项工作评估了<3>TAM</3>对离体人红细胞的影响，试图确定<4>TAM</4>诱导<32>溶血性贫血</32>的潜在机制和生物膜的参与在其细胞抑制作用机制中。<5>TAM</5>诱导红细胞<21>溶血</21>作为浓度的函数。 <22>溶血</22>的延长因红细胞样本而异，但12.5微米的<6>TAM</6>诱导所有测试悬浮液的总<23>溶血</23>。尽管诱导广泛的红细胞裂解，<7>TAM</7>不会改变红细胞的渗透脆性曲线。低浓度的<34>α-生育酚</34>（<35>α-T</35>）和<36>α-生育酚乙酸酯</36>（<37>α-TAc</37>）可防止<8>TAM</8>的<24>溶血</24>作用，<40>失活功能性羟基</40>表明<9>TAM</9>诱导的<25>溶血</25>与氧化膜损伤无关。这进一步通过<41>氧气</41>消耗和血红蛋白氧化的缺乏进一步证明，这两者与<10>TAM</10>诱导的<26>溶血</26>平行检测。此外，观察到<11>TAM</11>抑制<42>AAPH</42>诱导的人红细胞过氧化，从而排除了<12>TAM</12>诱导的细胞氧化应激。<13> TAM </13> 引起的<27>溶血</27>之前没有<43>K</43>(+)从细胞中泄漏，也排除了<28>胶体渗透型机制</28>，根据对渗透脆性曲线的影响。然而，<14>TAM</14>诱导膜细胞骨架外周蛋白的释放和基本上与带3结合的胞质溶胶蛋白。<38>α-T</38>或<39>α-TAc</39>增加膜堆积并防止<15>TAM</15>分配到模型膜中。这些作用表明，<44>生育酚</44>对<29>溶血</29>的保护与凝结膜中<16>TAM</16>掺入的减少有关，红细胞膜的结构损伤是因而避免的。因此，<17>TAM</17>诱导的<30>溶血</30>是红细胞膜结构扰动的结果，由于其在膜。这些缺陷解释了<18>TAM</18>促进的红细胞形状异常和机械稳定性降低，从而导致<33>溶血性贫血</33>。此外，由于膜渗漏是细胞毒性的最后阶段，<19>TAM</19>对生物膜结构特征的破坏可能有助于其抗癌作用的多种机制。", "revised": true}
{"doc_key": "9727773", "sentences": [["High", "incidence", "of", "primary", "pulmonary", "hypertension", "associated", "with", "appetite", "suppressants", "in", "Belgium", ".", "Primary", "pulmonary", "hypertension", "is", "a", "rare", ",", "progressive", "and", "incurable", "disease", ",", "which", "has", "been", "associated", "with", "the", "intake", "of", "appetite", "suppressant", "drugs", ".", "The", "importance", "of", "this", "association", "was", "evaluated", "in", "Belgium", "while", "this", "country", "still", "had", "no", "restriction", "on", "the", "prescription", "of", "appetite", "suppressants", ".", "Thirty", "-", "five", "patients", "with", "primary", "pulmonary", "hypertension", "and", "85", "matched", "controls", "were", "recruited", "over", "32", "months", "(", "1992", "-", "1994", ")", "in", "Belgium", ".", "Exposure", "to", "appetite", "-", "suppressants", "was", "assessed", "on", "the", "basis", "of", "hospital", "records", "and", "standardized", "interview", ".", "Twenty", "-", "three", "of", "the", "patients", "had", "previously", "taken", "appetite", "suppressants", ",", "mainly", "fenfluramines", ",", "as", "compared", "with", "only", "5", "of", "the", "controls", "(", "66", "versus", "6", "%", ",", "p", "<", "0", ".", "0001", ")", ".", "Five", "patients", "died", "before", "the", "interview", ",", "all", "of", "them", "had", "taken", "appetite", "suppressants", ".", "In", "8", "patients", "the", "diagnosis", "of", "primary", "pulmonary", "hypertension", "was", "uncertain", ",", "5", "of", "them", "had", "taken", "appetite", "suppressants", ".", "The", "patients", "who", "had", "been", "exposed", "to", "appetite", "suppressants", "tended", "to", "be", "on", "average", "more", "severely", "ill", ",", "and", "to", "have", "a", "shorter", "median", "delay", "between", "onset", "of", "symptoms", "and", "diagnosis", ".", "A", "policy", "of", "unrestricted", "prescription", "of", "appetite", "suppressants", "may", "lead", "to", "a", "high", "incidence", "of", "associated", "primary", "pulmonary", "hypertension", ".", "Intake", "of", "appetite", "suppressants", "may", "accelerate", "the", "progression", "of", "the", "disease", "."]], "ner": [[[8, 9, "Chemical"], [33, 34, "Chemical"], [57, 58, "Chemical"], [87, 89, "Chemical"], [111, 112, "Chemical"], [150, 151, "Chemical"], [170, 171, "Chemical"], [180, 181, "Chemical"], [211, 212, "Chemical"], [227, 228, "Chemical"], [3, 5, "Disease"], [13, 15, "Disease"], [65, 67, "Disease"], [159, 161, "Disease"], [221, 223, "Disease"], [115, 115, "Chemical"]]], "relations": [[[8, 9, 3, 5, "CID"], [8, 9, 13, 15, "CID"], [8, 9, 65, 67, "CID"], [8, 9, 159, 161, "CID"], [8, 9, 221, 223, "CID"], [33, 34, 3, 5, "CID"], [33, 34, 13, 15, "CID"], [33, 34, 65, 67, "CID"], [33, 34, 159, 161, "CID"], [33, 34, 221, 223, "CID"], [57, 58, 3, 5, "CID"], [57, 58, 13, 15, "CID"], [57, 58, 65, 67, "CID"], [57, 58, 159, 161, "CID"], [57, 58, 221, 223, "CID"], [87, 89, 3, 5, "CID"], [87, 89, 13, 15, "CID"], [87, 89, 65, 67, "CID"], [87, 89, 159, 161, "CID"], [87, 89, 221, 223, "CID"], [111, 112, 3, 5, "CID"], [111, 112, 13, 15, "CID"], [111, 112, 65, 67, "CID"], [111, 112, 159, 161, "CID"], [111, 112, 221, 223, "CID"], [150, 151, 3, 5, "CID"], [150, 151, 13, 15, "CID"], [150, 151, 65, 67, "CID"], [150, 151, 159, 161, "CID"], [150, 151, 221, 223, "CID"], [170, 171, 3, 5, "CID"], [170, 171, 13, 15, "CID"], [170, 171, 65, 67, "CID"], [170, 171, 159, 161, "CID"], [170, 171, 221, 223, "CID"], [180, 181, 3, 5, "CID"], [180, 181, 13, 15, "CID"], [180, 181, 65, 67, "CID"], [180, 181, 159, 161, "CID"], [180, 181, 221, 223, "CID"], [211, 212, 3, 5, "CID"], [211, 212, 13, 15, "CID"], [211, 212, 65, 67, "CID"], [211, 212, 159, 161, "CID"], [211, 212, 221, 223, "CID"], [227, 228, 3, 5, "CID"], [227, 228, 13, 15, "CID"], [227, 228, 65, 67, "CID"], [227, 228, 159, 161, "CID"], [227, 228, 221, 223, "CID"], [115, 115, 3, 5, "CID"], [115, 115, 13, 15, "CID"], [115, 115, 65, 67, "CID"], [115, 115, 159, 161, "CID"], [115, 115, 221, 223, "CID"]]], "clusters": [], "translated": "在比利时，与<0>食欲抑制剂</0> 相关的<10>原发性肺动脉高压</10>发生率很高。<11>原发性肺动脉高压</11>是一种罕见的、进行性的和无法治愈的疾病，与服用<1>抑制食欲</1>药物有关。该协会的重要性在比利时进行了评估，而该国家对<2>食欲抑制剂</2>的处方仍然没有限制。在32个月（1992-1994年）期间，在比利时招募了35名<12>原发性肺动脉高压</12>患者和85名匹配的对照组。接触<3>食欲抑制剂</3>是根据医院记录和标准化访谈评估的。23名患者之前服用过<4>食欲抑制剂</4>，主要是<15>芬氟拉明</15>，而对照组只有5名（66对6%，p<0.0001）。访谈前有5名患者死亡，均服用<5>食欲抑制剂</5>。8例<13>原发性肺动脉高压</13>诊断不明确，其中5例曾服用<6>食欲抑制剂</6>。接触过<7>食欲抑制剂</7>的患者往往病情平均更严重，并且从出现症状到诊断之间的中位延迟时间更短。<8>食欲抑制剂</8>的无限制处方政策可能导致相关<14>原发性肺动脉高压</14>的高发病率。摄入<9>食欲抑制剂</9>可能会加速疾病的进展。", "revised": true}
{"doc_key": "12063090", "sentences": [["Metamizol", "potentiates", "morphine", "antinociception", "but", "not", "constipation", "after", "chronic", "treatment", ".", "This", "work", "evaluates", "the", "antinociceptive", "and", "constipating", "effects", "of", "the", "combination", "of", "3", ".", "2", "mg", "/", "kg", "s", ".", "c", ".", "morphine", "with", "177", ".", "8", "mg", "/", "kg", "s", ".", "c", ".", "metamizol", "in", "acutely", "and", "chronically", "treated", "(", "once", "a", "day", "for", "12", "days", ")", "rats", ".", "On", "the", "13th", "day", ",", "antinociceptive", "effects", "were", "assessed", "using", "a", "model", "of", "inflammatory", "nociception", ",", "pain", "-", "induced", "functional", "impairment", "model", ",", "and", "the", "charcoal", "meal", "test", "was", "used", "to", "evaluate", "the", "intestinal", "transit", ".", "Simultaneous", "administration", "of", "morphine", "with", "metamizol", "resulted", "in", "a", "markedly", "antinociceptive", "potentiation", "and", "an", "increasing", "of", "the", "duration", "of", "action", "after", "a", "single", "(", "298", "+", "/", "-", "7", "vs", ".", "139", "+", "/", "-", "36", "units", "area", "(", "ua", ")", ";", "P", "<", "0", ".", "001", ")", "and", "repeated", "administration", "(", "280", "+", "/", "-", "17", "vs", ".", "131", "+", "/", "-", "22", "ua", ";", "P", "<", "0", ".", "001", ")", ".", "Antinociceptive", "effect", "of", "morphine", "was", "reduced", "in", "chronically", "treated", "rats", "(", "39", "+", "/", "-", "10", "vs", ".", "18", "+", "/", "-", "5", "au", ")", "while", "the", "combination", "-", "induced", "antinociception", "was", "remained", "similar", "as", "an", "acute", "treatment", "(", "298", "+", "/", "-", "7", "vs", ".", "280", "+", "/", "-", "17", "au", ")", ".", "Acute", "antinociceptive", "effects", "of", "the", "combination", "were", "partially", "prevented", "by", "3", ".", "2", "mg", "/", "kg", "naloxone", "s", ".", "c", ".", "(", "P", "<", "0", ".", "05", ")", ",", "suggesting", "the", "partial", "involvement", "of", "the", "opioidergic", "system", "in", "the", "synergism", "observed", ".", "In", "independent", "groups", ",", "morphine", "inhibited", "the", "intestinal", "transit", "in", "48", "+", "/", "-", "4", "%", "and", "38", "+", "/", "-", "4", "%", "after", "acute", "and", "chronic", "treatment", ",", "respectively", ",", "suggesting", "that", "tolerance", "did", "not", "develop", "to", "the", "constipating", "effects", ".", "The", "combination", "inhibited", "intestinal", "transit", "similar", "to", "that", "produced", "by", "morphine", "regardless", "of", "the", "time", "of", "treatment", ",", "suggesting", "that", "metamizol", "did", "not", "potentiate", "morphine", "-", "induced", "constipation", ".", "These", "findings", "show", "a", "significant", "interaction", "between", "morphine", "and", "metamizol", "in", "chronically", "treated", "rats", ",", "suggesting", "that", "this", "combination", "could", "be", "useful", "for", "the", "treatment", "of", "chronic", "pain", "."]], "ner": [[[2, 2, "Chemical"], [33, 33, "Chemical"], [100, 100, "Chemical"], [173, 173, "Chemical"], [270, 270, "Chemical"], [318, 318, "Chemical"], [332, 332, "Chemical"], [344, 344, "Chemical"], [6, 6, "Disease"], [17, 17, "Disease"], [305, 305, "Disease"], [335, 335, "Disease"], [0, 0, "Chemical"], [45, 45, "Chemical"], [102, 102, "Chemical"], [328, 328, "Chemical"], [346, 346, "Chemical"], [77, 77, "Disease"], [363, 364, "Disease"], [86, 86, "Chemical"], [240, 240, "Chemical"]]], "relations": [[[2, 2, 6, 6, "CID"], [2, 2, 17, 17, "CID"], [2, 2, 305, 305, "CID"], [2, 2, 335, 335, "CID"], [33, 33, 6, 6, "CID"], [33, 33, 17, 17, "CID"], [33, 33, 305, 305, "CID"], [33, 33, 335, 335, "CID"], [100, 100, 6, 6, "CID"], [100, 100, 17, 17, "CID"], [100, 100, 305, 305, "CID"], [100, 100, 335, 335, "CID"], [173, 173, 6, 6, "CID"], [173, 173, 17, 17, "CID"], [173, 173, 305, 305, "CID"], [173, 173, 335, 335, "CID"], [270, 270, 6, 6, "CID"], [270, 270, 17, 17, "CID"], [270, 270, 305, 305, "CID"], [270, 270, 335, 335, "CID"], [318, 318, 6, 6, "CID"], [318, 318, 17, 17, "CID"], [318, 318, 305, 305, "CID"], [318, 318, 335, 335, "CID"], [332, 332, 6, 6, "CID"], [332, 332, 17, 17, "CID"], [332, 332, 305, 305, "CID"], [332, 332, 335, 335, "CID"], [344, 344, 6, 6, "CID"], [344, 344, 17, 17, "CID"], [344, 344, 305, 305, "CID"], [344, 344, 335, 335, "CID"]]], "clusters": [], "translated": " <12>安乃近</12>增强了慢性治疗后<0>吗啡</0>的抗伤害作用，但不增强<8>便秘</8>。这项工作评估了 3.2 毫克/千克·秒。C。<1>吗啡</1>与177.8毫克/千克·秒。C。<13>安乃近</13>在急性和慢性治疗（每天一次，持续 12 天）的大鼠中的镇痛作用和<9>便秘</9>作用的组合。第 13 天，采用炎症伤害感受模型、<17>疼痛</17>诱发的功能障碍模型评价抗伤害作用，采用<19>木炭</19>餐试验评价肠道转运。与<14>安乃近</14>同时给药的<2>吗啡</2>在单次给药后导致显著的镇痛作用增强和作用持续时间的增加（298+/-7 vs 139+/-36单位面积(ua); P < 0.001）和重复给药（280+/-17 vs 131+/-22 ua; P < 0.001）。在长期治疗的大鼠中，<3>吗啡</3>的镇痛作用减弱（39+/-10 vs 18+/-5 au），而联合诱导的镇痛作用的作用与急性治疗时作用相似（298+/-7 vs 280+/-17 ua）<20>纳洛酮</20>3.2毫克/千克的部分阻止了该组合的急性抗伤害作用，暗示这种协同作用部分涉及阿片类系统。在独立组中，<4>吗啡</4>在急性和慢性治疗后分别抑制了 48+/-4%和38+/-4%的肠道转运，表明对<10>便秘</10>的耐受性没有产生。无论治疗时间如何，该组合对肠道转运的抑制与<5>吗啡</5>诱导的相似，表明<15>安乃近</15>不会增强<6>吗啡</6>诱导的<11>便秘</11>。这些发现表明，在长期接受治疗的大鼠中，<7>吗啡</7>和<16>安乃近</16>之间存在显著的相互作用，表明该组合可用于治疗<18>慢性疼痛</18>。", "revised": true}
{"doc_key": "15009014", "sentences": [["Noxious", "chemical", "stimulation", "of", "rat", "facial", "mucosa", "increases", "intracranial", "blood", "flow", "through", "a", "trigemino", "-", "parasympathetic", "reflex", "-", "-", "an", "experimental", "model", "for", "vascular", "dysfunctions", "in", "cluster", "headache", ".", "Cluster", "headache", "is", "characterized", "by", "typical", "autonomic", "dysfunctions", "including", "facial", "and", "intracranial", "vascular", "disturbances", ".", "Both", "the", "trigeminal", "and", "the", "cranial", "parasympathetic", "systems", "may", "be", "involved", "in", "mediating", "these", "dysfunctions", ".", "An", "experimental", "model", "was", "developed", "in", "the", "rat", "to", "measure", "changes", "in", "lacrimation", "and", "intracranial", "blood", "flow", "following", "noxious", "chemical", "stimulation", "of", "facial", "mucosa", ".", "Blood", "flow", "was", "monitored", "in", "arteries", "of", "the", "exposed", "cranial", "dura", "mater", "and", "the", "parietal", "cortex", "using", "laser", "Doppler", "flowmetry", ".", "Capsaicin", "(", "0", ".", "01", "-", "1", "mm", ")", "applied", "to", "oral", "or", "nasal", "mucosa", "induced", "increases", "in", "dural", "and", "cortical", "blood", "flow", "and", "provoked", "lacrimation", ".", "These", "responses", "were", "blocked", "by", "systemic", "pre", "-", "administration", "of", "hexamethonium", "chloride", "(", "20", "mg", "/", "kg", ")", ".", "The", "evoked", "increases", "in", "dural", "blood", "flow", "were", "also", "abolished", "by", "topical", "pre", "-", "administration", "of", "atropine", "(", "1", "mm", ")", "and", "[", "Lys1", ",", "Pro2", ",", "5", ",", "Arg3", ",", "4", ",", "Tyr6", "]", "-", "VIP", "(", "0", ".", "1", "mm", ")", ",", "a", "vasoactive", "intestinal", "polypeptide", "(", "VIP", ")", "antagonist", ",", "onto", "the", "exposed", "dura", "mater", ".", "We", "conclude", "that", "noxious", "stimulation", "of", "facial", "mucosa", "increases", "intracranial", "blood", "flow", "and", "lacrimation", "via", "a", "trigemino", "-", "parasympathetic", "reflex", ".", "The", "blood", "flow", "responses", "seem", "to", "be", "mediated", "by", "the", "release", "of", "acetylcholine", "and", "VIP", "within", "the", "meninges", ".", "Similar", "mechanisms", "may", "be", "involved", "in", "the", "pathogenesis", "of", "cluster", "headache", "."]], "ner": [[[106, 106, "Chemical"], [23, 24, "Disease"], [40, 42, "Disease"], [122, 128, "Disease"], [154, 158, "Disease"], [143, 144, "Chemical"], [168, 168, "Chemical"], [244, 244, "Chemical"], [26, 27, "Disease"], [29, 30, "Disease"], [260, 261, "Disease"]]], "relations": [[[106, 106, 23, 24, "CID"], [106, 106, 40, 42, "CID"], [106, 106, 122, 128, "CID"], [106, 106, 154, 158, "CID"]]], "clusters": [], "translated": "大鼠面部粘膜的有害化学刺激通过三叉神经-副交感神经反射增加颅内血流量-<1>血管功能障碍</1>，是<8>丛集性头痛</8>的实验模型。 <9>丛集性头痛</9>的特征是典型的自主神经功能障碍，包括面部和<2>颅内血管障碍</2>。三叉神经系统和颅副交感神经系统都可能参与调节这些功能障碍。在大鼠中开发了一个实验模型，以测量面部粘膜受到有害化学刺激后流泪和颅内血流的变化。使用激光多普勒血流计监测暴露的颅骨硬脑膜和顶叶皮质的动脉血流。 <0>辣椒素</0>（0.01-1mm）应用于口腔或鼻粘膜引起<3>硬脑膜和皮质血流增加</3>并引起流泪。这些反应被系统性预给药<5>氯化六甲铵</5>（20 mg/kg）所阻断。局部预先给予<6> 阿托品</6>（1mm）和[Lys1,Pro2,5,Arg3,4,Tyr6]-VIP（0.1mm），一种血管活性肠多肽（VIP）拮抗剂，涂在暴露的硬脑膜上，也消除了诱发的<4>硬脑膜血流增加</4>。我们得出结论，面部粘膜的伤害性刺激会通过三叉神经-副交感神经反射增加颅内血流和流泪。血流反应似乎是由脑膜内<7>乙酰胆碱</7>和VIP的释放介导的。<10>丛集性头痛</10>的发病机制可能涉及类似的机制。", "revised": true}
{"doc_key": "11007689", "sentences": [["Cyclosporine", "and", "tacrolimus", "-", "associated", "thrombotic", "microangiopathy", ".", "The", "development", "of", "thrombotic", "microangiopathy", "(", "TMA", ")", "associated", "with", "the", "use", "of", "cyclosporine", "has", "been", "well", "documented", ".", "Treatments", "have", "included", "discontinuation", "or", "reduction", "of", "cyclosporine", "dose", "with", "or", "without", "concurrent", "plasma", "exchange", ",", "plasma", "infusion", ",", "anticoagulation", ",", "and", "intravenous", "immunoglobulin", "G", "infusion", ".", "However", ",", "for", "recipients", "of", "organ", "transplantation", ",", "removing", "the", "inciting", "agent", "is", "not", "without", "the", "attendant", "risk", "of", "precipitating", "acute", "rejection", "and", "graft", "loss", ".", "The", "last", "decade", "has", "seen", "the", "emergence", "of", "tacrolimus", "as", "a", "potent", "immunosuppressive", "agent", "with", "mechanisms", "of", "action", "virtually", "identical", "to", "those", "of", "cyclosporine", ".", "As", "a", "result", ",", "switching", "to", "tacrolimus", "has", "been", "reported", "to", "be", "a", "viable", "therapeutic", "option", "in", "the", "setting", "of", "cyclosporine", "-", "induced", "TMA", ".", "With", "the", "more", "widespread", "application", "of", "tacrolimus", "in", "organ", "transplantation", ",", "tacrolimus", "-", "associated", "TMA", "has", "also", "been", "recognized", ".", "However", ",", "literature", "regarding", "the", "incidence", "of", "the", "recurrence", "of", "TMA", "in", "patients", "exposed", "sequentially", "to", "cyclosporine", "and", "tacrolimus", "is", "limited", ".", "We", "report", "a", "case", "of", "a", "living", "donor", "renal", "transplant", "recipient", "who", "developed", "cyclosporine", "-", "induced", "TMA", "that", "responded", "to", "the", "withdrawal", "of", "cyclosporine", "in", "conjunction", "with", "plasmapheresis", "and", "fresh", "frozen", "plasma", "replacement", "therapy", ".", "Introduction", "of", "tacrolimus", "as", "an", "alternative", "immunosuppressive", "agent", "resulted", "in", "the", "recurrence", "of", "TMA", "and", "the", "subsequent", "loss", "of", "the", "renal", "allograft", ".", "Patients", "who", "are", "switched", "from", "cyclosporine", "to", "tacrolimus", "or", "vice", "versa", "should", "be", "closely", "monitored", "for", "the", "signs", "and", "symptoms", "of", "recurrent", "TMA", "."]], "ner": [[[0, 0, "Chemical"], [21, 21, "Chemical"], [34, 34, "Chemical"], [103, 103, "Chemical"], [125, 125, "Chemical"], [166, 166, "Chemical"], [185, 185, "Chemical"], [195, 195, "Chemical"], [235, 235, "Chemical"], [5, 6, "Disease"], [11, 12, "Disease"], [14, 14, "Disease"], [128, 128, "Disease"], [144, 144, "Disease"], [160, 160, "Disease"], [188, 188, "Disease"], [220, 220, "Disease"], [252, 252, "Disease"], [2, 2, "Chemical"], [88, 88, "Chemical"], [111, 111, "Chemical"], [136, 136, "Chemical"], [141, 141, "Chemical"], [168, 168, "Chemical"], [209, 209, "Chemical"], [237, 237, "Chemical"]]], "relations": [[[0, 0, 5, 6, "CID"], [0, 0, 11, 12, "CID"], [0, 0, 14, 14, "CID"], [0, 0, 128, 128, "CID"], [0, 0, 144, 144, "CID"], [0, 0, 160, 160, "CID"], [0, 0, 188, 188, "CID"], [0, 0, 220, 220, "CID"], [0, 0, 252, 252, "CID"], [21, 21, 5, 6, "CID"], [21, 21, 11, 12, "CID"], [21, 21, 14, 14, "CID"], [21, 21, 128, 128, "CID"], [21, 21, 144, 144, "CID"], [21, 21, 160, 160, "CID"], [21, 21, 188, 188, "CID"], [21, 21, 220, 220, "CID"], [21, 21, 252, 252, "CID"], [34, 34, 5, 6, "CID"], [34, 34, 11, 12, "CID"], [34, 34, 14, 14, "CID"], [34, 34, 128, 128, "CID"], [34, 34, 144, 144, "CID"], [34, 34, 160, 160, "CID"], [34, 34, 188, 188, "CID"], [34, 34, 220, 220, "CID"], [34, 34, 252, 252, "CID"], [103, 103, 5, 6, "CID"], [103, 103, 11, 12, "CID"], [103, 103, 14, 14, "CID"], [103, 103, 128, 128, "CID"], [103, 103, 144, 144, "CID"], [103, 103, 160, 160, "CID"], [103, 103, 188, 188, "CID"], [103, 103, 220, 220, "CID"], [103, 103, 252, 252, "CID"], [125, 125, 5, 6, "CID"], [125, 125, 11, 12, "CID"], [125, 125, 14, 14, "CID"], [125, 125, 128, 128, "CID"], [125, 125, 144, 144, "CID"], [125, 125, 160, 160, "CID"], [125, 125, 188, 188, "CID"], [125, 125, 220, 220, "CID"], [125, 125, 252, 252, "CID"], [166, 166, 5, 6, "CID"], [166, 166, 11, 12, "CID"], [166, 166, 14, 14, "CID"], [166, 166, 128, 128, "CID"], [166, 166, 144, 144, "CID"], [166, 166, 160, 160, "CID"], [166, 166, 188, 188, "CID"], [166, 166, 220, 220, "CID"], [166, 166, 252, 252, "CID"], [185, 185, 5, 6, "CID"], [185, 185, 11, 12, "CID"], [185, 185, 14, 14, "CID"], [185, 185, 128, 128, "CID"], [185, 185, 144, 144, "CID"], [185, 185, 160, 160, "CID"], [185, 185, 188, 188, "CID"], [185, 185, 220, 220, "CID"], [185, 185, 252, 252, "CID"], [195, 195, 5, 6, "CID"], [195, 195, 11, 12, "CID"], [195, 195, 14, 14, "CID"], [195, 195, 128, 128, "CID"], [195, 195, 144, 144, "CID"], [195, 195, 160, 160, "CID"], [195, 195, 188, 188, "CID"], [195, 195, 220, 220, "CID"], [195, 195, 252, 252, "CID"], [235, 235, 5, 6, "CID"], [235, 235, 11, 12, "CID"], [235, 235, 14, 14, "CID"], [235, 235, 128, 128, "CID"], [235, 235, 144, 144, "CID"], [235, 235, 160, 160, "CID"], [235, 235, 188, 188, "CID"], [235, 235, 220, 220, "CID"], [235, 235, 252, 252, "CID"], [2, 2, 5, 6, "CID"], [2, 2, 11, 12, "CID"], [2, 2, 14, 14, "CID"], [2, 2, 128, 128, "CID"], [2, 2, 144, 144, "CID"], [2, 2, 160, 160, "CID"], [2, 2, 188, 188, "CID"], [2, 2, 220, 220, "CID"], [2, 2, 252, 252, "CID"], [88, 88, 5, 6, "CID"], [88, 88, 11, 12, "CID"], [88, 88, 14, 14, "CID"], [88, 88, 128, 128, "CID"], [88, 88, 144, 144, "CID"], [88, 88, 160, 160, "CID"], [88, 88, 188, 188, "CID"], [88, 88, 220, 220, "CID"], [88, 88, 252, 252, "CID"], [111, 111, 5, 6, "CID"], [111, 111, 11, 12, "CID"], [111, 111, 14, 14, "CID"], [111, 111, 128, 128, "CID"], [111, 111, 144, 144, "CID"], [111, 111, 160, 160, "CID"], [111, 111, 188, 188, "CID"], [111, 111, 220, 220, "CID"], [111, 111, 252, 252, "CID"], [136, 136, 5, 6, "CID"], [136, 136, 11, 12, "CID"], [136, 136, 14, 14, "CID"], [136, 136, 128, 128, "CID"], [136, 136, 144, 144, "CID"], [136, 136, 160, 160, "CID"], [136, 136, 188, 188, "CID"], [136, 136, 220, 220, "CID"], [136, 136, 252, 252, "CID"], [141, 141, 5, 6, "CID"], [141, 141, 11, 12, "CID"], [141, 141, 14, 14, "CID"], [141, 141, 128, 128, "CID"], [141, 141, 144, 144, "CID"], [141, 141, 160, 160, "CID"], [141, 141, 188, 188, "CID"], [141, 141, 220, 220, "CID"], [141, 141, 252, 252, "CID"], [168, 168, 5, 6, "CID"], [168, 168, 11, 12, "CID"], [168, 168, 14, 14, "CID"], [168, 168, 128, 128, "CID"], [168, 168, 144, 144, "CID"], [168, 168, 160, 160, "CID"], [168, 168, 188, 188, "CID"], [168, 168, 220, 220, "CID"], [168, 168, 252, 252, "CID"], [209, 209, 5, 6, "CID"], [209, 209, 11, 12, "CID"], [209, 209, 14, 14, "CID"], [209, 209, 128, 128, "CID"], [209, 209, 144, 144, "CID"], [209, 209, 160, 160, "CID"], [209, 209, 188, 188, "CID"], [209, 209, 220, 220, "CID"], [209, 209, 252, 252, "CID"], [237, 237, 5, 6, "CID"], [237, 237, 11, 12, "CID"], [237, 237, 14, 14, "CID"], [237, 237, 128, 128, "CID"], [237, 237, 144, 144, "CID"], [237, 237, 160, 160, "CID"], [237, 237, 188, 188, "CID"], [237, 237, 220, 220, "CID"], [237, 237, 252, 252, "CID"]]], "clusters": [], "translated": " <0>环孢菌素</0>和<18>他克莫司</18> - 相关的<9>血栓性微血管病</9>。<10>血栓性微血管病</10> (<11>TMA</11>) 的发生与<1>环孢菌素</1>的使用相关，已有大量文献记载。治疗包括停用或减少<2>环孢菌素</2>剂量，同时进行或不进行血浆置换、血浆输注、抗凝和静脉注射免疫球蛋白G。然而，对于器官移植的接受者来说，去除刺激剂并非没有伴随急性排斥反应和移植物丢失的风险。在过去十年中，<19>他克莫司</19>作为一种有效的免疫抑制剂出现，其作用机制与<3>环孢菌素</3>几乎相同。因此，据报道，在<4>环孢菌素</4>诱导的<12>TMA</12>中，改用<20>他克莫司</20>是一种可行的治疗选择。随着<21>他克莫司</21>在器官移植中的广泛应用，<22>他克莫司</22>相关的<13>TMA</13>也得到认可。然而，关于序贯暴露于<5>环孢菌素</5>和<23>他克莫司</23>的患者<14>TMA</14>复发率的文献有限。我们报告了一个活体肾移植受者的病例，该病例发生了<6>环孢菌素</6>-诱导的<15>TMA</15>对撤除<7>环孢菌素</7>和血浆置换有反应，新鲜冰冻血浆替代疗法。引入<24>他克莫司</24>作为替代免疫抑制剂导致<16>TMA</16>复发和随后的同种异体移植肾丢失。从<8>环孢菌素</8>转换为<25>他克莫司</25>或相反的患者应密切监测复发性<17>TMA</17>的体征和症状。", "revised": true}
{"doc_key": "16181582", "sentences": [["Valproate", "-", "induced", "encephalopathy", ".", "Valproate", "-", "induced", "encephalopathy", "is", "a", "rare", "syndrome", "that", "may", "manifest", "in", "otherwise", "normal", "epileptic", "individuals", ".", "It", "may", "even", "present", "in", "patients", "who", "have", "tolerated", "this", "medicine", "well", "in", "the", "past", ".", "It", "is", "usually", "but", "not", "necessarily", "associated", "with", "hyperammonemia", ".", "The", "EEG", "shows", "characteristic", "triphasic", "waves", "in", "most", "patients", "with", "this", "complication", ".", "A", "case", "of", "valproate", "-", "induced", "encephalopathy", "is", "presented", ".", "The", "problems", "in", "diagnosing", "this", "condition", "are", "subsequently", "discussed", "."]], "ner": [[[0, 0, "Chemical"], [5, 5, "Chemical"], [64, 64, "Chemical"], [3, 3, "Disease"], [8, 8, "Disease"], [67, 67, "Disease"], [19, 19, "Disease"], [46, 46, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 8, 8, "CID"], [0, 0, 67, 67, "CID"], [5, 5, 3, 3, "CID"], [5, 5, 8, 8, "CID"], [5, 5, 67, 67, "CID"], [64, 64, 3, 3, "CID"], [64, 64, 8, 8, "CID"], [64, 64, 67, 67, "CID"]]], "clusters": [], "translated": "<0>丙戊酸盐</0> - 诱发<3>脑病</3>。 <1>丙戊酸盐</1>诱发的<4>脑病</4>是一种罕见的综合征，可能在其他方面正常的<6>癫痫</6>个体中出现。甚至可能出现在过去对这种药物耐受良好的患者身上。它通常但不一定与<7>高氨血症</7>有关。大多数患有这种并发症的患者的脑电图显示出特征性的三相波。介绍了一例<2>丙戊酸盐</2> - 诱发的<5>脑病</5>。随后讨论诊断这种情况的问题。", "revised": true}
{"doc_key": "15602202", "sentences": [["Recurrent", "acute", "interstitial", "nephritis", "induced", "by", "azithromycin", ".", "A", "14", "-", "year", "-", "old", "girl", "is", "reported", "with", "recurrent", ",", "azithromycin", "-", "induced", ",", "acute", "interstitial", "nephritis", ".", "The", "second", "episode", "was", "more", "severe", "than", "the", "first", ";", "and", "although", "both", "were", "treated", "with", "intensive", "corticosteroid", "therapy", ",", "renal", "function", "remained", "impaired", ".", "Although", "most", "cases", "of", "antibiotic", "induced", "acute", "interstitial", "nephritis", "are", "benign", "and", "self", "-", "limited", ",", "some", "patients", "are", "at", "risk", "for", "permanent", "renal", "injury", "."]], "ner": [[[6, 6, "Chemical"], [20, 20, "Chemical"], [2, 3, "Disease"], [25, 26, "Disease"], [60, 61, "Disease"], [76, 77, "Disease"]]], "relations": [[[6, 6, 2, 3, "CID"], [6, 6, 25, 26, "CID"], [6, 6, 60, 61, "CID"], [20, 20, 2, 3, "CID"], [20, 20, 25, 26, "CID"], [20, 20, 60, 61, "CID"]]], "clusters": [], "translated": "<0>阿奇霉素</0>所致反复发作的急性<2>间质性肾炎</2>。据报道，一名 14 岁的女孩患有<1>阿奇霉素</1>诱发的复发性急性<3>间质性肾炎</3>。第二个事件比第一个更严重；尽管两者都接受了强化皮质类固醇治疗，但肾功能仍然受损。虽然大多数抗生素引起的急性<4>间质性肾炎</4>病例是良性和自限性的，但一些患者有发生永久性<5>肾损伤</5>的风险。", "revised": true}
{"doc_key": "12084448", "sentences": [["Ifosfamide", "encephalopathy", "presenting", "with", "asterixis", ".", "CNS", "toxic", "effects", "of", "the", "antineoplastic", "agent", "ifosfamide", "(", "IFX", ")", "are", "frequent", "and", "include", "a", "variety", "of", "neurological", "symptoms", "that", "can", "limit", "drug", "use", ".", "We", "report", "a", "case", "of", "a", "51", "-", "year", "-", "old", "man", "who", "developed", "severe", ",", "disabling", "negative", "myoclonus", "of", "the", "upper", "and", "lower", "extremities", "after", "the", "infusion", "of", "ifosfamide", "for", "plasmacytoma", ".", "He", "was", "awake", ",", "revealed", "no", "changes", "of", "mental", "status", "and", "at", "rest", "there", "were", "no", "further", "motor", "symptoms", ".", "Cranial", "magnetic", "resonance", "imaging", "and", "extensive", "laboratory", "studies", "failed", "to", "reveal", "structural", "lesions", "of", "the", "brain", "and", "metabolic", "abnormalities", ".", "An", "electroencephalogram", "showed", "continuous", ",", "generalized", "irregular", "slowing", "with", "admixed", "periodic", "triphasic", "waves", "indicating", "symptomatic", "encephalopathy", ".", "The", "administration", "of", "ifosfamide", "was", "discontinued", "and", "within", "12", "h", "the", "asterixis", "resolved", "completely", ".", "In", "the", "patient", "described", ",", "the", "presence", "of", "asterixis", "during", "infusion", "of", "ifosfamide", ",", "normal", "laboratory", "findings", "and", "imaging", "studies", "and", "the", "resolution", "of", "symptoms", "following", "the", "discontinuation", "of", "the", "drug", "suggest", "that", "negative", "myoclonus", "is", "associated", "with", "the", "use", "of", "IFX", "."]], "ner": [[[0, 0, "Chemical"], [13, 13, "Chemical"], [15, 15, "Chemical"], [61, 61, "Chemical"], [125, 125, "Chemical"], [149, 149, "Chemical"], [178, 178, "Chemical"], [1, 1, "Disease"], [96, 100, "Disease"], [120, 120, "Disease"], [50, 50, "Disease"], [171, 171, "Disease"], [4, 4, "Disease"], [133, 133, "Disease"], [145, 145, "Disease"], [63, 63, "Disease"], [102, 103, "Disease"]]], "relations": [[[0, 0, 1, 1, "CID"], [0, 0, 96, 100, "CID"], [0, 0, 120, 120, "CID"], [13, 13, 1, 1, "CID"], [13, 13, 96, 100, "CID"], [13, 13, 120, 120, "CID"], [15, 15, 1, 1, "CID"], [15, 15, 96, 100, "CID"], [15, 15, 120, 120, "CID"], [61, 61, 1, 1, "CID"], [61, 61, 96, 100, "CID"], [61, 61, 120, 120, "CID"], [125, 125, 1, 1, "CID"], [125, 125, 96, 100, "CID"], [125, 125, 120, 120, "CID"], [149, 149, 1, 1, "CID"], [149, 149, 96, 100, "CID"], [149, 149, 120, 120, "CID"], [178, 178, 1, 1, "CID"], [178, 178, 96, 100, "CID"], [178, 178, 120, 120, "CID"], [0, 0, 50, 50, "CID"], [0, 0, 171, 171, "CID"], [13, 13, 50, 50, "CID"], [13, 13, 171, 171, "CID"], [15, 15, 50, 50, "CID"], [15, 15, 171, 171, "CID"], [61, 61, 50, 50, "CID"], [61, 61, 171, 171, "CID"], [125, 125, 50, 50, "CID"], [125, 125, 171, 171, "CID"], [149, 149, 50, 50, "CID"], [149, 149, 171, 171, "CID"], [178, 178, 50, 50, "CID"], [178, 178, 171, 171, "CID"]]], "clusters": [], "translated": "<0>异环磷酰胺</0><7>脑病</7>表现为<12>扑翼样震颤</12>。抗肿瘤药<1>异环磷酰胺</1> (<2>IFX</2>)的中枢神经系统毒性作用很常见，包括各种神经系统症状，这些症状会限制药物的使用。我们报告了一名51岁男性的病例，在输注<3>异环磷酰胺</3>治疗<15>浆细胞瘤</15>后，发生严重的、瘫痪性<10>阴性肌阵挛</10>，累及上下肢。他醒着，精神状态没有变化，休息时也没有其他运动症状。头颅磁共振成像和广泛的实验室研究未能揭示<8>大脑结构性病变</8>和<16>代谢异常</16>。脑电图显示持续的、普遍的不规则减慢，伴有混合的周期性三相波，表明有症状的<9>脑病</9>。停止给予<4>异环磷酰胺</4>，12小时内<13>扑翼样震颤</13>完全消失。在所述患者中，在输注<5>异环磷酰胺</5>期间出现<14>扑翼样震颤</14>，正常的实验室检查结果和影像学检查以及停药后症状的消退表明阴性<11>肌阵挛</11>与<6>IFX</6>的使用有关。", "revised": true}
{"doc_key": "12716030", "sentences": [["Amount", "of", "bleeding", "and", "hematoma", "size", "in", "the", "collagenase", "-", "induced", "intracerebral", "hemorrhage", "rat", "model", ".", "The", "aggravated", "risk", "on", "intracerebral", "hemorrhage", "(", "ICH", ")", "with", "drugs", "used", "for", "stroke", "patients", "should", "be", "estimated", "carefully", ".", "We", "therefore", "established", "sensitive", "quantification", "methods", "and", "provided", "a", "rat", "ICH", "model", "for", "detection", "of", "ICH", "deterioration", ".", "In", "ICH", "intrastriatally", "induced", "by", "0", ".", "014", "-", "unit", ",", "0", ".", "070", "-", "unit", ",", "and", "0", ".", "350", "-", "unit", "collagenase", ",", "the", "amount", "of", "bleeding", "was", "measured", "using", "a", "hemoglobin", "assay", "developed", "in", "the", "present", "study", "and", "was", "compared", "with", "the", "morphologically", "determined", "hematoma", "volume", ".", "The", "blood", "amounts", "and", "hematoma", "volumes", "were", "significantly", "correlated", ",", "and", "the", "hematoma", "induced", "by", "0", ".", "014", "-", "unit", "collagenase", "was", "adequate", "to", "detect", "ICH", "deterioration", ".", "In", "ICH", "induction", "using", "0", ".", "014", "-", "unit", "collagenase", ",", "heparin", "enhanced", "the", "hematoma", "volume", "3", ".", "4", "-", "fold", "over", "that", "seen", "in", "control", "ICH", "animals", "and", "the", "bleeding", "7", ".", "6", "-", "fold", ".", "Data", "suggest", "that", "this", "sensitive", "hemoglobin", "assay", "is", "useful", "for", "ICH", "detection", ",", "and", "that", "a", "model", "with", "a", "small", "ICH", "induced", "with", "a", "low", "-", "dose", "collagenase", "should", "be", "used", "for", "evaluation", "of", "drugs", "that", "may", "affect", "ICH", "."]], "ner": [[[143, 143, "Chemical"], [4, 4, "Disease"], [101, 101, "Disease"], [108, 108, "Disease"], [116, 116, "Disease"], [146, 146, "Disease"], [2, 2, "Disease"], [82, 82, "Disease"], [162, 162, "Disease"], [11, 12, "Disease"], [20, 21, "Disease"], [23, 23, "Disease"], [46, 46, "Disease"], [51, 51, "Disease"], [55, 55, "Disease"], [129, 129, "Disease"], [133, 133, "Disease"], [158, 158, "Disease"], [179, 179, "Disease"], [189, 189, "Disease"], [207, 207, "Disease"], [29, 29, "Disease"]]], "relations": [[[143, 143, 4, 4, "CID"], [143, 143, 101, 101, "CID"], [143, 143, 108, 108, "CID"], [143, 143, 116, 116, "CID"], [143, 143, 146, 146, "CID"]]], "clusters": [], "translated": "胶原酶诱导的<9>脑出血</9>大鼠模型<6>出血量</6>和<1>血肿</1>大小。应仔细评估<21>脑卒中</21>患者使用的药物对<10>脑出血</10>（<11>ICH</11>）的加重风险。因此，我们建立了灵敏的量化方法，并提供了大鼠<12>ICH</12> 模型来检测<13>ICH</13>恶化。在 <14>ICH</14>中，由0.014单元、0.070单元和0.350单元胶原酶诱发的<2>血肿</2>体积使用我们开发的血红蛋白测定法进行测量，<7>出血</7>量与之进行比较。血量与<3>血肿</3>体积显着相关，0.014单位胶原酶诱导的<4>血肿</4>足以检测<15>ICH</15>恶化。在使用0.014单位胶原酶诱导的<16>ICH</16>中，<0>肝素</0>增强<5>血肿</5>体积3.4倍于对照<17>ICH</17>动物和7.6倍的<8>出血</8>量。数据表明，这种灵敏的血红蛋白测定可用于检测<18>ICH</18>，且用低剂量胶原酶诱导的小<19>ICH</19>模型，可以应用于评估药物对<20>ICH</20>的影响。", "revised": true}
{"doc_key": "14513889", "sentences": [["Ketoconazole", "-", "induced", "neurologic", "sequelae", ".", "A", "77", "-", "y", "-", "old", "patient", "developed", "weakness", "of", "extremities", ",", "legs", "paralysis", ",", "dysarthria", "and", "tremor", "1", "h", "after", "ingestion", "of", "200", "mg", "ketoconazole", "for", "the", "first", "time", "in", "his", "life", ".", "All", "complaints", "faded", "away", "within", "24", "h", ".", "Few", "days", "later", ",", "the", "patient", "used", "another", "200", "mg", "ketoconazole", "tablet", ",", "and", "within", "an", "hour", "experienced", "a", "similar", "clinical", "picture", ",", "which", "resolved", "again", "spontaneously", "within", "hours", ".", "Laboratory", "evaluations", ",", "including", "head", "CT", "scan", ",", "were", "normal", ".", "This", "case", "illustrates", "the", "need", "for", "close", "vigilance", "in", "adverse", "drug", "reactions", ",", "particularly", "in", "the", "elderly", "."]], "ner": [[[0, 0, "Chemical"], [31, 31, "Chemical"], [58, 58, "Chemical"], [14, 16, "Disease"], [18, 19, "Disease"], [21, 21, "Disease"], [23, 23, "Disease"], [3, 4, "Disease"], [98, 100, "Disease"]]], "relations": [[[0, 0, 14, 16, "CID"], [31, 31, 14, 16, "CID"], [58, 58, 14, 16, "CID"], [0, 0, 18, 19, "CID"], [31, 31, 18, 19, "CID"], [58, 58, 18, 19, "CID"], [0, 0, 21, 21, "CID"], [31, 31, 21, 21, "CID"], [58, 58, 21, 21, "CID"], [0, 0, 23, 23, "CID"], [31, 31, 23, 23, "CID"], [58, 58, 23, 23, "CID"]]], "clusters": [], "translated": "<0>酮康唑</0> - 诱发<7>神经系统后遗症</7>。一名77岁患者在他生命中的第一次摄入了200毫克<1>酮康唑</1>之后的1小时内出现<3>四肢无力</3>、<4>腿部麻痹</4>、<5>构音障碍</5>和<6>震颤</6>。所有投诉在24小时内自行消失。几天后，患者再次服用200毫克<2>酮康唑</2>片剂，在一小时内经历了类似的临床表现，并在数小时内再次自发消退。包括头部CT扫描在内的实验室评估均正常。该病例说明需要密切警惕<8>药物不良反应</8>，尤其是老年人。", "revised": true}
{"doc_key": "15275829", "sentences": [["The", "alpha3", "and", "beta4", "nicotinic", "acetylcholine", "receptor", "subunits", "are", "necessary", "for", "nicotine", "-", "induced", "seizures", "and", "hypolocomotion", "in", "mice", ".", "Binding", "of", "nicotine", "to", "nicotinic", "acetylcholine", "receptors", "(", "nAChRs", ")", "elicits", "a", "series", "of", "dose", "-", "dependent", "behaviors", "that", "go", "from", "altered", "exploration", ",", "sedation", ",", "and", "tremors", ",", "to", "seizures", "and", "death", ".", "nAChRs", "are", "pentameric", "ion", "channels", "usually", "composed", "of", "alpha", "and", "beta", "subunits", ".", "A", "gene", "cluster", "comprises", "the", "alpha3", ",", "alpha5", "and", "beta4", "subunits", ",", "which", "coassemble", "to", "form", "functional", "receptors", ".", "We", "examined", "the", "role", "of", "the", "beta4", "subunits", "in", "nicotine", "-", "induced", "seizures", "and", "hypolocomotion", "in", "beta4", "homozygous", "null", "(", "beta4", "-", "/", "-", ")", "and", "alpha3", "heterozygous", "(", "+", "/", "-", ")", "mice", ".", "beta4", "-", "/", "-", "mice", "were", "less", "sensitive", "to", "the", "effects", "of", "nicotine", "both", "at", "low", "doses", ",", "measured", "as", "decreased", "exploration", "in", "an", "open", "field", ",", "and", "at", "high", "doses", ",", "measured", "as", "sensitivity", "to", "nicotine", "-", "induced", "seizures", ".", "Using", "in", "situ", "hybridization", "probes", "for", "the", "alpha3", "and", "alpha5", "subunits", ",", "we", "showed", "that", "alpha5", "mRNA", "levels", "are", "unchanged", ",", "whereas", "alpha3", "mRNA", "levels", "are", "selectively", "decreased", "in", "the", "mitral", "cell", "layer", "of", "the", "olfactory", "bulb", ",", "and", "the", "inferior", "and", "the", "superior", "colliculus", "of", "beta4", "-", "/", "-", "brains", ".", "alpha3", "+", "/", "-", "mice", "were", "partially", "resistant", "to", "nicotine", "-", "induced", "seizures", "when", "compared", "to", "wild", "-", "type", "littermates", ".", "mRNA", "levels", "for", "the", "alpha5", "and", "the", "beta4", "subunits", "were", "unchanged", "in", "alpha3", "+", "/", "-", "brains", ".", "Together", ",", "these", "results", "suggest", "that", "the", "beta4", "and", "the", "alpha3", "subunits", "are", "mediators", "of", "nicotine", "-", "induced", "seizures", "and", "hypolocomotion", "."]], "ner": [[[11, 11, "Chemical"], [22, 22, "Chemical"], [95, 95, "Chemical"], [133, 133, "Chemical"], [157, 157, "Chemical"], [223, 223, "Chemical"], [268, 268, "Chemical"], [14, 14, "Disease"], [50, 50, "Disease"], [98, 98, "Disease"], [160, 160, "Disease"], [226, 226, "Disease"], [271, 271, "Disease"], [5, 5, "Chemical"], [25, 25, "Chemical"], [16, 16, "Disease"], [100, 100, "Disease"], [273, 273, "Disease"], [47, 47, "Disease"], [52, 52, "Disease"]]], "relations": [[[11, 11, 14, 14, "CID"], [11, 11, 50, 50, "CID"], [11, 11, 98, 98, "CID"], [11, 11, 160, 160, "CID"], [11, 11, 226, 226, "CID"], [11, 11, 271, 271, "CID"], [22, 22, 14, 14, "CID"], [22, 22, 50, 50, "CID"], [22, 22, 98, 98, "CID"], [22, 22, 160, 160, "CID"], [22, 22, 226, 226, "CID"], [22, 22, 271, 271, "CID"], [95, 95, 14, 14, "CID"], [95, 95, 50, 50, "CID"], [95, 95, 98, 98, "CID"], [95, 95, 160, 160, "CID"], [95, 95, 226, 226, "CID"], [95, 95, 271, 271, "CID"], [133, 133, 14, 14, "CID"], [133, 133, 50, 50, "CID"], [133, 133, 98, 98, "CID"], [133, 133, 160, 160, "CID"], [133, 133, 226, 226, "CID"], [133, 133, 271, 271, "CID"], [157, 157, 14, 14, "CID"], [157, 157, 50, 50, "CID"], [157, 157, 98, 98, "CID"], [157, 157, 160, 160, "CID"], [157, 157, 226, 226, "CID"], [157, 157, 271, 271, "CID"], [223, 223, 14, 14, "CID"], [223, 223, 50, 50, "CID"], [223, 223, 98, 98, "CID"], [223, 223, 160, 160, "CID"], [223, 223, 226, 226, "CID"], [223, 223, 271, 271, "CID"], [268, 268, 14, 14, "CID"], [268, 268, 50, 50, "CID"], [268, 268, 98, 98, "CID"], [268, 268, 160, 160, "CID"], [268, 268, 226, 226, "CID"], [268, 268, 271, 271, "CID"]]], "clusters": [], "translated": "alpha3 和 beta4 烟碱型 <13>乙酰胆碱</13> 受体亚基是小鼠<0>尼古丁</0>诱导的<7>癫痫发作</7>和<15>运动不足</15>所必需的。 <1>尼古丁</1>与烟碱型<14>乙酰胆碱</14>受体 (nAChRs) 的结合会引发一系列剂量依赖性行为，这些行为来自探索改变、镇静和<18>震颤</18>，到<8>癫痫发作</8>和<19>死亡</19>。nAChRs是五聚体离子通道，通常由alpha和beta亚基组成。一个基因簇包含alpha3、alpha5和beta4亚基，它们共同组装形成功能性受体。我们检查了beta4 亚基在<2>尼古丁</2>诱导的<9>癫痫发作</9>和<16>运动不足</16>中的作用，在beta4纯合子无效(beta4 -/-)和alpha3杂合子(+/-)老鼠。beta4-/-小鼠对<3>尼古丁</3>的影响不太敏感，这两种情况在低剂量下（测量为在开阔场地探索减少）和高剂量下（测量为对<4>尼古丁</4>的敏感性） - 诱发<10>癫痫发作</10>。使用alpha3和alpha5亚基的原位杂交探针，我们发现alpha5 mRNA水平没有变化，而alpha3 mRNA水平在嗅球的二尖瓣细胞层和beta4的下丘和上丘中选择性降低。alpha3+/-小鼠对<5>尼古丁</5>诱导的<11>癫痫发作</11>有部分抵抗力。alpha5和beta4亚基的mRNA水平在alpha3+/-大脑中没有变化。总之，这些结果表明beta4和alpha3亚基是<6>尼古丁</6>诱导的<12>癫痫发作</12>和<17>运动不足</17>的介质。", "revised": true}
{"doc_key": "15120741", "sentences": [["Recurrent", "excitation", "in", "the", "dentate", "gyrus", "of", "a", "murine", "model", "of", "temporal", "lobe", "epilepsy", ".", "Similar", "to", "rats", ",", "systemic", "pilocarpine", "injection", "causes", "status", "epilepticus", "(", "SE", ")", "and", "the", "eventual", "development", "of", "spontaneous", "seizures", "and", "mossy", "fiber", "sprouting", "in", "C57BL", "/", "6", "and", "CD1", "mice", ",", "but", "the", "physiological", "correlates", "of", "these", "events", "have", "not", "been", "identified", "in", "mice", ".", "Population", "responses", "in", "granule", "cells", "of", "the", "dentate", "gyrus", "were", "examined", "in", "transverse", "slices", "of", "the", "ventral", "hippocampus", "from", "pilocarpine", "-", "treated", "and", "untreated", "mice", ".", "In", "Mg", "(", "2", "+", ")", "-", "free", "bathing", "medium", "containing", "bicuculline", ",", "conditions", "designed", "to", "increase", "excitability", "in", "the", "slices", ",", "electrical", "stimulation", "of", "the", "hilus", "resulted", "in", "a", "single", "population", "spike", "in", "granule", "cells", "from", "control", "mice", "and", "pilocarpine", "-", "treated", "mice", "that", "did", "not", "experience", "SE", ".", "In", "SE", "survivors", ",", "similar", "stimulation", "resulted", "in", "a", "population", "spike", "followed", ",", "at", "a", "variable", "latency", ",", "by", "negative", "DC", "shifts", "and", "repetitive", "afterdischarges", "of", "3", "-", "60", "s", "duration", ",", "which", "were", "blocked", "by", "ionotropic", "glutamate", "receptor", "antagonists", ".", "Focal", "glutamate", "photostimulation", "of", "the", "granule", "cell", "layer", "at", "sites", "distant", "from", "the", "recording", "pipette", "resulted", "in", "population", "responses", "of", "1", "-", "30", "s", "duration", "in", "slices", "from", "SE", "survivors", "but", "not", "other", "groups", ".", "These", "data", "support", "the", "hypothesis", "that", "SE", "-", "induced", "mossy", "fiber", "sprouting", "and", "synaptic", "reorganization", "are", "relevant", "characteristics", "of", "seizure", "development", "in", "these", "murine", "strains", ",", "resembling", "rat", "models", "of", "human", "temporal", "lobe", "epilepsy", "."]], "ner": [[[20, 20, "Chemical"], [80, 80, "Chemical"], [127, 127, "Chemical"], [23, 24, "Disease"], [26, 26, "Disease"], [135, 135, "Disease"], [138, 138, "Disease"], [206, 206, "Disease"], [219, 219, "Disease"], [34, 34, "Disease"], [232, 232, "Disease"], [11, 13, "Disease"], [244, 246, "Disease"], [88, 88, "Chemical"], [98, 98, "Chemical"], [174, 174, "Chemical"], [179, 179, "Chemical"]]], "relations": [[[20, 20, 23, 24, "CID"], [20, 20, 26, 26, "CID"], [20, 20, 135, 135, "CID"], [20, 20, 138, 138, "CID"], [20, 20, 206, 206, "CID"], [20, 20, 219, 219, "CID"], [80, 80, 23, 24, "CID"], [80, 80, 26, 26, "CID"], [80, 80, 135, 135, "CID"], [80, 80, 138, 138, "CID"], [80, 80, 206, 206, "CID"], [80, 80, 219, 219, "CID"], [127, 127, 23, 24, "CID"], [127, 127, 26, 26, "CID"], [127, 127, 135, 135, "CID"], [127, 127, 138, 138, "CID"], [127, 127, 206, 206, "CID"], [127, 127, 219, 219, "CID"], [20, 20, 34, 34, "CID"], [20, 20, 232, 232, "CID"], [80, 80, 34, 34, "CID"], [80, 80, 232, 232, "CID"], [127, 127, 34, 34, "CID"], [127, 127, 232, 232, "CID"]]], "clusters": [], "translated": "<11>颞叶癫痫</11>小鼠模型中齿状回的反复兴奋。与大鼠相似，全身性<0>毛果芸香碱</0>注射引起<3>癫痫持续状态</3> (<4>SE</4>)和自发性<9>癫痫发作</9>以及C57BL/6和CD1小鼠的苔藓纤维分支，但这些事件的生理相关性尚未在小鼠中确定。在<1>毛果芸香碱</1>治疗和未治疗小鼠的腹侧海马体横切片中检查齿状回颗粒细胞的群体反应。在<13>Mg</13>(2+) - 不含<14>比库鸟碱</14>的沐浴介质中，旨在提高切片兴奋性的条件下，门区的电刺激导致对照小鼠和未经历<5>SE</5>的<2>毛果芸香碱</2>治疗小鼠的颗粒细胞中出现单个群体尖峰。在<6>SE</6>幸存者中，类似的刺激导致群体尖峰，随后在可变的潜伏期内出现负向直流偏移和3-60秒的重复后放电，这被离子型<15>谷氨酸</15>受体拮抗剂所阻断。在远离记录吸管的颗粒细胞层位置，对小鼠进行局部<16>谷氨酸</16>光刺激，导致<7>SE</7>幸存者切片中的种群反应持续时间为1-30秒，而其他组则没有。这些数据支持<8>SE</8>诱导的苔藓纤维分支和突触重组是这些小鼠品系中<10>癫痫发作</10>发展的相关特征，类似于人类<12>颞叶癫痫</12>的大鼠模型。", "revised": true}
{"doc_key": "16298782", "sentences": [["Nitro", "-", "L", "-", "arginine", "methyl", "ester", ":", "a", "potential", "protector", "against", "gentamicin", "ototoxicity", ".", "The", "nitric", "oxide", "(", "NO", ")", "inhibitor", "nitro", "-", "L", "-", "arginine", "methyl", "ester", "(", "L", "-", "NAME", ")", "may", "act", "as", "an", "otoprotectant", "against", "high", "-", "frequency", "hearing", "loss", "caused", "by", "gentamicin", ",", "but", "further", "studies", "are", "needed", "to", "confirm", "this", ".", "Aminoglycoside", "antibiotics", "are", "still", "widely", "used", "by", "virtue", "of", "their", "efficacy", "and", "low", "cost", ".", "Their", "ototoxicity", "is", "a", "serious", "health", "problem", "and", ",", "as", "their", "ototoxic", "mechanism", "involves", "the", "production", "of", "NO", ",", "we", "need", "to", "assess", "the", "use", "of", "NO", "inhibitors", "for", "the", "prevention", "of", "aminoglycoside", "-", "induced", "sensorineural", "hearing", "loss", ".", "In", "this", "experimental", "study", "we", "used", "30", "Sprague", "-", "Dawley", "rats", ",", "27", "of", "which", "had", "gentamicin", "instilled", "into", "the", "middle", "ear", ".", "The", "otoprotectant", "L", "-", "NAME", "was", "administered", "topically", "to", "12", "/", "27", "animals", ".", "Its", "effect", "was", "determined", "in", "terms", "of", "attenuation", "of", "hearing", "loss", ",", "measured", "by", "shifts", "in", "the", "auditory", "brainstem", "response", "threshold", ".", "L", "-", "NAME", "reduced", "gentamicin", "-", "induced", "hearing", "loss", "in", "the", "high", "-", "frequency", "range", ",", "but", "gave", "no", "protection", "in", "the", "middle", "or", "low", "frequencies", "."]], "ner": [[[12, 12, "Chemical"], [47, 47, "Chemical"], [128, 128, "Chemical"], [175, 175, "Chemical"], [158, 159, "Disease"], [178, 179, "Disease"], [0, 6, "Chemical"], [22, 28, "Chemical"], [30, 32, "Chemical"], [137, 139, "Chemical"], [171, 173, "Chemical"], [13, 13, "Disease"], [74, 74, "Disease"], [84, 84, "Disease"], [40, 44, "Disease"], [108, 110, "Disease"], [16, 17, "Chemical"], [19, 19, "Chemical"], [90, 90, "Chemical"], [99, 99, "Chemical"], [58, 58, "Chemical"], [105, 105, "Chemical"]]], "relations": [[[12, 12, 158, 159, "CID"], [12, 12, 178, 179, "CID"], [47, 47, 158, 159, "CID"], [47, 47, 178, 179, "CID"], [128, 128, 158, 159, "CID"], [128, 128, 178, 179, "CID"], [175, 175, 158, 159, "CID"], [175, 175, 178, 179, "CID"]]], "clusters": [], "translated": " <6>硝基-L-精氨酸甲酯</6>：一种潜在的<0>庆大霉素</0> <11>耳毒性</11>保护剂。 <16>一氧化氮</16>（<17>NO</17>）抑制剂<7>硝基-L-精氨酸甲酯</7>（<8>L-NAME</8>）可作为一种防止<1>庆大霉素</1>引起的<14>高频听力损失</14>的耳保护剂，但需要进一步的研究来证实这一点。 <20>氨基糖苷类</20>抗生素凭借疗效好、成本低等优点，至今仍被广泛使用。它们的<12>耳毒性</12>是一个严重的健康问题，由于它们的<13>耳毒性</13>机制涉及<18>NO</18>的产生，我们需要评估使用<19>NO</19>抑制剂用于预防<21>氨基糖苷类</21>引起的<15>感音神经性听力损失</15>。在这项实验研究中，我们使用了30只Sprague-Dawley大鼠，其中27只在中耳中滴注了<2>庆大霉素</2>。耳保护剂<9>L-NAME</9>被局部给药于12/27只动物。它的效果是根据<4>听力损失</4>的衰减来确定的，通过听觉脑干反应阈值的变化来衡量。<10>L-NAME</10>降低<3>庆大霉素</3>引起的<5>听力损失</5>在高频范围内，但在中频或低频范围内没有保护作用。", "revised": true}
{"doc_key": "17639754", "sentences": [["Interaction", "between", "warfarin", "and", "levofloxacin", ":", "case", "series", ".", "Warfarin", "is", "the", "most", "widely", "used", "oral", "anticoagulant", "and", "is", "indicated", "for", "many", "clinical", "conditions", ".", "Levofloxacin", ",", "a", "fluoroquinolone", ",", "is", "one", "of", "the", "most", "commonly", "prescribed", "antibiotics", "in", "clinical", "practice", "and", "is", "effective", "against", "Gram", "-", "positive", ",", "Gram", "-", "negative", ",", "and", "atypical", "bacteria", ".", "While", "small", "prospective", "studies", "have", "not", "revealed", "any", "significant", "drug", "-", "drug", "interaction", "between", "warfarin", "and", "levofloxacin", ",", "several", "case", "reports", "have", "indicated", "that", "levofloxacin", "may", "significantly", "potentiate", "the", "anticoagulation", "effect", "of", "warfarin", ".", "We", "report", "3", "cases", "of", "serious", "bleeding", "complications", "that", "appear", "to", "be", "the", "result", "of", "the", "interaction", "between", "warfarin", "and", "levofloxacin", ".", "Physicians", "should", "be", "aware", "of", "this", "potential", "interaction", "and", "use", "caution", "when", "prescribing", "levofloxacin", "to", "patients", "taking", "warfarin", "."]], "ner": [[[2, 2, "Chemical"], [9, 9, "Chemical"], [71, 71, "Chemical"], [89, 89, "Chemical"], [109, 109, "Chemical"], [130, 130, "Chemical"], [97, 97, "Disease"], [4, 4, "Chemical"], [25, 25, "Chemical"], [73, 73, "Chemical"], [81, 81, "Chemical"], [111, 111, "Chemical"], [126, 126, "Chemical"], [28, 28, "Chemical"]]], "relations": [[[2, 2, 97, 97, "CID"], [9, 9, 97, 97, "CID"], [71, 71, 97, 97, "CID"], [89, 89, 97, 97, "CID"], [109, 109, 97, 97, "CID"], [130, 130, 97, 97, "CID"], [4, 4, 97, 97, "CID"], [25, 25, 97, 97, "CID"], [73, 73, 97, 97, "CID"], [81, 81, 97, 97, "CID"], [111, 111, 97, 97, "CID"], [126, 126, 97, 97, "CID"]]], "clusters": [], "translated": "<0>华法林</0> 和 <7>左氧氟沙星</7> 之间的相互作用：病例系列。 <1>华法林</1> 是使用最广泛的口服抗凝剂，适用于多种临床情况。 <8>左氧氟沙星</8>，一种 <13>氟喹诺酮</13>，是临床实践中最常用的抗生素之一，对革兰氏阳性、革兰氏阴性和非典型细菌有效。虽然小型前瞻性研究未显示<2>华法林</2>和<9>左氧氟沙星</9>之间有任何显着的药物相互作用，但一些病例报告表明<10>左氧氟沙星</10>可能显著增强<3>华法林</3>的抗凝作用。我们报告了3例严重的<6>出血</6>并发症，这些并发症似乎是<4>华法林</4>和<11>左氧氟沙星</11>相互作用的结果。医生在给服用<5>华法林</5>的患者开具<12>左氧氟沙星</12>处方时应注意这种潜在的相互作用并谨慎使用。", "revised": true}
{"doc_key": "16755009", "sentences": [["Pharmacological", "evidence", "for", "the", "potential", "of", "Daucus", "carota", "in", "the", "management", "of", "cognitive", "dysfunctions", ".", "The", "present", "study", "was", "aimed", "at", "investigating", "the", "effects", "of", "Daucus", "carota", "seeds", "on", "cognitive", "functions", ",", "total", "serum", "cholesterol", "levels", "and", "brain", "cholinesterase", "activity", "in", "mice", ".", "The", "ethanolic", "extract", "of", "Daucus", "carota", "seeds", "(", "DCE", ")", "was", "administered", "orally", "in", "three", "doses", "(", "100", ",", "200", ",", "400", "mg", "/", "kg", ")", "for", "seven", "successive", "days", "to", "different", "groups", "of", "young", "and", "aged", "mice", ".", "Elevated", "plus", "maze", "and", "passive", "avoidance", "apparatus", "served", "as", "the", "exteroceptive", "behavioral", "models", "for", "testing", "memory", ".", "Diazepam", "-", ",", "scopolamine", "-", "and", "ageing", "-", "induced", "amnesia", "served", "as", "the", "interoceptive", "behavioral", "models", ".", "DCE", "(", "200", ",", "400", "mg", "/", "kg", ",", "p", ".", "o", ".", ")", "showed", "significant", "improvement", "in", "memory", "scores", "of", "young", "and", "aged", "mice", ".", "The", "extent", "of", "memory", "improvement", "evoked", "by", "DCE", "was", "23", "%", "at", "the", "dose", "of", "200", "mg", "/", "kg", "and", "35", "%", "at", "the", "dose", "of", "400", "mg", "/", "kg", "in", "young", "mice", "using", "elevated", "plus", "maze", ".", "Similarly", ",", "significant", "improvements", "in", "memory", "scores", "were", "observed", "using", "passive", "avoidance", "apparatus", "and", "aged", "mice", ".", "Furthermore", ",", "DCE", "reversed", "the", "amnesia", "induced", "by", "scopolamine", "(", "0", ".", "4", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", "and", "diazepam", "(", "1", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", ".", "Daucus", "carota", "extract", "(", "200", ",", "400", "mg", "/", "kg", ",", "p", ".", "o", ".", ")", "reduced", "significantly", "the", "brain", "acetylcholinesterase", "activity", "and", "cholesterol", "levels", "in", "young", "and", "aged", "mice", ".", "The", "extent", "of", "inhibition", "of", "brain", "cholinesterase", "activity", "evoked", "by", "DCE", "at", "the", "dose", "of", "400", "mg", "/", "kg", "was", "22", "%", "in", "young", "and", "19", "%", "in", "aged", "mice", ".", "There", "was", "a", "remarkable", "reduction", "in", "total", "cholesterol", "level", "as", "well", ",", "to", "the", "extent", "of", "23", "%", "in", "young", "and", "21", "%", "in", "aged", "animals", "with", "this", "dose", "of", "DCE", ".", "Therefore", ",", "DCE", "may", "prove", "to", "be", "a", "useful", "remedy", "for", "the", "management", "of", "cognitive", "dysfunctions", "on", "account", "of", "its", "multifarious", "beneficial", "effects", "such", "as", ",", "memory", "improving", "property", ",", "cholesterol", "lowering", "property", "and", "anticholinesterase", "activity", "."]], "ner": [[[99, 99, "Chemical"], [220, 220, "Chemical"], [108, 108, "Disease"], [202, 202, "Disease"], [102, 102, "Chemical"], [205, 205, "Chemical"], [34, 34, "Chemical"], [256, 256, "Chemical"], [302, 302, "Chemical"], [357, 357, "Chemical"], [12, 13, "Disease"], [341, 342, "Disease"], [45, 49, "Chemical"], [51, 51, "Chemical"], [116, 116, "Chemical"], [149, 149, "Chemical"], [199, 199, "Chemical"], [233, 235, "Chemical"], [274, 274, "Chemical"], [325, 325, "Chemical"], [329, 329, "Chemical"]]], "relations": [[[99, 99, 108, 108, "CID"], [99, 99, 202, 202, "CID"], [220, 220, 108, 108, "CID"], [220, 220, 202, 202, "CID"], [102, 102, 108, 108, "CID"], [102, 102, 202, 202, "CID"], [205, 205, 108, 108, "CID"], [205, 205, 202, 202, "CID"]]], "clusters": [], "translated": "胡萝卜在治疗 <10>认知功能障碍</10> 方面潜力的药理学证据。本研究旨在探讨胡萝卜籽对小鼠认知功能、血清总<6>胆固醇</6>水平和脑胆碱酯酶活性的影响。胡萝卜种子乙醇<12>提取物</12>（<13>DCE</13>）以三种剂量（100、200、400 mg/kg）连续7天口服给药于不同组的年轻和老老鼠。高架十字迷宫和被动回避装置作为测试记忆的外感受行为模型。<0>安定</0>-、<4>东莨菪碱</4>-和衰老引起的<2>失忆</2>作为内感受行为模型。<14>DCE</14>（200、400 mg/kg，p.o.）显着改善年轻和年老小鼠的记忆力。在使用高架十字迷宫的年轻小鼠中，<15>DCE</15>在200 mg/kg剂量和400 mg/kg剂量下引起的记忆改善程度分别为23%和35%。同样，使用被动回避装置和老年小鼠观察到记忆分数有显着改善。此外，<16>DCE</16>可逆转<1>安定</1>（1 mg/kg，i.p.）和<5>东莨菪碱</5>（0.4mg/kg，i.p.）引起的<3>失忆</3>。<17>胡萝卜提取物</17>（200、400 mg/kg，p.o.）显着降低年轻和年老小鼠的脑乙酰胆碱酯酶活性和<7>胆固醇</7>水平。<18>DCE</18>在400 mg/kg剂量下引起的脑胆碱酯酶活性抑制程度在年轻小鼠和老年小鼠中分别为22%和19%。使用此剂量的<19>DCE</19>，总<8>胆固醇</8>水平也显着降低，在年轻动物和老年动物中分别降低了23%和21%。因此，<20>DCE</20>可能被证明是治疗<11>认知功能障碍</11>的有效药物，因为它具有多种有益作用，例如改善记忆力、<9>胆固醇</9>降低作用和抗胆碱酯酶活性。", "revised": true}
{"doc_key": "16428221", "sentences": [["Cerebral", "vasculitis", "following", "oral", "methylphenidate", "intake", "in", "an", "adult", ":", "a", "case", "report", ".", "Methylphenidate", "is", "structurally", "and", "functionally", "similar", "to", "amphetamine", ".", "Cerebral", "vasculitis", "associated", "with", "amphetamine", "abuse", "is", "well", "documented", ",", "and", "in", "rare", "cases", "ischaemic", "stroke", "has", "been", "reported", "after", "methylphenidate", "intake", "in", "children", ".", "We", "report", "the", "case", "of", "a", "63", "-", "year", "-", "old", "female", "who", "was", "treated", "with", "methylphenidate", "due", "to", "hyperactivity", "and", "suffered", "from", "multiple", "ischaemic", "strokes", ".", "We", "consider", "drug", "-", "induced", "cerebral", "vasculitis", "as", "the", "most", "likely", "cause", "of", "recurrent", "ischaemic", "strokes", "in", "the", "absence", "of", "any", "pathological", "findings", "during", "the", "diagnostic", "work", "-", "up", ".", "We", "conclude", "that", "methylphenidate", "mediated", "vasculitis", "should", "be", "considered", "in", "patients", "with", "neurological", "symptoms", "and", "a", "history", "of", "methylphenidate", "therapy", ".", "This", "potential", "side", "-", "effect", ",", "though", "very", "rare", ",", "represents", "one", "more", "reason", "to", "be", "very", "restrictive", "in", "the", "use", "of", "methylphenidate", "."]], "ner": [[[4, 4, "Chemical"], [14, 14, "Chemical"], [43, 43, "Chemical"], [64, 64, "Chemical"], [108, 108, "Chemical"], [123, 123, "Chemical"], [148, 148, "Chemical"], [0, 1, "Disease"], [23, 24, "Disease"], [80, 81, "Disease"], [21, 21, "Chemical"], [27, 28, "Disease"], [37, 38, "Disease"], [72, 73, "Disease"], [89, 90, "Disease"], [67, 67, "Disease"], [110, 110, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 23, 24, "CID"], [4, 4, 80, 81, "CID"], [14, 14, 0, 1, "CID"], [14, 14, 23, 24, "CID"], [14, 14, 80, 81, "CID"], [43, 43, 0, 1, "CID"], [43, 43, 23, 24, "CID"], [43, 43, 80, 81, "CID"], [64, 64, 0, 1, "CID"], [64, 64, 23, 24, "CID"], [64, 64, 80, 81, "CID"], [108, 108, 0, 1, "CID"], [108, 108, 23, 24, "CID"], [108, 108, 80, 81, "CID"], [123, 123, 0, 1, "CID"], [123, 123, 23, 24, "CID"], [123, 123, 80, 81, "CID"], [148, 148, 0, 1, "CID"], [148, 148, 23, 24, "CID"], [148, 148, 80, 81, "CID"]]], "clusters": [], "translated": "成人口服<0>哌甲酯</0>后发生<7>脑血管炎</7>：病例报告。 <1>哌醋甲酯</1>在结构和功能上与<10>苯丙胺</10>相似。已经充分证实<11>苯丙胺滥用</11>与<8>脑血管炎</8>相关，并且在极少数情况下，儿童使用<2>哌醋甲酯</2>后有<12>缺血性中风</12>的报道。我们报告了一名63岁女性，因<15>多动症</15>接受<3> 哌醋甲酯 </3>治疗，并患有多次<13>缺血性中风</13>的病例。我们认为药物引起的<9>脑血管炎</9>是复发性<14>缺血性中风</14>的最可能原因，在诊断检查期间没有找到任何病理学异常。我们得出结论，对于具有神经症状和<5>哌甲酯</5>治疗史的患者，应该考虑到<4>哌甲酯</4>介导的<16>血管炎</16>。尽管这种潜在的副作用非常罕见，但它确实是对<6>哌醋甲酯</6>使用非常严格限制的又一个原因。", "revised": true}
{"doc_key": "17466854", "sentences": [["Side", "effects", "of", "postoperative", "administration", "of", "methylprednisolone", "and", "gentamicin", "into", "the", "posterior", "sub", "-", "Tenon", "'s", "space", ".", "PURPOSE", ":", "To", "assess", "the", "incidence", "of", "postoperative", "emetic", "side", "effects", "after", "the", "administration", "of", "methylprednisolone", "and", "gentamicin", "into", "the", "posterior", "sub", "-", "Tenon", "'s", "space", "at", "the", "end", "of", "routine", "cataract", "surgery", ".", "SETTING", ":", "St", ".", "Luke", "'s", "Hospital", ",", "Gwardamangia", ",", "Malta", ".", "METHODS", ":", "A", "double", "-", "blind", "double", "-", "armed", "prospective", "study", "comprised", "40", "patients", "who", "had", "uneventful", "sutureless", "phacoemulsification", "under", "sub", "-", "Tenon", "'s", "local", "infiltration", "of", "3", "mL", "of", "plain", "lignocaine", ".", "At", "the", "end", "of", "the", "procedure", ",", "Group", "A", "(", "n", "=", "20", ")", "had", "20", "mg", "/", "0", ".", "5", "mL", "of", "methylprednisolone", "and", "10", "mg", "/", "0", ".", "5", "mL", "of", "gentamicin", "injected", "into", "the", "posterior", "sub", "-", "Tenon", "'s", "space", "and", "Group", "B", "(", "n", "=", "20", ")", "had", "the", "same", "combination", "injected", "into", "the", "anterior", "sub", "-", "Tenon", "'s", "space", ".", "Postoperatively", ",", "all", "patients", "were", "assessed", "for", "symptoms", "of", "nausea", ",", "vomiting", ",", "and", "headache", ".", "A", "chi", "-", "square", "test", "was", "used", "to", "assess", "the", "statistical", "significance", "of", "results", ".", "RESULTS", ":", "Sixty", "percent", "in", "Group", "A", "developed", "postoperative", "emetic", "symptoms", ",", "headache", ",", "or", "both", ";", "1", "patient", "in", "Group", "B", "developed", "symptoms", ".", "CONCLUSIONS", ":", "The", "administration", "of", "methylprednisolone", "and", "gentamicin", "in", "the", "posterior", "sub", "-", "Tenon", "'s", "space", "was", "related", "to", "a", "high", "incidence", "of", "side", "effects", "including", "nausea", ",", "vomiting", ",", "and", "headache", ".", "All", "adverse", "effects", "were", "self", "-", "limiting", "."]], "ner": [[[6, 6, "Chemical"], [33, 33, "Chemical"], [120, 120, "Chemical"], [223, 223, "Chemical"], [171, 173, "Disease"], [201, 203, "Disease"], [244, 246, "Disease"], [176, 176, "Disease"], [205, 205, "Disease"], [249, 249, "Disease"], [8, 8, "Chemical"], [35, 35, "Chemical"], [130, 130, "Chemical"], [225, 225, "Chemical"], [49, 49, "Disease"], [95, 95, "Chemical"]]], "relations": [[[6, 6, 171, 173, "CID"], [6, 6, 201, 203, "CID"], [6, 6, 244, 246, "CID"], [33, 33, 171, 173, "CID"], [33, 33, 201, 203, "CID"], [33, 33, 244, 246, "CID"], [120, 120, 171, 173, "CID"], [120, 120, 201, 203, "CID"], [120, 120, 244, 246, "CID"], [223, 223, 171, 173, "CID"], [223, 223, 201, 203, "CID"], [223, 223, 244, 246, "CID"], [6, 6, 176, 176, "CID"], [6, 6, 205, 205, "CID"], [6, 6, 249, 249, "CID"], [33, 33, 176, 176, "CID"], [33, 33, 205, 205, "CID"], [33, 33, 249, 249, "CID"], [120, 120, 176, 176, "CID"], [120, 120, 205, 205, "CID"], [120, 120, 249, 249, "CID"], [223, 223, 176, 176, "CID"], [223, 223, 205, 205, "CID"], [223, 223, 249, 249, "CID"], [8, 8, 171, 173, "CID"], [8, 8, 201, 203, "CID"], [8, 8, 244, 246, "CID"], [35, 35, 171, 173, "CID"], [35, 35, 201, 203, "CID"], [35, 35, 244, 246, "CID"], [130, 130, 171, 173, "CID"], [130, 130, 201, 203, "CID"], [130, 130, 244, 246, "CID"], [225, 225, 171, 173, "CID"], [225, 225, 201, 203, "CID"], [225, 225, 244, 246, "CID"], [8, 8, 176, 176, "CID"], [8, 8, 205, 205, "CID"], [8, 8, 249, 249, "CID"], [35, 35, 176, 176, "CID"], [35, 35, 205, 205, "CID"], [35, 35, 249, 249, "CID"], [130, 130, 176, 176, "CID"], [130, 130, 205, 205, "CID"], [130, 130, 249, 249, "CID"], [225, 225, 176, 176, "CID"], [225, 225, 205, 205, "CID"], [225, 225, 249, 249, "CID"]]], "clusters": [], "translated": "<0>甲基泼尼松龙</0>和<10>庆大霉素</10>术后后筋膜下间隙给药的副作用。目的：评估在常规<14>白内障</14>手术结束后将<1>甲基泼尼松龙</1>和<11>庆大霉素</11>进入<14>白内障</14>后眼筋膜下间隙后的术后呕吐副作用的发生率。设置：圣。Luke医院，Gwardamangia，马耳他。方法：一项双盲双臂前瞻性研究包括40名患者，他们在3 mL普通<15>利多卡因</15>的Tenon下局部浸润下进行了顺利的无缝线超声乳化术。在程序结束时，A组(n=20)有20mg/0.5mL<2>甲泼尼龙</2>和10mg/0.5mL<12>庆大霉素</12>注入后眼筋膜下间隙，B组(n=20)同样组合注入前眼筋膜下间隙。术后，对所有患者进行了<4>恶心、呕吐</4>和<7>头痛</7>的症状评估。卡方检验用于评估结果的统计显着性。结果：A组中有60%的患者出现术后<5>呕吐症状</5>、<8>头痛</8>，或两者兼而有之；B组有1名患者出现症状。结论：<3>甲基泼尼松龙</3>和<13>庆大霉素</13>在<14>白内障</14>后眼筋膜下间隙给药与<6>恶心、呕吐</6>等不良反应发生率高有关，<9>头痛</9>也有发生。所有不良反应都是自限性的。", "revised": true}
{"doc_key": "3503576", "sentences": [["Serial", "studies", "of", "auditory", "neurotoxicity", "in", "patients", "receiving", "deferoxamine", "therapy", ".", "Visual", "and", "auditory", "neurotoxicity", "was", "previously", "documented", "in", "42", "of", "89", "patients", "with", "transfusion", "-", "dependent", "anemia", "who", "were", "receiving", "iron", "chelation", "therapy", "with", "daily", "subcutaneous", "deferoxamine", ".", "Twenty", "-", "two", "patients", "in", "the", "affected", "group", "had", "abnormal", "audiograms", "with", "deficits", "mostly", "in", "the", "high", "frequency", "range", "of", "4", ",", "000", "to", "8", ",", "000", "Hz", "and", "in", "the", "hearing", "threshold", "levels", "of", "30", "to", "100", "decibels", ".", "When", "deferoxamine", "therapy", "was", "discontinued", "and", "serial", "studies", "were", "performed", ",", "audiograms", "in", "seven", "cases", "reverted", "to", "normal", "or", "near", "normal", "within", "two", "to", "three", "weeks", ",", "and", "nine", "of", "13", "patients", "with", "symptoms", "became", "asymptomatic", ".", "Audiograms", "from", "15", "patients", "remained", "abnormal", "and", "four", "patients", "required", "hearing", "aids", "because", "of", "permanent", "disability", ".", "Since", "18", "of", "the", "22", "patients", "were", "initially", "receiving", "deferoxamine", "doses", "in", "excess", "of", "the", "commonly", "recommended", "50", "mg", "/", "kg", "per", "dose", ",", "therapy", "was", "restarted", "with", "lower", "doses", ",", "usually", "50", "mg", "/", "kg", "per", "dose", "or", "less", "depending", "on", "the", "degree", "of", "auditory", "abnormality", ",", "and", "with", "the", "exception", "of", "two", "cases", "no", "further", "toxicity", "was", "demonstrated", ".", "Auditory", "deterioration", "and", "improvement", ",", "demonstrated", "serially", "in", "individual", "patients", "receiving", "and", "not", "receiving", "deferoxamine", ",", "respectively", ",", "provided", "convincing", "evidence", "for", "a", "cause", "-", "and", "-", "effect", "relation", "between", "deferoxamine", "administration", "and", "ototoxicity", ".", "Based", "on", "these", "data", ",", "a", "plan", "of", "management", "was", "developed", "that", "allows", "effective", "yet", "safe", "administration", "of", "deferoxamine", ".", "A", "dose", "of", "50", "mg", "/", "kg", "is", "recommended", "in", "those", "without", "audiogram", "abnormalities", ".", "With", "mild", "toxicity", ",", "a", "reduction", "to", "30", "or", "40", "mg", "/", "kg", "per", "dose", "should", "result", "in", "a", "reversal", "of", "the", "abnormal", "results", "to", "normal", "within", "four", "weeks", ".", "Moderate", "abnormalities", "require", "a", "reduction", "of", "deferoxamine", "to", "25", "mg", "/", "kg", "per", "dose", "with", "careful", "monitoring", ".", "In", "those", "with", "symptoms", "of", "hearing", "loss", ",", "the", "drug", "should", "be", "stopped", "for", "four", "weeks", ",", "and", "when", "the", "audiogram", "is", "stable", "or", "improved", ",", "therapy", "should", "be", "restarted", "at", "10", "to", "25", "mg", "/", "kg", "per", "dose", ".", "Serial", "audiograms", "should", "be", "performed", "every", "six", "months", "in", "those", "without", "problems", "and", "more", "frequently", "in", "young", "patients", "with", "normal", "serum", "ferritin", "values", "and", "in", "those", "with", "auditory", "dysfunction", "."]], "ner": [[[8, 8, "Chemical"], [37, 37, "Chemical"], [80, 80, "Chemical"], [142, 142, "Chemical"], [208, 208, "Chemical"], [224, 224, "Chemical"], [247, 247, "Chemical"], [300, 300, "Chemical"], [11, 14, "Disease"], [48, 66, "Disease"], [3, 4, "Disease"], [178, 179, "Disease"], [227, 227, "Disease"], [379, 380, "Disease"], [31, 31, "Chemical"], [27, 27, "Disease"], [130, 131, "Disease"], [190, 190, "Disease"], [266, 266, "Disease"], [317, 318, "Disease"]]], "relations": [[[8, 8, 11, 14, "CID"], [37, 37, 11, 14, "CID"], [80, 80, 11, 14, "CID"], [142, 142, 11, 14, "CID"], [208, 208, 11, 14, "CID"], [224, 224, 11, 14, "CID"], [247, 247, 11, 14, "CID"], [300, 300, 11, 14, "CID"], [8, 8, 48, 66, "CID"], [37, 37, 48, 66, "CID"], [80, 80, 48, 66, "CID"], [142, 142, 48, 66, "CID"], [208, 208, 48, 66, "CID"], [224, 224, 48, 66, "CID"], [247, 247, 48, 66, "CID"], [300, 300, 48, 66, "CID"]]], "clusters": [], "translated": "接受<0>去铁胺</0>治疗的患者<10>听觉神经毒性</10>系列研究。<8>视觉和听觉神经毒性</8>先前在89名输血依赖性<15>贫血</15>患者中42位因每日皮下注射<1>去铁胺</1>的<14>铁</14>螯合治疗而引发。受影响的组中22名患者<9>听力图异常，主要在4,000至8,000赫兹的高频范围内，听阈水平为30至100分贝</9>。当停止<2>去铁胺</2>治疗并进行系列研究时，7例患者的听力图在两到三周内恢复正常或接近正常，13名有症状的患者中有9名变得无症状。15名患者的听力图仍然异常，4名患者因<16>永久性残疾</16>需要助听器。由于22名患者中有18名最初接受的<3>去铁胺</3>剂量超过通常推荐的每剂50毫克/千克，因此以较低剂量重新开始治疗，通常每剂50毫克/千克或更少，具体取决于<11>听觉异常</11>的程度，除两例外，没有进一步的<17>毒性</17>被证明。分别在接受和未接受<4>去铁胺</4>治疗的个体患者中连续证明听觉恶化和改善，为<5>去铁胺</5>给药和<12>耳毒性</12>之间的因果关系提供了令人信服的证据。根据这些数据，制定了一项管理计划，可以有效且安全地使用<6>去铁胺</6>。对于没有听力异常的患者，推荐剂量为50毫克/千克。具有轻微<18>毒性</18>的患者，每剂量减少到30或40毫克/千克应该会导致异常结果在4周内逆转为正常。中度异常需要在仔细监测下将<7>去铁胺</7>减少至每剂量25毫克/千克。有<19>听力下降</19>症状的患者，停药4周，听力稳定或好转后，重新开始治疗，剂量为10到25毫克/千克/次。对于没有问题的患者，应每六个月进行一次连续听力图检查;对于血清铁蛋白值正常的年轻患者和有<13>听力功能障碍</13>的患者，应更频繁地进行检查。", "revised": true}
{"doc_key": "18503483", "sentences": [["Recovery", "of", "tacrolimus", "-", "associated", "brachial", "neuritis", "after", "conversion", "to", "everolimus", "in", "a", "pediatric", "renal", "transplant", "recipient", "-", "-", "case", "report", "and", "review", "of", "the", "literature", ".", "TAC", "has", "been", "shown", "to", "be", "a", "potent", "immunosuppressive", "agent", "for", "solid", "organ", "transplantation", "in", "pediatrics", ".", "Neurotoxicity", "is", "a", "potentially", "serious", "toxic", "effect", ".", "It", "is", "characterized", "by", "encephalopathy", ",", "headaches", ",", "seizures", ",", "or", "neurological", "deficits", ".", "Here", ",", "we", "describe", "an", "eight", "-", "and", "-", "a", "-", "half", "-", "yr", "-", "old", "male", "renal", "transplant", "recipient", "with", "right", "BN", ".", "MRI", "demonstrated", "hyperintense", "T2", "signals", "in", "the", "cervical", "cord", "and", "right", "brachial", "plexus", "roots", "indicative", "of", "both", "myelitis", "and", "right", "brachial", "plexitis", ".", "Symptoms", "persisted", "for", "three", "months", "despite", "TAC", "dose", "reduction", ",", "administration", "of", "IVIG", "and", "four", "doses", "of", "methylprednisolone", "pulse", "therapy", ".", "Improvement", "and", "eventually", "full", "recovery", "only", "occurred", "after", "TAC", "was", "completely", "discontinued", "and", "successfully", "replaced", "by", "everolimus", "."]], "ner": [[[2, 2, "Chemical"], [27, 27, "Chemical"], [119, 119, "Chemical"], [142, 142, "Chemical"], [5, 6, "Disease"], [110, 111, "Disease"], [44, 44, "Disease"], [56, 56, "Disease"], [58, 58, "Disease"], [60, 60, "Disease"], [63, 64, "Disease"], [107, 107, "Disease"], [10, 10, "Chemical"], [150, 150, "Chemical"], [130, 130, "Chemical"]]], "relations": [[[2, 2, 5, 6, "CID"], [2, 2, 110, 111, "CID"], [27, 27, 5, 6, "CID"], [27, 27, 110, 111, "CID"], [119, 119, 5, 6, "CID"], [119, 119, 110, 111, "CID"], [142, 142, 5, 6, "CID"], [142, 142, 110, 111, "CID"]]], "clusters": [], "translated": "<0>他克莫司</0>相关<4>臂神经炎</4>在小儿肾移植受者转换为<12>依维莫司</12>后的恢复 - 个案报告和文献回顾。<1>TAC</1>已被证明是儿科实体器官移植的有效免疫抑制剂。 <6>神经毒性</6>是一种潜在的严重毒性作用。其特征是<7>脑病</7>、<8>头痛</8>、<9>癫痫发作</9>或<10>神经功能障碍</10>。在这里，我们描述了一名患有右侧 BN 的 8 岁半男性肾移植受者。MRI显示颈髓和右臂丛神经根中的高信号 T2 信号表明<11>脊髓炎</11>和右<5>臂丛神经炎</5>。尽管减少了<2>TAC</2>剂量、给予IVIG和四剂<14>甲泼尼龙</14>冲击疗法，但症状仍持续了三个月。只有在<3>TAC</3>完全停用并成功替换为<13>依维莫司</13>后，才会出现改善并最终完全康复。", "revised": true}
{"doc_key": "12905102", "sentences": [["Delirium", "during", "clozapine", "treatment", ":", "incidence", "and", "associated", "risk", "factors", ".", "BACKGROUND", ":", "Incidence", "and", "risk", "factors", "for", "delirium", "during", "clozapine", "treatment", "require", "further", "clarification", ".", "METHODS", ":", "We", "used", "computerized", "pharmacy", "records", "to", "identify", "all", "adult", "psychiatric", "inpatients", "treated", "with", "clozapine", "(", "1995", "-", "96", ")", ",", "reviewed", "their", "medical", "records", "to", "score", "incidence", "and", "severity", "of", "delirium", ",", "and", "tested", "associations", "with", "potential", "risk", "factors", ".", "RESULTS", ":", "Subjects", "(", "n", "=", "139", ")", "were", "72", "women", "and", "67", "men", ",", "aged", "40", ".", "8", "+", "/", "-", "12", ".", "1", "years", ",", "hospitalized", "for", "24", ".", "9", "+", "/", "-", "23", ".", "3", "days", ",", "and", "given", "clozapine", ",", "gradually", "increased", "to", "an", "average", "daily", "dose", "of", "282", "+", "/", "-", "203", "mg", "(", "3", ".", "45", "+", "/", "-", "2", ".", "45", "mg", "/", "kg", ")", "for", "18", ".", "9", "+", "/", "-", "16", ".", "4", "days", ".", "Delirium", "was", "diagnosed", "in", "14", "(", "10", ".", "1", "%", "incidence", ",", "or", "1", ".", "48", "cases", "/", "person", "-", "years", "of", "exposure", ")", ";", "71", ".", "4", "%", "of", "cases", "were", "moderate", "or", "severe", ".", "Associated", "factors", "were", "co", "-", "treatment", "with", "other", "centrally", "antimuscarinic", "agents", ",", "poor", "clinical", "outcome", ",", "older", "age", ",", "and", "longer", "hospitalization", "(", "by", "17", ".", "5", "days", ",", "increasing", "cost", ")", ";", "sex", ",", "diagnosis", "or", "medical", "co", "-", "morbidity", ",", "and", "daily", "clozapine", "dose", ",", "which", "fell", "with", "age", ",", "were", "unrelated", ".", "CONCLUSIONS", ":", "Delirium", "was", "found", "in", "10", "%", "of", "clozapine", "-", "treated", "inpatients", ",", "particularly", "in", "older", "patients", "exposed", "to", "other", "central", "anticholinergics", ".", "Delirium", "was", "inconsistently", "recognized", "clinically", "in", "milder", "cases", "and", "was", "associated", "with", "increased", "length", "-", "of", "-", "stay", "and", "higher", "costs", ",", "and", "inferior", "clinical", "outcome", "."]], "ner": [[[2, 2, "Chemical"], [20, 20, "Chemical"], [41, 41, "Chemical"], [110, 110, "Chemical"], [232, 232, "Chemical"], [252, 252, "Chemical"], [0, 0, "Disease"], [18, 18, "Disease"], [58, 58, "Disease"], [152, 152, "Disease"], [245, 245, "Disease"], [267, 267, "Disease"], [37, 37, "Disease"]]], "relations": [[[2, 2, 0, 0, "CID"], [2, 2, 18, 18, "CID"], [2, 2, 58, 58, "CID"], [2, 2, 152, 152, "CID"], [2, 2, 245, 245, "CID"], [2, 2, 267, 267, "CID"], [20, 20, 0, 0, "CID"], [20, 20, 18, 18, "CID"], [20, 20, 58, 58, "CID"], [20, 20, 152, 152, "CID"], [20, 20, 245, 245, "CID"], [20, 20, 267, 267, "CID"], [41, 41, 0, 0, "CID"], [41, 41, 18, 18, "CID"], [41, 41, 58, 58, "CID"], [41, 41, 152, 152, "CID"], [41, 41, 245, 245, "CID"], [41, 41, 267, 267, "CID"], [110, 110, 0, 0, "CID"], [110, 110, 18, 18, "CID"], [110, 110, 58, 58, "CID"], [110, 110, 152, 152, "CID"], [110, 110, 245, 245, "CID"], [110, 110, 267, 267, "CID"], [232, 232, 0, 0, "CID"], [232, 232, 18, 18, "CID"], [232, 232, 58, 58, "CID"], [232, 232, 152, 152, "CID"], [232, 232, 245, 245, "CID"], [232, 232, 267, 267, "CID"], [252, 252, 0, 0, "CID"], [252, 252, 18, 18, "CID"], [252, 252, 58, 58, "CID"], [252, 252, 152, 152, "CID"], [252, 252, 245, 245, "CID"], [252, 252, 267, 267, "CID"]]], "clusters": [], "translated": "<6>谵妄</6>在<0>氯氮平</0>治疗期间的发病率和相关危险因素：回顾与展望。背景：进一步阐明<1>氯氮平</1>治疗期间<7>谵妄</7>的发生率和危险因素。方</8>使用计算机化药房记录识别了全部使用<2>氯氮平</2>（1995-1996）的18岁以上<12>精神科</12>住院患者，并回顾其医疗记录以评分<8>谵妄</8>的发生和严重程度，并测试与潜在危险因素的相关性。结果：受试者（n = 139）中，72为女性，67为男性，年龄为40.8年，住院时间为24.9 + / - 23.3天，并逐渐给予<3>氯氮平</3>，平均每日剂量为282 +/- 203毫克（3.45 + / - 2.45毫克/千克），治疗时间为18.9 + / - 16.4天。 <9>谵妄</9>被诊断为14例（10.1%的发生率，或每人-年暴露1.48例），其中71.4%的病例为中度或重度。相关因素包括与其他抗胆碱能中枢性药物联合治疗、恶劣的临床结果、较高的年龄和较长的住院时间（增加17.5天的费用）；性别、诊断或共病和随年龄降低的每日<4>氯氮平</4>剂量均无关。结论：在接受<5>氯氮平</5>治疗的住院患者中，发现了10%的<10>谵妄</10>，尤其是在老年患者中暴露于其他中枢性抗胆碱药物。在较轻的病例中，<11>谵妄</11>的临床识别不一致，并且与住院时间延长、费用增加和临床结果较差有关。", "revised": true}
{"doc_key": "16858720", "sentences": [["Cerebral", "haemorrhage", "induced", "by", "warfarin", "-", "the", "influence", "of", "drug", "-", "drug", "interactions", ".", "PURPOSE", ":", "To", "evaluate", "the", "frequency", ",", "severity", "and", "preventability", "of", "warfarin", "-", "induced", "cerebral", "haemorrhages", "due", "to", "warfarin", "and", "warfarin", "-", "drug", "interactions", "in", "patients", "living", "in", "the", "county", "of", "Osterg", "tland", ",", "Sweden", ".", "METHODS", ":", "All", "patients", "with", "a", "diagnosed", "cerebral", "haemorrhage", "at", "three", "hospitals", "during", "the", "period", "2000", "-", "2002", "were", "identified", ".", "Medical", "records", "were", "studied", "retrospectively", "to", "evaluate", "whether", "warfarin", "and", "warfarin", "-", "drug", "interactions", "could", "have", "caused", "the", "cerebral", "haemorrhage", ".", "The", "proportion", "of", "possibly", "avoidable", "cases", "due", "to", "drug", "interactions", "was", "estimated", ".", "RESULTS", ":", "Among", "593", "patients", "with", "cerebral", "haemorrhage", ",", "59", "(", "10", "%", ")", "were", "assessed", "as", "related", "to", "warfarin", "treatment", ".", "This", "imply", "an", "incidence", "of", "1", ".", "7", "/", "100", ",", "000", "treatment", "years", ".", "Of", "the", "59", "cases", ",", "26", "(", "44", "%", ")", "had", "a", "fatal", "outcome", ",", "compared", "to", "136", "(", "25", "%", ")", "among", "the", "non", "-", "warfarin", "patients", "(", "p", "<", "0", ".", "01", ")", ".", "A", "warfarin", "-", "drug", "interaction", "could", "have", "contributed", "to", "the", "haemorrhage", "in", "24", "(", "41", "%", ")", "of", "the", "warfarin", "patients", "and", "in", "7", "of", "these", "(", "12", "%", ")", "the", "bleeding", "complication", "was", "considered", "being", "possible", "to", "avoid", ".", "CONCLUSIONS", ":", "Warfarin", "-", "induced", "cerebral", "haemorrhages", "are", "a", "major", "clinical", "problem", "with", "a", "high", "fatality", "rate", ".", "Almost", "half", "of", "the", "cases", "was", "related", "to", "a", "warfarin", "-", "drug", "interaction", ".", "A", "significant", "proportion", "of", "warfarin", "-", "related", "cerebral", "haemorrhages", "might", "have", "been", "prevented", "if", "greater", "caution", "had", "been", "taken", "when", "prescribing", "drugs", "known", "to", "interact", "with", "warfarin", "."]], "ner": [[[4, 4, "Chemical"], [25, 25, "Chemical"], [32, 32, "Chemical"], [34, 34, "Chemical"], [79, 79, "Chemical"], [81, 81, "Chemical"], [124, 124, "Chemical"], [168, 168, "Chemical"], [179, 179, "Chemical"], [197, 197, "Chemical"], [220, 220, "Chemical"], [245, 245, "Chemical"], [254, 254, "Chemical"], [276, 276, "Chemical"], [0, 1, "Disease"], [28, 29, "Disease"], [57, 58, "Disease"], [89, 90, "Disease"], [111, 112, "Disease"], [223, 224, "Disease"], [257, 258, "Disease"], [188, 188, "Disease"], [209, 209, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 28, 29, "CID"], [4, 4, 57, 58, "CID"], [4, 4, 89, 90, "CID"], [4, 4, 111, 112, "CID"], [4, 4, 223, 224, "CID"], [4, 4, 257, 258, "CID"], [25, 25, 0, 1, "CID"], [25, 25, 28, 29, "CID"], [25, 25, 57, 58, "CID"], [25, 25, 89, 90, "CID"], [25, 25, 111, 112, "CID"], [25, 25, 223, 224, "CID"], [25, 25, 257, 258, "CID"], [32, 32, 0, 1, "CID"], [32, 32, 28, 29, "CID"], [32, 32, 57, 58, "CID"], [32, 32, 89, 90, "CID"], [32, 32, 111, 112, "CID"], [32, 32, 223, 224, "CID"], [32, 32, 257, 258, "CID"], [34, 34, 0, 1, "CID"], [34, 34, 28, 29, "CID"], [34, 34, 57, 58, "CID"], [34, 34, 89, 90, "CID"], [34, 34, 111, 112, "CID"], [34, 34, 223, 224, "CID"], [34, 34, 257, 258, "CID"], [79, 79, 0, 1, "CID"], [79, 79, 28, 29, "CID"], [79, 79, 57, 58, "CID"], [79, 79, 89, 90, "CID"], [79, 79, 111, 112, "CID"], [79, 79, 223, 224, "CID"], [79, 79, 257, 258, "CID"], [81, 81, 0, 1, "CID"], [81, 81, 28, 29, "CID"], [81, 81, 57, 58, "CID"], [81, 81, 89, 90, "CID"], [81, 81, 111, 112, "CID"], [81, 81, 223, 224, "CID"], [81, 81, 257, 258, "CID"], [124, 124, 0, 1, "CID"], [124, 124, 28, 29, "CID"], [124, 124, 57, 58, "CID"], [124, 124, 89, 90, "CID"], [124, 124, 111, 112, "CID"], [124, 124, 223, 224, "CID"], [124, 124, 257, 258, "CID"], [168, 168, 0, 1, "CID"], [168, 168, 28, 29, "CID"], [168, 168, 57, 58, "CID"], [168, 168, 89, 90, "CID"], [168, 168, 111, 112, "CID"], [168, 168, 223, 224, "CID"], [168, 168, 257, 258, "CID"], [179, 179, 0, 1, "CID"], [179, 179, 28, 29, "CID"], [179, 179, 57, 58, "CID"], [179, 179, 89, 90, "CID"], [179, 179, 111, 112, "CID"], [179, 179, 223, 224, "CID"], [179, 179, 257, 258, "CID"], [197, 197, 0, 1, "CID"], [197, 197, 28, 29, "CID"], [197, 197, 57, 58, "CID"], [197, 197, 89, 90, "CID"], [197, 197, 111, 112, "CID"], [197, 197, 223, 224, "CID"], [197, 197, 257, 258, "CID"], [220, 220, 0, 1, "CID"], [220, 220, 28, 29, "CID"], [220, 220, 57, 58, "CID"], [220, 220, 89, 90, "CID"], [220, 220, 111, 112, "CID"], [220, 220, 223, 224, "CID"], [220, 220, 257, 258, "CID"], [245, 245, 0, 1, "CID"], [245, 245, 28, 29, "CID"], [245, 245, 57, 58, "CID"], [245, 245, 89, 90, "CID"], [245, 245, 111, 112, "CID"], [245, 245, 223, 224, "CID"], [245, 245, 257, 258, "CID"], [254, 254, 0, 1, "CID"], [254, 254, 28, 29, "CID"], [254, 254, 57, 58, "CID"], [254, 254, 89, 90, "CID"], [254, 254, 111, 112, "CID"], [254, 254, 223, 224, "CID"], [254, 254, 257, 258, "CID"], [276, 276, 0, 1, "CID"], [276, 276, 28, 29, "CID"], [276, 276, 57, 58, "CID"], [276, 276, 89, 90, "CID"], [276, 276, 111, 112, "CID"], [276, 276, 223, 224, "CID"], [276, 276, 257, 258, "CID"]]], "clusters": [], "translated": "<0>华法林</0>引起的<14>脑出血</14>——药物相互作用的影响。目的：评估<1>华法林</1>引起的<15>脑出血</15>的频率、严重性和可预防性，<2>华法林</2>和<3>华法林</3>药物相互作用在居住在瑞典Ostergtland县的患者中的影响。方法：对2000年至2002年期间在三所医院诊断为<16>脑出血</16>的所有患者进行了鉴定。对医疗记录进行回顾性研究，以评估<4>华法林</4>和<5>华法林</5>药物相互作用是否可能导致<17>脑出血</17>。估计由于药物相互作用而可能避免的病例的比例。结果：在593例<18>脑出血</18>患者中，59例（10%）被评估为与<6>华法林</6>治疗有关。这意味着发生率为1.7/100,000治疗年。在59例患者中，有26例 (44%)死亡，而在未服用<7>华法林</7>的患者中有136例(25%)(p<0.01)。<8>华法林</8>-药物相互作用可能导致<21>出血</21>，<9>华法林</9>患者中有24例(41%)，其中7例(12%)<22>出血</22>并发症被认为可以避免。结论：<10>华法林</10>引起的<19>脑出血</19>是临床上主要的致死率高的问题。几乎一半的病例与<11>华法林</11>药物相互作用有关。如果在开已知会与<13>华法林</13>相互作用的药物时更加谨慎，则可以预防很大一部分<12>华法林</12>相关的<20>脑出血</20>。", "revised": true}
{"doc_key": "18329269", "sentences": [["Synthesis", "of", "N", "-", "pyrimidinyl", "-", "2", "-", "phenoxyacetamides", "as", "adenosine", "A2A", "receptor", "antagonists", ".", "A", "series", "of", "N", "-", "pyrimidinyl", "-", "2", "-", "phenoxyacetamide", "adenosine", "A", "(", "2A", ")", "antagonists", "is", "described", ".", "SAR", "studies", "led", "to", "compound", "14", "with", "excellent", "potency", "(", "K", "(", "i", ")", "=", "0", ".", "4", "nM", ")", ",", "selectivity", "(", "A", "(", "1", ")", "/", "A", "(", "2A", ")", ">", "100", ")", ",", "and", "efficacy", "(", "MED", "10", "mg", "/", "kg", "p", ".", "o", ".", ")", "in", "the", "rat", "haloperidol", "-", "induced", "catalepsy", "model", "for", "Parkinson", "'s", "disease", "."]], "ner": [[[86, 86, "Chemical"], [89, 89, "Disease"], [2, 8, "Chemical"], [18, 24, "Chemical"], [92, 94, "Disease"], [10, 10, "Chemical"], [25, 25, "Chemical"]]], "relations": [[[86, 86, 89, 89, "CID"]]], "clusters": [], "translated": "<2>N-嘧啶基-2-苯氧基乙酰胺</2>作为<5>腺苷</5>A2A受体拮抗剂的合成。描述了一系列<3>N-嘧啶基-2-苯氧基乙酰胺</3><6>腺苷</6>A (2A)拮抗剂。SAR研究导致化合物14具有出色的效力(K(i)=0.4 nM)、选择性(A(1)/A(2A)>100)和功效(MED 10 mg/kg p.o.)在大鼠的<1>僵直</1>模型中采用<0>氟哌啶醇</0>诱导，用于<4>帕金森病</4>。", "revised": true}
{"doc_key": "19299179", "sentences": [["Severe", "and", "long", "lasting", "cholestasis", "after", "high", "-", "dose", "co", "-", "trimoxazole", "treatment", "for", "Pneumocystis", "pneumonia", "in", "HIV", "-", "infected", "patients", "-", "-", "a", "report", "of", "two", "cases", ".", "Pneumocystis", "pneumonia", "(", "PCP", ")", ",", "a", "common", "opportunistic", "infection", "in", "HIV", "-", "infected", "individuals", ",", "is", "generally", "treated", "with", "high", "doses", "of", "co", "-", "trimoxazole", ".", "However", ",", "treatment", "is", "often", "limited", "by", "adverse", "effects", ".", "Here", ",", "we", "report", "two", "cases", "of", "severely", "immunocompromised", "HIV", "-", "infected", "patients", "who", "developed", "severe", "intrahepatic", "cholestasis", ",", "and", "in", "one", "patient", "lesions", "mimicking", "liver", "abscess", "formation", "on", "radiologic", "exams", ",", "during", "co", "-", "trimoxazole", "treatment", "for", "PCP", ".", "Whereas", "patient", "1", "showed", "lesions", "of", "up", "to", "1", "cm", "readily", "detectable", "on", "magnetic", "resonance", "imaging", "under", "prolonged", "co", "-", "trimoxazole", "treatment", ",", "therapy", "of", "patient", "2", "was", "switched", "early", "."]], "ner": [[[9, 11, "Chemical"], [52, 54, "Chemical"], [99, 101, "Chemical"], [124, 126, "Chemical"], [82, 83, "Disease"], [4, 4, "Disease"], [14, 15, "Disease"], [29, 30, "Disease"], [32, 32, "Disease"], [104, 104, "Disease"], [17, 19, "Disease"], [40, 42, "Disease"], [75, 77, "Disease"], [37, 38, "Disease"], [91, 92, "Disease"]]], "relations": [[[9, 11, 82, 83, "CID"], [52, 54, 82, 83, "CID"], [99, 101, 82, 83, "CID"], [124, 126, 82, 83, "CID"]]], "clusters": [], "translated": "高剂量<0>复方新诺明</0>治疗<10>HIV感染</10>患者的<6>肺孢子菌肺炎</6>后出现严重且持久的<5>胆汁淤积</5> - - 两例报告。 <7>肺孢子虫肺炎</7>(<8>PCP</8>)是<11>HIV感染者</11>中常见的<13>机会性感染</13>，通常采用高剂量治疗<1>复方新诺明</1>。然而，治疗往往受到不良反应的限制。在此，我们报告了两例严重免疫功能低下<12>HIV感染</12>患者，在 <9>PCP</9> 治疗期间出现严重的<4>肝内胆汁淤积</4>，其中一名患者的病变类似于<14>肝脓肿</14>形成，使用<2>复方新诺明</2>。在长期<3>复方新诺明</3>治疗下，患者1显示在磁共振成像上很容易检测到高达1cm的病灶，而患者2的治疗则提前转换。", "revised": true}
{"doc_key": "9406968", "sentences": [["Upregulation", "of", "the", "expression", "of", "vasopressin", "gene", "in", "the", "paraventricular", "and", "supraoptic", "nuclei", "of", "the", "lithium", "-", "induced", "diabetes", "insipidus", "rat", ".", "The", "expression", "of", "arginine", "vasopressin", "(", "AVP", ")", "gene", "in", "the", "paraventricular", "(", "PVN", ")", "and", "supraoptic", "nuclei", "(", "SON", ")", "was", "investigated", "in", "rats", "with", "lithium", "(", "Li", ")", "-", "induced", "polyuria", ",", "using", "in", "situ", "hybridization", "histochemistry", "and", "radioimmunoassay", ".", "The", "male", "Wistar", "rats", "consuming", "a", "diet", "that", "contained", "LiCl", "(", "60", "mmol", "/", "kg", ")", "for", "4", "weeks", "developed", "marked", "polyuria", ".", "The", "Li", "-", "treated", "rats", "produced", "a", "large", "volume", "of", "hypotonic", "urine", "with", "low", "ionic", "concentrations", ".", "Plasma", "sodium", "concentrations", "were", "found", "to", "be", "slightly", "increased", "in", "the", "Li", "-", "treated", "rats", "compared", "with", "those", "in", "controls", ".", "Plasma", "concentration", "of", "AVP", "and", "transcripts", "of", "AVP", "gene", "in", "the", "PVN", "and", "SON", "were", "significantly", "increased", "in", "the", "Li", "-", "treated", "rats", "compared", "with", "controls", ".", "These", "results", "suggest", "that", "dehydration", "and", "/", "or", "the", "activation", "of", "visceral", "afferent", "inputs", "may", "contribute", "to", "the", "elevation", "of", "plasma", "AVP", "and", "the", "upregulation", "of", "AVP", "gene", "expression", "in", "the", "PVN", "and", "the", "SON", "of", "the", "Li", "-", "induced", "diabetes", "insipidus", "rat", "."]], "ner": [[[73, 73, "Chemical"], [54, 54, "Disease"], [85, 85, "Disease"], [5, 5, "Chemical"], [18, 19, "Disease"], [192, 193, "Disease"], [156, 156, "Disease"], [15, 15, "Chemical"], [48, 48, "Chemical"], [50, 50, "Chemical"], [88, 88, "Chemical"], [115, 115, "Chemical"], [144, 144, "Chemical"], [189, 189, "Chemical"], [25, 26, "Chemical"], [28, 28, "Chemical"], [128, 128, "Chemical"], [132, 132, "Chemical"], [173, 173, "Chemical"], [178, 178, "Chemical"], [105, 105, "Chemical"]]], "relations": [[[73, 73, 54, 54, "CID"], [73, 73, 85, 85, "CID"]]], "clusters": [], "translated": " <7>锂</7>诱发<4>尿崩症</4>大鼠室旁核和视上核中<3>加压素</3>基因表达上调。采用原位杂交组织化学和放射免疫分析研究了<8>锂</8>（<9>Li</9>)-诱导的<1>多尿</1>大鼠中<14>精氨酸加压素</14>（<15>AVP</15>）基因在室旁核(PVN)和视上核(SON)的表达情况。雄性 Wistar 大鼠食用含有<0>LiCl</0> (60 mmol/kg) 的食物 4 周后出现明显的<2>多尿</2>。<10>Li</10>处理的大鼠产生大量离子浓度低的低渗尿液。与对照组相比，<11>Li</11>治疗大鼠的血浆<20>钠</20>浓度略有升高。<12>Li</12>处理大鼠的PVN和SON中，<16>AVP</16>和<17>AVP</17>基因转录物的浓度显着升高。这些结果表明<6>脱水</6>和/或内脏传入输入的激活可能有助于血浆<18>AVP</18>的升高和<19>AVP</19>基因表达的上调，在<13>锂</13>诱导的<5>尿崩症</5>大鼠的PVN和SON中。", "revised": true}
{"doc_key": "17562951", "sentences": [["Cardiac", "Angiography", "in", "Renally", "Impaired", "Patients", "(", "CARE", ")", "study", ":", "a", "randomized", "double", "-", "blind", "trial", "of", "contrast", "-", "induced", "nephropathy", "in", "patients", "with", "chronic", "kidney", "disease", ".", "BACKGROUND", ":", "No", "direct", "comparisons", "exist", "of", "the", "renal", "tolerability", "of", "the", "low", "-", "osmolality", "contrast", "medium", "iopamidol", "with", "that", "of", "the", "iso", "-", "osmolality", "contrast", "medium", "iodixanol", "in", "high", "-", "risk", "patients", ".", "METHODS", "AND", "RESULTS", ":", "The", "present", "study", "is", "a", "multicenter", ",", "randomized", ",", "double", "-", "blind", "comparison", "of", "iopamidol", "and", "iodixanol", "in", "patients", "with", "chronic", "kidney", "disease", "(", "estimated", "glomerular", "filtration", "rate", ",", "20", "to", "59", "mL", "/", "min", ")", "who", "underwent", "cardiac", "angiography", "or", "percutaneous", "coronary", "interventions", ".", "Serum", "creatinine", "(", "SCr", ")", "levels", "and", "estimated", "glomerular", "filtration", "rate", "were", "assessed", "at", "baseline", "and", "2", "to", "5", "days", "after", "receiving", "medications", ".", "The", "primary", "outcome", "was", "a", "postdose", "SCr", "increase", ">", "or", "=", "0", ".", "5", "mg", "/", "dL", "(", "44", ".", "2", "micromol", "/", "L", ")", "over", "baseline", ".", "Secondary", "outcomes", "were", "a", "postdose", "SCr", "increase", ">", "or", "=", "25", "%", ",", "a", "postdose", "estimated", "glomerular", "filtration", "rate", "decrease", "of", ">", "or", "=", "25", "%", ",", "and", "the", "mean", "peak", "change", "in", "SCr", ".", "In", "414", "patients", ",", "contrast", "volume", ",", "presence", "of", "diabetes", "mellitus", ",", "use", "of", "N", "-", "acetylcysteine", ",", "mean", "baseline", "SCr", ",", "and", "estimated", "glomerular", "filtration", "rate", "were", "comparable", "in", "the", "2", "groups", ".", "SCr", "increases", ">", "or", "=", "0", ".", "5", "mg", "/", "dL", "occurred", "in", "4", ".", "4", "%", "(", "9", "of", "204", "patients", ")", "after", "iopamidol", "and", "6", ".", "7", "%", "(", "14", "of", "210", "patients", ")", "after", "iodixanol", "(", "P", "=", "0", ".", "39", ")", ",", "whereas", "rates", "of", "SCr", "increases", ">", "or", "=", "25", "%", "were", "9", ".", "8", "%", "and", "12", ".", "4", "%", ",", "respectively", "(", "P", "=", "0", ".", "44", ")", ".", "In", "patients", "with", "diabetes", ",", "SCr", "increases", ">", "or", "=", "0", ".", "5", "mg", "/", "dL", "were", "5", ".", "1", "%", "(", "4", "of", "78", "patients", ")", "with", "iopamidol", "and", "13", ".", "0", "%", "(", "12", "of", "92", "patients", ")", "with", "iodixanol", "(", "P", "=", "0", ".", "11", ")", ",", "whereas", "SCr", "increases", ">", "or", "=", "25", "%", "were", "10", ".", "3", "%", "and", "15", ".", "2", "%", ",", "respectively", "(", "P", "=", "0", ".", "37", ")", ".", "Mean", "post", "-", "SCr", "increases", "were", "significantly", "less", "with", "iopamidol", "(", "all", "patients", ":", "0", ".", "07", "versus", "0", ".", "12", "mg", "/", "dL", ",", "6", ".", "2", "versus", "10", ".", "6", "micromol", "/", "L", ",", "P", "=", "0", ".", "03", ";", "patients", "with", "diabetes", ":", "0", ".", "07", "versus", "0", ".", "16", "mg", "/", "dL", ",", "6", ".", "2", "versus", "14", ".", "1", "micromol", "/", "L", ",", "P", "=", "0", ".", "01", ")", ".", "CONCLUSIONS", ":", "The", "rate", "of", "contrast", "-", "induced", "nephropathy", ",", "defined", "by", "multiple", "end", "points", ",", "is", "not", "statistically", "different", "after", "the", "intraarterial", "administration", "of", "iopamidol", "or", "iodixanol", "to", "high", "-", "risk", "patients", ",", "with", "or", "without", "diabetes", "mellitus", ".", "Any", "true", "difference", "between", "the", "agents", "is", "small", "and", "not", "likely", "to", "be", "clinically", "significant", "."]], "ner": [[[44, 45, "Chemical"], [54, 55, "Chemical"], [21, 21, "Disease"], [470, 470, "Disease"], [46, 46, "Chemical"], [81, 81, "Chemical"], [257, 257, "Chemical"], [337, 337, "Chemical"], [396, 396, "Chemical"], [487, 487, "Chemical"], [56, 56, "Chemical"], [83, 83, "Chemical"], [270, 270, "Chemical"], [350, 350, "Chemical"], [489, 489, "Chemical"], [113, 113, "Chemical"], [213, 215, "Chemical"], [25, 27, "Disease"], [87, 89, "Disease"], [208, 209, "Disease"], [312, 312, "Disease"], [431, 431, "Disease"], [499, 500, "Disease"]]], "relations": [[[44, 45, 21, 21, "CID"], [44, 45, 470, 470, "CID"], [54, 55, 21, 21, "CID"], [54, 55, 470, 470, "CID"], [46, 46, 21, 21, "CID"], [46, 46, 470, 470, "CID"], [81, 81, 21, 21, "CID"], [81, 81, 470, 470, "CID"], [257, 257, 21, 21, "CID"], [257, 257, 470, 470, "CID"], [337, 337, 21, 21, "CID"], [337, 337, 470, 470, "CID"], [396, 396, 21, 21, "CID"], [396, 396, 470, 470, "CID"], [487, 487, 21, 21, "CID"], [487, 487, 470, 470, "CID"], [56, 56, 21, 21, "CID"], [56, 56, 470, 470, "CID"], [83, 83, 21, 21, "CID"], [83, 83, 470, 470, "CID"], [270, 270, 21, 21, "CID"], [270, 270, 470, 470, "CID"], [350, 350, 21, 21, "CID"], [350, 350, 470, 470, "CID"], [489, 489, 21, 21, "CID"], [489, 489, 470, 470, "CID"]]], "clusters": [], "translated": "肾功能不全患者的心脏血管造影 (CARE) 研究：一项针对 <17>慢性肾病</17> 患者造影剂引起的 <2>肾病</2> 的随机双盲试验。背景：没有直接比较低渗透压 <0>造影剂</0> <4>碘帕醇</4> 与等渗透压 <1>造影剂</1> <10>碘克沙醇</10> 用于高危患者。方法和结果：本研究是一项多中心、随机、双盲对比 <5>碘帕醇</5> 和 <11>碘克沙醇</11> 的试验，针对患有 <18>慢性肾病</18>（估计的肾小球滤过率，20 至 59 毫升/分钟）的患者进行心脏血管造影或经皮冠状动脉介入治疗。在基线和接受药物治疗后2至5天，评估血清<15>肌酐</15> (SCr)水平和估计的肾小球滤过率。主要结果是给药后 SCr 升高 > 或 = 0。 5 mg/dL (44.2 微摩尔/L)，超过基线。次要结果是给药后 SCr 升高 > 或 = 25%，给药后估计的肾小球滤过率降低 > 或 = 25%，以及 SCr 的平均峰值变化。在414名患者中，对比剂量、<19>糖尿病</19>的存在、<16>N-乙酰半胱氨酸</16>的使用、平均基线 SCr 和估算的肾小球滤过率在两组中具有可比性。 SCr 增加 > 或 = 0。5 mg/dL 发生在 4.4%（204 名患者中的 9 名）在 <6>碘帕醇</6>和 6.7%（210 名患者中的 14 名）在 <12>碘克沙醇</12> 后 (P = 0.39)，而 SCr 增加率 > 或 = 25% 为 9.8% 和 12.4%，<9>碘帕醇</9> 和 <14>碘克沙醇</14> 之间无显著差异 (P = 0.44)。在<20>糖尿病</20>患者中，SCr 升高 > 或 = 0。5 mg/dL 分别为 5.1%（78 名患者中的 4 名）服用 <7>碘帕醇</7> 和 13.0%（92 名患者中的 12 名）使用 <13>碘克沙醇</13> (P = 0.11)，而 SCr 升高 > 或 = 25% 为 10.3% 和 15.2%，<8>碘帕醇</8> 后平均 SCr 升高显着减少（所有患者：0.07 对比 0.12 mg/dL，6.2 对比 10.6 微摩尔/L，P = 0.03；患者<21>糖尿病</21>：0.07 对比 0.16 mg/dL，6.2 对比 14.1 微摩尔/升，P = 0.01)。结论：造影剂引起的 <3>肾病</3> 的发生率（由多个终点定义）在动脉内注射<9>碘帕醇</9>或<14>碘克沙醇</14>后没有统计学差异高危患者，有或没有<22>糖尿病</22>。药剂之间的真正差异很小，而且不太可能具有临床意义。", "revised": true}
{"doc_key": "18410508", "sentences": [["Methamphetamine", "-", "induced", "neurotoxicity", "and", "microglial", "activation", "are", "not", "mediated", "by", "fractalkine", "receptor", "signaling", ".", "Methamphetamine", "(", "METH", ")", "damages", "dopamine", "(", "DA", ")", "nerve", "endings", "by", "a", "process", "that", "has", "been", "linked", "to", "microglial", "activation", "but", "the", "signaling", "pathways", "that", "mediate", "this", "response", "have", "not", "yet", "been", "delineated", ".", "Cardona", "et", "al", ".", "[", "Nat", ".", "Neurosci", ".", "9", "(", "2006", ")", ",", "917", "]", "recently", "identified", "the", "microglial", "-", "specific", "fractalkine", "receptor", "(", "CX3CR1", ")", "as", "an", "important", "mediator", "of", "MPTP", "-", "induced", "neurodegeneration", "of", "DA", "neurons", ".", "Because", "the", "CNS", "damage", "caused", "by", "METH", "and", "MPTP", "is", "highly", "selective", "for", "the", "DA", "neuronal", "system", "in", "mouse", "models", "of", "neurotoxicity", ",", "we", "hypothesized", "that", "the", "CX3CR1", "plays", "a", "role", "in", "METH", "-", "induced", "neurotoxicity", "and", "microglial", "activation", ".", "Mice", "in", "which", "the", "CX3CR1", "gene", "has", "been", "deleted", "and", "replaced", "with", "a", "cDNA", "encoding", "enhanced", "green", "fluorescent", "protein", "(", "eGFP", ")", "were", "treated", "with", "METH", "and", "examined", "for", "striatal", "neurotoxicity", ".", "METH", "depleted", "DA", ",", "caused", "microglial", "activation", ",", "and", "increased", "body", "temperature", "in", "CX3CR1", "knockout", "mice", "to", "the", "same", "extent", "and", "over", "the", "same", "time", "course", "seen", "in", "wild", "-", "type", "controls", ".", "The", "effects", "of", "METH", "in", "CX3CR1", "knockout", "mice", "were", "not", "gender", "-", "dependent", "and", "did", "not", "extend", "beyond", "the", "striatum", ".", "Striatal", "microglia", "expressing", "eGFP", "constitutively", "show", "morphological", "changes", "after", "METH", "that", "are", "characteristic", "of", "activation", ".", "This", "response", "was", "restricted", "to", "the", "striatum", "and", "contrasted", "sharply", "with", "unresponsive", "eGFP", "-", "microglia", "in", "surrounding", "brain", "areas", "that", "are", "not", "damaged", "by", "METH", ".", "We", "conclude", "from", "these", "studies", "that", "CX3CR1", "signaling", "does", "not", "modulate", "METH", "neurotoxicity", "or", "microglial", "activation", ".", "Furthermore", ",", "it", "appears", "that", "striatal", "-", "resident", "microglia", "respond", "to", "METH", "with", "an", "activation", "cascade", "and", "then", "return", "to", "a", "surveying", "state", "without", "undergoing", "apoptosis", "or", "migration", "."]], "ner": [[[0, 0, "Chemical"], [15, 15, "Chemical"], [17, 17, "Chemical"], [96, 96, "Chemical"], [122, 122, "Chemical"], [155, 155, "Chemical"], [162, 162, "Chemical"], [198, 198, "Chemical"], [225, 225, "Chemical"], [256, 256, "Chemical"], [269, 269, "Chemical"], [286, 286, "Chemical"], [85, 85, "Disease"], [92, 93, "Disease"], [82, 82, "Chemical"], [98, 98, "Chemical"], [3, 3, "Disease"], [111, 111, "Disease"], [125, 125, "Disease"], [160, 160, "Disease"], [270, 270, "Disease"], [20, 20, "Chemical"], [22, 22, "Chemical"], [87, 87, "Chemical"], [104, 104, "Chemical"], [164, 164, "Chemical"]]], "relations": [[[0, 0, 85, 85, "CID"], [0, 0, 92, 93, "CID"], [15, 15, 85, 85, "CID"], [15, 15, 92, 93, "CID"], [17, 17, 85, 85, "CID"], [17, 17, 92, 93, "CID"], [96, 96, 85, 85, "CID"], [96, 96, 92, 93, "CID"], [122, 122, 85, 85, "CID"], [122, 122, 92, 93, "CID"], [155, 155, 85, 85, "CID"], [155, 155, 92, 93, "CID"], [162, 162, 85, 85, "CID"], [162, 162, 92, 93, "CID"], [198, 198, 85, 85, "CID"], [198, 198, 92, 93, "CID"], [225, 225, 85, 85, "CID"], [225, 225, 92, 93, "CID"], [256, 256, 85, 85, "CID"], [256, 256, 92, 93, "CID"], [269, 269, 85, 85, "CID"], [269, 269, 92, 93, "CID"], [286, 286, 85, 85, "CID"], [286, 286, 92, 93, "CID"], [82, 82, 85, 85, "CID"], [82, 82, 92, 93, "CID"], [98, 98, 85, 85, "CID"], [98, 98, 92, 93, "CID"]]], "clusters": [], "translated": " <0>甲基苯丙胺</0>诱导的<16>神经毒性</16>和小胶质细胞激活不是由 fractalkine 受体信号介导的。 <1>甲基苯丙胺</1>（<2>METH</2>）通过与小胶质细胞激活有关的过程损害<21>多巴胺</21>（<22>DA</22>）神经末梢，但尚未描述介导这种反应的信号通路。Cardona 等人 [纳特。神经科学。9（2006），917] 最近发现小胶质细胞特异性 fractalkine 受体（CX3CR1）作为<14>MPTP</14>诱导<12>神经变性</12>的<23>DA</23>神经元的重要介质。因为<3>METH</3>和<15>MPTP</15>引起的<13>CNS损伤</13>对<24>DA</24>神经元系统具有高度选择性的<17>神经毒性</17>，我们假设CX3CR1在<4>METH</4>诱导的<18>神经毒性</18>和小胶质细胞激活中起作用。用编码增强型绿色荧光蛋白（eGFP）的cDNA代替删除了 CX3CR1 基因的小鼠用<5>METH</5>处理并检查纹状体<19>神经毒性</19>。 <6>METH</6>消耗<25>DA</25>，导致小鼠的 CX3CR1 基因敲除小鼠发生小胶质细胞激活，体温上升到与野生型对照小鼠相同的程度，且时间进程相同。<7>METH</7> 对 CX3CR1 敲除小鼠的作用不依赖于性别，也没有超出纹状体。表达 eGFP 的纹状体小胶质细胞组成性地显示出<8>METH</8>后激活的特征，响应仅限于纹状体，并且与周围未受<9>METH</9>破坏的大脑区域中无反应的 eGFP-小胶质细胞形成鲜明对比。我们从这些研究中得出结论，CX3CR1 信号不调节<10>METH</10><20>神经毒性</20>或小胶质细胞激活。此外，看起来纹状体驻留的小胶质细胞通过激活级联对<11>METH</11>作出反应，然后在不经历细胞凋亡或迁移的情况下返回到监视状态。", "revised": true}
{"doc_key": "18221780", "sentences": [["Sex", "differences", "in", "NMDA", "antagonist", "enhancement", "of", "morphine", "antihyperalgesia", "in", "a", "capsaicin", "model", "of", "persistent", "pain", ":", "comparisons", "to", "two", "models", "of", "acute", "pain", ".", "In", "acute", "pain", "models", ",", "N", "-", "methyl", "-", "D", "-", "aspartate", "(", "NMDA", ")", "antagonists", "enhance", "the", "antinociceptive", "effects", "of", "morphine", "to", "a", "greater", "extent", "in", "males", "than", "females", ".", "The", "purpose", "of", "this", "investigation", "was", "to", "extend", "these", "findings", "to", "a", "persistent", "pain", "model", "which", "could", "be", "distinguished", "from", "acute", "pain", "models", "on", "the", "basis", "of", "the", "nociceptive", "fibers", "activated", ",", "neurochemical", "substrates", ",", "and", "duration", "of", "the", "nociceptive", "stimulus", ".", "To", "this", "end", ",", "persistent", "hyperalgesia", "was", "induced", "by", "administration", "of", "capsaicin", "in", "the", "tail", "of", "gonadally", "intact", "F344", "rats", ",", "following", "which", "the", "tail", "was", "immersed", "in", "a", "mildly", "noxious", "thermal", "stimulus", ",", "and", "tail", "-", "withdrawal", "latencies", "measured", ".", "For", "comparison", ",", "tests", "were", "conducted", "in", "two", "acute", "pain", "models", ",", "the", "hotplate", "and", "warm", "water", "tail", "-", "withdrawal", "procedures", ".", "In", "males", ",", "the", "non", "-", "competitive", "NMDA", "antagonist", "dextromethorphan", "enhanced", "the", "antihyperalgesic", "effect", "of", "low", "to", "moderate", "doses", "of", "morphine", "in", "a", "dose", "-", "and", "time", "-", "dependent", "manner", ".", "Across", "the", "doses", "and", "pretreatment", "times", "examined", ",", "enhancement", "was", "not", "observed", "in", "females", ".", "Enhancement", "of", "morphine", "antinociception", "by", "dextromethorphan", "was", "seen", "in", "both", "males", "and", "females", "in", "the", "acute", "pain", "models", ",", "with", "the", "magnitude", "of", "this", "effect", "being", "greater", "in", "males", ".", "These", "findings", "demonstrate", "a", "sexually", "-", "dimorphic", "interaction", "between", "NMDA", "antagonists", "and", "morphine", "in", "a", "persistent", "pain", "model", "that", "can", "be", "distinguished", "from", "those", "observed", "in", "acute", "pain", "models", "."]], "ner": [[[11, 11, "Chemical"], [109, 109, "Chemical"], [103, 103, "Disease"], [3, 3, "Chemical"], [30, 36, "Chemical"], [38, 38, "Chemical"], [168, 168, "Chemical"], [246, 246, "Chemical"], [15, 15, "Disease"], [69, 69, "Disease"], [253, 253, "Disease"], [22, 23, "Disease"], [26, 27, "Disease"], [76, 77, "Disease"], [147, 148, "Disease"], [222, 223, "Disease"], [263, 264, "Disease"], [7, 7, "Chemical"], [46, 46, "Chemical"], [181, 181, "Chemical"], [209, 209, "Chemical"], [249, 249, "Chemical"], [170, 170, "Chemical"], [212, 212, "Chemical"]]], "relations": [[[11, 11, 103, 103, "CID"], [109, 109, 103, 103, "CID"]]], "clusters": [], "translated": "<3>NMDA</3> 拮抗剂增强<17>吗啡</17>的抗痛觉过敏作用在<0>辣椒素</0>持续性<8>疼痛</8>模型中存在性别差异：与两种<11>急性疼痛</11>模型的比较。在<12>急性疼痛</12>模型中，<4>N-甲基-D-天冬氨酸</4>（<5>NMDA</5>）拮抗剂对<18>吗啡</18>的止痛效果男性比女性更为强烈。这项研究的目的在于将这些发现扩展到持续性<9>疼痛</9>模型，该模型可以根据激活的伤害性纤维、神经化学底物和伤害性刺激的持续时间与<13>急性疼痛</13>模型进行区分。为此，在性腺完整的F344大鼠的尾巴中使用<1>辣椒素</1>诱导持续性<2>痛觉过敏</2>，随后将尾巴浸入温和的有害热刺激中，并且测量了尾巴撤回潜伏期。为了比较，测试了两个<14>急性疼痛</14>模型，热板和温水尾部退缩程序。在男性中，非竞争性<6>NMDA</6>拮抗剂<22>右美沙芬</22>以剂量和时间依赖性方式增强低至中等剂量的<19>吗啡</19>的抗痛觉过敏作用，但在女性中没有观察到增强效应。在<15>急性疼痛</15>模型中，<23>右美沙芬</23>增强了<20>吗啡</20>的镇痛作用，无论男性还是女性，但这种效应在男性中更为显著。这些发现表明，在持续性<10>疼痛</10>模型中，<7>NMDA</7>拮抗剂和<21>吗啡</21>之间存在性二态相互作用，可与<16>急性疼痛</16>模型中观察到的效应区别开来。", "revised": true}
{"doc_key": "18768591", "sentences": [["Serum", "-", "and", "glucocorticoid", "-", "inducible", "kinase", "1", "in", "doxorubicin", "-", "induced", "nephrotic", "syndrome", ".", "Doxorubicin", "-", "induced", "nephropathy", "leads", "to", "epithelial", "sodium", "channel", "(", "ENaC", ")", "-", "dependent", "volume", "retention", "and", "renal", "fibrosis", ".", "The", "aldosterone", "-", "sensitive", "serum", "-", "and", "glucocorticoid", "-", "inducible", "kinase", "SGK1", "has", "been", "shown", "to", "participate", "in", "the", "stimulation", "of", "ENaC", "and", "to", "mediate", "renal", "fibrosis", "following", "mineralocorticoid", "and", "salt", "excess", ".", "The", "present", "study", "was", "performed", "to", "elucidate", "the", "role", "of", "SGK1", "in", "the", "volume", "retention", "and", "fibrosis", "during", "nephrotic", "syndrome", ".", "To", "this", "end", ",", "doxorubicin", "(", "15", "mug", "/", "g", "body", "wt", ")", "was", "injected", "intravenously", "into", "gene", "-", "targeted", "mice", "lacking", "SGK1", "(", "sgk1", "(", "-", "/", "-", ")", ")", "and", "their", "wild", "-", "type", "littermates", "(", "sgk1", "(", "+", "/", "+", ")", ")", ".", "Doxorubicin", "treatment", "resulted", "in", "heavy", "proteinuria", "(", ">", "100", "mg", "protein", "/", "mg", "crea", ")", "in", "15", "/", "44", "of", "sgk1", "(", "+", "/", "+", ")", "and", "15", "/", "44", "of", "sgk1", "(", "-", "/", "-", ")", "mice", "leading", "to", "severe", "nephrotic", "syndrome", "with", "ascites", ",", "lipidemia", ",", "and", "hypoalbuminemia", "in", "both", "genotypes", ".", "Plasma", "aldosterone", "levels", "increased", "in", "nephrotic", "mice", "of", "both", "genotypes", "and", "was", "followed", "by", "increased", "SGK1", "protein", "expression", "in", "sgk1", "(", "+", "/", "+", ")", "mice", ".", "Urinary", "sodium", "excretion", "reached", "signficantly", "lower", "values", "in", "sgk1", "(", "+", "/", "+", ")", "mice", "(", "15", "+", "/", "-", "5", "mumol", "/", "mg", "crea", ")", "than", "in", "sgk1", "(", "-", "/", "-", ")", "mice", "(", "35", "+", "/", "-", "5", "mumol", "/", "mg", "crea", ")", "and", "was", "associated", "with", "a", "significantly", "higher", "body", "weight", "gain", "in", "sgk1", "(", "+", "/", "+", ")", "compared", "with", "sgk1", "(", "-", "/", "-", ")", "mice", "(", "+", "6", ".", "6", "+", "/", "-", "0", ".", "7", "vs", ".", "+", "4", ".", "1", "+", "/", "-", "0", ".", "8", "g", ")", ".", "During", "the", "course", "of", "nephrotic", "syndrome", ",", "serum", "urea", "concentrations", "increased", "significantly", "faster", "in", "sgk1", "(", "-", "/", "-", ")", "mice", "than", "in", "sgk1", "(", "+", "/", "+", ")", "mice", "leading", "to", "uremia", "and", "a", "reduced", "median", "survival", "in", "sgk1", "(", "-", "/", "-", ")", "mice", "(", "29", "vs", ".", "40", "days", "in", "sgk1", "(", "+", "/", "+", ")", "mice", ")", ".", "In", "conclusion", ",", "gene", "-", "targeted", "mice", "lacking", "SGK1", "showed", "blunted", "volume", "retention", ",", "yet", "were", "not", "protected", "against", "renal", "fibrosis", "during", "experimental", "nephrotic", "syndrome", "."]], "ner": [[[9, 9, "Chemical"], [15, 15, "Chemical"], [93, 93, "Chemical"], [135, 135, "Chemical"], [12, 13, "Disease"], [86, 87, "Disease"], [176, 177, "Disease"], [194, 194, "Disease"], [318, 319, "Disease"], [399, 400, "Disease"], [140, 140, "Disease"], [179, 179, "Disease"], [181, 181, "Disease"], [184, 184, "Disease"], [18, 18, "Disease"], [29, 30, "Disease"], [81, 82, "Disease"], [387, 388, "Disease"], [33, 33, "Disease"], [61, 61, "Disease"], [84, 84, "Disease"], [396, 396, "Disease"], [270, 271, "Disease"], [346, 346, "Disease"], [22, 22, "Chemical"], [217, 217, "Chemical"], [36, 36, "Chemical"], [190, 190, "Chemical"], [322, 322, "Chemical"]]], "relations": [[[9, 9, 12, 13, "CID"], [9, 9, 86, 87, "CID"], [9, 9, 176, 177, "CID"], [9, 9, 194, 194, "CID"], [9, 9, 318, 319, "CID"], [9, 9, 399, 400, "CID"], [15, 15, 12, 13, "CID"], [15, 15, 86, 87, "CID"], [15, 15, 176, 177, "CID"], [15, 15, 194, 194, "CID"], [15, 15, 318, 319, "CID"], [15, 15, 399, 400, "CID"], [93, 93, 12, 13, "CID"], [93, 93, 86, 87, "CID"], [93, 93, 176, 177, "CID"], [93, 93, 194, 194, "CID"], [93, 93, 318, 319, "CID"], [93, 93, 399, 400, "CID"], [135, 135, 12, 13, "CID"], [135, 135, 86, 87, "CID"], [135, 135, 176, 177, "CID"], [135, 135, 194, 194, "CID"], [135, 135, 318, 319, "CID"], [135, 135, 399, 400, "CID"], [9, 9, 140, 140, "CID"], [15, 15, 140, 140, "CID"], [93, 93, 140, 140, "CID"], [135, 135, 140, 140, "CID"], [9, 9, 179, 179, "CID"], [15, 15, 179, 179, "CID"], [93, 93, 179, 179, "CID"], [135, 135, 179, 179, "CID"], [9, 9, 181, 181, "CID"], [15, 15, 181, 181, "CID"], [93, 93, 181, 181, "CID"], [135, 135, 181, 181, "CID"], [9, 9, 184, 184, "CID"], [15, 15, 184, 184, "CID"], [93, 93, 184, 184, "CID"], [135, 135, 184, 184, "CID"]]], "clusters": [], "translated": "<0>多柔比星</0>诱导的<4>肾病综合征</4>中的血清和糖皮质激素诱导激酶1。 <1>多柔比星</1>诱导的<14>肾病</14>导致上皮<24>钠</24>通道（ENaC）依赖性<15>体积潴留</15>和<18>肾纤维化</18>。<26> 醛固酮</26>敏感的血清和糖皮质激素诱导激酶SGK1已被证明参与ENaC的刺激，并在盐皮质激素和盐过量后介导<19>肾纤维化</19>。本研究旨在阐明SGK1在<5>肾病综合征</5>期间<16>体积潴留</16>和<20>肾纤维化</20>中的作用。为此，将<2>多柔比星</2>（15 mug / g体重）静脉注射到缺乏SGK1 (sgk1(-/-))的基因靶向小鼠及其野生型同胞小鼠（sgk1(+/+)). <3>多柔比星</3>治疗导致15/44 sgk1(+/+ )和15/44 sgk1(-/-)小鼠中重度的<10>蛋白尿</10>（>100 mg protein / mg crea），两种基因型的小鼠均导致<6>严重的肾病综合征</6>，伴有<11>腹水</11>、<12>血脂</12>和<13>低白蛋白血症</13>。两种基因型的<7>肾病</7>小鼠血浆<27>醛固酮</27>水平均升高，随后sgk1(+/+)小鼠的SGK1蛋白表达升高。尿<25>钠</25>排泄在sgk1(+/-)小鼠(15+/-5 mumol/mg crea)中显着更低，高于sgk1(-/-) 小鼠(35+/-5 mumol/mg crea)，与sgk1(+/-) 相比，sgk1(+/+)<22>体重增加</22>更显著（+6.6+/-0.7 vs.+4.1+/-0.8g）。在<8>肾病综合征</8>病程中，sgk1(-/-)小鼠血清<28>尿素</28>浓度升高明显快于sgk1(+/+)小鼠，导致<23>尿毒症</23>和sgk1(-/-)小鼠的中位生存期缩短（sgk1(+/-)小鼠的中位生存期为29天，sgk1(+/+)小鼠的中位生存期为40天）。总之，缺乏SGK1的基因靶向小鼠表现出迟钝的<17>体积潴留</17>，但在实验性<9>肾病综合征</9>期间不能防止<21>肾纤维化</21>。", "revised": true}
{"doc_key": "19729346", "sentences": [["Comparative", "cognitive", "and", "subjective", "side", "effects", "of", "immediate", "-", "release", "oxycodone", "in", "healthy", "middle", "-", "aged", "and", "older", "adults", ".", "This", "study", "measured", "the", "objective", "and", "subjective", "neurocognitive", "effects", "of", "a", "single", "10", "-", "mg", "dose", "of", "immediate", "-", "release", "oxycodone", "in", "healthy", ",", "older", "(", ">", "65", "years", ")", ",", "and", "middle", "-", "aged", "(", "35", "to", "55", "years", ")", "adults", "who", "were", "not", "suffering", "from", "chronic", "or", "significant", "daily", "pain", ".", "Seventy", "-", "one", "participants", "completed", "2", "separate", "study", "days", "and", "were", "blind", "to", "medication", "condition", "(", "placebo", ",", "10", "-", "mg", "oxycodone", ")", ".", "Plasma", "oxycodone", "concentration", "peaked", "between", "60", "and", "90", "minutes", "postdose", "(", "P", "<", ".", "01", ")", "and", "pupil", "size", ",", "an", "indication", "of", "physiological", "effects", "of", "the", "medication", ",", "peaked", "at", "approximately", "90", "to", "120", "minutes", "postdose", "(", "P", "<", ".", "01", ")", ".", "Significant", "declines", "in", "simple", "and", "sustained", "attention", ",", "working", "memory", ",", "and", "verbal", "memory", "were", "observed", "at", "1", "hour", "postdose", "compared", "to", "baseline", "for", "both", "age", "groups", "with", "a", "trend", "toward", "return", "to", "baseline", "by", "5", "hours", "postdose", ".", "For", "almost", "all", "cognitive", "measures", ",", "there", "were", "no", "medication", "by", "age", "-", "interaction", "effects", ",", "which", "indicates", "that", "the", "2", "age", "groups", "exhibited", "similar", "responses", "to", "the", "medication", "challenge", ".", "This", "study", "suggests", "that", "for", "healthy", "older", "adults", "who", "are", "not", "suffering", "from", "chronic", "pain", ",", "neurocognitive", "and", "pharmacodynamic", "changes", "in", "response", "to", "a", "10", "-", "mg", "dose", "of", "immediate", "-", "release", "oxycodone", "are", "similar", "to", "those", "observed", "for", "middle", "-", "aged", "adults", ".", "PERSPECTIVE", ":", "Study", "findings", "indicate", "that", "the", "metabolism", ",", "neurocognitive", "effects", ",", "and", "physical", "side", "effects", "of", "oral", "oxycodone", "are", "similar", "for", "healthy", "middle", "-", "aged", "and", "older", "adults", ".", "Therefore", ",", "clinicians", "should", "not", "avoid", "prescribing", "oral", "opioids", "to", "older", "adults", "based", "on", "the", "belief", "that", "older", "adults", "are", "at", "higher", "risk", "for", "side", "effects", "than", "younger", "adults", "."]], "ner": [[[10, 10, "Chemical"], [40, 40, "Chemical"], [94, 94, "Chemical"], [98, 98, "Chemical"], [243, 243, "Chemical"], [273, 273, "Chemical"], [142, 154, "Disease"], [71, 71, "Disease"], [224, 225, "Disease"]]], "relations": [[[10, 10, 142, 154, "CID"], [40, 40, 142, 154, "CID"], [94, 94, 142, 154, "CID"], [98, 98, 142, 154, "CID"], [243, 243, 142, 154, "CID"], [273, 273, 142, 154, "CID"]]], "clusters": [], "translated": "速释 <0>羟考酮</0> 对健康中老年人的比较认知和主观副作用。这项研究测量了单次 10 mg 速释<1>羟考酮</1> 对健康、老年（> 65 岁）和中年（35 至 55 岁）成人的客观和主观神经认知影响，没有患有慢性或显着的日常<7>疼痛</7>。71 名参与者完成了 2 个独立的研究日，并且不知道药物情况（安慰剂、10 毫克<2>羟考酮</2>）。血浆<3>羟考酮</3>浓度在服药后 60 至 90 分钟达到峰值（P <. 01），而瞳孔大小是药物生理效应的指标，在服药后约 90 至 120 分钟达到峰值（P <. 01）。与基线相比，两个年龄组在服药后 1 小时观察到简单和持续注意力、工作记忆和语言记忆<6>显着下降</6>，并有在服药后 5 小时恢复到基线的趋势。对于几乎所有的认知测量，没有年龄交互影响的药物治疗，这表明 2 个年龄组对药物挑战表现出相似的反应。这项研究表明，对于未患有<8>慢性疼痛</8>的健康老年人，神经认知和药效学变化对 10 毫克剂量的速释<4>羟考酮</4>的反应类似于那些观察到的中年人。观点：研究结果表明，健康的中年人和老年人口服<5>羟考酮</5>后的代谢、神经认知作用和身体副作用相似。因此，临床医生不应因为认为老年人比年轻人有更高的副作用风险而避免给老年人开口服阿片类药物。", "revised": true}
{"doc_key": "19820426", "sentences": [["Twin", "preterm", "neonates", "with", "cardiac", "toxicity", "related", "to", "lopinavir", "/", "ritonavir", "therapy", ".", "We", "report", "twin", "neonates", "who", "were", "born", "prematurely", "at", "32", "weeks", "of", "gestation", "to", "a", "mother", "with", "human", "immunodeficiency", "virus", "infection", ".", "One", "of", "the", "twins", "developed", "complete", "heart", "block", "and", "dilated", "cardiomyopathy", "related", "to", "lopinavir", "/", "ritonavir", "therapy", ",", "a", "boosted", "protease", "-", "inhibitor", "agent", ",", "while", "the", "other", "twin", "developed", "mild", "bradycardia", ".", "We", "recommend", "caution", "in", "the", "use", "of", "lopinavir", "/", "ritonavir", "in", "the", "immediate", "neonatal", "period", "."]], "ner": [[[8, 10, "Chemical"], [48, 50, "Chemical"], [75, 77, "Chemical"], [41, 42, "Disease"], [44, 45, "Disease"], [66, 66, "Disease"], [4, 5, "Disease"], [30, 33, "Disease"]]], "relations": [[[8, 10, 41, 42, "CID"], [48, 50, 41, 42, "CID"], [75, 77, 41, 42, "CID"], [8, 10, 44, 45, "CID"], [48, 50, 44, 45, "CID"], [75, 77, 44, 45, "CID"], [8, 10, 66, 66, "CID"], [48, 50, 66, 66, "CID"], [75, 77, 66, 66, "CID"]]], "clusters": [], "translated": "与<0>洛匹那韦/利托那韦</0>治疗相关的<6>心脏毒性</6>的双胞胎早产儿。我们报告了一位患有<7>人类免疫缺陷病毒感染</7>的母亲在妊娠32周时早产的双胞胎新生儿。双胞胎中的一个患上了完全性<3>心脏传导阻滞</3>和<4>扩张型心肌病</4>，这与<1>洛匹那韦/利托那韦</1>疗法有关，这是一种增强的蛋白酶抑制剂，而另一对双胞胎出现轻度<5>心动过缓</5>。我们建议在新生儿期谨慎使用<2>洛匹那韦/利托那韦</2>。", "revised": true}
{"doc_key": "18261172", "sentences": [["Development", "of", "proteinuria", "after", "switch", "to", "sirolimus", "-", "based", "immunosuppression", "in", "long", "-", "term", "cardiac", "transplant", "patients", ".", "Calcineurin", "-", "inhibitor", "therapy", "can", "lead", "to", "renal", "dysfunction", "in", "heart", "transplantation", "patients", ".", "The", "novel", "immunosuppressive", "(", "IS", ")", "drug", "sirolmus", "(", "Srl", ")", "lacks", "nephrotoxic", "effects", ";", "however", ",", "proteinuria", "associated", "with", "Srl", "has", "been", "reported", "following", "renal", "transplantation", ".", "In", "cardiac", "transplantation", ",", "the", "incidence", "of", "proteinuria", "associated", "with", "Srl", "is", "unknown", ".", "In", "this", "study", ",", "long", "-", "term", "cardiac", "transplant", "patients", "were", "switched", "from", "cyclosporine", "to", "Srl", "-", "based", "IS", ".", "Concomitant", "IS", "consisted", "of", "mycophenolate", "mofetil", "+", "/", "-", "steroids", ".", "Proteinuria", "increased", "significantly", "from", "a", "median", "of", "0", ".", "13", "g", "/", "day", "(", "range", "0", "-", "5", ".", "7", ")", "preswitch", "to", "0", ".", "23", "g", "/", "day", "(", "0", "-", "9", ".", "88", ")", "at", "24", "months", "postswitch", "(", "p", "=", "0", ".", "0024", ")", ".", "Before", "the", "switch", ",", "11", ".", "5", "%", "of", "patients", "had", "high", "-", "grade", "proteinuria", "(", ">", "1", ".", "0", "g", "/", "day", ")", ";", "this", "increased", "to", "22", ".", "9", "%", "postswitch", "(", "p", "=", "0", ".", "006", ")", ".", "ACE", "inhibitor", "and", "angiotensin", "-", "releasing", "blocker", "(", "ARB", ")", "therapy", "reduced", "proteinuria", "development", ".", "Patients", "without", "proteinuria", "had", "increased", "renal", "function", "(", "median", "42", ".", "5", "vs", ".", "64", ".", "1", ",", "p", "=", "0", ".", "25", ")", ",", "whereas", "patients", "who", "developed", "high", "-", "grade", "proteinuria", "showed", "decreased", "renal", "function", "at", "the", "end", "of", "follow", "-", "up", "(", "median", "39", ".", "6", "vs", ".", "29", ".", "2", ",", "p", "=", "0", ".", "125", ")", ".", "Thus", ",", "proteinuria", "may", "develop", "in", "cardiac", "transplant", "patients", "after", "switch", "to", "Srl", ",", "which", "may", "have", "an", "adverse", "effect", "on", "renal", "function", "in", "these", "patients", ".", "Srl", "should", "be", "used", "with", "ACEi", "/", "ARB", "therapy", "and", "patients", "monitored", "for", "proteinuria", "and", "increased", "renal", "dysfunction", "."]], "ner": [[[6, 6, "Chemical"], [39, 39, "Chemical"], [41, 41, "Chemical"], [52, 52, "Chemical"], [70, 70, "Chemical"], [89, 89, "Chemical"], [283, 283, "Chemical"], [298, 298, "Chemical"], [2, 2, "Disease"], [49, 49, "Disease"], [67, 67, "Disease"], [167, 167, "Disease"], [206, 206, "Disease"], [211, 211, "Disease"], [241, 241, "Disease"], [273, 273, "Disease"], [311, 311, "Disease"], [87, 87, "Chemical"], [98, 99, "Chemical"], [103, 103, "Chemical"], [194, 195, "Chemical"], [303, 303, "Chemical"], [197, 200, "Chemical"], [202, 202, "Chemical"], [305, 305, "Chemical"], [25, 26, "Disease"], [44, 44, "Disease"], [314, 315, "Disease"]]], "relations": [[[6, 6, 2, 2, "CID"], [6, 6, 49, 49, "CID"], [6, 6, 67, 67, "CID"], [6, 6, 167, 167, "CID"], [6, 6, 206, 206, "CID"], [6, 6, 211, 211, "CID"], [6, 6, 241, 241, "CID"], [6, 6, 273, 273, "CID"], [6, 6, 311, 311, "CID"], [39, 39, 2, 2, "CID"], [39, 39, 49, 49, "CID"], [39, 39, 67, 67, "CID"], [39, 39, 167, 167, "CID"], [39, 39, 206, 206, "CID"], [39, 39, 211, 211, "CID"], [39, 39, 241, 241, "CID"], [39, 39, 273, 273, "CID"], [39, 39, 311, 311, "CID"], [41, 41, 2, 2, "CID"], [41, 41, 49, 49, "CID"], [41, 41, 67, 67, "CID"], [41, 41, 167, 167, "CID"], [41, 41, 206, 206, "CID"], [41, 41, 211, 211, "CID"], [41, 41, 241, 241, "CID"], [41, 41, 273, 273, "CID"], [41, 41, 311, 311, "CID"], [52, 52, 2, 2, "CID"], [52, 52, 49, 49, "CID"], [52, 52, 67, 67, "CID"], [52, 52, 167, 167, "CID"], [52, 52, 206, 206, "CID"], [52, 52, 211, 211, "CID"], [52, 52, 241, 241, "CID"], [52, 52, 273, 273, "CID"], [52, 52, 311, 311, "CID"], [70, 70, 2, 2, "CID"], [70, 70, 49, 49, "CID"], [70, 70, 67, 67, "CID"], [70, 70, 167, 167, "CID"], [70, 70, 206, 206, "CID"], [70, 70, 211, 211, "CID"], [70, 70, 241, 241, "CID"], [70, 70, 273, 273, "CID"], [70, 70, 311, 311, "CID"], [89, 89, 2, 2, "CID"], [89, 89, 49, 49, "CID"], [89, 89, 67, 67, "CID"], [89, 89, 167, 167, "CID"], [89, 89, 206, 206, "CID"], [89, 89, 211, 211, "CID"], [89, 89, 241, 241, "CID"], [89, 89, 273, 273, "CID"], [89, 89, 311, 311, "CID"], [283, 283, 2, 2, "CID"], [283, 283, 49, 49, "CID"], [283, 283, 67, 67, "CID"], [283, 283, 167, 167, "CID"], [283, 283, 206, 206, "CID"], [283, 283, 211, 211, "CID"], [283, 283, 241, 241, "CID"], [283, 283, 273, 273, "CID"], [283, 283, 311, 311, "CID"], [298, 298, 2, 2, "CID"], [298, 298, 49, 49, "CID"], [298, 298, 67, 67, "CID"], [298, 298, 167, 167, "CID"], [298, 298, 206, 206, "CID"], [298, 298, 211, 211, "CID"], [298, 298, 241, 241, "CID"], [298, 298, 273, 273, "CID"], [298, 298, 311, 311, "CID"]]], "clusters": [], "translated": "长期心脏移植患者转用<0>西罗莫司</0>为基础的免疫抑制后发生<8>蛋白尿</8>。钙调神经磷酸酶抑制剂治疗可导致心脏移植患者<25>肾功能障碍</25>。新型免疫抑制 (IS)药物<1>西罗莫司</1>(<2>Srl</2>)无<26>肾毒性</26>作用；然而，<9>蛋白尿</9>与<3>Srl</3>相关已在肾移植后被报道。在心脏移植中，与<4>Srl</4>相关的<10>蛋白尿</10>的发生率尚不清楚。在这项研究中，长期心脏移植患者从<17>环孢菌素</17>转为<5>Srl</5>为基础的IS。伴随的 IS 由<18>霉酚酸酯</18>+/-<19>类固醇</19>组成。蛋白尿从中位数 0.13 g/天 (范围 0-5.7) 预切换到 0.23 g/天 (0-9.88) 在转换后 24 个月 (p = 0.0024)显着增加。在转换之前，11.5%的患者有高级别<11>蛋白尿</11> (>1.0 g/天);这增加到22.9%转换后(p = 0.006)。<20>ACE 抑制剂</20>和<22>血管紧张素释放阻滞剂</22>(<23>ARB</23>)治疗可减少<12>蛋白尿</12>的发生。没有<13>蛋白尿</13>的患者肾功能增加(中位数 42.5 vs. 64.1, p = 0.25)，而出现严重<14>蛋白尿</14>的患者随访结束时肾功能下降(中位数39.6 vs. 29.2, p = 0.125)。因此，心脏移植患者在改用<6>Srl</6>后可能会出现<15>蛋白尿</15>，这可能对这些患者的肾功能产生不良影响。<7>Srl</7>应与<21>ACEi</21>/<24>ARB</24>治疗一起使用，并监测患者的<16>蛋白尿</16>和增加的<27>肾功能障碍</27>。", "revised": true}
{"doc_key": "18726058", "sentences": [["Adverse", "effects", "of", "topical", "papaverine", "on", "auditory", "nerve", "function", ".", "BACKGROUND", ":", "Papaverine", "hydrochloride", "is", "a", "direct", "-", "acting", "vasodilator", "used", "to", "manage", "vasospasm", "during", "various", "neurosurgical", "operations", ".", "Transient", "cranial", "nerve", "dysfunction", "has", "been", "described", "in", "a", "few", "cases", "with", "topical", "papaverine", ".", "This", "study", "supports", "previous", "reports", "and", "provides", "neurophysiological", "evidence", "of", "an", "adverse", "effect", "on", "the", "auditory", "nerve", ".", "METHODS", ":", "We", "conducted", "a", "retrospective", "review", "of", "70", "consecutive", "microvascular", "decompression", "operations", "and", "studied", "those", "patients", "who", "received", "topical", "papaverine", "for", "vasospasm", ".", "Topical", "papaverine", "was", "used", "as", "a", "direct", "therapeutic", "action", "to", "manage", "vasospasm", "in", "a", "total", "of", "11", "patients", ".", "The", "timing", "of", "papaverine", "application", "and", "ongoing", "operative", "events", "was", "reviewed", "relative", "to", "changes", "in", "neurophysiological", "recordings", ".", "Brainstem", "auditory", "evoked", "potentials", "(", "BAEPs", ")", "were", "routinely", "used", "to", "monitor", "cochlear", "nerve", "function", "during", "these", "operations", ".", "FINDINGS", ":", "A", "temporal", "relationship", "was", "found", "between", "topical", "papaverine", "and", "BAEP", "changes", "leading", "to", "complete", "waveform", "loss", ".", "The", "average", "temporal", "delay", "between", "papaverine", "and", "the", "onset", "of", "an", "adverse", "BAEP", "change", "was", "5", "min", ".", "In", "10", "of", "11", "patients", ",", "BAEP", "waves", "II", "/", "III", "-", "V", "completely", "disappeared", "within", "2", "to", "25", "min", "after", "papaverine", ".", "Eight", "of", "these", "10", "patients", "had", "complete", "loss", "of", "BAEP", "waveforms", "within", "10", "min", ".", "One", "patient", "showed", "no", "recovery", "of", "later", "waves", "and", "a", "delayed", "profound", "sensorineural", "hearing", "loss", ".", "The", "average", "recovery", "time", "of", "BAEP", "waveforms", "to", "pre", "-", "papaverine", "baseline", "values", "was", "39", "min", ".", "CONCLUSIONS", ":", "Topical", "papaverine", "for", "the", "treatment", "of", "vasospasm", "was", "associated", "with", "the", "onset", "of", "a", "transient", "disturbance", "in", "neurophysiological", "function", "of", "the", "ascending", "auditory", "brainstem", "pathway", ".", "The", "complete", "disappearance", "of", "BAEP", "waveforms", "with", "a", "consistent", "temporal", "delay", "suggests", "a", "possible", "adverse", "effect", "on", "the", "proximal", "eighth", "nerve", ".", "Recommendations", "to", "avoid", "potential", "cranial", "nerve", "deficits", "from", "papaverine", "are", "provided", "."]], "ner": [[[4, 4, "Chemical"], [12, 13, "Chemical"], [42, 42, "Chemical"], [82, 82, "Chemical"], [87, 87, "Chemical"], [108, 108, "Chemical"], [151, 151, "Chemical"], [166, 166, "Chemical"], [200, 200, "Chemical"], [243, 243, "Chemical"], [253, 253, "Chemical"], [308, 308, "Chemical"], [229, 231, "Disease"], [292, 298, "Disease"], [23, 23, "Disease"], [84, 84, "Disease"], [97, 97, "Disease"], [258, 258, "Disease"], [30, 32, "Disease"], [304, 306, "Disease"]]], "relations": [[[4, 4, 229, 231, "CID"], [12, 13, 229, 231, "CID"], [42, 42, 229, 231, "CID"], [82, 82, 229, 231, "CID"], [87, 87, 229, 231, "CID"], [108, 108, 229, 231, "CID"], [151, 151, 229, 231, "CID"], [166, 166, 229, 231, "CID"], [200, 200, 229, 231, "CID"], [243, 243, 229, 231, "CID"], [253, 253, 229, 231, "CID"], [308, 308, 229, 231, "CID"], [4, 4, 292, 298, "CID"], [12, 13, 292, 298, "CID"], [42, 42, 292, 298, "CID"], [82, 82, 292, 298, "CID"], [87, 87, 292, 298, "CID"], [108, 108, 292, 298, "CID"], [151, 151, 292, 298, "CID"], [166, 166, 292, 298, "CID"], [200, 200, 292, 298, "CID"], [243, 243, 292, 298, "CID"], [253, 253, 292, 298, "CID"], [308, 308, 292, 298, "CID"]]], "clusters": [], "translated": "局部<0>罂粟碱</0>对听觉神经功能的不利影响。背景：<1>盐酸罂粟碱</1>是一种直接作用的血管扩张剂，用于控制各种神经外科手术中的<14>血管痉挛</14>。一过性<18>颅神经功能障碍</18>已在局部<2>罂粟碱</2>的少数病例中得到描述。这项研究支持以前的报告，并提供了对听觉神经产生不利影响的神经生理学证据。方法：我们对70例连续的微血管减压手术进行了回顾性研究，并研究了因<15>血管痉挛</15>而接受局部<3>罂粟碱</3>治疗的患者。外用<4>罂粟碱</4>被用作直接治疗作用，以控制总共11名患者的<16>血管痉挛</16>。相对于神经生理学记录的变化，回顾了<5>罂粟碱</5>应用的时间和正在进行的手术事件。在这些手术中，脑干听觉诱发电位(BAEP)通常用于监测耳蜗神经功能。调查结果：发现局部<6>罂粟碱</6>和导致波形完全丢失的BAEP变化之间存在时间关系。<7>罂粟碱</7>与不良BAEP变化开始之间的平均时间延迟为5分钟。11例患者中有10例在服用<8>罂粟碱</8>后2～25分钟内BAEP II/III-V波完全消失。这10名患者中有8名在10分钟内完全失去了BAEP波形。一名患者表现出后波没有恢复和延迟的深度<12>感音神经性听力损失</12>。BAEP波形恢复到前<9>罂粟碱</9>基线值的平均时间为39分钟。结论：外用<10>罂粟碱</10>治疗<17>血管痉挛</17>与上行听性脑干通路神经生理功能的短暂紊乱有关。具有一致时间延迟的BAEP波形完全消失表明可能<13>对近端第八神经的不利影响</13>。提供了避免因<11>罂粟碱</11>引起的潜在<19>颅神经缺陷</19>的建议。", "revised": true}
{"doc_key": "20520283", "sentences": [["Efficacy", "and", "safety", "of", "asenapine", "in", "a", "placebo", "-", "and", "haloperidol", "-", "controlled", "trial", "in", "patients", "with", "acute", "exacerbation", "of", "schizophrenia", ".", "Asenapine", "is", "approved", "by", "the", "Food", "and", "Drugs", "Administration", "in", "adults", "for", "acute", "treatment", "of", "schizophrenia", "or", "of", "manic", "or", "mixed", "episodes", "associated", "with", "bipolar", "I", "disorder", "with", "or", "without", "psychotic", "features", ".", "In", "a", "double", "-", "blind", "6", "-", "week", "trial", ",", "458", "patients", "with", "acute", "schizophrenia", "were", "randomly", "assigned", "to", "fixed", "-", "dose", "treatment", "with", "asenapine", "at", "5", "mg", "twice", "daily", "(", "BID", ")", ",", "asenapine", "at", "10", "mg", "BID", ",", "placebo", ",", "or", "haloperidol", "at", "4", "mg", "BID", "(", "to", "verify", "assay", "sensitivity", ")", ".", "With", "last", "observations", "carried", "forward", "(", "LOCF", ")", ",", "mean", "Positive", "and", "Negative", "Syndrome", "Scale", "total", "score", "reductions", "from", "baseline", "to", "endpoint", "were", "significantly", "greater", "with", "asenapine", "at", "5", "mg", "BID", "(", "-", "16", ".", "2", ")", "and", "haloperidol", "(", "-", "15", ".", "4", ")", "than", "placebo", "(", "-", "10", ".", "7", ";", "both", "P", "<", "0", ".", "05", ")", ";", "using", "mixed", "model", "for", "repeated", "measures", "(", "MMRM", ")", ",", "changes", "at", "day", "42", "were", "significantly", "greater", "with", "asenapine", "at", "5", "and", "10", "mg", "BID", "(", "-", "21", ".", "3", "and", "-", "19", ".", "4", ",", "respectively", ")", "and", "haloperidol", "(", "-", "20", ".", "0", ")", "than", "placebo", "(", "-", "14", ".", "6", ";", "all", "P", "<", "0", ".", "05", ")", ".", "On", "the", "Positive", "and", "Negative", "Syndrome", "Scale", "positive", "subscale", ",", "all", "treatments", "were", "superior", "to", "placebo", "with", "LOCF", "and", "MMRM", ";", "asenapine", "at", "5", "mg", "BID", "was", "superior", "to", "placebo", "on", "the", "negative", "subscale", "with", "MMRM", "and", "on", "the", "general", "psychopathology", "subscale", "with", "LOCF", "and", "MMRM", ".", "Treatment", "-", "related", "adverse", "events", "(", "AEs", ")", "occurred", "in", "44", "%", "and", "52", "%", ",", "57", "%", ",", "and", "41", "%", "of", "the", "asenapine", "at", "5", "and", "10", "mg", "BID", ",", "haloperidol", ",", "and", "placebo", "groups", ",", "respectively", ".", "Extrapyramidal", "symptoms", "reported", "as", "AEs", "occurred", "in", "15", "%", "and", "18", "%", ",", "34", "%", ",", "and", "10", "%", "of", "the", "asenapine", "at", "5", "and", "10", "mg", "BID", ",", "haloperidol", ",", "and", "placebo", "groups", ",", "respectively", ".", "Across", "all", "groups", ",", "no", "more", "than", "5", "%", "of", "patients", "had", "clinically", "significant", "weight", "change", ".", "Post", "hoc", "analyses", "indicated", "that", "efficacy", "was", "similar", "with", "asenapine", "and", "haloperidol", ";", "greater", "contrasts", "were", "seen", "in", "AEs", ",", "especially", "extrapyramidal", "symptoms", "."]], "ner": [[[4, 4, "Chemical"], [22, 22, "Chemical"], [79, 79, "Chemical"], [89, 89, "Chemical"], [136, 136, "Chemical"], [189, 189, "Chemical"], [254, 254, "Chemical"], [304, 304, "Chemical"], [341, 341, "Chemical"], [383, 383, "Chemical"], [320, 321, "Disease"], [395, 396, "Disease"], [10, 10, "Chemical"], [98, 98, "Chemical"], [148, 148, "Chemical"], [210, 210, "Chemical"], [312, 312, "Chemical"], [349, 349, "Chemical"], [385, 385, "Chemical"], [20, 20, "Disease"], [37, 37, "Disease"], [69, 69, "Disease"], [40, 40, "Disease"], [46, 48, "Disease"], [52, 52, "Disease"]]], "relations": [[[4, 4, 320, 321, "CID"], [4, 4, 395, 396, "CID"], [22, 22, 320, 321, "CID"], [22, 22, 395, 396, "CID"], [79, 79, 320, 321, "CID"], [79, 79, 395, 396, "CID"], [89, 89, 320, 321, "CID"], [89, 89, 395, 396, "CID"], [136, 136, 320, 321, "CID"], [136, 136, 395, 396, "CID"], [189, 189, 320, 321, "CID"], [189, 189, 395, 396, "CID"], [254, 254, 320, 321, "CID"], [254, 254, 395, 396, "CID"], [304, 304, 320, 321, "CID"], [304, 304, 395, 396, "CID"], [341, 341, 320, 321, "CID"], [341, 341, 395, 396, "CID"], [383, 383, 320, 321, "CID"], [383, 383, 395, 396, "CID"], [10, 10, 320, 321, "CID"], [10, 10, 395, 396, "CID"], [98, 98, 320, 321, "CID"], [98, 98, 395, 396, "CID"], [148, 148, 320, 321, "CID"], [148, 148, 395, 396, "CID"], [210, 210, 320, 321, "CID"], [210, 210, 395, 396, "CID"], [312, 312, 320, 321, "CID"], [312, 312, 395, 396, "CID"], [349, 349, 320, 321, "CID"], [349, 349, 395, 396, "CID"], [385, 385, 320, 321, "CID"], [385, 385, 395, 396, "CID"]]], "clusters": [], "translated": "<0>阿塞那平</0>在安慰剂和<12>氟哌啶醇</12>对照试验中对<19>精神分裂症</19>患者的疗效和安全性。<1>阿塞那平</1>经美国食品和药物管理局批准用于成人急性治疗<20>精神分裂症</20>或<22>躁狂</22>或与<23>双相I相关的混合发作障碍</23>有或没有<24>精神病</24>特征。在一项为期6周的双盲试验中，458名急性<21>精神分裂症</21>患者被随机分配接受固定剂量的<2>阿塞那平</2>治疗，每次5毫克，每天两次(BID)，<3>阿塞那平</3> 10 mg BID、安慰剂或<13>氟哌啶醇</13> 4 mg BID（以验证检测灵敏度）。随着上次观察结转 (LOCF)，<4>阿塞那平</4>5mgBID(-16.2)和<14>氟哌啶醇</14>(-15.4)优于安慰剂(-10.7; 两者P < 0.05)；使用重复测量的混合模型(MMRM)，第42天的变化显着大于<5>阿塞那平</5>5和10mg BID（分别为-21.3和-19.4）和<15>氟哌啶醇</15>(-20.0)优于安慰剂(-14.6；所有P < 0.05)。在阳性和阴性症状量表阳性子量表上，所有治疗均优于安慰剂，包括LOCF和MMRM；<6>阿塞那平</6>5mgBID在MMRM的负分量表和LOCF和MMRM的一般精神病理学分量表上优于安慰剂。与治疗相关的不良事件(AE)发生在44%和52%、57%和41%的<7>阿塞那平</7>5和10mgBID、<16>氟哌啶醇</16>和安慰剂中分别分组。<10>锥体外系症状</10>报告为AE的发生率分别为15%和18%、34%和10%的<8>阿塞那平</8>5和10mg BID，<17>氟哌啶醇</17>和安慰剂组。在所有组中，不超过5%的患者有临床显着的体重变化。事后分析表明，<9>阿塞那平</9>和<18>氟哌啶醇</18>的疗效相似；在AE中观察到更大的对比，尤其是<11>锥体外系症状</11>。", "revised": true}
{"doc_key": "567256", "sentences": [["Angiosarcoma", "of", "the", "liver", "associated", "with", "diethylstilbestrol", ".", "Angiosarcoma", "of", "the", "liver", "occurred", "in", "a", "76", "-", "year", "-", "old", "man", "who", "had", "been", "treated", "for", "a", "well", "-", "differentiated", "adenocarcinoma", "of", "the", "liver", "with", "diethylstilbestrol", "for", "13", "years", ".", "Angiosarcoma", "was", "also", "present", "within", "pulmonary", "and", "renal", "arteries", ".", "The", "possibility", "that", "the", "intraarterial", "lesions", "might", "represent", "independent", "primary", "tumors", "is", "considered", "."]], "ner": [[[6, 6, "Chemical"], [35, 35, "Chemical"], [0, 3, "Disease"], [8, 11, "Disease"], [40, 40, "Disease"], [30, 33, "Disease"], [54, 55, "Disease"], [60, 60, "Disease"]]], "relations": [[[6, 6, 0, 3, "CID"], [6, 6, 8, 11, "CID"], [6, 6, 40, 40, "CID"], [35, 35, 0, 3, "CID"], [35, 35, 8, 11, "CID"], [35, 35, 40, 40, "CID"], [6, 6, 30, 33, "CID"], [35, 35, 30, 33, "CID"]]], "clusters": [], "translated": "<2>肝脏血管肉瘤</2>与<0>己烯雌酚</0>有关。 <3>肝脏血管肉瘤</3>发生在一名76岁的男性身上，他因为分化良好的<5>肝脏腺癌</5>接受了长达13年的<1>己烯雌酚</1>治疗。此外，<4>血管肉瘤</4>也存在于肺动脉和肾动脉内。考虑到<6>动脉内病变</6>可能代表独立的原发性<7>肿瘤</7>的可能性。", "revised": true}
{"doc_key": "19356053", "sentences": [["Clinically", "significant", "proteinuria", "following", "the", "administration", "of", "sirolimus", "to", "renal", "transplant", "recipients", ".", "BACKGROUND", ":", "Sirolimus", "is", "the", "latest", "immunosuppressive", "agent", "used", "to", "prevent", "rejection", ",", "and", "may", "have", "less", "nephrotoxicity", "than", "calcineurin", "inhibitor", "(", "CNI", ")", "-", "based", "regimens", ".", "To", "date", "there", "has", "been", "little", "documentation", "of", "clinically", "significant", "proteinuria", "linked", "with", "the", "use", "of", "sirolimus", ".", "We", "have", "encountered", "several", "patients", "who", "developed", "substantial", "proteinuria", "associated", "with", "sirolimus", "use", ".", "In", "each", "patient", ",", "the", "close", "temporal", "association", "between", "the", "commencement", "of", "sirolimus", "therapy", "and", "proteinuria", "implicated", "sirolimus", "as", "the", "most", "likely", "etiology", "of", "the", "proteinuria", ".", "METHODS", ":", "We", "analyzed", "the", "clinical", "and", "laboratory", "information", "available", "for", "all", "119", "patients", "transplanted", "at", "the", "Washington", "Hospital", "Center", "between", "1999", "-", "2003", "for", "whom", "sirolimus", "was", "a", "component", "of", "their", "immunosuppressant", "regimen", ".", "In", "these", "patients", ",", "the", "magnitude", "of", "proteinuria", "was", "assessed", "on", "morning", "urine", "samples", "by", "turbidometric", "measurement", "or", "random", "urine", "protein", ":", "creatinine", "ratios", ",", "an", "estimate", "of", "grams", "of", "proteinuria", "/", "day", ".", "Laboratory", "results", "were", "compared", "between", "prior", ",", "during", "and", "following", "sirolimus", "use", ".", "RESULTS", ":", "Twenty", "-", "eight", "patients", "(", "24", "%", ")", "developed", "increased", "proteinuria", "from", "baseline", "during", "their", "post", "-", "transplantation", "course", ".", "In", "21", "patients", "an", "alternative", "cause", "of", "proteinuria", "was", "either", "obvious", "or", "insufficient", "data", "was", "available", "to", "be", "conclusive", ".", "In", "7", "of", "the", "28", "patients", "there", "was", "a", "striking", "temporal", "association", "between", "the", "initiation", "of", "sirolimus", "and", "the", "development", "of", "nephrotic", "-", "range", "proteinuria", ".", "Proteinuria", "correlated", "most", "strongly", "with", "sirolimus", "therapy", "when", "compared", "to", "other", "demographic", "and", "clinical", "variables", ".", "In", "most", "patients", ",", "discontinuation", "of", "sirolimus", "resulted", "in", "a", "decrease", ",", "but", "not", "resolution", ",", "of", "proteinuria", ".", "CONCLUSIONS", ":", "Sirolimus", "induces", "or", "aggravates", "pre", "-", "existing", "proteinuria", "in", "an", "unpredictable", "subset", "of", "renal", "allograft", "recipients", ".", "Proteinuria", "may", "improve", ",", "but", "does", "not", "resolve", ",", "when", "sirolimus", "is", "withdrawn", "."]], "ner": [[[7, 7, "Chemical"], [15, 15, "Chemical"], [57, 57, "Chemical"], [70, 70, "Chemical"], [85, 85, "Chemical"], [90, 90, "Chemical"], [126, 126, "Chemical"], [179, 179, "Chemical"], [240, 240, "Chemical"], [255, 255, "Chemical"], [272, 272, "Chemical"], [287, 287, "Chemical"], [314, 314, "Chemical"], [2, 2, "Disease"], [51, 51, "Disease"], [67, 67, "Disease"], [88, 88, "Disease"], [98, 98, "Disease"], [142, 142, "Disease"], [165, 165, "Disease"], [194, 194, "Disease"], [211, 211, "Disease"], [248, 248, "Disease"], [250, 250, "Disease"], [283, 283, "Disease"], [294, 294, "Disease"], [304, 304, "Disease"], [157, 157, "Chemical"], [30, 30, "Disease"], [245, 245, "Disease"]]], "relations": [[[7, 7, 2, 2, "CID"], [7, 7, 51, 51, "CID"], [7, 7, 67, 67, "CID"], [7, 7, 88, 88, "CID"], [7, 7, 98, 98, "CID"], [7, 7, 142, 142, "CID"], [7, 7, 165, 165, "CID"], [7, 7, 194, 194, "CID"], [7, 7, 211, 211, "CID"], [7, 7, 248, 248, "CID"], [7, 7, 250, 250, "CID"], [7, 7, 283, 283, "CID"], [7, 7, 294, 294, "CID"], [7, 7, 304, 304, "CID"], [15, 15, 2, 2, "CID"], [15, 15, 51, 51, "CID"], [15, 15, 67, 67, "CID"], [15, 15, 88, 88, "CID"], [15, 15, 98, 98, "CID"], [15, 15, 142, 142, "CID"], [15, 15, 165, 165, "CID"], [15, 15, 194, 194, "CID"], [15, 15, 211, 211, "CID"], [15, 15, 248, 248, "CID"], [15, 15, 250, 250, "CID"], [15, 15, 283, 283, "CID"], [15, 15, 294, 294, "CID"], [15, 15, 304, 304, "CID"], [57, 57, 2, 2, "CID"], [57, 57, 51, 51, "CID"], [57, 57, 67, 67, "CID"], [57, 57, 88, 88, "CID"], [57, 57, 98, 98, "CID"], [57, 57, 142, 142, "CID"], [57, 57, 165, 165, "CID"], [57, 57, 194, 194, "CID"], [57, 57, 211, 211, "CID"], [57, 57, 248, 248, "CID"], [57, 57, 250, 250, "CID"], [57, 57, 283, 283, "CID"], [57, 57, 294, 294, "CID"], [57, 57, 304, 304, "CID"], [70, 70, 2, 2, "CID"], [70, 70, 51, 51, "CID"], [70, 70, 67, 67, "CID"], [70, 70, 88, 88, "CID"], [70, 70, 98, 98, "CID"], [70, 70, 142, 142, "CID"], [70, 70, 165, 165, "CID"], [70, 70, 194, 194, "CID"], [70, 70, 211, 211, "CID"], [70, 70, 248, 248, "CID"], [70, 70, 250, 250, "CID"], [70, 70, 283, 283, "CID"], [70, 70, 294, 294, "CID"], [70, 70, 304, 304, "CID"], [85, 85, 2, 2, "CID"], [85, 85, 51, 51, "CID"], [85, 85, 67, 67, "CID"], [85, 85, 88, 88, "CID"], [85, 85, 98, 98, "CID"], [85, 85, 142, 142, "CID"], [85, 85, 165, 165, "CID"], [85, 85, 194, 194, "CID"], [85, 85, 211, 211, "CID"], [85, 85, 248, 248, "CID"], [85, 85, 250, 250, "CID"], [85, 85, 283, 283, "CID"], [85, 85, 294, 294, "CID"], [85, 85, 304, 304, "CID"], [90, 90, 2, 2, "CID"], [90, 90, 51, 51, "CID"], [90, 90, 67, 67, "CID"], [90, 90, 88, 88, "CID"], [90, 90, 98, 98, "CID"], [90, 90, 142, 142, "CID"], [90, 90, 165, 165, "CID"], [90, 90, 194, 194, "CID"], [90, 90, 211, 211, "CID"], [90, 90, 248, 248, "CID"], [90, 90, 250, 250, "CID"], [90, 90, 283, 283, "CID"], [90, 90, 294, 294, "CID"], [90, 90, 304, 304, "CID"], [126, 126, 2, 2, "CID"], [126, 126, 51, 51, "CID"], [126, 126, 67, 67, "CID"], [126, 126, 88, 88, "CID"], [126, 126, 98, 98, "CID"], [126, 126, 142, 142, "CID"], [126, 126, 165, 165, "CID"], [126, 126, 194, 194, "CID"], [126, 126, 211, 211, "CID"], [126, 126, 248, 248, "CID"], [126, 126, 250, 250, "CID"], [126, 126, 283, 283, "CID"], [126, 126, 294, 294, "CID"], [126, 126, 304, 304, "CID"], [179, 179, 2, 2, "CID"], [179, 179, 51, 51, "CID"], [179, 179, 67, 67, "CID"], [179, 179, 88, 88, "CID"], [179, 179, 98, 98, "CID"], [179, 179, 142, 142, "CID"], [179, 179, 165, 165, "CID"], [179, 179, 194, 194, "CID"], [179, 179, 211, 211, "CID"], [179, 179, 248, 248, "CID"], [179, 179, 250, 250, "CID"], [179, 179, 283, 283, "CID"], [179, 179, 294, 294, "CID"], [179, 179, 304, 304, "CID"], [240, 240, 2, 2, "CID"], [240, 240, 51, 51, "CID"], [240, 240, 67, 67, "CID"], [240, 240, 88, 88, "CID"], [240, 240, 98, 98, "CID"], [240, 240, 142, 142, "CID"], [240, 240, 165, 165, "CID"], [240, 240, 194, 194, "CID"], [240, 240, 211, 211, "CID"], [240, 240, 248, 248, "CID"], [240, 240, 250, 250, "CID"], [240, 240, 283, 283, "CID"], [240, 240, 294, 294, "CID"], [240, 240, 304, 304, "CID"], [255, 255, 2, 2, "CID"], [255, 255, 51, 51, "CID"], [255, 255, 67, 67, "CID"], [255, 255, 88, 88, "CID"], [255, 255, 98, 98, "CID"], [255, 255, 142, 142, "CID"], [255, 255, 165, 165, "CID"], [255, 255, 194, 194, "CID"], [255, 255, 211, 211, "CID"], [255, 255, 248, 248, "CID"], [255, 255, 250, 250, "CID"], [255, 255, 283, 283, "CID"], [255, 255, 294, 294, "CID"], [255, 255, 304, 304, "CID"], [272, 272, 2, 2, "CID"], [272, 272, 51, 51, "CID"], [272, 272, 67, 67, "CID"], [272, 272, 88, 88, "CID"], [272, 272, 98, 98, "CID"], [272, 272, 142, 142, "CID"], [272, 272, 165, 165, "CID"], [272, 272, 194, 194, "CID"], [272, 272, 211, 211, "CID"], [272, 272, 248, 248, "CID"], [272, 272, 250, 250, "CID"], [272, 272, 283, 283, "CID"], [272, 272, 294, 294, "CID"], [272, 272, 304, 304, "CID"], [287, 287, 2, 2, "CID"], [287, 287, 51, 51, "CID"], [287, 287, 67, 67, "CID"], [287, 287, 88, 88, "CID"], [287, 287, 98, 98, "CID"], [287, 287, 142, 142, "CID"], [287, 287, 165, 165, "CID"], [287, 287, 194, 194, "CID"], [287, 287, 211, 211, "CID"], [287, 287, 248, 248, "CID"], [287, 287, 250, 250, "CID"], [287, 287, 283, 283, "CID"], [287, 287, 294, 294, "CID"], [287, 287, 304, 304, "CID"], [314, 314, 2, 2, "CID"], [314, 314, 51, 51, "CID"], [314, 314, 67, 67, "CID"], [314, 314, 88, 88, "CID"], [314, 314, 98, 98, "CID"], [314, 314, 142, 142, "CID"], [314, 314, 165, 165, "CID"], [314, 314, 194, 194, "CID"], [314, 314, 211, 211, "CID"], [314, 314, 248, 248, "CID"], [314, 314, 250, 250, "CID"], [314, 314, 283, 283, "CID"], [314, 314, 294, 294, "CID"], [314, 314, 304, 304, "CID"]]], "clusters": [], "translated": "给肾移植受者服用<0>西罗莫司</0>后出现具有临床意义的<13>蛋白尿</13>。背景：<1>西罗莫司</1>是最新用于预防排斥反应的免疫抑制剂，与基于钙调磷酸酶抑制剂 (CNI) 的方案相比，其<28>肾毒性</28>可能更小。迄今为止，临床上显着的<14>蛋白尿</14>与使用<2>西罗莫司</2>相关的文献很少。我们遇到过一些因使用<3>西罗莫司</3>而出现大量<15>蛋白尿</15>的患者。在每位患者中，开始<4>西罗莫司</4>治疗与<16>蛋白尿</16>之间的密切时间关联暗示<5>西罗莫司</5>是<17>蛋白尿</17>最可能的病因。方法：我们分析了1999年至2003年期间在华盛顿医院中心接受移植手术的所有119名患者的临床和实验室信息，其中<6>西罗莫司</6>是其免疫抑制方案的组成部分。在这些患者中，<18>蛋白尿</18>的严重程度是通过比浊测量法或随机尿蛋白：<27>肌酐</27>比值（估计<19>蛋白尿</19>的克数）对晨尿样本进行评估的/天。对使用<7>西罗莫司</7>之前、期间和之后的实验室结果进行了比较。结果：28名患者（24%）在移植后的过程中<20>蛋白尿</20>较基线增加。在21名患者中，<21>蛋白尿</21>的另一个原因要么很明显，要么没有足够的数据来确定。在28名患者中的7名患者中，<8>西罗莫司</8>的开始与<22>蛋白尿</22>的发展之间存在显着的时间关联，而蛋白尿的程度达到<29>肾病</29>范围。<23>蛋白尿</23>与<9>西罗莫司</9>疗法的相关性最强，与其他人口统计学和临床变量相比。在大多数患者中，停用<10>西罗莫司</10>会导致<24>蛋白尿</24>减少，但不会消失。结论：<11>西罗莫司</11>诱导或加重不可预测的肾同种异体移植受者亚群中已有的<25>蛋白尿</25>。停用<12>西罗莫司</12>后，<26>蛋白尿</26>可能会改善但不会消失。", "revised": true}
{"doc_key": "1616457", "sentences": [["Learning", "of", "rats", "under", "amnesia", "caused", "by", "pentobarbital", ".", "Dissociated", "learning", "of", "rats", "in", "the", "normal", "state", "and", "the", "state", "of", "amnesia", "produced", "by", "pentobarbital", "(", "15", "mg", "/", "kg", ",", "ip", ")", "was", "carried", "out", ".", "Rats", "were", "trained", "to", "approach", "a", "shelf", "where", "they", "received", "food", "reinforcement", ".", "In", "Group", "1", "the", "rats", "were", "trained", "under", "the", "influence", "of", "pentobarbital", "to", "run", "to", "the", "same", "shelf", "as", "in", "the", "normal", "state", ".", "In", "Group", "2", "the", "rats", "were", "trained", "to", "approach", "different", "shelves", "in", "different", "drug", "states", ".", "It", "was", "shown", "that", "memory", "dissociation", "occurred", "in", "both", "groups", ".", "Differences", "in", "the", "parameters", "of", "training", "under", "the", "influence", "of", "pentobarbital", "between", "Groups", "1", "and", "2", "were", "revealed", ".", "These", "findings", "show", "that", "the", "brain", "-", "dissociated", "state", "induced", "by", "pentobarbital", "is", "formed", "with", "the", "participation", "of", "the", "mechanisms", "of", "information", "perception", "."]], "ner": [[[7, 7, "Chemical"], [24, 24, "Chemical"], [61, 61, "Chemical"], [111, 111, "Chemical"], [131, 131, "Chemical"], [4, 4, "Disease"], [21, 21, "Disease"], [94, 95, "Disease"]]], "relations": [[[7, 7, 4, 4, "CID"], [7, 7, 21, 21, "CID"], [24, 24, 4, 4, "CID"], [24, 24, 21, 21, "CID"], [61, 61, 4, 4, "CID"], [61, 61, 21, 21, "CID"], [111, 111, 4, 4, "CID"], [111, 111, 21, 21, "CID"], [131, 131, 4, 4, "CID"], [131, 131, 21, 21, "CID"]]], "clusters": [], "translated": "<0>戊巴比妥</0>致大鼠<5>失忆</5>的学习。对正常状态和<1>戊巴比妥</1>（15 mg/kg，ip）引起的<6>失忆</6>状态大鼠进行游离学习。老鼠被训练接近一个他们接受食物强化的架子。在第 1 组中，大鼠在<2>戊巴比妥</2>的影响下被训练跑到与正常状态下相同的架子。在第 2 组中，大鼠被训练在不同的药物状态下接近不同的货架。结果表明，<7>记忆分离</7>在两组中均有发生。第 1 组和第 2 组在<3>戊巴比妥</3>影响下的训练参数存在差异。这些研究结果表明，<4>戊巴比妥</4>诱导的脑解离状态是在信息感知机制的参与下形成的。", "revised": true}
{"doc_key": "20588063", "sentences": [["Permeability", ",", "ultrastructural", "changes", ",", "and", "distribution", "of", "novel", "proteins", "in", "the", "glomerular", "barrier", "in", "early", "puromycin", "aminonucleoside", "nephrosis", ".", "BACKGROUND", "/", "AIMS", ":", "It", "is", "still", "unclear", "what", "happens", "in", "the", "glomerulus", "when", "proteinuria", "starts", ".", "Using", "puromycin", "aminonucleoside", "nephrosis", "(", "PAN", ")", "rats", ",", "we", "studied", "early", "ultrastructural", "and", "permeability", "changes", "in", "relation", "to", "the", "expression", "of", "the", "podocyte", "-", "associated", "molecules", "nephrin", ",", "a", "-", "actinin", ",", "dendrin", ",", "and", "plekhh2", ",", "the", "last", "two", "of", "which", "were", "only", "recently", "discovered", "in", "podocytes", ".", "METHODS", ":", "Using", "immune", "stainings", ",", "semiquantitative", "measurement", "was", "performed", "under", "the", "electron", "microscope", ".", "Permeability", "was", "assessed", "using", "isolated", "kidney", "perfusion", "with", "tracers", ".", "Possible", "effects", "of", "ACE", "inhibition", "were", "tested", ".", "RESULTS", ":", "By", "day", "2", ",", "some", "patchy", "foot", "process", "effacement", ",", "but", "no", "proteinuria", ",", "appeared", ".", "The", "amount", "of", "nephrin", "was", "reduced", "in", "both", "diseased", "and", "normal", "areas", ".", "The", "other", "proteins", "showed", "few", "changes", ",", "which", "were", "limited", "to", "diseased", "areas", ".", "By", "day", "4", ",", "foot", "process", "effacement", "was", "complete", "and", "proteinuria", "appeared", "in", "parallel", "with", "signs", "of", "size", "barrier", "damage", ".", "Nephrin", "decreased", "further", ",", "while", "dendrin", "and", "plekhh2", "also", "decreased", "but", "a", "-", "actinin", "remained", "unchanged", ".", "ACE", "inhibition", "had", "no", "significant", "protective", "effect", ".", "CONCLUSIONS", ":", "PAN", "glomeruli", "already", "showed", "significant", "pathology", "by", "day", "4", ",", "despite", "relatively", "mild", "proteinuria", ".", "This", "was", "preceded", "by", "altered", "nephrin", "expression", ",", "supporting", "its", "pivotal", "role", "in", "podocyte", "morphology", ".", "The", "novel", "proteins", "dendrin", "and", "plekhh2", "were", "both", "reduced", ",", "suggesting", "roles", "in", "PAN", ",", "whereas", "a", "-", "actinin", "was", "unchanged", "."]], "ner": [[[16, 17, "Chemical"], [38, 39, "Chemical"], [18, 18, "Disease"], [40, 40, "Disease"], [34, 34, "Disease"], [134, 134, "Disease"], [175, 175, "Disease"], [226, 226, "Disease"]]], "relations": [[[16, 17, 18, 18, "CID"], [16, 17, 40, 40, "CID"], [38, 39, 18, 18, "CID"], [38, 39, 40, 40, "CID"], [16, 17, 34, 34, "CID"], [16, 17, 134, 134, "CID"], [16, 17, 175, 175, "CID"], [16, 17, 226, 226, "CID"], [38, 39, 34, 34, "CID"], [38, 39, 134, 134, "CID"], [38, 39, 175, 175, "CID"], [38, 39, 226, 226, "CID"]]], "clusters": [], "translated": "早期<0>嘌呤霉素氨基核苷</0><2>肾病</2>肾小球屏障中新蛋白的渗透性、超微结构变化和分布。背景/目的：目前还不清楚当<4>蛋白尿</4>开始时肾小球发生了什么。使用<1>嘌呤霉素氨基核苷</1><3>肾病</3> (PAN)大鼠，我们研究了早期超微结构和渗透性变化与足细胞相关分子nephrin、 a-actinin、dendrin和plekhh2，其中最后两个是最近才在足细胞中发现的。方法：采用免疫染色法，在电子显微镜下进行半定量测定。使用带示踪剂的离体肾脏灌注评估渗透性。测试了ACE抑制的可能影响。结果：第2天，足突出现部分斑片状消失，无<5>蛋白尿</5>。患病和正常区域的nephrin数量均有所减少。其他蛋白质变化不大，仅限于病变部位。到第4天时，足突完全消失，<6>蛋白尿</6>与大小屏障损伤迹象同时出现。Nephrin进一步下降，dendrin和plekhh2也下降，但a-actinin没有变化。ACE抑制剂无明显保护作用。结论：尽管<7>蛋白尿</7>相对较轻，PAN肾小球在第4天时已经显示出明显的病理变化。在此之前nephrin表达发生了改变，支持其在足细胞形态学中的关键作用。新蛋白dendrin和plekhh2都减少了，表明在PAN中起作用，而a-actinin没有变化。", "revised": true}
{"doc_key": "3070035", "sentences": [["Reversibility", "of", "captopril", "-", "induced", "renal", "insufficiency", "after", "prolonged", "use", "in", "an", "unusual", "case", "of", "renovascular", "hypertension", ".", "We", "report", "a", "case", "of", "severe", "hypertension", "with", "an", "occluded", "renal", "artery", "to", "a", "solitary", "kidney", ",", "who", "developed", "sudden", "deterioration", "of", "renal", "function", "following", "treatment", "with", "captopril", ".", "His", "renal", "function", "remained", "impaired", "but", "stable", "during", "2", "years", "'", "treatment", "with", "captopril", "but", "returned", "to", "pre", "-", "treatment", "levels", "soon", "after", "cessation", "of", "the", "drug", ".", "This", "indicates", "reversibility", "in", "captopril", "-", "induced", "renal", "failure", "even", "after", "its", "prolonged", "use", "and", "suggests", "that", "no", "organic", "damage", "occurs", "to", "glomerular", "arterioles", "following", "chronic", "ACE", "inhibition", "."]], "ner": [[[2, 2, "Chemical"], [45, 45, "Chemical"], [60, 60, "Chemical"], [79, 79, "Chemical"], [37, 41, "Disease"], [5, 6, "Disease"], [82, 83, "Disease"], [15, 16, "Disease"], [24, 24, "Disease"]]], "relations": [[[2, 2, 37, 41, "CID"], [45, 45, 37, 41, "CID"], [60, 60, 37, 41, "CID"], [79, 79, 37, 41, "CID"]]], "clusters": [], "translated": "<0>卡托普利</0>的可逆性 - 在<7>肾血管性高血压</7>的异常情况下长期使用后诱导的<5>肾功能不全</5>。我们报告了一例严重<8>高血压</8>并伴有至孤立肾的肾动脉阻塞，该患者在接受<1>卡托普利</1>治疗后<4>肾功能突然恶化</4>。在用<2>卡托普利</2>治疗2年期间，他的肾功能仍然受损但稳定，但在停药后很快恢复到治疗前水平。这表明<3>卡托普利</3>诱导的<6>肾功能衰竭</6>即使在长期使用后也是可逆的，并且表明慢性ACE抑制后肾小球小动脉不会发生器质性损伤。", "revised": true}
{"doc_key": "20080983", "sentences": [["Normalizing", "effects", "of", "modafinil", "on", "sleep", "in", "chronic", "cocaine", "users", ".", "OBJECTIVE", ":", "The", "purpose", "of", "the", "present", "study", "was", "to", "determine", "the", "effect", "of", "morning", "-", "dosed", "modafinil", "on", "sleep", "and", "daytime", "sleepiness", "in", "chronic", "cocaine", "users", ".", "METHOD", ":", "Twenty", "cocaine", "-", "dependent", "participants", "were", "randomly", "assigned", "to", "receive", "modafinil", ",", "400", "mg", "(", "N", "=", "10", ")", ",", "or", "placebo", "(", "N", "=", "10", ")", "every", "morning", "at", "7", ":", "30", "a", ".", "m", ".", "for", "16", "days", "in", "an", "inpatient", ",", "double", "-", "blind", "randomized", "trial", ".", "Participants", "underwent", "polysomnographic", "sleep", "recordings", "on", "days", "1", "to", "3", ",", "7", "to", "9", ",", "and", "14", "to", "16", "(", "first", ",", "second", ",", "and", "third", "weeks", "of", "abstinence", ")", ".", "The", "Multiple", "Sleep", "Latency", "Test", "was", "performed", "at", "11", ":", "30", "a", ".", "m", ".", ",", "2", ":", "00", "p", ".", "m", ".", ",", "and", "4", ":", "30", "p", ".", "m", ".", "on", "days", "2", ",", "8", ",", "and", "15", ".", "For", "comparison", "of", "sleep", "architecture", "variables", ",", "12", "healthy", "comparison", "participants", "underwent", "a", "single", "night", "of", "experimental", "polysomnography", "that", "followed", "1", "night", "of", "accommodation", "polysomnography", ".", "RESULTS", ":", "Progressive", "abstinence", "from", "cocaine", "was", "associated", "with", "worsening", "of", "all", "measured", "polysomnographic", "sleep", "outcomes", ".", "Compared", "with", "placebo", ",", "modafinil", "decreased", "nighttime", "sleep", "latency", "and", "increased", "slow", "-", "wave", "sleep", "time", "in", "cocaine", "-", "dependent", "participants", ".", "The", "effect", "of", "modafinil", "interacted", "with", "the", "abstinence", "week", "and", "was", "associated", "with", "longer", "total", "sleep", "time", "and", "shorter", "REM", "sleep", "latency", "in", "the", "third", "week", "of", "abstinence", ".", "Comparison", "of", "slow", "-", "wave", "sleep", "time", ",", "total", "sleep", "time", ",", "and", "sleep", "latency", "in", "cocaine", "-", "dependent", "and", "healthy", "participants", "revealed", "a", "normalizing", "effect", "of", "modafinil", "in", "cocaine", "-", "dependent", "participants", ".", "Modafinil", "was", "associated", "with", "increased", "daytime", "sleep", "latency", ",", "as", "measured", "by", "the", "Multiple", "Sleep", "Latency", "Test", ",", "and", "a", "nearly", "significant", "decrease", "in", "subjective", "daytime", "sleepiness", ".", "CONCLUSIONS", ":", "Morning", "-", "dosed", "modafinil", "promotes", "nocturnal", "sleep", ",", "normalizes", "sleep", "architecture", ",", "and", "decreases", "daytime", "sleepiness", "in", "abstinent", "cocaine", "users", ".", "These", "effects", "may", "be", "relevant", "in", "the", "treatment", "of", "cocaine", "dependence", "."]], "ner": [[[8, 8, "Chemical"], [36, 36, "Chemical"], [42, 42, "Chemical"], [194, 194, "Chemical"], [223, 223, "Chemical"], [273, 273, "Chemical"], [286, 286, "Chemical"], [339, 339, "Chemical"], [351, 351, "Chemical"], [32, 33, "Disease"], [316, 317, "Disease"], [335, 336, "Disease"], [3, 3, "Chemical"], [28, 28, "Chemical"], [51, 51, "Chemical"], [210, 210, "Chemical"], [231, 231, "Chemical"], [284, 284, "Chemical"], [291, 291, "Chemical"], [324, 324, "Chemical"]]], "relations": [[[8, 8, 32, 33, "CID"], [8, 8, 316, 317, "CID"], [8, 8, 335, 336, "CID"], [36, 36, 32, 33, "CID"], [36, 36, 316, 317, "CID"], [36, 36, 335, 336, "CID"], [42, 42, 32, 33, "CID"], [42, 42, 316, 317, "CID"], [42, 42, 335, 336, "CID"], [194, 194, 32, 33, "CID"], [194, 194, 316, 317, "CID"], [194, 194, 335, 336, "CID"], [223, 223, 32, 33, "CID"], [223, 223, 316, 317, "CID"], [223, 223, 335, 336, "CID"], [273, 273, 32, 33, "CID"], [273, 273, 316, 317, "CID"], [273, 273, 335, 336, "CID"], [286, 286, 32, 33, "CID"], [286, 286, 316, 317, "CID"], [286, 286, 335, 336, "CID"], [339, 339, 32, 33, "CID"], [339, 339, 316, 317, "CID"], [339, 339, 335, 336, "CID"], [351, 351, 32, 33, "CID"], [351, 351, 316, 317, "CID"], [351, 351, 335, 336, "CID"]]], "clusters": [], "translated": "对长期<0>可卡因</0>使用者睡眠的正常化作用：<12>莫达非尼</12>。目的：本研究的目的是确定早晨服用<13>莫达非尼</13>对长期<1>可卡因</1>使用者的睡眠和<9>白天嗜睡</9>的影响。方法：20名<2>可卡因</2>依赖参与者被随机分配接受<14>莫达非尼</14>，400毫克（N = 10），或安慰剂（N = 10），每天早上7:30 a.m.进行为期16天的住院双盲随机试验。参与者在禁欲的第一周、第二周和第三周（第1至3天，第7至9天和第14到16天）接受多导睡眠图睡眠记录。多次睡眠潜伏期测试分别于上午11:30、下午2:00和4:30进行。第2、8和15天的睡眠潜伏期测试。为了比较睡眠结构变量，12名健康对照参与者接受了一个晚上的实验性多导睡眠监测，随后进行了1晚的适应性多导睡眠监测。结果：逐渐戒断<3>可卡因</3>会导致所有测量的多导睡眠图睡眠结果的恶化。与安慰剂相比，<15>莫达非尼</15>减少了<4>可卡因</4>依赖参与者的夜间睡眠潜伏期并增加了慢波睡眠时间。 <16>莫达非尼</16>的作用与戒断周相互作用，与戒断第三周较长的总睡眠时间和较短的快速眼动睡眠潜伏期相关。比较<5>可卡因</5>依赖者和健康参与者的慢波睡眠时间、总睡眠时间和睡眠潜伏期显示莫达非尼<17>对可卡因</17><6>依赖参与者的正常化作用</6>。<18>莫达非尼</18>与增加的白天睡眠潜伏期有关（通过多次睡眠潜伏期测试测量），并且主观<10>白天嗜睡</10> 几乎显着减少。结论：早晨服用莫达非尼<19>促进夜间睡眠</19>，使睡眠结构正常化，并减少戒断<7>可卡因</7>使用者<11>日间嗜睡</11>。这些作用可能与治疗<8>可卡因</8>依赖有关。", "revised": true}
{"doc_key": "9351491", "sentences": [["Extrapyramidal", "side", "effects", "with", "risperidone", "and", "haloperidol", "at", "comparable", "D2", "receptor", "occupancy", "levels", ".", "Risperidone", "is", "an", "antipsychotic", "drug", "with", "high", "affinity", "at", "dopamine", "D2", "and", "serotonin", "5", "-", "HT2", "receptors", ".", "Previous", "clinical", "studies", "have", "proposed", "that", "risperidone", "'s", "pharmacologic", "profile", "may", "produce", "improved", "efficacy", "for", "negative", "psychotic", "symptoms", "and", "decreased", "propensity", "for", "extrapyramidal", "side", "effects", ";", "features", "shared", "by", "so", "-", "called", "'", "atypical", "'", "neuroleptics", ".", "To", "determine", "if", "routine", "risperidone", "treatment", "is", "associated", "with", "a", "unique", "degree", "of", "D2", "receptor", "occupancy", "and", "pattern", "of", "clinical", "effects", ",", "we", "used", "[", "123I", "]", "IBZM", "SPECT", "to", "determine", "D2", "occupancy", "in", "subjects", "treated", "with", "routine", "clinical", "doses", "of", "risperidone", "(", "n", "=", "12", ")", "or", "haloperidol", "(", "n", "=", "7", ")", ".", "Both", "risperidone", "and", "haloperidol", "produced", "D2", "occupancy", "levels", "between", "approximately", "60", "and", "90", "%", "at", "standard", "clinical", "doses", ".", "There", "was", "no", "significant", "difference", "between", "occupancy", "levels", "obtained", "with", "haloperidol", "or", "risperidone", ".", "Drug", "-", "induced", "parkinsonism", "was", "observed", "in", "subjects", "treated", "with", "risperidone", "(", "42", "%", ")", "and", "haloperidol", "(", "29", "%", ")", "and", "was", "observed", "at", "occupancy", "levels", "above", "60", "%", ".", "Based", "on", "these", "observations", ",", "it", "is", "concluded", "that", "5", "-", "HT2", "blockade", "obtained", "with", "risperidone", "at", "D2", "occupancy", "rates", "of", "60", "%", "and", "above", "does", "not", "appear", "to", "protect", "against", "the", "risk", "for", "extrapyramidal", "side", "effects", "."]], "ner": [[[4, 4, "Chemical"], [14, 14, "Chemical"], [38, 38, "Chemical"], [73, 73, "Chemical"], [110, 110, "Chemical"], [125, 125, "Chemical"], [155, 155, "Chemical"], [167, 167, "Chemical"], [203, 203, "Chemical"], [157, 160, "Disease"], [6, 6, "Chemical"], [117, 117, "Chemical"], [127, 127, "Chemical"], [153, 153, "Chemical"], [173, 173, "Chemical"], [48, 49, "Disease"], [23, 23, "Chemical"], [26, 29, "Chemical"]]], "relations": [[[4, 4, 157, 160, "CID"], [14, 14, 157, 160, "CID"], [38, 38, 157, 160, "CID"], [73, 73, 157, 160, "CID"], [110, 110, 157, 160, "CID"], [125, 125, 157, 160, "CID"], [155, 155, 157, 160, "CID"], [167, 167, 157, 160, "CID"], [203, 203, 157, 160, "CID"], [6, 6, 157, 160, "CID"], [117, 117, 157, 160, "CID"], [127, 127, 157, 160, "CID"], [153, 153, 157, 160, "CID"], [173, 173, 157, 160, "CID"]]], "clusters": [], "translated": "<0>利培酮</0> 和 <10>氟哌啶醇</10> 在相当的 D2 受体占据水平下的锥体外系副作用。 <1>利培酮</1>是一种抗精神病药，对<16>多巴胺</16> D2 和 <17>5-羟色胺 5-HT2</17> 受体具有高亲和力。先前的临床研究表明，<2>利培酮</2> 的药理学特性可能会改善阴性<15>精神病症状</15>的疗效，并降低锥体外系副作用的倾向；所谓的“非典型”抗精神病药共有的特征。为确定常规<3>利培酮</3>治疗是否与独特的 D2 受体占有率和临床效果模式相关，我们使用[123I]IBZM SPECT 确定接受常规临床剂量<4>利培酮</4> (n = 12) 或<11>氟哌啶醇</11> (n = 7) 的受试者的 D2 占有率。 <5>利培酮</5>和<12>氟哌啶醇</12>在标准临床剂量下产生的 D2 占有率大约在 60% 到 90% 之间。<13>氟哌啶醇</13>或<6>利培酮</6>获得的占用率之间没有显着差异。<9>药物诱发的帕金森症</9>在接受<7>利培酮</7>（42%）和<14>氟哌啶醇</14>（29%）治疗的受试者中观察到，并且在 60% 以上的占用水平下观察到。基于这些观察结果，可以得出结论，在 D2 占用率为 60% 及以上时，<8>利培酮</8>获得的5-HT2 阻断似乎无法预防锥体外系副作用的风险。", "revised": true}
{"doc_key": "21029050", "sentences": [["Butyrylcholinesterase", "gene", "mutations", "in", "patients", "with", "prolonged", "apnea", "after", "succinylcholine", "for", "electroconvulsive", "therapy", ".", "BACKGROUND", ":", "patients", "undergoing", "electroconvulsive", "therapy", "(", "ECT", ")", "often", "receive", "succinylcholine", "as", "part", "of", "the", "anesthetic", "procedure", ".", "The", "duration", "of", "action", "may", "be", "prolonged", "in", "patients", "with", "genetic", "variants", "of", "the", "butyrylcholinesterase", "enzyme", "(", "BChE", ")", ",", "the", "most", "common", "being", "the", "K", "-", "and", "the", "A", "-", "variants", ".", "The", "aim", "of", "the", "study", "was", "to", "assess", "the", "clinical", "significance", "of", "genetic", "variants", "in", "butyrylcholinesterase", "gene", "(", "BCHE", ")", "in", "patients", "with", "a", "suspected", "prolonged", "duration", "of", "action", "of", "succinylcholine", "after", "ECT", ".", "METHODS", ":", "a", "total", "of", "13", "patients", "were", "referred", "to", "the", "Danish", "Cholinesterase", "Research", "Unit", "after", "ECT", "during", "38", "months", ".", "We", "determined", "the", "BChE", "activity", "and", "the", "BCHE", "genotype", "using", "molecular", "genetic", "methods", ",", "the", "duration", "of", "apnea", ",", "time", "to", "sufficient", "spontaneous", "ventilation", "and", "whether", "neuromuscular", "monitoring", "was", "used", ".", "The", "duration", "of", "apnea", "was", "compared", "with", "published", "data", "on", "normal", "subjects", ".", "RESULTS", ":", "in", "11", "patients", ",", "mutations", "were", "found", "in", "the", "BCHE", "gene", ",", "the", "K", "-", "variant", "being", "the", "most", "frequent", ".", "The", "duration", "of", "apnea", "was", "5", "-", "15", "min", "compared", "with", "3", "-", "5", ".", "3", "min", "from", "the", "literature", ".", "Severe", "distress", "was", "noted", "in", "the", "recovery", "phase", "in", "two", "patients", ".", "Neuromuscular", "monitoring", "was", "used", "in", "two", "patients", ".", "CONCLUSION", ":", "eleven", "of", "13", "patients", "with", "a", "prolonged", "duration", "of", "action", "of", "succinylcholine", "had", "mutations", "in", "BCHE", ",", "indicating", "that", "this", "is", "the", "possible", "reason", "for", "a", "prolonged", "period", "of", "apnea", ".", "We", "recommend", "objective", "neuromuscular", "monitoring", "during", "the", "first", "ECT", "."]], "ner": [[[9, 9, "Chemical"], [25, 25, "Chemical"], [96, 96, "Chemical"], [242, 242, "Chemical"], [7, 7, "Disease"], [138, 138, "Disease"], [155, 155, "Disease"], [191, 191, "Disease"], [260, 260, "Disease"]]], "relations": [[[9, 9, 7, 7, "CID"], [9, 9, 138, 138, "CID"], [9, 9, 155, 155, "CID"], [9, 9, 191, 191, "CID"], [9, 9, 260, 260, "CID"], [25, 25, 7, 7, "CID"], [25, 25, 138, 138, "CID"], [25, 25, 155, 155, "CID"], [25, 25, 191, 191, "CID"], [25, 25, 260, 260, "CID"], [96, 96, 7, 7, "CID"], [96, 96, 138, 138, "CID"], [96, 96, 155, 155, "CID"], [96, 96, 191, 191, "CID"], [96, 96, 260, 260, "CID"], [242, 242, 7, 7, "CID"], [242, 242, 138, 138, "CID"], [242, 242, 155, 155, "CID"], [242, 242, 191, 191, "CID"], [242, 242, 260, 260, "CID"]]], "clusters": [], "translated": "<0>琥珀酰胆碱</0>电休克治疗后长期<4>呼吸暂停</4>患者的丁酰胆碱酯酶基因突变。背景：接受电休克疗法 (ECT) 的患者通常会接受<1>琥珀酰胆碱</1>作为麻醉程序的一部分。具有丁酰胆碱酯酶 (BChE) 遗传变异的患者的作用持续时间可能会延长，最常见的是 K 和 A 变异。该研究的目的是评估丁酰胆碱酯酶基因 (BCHE) 基因变异在疑似 ECT 后<2>琥珀酰胆碱</2>作用持续时间延长的患者中的临床意义。方法：在 38 个月内，共有 13 名患者在 ECT 后转诊至丹麦胆碱酯酶研究中心。我们使用分子遗传学方法确定了 BChE 活性和 BCHE 基因型、<5>呼吸暂停</5>的持续时间、充分自主通气的时间以及是否使用了神经肌肉监测。<6>呼吸暂停</6>的持续时间与已发表的正常受试者数据进行了比较。结果：11例患者 BCHE基因发生突变，以 K-变异最为常见。<7>呼吸暂停</7>的持续时间为 5-15 分钟，而文献中为 3-5.3 分钟。两名患者在恢复阶段出现严重痛苦。两名患者进行了神经肌肉监测。结论：13例<3>琥珀酰胆碱</3>作用时间延长的患者中有 11 例 BCHE 发生突变，这可能是<8>呼吸暂停</8>时间延长的原因。我们建议在第一次 ECT 期间进行客观的神经肌肉监测。", "revised": true}
{"doc_key": "18560792", "sentences": [["Valvular", "heart", "disease", "in", "patients", "with", "Parkinson", "'s", "disease", "treated", "with", "pergolide", ".", "Course", "following", "treatment", "modifications", ".", "Valvular", "heart", "abnormalities", "have", "been", "reported", "in", "patients", "with", "Parkinson", "'s", "disease", "(", "PD", ")", "treated", "with", "pergolide", ".", "However", ",", "the", "incidence", "and", "severity", "of", "these", "abnormalities", "vary", "from", "study", "to", "study", "and", "their", "course", "after", "drug", "withdrawal", "has", "not", "been", "systematically", "assessed", ".", "OBJECTIVES", ":", "To", "estimate", "the", "frequency", "and", "severity", "of", "valvular", "heart", "abnormality", "and", "its", "possible", "reversibility", "after", "drug", "withdrawal", "in", "a", "case", "-", "control", "study", ".", "METHODS", ":", "All", "PD", "patients", "in", "the", "Amiens", "area", "treated", "with", "pergolide", "were", "invited", "to", "attend", "a", "cardiologic", "assessment", "including", "transthoracic", "echocardiography", ".", "Thirty", "PD", "patients", "participated", "in", "the", "study", ".", "A", "second", "echocardiography", "was", "performed", "(", "median", "interval", ":", "13", "months", ")", "after", "pergolide", "withdrawal", "(", "n", "=", "10", "patients", ")", ".", "Controls", "were", "age", "-", "and", "sex", "-", "matched", "non", "-", "PD", "patients", "referred", "to", "the", "cardiology", "department", ".", "RESULTS", ":", "Compared", "to", "controls", ",", "aortic", "regurgitation", "(", "OR", ":", "3", ".", "1", ";", "95", "%", "IC", ":", "1", ".", "1", "-", "8", ".", "8", ")", "and", "mitral", "regurgitation", "(", "OR", ":", "10", ".", "7", ";", "95", "%", "IC", ":", "2", ".", "1", "-", "53", ")", "were", "more", "frequent", "in", "PD", "patients", "(", "tricuspid", ":", "NS", ")", ".", "The", "number", "of", "affected", "valves", "(", "n", "=", "2", ".", "4", "+", "/", "-", "0", ".", "7", ")", "and", "the", "sum", "of", "regurgitation", "grades", "(", "n", "=", "2", ".", "8", "+", "/", "-", "1", ".", "09", ")", "were", "higher", "(", "p", "=", "0", ".", "008", "and", "p", "=", "0", ".", "006", ",", "respectively", ")", "in", "the", "pergolide", "group", ".", "Severity", "of", "regurgitation", "was", "not", "correlated", "with", "pergolide", "cumulative", "dose", ".", "A", "restrictive", "pattern", "of", "valvular", "regurgitation", ",", "suggestive", "of", "the", "role", "of", "pergolide", ",", "was", "observed", "in", "12", "/", "30", "(", "40", "%", ")", "patients", "including", "two", "with", "heart", "failure", ".", "Pergolide", "was", "discontinued", "in", "10", "patients", "with", "valvular", "heart", "disease", ",", "resulting", "in", "a", "lower", "regurgitation", "grade", "(", "p", "=", "0", ".", "01", ")", "at", "the", "second", "transthoracic", "echocardiography", "and", "the", "two", "patients", "with", "heart", "failure", "returned", "to", "nearly", "normal", "clinical", "examination", ".", "This", "study", "supports", "the", "high", "frequency", "of", "restrictive", "valve", "regurgitation", "in", "PD", "patients", "treated", "with", "pergolide", "and", "reveals", "that", "a", "significant", "improvement", "is", "usual", "when", "the", "treatment", "is", "converted", "to", "non", "-", "ergot", "dopamine", "agonists", "."]], "ner": [[[11, 11, "Chemical"], [35, 35, "Chemical"], [100, 100, "Chemical"], [133, 133, "Chemical"], [275, 275, "Chemical"], [285, 285, "Chemical"], [301, 301, "Chemical"], [320, 320, "Chemical"], [378, 378, "Chemical"], [166, 167, "Disease"], [188, 189, "Disease"], [0, 2, "Disease"], [18, 20, "Disease"], [72, 74, "Disease"], [293, 294, "Disease"], [327, 329, "Disease"], [371, 372, "Disease"], [396, 396, "Chemical"], [6, 8, "Disease"], [27, 29, "Disease"], [31, 31, "Disease"], [92, 92, "Disease"], [113, 113, "Disease"], [152, 152, "Disease"], [211, 211, "Disease"], [374, 374, "Disease"], [317, 318, "Disease"], [354, 355, "Disease"]]], "relations": [[[11, 11, 166, 167, "CID"], [35, 35, 166, 167, "CID"], [100, 100, 166, 167, "CID"], [133, 133, 166, 167, "CID"], [275, 275, 166, 167, "CID"], [285, 285, 166, 167, "CID"], [301, 301, 166, 167, "CID"], [320, 320, 166, 167, "CID"], [378, 378, 166, 167, "CID"], [11, 11, 188, 189, "CID"], [35, 35, 188, 189, "CID"], [100, 100, 188, 189, "CID"], [133, 133, 188, 189, "CID"], [275, 275, 188, 189, "CID"], [285, 285, 188, 189, "CID"], [301, 301, 188, 189, "CID"], [320, 320, 188, 189, "CID"], [378, 378, 188, 189, "CID"]]], "clusters": [], "translated": "<11>心脏瓣膜病</11>在<18>帕金森病</18>患者接受<0>培高利特</0>治疗时曾发生过。治疗进行修改后的病程。 已有报道指出，接受<1>培高利特</1>治疗的<19>帕金森病</19>（<20>PD</20>）患者中存在<12>心脏瓣膜异常</12>。然而，这些异常的发生率和严重程度因研究而异，而且它们在停药后的病程尚未得到系统评估。目的：通过病例对照研究评估<13>瓣膜性心脏异常</13>的发生频率和严重程度及其在停药后可能的可逆性。方法：亚眠地区接受<2>培高利特</2>治疗的所有<21>PD</21>患者都被邀请参加包括经胸超声心动图在内的心脏病学评估。三十名<22>PD</22>患者参与了这项研究。第二次超声心动图检查（中位时间间隔：13个月）于<3>培高利特</3>停药后进行（n = 10名患者）。对照组是年龄和性别匹配的非<23>PD</23>患者，由心脏病科转诊。结果：与对照组相比，在<24>PD</24>患者中，<9>主动脉反流</9>（OR：3.1；95% AI：1.2-8.8）和<10>二尖瓣反流</10>（OR：10.7；95% AI：2.1-53）较为常见（三尖瓣：无差异）。<4>培高利特</4>组中受影响的瓣膜数量（n = 2.4+/-0.7）和反流等级总和（n = 2.8+/-1.09）较高（分别为 p = 0.008 和 p = 0.006）。反流的严重程度与<5>培高利特</5>累积剂量无关。在 12/30（40％）的患者中，观察到<14> 瓣膜反流 </14>的限制性模式，提示<6>培高利特</6>的作用，其中包括两名<26>心力衰竭</26>患者。在10名<15>瓣膜性心脏病</15>患者中停用<7>培高利特</7>，导致在第二次经胸超声心动图检查时反流等级降低（p = 0.01），并且两名<27>心力衰竭</27>患者恢复到接近正常的临床检查。该研究支持<8>培高利特</8>治疗的<25>PD</25>患者中限制性<16>瓣膜反流</16>的高频率，并表明当治疗转换为非麦角<17>多巴胺</17>激动剂时通常会有显着改善。", "revised": true}
{"doc_key": "17608141", "sentences": [["Attenuation", "of", "methamphetamine", "-", "induced", "nigrostriatal", "dopaminergic", "neurotoxicity", "in", "mice", "by", "lipopolysaccharide", "pretreatment", ".", "Immunological", "activation", "has", "been", "proposed", "to", "play", "a", "role", "in", "methamphetamine", "-", "induced", "dopaminergic", "terminal", "damage", ".", "In", "this", "study", ",", "we", "examined", "the", "roles", "of", "lipopolysaccharide", ",", "a", "pro", "-", "inflammatory", "and", "inflammatory", "factor", ",", "treatment", "in", "modulating", "the", "methamphetamine", "-", "induced", "nigrostriatal", "dopamine", "neurotoxicity", ".", "Lipopolysaccharide", "pretreatment", "did", "not", "affect", "the", "basal", "body", "temperature", "or", "methamphetamine", "-", "elicited", "hyperthermia", "three", "days", "later", ".", "Such", "systemic", "lipopolysaccharide", "treatment", "mitigated", "methamphetamine", "-", "induced", "striatal", "dopamine", "and", "3", ",", "4", "-", "dihydroxyphenylacetic", "acid", "depletions", "in", "a", "dose", "-", "dependent", "manner", ".", "As", "the", "most", "potent", "dose", "(", "1", "mg", "/", "kg", ")", "of", "lipopolysaccharide", "was", "administered", "two", "weeks", ",", "one", "day", "before", "or", "after", "the", "methamphetamine", "dosing", "regimen", ",", "methamphetamine", "-", "induced", "striatal", "dopamine", "and", "3", ",", "4", "-", "dihydroxyphenylacetic", "acid", "depletions", "remained", "unaltered", ".", "Moreover", ",", "systemic", "lipopolysaccharide", "pretreatment", "(", "1", "mg", "/", "kg", ")", "attenuated", "local", "methamphetamine", "infusion", "-", "produced", "dopamine", "and", "3", ",", "4", "-", "dihydroxyphenylacetic", "acid", "depletions", "in", "the", "striatum", ",", "indicating", "that", "the", "protective", "effect", "of", "lipopolysaccharide", "is", "less", "likely", "due", "to", "interrupted", "peripheral", "distribution", "or", "metabolism", "of", "methamphetamine", ".", "We", "concluded", "a", "critical", "time", "window", "for", "systemic", "lipopolysaccharide", "pretreatment", "in", "exerting", "effective", "protection", "against", "methamphetamine", "-", "induced", "nigrostriatal", "dopamine", "neurotoxicity", "."]], "ner": [[[2, 2, "Chemical"], [24, 24, "Chemical"], [54, 54, "Chemical"], [71, 71, "Chemical"], [84, 84, "Chemical"], [128, 128, "Chemical"], [132, 132, "Chemical"], [161, 161, "Chemical"], [196, 196, "Chemical"], [213, 213, "Chemical"], [74, 74, "Disease"], [7, 7, "Disease"], [59, 59, "Disease"], [218, 218, "Disease"], [27, 29, "Disease"], [11, 11, "Chemical"], [40, 40, "Chemical"], [61, 61, "Chemical"], [81, 81, "Chemical"], [116, 116, "Chemical"], [151, 151, "Chemical"], [184, 184, "Chemical"], [206, 206, "Chemical"], [58, 58, "Chemical"], [88, 88, "Chemical"], [136, 136, "Chemical"], [165, 165, "Chemical"], [217, 217, "Chemical"], [90, 95, "Chemical"], [138, 143, "Chemical"], [167, 172, "Chemical"]]], "relations": [[[2, 2, 74, 74, "CID"], [24, 24, 74, 74, "CID"], [54, 54, 74, 74, "CID"], [71, 71, 74, 74, "CID"], [84, 84, 74, 74, "CID"], [128, 128, 74, 74, "CID"], [132, 132, 74, 74, "CID"], [161, 161, 74, 74, "CID"], [196, 196, 74, 74, "CID"], [213, 213, 74, 74, "CID"]]], "clusters": [], "translated": "通过<15>脂多糖</15>预处理减轻<0>甲基苯丙胺</0> - 诱导的小鼠黑质纹状体多巴胺能<11>神经毒性</11>。已提出免疫激活在<1>甲基苯丙胺</1> - 诱导的<14>多巴胺能终末损伤</14>中发挥作用。在这项研究中，我们检查了<16>脂多糖</16>（一种促炎和炎症因子）在调节<2>甲基苯丙胺</2> - 诱导的黑质纹状体<23>多巴胺</23><12>神经毒性</12>的作用。 <17>脂多糖</17>预处理不影响三天后的基础体温或<3>甲基苯丙胺</3>引起的<10>体温过高</10>。这种全身性<18>脂多糖</18>治疗以剂量依赖方式减缓了<4>甲基苯丙胺</4> - 诱导的纹状体<24>多巴胺</24>和<28>3, 4-二羟基苯乙酸</28>消耗。由于在<5>甲基苯丙胺</5>给药方案之前或之后的两周给予剂量最大的<19>脂多糖</19>（1 mg/kg），<6>甲基苯丙胺</6> - 诱导的的纹状体<25>多巴胺</25>和<29>3, 4-二羟基苯乙酸</29>消耗保持不变。此外，全身性<20>脂多糖</20>预处理（1 mg/kg）减轻了局部<7>甲基苯丙胺</7>输入 - 产生的<26>多巴胺</26>和<30>3, 4-二羟基苯乙酸</30>纹状体消耗，表明<21>脂多糖</21>的保护作用不太可能是由于<8>甲基苯丙胺</8>的外周分布或代谢中断所致。我们总结了全身性<22>脂多糖</22>预处理对<9>甲基苯丙胺</9> - 诱导的黑质纹状体<27>多巴胺</27> <13>神经毒性</13>发挥有效保护作用的关键时间窗。", "revised": true}
{"doc_key": "18754075", "sentences": [["Massive", "proteinuria", "and", "acute", "renal", "failure", "after", "oral", "bisphosphonate", "(", "alendronate", ")", "administration", "in", "a", "patient", "with", "focal", "segmental", "glomerulosclerosis", ".", "A", "61", "-", "year", "-", "old", "Japanese", "man", "with", "nephrotic", "syndrome", "due", "to", "focal", "segmental", "glomerulosclerosis", "was", "initially", "responding", "well", "to", "steroid", "therapy", ".", "The", "amount", "of", "daily", "urinary", "protein", "decreased", "from", "15", ".", "6", "to", "2", ".", "8", "g", ".", "Within", "14", "days", "of", "the", "oral", "bisphosphonate", "(", "alendronate", "sodium", ")", "administration", ",", "the", "amount", "of", "daily", "urinary", "protein", "increased", "rapidly", "up", "to", "12", ".", "8", "g", "with", "acute", "renal", "failure", ".", "After", "discontinuing", "the", "oral", "alendronate", ",", "the", "patient", "underwent", "six", "cycles", "of", "hemodialysis", "and", "four", "cycles", "of", "LDL", "apheresis", ".", "Urinary", "volume", "and", "serum", "creatinine", "levels", "recovered", "to", "the", "normal", "range", ",", "with", "urinary", "protein", "disappearing", "completely", "within", "40", "days", ".", "This", "report", "demonstrates", "that", "not", "only", "intravenous", ",", "but", "also", "oral", "bisphosphonates", "can", "aggravate", "proteinuria", "and", "acute", "renal", "failure", "."]], "ner": [[[10, 10, "Chemical"], [70, 71, "Chemical"], [98, 98, "Chemical"], [1, 1, "Disease"], [149, 149, "Disease"], [3, 5, "Disease"], [90, 92, "Disease"], [151, 153, "Disease"], [8, 8, "Chemical"], [68, 68, "Chemical"], [146, 146, "Chemical"], [42, 42, "Chemical"], [118, 118, "Chemical"], [17, 19, "Disease"], [34, 36, "Disease"], [30, 31, "Disease"]]], "relations": [[[10, 10, 1, 1, "CID"], [10, 10, 149, 149, "CID"], [70, 71, 1, 1, "CID"], [70, 71, 149, 149, "CID"], [98, 98, 1, 1, "CID"], [98, 98, 149, 149, "CID"], [10, 10, 3, 5, "CID"], [10, 10, 90, 92, "CID"], [10, 10, 151, 153, "CID"], [70, 71, 3, 5, "CID"], [70, 71, 90, 92, "CID"], [70, 71, 151, 153, "CID"], [98, 98, 3, 5, "CID"], [98, 98, 90, 92, "CID"], [98, 98, 151, 153, "CID"]]], "clusters": [], "translated": "<13>局灶性节段性肾小球硬化</13>患者口服<8>双膦酸盐</8>（<0>阿仑膦酸盐</0>）后大量<3>蛋白尿</3>和<5>急性肾功能衰竭</5>。一名61岁的日本男性因<14>局灶性节段性肾小球硬化</14>而患有<15>肾病综合征</15>，最初对<11>类固醇</11>治疗反应良好。每日尿蛋白量从15.6比2.8克。口服<9>阿仑膦酸钠</9>（<1>双膦酸盐</1>）后14天内，每日尿蛋白量迅速增加至12.8克，伴有<6>急性肾功能衰竭</6>。停止口服<2>阿仑膦酸盐</2>后，患者接受了六个周期的血液透析和四个周期的低密度脂蛋白单采术。尿量和血清<12>肌酐</12>水平恢复到正常范围，尿蛋白在40天内完全消失。该报告表明，不仅静脉注射，而且口服<10>双膦酸盐</10>都可加重<4>蛋白尿</4>和<7>急性肾功能衰竭</7>。", "revised": true}
{"doc_key": "1147734", "sentences": [["Liver", "disease", "caused", "by", "propylthiouracil", ".", "This", "report", "presents", "the", "clinical", ",", "laboratory", ",", "and", "light", "and", "electron", "microscopic", "observations", "on", "a", "patient", "with", "chronic", "active", "(", "aggressive", ")", "hepatitis", "caused", "by", "the", "administration", "of", "propylthiouracil", ".", "This", "is", "an", "addition", "to", "the", "list", "of", "drugs", "that", "must", "be", "considered", "in", "the", "evaluation", "of", "chronic", "liver", "disease", "."]], "ner": [[[4, 4, "Chemical"], [35, 35, "Chemical"], [24, 29, "Disease"], [0, 1, "Disease"], [55, 56, "Disease"]]], "relations": [[[4, 4, 24, 29, "CID"], [35, 35, 24, 29, "CID"]]], "clusters": [], "translated": " <3>肝病</3>由<0>丙基硫氧嘧啶</0>引起。本报告介绍了一名因<1>丙基硫氧嘧啶</1>引起的<2>慢性活动性（侵袭性）肝炎</2>患者的临床、实验室、光学和电子显微镜观察结果。这是在评估慢性<4>肝病</4>时必须考虑的药物清单的补充。", "revised": true}
{"doc_key": "17439425", "sentences": [["Role", "of", "xanthine", "oxidase", "in", "dexamethasone", "-", "induced", "hypertension", "in", "rats", ".", "1", ".", "Glucocorticoid", "-", "induced", "hypertension", "(", "GC", "-", "HT", ")", "in", "the", "rat", "is", "associated", "with", "nitric", "oxide", "-", "redox", "imbalance", ".", "2", ".", "We", "studied", "the", "role", "of", "xanthine", "oxidase", "(", "XO", ")", ",", "which", "is", "implicated", "in", "the", "production", "of", "reactive", "oxygen", "species", ",", "in", "dexamethasone", "-", "induced", "hypertension", "(", "dex", "-", "HT", ")", ".", "3", ".", "Thirty", "male", "Sprague", "-", "Dawley", "rats", "were", "divided", "randomly", "into", "four", "treatment", "groups", ":", "saline", ",", "dexamethasone", "(", "dex", ")", ",", "allopurinol", "plus", "saline", ",", "and", "allopurinol", "plus", "dex", ".", "4", ".", "Systolic", "blood", "pressures", "(", "SBP", ")", "and", "bodyweights", "were", "recorded", "each", "alternate", "day", ".", "Thymus", "weight", "was", "used", "as", "a", "marker", "of", "glucocorticoid", "activity", ",", "and", "serum", "urate", "to", "assess", "XO", "inhibition", ".", "5", ".", "Dex", "increased", "SBP", "(", "110", "+", "/", "-", "2", "-", "126", "+", "/", "-", "3", "mmHg", ";", "P", "<", "0", ".", "001", ")", "and", "decreased", "thymus", "(", "P", "<", "0", ".", "001", ")", "and", "bodyweights", "(", "P", "\"", "<", "0", ".", "01", ")", ".", "Allopurinol", "decreased", "serum", "urate", "from", "76", "+", "/", "-", "5", "to", "30", "+", "/", "-", "3", "micromol", "/", "L", "(", "P", "<", "0", ".", "001", ")", "in", "saline", "and", "from", "84", "+", "/", "-", "13", "to", "28", "+", "/", "-", "2", "micromol", "/", "L", "in", "dex", "-", "treated", "(", "P", "<", "0", ".", "01", ")", "groups", ".", "6", ".", "Allopurinol", "did", "not", "prevent", "dex", "-", "HT", ".", "This", ",", "together", "with", "our", "previous", "findings", "that", "allopurinol", "failed", "to", "prevent", "adrenocorticotrophic", "hormone", "induced", "hypertension", ",", "suggests", "that", "XO", "activity", "is", "not", "a", "major", "determinant", "of", "GC", "-", "HT", "in", "the", "rat", "."]], "ner": [[[5, 5, "Chemical"], [60, 60, "Chemical"], [65, 65, "Chemical"], [88, 88, "Chemical"], [90, 90, "Chemical"], [100, 100, "Chemical"], [139, 139, "Chemical"], [228, 228, "Chemical"], [246, 246, "Chemical"], [8, 8, "Disease"], [17, 17, "Disease"], [21, 21, "Disease"], [63, 63, "Disease"], [67, 67, "Disease"], [140, 141, "Disease"], [248, 248, "Disease"], [265, 265, "Disease"], [279, 279, "Disease"], [163, 173, "Disease"], [2, 2, "Chemical"], [42, 42, "Chemical"], [29, 30, "Chemical"], [93, 93, "Chemical"], [98, 98, "Chemical"], [183, 183, "Chemical"], [242, 242, "Chemical"], [258, 258, "Chemical"], [131, 131, "Chemical"], [186, 186, "Chemical"]]], "relations": [[[5, 5, 8, 8, "CID"], [5, 5, 17, 17, "CID"], [5, 5, 21, 21, "CID"], [5, 5, 63, 63, "CID"], [5, 5, 67, 67, "CID"], [5, 5, 140, 141, "CID"], [5, 5, 248, 248, "CID"], [5, 5, 265, 265, "CID"], [5, 5, 279, 279, "CID"], [60, 60, 8, 8, "CID"], [60, 60, 17, 17, "CID"], [60, 60, 21, 21, "CID"], [60, 60, 63, 63, "CID"], [60, 60, 67, 67, "CID"], [60, 60, 140, 141, "CID"], [60, 60, 248, 248, "CID"], [60, 60, 265, 265, "CID"], [60, 60, 279, 279, "CID"], [65, 65, 8, 8, "CID"], [65, 65, 17, 17, "CID"], [65, 65, 21, 21, "CID"], [65, 65, 63, 63, "CID"], [65, 65, 67, 67, "CID"], [65, 65, 140, 141, "CID"], [65, 65, 248, 248, "CID"], [65, 65, 265, 265, "CID"], [65, 65, 279, 279, "CID"], [88, 88, 8, 8, "CID"], [88, 88, 17, 17, "CID"], [88, 88, 21, 21, "CID"], [88, 88, 63, 63, "CID"], [88, 88, 67, 67, "CID"], [88, 88, 140, 141, "CID"], [88, 88, 248, 248, "CID"], [88, 88, 265, 265, "CID"], [88, 88, 279, 279, "CID"], [90, 90, 8, 8, "CID"], [90, 90, 17, 17, "CID"], [90, 90, 21, 21, "CID"], [90, 90, 63, 63, "CID"], [90, 90, 67, 67, "CID"], [90, 90, 140, 141, "CID"], [90, 90, 248, 248, "CID"], [90, 90, 265, 265, "CID"], [90, 90, 279, 279, "CID"], [100, 100, 8, 8, "CID"], [100, 100, 17, 17, "CID"], [100, 100, 21, 21, "CID"], [100, 100, 63, 63, "CID"], [100, 100, 67, 67, "CID"], [100, 100, 140, 141, "CID"], [100, 100, 248, 248, "CID"], [100, 100, 265, 265, "CID"], [100, 100, 279, 279, "CID"], [139, 139, 8, 8, "CID"], [139, 139, 17, 17, "CID"], [139, 139, 21, 21, "CID"], [139, 139, 63, 63, "CID"], [139, 139, 67, 67, "CID"], [139, 139, 140, 141, "CID"], [139, 139, 248, 248, "CID"], [139, 139, 265, 265, "CID"], [139, 139, 279, 279, "CID"], [228, 228, 8, 8, "CID"], [228, 228, 17, 17, "CID"], [228, 228, 21, 21, "CID"], [228, 228, 63, 63, "CID"], [228, 228, 67, 67, "CID"], [228, 228, 140, 141, "CID"], [228, 228, 248, 248, "CID"], [228, 228, 265, 265, "CID"], [228, 228, 279, 279, "CID"], [246, 246, 8, 8, "CID"], [246, 246, 17, 17, "CID"], [246, 246, 21, 21, "CID"], [246, 246, 63, 63, "CID"], [246, 246, 67, 67, "CID"], [246, 246, 140, 141, "CID"], [246, 246, 248, 248, "CID"], [246, 246, 265, 265, "CID"], [246, 246, 279, 279, "CID"], [5, 5, 163, 173, "CID"], [60, 60, 163, 173, "CID"], [65, 65, 163, 173, "CID"], [88, 88, 163, 173, "CID"], [90, 90, 163, 173, "CID"], [100, 100, 163, 173, "CID"], [139, 139, 163, 173, "CID"], [228, 228, 163, 173, "CID"], [246, 246, 163, 173, "CID"]]], "clusters": [], "translated": "<19>黄嘌呤</19>氧化酶在<0>地塞米松</0>诱导大鼠<9>高血压</9>中的作用。1.大鼠糖皮质激素引起的<10>高血压</10>（GC-<11>HT</11>）与<21>一氧化氮</21>-氧化还原失衡有关。2.我们研究了<20>黄嘌呤</20>氧化酶(XO)的作用，它与活性氧的产生有关，在<1>地塞米松</1>诱导的<12>高血压</12>（<2>dex</2>-<13>HT</13>）。3.将30只雄性Sprague-Dawley大鼠随机分为四个治疗组：生理盐水、<3>地塞米松</3>(<4>dex</4>)、<22>别嘌醇</22>加生理盐水和<23>别嘌醇</23>加上<5>dex</5>。4.每隔一天记录一次收缩压（SBP）和体重。胸腺重量被用作糖皮质激素活性的标志，血清<27>尿酸</27>用来评估XO抑制。5.<6>dex</6><14>增加SBP</14>(110+/-2-126+/-3mmHg;P<0.001)和<18>减少胸腺(P<0.001)和体重</18>(P\"<0.01)。<24>别嘌醇</24>降低血清<28>尿酸</28>从76+/-5到30+/-3微摩尔/升(P<0.001)在盐水中和从84+/-13到28+/-2微摩尔/升<7>dex</7>-处理(P<0.01)组。6.<25>别嘌醇</25>没有预防<8>dex</8>-<15>HT</15>。这与我们之前的发现<26>别嘌醇</26>未能预防促肾上腺皮质激素引起的<16>高血压</16>，提示XO活性不是大鼠GC-<17>HT</17>的主要决定因素。", "revised": true}
{"doc_key": "8231633", "sentences": [["Effects", "of", "calcium", "channel", "blockers", "on", "bupivacaine", "-", "induced", "toxicity", ".", "The", "purpose", "of", "this", "study", "was", "to", "investigate", "the", "influence", "of", "calcium", "channel", "blockers", "on", "bupivacaine", "-", "induced", "acute", "toxicity", ".", "For", "each", "of", "the", "three", "tested", "calcium", "channel", "blockers", "(", "diltiazem", ",", "verapamil", "and", "bepridil", ")", "6", "groups", "of", "mice", "were", "treated", "by", "two", "different", "doses", ",", "i", ".", "e", ".", "2", "and", "10", "mg", "/", "kg", "/", "i", ".", "p", ".", ",", "or", "an", "equal", "volume", "of", "saline", "for", "the", "control", "group", "(", "n", "=", "20", ")", ";", "15", "minutes", "later", ",", "all", "the", "animals", "were", "injected", "with", "a", "single", "50", "mg", "/", "kg", "/", "i", ".", "p", ".", "dose", "of", "bupivacaine", ".", "The", "convulsant", "activity", ",", "the", "time", "of", "latency", "to", "convulse", "and", "the", "mortality", "rate", "were", "assessed", "in", "each", "group", ".", "The", "local", "anesthetic", "-", "induced", "mortality", "was", "significantly", "increased", "by", "the", "three", "different", "calcium", "channel", "blockers", ".", "The", "convulsant", "activity", "of", "bupivacaine", "was", "not", "significantly", "modified", "but", "calcium", "channel", "blockers", "decreased", "the", "time", "of", "latency", "to", "obtain", "bupivacaine", "-", "induced", "convulsions", ";", "this", "effect", "was", "less", "pronounced", "with", "bepridil", "."]], "ner": [[[6, 6, "Chemical"], [26, 26, "Chemical"], [114, 114, "Chemical"], [157, 157, "Chemical"], [173, 173, "Chemical"], [176, 176, "Disease"], [2, 2, "Chemical"], [22, 22, "Chemical"], [38, 38, "Chemical"], [149, 149, "Chemical"], [163, 163, "Chemical"], [9, 9, "Disease"], [30, 30, "Disease"], [42, 42, "Chemical"], [44, 44, "Chemical"], [46, 46, "Chemical"], [184, 184, "Chemical"]]], "relations": [[[6, 6, 176, 176, "CID"], [26, 26, 176, 176, "CID"], [114, 114, 176, 176, "CID"], [157, 157, 176, 176, "CID"], [173, 173, 176, 176, "CID"]]], "clusters": [], "translated": "<6>钙</6>通道阻滞剂对<0>布比卡因</0>引起的<11>毒性</11>的影响。本研究的目的是研究<7>钙</7>通道阻滞剂对<1>布比卡因</1>诱导的急性<12>毒性</12>的影响。对于三种测试的<8>钙</8>通道阻滞剂（<13>地尔硫卓</13>、<14>维拉帕米</14>和<15>苄普地尔</15>）中的每一种，治疗了6组小鼠，通过两种不同的剂量，即 2 和 10 毫克/千克/i.p.，或等体积的生理盐水对照组（n=20）；15分钟后，所有动物注射单次 50 毫克/千克/i.p. 的<2>布比卡因</2>。评估每组的惊厥活性、惊厥潜伏时间和死亡率。三种不同的<9>钙</9>通道阻滞剂显着增加了局麻药引起的死亡率。<3>布比卡因</3>的惊厥活性并未显着改变，但<10>钙</10>通道阻滞剂减少了获得<4>布比卡因</4>诱导的<5>惊厥</5>；这种效果在<16>苄普地尔</16>中不太明显。", "revised": true}
{"doc_key": "20098969", "sentences": [["Oral", "manifestations", "of", "\"", "meth", "mouth", "\"", ":", "a", "case", "report", ".", "AIM", ":", "The", "aim", "of", "the", "documentation", "of", "this", "clinical", "case", "is", "to", "make", "clinicians", "aware", "of", "\"", "meth", "mouth", "\"", "and", "the", "medical", "risks", "associated", "with", "this", "serious", "condition", ".", "BACKGROUND", ":", "Methamphetamine", "is", "a", "very", "addictive", ",", "powerful", "stimulant", "that", "increases", "wakefulness", "and", "physical", "activity", "and", "can", "produce", "other", "effects", "such", "as", "cardiac", "dysrhythmias", ",", "hypertension", ",", "hallucinations", ",", "and", "violent", "behavior", ".", "Dental", "patients", "abusing", "methamphetamine", "can", "present", "with", "poor", "oral", "hygiene", ",", "xerostomia", ",", "rampant", "caries", "(", "\"", "meth", "mouth", "\"", ")", ",", "and", "excessive", "tooth", "wear", ".", "Oral", "rehabilitation", "of", "patients", "using", "methamphetamine", "can", "be", "challenging", ".", "CASE", "DESCRIPTION", ":", "A", "30", "-", "year", "-", "old", "Caucasian", "woman", "presented", "with", "dental", "pain", ",", "bad", "breath", ",", "and", "self", "-", "reported", "poor", "esthetics", ".", "A", "comprehensive", "examination", "including", "her", "medical", "history", ",", "panoramic", "radiograph", ",", "and", "intraoral", "examination", "revealed", "19", "carious", "lesions", ",", "which", "is", "not", "very", "common", "for", "a", "healthy", "adult", ".", "She", "reported", "her", "use", "of", "methamphetamine", "for", "five", "years", "and", "had", "not", "experienced", "any", "major", "carious", "episodes", "before", "she", "started", "using", "the", "drug", ".", "SUMMARY", ":", "The", "patient", "'s", "medical", "and", "dental", "histories", "along", "with", "radiographic", "and", "clinical", "findings", "lead", "to", "a", "diagnosis", "of", "\"", "meth", "mouth", ".", "\"", "Although", "three", "different", "dental", "treatment", "modalities", "(", "either", "conventional", "or", "implant", "-", "supported", ")", "have", "been", "offered", "to", "the", "patient", "since", "August", "2007", ",", "the", "patient", "has", "yet", "to", "initiate", "any", "treatment", ".", "CLINICAL", "SIGNIFICANCE", ":", "This", "clinical", "case", "showing", "oral", "manifestations", "of", "meth", "mouth", "was", "presented", "to", "help", "dental", "practitioners", "recognize", "and", "manage", "patients", "who", "may", "be", "abusing", "methamphetamines", ".", "Dental", "practitioners", "also", "may", "be", "skeptical", "about", "the", "reliability", "of", "appointment", "keeping", "by", "these", "patients", ",", "as", "they", "frequently", "miss", "their", "appointments", "without", "reasonable", "justification", "."]], "ner": [[[45, 45, "Chemical"], [80, 80, "Chemical"], [109, 109, "Chemical"], [174, 174, "Chemical"], [277, 277, "Chemical"], [91, 91, "Disease"], [156, 157, "Disease"], [184, 185, "Disease"], [66, 67, "Disease"], [69, 69, "Disease"], [71, 71, "Disease"], [74, 75, "Disease"], [88, 88, "Disease"], [101, 102, "Disease"], [128, 128, "Disease"], [130, 131, "Disease"]]], "relations": [[[45, 45, 91, 91, "CID"], [45, 45, 156, 157, "CID"], [45, 45, 184, 185, "CID"], [80, 80, 91, 91, "CID"], [80, 80, 156, 157, "CID"], [80, 80, 184, 185, "CID"], [109, 109, 91, 91, "CID"], [109, 109, 156, 157, "CID"], [109, 109, 184, 185, "CID"], [174, 174, 91, 91, "CID"], [174, 174, 156, 157, "CID"], [174, 174, 184, 185, "CID"], [277, 277, 91, 91, "CID"], [277, 277, 156, 157, "CID"], [277, 277, 184, 185, "CID"]]], "clusters": [], "translated": "”冰毒嘴“的口腔表现：病例报告。目的：记录此临床病例的目的是让临床医生了解”冰毒口“以及与这种严重情况相关的医疗风险。背景：<0>甲基苯丙胺</0>是一种非常容易上瘾的强效兴奋剂，可增加觉醒和身体活动，并可产生其他影响，例如<8>心律失常</8>、<9>高血压</9>、<10>幻觉</10>和<11>暴力行为</11>。滥用<1>甲基苯丙胺</1>的牙科患者可能会出现口腔卫生差、<12>口干</12>、猖獗的<5>龋齿</5>（“冰毒口”）和过度<13>牙齿磨损</13>。使用<2>甲基苯丙胺</2>的患者的口腔康复可能具有挑战性。病例描述：一名30岁的白人女性因牙科<14>疼痛</14>、<15>口臭</15>和自我报告的美观不良就诊。包括她的病史、全景X光片和口腔内检查在内的综合检查显示19个<6>龋齿病变</6>，这对于健康成年人来说并不常见。她报告说她使用了<3>甲基苯丙胺</3>五年，并且在她开始使用该药物之前没有经历过任何重大的<7>龋齿发作</7>。概要：根据患者的医疗和牙科病史以及放射照相和临床发现，诊断为\"冰毒口\"。尽管自2007年8月以来已经向患者提供了三种不同的牙科治疗方式（传统的或植入支持的），患者尚未开始任何治疗。临床意义：这个临床病例显示”冰毒口“口腔表现，旨在帮助牙科医生识别和管理可能滥用<4>甲基苯丙胺</4>的患者。牙医也可能对这些患者遵守预约的可靠性持怀疑态度，因为他们经常在没有合理理由的情况下错过预约。", "revised": true}
{"doc_key": "2559236", "sentences": [["Effect", "of", "converting", "enzyme", "inhibition", "on", "the", "course", "of", "adriamycin", "-", "induced", "nephropathy", ".", "The", "effect", "of", "the", "converting", "enzyme", "inhibitor", "(", "CEI", ")", "enalapril", "was", "assessed", "in", "Munich", "-", "Wistar", "rats", "with", "established", "adriamycin", "nephrosis", ".", "Rats", "were", "given", "a", "single", "dose", "of", "adriamycin", "and", "one", "month", "later", "divided", "into", "four", "groups", "matched", "for", "albuminuria", ",", "blood", "pressure", ",", "and", "plasma", "albumin", "concentration", ".", "Groups", "1", "and", "3", "remained", "untreated", "while", "groups", "2", "and", "4", "received", "enalapril", ".", "Groups", "1", "and", "2", "underwent", "micropuncture", "studies", "after", "10", "days", ".", "These", "short", "-", "term", "studies", "showed", "that", "enalapril", "reduced", "arterial", "blood", "pressure", "(", "101", "+", "/", "-", "2", "vs", ".", "124", "+", "/", "-", "3", "mm", "Hg", ",", "group", "2", "vs", ".", "1", ",", "P", "less", "than", "0", ".", "05", ")", "and", "glomerular", "capillary", "pressure", "(", "54", "+", "/", "-", "1", "vs", ".", "61", "+", "/", "-", "2", "mm", "Hg", ",", "P", "less", "than", "0", ".", "05", ")", "without", "reducing", "albuminuria", "(", "617", "+", "/", "-", "50", "vs", ".", "570", "+", "/", "-", "47", "mg", "/", "day", ")", "or", "GFR", "(", "1", ".", "03", "+", "/", "-", "0", ".", "04", "vs", ".", "1", ".", "04", "+", "/", "-", "0", ".", "11", "ml", "/", "min", ")", ".", "Groups", "3", "and", "4", "were", "studied", "at", "four", "and", "at", "six", "months", "to", "assess", "the", "effect", "of", "enalapril", "on", "progression", "of", "renal", "injury", "in", "adriamycin", "nephrosis", ".", "Chronic", "enalapril", "treatment", "reduced", "blood", "pressure", "without", "reducing", "albuminuria", "in", "group", "4", ".", "Untreated", "group", "3", "rats", "exhibited", "a", "progressive", "reduction", "in", "GFR", "(", "0", ".", "35", "+", "/", "-", "0", ".", "08", "ml", "/", "min", "at", "4", "months", ",", "0", ".", "27", "+", "/", "-", "0", ".", "07", "ml", "/", "min", "at", "6", "months", ")", ".", "Enalapril", "treatment", "blunted", "but", "did", "not", "prevent", "reduction", "in", "GFR", "in", "group", "4", "(", "0", ".", "86", "+", "/", "-", "0", ".", "15", "ml", "/", "min", "at", "4", "months", ",", "0", ".", "69", "+", "/", "-", "0", ".", "13", "ml", "/", "min", "at", "6", "months", ",", "both", "P", "less", "than", "0", ".", "05", "vs", ".", "group", "3", ")", ".", "Reduction", "in", "GFR", "was", "associated", "with", "the", "development", "of", "glomerular", "sclerosis", "in", "both", "treated", "and", "untreated", "rats", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[9, 9, "Chemical"], [34, 34, "Chemical"], [44, 44, "Chemical"], [230, 230, "Chemical"], [35, 35, "Disease"], [231, 231, "Disease"], [55, 55, "Disease"], [160, 160, "Disease"], [241, 241, "Disease"], [12, 12, "Disease"], [227, 228, "Disease"], [358, 359, "Disease"], [24, 24, "Chemical"], [77, 77, "Chemical"], [97, 97, "Chemical"], [223, 223, "Chemical"], [234, 234, "Chemical"], [290, 290, "Chemical"]]], "relations": [[[9, 9, 35, 35, "CID"], [9, 9, 231, 231, "CID"], [34, 34, 35, 35, "CID"], [34, 34, 231, 231, "CID"], [44, 44, 35, 35, "CID"], [44, 44, 231, 231, "CID"], [230, 230, 35, 35, "CID"], [230, 230, 231, 231, "CID"], [9, 9, 55, 55, "CID"], [9, 9, 160, 160, "CID"], [9, 9, 241, 241, "CID"], [34, 34, 55, 55, "CID"], [34, 34, 160, 160, "CID"], [34, 34, 241, 241, "CID"], [44, 44, 55, 55, "CID"], [44, 44, 160, 160, "CID"], [44, 44, 241, 241, "CID"], [230, 230, 55, 55, "CID"], [230, 230, 160, 160, "CID"], [230, 230, 241, 241, "CID"]]], "clusters": [], "translated": "抑制转化酶对<0>阿霉素</0>所致<9>肾病</9>病程的影响。转化酶抑制剂 (CEI) <12>依那普利</12>的作用在患有<1>阿霉素</1><4>肾病</4>的 Munich-Wistar 大鼠中进行了评估。给大鼠单剂量<2>阿霉素</2>，一个月后分为四组，根据<6>白蛋白尿</6>、血压和血浆白蛋白浓度进行匹配。第 1 组和第 3 组未接受治疗，而第 2 组和第 4 组接受了<13>依那普利</13>。第 1 组和第 2 组在 10 天后接受微穿刺研究。这些短期研究表明，<14>依那普利</14> 降低了动脉血压（101 +/- 2 vs. 124 +/- 3 mm Hg，组 2 vs. 组 1，P 小于 0.05）和肾小球毛细管压力（54 +/- 1 vs. 61 +/- 2 毫米汞柱，P 小于 0.05）并不降低<7>蛋白尿</7>（617 +/- 50 vs. 570 +/- 47 毫克/天）或 GFR（1.03 +/- 0.04 vs. 1.04 +/- 0.11 毫升/分钟）。\n\n第 3 组和第 4 组在第 4 个月和第 6 个月时进行研究，以评估<15>依那普利</15>对<3>阿霉素</3><5>肾病中的</5><10>肾损伤</10>进展的影响。慢性<16>依那普利</16>治疗降低了第 4 组的血压，但未减少<8>白蛋白尿</8>。未经治疗的第 3 组大鼠表现出 GFR 逐渐降低（4 个月时为0.35 +/- 0.08 毫升/分钟，6 个月时为0.27 +/- 0.07 毫升/分钟）。<17>依那普利</17>治疗减弱但并未阻止第 4 组 GFR 的降低（第 4 个月时为0.86 +/- 0.15 毫升/分钟，第 6 个月时为0.69 +/- 0.13 毫升/分钟，P 均小于 0.05 vs. 组 3）。在治疗和未治疗的大鼠中，GFR 的降低与<11>肾小球硬化</11>的发展有关。（摘要被截断为 250 个单词）", "revised": true}
{"doc_key": "19269743", "sentences": [["Explicit", "episodic", "memory", "for", "sensory", "-", "discriminative", "components", "of", "capsaicin", "-", "induced", "pain", ":", "immediate", "and", "delayed", "ratings", ".", "Pain", "memory", "is", "thought", "to", "affect", "future", "pain", "sensitivity", "and", "thus", "contribute", "to", "clinical", "pain", "conditions", ".", "Systematic", "investigations", "of", "the", "human", "capacity", "to", "remember", "sensory", "features", "of", "experimental", "pain", "are", "sparse", ".", "In", "order", "to", "address", "long", "-", "term", "pain", "memory", ",", "nine", "healthy", "male", "volunteers", "received", "intradermal", "injections", "of", "three", "doses", "of", "capsaicin", "(", "0", ".", "05", ",", "1", "and", "20", "microg", ",", "separated", "by", "15", "min", "breaks", ")", ",", "each", "given", "three", "times", "in", "a", "balanced", "design", "across", "three", "sessions", "at", "one", "week", "intervals", ".", "Pain", "rating", "was", "performed", "using", "a", "computerized", "visual", "analogue", "scale", "(", "0", "-", "100", ")", "digitized", "at", "1", "/", "s", ",", "either", "immediately", "online", "or", "one", "hour", "or", "one", "day", "after", "injection", ".", "Subjects", "also", "recalled", "their", "pains", "one", "week", "later", ".", "Capsaicin", "injection", "reliably", "induced", "a", "dose", "-", "dependent", "flare", "(", "p", "<", "0", ".", "001", ")", "without", "any", "difference", "within", "or", "across", "sessions", ".", "The", "strong", "burning", "pain", "decayed", "exponentially", "within", "a", "few", "minutes", ".", "Subjects", "were", "able", "to", "reliably", "discriminate", "pain", "magnitude", "and", "duration", "across", "capsaicin", "doses", "(", "both", "p", "<", "0", ".", "001", ")", ",", "regardless", "of", "whether", "first", "-", "time", "ratings", "were", "requested", "immediately", ",", "after", "one", "hour", "or", "after", "one", "day", ".", "Pain", "recall", "after", "one", "week", "was", "similarly", "precise", "(", "magnitude", ":", "p", "<", "0", ".", "01", ",", "duration", ":", "p", "<", "0", ".", "05", ")", ".", "Correlation", "with", "rating", "recall", "after", "one", "week", "was", "best", "when", "first", "-", "time", "ratings", "were", "requested", "as", "late", "as", "one", "day", "after", "injection", "(", "R", "(", "2", ")", "=", "0", ".", "79", ")", "indicating", "that", "both", "rating", "retrievals", "utilized", "similar", "memory", "traces", ".", "These", "results", "indicate", "a", "reliable", "memory", "for", "magnitude", "and", "duration", "of", "experimentally", "induced", "pain", ".", "The", "data", "further", "suggest", "that", "the", "consolidation", "of", "this", "memory", "is", "an", "important", "interim", "stage", ",", "and", "may", "take", "up", "to", "one", "day", "."]], "ner": [[[9, 9, "Chemical"], [73, 73, "Chemical"], [149, 149, "Chemical"], [195, 195, "Chemical"], [12, 12, "Disease"], [19, 19, "Disease"], [26, 26, "Disease"], [33, 33, "Disease"], [48, 48, "Disease"], [59, 59, "Disease"], [107, 107, "Disease"], [144, 144, "Disease"], [176, 176, "Disease"], [190, 190, "Disease"], [225, 225, "Disease"], [307, 307, "Disease"]]], "relations": [[[9, 9, 12, 12, "CID"], [9, 9, 19, 19, "CID"], [9, 9, 26, 26, "CID"], [9, 9, 33, 33, "CID"], [9, 9, 48, 48, "CID"], [9, 9, 59, 59, "CID"], [9, 9, 107, 107, "CID"], [9, 9, 144, 144, "CID"], [9, 9, 176, 176, "CID"], [9, 9, 190, 190, "CID"], [9, 9, 225, 225, "CID"], [9, 9, 307, 307, "CID"], [73, 73, 12, 12, "CID"], [73, 73, 19, 19, "CID"], [73, 73, 26, 26, "CID"], [73, 73, 33, 33, "CID"], [73, 73, 48, 48, "CID"], [73, 73, 59, 59, "CID"], [73, 73, 107, 107, "CID"], [73, 73, 144, 144, "CID"], [73, 73, 176, 176, "CID"], [73, 73, 190, 190, "CID"], [73, 73, 225, 225, "CID"], [73, 73, 307, 307, "CID"], [149, 149, 12, 12, "CID"], [149, 149, 19, 19, "CID"], [149, 149, 26, 26, "CID"], [149, 149, 33, 33, "CID"], [149, 149, 48, 48, "CID"], [149, 149, 59, 59, "CID"], [149, 149, 107, 107, "CID"], [149, 149, 144, 144, "CID"], [149, 149, 176, 176, "CID"], [149, 149, 190, 190, "CID"], [149, 149, 225, 225, "CID"], [149, 149, 307, 307, "CID"], [195, 195, 12, 12, "CID"], [195, 195, 19, 19, "CID"], [195, 195, 26, 26, "CID"], [195, 195, 33, 33, "CID"], [195, 195, 48, 48, "CID"], [195, 195, 59, 59, "CID"], [195, 195, 107, 107, "CID"], [195, 195, 144, 144, "CID"], [195, 195, 176, 176, "CID"], [195, 195, 190, 190, "CID"], [195, 195, 225, 225, "CID"], [195, 195, 307, 307, "CID"]]], "clusters": [], "translated": "<0>辣椒素</0> 引起的<4>疼痛</4> 的感觉辨别成分的外显情景记忆：即时和延迟评级。<5>疼痛</5>记忆被认为会影响未来的<6>疼痛</6>敏感性，从而导致临床<7>疼痛</7>状况。对人类记忆实验性<8>疼痛</8>感觉特征的能力的系统研究很少。为了解决长期<9>疼痛</9>记忆问题，九名健康男性志愿者接受了三剂<1>辣椒素</1>的皮内注射（0.05, 1和20微克，间隔15分钟休息），每一个在一个星期的间隔内在三个会话的平衡设计中给出三次。<10>疼痛</10>评级是使用计算机视觉模拟量表 (0-100) 以1/s 的速度进行数字化的，可以立即在线进行，也可以在注射后一小时或一天进行。受试者还在一周后回忆起他们的<11>疼痛</11>。   <2>辣椒素</2>注射可靠地诱导剂量依赖性耀斑 (p < 0.001)，在和疗程内或疗程间没有任何差异。强烈的<12>疼痛</12>在几分钟内呈指数衰减。受试者能够可靠地区分<13>疼痛</13>强度和持续时间跨越<3>辣椒素</3>剂量（均 p < 0.001），无论是否在一小时后立即要求首次评级或一天后。<14>疼痛</14>一周后的回忆同样准确（幅度：p < 0.01，持续时间：p < 0.05）。当在注射后最迟一天要求首次评级时，一周后与评级回忆的相关性最好(R(2)=0.79)，这表明两种评级检索都使用了相似的记忆痕迹。这些结果表明对实验诱发的<15>疼痛</15>的强度和持续时间有可靠的记忆。数据进一步表明，这种记忆的巩固是一个重要的过渡阶段，可能需要长达一天的时间。", "revised": true}
{"doc_key": "19037603", "sentences": [["Prophylactic", "use", "of", "lamivudine", "with", "chronic", "immunosuppressive", "therapy", "for", "rheumatologic", "disorders", ".", "The", "objective", "of", "this", "study", "was", "to", "report", "our", "experience", "concerning", "the", "effectiveness", "of", "the", "prophylactic", "administration", "of", "lamivudine", "in", "hepatitis", "B", "virus", "surface", "antigen", "(", "HBs", "Ag", ")", "positive", "patients", "with", "rheumatologic", "disease", ".", "From", "June", "2004", "to", "October", "2006", ",", "11", "HBs", "Ag", "positive", "patients", "with", "rheumatologic", "diseases", ",", "who", "were", "on", "both", "immunosuppressive", "and", "prophylactic", "lamivudine", "therapies", ",", "were", "retrospectively", "assessed", ".", "Liver", "function", "tests", ",", "hepatitis", "B", "virus", "(", "HBV", ")", "serologic", "markers", ",", "and", "HBV", "DNA", "levels", "of", "the", "patients", "during", "follow", "-", "up", "were", "obtained", "from", "hospital", "file", "records", ".", "Eleven", "patients", "(", "six", "male", ")", "with", "median", "age", "47", "years", "(", "range", "27", "-", "73", ")", ",", "median", "disease", "duration", "50", "months", "(", "range", "9", "-", "178", ")", "and", "median", "follow", "-", "up", "period", "of", "patients", "13", ".", "8", "months", "(", "range", "5", "-", "27", ")", "were", "enrolled", "in", "this", "study", ".", "Lamivudine", "therapy", "was", "started", "3", "-", "7", "days", "prior", "to", "immunosuppressive", "therapy", "in", "all", "patients", ".", "Baseline", ",", "liver", "function", "tests", "were", "elevated", "in", "two", "patients", "(", "fourth", "patient", ":", "ALT", ":", "122", "IU", "/", "l", ",", "AST", ":", "111", "IU", "/", "l", ",", "tenth", "patient", ":", "ALT", ":", "294", "IU", "/", "l", ",", "AST", ":", "274", "IU", "/", "l", ",", "with", "minimal", "changes", "in", "the", "liver", "biopsy", "in", "both", ")", ".", "Shortly", "after", "treatment", "their", "tests", "normalized", "and", "during", "follow", "-", "up", "period", "none", "of", "the", "patients", "had", "abnormal", "liver", "function", "tests", ".", "In", "four", "patients", "HBV", "DNA", "levels", "were", "higher", "than", "normal", "at", "baseline", ".", "Two", "of", "these", "normalized", "and", "the", "others", "increased", "later", ".", "In", "three", "additional", "patients", ",", "HBV", "DNA", "levels", "were", "increased", "during", "follow", "-", "up", ".", "None", "of", "the", "patients", "had", "significant", "clinical", "sings", "of", "HBV", "activation", ".", "Lamivudine", "was", "well", "tolerated", "and", "was", "continued", "in", "all", "patients", ".", "Prophylactic", "administration", "of", "lamivudine", "in", "patients", "who", "required", "immunosuppressive", "therapy", "seems", "to", "be", "safe", ",", "well", "tolerated", "and", "effective", "in", "preventing", "HBV", "reactivation", "."]], "ner": [[[32, 36, "Chemical"], [38, 39, "Chemical"], [55, 56, "Chemical"], [81, 82, "Disease"], [3, 3, "Chemical"], [30, 30, "Chemical"], [70, 70, "Chemical"], [161, 161, "Chemical"], [305, 305, "Chemical"], [319, 319, "Chemical"], [9, 10, "Disease"], [44, 45, "Disease"], [60, 61, "Disease"], [250, 252, "Disease"]]], "relations": [[[32, 36, 81, 82, "CID"], [38, 39, 81, 82, "CID"], [55, 56, 81, 82, "CID"]]], "clusters": [], "translated": "预防性使用<4>拉米夫定</4>与慢性免疫抑制治疗<10>风湿病</10>。本研究的目的是报告我们关于预防性给予<5>拉米夫定</5>对<0>乙型肝炎病毒表面抗原</0>(<1>HBs Ag</1>)的有效性的经验<11>阳性患者</11>风湿病。2004年6月至2006年10月，对11例<2>HBs Ag</2>阳性<12>风湿病</12>患者进行了回顾性评估，这些患者同时接受免疫抑制和预防性<6>拉米夫定</6>治疗。从医院档案记录中获取患者随访期间的肝功能检查、<3>乙型肝炎</3>病毒(HBV)血清学标志物和HBV DNA水平。11名患者（6名男性）中位年龄47岁（范围27-73），中位病程50个月（范围9-178），中位随访期患者13.8个月（范围5-27）被纳入这项研究。<7>拉米夫定</7>治疗在所有患者的免疫抑制治疗前3-7天开始。两名患者的基线肝功能测试升高（第四名患者：ALT：122 IU/l，AST：111 IU/l，第十名患者：ALT：294 IU/l，AST：274 IU/l，变化很小，肝活检均有）。治疗后不久，他们的检查恢复正常，在随访期间，没有患者出现<13>肝功能异常</13>检查。4名患者的HBV DNA水平高于基线的正常水平。其中两个正常化，其他的后来增加。在另外三名患者中，HBV DNA水平在随访期间升高。没有患者有显着的HBV激活临床表现。<8>拉米夫定</8>耐受性良好，并且所有患者均继续服用。在需要免疫抑制治疗的患者中预防性使用<9>拉米夫定</9>似乎是安全的、耐受性良好的并且能有效预防HBV再激活。", "revised": true}
{"doc_key": "17854040", "sentences": [["Mutations", "associated", "with", "lamivudine", "-", "resistance", "in", "therapy", "-", "na", "ve", "hepatitis", "B", "virus", "(", "HBV", ")", "infected", "patients", "with", "and", "without", "HIV", "co", "-", "infection", ":", "implications", "for", "antiretroviral", "therapy", "in", "HBV", "and", "HIV", "co", "-", "infected", "South", "African", "patients", ".", "This", "was", "an", "exploratory", "study", "to", "investigate", "lamivudine", "-", "resistant", "hepatitis", "B", "virus", "(", "HBV", ")", "strains", "in", "selected", "lamivudine", "-", "na", "ve", "HBV", "carriers", "with", "and", "without", "human", "immunodeficiency", "virus", "(", "HIV", ")", "co", "-", "infection", "in", "South", "African", "patients", ".", "Thirty", "-", "five", "lamivudine", "-", "na", "ve", "HBV", "infected", "patients", "with", "or", "without", "HIV", "co", "-", "infection", "were", "studied", ":", "15", "chronic", "HBV", "mono", "-", "infected", "patients", "and", "20", "HBV", "-", "HIV", "co", "-", "infected", "patients", ".", "The", "latter", "group", "was", "further", "sub", "-", "divided", "into", "13", "occult", "HBV", "(", "HBsAg", "-", "negative", ")", "and", "7", "overt", "HBV", "(", "HBsAg", "-", "positive", ")", "patients", ".", "HBsAg", ",", "anti", "-", "HBs", ",", "anti", "-", "HBc", ",", "and", "anti", "-", "HIV", "1", "/", "2", "were", "determined", "as", "part", "of", "routine", "diagnosis", "using", "Axsym", "assays", "(", "Abbott", "Laboratories", ",", "North", "Chicago", ",", "IL", ")", ".", "Serum", "samples", "were", "PCR", "amplified", "with", "HBV", "reverse", "transcriptase", "(", "RT", ")", "primers", ",", "followed", "by", "direct", "sequencing", "across", "the", "tyrosine", "-", "methionine", "-", "aspartate", "-", "aspartate", "(", "YMDD", ")", "motif", "of", "the", "major", "catalytic", "region", "in", "the", "C", "domain", "of", "the", "HBV", "RT", "enzyme", ".", "HBV", "viral", "load", "was", "performed", "with", "Amplicor", "HBV", "Monitor", "test", "v2", ".", "0", "(", "Roche", "Diagnostics", ",", "Penzberg", ",", "Germany", ")", ".", "HBV", "lamivudine", "-", "resistant", "strains", "were", "detected", "in", "3", "of", "15", "mono", "-", "infected", "chronic", "hepatitis", "B", "patients", "and", "10", "of", "20", "HBV", "-", "HIV", "co", "-", "infected", "patients", ".", "To", "the", "best", "of", "our", "knowledge", ",", "this", "constitutes", "the", "first", "report", "of", "HBV", "lamivudine", "-", "resistant", "strains", "in", "therapy", "-", "na", "ve", "HBV", "-", "HIV", "co", "-", "infected", "patients", ".", "The", "HBV", "viral", "loads", "for", "mono", "-", "infected", "and", "co", "-", "infected", "patients", "ranged", "from", "3", ".", "32", "x", "10", "(", "2", ")", "to", "3", ".", "82", "x", "10", "(", "7", ")", "and", "<", "200", "to", "4", ".", "40", "x", "10", "(", "3", ")", "copies", "/", "ml", ",", "respectively", ".", "It", "remains", "to", "be", "seen", "whether", "such", "pre", "-", "existing", "antiviral", "mutations", "could", "result", "in", "widespread", "emergence", "of", "HBV", "resistant", "strains", "when", "lamivudine", "-", "containing", "highly", "active", "antiretroviral", "(", "ARV", ")", "treatment", "(", "HAART", ")", "regimens", "become", "widely", "applied", "in", "South", "Africa", ",", "as", "this", "is", "likely", "to", "have", "potential", "implications", "in", "the", "management", "of", "HBV", "-", "HIV", "co", "-", "infected", "patients", "."]], "ner": [[[134, 134, "Chemical"], [143, 143, "Chemical"], [149, 149, "Chemical"], [11, 17, "Disease"], [32, 37, "Disease"], [52, 53, "Disease"], [91, 92, "Disease"], [106, 109, "Disease"], [113, 118, "Disease"], [269, 270, "Disease"], [276, 281, "Disease"], [307, 312, "Disease"], [420, 425, "Disease"], [3, 3, "Chemical"], [49, 49, "Chemical"], [61, 61, "Chemical"], [87, 87, "Chemical"], [255, 255, "Chemical"], [298, 298, "Chemical"], [387, 387, "Chemical"], [22, 25, "Disease"], [70, 78, "Disease"], [97, 100, "Disease"], [9, 9, "Chemical"], [63, 63, "Chemical"], [89, 89, "Chemical"], [305, 305, "Chemical"], [206, 206, "Chemical"], [208, 208, "Chemical"], [210, 210, "Chemical"], [212, 212, "Chemical"]]], "relations": [[[134, 134, 11, 17, "CID"], [134, 134, 32, 37, "CID"], [134, 134, 52, 53, "CID"], [134, 134, 91, 92, "CID"], [134, 134, 106, 109, "CID"], [134, 134, 113, 118, "CID"], [134, 134, 269, 270, "CID"], [134, 134, 276, 281, "CID"], [134, 134, 307, 312, "CID"], [134, 134, 420, 425, "CID"], [143, 143, 11, 17, "CID"], [143, 143, 32, 37, "CID"], [143, 143, 52, 53, "CID"], [143, 143, 91, 92, "CID"], [143, 143, 106, 109, "CID"], [143, 143, 113, 118, "CID"], [143, 143, 269, 270, "CID"], [143, 143, 276, 281, "CID"], [143, 143, 307, 312, "CID"], [143, 143, 420, 425, "CID"], [149, 149, 11, 17, "CID"], [149, 149, 32, 37, "CID"], [149, 149, 52, 53, "CID"], [149, 149, 91, 92, "CID"], [149, 149, 106, 109, "CID"], [149, 149, 113, 118, "CID"], [149, 149, 269, 270, "CID"], [149, 149, 276, 281, "CID"], [149, 149, 307, 312, "CID"], [149, 149, 420, 425, "CID"]]], "clusters": [], "translated": "与 <13> 拉米夫定 </13> 相关的突变 - 治疗耐药 - <23> 初治 </23> 感染 <3> 乙型肝炎病毒 (HBV) 的 </3> 患者伴有和不伴有 <20> HIV 合并感染 </20>： <4> HBV 和 HIV 合并感染 </4> 南非患者抗逆转录病毒治疗的意义。这是一项探索性研究，旨在调查选定的 <15> 拉米夫定 </15> - <24> naive </24>中对 <14> 拉米夫定 </14> 耐药的 <5> 乙型肝炎 </5> 病毒 (HBV) 株南非患者中有和没有 <21> 人类免疫缺陷病毒 (HIV) 合并感染 </21> 的乙肝病毒携带者。研究了三十五名 <16> 拉米夫定 </16> - <25> naive </25> 感染的 <6> HBV </6> 患者有或没有 <22> HIV 合并感染 </22>：15 慢性 <7> HBV 单一感染 </7> 患者和20例 <8> HBV-HIV 合并感染 </8> 患者。后一组进一步细分为13例隐匿性HBV（<0> HBsAg </0> - 阴性）和7例显性HBV（<1> HBsAg </1> - 阳性）患者。 <2> HBsAg </2>、抗-HBs、抗-HBc 和抗-HIV1/2 作为常规诊断的一部分使用 Axsym 测定法（Abbott Laboratories，North Chicago，IL）测定。血清样本用 HBV 逆转录酶 (RT) 引物进行 PCR 扩增，然后对 <27> 酪氨酸 </27> - <28> 甲硫氨酸 </28> - <29> 天冬氨酸 </29> - <30> 进行直接测序，HBV RT 酶 C 结构域中主要催化区域的天冬氨酸 </30> (YMDD) 基序。 HBV 病毒载量使用 Amplicor HBV Monitor test v2 进行。 0（罗氏诊断公司，彭茨贝格，德国）。 HBV <17> 拉米夫定 </17> 耐药菌株在 15 名慢性 <9> 乙型肝炎 </9> 患者中的 3 名和20名 <10> HBV-HIV 合并感染 </10> 患者中的10名检测到。据我们所知，这是首次报告 HBV <18> 拉米夫定 </18> 耐药菌株在治疗中- <26> naive </26> 的 <11> HBV-HIV 合并感染 </11> 患者。单一感染和合并感染患者的 HBV 病毒载量范围为 3 . 32 x 10 (2) 至 3 . 82 x 10 (7) 和 < 200 至 4 . 40 x 10 (3) 份/毫升，分别。当含有 <19> 拉米夫定 </19> 的高效抗逆转录病毒 (ARV) 治疗 (HAART) 方案在南非广泛应用时，这种预先存在的抗病毒突变是否会导致 HBV 耐药株的广泛出现还有待观察，因为这可能对 <12> HBV-HIV 合并感染 </12> 患者的管理有潜在影响。", "revised": true}
{"doc_key": "12202650", "sentences": [["Capsaicin", "-", "induced", "muscle", "pain", "alters", "the", "excitability", "of", "the", "human", "jaw", "-", "stretch", "reflex", ".", "The", "pathophysiology", "of", "painful", "temporomandibular", "disorders", "is", "not", "fully", "understood", ",", "but", "evidence", "suggests", "that", "muscle", "pain", "modulates", "motor", "function", "in", "characteristic", "ways", ".", "This", "study", "tested", "the", "hypothesis", "that", "activation", "of", "nociceptive", "muscle", "afferent", "fibers", "would", "be", "linked", "to", "an", "increased", "excitability", "of", "the", "human", "jaw", "-", "stretch", "reflex", "and", "whether", "this", "process", "would", "be", "sensitive", "to", "length", "and", "velocity", "of", "the", "stretch", ".", "Capsaicin", "(", "10", "micro", "g", ")", "was", "injected", "into", "the", "masseter", "muscle", "to", "induce", "pain", "in", "11", "healthy", "volunteers", ".", "Short", "-", "latency", "reflex", "responses", "were", "evoked", "in", "the", "masseter", "and", "temporalis", "muscles", "by", "a", "stretch", "device", "with", "different", "velocities", "and", "displacements", "before", ",", "during", ",", "and", "after", "the", "pain", ".", "The", "normalized", "reflex", "amplitude", "increased", "with", "an", "increase", "in", "velocity", "at", "a", "given", "displacement", ",", "but", "remained", "constant", "with", "different", "displacements", "at", "a", "given", "velocity", ".", "The", "normalized", "reflex", "amplitude", "was", "significantly", "higher", "during", "pain", ",", "but", "only", "at", "faster", "stretches", "in", "the", "painful", "muscle", ".", "Increased", "sensitivity", "of", "the", "fusimotor", "system", "during", "acute", "muscle", "pain", "could", "be", "one", "likely", "mechanism", "to", "explain", "the", "findings", "."]], "ner": [[[0, 0, "Chemical"], [81, 81, "Chemical"], [95, 95, "Disease"], [130, 130, "Disease"], [166, 166, "Disease"], [3, 4, "Disease"], [31, 32, "Disease"], [48, 49, "Disease"], [175, 176, "Disease"], [186, 187, "Disease"], [20, 21, "Disease"]]], "relations": [[[0, 0, 95, 95, "CID"], [0, 0, 130, 130, "CID"], [0, 0, 166, 166, "CID"], [81, 81, 95, 95, "CID"], [81, 81, 130, 130, "CID"], [81, 81, 166, 166, "CID"]]], "clusters": [], "translated": "<0>辣椒素</0>引起的<5>肌肉疼痛</5>改变了人类下颌伸展反射的兴奋性。疼痛性<10>颞下颌关节紊乱</10>的病理生理学尚不完全清楚，但有证据表明<6>肌肉疼痛</6>以特有的方式调节运动功能。这项研究检验了以下假设：<7>伤害性肌肉</7>传入纤维的激活与人类下颌伸展反射的兴奋性增加有关，以及该过程是否对伸展的长度和速度敏感。 <1>辣椒素</1>（10微克）被注射到咬肌中，在11名健康志愿者中引起<2>疼痛</2>。在<3>疼痛</3>之前、期间和之后，通过不同速度和位移的拉伸装置在咬肌和颞肌中诱发短潜伏期反射反应。在给定位移下，归一化反射振幅随着速度的增加而增加，但在给定速度下随着不同位移保持不变。在<4>疼痛</4>期间，归一化反射振幅明显更高，但仅在<8>疼痛肌肉</8>的较快伸展时。急性<9>肌肉疼痛</9>期间梭肌运动系统的敏感性增加可能是解释这些发现的一种可能机制。", "revised": true}
{"doc_key": "11431197", "sentences": [["Ranitidine", "-", "induced", "acute", "interstitial", "nephritis", "in", "a", "cadaveric", "renal", "allograft", ".", "Ranitidine", "frequently", "is", "used", "for", "preventing", "peptic", "ulceration", "after", "renal", "transplantation", ".", "This", "drug", "occasionally", "has", "been", "associated", "with", "acute", "interstitial", "nephritis", "in", "native", "kidneys", ".", "There", "are", "no", "similar", "reports", "with", "renal", "transplantation", ".", "We", "report", "a", "case", "of", "ranitidine", "-", "induced", "acute", "interstitial", "nephritis", "in", "a", "recipient", "of", "a", "cadaveric", "renal", "allograft", "presenting", "with", "acute", "allograft", "dysfunction", "within", "48", "hours", "of", "exposure", "to", "the", "drug", ".", "The", "biopsy", "specimen", "showed", "pathognomonic", "features", ",", "including", "eosinophilic", "infiltration", "of", "the", "interstitial", "compartment", ".", "Allograft", "function", "improved", "rapidly", "and", "returned", "to", "baseline", "after", "stopping", "the", "drug", "."]], "ner": [[[0, 0, "Chemical"], [12, 12, "Chemical"], [52, 52, "Chemical"], [4, 5, "Disease"], [32, 33, "Disease"], [56, 57, "Disease"]]], "relations": [[[0, 0, 4, 5, "CID"], [0, 0, 32, 33, "CID"], [0, 0, 56, 57, "CID"], [12, 12, 4, 5, "CID"], [12, 12, 32, 33, "CID"], [12, 12, 56, 57, "CID"], [52, 52, 4, 5, "CID"], [52, 52, 32, 33, "CID"], [52, 52, 56, 57, "CID"]]], "clusters": [], "translated": "<0>雷尼替丁</0> - 在尸体肾同种异体移植物中诱发急性<3>间质性肾炎</3>。<1>雷尼替丁</1>常用于预防肾移植术后消化性溃疡。这种药物偶尔会与<4>自体肾脏中的</4>急性<4>间质性肾炎</4>相关。与肾移植尚无类似报道。我们报告了一例<2>雷尼替丁</2>诱发的急性<5>间质性肾炎</5>，该病例发生在尸体肾同种异体移植物的接受者身上，在接触药物后48小时内出现急性同种异体移植物功能障碍。活检标本显示出病理特征，包括间质室的嗜酸性粒细胞浸润。同种异体移植物功能迅速改善并在停药后恢复到基线水平。", "revised": true}
{"doc_key": "7449470", "sentences": [["Late", ",", "late", "doxorubicin", "cardiotoxicity", ".", "Cardiac", "toxicity", "is", "a", "major", "complication", "which", "limits", "the", "use", "of", "adriamycin", "as", "a", "chemotherapeutic", "agent", ".", "Cardiomyopathy", "is", "frequent", "when", "the", "total", "dose", "exceeds", "600", "mg", "/", "m2", "and", "occurs", "within", "one", "to", "six", "months", "after", "cessation", "of", "therapy", ".", "A", "patient", "is", "reported", "who", "developed", "progressive", "cardiomyopathy", "two", "and", "one", "-", "half", "years", "after", "receiving", "580", "mg", "/", "m2", "which", "apparently", "represents", "late", ",", "late", "cardiotoxicity", "."]], "ner": [[[3, 3, "Chemical"], [17, 17, "Chemical"], [23, 23, "Disease"], [54, 54, "Disease"], [4, 4, "Disease"], [6, 7, "Disease"], [73, 73, "Disease"]]], "relations": [[[3, 3, 23, 23, "CID"], [3, 3, 54, 54, "CID"], [17, 17, 23, 23, "CID"], [17, 17, 54, 54, "CID"]]], "clusters": [], "translated": "晚期，晚期<0>多柔比星</0> <4>心脏毒性</4>。 <5>心脏毒性</5>是一种主要并发症，它限制了<1>阿霉素</1>作为化疗药物的使用。<2>心肌病</2>常发生于总剂量超过600 mg/m2且在停药后1至6个月内发生。据报道，一名患者在接受580 mg/m2治疗后两年半后发展为进行性<3>心肌病</3>，这显然代表晚期、晚期<6>心脏毒性</6>。", "revised": true}
{"doc_key": "18951540", "sentences": [["Repetitive", "transcranial", "magnetic", "stimulation", "for", "levodopa", "-", "induced", "dyskinesias", "in", "Parkinson", "'s", "disease", ".", "In", "a", "placebo", "-", "controlled", ",", "single", "-", "blinded", ",", "crossover", "study", ",", "we", "assessed", "the", "effect", "of", "\"", "real", "\"", "repetitive", "transcranial", "magnetic", "stimulation", "(", "rTMS", ")", "versus", "\"", "sham", "\"", "rTMS", "(", "placebo", ")", "on", "peak", "dose", "dyskinesias", "in", "patients", "with", "Parkinson", "'s", "disease", "(", "PD", ")", ".", "Ten", "patients", "with", "PD", "and", "prominent", "dyskinesias", "had", "rTMS", "(", "1", ",", "800", "pulses", ";", "1", "Hz", "rate", ")", "delivered", "over", "the", "motor", "cortex", "for", "4", "consecutive", "days", "twice", ",", "once", "real", "stimuli", "and", "once", "sham", "stimulation", "were", "used", ";", "evaluations", "were", "done", "at", "the", "baseline", "and", "1", "day", "after", "the", "end", "of", "each", "of", "the", "treatment", "series", ".", "Direct", "comparison", "between", "sham", "and", "real", "rTMS", "effects", "showed", "no", "significant", "difference", "in", "clinician", "-", "assessed", "dyskinesia", "severity", ".", "However", ",", "comparison", "with", "the", "baseline", "showed", "small", "but", "significant", "reduction", "in", "dyskinesia", "severity", "following", "real", "rTMS", "but", "not", "placebo", ".", "The", "major", "effect", "was", "on", "dystonia", "subscore", ".", "Similarly", ",", "in", "patient", "diaries", ",", "although", "both", "treatments", "caused", "reduction", "in", "subjective", "dyskinesia", "scores", "during", "the", "days", "of", "intervention", ",", "the", "effect", "was", "sustained", "for", "3", "days", "after", "the", "intervention", "for", "the", "real", "rTMS", "only", ".", "Following", "rTMS", ",", "no", "side", "effects", "and", "no", "adverse", "effects", "on", "motor", "function", "and", "PD", "symptoms", "were", "noted", ".", "The", "results", "suggest", "the", "existence", "of", "residual", "beneficial", "clinical", "aftereffects", "of", "consecutive", "daily", "applications", "of", "low", "-", "frequency", "rTMS", "on", "dyskinesias", "in", "PD", ".", "The", "effects", "may", "be", "further", "exploited", "for", "potential", "therapeutic", "uses", "."]], "ner": [[[5, 5, "Chemical"], [8, 8, "Disease"], [53, 53, "Disease"], [70, 70, "Disease"], [139, 139, "Disease"], [154, 154, "Disease"], [184, 184, "Disease"], [247, 247, "Disease"], [10, 12, "Disease"], [57, 59, "Disease"], [61, 61, "Disease"], [67, 67, "Disease"], [222, 222, "Disease"], [249, 249, "Disease"], [168, 168, "Disease"]]], "relations": [[[5, 5, 8, 8, "CID"], [5, 5, 53, 53, "CID"], [5, 5, 70, 70, "CID"], [5, 5, 139, 139, "CID"], [5, 5, 154, 154, "CID"], [5, 5, 184, 184, "CID"], [5, 5, 247, 247, "CID"]]], "clusters": [], "translated": "<0>左旋多巴</0>引起的<1>运动障碍</1>在<8>帕金森病</8>中的重复经颅磁刺激。在安慰剂对照、单盲、交叉研究中，我们评估了“真正的”重复经颅磁刺激（rTMS）与“假”rTMS（安慰剂）对峰值剂量 <2>运动障碍</2>患者的影响<9>帕金森病</9>（<10>PD</10>）。十名<11>PD</11>和显着的<3>运动障碍</3>患者接受了rTMS（1,800脉冲；1 Hz频率）连续4天在运动皮层传递两次，一次是真实刺激，一次是假刺激使用了刺激；在基线和每个治疗系列结束后1天进行评估。假和真实rTMS效果之间的直接比较表明临床医生评估的<4>运动障碍</4>严重程度没有显着差异。然而，与基线的比较表明，使用真正的rTMS而不是安慰剂后，<5>运动障碍</5>的严重程度有小幅但显着的降低。主要影响是<14>肌张力障碍</14>子评分。同样，在患者日记中，虽然两种治疗都在干预期间降低了主观<6>运动障碍</6>评分，但仅在真正的rTMS干预后效果持续了3天。在rTMS之后，没有发现副作用，也没有对运动功能和<12>PD</12>症状产生不利影响。结果表明，每天连续应用低频rTMS对<7>运动障碍</7>在<13> PD </13>中存在残留的有益临床后遗症。这些影响可进一步用于潜在的治疗用途。", "revised": true}
{"doc_key": "10091617", "sentences": [["Selegiline", "-", "induced", "postural", "hypotension", "in", "Parkinson", "'s", "disease", ":", "a", "longitudinal", "study", "on", "the", "effects", "of", "drug", "withdrawal", ".", "OBJECTIVES", ":", "The", "United", "Kingdom", "Parkinson", "'s", "Disease", "Research", "Group", "(", "UKPDRG", ")", "trial", "found", "an", "increased", "mortality", "in", "patients", "with", "Parkinson", "'s", "disease", "(", "PD", ")", "randomized", "to", "receive", "10", "mg", "selegiline", "per", "day", "and", "L", "-", "dopa", "compared", "with", "those", "taking", "L", "-", "dopa", "alone", ".", "Recently", ",", "we", "found", "that", "therapy", "with", "selegiline", "and", "L", "-", "dopa", "was", "associated", "with", "selective", "systolic", "orthostatic", "hypotension", "which", "was", "abolished", "by", "withdrawal", "of", "selegiline", ".", "This", "unwanted", "effect", "on", "postural", "blood", "pressure", "was", "not", "the", "result", "of", "underlying", "autonomic", "failure", ".", "The", "aims", "of", "this", "study", "were", "to", "confirm", "our", "previous", "findings", "in", "a", "separate", "cohort", "of", "patients", "and", "to", "determine", "the", "time", "course", "of", "the", "cardiovascular", "consequences", "of", "stopping", "selegiline", "in", "the", "expectation", "that", "this", "might", "shed", "light", "on", "the", "mechanisms", "by", "which", "the", "drug", "causes", "orthostatic", "hypotension", ".", "METHODS", ":", "The", "cardiovascular", "responses", "to", "standing", "and", "head", "-", "up", "tilt", "were", "studied", "repeatedly", "in", "PD", "patients", "receiving", "selegiline", "and", "as", "the", "drug", "was", "withdrawn", ".", "RESULTS", ":", "Head", "-", "up", "tilt", "caused", "systolic", "orthostatic", "hypotension", "which", "was", "marked", "in", "six", "of", "20", "PD", "patients", "on", "selegiline", ",", "one", "of", "whom", "lost", "consciousness", "with", "unrecordable", "blood", "pressures", ".", "A", "lesser", "degree", "of", "orthostatic", "hypotension", "occurred", "with", "standing", ".", "Orthostatic", "hypotension", "was", "ameliorated", "4", "days", "after", "withdrawal", "of", "selegiline", "and", "totally", "abolished", "7", "days", "after", "discontinuation", "of", "the", "drug", ".", "Stopping", "selegiline", "also", "significantly", "reduced", "the", "supine", "systolic", "and", "diastolic", "blood", "pressures", "consistent", "with", "a", "previously", "undescribed", "supine", "pressor", "action", ".", "CONCLUSION", ":", "This", "study", "confirms", "our", "previous", "finding", "that", "selegiline", "in", "combination", "with", "L", "-", "dopa", "is", "associated", "with", "selective", "orthostatic", "hypotension", ".", "The", "possibilities", "that", "these", "cardiovascular", "findings", "might", "be", "the", "result", "of", "non", "-", "selective", "inhibition", "of", "monoamine", "oxidase", "or", "of", "amphetamine", "and", "metamphetamine", "are", "discussed", "."]], "ner": [[[0, 0, "Chemical"], [52, 52, "Chemical"], [75, 75, "Chemical"], [93, 93, "Chemical"], [140, 140, "Chemical"], [179, 179, "Chemical"], [207, 207, "Chemical"], [238, 238, "Chemical"], [251, 251, "Chemical"], [280, 280, "Chemical"], [3, 4, "Disease"], [84, 86, "Disease"], [157, 158, "Disease"], [194, 196, "Disease"], [223, 224, "Disease"], [229, 230, "Disease"], [254, 261, "Disease"], [291, 292, "Disease"], [6, 8, "Disease"], [25, 27, "Disease"], [41, 43, "Disease"], [45, 45, "Disease"], [176, 176, "Disease"], [204, 204, "Disease"], [56, 58, "Chemical"], [63, 65, "Chemical"], [77, 79, "Chemical"], [284, 286, "Chemical"], [314, 314, "Chemical"], [316, 316, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 84, 86, "CID"], [0, 0, 157, 158, "CID"], [0, 0, 194, 196, "CID"], [0, 0, 223, 224, "CID"], [0, 0, 229, 230, "CID"], [0, 0, 254, 261, "CID"], [0, 0, 291, 292, "CID"], [52, 52, 3, 4, "CID"], [52, 52, 84, 86, "CID"], [52, 52, 157, 158, "CID"], [52, 52, 194, 196, "CID"], [52, 52, 223, 224, "CID"], [52, 52, 229, 230, "CID"], [52, 52, 254, 261, "CID"], [52, 52, 291, 292, "CID"], [75, 75, 3, 4, "CID"], [75, 75, 84, 86, "CID"], [75, 75, 157, 158, "CID"], [75, 75, 194, 196, "CID"], [75, 75, 223, 224, "CID"], [75, 75, 229, 230, "CID"], [75, 75, 254, 261, "CID"], [75, 75, 291, 292, "CID"], [93, 93, 3, 4, "CID"], [93, 93, 84, 86, "CID"], [93, 93, 157, 158, "CID"], [93, 93, 194, 196, "CID"], [93, 93, 223, 224, "CID"], [93, 93, 229, 230, "CID"], [93, 93, 254, 261, "CID"], [93, 93, 291, 292, "CID"], [140, 140, 3, 4, "CID"], [140, 140, 84, 86, "CID"], [140, 140, 157, 158, "CID"], [140, 140, 194, 196, "CID"], [140, 140, 223, 224, "CID"], [140, 140, 229, 230, "CID"], [140, 140, 254, 261, "CID"], [140, 140, 291, 292, "CID"], [179, 179, 3, 4, "CID"], [179, 179, 84, 86, "CID"], [179, 179, 157, 158, "CID"], [179, 179, 194, 196, "CID"], [179, 179, 223, 224, "CID"], [179, 179, 229, 230, "CID"], [179, 179, 254, 261, "CID"], [179, 179, 291, 292, "CID"], [207, 207, 3, 4, "CID"], [207, 207, 84, 86, "CID"], [207, 207, 157, 158, "CID"], [207, 207, 194, 196, "CID"], [207, 207, 223, 224, "CID"], [207, 207, 229, 230, "CID"], [207, 207, 254, 261, "CID"], [207, 207, 291, 292, "CID"], [238, 238, 3, 4, "CID"], [238, 238, 84, 86, "CID"], [238, 238, 157, 158, "CID"], [238, 238, 194, 196, "CID"], [238, 238, 223, 224, "CID"], [238, 238, 229, 230, "CID"], [238, 238, 254, 261, "CID"], [238, 238, 291, 292, "CID"], [251, 251, 3, 4, "CID"], [251, 251, 84, 86, "CID"], [251, 251, 157, 158, "CID"], [251, 251, 194, 196, "CID"], [251, 251, 223, 224, "CID"], [251, 251, 229, 230, "CID"], [251, 251, 254, 261, "CID"], [251, 251, 291, 292, "CID"], [280, 280, 3, 4, "CID"], [280, 280, 84, 86, "CID"], [280, 280, 157, 158, "CID"], [280, 280, 194, 196, "CID"], [280, 280, 223, 224, "CID"], [280, 280, 229, 230, "CID"], [280, 280, 254, 261, "CID"], [280, 280, 291, 292, "CID"]]], "clusters": [], "translated": "<0>司来吉兰</0>诱导的<10>体位性低血压</10>在<18>帕金森病</18>中：一项关于药物戒断影响的纵向研究。目的：英国<19>帕金森病</19>研究组（UKPDRG）试验发现<20>帕金森病</20>（<21>PD</21>）患者的死亡率增加随机接受每天 10 毫克<1>司来吉兰</1>和<24>左旋多巴</24>的患者与单独服用<25>左旋多巴</25>的患者进行比较。最近，我们发现<2>司来吉兰</2>和<26>左旋多巴</26>治疗与选择性<11>直立性收缩性低血压</11>相关，而<3>停药后这种情况消失了</3>。这种对体位血压的不利影响并不是潜在的自主神经衰竭的结果。本研究的目的是证实我们之前在一个单独的患者队列中的发现，并确定停止<4>司来吉兰</4>的心血管后果的时间进程，以期这可能阐明其中的机制药物引起<12>直立性低血压</12>。方法：在接受<5>司来吉兰</5>治疗和停药后的<22>PD</22>患者中反复研究站立和抬头倾斜的心血管反应。结果：抬头倾斜导致<13>收缩性直立性低血压</13>，这在<6>司来吉兰</6>的 20 名<23> PD </23>患者中有6名出现，其中1名患者失去意识并无法记录血压。较小程度的<14>直立性低血压</14>发生在站立时。停用<7>司来吉兰</7>后4天，<15>直立性低血压</15>得到改善，停药7天后完全消除。停止<8>司来吉兰</8>也显着<16>降低了仰卧收缩压和舒张压</16>，这与之前未描述的仰卧升压作用一致。结论：本研究证实了我们之前的发现，即<9>司来吉兰</9>与<27>左旋多巴</27>联合使用与选择性<17>直立性低血压</17>相关。讨论了这些心血管发现可能是单胺氧化酶或<28>苯丙胺</28>和<29>甲基苯丙胺</29>非选择性抑制的结果的可能性。", "revised": true}
{"doc_key": "9195768", "sentences": [["The", "site", "of", "common", "side", "effects", "of", "sumatriptan", ".", "Atypical", "sensations", "following", "the", "use", "of", "subcutaneous", "sumatriptan", "are", "common", ",", "but", "of", "uncertain", "origin", ".", "They", "are", "almost", "always", "benign", ",", "but", "can", "be", "mistaken", "for", "a", "serious", "adverse", "event", "by", "the", "patient", ".", "Two", "patients", "are", "presented", "with", "tingling", "or", "burning", "sensations", "limited", "to", "areas", "of", "heat", "exposure", "or", "sunburn", ".", "In", "these", "individuals", ",", "side", "effects", "are", "most", "likely", "generated", "superficially", "in", "the", "skin", "."]], "ner": [[[7, 7, "Chemical"], [16, 16, "Chemical"], [9, 10, "Disease"], [49, 52, "Disease"], [60, 60, "Disease"]]], "relations": [[[7, 7, 9, 10, "CID"], [7, 7, 49, 52, "CID"], [16, 16, 9, 10, "CID"], [16, 16, 49, 52, "CID"]]], "clusters": [], "translated": "<0>舒马普坦</0>的常见副作用部位。皮下使用<1>舒马普坦</1>后<2>非典型感觉</2>很常见，但原因不明。它们几乎总是良性的，但可能被患者误认为是严重的不良事件。两名患者出现<3>刺痛感或灼烧感</3>，仅限于热暴露或<4>晒伤</4>的区域。在这些人中，副作用很可能是在皮肤表面产生的。", "revised": true}
{"doc_key": "8170551", "sentences": [["Acetazolamide", "-", "induced", "nephrolithiasis", ":", "implications", "for", "treatment", "of", "neuromuscular", "disorders", ".", "Carbonic", "anhydrase", "inhibitors", "can", "cause", "nephrolithiasis", ".", "We", "studied", "20", "patients", "receiving", "long", "-", "term", "carbonic", "anhydrase", "inhibitor", "treatment", "for", "periodic", "paralysis", "and", "myotonia", ".", "Three", "patients", "on", "acetazolamide", "(", "15", "%", ")", "developed", "renal", "calculi", ".", "Extracorporeal", "lithotripsy", "successfully", "removed", "a", "renal", "calculus", "in", "one", "patient", "and", "surgery", "removed", "a", "staghorn", "calculus", "in", "another", ",", "permitting", "continued", "treatment", ".", "Renal", "function", "remained", "normal", "in", "all", "patients", ".", "Nephrolithiasis", "is", "a", "complication", "of", "acetazolamide", "but", "does", "not", "preclude", "its", "use", "."]], "ner": [[[0, 0, "Chemical"], [40, 40, "Chemical"], [85, 85, "Chemical"], [46, 47, "Disease"], [54, 55, "Disease"], [3, 3, "Disease"], [17, 17, "Disease"], [80, 80, "Disease"], [9, 10, "Disease"], [33, 33, "Disease"], [35, 35, "Disease"], [64, 64, "Disease"]]], "relations": [[[0, 0, 46, 47, "CID"], [0, 0, 54, 55, "CID"], [40, 40, 46, 47, "CID"], [40, 40, 54, 55, "CID"], [85, 85, 46, 47, "CID"], [85, 85, 54, 55, "CID"]]], "clusters": [], "translated": " <0>乙酰唑胺</0> - 诱导的<5>肾结石</5>：对治疗<8>神经肌肉疾病</8>的影响。碳酸酐酶抑制剂可引起<6>肾结石</6>。我们研究了 20 名因周期性<9>麻痹</9>和<10>肌强直</10>而接受长期碳酸酐酶抑制剂治疗的患者。服用<1>乙酰唑胺</1>的三名患者 (15%)出现了<3>肾结石</3>。体外碎石术成功地去除了一名患者的<4>肾结石</4>，手术切除了另一名患者的<11>鹿角状肾结石</11>，允许继续治疗。所有患者的肾功能均保持正常。<7>肾结石</7>是<2>乙酰唑胺</2>的并发症，但不排除其使用。", "revised": true}
{"doc_key": "20084309", "sentences": [["Safety", "of", "transesophageal", "echocardiography", "in", "adults", ":", "study", "in", "a", "multidisciplinary", "hospital", ".", "BACKGROUND", ":", "TEE", "is", "a", "semi", "-", "invasive", "tool", "broadly", "used", "and", "its", "utilization", "associated", "to", "sedatives", "drugs", "might", "to", "affect", "the", "procedure", "safety", ".", "OBJECTIVE", ":", "to", "analyze", "aspects", "of", "TEE", "safety", "associated", "to", "the", "use", "of", "Midazolan", "(", "MZ", ")", "and", "Flumazenil", "(", "FL", ")", "and", "the", "influence", "of", "the", "clinical", "variables", "on", "the", "event", "rate", ".", "METHOD", ":", "prospective", "study", "with", "137", "patients", "that", "underwent", "TEE", "with", "MZ", "associated", "to", "moderate", "sedation", ".", "We", "analyzed", "the", "following", "events", ":", "complications", "related", "with", "the", "topical", "anesthesia", ",", "with", "MZ", "use", "and", "with", "the", "procedure", ".", "Uni", "-", "and", "multivariate", "analyses", "were", "used", "to", "test", "the", "influence", "of", "the", "clinical", "variables", ":", "age", ",", "sex", ",", "stroke", ",", "myocardiopathy", "(", "MP", ")", ",", "duration", "of", "the", "test", ",", "mitral", "regurgitation", "(", "MR", ")", "and", "the", "MZ", "dose", ".", "RESULTS", ":", "All", "patients", "(", "65", "+", "/", "-", "16", "yrs", ";", "58", "%", "males", ")", "finished", "the", "examination", ".", "The", "mean", "doses", "of", "MZ", "and", "FL", "were", "4", ".", "3", "+", "/", "-", "1", ".", "9", "mg", "and", "0", ".", "28", "+", "/", "-", "0", ".", "2", "mg", ",", "respectively", ".", "The", "duration", "of", "the", "examination", "and", "the", "mean", "ejection", "fraction", "(", "EF", ")", "were", "16", ".", "4", "+", "/", "-", "6", ".", "1", "minutes", "and", "60", "+", "/", "-", "9", "%", ",", "respectively", ".", "Mild", "hypoxia", "(", "SO2", "<", "90", "%", ")", "was", "the", "most", "common", "event", "(", "11", "patients", ")", ";", "3", "patients", "(", "2", "%", ")", "presented", "transient", "hypoxia", "due", "to", "upper", "airway", "obstruction", "by", "probe", "introduction", "and", "8", "(", "5", ".", "8", "%", ")", "due", "to", "hypoxia", "caused", "by", "MZ", "use", ".", "Transient", "hypotension", "(", "SAP", "<", "90mmHg", ")", "occurred", "in", "1", "patient", "(", "0", ".", "7", "%", ")", ".", "The", "multivariate", "analysis", "showed", "that", "severe", "MR", ",", "MP", "(", "EF", "<", "45", "%", ")", "and", "high", "doses", "of", "MZ", "(", ">", "5mg", ")", "were", "associated", "with", "events", "(", "p", "<", "0", ".", "001", ")", ".", "The", "EF", "was", "40", "%", ",", "in", "the", "group", "with", "MP", "and", "44", "%", "in", "the", "group", "with", "severe", "MR", "and", "it", "can", "be", "a", "factor", "associated", "with", "clinical", "events", "in", "the", "last", "group", ".", "CONCLUSION", ":", "TEE", "with", "sedation", "presents", "a", "low", "rate", "of", "events", ".", "There", "were", "no", "severe", "events", "and", "there", "was", "no", "need", "to", "interrupt", "the", "examinations", "."]], "ner": [[[51, 51, "Chemical"], [53, 53, "Chemical"], [83, 83, "Chemical"], [103, 103, "Chemical"], [149, 149, "Chemical"], [176, 176, "Chemical"], [286, 286, "Chemical"], [326, 326, "Chemical"], [239, 239, "Disease"], [264, 264, "Disease"], [283, 283, "Disease"], [130, 130, "Disease"], [132, 132, "Disease"], [134, 134, "Disease"], [315, 315, "Disease"], [353, 353, "Disease"], [142, 143, "Disease"], [145, 145, "Disease"], [313, 313, "Disease"], [362, 362, "Disease"], [268, 269, "Disease"], [290, 290, "Disease"], [56, 56, "Chemical"], [58, 58, "Chemical"], [178, 178, "Chemical"]]], "relations": [[[51, 51, 239, 239, "CID"], [51, 51, 264, 264, "CID"], [51, 51, 283, 283, "CID"], [53, 53, 239, 239, "CID"], [53, 53, 264, 264, "CID"], [53, 53, 283, 283, "CID"], [83, 83, 239, 239, "CID"], [83, 83, 264, 264, "CID"], [83, 83, 283, 283, "CID"], [103, 103, 239, 239, "CID"], [103, 103, 264, 264, "CID"], [103, 103, 283, 283, "CID"], [149, 149, 239, 239, "CID"], [149, 149, 264, 264, "CID"], [149, 149, 283, 283, "CID"], [176, 176, 239, 239, "CID"], [176, 176, 264, 264, "CID"], [176, 176, 283, 283, "CID"], [286, 286, 239, 239, "CID"], [286, 286, 264, 264, "CID"], [286, 286, 283, 283, "CID"], [326, 326, 239, 239, "CID"], [326, 326, 264, 264, "CID"], [326, 326, 283, 283, "CID"]]], "clusters": [], "translated": "成人经食管超声心动图的安全性：多学科医院的研究。背景：TEE是一种广泛使用的半侵入性工具，其与镇静药物的使用可能会影响手术的安全性。目的：分析与使用 <0>咪达唑仑</0>（<1>MZ</1>）和<22>氟马西尼</22>（<23>FL</23>）相关的 TEE 安全性方面以及临床变量对事件发生率的影响。方法：前瞻性研究纳入了 137 名接受 TEE 并伴有<2>MZ</2>和中度镇静的患者。我们分析了以下事件：与局部麻醉相关的并发症、<3>MZ</3>的使用以及手术相关的并发症。单变量和多变量分析用于检验临床变量的影响：年龄、性别、<11>中风</11>、<12>心肌病</12>（<13>MP</13>）、持续时间、<16>二尖瓣反流</16>（<17>MR</17>）和<4>MZ</4>剂量。结果：所有患者（65 +/-16 岁；58% 为男性）均完成了检查。平均<5>MZ</5>和<24>FL</24>的剂量分别为4.3 + / - 1.9 毫克和0.28 + / - 0.2 毫克。检查持续时间和平均射血分数（EF）分别为16.4 + / - 6.1 分钟和60 + / - 9%。轻度<8>缺氧</8>（SO2 < 90%）是最常见的事件（11 名患者）；3 例（2%）因探头引入导致上<20>气道阻塞</20>而出现一过性<9>缺氧</9>，8 例（5.8%）由于<6>MZ</6>使用导致<10>缺氧</10>。一过性<21>低血压</21> (SAP < 90mmHg) 发生在1例患者 (0.7%) 中。多变量分析显示，严重的<18>MR</18>、<14>MP</14> (EF < 45%) 和高剂量的<7>MZ</7> (> 5mg) 与事件相关(p < 0.001)。 <15>MP</15>组的 EF 为40%，严重<19>MR</19>组的 EF 为44%，这可能是最后一组临床事件的相关因素。结论：镇静TEE的事件发生率较低。没有发生严重事件，也没有必要中断检查。", "revised": true}
{"doc_key": "19803309", "sentences": [["Anaesthetists", "'", "nightmare", ":", "masseter", "spasm", "after", "induction", "in", "an", "undiagnosed", "case", "of", "myotonia", "congenita", ".", "We", "report", "an", "undiagnosed", "case", "of", "myotonia", "congenita", "in", "a", "24", "-", "year", "-", "old", "previously", "healthy", "primigravida", ",", "who", "developed", "life", "threatening", "masseter", "spasm", "following", "a", "standard", "dose", "of", "intravenous", "suxamethonium", "for", "induction", "of", "anaesthesia", ".", "Neither", "the", "patient", "nor", "the", "anaesthetist", "was", "aware", "of", "the", "diagnosis", "before", "this", "potentially", "lethal", "complication", "occurred", "."]], "ner": [[[47, 47, "Chemical"], [4, 5, "Disease"], [39, 40, "Disease"], [13, 14, "Disease"], [22, 23, "Disease"]]], "relations": [[[47, 47, 4, 5, "CID"], [47, 47, 39, 40, "CID"]]], "clusters": [], "translated": "麻醉师的噩梦：<1>咬肌痉挛</1> 在未确诊患有<3>先天性肌强直</3>的病例诱导后发生。我们报告了一名24岁的既往健康的初产妇，她患有未确诊的<4>先天性肌强直</4>。在接受标准剂量的静脉注射<0>琥珀</0>诱导麻醉后，她发生了危及生命的<2>咬肌痉挛</2>。在这种可能致命的并发症发生之前，患者和麻醉师都不知道她有这个病。", "revised": true}
{"doc_key": "9660111", "sentences": [["Repeated", "trimipramine", "induces", "dopamine", "D2", "/", "D3", "and", "alpha1", "-", "adrenergic", "up", "-", "regulation", ".", "Trimipramine", "(", "TRI", ")", ",", "which", "shows", "a", "clinical", "antidepressant", "activity", ",", "is", "chemically", "related", "to", "imipramine", "but", "does", "not", "inhibit", "the", "reuptake", "of", "noradrenaline", "and", "5", "-", "hydroxytryptamine", ",", "nor", "does", "it", "induce", "beta", "-", "adrenergic", "down", "-", "regulation", ".", "The", "mechanism", "of", "its", "antidepressant", "activity", "is", "still", "unknown", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "find", "out", "whether", "TRI", "given", "repeatedly", "was", "able", "to", "induce", "adaptive", "changes", "in", "the", "dopaminergic", "and", "alpha1", "-", "adrenergic", "systems", ",", "demonstrated", "by", "us", "previously", "for", "various", "antidepressants", ".", "TRI", "was", "given", "to", "male", "Wistar", "rats", "and", "male", "Albino", "Swiss", "mice", "perorally", "twice", "daily", "for", "14", "days", ".", "In", "the", "acute", "experiment", "TRI", "(", "given", "i", ".", "p", ".", ")", "does", "not", "antagonize", "the", "reserpine", "hypothermia", "in", "mice", "and", "does", "not", "potentiate", "the", "5", "-", "hydroxytryptophan", "head", "twitches", "in", "rats", ".", "TRI", "given", "repeatedly", "to", "rats", "increases", "the", "locomotor", "hyperactivity", "induced", "by", "d", "-", "amphetamine", ",", "quinpirole", "and", "(", "+", ")", "-", "7", "-", "hydroxy", "-", "dipropyloaminotetralin", "(", "dopamine", "D2", "and", "D3", "effects", ")", ".", "The", "stereotypies", "induced", "by", "d", "-", "amphetamine", "or", "apomorphine", "are", "not", "potentiated", "by", "TRI", ".", "It", "increases", "the", "behaviour", "stimulation", "evoked", "by", "phenylephrine", "(", "given", "intraventricularly", ")", "in", "rats", ",", "evaluated", "in", "the", "open", "field", "test", "as", "well", "as", "the", "aggressiveness", "evoked", "by", "clonidine", "in", "mice", ",", "both", "these", "effects", "being", "mediated", "by", "an", "alpha1", "-", "adrenergic", "receptor", ".", "It", "may", "be", "concluded", "that", ",", "like", "other", "tricyclic", "antidepressants", "studied", "previously", ",", "TRI", "given", "repeatedly", "increases", "the", "responsiveness", "of", "brain", "dopamine", "D2", "and", "D3", "(", "locomotor", "activity", "but", "not", "stereotypy", ")", "as", "well", "as", "alpha1", "-", "adrenergic", "receptors", "to", "their", "agonists", ".", "A", "question", "arises", "whether", "the", "reuptake", "inhibition", "is", "of", "any", "importance", "to", "the", "adaptive", "changes", "induced", "by", "repeated", "antidepressants", ",", "suggested", "to", "be", "responsible", "for", "the", "antidepressant", "activity", "."]], "ner": [[[1, 1, "Chemical"], [15, 15, "Chemical"], [17, 17, "Chemical"], [77, 77, "Chemical"], [103, 103, "Chemical"], [126, 126, "Chemical"], [155, 155, "Chemical"], [202, 202, "Chemical"], [261, 261, "Chemical"], [163, 163, "Disease"], [138, 138, "Chemical"], [139, 139, "Disease"], [166, 168, "Chemical"], [193, 195, "Chemical"], [170, 170, "Chemical"], [229, 229, "Disease"], [3, 3, "Chemical"], [182, 182, "Chemical"], [269, 269, "Chemical"], [24, 24, "Chemical"], [60, 60, "Chemical"], [101, 101, "Chemical"], [257, 257, "Chemical"], [309, 309, "Chemical"], [317, 317, "Chemical"], [31, 31, "Chemical"], [39, 39, "Chemical"], [41, 43, "Chemical"], [147, 149, "Chemical"], [197, 197, "Chemical"], [211, 211, "Chemical"], [232, 232, "Chemical"]]], "relations": [[[1, 1, 163, 163, "CID"], [15, 15, 163, 163, "CID"], [17, 17, 163, 163, "CID"], [77, 77, 163, 163, "CID"], [103, 103, 163, 163, "CID"], [126, 126, 163, 163, "CID"], [155, 155, 163, 163, "CID"], [202, 202, 163, 163, "CID"], [261, 261, 163, 163, "CID"], [138, 138, 139, 139, "CID"], [166, 168, 163, 163, "CID"], [193, 195, 163, 163, "CID"], [170, 170, 163, 163, "CID"]]], "clusters": [], "translated": "重复<0>曲米帕明</0>诱导<16>多巴胺</16>D2/D3和α1-肾上腺素能上调。 <1>曲米帕明</1> (<2>TRI</2>)显示出临床<19>抗抑郁</19>活性，与<25>丙咪嗪</25>化学相关，但不抑制<26>去甲肾上腺素</26>和<27>5-羟色胺</27>的再摄取，也不会引起β-肾上腺素能下调。其<20>抗抑郁</20>作用的机制尚不清楚。本研究的目的是确定反复给予<3>TRI</3>是否能够诱导多巴胺能和alpha1-肾上腺素能系统的适应性变化，我们之前针对各种<21>抗抑郁药</21>进行了证明。<4>TRI</4>给予雄性Wistar大鼠和雄性Albino Swiss小鼠口服，每天两次，持续14天。在急性实验中，<5>TRI</5>(给予i.p.)不会拮抗小鼠的<10>利血平</10><11>体温过低</11>并且不会增强<28>5 - 羟色氨酸</28>大鼠的头部抽搐。<6>TRI</6>反复给予大鼠可增加<12>d-苯丙胺</12>、<14>喹吡罗</14>和(+) - 7 - 羟基 - 二丙基氨基四氢化萘(<17>多巴胺</17>D2和D3作用)诱导的运动<9>多动</9>。 <13>d-苯丙胺</13>或<29>阿扑吗啡</29>诱导的刻板印象不会被<7>TRI</7>增强。它增加了大鼠中<30>去氧肾上腺素</30>(脑室内给药)引起的行为刺激，在旷场试验以及<31>可乐定</31>引起的<15>攻击性</15>中进行了评估在小鼠中，这两种作用均由α1-肾上腺素能受体介导。可以得出结论，与之前研究的其他三环类<22>抗抑郁药</22>一样，反复给予<8>TRI</8>会增加大脑<18>多巴胺</18>D2和D3(运动活动但不是刻板印象)以及alpha1-肾上腺素能受体对它们的激动剂。一个问题是，再摄取抑制是否对重复<23>抗抑郁药</23>引起的适应性变化有任何重要性，这表明它与<24>抗抑郁药</24>活性有关。", "revised": true}
{"doc_key": "8372922", "sentences": [["Neuroplasticity", "of", "the", "adult", "primate", "auditory", "cortex", "following", "cochlear", "hearing", "loss", ".", "Tonotopic", "organization", "is", "an", "essential", "feature", "of", "the", "primary", "auditory", "area", "(", "A1", ")", "of", "primate", "cortex", ".", "In", "A1", "of", "macaque", "monkeys", ",", "low", "frequencies", "are", "represented", "rostrolaterally", "and", "high", "frequencies", "are", "represented", "caudomedially", ".", "The", "purpose", "of", "this", "study", "was", "to", "determine", "if", "changes", "occur", "in", "this", "tonotopic", "organization", "following", "cochlear", "hearing", "loss", ".", "Under", "anesthesia", ",", "the", "superior", "temporal", "gyrus", "of", "adult", "macaque", "monkeys", "was", "exposed", ",", "and", "the", "tonotopic", "organization", "of", "A1", "was", "mapped", "using", "conventional", "microelectrode", "recording", "techniques", ".", "Following", "recovery", ",", "the", "monkeys", "were", "selectively", "deafened", "for", "high", "frequencies", "using", "kanamycin", "and", "furosemide", ".", "The", "actual", "frequencies", "deafened", "were", "determined", "by", "the", "loss", "of", "tone", "-", "burst", "elicited", "auditory", "brainstem", "responses", ".", "Three", "months", "after", "deafening", ",", "A1", "was", "remapped", ".", "Postmortem", "cytoarchitectural", "features", "identifying", "A1", "were", "correlated", "with", "the", "electrophysiologic", "data", ".", "The", "results", "indicate", "that", "the", "deprived", "area", "of", "A1", "undergoes", "extensive", "reorganization", "and", "becomes", "responsive", "to", "intact", "cochlear", "frequencies", ".", "The", "region", "of", "cortex", "that", "represents", "the", "low", "frequencies", "was", "not", "obviously", "affected", "by", "the", "cochlear", "hearing", "loss", "."]], "ner": [[[108, 108, "Chemical"], [9, 10, "Disease"], [65, 66, "Disease"], [187, 188, "Disease"], [110, 110, "Chemical"]]], "relations": [[[108, 108, 9, 10, "CID"], [108, 108, 65, 66, "CID"], [108, 108, 187, 188, "CID"], [110, 110, 9, 10, "CID"], [110, 110, 65, 66, "CID"], [110, 110, 187, 188, "CID"]]], "clusters": [], "translated": "耳蜗<1>听力损失</1>后成年灵长类动物听觉皮层的神经可塑性。Tonotopic组织是灵长类动物皮层初级听觉区 (A1) 的基本特征。在猕猴的 A1 中，低频在头外侧代表，高频在尾内侧代表。本研究的目的是确定在耳蜗<2>听力损失</2>后这种音调组织是否发生变化。在麻醉下，暴露成年猕猴的颞上回，并使用常规微电极记录技术绘制A1的紧张性组织图。恢复后，使用<0>卡那霉素</0>和<4>呋塞米</4>选择性地使猴子的高频耳聋。耳聋的实际频率是由突发音引起的听觉脑干反应的丧失决定的。震耳欲聋三个月后，A1被重新映射。鉴定A1的死后细胞结构特征与电生理数据相关。结果表明，A1的剥夺区域经历了广泛的重组，并对完整的耳蜗频率产生了反应。代表低频的皮层区域受耳蜗<3>听力损失</3>的影响不明显。", "revised": true}
{"doc_key": "2476560", "sentences": [["Is", "the", "treatment", "of", "scabies", "hazardous", "?", "Treatment", "for", "scabies", "is", "usually", "initiated", "by", "general", "practitioners", ";", "most", "consider", "lindane", "(", "gamma", "benzene", "hexachloride", ")", "the", "treatment", "of", "choice", ".", "Lindane", "is", "also", "widely", "used", "as", "an", "agricultural", "and", "industrial", "pesticide", ",", "and", "as", "a", "result", "the", "toxic", "profile", "of", "this", "insecticide", "is", "well", "understood", ".", "Evidence", "is", "accumulating", "that", "lindane", "can", "be", "toxic", "to", "the", "central", "nervous", "system", "and", "may", "be", "associated", "with", "aplastic", "anaemia", ".", "Preparations", "containing", "lindane", "continue", "to", "be", "sold", "over", "the", "counter", "and", "may", "represent", "a", "hazard", "to", "poorly", "informed", "patients", ".", "This", "literature", "review", "suggests", "that", "general", "practitioners", "should", "prescribe", "scabicides", "with", "increased", "caution", "for", "certain", "at", "-", "risk", "groups", ",", "and", "give", "adequate", "warnings", "regarding", "potential", "toxicity", "."]], "ner": [[[19, 19, "Chemical"], [21, 23, "Chemical"], [30, 30, "Chemical"], [60, 60, "Chemical"], [79, 79, "Chemical"], [63, 68, "Disease"], [74, 75, "Disease"], [4, 4, "Disease"], [9, 9, "Disease"], [123, 123, "Disease"]]], "relations": [[[19, 19, 63, 68, "CID"], [21, 23, 63, 68, "CID"], [30, 30, 63, 68, "CID"], [60, 60, 63, 68, "CID"], [79, 79, 63, 68, "CID"], [19, 19, 74, 75, "CID"], [21, 23, 74, 75, "CID"], [30, 30, 74, 75, "CID"], [60, 60, 74, 75, "CID"], [79, 79, 74, 75, "CID"]]], "clusters": [], "translated": "治疗<7>疥疮</7>有危险吗？<8>疥疮</8>的治疗通常由全科医生发起；大多数人考虑选择<0>林丹</0>（<1>γ-六氯化苯</1>）作为治疗选择。<2>林丹</2>也被广泛用作农业和工业杀虫剂，因此这种杀虫剂的毒性是众所周知的。越来越多的证据表明，<3>林丹</3>可能会<5>对中枢神经系统有毒</5>，并且可能与<6>再生障碍性贫血</6>有关。含有<4>林丹</4>的制剂继续在柜台销售，可能对消息不灵通的患者构成危害。这篇文献综述表明，全科医生在开具杀螨剂处方时应更加谨慎地对待某些高危人群，并就潜在的<9>毒性</9>给予足够的警告。", "revised": true}
{"doc_key": "18752389", "sentences": [["Simvastatin", "-", "ezetimibe", "-", "induced", "hepatic", "failure", "necessitating", "liver", "transplantation", ".", "Abstract", "Serum", "aminotransferase", "elevations", "are", "a", "commonly", "known", "adverse", "effect", "of", "3", "-", "hydroxy", "-", "3", "-", "methylglutaryl", "coenzyme", "A", "reductase", "inhibitor", "(", "statin", ")", "therapy", ".", "However", ",", "hepatotoxic", "events", "have", "not", "been", "widely", "published", "with", "ezetimibe", "or", "the", "combination", "agent", "simvastatin", "-", "ezetimibe", ".", "We", "describe", "a", "70", "-", "year", "-", "old", "Hispanic", "woman", "who", "developed", "fulminant", "hepatic", "failure", "necessitating", "liver", "transplantation", "10", "weeks", "after", "conversion", "from", "simvastatin", "40", "mg", "/", "day", "to", "simvastatin", "10", "mg", "-", "ezetimibe", "40", "mg", "/", "day", ".", "The", "patient", "'s", "lipid", "panel", "had", "been", "maintained", "with", "simvastatin", "for", "18", "months", "before", "the", "conversion", "without", "evidence", "of", "hepatotoxicity", ".", "A", "routine", "laboratory", "work", "-", "up", "10", "weeks", "after", "conversion", "revealed", "elevated", "serum", "aminotransferase", "levels", ".", "Simvastatinezetimibe", "and", "escitalopram", "(", "which", "she", "was", "taking", "for", "depression", ")", "were", "discontinued", ",", "and", "other", "potential", "causes", "of", "hepatotoxicity", "were", "excluded", ".", "A", "repeat", "work", "-", "up", "revealed", "further", "elevations", "in", "aminotransferase", "levels", ",", "and", "liver", "biopsy", "revealed", "evidence", "of", "moderate", "-", "to", "-", "severe", "drug", "toxicity", ".", "She", "underwent", "liver", "transplantation", "with", "an", "uneventful", "postoperative", "course", ".", "Her", "aminotransferase", "levels", "returned", "to", "normal", "by", "postoperative", "day", "23", ",", "and", "her", "2", "-", "year", "follow", "-", "up", "showed", "no", "adverse", "events", ".", "Ezetimibe", "undergoes", "extensive", "glucuronidation", "by", "uridine", "diphosphate", "glucoronosyltransferases", "(", "UGT", ")", "in", "the", "intestine", "and", "liver", "and", "may", "have", "inhibited", "the", "glucuronidation", "of", "simvastatin", "hydroxy", "acid", ",", "resulting", "in", "increased", "simvastatin", "exposure", "and", "subsequent", "hepatotoxicity", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "report", "of", "simvastatin", "-", "ezetimibe", "-", "induced", "liver", "failure", "that", "resulted", "in", "liver", "transplantation", ".", "We", "postulate", "that", "the", "mechanism", "of", "the", "simvastatinezetimibe", "-", "induced", "hepatotoxicity", "is", "the", "increased", "simvastatin", "exposure", "by", "ezetimibe", "inhibition", "of", "UGT", "enzymes", ".", "Clinicians", "should", "be", "aware", "of", "potential", "hepatotoxicity", "with", "simvastatin", "-", "ezetimibe", "especially", "in", "elderly", "patients", "and", "should", "carefully", "monitor", "serum", "aminotransferase", "levels", "when", "starting", "therapy", "and", "titrating", "the", "dosage", "."]], "ner": [[[0, 2, "Chemical"], [53, 55, "Chemical"], [86, 92, "Chemical"], [133, 133, "Chemical"], [263, 265, "Chemical"], [283, 283, "Chemical"], [307, 309, "Chemical"], [40, 40, "Disease"], [115, 115, "Disease"], [152, 152, "Disease"], [250, 250, "Disease"], [286, 286, "Disease"], [305, 305, "Disease"], [69, 71, "Disease"], [5, 6, "Disease"], [268, 269, "Disease"], [142, 142, "Disease"], [179, 180, "Disease"], [34, 34, "Chemical"], [80, 80, "Chemical"], [105, 105, "Chemical"], [246, 246, "Chemical"], [290, 290, "Chemical"], [48, 48, "Chemical"], [216, 216, "Chemical"], [293, 293, "Chemical"], [135, 135, "Chemical"], [221, 222, "Chemical"], [239, 241, "Chemical"]]], "relations": [[[0, 2, 40, 40, "CID"], [0, 2, 115, 115, "CID"], [0, 2, 152, 152, "CID"], [0, 2, 250, 250, "CID"], [0, 2, 286, 286, "CID"], [0, 2, 305, 305, "CID"], [53, 55, 40, 40, "CID"], [53, 55, 115, 115, "CID"], [53, 55, 152, 152, "CID"], [53, 55, 250, 250, "CID"], [53, 55, 286, 286, "CID"], [53, 55, 305, 305, "CID"], [86, 92, 40, 40, "CID"], [86, 92, 115, 115, "CID"], [86, 92, 152, 152, "CID"], [86, 92, 250, 250, "CID"], [86, 92, 286, 286, "CID"], [86, 92, 305, 305, "CID"], [133, 133, 40, 40, "CID"], [133, 133, 115, 115, "CID"], [133, 133, 152, 152, "CID"], [133, 133, 250, 250, "CID"], [133, 133, 286, 286, "CID"], [133, 133, 305, 305, "CID"], [263, 265, 40, 40, "CID"], [263, 265, 115, 115, "CID"], [263, 265, 152, 152, "CID"], [263, 265, 250, 250, "CID"], [263, 265, 286, 286, "CID"], [263, 265, 305, 305, "CID"], [283, 283, 40, 40, "CID"], [283, 283, 115, 115, "CID"], [283, 283, 152, 152, "CID"], [283, 283, 250, 250, "CID"], [283, 283, 286, 286, "CID"], [283, 283, 305, 305, "CID"], [307, 309, 40, 40, "CID"], [307, 309, 115, 115, "CID"], [307, 309, 152, 152, "CID"], [307, 309, 250, 250, "CID"], [307, 309, 286, 286, "CID"], [307, 309, 305, 305, "CID"], [0, 2, 69, 71, "CID"], [53, 55, 69, 71, "CID"], [86, 92, 69, 71, "CID"], [133, 133, 69, 71, "CID"], [263, 265, 69, 71, "CID"], [283, 283, 69, 71, "CID"], [307, 309, 69, 71, "CID"]]], "clusters": [], "translated": "<0>辛伐他汀-依折麦布</0>诱发的<14>肝功能衰竭</14>需要肝移植。摘要：血清转氨酶升高是 3-羟基-3-甲基戊二酰辅酶 A 还原酶抑制剂（<18>他汀</18>）治疗的常见不良反应。然而，<23>依折麦布</23>或联合用药 <1>辛伐他汀-依折麦布</1> 的 <7>肝毒性</7> 事件尚未广泛发表。我们描述了一名 70 岁的西班牙裔女性，她在从 <19>辛伐他汀</19> 40 毫克/天转换为 <2>辛伐他汀-依折麦布</2> 10 毫克/天后 10 周发生 <13>暴发性肝功能衰竭</13> 需要进行肝移植。患者的血脂指标已使用 <20>辛伐他汀</20> 维持 18 个月，没有 <8>肝毒性</8> 的证据。转化后 10 周的常规实验室检查显示血清转氨酶水平升高。<3>辛伐他汀-依折麦布</3> 和<26> escitalopram </26>（她因<16>抑郁症</16>而服用）已停用，并排除了<9>肝毒性</9>的其他潜在原因。重复检查显示转氨酶水平进一步升高，肝活检显示中度至重度<17>药物毒性</17>。她接受了肝移植手术，术后过程顺利。到术后第 23 天，她的转氨酶水平恢复正常，2 年的随访显示没有不良事件发生。<24>依折麦布</24>在肠道和肝脏中通过 <27>尿苷二磷酸</27> 葡萄糖醛酸转移酶 (UGT) 进行广泛的葡萄糖醛酸化，并可能抑制<28>辛伐他汀羟基酸</28> 的葡萄糖醛酸化，导致增加<21>辛伐他汀</21> 暴露和随后的<10>肝毒性</10>。据了解，这是首例因 <4>辛伐他汀-依折麦布</4> 诱发<15>肝功能衰竭</15> 而进行肝移植的病例报告。我们假设<5>辛伐他汀</5>诱导的<11>肝毒性</11>的机制是通过<25>依折麦布</25> 抑制 UGT 酶增加 <22>辛伐他汀</22> 暴露。临床医生应注意<6>辛伐他汀-依折麦布</6>的潜在<12>肝毒性</12>，尤其是老年患者，在开始治疗和调整剂量时应仔细监测血清转氨酶水平。", "revised": true}
{"doc_key": "17344566", "sentences": [["Simvastatin", "-", "induced", "bilateral", "leg", "compartment", "syndrome", "and", "myonecrosis", "associated", "with", "hypothyroidism", ".", "A", "54", "-", "year", "-", "old", "hypothyroid", "male", "taking", "thyroxine", "and", "simvastatin", "presented", "with", "bilateral", "leg", "compartment", "syndrome", "and", "myonecrosis", ".", "Urgent", "fasciotomies", "were", "performed", "and", "the", "patient", "made", "an", "uneventful", "recovery", "with", "the", "withdrawal", "of", "simvastatin", ".", "It", "is", "likely", "that", "this", "complication", "will", "be", "seen", "more", "often", "with", "the", "increased", "worldwide", "use", "of", "this", "drug", "and", "its", "approval", "for", "all", "arteriopathic", "patients", "."]], "ner": [[[0, 0, "Chemical"], [24, 24, "Chemical"], [49, 49, "Chemical"], [5, 6, "Disease"], [29, 30, "Disease"], [8, 8, "Disease"], [32, 32, "Disease"], [11, 11, "Disease"], [19, 19, "Disease"], [75, 75, "Disease"], [22, 22, "Chemical"]]], "relations": [[[0, 0, 5, 6, "CID"], [0, 0, 29, 30, "CID"], [24, 24, 5, 6, "CID"], [24, 24, 29, 30, "CID"], [49, 49, 5, 6, "CID"], [49, 49, 29, 30, "CID"]]], "clusters": [], "translated": " <0>辛伐他汀</0>诱发的双侧腿<3>筋膜室综合征</3>和<5>肌坏死</5>与<7>甲状腺功能减退症</7>有关。一名服用<10>甲状腺素</10>和 <1>辛伐他汀</1> 的 54 岁<8>甲状腺功能减退</8>男性出现双侧腿<4>间室综合征</4>和 <6>肌坏死</6>。进行了紧急筋膜切开术，患者在停用<2>辛伐他汀</2>后顺利康复。随着这种药物在世界范围内的使用增加以及它被批准用于所有<9>动脉病</9>患者，这种并发症很可能会更频繁地出现。", "revised": true}
{"doc_key": "6634932", "sentences": [["Sublingual", "absorption", "of", "the", "quaternary", "ammonium", "antiarrhythmic", "agent", ",", "UM", "-", "272", ".", "UM", "-", "272", "(", "N", ",", "N", "-", "dimethylpropranolol", ")", ",", "a", "quaternary", "antiarrhythmic", "agent", ",", "was", "administered", "sublingually", "to", "dogs", "with", "ouabain", "-", "induced", "ventricular", "tachycardias", ".", "Both", "anti", "-", "arrhythmic", "efficacy", "and", "bioavailability", "were", "compared", "to", "oral", "drug", ".", "Sublingual", "UM", "-", "272", "converted", "ventricular", "tachycardia", "to", "sinus", "rhythm", "in", "all", "5", "dogs", ".", "The", "area", "under", "the", "plasma", "concentration", "time", "curve", "at", "90", "min", "was", "4", "-", "12", "times", "greater", "than", "for", "oral", "drug", ",", "suggesting", "the", "existence", "of", "an", "absorption", "-", "limiting", "process", "in", "the", "intestine", ",", "and", "providing", "an", "alternate", "form", "of", "administration", "for", "quaternary", "drugs", "."]], "ner": [[[35, 35, "Chemical"], [38, 39, "Disease"], [59, 60, "Disease"], [4, 5, "Chemical"], [9, 11, "Chemical"], [13, 15, "Chemical"], [17, 21, "Chemical"], [55, 57, "Chemical"]]], "relations": [[[35, 35, 38, 39, "CID"], [35, 35, 59, 60, "CID"]]], "clusters": [], "translated": "<3>季铵盐</3>抗心律失常药<4>UM-272</4>的舌下吸收。 <5>UM-272</5>(<6>N,N-二甲基普萘洛尔</6>)是一种季铵盐类抗心律失常药，舌下给予犬<0>哇巴因</0>诱导的<1>心室心动过速</1>。抗心律失常功效和生物利用度均与口服药物进行了比较。舌下含服<7>UM-272</7>将所有5只犬的<2>室性心动过速</2>转为窦性心律。90分钟时血浆浓度时间曲线下的面积比口服药物大4-12倍，表明在肠道中存在吸收限制过程，并为季铵盐药物提供了另一种给药方式。", "revised": true}
{"doc_key": "2348231", "sentences": [["Pentoxifylline", "(", "Trental", ")", "does", "not", "inhibit", "dipyridamole", "-", "induced", "coronary", "hyperemia", ":", "implications", "for", "dipyridamole", "-", "thallium", "-", "201", "myocardial", "imaging", ".", "Dipyridamole", "-", "thallium", "-", "201", "imaging", "is", "often", "performed", "in", "patients", "unable", "to", "exercise", "because", "of", "peripheral", "vascular", "disease", ".", "Many", "of", "these", "patients", "are", "taking", "pentoxifylline", "(", "Trental", ")", ",", "a", "methylxanthine", "derivative", "which", "may", "improve", "intermittent", "claudication", ".", "Whether", "pentoxifylline", "inhibits", "dipyridamole", "-", "induced", "coronary", "hyperemia", "like", "other", "methylxanthines", "such", "as", "theophylline", "and", "should", "be", "stopped", "prior", "to", "dipyridamole", "-", "thallium", "-", "201", "imaging", "is", "unknown", ".", "Therefore", ",", "we", "studied", "the", "hyperemic", "response", "to", "dipyridamole", "in", "seven", "open", "-", "chest", "anesthetized", "dogs", "after", "pretreatment", "with", "either", "pentoxifylline", "(", "0", ",", "7", ".", "5", ",", "or", "15", "mg", "/", "kg", "i", ".", "v", ".", ")", "or", "theophylline", "(", "3", "mg", "/", "kg", "i", ".", "v", ".", ")", ".", "Baseline", "circumflex", "coronary", "blood", "flows", "did", "not", "differ", "significantly", "among", "treatment", "groups", ".", "Dipyridamole", "significantly", "increased", "coronary", "blood", "flow", "before", "and", "after", "7", ".", "5", "or", "15", "mm", "/", "kg", "i", ".", "v", ".", "pentoxifylline", "(", "p", "less", "than", "0", ".", "002", ")", ".", "Neither", "dose", "of", "pentoxifylline", "significantly", "decreased", "the", "dipyridamole", "-", "induced", "hyperemia", ",", "while", "peak", "coronary", "blood", "flow", "was", "significantly", "lower", "after", "theophylline", "(", "p", "less", "than", "0", ".", "01", ")", ".", "We", "conclude", "that", "pentoxyifylline", "does", "not", "inhibit", "dipyridamole", "-", "induced", "coronary", "hyperemia", "even", "at", "high", "doses", "."]], "ner": [[[0, 0, "Chemical"], [2, 2, "Chemical"], [49, 49, "Chemical"], [51, 51, "Chemical"], [64, 64, "Chemical"], [112, 112, "Chemical"], [177, 177, "Chemical"], [190, 190, "Chemical"], [221, 221, "Chemical"], [60, 61, "Disease"], [7, 7, "Chemical"], [15, 15, "Chemical"], [23, 23, "Chemical"], [66, 66, "Chemical"], [83, 83, "Chemical"], [100, 100, "Chemical"], [156, 156, "Chemical"], [194, 194, "Chemical"], [225, 225, "Chemical"], [11, 11, "Disease"], [70, 70, "Disease"], [197, 197, "Disease"], [229, 229, "Disease"], [39, 41, "Disease"], [17, 17, "Chemical"], [25, 25, "Chemical"], [85, 85, "Chemical"], [55, 55, "Chemical"], [73, 73, "Chemical"], [76, 76, "Chemical"], [131, 131, "Chemical"], [208, 208, "Chemical"]]], "relations": [[[0, 0, 60, 61, "CID"], [2, 2, 60, 61, "CID"], [49, 49, 60, 61, "CID"], [51, 51, 60, 61, "CID"], [64, 64, 60, 61, "CID"], [112, 112, 60, 61, "CID"], [177, 177, 60, 61, "CID"], [190, 190, 60, 61, "CID"], [221, 221, 60, 61, "CID"], [7, 7, 11, 11, "CID"], [7, 7, 70, 70, "CID"], [7, 7, 197, 197, "CID"], [7, 7, 229, 229, "CID"], [15, 15, 11, 11, "CID"], [15, 15, 70, 70, "CID"], [15, 15, 197, 197, "CID"], [15, 15, 229, 229, "CID"], [23, 23, 11, 11, "CID"], [23, 23, 70, 70, "CID"], [23, 23, 197, 197, "CID"], [23, 23, 229, 229, "CID"], [66, 66, 11, 11, "CID"], [66, 66, 70, 70, "CID"], [66, 66, 197, 197, "CID"], [66, 66, 229, 229, "CID"], [83, 83, 11, 11, "CID"], [83, 83, 70, 70, "CID"], [83, 83, 197, 197, "CID"], [83, 83, 229, 229, "CID"], [100, 100, 11, 11, "CID"], [100, 100, 70, 70, "CID"], [100, 100, 197, 197, "CID"], [100, 100, 229, 229, "CID"], [156, 156, 11, 11, "CID"], [156, 156, 70, 70, "CID"], [156, 156, 197, 197, "CID"], [156, 156, 229, 229, "CID"], [194, 194, 11, 11, "CID"], [194, 194, 70, 70, "CID"], [194, 194, 197, 197, "CID"], [194, 194, 229, 229, "CID"], [225, 225, 11, 11, "CID"], [225, 225, 70, 70, "CID"], [225, 225, 197, 197, "CID"], [225, 225, 229, 229, "CID"]]], "clusters": [], "translated": " <0>己酮可可碱</0> (<1>Trental</1>) 不抑制<10>双嘧达莫</10>-诱导的冠状动脉<19>充血</19>：对<11>双嘧达莫</11>-<24>铊</24>-201心肌显像的影响。 <12>双嘧达莫</12>-<25>铊</25>-201成像常用于因<23>外周血管疾病</23>而无法运动的患者。许多这些患者正在服用<2>己酮可可碱</2> (<3>Trental</3>)，这是一种<27>甲基黄嘌呤</27>衍生物，可以改善<9>间歇性跛行</9>。<4>己酮可可碱</4>是否像其他<28>甲基黄嘌呤</28>如<29>茶碱</29>一样抑制<13>双嘧达莫</13>-诱导的冠状动脉<20>充血</20>并需停用在进行<14>双嘧达莫</14>-<26>铊</26>-201显像前尚不明确。因此，我们研究了用<5>己酮可可碱</5> (0, 7.5或15毫克/千克i.v.)或<30>茶碱</30> (3毫克/千克i.v.)预处理后七只开胸麻醉狗，对<15>双嘧达莫</15>的充血反应进行了研究。治疗组的基线回旋支冠状动脉血流量没有显着差异。<16>双嘧达莫</16>显著增加冠状动脉血流量，而<6>己酮可可碱</6>在7.5或15毫克/千克i.v.后并未显著降低<17>双嘧达莫</17>-诱导的<21>充血</21>。在<7>己酮可可碱</7>的消费下<17>双嘧达莫</17>-诱导的<21>充血</21>也未显著降低，而<31>茶碱</31>后峰值冠状动脉血流量显著降低(p<0.01)。我们得出结论，即使在高剂量下，<8>己酮可可碱</8>也不会抑制<18>双嘧达莫</18>-诱导的冠状动脉<22>充血</22>。", "revised": true}
{"doc_key": "15338796", "sentences": [["Tremor", "side", "effects", "of", "salbutamol", ",", "quantified", "by", "a", "laser", "pointer", "technique", ".", "OBJECTIVE", ":", "To", "study", "tremor", "side", "effects", "of", "salbutamol", "an", "easily", "applicable", ",", "quick", "and", "low", "-", "priced", "method", "is", "needed", ".", "A", "new", "method", "using", "a", "commercially", "available", ",", "pen", "-", "shaped", "laser", "pointer", "was", "developed", ".", "Aim", "of", "the", "study", "was", "to", "determine", "sensitivity", ",", "reproducibility", ",", "reference", "values", "and", "the", "agreement", "with", "a", "questionnaire", ".", "METHODS", ":", "Tremor", "was", "measured", "using", "a", "laser", "pointer", "technique", ".", "To", "determine", "sensitivity", "we", "assessed", "tremor", "in", "44", "patients", "with", "obstructive", "lung", "disease", "after", "administration", "of", "cumulative", "doses", "of", "salbutamol", ".", "Subjects", "were", "asked", "to", "aim", "at", "the", "centre", "of", "a", "target", ",", "subdivided", "in", "concentric", "circles", ",", "from", "5", "m", "distance", ".", "The", "circle", "in", "which", "the", "participant", "succeeded", "to", "aim", "was", "recorded", "in", "millimetres", "radius", ".", "In", "another", "series", "of", "measurements", ",", "reproducibility", "and", "reference", "values", "of", "the", "tremor", "was", "assessed", "in", "65", "healthy", "subjects", "in", "three", "sessions", ",", "at", "9", "a", ".", "m", ".", ",", "4", "p", ".", "m", ".", "and", "9", "a", ".", "m", ".", ",", "respectively", ",", "1", "week", "later", ".", "Postural", "tremor", "was", "measured", "with", "the", "arm", "horizontally", "outstretched", "rest", "tremor", "with", "the", "arm", "supported", "by", "an", "armrest", "and", "finally", "tremor", "was", "measured", "after", "holding", "a", "2", "-", "kg", "weight", "until", "exhaustion", ".", "Inter", "-", "observer", "variability", "was", "measured", "in", "a", "series", "of", "10", "healthy", "subjects", ".", "Tremor", "was", "measured", "simultaneously", "by", "two", "independent", "observers", ".", "RESULTS", ":", "Salbutamol", "significantly", "increased", "tremor", "severity", "in", "patients", "in", "a", "dose", "-", "dependent", "way", ".", "Within", "healthy", "adults", "no", "age", "-", "dependency", "could", "be", "found", "(", "b", "=", "0", ".", "262", "mm", "/", "year", ";", "P", "=", "0", ".", "72", ")", ".", "There", "was", "no", "agreement", "between", "the", "questionnaire", "and", "tremor", "severity", "(", "r", "=", "0", ".", "093", ";", "P", "=", "0", ".", "53", ")", ".", "Postural", "tremor", "showed", "no", "significant", "difference", "between", "the", "first", "and", "third", "session", "(", "P", "=", "0", ".", "07", ")", ".", "Support", "of", "the", "arm", "decreased", "tremor", "severity", ",", "exhaustion", "increased", "tremor", "severity", "significantly", ".", "A", "good", "agreement", "was", "found", "between", "two", "independent", "observers", "(", "interclass", "correlation", "coefficient", "0", ".", "72", ")", ".", "DISCUSSION", ":", "Quantifying", "tremor", "by", "using", "an", "inexpensive", "laser", "pointer", "is", ",", "with", "the", "exception", "of", "children", "(", "<", "12", "years", ")", "a", "sensitive", "and", "reproducible", "method", "."]], "ner": [[[4, 4, "Chemical"], [21, 21, "Chemical"], [101, 101, "Chemical"], [246, 246, "Chemical"], [0, 0, "Disease"], [17, 17, "Disease"], [73, 73, "Disease"], [87, 87, "Disease"], [152, 152, "Disease"], [189, 189, "Disease"], [198, 198, "Disease"], [208, 208, "Disease"], [235, 235, "Disease"], [249, 249, "Disease"], [295, 295, "Disease"], [312, 312, "Disease"], [336, 336, "Disease"], [341, 341, "Disease"], [366, 366, "Disease"], [92, 94, "Disease"]]], "relations": [[[4, 4, 0, 0, "CID"], [4, 4, 17, 17, "CID"], [4, 4, 73, 73, "CID"], [4, 4, 87, 87, "CID"], [4, 4, 152, 152, "CID"], [4, 4, 189, 189, "CID"], [4, 4, 198, 198, "CID"], [4, 4, 208, 208, "CID"], [4, 4, 235, 235, "CID"], [4, 4, 249, 249, "CID"], [4, 4, 295, 295, "CID"], [4, 4, 312, 312, "CID"], [4, 4, 336, 336, "CID"], [4, 4, 341, 341, "CID"], [4, 4, 366, 366, "CID"], [21, 21, 0, 0, "CID"], [21, 21, 17, 17, "CID"], [21, 21, 73, 73, "CID"], [21, 21, 87, 87, "CID"], [21, 21, 152, 152, "CID"], [21, 21, 189, 189, "CID"], [21, 21, 198, 198, "CID"], [21, 21, 208, 208, "CID"], [21, 21, 235, 235, "CID"], [21, 21, 249, 249, "CID"], [21, 21, 295, 295, "CID"], [21, 21, 312, 312, "CID"], [21, 21, 336, 336, "CID"], [21, 21, 341, 341, "CID"], [21, 21, 366, 366, "CID"], [101, 101, 0, 0, "CID"], [101, 101, 17, 17, "CID"], [101, 101, 73, 73, "CID"], [101, 101, 87, 87, "CID"], [101, 101, 152, 152, "CID"], [101, 101, 189, 189, "CID"], [101, 101, 198, 198, "CID"], [101, 101, 208, 208, "CID"], [101, 101, 235, 235, "CID"], [101, 101, 249, 249, "CID"], [101, 101, 295, 295, "CID"], [101, 101, 312, 312, "CID"], [101, 101, 336, 336, "CID"], [101, 101, 341, 341, "CID"], [101, 101, 366, 366, "CID"], [246, 246, 0, 0, "CID"], [246, 246, 17, 17, "CID"], [246, 246, 73, 73, "CID"], [246, 246, 87, 87, "CID"], [246, 246, 152, 152, "CID"], [246, 246, 189, 189, "CID"], [246, 246, 198, 198, "CID"], [246, 246, 208, 208, "CID"], [246, 246, 235, 235, "CID"], [246, 246, 249, 249, "CID"], [246, 246, 295, 295, "CID"], [246, 246, 312, 312, "CID"], [246, 246, 336, 336, "CID"], [246, 246, 341, 341, "CID"], [246, 246, 366, 366, "CID"]]], "clusters": [], "translated": " <4>震颤</4><0>沙丁胺醇</0>的副作用，通过激光笔技术量化。目的：研究<1>沙丁胺醇</1>的<5>震颤</5>副作用，需要一种简便、快速、廉价的方法。开发了一种使用市售笔形激光指示器的新方法。该研究的目的是确定灵敏度、再现性、参考值和与问卷的一致性。方法：<6>震颤</6>是用激光笔技术测量的。为确定敏感性，我们评估了 44 名患有<19>阻塞性肺病</19>的患者在服用累积剂量的<2>沙丁胺醇</2>后的<7>震颤</7>。受试者被要求从 5 米的距离瞄准目标的中心，目标被细分为同心圆。参与者成功瞄准的圆圈以毫米为半径记录。在另一系列测量中，<8>震颤</8>的可重复性和参考值在上午 9 点的三个疗程中对 65 名健康受试者进行了评估，在1周后分别为上午9点，下午4点和上午9点。姿势<9>震颤</9>是在水平伸展的手臂休息时测量，<10>手抖</10>是在由扶手支撑的手臂上测量，最后，在握住2公斤的重量直至筋疲力尽后测量<11>震颤</11>。在一系列的10名健康受试者中测量了观察者间的变异性。同时，由两名独立的观察者进行<12>震颤</12>测量。结果显示：<3>沙丁胺醇</3>显着增加患者<13>震颤</13>的严重程度，呈剂量依赖性。在健康成人中未发现年龄相关性(b=0.262 毫米/年；P=0.72)。问卷调查与<14>震颤</14>的严重程度不一致(r=0.093;P=0.53)。姿势性<15>震颤</15>在第一次和第三次之间没有显着差异(P=0.07)。手臂的支撑可以降低<16>震颤</16>的严重程度，而压力测试会显著增加<17>震颤</17>的严重程度。两名独立观察者之间发现了良好的一致性(组间相关系数0.72)。讨论：除儿童(<12岁)外，使用便宜的激光指示器量化<18>震颤</18>是一种灵敏且可重复的方法。", "revised": true}
{"doc_key": "7234705", "sentences": [["Procainamide", "-", "induced", "polymorphous", "ventricular", "tachycardia", ".", "Seven", "cases", "of", "procainamide", "-", "induced", "polymorphous", "ventricular", "tachycardia", "are", "presented", ".", "In", "four", "patients", ",", "polymorphous", "ventricular", "tachycardia", "appeared", "after", "intravenous", "administration", "of", "200", "to", "400", "mg", "of", "procainamide", "for", "the", "treatment", "of", "sustained", "ventricular", "tachycardia", ".", "In", "the", "remaining", "three", "patients", ",", "procainamide", "was", "administered", "orally", "for", "treatment", "of", "chronic", "premature", "ventricular", "contractions", "or", "atrial", "flutter", ".", "These", "patients", "had", "Q", "-", "T", "prolongation", "and", "recurrent", "syncope", "due", "to", "polymorphous", "ventricular", "tachycardia", ".", "In", "four", "patients", ",", "the", "arrhythmia", "was", "rapidly", "diagnosed", "and", "treated", "with", "disappearance", "of", "further", "episodes", "of", "the", "arrhythmia", ".", "In", "two", "patients", ",", "the", "arrhythmia", "degenerated", "into", "irreversible", "ventricular", "fibrillation", "and", "both", "patients", "died", ".", "In", "the", "seventh", "patient", ",", "a", "permanent", "ventricular", "pacemaker", "was", "inserted", "and", ",", "despite", "continuation", "of", "procainamide", "therapy", ",", "polymorphous", "ventricular", "tachycardia", "did", "not", "reoccur", ".", "These", "seven", "cases", "demonstrate", "that", "procainamide", "can", "produce", "an", "acquired", "prolonged", "Q", "-", "T", "syndrome", "with", "polymorphous", "ventricular", "tachycardia", "."]], "ner": [[[0, 0, "Chemical"], [10, 10, "Chemical"], [36, 36, "Chemical"], [51, 51, "Chemical"], [134, 134, "Chemical"], [149, 149, "Chemical"], [4, 5, "Disease"], [14, 15, "Disease"], [24, 25, "Disease"], [42, 43, "Disease"], [79, 80, "Disease"], [138, 139, "Disease"], [161, 162, "Disease"], [59, 61, "Disease"], [63, 64, "Disease"], [69, 72, "Disease"], [154, 158, "Disease"], [75, 75, "Disease"], [87, 87, "Disease"], [100, 100, "Disease"], [107, 107, "Disease"], [111, 112, "Disease"]]], "relations": [[[0, 0, 4, 5, "CID"], [0, 0, 14, 15, "CID"], [0, 0, 24, 25, "CID"], [0, 0, 42, 43, "CID"], [0, 0, 79, 80, "CID"], [0, 0, 138, 139, "CID"], [0, 0, 161, 162, "CID"], [10, 10, 4, 5, "CID"], [10, 10, 14, 15, "CID"], [10, 10, 24, 25, "CID"], [10, 10, 42, 43, "CID"], [10, 10, 79, 80, "CID"], [10, 10, 138, 139, "CID"], [10, 10, 161, 162, "CID"], [36, 36, 4, 5, "CID"], [36, 36, 14, 15, "CID"], [36, 36, 24, 25, "CID"], [36, 36, 42, 43, "CID"], [36, 36, 79, 80, "CID"], [36, 36, 138, 139, "CID"], [36, 36, 161, 162, "CID"], [51, 51, 4, 5, "CID"], [51, 51, 14, 15, "CID"], [51, 51, 24, 25, "CID"], [51, 51, 42, 43, "CID"], [51, 51, 79, 80, "CID"], [51, 51, 138, 139, "CID"], [51, 51, 161, 162, "CID"], [134, 134, 4, 5, "CID"], [134, 134, 14, 15, "CID"], [134, 134, 24, 25, "CID"], [134, 134, 42, 43, "CID"], [134, 134, 79, 80, "CID"], [134, 134, 138, 139, "CID"], [134, 134, 161, 162, "CID"], [149, 149, 4, 5, "CID"], [149, 149, 14, 15, "CID"], [149, 149, 24, 25, "CID"], [149, 149, 42, 43, "CID"], [149, 149, 79, 80, "CID"], [149, 149, 138, 139, "CID"], [149, 149, 161, 162, "CID"]]], "clusters": [], "translated": " <0>普鲁卡因胺</0> -诱发多形性<6>室性心动过速</6>。报告了7例<1>普鲁卡因胺</1>诱发的多形性<7>室性心动过速</7>。4例患者为治疗持续性<9>室性心动过速</9>而静脉注射了200至400mg<2>普鲁卡因胺</2>，随后出现多形性<8>室性心动过速</8>。在其余三名患者中，<3>普鲁卡因胺</3>口服治疗慢性<13>室性早搏</13>或<14>心房扑动</14>。这些患者由于多形性<10>室性心动过速</10>表现为<15>Q-T间期延长</15>和复发性<17>晕厥</17>。在四名患者中，<18>心律失常</18>得到快速诊断并治疗，<19>心律失常</19>的进一步发作消失。在两名患者中，<20>心律失常</20>恶化为不可逆的<21>室性颤动</21>，两名患者均死亡。第七名患者安装了永久性室性起搏器，尽管继续使用<4>普鲁卡因胺</4>治疗，但多形性<11>室性心动过速</11>没有再次发生。这7例表明，<5>普鲁卡因胺</5>可导致获得性<16>Q-T间期延长综合征</16>伴多形性<12>室性心动过速</12>。", "revised": true}
{"doc_key": "3173179", "sentences": [["Verapamil", "withdrawal", "as", "a", "possible", "cause", "of", "myocardial", "infarction", "in", "a", "hypertensive", "woman", "with", "a", "normal", "coronary", "angiogram", ".", "Verapamil", "is", "an", "effective", "and", "relatively", "-", "safe", "antihypertensive", "drug", ".", "Serious", "adverse", "effects", "are", "uncommon", "and", "mainly", "have", "been", "related", "to", "the", "depression", "of", "cardiac", "contractility", "and", "conduction", ",", "especially", "when", "the", "drug", "is", "combined", "with", "beta", "-", "blocking", "agents", ".", "We", "report", "a", "case", "in", "which", "myocardial", "infarction", "coincided", "with", "the", "introduction", "of", "captopril", "and", "the", "withdrawal", "of", "verapamil", "in", "a", "previously", "asymptomatic", "woman", "with", "severe", "hypertension", ".", "Possible", "mechanisms", "that", "involve", "a", "verapamil", "-", "related", "increase", "in", "platelet", "and", "/", "or", "vascular", "alpha", "2", "-", "adrenoreceptor", "affinity", "for", "catecholamines", "are", "discussed", "."]], "ner": [[[0, 0, "Chemical"], [19, 19, "Chemical"], [79, 79, "Chemical"], [94, 94, "Chemical"], [7, 8, "Disease"], [67, 68, "Disease"], [11, 11, "Disease"], [87, 87, "Disease"], [42, 42, "Disease"], [74, 74, "Chemical"], [110, 110, "Chemical"]]], "relations": [[[0, 0, 7, 8, "CID"], [0, 0, 67, 68, "CID"], [19, 19, 7, 8, "CID"], [19, 19, 67, 68, "CID"], [79, 79, 7, 8, "CID"], [79, 79, 67, 68, "CID"], [94, 94, 7, 8, "CID"], [94, 94, 67, 68, "CID"]]], "clusters": [], "translated": " <0>维拉帕米</0> 停药是 <4>心肌梗死</4> 的一个可能原因，该患者 <6>高血压</6> 且冠状动脉造影正常。 <1>维拉帕米</1> 是一种有效且相对安全的降压药。严重的不良反应并不常见，主要与心脏收缩和传导的<8>抑制</8>有关，尤其是当药物与β受体阻滞剂联合使用时。我们报告了一个病例，其中<5>心肌梗死</5>与<9>卡托普利</9>的引入和<2>维拉帕米</2>的撤回同时发生在一名先前无症状的严重<7>妇女中高血压</7>。讨论了涉及<3>维拉帕米</3>相关增加血小板和/或血管α2-肾上腺素受体对<10>儿茶酚胺</10>亲和力的可能机制。", "revised": true}
{"doc_key": "17600377", "sentences": [["A", "novel", "compound", ",", "maltolyl", "p", "-", "coumarate", ",", "attenuates", "cognitive", "deficits", "and", "shows", "neuroprotective", "effects", "in", "vitro", "and", "in", "vivo", "dementia", "models", ".", "To", "develop", "a", "novel", "and", "effective", "drug", "that", "could", "enhance", "cognitive", "function", "and", "neuroprotection", ",", "we", "newly", "synthesized", "maltolyl", "p", "-", "coumarate", "by", "the", "esterification", "of", "maltol", "and", "p", "-", "coumaric", "acid", ".", "In", "the", "present", "study", ",", "we", "investigated", "whether", "maltolyl", "p", "-", "coumarate", "could", "improve", "cognitive", "decline", "in", "scopolamine", "-", "injected", "rats", "and", "in", "amyloid", "beta", "peptide", "(", "1", "-", "42", ")", "-", "infused", "rats", ".", "Maltolyl", "p", "-", "coumarate", "was", "found", "to", "attenuate", "cognitive", "deficits", "in", "both", "rat", "models", "using", "passive", "avoidance", "test", "and", "to", "reduce", "apoptotic", "cell", "death", "observed", "in", "the", "hippocampus", "of", "the", "amyloid", "beta", "peptide", "(", "1", "-", "42", ")", "-", "infused", "rats", ".", "We", "also", "examined", "the", "neuroprotective", "effects", "of", "maltolyl", "p", "-", "coumarate", "in", "vitro", "using", "SH", "-", "SY5Y", "cells", ".", "Cells", "were", "pretreated", "with", "maltolyl", "p", "-", "coumarate", ",", "before", "exposed", "to", "amyloid", "beta", "peptide", "(", "1", "-", "42", ")", ",", "glutamate", "or", "H2O2", ".", "We", "found", "that", "maltolyl", "p", "-", "coumarate", "significantly", "decreased", "apoptotic", "cell", "death", "and", "reduced", "reactive", "oxygen", "species", ",", "cytochrome", "c", "release", ",", "and", "caspase", "3", "activation", ".", "Taking", "these", "in", "vitro", "and", "in", "vivo", "results", "together", ",", "our", "study", "suggests", "that", "maltolyl", "p", "-", "coumarate", "is", "a", "potentially", "effective", "candidate", "against", "Alzheimer", "'s", "disease", "that", "is", "characterized", "by", "wide", "spread", "neuronal", "death", "and", "progressive", "decline", "of", "cognitive", "function", "."]], "ner": [[[74, 74, "Chemical"], [10, 11, "Disease"], [71, 72, "Disease"], [100, 101, "Disease"], [242, 245, "Disease"], [4, 7, "Chemical"], [42, 45, "Chemical"], [65, 68, "Chemical"], [92, 95, "Chemical"], [141, 144, "Chemical"], [157, 160, "Chemical"], [181, 184, "Chemical"], [219, 222, "Chemical"], [21, 21, "Disease"], [229, 231, "Disease"], [238, 239, "Disease"], [50, 50, "Chemical"], [52, 55, "Chemical"], [80, 87, "Chemical"], [122, 129, "Chemical"], [165, 172, "Chemical"], [174, 174, "Chemical"], [176, 176, "Chemical"]]], "relations": [[[74, 74, 10, 11, "CID"], [74, 74, 71, 72, "CID"], [74, 74, 100, 101, "CID"], [74, 74, 242, 245, "CID"]]], "clusters": [], "translated": "一种新型化合物<5> 麦芽酚对香豆酸酯 </5>可减轻<1>认知缺陷</1>并在体外和体内<13>痴呆</13>模型中显示出神经保护作用。为开发一种新型有效的增强认知功能和神经保护作用的药物，我们通过酯化<16>麦芽酚</16>和<17>对香豆酸</17>合成了<6>麦芽酚对香豆酸酯</6>。在本研究中，我们研究了<7>麦芽酚对香豆酸酯</7>是否可以改善使用<0>东莨菪碱</0>注射大鼠和<18>淀粉样蛋白β肽</18>(1-42)-注入大鼠的<2>认知能力下降</2>。 <8>麦芽酚对香豆酸酯</8>被发现能够减轻<3>两种大鼠模型中通过被动回避试验测试的认知缺陷</3>，并减少<19>注入淀粉样蛋白 β 肽海马中观察到的凋亡细胞死亡(1-42)</19>。我们还使用SH-SY5Y细胞检测了<9>麦芽酚对香豆酸酯</9>的神经保护作用。在暴露于<20>淀粉样蛋白β肽(1-42)</20>、<21>谷氨酸</21>或<22>H2O2</22>之前，细胞预先用<10>麦芽酚对香豆酸酯</10>处理。我们发现，<11>麦芽酚对香豆酸酯</11>显著降低了细胞凋亡、减少了反应性氧化物、细胞色素C释放和caspase 3的活化。将这些体内和体外结果结合起来，我们的研究表明，<12>麦芽酚对香豆酸酯</12>是一种潜在有效的药物，可对抗具有广泛<15>神经元死亡</15>和<4>认知功能下降</4>特征的<14>阿尔茨海默病</14>。", "revised": true}
{"doc_key": "9293063", "sentences": [["Bile", "duct", "hamartoma", "occurring", "in", "association", "with", "long", "-", "term", "treatment", "with", "danazol", ".", "We", "report", "a", "case", "of", "bile", "duct", "hamartoma", "which", "developed", "in", "a", "patient", "who", "had", "been", "on", "long", "-", "term", "danazol", "treatment", ".", "Such", "patients", "should", "be", "under", "close", "follow", "-", "up", ",", "preferably", "with", "periodic", "ultrasound", "examination", "of", "the", "liver", ".", "If", "the", "patient", "develops", "a", "liver", "mass", ",", "because", "of", "non", "-", "specific", "clinical", "features", "and", "imaging", "appearances", ",", "biopsy", "may", "be", "the", "only", "way", "to", "achieve", "a", "definitive", "diagnosis", "."]], "ner": [[[12, 12, "Chemical"], [34, 34, "Chemical"], [0, 2, "Disease"], [19, 21, "Disease"], [61, 62, "Disease"]]], "relations": [[[12, 12, 0, 2, "CID"], [12, 12, 19, 21, "CID"], [34, 34, 0, 2, "CID"], [34, 34, 19, 21, "CID"]]], "clusters": [], "translated": "<2>胆管错构瘤</2> 与<0>达那唑</0>的长期治疗有关。我们报告了一例<3>胆管错构瘤</3>，患者长期接受<1>达那唑</1>治疗。此类患者应密切随访，最好定期进行肝脏超声检查。如果患者出现<4>肝脏肿块</4>，由于临床特征和影像学表现非特异性，活检可能是获得明确诊断的唯一方法。", "revised": true}
{"doc_key": "2578334", "sentences": [["5", "-", "azacytidine", "potentiates", "initiation", "induced", "by", "carcinogens", "in", "rat", "liver", ".", "To", "test", "the", "validity", "of", "the", "hypothesis", "that", "hypomethylation", "of", "DNA", "plays", "an", "important", "role", "in", "the", "initiation", "of", "carcinogenic", "process", ",", "5", "-", "azacytidine", "(", "5", "-", "AzC", ")", "(", "10", "mg", "/", "kg", ")", ",", "an", "inhibitor", "of", "DNA", "methylation", ",", "was", "given", "to", "rats", "during", "the", "phase", "of", "repair", "synthesis", "induced", "by", "the", "three", "carcinogens", ",", "benzo", "[", "a", "]", "-", "pyrene", "(", "200", "mg", "/", "kg", ")", ",", "N", "-", "methyl", "-", "N", "-", "nitrosourea", "(", "60", "mg", "/", "kg", ")", "and", "1", ",", "2", "-", "dimethylhydrazine", "(", "1", ",", "2", "-", "DMH", ")", "(", "100", "mg", "/", "kg", ")", ".", "The", "initiated", "hepatocytes", "in", "the", "liver", "were", "assayed", "as", "the", "gamma", "-", "glutamyltransferase", "(", "gamma", "-", "GT", ")", "positive", "foci", "formed", "following", "a", "2", "-", "week", "selection", "regimen", "consisting", "of", "dietary", "0", ".", "02", "%", "2", "-", "acetylaminofluorene", "coupled", "with", "a", "necrogenic", "dose", "of", "CCl4", ".", "The", "results", "obtained", "indicate", "that", "with", "all", "three", "carcinogens", ",", "administration", "of", "5", "-", "AzC", "during", "repair", "synthesis", "increased", "the", "incidence", "of", "initiated", "hepatocytes", ",", "for", "example", "10", "-", "20", "foci", "/", "cm2", "in", "5", "-", "AzC", "and", "carcinogen", "-", "treated", "rats", "compared", "with", "3", "-", "5", "foci", "/", "cm2", "in", "rats", "treated", "with", "carcinogen", "only", ".", "Administration", "of", "[", "3H", "]", "-", "5", "-", "azadeoxycytidine", "during", "the", "repair", "synthesis", "induced", "by", "1", ",", "2", "-", "DMH", "further", "showed", "that", "0", ".", "019", "mol", "%", "of", "cytosine", "residues", "in", "DNA", "were", "substituted", "by", "the", "analogue", ",", "indicating", "that", "incorporation", "of", "5", "-", "AzC", "occurs", "during", "repair", "synthesis", ".", "In", "the", "absence", "of", "the", "carcinogen", ",", "5", "-", "AzC", "given", "after", "a", "two", "thirds", "partial", "hepatectomy", ",", "when", "its", "incorporation", "should", "be", "maximum", ",", "failed", "to", "induce", "any", "gamma", "-", "GT", "positive", "foci", ".", "The", "results", "suggest", "that", "hypomethylation", "of", "DNA", "per", "se", "may", "not", "be", "sufficient", "for", "initiation", ".", "Perhaps", "two", "events", "might", "be", "necessary", "for", "initiation", ",", "the", "first", "caused", "by", "the", "carcinogen", "and", "a", "second", "involving", "hypomethylation", "of", "DNA", "."]], "ner": [[[0, 2, "Chemical"], [34, 36, "Chemical"], [38, 40, "Chemical"], [175, 177, "Chemical"], [197, 199, "Chemical"], [263, 265, "Chemical"], [278, 280, "Chemical"], [4, 7, "Disease"], [29, 32, "Disease"], [71, 76, "Chemical"], [84, 90, "Chemical"], [98, 102, "Chemical"], [104, 108, "Chemical"], [235, 239, "Chemical"], [152, 154, "Chemical"], [161, 161, "Chemical"], [222, 228, "Chemical"], [249, 249, "Chemical"]]], "relations": [[[0, 2, 4, 7, "CID"], [0, 2, 29, 32, "CID"], [34, 36, 4, 7, "CID"], [34, 36, 29, 32, "CID"], [38, 40, 4, 7, "CID"], [38, 40, 29, 32, "CID"], [175, 177, 4, 7, "CID"], [175, 177, 29, 32, "CID"], [197, 199, 4, 7, "CID"], [197, 199, 29, 32, "CID"], [263, 265, 4, 7, "CID"], [263, 265, 29, 32, "CID"], [278, 280, 4, 7, "CID"], [278, 280, 29, 32, "CID"], [71, 76, 4, 7, "CID"], [71, 76, 29, 32, "CID"], [84, 90, 4, 7, "CID"], [84, 90, 29, 32, "CID"], [98, 102, 4, 7, "CID"], [98, 102, 29, 32, "CID"], [104, 108, 4, 7, "CID"], [104, 108, 29, 32, "CID"], [235, 239, 4, 7, "CID"], [235, 239, 29, 32, "CID"], [152, 154, 4, 7, "CID"], [152, 154, 29, 32, "CID"], [161, 161, 4, 7, "CID"], [161, 161, 29, 32, "CID"]]], "clusters": [], "translated": "<0> 5-氮胞苷</0> 增强大鼠肝脏中致癌物诱导的<7>启动</7>。检验 DNA 的低甲基化在<8>致癌过程的启动</8>中起重要作用的假说的有效性，<1>5-氮杂胞苷</1>（<2>5-AzC</2>）（10mg / kg），一种 DNA 甲基化抑制剂，在三种致癌物<9>苯并[a] - 芘</9>（200mg / kg）、<10>N-甲基-N-亚硝基脲</10>（60mg / kg）和<11>1,2-二甲基肼</11>（<12>1,2-DMH</12>）（100mg / kg）诱导的修复合成阶段给予大鼠。肝脏中启动的肝细胞被检测为在由饮食0.02%<14> 2-乙酰氨基芴</14>和致死剂量的<15>CCl4</15>结合后的 2 周选择方案中披露的γ-谷氨酰转移酶（γ-GT）阳性小结节。获得的结果表明，在所有三种致癌物中，在修复合成过程中施用<3> 5-AzC </3>增加了引起肝细胞的发生率，例如在<4> 5-AzC </4>和致癌物治疗的大鼠中为10-20个小结节/cm^{2}，而在仅受致癌物治疗的大鼠中为3-5个小结节/cm^{2}。在由<13> 1,2-DMH </13>诱导的修复合成过程中给予<16>[3H]-5-氮脱氧胞苷</16>进一步表明，DNA 中的 0.019mol%的<17>胞嘧啶</17>残基被替换为类似物，表明<5> 5-AzC</5>在修复合成过程中被掺入。在没有致癌物的情况下，在三分之二的部分肝切除术后给予<6> 5-AzC </6>（当其掺入量达到最大时）未能诱导任何γ-GT阳性小结节。结果表明，DNA 本身的低甲基化可能不足以启动。启动可能需要两个事件，第一个是由致癌物引起的，第二个涉及 DNA 的低甲基化。", "revised": true}
{"doc_key": "11532387", "sentences": [["Withdrawal", "-", "emergent", "rabbit", "syndrome", "during", "dose", "reduction", "of", "risperidone", ".", "Rabbit", "syndrome", "(", "RS", ")", "is", "a", "rare", "extrapyramidal", "side", "effect", "caused", "by", "prolonged", "neuroleptic", "medication", ".", "Here", "we", "present", "a", "case", "of", "withdrawal", "-", "emergent", "RS", ",", "which", "is", "the", "first", "of", "its", "kind", "to", "be", "reported", ".", "The", "patient", "developed", "RS", "during", "dose", "reduction", "of", "risperidone", ".", "The", "symptom", "was", "treated", "successfully", "with", "trihexyphenidyl", "anticholinergic", "therapy", ".", "The", "underlying", "mechanism", "of", "withdrawal", "-", "emergent", "RS", "in", "the", "present", "case", "may", "have", "been", "related", "to", "the", "pharmacological", "profile", "of", "risperidone", ",", "a", "serotonin", "-", "dopamine", "antagonist", ",", "suggesting", "the", "pathophysiologic", "influence", "of", "the", "serotonin", "system", "in", "the", "development", "of", "RS", "."]], "ner": [[[9, 9, "Chemical"], [58, 58, "Chemical"], [91, 91, "Chemical"], [0, 4, "Disease"], [34, 37, "Disease"], [74, 77, "Disease"], [11, 12, "Disease"], [14, 14, "Disease"], [53, 53, "Disease"], [111, 111, "Disease"], [66, 66, "Chemical"], [94, 94, "Chemical"], [105, 105, "Chemical"], [96, 96, "Chemical"]]], "relations": [[[9, 9, 0, 4, "CID"], [9, 9, 34, 37, "CID"], [9, 9, 74, 77, "CID"], [58, 58, 0, 4, "CID"], [58, 58, 34, 37, "CID"], [58, 58, 74, 77, "CID"], [91, 91, 0, 4, "CID"], [91, 91, 34, 37, "CID"], [91, 91, 74, 77, "CID"], [9, 9, 11, 12, "CID"], [9, 9, 14, 14, "CID"], [9, 9, 53, 53, "CID"], [9, 9, 111, 111, "CID"], [58, 58, 11, 12, "CID"], [58, 58, 14, 14, "CID"], [58, 58, 53, 53, "CID"], [58, 58, 111, 111, "CID"], [91, 91, 11, 12, "CID"], [91, 91, 14, 14, "CID"], [91, 91, 53, 53, "CID"], [91, 91, 111, 111, "CID"]]], "clusters": [], "translated": "<0>利培酮</0>减量期间的<3>戒断-紧急兔综合征</3>。 <6>兔综合征</6>（<7>RS</7>）是一种罕见的由长期服用抗精神病药引起的锥体外系副作用。在此我们介绍一例<4>戒断-紧急RS</4>病例，这是同类报道中的第一例。患者在<1>利培酮</1>剂量减少期间出现了<8>RS</8>。<5>本例中 戒断-紧急RS</5> 的潜在机制可能与 <2>利培酮</2>的药理学特征有关，为<11>血清素</11> - <13>多巴胺</13> 拮抗剂，提示<12>血清素</12>系统在<9>RS</9>发展中的病理生理学影响。<10>苯海索</10>抗胆碱能疗法成功治疗了该症状。", "revised": true}
{"doc_key": "19657887", "sentences": [["Disulfiram", "-", "like", "syndrome", "after", "hydrogen", "cyanamide", "professional", "skin", "exposure", ":", "two", "case", "reports", "in", "France", ".", "Hydrogen", "cyanamide", "is", "a", "plant", "growth", "regulator", "used", "in", "agriculture", "to", "induce", "bud", "break", "in", "fruit", "trees", ".", "Contact", "with", "the", "skin", "can", "result", "in", "percutaneous", "absorption", "of", "the", "substance", "that", "inhibits", "aldehyde", "dehydrogenase", "and", "can", "induce", "acetaldehyde", "syndrome", "in", "case", "of", "alcohol", "use", ".", "The", "purpose", "of", "this", "report", "is", "to", "describe", "two", "cases", "of", "a", "disulfiram", "-", "like", "syndrome", "following", "occupational", "exposure", "to", "hydrogen", "cyanamide", ".", "The", "first", "case", "involved", "a", "59", "-", "year", "-", "old", "man", "who", "used", "Dormex", ",", "which", "contains", "hydrogen", "cyanamide", ",", "without", "protection", "after", "consuming", "a", "large", "amount", "of", "alcohol", "during", "a", "meal", ".", "In", "less", "than", "1", "hour", "after", "the", "ingestion", "of", "alcohol", ",", "he", "developed", "malaise", "with", "flushing", "of", "the", "face", ",", "tachycardia", ",", "and", "dyspnea", ".", "Manifestations", "regressed", "spontaneously", "under", "surveillance", "in", "the", "hospital", ".", "The", "second", "case", "occurred", "in", "a", "55", "-", "year", "-", "old", "farmer", "following", "cutaneous", "contact", "with", "Dormex", ".", "Five", "hours", "after", "exposure", ",", "he", "developed", "disulfiram", "-", "like", "syndrome", "with", "flushing", ",", "tachycardia", ",", "and", "arterial", "hypotension", "after", "consuming", "three", "glasses", "of", "wine", ".", "The", "patient", "recovered", "spontaneously", "in", "3", "hours", "under", "surveillance", "in", "the", "hospital", ".", "These", "cases", "confirm", "the", "necessity", "of", "avoiding", "alcohol", "consumption", "as", "recommended", "in", "the", "instructions", "for", "use", "of", "Dormex", "and", "of", "preventing", "cutaneous", "contact", "during", "use", "."]], "ner": [[[5, 6, "Chemical"], [17, 18, "Chemical"], [82, 83, "Chemical"], [98, 98, "Chemical"], [102, 103, "Chemical"], [168, 168, "Chemical"], [226, 226, "Chemical"], [133, 136, "Disease"], [182, 182, "Disease"], [138, 138, "Disease"], [184, 184, "Disease"], [141, 141, "Disease"], [187, 188, "Disease"], [59, 59, "Chemical"], [113, 113, "Chemical"], [127, 127, "Chemical"], [216, 216, "Chemical"], [0, 0, "Chemical"], [74, 74, "Chemical"], [177, 177, "Chemical"], [49, 49, "Chemical"], [54, 54, "Chemical"]]], "relations": [[[5, 6, 133, 136, "CID"], [5, 6, 182, 182, "CID"], [17, 18, 133, 136, "CID"], [17, 18, 182, 182, "CID"], [82, 83, 133, 136, "CID"], [82, 83, 182, 182, "CID"], [98, 98, 133, 136, "CID"], [98, 98, 182, 182, "CID"], [102, 103, 133, 136, "CID"], [102, 103, 182, 182, "CID"], [168, 168, 133, 136, "CID"], [168, 168, 182, 182, "CID"], [226, 226, 133, 136, "CID"], [226, 226, 182, 182, "CID"], [5, 6, 138, 138, "CID"], [5, 6, 184, 184, "CID"], [17, 18, 138, 138, "CID"], [17, 18, 184, 184, "CID"], [82, 83, 138, 138, "CID"], [82, 83, 184, 184, "CID"], [98, 98, 138, 138, "CID"], [98, 98, 184, 184, "CID"], [102, 103, 138, 138, "CID"], [102, 103, 184, 184, "CID"], [168, 168, 138, 138, "CID"], [168, 168, 184, 184, "CID"], [226, 226, 138, 138, "CID"], [226, 226, 184, 184, "CID"], [5, 6, 141, 141, "CID"], [17, 18, 141, 141, "CID"], [82, 83, 141, 141, "CID"], [98, 98, 141, 141, "CID"], [102, 103, 141, 141, "CID"], [168, 168, 141, 141, "CID"], [226, 226, 141, 141, "CID"], [5, 6, 187, 188, "CID"], [17, 18, 187, 188, "CID"], [82, 83, 187, 188, "CID"], [98, 98, 187, 188, "CID"], [102, 103, 187, 188, "CID"], [168, 168, 187, 188, "CID"], [226, 226, 187, 188, "CID"], [59, 59, 133, 136, "CID"], [59, 59, 182, 182, "CID"], [113, 113, 133, 136, "CID"], [113, 113, 182, 182, "CID"], [127, 127, 133, 136, "CID"], [127, 127, 182, 182, "CID"], [216, 216, 133, 136, "CID"], [216, 216, 182, 182, "CID"], [59, 59, 138, 138, "CID"], [59, 59, 184, 184, "CID"], [113, 113, 138, 138, "CID"], [113, 113, 184, 184, "CID"], [127, 127, 138, 138, "CID"], [127, 127, 184, 184, "CID"], [216, 216, 138, 138, "CID"], [216, 216, 184, 184, "CID"], [59, 59, 141, 141, "CID"], [113, 113, 141, 141, "CID"], [127, 127, 141, 141, "CID"], [216, 216, 141, 141, "CID"], [59, 59, 187, 188, "CID"], [113, 113, 187, 188, "CID"], [127, 127, 187, 188, "CID"], [216, 216, 187, 188, "CID"]]], "clusters": [], "translated": "<17>双硫仑</17> 类<0>氰氨化氢</0> 专业皮肤暴露后的综合征：法国的两例病例报告。<1>氰氨</1>是一种植物生长调节剂，在农业中用于诱导果树发芽。与皮肤接触可导致抑制<20>醛</20>脱氢酶的物质经皮吸收，在<13>酒精</13>使用时可诱发<21>乙醛</21>综合征。本报告的目的是描述两例因职业接触<2>氰氨</2>而出现<18>双硫仑</18>样综合征的病例。第一宗个案涉及一名 59 岁男子，他在大量饮用<14>酒精</14>后在没有任何防护措施的情况下使用了含有<4>氰氨</4>的<3>Dormex</3>。在摄入<15>酒精</15>不到1小时后，他出现了不适，伴有<7>面部潮红</7>、<9>心动过速</9>和<11>呼吸困难</11>。在医院观察下症状自发消退。第二个病例发生在一位 55 岁的农民身上，他在皮肤接触了<5>Dormex</5>之后。接触5小时后，他出现了<19>双硫仑</19>样综合征，并在饮用3杯酒后出现<8>潮红</8>、<10>心动过速</10>和<12>动脉低血压</12>。患者在医院监护下 3 小时后自然痊愈。这些病例证实有必要按照<6>Dormex</6>使用说明中的建议避免<16>酒精</16>消费，并在使用过程中防止皮肤接触。", "revised": true}
{"doc_key": "12536034", "sentences": [["Anti", "-", "epileptic", "drugs", "-", "induced", "de", "novo", "absence", "seizures", ".", "The", "authors", "present", "three", "patients", "with", "de", "novo", "absence", "epilepsy", "after", "administration", "of", "carbamazepine", "and", "vigabatrin", ".", "Despite", "the", "underlying", "diseases", ",", "the", "prognosis", "for", "drug", "-", "induced", "de", "novo", "absence", "seizure", "is", "good", "because", "it", "subsides", "rapidly", "after", "discontinuing", "the", "use", "of", "the", "offending", "drugs", ".", "The", "gamma", "-", "aminobutyric", "acid", "-", "transmitted", "thalamocortical", "circuitry", "accounts", "for", "a", "major", "part", "of", "the", "underlying", "neurophysiology", "of", "the", "absence", "epilepsy", ".", "Because", "drug", "-", "induced", "de", "novo", "absence", "seizure", "is", "rare", ",", "pro", "-", "absence", "drugs", "can", "only", "be", "considered", "a", "promoting", "factor", ".", "The", "underlying", "epileptogenecity", "of", "the", "patients", "or", "the", "synergistic", "effects", "of", "the", "accompanying", "drugs", "is", "required", "to", "trigger", "the", "de", "novo", "absence", "seizure", ".", "The", "possibility", "of", "drug", "-", "induced", "aggravation", "should", "be", "considered", "whenever", "an", "unexpected", "increase", "in", "seizure", "frequency", "and", "/", "or", "new", "seizure", "types", "appear", "following", "a", "change", "in", "drug", "treatment", ".", "By", "understanding", "the", "underlying", "mechanism", "of", "absence", "epilepsy", ",", "we", "can", "avoid", "the", "inappropriate", "use", "of", "anticonvulsants", "in", "children", "with", "epilepsy", "and", "prevent", "drug", "-", "induced", "absence", "seizures", "."]], "ner": [[[24, 24, "Chemical"], [8, 9, "Disease"], [19, 20, "Disease"], [41, 42, "Disease"], [78, 79, "Disease"], [87, 88, "Disease"], [125, 126, "Disease"], [165, 166, "Disease"], [185, 186, "Disease"], [26, 26, "Chemical"], [2, 2, "Disease"], [179, 179, "Disease"], [59, 62, "Chemical"], [143, 143, "Disease"], [149, 149, "Disease"]]], "relations": [[[24, 24, 8, 9, "CID"], [24, 24, 19, 20, "CID"], [24, 24, 41, 42, "CID"], [24, 24, 78, 79, "CID"], [24, 24, 87, 88, "CID"], [24, 24, 125, 126, "CID"], [24, 24, 165, 166, "CID"], [24, 24, 185, 186, "CID"], [26, 26, 8, 9, "CID"], [26, 26, 19, 20, "CID"], [26, 26, 41, 42, "CID"], [26, 26, 78, 79, "CID"], [26, 26, 87, 88, "CID"], [26, 26, 125, 126, "CID"], [26, 26, 165, 166, "CID"], [26, 26, 185, 186, "CID"]]], "clusters": [], "translated": "抗<10>癫痫</10>药物引起的新发<1>失神发作</1>。作者介绍了三名服用<0>卡马西平</0>和<9>氨己烯酸</9>后新发<2>失神性癫痫</2>的患者。尽管存在基础疾病，但药物诱发的新发<3>失神发作</3>的预后良好，因为它在停止使用致病药物后会迅速消退。<12> γ-氨基丁酸</12> - 传递的丘脑皮质回路占据了<4>失神性癫痫</4>潜在神经生理学的主要部分。由于药物引起的新发<5>失神发作</5>很少见，促失神药物只能被认为是一个促进因素。需要患者潜在的致癫痫性或伴随药物的协同作用来触发新发<6>失神发作</6>。当药物治疗改变后，应考虑药物诱发加重的可能性，例如当<13>癫痫发作</13>频率意外增加和/或出现新的<14>癫痫发作</14>类型时。通过了解<7>失神性癫痫</7>的发病机制，我们可以避免在<11>癫痫</11>患儿中不当使用抗惊厥药物并预防药物性<8>失神性发作</8>的出现。", "revised": true}
{"doc_key": "18821488", "sentences": [["Toxicity", "in", "rhesus", "monkeys", "following", "administration", "of", "the", "8", "-", "aminoquinoline", "8", "-", "[", "(", "4", "-", "amino", "-", "l", "-", "methylbutyl", ")", "amino", "]", "-", "5", "-", "(", "l", "-", "hexyloxy", ")", "-", "6", "-", "methoxy", "-", "4", "-", "methylquinoline", "(", "WR242511", ")", ".", "INTRODUCTION", ":", "Many", "substances", "that", "form", "methemoglobin", "(", "MHb", ")", "effectively", "counter", "cyanide", "(", "CN", ")", "toxicity", ".", "Although", "MHb", "formers", "are", "generally", "applied", "as", "treatments", "for", "CN", "poisoning", ",", "it", "has", "been", "proposed", "that", "a", "stable", ",", "long", "-", "acting", "MHb", "former", "could", "serve", "as", "a", "CN", "pretreatment", ".", "Using", "this", "rationale", ",", "the", "8", "-", "aminoquinoline", "WR242511", ",", "a", "potent", "long", "-", "lasting", "MHb", "former", "in", "rodents", "and", "beagle", "dogs", ",", "was", "studied", "in", "the", "rhesus", "monkey", "for", "advanced", "development", "as", "a", "potential", "CN", "pretreatment", ".", "METHODS", ":", "In", "this", "study", ",", "WR242511", "was", "administered", "intravenously", "(", "IV", ")", "in", "2", "female", "and", "4", "male", "rhesus", "monkeys", "in", "doses", "of", "3", ".", "5", "and", "/", "or", "7", ".", "0", "mg", "/", "kg", ";", "a", "single", "male", "also", "received", "WR242511", "orally", "(", "PO", ")", "at", "7", ".", "0", "mg", "/", "kg", ".", "Health", "status", "and", "MHb", "levels", "were", "monitored", "following", "exposure", ".", "RESULTS", ":", "The", "selected", "doses", "of", "WR242511", ",", "which", "produced", "significant", "methemoglobinemia", "in", "beagle", "dogs", "in", "earlier", "studies", "conducted", "elsewhere", ",", "produced", "very", "little", "MHb", "(", "mean", "<", "2", ".", "0", "%", ")", "in", "the", "rhesus", "monkey", ".", "Furthermore", ",", "transient", "hemoglobinuria", "was", "noted", "approximately", "60", "minutes", "postinjection", "of", "WR242511", "(", "3", ".", "5", "or", "7", ".", "0", "mg", "/", "kg", ")", ",", "and", "2", "lethalities", "occurred", "(", "one", "IV", "and", "one", "PO", ")", "following", "the", "7", ".", "0", "mg", "/", "kg", "dose", ".", "Myoglobinuria", "was", "also", "observed", "following", "the", "7", ".", "0", "mg", "/", "kg", "dose", ".", "Histopathology", "analyses", "in", "the", "2", "animals", "that", "died", "revealed", "liver", "and", "kidney", "toxicity", ",", "with", "greater", "severity", "in", "the", "orally", "-", "treated", "animal", ".", "CONCLUSIONS", ":", "These", "data", "demonstrate", "direct", "and", "/", "or", "indirect", "drug", "-", "induced", "toxicity", ".", "It", "is", "concluded", "that", "WR242511", "should", "not", "be", "pursued", "as", "a", "pretreatment", "for", "CN", "poisoning", "unless", "the", "anti", "-", "CN", "characteristics", "of", "this", "compound", "can", "be", "successfully", "dissociated", "from", "those", "producing", "undesirable", "toxicity", "."]], "ner": [[[11, 40, "Chemical"], [42, 42, "Chemical"], [103, 103, "Chemical"], [139, 139, "Chemical"], [175, 175, "Chemical"], [204, 204, "Chemical"], [247, 247, "Chemical"], [339, 339, "Chemical"], [239, 239, "Disease"], [282, 282, "Disease"], [305, 308, "Disease"], [8, 10, "Chemical"], [100, 102, "Chemical"], [0, 0, "Disease"], [61, 61, "Disease"], [333, 333, "Disease"], [367, 367, "Disease"], [73, 73, "Disease"], [349, 349, "Disease"], [209, 209, "Disease"]]], "relations": [[[11, 40, 239, 239, "CID"], [42, 42, 239, 239, "CID"], [103, 103, 239, 239, "CID"], [139, 139, 239, 239, "CID"], [175, 175, 239, 239, "CID"], [204, 204, 239, 239, "CID"], [247, 247, 239, 239, "CID"], [339, 339, 239, 239, "CID"], [11, 40, 282, 282, "CID"], [42, 42, 282, 282, "CID"], [103, 103, 282, 282, "CID"], [139, 139, 282, 282, "CID"], [175, 175, 282, 282, "CID"], [204, 204, 282, 282, "CID"], [247, 247, 282, 282, "CID"], [339, 339, 282, 282, "CID"], [11, 40, 305, 308, "CID"], [42, 42, 305, 308, "CID"], [103, 103, 305, 308, "CID"], [139, 139, 305, 308, "CID"], [175, 175, 305, 308, "CID"], [204, 204, 305, 308, "CID"], [247, 247, 305, 308, "CID"], [339, 339, 305, 308, "CID"]]], "clusters": [], "translated": "<13>毒性</13> 给恒河猴服用<11>8-氨基喹啉</11> <0>8-[(4-氨基-1-甲基丁基)氨基]-5-(1-己氧基)-6-甲氧基-4-甲基喹啉</0>（<1>WR242511</1>）。简介：许多形成高铁血红蛋白(MHb)的物质可有效对抗氰化物(CN)<14>毒性</14>。尽管MHb形成剂通常用于治疗CN<17>中毒</17>，但有人提出稳定、长效的MHb形成剂可作为CN的预处理。利用这一原理，<12>8-氨基喹啉</12> <2>WR242511</2>是一种在啮齿动物和比格犬中有效的长效MHb前体，在恒河猴中进行了研究，以进一步开发作为潜在的CN预处理。方法：在这项研究中，<3>WR242511</3>以3.5和/或7.0毫克/千克；一名单身男性还在7岁时口服(PO)<4>WR242511</4>。0毫克/千克。暴露后监测健康状况和MHb水平。结果：<5>WR242511</5>的选定剂量在别处进行的早期研究中在比格犬中产生了显着的<19>高铁血红蛋白血症</19>，而在恒河猴中产生的MHb非常少(平均<2.0%）猴子。此外，在注射 <6>WR242511</6>（3.5或7.0mg/kg）后大约60分钟，注意到短暂的<8>血红蛋白尿</8>，并且发生了2例致死事件(一例IV和一例PO)以下7。0毫克/千克剂量。<9>肌红蛋白尿</9>在 7.0毫克/千克剂量后也被观察到。对2只死亡动物的组织病理学分析显示<10>肝脏和肾脏毒性</10>，口服治疗的动物更严重。结论：这些数据证明了直接和/或间接药物诱导的<15>毒性</15>。得出的结论是，<7>WR242511</7>不应作为CN<18>中毒</18>的预处理，除非该化合物的抗CN特性可以成功地与那些产生不良<16>毒性的化合物分离</16>。", "revised": true}
{"doc_key": "1728522", "sentences": [["Granulomatous", "hepatitis", "due", "to", "combination", "of", "amoxicillin", "and", "clavulanic", "acid", ".", "We", "report", "the", "case", "of", "a", "patient", "with", "amoxicillin", "-", "clavulanic", "acid", "-", "induced", "hepatitis", "with", "histologic", "multiple", "granulomas", ".", "This", "type", "of", "lesion", "broadens", "the", "spectrum", "of", "liver", "injury", "due", "to", "this", "drug", "combination", ",", "mainly", "represented", "by", "a", "benign", "cholestatic", "syndrome", ".", "The", "association", "of", "granulomas", "and", "eosinophilia", "favor", "an", "immunoallergic", "mechanism", ".", "As", "penicillin", "derivatives", "and", "amoxicillin", "alone", "are", "known", "to", "induce", "such", "types", "of", "lesions", ",", "the", "amoxicillin", "component", ",", "with", "or", "without", "a", "potentiating", "effect", "of", "clavulanic", "acid", ",", "might", "have", "a", "major", "role", "."]], "ner": [[[4, 9, "Chemical"], [19, 22, "Chemical"], [0, 1, "Disease"], [29, 29, "Disease"], [58, 58, "Disease"], [25, 25, "Disease"], [39, 40, "Disease"], [52, 53, "Disease"], [67, 67, "Chemical"], [70, 70, "Chemical"], [82, 82, "Chemical"], [92, 93, "Chemical"], [60, 60, "Disease"]]], "relations": [[[4, 9, 0, 1, "CID"], [4, 9, 29, 29, "CID"], [4, 9, 58, 58, "CID"], [19, 22, 0, 1, "CID"], [19, 22, 29, 29, "CID"], [19, 22, 58, 58, "CID"], [4, 9, 25, 25, "CID"], [4, 9, 39, 40, "CID"], [19, 22, 25, 25, "CID"], [19, 22, 39, 40, "CID"], [4, 9, 52, 53, "CID"], [19, 22, 52, 53, "CID"]]], "clusters": [], "translated": "<2>肉芽肿性肝炎</2>由于<0>阿莫西林和克拉维酸的组合</0>。我们报告了一例<1>阿莫西林-克拉维酸</1>诱发的<5>肝炎</5>，并伴有组织学多发性<3>肉芽肿</3>的患者。由于这种药物组合，这种类型的病变扩大了<6>肝损伤</6>的范围，主要表现为良性<7>胆汁淤积综合征</7>。关联<4>肉芽肿</4>和<12>嗜酸性粒细胞增多</12>有利于免疫过敏机制。由于已知<8>青霉素</8>衍生物和<9>阿莫西林</9>单独引起此类病变，因此<10>阿莫西林</10>成分，具有或不具有<11>克拉维酸的增强作用</11>，可能起主要作用。", "revised": true}
{"doc_key": "8741744", "sentences": [["The", "interpeduncular", "nucleus", "regulates", "nicotine", "'s", "effects", "on", "free", "-", "field", "activity", ".", "Partial", "lesions", "were", "made", "with", "kainic", "acid", "in", "the", "interpeduncular", "nucleus", "of", "the", "ventral", "midbrain", "of", "the", "rat", ".", "Compared", "with", "sham", "-", "operated", "controls", ",", "lesions", "significantly", "(", "p", "<", "0", ".", "25", ")", "blunted", "the", "early", "(", "<", "60", "min", ")", "free", "-", "field", "locomotor", "hypoactivity", "caused", "by", "nicotine", "(", "0", ".", "5", "mg", "kg", "(", "-", "1", ")", ",", "i", ".", "m", ".", ")", ",", "enhanced", "the", "later", "(", "60", "-", "120", "min", ")", "nicotine", "-", "induced", "hyperactivity", ",", "and", "raised", "spontaneous", "nocturnal", "activity", ".", "Lesions", "reduced", "the", "extent", "of", "immunohistological", "staining", "for", "choline", "acetyltransferase", "in", "the", "interpeduncular", "nucleus", "(", "p", "<", "0", ".", "025", ")", ",", "but", "not", "for", "tyrosine", "hydroxylase", "in", "the", "surrounding", "catecholaminergic", "A10", "region", ".", "We", "conclude", "that", "the", "interpeduncular", "nucleus", "mediates", "nicotinic", "depression", "of", "locomotor", "activity", "and", "dampens", "nicotinic", "arousal", "mechanisms", "located", "elsewhere", "in", "the", "brain", "."]], "ner": [[[4, 4, "Chemical"], [63, 63, "Chemical"], [90, 90, "Chemical"], [93, 93, "Disease"], [59, 60, "Disease"], [143, 143, "Disease"], [18, 19, "Chemical"], [109, 109, "Chemical"], [126, 126, "Chemical"]]], "relations": [[[4, 4, 93, 93, "CID"], [63, 63, 93, 93, "CID"], [90, 90, 93, 93, "CID"]]], "clusters": [], "translated": "脚间核调节<0>尼古丁</0>对自由场活动的影响。用<6>红藻氨酸</6>对大鼠中脑腹侧脚间核进行局部损伤。与假手术对照组相比，损伤显着 (p<0.25) 减弱了由<1>尼古丁</1> (0.5 mg kg(-1), i.m.) 引起的早期(<60分钟)自由场<4>运动能力减退</4>，增强后期(60-120分钟)<2>尼古丁</2>诱发的<3>多动症状</3>，并提高自发性夜间活动。损伤降低了<7>脚间核</7>中胆碱乙酰转移酶的免疫组织学染色范围 (p<0.025)，但周围儿茶酚胺能 A10 区域的<8>酪氨酸羟化酶</8>免疫组织学染色范围却没有变小。我们得出结论，脚间核介导<5>烟碱的抑制作用</5>，并抑制位于大脑其他部位的烟碱唤醒机制。", "revised": true}
{"doc_key": "12443032", "sentences": [["Cocaine", "related", "chest", "pain", ":", "are", "we", "seeing", "the", "tip", "of", "an", "iceberg", "?", "The", "recreational", "use", "of", "cocaine", "is", "on", "the", "increase", ".", "The", "emergency", "nurse", "ought", "to", "be", "familiar", "with", "some", "of", "the", "cardiovascular", "consequences", "of", "cocaine", "use", ".", "In", "particular", ",", "the", "tendency", "of", "cocaine", "to", "produce", "chest", "pain", "ought", "to", "be", "in", "the", "mind", "of", "the", "emergency", "nurse", "when", "faced", "with", "a", "young", "victim", "of", "chest", "pain", "who", "is", "otherwise", "at", "low", "risk", ".", "The", "mechanism", "of", "chest", "pain", "related", "to", "cocaine", "use", "is", "discussed", "and", "treatment", "dilemmas", "are", "discussed", ".", "Finally", ",", "moral", "issues", "relating", "to", "the", "testing", "of", "potential", "cocaine", "users", "will", "be", "addressed", "."]], "ner": [[[0, 0, "Chemical"], [18, 18, "Chemical"], [38, 38, "Chemical"], [47, 47, "Chemical"], [85, 85, "Chemical"], [105, 105, "Chemical"], [2, 3, "Disease"], [50, 51, "Disease"], [69, 70, "Disease"], [81, 82, "Disease"]]], "relations": [[[0, 0, 2, 3, "CID"], [0, 0, 50, 51, "CID"], [0, 0, 69, 70, "CID"], [0, 0, 81, 82, "CID"], [18, 18, 2, 3, "CID"], [18, 18, 50, 51, "CID"], [18, 18, 69, 70, "CID"], [18, 18, 81, 82, "CID"], [38, 38, 2, 3, "CID"], [38, 38, 50, 51, "CID"], [38, 38, 69, 70, "CID"], [38, 38, 81, 82, "CID"], [47, 47, 2, 3, "CID"], [47, 47, 50, 51, "CID"], [47, 47, 69, 70, "CID"], [47, 47, 81, 82, "CID"], [85, 85, 2, 3, "CID"], [85, 85, 50, 51, "CID"], [85, 85, 69, 70, "CID"], [85, 85, 81, 82, "CID"], [105, 105, 2, 3, "CID"], [105, 105, 50, 51, "CID"], [105, 105, 69, 70, "CID"], [105, 105, 81, 82, "CID"]]], "clusters": [], "translated": " <0>可卡因</0> 相关 <6>胸痛</6>：我们看到的是冰山一角吗？消遣性使用的<1>可卡因</1>正在增加。急诊护士应该熟悉使用<2>可卡因</2>的一些心血管后果。特别是，急诊护士在面对<8>胸痛</8>的年轻受害者时，应该牢记<3>可卡因</3>导致<7>胸痛</7>的倾向，在其他方面风险较低的人。讨论了与<4>可卡因</4>使用相关的<9>胸痛</9>机制，并讨论了治疗困境。最后，与潜在的<5>可卡因</5>使用者测试相关的道德问题将得到解决。", "revised": true}
{"doc_key": "10807237", "sentences": [["Intracranial", "aneurysms", "and", "cocaine", "abuse", ":", "analysis", "of", "prognostic", "indicators", ".", "OBJECTIVE", ":", "The", "outcome", "of", "subarachnoid", "hemorrhage", "associated", "with", "cocaine", "abuse", "is", "reportedly", "poor", ".", "However", ",", "no", "study", "in", "the", "literature", "has", "reported", "the", "use", "of", "a", "statistical", "model", "to", "analyze", "the", "variables", "that", "influence", "outcome", ".", "METHODS", ":", "A", "review", "of", "admissions", "during", "a", "6", "-", "year", "period", "revealed", "14", "patients", "with", "cocaine", "-", "related", "aneurysms", ".", "This", "group", "was", "compared", "with", "a", "control", "group", "of", "135", "patients", "with", "ruptured", "aneurysms", "and", "no", "history", "of", "cocaine", "abuse", ".", "Age", "at", "presentation", ",", "time", "of", "ictus", "after", "intoxication", ",", "Hunt", "and", "Hess", "grade", "of", "subarachnoid", "hemorrhage", ",", "size", "of", "the", "aneurysm", ",", "location", "of", "the", "aneurysm", ",", "and", "the", "Glasgow", "Outcome", "Scale", "score", "were", "assessed", "and", "compared", ".", "RESULTS", ":", "The", "patients", "in", "the", "study", "group", "were", "significantly", "younger", "than", "the", "patients", "in", "the", "control", "group", "(", "P", "<", "0", ".", "002", ")", ".", "In", "patients", "in", "the", "study", "group", ",", "all", "aneurysms", "were", "located", "in", "the", "anterior", "circulation", ".", "The", "majority", "of", "these", "aneurysms", "were", "smaller", "than", "those", "of", "the", "control", "group", "(", "8", "+", "/", "-", "6", ".", "08", "mm", "versus", "11", "+", "/", "-", "5", ".", "4", "mm", ";", "P", "=", "0", ".", "05", ")", ".", "The", "differences", "in", "mortality", "and", "morbidity", "between", "the", "two", "groups", "were", "not", "significant", ".", "Hunt", "and", "Hess", "grade", "(", "P", "<", "0", ".", "005", ")", "and", "age", "(", "P", "<", "0", ".", "007", ")", "were", "significant", "predictors", "of", "outcome", "for", "the", "patients", "with", "cocaine", "-", "related", "aneurysms", ".", "CONCLUSION", ":", "Cocaine", "use", "predisposed", "aneurysmal", "rupture", "at", "a", "significantly", "earlier", "age", "and", "in", "much", "smaller", "aneurysms", ".", "Contrary", "to", "the", "published", "literature", ",", "this", "group", "did", "reasonably", "well", "with", "aggressive", "management", "."]], "ner": [[[65, 65, "Chemical"], [254, 254, "Chemical"], [261, 261, "Chemical"], [82, 83, "Disease"], [264, 265, "Disease"], [0, 1, "Disease"], [3, 4, "Disease"], [20, 21, "Disease"], [88, 89, "Disease"], [16, 17, "Disease"], [106, 107, "Disease"], [68, 68, "Disease"], [112, 112, "Disease"], [117, 117, "Disease"], [164, 164, "Disease"], [176, 176, "Disease"], [257, 257, "Disease"], [275, 275, "Disease"]]], "relations": [[[65, 65, 82, 83, "CID"], [65, 65, 264, 265, "CID"], [254, 254, 82, 83, "CID"], [254, 254, 264, 265, "CID"], [261, 261, 82, 83, "CID"], [261, 261, 264, 265, "CID"]]], "clusters": [], "translated": " <5>颅内动脉瘤</5>和<6>可卡因滥用</6>：预后指标分析。目的：据报道，与<7>可卡因滥用</7>相关的<9>蛛网膜下腔出血</9>结果很差。然而，文献中没有研究报告使用统计模型来分析影响结果的变量。方法：对6年期间入院的回顾显示，14名患者患有<0>可卡因</0>-相关<11>动脉瘤</11>。将该组与135名<3>破裂动脉瘤</3>且无<8>可卡因滥用史</8>的对照组进行比较。就诊时的年龄、中毒后发作的时间、<10>蛛网膜下腔出血的Hunt和Hess分级</10>、<12>动脉瘤</12>的大小、<13>动脉瘤</13>的位置，以及对格拉斯哥结果量表评分进行评估和比较。结果：研究组患者年龄显着低于对照组患者（P<0.002）。在研究组的患者中，所有<14>动脉瘤</14>都位于前循环。这些<15>动脉瘤</15>中的大多数小于对照组（8+/-6.08毫米对11+/-5.4毫米；P=0.05）。两组死亡率和发病率差异无显着性。Hunt和Hess等级（P<0.005）和年龄（P<0.007）是<1>可卡因</1>-相关<16>动脉瘤</16>患者预后的重要预测因子。结论：<2>可卡因</2>使用易患<4>动脉瘤破裂</4>的年龄明显更早且<17>动脉瘤</17>更小。与已发表的文献相反，该小组在积极管理方面做得相当好。", "revised": true}
{"doc_key": "10901305", "sentences": [["Ketamine", "sedation", "for", "the", "reduction", "of", "children", "'s", "fractures", "in", "the", "emergency", "department", ".", "BACKGROUND", ":", "There", "recently", "has", "been", "a", "resurgence", "in", "the", "utilization", "of", "ketamine", ",", "a", "unique", "anesthetic", ",", "for", "emergency", "-", "department", "procedures", "requiring", "sedation", ".", "The", "purpose", "of", "the", "present", "study", "was", "to", "examine", "the", "safety", "and", "efficacy", "of", "ketamine", "for", "sedation", "in", "the", "treatment", "of", "children", "'s", "fractures", "in", "the", "emergency", "department", ".", "METHODS", ":", "One", "hundred", "and", "fourteen", "children", "(", "average", "age", ",", "5", ".", "3", "years", ";", "range", ",", "twelve", "months", "to", "ten", "years", "and", "ten", "months", ")", "who", "underwent", "closed", "reduction", "of", "an", "isolated", "fracture", "or", "dislocation", "in", "the", "emergency", "department", "at", "a", "level", "-", "I", "trauma", "center", "were", "prospectively", "evaluated", ".", "Ketamine", "hydrochloride", "was", "administered", "intravenously", "(", "at", "a", "dose", "of", "two", "milligrams", "per", "kilogram", "of", "body", "weight", ")", "in", "ninety", "-", "nine", "of", "the", "patients", "and", "intramuscularly", "(", "at", "a", "dose", "of", "four", "milligrams", "per", "kilogram", "of", "body", "weight", ")", "in", "the", "other", "fifteen", ".", "A", "board", "-", "certified", "emergency", "physician", "skilled", "in", "airway", "management", "supervised", "administration", "of", "the", "anesthetic", ",", "and", "the", "patients", "were", "monitored", "by", "a", "registered", "nurse", ".", "Any", "pain", "during", "the", "reduction", "was", "rated", "by", "the", "orthopaedic", "surgeon", "treating", "the", "patient", "according", "to", "the", "Children", "'s", "Hospital", "of", "Eastern", "Ontario", "Pain", "Scale", "(", "CHEOPS", ")", ".", "RESULTS", ":", "The", "average", "time", "from", "intravenous", "administration", "of", "ketamine", "to", "manipulation", "of", "the", "fracture", "or", "dislocation", "was", "one", "minute", "and", "thirty", "-", "six", "seconds", "(", "range", ",", "twenty", "seconds", "to", "five", "minutes", ")", ",", "and", "the", "average", "time", "from", "intramuscular", "administration", "to", "manipulation", "was", "four", "minutes", "and", "forty", "-", "two", "seconds", "(", "range", ",", "sixty", "seconds", "to", "fifteen", "minutes", ")", ".", "The", "average", "score", "according", "to", "the", "Children", "'s", "Hospital", "of", "Eastern", "Ontario", "Pain", "Scale", "was", "6", ".", "4", "points", "(", "range", ",", "5", "to", "10", "points", ")", ",", "reflecting", "minimal", "or", "no", "pain", "during", "fracture", "reduction", ".", "Adequate", "fracture", "reduction", "was", "obtained", "in", "111", "of", "the", "children", ".", "Ninety", "-", "nine", "percent", "(", "sixty", "-", "eight", ")", "of", "the", "sixty", "-", "nine", "parents", "present", "during", "the", "reduction", "were", "pleased", "with", "the", "sedation", "and", "would", "allow", "it", "to", "be", "used", "again", "in", "a", "similar", "situation", ".", "Patency", "of", "the", "airway", "and", "independent", "respiration", "were", "maintained", "in", "all", "of", "the", "patients", ".", "Blood", "pressure", "and", "heart", "rate", "remained", "stable", ".", "Minor", "side", "effects", "included", "nausea", "(", "thirteen", "patients", ")", ",", "emesis", "(", "eight", "of", "the", "thirteen", "patients", "with", "nausea", ")", ",", "clumsiness", "(", "evident", "as", "ataxic", "movements", "in", "ten", "patients", ")", ",", "and", "dysphoric", "reaction", "(", "one", "patient", ")", ".", "No", "long", "-", "term", "sequelae", "were", "noted", ",", "and", "no", "patients", "had", "hallucinations", "or", "nightmares", ".", "CONCLUSIONS", ":", "Ketamine", "reliably", ",", "safely", ",", "and", "quickly", "provided", "adequate", "sedation", "to", "effectively", "facilitate", "the", "reduction", "of", "children", "'s", "fractures", "in", "the", "emergency", "department", "at", "our", "institution", ".", "Ketamine", "should", "only", "be", "used", "in", "an", "environment", "such", "as", "the", "emergency", "department", ",", "where", "proper", "one", "-", "on", "-", "one", "monitoring", "is", "used", "and", "board", "-", "certified", "physicians", "skilled", "in", "airway", "management", "are", "directly", "involved", "in", "the", "care", "of", "the", "patient", "."]], "ner": [[[0, 0, "Chemical"], [26, 26, "Chemical"], [54, 54, "Chemical"], [121, 122, "Chemical"], [230, 230, "Chemical"], [449, 449, "Chemical"], [476, 476, "Chemical"], [395, 395, "Disease"], [409, 409, "Disease"], [401, 401, "Disease"], [412, 412, "Disease"], [416, 417, "Disease"], [8, 8, "Disease"], [63, 63, "Disease"], [103, 103, "Disease"], [235, 235, "Disease"], [317, 317, "Disease"], [321, 321, "Disease"], [467, 467, "Disease"], [105, 105, "Disease"], [237, 237, "Disease"], [115, 115, "Disease"], [193, 193, "Disease"], [215, 215, "Disease"], [295, 295, "Disease"], [315, 315, "Disease"], [443, 443, "Disease"]]], "relations": [[[0, 0, 395, 395, "CID"], [0, 0, 409, 409, "CID"], [26, 26, 395, 395, "CID"], [26, 26, 409, 409, "CID"], [54, 54, 395, 395, "CID"], [54, 54, 409, 409, "CID"], [121, 122, 395, 395, "CID"], [121, 122, 409, 409, "CID"], [230, 230, 395, 395, "CID"], [230, 230, 409, 409, "CID"], [449, 449, 395, 395, "CID"], [449, 449, 409, 409, "CID"], [476, 476, 395, 395, "CID"], [476, 476, 409, 409, "CID"], [0, 0, 401, 401, "CID"], [26, 26, 401, 401, "CID"], [54, 54, 401, 401, "CID"], [121, 122, 401, 401, "CID"], [230, 230, 401, 401, "CID"], [449, 449, 401, 401, "CID"], [476, 476, 401, 401, "CID"], [0, 0, 412, 412, "CID"], [0, 0, 416, 417, "CID"], [26, 26, 412, 412, "CID"], [26, 26, 416, 417, "CID"], [54, 54, 412, 412, "CID"], [54, 54, 416, 417, "CID"], [121, 122, 412, 412, "CID"], [121, 122, 416, 417, "CID"], [230, 230, 412, 412, "CID"], [230, 230, 416, 417, "CID"], [449, 449, 412, 412, "CID"], [449, 449, 416, 417, "CID"], [476, 476, 412, 412, "CID"], [476, 476, 416, 417, "CID"]]], "clusters": [], "translated": " <0>氯胺酮</0>镇静用于减少急诊科儿童<12>骨折</12>。背景：最近，<1>氯胺酮</1>（一种独特的麻醉剂）在需要镇静的急诊手术中重新流行起来。本研究的目的是检验<2>氯胺酮</2>在急诊科儿童<13>骨折</13>镇静治疗中的安全性和有效性。方法：114 名儿童（平均年龄 5 . 3 岁；范围 12 个月至 10 岁 10 个月）接受了孤立性<14>骨折</14>或<19>脱位</19>的闭合复位。在一级<21>创伤</21>中心的急诊科进行了前瞻性评估。<3>盐酸氯胺酮</3>在99名患者中静脉注射（剂量为每公斤体重2毫克），在其他患者中肌肉注射（剂量为每公斤体重4毫克）。一位在气道管理方面熟练的经过委员会认证的急诊医师监督麻醉剂的使用，而患者则由一位注册护士监护。复位过程中的任何<22>疼痛</22>均由治疗患者的整形外科医生根据东安大略省儿童医院<23>疼痛</23>量表（CHEOPS）进行评分。结果：从静脉注射<4>氯胺酮</4>到操作<15>骨折</15>或<20>脱位</20>的平均时间为1分36秒（范围，20秒到五分钟），从肌肉注射到操作的平均时间是四分四十二秒（范围，六十秒到十五分钟）。根据东安大略省儿童医院<24>疼痛</24>量表的平均得分为6分4分（范围，5～10分），反映<16>骨折</16>复位过程中<25>疼痛</25>极小或无。111名儿童获得了充分的<17>骨折</17>复位。在复位过程中在场的69名家长中，百分之九十九（六十八）对镇静剂感到满意，并愿意在类似情况下再次使用镇静剂。所有患者均保持气道通畅和自主呼吸。血压和心率保持稳定。轻微副作用包括<7>恶心</7>（13名患者）、<9>呕吐</9>（13名患者中有8名<8>恶心</8>）、<10>笨拙</10>（在10名患者中表现为<11>共济失调运动</11>）和烦躁反应（1名患者）。没有发现长期后遗症，也没有患者出现<26>幻觉</26>或噩梦。结论：<5>氯胺酮</5>可靠、安全、快速地提供了足够的镇静作用，有效地促进了我们机构急诊科儿童<18>骨折</18>的减少。<6>氯胺酮</6>只能在急诊室等环境中使用，在这种环境中使用适当的一对一监测，并且在气道管理方面熟练的经过委员会认证的医生直接参与患者的护理。", "revised": true}
{"doc_key": "12627929", "sentences": [["Increased", "frequency", "of", "venous", "thromboembolism", "with", "the", "combination", "of", "docetaxel", "and", "thalidomide", "in", "patients", "with", "metastatic", "androgen", "-", "independent", "prostate", "cancer", ".", "STUDY", "OBJECTIVE", ":", "To", "evaluate", "the", "frequency", "of", "venous", "thromboembolism", "(", "VTE", ")", "in", "patients", "with", "advanced", "androgen", "-", "independent", "prostate", "cancer", "who", "were", "treated", "with", "docetaxel", "alone", "or", "in", "combination", "with", "thalidomide", ".", "DESIGN", ":", "Retrospective", "analysis", "of", "a", "randomized", "phase", "II", "trial", ".", "SETTING", ":", "National", "Institutes", "of", "Health", "clinical", "research", "center", ".", "PATIENTS", ":", "Seventy", "men", ",", "aged", "50", "-", "80", "years", ",", "with", "advanced", "androgen", "-", "independent", "prostate", "cancer", ".", "INTERVENTION", ":", "Each", "patient", "received", "either", "intravenous", "docetaxel", "30", "mg", "/", "m2", "/", "week", "for", "3", "consecutive", "weeks", ",", "followed", "by", "1", "week", "off", ",", "or", "the", "combination", "of", "continuous", "oral", "thalidomide", "200", "mg", "every", "evening", "plus", "the", "same", "docetaxel", "regimen", ".", "This", "4", "-", "week", "cycle", "was", "repeated", "until", "there", "was", "evidence", "of", "excessive", "toxicity", "or", "disease", "progression", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", ":", "None", "of", "23", "patients", "who", "received", "docetaxel", "alone", "developed", "VTE", ",", "whereas", "9", "of", "47", "patients", "(", "19", "%", ")", "who", "received", "docetaxel", "plus", "thalidomide", "developed", "VTE", "(", "p", "=", "0", ".", "025", ")", ".", "CONCLUSION", ":", "The", "addition", "of", "thalidomide", "to", "docetaxel", "in", "the", "treatment", "of", "prostate", "cancer", "significantly", "increases", "the", "frequency", "of", "VTE", ".", "Clinicians", "should", "be", "aware", "of", "this", "potential", "complication", "when", "adding", "thalidomide", "to", "chemotherapeutic", "regimens", "."]], "ner": [[[9, 9, "Chemical"], [48, 48, "Chemical"], [103, 103, "Chemical"], [135, 135, "Chemical"], [167, 167, "Chemical"], [183, 183, "Chemical"], [203, 203, "Chemical"], [3, 4, "Disease"], [30, 31, "Disease"], [33, 33, "Disease"], [170, 170, "Disease"], [187, 187, "Disease"], [215, 215, "Disease"], [11, 11, "Chemical"], [54, 54, "Chemical"], [127, 127, "Chemical"], [185, 185, "Chemical"], [201, 201, "Chemical"], [227, 227, "Chemical"], [19, 20, "Disease"], [42, 43, "Disease"], [93, 94, "Disease"], [208, 209, "Disease"], [151, 151, "Disease"]]], "relations": [[[9, 9, 3, 4, "CID"], [9, 9, 30, 31, "CID"], [9, 9, 33, 33, "CID"], [9, 9, 170, 170, "CID"], [9, 9, 187, 187, "CID"], [9, 9, 215, 215, "CID"], [48, 48, 3, 4, "CID"], [48, 48, 30, 31, "CID"], [48, 48, 33, 33, "CID"], [48, 48, 170, 170, "CID"], [48, 48, 187, 187, "CID"], [48, 48, 215, 215, "CID"], [103, 103, 3, 4, "CID"], [103, 103, 30, 31, "CID"], [103, 103, 33, 33, "CID"], [103, 103, 170, 170, "CID"], [103, 103, 187, 187, "CID"], [103, 103, 215, 215, "CID"], [135, 135, 3, 4, "CID"], [135, 135, 30, 31, "CID"], [135, 135, 33, 33, "CID"], [135, 135, 170, 170, "CID"], [135, 135, 187, 187, "CID"], [135, 135, 215, 215, "CID"], [167, 167, 3, 4, "CID"], [167, 167, 30, 31, "CID"], [167, 167, 33, 33, "CID"], [167, 167, 170, 170, "CID"], [167, 167, 187, 187, "CID"], [167, 167, 215, 215, "CID"], [183, 183, 3, 4, "CID"], [183, 183, 30, 31, "CID"], [183, 183, 33, 33, "CID"], [183, 183, 170, 170, "CID"], [183, 183, 187, 187, "CID"], [183, 183, 215, 215, "CID"], [203, 203, 3, 4, "CID"], [203, 203, 30, 31, "CID"], [203, 203, 33, 33, "CID"], [203, 203, 170, 170, "CID"], [203, 203, 187, 187, "CID"], [203, 203, 215, 215, "CID"], [11, 11, 3, 4, "CID"], [11, 11, 30, 31, "CID"], [11, 11, 33, 33, "CID"], [11, 11, 170, 170, "CID"], [11, 11, 187, 187, "CID"], [11, 11, 215, 215, "CID"], [54, 54, 3, 4, "CID"], [54, 54, 30, 31, "CID"], [54, 54, 33, 33, "CID"], [54, 54, 170, 170, "CID"], [54, 54, 187, 187, "CID"], [54, 54, 215, 215, "CID"], [127, 127, 3, 4, "CID"], [127, 127, 30, 31, "CID"], [127, 127, 33, 33, "CID"], [127, 127, 170, 170, "CID"], [127, 127, 187, 187, "CID"], [127, 127, 215, 215, "CID"], [185, 185, 3, 4, "CID"], [185, 185, 30, 31, "CID"], [185, 185, 33, 33, "CID"], [185, 185, 170, 170, "CID"], [185, 185, 187, 187, "CID"], [185, 185, 215, 215, "CID"], [201, 201, 3, 4, "CID"], [201, 201, 30, 31, "CID"], [201, 201, 33, 33, "CID"], [201, 201, 170, 170, "CID"], [201, 201, 187, 187, "CID"], [201, 201, 215, 215, "CID"], [227, 227, 3, 4, "CID"], [227, 227, 30, 31, "CID"], [227, 227, 33, 33, "CID"], [227, 227, 170, 170, "CID"], [227, 227, 187, 187, "CID"], [227, 227, 215, 215, "CID"]]], "clusters": [], "translated": "<7>静脉血栓栓塞</7>与<0>多西紫杉醇</0>和<13>沙利度胺</13>相结合的转移性雄激素非依赖性<19>前列腺癌</19>患者的发生率增加。研究目的：评估接受<1>多西紫杉醇</1>单独使用或与<14>沙利度胺</14>联合使用的晚期雄激素非依赖性<20>前列腺癌</20>患者的<8>静脉血栓栓塞症</8> (<9>VTE</9>)的发生率。设计：一项随机II期试验的回顾性分析。地点：国立卫生研究院临床研究中心。患者：70名男性，年龄在50-80岁之间，患有晚期雄激素非依赖性<21>前列腺癌</21>。干预：每位患者连续3周接受静脉<2>多西紫杉醇</2> 30毫克/平方米/周，然后停药1周，或每晚连续口服<15>沙利度胺</15> 200毫克加上相同的<3>多西紫杉醇</3>方案。重复这个4周的周期，直到出现过度<23>毒性</23>或疾病进展的证据。测量和主要结果：23名单独接受<4>多西紫杉醇</4>治疗的患者均未发生<10>VTE</10>，而接受<5>多西紫杉醇</5>联合<16>沙利度胺</16>治疗的47名患者中有9名 (19%) 发生<11> VTE </11> (p = 0.025)。结论：<6>多西紫杉醇</6>联合<17>沙利度胺</17>治疗<22>前列腺癌</22>可显着增加<12>VTE</12>的发生率。临床医生在将<18>沙利度胺</18>加入化疗方案时应注意这种潜在的并发症。", "revised": true}
{"doc_key": "2522601", "sentences": [["Hypersensitivity", "to", "carbamazepine", "presenting", "with", "a", "leukemoid", "reaction", ",", "eosinophilia", ",", "erythroderma", ",", "and", "renal", "failure", ".", "We", "report", "a", "patient", "in", "whom", "hypersensitivity", "to", "carbamazepine", "presented", "with", "generalized", "erythroderma", ",", "a", "severe", "leukemoid", "reaction", ",", "eosinophilia", ",", "hyponatremia", ",", "and", "renal", "failure", ".", "This", "is", "the", "first", "report", "of", "such", "an", "unusual", "reaction", "to", "carbamazepine", "."]], "ner": [[[2, 2, "Chemical"], [25, 25, "Chemical"], [55, 55, "Chemical"], [0, 0, "Disease"], [23, 23, "Disease"], [6, 7, "Disease"], [33, 34, "Disease"], [11, 11, "Disease"], [29, 29, "Disease"], [14, 15, "Disease"], [41, 42, "Disease"], [38, 38, "Disease"], [9, 9, "Disease"], [36, 36, "Disease"]]], "relations": [[[2, 2, 0, 0, "CID"], [2, 2, 23, 23, "CID"], [25, 25, 0, 0, "CID"], [25, 25, 23, 23, "CID"], [55, 55, 0, 0, "CID"], [55, 55, 23, 23, "CID"], [2, 2, 6, 7, "CID"], [2, 2, 33, 34, "CID"], [25, 25, 6, 7, "CID"], [25, 25, 33, 34, "CID"], [55, 55, 6, 7, "CID"], [55, 55, 33, 34, "CID"], [2, 2, 11, 11, "CID"], [2, 2, 29, 29, "CID"], [25, 25, 11, 11, "CID"], [25, 25, 29, 29, "CID"], [55, 55, 11, 11, "CID"], [55, 55, 29, 29, "CID"], [2, 2, 14, 15, "CID"], [2, 2, 41, 42, "CID"], [25, 25, 14, 15, "CID"], [25, 25, 41, 42, "CID"], [55, 55, 14, 15, "CID"], [55, 55, 41, 42, "CID"], [2, 2, 38, 38, "CID"], [25, 25, 38, 38, "CID"], [55, 55, 38, 38, "CID"]]], "clusters": [], "translated": "对<0>卡马西平</0><3>过敏</3>，表现为<5>类白血病反应</5>、<12>嗜酸性粒细胞增多</12>、<7>红皮病</7>和<9>肾功能衰竭</9>。我们报告一名患者对<1>卡马西平</1><4>过敏</4>，出现全身性<8>红皮病</8>、严重<6>类白血病反应</6>、<13>嗜酸性粒细胞增多</13>、<11>低钠血症</11>和<10>肾功能衰竭</10>。这是对<2>卡马西平</2>的这种异常反应的首次报道。", "revised": true}
{"doc_key": "2096243", "sentences": [["Carmofur", "-", "induced", "organic", "mental", "disorders", ".", "Organic", "mental", "disorder", "was", "observed", "in", "a", "29", "-", "year", "-", "old", "female", "in", "the", "prognostic", "period", "after", "the", "onset", "of", "carmofur", "-", "induced", "leukoencephalopathy", ".", "Symptoms", "such", "as", "euphoria", ",", "emotional", "lability", "and", "puerile", "attitude", "noted", "in", "the", "patient", "were", "diagnosed", "as", "organic", "personality", "syndrome", "according", "to", "the", "criteria", "defined", "in", "the", "DSM", "-", "III", "-", "R", ".", "It", "is", "referred", "to", "as", "a", "frontal", "lobe", "syndrome", ".", "Brain", "CT", "revealed", "a", "periventricular", "low", "density", "area", "in", "the", "frontal", "white", "matter", "and", "moderate", "dilatation", "of", "the", "lateral", "ventricles", "especially", "at", "the", "bilateral", "anterior", "horns", ".", "Consequently", ",", "carmofur", "-", "induced", "leukoencephalopathy", "may", "uncommonly", "result", "in", "organic", "personality", "syndrome", "in", "the", "residual", "state", ".", "It", "may", "be", "attributed", "to", "the", "structural", "damage", "to", "the", "frontal", "lobe", "."]], "ner": [[[0, 0, "Chemical"], [28, 28, "Chemical"], [105, 105, "Chemical"], [3, 5, "Disease"], [7, 9, "Disease"], [31, 31, "Disease"], [108, 108, "Disease"], [50, 52, "Disease"], [113, 115, "Disease"], [72, 74, "Disease"], [127, 132, "Disease"]]], "relations": [[[0, 0, 3, 5, "CID"], [0, 0, 7, 9, "CID"], [28, 28, 3, 5, "CID"], [28, 28, 7, 9, "CID"], [105, 105, 3, 5, "CID"], [105, 105, 7, 9, "CID"], [0, 0, 31, 31, "CID"], [0, 0, 108, 108, "CID"], [28, 28, 31, 31, "CID"], [28, 28, 108, 108, "CID"], [105, 105, 31, 31, "CID"], [105, 105, 108, 108, "CID"]]], "clusters": [], "translated": " <0>卡莫氟</0> - 诱发<3>器质性精神障碍</3>。 <4>器质性精神障碍</4>在<1>卡莫氟</1> 诱发的<5>白质脑病</5>发作后的预后期观察到一名 29 岁女性。患者表现出的欣快感、情绪不稳、态度幼稚等症状被诊断为<7>器质性人格综合征</7>，根据 DSM-III-R定义的标准。它被称为<9>额叶综合症</9>。脑部CT显示额叶白质脑室周围低密度区和侧脑室中度扩张，尤其是双侧前角。因此，<2>卡莫氟</2> 诱发的<6>白质脑病</6>可能在残留状态下罕见地导致<8>器质性人格综合征</8>，这可能归因于<10>额叶的结构性损伤</10>。", "revised": true}
{"doc_key": "8558192", "sentences": [["Phase", "II", "trial", "of", "vinorelbine", "in", "metastatic", "squamous", "cell", "esophageal", "carcinoma", ".", "European", "Organization", "for", "Research", "and", "Treatment", "of", "Cancer", "Gastrointestinal", "Treat", "Cancer", "Cooperative", "Group", ".", "PURPOSE", ":", "To", "evaluate", "the", "response", "rate", "and", "toxic", "effects", "of", "vinorelbine", "(", "VNB", ")", "administered", "as", "a", "single", "agent", "in", "metastatic", "squamous", "cell", "esophageal", "carcinoma", ".", "PATIENTS", "AND", "METHODS", ":", "Forty", "-", "six", "eligible", "patients", "with", "measurable", "lesions", "were", "included", "and", "were", "stratified", "according", "to", "previous", "chemotherapy", ".", "Thirty", "patients", "without", "prior", "chemotherapy", "and", "16", "pretreated", "with", "cisplatin", "-", "based", "chemotherapy", "were", "assessable", "for", "toxicity", "and", "response", ".", "VNB", "was", "administered", "weekly", "as", "a", "25", "-", "mg", "/", "m2", "short", "intravenous", "(", "i", ".", "v", ".", ")", "infusion", ".", "RESULTS", ":", "Six", "of", "30", "patients", "(", "20", "%", ")", "without", "prior", "chemotherapy", "achieved", "a", "partial", "response", "(", "PR", ")", "(", "95", "%", "confidence", "interval", "[", "CI", "]", ",", "8", "%", "to", "39", "%", ")", ".", "The", "median", "duration", "of", "response", "was", "21", "weeks", "(", "range", ",", "17", "to", "28", ")", ".", "One", "of", "16", "patients", "(", "6", "%", ")", "with", "prior", "chemotherapy", "had", "a", "complete", "response", "(", "CR", ")", "of", "31", "weeks", "'", "duration", "(", "95", "%", "CI", ",", "0", "%", "to", "30", "%", ")", ".", "The", "overall", "response", "rate", "(", "World", "Health", "Organization", "[", "WHO", "]", "criteria", ")", "was", "15", "%", "(", "CR", ",", "2", "%", ";", "PR", "13", "%", ";", "95", "%", "CI", ",", "6", "%", "to", "29", "%", ")", ".", "The", "median", "dose", "-", "intensity", "(", "DI", ")", "was", "20", "mg", "/", "m2", "/", "wk", ".", "VNB", "was", "well", "tolerated", "and", "zero", "instances", "of", "WHO", "grade", "4", "nonhematologic", "toxicity", "occurred", ".", "At", "least", "one", "episode", "of", "grade", "3", "or", "4", "granulocytopenia", "was", "seen", "in", "59", "%", "of", "patients", ".", "A", "grade", "2", "or", "3", "infection", "occurred", "in", "16", "%", "of", "patients", ",", "but", "no", "toxic", "deaths", "occurred", ".", "Other", "side", "effects", "were", "rare", ",", "and", "peripheral", "neurotoxicity", "has", "been", "minor", "(", "26", "%", "grade", "1", ")", ".", "CONCLUSION", ":", "These", "data", "indicate", "that", "VNB", "is", "an", "active", "agent", "in", "metastatic", "esophageal", "squamous", "cell", "carcinoma", ".", "Given", "its", "excellent", "tolerance", "profile", "and", "low", "toxicity", ",", "further", "evaluation", "of", "VNB", "in", "combination", "therapy", "is", "warranted", "."]], "ner": [[[4, 4, "Chemical"], [37, 37, "Chemical"], [39, 39, "Chemical"], [95, 95, "Chemical"], [256, 256, "Chemical"], [333, 333, "Chemical"], [357, 357, "Chemical"], [280, 280, "Disease"], [315, 316, "Disease"], [7, 10, "Disease"], [48, 51, "Disease"], [340, 343, "Disease"], [19, 19, "Disease"], [22, 22, "Disease"], [91, 91, "Disease"], [268, 268, "Disease"], [352, 352, "Disease"], [294, 294, "Disease"], [305, 305, "Disease"], [84, 84, "Chemical"]]], "relations": [[[4, 4, 280, 280, "CID"], [37, 37, 280, 280, "CID"], [39, 39, 280, 280, "CID"], [95, 95, 280, 280, "CID"], [256, 256, 280, 280, "CID"], [333, 333, 280, 280, "CID"], [357, 357, 280, 280, "CID"], [4, 4, 315, 316, "CID"], [37, 37, 315, 316, "CID"], [39, 39, 315, 316, "CID"], [95, 95, 315, 316, "CID"], [256, 256, 315, 316, "CID"], [333, 333, 315, 316, "CID"], [357, 357, 315, 316, "CID"]]], "clusters": [], "translated": "<0>长春瑞滨</0>治疗转移性<9>鳞状细胞食管癌</9>的II期临床试验。欧洲<12>癌症研究与治疗组织</12>胃肠道治疗<13>癌症</13>合作组。目的：评价<1>长春瑞滨</1>（<2>VNB</2>）单药治疗转移性<10>鳞状细胞食管癌</10>的反应率和毒性作用。患者和方法：46 名具有可测量病变的符合条件的患者被纳入，并根据之前的化疗进行分层。30 名未接受过化疗的患者和16 名接受过基于<19>顺铂</19>的化疗的患者可评估<14>毒性</14>和反应。<3>VNB</3>每周以25 mg/m2 的短时间静脉内（i.v.）输注给药。结果：30 名未接受化疗的患者中有6 名（20%）达到部分缓解（PR）（95% 置信区间 [CI]，8% 至 39%）。中位反应持续时间为21 周（范围17 至 28）。16 名接受过化疗的患者中有1 名（6%）获得了持续31 周的完全缓解（CR）（95% CI，0% 至 30%）。总体缓解率（世界卫生组织 [WHO] 标准）为15%（CR，2%；PR 13%；95% CI，6% 至 29%）。中位剂量强度(DI)为20 mg/m2/wk。<4>VNB</4>耐受性良好，零例WHO 4 级非血液学<15>毒性</15>的发生。至少有1 次3 级或4 级的<7>粒细胞减少症</7>在59%的患者中观察到。16%的患者发生2 级或3 级的<17>感染</17>，但没有<18>毒性</18>死亡发生。其他副作用很少见，<8>外周神经毒性</8>也很轻微（26%为1 级）。结论：这些数据表明<5>VNB</5>是转移性<11>食管鳞状细胞癌</11>的活性药物。鉴于其出色的耐受性和低<16>毒性</16>，有必要对<6>VNB</6>联合治疗进行进一步评估。", "revised": true}
{"doc_key": "3615541", "sentences": [["Regional", "localization", "of", "the", "antagonism", "of", "amphetamine", "-", "induced", "hyperactivity", "by", "intracerebral", "calcitonin", "injections", ".", "Calcitonin", "receptors", "are", "found", "in", "the", "brain", ",", "and", "intracerebral", "infusions", "of", "calcitonin", "can", "produce", "behavioral", "effects", ".", "Among", "these", "behavioral", "effects", "are", "decreases", "in", "food", "intake", "and", "decreases", "in", "amphetamine", "-", "induced", "locomotor", "activity", ".", "In", "previous", "experiments", "we", "found", "that", "decreases", "in", "food", "intake", "were", "induced", "by", "local", "administration", "of", "calcitonin", "into", "several", "hypothalamic", "sites", "and", "into", "the", "nucleus", "accumbens", ".", "In", "the", "present", "experiment", "calcitonin", "decreased", "locomotor", "activity", "when", "locally", "injected", "into", "the", "same", "sites", "where", "it", "decreases", "food", "intake", ".", "The", "areas", "where", "calcitonin", "is", "most", "effective", "in", "decreasing", "locomotor", "activity", "are", "located", "in", "the", "hypothalamus", "and", "nucleus", "accumbens", ",", "suggesting", "that", "these", "areas", "are", "the", "major", "sites", "of", "action", "of", "calcitonin", "in", "inhibiting", "amphetamine", "-", "induced", "locomotor", "activity", "."]], "ner": [[[6, 6, "Chemical"], [45, 45, "Chemical"], [133, 133, "Chemical"], [9, 9, "Disease"], [12, 12, "Chemical"], [15, 15, "Chemical"], [27, 27, "Chemical"], [67, 67, "Chemical"], [82, 82, "Chemical"], [102, 102, "Chemical"], [130, 130, "Chemical"]]], "relations": [[[6, 6, 9, 9, "CID"], [45, 45, 9, 9, "CID"], [133, 133, 9, 9, "CID"]]], "clusters": [], "translated": "<0>苯丙胺</0>的拮抗作用的区域定位-通过脑内<4>降钙素</4>注射引起的<3>活动过度</3>。<5>降钙素</5>受体存在于大脑中，脑内输注<6>降钙素</6>可产生行为效应。这些行为影响包括食物摄入减少和<1>苯丙胺</1>诱导的运动活动减少。在之前的实验中，我们发现食物摄入量的减少是由<7>降钙素</7>局部给药到下丘脑的几个部位和伏隔核引起的。在本实验中，<8> 降钙素</8>在局部注射到降低食物摄入量的相同部位时，会降低运动活性。<9>降钙素</9>在降低运动活性方面最有效的区域位于下丘脑和伏隔核，表明这些区域是<10>降钙素</10>抑制<2>安非他明</2>-诱导的运动活动的主要作用部位。", "revised": true}
{"doc_key": "18004067", "sentences": [["Acute", "liver", "failure", "in", "two", "patients", "with", "regular", "alcohol", "consumption", "ingesting", "paracetamol", "at", "therapeutic", "dosage", ".", "BACKGROUND", ":", "The", "possible", "role", "of", "alcohol", "in", "the", "development", "of", "hepatotoxicity", "associated", "with", "therapeutic", "doses", "of", "paracetamol", "(", "acetaminophen", ")", "is", "currently", "debated", ".", "CASE", "REPORT", ":", "We", "describe", "2", "patients", "who", "were", "regular", "consumers", "of", "alcohol", "and", "who", "developed", "liver", "failure", "within", "3", "-", "5", "days", "after", "hospitalization", "and", "stopping", "alcohol", "consumption", "while", "being", "treated", "with", "4", "g", "paracetamol", "/", "day", ".", "A", "paracetamol", "serum", "level", "obtained", "in", "one", "of", "these", "patients", "was", "not", "in", "the", "toxic", "range", ".", "Possible", "risk", "factors", "for", "the", "development", "of", "hepatotoxicity", "in", "patients", "treated", "with", "therapeutic", "doses", "of", "paracetamol", "are", "discussed", ".", "CONCLUSION", ":", "In", "patients", "with", "risk", "factors", ",", "e", ".", "g", ".", "regular", "consumption", "of", "alcohol", ",", "liver", "failure", "is", "possible", "when", "therapeutic", "doses", "are", "ingested", ".", "We", "propose", "that", "the", "paracetamol", "dose", "should", "not", "exceed", "2", "g", "/", "day", "in", "such", "patients", "and", "that", "their", "liver", "function", "should", "be", "monitored", "closely", "while", "being", "treated", "with", "paracetamol", "."]], "ner": [[[11, 11, "Chemical"], [33, 33, "Chemical"], [35, 35, "Chemical"], [76, 76, "Chemical"], [81, 81, "Chemical"], [112, 112, "Chemical"], [147, 147, "Chemical"], [172, 172, "Chemical"], [27, 27, "Disease"], [104, 104, "Disease"], [57, 58, "Disease"], [133, 134, "Disease"], [8, 8, "Chemical"], [22, 22, "Chemical"], [53, 53, "Chemical"], [68, 68, "Chemical"], [131, 131, "Chemical"], [0, 2, "Disease"]]], "relations": [[[11, 11, 27, 27, "CID"], [11, 11, 104, 104, "CID"], [33, 33, 27, 27, "CID"], [33, 33, 104, 104, "CID"], [35, 35, 27, 27, "CID"], [35, 35, 104, 104, "CID"], [76, 76, 27, 27, "CID"], [76, 76, 104, 104, "CID"], [81, 81, 27, 27, "CID"], [81, 81, 104, 104, "CID"], [112, 112, 27, 27, "CID"], [112, 112, 104, 104, "CID"], [147, 147, 27, 27, "CID"], [147, 147, 104, 104, "CID"], [172, 172, 27, 27, "CID"], [172, 172, 104, 104, "CID"], [11, 11, 57, 58, "CID"], [11, 11, 133, 134, "CID"], [33, 33, 57, 58, "CID"], [33, 33, 133, 134, "CID"], [35, 35, 57, 58, "CID"], [35, 35, 133, 134, "CID"], [76, 76, 57, 58, "CID"], [76, 76, 133, 134, "CID"], [81, 81, 57, 58, "CID"], [81, 81, 133, 134, "CID"], [112, 112, 57, 58, "CID"], [112, 112, 133, 134, "CID"], [147, 147, 57, 58, "CID"], [147, 147, 133, 134, "CID"], [172, 172, 57, 58, "CID"], [172, 172, 133, 134, "CID"]]], "clusters": [], "translated": " <17> 急性肝功能衰竭 </17> 两名定期<12>饮酒</12>并摄入治疗剂量的<0>对乙酰氨基酚</0>的患者。背景: 在与治疗剂量的<1>扑热息痛</1>（<2>对乙酰氨基酚</2>）相关的<8>肝毒性</8>中，<13>酒精</13>的可能作用目前争论不休。病例报告: 我们描述了2名患者，他们是<14>酒精</14>的经常消费者，并且在住院和停止<15>饮酒</15>消费后3-5天内发生了<10>肝功能衰竭</10>，同时接受4克<3>对乙酰氨基酚</3> /天的治疗。其中一名患者的<4>对乙酰氨基酚</4>血清水平不在毒性范围内。讨论了接受治疗剂量的<5>对乙酰氨基酚</5>治疗的患者发生<9>肝毒性</9>的可能危险因素。结论：在有危险因素的患者中，例如经常<16>饮酒</16>，摄入治疗剂量时可能发生<11>肝功能衰竭</11>。我们建议此类患者的<6>对乙酰氨基酚</6>剂量不应超过2克/天，并且在使用<7>对乙酰氨基酚</7>治疗期间应密切监测其肝功能。", "revised": true}
{"doc_key": "8955532", "sentences": [["Role", "of", "activation", "of", "bradykinin", "B2", "receptors", "in", "disruption", "of", "the", "blood", "-", "brain", "barrier", "during", "acute", "hypertension", ".", "Cellular", "mechanisms", "which", "account", "for", "disruption", "the", "blood", "-", "brain", "barrier", "during", "acute", "hypertension", "are", "not", "clear", ".", "The", "goal", "of", "this", "study", "was", "to", "determine", "the", "role", "of", "synthesis", "/", "release", "of", "bradykinin", "to", "activate", "B2", "receptors", "in", "disruption", "of", "the", "blood", "-", "brain", "barrier", "during", "acute", "hypertension", ".", "Permeability", "of", "the", "blood", "-", "brain", "barrier", "was", "quantitated", "by", "clearance", "of", "fluorescent", "-", "labeled", "dextran", "before", "and", "during", "phenylephrine", "-", "induced", "acute", "hypertension", "in", "rats", "treated", "with", "vehicle", "and", "Hoe", "-", "140", "(", "0", ".", "1", "microM", ")", ".", "Phenylephrine", "infusion", "increased", "arterial", "pressure", ",", "arteriolar", "diameter", "and", "clearance", "of", "fluorescent", "dextran", "by", "a", "similar", "magnitude", "in", "both", "groups", ".", "These", "findings", "suggest", "that", "disruption", "of", "the", "blood", "-", "brain", "barrier", "during", "acute", "hypertension", "is", "not", "related", "to", "the", "synthesis", "/", "release", "of", "bradykinin", "to", "activate", "B2", "receptors", "."]], "ner": [[[88, 88, "Chemical"], [109, 109, "Chemical"], [17, 17, "Disease"], [32, 32, "Disease"], [67, 67, "Disease"], [92, 92, "Disease"], [143, 143, "Disease"], [4, 4, "Chemical"], [52, 52, "Chemical"], [153, 153, "Chemical"], [84, 84, "Chemical"], [121, 121, "Chemical"], [99, 101, "Chemical"]]], "relations": [[[88, 88, 17, 17, "CID"], [88, 88, 32, 32, "CID"], [88, 88, 67, 67, "CID"], [88, 88, 92, 92, "CID"], [88, 88, 143, 143, "CID"], [109, 109, 17, 17, "CID"], [109, 109, 32, 32, "CID"], [109, 109, 67, 67, "CID"], [109, 109, 92, 92, "CID"], [109, 109, 143, 143, "CID"]]], "clusters": [], "translated": "<7>缓激肽</7> B2 受体激活在急性<2>高血压</2>期间血脑屏障破坏中的作用。导致急性<3>高血压</3>期间血脑屏障破坏的细胞机制尚不清楚。本研究的目的是确定<8>缓激肽</8>的合成/释放对激活 B2 受体在急性<4>高血压</4>期间血脑屏障破坏中的作用。在<0>苯肾上腺素</0>诱发急性<5>高血压</5>之前和期间，通过清除荧光标记的<10>葡聚糖</10>定量血脑屏障的渗透性和<12>Hoe-140</12> (0.1 microM)。<1>去氧肾上腺素</1>输注使两组的动脉压、小动脉直径和荧光<11>葡聚糖</11>清除率增加幅度相似。这些发现表明，急性<6>高血压</6>期间血脑屏障的破坏与激活B2受体的<9>缓激肽</9>的合成/释放无关。", "revised": true}
{"doc_key": "3782049", "sentences": [["A", "case", "of", "massive", "rhabdomyolysis", "following", "molindone", "administration", ".", "Rhabdomyolysis", "is", "a", "potentially", "lethal", "syndrome", "that", "psychiatric", "patients", "seem", "predisposed", "to", "develop", ".", "The", "clinical", "signs", "and", "symptoms", ",", "typical", "laboratory", "features", ",", "and", "complications", "of", "rhabdomyolysis", "are", "presented", ".", "The", "case", "of", "a", "schizophrenic", "patient", "is", "reported", "to", "illustrate", "massive", "rhabdomyolysis", "and", "subsequent", "acute", "renal", "failure", "following", "molindone", "administration", ".", "Physicians", "who", "prescribe", "molindone", "should", "be", "aware", "of", "this", "reaction", "."]], "ner": [[[6, 6, "Chemical"], [58, 58, "Chemical"], [64, 64, "Chemical"], [4, 4, "Disease"], [9, 9, "Disease"], [36, 36, "Disease"], [51, 51, "Disease"], [54, 56, "Disease"], [16, 16, "Disease"], [44, 44, "Disease"]]], "relations": [[[6, 6, 4, 4, "CID"], [6, 6, 9, 9, "CID"], [6, 6, 36, 36, "CID"], [6, 6, 51, 51, "CID"], [58, 58, 4, 4, "CID"], [58, 58, 9, 9, "CID"], [58, 58, 36, 36, "CID"], [58, 58, 51, 51, "CID"], [64, 64, 4, 4, "CID"], [64, 64, 9, 9, "CID"], [64, 64, 36, 36, "CID"], [64, 64, 51, 51, "CID"], [6, 6, 54, 56, "CID"], [58, 58, 54, 56, "CID"], [64, 64, 54, 56, "CID"]]], "clusters": [], "translated": "<0>吗啉酮</0>给药后大量<3>横纹肌溶解症</3>一例。<4>横纹肌溶解症</4>是一种潜在的致命综合征，<8>精神病患者</8>似乎容易患上这种疾病。介绍了<5>横纹肌溶解症</5>的临床体征和症状、典型的实验室特征和并发症。据报道，一名<9>精神分裂症</9>患者在服用<1>吗啉酮</1>后出现了大规模的<6>横纹肌溶解症</6>和随后的<7>急性肾功能衰竭</7>。开<2>吗啉酮</2>处方的医生应该意识到这种反应。", "revised": true}
{"doc_key": "17491223", "sentences": [["Assessment", "of", "a", "new", "non", "-", "invasive", "index", "of", "cardiac", "performance", "for", "detection", "of", "dobutamine", "-", "induced", "myocardial", "ischemia", ".", "BACKGROUND", ":", "Electrocardiography", "has", "a", "very", "low", "sensitivity", "in", "detecting", "dobutamine", "-", "induced", "myocardial", "ischemia", ".", "OBJECTIVES", ":", "To", "assess", "the", "added", "diagnostic", "value", "of", "a", "new", "cardiac", "performance", "index", "(", "dP", "/", "dtejc", ")", "measurement", ",", "based", "on", "brachial", "artery", "flow", "changes", ",", "as", "compared", "to", "standard", "12", "-", "lead", "ECG", ",", "for", "detecting", "dobutamine", "-", "induced", "myocardial", "ischemia", ",", "using", "Tc99m", "-", "Sestamibi", "single", "-", "photon", "emission", "computed", "tomography", "as", "the", "gold", "standard", "of", "comparison", "to", "assess", "the", "presence", "or", "absence", "of", "ischemia", ".", "METHODS", ":", "The", "study", "group", "comprised", "40", "patients", "undergoing", "Sestamibi", "-", "SPECT", "/", "dobutamine", "stress", "test", ".", "Simultaneous", "measurements", "of", "ECG", "and", "brachial", "artery", "dP", "/", "dtejc", "were", "performed", "at", "each", "dobutamine", "level", ".", "In", "19", "of", "the", "40", "patients", "perfusion", "defects", "compatible", "with", "ischemia", "were", "detected", "on", "SPECT", ".", "The", "increase", "in", "dP", "/", "dtejc", "during", "infusion", "of", "dobutamine", "in", "this", "group", "was", "severely", "impaired", "as", "compared", "to", "the", "non", "-", "ischemic", "group", ".", "dP", "/", "dtejc", "outcome", "was", "combined", "with", "the", "ECG", "results", ",", "giving", "an", "ECG", "-", "enhanced", "value", ",", "and", "compared", "to", "ECG", "alone", ".", "RESULTS", ":", "The", "sensitivity", "improved", "dramatically", "from", "16", "%", "to", "79", "%", ",", "positive", "predictive", "value", "increased", "from", "60", "%", "to", "68", "%", "and", "negative", "predictive", "value", "from", "54", "%", "to", "78", "%", ",", "and", "specificity", "decreased", "from", "90", "%", "to", "67", "%", ".", "CONCLUSIONS", ":", "If", "ECG", "alone", "is", "used", "for", "specificity", ",", "the", "combination", "with", "dP", "/", "dtejc", "improved", "the", "sensitivity", "of", "the", "test", "and", "could", "be", "a", "cost", "-", "savings", "alternative", "to", "cardiac", "imaging", "or", "perfusion", "studies", "to", "detect", "myocardial", "ischemia", ",", "especially", "in", "patients", "unable", "to", "exercise", "."]], "ner": [[[14, 14, "Chemical"], [30, 30, "Chemical"], [75, 75, "Chemical"], [119, 119, "Chemical"], [137, 137, "Chemical"], [165, 165, "Chemical"], [17, 18, "Disease"], [33, 34, "Disease"], [78, 79, "Disease"], [287, 288, "Disease"], [104, 104, "Disease"], [150, 150, "Disease"], [82, 84, "Chemical"], [115, 115, "Chemical"]]], "relations": [[[14, 14, 17, 18, "CID"], [14, 14, 33, 34, "CID"], [14, 14, 78, 79, "CID"], [14, 14, 287, 288, "CID"], [30, 30, 17, 18, "CID"], [30, 30, 33, 34, "CID"], [30, 30, 78, 79, "CID"], [30, 30, 287, 288, "CID"], [75, 75, 17, 18, "CID"], [75, 75, 33, 34, "CID"], [75, 75, 78, 79, "CID"], [75, 75, 287, 288, "CID"], [119, 119, 17, 18, "CID"], [119, 119, 33, 34, "CID"], [119, 119, 78, 79, "CID"], [119, 119, 287, 288, "CID"], [137, 137, 17, 18, "CID"], [137, 137, 33, 34, "CID"], [137, 137, 78, 79, "CID"], [137, 137, 287, 288, "CID"], [165, 165, 17, 18, "CID"], [165, 165, 33, 34, "CID"], [165, 165, 78, 79, "CID"], [165, 165, 287, 288, "CID"]]], "clusters": [], "translated": "评估用于检测<0>多巴酚丁胺</0>引起的<6>心肌缺血</6>的新的无创心脏性能指标。背景：心电图检测<1>多巴酚丁胺</1>引起的<7>心肌缺血</7>的敏感性非常低。目的：评估新的心脏性能指数 ( dP/dtejc ) 测量的附加诊断价值，该测量基于肱动脉血流变化，用于检测<2>多巴酚丁胺</2>诱导的<8>心肌缺血</8>，使用<12>Tc99m-Sestamibi</12>单光子发射计算机断层扫描作为比较的金标准来评估是否存在<10>缺血</10>。方法：研究组包括40名接受<13>Sestamibi</13>-SPECT/<3>多巴酚丁胺</3>负荷试验的患者。在每个<4>多巴酚丁胺</4>水平下同时测量 ECG 和肱动脉 dP/dtejc。在40名患者中，有19名患者在 SPECT 上检测到与<11>缺血</11>相容的灌注缺陷。与非缺血组相比，该组输注<5>多巴酚丁胺</5>期间 dP/dtejc 增加受到严重损害。dP/dtejc 结果与 ECG 结果相结合，给出了 ECG-增强值，并与单独的 ECG 进行了比较。结果：敏感性从16%显着提高到79%，阳性预测值从60%提高到68%，阴性预测值从54%提高到78%，特异性从90%降低到67%。结论：如果 ECG 单独用于特异性，与 dP/dtejc 的组合提高了测试的灵敏度，并且可以作为心脏成像或灌注研究的一种节省成本的替代方法来检测<9>心肌缺血</9>，尤其是在患者无法运动。", "revised": true}
{"doc_key": "3856631", "sentences": [["Remission", "induction", "of", "meningeal", "leukemia", "with", "high", "-", "dose", "intravenous", "methotrexate", ".", "Twenty", "children", "with", "acute", "lymphoblastic", "leukemia", "who", "developed", "meningeal", "disease", "were", "treated", "with", "a", "high", "-", "dose", "intravenous", "methotrexate", "regimen", "that", "was", "designed", "to", "achieve", "and", "maintain", "CSF", "methotrexate", "concentrations", "of", "10", "(", "-", "5", ")", "mol", "/", "L", "without", "the", "need", "for", "concomitant", "intrathecal", "dosing", ".", "The", "methotrexate", "was", "administered", "as", "a", "loading", "dose", "of", "6", ",", "000", "mg", "/", "m2", "for", "a", "period", "of", "one", "hour", "followed", "by", "an", "infusion", "of", "1", ",", "200", "mg", "/", "m2", "/", "h", "for", "23", "hours", ".", "Leucovorin", "rescue", "was", "initiated", "12", "hours", "after", "the", "end", "of", "the", "infusion", "with", "a", "loading", "dose", "of", "200", "mg", "/", "m2", "followed", "by", "12", "mg", "/", "m2", "every", "three", "hours", "for", "six", "doses", "and", "then", "every", "six", "hours", "until", "the", "plasma", "methotrexate", "level", "decreased", "to", "less", "than", "1", "X", "10", "(", "-", "7", ")", "mol", "/", "L", ".", "The", "mean", "steady", "-", "state", "plasma", "and", "CSF", "methotrexate", "concentrations", "achieved", "were", "1", ".", "1", "X", "10", "(", "-", "3", ")", "mol", "/", "L", "and", "3", ".", "6", "X", "10", "(", "-", "5", ")", "mol", "/", "L", ",", "respectively", ".", "All", "20", "patients", "responded", "to", "this", "regimen", ",", "16", "/", "20", "(", "80", "%", ")", "achieved", "a", "complete", "remission", ",", "and", "20", "%", "obtained", "a", "partial", "remission", ".", "The", "most", "common", "toxicities", "encountered", "were", "transient", "serum", "transaminase", "and", "bilirubin", "elevations", ",", "neutropenia", ",", "and", "mucositis", ".", "One", "patient", "had", "focal", "seizures", "and", "transient", "hemiparesis", "but", "recovered", "completely", ".", "High", "-", "dose", "intravenous", "methotrexate", "is", "an", "effective", "treatment", "for", "the", "induction", "of", "remission", "after", "meningeal", "relapse", "in", "acute", "lymphoblastic", "leukemia", "."]], "ner": [[[10, 10, "Chemical"], [30, 30, "Chemical"], [40, 40, "Chemical"], [60, 60, "Chemical"], [138, 138, "Chemical"], [163, 163, "Chemical"], [257, 257, "Chemical"], [236, 236, "Disease"], [239, 239, "Disease"], [245, 245, "Disease"], [247, 248, "Disease"], [3, 4, "Disease"], [97, 97, "Chemical"], [233, 233, "Chemical"], [15, 17, "Disease"], [271, 273, "Disease"], [20, 21, "Disease"], [226, 226, "Disease"]]], "relations": [[[10, 10, 236, 236, "CID"], [30, 30, 236, 236, "CID"], [40, 40, 236, 236, "CID"], [60, 60, 236, 236, "CID"], [138, 138, 236, 236, "CID"], [163, 163, 236, 236, "CID"], [257, 257, 236, 236, "CID"], [10, 10, 239, 239, "CID"], [30, 30, 239, 239, "CID"], [40, 40, 239, 239, "CID"], [60, 60, 239, 239, "CID"], [138, 138, 239, 239, "CID"], [163, 163, 239, 239, "CID"], [257, 257, 239, 239, "CID"], [10, 10, 245, 245, "CID"], [30, 30, 245, 245, "CID"], [40, 40, 245, 245, "CID"], [60, 60, 245, 245, "CID"], [138, 138, 245, 245, "CID"], [163, 163, 245, 245, "CID"], [257, 257, 245, 245, "CID"], [10, 10, 247, 248, "CID"], [30, 30, 247, 248, "CID"], [40, 40, 247, 248, "CID"], [60, 60, 247, 248, "CID"], [138, 138, 247, 248, "CID"], [163, 163, 247, 248, "CID"], [257, 257, 247, 248, "CID"]]], "clusters": [], "translated": "大剂量静脉注射<0>甲氨蝶呤</0>诱导<11>脑膜白血病</11>缓解。20名患有<14>急性淋巴细胞白血病</14>并发展为<16>脑膜疾病</16>的儿童接受了高剂量静脉内<1>甲氨蝶呤</1>方案治疗，该方案旨在实现和维持CSF<2>甲氨蝶呤</2>浓度为10(-5)mol/L，无需同时鞘内给药。<3>甲氨蝶呤</3>以6,000mg/m2的负荷剂量给药1小时，然后以1,200mg/m2/h的速度输注23小时。<12>亚叶酸</12>救援在输注结束后12小时开始，负荷剂量为200mg/m2，随后每3小时12mg/m2，共6剂，之后每6小时一次，直至血浆<4>甲氨蝶呤</4>水平降低至低于1X10(-7)mol/L。达到的平均稳态血浆和CSF<5>甲氨蝶呤</5>浓度分别为1.1X10(-3)mol/L和3.6X10(-5)mol/L。所有20名患者对该方案均有反应，其中16/20(80%)达到完全缓解，20%获得部分缓解。最常见的<17>毒性</17>是短暂的血清转氨酶和<13>胆红素</13>升高、<7>中性粒细胞减少</7>和<8>粘膜炎</8>。一名患者出现局灶性<9>癫痫发作</9>和<10>短暂性偏瘫</10>，但完全康复。大剂量静脉注射<6>甲氨蝶呤</6>是诱导<15>急性淋巴细胞白血病</15>脑膜复发后缓解的有效治疗方法。", "revised": true}
{"doc_key": "6209318", "sentences": [["International", "mexiletine", "and", "placebo", "antiarrhythmic", "coronary", "trial", ":", "I", ".", "Report", "on", "arrhythmia", "and", "other", "findings", ".", "Impact", "Research", "Group", ".", "The", "antiarrhythmic", "effects", "of", "the", "sustained", "release", "form", "of", "mexiletine", "(", "Mexitil", "-", "Perlongets", ")", "were", "evaluated", "in", "a", "double", "-", "blind", "placebo", "trial", "in", "630", "patients", "with", "recent", "documented", "myocardial", "infarction", ".", "The", "primary", "response", "variable", "was", "based", "on", "central", "reading", "of", "24", "hour", "ambulatory", "electrocardiographic", "recordings", "and", "was", "defined", "as", "the", "occurrence", "of", "30", "or", "more", "single", "premature", "ventricular", "complexes", "in", "any", "two", "consecutive", "30", "minute", "blocks", "or", "one", "or", "more", "runs", "of", "two", "or", "more", "premature", "ventricular", "complexes", "in", "the", "entire", "24", "hour", "electrocardiographic", "recording", ".", "Large", "differences", ",", "regarded", "as", "statistically", "significant", ",", "between", "the", "mexiletine", "and", "placebo", "groups", "were", "noted", "in", "that", "end", "point", "at", "months", "1", "and", "4", ",", "but", "only", "trends", "were", "observed", "at", "month", "12", ".", "These", "differences", "were", "observed", "even", "though", "the", "serum", "mexiletine", "levels", "obtained", "in", "this", "study", "were", "generally", "lower", "than", "those", "observed", "in", "studies", "that", "have", "used", "the", "regular", "form", "of", "the", "drug", ".", "There", "were", "more", "deaths", "in", "the", "mexiletine", "group", "(", "7", ".", "6", "%", ")", "than", "in", "the", "placebo", "group", "(", "4", ".", "8", "%", ")", ";", "the", "difference", "was", "not", "statistically", "significant", ".", "The", "incidence", "of", "coronary", "events", "was", "similar", "in", "both", "groups", ".", "Previously", "recognized", "side", "effects", ",", "particularly", "tremor", "and", "gastrointestinal", "problems", ",", "were", "more", "frequent", "in", "the", "mexiletine", "group", "than", "in", "the", "placebo", "group", "."]], "ner": [[[1, 1, "Chemical"], [30, 30, "Chemical"], [32, 34, "Chemical"], [120, 120, "Chemical"], [153, 153, "Chemical"], [183, 183, "Chemical"], [237, 237, "Chemical"], [227, 227, "Disease"], [229, 230, "Disease"], [12, 12, "Disease"], [51, 52, "Disease"], [180, 180, "Disease"]]], "relations": [[[1, 1, 227, 227, "CID"], [30, 30, 227, 227, "CID"], [32, 34, 227, 227, "CID"], [120, 120, 227, 227, "CID"], [153, 153, 227, 227, "CID"], [183, 183, 227, 227, "CID"], [237, 237, 227, 227, "CID"], [1, 1, 229, 230, "CID"], [30, 30, 229, 230, "CID"], [32, 34, 229, 230, "CID"], [120, 120, 229, 230, "CID"], [153, 153, 229, 230, "CID"], [183, 183, 229, 230, "CID"], [237, 237, 229, 230, "CID"]]], "clusters": [], "translated": "国际<0>美西律</0>和安慰剂抗心律失常冠脉试验：I.报告<9>心律失常</9>和其他发现。影响研究小组。在一项双盲安慰剂试验中评估了<1>美西律</1>(<2>Mexitil-Perlongets</2>)缓释剂的抗心律失常作用，该试验纳入了630名最近有记录的<10>心肌梗死</10>。主要反应变量基于24小时动态心电图记录的集中读取，定义为在任何两个连续的30分钟阻滞中出现30次或更多次单个室性早搏，或一次或两次以上运行的两个或更多次室性早搏全程24小时心电图记录。在第1个月和第4个月的终点时，注意到<3>美西律</3>和安慰剂组之间存在统计学显着差异，但在第12个月时仅观察到趋势。尽管本研究中获得的血清<4>美西律</4>水平通常低于使用常规形式药物的研究中观察到的水平，但观察到这些差异。<5>美西律</5>组（7.6%）的<11>死亡</11>高于安慰剂组（4.8%）；差异无统计学意义。两组的冠脉事件发生率相似。以前公认的副作用，特别是<7>震颤</7>和<8>胃肠道问题</8>，在<6>美西律</6>组比安慰剂组更常见。", "revised": true}
{"doc_key": "8953972", "sentences": [["Fatal", "intracranial", "bleeding", "associated", "with", "prehospital", "use", "of", "epinephrine", ".", "We", "present", "a", "case", "of", "paramedic", "misjudgment", "in", "the", "execution", "of", "a", "protocol", "for", "the", "treatment", "of", "allergic", "reaction", "in", "a", "case", "of", "pulmonary", "edema", "with", "wheezing", ".", "The", "sudden", "onset", "of", "respiratory", "distress", ",", "rash", ",", "and", "a", "history", "of", "a", "new", "medicine", "led", "the", "two", "paramedics", "on", "the", "scene", "to", "administer", "subcutaneous", "epinephrine", ".", "Subsequently", ",", "acute", "cardiac", "arrest", "and", "fatal", "subarachnoid", "hemorrhage", "occurred", ".", "Epinephrine", "has", "a", "proven", "role", "in", "cardiac", "arrest", "in", "prehospital", "care", ";", "however", ",", "use", "by", "paramedics", "in", "patients", "with", "suspected", "allergic", "reaction", "and", "severe", "hypertension", "should", "be", "viewed", "with", "caution", "."]], "ner": [[[8, 8, "Chemical"], [64, 64, "Chemical"], [77, 77, "Chemical"], [1, 2, "Disease"], [73, 74, "Disease"], [69, 70, "Disease"], [83, 84, "Disease"], [27, 28, "Disease"], [98, 99, "Disease"], [33, 34, "Disease"], [36, 36, "Disease"], [42, 43, "Disease"], [45, 45, "Disease"], [102, 102, "Disease"]]], "relations": [[[8, 8, 1, 2, "CID"], [8, 8, 73, 74, "CID"], [64, 64, 1, 2, "CID"], [64, 64, 73, 74, "CID"], [77, 77, 1, 2, "CID"], [77, 77, 73, 74, "CID"], [8, 8, 69, 70, "CID"], [8, 8, 83, 84, "CID"], [64, 64, 69, 70, "CID"], [64, 64, 83, 84, "CID"], [77, 77, 69, 70, "CID"], [77, 77, 83, 84, "CID"]]], "clusters": [], "translated": "致命的<3>颅内出血</3>与院前使用<0>肾上腺素</0>有关。我们介绍了一个护理人员在执行治疗<7>过敏反应</7>的方案时误判的案例，该方案是在<9>肺水肿</9>伴有<10>喘息</10>的情况下进行的。<11>呼吸困难</11>、<12>皮疹</12>和新药史的突然发作导致现场的两名护理人员皮下注射<1>肾上腺素</1>。随后，发生了急性<5>心脏骤停</5>和致命的<4>蛛网膜下腔出血</4>。<2>肾上腺素</2>在院前急救中<6>心脏骤停</6>中已被证明具有作用；但是，医护人员对疑似<8>过敏反应</8>和严重<13>高血压</13>的患者使用本品时应谨慎。", "revised": true}
{"doc_key": "9100294", "sentences": [["Cardiovascular", "alterations", "in", "rat", "fetuses", "exposed", "to", "calcium", "channel", "blockers", ".", "Preclinical", "toxicologic", "investigation", "suggested", "that", "a", "new", "calcium", "channel", "blocker", ",", "Ro", "40", "-", "5967", ",", "induced", "cardiovascular", "alterations", "in", "rat", "fetuses", "exposed", "to", "this", "agent", "during", "organogenesis", ".", "The", "present", "study", "was", "designed", "to", "investigate", "the", "hypothesis", "that", "calcium", "channel", "blockers", "in", "general", "induce", "cardiovascular", "malformations", "indicating", "a", "pharmacologic", "class", "effect", ".", "We", "studied", "three", "calcium", "channel", "blockers", "of", "different", "structure", ",", "nifedipine", ",", "diltiazem", ",", "and", "verapamil", ",", "along", "with", "the", "new", "agent", ".", "Pregnant", "rats", "were", "administered", "one", "of", "these", "calcium", "channel", "blockers", "during", "the", "period", "of", "cardiac", "morphogenesis", "and", "the", "offspring", "examined", "on", "day", "20", "of", "gestation", "for", "cardiovascular", "malformations", ".", "A", "low", "incidence", "of", "cardiovascular", "malformations", "was", "observed", "after", "exposure", "to", "each", "of", "the", "four", "calcium", "channel", "blockers", ",", "but", "this", "incidence", "was", "statistically", "significant", "only", "for", "verapamil", "and", "nifedipine", ".", "All", "four", "agents", "were", "associated", "with", "aortic", "arch", "branching", "variants", ",", "although", "significantly", "increased", "only", "for", "Ro", "40", "-", "5967", "and", "verapamil", "."]], "ner": [[[22, 25, "Chemical"], [163, 166, "Chemical"], [0, 1, "Disease"], [28, 29, "Disease"], [56, 57, "Disease"], [113, 114, "Disease"], [120, 121, "Disease"], [74, 74, "Chemical"], [145, 145, "Chemical"], [79, 79, "Chemical"], [143, 143, "Chemical"], [168, 168, "Chemical"], [7, 7, "Chemical"], [18, 18, "Chemical"], [50, 50, "Chemical"], [67, 67, "Chemical"], [94, 94, "Chemical"], [131, 131, "Chemical"], [76, 76, "Chemical"]]], "relations": [[[22, 25, 0, 1, "CID"], [22, 25, 28, 29, "CID"], [22, 25, 56, 57, "CID"], [22, 25, 113, 114, "CID"], [22, 25, 120, 121, "CID"], [163, 166, 0, 1, "CID"], [163, 166, 28, 29, "CID"], [163, 166, 56, 57, "CID"], [163, 166, 113, 114, "CID"], [163, 166, 120, 121, "CID"], [74, 74, 0, 1, "CID"], [74, 74, 28, 29, "CID"], [74, 74, 56, 57, "CID"], [74, 74, 113, 114, "CID"], [74, 74, 120, 121, "CID"], [145, 145, 0, 1, "CID"], [145, 145, 28, 29, "CID"], [145, 145, 56, 57, "CID"], [145, 145, 113, 114, "CID"], [145, 145, 120, 121, "CID"], [79, 79, 0, 1, "CID"], [79, 79, 28, 29, "CID"], [79, 79, 56, 57, "CID"], [79, 79, 113, 114, "CID"], [79, 79, 120, 121, "CID"], [143, 143, 0, 1, "CID"], [143, 143, 28, 29, "CID"], [143, 143, 56, 57, "CID"], [143, 143, 113, 114, "CID"], [143, 143, 120, 121, "CID"], [168, 168, 0, 1, "CID"], [168, 168, 28, 29, "CID"], [168, 168, 56, 57, "CID"], [168, 168, 113, 114, "CID"], [168, 168, 120, 121, "CID"]]], "clusters": [], "translated": "暴露于<12>钙</12>通道阻滞剂的大鼠胎儿的<2>心血管改变</2>。临床前毒理学研究表明，一种新的<13>钙</13>通道阻滞剂<0>Ro 40-5967</0>在器官形成期间暴露于该药物的大鼠胎儿中诱导了<3>心血管改变</3>。本研究旨在调查<14>钙</14>通道阻滞剂通常会诱发<4>心血管畸形</4>的假设，这表明存在药理类效应。我们研究了三种不同结构的<15>钙</15>通道阻滞剂，<7>硝苯地平</7>，<18>地尔硫卓</18>，<9>维拉帕米</9>，以及新药。妊娠大鼠在心脏形态发生期间给予这些<16>钙</16>通道阻滞剂之一，并在妊娠第20天检查后代是否有<5>心血管畸形</5>。在暴露于四种<17>钙</17>通道阻滞剂中的每一种后，观察到<6>心血管畸形</6>的低发生率，但这种发生率仅对<10>维拉帕米</10>和<8>硝苯地平</8>是统计学显著的。所有四种药物都与主动脉弓分支变异有关，尽管只有<1>Ro 40-5967</1>和 <11>维拉帕米</11>显着增加。", "revised": true}
{"doc_key": "8996652", "sentences": [["Risk", "factors", "of", "sensorineural", "hearing", "loss", "in", "preterm", "infants", ".", "Among", "547", "preterm", "infants", "of", "<", "or", "=", "34", "weeks", "gestation", "born", "between", "1987", "and", "1991", ",", "8", "children", "(", "1", ".", "46", "%", ")", "developed", "severe", "progressive", "and", "bilateral", "sensorineural", "hearing", "loss", ".", "Perinatal", "risk", "factors", "of", "infants", "with", "hearing", "loss", "were", "compared", "with", "those", "of", "two", "control", "groups", "matched", "for", "gestation", "and", "birth", "weight", "and", "for", "perinatal", "complications", ".", "Our", "observations", "demonstrated", "an", "association", "of", "hearing", "loss", "with", "a", "higher", "incidence", "of", "perinatal", "complications", ".", "Ototoxicity", "appeared", "closely", "related", "to", "a", "prolonged", "administration", "and", "higher", "total", "dose", "of", "ototoxic", "drugs", ",", "particularly", "aminoglycosides", "and", "furosemide", ".", "Finally", ",", "we", "strongly", "recommend", "to", "prospectively", "and", "regularly", "perform", "audiologic", "assessment", "in", "sick", "preterm", "children", "as", "hearing", "loss", "is", "of", "delayed", "onset", "and", "in", "most", "cases", "bilateral", "and", "severe", "."]], "ner": [[[104, 104, "Chemical"], [3, 5, "Disease"], [40, 42, "Disease"], [106, 106, "Chemical"], [50, 51, "Disease"], [77, 78, "Disease"], [125, 126, "Disease"], [87, 87, "Disease"], [100, 100, "Disease"]]], "relations": [[[104, 104, 3, 5, "CID"], [104, 104, 40, 42, "CID"], [106, 106, 3, 5, "CID"], [106, 106, 40, 42, "CID"]]], "clusters": [], "translated": "早产儿<1>感音神经性听力损失</1>的危险因素。在1987年至1991年间出生的547名<或=34周妊娠的早产儿中，有8名儿童(1.46%)出现严重进行性双侧<2>感音神经性听力损失</2>。将<4>听力损失</4>婴儿的围产期危险因素与妊娠和出生体重匹配的两个对照组以及围产期并发症进行了比较。我们的观察表明，<5>听力损失</5>与较高的围产期并发症发生率有关。<7>耳毒性</7>似乎与<8>耳毒性</8>药物（尤其是<0>氨基糖苷类</0>和<3>呋塞米</3>的给药时间延长和总剂量较高）密切相关。最后，我们强烈建议对生病的早产儿进行前瞻性和定期的听力学评估，因为<6>听力损失</6>是延迟发作的，并且在大多数情况下是双侧的和严重的。", "revised": true}
{"doc_key": "11897407", "sentences": [["99mTc", "-", "glucarate", "for", "detection", "of", "isoproterenol", "-", "induced", "myocardial", "infarction", "in", "rats", ".", "Infarct", "-", "avid", "radiopharmaceuticals", "are", "necessary", "for", "rapid", "and", "timely", "diagnosis", "of", "acute", "myocardial", "infarction", ".", "The", "animal", "model", "used", "to", "produce", "infarction", "implies", "artery", "ligation", "but", "chemical", "induction", "can", "be", "easily", "obtained", "with", "isoproterenol", ".", "A", "new", "infarct", "-", "avid", "radiopharmaceutical", "based", "on", "glucaric", "acid", "was", "prepared", "in", "the", "hospital", "radiopharmacy", "of", "the", "INCMNSZ", ".", "99mTc", "-", "glucarate", "was", "easy", "to", "prepare", ",", "stable", "for", "96", "h", "and", "was", "used", "to", "study", "its", "biodistribution", "in", "rats", "with", "isoproterenol", "-", "induced", "acute", "myocardial", "infarction", ".", "Histological", "studies", "demonstrated", "that", "the", "rats", "developed", "an", "infarct", "18", "h", "after", "isoproterenol", "administration", ".", "The", "rat", "biodistribution", "studies", "showed", "a", "rapid", "blood", "clearance", "via", "the", "kidneys", ".", "Thirty", "minutes", "after", "99mTc", "-", "glucarate", "administration", "the", "standardised", "heart", "uptake", "value", "S", "(", "h", ")", "UV", "was", "4", ".", "7", "in", "infarcted", "rat", "heart", "which", "is", "six", "times", "more", "than", "in", "normal", "rats", ".", "ROIs", "drawn", "over", "the", "gamma", "camera", "images", "showed", "a", "ratio", "of", "4", ".", "4", ".", "The", "high", "image", "quality", "suggests", "that", "high", "contrast", "images", "can", "be", "obtained", "in", "humans", "and", "the", "96", "h", "stability", "makes", "it", "an", "ideal", "agent", "to", "detect", ",", "in", "patients", ",", "early", "cardiac", "infarction", "."]], "ner": [[[6, 6, "Chemical"], [48, 48, "Chemical"], [92, 92, "Chemical"], [111, 111, "Chemical"], [9, 10, "Disease"], [27, 28, "Disease"], [96, 97, "Disease"], [208, 209, "Disease"], [0, 2, "Chemical"], [70, 72, "Chemical"], [130, 132, "Chemical"], [14, 14, "Disease"], [36, 36, "Disease"], [52, 52, "Disease"], [107, 107, "Disease"], [58, 59, "Chemical"]]], "relations": [[[6, 6, 9, 10, "CID"], [6, 6, 27, 28, "CID"], [6, 6, 96, 97, "CID"], [6, 6, 208, 209, "CID"], [48, 48, 9, 10, "CID"], [48, 48, 27, 28, "CID"], [48, 48, 96, 97, "CID"], [48, 48, 208, 209, "CID"], [92, 92, 9, 10, "CID"], [92, 92, 27, 28, "CID"], [92, 92, 96, 97, "CID"], [92, 92, 208, 209, "CID"], [111, 111, 9, 10, "CID"], [111, 111, 27, 28, "CID"], [111, 111, 96, 97, "CID"], [111, 111, 208, 209, "CID"]]], "clusters": [], "translated": " <8>99mTc-glucarate</8>检测<0>异丙肾上腺素</0>诱导的大鼠<4>心肌梗死</4>。 <11>梗塞</11> - 快速及时地诊断急性<5>心肌梗塞</5>需要大量的放射性药物。用于产生<12>梗塞</12>的动物模型意味着动脉结扎，但可以轻松使用<1>异丙肾上腺素</1>获得化学诱导。一种新的<13>梗塞</13>-avid放射性药物基于<15>葡萄糖酸</15>制备于INCMNSZ医院放射性药学部门。 <9>99mTc-glucarate</9>易于制备，稳定96小时，用于研究其在<2>异丙肾上腺素</2>诱导的急性<6>心肌梗死</6>大鼠体内的生物分布情况。 组织学研究表明，大鼠在<3>异丙肾上腺素</3>给药后18小时发生了<14>梗塞</14>。大鼠生物分布研究显示，通过肾脏快速清除血液。 <10>99mTc- glucarate</10>给药30分钟后，标准化心脏摄取值S(h)UV为4.7，梗塞大鼠心脏中是正常大鼠的六倍。在伽玛相机图像上绘制的ROI显示比例为4.4。高图像质量表明可以在人体中获得高对比度图像，并且96小时的稳定性使其成为检测患者早期<7>心肌梗死</7>的理想试剂。", "revised": true}
{"doc_key": "17532790", "sentences": [["Proteomic", "analysis", "of", "striatal", "proteins", "in", "the", "rat", "model", "of", "L", "-", "DOPA", "-", "induced", "dyskinesia", ".", "L", "-", "DOPA", "-", "induced", "dyskinesia", "(", "LID", ")", "is", "among", "the", "motor", "complications", "that", "arise", "in", "Parkinson", "'s", "disease", "(", "PD", ")", "patients", "after", "a", "prolonged", "treatment", "with", "L", "-", "DOPA", ".", "To", "this", "day", ",", "transcriptome", "analysis", "has", "been", "performed", "in", "a", "rat", "model", "of", "LID", "[", "Neurobiol", ".", "Dis", ".", ",", "17", "(", "2004", ")", ",", "219", "]", "but", "information", "regarding", "the", "proteome", "is", "still", "lacking", ".", "In", "the", "present", "study", ",", "we", "investigated", "the", "changes", "occurring", "at", "the", "protein", "level", "in", "striatal", "samples", "obtained", "from", "the", "unilaterally", "6", "-", "hydroxydopamine", "-", "lesion", "rat", "model", "of", "PD", "treated", "with", "saline", ",", "L", "-", "DOPA", "or", "bromocriptine", "using", "two", "-", "dimensional", "difference", "gel", "electrophoresis", "and", "mass", "spectrometry", "(", "MS", ")", ".", "Rats", "treated", "with", "L", "-", "DOPA", "were", "allocated", "to", "two", "groups", "based", "on", "the", "presence", "or", "absence", "of", "LID", ".", "Among", "the", "2000", "spots", "compared", "for", "statistical", "difference", ",", "67", "spots", "were", "significantly", "changed", "in", "abundance", "and", "identified", "using", "matrix", "-", "assisted", "laser", "desorption", "/", "ionization", "time", "-", "of", "-", "flight", "MS", ",", "atmospheric", "pressure", "matrix", "-", "assisted", "laser", "desorption", "/", "ionization", "and", "HPLC", "coupled", "tandem", "MS", "(", "LC", "/", "MS", "/", "MS", ")", ".", "Out", "of", "these", "67", "proteins", ",", "LID", "significantly", "changed", "the", "expression", "level", "of", "five", "proteins", ":", "alphabeta", "-", "crystalin", ",", "gamma", "-", "enolase", ",", "guanidoacetate", "methyltransferase", ",", "vinculin", ",", "and", "proteasome", "alpha", "-", "2", "subunit", ".", "Complementary", "techniques", "such", "as", "western", "immunoblotting", "and", "immunohistochemistry", "were", "performed", "to", "investigate", "the", "validity", "of", "the", "data", "obtained", "using", "the", "proteomic", "approach", ".", "In", "conclusion", ",", "this", "study", "provides", "new", "insights", "into", "the", "protein", "changes", "occurring", "in", "LID", "."]], "ner": [[[10, 12, "Chemical"], [17, 19, "Chemical"], [46, 48, "Chemical"], [121, 123, "Chemical"], [143, 145, "Chemical"], [15, 15, "Disease"], [22, 22, "Disease"], [24, 24, "Disease"], [64, 64, "Disease"], [158, 158, "Disease"], [221, 221, "Disease"], [288, 288, "Disease"], [34, 36, "Disease"], [38, 38, "Disease"], [116, 116, "Disease"], [108, 110, "Chemical"], [125, 125, "Chemical"]]], "relations": [[[10, 12, 15, 15, "CID"], [10, 12, 22, 22, "CID"], [10, 12, 24, 24, "CID"], [10, 12, 64, 64, "CID"], [10, 12, 158, 158, "CID"], [10, 12, 221, 221, "CID"], [10, 12, 288, 288, "CID"], [17, 19, 15, 15, "CID"], [17, 19, 22, 22, "CID"], [17, 19, 24, 24, "CID"], [17, 19, 64, 64, "CID"], [17, 19, 158, 158, "CID"], [17, 19, 221, 221, "CID"], [17, 19, 288, 288, "CID"], [46, 48, 15, 15, "CID"], [46, 48, 22, 22, "CID"], [46, 48, 24, 24, "CID"], [46, 48, 64, 64, "CID"], [46, 48, 158, 158, "CID"], [46, 48, 221, 221, "CID"], [46, 48, 288, 288, "CID"], [121, 123, 15, 15, "CID"], [121, 123, 22, 22, "CID"], [121, 123, 24, 24, "CID"], [121, 123, 64, 64, "CID"], [121, 123, 158, 158, "CID"], [121, 123, 221, 221, "CID"], [121, 123, 288, 288, "CID"], [143, 145, 15, 15, "CID"], [143, 145, 22, 22, "CID"], [143, 145, 24, 24, "CID"], [143, 145, 64, 64, "CID"], [143, 145, 158, 158, "CID"], [143, 145, 221, 221, "CID"], [143, 145, 288, 288, "CID"]]], "clusters": [], "translated": "<0>左旋多巴</0>诱导的<5>运动障碍</5>大鼠模型纹状体蛋白的蛋白质组学分析。<1>L-DOPA</1>-诱发的<6>运动障碍</6>（<7>LID</7>）是<12>帕金森病</12>中出现的运动并发症之一（<13>PD</13>）长期接受<2>L-DOPA</2>治疗的患者。时至今日，已经在<8>LID</8>大鼠模型中进行了转录组分析[Neurobiol。Dis。, 17 (2004), 219]但有关蛋白质组的信息仍然缺乏。在本研究中，我们研究了单侧<15>6-羟基多巴胺</15>-损伤<14>PD</14>大鼠模型纹状体样品中蛋白质水平发生的变化，用生理盐水处理，<3>左旋多巴</3>或<16>溴隐亭</16>。采用二维差分凝胶电泳和质谱法（MS）。用<4>L-DOPA</4>治疗的大鼠被分配到两组，根据是否存在<9>LID</9>。在统计差异比较的2000个点中，有67个点的丰度发生了显着变化，并使用基质辅助激光解吸/电离飞行时间质谱、大气压基质辅助激光解吸/电离和HPLC耦合串联质谱（LC/MS/MS）。在这67种蛋白质中，<10>LID</10>显着改变了5种蛋白质的表达水平：alphabeta-晶体蛋白、γ-烯醇化酶、胍基乙酸甲基转移酶、纽蛋白和蛋白酶体alpha-2亚基。进行了免疫印迹和免疫组织化学等补充技术，以研究使用蛋白质组学方法获得的数据的有效性。总之，这项研究为<11>LID</11>中发生的蛋白质变化提供了新的见解。", "revised": true}
{"doc_key": "11135224", "sentences": [["Paclitaxel", ",", "cisplatin", ",", "and", "gemcitabine", "combination", "chemotherapy", "within", "a", "multidisciplinary", "therapeutic", "approach", "in", "metastatic", "nonsmall", "cell", "lung", "carcinoma", ".", "BACKGROUND", ":", "Cisplatin", "-", "based", "chemotherapy", "combinations", "improve", "quality", "of", "life", "and", "survival", "in", "advanced", "nonsmall", "cell", "lung", "carcinoma", "(", "NSCLC", ")", ".", "The", "emergence", "of", "new", "active", "drugs", "might", "translate", "into", "more", "effective", "regimens", "for", "the", "treatment", "of", "this", "disease", ".", "METHODS", ":", "The", "objective", "of", "this", "study", "was", "to", "determine", "the", "feasibility", ",", "response", "rate", ",", "and", "toxicity", "of", "a", "paclitaxel", ",", "cisplatin", ",", "and", "gemcitabine", "combination", "to", "treat", "metastatic", "NSCLC", ".", "Thirty", "-", "five", "consecutive", "chemotherapy", "-", "naive", "patients", "with", "Stage", "IV", "NSCLC", "and", "an", "Eastern", "Cooperative", "Oncology", "Group", "performance", "status", "of", "0", "-", "2", "were", "treated", "with", "a", "combination", "of", "paclitaxel", "(", "135", "mg", "/", "m", "(", "2", ")", "given", "intravenously", "in", "3", "hours", ")", "on", "Day", "1", ",", "cisplatin", "(", "120", "mg", "/", "m", "(", "2", ")", "given", "intravenously", "in", "6", "hours", ")", "on", "Day", "1", ",", "and", "gemcitabine", "(", "800", "mg", "/", "m", "(", "2", ")", "given", "intravenously", "in", "30", "minutes", ")", "on", "Days", "1", "and", "8", ",", "every", "4", "weeks", ".", "Although", "responding", "patients", "were", "scheduled", "to", "receive", "consolidation", "radiotherapy", "and", "24", "patients", "received", "preplanned", "second", "-", "line", "chemotherapy", "after", "disease", "progression", ",", "the", "response", "and", "toxicity", "rates", "reported", "refer", "only", "to", "the", "chemotherapy", "regimen", "given", ".", "RESULTS", ":", "All", "the", "patients", "were", "examined", "for", "toxicity", ";", "34", "were", "examinable", "for", "response", ".", "An", "objective", "response", "was", "observed", "in", "73", ".", "5", "%", "of", "the", "patients", "(", "95", "%", "confidence", "interval", "[", "CI", "]", ",", "55", ".", "6", "-", "87", ".", "1", "%", ")", ",", "including", "4", "complete", "responses", "(", "11", ".", "7", "%", ")", ".", "According", "to", "intention", "-", "to", "-", "treat", ",", "the", "overall", "response", "rate", "was", "71", ".", "4", "%", "(", "95", "%", "CI", ",", "53", ".", "7", "-", "85", ".", "4", "%", ")", ".", "After", "154", "courses", "of", "therapy", ",", "the", "median", "dose", "intensity", "was", "131", "mg", "/", "m", "(", "2", ")", "for", "paclitaxel", "(", "97", ".", "3", "%", ")", ",", "117", "mg", "/", "m", "(", "2", ")", "for", "cisplatin", "(", "97", ".", "3", "%", ")", ",", "and", "1378", "mg", "/", "m", "(", "2", ")", "for", "gemcitabine", "(", "86", ".", "2", "%", ")", ".", "World", "Health", "Organization", "Grade", "3", "-", "4", "neutropenia", "and", "thrombocytopenia", "occurred", "in", "39", ".", "9", "%", "and", "11", ".", "4", "%", "of", "patients", ",", "respectively", ".", "There", "was", "one", "treatment", "-", "related", "death", ".", "Nonhematologic", "toxicities", "were", "mild", ".", "After", "a", "median", "follow", "-", "up", "of", "22", "months", ",", "the", "median", "progression", "free", "survival", "rate", "was", "7", "months", ",", "and", "the", "median", "survival", "time", "was", "16", "months", ".", "CONCLUSIONS", ":", "The", "combination", "of", "paclitaxel", ",", "cisplatin", ",", "and", "gemcitabine", "is", "well", "tolerated", "and", "shows", "high", "activity", "in", "metastatic", "NSCLC", ".", "This", "treatment", "merits", "further", "comparison", "with", "other", "cisplatin", "-", "based", "regimens", "."]], "ner": [[[0, 0, "Chemical"], [82, 82, "Chemical"], [124, 124, "Chemical"], [334, 334, "Chemical"], [448, 448, "Chemical"], [382, 382, "Disease"], [384, 384, "Disease"], [2, 2, "Chemical"], [22, 22, "Chemical"], [84, 84, "Chemical"], [143, 143, "Chemical"], [350, 350, "Chemical"], [450, 450, "Chemical"], [472, 472, "Chemical"], [5, 5, "Chemical"], [87, 87, "Chemical"], [163, 163, "Chemical"], [367, 367, "Chemical"], [453, 453, "Chemical"], [15, 18, "Disease"], [35, 38, "Disease"], [40, 40, "Disease"], [92, 92, "Disease"], [105, 105, "Disease"], [463, 463, "Disease"], [79, 79, "Disease"], [213, 213, "Disease"], [232, 232, "Disease"], [410, 410, "Disease"], [407, 407, "Disease"]]], "relations": [[[0, 0, 382, 382, "CID"], [82, 82, 382, 382, "CID"], [124, 124, 382, 382, "CID"], [334, 334, 382, 382, "CID"], [448, 448, 382, 382, "CID"], [0, 0, 384, 384, "CID"], [82, 82, 384, 384, "CID"], [124, 124, 384, 384, "CID"], [334, 334, 384, 384, "CID"], [448, 448, 384, 384, "CID"], [2, 2, 382, 382, "CID"], [22, 22, 382, 382, "CID"], [84, 84, 382, 382, "CID"], [143, 143, 382, 382, "CID"], [350, 350, 382, 382, "CID"], [450, 450, 382, 382, "CID"], [472, 472, 382, 382, "CID"], [2, 2, 384, 384, "CID"], [22, 22, 384, 384, "CID"], [84, 84, 384, 384, "CID"], [143, 143, 384, 384, "CID"], [350, 350, 384, 384, "CID"], [450, 450, 384, 384, "CID"], [472, 472, 384, 384, "CID"], [5, 5, 382, 382, "CID"], [87, 87, 382, 382, "CID"], [163, 163, 382, 382, "CID"], [367, 367, 382, 382, "CID"], [453, 453, 382, 382, "CID"], [5, 5, 384, 384, "CID"], [87, 87, 384, 384, "CID"], [163, 163, 384, 384, "CID"], [367, 367, 384, 384, "CID"], [453, 453, 384, 384, "CID"]]], "clusters": [], "translated": "<0>紫杉醇</0>、<7>顺铂</7>和<14>吉西他滨</14>联合化疗在转移性<19>非小细胞肺癌</19>中的多学科治疗方法。背景：以<8>顺铂</8>为基础的联合化疗可改善晚期<20>非小细胞肺癌</20>（<21>NSCLC</21>）。新的活性药物的出现可能会转化为更有效的治疗这种疾病的方案。方法：本研究的目的是确定<1>紫杉醇</1>、<9>顺铂</9>和<15>吉西他滨</15>联合治疗转移性<22>NSCLC</22>的可行性、反应率和<25>毒性</25>。35名连续接受化疗的初治IV期<23>NSCLC</23>患者和东部合作肿瘤学组体能状态为0-2的患者联合使用<2>紫杉醇</2>（135mg/m(2)第1天3小时静脉给药）、第1天<10>顺铂</10>（120mg/m(2)6小时静脉给药）和<16>吉西他滨</16>（800mg/m(2)在第1天和第8天在30分钟内静脉内给药），每4周一次。尽管有反应的患者计划接受巩固放疗，24名患者在疾病进展后接受了预先计划的二线化疗，但报告的反应率和<26>毒性</26>率仅指所给予的化疗方案。结果：所有患者均进行了<27>毒性</27>检查；34人接受了回应检查。在73.5%的患者（95%置信区间[CI]，55.6-87.1%），包括4例完全缓解（11.7%），观察到客观反应。根据意向治疗，总体反应率为71.4%（95%CI，53.7-85.4%）。154个疗程后，<3>紫杉醇</3>的中位剂量强度为131mg/m(2)（97.3%），<11>顺铂</11>的中位剂量强度为117mg/m(2)（97.3%），<17>吉西他滨</17>（86.2%）为1378mg/m(2)。39.9%和11.4%的患者出现了世界卫生组织3-4级<5>中性粒细胞减少</5>和<6>血小板减少</6>。发生1例与治疗相关的<29>死亡</29>。非血液学<28>毒性</28>是轻微的。中位随访22个月后，中位无进展生存期为7个月，中位生存期为16个月。结论：<4>紫杉醇</4>、<12>顺铂</12>和<18>吉西他滨</18>联合用药在转移性<24>NSCLC</24>中具有良好的耐受性和高活性。这种治疗值得与其他基于<13>顺铂</13>的方案进一步比较。", "revised": true}
{"doc_key": "17615423", "sentences": [["Severe", "rhabdomyolysis", "and", "acute", "renal", "failure", "secondary", "to", "concomitant", "use", "of", "simvastatin", ",", "amiodarone", ",", "and", "atazanavir", ".", "OBJECTIVE", ":", "To", "report", "a", "case", "of", "a", "severe", "interaction", "between", "simvastatin", ",", "amiodarone", ",", "and", "atazanavir", "resulting", "in", "rhabdomyolysis", "and", "acute", "renal", "failure", ".", "BACKGROUND", ":", "A", "72", "-", "year", "-", "old", "white", "man", "with", "underlying", "human", "immunodeficiency", "virus", ",", "atrial", "fibrillation", ",", "coronary", "artery", "disease", ",", "and", "hyperlipidemia", "presented", "with", "generalized", "pain", ",", "fatigue", ",", "and", "dark", "orange", "urine", "for", "3", "days", ".", "The", "patient", "was", "taking", "80", "mg", "simvastatin", "at", "bedtime", "(", "initiated", "27", "days", "earlier", ")", ";", "amiodarone", "at", "a", "dose", "of", "400", "mg", "daily", "for", "7", "days", ",", "then", "200", "mg", "daily", "(", "initiated", "19", "days", "earlier", ")", ";", "and", "400", "mg", "atazanavir", "daily", "(", "initiated", "at", "least", "2", "years", "previously", ")", ".", "Laboratory", "evaluation", "revealed", "66", ",", "680", "U", "/", "L", "creatine", "kinase", ",", "93", "mg", "/", "dL", "blood", "urea", "nitrogen", ",", "4", ".", "6", "mg", "/", "dL", "creatinine", ",", "1579", "U", "/", "L", "aspartate", "aminotransferase", ",", "and", "738", "U", "/", "L", "alanine", "aminotransferase", ".", "Simvastatin", ",", "amiodarone", ",", "and", "the", "patient", "'s", "human", "immunodeficiency", "virus", "medications", "were", "all", "temporarily", "discontinued", "and", "the", "patient", "was", "given", "forced", "alkaline", "diuresis", "and", "started", "on", "dialysis", ".", "Nine", "days", "later", "the", "patient", "'s", "creatine", "kinase", "had", "dropped", "to", "1695", "U", "/", "L", "and", "creatinine", "was", "3", ".", "3", "mg", "/", "dL", ".", "The", "patient", "was", "discharged", "and", "continued", "outpatient", "dialysis", "for", "1", "month", "until", "his", "renal", "function", "recovered", ".", "DISCUSSION", ":", "The", "risk", "of", "rhabdomyolysis", "is", "increased", "in", "the", "presence", "of", "concomitant", "drugs", "that", "inhibit", "simvastatin", "metabolism", ".", "Simvastatin", "is", "metabolized", "by", "CYP3A4", ".", "Amiodarone", "and", "atazanavir", "are", "recognized", "CYP3A4", "inhibitors", ".", "CONCLUSIONS", ":", "Pharmacokinetic", "differences", "in", "statins", "are", "an", "important", "consideration", "for", "assessing", "the", "risk", "of", "potential", "drug", "interactions", ".", "In", "patients", "requiring", "the", "concurrent", "use", "of", "statins", "and", "CYP3A4", "inhibitors", ",", "pravastatin", ",", "fluvastatin", ",", "and", "rosuvastatin", "carry", "the", "lowest", "risk", "of", "drug", "interactions", ";", "atorvastatin", "carries", "moderate", "risk", ",", "whereas", "simvastatin", "and", "lovastatin", "have", "the", "highest", "risk", "and", "should", "be", "avoided", "in", "patients", "taking", "concomitant", "CYP3A4", "inhibitors", "."]], "ner": [[[11, 11, "Chemical"], [29, 29, "Chemical"], [89, 89, "Chemical"], [179, 179, "Chemical"], [266, 266, "Chemical"], [269, 269, "Chemical"], [288, 288, "Chemical"], [309, 309, "Chemical"], [334, 334, "Chemical"], [1, 1, "Disease"], [37, 37, "Disease"], [255, 255, "Disease"], [13, 13, "Chemical"], [31, 31, "Chemical"], [99, 99, "Chemical"], [181, 181, "Chemical"], [275, 275, "Chemical"], [16, 16, "Chemical"], [34, 34, "Chemical"], [125, 125, "Chemical"], [277, 277, "Chemical"], [3, 5, "Disease"], [39, 41, "Disease"], [145, 145, "Chemical"], [214, 214, "Chemical"], [152, 154, "Chemical"], [162, 162, "Chemical"], [224, 224, "Chemical"], [168, 168, "Chemical"], [176, 176, "Chemical"], [314, 314, "Chemical"], [316, 316, "Chemical"], [319, 319, "Chemical"], [328, 328, "Chemical"], [336, 336, "Chemical"], [55, 57, "Disease"], [187, 189, "Disease"], [59, 60, "Disease"], [62, 64, "Disease"], [67, 67, "Disease"], [71, 71, "Disease"], [73, 73, "Disease"]]], "relations": [[[11, 11, 1, 1, "CID"], [11, 11, 37, 37, "CID"], [11, 11, 255, 255, "CID"], [29, 29, 1, 1, "CID"], [29, 29, 37, 37, "CID"], [29, 29, 255, 255, "CID"], [89, 89, 1, 1, "CID"], [89, 89, 37, 37, "CID"], [89, 89, 255, 255, "CID"], [179, 179, 1, 1, "CID"], [179, 179, 37, 37, "CID"], [179, 179, 255, 255, "CID"], [266, 266, 1, 1, "CID"], [266, 266, 37, 37, "CID"], [266, 266, 255, 255, "CID"], [269, 269, 1, 1, "CID"], [269, 269, 37, 37, "CID"], [269, 269, 255, 255, "CID"], [288, 288, 1, 1, "CID"], [288, 288, 37, 37, "CID"], [288, 288, 255, 255, "CID"], [309, 309, 1, 1, "CID"], [309, 309, 37, 37, "CID"], [309, 309, 255, 255, "CID"], [334, 334, 1, 1, "CID"], [334, 334, 37, 37, "CID"], [334, 334, 255, 255, "CID"], [13, 13, 1, 1, "CID"], [13, 13, 37, 37, "CID"], [13, 13, 255, 255, "CID"], [31, 31, 1, 1, "CID"], [31, 31, 37, 37, "CID"], [31, 31, 255, 255, "CID"], [99, 99, 1, 1, "CID"], [99, 99, 37, 37, "CID"], [99, 99, 255, 255, "CID"], [181, 181, 1, 1, "CID"], [181, 181, 37, 37, "CID"], [181, 181, 255, 255, "CID"], [275, 275, 1, 1, "CID"], [275, 275, 37, 37, "CID"], [275, 275, 255, 255, "CID"], [16, 16, 1, 1, "CID"], [16, 16, 37, 37, "CID"], [16, 16, 255, 255, "CID"], [34, 34, 1, 1, "CID"], [34, 34, 37, 37, "CID"], [34, 34, 255, 255, "CID"], [125, 125, 1, 1, "CID"], [125, 125, 37, 37, "CID"], [125, 125, 255, 255, "CID"], [277, 277, 1, 1, "CID"], [277, 277, 37, 37, "CID"], [277, 277, 255, 255, "CID"], [11, 11, 3, 5, "CID"], [11, 11, 39, 41, "CID"], [29, 29, 3, 5, "CID"], [29, 29, 39, 41, "CID"], [89, 89, 3, 5, "CID"], [89, 89, 39, 41, "CID"], [179, 179, 3, 5, "CID"], [179, 179, 39, 41, "CID"], [266, 266, 3, 5, "CID"], [266, 266, 39, 41, "CID"], [269, 269, 3, 5, "CID"], [269, 269, 39, 41, "CID"], [288, 288, 3, 5, "CID"], [288, 288, 39, 41, "CID"], [309, 309, 3, 5, "CID"], [309, 309, 39, 41, "CID"], [334, 334, 3, 5, "CID"], [334, 334, 39, 41, "CID"], [13, 13, 3, 5, "CID"], [13, 13, 39, 41, "CID"], [31, 31, 3, 5, "CID"], [31, 31, 39, 41, "CID"], [99, 99, 3, 5, "CID"], [99, 99, 39, 41, "CID"], [181, 181, 3, 5, "CID"], [181, 181, 39, 41, "CID"], [275, 275, 3, 5, "CID"], [275, 275, 39, 41, "CID"], [16, 16, 3, 5, "CID"], [16, 16, 39, 41, "CID"], [34, 34, 3, 5, "CID"], [34, 34, 39, 41, "CID"], [125, 125, 3, 5, "CID"], [125, 125, 39, 41, "CID"], [277, 277, 3, 5, "CID"], [277, 277, 39, 41, "CID"]]], "clusters": [], "translated": "继发于同时使用<0>辛伐他汀</0>、<12>胺碘酮</12>和<17>阿扎那韦</17>的严重<9>横纹肌溶解</9>和<21>急性肾功能衰竭</21>。目的：报告<1>辛伐他汀</1>、<13>胺碘酮</13>和<18>阿扎那韦</18>之间的严重相互作用导致<10>横纹肌溶解</10>和<22>急性肾功能衰竭</22>。背景：一名72岁的白人男性，患有潜在的<35>人类免疫缺陷病毒</35>、<37>房颤</37>、<38>冠状动脉疾病</38>和<39>高脂血症</39>出现全身性<40>疼痛</40>、<41>疲劳</41>和深橙色尿液3天。患者睡前服用80 mg<2>辛伐他汀</2>（27天前开始服用）；<14>胺碘酮</14>每天400毫克，持续7天，然后每天200毫克（19天前开始）；和400毫克<19>阿扎那韦</19>每天（至少2年前开始）。实验室评估显示66,680 U/L<23>肌酸</23>激酶，93 mg/dL<25>血尿素氮</25>，4.6mg/dL<26>肌酐</26>，1579 U/L<28>天冬氨酸</28>转氨酶，738 U/L<29>丙氨酸</29>转氨酶。 <3>辛伐他汀</3>、<15>胺碘酮</15>、患者的<36>人类免疫缺陷病毒</36>药物均暂时停用，强制碱性利尿并开始透析。九天后，患者的<24>肌酸</24>激酶降至1695 U/L，<27>肌酐</27>为3.3毫克/分升。出院后继续门诊透析1个月，直至肾功能恢复。讨论：<11>横纹肌溶解症</11>的风险在同时使用抑制<4>辛伐他汀</4>代谢的药物时增加。<5>辛伐他汀</5>由 CYP3A4代谢。<16>胺碘酮</16>和<20>阿扎那韦</20>是公认的CYP3A4抑制剂。结论：<6>他汀类药物</6>的药代动力学差异是评估潜在药物相互作用风险的重要考虑因素。在需要同时使用<7>他汀类药物</7>和CYP3A4抑制剂的患者中，<30>普伐他汀</30>、<31>氟伐他汀</31>和<32>瑞舒伐他汀</32>的风险最低；<33>阿托伐他汀</33>具有中等风险，而<8>辛伐他汀</8>和<34>洛伐他汀</34>具有最高风险，同时服用CYP3A4抑制剂的患者应避免使用。", "revised": true}
{"doc_key": "8590259", "sentences": [["Evaluation", "of", "adverse", "reactions", "of", "aponidine", "hydrochloride", "ophthalmic", "solution", ".", "We", "prospectively", "evaluated", "the", "adverse", "reactions", "of", "apraclonidine", "in", "20", "normal", "volunteers", "by", "instilling", "a", "single", "drop", "of", "1", "%", "apraclonidine", "in", "their", "right", "eyes", ".", "Examinations", ",", "including", "blood", "pressure", ",", "pulse", "rate", ",", "conjunctiva", "and", "cornea", ",", "intraocular", "pressure", "(", "IOP", ")", ",", "pupil", "diameter", ",", "basal", "tear", "secretion", "and", "margin", "reflex", "distance", "of", "both", "upper", "and", "lower", "eyelids", ",", "were", "performed", "prior", "to", "entry", "and", "at", "1", ",", "3", ",", "5", "and", "7", "hours", "after", "instillation", ".", "The", "ocular", "hypotensive", "effects", "were", "statistically", "significant", "for", "apraclonidine", "-", "treated", "eyes", "throughout", "the", "study", "and", "also", "statistically", "significant", "for", "contralateral", "eyes", "from", "three", "hours", "after", "topical", "administration", "of", "1", "%", "apraclonidine", ".", "Decreases", "in", "systolic", "blood", "pressure", "were", "statistically", ",", "but", "not", "clinically", ",", "significant", ".", "No", "significant", "changes", "in", "diastolic", "blood", "pressure", ",", "pulse", "rate", "and", "basal", "tear", "secretion", "were", "noted", ".", "Conjunctival", "blanching", "and", "mydriasis", "were", "commonly", "found", ".", "Upper", "lid", "retraction", "was", "frequently", "noted", ".", "While", "the", "elevations", "of", "the", "upper", "lid", "margin", "in", "most", "subjects", "were", "not", "more", "than", "2", "mm", "and", "did", "not", "cause", "noticeable", "change", "in", "appearance", ",", "one", "subject", "suffered", "from", "mechanical", "entropion", "and", "marked", "corneal", "abrasion", "3", "hours", "after", "instillation", "of", "the", "medication", ".", "This", "may", "well", "be", "a", "particularly", "notable", "finding", "in", "Asian", "people", "."]], "ner": [[[5, 6, "Chemical"], [17, 17, "Chemical"], [30, 30, "Chemical"], [98, 98, "Chemical"], [121, 121, "Chemical"], [91, 92, "Disease"], [154, 155, "Disease"], [157, 157, "Disease"], [200, 200, "Disease"], [203, 204, "Disease"], [123, 127, "Disease"]]], "relations": [[[5, 6, 91, 92, "CID"], [17, 17, 91, 92, "CID"], [30, 30, 91, 92, "CID"], [98, 98, 91, 92, "CID"], [121, 121, 91, 92, "CID"], [5, 6, 154, 155, "CID"], [17, 17, 154, 155, "CID"], [30, 30, 154, 155, "CID"], [98, 98, 154, 155, "CID"], [121, 121, 154, 155, "CID"], [5, 6, 157, 157, "CID"], [17, 17, 157, 157, "CID"], [30, 30, 157, 157, "CID"], [98, 98, 157, 157, "CID"], [121, 121, 157, 157, "CID"], [5, 6, 200, 200, "CID"], [17, 17, 200, 200, "CID"], [30, 30, 200, 200, "CID"], [98, 98, 200, 200, "CID"], [121, 121, 200, 200, "CID"], [5, 6, 203, 204, "CID"], [17, 17, 203, 204, "CID"], [30, 30, 203, 204, "CID"], [98, 98, 203, 204, "CID"], [121, 121, 203, 204, "CID"]]], "clusters": [], "translated": " <0>盐酸皂苷</0> 滴眼液不良反应评价。我们通过在 20 名正常志愿者的右眼滴入一滴 1% <2>安可乐定</2> 来前瞻性地评估 <1>安可乐定</1> 的不良反应。入组前及入组第1、3、5、7时进行血压、脉率、结膜和角膜、眼压、瞳孔直径、基础泪液分泌量和上下眼睑边缘反射距离的检查。滴注后数小时。<5>眼压降低</5>对<3>安可乐定</3>的影响在整个研究过程中具有统计学显着性，并且在局部施用1%<4>安可乐定</4>后三小时对对侧眼也具有统计学显着性。 <10>收缩压下降</10>具有统计学意义，但在临床上不显着。舒张压、脉率和基础泪液分泌没有显着变化。常见<6>结膜变白</6>和<7>瞳孔散大</7>。经常注意到上眼睑收缩。虽然大多数受试者的上眼睑边缘升高不超过2毫米，并且不会引起明显的外观变化，但一名受试者患有机械性<8>内翻</8>和明显的<9>角膜擦伤</9>，是滴注药物后3小时。这可能是亚洲人特别值得注意的发现。", "revised": true}
{"doc_key": "16787750", "sentences": [["Valproic", "acid", "induced", "encephalopathy", "-", "-", "19", "new", "cases", "in", "Germany", "from", "1994", "to", "2003", "-", "-", "a", "side", "effect", "associated", "to", "VPA", "-", "therapy", "not", "only", "in", "young", "children", ".", "Valproic", "acid", "(", "VPA", ")", "is", "a", "broad", "-", "spectrum", "antiepileptic", "drug", "and", "is", "usually", "well", "-", "tolerated", ".", "Rare", "serious", "complications", "may", "occur", "in", "some", "patients", ",", "including", "haemorrhagic", "pancreatitis", ",", "bone", "marrow", "suppression", ",", "VPA", "-", "induced", "hepatotoxicity", "and", "VPA", "-", "induced", "encephalopathy", ".", "The", "typical", "signs", "of", "VPA", "-", "induced", "encephalopathy", "are", "impaired", "consciousness", ",", "sometimes", "marked", "EEG", "background", "slowing", ",", "increased", "seizure", "frequency", ",", "with", "or", "without", "hyperammonemia", ".", "There", "is", "still", "no", "proof", "of", "causative", "effect", "of", "VPA", "in", "patients", "with", "encephalopathy", ",", "but", "only", "of", "an", "association", "with", "an", "assumed", "causal", "relation", ".", "We", "report", "19", "patients", "with", "VPA", "-", "associated", "encephalopathy", "in", "Germany", "from", "the", "years", "1994", "to", "2003", ",", "none", "of", "whom", "had", "been", "published", "previously", "."]], "ner": [[[0, 1, "Chemical"], [22, 22, "Chemical"], [31, 32, "Chemical"], [34, 34, "Chemical"], [67, 67, "Chemical"], [72, 72, "Chemical"], [81, 81, "Chemical"], [113, 113, "Chemical"], [135, 135, "Chemical"], [3, 3, "Disease"], [75, 75, "Disease"], [84, 84, "Disease"], [117, 117, "Disease"], [138, 138, "Disease"], [61, 61, "Disease"], [63, 65, "Disease"], [70, 70, "Disease"], [86, 87, "Disease"], [96, 96, "Disease"], [102, 102, "Disease"]]], "relations": [[[0, 1, 3, 3, "CID"], [0, 1, 75, 75, "CID"], [0, 1, 84, 84, "CID"], [0, 1, 117, 117, "CID"], [0, 1, 138, 138, "CID"], [22, 22, 3, 3, "CID"], [22, 22, 75, 75, "CID"], [22, 22, 84, 84, "CID"], [22, 22, 117, 117, "CID"], [22, 22, 138, 138, "CID"], [31, 32, 3, 3, "CID"], [31, 32, 75, 75, "CID"], [31, 32, 84, 84, "CID"], [31, 32, 117, 117, "CID"], [31, 32, 138, 138, "CID"], [34, 34, 3, 3, "CID"], [34, 34, 75, 75, "CID"], [34, 34, 84, 84, "CID"], [34, 34, 117, 117, "CID"], [34, 34, 138, 138, "CID"], [67, 67, 3, 3, "CID"], [67, 67, 75, 75, "CID"], [67, 67, 84, 84, "CID"], [67, 67, 117, 117, "CID"], [67, 67, 138, 138, "CID"], [72, 72, 3, 3, "CID"], [72, 72, 75, 75, "CID"], [72, 72, 84, 84, "CID"], [72, 72, 117, 117, "CID"], [72, 72, 138, 138, "CID"], [81, 81, 3, 3, "CID"], [81, 81, 75, 75, "CID"], [81, 81, 84, 84, "CID"], [81, 81, 117, 117, "CID"], [81, 81, 138, 138, "CID"], [113, 113, 3, 3, "CID"], [113, 113, 75, 75, "CID"], [113, 113, 84, 84, "CID"], [113, 113, 117, 117, "CID"], [113, 113, 138, 138, "CID"], [135, 135, 3, 3, "CID"], [135, 135, 75, 75, "CID"], [135, 135, 84, 84, "CID"], [135, 135, 117, 117, "CID"], [135, 135, 138, 138, "CID"], [0, 1, 61, 61, "CID"], [22, 22, 61, 61, "CID"], [31, 32, 61, 61, "CID"], [34, 34, 61, 61, "CID"], [67, 67, 61, 61, "CID"], [72, 72, 61, 61, "CID"], [81, 81, 61, 61, "CID"], [113, 113, 61, 61, "CID"], [135, 135, 61, 61, "CID"], [0, 1, 63, 65, "CID"], [22, 22, 63, 65, "CID"], [31, 32, 63, 65, "CID"], [34, 34, 63, 65, "CID"], [67, 67, 63, 65, "CID"], [72, 72, 63, 65, "CID"], [81, 81, 63, 65, "CID"], [113, 113, 63, 65, "CID"], [135, 135, 63, 65, "CID"], [0, 1, 70, 70, "CID"], [22, 22, 70, 70, "CID"], [31, 32, 70, 70, "CID"], [34, 34, 70, 70, "CID"], [67, 67, 70, 70, "CID"], [72, 72, 70, 70, "CID"], [81, 81, 70, 70, "CID"], [113, 113, 70, 70, "CID"], [135, 135, 70, 70, "CID"], [0, 1, 86, 87, "CID"], [22, 22, 86, 87, "CID"], [31, 32, 86, 87, "CID"], [34, 34, 86, 87, "CID"], [67, 67, 86, 87, "CID"], [72, 72, 86, 87, "CID"], [81, 81, 86, 87, "CID"], [113, 113, 86, 87, "CID"], [135, 135, 86, 87, "CID"]]], "clusters": [], "translated": " <0>丙戊酸</0> 诱发的<9> 脑病</9> - - 德国 1994 年至 2003 年 19 例新病例 - - <1>VPA</1> 相关的副作用 - 治疗不仅在年轻人中孩子们 。 <2>丙戊酸</2>（<3>VPA</3>）是一种广谱抗癫痫药，通常耐受性良好。部分患者可能出现罕见的严重并发症，包括出血性<14>胰腺炎</14>、<15>骨髓抑制</15>、<4>VPA</4>诱发的<16>肝毒性</16>和<5>VPA</5>诱发的<10>脑病</10>。 <6>VPA</6>诱发的<11>脑病</11>的典型症状是<17>意识障碍</17>，有时脑电图背景明显减慢，<18>癫痫发作</18>频率增加，有或没有<19>高氨血症</19>。目前还没有证据表明<7>VPA</7>对<12>脑病</12>患者有致病作用，只是与假定的因果关系有关。我们报告了1994年至2003年间在德国发生<8>VPA</8>相关<13>脑病</13>的19例患者，这些患者之前均未发表过。", "revised": true}
{"doc_key": "15515654", "sentences": [["Long", "term", "audiological", "evaluation", "of", "beta", "-", "thalassemic", "patients", ".", "OBJECTIVE", ":", "The", "objective", "of", "this", "study", "was", "to", "identify", "the", "incidence", "and", "to", "monitor", "the", "progression", "of", "hearing", "loss", "in", "children", "and", "young", "adults", "with", "beta", "-", "thalassemia", "major", ".", "METHODS", ":", "One", "hundred", "and", "four", "(", "104", ")", "patients", "aged", "6", "-", "35", "years", "(", "mean", "17", ",", "2", "years", ")", "participated", "in", "the", "study", ".", "All", "patients", "were", "on", "a", "regular", "transfusion", "-", "chelation", "program", "maintaining", "a", "mean", "hemoglobin", "level", "of", "9", ".", "5", "gr", "/", "dl", ".", "Subjects", "were", "receiving", "desferrioxamine", "(", "DFO", ")", "chelation", "treatment", "with", "a", "mean", "daily", "dose", "of", "50", "-", "60", "mg", "/", "kg", ",", "5", "-", "6", "days", "a", "week", "during", "the", "first", "six", "years", "of", "the", "study", ",", "which", "was", "then", "reduced", "to", "40", "-", "50", "mg", "/", "kg", "for", "the", "following", "eight", "years", ".", "Patients", "were", "followed", "for", "8", "-", "14", "years", ".", "RESULTS", ":", "Overall", ",", "21", "out", "of", "104", "patients", "(", "20", ".", "2", "%", ")", "presented", "with", "high", "frequency", "sensorineural", "hearing", "loss", "(", "SNHL", ")", ",", "either", "unilateral", "or", "bilateral", ".", "No", "ototoxic", "factor", ",", "other", "than", "DFO", ",", "was", "present", "in", "any", "of", "the", "patients", ".", "Patients", "with", "SNHL", "presented", "with", "relatively", "lower", "serum", "ferritin", "levels", "than", "those", "with", "normal", "hearing", ",", "however", ",", "no", "statistically", "significant", "difference", "was", "observed", ".", "Subjects", "with", "SNHL", "were", "submitted", "to", "DFO", "reduction", "or", "temporary", "withdrawal", ".", "Following", "intervention", ",", "7", "out", "of", "21", "affected", "patients", "recovered", ",", "10", "remained", "stable", "and", "4", "demonstrated", "aggravation", ".", "CONCLUSION", ":", "The", "findings", "are", "indicative", "of", "DFO", "'s", "contributing", "role", "in", "the", "development", "of", "hearing", "impairment", ".", "Regular", "audiologic", "evaluation", "is", "imperative", "in", "all", "thalassemic", "patients", "so", "that", "early", "changes", "may", "be", "recognized", "and", "treatment", "may", "be", "judiciously", "adjusted", "in", "order", "to", "prevent", "or", "reverse", "hearing", "impairment", "."]], "ner": [[[94, 94, "Chemical"], [96, 96, "Chemical"], [191, 191, "Chemical"], [232, 232, "Chemical"], [264, 264, "Chemical"], [173, 175, "Disease"], [177, 177, "Disease"], [203, 203, "Disease"], [228, 228, "Disease"], [5, 7, "Disease"], [36, 38, "Disease"], [28, 29, "Disease"], [272, 273, "Disease"], [303, 304, "Disease"], [186, 186, "Disease"], [282, 282, "Disease"]]], "relations": [[[94, 94, 173, 175, "CID"], [94, 94, 177, 177, "CID"], [94, 94, 203, 203, "CID"], [94, 94, 228, 228, "CID"], [96, 96, 173, 175, "CID"], [96, 96, 177, 177, "CID"], [96, 96, 203, 203, "CID"], [96, 96, 228, 228, "CID"], [191, 191, 173, 175, "CID"], [191, 191, 177, 177, "CID"], [191, 191, 203, 203, "CID"], [191, 191, 228, 228, "CID"], [232, 232, 173, 175, "CID"], [232, 232, 177, 177, "CID"], [232, 232, 203, 203, "CID"], [232, 232, 228, 228, "CID"], [264, 264, 173, 175, "CID"], [264, 264, 177, 177, "CID"], [264, 264, 203, 203, "CID"], [264, 264, 228, 228, "CID"]]], "clusters": [], "translated": "长期听力评估：<9>β-地中海贫血</9>患者。目的: 本研究的目的是确定患有<10>β-地中海贫血</10>的儿童和年轻人的<11>听力损失</11>的发生率并监测其进展。方法: 104名年龄在6-35岁（平均17,2岁）的患者参与了这项研究。所有患者均接受定期输血螯合计划，维持平均血红蛋白水平为9.5克/分升。受试者正在接受<0>去铁胺</0>（<1>DFO</1>）螯合治疗，平均日剂量为50-60毫克/千克，在研究的前六年每周5-6天，然后在接下来的八年中减少到40-50毫克/千克。患者随访8-14年。结果: 总体而言，104名患者中有21名（20.2％）出现单侧或双侧高频<5>感音神经性听力损失</5>（<6>SNHL</6>）。除<2>DFO</2>外，所有患者均未发生<14>耳毒性</14>因子。患有<7> SNHL</7>的患者的血清铁蛋白水平低于听力正常患者，但差异无统计学意义。<8> SNHL</8>患者被提交给<3>DFO</3>减少或暂时停止。干预后，受影响的21名患者中，7名恢复，10名稳定，4名恶化。结论: 这些发现表明<4>DFO</4>在<12>听力障碍</12>的发展中起到了促进作用。所有<15>地中海贫血</15>患者必须定期接受听力学评估，以便识别早期变化并明智地调整治疗，以预防或逆转<13>听力障碍</13>。", "revised": true}
{"doc_key": "19889778", "sentences": [["Differential", "impact", "of", "immune", "escape", "mutations", "G145R", "and", "P120T", "on", "the", "replication", "of", "lamivudine", "-", "resistant", "hepatitis", "B", "virus", "e", "antigen", "-", "positive", "and", "-", "negative", "strains", ".", "Immune", "escape", "variants", "of", "the", "hepatitis", "B", "virus", "(", "HBV", ")", "represent", "an", "emerging", "clinical", "challenge", ",", "because", "they", "can", "be", "associated", "with", "vaccine", "escape", ",", "HBV", "reactivation", ",", "and", "failure", "of", "diagnostic", "tests", ".", "Recent", "data", "suggest", "a", "preferential", "selection", "of", "immune", "escape", "mutants", "in", "distinct", "peripheral", "blood", "leukocyte", "compartments", "of", "infected", "individuals", ".", "We", "therefore", "systematically", "analyzed", "the", "functional", "impact", "of", "the", "most", "prevalent", "immune", "escape", "variants", ",", "the", "sG145R", "and", "sP120T", "mutants", ",", "on", "the", "viral", "replication", "efficacy", "and", "antiviral", "drug", "susceptibility", "of", "common", "treatment", "-", "associated", "mutants", "with", "resistance", "to", "lamivudine", "(", "LAM", ")", "and", "/", "or", "HBeAg", "negativity", ".", "Replication", "-", "competent", "HBV", "strains", "with", "sG145R", "or", "sP120T", "and", "LAM", "resistance", "(", "rtM204I", "or", "rtL180M", "/", "rtM204V", ")", "were", "generated", "on", "an", "HBeAg", "-", "positive", "and", "an", "HBeAg", "-", "negative", "background", "with", "precore", "(", "PC", ")", "and", "basal", "core", "promoter", "(", "BCP", ")", "mutants", ".", "The", "sG145R", "mutation", "strongly", "reduced", "HBsAg", "levels", "and", "was", "able", "to", "fully", "restore", "the", "impaired", "replication", "of", "LAM", "-", "resistant", "HBV", "mutants", "to", "the", "levels", "of", "wild", "-", "type", "HBV", ",", "and", "PC", "or", "BCP", "mutations", "further", "enhanced", "viral", "replication", ".", "Although", "the", "sP120T", "substitution", "also", "impaired", "HBsAg", "secretion", ",", "it", "did", "not", "enhance", "the", "replication", "of", "LAM", "-", "resistant", "clones", ".", "However", ",", "the", "concomitant", "occurrence", "of", "HBeAg", "negativity", "(", "PC", "/", "BCP", ")", ",", "sP120T", ",", "and", "LAM", "resistance", "resulted", "in", "the", "restoration", "of", "replication", "to", "levels", "of", "wild", "-", "type", "HBV", ".", "In", "all", "clones", "with", "combined", "immune", "escape", "and", "LAM", "resistance", "mutations", ",", "the", "nucleotide", "analogues", "adefovir", "and", "tenofovir", "remained", "effective", "in", "suppressing", "viral", "replication", "in", "vitro", ".", "These", "findings", "reveal", "the", "differential", "impact", "of", "immune", "escape", "variants", "on", "the", "replication", "and", "drug", "susceptibility", "of", "complex", "HBV", "mutants", ",", "supporting", "the", "need", "of", "close", "surveillance", "and", "treatment", "adjustment", "in", "response", "to", "the", "selection", "of", "distinct", "mutational", "patterns", "."]], "ner": [[[16, 20, "Chemical"], [129, 129, "Chemical"], [155, 155, "Chemical"], [160, 160, "Chemical"], [246, 246, "Chemical"], [33, 34, "Disease"], [183, 183, "Chemical"], [225, 225, "Chemical"], [13, 13, "Chemical"], [122, 122, "Chemical"], [124, 124, "Chemical"], [142, 142, "Chemical"], [195, 195, "Chemical"], [235, 235, "Chemical"], [257, 257, "Chemical"], [281, 281, "Chemical"], [286, 286, "Chemical"], [288, 288, "Chemical"], [290, 290, "Chemical"]]], "relations": [[[16, 20, 33, 34, "CID"], [129, 129, 33, 34, "CID"], [155, 155, 33, 34, "CID"], [160, 160, 33, 34, "CID"], [246, 246, 33, 34, "CID"], [183, 183, 33, 34, "CID"], [225, 225, 33, 34, "CID"]]], "clusters": [], "translated": "免疫逃逸突变<0>G145R</0>和<1>P120T</1>对<8>拉米夫定</8>耐药<0>乙型肝炎病毒e抗原</0>阳性和阴性株复制的差异影响。<5>乙型肝炎</5>病毒（HBV）的免疫逃逸变体代表了一种新兴的临床挑战，因为它们可能与疫苗逃逸、HBV再激活和诊断测试失败有关。最近的数据表明，在受感染个体的不同外周血白细胞区室中优先选​​择免疫逃逸突变体。因此，我们系统地分析了最普遍的免疫逃逸变异体<2>sG145R</2>和<3>sP120T</3>突变体对常见治疗相关突变体的病毒复制功效和抗病毒药物敏感性的功能影响，这些突变体对<9>拉米夫定</9>(<10>LAM</10>)和/或<1>HBeAg</1>阴性。复制型HBV菌株具有<2>sG145R</2>或<3>sP120T</3>和<11>LAM</11>耐药性（rtM204I或rtL180M/rtM204V）-前核心(PC)和基础核心启动子(BCP)突变体的<0>HBeAg</0>阳性和阴性背景。<2>sG145R</2>突变显着降低了<6>HBsAg</6>水平，并能够将<12>LAM</12>耐药HBV突变体的复制受损完全恢复到野生型HBV，<0>PC</0>或<1>BCP</1>突变的水平病毒复制进一步增强。尽管<3>sP120T</3>替代也损害了<7>HBsAg</7>的分泌，但它并没有增强<13>LAM</13>耐药克隆的复制。然而，<0>PC/BCP</0>突变导致的<4>HBeAg</4>阴性、<3>sP120T</3>和<14>LAM</14>耐药的同时发生，使病毒复制恢复到野生型HBV水平。在所有具有联合的免疫逃逸和<15>LAM</15>抗性突变的克隆中，<16>核苷酸</16>类似物<17>阿德福韦</17>和<18>替诺福韦</18>仍然有效地抑制病毒的体外复制。这些发现揭示了免疫逃逸变异对复杂HBV突变体的复制和药物敏感性的不同影响，支持密切监测和治疗调整的需要，以响应不同突变模式的选择。", "revised": true}
{"doc_key": "9812111", "sentences": [["A", "randomized", ",", "placebo", "-", "controlled", "dose", "-", "comparison", "trial", "of", "haloperidol", "for", "psychosis", "and", "disruptive", "behaviors", "in", "Alzheimer", "'s", "disease", ".", "OBJECTIVE", ":", "The", "goal", "of", "this", "study", "was", "to", "compare", "the", "efficacy", "and", "side", "effects", "of", "two", "doses", "of", "haloperidol", "and", "placebo", "in", "the", "treatment", "of", "psychosis", "and", "disruptive", "behaviors", "in", "patients", "with", "Alzheimer", "'s", "disease", ".", "METHOD", ":", "In", "a", "6", "-", "week", "random", "-", "assignment", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "(", "phase", "A", ")", ",", "haloperidol", ",", "2", "-", "3", "mg", "/", "day", "(", "standard", "dose", ")", ",", "and", "haloperidol", ",", "0", ".", "50", "-", "0", ".", "75", "mg", "/", "day", "(", "low", "dose", ")", ",", "were", "compared", "in", "71", "outpatients", "with", "Alzheimer", "'s", "disease", ".", "For", "the", "subsequent", "6", "-", "week", "double", "-", "blind", "crossover", "phase", "(", "phase", "B", ")", ",", "patients", "taking", "standard", "-", "or", "low", "-", "dose", "haloperidol", "were", "switched", "to", "placebo", ",", "and", "patients", "taking", "placebo", "were", "randomly", "assigned", "to", "standard", "-", "or", "low", "-", "dose", "haloperidol", ".", "RESULTS", ":", "For", "the", "60", "patients", "who", "completed", "phase", "A", ",", "standard", "-", "dose", "haloperidol", "was", "efficacious", "and", "superior", "to", "both", "low", "-", "dose", "haloperidol", "and", "placebo", "for", "scores", "on", "the", "Brief", "Psychiatric", "Rating", "Scale", "psychosis", "factor", "and", "on", "psychomotor", "agitation", ".", "Response", "rates", "according", "to", "three", "sets", "of", "criteria", "were", "greater", "with", "the", "standard", "dose", "(", "55", "%", "-", "60", "%", ")", "than", "the", "low", "dose", "(", "25", "%", "-", "35", "%", ")", "and", "placebo", "(", "25", "%", "-", "30", "%", ")", ".", "The", "advantage", "of", "standard", "dose", "over", "low", "dose", "was", "replicated", "in", "phase", "B", ".", "In", "phase", "A", ",", "extrapyramidal", "signs", "tended", "to", "be", "greater", "with", "the", "standard", "dose", "than", "in", "the", "other", "two", "conditions", ",", "primarily", "because", "of", "a", "subgroup", "(", "20", "%", ")", "who", "developed", "moderate", "to", "severe", "signs", ".", "Low", "-", "dose", "haloperidol", "did", "not", "differ", "from", "placebo", "on", "any", "measure", "of", "efficacy", "or", "side", "effects", ".", "CONCLUSIONS", ":", "The", "results", "indicated", "a", "favorable", "therapeutic", "profile", "for", "haloperidol", "in", "doses", "of", "2", "-", "3", "mg", "/", "day", ",", "although", "a", "subgroup", "developed", "moderate", "to", "severe", "extrapyramidal", "signs", ".", "A", "starting", "dose", "of", "1", "mg", "/", "day", "with", "gradual", ",", "upward", "dose", "titration", "is", "recommended", ".", "The", "narrow", "therapeutic", "window", "observed", "with", "haloperidol", "may", "also", "apply", "to", "other", "neuroleptics", "used", "in", "Alzheimer", "'s", "disease", "patients", "with", "psychosis", "and", "disruptive", "behaviors", "."]], "ner": [[[11, 11, "Chemical"], [41, 41, "Chemical"], [83, 83, "Chemical"], [97, 97, "Chemical"], [148, 148, "Chemical"], [168, 168, "Chemical"], [184, 184, "Chemical"], [194, 194, "Chemical"], [308, 308, "Chemical"], [333, 333, "Chemical"], [377, 377, "Chemical"], [272, 273, "Disease"], [351, 352, "Disease"], [13, 13, "Disease"], [48, 48, "Disease"], [205, 205, "Disease"], [391, 391, "Disease"], [15, 16, "Disease"], [50, 51, "Disease"], [393, 394, "Disease"], [18, 20, "Disease"], [55, 57, "Disease"], [120, 122, "Disease"], [386, 388, "Disease"], [209, 210, "Disease"]]], "relations": [[[11, 11, 272, 273, "CID"], [11, 11, 351, 352, "CID"], [41, 41, 272, 273, "CID"], [41, 41, 351, 352, "CID"], [83, 83, 272, 273, "CID"], [83, 83, 351, 352, "CID"], [97, 97, 272, 273, "CID"], [97, 97, 351, 352, "CID"], [148, 148, 272, 273, "CID"], [148, 148, 351, 352, "CID"], [168, 168, 272, 273, "CID"], [168, 168, 351, 352, "CID"], [184, 184, 272, 273, "CID"], [184, 184, 351, 352, "CID"], [194, 194, 272, 273, "CID"], [194, 194, 351, 352, "CID"], [308, 308, 272, 273, "CID"], [308, 308, 351, 352, "CID"], [333, 333, 272, 273, "CID"], [333, 333, 351, 352, "CID"], [377, 377, 272, 273, "CID"], [377, 377, 351, 352, "CID"]]], "clusters": [], "translated": "<0>氟哌啶醇</0>治疗<13>精神病</13>和<17>破坏性行为</17>在<20>阿尔茨海默病</20>患者中的一项随机安慰剂对照剂量比较试验。目的：本研究的目的是比较两种剂量的<1>氟哌啶醇</1>和安慰剂在治疗患有<21>阿尔茨海默病</21>的患者的<14>精神病</14>和<18>破坏性行为</18>中的疗效和副作用。方法：在持续6周的A期随机分配、双盲、安慰剂对照试验中，将2-3毫克/天（标准剂量）的<2>氟哌啶醇</2>和0.50-0.75毫克/天（低剂量）的<3>氟哌啶醇</3>与71名患有<22>阿尔茨海默病</22>的门诊患者进行比较。在随后的6周的双盲交叉B期，服用标准剂量或低剂量的<4>氟哌啶醇</4>的患者被转换为安慰剂，而服用安慰剂的患者被随机分配至标准剂量或低剂量的<5>氟哌啶醇</5>。结果：对于完成A期的60名患者，标准剂量的<6>氟哌啶醇</6>是有效的，并且在简明精神病评定量表上<15>精神病</15>因素和<24>精神运动性激越</24>分数上优于低剂量的<7>氟哌啶醇</7>和安慰剂。根据三个标准，标准剂量（55%-60%）的反应率比低剂量（25%-35%）和安慰剂（25%-30%）高。标准剂量相对于低剂量的优势在B期得到复制。在A期，由于有一个亚组（20%）出现了中等到重度的情况，<11>锥体外系体征</11>在标准剂量下往往比其他两种情况更严重低剂量的<8>氟哌啶醇</8>在任何疗效或副作用方面均与安慰剂无差异。结论：结果表明，剂量为2-3毫克/天的<9>氟哌啶醇</9>具有良好的治疗效果，尽管有一个亚组出现中等到重度的<12>锥体外系症状</12>。建议起始剂量为1毫克/天，并逐渐增加剂量。使用<10>氟哌啶醇</10>所观察到的狭窄治疗窗口也可能适用于患有<23>阿尔茨海默病</23>的患者的<16>精神病</16>和<19>破坏性行为</19>中。", "revised": true}
{"doc_key": "3173180", "sentences": [["Haemolytic", "-", "uraemic", "syndrome", "after", "treatment", "with", "metronidazole", ".", "This", "paper", "describes", "the", "clinical", "features", "of", "six", "children", "who", "developed", "the", "haemolytic", "-", "uraemic", "syndrome", "after", "treatment", "with", "metronidazole", ".", "These", "children", "were", "older", "and", "were", "more", "likely", "to", "have", "undergone", "recent", "bowel", "surgery", "than", "are", "other", "children", "with", "this", "condition", ".", "While", "the", "involvement", "of", "metronidazole", "in", "the", "aetiology", "of", "the", "haemolytic", "-", "uraemic", "syndrome", "is", "not", "established", "firmly", ",", "the", "action", "of", "this", "drug", "in", "sensitizing", "tissues", "to", "oxidation", "injury", "and", "the", "reported", "evidence", "of", "oxidation", "changes", "in", "the", "haemolytic", "-", "uraemic", "syndrome", "suggest", "a", "possible", "link", "between", "metronidazole", "treatment", "and", "some", "cases", "of", "the", "haemolytic", "-", "uraemic", "syndrome", "."]], "ner": [[[7, 7, "Chemical"], [28, 28, "Chemical"], [56, 56, "Chemical"], [100, 100, "Chemical"], [0, 3, "Disease"], [21, 24, "Disease"], [62, 65, "Disease"], [91, 94, "Disease"], [107, 110, "Disease"]]], "relations": [[[7, 7, 0, 3, "CID"], [7, 7, 21, 24, "CID"], [7, 7, 62, 65, "CID"], [7, 7, 91, 94, "CID"], [7, 7, 107, 110, "CID"], [28, 28, 0, 3, "CID"], [28, 28, 21, 24, "CID"], [28, 28, 62, 65, "CID"], [28, 28, 91, 94, "CID"], [28, 28, 107, 110, "CID"], [56, 56, 0, 3, "CID"], [56, 56, 21, 24, "CID"], [56, 56, 62, 65, "CID"], [56, 56, 91, 94, "CID"], [56, 56, 107, 110, "CID"], [100, 100, 0, 3, "CID"], [100, 100, 21, 24, "CID"], [100, 100, 62, 65, "CID"], [100, 100, 91, 94, "CID"], [100, 100, 107, 110, "CID"]]], "clusters": [], "translated": "<0>甲硝唑</0>治疗后的<4>溶血性尿毒症综合征</4>。本文介绍了6例使用<1>甲硝唑</1>治疗后出现<5>溶血性尿毒症</5>患儿的临床特征。与其他患有这种疾病的儿童相比，这些儿童年龄较大，而且最近接受过肠道手术的可能性更大。虽然<2>甲硝唑</2>在<6>溶血性尿毒症综合征</6>的病因学中的作用尚不明确，但该药物在使组织对氧化损伤敏感中的作用以及已报道的<7>氧化改变</7>表明<3>甲硝唑</3>治疗与某些<8>溶血性尿毒症综合征</8>之间可能存在联系。", "revised": true}
{"doc_key": "16680561", "sentences": [["Pharmacokinetics", "of", "desipramine", "HCl", "when", "administered", "with", "cinacalcet", "HCl", ".", "OBJECTIVE", ":", "In", "vitro", "work", "has", "demonstrated", "that", "cinacalcet", "is", "a", "strong", "inhibitor", "of", "cytochrome", "P450", "isoenzyme", "(", "CYP", ")", "2D6", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "effect", "of", "cinacalcet", "on", "CYP2D6", "activity", ",", "using", "desipramine", "as", "a", "probe", "substrate", ",", "in", "healthy", "subjects", ".", "METHODS", ":", "Seventeen", "subjects", "who", "were", "genotyped", "as", "CYP2D6", "extensive", "metabolizers", "were", "enrolled", "in", "this", "randomized", ",", "open", "-", "label", ",", "crossover", "study", "to", "receive", "a", "single", "oral", "dose", "of", "desipramine", "(", "50", "mg", ")", "on", "two", "separate", "occasions", ",", "once", "alone", "and", "once", "after", "multiple", "doses", "of", "cinacalcet", "(", "90", "mg", "for", "7", "days", ")", ".", "Blood", "samples", "were", "obtained", "predose", "and", "up", "to", "72", "h", "postdose", ".", "RESULTS", ":", "Fourteen", "subjects", "completed", "both", "treatment", "arms", ".", "Relative", "to", "desipramine", "alone", ",", "mean", "AUC", "and", "C", "(", "max", ")", "of", "desipramine", "increased", "3", ".", "6", "-", "and", "1", ".", "8", "-", "fold", "when", "coadministered", "with", "cinacalcet", ".", "The", "t", "(", "1", "/", "2", ",", "z", ")", "of", "desipramine", "was", "longer", "when", "desipramine", "was", "coadministered", "with", "cinacalcet", "(", "21", ".", "0", "versus", "43", ".", "3", "hs", ")", ".", "The", "t", "(", "max", ")", "was", "similar", "between", "the", "regimens", ".", "Fewer", "subjects", "reported", "adverse", "events", "following", "treatment", "with", "desipramine", "alone", "than", "when", "receiving", "desipramine", "with", "cinacalcet", "(", "33", "versus", "86", "%", ")", ",", "the", "most", "frequent", "of", "which", "(", "nausea", "and", "headache", ")", "have", "been", "reported", "for", "patients", "treated", "with", "either", "desipramine", "or", "cinacalcet", ".", "CONCLUSION", ":", "This", "study", "demonstrates", "that", "cinacalcet", "is", "a", "strong", "inhibitor", "of", "CYP2D6", ".", "These", "data", "suggest", "that", "during", "concomitant", "treatment", "with", "cinacalcet", ",", "dose", "adjustment", "may", "be", "necessary", "for", "drugs", "that", "demonstrate", "a", "narrow", "therapeutic", "index", "and", "are", "metabolized", "by", "CYP2D6", "."]], "ner": [[[2, 3, "Chemical"], [49, 49, "Chemical"], [89, 89, "Chemical"], [139, 139, "Chemical"], [150, 150, "Chemical"], [177, 177, "Chemical"], [181, 181, "Chemical"], [216, 216, "Chemical"], [221, 221, "Chemical"], [249, 249, "Chemical"], [237, 237, "Disease"], [239, 239, "Disease"], [7, 8, "Chemical"], [18, 18, "Chemical"], [43, 43, "Chemical"], [107, 107, "Chemical"], [165, 165, "Chemical"], [185, 185, "Chemical"], [223, 223, "Chemical"], [251, 251, "Chemical"], [259, 259, "Chemical"], [275, 275, "Chemical"]]], "relations": [[[2, 3, 237, 237, "CID"], [49, 49, 237, 237, "CID"], [89, 89, 237, 237, "CID"], [139, 139, 237, 237, "CID"], [150, 150, 237, 237, "CID"], [177, 177, 237, 237, "CID"], [181, 181, 237, 237, "CID"], [216, 216, 237, 237, "CID"], [221, 221, 237, 237, "CID"], [249, 249, 237, 237, "CID"], [2, 3, 239, 239, "CID"], [49, 49, 239, 239, "CID"], [89, 89, 239, 239, "CID"], [139, 139, 239, 239, "CID"], [150, 150, 239, 239, "CID"], [177, 177, 239, 239, "CID"], [181, 181, 239, 239, "CID"], [216, 216, 239, 239, "CID"], [221, 221, 239, 239, "CID"], [249, 249, 239, 239, "CID"], [7, 8, 237, 237, "CID"], [18, 18, 237, 237, "CID"], [43, 43, 237, 237, "CID"], [107, 107, 237, 237, "CID"], [165, 165, 237, 237, "CID"], [185, 185, 237, 237, "CID"], [223, 223, 237, 237, "CID"], [251, 251, 237, 237, "CID"], [259, 259, 237, 237, "CID"], [275, 275, 237, 237, "CID"], [7, 8, 239, 239, "CID"], [18, 18, 239, 239, "CID"], [43, 43, 239, 239, "CID"], [107, 107, 239, 239, "CID"], [165, 165, 239, 239, "CID"], [185, 185, 239, 239, "CID"], [223, 223, 239, 239, "CID"], [251, 251, 239, 239, "CID"], [259, 259, 239, 239, "CID"], [275, 275, 239, 239, "CID"]]], "clusters": [], "translated": "<0>盐酸地昔帕明</0>与<12>盐酸西那卡塞</12>一起给药时的药代动力学。目的：体外研究表明<13>西那卡塞</13>是细胞色素 P450 同工酶 (CYP) 2D6 的强抑制剂。本研究的目的是在健康受试者中使用<1>地昔帕明</1>作为探针底物，评估<14>西那卡塞</14>对 CYP2D6 活性的影响。方法：17 名基因分型为 CYP2D6 快代谢者的受试者被纳入这项随机、开放标签、交叉研究，在两个不同的场合接受单次口服剂量的<2>地昔帕明</2>（50 mg）一次单独和在多次服用<15>西那卡塞</15>（90 毫克，持续 7 天）后服用一次。血样在给药前和给药后 72 小时内获取。结果：14 名受试者完成了两个治疗组。相对于<3>地昔帕明</3>单药，<4>地昔帕明</4>的平均 AUC 和 C<sub>max</sub> 增加 3.6-和 1.8-倍，当与<16>西那卡塞</16>联合给药时。当<6>地昔帕明</6>与<17>西那卡塞</17>联合给药时，<5>地昔帕明</5>的 t(1/2, z)更长（21.0 对比 43.3 h）, t<sub>max</sub> 相似。与接受<8>地昔帕明</8>和<18>西那卡塞</18>相比，单独使用<7>地昔帕明</7>治疗后报告不良事件的受试者较少（33% 对 86%），其中最常见的是（<10>恶心</10>和<11>头痛</11>），已被报告用于接受<9>地昔帕明</9>或<19>西那卡塞</19>治疗的患者。结论：本研究表明<20>西那卡塞</20>是 CYP2D6 的强抑制剂。这些数据表明，在与<21>西那卡塞</21>联合治疗期间，对于治疗指数窄且由 CYP2D6 代谢的药物，可能需要调整剂量。", "revised": true}
{"doc_key": "7420681", "sentences": [["Clinical", "nephrotoxicity", "of", "tobramycin", "and", "gentamicin", ".", "A", "prospective", "study", ".", "Nearly", "3", ".", "2", "million", "people", "in", "this", "country", "receive", "aminoglycoside", "antibiotics", "annually", ".", "Gentamicin", "sulfate", "and", "tobramycin", "sulfate", "continue", "to", "demonstrate", "ototoxicity", "and", "nephrotoxicity", "in", "both", "animal", "and", "clinical", "studies", ".", "In", "this", "study", ",", "62", "patients", "with", "confirmed", "initial", "normal", "renal", "function", "and", "treated", "with", "2", "to", "5", "mg", "/", "kg", "/", "day", "of", "gentamicin", "sulfate", "or", "tobramycin", "sulfate", "for", "a", "minimum", "of", "seven", "days", "were", "followed", "up", "prospectively", "for", "the", "development", "of", "aminoglycoside", "-", "related", "renal", "failure", ",", "defined", "as", "at", "least", "a", "one", "-", "third", "reduction", "in", "renal", "function", ".", "In", "these", "62", "patients", ",", "no", "other", "causes", "for", "renal", "failure", "could", "be", "identified", ".", "Five", "of", "33", "(", "15", "%", ")", "of", "the", "tobramycin", "-", "treated", "patients", "and", "16", "of", "29", "(", "55", ".", "2", "%", ")", "of", "the", "gentamicin", "-", "treated", "patients", "had", "renal", "failure", ".", "Thus", ",", "gentamicin", "was", "associated", "with", "renal", "failure", "more", "than", "three", "times", "as", "often", "as", "was", "tobramycin", "."]], "ner": [[[3, 3, "Chemical"], [28, 29, "Chemical"], [70, 71, "Chemical"], [129, 129, "Chemical"], [169, 169, "Chemical"], [89, 90, "Disease"], [114, 115, "Disease"], [150, 151, "Disease"], [159, 160, "Disease"], [5, 5, "Chemical"], [25, 26, "Chemical"], [67, 68, "Chemical"], [145, 145, "Chemical"], [155, 155, "Chemical"], [1, 1, "Disease"], [35, 35, "Disease"], [21, 21, "Chemical"], [86, 86, "Chemical"], [33, 33, "Disease"]]], "relations": [[[3, 3, 89, 90, "CID"], [3, 3, 114, 115, "CID"], [3, 3, 150, 151, "CID"], [3, 3, 159, 160, "CID"], [28, 29, 89, 90, "CID"], [28, 29, 114, 115, "CID"], [28, 29, 150, 151, "CID"], [28, 29, 159, 160, "CID"], [70, 71, 89, 90, "CID"], [70, 71, 114, 115, "CID"], [70, 71, 150, 151, "CID"], [70, 71, 159, 160, "CID"], [129, 129, 89, 90, "CID"], [129, 129, 114, 115, "CID"], [129, 129, 150, 151, "CID"], [129, 129, 159, 160, "CID"], [169, 169, 89, 90, "CID"], [169, 169, 114, 115, "CID"], [169, 169, 150, 151, "CID"], [169, 169, 159, 160, "CID"], [5, 5, 89, 90, "CID"], [5, 5, 114, 115, "CID"], [5, 5, 150, 151, "CID"], [5, 5, 159, 160, "CID"], [25, 26, 89, 90, "CID"], [25, 26, 114, 115, "CID"], [25, 26, 150, 151, "CID"], [25, 26, 159, 160, "CID"], [67, 68, 89, 90, "CID"], [67, 68, 114, 115, "CID"], [67, 68, 150, 151, "CID"], [67, 68, 159, 160, "CID"], [145, 145, 89, 90, "CID"], [145, 145, 114, 115, "CID"], [145, 145, 150, 151, "CID"], [145, 145, 159, 160, "CID"], [155, 155, 89, 90, "CID"], [155, 155, 114, 115, "CID"], [155, 155, 150, 151, "CID"], [155, 155, 159, 160, "CID"]]], "clusters": [], "translated": "<0>妥布霉素</0>和<9>庆大霉素</9>的临床<14>肾毒性</14>。一项前瞻性研究。将近3.2万人在这个国家每年接受<16>氨基糖苷类</16>抗生素治疗。 <10>庆大霉素硫酸盐</10>和<1>妥布霉素硫酸盐</1>在动物和临床研究中继续表现出<18>耳毒性</18>和<15>肾毒性</15>。在这项研究中，62名确认初始肾功能正常并接受2至5毫克/千克/天的<11>庆大霉素硫酸盐</11>或<2>妥布霉素硫酸盐</2>治疗至少7天的患者被对<17>氨基糖苷类</17>相关<5>肾衰竭</5>的发展进行前瞻性随访，定义为肾功能至少降低三分之一。在这62名患者中，未发现<6>肾衰竭</6>的其他原因。33名接受<3>妥布霉素</3>治疗的患者中有5名（15%），接受<12>庆大霉素</12>治疗的29名患者中有16名（55.2%）出现<7>肾衰竭</7>。因此，<13>庆大霉素</13>与<8>肾衰竭</8>的相关性是<4>妥布霉素</4>的三倍多。", "revised": true}
{"doc_key": "84204", "sentences": [["Pharmacokinetic", "and", "clinical", "studies", "in", "patients", "with", "cimetidine", "-", "associated", "mental", "confusion", ".", "15", "cases", "of", "cimetidine", "-", "associated", "mental", "confusion", "have", "been", "reported", ".", "In", "order", "that", "this", "syndrome", "might", "be", "investigated", "changes", "in", "mental", "status", "(", "M", ".", "S", ".", ")", "were", "correlated", "with", "serum", "concentrations", "and", "renal", "and", "hepatic", "function", "in", "36", "patients", ",", "30", "patients", "had", "no", "M", ".", "S", ".", "change", "on", "cimetidine", "and", "6", "had", "moderate", "to", "severe", "changes", ".", "These", "6", "patients", "had", "both", "renal", "and", "liver", "dysfunction", "(", "P", "less", "than", "0", ".", "05", ")", ",", "as", "well", "as", "cimetidine", "trough", "-", "concentrations", "of", "more", "than", "1", ".", "25", "microgram", "/", "ml", "(", "P", "less", "than", "0", ".", "05", ")", ".", "The", "severity", "of", "M", ".", "S", ".", "changes", "increased", "as", "trough", "-", "concentrations", "rose", ",", "5", "patients", "had", "lumbar", "puncture", ".", "The", "cerebrospinal", "fluid", ":", "serum", "ratio", "of", "cimetidine", "concentrations", "was", "0", ".", "24", ":", "1", "and", "indicates", "that", "cimetidine", "passes", "the", "blood", "-", "brain", "barrier", ";", "it", "also", "raises", "the", "possibility", "that", "M", ".", "S", ".", "changes", "are", "due", "to", "blockade", "of", "histamine", "H2", "-", "receptors", "in", "the", "central", "nervous", "system", ".", "Patients", "likely", "to", "have", "both", "raised", "trough", "-", "concentrations", "and", "mental", "confusion", "are", "those", "with", "both", "severe", "renal", "and", "hepatic", "dysfunction", ".", "They", "should", "be", "closely", "observed", "and", "should", "be", "given", "reduced", "doses", "of", "cimetidine", "."]], "ner": [[[7, 7, "Chemical"], [16, 16, "Chemical"], [67, 67, "Chemical"], [97, 97, "Chemical"], [147, 147, "Chemical"], [158, 158, "Chemical"], [226, 226, "Chemical"], [11, 11, "Disease"], [20, 20, "Disease"], [203, 203, "Disease"], [81, 84, "Disease"], [209, 212, "Disease"], [182, 182, "Chemical"]]], "relations": [[[7, 7, 11, 11, "CID"], [7, 7, 20, 20, "CID"], [7, 7, 203, 203, "CID"], [16, 16, 11, 11, "CID"], [16, 16, 20, 20, "CID"], [16, 16, 203, 203, "CID"], [67, 67, 11, 11, "CID"], [67, 67, 20, 20, "CID"], [67, 67, 203, 203, "CID"], [97, 97, 11, 11, "CID"], [97, 97, 20, 20, "CID"], [97, 97, 203, 203, "CID"], [147, 147, 11, 11, "CID"], [147, 147, 20, 20, "CID"], [147, 147, 203, 203, "CID"], [158, 158, 11, 11, "CID"], [158, 158, 20, 20, "CID"], [158, 158, 203, 203, "CID"], [226, 226, 11, 11, "CID"], [226, 226, 20, 20, "CID"], [226, 226, 203, 203, "CID"]]], "clusters": [], "translated": " <0>西咪替丁</0> 相关精神<7>混乱</7>患者的药代动力学和临床研究。已报道15例<1>西咪替丁</1>相关精神<8>混乱</8>。为了研究这种综合征，36名患者精神状态 (M.S.) 的变化与血清浓度和肾肝功能相关，30名患者没有 M.年代。 <2>西咪替丁</2>和6名患者有中度至重度变化。这6名患者均有<10>肝肾功能不全</10>（ P 小于 0.05 ）， <3>西咪替丁</3> 谷浓度大于 1.25 微克/毫升（ P 小于 0.05 ）。M.年代。的严重性随着谷浓度的升高而增加。5名患者进行了腰穿。脑脊液：血清<4>西咪替丁</4>浓度比值为 0.24：1，表明<5>西咪替丁</5>可通过血脑屏障；它还增加了 M.年代。变化是由于中枢神经系统中<12>组胺</12> H2-受体的阻滞。可能同时出现谷浓度升高和精神<9>意识模糊</9>的患者是同时伴有严重<11>肾功能和肝功能障碍</11>的患者。应密切观察，并减少<6>西咪替丁</6>的剂量。", "revised": true}
{"doc_key": "15572383", "sentences": [["Individual", "differences", "in", "renal", "ACE", "activity", "in", "healthy", "rats", "predict", "susceptibility", "to", "adriamycin", "-", "induced", "renal", "damage", ".", "BACKGROUND", ":", "In", "man", ",", "differences", "in", "angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "levels", ",", "related", "to", "ACE", "(", "I", "/", "D", ")", "genotype", ",", "are", "associated", "with", "renal", "prognosis", ".", "This", "raises", "the", "hypothesis", "that", "individual", "differences", "in", "renal", "ACE", "activity", "are", "involved", "in", "renal", "susceptibility", "to", "inflicted", "damage", ".", "Therefore", ",", "we", "studied", "the", "predictive", "effect", "of", "renal", "ACE", "activity", "for", "the", "severity", "of", "renal", "damage", "induced", "by", "a", "single", "injection", "of", "adriamycin", "in", "rats", ".", "METHODS", ":", "Renal", "ACE", "activity", "(", "Hip", "-", "His", "-", "Leu", "cleavage", "by", "cortical", "homogenates", ")", "was", "determined", "by", "renal", "biopsy", "in", "27", "adult", "male", "Wistar", "rats", ".", "After", "1", "week", "of", "recovery", ",", "proteinuria", "was", "induced", "by", "adriamycin", "[", "1", ".", "5", "mg", "/", "kg", "intravenously", "(", "i", ".", "v", ".", ")", "n", "=", "18", ";", "controls", ",", "saline", "i", ".", "v", ".", "n", "=", "9", "]", ".", "Proteinuria", "was", "measured", "every", "2", "weeks", ".", "After", "12", "weeks", ",", "rats", "were", "sacrificed", "and", "their", "kidneys", "harvested", ".", "RESULTS", ":", "As", "anticipated", ",", "adriamycin", "elicited", "nephrotic", "range", "proteinuria", ",", "renal", "interstitial", "damage", "and", "mild", "focal", "glomerulosclerosis", ".", "Baseline", "renal", "ACE", "positively", "correlated", "with", "the", "relative", "rise", "in", "proteinuria", "after", "adriamycin", "(", "r", "=", "0", ".", "62", ",", "P", "<", "0", ".", "01", ")", ",", "renal", "interstitial", "alpha", "-", "smooth", "muscle", "actin", "(", "r", "=", "0", ".", "49", ",", "P", "<", "0", ".", "05", ")", ",", "interstitial", "macrophage", "influx", "(", "r", "=", "0", ".", "56", ",", "P", "<", "0", ".", "05", ")", ",", "interstitial", "collagen", "III", "(", "r", "=", "0", ".", "53", ",", "P", "<", "0", ".", "05", ")", ",", "glomerular", "alpha", "-", "smooth", "muscle", "actin", "(", "r", "=", "0", ".", "74", ",", "P", "<", "0", ".", "01", ")", "and", "glomerular", "desmin", "(", "r", "=", "0", ".", "48", ",", "P", "<", "0", ".", "05", ")", ".", "Baseline", "renal", "ACE", "did", "not", "correlate", "with", "focal", "glomerulosclerosis", "(", "r", "=", "0", ".", "22", ",", "NS", ")", ".", "In", "controls", ",", "no", "predictive", "values", "for", "renal", "parameters", "were", "observed", ".", "CONCLUSION", ":", "Individual", "differences", "in", "renal", "ACE", "activity", "predict", "the", "severity", "of", "adriamycin", "-", "induced", "renal", "damage", "in", "this", "outbred", "rat", "strain", ".", "This", "supports", "the", "assumption", "that", "differences", "in", "renal", "ACE", "activity", "predispose", "to", "a", "less", "favourable", "course", "of", "renal", "damage", "."]], "ner": [[[12, 12, "Chemical"], [93, 93, "Chemical"], [135, 135, "Chemical"], [190, 190, "Chemical"], [216, 216, "Chemical"], [365, 365, "Chemical"], [131, 131, "Disease"], [166, 166, "Disease"], [194, 194, "Disease"], [214, 214, "Disease"], [15, 16, "Disease"], [85, 86, "Disease"], [196, 198, "Disease"], [368, 369, "Disease"], [393, 394, "Disease"], [192, 192, "Disease"], [201, 202, "Disease"], [329, 330, "Disease"], [25, 25, "Chemical"], [103, 107, "Chemical"]]], "relations": [[[12, 12, 131, 131, "CID"], [12, 12, 166, 166, "CID"], [12, 12, 194, 194, "CID"], [12, 12, 214, 214, "CID"], [93, 93, 131, 131, "CID"], [93, 93, 166, 166, "CID"], [93, 93, 194, 194, "CID"], [93, 93, 214, 214, "CID"], [135, 135, 131, 131, "CID"], [135, 135, 166, 166, "CID"], [135, 135, 194, 194, "CID"], [135, 135, 214, 214, "CID"], [190, 190, 131, 131, "CID"], [190, 190, 166, 166, "CID"], [190, 190, 194, 194, "CID"], [190, 190, 214, 214, "CID"], [216, 216, 131, 131, "CID"], [216, 216, 166, 166, "CID"], [216, 216, 194, 194, "CID"], [216, 216, 214, 214, "CID"], [365, 365, 131, 131, "CID"], [365, 365, 166, 166, "CID"], [365, 365, 194, 194, "CID"], [365, 365, 214, 214, "CID"]]], "clusters": [], "translated": "健康大鼠肾脏 ACE 活性的个体差异预测了对<0>阿霉素</0>诱导的<10>肾损伤</10>的易感性。背景：在人类中，与 ACE (I/D) 基因型相关的<18>血管紧张素</18>转换酶 (ACE)水平的差异与肾脏预后有关。这提出了这样的假设，即肾脏 ACE 活性的个体差异与肾脏对造成损害的易感性有关。因此，我们研究了肾脏 ACE 活性对大鼠单次注射<1>阿霉素</1>所致<11>肾损伤</11>严重程度的预测作用。方法：在 27 只成年雄性 Wistar 大鼠中通过肾活检检定肾 ACE 活性（<19>Hip-His-Leu</19> 皮质匀浆裂解）。恢复 1 周后，<2>阿霉素</2>引起<6>蛋白尿</6>（1.5 mg/kg 静脉内 (i.v.) n = 18；对照，生理盐水 i.v. n = 9）。<7>蛋白尿</7>每 2 周测量一次。12 周后，处死大鼠并收集它们的肾脏。结果：正如预期的那样，<3>阿霉素</3>引起<15>肾病</15>范围<8>蛋白尿</8>、<12>肾间质损伤</12>和轻度<16>局灶性肾小球硬化</16>。基线肾 ACE 与<4>阿霉素</4>后<9>蛋白尿</9>的相对升高正相关 (r = 0.62，P < 0.01)，肾间质α-平滑肌肌动蛋白 (r = 0.49，P < 0.05)，间质巨噬细胞流入 (r = 0.56，P < 0.05)，间质胶原 III (r = 0.53，P < 0.05)，肾小球 alpha-平滑肌肉肌动蛋白 (r = 0.74，P < 0.01) 和肾小球结蛋白 (r = 0.48，P < 0.05)。基线肾 ACE 与<17>局灶性肾小球硬化</17>不相关 (r = 0.22，NS)。在对照组中，没有观察到肾脏参数的预测值。结论：肾脏 ACE 活性的个体差异预测了<5>阿霉素</5>诱导的<13>肾损伤</13>在该远交系大鼠中的严重程度。这支持这样的假设，即肾 ACE 活性的差异会导致不太有利的<14>肾损伤</14>。", "revised": true}
{"doc_key": "15278670", "sentences": [["The", "effects", "of", "sevoflurane", "on", "lidocaine", "-", "induced", "convulsions", ".", "The", "influence", "of", "sevoflurane", "on", "lidocaine", "-", "induced", "convulsions", "was", "studied", "in", "cats", ".", "The", "convulsive", "threshold", "(", "mean", "+", "/", "-", "SD", ")", "was", "41", ".", "4", "+", "/", "-", "6", ".", "5", "mg", ".", "l", "(", "-", "1", ")", "with", "lidocaine", "infusion", "(", "6", "mg", ".", "kg", "(", "-", "1", ")", ".", "min", "(", "-", "1", ")", ")", ",", "increasing", "significantly", "to", "66", ".", "6", "+", "/", "-", "10", ".", "9", "mg", ".", "l", "(", "-", "1", ")", "when", "the", "end", "-", "tidal", "concentration", "of", "sevoflurane", "was", "0", ".", "8", "%", ".", "However", ",", "the", "threshold", "(", "61", ".", "6", "+", "/", "-", "8", ".", "7", "mg", ".", "l", "(", "-", "1", ")", ")", "during", "1", ".", "6", "%", "sevoflurane", "was", "not", "significant", "from", "that", "during", "0", ".", "8", "%", "sevoflurane", ",", "indicating", "a", "celling", "effect", ".", "There", "was", "no", "significant", "difference", "in", "the", "convulsive", "threshold", "between", "sevoflurane", "and", "enflurane", ".", "The", "rise", "in", "blood", "pressure", "became", "less", "marked", "when", "higher", "concentrations", "of", "sevoflurane", "or", "enflurane", "were", "administered", "and", "the", "blood", "pressure", "at", "convulsions", "decreased", "significantly", "in", "1", ".", "6", "%", "sevoflurane", ",", "and", "in", "0", ".", "8", "%", "and", "1", ".", "6", "%", "enflurane", ".", "However", ",", "there", "was", "no", "significant", "difference", "in", "the", "lidocaine", "concentrations", "measured", "when", "the", "systolic", "blood", "pressure", "became", "70", "mmHg", ".", "Apamin", ",", "a", "selective", "blocker", "of", "calcium", "-", "dependent", "potassium", "channels", ",", "was", "administered", "intracerebroventricularly", "in", "rats", "anesthetized", "with", "0", ".", "8", "%", "sevoflurane", "to", "investigate", "the", "mechanism", "of", "the", "anticonvulsive", "effects", ".", "Apamin", "(", "10", "ng", ")", "had", "a", "tendency", "to", "decrease", "the", "convulsive", "threshold", "(", "21", ".", "6", "+", "/", "-", "2", ".", "2", "to", "19", ".", "9", "+", "/", "-", "2", ".", "5", "mg", ".", "l", "(", "-", "1", ")", ")", "but", "this", "was", "not", "statistically", "significant", ".", "It", "is", "suggested", "that", "sevoflurane", "reduces", "the", "convulsive", "effect", "of", "lidocaine", "toxicity", "but", "carries", "some", "risk", "due", "to", "circulatory", "depression", "."]], "ner": [[[5, 5, "Chemical"], [15, 15, "Chemical"], [52, 52, "Chemical"], [217, 217, "Chemical"], [320, 320, "Chemical"], [8, 8, "Disease"], [18, 18, "Disease"], [25, 25, "Disease"], [156, 156, "Disease"], [185, 185, "Disease"], [273, 273, "Disease"], [317, 317, "Disease"], [3, 3, "Chemical"], [13, 13, "Chemical"], [97, 97, "Chemical"], [131, 131, "Chemical"], [142, 142, "Chemical"], [159, 159, "Chemical"], [175, 175, "Chemical"], [193, 193, "Chemical"], [252, 252, "Chemical"], [314, 314, "Chemical"], [321, 321, "Disease"], [329, 329, "Disease"], [161, 161, "Chemical"], [177, 177, "Chemical"], [206, 206, "Chemical"], [229, 229, "Chemical"], [262, 262, "Chemical"], [235, 235, "Chemical"], [238, 238, "Chemical"]]], "relations": [[[5, 5, 8, 8, "CID"], [5, 5, 18, 18, "CID"], [5, 5, 25, 25, "CID"], [5, 5, 156, 156, "CID"], [5, 5, 185, 185, "CID"], [5, 5, 273, 273, "CID"], [5, 5, 317, 317, "CID"], [15, 15, 8, 8, "CID"], [15, 15, 18, 18, "CID"], [15, 15, 25, 25, "CID"], [15, 15, 156, 156, "CID"], [15, 15, 185, 185, "CID"], [15, 15, 273, 273, "CID"], [15, 15, 317, 317, "CID"], [52, 52, 8, 8, "CID"], [52, 52, 18, 18, "CID"], [52, 52, 25, 25, "CID"], [52, 52, 156, 156, "CID"], [52, 52, 185, 185, "CID"], [52, 52, 273, 273, "CID"], [52, 52, 317, 317, "CID"], [217, 217, 8, 8, "CID"], [217, 217, 18, 18, "CID"], [217, 217, 25, 25, "CID"], [217, 217, 156, 156, "CID"], [217, 217, 185, 185, "CID"], [217, 217, 273, 273, "CID"], [217, 217, 317, 317, "CID"], [320, 320, 8, 8, "CID"], [320, 320, 18, 18, "CID"], [320, 320, 25, 25, "CID"], [320, 320, 156, 156, "CID"], [320, 320, 185, 185, "CID"], [320, 320, 273, 273, "CID"], [320, 320, 317, 317, "CID"]]], "clusters": [], "translated": "<12>七氟烷</12>对<0>利多卡因</0>诱发的<5>惊厥</5>的影响。在猫身上研究了<13>七氟烷</13>对<1>利多卡因</1>诱发的<6>惊厥</6>的影响。<7>抽搐</7>阈值（平均+/-SD）为41.4+/-6.5毫克。l(-1)，与<2>利多卡因</2>输注（6毫克/千克.分（-1））显着增加至66.6+/-10.9毫克。l(-1)<14>七氟烷</14>呼气末浓度为0.8%。然而，阈值（61.6+/-8.7毫克。l(-1)）在1.6%<15>七氟烷</15>与0.8%<16>七氟烷</16>期间相比无显着性，表明有细胞作用。<17>七氟烷</17>和<24>恩氟烷</24>的<8>抽搐</8>阈值无显着差异。当给予较高浓度的<18>七氟烷</18>或<25>恩氟烷</25>时，血压升高变得不那么明显，<9>抽搐</9>时的血压在1.6% <19>七氟烷</19>，以及在0.8%和1.6% <26>恩氟烷</26>中显着下降。然而，当收缩压变为70 mmHg时，所测得的<3>利多卡因</3>浓度没有显着差异。<27>Apamin</27>是一种选择性阻滞<29>钙</29>依赖性<30>钾</30>通道的药物，用于研究0.8%<20>七氟烷</20>的抗抽搐作用机制。<28>Apamin</28>(10 ng)有降低<10>抽搐</10>阈值的趋势（21.6+/-2.2至19.9+/-2.5毫克。l(-1)），但这在统计上并不显着。表明<21>七氟烷</21>可降低<4>利多卡因</4><22>毒性</22>的<11>抽搐</11>，但由于循环<23>抑郁症</23>可能会产生一些风险。", "revised": true}
{"doc_key": "7582165", "sentences": [["Pseudo", "-", "allergic", "reactions", "to", "corticosteroids", ":", "diagnosis", "and", "alternatives", ".", "Two", "patients", "treated", "with", "parenteral", "paramethasone", "(", "Triniol", ")", "and", "dexamethasone", "(", "Sedionbel", ")", "are", "described", ".", "A", "few", "minutes", "after", "administration", "of", "the", "drugs", ",", "they", "presented", "urticaria", "(", "patients", "1", "and", "2", ")", "and", "conjunctivitis", "(", "patient", "1", ")", ".", "The", "purpose", "of", "our", "study", "was", "to", "determine", "the", "cause", "of", "the", "patients", "'", "reactions", ",", "the", "immunological", "mechanisms", "involved", "and", "whether", "these", "patients", "would", "be", "able", "to", "tolerate", "any", "kind", "of", "corticoid", ".", "Clinical", "examinations", "and", "skin", ",", "oral", "and", "parenteral", "challenges", "with", "different", "corticosteroids", "and", "ELISA", "tests", "were", "performed", ".", "In", "the", "two", "patients", ",", "skin", "and", "ELISA", "tests", "with", "paramethasone", "were", "negative", ",", "as", "was", "the", "prick", "test", "with", "each", "of", "its", "excipients", ".", "A", "single", "-", "blind", "parenteral", "challenge", "with", "Triniol", "was", "positive", "in", "both", "patients", "after", "the", "administration", "of", "1", "ml", "of", "the", "drug", ",", "and", "negative", "with", "its", "excipients", ".", "We", "also", "carried", "out", "oral", "and", "parenteral", "challenges", "with", "other", "corticosteroids", "and", "found", "intolerance", "to", "some", "of", "them", ".", "These", "results", "suggest", "that", "paramethasone", "caused", "pseudoallergic", "reactions", "in", "our", "patients", ".", "Corticosteroids", "different", "from", "paramethasone", "also", "produced", "hypersensitivity", "reactions", "in", "these", "patients", ";", "however", ",", "a", "few", "of", "them", "were", "tolerated", ".", "The", "basic", "mechanisms", "of", "those", "reactions", "are", "not", "yet", "fully", "understood", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "report", "of", "a", "pseudo", "-", "allergy", "caused", "by", "paramethasone", "."]], "ner": [[[16, 16, "Chemical"], [115, 115, "Chemical"], [182, 182, "Chemical"], [193, 193, "Chemical"], [239, 239, "Chemical"], [39, 39, "Disease"], [47, 47, "Disease"], [21, 21, "Chemical"], [5, 5, "Chemical"], [98, 98, "Chemical"], [169, 169, "Chemical"], [2, 3, "Disease"], [196, 196, "Disease"], [236, 236, "Disease"]]], "relations": [[[16, 16, 39, 39, "CID"], [115, 115, 39, 39, "CID"], [182, 182, 39, 39, "CID"], [193, 193, 39, 39, "CID"], [239, 239, 39, 39, "CID"], [16, 16, 47, 47, "CID"], [115, 115, 47, 47, "CID"], [182, 182, 47, 47, "CID"], [193, 193, 47, 47, "CID"], [239, 239, 47, 47, "CID"], [21, 21, 39, 39, "CID"], [21, 21, 47, 47, "CID"]]], "clusters": [], "translated": "对<8>皮质类固醇</8>的假性<11>过敏反应</11>：诊断和替代方案。描述了两名接受胃肠外<0>帕拉米松</0>（Triniol）和<7>地塞米松</7>（Sedionbel）治疗的患者。服药几分钟后，他们出现了<5>荨麻疹</5>（患者1和2）和<6>结膜炎</6>（患者1）。我们研究的目的是确定患者反应的原因、涉及的免疫机制以及这些患者是否能够耐受任何类型的皮质激素。进行了临床检查和皮肤、口腔和胃肠外刺激试验，以及使用不同的<9>皮质类固醇</9>和 ELISA 测试。在这两名患者中，<1>paramethasone</1>的皮肤和ELISA测试均为阴性，其每种赋形剂的点刺试验也是如此。单盲胃肠外激发试验表明，给予药物1 ml后，两名患者使用 Triniol 均呈阳性，而其赋形剂则呈阴性。我们还对其他<10>皮质类固醇</10>进行了口服和胃肠外给药试验，发现其中一些药物不耐受。这些结果表明，<2>paramethasone</2>在我们的患者中引起了假性过敏反应。不同于<3>paramethasone</3>的皮质类固醇在这些患者中也产生了<12>超敏反应</12>反应；然而，他们中的一些人得到了容忍。这些反应的基本机制尚未完全了解。据我们所知，这是第一例关于<4>paramethasone</4>引起的假性<13>过敏</13>的报告。", "revised": true}
{"doc_key": "9653867", "sentences": [["Thyroxine", "abuse", ":", "an", "unusual", "case", "of", "thyrotoxicosis", "in", "pregnancy", ".", "Eating", "disorders", "and", "the", "associated", "behavioural", "problems", "and", "drug", "abuse", "are", "uncommon", "in", "pregnancy", ".", "When", "they", "do", "occur", "they", "are", "often", "unrecognized", "because", "of", "denial", "but", "when", "significant", "may", "pose", "a", "risk", "to", "both", "the", "mother", "and", "her", "fetus", ".", "This", "case", "illustrates", "a", "number", "of", "problems", "that", "may", "be", "encountered", "in", "women", "with", "eating", "disorders", "in", "pregnancy", ",", "including", "prolonged", "and", "recurrent", "metabolic", "disturbances", "and", "diuretic", "abuse", ".", "In", "particular", "it", "illustrates", "the", "derangements", "of", "thyroid", "function", "seen", "in", "pregnant", "women", "with", "eating", "disorders", "and", "reminds", "us", "that", "when", "a", "cause", "for", "thyrotoxicosis", "remains", "obscure", ",", "thyroxine", "abuse", "should", "be", "considered", "and", "explored", "."]], "ner": [[[0, 0, "Chemical"], [109, 109, "Chemical"], [7, 7, "Disease"], [105, 105, "Disease"], [11, 12, "Disease"], [66, 67, "Disease"], [95, 96, "Disease"], [19, 20, "Disease"]]], "relations": [[[0, 0, 7, 7, "CID"], [0, 0, 105, 105, "CID"], [109, 109, 7, 7, "CID"], [109, 109, 105, 105, "CID"]]], "clusters": [], "translated": "<0>甲状腺素</0>滥用：妊娠期<2>甲状腺毒症</2>的罕见病例。<4>饮食失调</4>和相关的行为问题以及<7>药物滥用</7>在怀孕期间并不常见。当它们确实发生时，由于否认而常常无法识别，但当它们发生时，可能会对母亲和胎儿都构成风险。这个案例说明了怀孕期间患有<5>饮食失调</5>的妇女可能会遇到的一些问题，包括长期和反复发作的代谢紊乱和滥用利尿剂。特别是它说明了患有<6>饮食失调</6>的孕妇身上看到的甲状腺功能紊乱，并提醒我们当<3>甲状腺毒症</3>的原因仍然不明时，应考虑和探讨<1>甲状腺素</1>滥用问题。", "revised": true}
{"doc_key": "17042910", "sentences": [["Anti", "-", "oxidant", "effects", "of", "atorvastatin", "in", "dexamethasone", "-", "induced", "hypertension", "in", "the", "rat", ".", "1", ".", "Dexamethasone", "(", "Dex", ")", "-", "induced", "hypertension", "is", "characterized", "by", "endothelial", "dysfunction", "associated", "with", "nitric", "oxide", "(", "NO", ")", "deficiency", "and", "increased", "superoxide", "(", "O2", "-", ")", "production", ".", "Atorvastatin", "(", "Ato", ")", "possesses", "pleiotropic", "properties", "that", "have", "been", "reported", "to", "improve", "endothelial", "function", "through", "increased", "availability", "of", "NO", "and", "reduced", "O2", "-", "production", "in", "various", "forms", "of", "hypertension", ".", "In", "the", "present", "study", ",", "we", "investigated", "whether", "50", "mg", "/", "kg", "per", "day", ",", "p", ".", "o", ".", ",", "Ato", "could", "prevent", "endothelial", "NO", "synthase", "(", "eNOS", ")", "downregulation", "and", "the", "increase", "in", "O2", "-", "in", "Sprague", "-", "Dawley", "(", "SD", ")", "rats", ",", "thereby", "reducing", "blood", "pressure", ".", "2", ".", "Male", "SD", "rats", "(", "n", "=", "30", ")", "were", "treated", "with", "Ato", "(", "50", "mg", "/", "kg", "per", "day", "in", "drinking", "water", ")", "or", "tap", "water", "for", "15", "days", ".", "Dexamethasone", "(", "10", "microg", "/", "kg", "per", "day", ",", "s", ".", "c", ".", ")", "or", "saline", "was", "started", "after", "4", "days", "in", "Ato", "-", "treated", "and", "non", "-", "treated", "rats", "and", "continued", "for", "11", "-", "13", "days", ".", "Systolic", "blood", "pressure", "(", "SBP", ")", "was", "measured", "on", "alternate", "days", "using", "the", "tail", "-", "cuff", "method", ".", "Endothelial", "function", "was", "assessed", "by", "acetylcholine", "-", "induced", "vasorelaxation", "and", "phenylephrine", "-", "induced", "vasoconstriction", "in", "aortic", "segments", ".", "Vascular", "eNOS", "mRNA", "was", "assessed", "by", "semi", "-", "quantitative", "reverse", "transcription", "-", "polymerase", "chain", "reaction", ".", "3", ".", "In", "rats", "treated", "with", "Dex", "alone", ",", "SBP", "was", "increased", "from", "109", "+", "/", "-", "2", "to", "133", "+", "/", "-", "2", "mmHg", "on", "Days", "4", "and", "Day", "14", ",", "respectively", "(", "P", "<", "0", ".", "001", ")", ".", "In", "the", "Ato", "+", "Dex", "group", ",", "SBP", "was", "increased", "from", "113", "+", "/", "-", "2", "to", "119", "+", "/", "-", "2", "mmHg", "on", "Days", "4", "to", "14", ",", "respectively", "(", "P", "<", "0", ".", "001", ")", ",", "but", "was", "significantly", "lower", "than", "SBP", "in", "the", "group", "treated", "with", "Dex", "alone", "(", "P", "<", "0", ".", "05", ")", ".", "Endothelial", "-", "dependent", "relaxation", "and", "eNOS", "mRNA", "expression", "were", "greater", "in", "the", "Dex", "+", "Ato", "group", "than", "in", "the", "Dex", "only", "group", "(", "P", "<", "0", ".", "05", "and", "P", "<", "0", ".", "0001", ",", "respectively", ")", ".", "Aortic", "superoxide", "production", "was", "lower", "in", "the", "Dex", "+", "Ato", "group", "compared", "with", "the", "group", "treated", "with", "Dex", "alone", "(", "P", "<", "0", ".", "0001", ")", ".", "4", ".", "Treatment", "with", "Ato", "improved", "endothelial", "function", ",", "reduced", "superoxide", "production", "and", "reduced", "SBP", "in", "Dex", "-", "treated", "SD", "rats", "."]], "ner": [[[7, 7, "Chemical"], [17, 17, "Chemical"], [19, 19, "Chemical"], [159, 159, "Chemical"], [255, 255, "Chemical"], [294, 294, "Chemical"], [339, 339, "Chemical"], [361, 361, "Chemical"], [368, 368, "Chemical"], [394, 394, "Chemical"], [404, 404, "Chemical"], [430, 430, "Chemical"], [10, 10, "Disease"], [23, 23, "Disease"], [75, 75, "Disease"], [5, 5, "Chemical"], [46, 46, "Chemical"], [48, 48, "Chemical"], [97, 97, "Chemical"], [140, 140, "Chemical"], [181, 181, "Chemical"], [292, 292, "Chemical"], [363, 363, "Chemical"], [396, 396, "Chemical"], [418, 418, "Chemical"], [31, 32, "Chemical"], [34, 34, "Chemical"], [65, 65, "Chemical"], [101, 101, "Chemical"], [39, 39, "Chemical"], [41, 42, "Chemical"], [68, 69, "Chemical"], [111, 112, "Chemical"], [388, 388, "Chemical"], [424, 424, "Chemical"], [220, 220, "Chemical"], [225, 225, "Chemical"]]], "relations": [[[7, 7, 10, 10, "CID"], [7, 7, 23, 23, "CID"], [7, 7, 75, 75, "CID"], [17, 17, 10, 10, "CID"], [17, 17, 23, 23, "CID"], [17, 17, 75, 75, "CID"], [19, 19, 10, 10, "CID"], [19, 19, 23, 23, "CID"], [19, 19, 75, 75, "CID"], [159, 159, 10, 10, "CID"], [159, 159, 23, 23, "CID"], [159, 159, 75, 75, "CID"], [255, 255, 10, 10, "CID"], [255, 255, 23, 23, "CID"], [255, 255, 75, 75, "CID"], [294, 294, 10, 10, "CID"], [294, 294, 23, 23, "CID"], [294, 294, 75, 75, "CID"], [339, 339, 10, 10, "CID"], [339, 339, 23, 23, "CID"], [339, 339, 75, 75, "CID"], [361, 361, 10, 10, "CID"], [361, 361, 23, 23, "CID"], [361, 361, 75, 75, "CID"], [368, 368, 10, 10, "CID"], [368, 368, 23, 23, "CID"], [368, 368, 75, 75, "CID"], [394, 394, 10, 10, "CID"], [394, 394, 23, 23, "CID"], [394, 394, 75, 75, "CID"], [404, 404, 10, 10, "CID"], [404, 404, 23, 23, "CID"], [404, 404, 75, 75, "CID"], [430, 430, 10, 10, "CID"], [430, 430, 23, 23, "CID"], [430, 430, 75, 75, "CID"]]], "clusters": [], "translated": "<15>阿托伐他汀</15>在<0>地塞米松</0>诱导的<12>大鼠高血压</12>中具有抗氧化作用。1. <1>地塞米松</1>（<2>Dex</2>）-诱发的<13>高血压</13>以<25>一氧化氮</25>（<26>NO</26>）缺乏和增加<29>超氧化物</29>（<30>O2-</30>）的产生为特征。<16>阿托伐他汀</16>（<17>Ato</17>）具有多效性，在改善内皮功能方面通过增加<27>NO</27>的可用性和减少多种形式<14>高血压</14>的<31>O2-</31>产生已被报道。在本研究中，我们调查了每天50毫克/千克的<18>Ato</18>是否能够防止Sprague-Dawley（SD）大鼠内皮<28>一氧化氮合酶（eNOS）</28>的下调和<32>O2-</32>的增加，从而降低血压。2.雄性SD大鼠（n = 30）用<19>Ato</19>（每天50毫克/千克的饮用水）或自来水处理15天。4天后，在<20>Ato</20>处理和未处理的大鼠中开始使用<3>地塞米松</3>（每天10微克/千克，s.c.）或生理盐水，并持续11-13天。通过尾套法隔日测量收缩压（SBP）。通过<35>乙酰胆碱</35>诱导的血管舒张和<36>苯肾上腺素</36>诱导的主动脉段血管收缩评估内皮功能。通过半定量逆转录-聚合酶链反应评估血管eNOS mRNA。3.在仅使用<4>Dex</4>治疗的大鼠中，SBP从109 +/- 2增加到133 +/- 2 mmHg，分别为第4天和第14天（P < 0.001）。在<21>Ato</21> + <5>Dex</5>组中，SBP在第4天到第14天分别从113 +/- 2增加到119 +/- 2 mmHg（P < 0.001），但显着低于仅用<6>Dex</6>组的SBP（P < 0.05）。<7>Dex</7> + <22>Ato</22>组的内皮依赖性松弛和eNOS mRNA表达高于仅用<8>Dex</8>组（P <0.05和P <0.0001，分别）。<9>Dex</9> + <23>Ato</23>组的主动脉<33>超氧化物</33>产生低于仅使用<10>Dex</10>的组（P < 0.0001）。4.<24>Ato</24>治疗改善了内皮功能，减少了<34>超氧化物</34>的产生，并降低了使用<11>Dex</11>治疗的SD大鼠的SBP。", "revised": true}
{"doc_key": "12090760", "sentences": [["Antagonism", "between", "interleukin", "3", "and", "erythropoietin", "in", "mice", "with", "azidothymidine", "-", "induced", "anemia", "and", "in", "bone", "marrow", "endothelial", "cells", ".", "Azidothymidine", "(", "AZT", ")", "-", "induced", "anemia", "in", "mice", "can", "be", "reversed", "by", "the", "administration", "of", "IGF", "-", "IL", "-", "3", "(", "fusion", "protein", "of", "insulin", "-", "like", "growth", "factor", "II", "(", "IGF", "II", ")", "and", "interleukin", "3", ")", ".", "Although", "interleukin", "3", "(", "IL", "-", "3", ")", "and", "erythropoietin", "(", "EPO", ")", "are", "known", "to", "act", "synergistically", "on", "hematopoietic", "cell", "proliferation", "in", "vitro", ",", "injection", "of", "IGF", "-", "IL", "-", "3", "and", "EPO", "in", "AZT", "-", "treated", "mice", "resulted", "in", "a", "reduction", "of", "red", "cells", "and", "an", "increase", "of", "plasma", "EPO", "levels", "as", "compared", "to", "animals", "treated", "with", "IGF", "-", "IL", "-", "3", "or", "EPO", "alone", ".", "We", "tested", "the", "hypothesis", "that", "the", "antagonistic", "effect", "of", "IL", "-", "3", "and", "EPO", "on", "erythroid", "cells", "may", "be", "mediated", "by", "endothelial", "cells", ".", "Bovine", "liver", "erythroid", "cells", "were", "cultured", "on", "monolayers", "of", "human", "bone", "marrow", "endothelial", "cells", "previously", "treated", "with", "EPO", "and", "IGF", "-", "IL", "-", "3", ".", "There", "was", "a", "significant", "reduction", "of", "thymidine", "incorporation", "into", "both", "erythroid", "and", "endothelial", "cells", "in", "cultures", "pre", "-", "treated", "with", "IGF", "-", "IL", "-", "3", "and", "EPO", ".", "Endothelial", "cell", "culture", "supernatants", "separated", "by", "ultrafiltration", "and", "ultracentrifugation", "from", "cells", "treated", "with", "EPO", "and", "IL", "-", "3", "significantly", "reduced", "thymidine", "incorporation", "into", "erythroid", "cells", "as", "compared", "to", "identical", "fractions", "obtained", "from", "the", "media", "of", "cells", "cultured", "with", "EPO", "alone", ".", "These", "results", "suggest", "that", "endothelial", "cells", "treated", "simultaneously", "with", "EPO", "and", "IL", "-", "3", "have", "a", "negative", "effect", "on", "erythroid", "cell", "production", "."]], "ner": [[[9, 9, "Chemical"], [20, 20, "Chemical"], [22, 22, "Chemical"], [95, 95, "Chemical"], [12, 12, "Disease"], [26, 26, "Disease"], [183, 183, "Chemical"], [225, 225, "Chemical"]]], "relations": [[[9, 9, 12, 12, "CID"], [9, 9, 26, 26, "CID"], [20, 20, 12, 12, "CID"], [20, 20, 26, 26, "CID"], [22, 22, 12, 12, "CID"], [22, 22, 26, 26, "CID"], [95, 95, 12, 12, "CID"], [95, 95, 26, 26, "CID"]]], "clusters": [], "translated": "白介素 3 和促红细胞生成素在<0>叠氮胸苷</0>诱导的<4>贫血</4>小鼠和骨髓内皮细胞中的拮抗作用。<1>叠氮胸苷</1> (<2>AZT</2>) - 诱导的小鼠<5>贫血</5>可以通过施用 IGF-IL-3（胰岛素样生长因子 II (IGF II) 和白细胞介素 3的融合蛋白）来逆转。虽然已知白细胞介素 3(IL-3)和促红细胞生成素(EPO)在体外对造血细胞增殖具有协同作用，但在<3>叠氮胸苷</3>处理的小鼠中注射 IGF-IL-3 和 EPO 导致红细胞减少和血浆 EPO 水平升高，相较单独使用 IGF-IL-3 或 EPO 治疗的小鼠。<br>我们检验了 IL-3 和 EPO 对红系细胞的拮抗作用可能是由内皮细胞介导的假设。<br>牛肝红系细胞在预先用 EPO 和 IGF-IL-3 处理过的单层人骨髓内皮细胞上培养。在预处理的 IGF-IL-3 和 EPO 培养物中，<6>胸苷</6>掺入红细胞和内皮细胞的情况显着减少。通过超滤和超速离心从经 EPO 和 IL-3 处理的细胞中分离出的内皮细胞培养上清液与仅经 EPO 培养的细胞培养基中获得的相同部分相比，显着减少了<7>胸苷</7>掺入红系细胞。这些结果表明，同时用 EPO 和 IL-3 处理的内皮细胞对红细胞生成具有负面影响。", "revised": true}
{"doc_key": "9862868", "sentences": [["Different", "lobular", "distributions", "of", "altered", "hepatocyte", "tight", "junctions", "in", "rat", "models", "of", "intrahepatic", "and", "extrahepatic", "cholestasis", ".", "Hepatocyte", "tight", "junctions", "(", "TJs", ")", ",", "the", "only", "intercellular", "barrier", "between", "the", "sinusoidal", "and", "the", "canalicular", "spaces", ",", "play", "a", "key", "role", "in", "bile", "formation", ".", "Although", "hepatocyte", "TJs", "are", "impaired", "in", "cholestasis", ",", "attempts", "to", "localize", "the", "precise", "site", "of", "hepatocyte", "TJ", "damage", "by", "freeze", "-", "fracture", "electron", "microscopy", "have", "produced", "limited", "information", ".", "Recently", ",", "several", "TJ", "-", "associated", "proteins", "like", "ZO", "-", "1", "and", "7H6", "have", "been", "identified", "and", "characterized", ".", "Immunolocalization", "of", "7H6", "appears", "to", "closely", "correlate", "with", "paracellular", "permeability", ".", "We", "used", "rat", "models", "of", "intrahepatic", "cholestasis", "by", "ethinyl", "estradiol", "(", "EE", ")", "treatment", "and", "extrahepatic", "cholestasis", "by", "bile", "duct", "ligation", "(", "BDL", ")", "to", "precisely", "determine", "the", "site", "of", "TJ", "damage", ".", "Alterations", "in", "hepatocyte", "TJs", "were", "assessed", "by", "double", "-", "immunolabeling", "for", "7H6", "and", "ZO", "-", "1", "using", "a", "confocal", "laser", "scanning", "microscope", ".", "In", "control", "rats", ",", "immunostaining", "for", "7H6", "and", "ZO", "-", "1", "colocalized", "to", "outline", "bile", "canaliculi", "in", "a", "continuous", "fashion", ".", "In", "contrast", ",", "7H6", "and", "ZO", "-", "1", "immunostaining", "was", "more", "discontinuous", ",", "outlining", "the", "bile", "canaliculi", "after", "BDL", ".", "Immunostaining", "for", "7H6", ",", "not", "ZO", "-", "1", ",", "decreased", "and", "predominantly", "appeared", "as", "discrete", "signals", "in", "the", "submembranous", "cytoplasm", "of", "periportal", "hepatocytes", "after", "BDL", ".", "After", "EE", "treatment", ",", "changes", "in", "immunostaining", "for", "7H6", "and", "ZO", "-", "1", "were", "similar", "to", "those", "seen", "in", "periportal", "hepatocytes", "after", "BDL", ",", "but", "distributed", "more", "diffusely", "throughout", "the", "lobule", ".", "This", "study", "is", "the", "first", "to", "demonstrate", "that", "impairment", "of", "hepatocyte", "TJs", "occurs", "heterogenously", "in", "the", "liver", "lobule", "after", "BDL", "and", "suggests", "that", "BDL", "and", "EE", "treatments", "produce", "different", "lobular", "distributions", "of", "increased", "paracellular", "permeability", "."]], "ner": [[[111, 112, "Chemical"], [114, 114, "Chemical"], [227, 227, "Chemical"], [283, 283, "Chemical"], [12, 15, "Disease"], [108, 109, "Disease"], [118, 119, "Disease"], [50, 50, "Disease"]]], "relations": [[[111, 112, 12, 15, "CID"], [111, 112, 108, 109, "CID"], [114, 114, 12, 15, "CID"], [114, 114, 108, 109, "CID"], [227, 227, 12, 15, "CID"], [227, 227, 108, 109, "CID"], [283, 283, 12, 15, "CID"], [283, 283, 108, 109, "CID"]]], "clusters": [], "translated": "不同 <4>肝内外胆汁淤积</4> 大鼠模型肝细胞紧密连接改变的不同小叶分布。肝细胞紧密连接 (TJ) 是肝窦和小管间隙之间唯一的细胞间屏障，在胆汁形成中起着关键作用。尽管肝细胞 TJ 在 <7>胆汁淤积</7> 中受损，但尝试通过冷冻断裂电子显微镜定位肝细胞 TJ 损伤的精确部位所获得的信息有限。最近，一些 TJ 相关蛋白如 ZO-1 和 7H6 已被鉴定和表征。 7H6 的免疫定位似乎与细胞旁通透性密切相关。我们使用 <0>乙炔雌二醇</0>（<1>EE</1>）治疗 <5>肝内胆汁淤积</5> 和胆管结扎 <6>肝外胆汁淤积</6> 大鼠模型（BDL）精确判断 TJ 损伤部位。使用共聚焦激光扫描显微镜对 7H6 和 ZO-1 进行双重免疫标记，评估肝细胞 TJ 的变化。在对照大鼠中，7H6 和 ZO-1 的免疫染色以连续的方式共定位以勾勒出胆小管的轮廓。相比之下，7H6 和 ZO-1 免疫染色更加不连续，勾勒出 BDL 后的胆小管。BDL 后，7H6 而非 ZO-1 的免疫染色减少，主要表现为门静脉周围肝细胞膜下细胞质中的离散信号。 <2>EE</2> 处理后，7H6 和 ZO-1 的免疫染色变化与 BDL 后门静脉周围肝细胞的变化相似，但更广泛地分布在整个小叶中。这项研究首次证明 BDL 后肝小叶中肝细胞 TJ 的损伤异质性发生，并表明 BDL 和 <3>EE</3> 治疗产生不同的细胞旁通透性增加的小叶分布。", "revised": true}
{"doc_key": "2024540", "sentences": [["Design", "and", "analysis", "of", "the", "HYPREN", "-", "trial", ":", "safety", "of", "enalapril", "and", "prazosin", "in", "the", "initial", "treatment", "phase", "of", "patients", "with", "congestive", "heart", "failure", ".", "Since", "the", "introduction", "of", "angiotensin", "converting", "enzyme", "(", "ACE", ")", "inhibitors", "into", "the", "adjunctive", "treatment", "of", "patients", "with", "congestive", "heart", "failure", ",", "cases", "of", "severe", "hypotension", ",", "especially", "on", "the", "first", "day", "of", "treatment", ",", "have", "occasionally", "been", "reported", ".", "To", "assess", "the", "safety", "of", "the", "ACE", "inhibitor", "enalapril", "a", "multicenter", ",", "randomized", ",", "prazosin", "-", "controlled", "trial", "was", "designed", "that", "compared", "the", "incidence", "and", "severity", "of", "symptomatic", "hypotension", "on", "the", "first", "day", "of", "treatment", ".", "Trial", "medication", "was", "2", ".", "5", "mg", "enalapril", "or", "0", ".", "5", "prazosin", ".", "Subjects", "were", "1210", "inpatients", "with", "New", "York", "Heart", "Association", "(", "NYHA", ")", "functional", "class", "II", "and", "III", ".", "Patients", "who", "received", "enalapril", "experienced", "clinically", "and", "statistically", "significantly", "less", "symptomatic", "hypotension", "(", "5", ".", "2", "%", ")", "than", "the", "patients", "who", "received", "prazosin", "(", "12", ".", "9", "%", ")", ".", "All", "patients", "recovered", ".", "It", "was", "concluded", "that", "treatment", "with", "enalapril", "was", "well", "tolerated", "and", "it", "is", ",", "therefore", ",", "unreasonable", "to", "restrict", "the", "initiation", "of", "treatment", "with", "enalapril", "to", "inpatients", "."]], "ner": [[[13, 13, "Chemical"], [80, 80, "Chemical"], [114, 114, "Chemical"], [157, 157, "Chemical"], [51, 51, "Disease"], [94, 94, "Disease"], [145, 145, "Disease"], [30, 36, "Chemical"], [72, 73, "Chemical"], [11, 11, "Chemical"], [74, 74, "Chemical"], [109, 109, "Chemical"], [137, 137, "Chemical"], [175, 175, "Chemical"], [193, 193, "Chemical"], [22, 24, "Disease"], [44, 46, "Disease"]]], "relations": [[[13, 13, 51, 51, "CID"], [13, 13, 94, 94, "CID"], [13, 13, 145, 145, "CID"], [80, 80, 51, 51, "CID"], [80, 80, 94, 94, "CID"], [80, 80, 145, 145, "CID"], [114, 114, 51, 51, "CID"], [114, 114, 94, 94, "CID"], [114, 114, 145, 145, "CID"], [157, 157, 51, 51, "CID"], [157, 157, 94, 94, "CID"], [157, 157, 145, 145, "CID"], [30, 36, 51, 51, "CID"], [30, 36, 94, 94, "CID"], [30, 36, 145, 145, "CID"], [72, 73, 51, 51, "CID"], [72, 73, 94, 94, "CID"], [72, 73, 145, 145, "CID"]]], "clusters": [], "translated": "HYPREN 试验的设计和分析：<9>依那普利</9>和<0>哌唑嗪</0>在<15>充血性心力衰竭</15>患者初始治疗阶段的安全性。自从将<7>血管紧张素转换酶 (ACE) 抑制剂</7>用于<16>充血性心力衰竭</16>患者的辅助治疗以来，重度<4>低血压</4>病例，尤其是治疗的第一天，偶有报道。为评估<8> ACE 抑制剂 </8> <10> 依那普利 </10>的安全性，设计了一项多中心、随机、<1> 哌唑嗪 </1>对照试验，该试验比较了症状<5>治疗第一天出现低血压</5>的发生率和严重程度。试验用药为 2.5 毫克<11> 依那普利 </11>或 0.5 <2>哌唑嗪</2>。受试者为 1210 名纽约心脏协会 (NYHA) 心功能分级为 II 级和 III 级的住院患者。接受<12> 依那普利 </12>治疗的患者的症状<6>低血压</6>发生率明显降低 (5.2%)，显著低于接受<3> 哌唑嗪 </3>治疗的患者（12.9%）。所有患者均恢复。得出的结论是，治疗<13>依那普利</13>的耐受性良好，因此，在住院患者中限制使用<14> 依那普利 </14>的开始是不合理的。", "revised": true}
{"doc_key": "12907309", "sentences": [["Neuroprotective", "action", "of", "MPEP", ",", "a", "selective", "mGluR5", "antagonist", ",", "in", "methamphetamine", "-", "induced", "dopaminergic", "neurotoxicity", "is", "associated", "with", "a", "decrease", "in", "dopamine", "outflow", "and", "inhibition", "of", "hyperthermia", "in", "rats", ".", "The", "aim", "of", "this", "study", "was", "to", "examine", "the", "role", "of", "metabotropic", "glutamate", "receptor", "5", "(", "mGluR5", ")", "in", "the", "toxic", "action", "of", "methamphetamine", "on", "dopaminergic", "neurones", "in", "rats", ".", "Methamphetamine", "(", "10", "mg", "/", "kg", "sc", ")", ",", "administered", "five", "times", ",", "reduced", "the", "levels", "of", "dopamine", "and", "its", "metabolites", "in", "striatal", "tissue", "when", "measured", "72", "h", "after", "the", "last", "injection", ".", "A", "selective", "antagonist", "of", "mGluR5", ",", "2", "-", "methyl", "-", "6", "-", "(", "phenylethynyl", ")", "pyridine", "(", "MPEP", ";", "5", "mg", "/", "kg", "ip", ")", ",", "when", "administered", "five", "times", "immediately", "before", "each", "methamphetamine", "injection", "reversed", "the", "above", "-", "mentioned", "methamphetamine", "effects", ".", "A", "single", "MPEP", "(", "5", "mg", "/", "kg", "ip", ")", "injection", "reduced", "the", "basal", "extracellular", "dopamine", "level", "in", "the", "striatum", ",", "as", "well", "as", "dopamine", "release", "stimulated", "either", "by", "methamphetamine", "(", "10", "mg", "/", "kg", "sc", ")", "or", "by", "intrastriatally", "administered", "veratridine", "(", "100", "microM", ")", ".", "Moreover", ",", "it", "transiently", "diminished", "the", "methamphetamine", "(", "10", "mg", "/", "kg", "sc", ")", "-", "induced", "hyperthermia", "and", "reduced", "basal", "body", "temperature", ".", "MPEP", "administered", "into", "the", "striatum", "at", "high", "concentrations", "(", "500", "microM", ")", "increased", "extracellular", "dopamine", "levels", ",", "while", "lower", "concentrations", "(", "50", "-", "100", "microM", ")", "were", "devoid", "of", "any", "effect", ".", "The", "results", "of", "this", "study", "suggest", "that", "the", "blockade", "of", "mGluR5", "by", "MPEP", "may", "protect", "dopaminergic", "neurones", "against", "methamphetamine", "-", "induced", "toxicity", ".", "Neuroprotection", "rendered", "by", "MPEP", "may", "be", "associated", "with", "the", "reduction", "of", "the", "methamphetamine", "-", "induced", "dopamine", "efflux", "in", "the", "striatum", "due", "to", "the", "blockade", "of", "extrastriatal", "mGluR5", ",", "and", "with", "a", "decrease", "in", "hyperthermia", "."]], "ner": [[[11, 11, "Chemical"], [54, 54, "Chemical"], [61, 61, "Chemical"], [127, 127, "Chemical"], [134, 134, "Chemical"], [166, 166, "Chemical"], [190, 190, "Chemical"], [257, 257, "Chemical"], [274, 274, "Chemical"], [27, 27, "Disease"], [200, 200, "Disease"], [295, 295, "Disease"], [3, 3, "Chemical"], [100, 109, "Chemical"], [111, 111, "Chemical"], [139, 139, "Chemical"], [207, 207, "Chemical"], [251, 251, "Chemical"], [265, 265, "Chemical"], [15, 15, "Disease"], [260, 260, "Disease"], [22, 22, "Chemical"], [78, 78, "Chemical"], [152, 152, "Chemical"], [161, 161, "Chemical"], [221, 221, "Chemical"], [277, 277, "Chemical"], [43, 43, "Chemical"], [178, 178, "Chemical"]]], "relations": [[[11, 11, 27, 27, "CID"], [11, 11, 200, 200, "CID"], [11, 11, 295, 295, "CID"], [54, 54, 27, 27, "CID"], [54, 54, 200, 200, "CID"], [54, 54, 295, 295, "CID"], [61, 61, 27, 27, "CID"], [61, 61, 200, 200, "CID"], [61, 61, 295, 295, "CID"], [127, 127, 27, 27, "CID"], [127, 127, 200, 200, "CID"], [127, 127, 295, 295, "CID"], [134, 134, 27, 27, "CID"], [134, 134, 200, 200, "CID"], [134, 134, 295, 295, "CID"], [166, 166, 27, 27, "CID"], [166, 166, 200, 200, "CID"], [166, 166, 295, 295, "CID"], [190, 190, 27, 27, "CID"], [190, 190, 200, 200, "CID"], [190, 190, 295, 295, "CID"], [257, 257, 27, 27, "CID"], [257, 257, 200, 200, "CID"], [257, 257, 295, 295, "CID"], [274, 274, 27, 27, "CID"], [274, 274, 200, 200, "CID"], [274, 274, 295, 295, "CID"]]], "clusters": [], "translated": "<12> MPEP </12> 的神经保护作用，一种选择性 mGluR5 拮抗剂，在<0>甲基苯丙胺</0>诱导的多巴胺能<19>神经毒性</19>中的神经保护作用与<21>多巴胺</21>的减少有关，大鼠<9>热疗</9>的流出和抑制。本研究的目的是检查代谢型<27>谷氨酸</27>受体 5 (mGluR5) 在<1>甲基苯丙胺</1>对大鼠多巴胺能神经元的毒性作用中的作用。<2>甲基苯丙胺</2>（10 mg/kg sc），给药五次，在最后一次注射后 72 小时测量时，降低了纹状体组织中<22>多巴胺</22>及其代谢物的水平。mGluR5的选择性拮抗剂，<13>2 - 甲基 - 6 - （苯乙炔基）吡啶</13>（<14>MPEP</14>；5 mg/kg ip），在每次<3>甲基苯丙胺</3>注射液之前立即给药五次逆转了上述<4>甲基苯丙胺</4>的作用。单次<15>MPEP</15>（5 mg/kg ip）注射可降低纹状体中基础细胞外<23>多巴胺</23>水平，以及<24>多巴胺</24>释放，可被<5>甲基苯丙胺</5>（10 mg/kg sc）或通过纹状体给药<28>藜芦定</28>（100 microM）刺激。此外，它还能暂时减少<6>甲基苯丙胺</6>（10 mg/kg sc）引起的<10>体温过高</10>并降低基础体温。<16>MPEP</16> 施用到纹状体中以高浓度 (500 microM) 可增加细胞外<25>多巴胺</25>水平，而较低浓度 (50-100 microM) 则没有任何影响。该研究的结果表明，<17>MPEP</17>对mGluR5的阻断可能保护多巴胺能神经元免受<7>甲基苯丙胺</7>诱导的<20>毒性</20>。 <18>MPEP</18>提供的神经保护作用可能与<8>甲基苯丙胺</8>减少相关-由于纹状体外mGluR5的阻断，诱导的<26>多巴胺</26>流出，和随着<11>体温过高</11>的减少。", "revised": true}
{"doc_key": "11263551", "sentences": [["Calcineurin", "-", "inhibitor", "induced", "pain", "syndrome", "(", "CIPS", ")", ":", "a", "severe", "disabling", "complication", "after", "organ", "transplantation", ".", "Bone", "pain", "after", "transplantation", "is", "a", "frequent", "complication", "that", "can", "be", "caused", "by", "several", "diseases", ".", "Treatment", "strategies", "depend", "on", "the", "correct", "diagnosis", "of", "the", "pain", ".", "Nine", "patients", "with", "severe", "pain", "in", "their", "feet", ",", "which", "was", "registered", "after", "transplantation", ",", "were", "investigated", ".", "Bone", "scans", "showed", "an", "increased", "tracer", "uptake", "of", "the", "foot", "bones", ".", "Magnetic", "resonance", "imaging", "demonstrated", "bone", "marrow", "oedema", "in", "the", "painful", "bones", ".", "Pain", "was", "not", "explained", "by", "other", "diseases", "causing", "foot", "pain", ",", "like", "reflex", "sympathetic", "dystrophy", ",", "polyneuropathy", ",", "Morton", "'s", "neuralgia", ",", "gout", ",", "osteoporosis", ",", "avascular", "necrosis", ",", "intermittent", "claudication", ",", "orthopaedic", "foot", "deformities", ",", "stress", "fractures", ",", "and", "hyperparathyroidism", ".", "The", "reduction", "of", "cyclosporine", "-", "or", "tacrolimus", "trough", "levels", "and", "the", "administration", "of", "calcium", "channel", "blockers", "led", "to", "relief", "of", "pain", ".", "The", "Calcineurin", "-", "inhibitor", "Induced", "Pain", "Syndrome", "(", "CIPS", ")", "is", "a", "rare", "but", "severe", "side", "effect", "of", "cyclosporine", "or", "tacrolimus", "and", "is", "accurately", "diagnosed", "by", "its", "typical", "presentation", ",", "magnetic", "resonance", "imaging", "and", "bone", "scans", ".", "Incorrect", "diagnosis", "of", "the", "syndrome", "will", "lead", "to", "a", "significant", "reduction", "of", "life", "quality", "in", "patients", "suffering", "from", "CIPS", "."]], "ner": [[[132, 132, "Chemical"], [169, 169, "Chemical"], [4, 4, "Disease"], [19, 19, "Disease"], [43, 43, "Disease"], [49, 49, "Disease"], [87, 87, "Disease"], [96, 96, "Disease"], [149, 149, "Disease"], [156, 156, "Disease"], [135, 135, "Chemical"], [171, 171, "Chemical"], [79, 81, "Disease"], [142, 142, "Chemical"], [99, 101, "Disease"], [103, 103, "Disease"], [105, 107, "Disease"], [109, 109, "Disease"], [111, 111, "Disease"], [113, 114, "Disease"], [116, 117, "Disease"], [120, 121, "Disease"], [123, 124, "Disease"], [127, 127, "Disease"]]], "relations": [[[132, 132, 4, 4, "CID"], [132, 132, 19, 19, "CID"], [132, 132, 43, 43, "CID"], [132, 132, 49, 49, "CID"], [132, 132, 87, 87, "CID"], [132, 132, 96, 96, "CID"], [132, 132, 149, 149, "CID"], [132, 132, 156, 156, "CID"], [169, 169, 4, 4, "CID"], [169, 169, 19, 19, "CID"], [169, 169, 43, 43, "CID"], [169, 169, 49, 49, "CID"], [169, 169, 87, 87, "CID"], [169, 169, 96, 96, "CID"], [169, 169, 149, 149, "CID"], [169, 169, 156, 156, "CID"], [135, 135, 4, 4, "CID"], [135, 135, 19, 19, "CID"], [135, 135, 43, 43, "CID"], [135, 135, 49, 49, "CID"], [135, 135, 87, 87, "CID"], [135, 135, 96, 96, "CID"], [135, 135, 149, 149, "CID"], [135, 135, 156, 156, "CID"], [171, 171, 4, 4, "CID"], [171, 171, 19, 19, "CID"], [171, 171, 43, 43, "CID"], [171, 171, 49, 49, "CID"], [171, 171, 87, 87, "CID"], [171, 171, 96, 96, "CID"], [171, 171, 149, 149, "CID"], [171, 171, 156, 156, "CID"], [132, 132, 79, 81, "CID"], [169, 169, 79, 81, "CID"], [135, 135, 79, 81, "CID"], [171, 171, 79, 81, "CID"]]], "clusters": [], "translated": "钙调神经磷酸酶抑制剂引起的 <2>疼痛</2>综合征 (CIPS)：器官移植后严重致残的并发症。移植后的骨<3>痛</3>是一种常见的并发症，可由多种疾病引起。治疗策略取决于对<4>疼痛</4>的正确诊断。调查了9名移植后足部有严重<5>疼痛</5>的患者。骨扫描显示足骨吸收示踪剂增加。磁共振成像显示<12>疼痛的骨骼骨髓水肿</12>。<6>疼痛</6>不能用引起足部<7>疼痛</7>的其他疾病来解释，例如<14>反射性交感神经营养不良</14>、<15>多发性神经病</15>、<16>Morton的神经痛</16>、<17>痛风</17>、<18>骨质疏松症</18>、<19>缺血性坏死</19>、<20>间歇性跛行</20>、骨科<21>足部畸形</21>、<22>应力性骨折</22>和<23>甲状旁腺功能亢进</23>。降低<0>环孢菌素</0>或<10>他克莫司</10>谷浓度和给予<13>钙</13>通道阻滞剂可缓解<8>疼痛</8>。钙调神经磷酸酶抑制剂诱导的<9>疼痛</9>综合征 (CIPS)是<1>环孢菌素</1>或<11>他克莫司</11>的一种罕见但严重的副作用，可通过其典型表现准确诊断、磁共振成像和骨骼扫描。该综合征的错误诊断将导致患有CIPS的患者的生活质量显着降低。", "revised": true}
{"doc_key": "2334618", "sentences": [["Comparison", "of", "the", "respiratory", "effects", "of", "i", ".", "v", ".", "infusions", "of", "morphine", "and", "regional", "analgesia", "by", "extradural", "block", ".", "The", "incidence", "of", "postoperative", "respiratory", "apnoea", "was", "compared", "between", "five", "patients", "receiving", "a", "continuous", "i", ".", "v", ".", "infusion", "of", "morphine", "(", "mean", "73", ".", "6", "mg", ")", "and", "five", "patients", "receiving", "a", "continuous", "extradural", "infusion", "of", "0", ".", "25", "%", "bupivacaine", "(", "mean", "192", "mg", ")", "in", "the", "24", "-", "h", "period", "following", "upper", "abdominal", "surgery", ".", "Monitoring", "consisted", "of", "airflow", "detection", "by", "a", "carbon", "dioxide", "analyser", ",", "chest", "wall", "movement", "detected", "by", "pneumatic", "capsules", ",", "and", "continuous", "electrocardiograph", "recorded", "with", "a", "Holter", "ambulatory", "monitor", ".", "Both", "obstructive", "(", "P", "less", "than", "0", ".", "05", ")", "and", "central", "apnoea", "(", "P", "less", "than", "0", ".", "05", ")", "occurred", "more", "frequently", "in", "patients", "who", "had", "a", "morphine", "infusion", ".", "There", "was", "also", "a", "higher", "incidence", "of", "tachyarrhythmias", "(", "P", "less", "than", "0", ".", "05", ")", "and", "ventricular", "ectopic", "beats", "(", "P", "less", "than", "0", ".", "05", ")", "in", "the", "morphine", "infusion", "group", "."]], "ner": [[[12, 12, "Chemical"], [40, 40, "Chemical"], [136, 136, "Chemical"], [169, 169, "Chemical"], [108, 119, "Disease"], [156, 158, "Disease"], [25, 25, "Disease"], [146, 146, "Disease"], [61, 61, "Chemical"], [85, 86, "Chemical"]]], "relations": [[[12, 12, 108, 119, "CID"], [40, 40, 108, 119, "CID"], [136, 136, 108, 119, "CID"], [169, 169, 108, 119, "CID"], [12, 12, 156, 158, "CID"], [40, 40, 156, 158, "CID"], [136, 136, 156, 158, "CID"], [169, 169, 156, 158, "CID"]]], "clusters": [], "translated": "比较了接受持续i.v.输注<0>吗啡</0>和硬膜外阻滞局部镇痛的呼吸效应。比较了接受连续i.v.输注<1>吗啡</1>（平均73.6mg）和接受连续硬膜外输注0.25%<8>布比卡因</8>（平均192mg）的五名患者在上腹部手术后24小时内的呼吸<6>呼吸暂停</6>的发生率。监测包括通过<9>二氧化碳</9>分析仪检测气流、通过气动胶囊检测胸壁运动，以及通过 Holter 动态监测仪记录的连续心电图。在输注<2>吗啡</2>的患者中，<4>阻塞性呼吸暂停</4>（P小于0.05）和<4>中枢性呼吸暂停</4> （P小于0.05）发生率更高。在<3>吗啡</3>输液组中还存在更高发生率的<7>室速</7>（P小于0.05）和<5>室性早搏</5>（P小于0.05）。", "revised": true}
{"doc_key": "8864707", "sentences": [["Magnetic", "resonance", "volumetry", "of", "the", "cerebellum", "in", "epileptic", "patients", "after", "phenytoin", "overdosages", ".", "The", "aim", "of", "this", "study", "was", "to", "evaluate", "the", "relationship", "between", "phenytoin", "medication", "and", "cerebellar", "atrophy", "in", "patients", "who", "had", "experienced", "clinical", "intoxication", ".", "Five", "females", "and", "6", "males", ",", "21", "-", "59", "years", "of", "age", ",", "were", "examined", "with", "a", "1", ".", "5", "-", "T", "whole", "-", "body", "system", "using", "a", "circular", "polarized", "head", "coil", ".", "Conventional", "spin", "echo", "images", "were", "acquired", "in", "the", "sagittal", "and", "transverse", "orientation", ".", "In", "addition", ",", "we", "performed", "a", "high", "-", "resolution", "3D", "gradient", "echo", ",", "T1", "-", "weighted", "sequences", "at", "a", "1", "-", "mm", "slice", "thickness", ".", "The", "images", "were", "subsequently", "processed", "to", "obtain", "volumetric", "data", "for", "the", "cerebellum", ".", "Cerebellar", "volume", "for", "the", "patient", "group", "ranged", "between", "67", ".", "66", "and", "131", ".", "08", "ml", "(", "mean", "108", ".", "9", "ml", ")", ".", "In", "addition", "3D", "gradient", "echo", "data", "sets", "from", "10", "healthy", "male", "and", "10", "healthy", "female", "age", "-", "matched", "volunteers", "were", "used", "to", "compare", "cerebellar", "volumes", ".", "Using", "linear", "regression", "we", "found", "that", "no", "correlation", "exists", "between", "seizure", "duration", ",", "elevation", "of", "phenytoin", "serum", "levels", "and", "cerebellar", "volume", ".", "However", ",", "multiple", "regression", "for", "the", "daily", "dosage", ",", "duration", "of", "phenytoin", "treatment", "and", "cerebellar", "volume", "revealed", "a", "correlation", "of", "these", "parameters", ".", "We", "conclude", "that", "phenytoin", "overdosage", "does", "not", "necessarily", "result", "in", "cerebellar", "atrophy", "and", "it", "is", "unlikely", "that", "phenytoin", "medication", "was", "the", "only", "cause", "of", "cerebellar", "atrophy", "in", "the", "remaining", "patients", ".", "Quantitative", "morphometric", "studies", "of", "the", "cerebellum", "provide", "valuable", "insights", "into", "the", "pathogenesis", "of", "cerebellar", "disorders", "."]], "ner": [[[10, 10, "Chemical"], [24, 24, "Chemical"], [186, 186, "Chemical"], [204, 204, "Chemical"], [219, 219, "Chemical"], [233, 233, "Chemical"], [11, 11, "Disease"], [220, 220, "Disease"], [7, 7, "Disease"], [27, 28, "Disease"], [226, 227, "Disease"], [240, 241, "Disease"], [260, 261, "Disease"], [181, 181, "Disease"]]], "relations": [[[10, 10, 11, 11, "CID"], [10, 10, 220, 220, "CID"], [24, 24, 11, 11, "CID"], [24, 24, 220, 220, "CID"], [186, 186, 11, 11, "CID"], [186, 186, 220, 220, "CID"], [204, 204, 11, 11, "CID"], [204, 204, 220, 220, "CID"], [219, 219, 11, 11, "CID"], [219, 219, 220, 220, "CID"], [233, 233, 11, 11, "CID"], [233, 233, 220, 220, "CID"]]], "clusters": [], "translated": "<0>苯妥英</0><6>药物过量</6>后<8>癫痫</8>患者小脑的磁共振体积测量。本研究的目的是评估临床中毒患者<1>苯妥英</1>药物治疗与<9>小脑萎缩</9>之间的关系。五名女性和六名男性，年龄在 21 - 59 岁之间，接受了 1.5-T全身系统采用圆极化头部线圈。传统的自旋回波图像是在矢状和横向方向上采集的。此外，我们还执行了高分辨率 3D 梯度回波、1毫米切片厚度的T1加权序列。这些图像随后被处理以获得小脑的体积数据。患者组的小脑体积介于67.66和131.08毫升（平均108.9毫升）。此外，来自10名健康男性和10名健康女性年龄匹配志愿者的3D梯度回波数据集被用于比较小脑体积。使用线性回归，我们发现癫痫发作<13>持续时间</13>、<2>苯妥英</2>血清水平升高和小脑体积之间不存在相关性。然而，每日剂量、<3>苯妥英</3>治疗持续时间和小脑体积的多元回归揭示了这些参数的相关性。我们的结论是<4>苯妥英</4><7>过量服用</7>不一定会导致<10>小脑萎缩</10>，并且<5>苯妥英</5>药物不太可能是唯一的<11>小脑萎缩</11>原因。小脑的定量形态学研究为<12>小脑疾病</12>的发病机制提供了有价值的见解。", "revised": true}
{"doc_key": "2802551", "sentences": [["Sodium", "status", "influences", "chronic", "amphotericin", "B", "nephrotoxicity", "in", "rats", ".", "The", "nephrotoxic", "potential", "of", "amphotericin", "B", "(", "5", "mg", "/", "kg", "per", "day", "intraperitoneally", "for", "3", "weeks", ")", "has", "been", "investigated", "in", "salt", "-", "depleted", ",", "normal", "-", "salt", ",", "and", "salt", "-", "loaded", "rats", ".", "In", "salt", "-", "depleted", "rats", ",", "amphotericin", "B", "decreased", "creatinine", "clearance", "linearly", "with", "time", ",", "with", "an", "85", "%", "reduction", "by", "week", "3", ".", "In", "contrast", ",", "in", "normal", "-", "salt", "rats", "creatinine", "clearance", "was", "decreased", "but", "to", "a", "lesser", "extent", "at", "week", "2", "and", "3", ",", "and", "in", "salt", "-", "loaded", "rats", "creatinine", "clearance", "did", "not", "change", "for", "2", "weeks", "and", "was", "decreased", "by", "43", "%", "at", "week", "3", ".", "All", "rats", "in", "the", "sodium", "-", "depleted", "group", "had", "histopathological", "evidence", "of", "patchy", "tubular", "cytoplasmic", "degeneration", "in", "tubules", "that", "was", "not", "observed", "in", "any", "normal", "-", "salt", "or", "salt", "-", "loaded", "rat", ".", "Concentrations", "of", "amphotericin", "B", "in", "plasma", "were", "not", "significantly", "different", "among", "the", "three", "groups", "at", "any", "time", "during", "the", "study", ".", "However", ",", "at", "the", "end", "of", "3", "weeks", ",", "amphotericin", "B", "levels", "in", "the", "kidneys", "and", "liver", "were", "significantly", "higher", "in", "salt", "-", "depleted", "and", "normal", "-", "salt", "rats", "than", "those", "in", "salt", "-", "loaded", "rats", ",", "with", "plasma", "/", "kidney", "ratios", "of", "21", ",", "14", ",", "and", "8", "in", "salt", "-", "depleted", ",", "normal", "-", "salt", ",", "and", "salt", "-", "loaded", "rats", ",", "respectively", ".", "In", "conclusion", ",", "reductions", "in", "creatinine", "clearance", "and", "renal", "amphotericin", "B", "accumulation", "after", "chronic", "amphotericin", "B", "administration", "were", "enhanced", "by", "salt", "depletion", "and", "attenuated", "by", "sodium", "loading", "in", "rats", "."]], "ner": [[[4, 5, "Chemical"], [14, 15, "Chemical"], [52, 53, "Chemical"], [152, 153, "Chemical"], [180, 181, "Chemical"], [246, 247, "Chemical"], [251, 252, "Chemical"], [6, 6, "Disease"], [11, 11, "Disease"], [0, 0, "Chemical"], [121, 121, "Chemical"], [262, 262, "Chemical"], [55, 55, "Chemical"], [78, 78, "Chemical"], [99, 99, "Chemical"], [242, 242, "Chemical"]]], "relations": [[[4, 5, 6, 6, "CID"], [4, 5, 11, 11, "CID"], [14, 15, 6, 6, "CID"], [14, 15, 11, 11, "CID"], [52, 53, 6, 6, "CID"], [52, 53, 11, 11, "CID"], [152, 153, 6, 6, "CID"], [152, 153, 11, 11, "CID"], [180, 181, 6, 6, "CID"], [180, 181, 11, 11, "CID"], [246, 247, 6, 6, "CID"], [246, 247, 11, 11, "CID"], [251, 252, 6, 6, "CID"], [251, 252, 11, 11, "CID"]]], "clusters": [], "translated": " <9>钠</9>状态对大鼠慢性<0>两性霉素B</0><7>肾毒性</7>的影响。<8>肾毒性</8><1>两性霉素B</1>（5毫克/千克每天腹膜内给药，持续3周）的潜在<8>肾毒性</8>已经在盐耗竭、正常盐和盐负荷大鼠中进行了研究。在盐耗竭大鼠中，<2>两性霉素B</2>随时间线性降低<12>肌酐</12>清除率，第3周时降低85%。相比之下，在正常盐大鼠中，<13>肌酐</13>清除率在第2周和第3周有所降低，但程度较小，而在盐负荷大鼠中，<14>肌酐</14>清除率在2周内没有变化，在第3周下降了43%。在<10>钠</10>耗尽组中的所有大鼠均有组织病理学证据显示肾小管中出现斑片状肾小管细胞质变性，而这在任何正常盐或盐负荷大鼠中均未观察到。在研究期间的任何时间，三组患者血浆中<3>两性霉素B</3>的浓度均无显着差异。然而，在3周结束时，盐耗竭和正常盐大鼠中的<4>两性霉素B</4>水平在肾脏和肝脏中显着高于盐负荷大鼠，血浆/肾脏比率为21、14和8，在盐耗竭、正常盐和盐负荷大鼠中分别。总之，慢性<6>两性霉素B</6>给药后<15>肌酐</15>清除率和肾<5>两性霉素B</5>蓄积的降低因盐耗竭而增强，因<11>钠</11>而减弱在大鼠中加载。", "revised": true}
{"doc_key": "10706004", "sentences": [["Changes", "of", "sodium", "and", "ATP", "affinities", "of", "the", "cardiac", "(", "Na", ",", "K", ")", "-", "ATPase", "during", "and", "after", "nitric", "oxide", "deficient", "hypertension", ".", "In", "the", "cardiovascular", "system", ",", "NO", "is", "involved", "in", "the", "regulation", "of", "a", "variety", "of", "functions", ".", "Inhibition", "of", "NO", "synthesis", "induces", "sustained", "hypertension", ".", "In", "several", "models", "of", "hypertension", ",", "elevation", "of", "intracellular", "sodium", "level", "was", "documented", "in", "cardiac", "tissue", ".", "To", "assess", "the", "molecular", "basis", "of", "disturbances", "in", "transmembraneous", "transport", "of", "Na", "+", ",", "we", "studied", "the", "response", "of", "cardiac", "(", "Na", ",", "K", ")", "-", "ATPase", "to", "NO", "-", "deficient", "hypertension", "induced", "in", "rats", "by", "NO", "-", "synthase", "inhibition", "with", "40", "mg", "/", "kg", "/", "day", "N", "(", "G", ")", "-", "nitro", "-", "L", "-", "arginine", "methyl", "ester", "(", "L", "-", "NAME", ")", "for", "4", "four", "weeks", ".", "After", "4", "-", "week", "administration", "of", "L", "-", "NAME", ",", "the", "systolic", "blood", "pressure", "(", "SBP", ")", "increased", "by", "36", "%", ".", "Two", "weeks", "after", "terminating", "the", "treatment", ",", "the", "SBP", "recovered", "to", "control", "value", ".", "When", "activating", "the", "(", "Na", ",", "K", ")", "-", "ATPase", "with", "its", "substrate", "ATP", ",", "no", "changes", "in", "Km", "and", "Vmax", "values", "were", "observed", "in", "NO", "-", "deficient", "rats", ".", "During", "activation", "with", "Na", "+", ",", "the", "Vmax", "remained", "unchanged", ",", "however", "the", "K", "(", "Na", ")", "increased", "by", "50", "%", ",", "indicating", "a", "profound", "decrease", "in", "the", "affinity", "of", "the", "Na", "+", "-", "binding", "site", "in", "NO", "-", "deficient", "rats", ".", "After", "recovery", "from", "hypertension", ",", "the", "activity", "of", "(", "Na", ",", "K", ")", "-", "ATPase", "increased", ",", "due", "to", "higher", "affinity", "of", "the", "ATP", "-", "binding", "site", ",", "as", "revealed", "from", "the", "lowered", "Km", "value", "for", "ATP", ".", "The", "K", "(", "Na", ")", "value", "for", "Na", "+", "returned", "to", "control", "value", ".", "Inhibition", "of", "NO", "-", "synthase", "induced", "a", "reversible", "hypertension", "accompanied", "by", "depressed", "Na", "+", "-", "extrusion", "from", "cardiac", "cells", "as", "a", "consequence", "of", "deteriorated", "Na", "+", "-", "binding", "properties", "of", "the", "(", "Na", ",", "K", ")", "-", "ATPase", ".", "After", "recovery", "of", "blood", "pressure", "to", "control", "values", ",", "the", "extrusion", "of", "Na", "+", "from", "cardiac", "cells", "was", "normalized", ",", "as", "revealed", "by", "restoration", "of", "the", "(", "Na", ",", "K", ")", "-", "ATPase", "activity", "."]], "ner": [[[19, 20, "Chemical"], [29, 29, "Chemical"], [43, 43, "Chemical"], [94, 94, "Chemical"], [102, 102, "Chemical"], [196, 196, "Chemical"], [238, 238, "Chemical"], [297, 297, "Chemical"], [22, 22, "Disease"], [47, 47, "Disease"], [53, 53, "Disease"], [97, 97, "Disease"], [246, 246, "Disease"], [303, 303, "Disease"], [2, 2, "Chemical"], [10, 10, "Chemical"], [58, 58, "Chemical"], [77, 77, "Chemical"], [87, 87, "Chemical"], [175, 175, "Chemical"], [204, 204, "Chemical"], [216, 216, "Chemical"], [232, 232, "Chemical"], [252, 252, "Chemical"], [284, 284, "Chemical"], [288, 288, "Chemical"], [307, 307, "Chemical"], [319, 319, "Chemical"], [327, 327, "Chemical"], [346, 346, "Chemical"], [361, 361, "Chemical"], [306, 306, "Disease"], [4, 4, "Chemical"], [184, 184, "Chemical"], [266, 266, "Chemical"], [279, 279, "Chemical"], [12, 12, "Chemical"], [89, 89, "Chemical"], [177, 177, "Chemical"], [214, 214, "Chemical"], [254, 254, "Chemical"], [282, 282, "Chemical"], [329, 329, "Chemical"], [363, 363, "Chemical"], [113, 124, "Chemical"], [126, 128, "Chemical"], [141, 143, "Chemical"]]], "relations": [[[19, 20, 22, 22, "CID"], [19, 20, 47, 47, "CID"], [19, 20, 53, 53, "CID"], [19, 20, 97, 97, "CID"], [19, 20, 246, 246, "CID"], [19, 20, 303, 303, "CID"], [29, 29, 22, 22, "CID"], [29, 29, 47, 47, "CID"], [29, 29, 53, 53, "CID"], [29, 29, 97, 97, "CID"], [29, 29, 246, 246, "CID"], [29, 29, 303, 303, "CID"], [43, 43, 22, 22, "CID"], [43, 43, 47, 47, "CID"], [43, 43, 53, 53, "CID"], [43, 43, 97, 97, "CID"], [43, 43, 246, 246, "CID"], [43, 43, 303, 303, "CID"], [94, 94, 22, 22, "CID"], [94, 94, 47, 47, "CID"], [94, 94, 53, 53, "CID"], [94, 94, 97, 97, "CID"], [94, 94, 246, 246, "CID"], [94, 94, 303, 303, "CID"], [102, 102, 22, 22, "CID"], [102, 102, 47, 47, "CID"], [102, 102, 53, 53, "CID"], [102, 102, 97, 97, "CID"], [102, 102, 246, 246, "CID"], [102, 102, 303, 303, "CID"], [196, 196, 22, 22, "CID"], [196, 196, 47, 47, "CID"], [196, 196, 53, 53, "CID"], [196, 196, 97, 97, "CID"], [196, 196, 246, 246, "CID"], [196, 196, 303, 303, "CID"], [238, 238, 22, 22, "CID"], [238, 238, 47, 47, "CID"], [238, 238, 53, 53, "CID"], [238, 238, 97, 97, "CID"], [238, 238, 246, 246, "CID"], [238, 238, 303, 303, "CID"], [297, 297, 22, 22, "CID"], [297, 297, 47, 47, "CID"], [297, 297, 53, 53, "CID"], [297, 297, 97, 97, "CID"], [297, 297, 246, 246, "CID"], [297, 297, 303, 303, "CID"]]], "clusters": [], "translated": "<14>钠</14>和<32>ATP</32>心脏亲和力的变化（<15>Na</15>，<36>K</36>）-ATP酶在<0>一氧化氮</0>不足<8>高血压</8>期间和之后。在心血管系统中，<1>NO</1>参与多种功能的调节。抑制<2>NO</2>合成会导致持续的<9>高血压</9>。在几种<10>高血压</10>模型中，已经证实心脏组织中细胞内<16>钠</16>水平升高。为了评估跨膜转运<17> Na </17> + 障碍的分子基础，我们研究了用40 mg/kg/day的<44> N（G）- 硝基 - L 合酶抑制-精氨酸甲酯 </44> (<45>L-NAME</45>)在大鼠中诱导的<11>高血压</11>缺陷，以评估心脏（<18> Na </18>，<37> K </37>）-ATP酶对<3> NO </3> - 缺乏 <4> NO </4>的反应。经过4周的<46>L-NAME</46>给药后，收缩压（SBP）升高了36％。治疗结束两周后，SBP恢复到控制值。激活（<19>Na</19>，<38>K</38>）-ATP酶及其底物<33>ATP </33> 时，未观察到在<5> NO </5> - 缺陷大鼠中 Km 和 Vmax 值的变化。在用<20> Na </20> +激活期间，Vmax保持不变，但是<39> K </39>（<21>Na</21>）增加了50％，表明<22> Na </22>+ -在<6>NO</6>- 缺陷大鼠中结合位点的亲和力明显降低。<12>高血压</12>恢复后，(<23>Na</23>，<40>K</40>)-ATP酶活性升高，由于<34> ATP </34> - 结合位点，例如<35> ATP </35>的Km值降低。<25>Na</25>+的<41>K</41>（<24> Na </24>）值恢复到对照值。抑制<7> NO </7> - 合成酶诱导可逆的<13>高血压</13>，并显示心肌细胞中<27> Na </27>+ - 绑定特性的恶化是由( <28> Na </28>，<42>K</42>)-ATP酶引起的，<31>其具有抑制的</31> <26>Na</26>+ - 结果从心肌细胞中排出。恢复到控制值的血压后，从心肌细胞排出的<29>Na</29>+ 恢复正常，正如(<30>Na</30>，<43>K</43>)-ATP酶活性恢复所示。", "revised": true}
{"doc_key": "19346865", "sentences": [["Reversible", "inferior", "colliculus", "lesion", "in", "metronidazole", "-", "induced", "encephalopathy", ":", "magnetic", "resonance", "findings", "on", "diffusion", "-", "weighted", "and", "fluid", "attenuated", "inversion", "recovery", "imaging", ".", "OBJECTIVE", ":", "This", "is", "to", "present", "reversible", "inferior", "colliculus", "lesions", "in", "metronidazole", "-", "induced", "encephalopathy", ",", "to", "focus", "on", "the", "diffusion", "-", "weighted", "imaging", "(", "DWI", ")", "and", "fluid", "attenuated", "inversion", "recovery", "(", "FLAIR", ")", "imaging", ".", "MATERIALS", "AND", "METHODS", ":", "From", "November", "2005", "to", "September", "2007", ",", "8", "patients", "(", "5", "men", "and", "3", "women", ")", "were", "diagnosed", "as", "having", "metronidazole", "-", "induced", "encephalopathy", "(", "age", "range", ";", "43", "-", "78", "years", ")", ".", "They", "had", "been", "taking", "metronidazole", "(", "total", "dosage", ",", "45", "-", "120", "g", ";", "duration", ",", "30", "days", "to", "2", "months", ")", "to", "treat", "the", "infection", "in", "various", "organs", ".", "Initial", "brain", "magnetic", "resonance", "imaging", "(", "MRI", ")", "were", "obtained", "after", "the", "hospitalization", ",", "including", "DWI", "(", "8", "/", "8", ")", ",", "apparent", "diffusion", "coefficient", "(", "ADC", ")", "map", "(", "4", "/", "8", ")", ",", "FLAIR", "(", "7", "/", "8", ")", ",", "and", "T2", "-", "weighted", "image", "(", "8", "/", "8", ")", ".", "Follow", "-", "up", "MRIs", "were", "performed", "on", "5", "patients", "from", "third", "to", "14th", "days", "after", "discontinuation", "of", "metronidazole", "administration", ".", "Findings", "of", "initial", "and", "follow", "-", "up", "MRIs", "were", "retrospectively", "evaluated", "by", "2", "neuroradiologists", "by", "consensus", ",", "to", "analyze", "the", "presence", "of", "abnormal", "signal", "intensities", ",", "their", "locations", ",", "and", "signal", "changes", "on", "follow", "-", "up", "images", ".", "RESULTS", ":", "Initial", "MRIs", "showed", "abnormal", "high", "signal", "intensities", "on", "DWI", "and", "FLAIR", "(", "or", "T2", "-", "weighted", "image", ")", "at", "the", "dentate", "nucleus", "(", "8", "/", "8", ")", ",", "inferior", "colliculus", "(", "6", "/", "8", ")", ",", "corpus", "callosum", "(", "2", "/", "8", ")", ",", "pons", "(", "2", "/", "8", ")", ",", "medulla", "(", "1", "/", "8", ")", ",", "and", "bilateral", "cerebral", "white", "matter", "(", "1", "/", "8", ")", ".", "High", "-", "signal", "intensity", "lesions", "on", "DWI", "tended", "to", "show", "low", "signal", "intensity", "on", "ADC", "map", "(", "3", "/", "4", ")", ",", "but", "in", "one", "patient", ",", "high", "signal", "intensity", "was", "shown", "at", "bilateral", "dentate", "nuclei", "on", "not", "only", "DWI", "but", "also", "ADC", "map", ".", "All", "the", "lesions", "in", "dentate", ",", "inferior", "colliculus", ",", "pons", ",", "and", "medullas", "had", "been", "resolved", "completely", "on", "follow", "-", "up", "MRIs", "in", "5", "patients", ",", "but", "in", "1", "patient", "of", "them", ",", "corpus", "callosal", "lesion", "persisted", ".", "CONCLUSIONS", ":", "Reversible", "inferior", "colliculus", "lesions", "could", "be", "considered", "as", "the", "characteristic", "for", "metronidazole", "-", "induced", "encephalopathy", ",", "next", "to", "the", "dentate", "nucleus", "involvement", "."]], "ner": [[[5, 5, "Chemical"], [35, 35, "Chemical"], [85, 85, "Chemical"], [103, 103, "Chemical"], [199, 199, "Chemical"], [407, 407, "Chemical"], [1, 3, "Disease"], [8, 8, "Disease"], [31, 33, "Disease"], [38, 38, "Disease"], [88, 88, "Disease"], [390, 391, "Disease"], [397, 399, "Disease"], [410, 410, "Disease"], [124, 124, "Disease"]]], "relations": [[[5, 5, 1, 3, "CID"], [5, 5, 8, 8, "CID"], [5, 5, 31, 33, "CID"], [5, 5, 38, 38, "CID"], [5, 5, 88, 88, "CID"], [5, 5, 390, 391, "CID"], [5, 5, 397, 399, "CID"], [5, 5, 410, 410, "CID"], [35, 35, 1, 3, "CID"], [35, 35, 8, 8, "CID"], [35, 35, 31, 33, "CID"], [35, 35, 38, 38, "CID"], [35, 35, 88, 88, "CID"], [35, 35, 390, 391, "CID"], [35, 35, 397, 399, "CID"], [35, 35, 410, 410, "CID"], [85, 85, 1, 3, "CID"], [85, 85, 8, 8, "CID"], [85, 85, 31, 33, "CID"], [85, 85, 38, 38, "CID"], [85, 85, 88, 88, "CID"], [85, 85, 390, 391, "CID"], [85, 85, 397, 399, "CID"], [85, 85, 410, 410, "CID"], [103, 103, 1, 3, "CID"], [103, 103, 8, 8, "CID"], [103, 103, 31, 33, "CID"], [103, 103, 38, 38, "CID"], [103, 103, 88, 88, "CID"], [103, 103, 390, 391, "CID"], [103, 103, 397, 399, "CID"], [103, 103, 410, 410, "CID"], [199, 199, 1, 3, "CID"], [199, 199, 8, 8, "CID"], [199, 199, 31, 33, "CID"], [199, 199, 38, 38, "CID"], [199, 199, 88, 88, "CID"], [199, 199, 390, 391, "CID"], [199, 199, 397, 399, "CID"], [199, 199, 410, 410, "CID"], [407, 407, 1, 3, "CID"], [407, 407, 8, 8, "CID"], [407, 407, 31, 33, "CID"], [407, 407, 38, 38, "CID"], [407, 407, 88, 88, "CID"], [407, 407, 390, 391, "CID"], [407, 407, 397, 399, "CID"], [407, 407, 410, 410, "CID"]]], "clusters": [], "translated": "<0>甲硝唑</0>引起的<7>脑病</7>可逆性<6>下丘损伤</6>：弥散加权和流体衰减反转恢复成像的磁共振发现。目的：这是在<1>甲硝唑</1>诱发的<9>脑病</9>中呈现可逆的<8>下丘病变</8>，重点关注弥散加权成像(DWI)和流体衰减反转恢复(FLAIR)成像。材料和方法：从2005年11月到2007年9月，8名患者（5名男性和3名女性）被诊断为患有<2>甲硝唑</2>-诱发的<10>脑病</10>（年龄范围；43-78岁）。一直服用<3>甲硝唑</3>（总剂量45～120g，疗程30天～2个月）治疗各脏器<14>感染</14>。入院后首次行脑磁共振(MRI)检查，包括DWI（8/8）、表观扩散系数(ADC)图（4/8）、FLAIR（7/8）、T2加权像（8/8）。在停止服用<4>甲硝唑</4>后的第3天至第14天，对5名患者进行了随访MRI检查。由2名神经放射学家以协商一致方式对初始和后续MRI的结果进行回顾性评估，以分析异常信号强度的存在、它们的位置以及后续图像上的信号变化。结果：初始MRI在DWI和FLAIR（或T2加权图像）上显示异常高信号强度，位于齿状核（8/8）、下丘（6/8）、胼胝体（2/8）、脑桥（2/8）、延髓（1/8）和双侧脑白质（1/8）。DWI上高信号的病灶在ADC图上往往呈低信号（3/4），但在1例患者中，双侧齿状核不仅在DWI上呈高信号，在ADC图上也呈高信号。5例患者随访MRI，齿状、下丘、脑桥、延髓等病灶均已完全消退，但其中1例患者<11>胼胝体病灶</11>持续存在。结论：可逆性<12>下丘病变</12>可认为是<5>甲硝唑</5>所致<13>脑病</13>的特征，仅次于齿状核受累。", "revised": true}
{"doc_key": "11807648", "sentences": [["Epileptic", "seizures", "following", "cortical", "application", "of", "fibrin", "sealants", "containing", "tranexamic", "acid", "in", "rats", ".", "BACKGROUND", ":", "Fibrin", "sealants", "(", "FS", ")", "derived", "from", "human", "plasma", "are", "frequently", "used", "in", "neurosurgery", ".", "In", "order", "to", "increase", "clot", "stability", ",", "FS", "typically", "contain", "aprotinin", ",", "a", "natural", "fibrinolysis", "inhibitor", ".", "Recently", ",", "synthetic", "fibrinolysis", "inhibitors", "such", "as", "tranexamic", "acid", "(", "tAMCA", ")", "have", "been", "considered", "as", "substitutes", "for", "aprotinin", ".", "However", ",", "tAMCA", "has", "been", "shown", "to", "cause", "epileptic", "seizures", ".", "We", "wanted", "to", "study", "whether", "tAMCA", "retains", "its", "convulsive", "action", "if", "incorporated", "into", "a", "FS", ".", "METHOD", ":", "FS", "containing", "aprotinin", "or", "different", "concentrations", "of", "tAMCA", "(", "0", ".", "5", "-", "47", ".", "5", "mg", "/", "ml", ")", "were", "applied", "to", "the", "pial", "surface", "of", "the", "cortex", "of", "anaesthetized", "rats", ".", "The", "response", "of", "the", "animals", "was", "evaluated", "using", "electroencephalography", "and", "by", "monitoring", "the", "clinical", "behaviour", "during", "and", "after", "recovery", "from", "anaesthesia", ".", "FINDINGS", ":", "FS", "containing", "tAMCA", "caused", "paroxysmal", "brain", "activity", "which", "was", "associated", "with", "distinct", "convulsive", "behaviours", ".", "The", "degree", "of", "these", "seizures", "increased", "with", "increasing", "concentration", "of", "tAMCA", ".", "Thus", ",", "FS", "containing", "47", ".", "5", "mg", "/", "ml", "tAMCA", "evoked", "generalized", "seizures", "in", "all", "tested", "rats", "(", "n", "=", "6", ")", "while", "the", "lowest", "concentration", "of", "tAMCA", "(", "0", ".", "5", "mg", "/", "ml", ")", "only", "evoked", "brief", "episodes", "of", "jerk", "-", "correlated", "convulsive", "potentials", "in", "1", "of", "6", "rats", ".", "In", "contrast", ",", "FS", "containing", "aprotinin", "did", "not", "evoke", "any", "paroxysmal", "activity", ".", "INTERPRETATION", ":", "Tranexamic", "acid", "retains", "its", "convulsive", "action", "within", "FS", ".", "Thus", ",", "use", "of", "FS", "containing", "tAMCA", "for", "surgery", "within", "or", "close", "to", "the", "CNS", "may", "pose", "a", "substantial", "risk", "to", "the", "patient", "."]], "ner": [[[9, 10, "Chemical"], [55, 56, "Chemical"], [58, 58, "Chemical"], [70, 70, "Chemical"], [84, 84, "Chemical"], [104, 104, "Chemical"], [156, 156, "Chemical"], [179, 179, "Chemical"], [191, 191, "Chemical"], [209, 209, "Chemical"], [249, 250, "Chemical"], [264, 264, "Chemical"], [87, 87, "Disease"], [166, 166, "Disease"], [173, 173, "Disease"], [193, 194, "Disease"], [226, 226, "Disease"], [253, 253, "Disease"], [0, 1, "Disease"], [76, 77, "Disease"]]], "relations": [[[9, 10, 87, 87, "CID"], [9, 10, 166, 166, "CID"], [9, 10, 173, 173, "CID"], [9, 10, 193, 194, "CID"], [9, 10, 226, 226, "CID"], [9, 10, 253, 253, "CID"], [55, 56, 87, 87, "CID"], [55, 56, 166, 166, "CID"], [55, 56, 173, 173, "CID"], [55, 56, 193, 194, "CID"], [55, 56, 226, 226, "CID"], [55, 56, 253, 253, "CID"], [58, 58, 87, 87, "CID"], [58, 58, 166, 166, "CID"], [58, 58, 173, 173, "CID"], [58, 58, 193, 194, "CID"], [58, 58, 226, 226, "CID"], [58, 58, 253, 253, "CID"], [70, 70, 87, 87, "CID"], [70, 70, 166, 166, "CID"], [70, 70, 173, 173, "CID"], [70, 70, 193, 194, "CID"], [70, 70, 226, 226, "CID"], [70, 70, 253, 253, "CID"], [84, 84, 87, 87, "CID"], [84, 84, 166, 166, "CID"], [84, 84, 173, 173, "CID"], [84, 84, 193, 194, "CID"], [84, 84, 226, 226, "CID"], [84, 84, 253, 253, "CID"], [104, 104, 87, 87, "CID"], [104, 104, 166, 166, "CID"], [104, 104, 173, 173, "CID"], [104, 104, 193, 194, "CID"], [104, 104, 226, 226, "CID"], [104, 104, 253, 253, "CID"], [156, 156, 87, 87, "CID"], [156, 156, 166, 166, "CID"], [156, 156, 173, 173, "CID"], [156, 156, 193, 194, "CID"], [156, 156, 226, 226, "CID"], [156, 156, 253, 253, "CID"], [179, 179, 87, 87, "CID"], [179, 179, 166, 166, "CID"], [179, 179, 173, 173, "CID"], [179, 179, 193, 194, "CID"], [179, 179, 226, 226, "CID"], [179, 179, 253, 253, "CID"], [191, 191, 87, 87, "CID"], [191, 191, 166, 166, "CID"], [191, 191, 173, 173, "CID"], [191, 191, 193, 194, "CID"], [191, 191, 226, 226, "CID"], [191, 191, 253, 253, "CID"], [209, 209, 87, 87, "CID"], [209, 209, 166, 166, "CID"], [209, 209, 173, 173, "CID"], [209, 209, 193, 194, "CID"], [209, 209, 226, 226, "CID"], [209, 209, 253, 253, "CID"], [249, 250, 87, 87, "CID"], [249, 250, 166, 166, "CID"], [249, 250, 173, 173, "CID"], [249, 250, 193, 194, "CID"], [249, 250, 226, 226, "CID"], [249, 250, 253, 253, "CID"], [264, 264, 87, 87, "CID"], [264, 264, 166, 166, "CID"], [264, 264, 173, 173, "CID"], [264, 264, 193, 194, "CID"], [264, 264, 226, 226, "CID"], [264, 264, 253, 253, "CID"]]], "clusters": [], "translated": " <18>癫痫发作</18> 在大鼠皮层应用含有<0>氨甲环酸</0>的纤维蛋白密封剂后。背景：源自人血浆的纤维蛋白密封剂(FS)经常用于神经外科手术。为了增加凝块的稳定性，FS通常含有抑肽酶，一种天然的纤维蛋白溶解抑制剂。最近，合成的纤维蛋白溶解抑制剂如<1>氨甲环酸</1>（<2>tAMCA</2>）被认为是抑肽酶的替代品。然而，<3>tAMCA</3>已被证明会引起<19>癫痫发作</19>。我们想研究<4>tAMCA</4>如果合并到FS中是否保留其<12>抽搐</12>作用。方法：将含抑肽酶或不同浓度的<5>tAMCA</5>（0.5-47.5 mg/ml）的FS涂于麻醉大鼠大脑皮质的软膜表面。使用脑电图和监测麻醉恢复期间和之后的临床行为来评估动物的反应。调查结果：<6>含有tAMCA的FS</6>引起阵发性大脑活动，这与明显的<13>惊厥</13>行为有关。这些<14>癫痫发作</14>的程度随着<7>tAMCA</7>浓度的增加而增加。这样，FS包含海拔高度达47.5 mg/ml的<8>tAMCA</8>在所有测试大鼠(n = 6)中诱发<15>全身性癫痫发作</15>，而最低浓度的<9>tAMCA</9>(0.5 mg/ml)仅在6只大鼠中的1只中诱发了与混蛋相关的<16>惊厥</16>电位的短暂发作。相反，含有抑肽酶的FS不会引起任何阵发性活动。解释：<10>氨甲环酸</10>在FS内保留其<17>惊厥</17>作用。因此，使用含有<11>tAMCA</11>的FS在CNS内或附近进行手术可能会给患者带来很大的风险。", "revised": true}
{"doc_key": "230316", "sentences": [["Neurotoxicity", "of", "halogenated", "hydroxyquinolines", ":", "clinical", "analysis", "of", "cases", "reported", "outside", "Japan", ".", "An", "analysis", "is", "presented", "of", "220", "cases", "of", "possible", "neurotoxic", "reactions", "to", "halogenated", "hydroxyquinolines", "reported", "from", "outside", "Japan", ".", "In", "80", "cases", "insufficient", "information", "was", "available", "for", "adequate", "comment", "and", "in", "29", "a", "relationship", "to", "the", "administration", "of", "clioquinol", "could", "be", "excluded", ".", "Of", "the", "remainder", ",", "a", "relationship", "to", "clioquinol", "was", "considered", "probable", "in", "42", "and", "possible", "in", "69", "cases", ".", "In", "six", "of", "the", "probable", "cases", "the", "neurological", "disturbance", "consisted", "of", "an", "acute", "reversible", "encephalopathy", "usually", "related", "to", "the", "ingestion", "of", "a", "high", "dose", "of", "clioquinol", "over", "a", "short", "period", ".", "The", "most", "common", "manifestation", ",", "observed", "in", "15", "further", "cases", ",", "was", "isolated", "optic", "atrophy", ".", "This", "was", "most", "frequently", "found", "in", "children", ",", "many", "of", "whom", "had", "received", "clioquinol", "as", "treatment", "for", "acrodermatitis", "enteropathica", ".", "In", "the", "remaining", "cases", ",", "a", "combination", "of", "myelopathy", ",", "visual", "disturbance", ",", "and", "peripheral", "neuropathy", "was", "the", "most", "common", "manifestation", ".", "Isolated", "myelopathy", "or", "peripheral", "neuropathy", ",", "or", "these", "manifestations", "occurring", "together", ",", "were", "infrequent", ".", "The", "onset", "of", "all", "manifestations", "(", "except", "toxic", "encephalopathy", ")", "was", "usually", "subacute", ",", "with", "subsequent", "partial", "recovery", ".", "Older", "subjects", "tended", "to", "display", "more", "side", "effects", ".", "The", "full", "syndrome", "of", "subacute", "myelo", "-", "optic", "neuropathy", "was", "more", "frequent", "in", "women", ",", "but", "they", "tended", "to", "have", "taken", "greater", "quantities", "of", "the", "drug", "."]], "ner": [[[51, 51, "Chemical"], [63, 63, "Chemical"], [100, 100, "Chemical"], [135, 135, "Chemical"], [89, 89, "Disease"], [187, 187, "Disease"], [119, 120, "Disease"], [150, 150, "Disease"], [165, 165, "Disease"], [212, 215, "Disease"], [152, 153, "Disease"], [156, 157, "Disease"], [167, 168, "Disease"], [2, 3, "Chemical"], [25, 26, "Chemical"], [0, 0, "Disease"], [22, 22, "Disease"], [82, 83, "Disease"], [139, 140, "Disease"]]], "relations": [[[51, 51, 89, 89, "CID"], [51, 51, 187, 187, "CID"], [63, 63, 89, 89, "CID"], [63, 63, 187, 187, "CID"], [100, 100, 89, 89, "CID"], [100, 100, 187, 187, "CID"], [135, 135, 89, 89, "CID"], [135, 135, 187, 187, "CID"], [51, 51, 119, 120, "CID"], [63, 63, 119, 120, "CID"], [100, 100, 119, 120, "CID"], [135, 135, 119, 120, "CID"], [51, 51, 150, 150, "CID"], [51, 51, 165, 165, "CID"], [51, 51, 212, 215, "CID"], [63, 63, 150, 150, "CID"], [63, 63, 165, 165, "CID"], [63, 63, 212, 215, "CID"], [100, 100, 150, 150, "CID"], [100, 100, 165, 165, "CID"], [100, 100, 212, 215, "CID"], [135, 135, 150, 150, "CID"], [135, 135, 165, 165, "CID"], [135, 135, 212, 215, "CID"], [51, 51, 152, 153, "CID"], [63, 63, 152, 153, "CID"], [100, 100, 152, 153, "CID"], [135, 135, 152, 153, "CID"], [51, 51, 156, 157, "CID"], [51, 51, 167, 168, "CID"], [63, 63, 156, 157, "CID"], [63, 63, 167, 168, "CID"], [100, 100, 156, 157, "CID"], [100, 100, 167, 168, "CID"], [135, 135, 156, 157, "CID"], [135, 135, 167, 168, "CID"]]], "clusters": [], "translated": "<13>卤化羟基喹啉</13>的<15>神经毒性</15>：日本以外报道病例的临床分析。对来自日本以外的220例可能的<16>神经毒性</16>反应<14>卤代羟基喹啉</14>进行了分析。在80个案例中，没有足够的信息来进行充分的评论，在29个案例中，可以排除与服用<0>氯碘羟喹</0>的关系。在其余的案例中，与<1>氯碘羟喹</1>的关系被认为是可能的的42例并在69例中被认为是可能的。在6个可能的病例中，<17>神经系统障碍</17>包括急性可逆性<4>脑病</4>，通常与短时间内摄入高剂量的<2>氯碘羟喹</2>有关。在另外15个病例中观察到的最常见表现是孤立的<6>视神经萎缩</6>。这在儿童中最常见，他们中的许多人接受过<3>氯碘羟喹</3>治疗<18>肠病性肢端皮炎</18>。在其余的病例中，<7>脊髓病</7>、<10>视力障碍</10>和<11>周围神经病</11>的组合是最常见的表现。孤立的<8>脊髓病</8>或<12>周围神经病</12>，或这些表现同时出现，并不常见。所有表现（中毒性<5>脑病</5>除外）的发作通常是亚急性的，随后会部分恢复。年长的受试者往往会出现更多的副作用。亚急性<9>脊髓视神经病变</9>的完全综合征在女性中更为常见，但她们往往服用了更多的药物。", "revised": true}
{"doc_key": "10520387", "sentences": [["The", "haemodynamic", "effects", "of", "propofol", "in", "combination", "with", "ephedrine", "in", "elderly", "patients", "(", "ASA", "groups", "3", "and", "4", ")", ".", "The", "marked", "vasodilator", "and", "negative", "inotropic", "effects", "of", "propofol", "are", "disadvantages", "in", "frail", "elderly", "patients", ".", "We", "investigated", "the", "safety", "and", "efficacy", "of", "adding", "different", "doses", "of", "ephedrine", "to", "propofol", "in", "order", "to", "obtund", "the", "hypotensive", "response", ".", "The", "haemodynamic", "effects", "of", "adding", "15", ",", "20", "or", "25", "mg", "of", "ephedrine", "to", "200", "mg", "of", "propofol", "were", "compared", "to", "control", "in", "40", "ASA", "3", "/", "4", "patients", "over", "60", "years", "presenting", "for", "genito", "-", "urinary", "surgery", ".", "The", "addition", "of", "ephedrine", "to", "propofol", "appears", "to", "be", "an", "effective", "method", "of", "obtunding", "the", "hypotensive", "response", "to", "propofol", "at", "all", "doses", "used", "in", "this", "study", ".", "However", ",", "marked", "tachycardia", "associated", "with", "the", "use", "of", "ephedrine", "in", "combination", "with", "propofol", "occurred", "in", "the", "majority", "of", "patients", ",", "occasionally", "reaching", "high", "levels", "in", "individual", "patients", ".", "Due", "to", "the", "risk", "of", "this", "tachycardia", "inducing", "myocardial", "ischemia", ",", "we", "would", "not", "recommend", "the", "use", "in", "elderly", "patients", "of", "any", "of", "the", "ephedrine", "/", "propofol", "/", "mixtures", "studied", "."]], "ner": [[[4, 4, "Chemical"], [28, 28, "Chemical"], [49, 49, "Chemical"], [75, 75, "Chemical"], [102, 102, "Chemical"], [115, 115, "Chemical"], [137, 137, "Chemical"], [179, 179, "Chemical"], [55, 55, "Disease"], [112, 112, "Disease"], [127, 127, "Disease"], [159, 159, "Disease"], [8, 8, "Chemical"], [47, 47, "Chemical"], [70, 70, "Chemical"], [100, 100, "Chemical"], [133, 133, "Chemical"], [177, 177, "Chemical"], [161, 162, "Disease"]]], "relations": [[[4, 4, 55, 55, "CID"], [4, 4, 112, 112, "CID"], [28, 28, 55, 55, "CID"], [28, 28, 112, 112, "CID"], [49, 49, 55, 55, "CID"], [49, 49, 112, 112, "CID"], [75, 75, 55, 55, "CID"], [75, 75, 112, 112, "CID"], [102, 102, 55, 55, "CID"], [102, 102, 112, 112, "CID"], [115, 115, 55, 55, "CID"], [115, 115, 112, 112, "CID"], [137, 137, 55, 55, "CID"], [137, 137, 112, 112, "CID"], [179, 179, 55, 55, "CID"], [179, 179, 112, 112, "CID"], [4, 4, 127, 127, "CID"], [4, 4, 159, 159, "CID"], [28, 28, 127, 127, "CID"], [28, 28, 159, 159, "CID"], [49, 49, 127, 127, "CID"], [49, 49, 159, 159, "CID"], [75, 75, 127, 127, "CID"], [75, 75, 159, 159, "CID"], [102, 102, 127, 127, "CID"], [102, 102, 159, 159, "CID"], [115, 115, 127, 127, "CID"], [115, 115, 159, 159, "CID"], [137, 137, 127, 127, "CID"], [137, 137, 159, 159, "CID"], [179, 179, 127, 127, "CID"], [179, 179, 159, 159, "CID"], [8, 8, 127, 127, "CID"], [8, 8, 159, 159, "CID"], [47, 47, 127, 127, "CID"], [47, 47, 159, 159, "CID"], [70, 70, 127, 127, "CID"], [70, 70, 159, 159, "CID"], [100, 100, 127, 127, "CID"], [100, 100, 159, 159, "CID"], [133, 133, 127, 127, "CID"], [133, 133, 159, 159, "CID"], [177, 177, 127, 127, "CID"], [177, 177, 159, 159, "CID"]]], "clusters": [], "translated": "<0>异丙酚</0>联合<12>麻黄碱</12>对老年患者（ASA 3 组和 4 组）的血液动力学影响。显着的<1>血管扩张作用</1>和<1>负性肌力作用</1>是体弱老年患者的缺点。我们研究了将不同剂量的<13>麻黄碱</13>添加到<2>丙泊酚</2>以减弱<8>低血压</8>反应的安全性和有效性。将15、20或25 mg的<14>麻黄碱</14>添加到200 mg的<3>丙泊酚</3>与对照相比，40名ASA 3/4患者的血液动力学效果超过60岁，出现生殖器-泌尿外科。向<4>异丙酚</4>中添加<15>麻黄碱</15>似乎是一种有效的方法，可以抑制所有剂量的<5>异丙酚</5>引起的<9>低血压</9>反应用于本研究。然而，与<16>麻黄碱</16>联合使用<6>丙泊酚</6>相关的显着<10>心动过速</10>发生在大多数患者中，个别患者偶尔会达到高水平。由于这种<11>心动过速</11>诱发<18>心肌缺血</18>的风险，我们不建议老年患者使用任何<17>麻黄碱</17>/<7>异丙酚</7>/混合物进行研究。", "revised": true}
{"doc_key": "18809400", "sentences": [["Alpha", "-", "lipoic", "acid", "prevents", "mitochondrial", "damage", "and", "neurotoxicity", "in", "experimental", "chemotherapy", "neuropathy", ".", "The", "study", "investigates", "if", "alpha", "-", "lipoic", "acid", "is", "neuroprotective", "against", "chemotherapy", "induced", "neurotoxicity", ",", "if", "mitochondrial", "damage", "plays", "a", "critical", "role", "in", "toxic", "neurodegenerative", "cascade", ",", "and", "if", "neuroprotective", "effects", "of", "alpha", "-", "lipoic", "acid", "depend", "on", "mitochondria", "protection", ".", "We", "used", "an", "in", "vitro", "model", "of", "chemotherapy", "induced", "peripheral", "neuropathy", "that", "closely", "mimic", "the", "in", "vivo", "condition", "by", "exposing", "primary", "cultures", "of", "dorsal", "root", "ganglion", "(", "DRG", ")", "sensory", "neurons", "to", "paclitaxel", "and", "cisplatin", ",", "two", "widely", "used", "and", "highly", "effective", "chemotherapeutic", "drugs", ".", "This", "approach", "allowed", "investigating", "the", "efficacy", "of", "alpha", "-", "lipoic", "acid", "in", "preventing", "axonal", "damage", "and", "apoptosis", "and", "the", "function", "and", "ultrastructural", "morphology", "of", "mitochondria", "after", "exposure", "to", "toxic", "agents", "and", "alpha", "-", "lipoic", "acid", ".", "Our", "results", "demonstrate", "that", "both", "cisplatin", "and", "paclitaxel", "cause", "early", "mitochondrial", "impairment", "with", "loss", "of", "membrane", "potential", "and", "induction", "of", "autophagic", "vacuoles", "in", "neurons", ".", "Alpha", "-", "lipoic", "acid", "exerts", "neuroprotective", "effects", "against", "chemotherapy", "induced", "neurotoxicity", "in", "sensory", "neurons", ":", "it", "rescues", "the", "mitochondrial", "toxicity", "and", "induces", "the", "expression", "of", "frataxin", ",", "an", "essential", "mitochondrial", "protein", "with", "anti", "-", "oxidant", "and", "chaperone", "properties", ".", "In", "conclusion", "mitochondrial", "toxicity", "is", "an", "early", "common", "event", "both", "in", "paclitaxel", "and", "cisplatin", "induced", "neurotoxicity", ".", "Alpha", "-", "lipoic", "acid", "protects", "sensory", "neurons", "through", "its", "anti", "-", "oxidant", "and", "mitochondrial", "regulatory", "functions", ",", "possibly", "inducing", "the", "expression", "of", "frataxin", ".", "These", "findings", "suggest", "that", "alpha", "-", "lipoic", "acid", "might", "reduce", "the", "risk", "of", "developing", "peripheral", "nerve", "toxicity", "in", "patients", "undergoing", "chemotherapy", "and", "encourage", "further", "confirmatory", "clinical", "trials", "."]], "ner": [[[87, 87, "Chemical"], [143, 143, "Chemical"], [211, 211, "Chemical"], [37, 39, "Disease"], [89, 89, "Chemical"], [141, 141, "Chemical"], [213, 213, "Chemical"], [64, 65, "Disease"], [255, 257, "Disease"], [0, 3, "Chemical"], [18, 21, "Chemical"], [46, 49, "Chemical"], [107, 110, "Chemical"], [131, 134, "Chemical"], [161, 164, "Chemical"], [217, 220, "Chemical"], [245, 248, "Chemical"], [5, 6, "Disease"], [30, 31, "Disease"], [146, 147, "Disease"], [179, 180, "Disease"], [202, 203, "Disease"], [8, 8, "Disease"], [27, 27, "Disease"], [171, 171, "Disease"], [215, 215, "Disease"], [12, 12, "Disease"], [113, 114, "Disease"]]], "relations": [[[87, 87, 37, 39, "CID"], [143, 143, 37, 39, "CID"], [211, 211, 37, 39, "CID"], [89, 89, 37, 39, "CID"], [141, 141, 37, 39, "CID"], [213, 213, 37, 39, "CID"], [87, 87, 64, 65, "CID"], [87, 87, 255, 257, "CID"], [143, 143, 64, 65, "CID"], [143, 143, 255, 257, "CID"], [211, 211, 64, 65, "CID"], [211, 211, 255, 257, "CID"], [89, 89, 64, 65, "CID"], [89, 89, 255, 257, "CID"], [141, 141, 64, 65, "CID"], [141, 141, 255, 257, "CID"], [213, 213, 64, 65, "CID"], [213, 213, 255, 257, "CID"]]], "clusters": [], "translated": " <9>α-硫辛酸</9>可预防实验性化疗<26>神经病变</26>中的<17>线粒体损伤</17>和<22>神经毒性</22>。该研究调查了<10>α-硫辛酸</10>是否对化疗引起的<23>神经毒性</23>具有神经保护作用，<18>线粒体损伤</18>是否在<3>毒性神经退行性级联反应中起关键作用</3>，以及<11>α-硫辛酸</11>的神经保护作用是否取决于线粒体保护。我们使用了化疗诱导的<7>周围神经病变</7>的体外模型，该模型通过将背根神经节 （DRG）感觉神经元的原代培养物暴露于<0>紫杉醇</0>和<4>顺铂</4>，两种应用广泛且疗效显着的化疗药物。这种方法可以研究<12>α-硫辛酸</12>在预防<27>轴突损伤</27>和细胞凋亡方面的功效，以及暴露于有毒物质和<13>α-硫辛酸</13>后线粒体的功能和超微结构形态。我们的结果表明，<5>顺铂</5>和<1>紫杉醇</1>都会引起早期的<19>线粒体损伤</19>，伴随着膜电位的丧失和神经元中自噬泡的诱导。<14>α-硫辛酸</14>对化疗引起的感觉神经元<24>神经毒性</24>发挥神经保护作用：它可以挽救<20>线粒体毒性</20>，并诱导frataxin的表达，这是一种必需的具有抗氧化和伴侣特性的线粒体蛋白。综上所述，<21>线粒体毒性</21>是<2>紫杉醇</2>和<6>顺铂</6>引起的<25>神经毒性</25>的早期常见事件。<15>α-硫辛酸</15>通过其抗氧化和线粒体调节功能保护感觉神经元，可能诱导frataxin的表达。这些发现表明，<16>α-硫辛酸</16>可能会降低接受化疗的患者发生<8>周围神经毒性</8>的风险，并鼓励开展进一步的验证性临床试验。", "revised": true}
{"doc_key": "1664218", "sentences": [["Phase", "II", "study", "of", "the", "amsacrine", "analogue", "CI", "-", "921", "(", "NSC", "343499", ")", "in", "non", "-", "small", "cell", "lung", "cancer", ".", "CI", "-", "921", "(", "NSC", "343499", ";", "9", "-", "[", "[", "2", "-", "methoxy", "-", "4", "-", "[", "(", "methylsulphonyl", ")", "amino", "]", "phenyl", "]", "amino", "]", "-", "N", ",", "5", "-", "dimethyl", "-", "4", "-", "acridinecarboxamide", ")", "is", "a", "topoisomerase", "II", "poison", "with", "high", "experimental", "antitumour", "activity", ".", "It", "was", "administered", "by", "15", "min", "infusion", "to", "16", "evaluable", "patients", "with", "non", "-", "small", "cell", "lung", "cancer", "(", "NSCLC", ")", "(", "7", "with", "no", "prior", "treatment", ",", "9", "patients", "in", "relapse", "following", "surgery", "/", "radiotherapy", ")", "at", "a", "dose", "(", "648", "mg", "/", "m2", "divided", "over", "3", "days", ",", "repeated", "every", "3", "weeks", ")", "determined", "by", "phase", "I", "trial", ".", "Patients", "had", "a", "median", "performance", "status", "of", "1", "(", "WHO", ")", ",", "and", "median", "age", "of", "61", "years", ".", "The", "histology", "comprised", "squamous", "carcinoma", "(", "11", ")", ",", "adenocarcinoma", "(", "1", ")", ",", "mixed", "histology", "(", "2", ")", ",", "bronchio", "-", "alveolar", "carcinoma", "(", "1", ")", "and", "large", "cell", "undifferentiated", "carcinoma", "(", "1", ")", ".", "Neutropenia", "grade", "greater", "than", "or", "equal", "to", "3", "was", "seen", "in", "15", "patients", ",", "infections", "with", "recovery", "in", "3", ",", "and", "grand", "mal", "seizures", "in", "1", "patient", ".", "Grade", "less", "than", "or", "equal", "to", "2", "nausea", "and", "vomiting", "occurred", "in", "66", "%", "courses", "and", "phlebitis", "in", "the", "infusion", "arm", "in", "37", "%", ".", "1", "patient", "with", "squamous", "cell", "carcinoma", "achieved", "a", "partial", "response", "lasting", "5", "months", ".", "Further", "testing", "in", "this", "and", "other", "tumour", "types", "using", "multiple", "daily", "schedules", "is", "warranted", "."]], "ner": [[[7, 9, "Chemical"], [11, 12, "Chemical"], [22, 24, "Chemical"], [26, 27, "Chemical"], [29, 58, "Chemical"], [187, 187, "Disease"], [201, 201, "Disease"], [210, 210, "Disease"], [222, 222, "Disease"], [224, 224, "Disease"], [231, 231, "Disease"], [5, 5, "Chemical"], [15, 20, "Disease"], [83, 88, "Disease"], [90, 90, "Disease"], [154, 155, "Disease"], [243, 245, "Disease"], [160, 160, "Disease"], [171, 174, "Disease"], [181, 182, "Disease"], [260, 260, "Disease"]]], "relations": [[[7, 9, 187, 187, "CID"], [11, 12, 187, 187, "CID"], [22, 24, 187, 187, "CID"], [26, 27, 187, 187, "CID"], [29, 58, 187, 187, "CID"], [7, 9, 201, 201, "CID"], [11, 12, 201, 201, "CID"], [22, 24, 201, 201, "CID"], [26, 27, 201, 201, "CID"], [29, 58, 201, 201, "CID"], [7, 9, 210, 210, "CID"], [11, 12, 210, 210, "CID"], [22, 24, 210, 210, "CID"], [26, 27, 210, 210, "CID"], [29, 58, 210, 210, "CID"], [7, 9, 222, 222, "CID"], [11, 12, 222, 222, "CID"], [22, 24, 222, 222, "CID"], [26, 27, 222, 222, "CID"], [29, 58, 222, 222, "CID"], [7, 9, 224, 224, "CID"], [11, 12, 224, 224, "CID"], [22, 24, 224, 224, "CID"], [26, 27, 224, 224, "CID"], [29, 58, 224, 224, "CID"], [7, 9, 231, 231, "CID"], [11, 12, 231, 231, "CID"], [22, 24, 231, 231, "CID"], [26, 27, 231, 231, "CID"], [29, 58, 231, 231, "CID"]]], "clusters": [], "translated": "<11>安吖啶</11>类似物<0>CI-921</0>（<1>NSC 343499</1>）在<12>非小细胞肺癌</12>中的II期研究。<2>CI-921</2>（<3>NSC 343499</3>；<4>9-[[2-甲氧基-4-[(甲基磺酰基)氨基]苯基]氨基]-N,5-二甲基-4-acridinecarboxamide</4>）是一种拓扑异构酶II毒物，具有较高的实验抗肿瘤活性。它通过15分钟输注给药于16名可评估的<13>非小细胞肺癌</13>（<14>NSCLC</14>）患者（7名未接受过治疗，9名患者在手术/放疗后复发）在I期试验确定的剂量（648毫克/平方米，分3天服用，每3周重复一次）。患者的中位体能状态为1(WHO)，中位年龄为61岁。组织学包括<15>鳞癌</15>（11），<17>腺癌</17>（1），混合组织学(2)，<18>支气管肺泡癌</18>（1）和大细胞<19>未分化癌</19>（1）。<5>中性粒细胞减少</5>≥3级15例，恢复3例的<6>感染</6>，1例的<7>大发作</7>。在输液组中，66%的疗程患者出现小于或等于2级的<8>恶心</8>和<9>呕吐</9>，37%的输液组患者出现<10>静脉炎</10>。1名<16>鳞状细胞癌</16>患者获得了持续5个月的部分缓解。有必要使用多个日常时间表对这种和其他<20>肿瘤</20>类型进行进一步测试。", "revised": true}
{"doc_key": "6666578", "sentences": [["D", "-", "penicillamine", "-", "induced", "angiopathy", "in", "rats", ".", "The", "effect", "of", "high", "dose", "D", "-", "penicillamine", "treatment", "on", "aortic", "permeability", "to", "albumin", "and", "on", "the", "ultrastructure", "of", "the", "vessel", ".", "Male", "Sprague", "-", "Dawley", "rats", "were", "treated", "with", "D", "-", "penicillamine", "(", "D", "-", "pen", ")", "500", "mg", "/", "kg", "/", "day", "for", "10", "or", "42", "days", ".", "Pair", "fed", "rats", "served", "as", "controls", ".", "Changes", "in", "aortic", "morphology", "were", "examined", "by", "light", "-", "and", "transmission", "-", "electron", "microscopy", "(", "TEM", ")", ".", "In", "addition", ",", "the", "endothelial", "permeability", "and", "the", "penetration", "through", "the", "aortic", "wall", "of", "albumin", "were", "studied", "10", "minutes", ",", "24", "and", "48", "hours", "after", "i", ".", "v", ".", "injection", "of", "human", "serum", "131I", "-", "albumin", "(", "131I", "-", "HSA", ")", ".", "TEM", "revealed", "extensive", "elastolysis", "in", "the", "arterial", "wall", "of", "D", "-", "pen", "-", "treated", "rats", ",", "consistent", "with", "an", "inhibitory", "effect", "on", "crosslink", "formation", ".", "In", "experimental", "animals", "excess", "deposition", "of", "collagen", "and", "glycoaminoglycans", "was", "observed", "in", "the", "subendothelial", "and", "medial", "layer", "of", "the", "aortic", "wall", ",", "together", "with", "prominent", "basal", "membrane", "substance", "around", "aortic", "smooth", "muscle", "cells", ".", "The", "aorta", "/", "serum", "-", "ratio", "and", "the", "radioactive", "build", "-", "up", "24", "and", "48", "hours", "after", "injection", "of", "131I", "-", "HSA", "was", "reduced", "in", "animals", "treated", "with", "D", "-", "pen", "for", "42", "days", ",", "indicating", "an", "impeded", "transmural", "transport", "of", "tracer", "which", "may", "be", "caused", "by", "a", "steric", "exclusion", "effect", "of", "abundant", "hyaluronate", ".", "The", "endothelial", "ultrastructure", "was", "unaffected", "by", "D", "-", "pen", ",", "and", "no", "differences", "in", "aortic", "131I", "-", "HSA", "radioactivity", "or", "aorta", "/", "serum", "-", "ratio", "were", "recorded", "between", "experimental", "and", "control", "groups", "10", "minutes", "after", "tracer", "injection", ",", "indicating", "that", "the", "permeability", "of", "the", "endothelial", "barrier", "to", "albumin", "remained", "unaffected", "by", "D", "-", "pen", "treatment", ".", "These", "observations", "support", "the", "hypothesis", "that", "treatment", "with", "high", "doses", "of", "D", "-", "pen", "may", "induce", "a", "fibroproliferative", "response", "in", "rat", "aorta", ",", "possibly", "by", "an", "inhibitory", "effect", "on", "the", "cross", "-", "linking", "of", "collagen", "and", "elastin", "."]], "ner": [[[0, 2, "Chemical"], [14, 16, "Chemical"], [39, 41, "Chemical"], [43, 45, "Chemical"], [135, 137, "Chemical"], [213, 215, "Chemical"], [246, 248, "Chemical"], [291, 293, "Chemical"], [307, 309, "Chemical"], [5, 5, "Disease"], [238, 238, "Chemical"]]], "relations": [[[0, 2, 5, 5, "CID"], [14, 16, 5, 5, "CID"], [39, 41, 5, 5, "CID"], [43, 45, 5, 5, "CID"], [135, 137, 5, 5, "CID"], [213, 215, 5, 5, "CID"], [246, 248, 5, 5, "CID"], [291, 293, 5, 5, "CID"], [307, 309, 5, 5, "CID"]]], "clusters": [], "translated": "<0>D-青霉胺</0>诱导的大鼠<9>血管病</9>。高剂量<1>D-青霉胺</1>治疗对主动脉白蛋白通透性和血管超微结构的影响。雄性Sprague-Dawley大鼠用<2>D-青霉胺</2>（<3>D-pen</3>）500mg/kg/天处理10或42天。配对喂养的大鼠作为对照。通过光学和透射电子显微镜（TEM）检查主动脉形态的变化。此外，在注射人血清131I-白蛋白（131I-HSA）后，研究内皮渗透性和白蛋白通过主动脉壁的渗透。TEM显示在<4>D-pen</4>处理的大鼠动脉壁中广泛的弹性蛋白溶解，与对交联形成的抑制作用一致。在实验动物中，主动脉壁的内皮下层和内侧层中观察到胶原蛋白和糖氨聚糖的过量沉积，以及主动脉平滑肌细胞周围明显的基底膜物质。注射131I-HSA后24和48小时，用<5>D-pen</5>治疗的动物的主动脉/血清比率和放射性积累减少，表明示踪剂的透壁运输受阻可能是由丰富的<10>透明质酸盐</10>的空间排阻作用引起的。 <6>D-pen</6>未影响内皮超微结构，示踪剂注射10分钟后实验组和对照组的主动脉131I-HSA放射性或主动脉/血清比值无差异，表明<7>D-pen</7>处理对白蛋白的内皮屏障没有影响。这些观察结果支持这样的假设，即用高剂量<8>D-pen</8>治疗可能会在大鼠主动脉中诱导纤维增生反应，这可能是通过抑制胶原蛋白和弹性蛋白的交联作用实现的。", "revised": true}
{"doc_key": "11279304", "sentences": [["Brain", "natriuretic", "peptide", "is", "a", "predictor", "of", "anthracycline", "-", "induced", "cardiotoxicity", ".", "Anthracyclines", "are", "effective", "antineoplastic", "drugs", ",", "but", "they", "frequently", "cause", "dose", "-", "related", "cardiotoxicity", ".", "The", "cardiotoxicity", "of", "conventional", "anthracycline", "therapy", "highlights", "a", "need", "to", "search", "for", "methods", "that", "are", "highly", "sensitive", "and", "capable", "of", "predicting", "cardiac", "dysfunction", ".", "We", "measured", "the", "plasma", "level", "of", "brain", "natriuretic", "peptide", "(", "BNP", ")", "to", "determine", "whether", "BNP", "might", "serve", "as", "a", "simple", "diagnostic", "indicator", "of", "anthracycline", "-", "induced", "cardiotoxicity", "in", "patients", "with", "acute", "leukemia", "treated", "with", "a", "daunorubicin", "(", "DNR", ")", "-", "containing", "regimen", ".", "Thirteen", "patients", "with", "acute", "leukemia", "were", "treated", "with", "a", "DNR", "-", "containing", "regimen", ".", "Cardiac", "functions", "were", "evaluated", "with", "radionuclide", "angiography", "before", "chemotherapies", ".", "The", "plasma", "levels", "of", "atrial", "natriuretic", "peptide", "(", "ANP", ")", "and", "BNP", "were", "measured", "at", "the", "time", "of", "radionuclide", "angiography", ".", "Three", "patients", "developed", "congestive", "heart", "failure", "after", "the", "completion", "of", "chemotherapy", ".", "Five", "patients", "were", "diagnosed", "as", "having", "subclinical", "heart", "failure", "after", "the", "completion", "of", "chemotherapy", ".", "The", "plasma", "levels", "of", "BNP", "in", "all", "the", "patients", "with", "clinical", "and", "subclinical", "heart", "failure", "increased", "above", "the", "normal", "limit", "(", "40", "pg", "/", "ml", ")", "before", "the", "detection", "of", "clinical", "or", "subclinical", "heart", "failure", "by", "radionuclide", "angiography", ".", "On", "the", "other", "hand", ",", "BNP", "did", "not", "increase", "in", "the", "patients", "without", "heart", "failure", "given", "DNR", ",", "even", "at", "more", "than", "700", "mg", "/", "m", "(", "2", ")", ".", "The", "plasma", "level", "of", "ANP", "did", "not", "always", "increase", "in", "all", "the", "patients", "with", "clinical", "and", "subclinical", "heart", "failure", ".", "These", "preliminary", "results", "suggest", "that", "BNP", "may", "be", "useful", "as", "an", "early", "and", "sensitive", "indicator", "of", "anthracycline", "-", "induced", "cardiotoxicity", "."]], "ner": [[[87, 87, "Chemical"], [89, 89, "Chemical"], [104, 104, "Chemical"], [222, 222, "Chemical"], [143, 145, "Disease"], [159, 160, "Disease"], [180, 181, "Disease"], [200, 201, "Disease"], [219, 220, "Disease"], [253, 254, "Disease"], [7, 7, "Chemical"], [12, 12, "Chemical"], [31, 31, "Chemical"], [75, 75, "Chemical"], [272, 272, "Chemical"], [10, 10, "Disease"], [25, 25, "Disease"], [28, 28, "Disease"], [78, 78, "Disease"], [275, 275, "Disease"], [48, 49, "Disease"], [82, 83, "Disease"], [98, 99, "Disease"]]], "relations": [[[87, 87, 143, 145, "CID"], [87, 87, 159, 160, "CID"], [87, 87, 180, 181, "CID"], [87, 87, 200, 201, "CID"], [87, 87, 219, 220, "CID"], [87, 87, 253, 254, "CID"], [89, 89, 143, 145, "CID"], [89, 89, 159, 160, "CID"], [89, 89, 180, 181, "CID"], [89, 89, 200, 201, "CID"], [89, 89, 219, 220, "CID"], [89, 89, 253, 254, "CID"], [104, 104, 143, 145, "CID"], [104, 104, 159, 160, "CID"], [104, 104, 180, 181, "CID"], [104, 104, 200, 201, "CID"], [104, 104, 219, 220, "CID"], [104, 104, 253, 254, "CID"], [222, 222, 143, 145, "CID"], [222, 222, 159, 160, "CID"], [222, 222, 180, 181, "CID"], [222, 222, 200, 201, "CID"], [222, 222, 219, 220, "CID"], [222, 222, 253, 254, "CID"]]], "clusters": [], "translated": "脑利钠肽是 <10>蒽环类药物</10>诱导的<15>心脏毒性</15>的预测因子。<11>蒽环类药物</11>是有效的抗肿瘤药物，但它们经常引起剂量相关的<16>心脏毒性</16>。常规<12>蒽环类药物</12>疗法的<17>心脏毒性</17>突出表明需要寻找高度敏感且能够预测<20>心脏功能障碍</20>的方法。我们测量了脑利钠肽(BNP)的血浆水平，以确定 BNP 是否可以作为<13>蒽环类药物</13>诱导的<18>心脏毒性</18>的简单诊断指标，在给<0>柔红霉素</0>(<1>DNR</1>)的方案治疗下治疗<21>急性白血病患者</21>。13名<22>急性白血病</22>患者接受了含<2>DNR</2>的方案治疗。化疗前用放射性核素血管造影评估心脏功能。放射性核素血管造影时测定血浆心房利钠肽(ANP)和BNP水平。3例患者在化疗结束后出现<4>充血性心力衰竭</4>。5例患者在完成化疗后被诊断为亚临床<5>心力衰竭</5>。所有临床和亚临床<6>心力衰竭</6>患者的血浆BNP水平升高超过正常限值（40 pg/ml）之前，在检测到临床或亚临床<7>心力衰竭</7>之前。另一方面，在没有<8>心力衰竭</8>的患者中，给予<3>DNR</3>，即使超过700mg/m(2)，BNP也没有升高。所有临床和亚临床<9>心力衰竭</9>患者的血浆ANP水平并不总是升高。这些初步结果表明，BNP可作为<14>蒽环类药物</14>引起的<19>心脏毒性</19>的早期敏感指标。", "revised": true}
{"doc_key": "2224762", "sentences": [["A", "phase", "I", "study", "of", "4", "'", "-", "0", "-", "tetrahydropyranyladriamycin", ".", "Clinical", "pharmacology", "and", "pharmacokinetics", ".", "A", "Phase", "I", "study", "of", "intravenous", "(", "IV", ")", "bolus", "4", "'", "-", "0", "-", "tetrahydropyranyladriamycin", "(", "Pirarubicin", ")", "was", "done", "in", "55", "patients", "in", "good", "performance", "status", "with", "refractory", "tumors", ".", "Twenty", "-", "six", "had", "minimal", "prior", "therapy", "(", "good", "risk", ")", ",", "23", "had", "extensive", "prior", "therapy", "(", "poor", "risk", ")", ",", "and", "six", "had", "renal", "and", "/", "or", "hepatic", "dysfunction", ".", "A", "total", "of", "167", "courses", "at", "doses", "of", "15", "to", "70", "mg", "/", "m2", "were", "evaluable", ".", "Maximum", "tolerated", "dose", "in", "good", "-", "risk", "patients", "was", "70", "mg", "/", "m2", ",", "and", "in", "poor", "-", "risk", "patients", ",", "60", "mg", "/", "m2", ".", "The", "dose", "-", "limiting", "toxic", "effect", "was", "transient", "noncumulative", "granulocytopenia", ".", "Granulocyte", "nadir", "was", "on", "day", "14", "(", "range", ",", "4", "-", "22", ")", ".", "Less", "frequent", "toxic", "effects", "included", "thrombocytopenia", ",", "anemia", ",", "nausea", ",", "mild", "alopecia", ",", "phlebitis", ",", "and", "mucositis", ".", "Myelosuppression", "was", "more", "in", "patients", "with", "hepatic", "dysfunction", ".", "Pharmacokinetic", "analyses", "in", "21", "patients", "revealed", "Pirarubicin", "plasma", "T", "1", "/", "2", "alpha", "(", "+", "/", "-", "SE", ")", "of", "2", ".", "5", "+", "/", "-", "0", ".", "85", "minutes", ",", "T", "beta", "1", "/", "2", "of", "25", ".", "6", "+", "/", "-", "6", ".", "5", "minutes", ",", "and", "T", "1", "/", "2", "gamma", "of", "23", ".", "6", "+", "/", "-", "7", ".", "6", "hours", ".", "The", "area", "under", "the", "curve", "was", "537", "+", "/", "-", "149", "ng", "/", "ml", "x", "hours", ",", "volume", "of", "distribution", "(", "Vd", ")", "3504", "+", "/", "-", "644", "l", "/", "m2", ",", "and", "total", "clearance", "(", "ClT", ")", "was", "204", "+", "39", ".", "3", "l", "/", "hour", "/", "m2", ".", "Adriamycinol", ",", "doxorubicin", ",", "adriamycinone", ",", "and", "tetrahydropyranyladriamycinol", "were", "the", "metabolites", "detected", "in", "plasma", "and", "the", "amount", "of", "doxorubicin", "was", "less", "than", "or", "equal", "to", "10", "%", "of", "the", "total", "metabolites", ".", "Urinary", "excretion", "of", "Pirarubicin", "in", "the", "first", "24", "hours", "was", "less", "than", "or", "equal", "to", "10", "%", ".", "Activity", "was", "noted", "in", "mesothelioma", ",", "leiomyosarcoma", ",", "and", "basal", "cell", "carcinoma", ".", "The", "recommended", "starting", "dose", "for", "Phase", "II", "trials", "is", "60", "mg", "/", "m2", "IV", "bolus", "every", "3", "weeks", "."]], "ner": [[[295, 295, "Chemical"], [311, 311, "Chemical"], [133, 133, "Disease"], [154, 154, "Disease"], [156, 156, "Disease"], [158, 158, "Disease"], [161, 161, "Disease"], [163, 163, "Disease"], [166, 166, "Disease"], [5, 10, "Chemical"], [27, 32, "Chemical"], [34, 34, "Chemical"], [183, 183, "Chemical"], [300, 300, "Chemical"], [328, 328, "Chemical"], [47, 47, "Disease"], [74, 79, "Disease"], [174, 175, "Disease"], [168, 168, "Disease"], [347, 347, "Disease"], [349, 349, "Disease"], [352, 354, "Disease"], [293, 293, "Chemical"], [297, 297, "Chemical"]]], "relations": [[[295, 295, 133, 133, "CID"], [311, 311, 133, 133, "CID"], [295, 295, 154, 154, "CID"], [311, 311, 154, 154, "CID"], [295, 295, 156, 156, "CID"], [311, 311, 156, 156, "CID"], [295, 295, 158, 158, "CID"], [311, 311, 158, 158, "CID"], [295, 295, 161, 161, "CID"], [311, 311, 161, 161, "CID"], [295, 295, 163, 163, "CID"], [311, 311, 163, 163, "CID"], [295, 295, 166, 166, "CID"], [311, 311, 166, 166, "CID"]]], "clusters": [], "translated": "一个关于<9>4'-0-四氢吡喃阿霉素</9>的I期研究。临床药理学和药代动力学。一项55例身体状态良好，患有难治性<15>肿瘤</15>的病人静脉内（IV）进行bolus<10>4'-0-四氢吡喃基阿霉素</10>（<11>Pirarubicin</11>）的I期研究。26例病人之前接受的治疗很少（风险高），23例病人之前接受了广泛治疗（风险低），6例病人存在<16>肾和/或肝功能障碍</16>。共有167个剂量为15到70mg/m2的疗程进行评估。高风险病人的最大耐受剂量为70mg/m2，低风险病人为60mg/m2。剂量限制性毒性作用是短暂的非累积性<2>粒细胞减少</2>。粒细胞最低点出现在第14天（范围4-22天）。不太常见的毒性反应包括<3>血小板减少</3>、<4>贫血</4>、<5>恶心</5>、轻度<6>脱发</6>、<7>静脉炎</7>和<8>粘膜炎</8>。<18>骨髓抑制</18>多见于<17>肝功能不全</17>的病人。21例病人的药代动力学分析显示，<12>Pirarubicin</12>的血浆T1/2α（+/- SE）为2.5+/-0.85分钟，Tbeta1/2为25.6+/-6.5分钟，T1/2 gamma为23.6+/-7.6小时。曲线下面积为537+/-149ng/ml x小时，分布容积（Vd）为3504+/-644L/m2，总清除率（ClT）为204+39.3升/小时/ m2。在血浆检测到的代谢物包括<22>Adriamycinol</22>、<0>Doxorubicin</0>、<23>Adriamycinone </23>和<13>四氢吡喃基阿霉素 </13>，<1>Doxorubicin</1>的量小于或等于总代谢物的10%。最初24小时的<14>Pirarubicin</14>的尿排泄小于或等于10%。<19>间皮瘤</19>、<20>平滑肌肉瘤</20>和<21>基底细胞癌</21>表现出活性。II期试验的推荐起始剂量为每3周60mg/m2 IV bolus。", "revised": true}
{"doc_key": "7516729", "sentences": [["Interactive", "effects", "of", "variations", "in", "[", "Na", "]", "o", "and", "[", "Ca", "]", "o", "on", "rat", "atrial", "spontaneous", "frequency", ".", "The", "effects", "of", "varying", "the", "extracellular", "concentrations", "of", "Na", "and", "Ca", "(", "[", "Na", "]", "o", "and", "[", "Ca", "]", "o", ")", "on", "both", ",", "the", "spontaneous", "beating", "and", "the", "negative", "chronotropic", "action", "of", "verapamil", ",", "were", "studied", "in", "the", "isolated", "rat", "atria", ".", "Basal", "frequency", "(", "BF", ")", "evaluated", "by", "surface", "electrogram", "was", "223", "+", "/", "-", "4", "beats", "/", "min", ".", "in", "control", "Krebs", "-", "Ringer", "containing", "137", "mM", "Na", "and", "1", ".", "35", "mM", "Ca", "(", "N", ")", ".", "It", "decreased", "by", "16", "+", "/", "-", "3", "%", "by", "lowering", "[", "Na", "]", "o", "to", "78", "mM", "(", "LNa", ")", ",", "23", "+", "/", "-", "2", "%", "by", "lowering", "simultaneously", "[", "Na", "]", "o", "to", "78", "mM", "and", "[", "Ca", "]", "o", "to", "0", ".", "675", "mM", "(", "LNa", "+", "LCa", ")", "and", "31", "+", "/", "-", "5", "%", "by", "lowering", "[", "Na", "]", "o", "to", "78", "mM", "plus", "increasing", "[", "Ca", "]", "o", "to", "3", ".", "6", "mM", "(", "LNa", "+", "HCa", ")", ".", "At", "normal", "[", "Na", "]", "o", ",", "decrease", "(", "0", ".", "675", "mM", ")", "or", "increase", "(", "3", ".", "6", "mM", ")", "of", "[", "Ca", "]", "o", "did", "not", "modify", "BF", ";", "a", "reduction", "of", "ten", "times", "(", "0", ".", "135", "mM", "of", "normal", "[", "Ca", "]", "o", "was", "effective", "to", "reduce", "BF", "by", "40", "+", "/", "-", "13", "%", ".", "All", "negative", "chronotropic", "effects", "were", "BF", "-", "dependent", ".", "Dose", "-", "dependent", "bradycardia", "induced", "by", "verapamil", "was", "potentiated", "by", "LNa", ",", "LCa", ",", "and", "HCa", ".", "Independent", "but", "not", "additive", "effects", "of", "Na", "and", "Ca", "are", "shown", "by", "decreases", "in", "the", "values", "of", "[", "verapamil", "]", "o", "needed", "to", "reduce", "BF", "by", "30", "%", "(", "IC30", ")", "with", "the", "following", "order", "of", "inhibitory", "potency", ":", "LNa", ">", "LCa", ">", "HCa", ">", "N", ",", "resulting", "LNa", "+", "HCa", "similar", "to", "LNa", ".", "The", "[", "verapamil", "]", "o", "that", "arrested", "atrial", "beating", "(", "AC", ")", "was", "also", "potentiated", "with", "the", "order", "LNa", "=", "LNa", "+", "LCa", "=", "LNa", "+", "HCa", "=", "LCa", ">", "HCa", "=", "N", ".", "The", "results", "indicate", "that", "rat", "atrial", "spontaneous", "beating", "is", "more", "dependent", "on", "[", "Na", "]", "o", "than", "on", "[", "Ca", "]", "o", "in", "a", "range", "of", "+", "/", "-", "50", "%", "of", "their", "normal", "concentration", ".", "Also", "the", "enhancement", "of", "verapamil", "effects", "on", "atrial", "beating", "was", "more", "pronounced", "at", "LNa", "than", "at", "LCa", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[54, 54, "Chemical"], [264, 264, "Chemical"], [293, 293, "Chemical"], [332, 332, "Chemical"], [404, 404, "Chemical"], [261, 261, "Disease"], [6, 6, "Chemical"], [28, 28, "Chemical"], [33, 33, "Chemical"], [91, 91, "Chemical"], [114, 114, "Chemical"], [134, 134, "Chemical"], [165, 165, "Chemical"], [191, 191, "Chemical"], [281, 281, "Chemical"], [377, 377, "Chemical"], [11, 11, "Chemical"], [30, 30, "Chemical"], [38, 38, "Chemical"], [97, 97, "Chemical"], [142, 142, "Chemical"], [174, 174, "Chemical"], [212, 212, "Chemical"], [233, 233, "Chemical"], [283, 283, "Chemical"], [383, 383, "Chemical"]]], "relations": [[[54, 54, 261, 261, "CID"], [264, 264, 261, 261, "CID"], [293, 293, 261, 261, "CID"], [332, 332, 261, 261, "CID"], [404, 404, 261, 261, "CID"]]], "clusters": [], "translated": "[<6>Na</6>]o和[<16>Ca</16>]o的变化对大鼠心房自发频率的交互作用。改变细胞外浓度的<7>Na</7>和<17>Ca</17> ([<8>Na</8>]o和[<18>Ca</18>]o)的影响在离体大鼠心房中研究了<0>维拉帕米</0>的自发搏动和负性变时作用。体表电图评估的基础频率(BF)为223±4次/分。在对照中，Krebs-Ringer含有137 mM<9>Na</9>和1.35毫米<19>Ca</19>(N)。通过将[<10>Na</10>]o降低到78 mM (LNa)，它降低了16+/-3%，通过将[<11>Na</11>]o同时降低到78 mM和[<20>Ca</20>]o到0.675 mM (LNa+LCa)降低了23 +/- 2％，通过将[<12>Na</12>]o降低至78 mM并增加[<21>Ca</21>]o至3.6毫米(LNa+HCa)降低了31+/-5％.在正常[<13>Na</13>]o下，[<22>Ca</22>]o减少(0.675 mM)或增加(3.6 mM)不改变BF;减少十倍(正常[<23>Ca</23>]o的0.135 mM可有效将BF降低40+/-13％。所有负性变时效应均依赖于BF。剂量依赖性由<1>维拉帕米</1>引起的<5>心动过缓</5>由LNa、LCa和HCa增强。<14>Na</14>和<24>Ca</24>的独立但非累加效应是[<2>维拉帕米</2>]o降低BF 30％(IC30)所需的值降低，抑制效力顺序如下：LNa>LCa>HCa>N，导致LNa+HCa类似于LNa. [<3>维拉帕米</3>] o抑制心房搏动(AC)的顺序也是LNa=LNa+LCa=LNa+HCa=LCa>HCa=N。结果表明大鼠心房自发在其正常浓度的+/-50％范围内，跳动更依赖于[<15>Na</15>]o而不是[<25>Ca</25>]o。<4>的增强维拉帕米</4>对心房搏动的影响在LNa比在LCa更明显。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "3970039", "sentences": [["Incidence", "of", "neoplasms", "in", "patients", "with", "rheumatoid", "arthritis", "exposed", "to", "different", "treatment", "regimens", ".", "Immunosuppressive", "drugs", "have", "been", "used", "during", "the", "last", "30", "years", "in", "treatment", "of", "patients", "with", "severe", "rheumatoid", "arthritis", ".", "The", "drugs", "commonly", "used", "are", "cyclophosphamide", "and", "chlorambucil", "(", "alkylating", "agents", ")", ",", "azathioprine", "(", "purine", "analogue", ")", ",", "and", "methotrexate", "(", "folic", "acid", "analogue", ")", ".", "There", "is", "evidence", "that", "all", "four", "immunosuppressive", "drugs", "can", "reduce", "synovitis", ",", "but", "disease", "activity", "almost", "always", "recurs", "after", "therapy", "is", "stopped", ".", "Since", "adverse", "reactions", "are", "frequent", ",", "less", "than", "50", "percent", "of", "patients", "are", "able", "to", "continue", "a", "particular", "drug", "for", "more", "than", "one", "year", ".", "Since", "it", "takes", "three", "to", "12", "months", "to", "achieve", "maximal", "effects", ",", "those", "patients", "who", "are", "unable", "to", "continue", "the", "drug", "receive", "little", "benefit", "from", "it", ".", "Patients", "treated", "with", "alkylating", "agents", "have", "an", "increased", "risk", "of", "development", "of", "acute", "nonlymphocytic", "leukemia", ",", "and", "both", "alkylating", "agents", "and", "azathioprine", "are", "associated", "with", "the", "development", "of", "non", "-", "Hodgkin", "'s", "lymphoma", ".", "Cyclophosphamide", "therapy", "increases", "the", "risk", "of", "carcinoma", "of", "the", "bladder", ".", "There", "have", "been", "several", "long", "-", "term", "studies", "of", "patients", "with", "rheumatoid", "arthritis", "treated", "with", "azathioprine", "and", "cyclophosphamide", "and", "the", "incidence", "of", "most", "of", "the", "common", "cancers", "is", "not", "increased", ".", "Data", "on", "the", "possible", "increased", "risk", "of", "malignancy", "in", "rheumatoid", "arthritis", "are", "still", "being", "collected", ",", "and", "until", "further", "information", "is", "available", ",", "the", "use", "of", "immunosuppressive", "drugs", ",", "particularly", "alkylating", "agents", ",", "in", "the", "treatment", "of", "rheumatoid", "arthritis", "should", "be", "reserved", "for", "patients", "with", "severe", "progressive", "disease", "or", "life", "-", "threatening", "complications", "."]], "ner": [[[38, 38, "Chemical"], [169, 169, "Chemical"], [197, 197, "Chemical"], [175, 178, "Disease"], [42, 43, "Chemical"], [138, 139, "Chemical"], [153, 154, "Chemical"], [241, 242, "Chemical"], [147, 149, "Disease"], [163, 167, "Disease"], [46, 46, "Chemical"], [156, 156, "Chemical"], [195, 195, "Chemical"], [2, 2, "Disease"], [206, 206, "Disease"], [218, 218, "Disease"], [40, 40, "Chemical"], [48, 48, "Chemical"], [53, 53, "Chemical"], [55, 56, "Chemical"], [6, 7, "Disease"], [30, 31, "Disease"], [191, 192, "Disease"], [220, 221, "Disease"], [248, 249, "Disease"], [70, 70, "Disease"]]], "relations": [[[38, 38, 175, 178, "CID"], [169, 169, 175, 178, "CID"], [197, 197, 175, 178, "CID"], [42, 43, 147, 149, "CID"], [138, 139, 147, 149, "CID"], [153, 154, 147, 149, "CID"], [241, 242, 147, 149, "CID"], [42, 43, 163, 167, "CID"], [138, 139, 163, 167, "CID"], [153, 154, 163, 167, "CID"], [241, 242, 163, 167, "CID"], [46, 46, 163, 167, "CID"], [156, 156, 163, 167, "CID"], [195, 195, 163, 167, "CID"]]], "clusters": [], "translated": "接受不同治疗方案的<20>类风湿性关节炎</20>患者中<13>肿瘤</13>的发生率。在过去的30年中，免疫抑制药物一直用于治疗重度<21>类风湿性关节炎</21>患者。常用的药物有<0>环磷酰胺</0>和<16>氯氨铂</16>（<4>烷化剂</4>），<10>硫唑嘌呤</10>（<17>嘌呤</17>类似物）和<18>甲氨蝶呤</18>（<19>叶酸</19>类似物）。有证据表明，所有四种免疫抑制药物均可减轻<25>滑膜炎</25>，但疾病活动几乎总是在治疗停止后复发。由于不良反应频繁发生，只有不到50%的患者能够持续服用某种药物超过一年。由于需要3到12个月才能达到最大效果，那些无法继续服药的患者从中获益甚微。接受<5>烷化剂</5>治疗的患者发生<8>急性非淋巴细胞白血病</8>的风险增加，<6>烷化剂</6>和<11>硫唑嘌呤</11>与<9>非霍奇金淋巴瘤</9>的发展有关。使用<1>环磷酰胺</1>治疗增加患者<3>膀胱癌</3>的风险。有几项长期研究对<22>类风湿性关节炎</22>患者接受<12>硫唑嘌呤</12>和<2>环磷酰胺</2>治疗，以及大多数常见<14>癌症</14>的发生率没有增加。关于<23>类风湿性关节炎</23>中<15>恶性肿瘤</15>可能增加的风险的数据仍在收集中，并且在获得进一步信息之前，使用免疫抑制药物，特别是<7>烷化剂</7>，在治疗<24>类风湿性关节炎</24>时，应保留给病情严重进展或有危及生命并发症的患者。", "revised": true}
{"doc_key": "3496378", "sentences": [["Prolonged", "cholestasis", "after", "troleandomycin", "-", "induced", "acute", "hepatitis", ".", "We", "report", "the", "case", "of", "a", "patient", "in", "whom", "troleandomycin", "-", "induced", "hepatitis", "was", "followed", "by", "prolonged", "anicteric", "cholestasis", ".", "Jaundice", "occurred", "after", "administration", "of", "troleandomycin", "for", "7", "days", "and", "was", "associated", "with", "hypereosinophilia", ".", "Jaundice", "disappeared", "within", "3", "months", "but", "was", "followed", "by", "prolonged", "anicteric", "cholestasis", "marked", "by", "pruritus", "and", "high", "levels", "of", "alkaline", "phosphatase", "and", "gammaglutamyltransferase", "activities", ".", "Finally", ",", "pruritus", "disappeared", "within", "19", "months", ",", "and", "liver", "tests", "returned", "to", "normal", "27", "months", "after", "the", "onset", "of", "hepatitis", ".", "This", "observation", "demonstrates", "that", "prolonged", "cholestasis", "can", "follow", "troleandomycin", "-", "induced", "acute", "hepatitis", "."]], "ner": [[[3, 3, "Chemical"], [18, 18, "Chemical"], [34, 34, "Chemical"], [99, 99, "Chemical"], [1, 1, "Disease"], [27, 27, "Disease"], [55, 55, "Disease"], [96, 96, "Disease"], [7, 7, "Disease"], [21, 21, "Disease"], [89, 89, "Disease"], [103, 103, "Disease"], [29, 29, "Disease"], [44, 44, "Disease"], [42, 42, "Disease"], [58, 58, "Disease"], [71, 71, "Disease"]]], "relations": [[[3, 3, 1, 1, "CID"], [3, 3, 27, 27, "CID"], [3, 3, 55, 55, "CID"], [3, 3, 96, 96, "CID"], [18, 18, 1, 1, "CID"], [18, 18, 27, 27, "CID"], [18, 18, 55, 55, "CID"], [18, 18, 96, 96, "CID"], [34, 34, 1, 1, "CID"], [34, 34, 27, 27, "CID"], [34, 34, 55, 55, "CID"], [34, 34, 96, 96, "CID"], [99, 99, 1, 1, "CID"], [99, 99, 27, 27, "CID"], [99, 99, 55, 55, "CID"], [99, 99, 96, 96, "CID"], [3, 3, 7, 7, "CID"], [3, 3, 21, 21, "CID"], [3, 3, 89, 89, "CID"], [3, 3, 103, 103, "CID"], [18, 18, 7, 7, "CID"], [18, 18, 21, 21, "CID"], [18, 18, 89, 89, "CID"], [18, 18, 103, 103, "CID"], [34, 34, 7, 7, "CID"], [34, 34, 21, 21, "CID"], [34, 34, 89, 89, "CID"], [34, 34, 103, 103, "CID"], [99, 99, 7, 7, "CID"], [99, 99, 21, 21, "CID"], [99, 99, 89, 89, "CID"], [99, 99, 103, 103, "CID"], [3, 3, 29, 29, "CID"], [3, 3, 44, 44, "CID"], [18, 18, 29, 29, "CID"], [18, 18, 44, 44, "CID"], [34, 34, 29, 29, "CID"], [34, 34, 44, 44, "CID"], [99, 99, 29, 29, "CID"], [99, 99, 44, 44, "CID"], [3, 3, 42, 42, "CID"], [18, 18, 42, 42, "CID"], [34, 34, 42, 42, "CID"], [99, 99, 42, 42, "CID"], [3, 3, 58, 58, "CID"], [3, 3, 71, 71, "CID"], [18, 18, 58, 58, "CID"], [18, 18, 71, 71, "CID"], [34, 34, 58, 58, "CID"], [34, 34, 71, 71, "CID"], [99, 99, 58, 58, "CID"], [99, 99, 71, 71, "CID"]]], "clusters": [], "translated": "<0>醋竹桃霉素</0>诱发的急性<8>肝炎</8>后，长期<4>胆汁淤积</4>。我们报告了一例患者，<1>醋竹桃霉素</1>引起的<9>肝炎</9>随后出现长期无黄疸性<5>胆汁淤积</5>。 <12>黄疸</12>发生在<2>醋竹桃霉素</2>给药7天后，并伴有<14>嗜酸性粒细胞增多症</14>。<13>黄疸</13>在3个月内消失，但随后出现长期无黄疸<6>胆汁淤积</6>，以<15>瘙痒</15>和高水平碱性磷酸酶和γ-谷氨酰转移酶活性为特征。最终，<16>瘙痒</16>在19个月内消失，肝功能检查在<10>肝炎</10>发作后27个月恢复正常。该观察结果表明，<3>醋竹桃霉素</3>诱发的急性<11>肝炎</11>可导致长期<7>胆汁淤积</7>。", "revised": true}
{"doc_key": "424937", "sentences": [["Patterns", "of", "hepatic", "injury", "induced", "by", "methyldopa", ".", "Twelve", "patients", "with", "liver", "disease", "related", "to", "methyldopa", "were", "seen", "between", "1967", "and", "1977", ".", "Illness", "occurred", "within", "1", "-", "-", "9", "weeks", "of", "commencement", "of", "therapy", "in", "9", "patients", ",", "the", "remaining", "3", "patients", "having", "received", "the", "drug", "for", "13", "months", ",", "15", "months", "and", "7", "years", "before", "experiencing", "symptoms", ".", "Jaundice", "with", "tender", "hepatomegaly", ",", "usually", "preceded", "by", "symptoms", "of", "malaise", ",", "anorexia", ",", "nausea", "and", "vomiting", ",", "and", "associated", "with", "upper", "abdominal", "pain", ",", "was", "an", "invariable", "finding", "in", "all", "patients", ".", "Biochemical", "liver", "function", "tests", "indicated", "hepatocellular", "necrosis", "and", "correlated", "with", "histopathological", "evidence", "of", "hepatic", "injury", ",", "the", "spectrum", "of", "which", "ranged", "from", "fatty", "change", "and", "focal", "hepatocellular", "necrosis", "to", "massive", "hepatic", "necrosis", ".", "Most", "patients", "showed", "moderate", "to", "severe", "acute", "hepatitis", "or", "chronic", "active", "hepatitis", "with", "associated", "cholestasis", ".", "The", "drug", "was", "withdrawn", "on", "presentation", "to", "hospital", "in", "11", "patients", ",", "with", "rapid", "clinical", "improvement", "in", "9", ".", "One", "patient", "died", ",", "having", "presented", "in", "hepatic", "failure", ",", "and", "another", ",", "who", "had", "been", "taking", "methyldopa", "for", "7", "years", ",", "showed", "slower", "clinical", "and", "biochemical", "resolution", "over", "a", "period", "of", "several", "months", ".", "The", "remaining", "patient", "in", "the", "series", "developed", "fulminant", "hepatitis", "when", "the", "drug", "was", "accidentally", "recommenced", "1", "year", "after", "a", "prior", "episode", "of", "methyldopa", "-", "induced", "hepatitis", ".", "In", "this", "latter", "patient", ",", "and", "in", "2", "others", ",", "the", "causal", "relationship", "between", "methyldopa", "and", "hepatic", "dysfunction", "was", "proved", "with", "the", "recurrence", "of", "hepatitis", "within", "2", "weeks", "of", "re", "-", "exposure", "to", "the", "drug", "."]], "ner": [[[6, 6, "Chemical"], [15, 15, "Chemical"], [178, 178, "Chemical"], [218, 218, "Chemical"], [237, 237, "Chemical"], [2, 3, "Disease"], [106, 107, "Disease"], [221, 221, "Disease"], [247, 247, "Disease"], [60, 60, "Disease"], [63, 63, "Disease"], [72, 72, "Disease"], [74, 74, "Disease"], [76, 76, "Disease"], [82, 83, "Disease"], [99, 99, "Disease"], [120, 120, "Disease"], [115, 116, "Disease"], [140, 140, "Disease"], [11, 12, "Disease"], [239, 240, "Disease"], [122, 124, "Disease"], [132, 133, "Disease"], [203, 204, "Disease"], [135, 137, "Disease"], [168, 169, "Disease"]]], "relations": [[[6, 6, 2, 3, "CID"], [6, 6, 106, 107, "CID"], [6, 6, 221, 221, "CID"], [6, 6, 247, 247, "CID"], [15, 15, 2, 3, "CID"], [15, 15, 106, 107, "CID"], [15, 15, 221, 221, "CID"], [15, 15, 247, 247, "CID"], [178, 178, 2, 3, "CID"], [178, 178, 106, 107, "CID"], [178, 178, 221, 221, "CID"], [178, 178, 247, 247, "CID"], [218, 218, 2, 3, "CID"], [218, 218, 106, 107, "CID"], [218, 218, 221, 221, "CID"], [218, 218, 247, 247, "CID"], [237, 237, 2, 3, "CID"], [237, 237, 106, 107, "CID"], [237, 237, 221, 221, "CID"], [237, 237, 247, 247, "CID"], [6, 6, 60, 60, "CID"], [15, 15, 60, 60, "CID"], [178, 178, 60, 60, "CID"], [218, 218, 60, 60, "CID"], [237, 237, 60, 60, "CID"], [6, 6, 63, 63, "CID"], [15, 15, 63, 63, "CID"], [178, 178, 63, 63, "CID"], [218, 218, 63, 63, "CID"], [237, 237, 63, 63, "CID"], [6, 6, 72, 72, "CID"], [15, 15, 72, 72, "CID"], [178, 178, 72, 72, "CID"], [218, 218, 72, 72, "CID"], [237, 237, 72, 72, "CID"], [6, 6, 74, 74, "CID"], [15, 15, 74, 74, "CID"], [178, 178, 74, 74, "CID"], [218, 218, 74, 74, "CID"], [237, 237, 74, 74, "CID"], [6, 6, 76, 76, "CID"], [15, 15, 76, 76, "CID"], [178, 178, 76, 76, "CID"], [218, 218, 76, 76, "CID"], [237, 237, 76, 76, "CID"], [6, 6, 82, 83, "CID"], [15, 15, 82, 83, "CID"], [178, 178, 82, 83, "CID"], [218, 218, 82, 83, "CID"], [237, 237, 82, 83, "CID"], [6, 6, 99, 99, "CID"], [6, 6, 120, 120, "CID"], [15, 15, 99, 99, "CID"], [15, 15, 120, 120, "CID"], [178, 178, 99, 99, "CID"], [178, 178, 120, 120, "CID"], [218, 218, 99, 99, "CID"], [218, 218, 120, 120, "CID"], [237, 237, 99, 99, "CID"], [237, 237, 120, 120, "CID"], [6, 6, 115, 116, "CID"], [15, 15, 115, 116, "CID"], [178, 178, 115, 116, "CID"], [218, 218, 115, 116, "CID"], [237, 237, 115, 116, "CID"], [6, 6, 140, 140, "CID"], [15, 15, 140, 140, "CID"], [178, 178, 140, 140, "CID"], [218, 218, 140, 140, "CID"], [237, 237, 140, 140, "CID"]]], "clusters": [], "translated": "<0>甲基多巴</0>致<5>肝损伤</5>的模式。 1967 年至 1977 年间，有 12 名与<1>甲基多巴</1>相关的<19>肝病</19>患者出现。9 名患者在开始治疗后 1-9 周内发病，其余 3 名患者在出现症状前接受药物治疗 13 个月、15 个月和 7 年。 <9>黄疸</9>伴有触痛<10>肝肿大</10>，通常先有不适症状，<11>厌食</11>，<12>恶心</12>和<13>呕吐</13>，并伴有上<14>腹痛</14>，是所有患者的不变发现。生化肝功能检查显示肝细胞<15>坏死</15>并与<6>肝损伤</6>的组织病理学证据相关，其范围包括<17>脂肪变化</17>和局灶性肝细胞<16>坏死</16>至<21>大量肝坏死</21>。大多数患者表现为中重度<22>急性肝炎</22>或<24>慢性活动性肝炎</24>并伴有<18>胆汁淤积</18>。11 名患者在入院时停药，9 名患者病情迅速改善。一名患者因 <25>肝功能衰竭</25> 死亡，另一名患者已服用<2>甲基多巴</2> 7 年，在几个月的时间里表现出较慢的临床和生化消退。该系列中的另一名患者在<3>甲基多巴</3>诱发的<7>肝炎</7>发作 1 年后意外重新开始服用该药，随后患上了<23>暴发性肝炎</23>。在这名患者和另外 2 名患者中，<4>甲基多巴</4>和<20>肝功能障碍</20>之间的因果关系被证明，并且<8>肝炎</8>在重新接触药物后 2 周内复发。", "revised": true}
{"doc_key": "3865016", "sentences": [["Interaction", "of", "cyclosporin", "A", "with", "antineoplastic", "agents", ".", "A", "synergistic", "effect", "of", "etoposide", "and", "cyclosporin", "A", "was", "observed", "in", "a", "patient", "with", "acute", "T", "-", "lymphocytic", "leukemia", "in", "relapse", ".", "The", "concomitant", "administration", "of", "etoposide", "and", "cyclosporin", "A", "resulted", "in", "eradication", "of", "hitherto", "refractory", "leukemic", "infiltration", "of", "bone", "marrow", ".", "Severe", "side", "effects", "in", "terms", "of", "mental", "confusion", "and", "progressive", "hyperbilirubinemia", ",", "however", ",", "point", "to", "an", "enhancement", "not", "only", "of", "antineoplastic", "effects", "but", "also", "of", "toxicity", "in", "normal", "tissues", ".", "This", "report", "demonstrates", "for", "the", "first", "time", "that", "the", "pharmacodynamic", "properties", "of", "cyclosporin", "A", "may", "not", "be", "confined", "strictly", "to", "suppression", "of", "normal", "T", "-", "cell", "functions", "."]], "ner": [[[2, 3, "Chemical"], [14, 15, "Chemical"], [36, 37, "Chemical"], [93, 94, "Chemical"], [57, 57, "Disease"], [60, 60, "Disease"], [12, 12, "Chemical"], [34, 34, "Chemical"], [22, 26, "Disease"], [44, 45, "Disease"], [76, 76, "Disease"]]], "relations": [[[2, 3, 57, 57, "CID"], [14, 15, 57, 57, "CID"], [36, 37, 57, 57, "CID"], [93, 94, 57, 57, "CID"], [2, 3, 60, 60, "CID"], [14, 15, 60, 60, "CID"], [36, 37, 60, 60, "CID"], [93, 94, 60, 60, "CID"], [12, 12, 57, 57, "CID"], [34, 34, 57, 57, "CID"], [12, 12, 60, 60, "CID"], [34, 34, 60, 60, "CID"]]], "clusters": [], "translated": "<0>环孢菌素 A</0> 与抗肿瘤药物的相互作用。在一例复发的<8>急性T淋巴细胞白血病</8>患者中，观察到<6>依托泊苷</6>和<1>环孢菌素 A</1> 的协同作用。同时给药<7>依托泊苷</7>和<2>环孢素 A</2> 可根除迄今难治的<9>白血病浸润</9>的骨髓。然而，<4>精神混乱</4>和进行性<5>高胆红素血症</5> 这些严重副作用表明，不仅抗肿瘤效果增强，而且 <10>毒性</10> 在正常组织中也增强了。该报告首次证明了<3>环孢菌素 A</3>的药效学特性可能不仅仅局限于抑制正常T细胞功能。", "revised": true}
{"doc_key": "18182964", "sentences": [["Clonidine", "for", "attention", "-", "deficit", "/", "hyperactivity", "disorder", ":", "II", ".", "ECG", "changes", "and", "adverse", "events", "analysis", ".", "OBJECTIVE", ":", "To", "examine", "the", "safety", "and", "tolerability", "of", "clonidine", "used", "alone", "or", "with", "methylphenidate", "in", "children", "with", "attention", "-", "deficit", "/", "hyperactivity", "disorder", "(", "ADHD", ")", ".", "METHOD", ":", "In", "a", "16", "-", "week", "multicenter", ",", "double", "-", "blind", "trial", ",", "122", "children", "with", "ADHD", "were", "randomly", "assigned", "to", "clonidine", "(", "n", "=", "31", ")", ",", "methylphenidate", "(", "n", "=", "29", ")", ",", "clonidine", "and", "methylphenidate", "(", "n", "=", "32", ")", ",", "or", "placebo", "(", "n", "=", "30", ")", ".", "Doses", "were", "flexibly", "titrated", "up", "to", "0", ".", "6", "mg", "/", "day", "for", "clonidine", "and", "60", "mg", "/", "day", "for", "methylphenidate", "(", "both", "with", "divided", "dosing", ")", ".", "Groups", "were", "compared", "regarding", "adverse", "events", "and", "changes", "from", "baseline", "to", "week", "16", "in", "electrocardiograms", "and", "vital", "signs", ".", "RESULTS", ":", "There", "were", "more", "incidents", "of", "bradycardia", "in", "subjects", "treated", "with", "clonidine", "compared", "with", "those", "not", "treated", "with", "clonidine", "(", "17", ".", "5", "%", "versus", "3", ".", "4", "%", ";", "p", "=", ".", "02", ")", ",", "but", "no", "other", "significant", "group", "differences", "regarding", "electrocardiogram", "and", "other", "cardiovascular", "outcomes", ".", "There", "were", "no", "suggestions", "of", "interactions", "between", "clonidine", "and", "methylphenidate", "regarding", "cardiovascular", "outcomes", ".", "Moderate", "or", "severe", "adverse", "events", "were", "more", "common", "in", "subjects", "on", "clonidine", "(", "79", ".", "4", "%", "versus", "49", ".", "2", "%", ";", "p", "=", ".", "0006", ")", "but", "not", "associated", "with", "higher", "rates", "of", "early", "study", "withdrawal", ".", "Drowsiness", "was", "common", "on", "clonidine", ",", "but", "generally", "resolved", "by", "6", "to", "8", "weeks", ".", "CONCLUSIONS", ":", "Clonidine", ",", "used", "alone", "or", "with", "methylphenidate", ",", "appears", "safe", "and", "well", "tolerated", "in", "childhood", "ADHD", ".", "Physicians", "prescribing", "clonidine", "should", "monitor", "for", "bradycardia", "and", "advise", "patients", "about", "the", "high", "likelihood", "of", "initial", "drowsiness", "."]], "ner": [[[0, 0, "Chemical"], [27, 27, "Chemical"], [68, 68, "Chemical"], [82, 82, "Chemical"], [112, 112, "Chemical"], [158, 158, "Chemical"], [165, 165, "Chemical"], [203, 203, "Chemical"], [221, 221, "Chemical"], [253, 253, "Chemical"], [266, 266, "Chemical"], [285, 285, "Chemical"], [153, 153, "Disease"], [289, 289, "Disease"], [2, 7, "Disease"], [36, 41, "Disease"], [43, 43, "Disease"], [63, 63, "Disease"], [281, 281, "Disease"], [249, 249, "Disease"], [299, 299, "Disease"], [32, 32, "Chemical"], [75, 75, "Chemical"], [84, 84, "Chemical"], [119, 119, "Chemical"], [205, 205, "Chemical"], [272, 272, "Chemical"]]], "relations": [[[0, 0, 153, 153, "CID"], [0, 0, 289, 289, "CID"], [27, 27, 153, 153, "CID"], [27, 27, 289, 289, "CID"], [68, 68, 153, 153, "CID"], [68, 68, 289, 289, "CID"], [82, 82, 153, 153, "CID"], [82, 82, 289, 289, "CID"], [112, 112, 153, 153, "CID"], [112, 112, 289, 289, "CID"], [158, 158, 153, 153, "CID"], [158, 158, 289, 289, "CID"], [165, 165, 153, 153, "CID"], [165, 165, 289, 289, "CID"], [203, 203, 153, 153, "CID"], [203, 203, 289, 289, "CID"], [221, 221, 153, 153, "CID"], [221, 221, 289, 289, "CID"], [253, 253, 153, 153, "CID"], [253, 253, 289, 289, "CID"], [266, 266, 153, 153, "CID"], [266, 266, 289, 289, "CID"], [285, 285, 153, 153, "CID"], [285, 285, 289, 289, "CID"]]], "clusters": [], "translated": "<0>可乐定</0> 用于 <14>注意缺陷/多动障碍</14>：II. 心电图变化及不良事件分析。目的：检查 <1>可乐定</1> 单独使用或与 <21>哌醋甲酯</21> 一起用于患有 <15>注意缺陷/多动障碍</15> 的儿童的安全性和耐受性（<16>ADHD</16>）。方法：在一项为期 16 周的多中心、双盲试验中，122 名患有 <17>ADHD</17> 的儿童被随机分配到 <2>可乐定</2>（n = 31），<22>哌醋甲酯</22>（n = 29） 、<3>可乐定</3> 和 <23>哌醋甲酯</23>（n = 32），或安慰剂 (n = 30)。剂量灵活滴定至 0.6 mg/天的<4>可乐定</4> 和 60 mg/天的<24>哌醋甲酯</24> （均分次给药）。比较各组的不良事件以及心电图和生命体征从基线到第 16 周的变化。结果：与未接受<6>可乐定</6>治疗的受试者相比，接受<5>可乐定</5>治疗的受试者<12>心动过缓</12>的发生率更高（17.5% 对 3.4%；p = .02），但在心电图和其他心血管结局方面没有其他显着的组间差异。没有关于<7>可乐定</7> 和<25>哌醋甲酯</25> 在心血管结局方面相互作用的建议。中度或重度不良事件在服用<8>可乐定</8>的受试者中更为常见（79.4% 对 49.2%；p = .0006），但与较高的早期研究退出率无关。<19>嗜睡</19>在服用<9>可乐定</9>时很常见，但通常会在 6 到 8 周后消失。结论：<10>可乐定</10>，单独使用或与<26>哌醋甲酯</26> 一起使用，在儿童 <18>多动症</18>中表现出安全且耐受性良好。开出<11>可乐定</11> 处方的医生应监测<13>心动过缓</13> 并告知患者初始<20>嗜睡</20>的可能性很高。", "revised": true}
{"doc_key": "150790", "sentences": [["A", "pyridoxine", "-", "dependent", "behavioral", "disorder", "unmasked", "by", "isoniazid", ".", "A", "3", "-", "year", "-", "old", "girl", "had", "behavioral", "deterioration", ",", "with", "hyperkinesis", ",", "irritability", ",", "and", "sleeping", "difficulties", "after", "the", "therapeutic", "administration", "of", "isoniazid", ".", "The", "administration", "of", "pharmacologic", "doses", "of", "pyridoxine", "hydrochloride", "led", "to", "a", "disappearance", "of", "symptoms", ".", "After", "discontinuing", "isoniazid", "therapy", "a", "similar", "pattern", "of", "behavior", "was", "noted", "that", "was", "controlled", "by", "pyridoxine", ".", "A", "placebo", "had", "no", "effect", ",", "but", "niacinamide", "was", "as", "effective", "as", "pyridoxine", ".", "Periodic", "withdrawal", "of", "pyridoxine", "was", "associated", "with", "return", "of", "the", "hyperkinesis", ".", "The", "level", "of", "pyridoxal", "in", "the", "blood", "was", "normal", "during", "the", "periods", "of", "relapse", ".", "Metabolic", "studies", "suggested", "a", "block", "in", "the", "kynurenine", "pathway", "of", "tryptophan", "metabolism", ".", "The", "patient", "has", "been", "followed", "for", "six", "years", "and", "has", "required", "pharmacologic", "doses", "of", "pyridoxine", "to", "control", "her", "behavior", "."]], "ner": [[[8, 8, "Chemical"], [34, 34, "Chemical"], [53, 53, "Chemical"], [4, 5, "Disease"], [18, 19, "Disease"], [22, 22, "Disease"], [92, 92, "Disease"], [1, 1, "Chemical"], [42, 43, "Chemical"], [66, 66, "Chemical"], [80, 80, "Chemical"], [85, 85, "Chemical"], [136, 136, "Chemical"], [24, 24, "Disease"], [27, 28, "Disease"], [75, 75, "Chemical"], [97, 97, "Chemical"], [116, 116, "Chemical"], [119, 119, "Chemical"]]], "relations": [[[8, 8, 4, 5, "CID"], [8, 8, 18, 19, "CID"], [34, 34, 4, 5, "CID"], [34, 34, 18, 19, "CID"], [53, 53, 4, 5, "CID"], [53, 53, 18, 19, "CID"], [8, 8, 22, 22, "CID"], [8, 8, 92, 92, "CID"], [34, 34, 22, 22, "CID"], [34, 34, 92, 92, "CID"], [53, 53, 22, 22, "CID"], [53, 53, 92, 92, "CID"]]], "clusters": [], "translated": "<7>吡哆醇</7> 依赖性 <3>行为障碍</3> 被 <0>异烟肼</0> 所掩盖。一名 3 岁女孩在治疗后出现 <4>行为恶化</4>、<5>运动过度</5>、<13>易怒</13> 和 <14>睡眠困难</14>，这是由<1>异烟肼</1>的给药引起的。给予药理学剂量的<8>盐酸吡哆醇</8>导致症状消失。停止<2>异烟肼</2>治疗后，观察到类似的行为模式，该行为由<9>吡哆醇</9> 控制。安慰剂没有效果，但<15>烟酰胺</15> 与 <10>吡哆醇</10>一样有效。定期停用<11>吡哆醇</11> 与<6>运动过度</6> 的恢复有关。复发期间血液中<16>吡哆醛</16>水平正常。代谢研究表明犬尿氨酸<17>通路</17>的堵塞会影响<18>色氨酸</18>代谢。该患者已被随访六年，需要服用药理剂量的<12>吡哆醇</12>来控制她的行为。", "revised": true}
{"doc_key": "3629586", "sentences": [["The", "hematologic", "effects", "of", "cefonicid", "and", "cefazedone", "in", "the", "dog", ":", "a", "potential", "model", "of", "cephalosporin", "hematotoxicity", "in", "man", ".", "Cephalosporin", "antibiotics", "cause", "a", "variety", "of", "hematologic", "disturbances", "in", "man", ",", "the", "pathogeneses", "and", "hematopathology", "of", "which", "remain", "poorly", "characterized", ".", "There", "is", "a", "need", "for", "a", "well", "-", "defined", "animal", "model", "in", "which", "these", "blood", "dyscrasias", "can", "be", "studied", ".", "In", "four", "subacute", "toxicity", "studies", ",", "the", "intravenous", "administration", "of", "cefonicid", "or", "cefazedone", "to", "beagle", "dogs", "caused", "a", "dose", "-", "dependent", "incidence", "of", "anemia", ",", "neutropenia", ",", "and", "thrombocytopenia", "after", "1", "-", "3", "months", "of", "treatment", ".", "A", "nonregenerative", "anemia", "was", "the", "most", "compromising", "of", "the", "cytopenias", "and", "occurred", "in", "approximately", "50", "%", "of", "dogs", "receiving", "400", "-", "500", "mg", "/", "kg", "cefonicid", "or", "540", "-", "840", "mg", "/", "kg", "cefazedone", ".", "All", "three", "cytopenias", "were", "completely", "reversible", "following", "cessation", "of", "treatment", ";", "the", "time", "required", "for", "recovery", "of", "the", "erythron", "(", "approximately", "1", "month", ")", "was", "considerably", "longer", "than", "that", "of", "the", "granulocytes", "and", "platelets", "(", "hours", "to", "a", "few", "days", ")", ".", "Upon", "rechallenge", "with", "either", "cephalosporin", ",", "the", "hematologic", "syndrome", "was", "reproduced", "in", "most", "dogs", "tested", ";", "cefonicid", "(", "but", "not", "cefazedone", ")", "-", "treated", "dogs", "showed", "a", "substantially", "reduced", "induction", "period", "(", "15", "+", "/", "-", "5", "days", ")", "compared", "to", "that", "of", "the", "first", "exposure", "to", "the", "drug", "(", "61", "+", "/", "-", "24", "days", ")", ".", "This", "observation", ",", "along", "with", "the", "rapid", "rate", "of", "decline", "in", "red", "cell", "mass", "parameters", "of", "affected", "dogs", ",", "suggests", "that", "a", "hemolytic", "component", "complicated", "the", "red", "cell", "production", "problem", "and", "that", "multiple", "toxicologic", "mechanisms", "contributed", "to", "the", "cytopenia", ".", "We", "conclude", "that", "the", "administration", "of", "high", "doses", "of", "cefonicid", "or", "cefazedone", "to", "dogs", "can", "induce", "hematotoxicity", "similar", "to", "the", "cephalosporin", "-", "induced", "blood", "dyscrasias", "described", "in", "man", "and", "thus", "provides", "a", "useful", "model", "for", "studying", "the", "mechanisms", "of", "these", "disorders", "."]], "ner": [[[4, 4, "Chemical"], [71, 71, "Chemical"], [123, 123, "Chemical"], [191, 191, "Chemical"], [282, 282, "Chemical"], [84, 84, "Disease"], [100, 100, "Disease"], [86, 86, "Disease"], [89, 89, "Disease"], [6, 6, "Chemical"], [73, 73, "Chemical"], [131, 131, "Chemical"], [195, 195, "Chemical"], [284, 284, "Chemical"], [16, 16, "Disease"], [26, 27, "Disease"], [55, 56, "Disease"], [107, 107, "Disease"], [135, 135, "Disease"], [182, 183, "Disease"], [271, 271, "Disease"], [289, 289, "Disease"], [296, 297, "Disease"], [64, 64, "Disease"], [255, 255, "Disease"], [15, 15, "Chemical"], [20, 20, "Chemical"], [179, 179, "Chemical"], [293, 293, "Chemical"]]], "relations": [[[4, 4, 84, 84, "CID"], [4, 4, 100, 100, "CID"], [71, 71, 84, 84, "CID"], [71, 71, 100, 100, "CID"], [123, 123, 84, 84, "CID"], [123, 123, 100, 100, "CID"], [191, 191, 84, 84, "CID"], [191, 191, 100, 100, "CID"], [282, 282, 84, 84, "CID"], [282, 282, 100, 100, "CID"], [4, 4, 86, 86, "CID"], [71, 71, 86, 86, "CID"], [123, 123, 86, 86, "CID"], [191, 191, 86, 86, "CID"], [282, 282, 86, 86, "CID"], [4, 4, 89, 89, "CID"], [71, 71, 89, 89, "CID"], [123, 123, 89, 89, "CID"], [191, 191, 89, 89, "CID"], [282, 282, 89, 89, "CID"], [6, 6, 84, 84, "CID"], [6, 6, 100, 100, "CID"], [73, 73, 84, 84, "CID"], [73, 73, 100, 100, "CID"], [131, 131, 84, 84, "CID"], [131, 131, 100, 100, "CID"], [195, 195, 84, 84, "CID"], [195, 195, 100, 100, "CID"], [284, 284, 84, 84, "CID"], [284, 284, 100, 100, "CID"], [6, 6, 86, 86, "CID"], [73, 73, 86, 86, "CID"], [131, 131, 86, 86, "CID"], [195, 195, 86, 86, "CID"], [284, 284, 86, 86, "CID"], [6, 6, 89, 89, "CID"], [73, 73, 89, 89, "CID"], [131, 131, 89, 89, "CID"], [195, 195, 89, 89, "CID"], [284, 284, 89, 89, "CID"]]], "clusters": [], "translated": "<0>头孢尼西</0>和<9>头孢西酮</9>对狗的血液学影响：<25>头孢菌素</25><14>血液毒性</14>对人的潜在模型。<26>头孢菌素</26>抗生素在人类中引起多种<15>血液学紊乱</15>，其发病机制和血液病理学特征仍然很差。需要一个定义明确的动物模型来研究这些<16>血液恶液质</16>。在四项亚急性<23>毒性</23>研究中，对比格犬静脉注射<1>头孢尼西</1>或<10>头孢西酮</10>导致<5>贫血</5>、<7>粒细胞减少</7>、<8>血小板减少</8>的剂量依赖性发生率治疗1-3个月后。非再生性<6>贫血</6>是 <17>血细胞减少症</17>中最严重的，并且在接受400-500 mg/kg<2>头孢尼西</2>或540-840 mg/kg<11>头孢西酮</11>的狗中发生。所有三种<18>血细胞减少</18>在停止治疗后都是完全可逆的；红细胞恢复所需的时间（大约1个月）比粒细胞和血小板的恢复时间（几小时到几天）长得多。再次使用<27>头孢菌素</27>后，大多数受试犬再次出现<19>血液学综合征</19>；<3>头孢尼西</3>（但不是<12>头孢西酮</12>）-与第一次接触该药物（61+/-24天）相比，受到的诱导期显著缩短（15+/-5天）。这一观察，连同受影响犬的红细胞质量参数的快速下降，表明<24>溶血性</24>成分使红细胞生成问题复杂化，并且多种毒理学机制导致<20>血细胞减少</20>。我们得出结论，给狗服用高剂量的<4>头孢尼西</4>或<13>头孢西酮</13>会引起<21>血液毒性</21>，类似于<28>头孢菌素</28>-诱导的<22>血液恶液质</22>在人类中被描述，因此为研究这些疾病的机制提供了一个有用的模型。", "revised": true}
{"doc_key": "2894766", "sentences": [["Sulfasalazine", "-", "induced", "lupus", "erythematosus", ".", "Pneumonitis", ",", "bilateral", "pleural", "effusions", ",", "echocardiographic", "evidence", "of", "cardiac", "tamponade", ",", "and", "positive", "autoantibodies", "developed", "in", "a", "43", "-", "year", "-", "old", "man", ",", "who", "was", "receiving", "long", "-", "term", "sulfasalazine", "therapy", "for", "chronic", "ulcerative", "colitis", ".", "After", "cessation", "of", "the", "sulfasalazine", "and", "completion", "of", "a", "six", "-", "week", "course", "of", "corticosteroids", ",", "these", "problems", "resolved", "over", "a", "period", "of", "four", "to", "six", "months", ".", "It", "is", "suggested", "that", "the", "patient", "had", "sulfasalazine", "-", "induced", "lupus", ",", "which", "manifested", "with", "serositis", "and", "pulmonary", "parenchymal", "involvement", "in", "the", "absence", "of", "joint", "symptoms", ".", "Physicians", "who", "use", "sulfasalazine", "to", "treat", "patients", "with", "inflammatory", "bowel", "disease", "should", "be", "aware", "of", "the", "signs", "of", "sulfasalazine", "-", "induced", "lupus", "syndrome", "."]], "ner": [[[0, 0, "Chemical"], [37, 37, "Chemical"], [48, 48, "Chemical"], [79, 79, "Chemical"], [102, 102, "Chemical"], [117, 117, "Chemical"], [3, 4, "Disease"], [82, 82, "Disease"], [120, 121, "Disease"], [6, 6, "Disease"], [9, 10, "Disease"], [15, 16, "Disease"], [41, 42, "Disease"], [87, 87, "Disease"], [107, 109, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 82, 82, "CID"], [0, 0, 120, 121, "CID"], [37, 37, 3, 4, "CID"], [37, 37, 82, 82, "CID"], [37, 37, 120, 121, "CID"], [48, 48, 3, 4, "CID"], [48, 48, 82, 82, "CID"], [48, 48, 120, 121, "CID"], [79, 79, 3, 4, "CID"], [79, 79, 82, 82, "CID"], [79, 79, 120, 121, "CID"], [102, 102, 3, 4, "CID"], [102, 102, 82, 82, "CID"], [102, 102, 120, 121, "CID"], [117, 117, 3, 4, "CID"], [117, 117, 82, 82, "CID"], [117, 117, 120, 121, "CID"], [0, 0, 6, 6, "CID"], [37, 37, 6, 6, "CID"], [48, 48, 6, 6, "CID"], [79, 79, 6, 6, "CID"], [102, 102, 6, 6, "CID"], [117, 117, 6, 6, "CID"], [0, 0, 9, 10, "CID"], [37, 37, 9, 10, "CID"], [48, 48, 9, 10, "CID"], [79, 79, 9, 10, "CID"], [102, 102, 9, 10, "CID"], [117, 117, 9, 10, "CID"], [0, 0, 15, 16, "CID"], [37, 37, 15, 16, "CID"], [48, 48, 15, 16, "CID"], [79, 79, 15, 16, "CID"], [102, 102, 15, 16, "CID"], [117, 117, 15, 16, "CID"]]], "clusters": [], "translated": " <0>柳氮磺胺吡啶</0> - 诱发<6>红斑狼疮</6>。 <9>肺炎</9>，双侧<10>胸腔积液</10>，<11>心脏压塞</11> 的超声心动图证据，以及一名43岁男性出现的阳性自身抗体，他正在接受长期治疗- 长期<1>柳氮磺胺吡啶</1>治疗慢性<12>溃疡性结肠炎</12>。在停止使用<2>柳氮磺胺吡啶</2>并完成为期六周的皮质类固醇疗程后，这些问题在四到六个月内得到解决。提示患者为<3>柳氮磺胺吡啶</3>诱发的<7>狼疮</7>，表现为<13>浆膜炎</13>和肺实质受累，无关节症状。使用<4>柳氮磺胺吡啶</4>治疗<14>炎症性肠病</14>患者的医生应注意<5>柳氮磺胺吡啶</5>诱发的<8>狼疮综合征</8>的体征。", "revised": true}
{"doc_key": "88336", "sentences": [["Alpha", "and", "beta", "coma", "in", "drug", "intoxication", "uncomplicated", "by", "cerebral", "hypoxia", ".", "Four", "patients", "who", "were", "rendered", "comatose", "or", "stuporous", "by", "drug", "intoxication", ",", "but", "who", "were", "not", "hypoxic", ",", "are", "described", ".", "Three", "patients", "received", "high", "doses", "of", "chlormethiazole", "for", "alcohol", "withdrawal", "symptoms", ",", "and", "one", "took", "a", "suicidal", "overdose", "of", "nitrazepam", ".", "The", "patient", "with", "nitrazepam", "overdose", "and", "two", "of", "those", "with", "chlormethiazole", "intoxication", "conformed", "to", "the", "criteria", "of", "'", "alpha", "coma", "'", ",", "showing", "non", "-", "reactive", "generalized", "or", "frontally", "predominant", "alpha", "activity", "in", "the", "EEG", ".", "The", "fourth", "patient", "who", "was", "unconscious", "after", "chlormethiazole", "administration", "exhibite", "generalized", "non", "-", "reactive", "activity", "in", "the", "slow", "beta", "range", ".", "All", "four", "recovered", "completely", "without", "neurological", "sequelae", "following", "the", "withdrawal", "of", "the", "offending", "agents", ".", "The", "similarities", "between", "the", "effects", "of", "structural", "lesions", "and", "pharmacological", "depression", "of", "the", "brain", "stem", "reticular", "formation", "are", "discussed", ".", "It", "is", "suggested", "that", "in", "both", "situations", "disturbed", "reticulo", "-", "thalamic", "interactions", "are", "important", "in", "the", "pathogenesis", "of", "alpha", "coma", ".", "It", "is", "concluded", "that", "when", "this", "electroencephalographic", "and", "behavioural", "picture", "is", "seen", "in", "drug", "intoxication", ",", "in", "the", "absence", "of", "significant", "hypoxaemia", ",", "a", "favourable", "outcome", "may", "be", "anticipated", "."]], "ner": [[[39, 39, "Chemical"], [64, 64, "Chemical"], [97, 97, "Chemical"], [3, 3, "Disease"], [17, 17, "Disease"], [73, 73, "Disease"], [165, 165, "Disease"], [52, 52, "Chemical"], [57, 57, "Chemical"], [19, 19, "Disease"], [50, 50, "Disease"], [58, 58, "Disease"], [41, 41, "Chemical"], [9, 10, "Disease"], [42, 43, "Disease"], [116, 117, "Disease"], [136, 136, "Disease"], [188, 188, "Disease"]]], "relations": [[[39, 39, 3, 3, "CID"], [39, 39, 17, 17, "CID"], [39, 39, 73, 73, "CID"], [39, 39, 165, 165, "CID"], [64, 64, 3, 3, "CID"], [64, 64, 17, 17, "CID"], [64, 64, 73, 73, "CID"], [64, 64, 165, 165, "CID"], [97, 97, 3, 3, "CID"], [97, 97, 17, 17, "CID"], [97, 97, 73, 73, "CID"], [97, 97, 165, 165, "CID"], [52, 52, 3, 3, "CID"], [52, 52, 17, 17, "CID"], [52, 52, 73, 73, "CID"], [52, 52, 165, 165, "CID"], [57, 57, 3, 3, "CID"], [57, 57, 17, 17, "CID"], [57, 57, 73, 73, "CID"], [57, 57, 165, 165, "CID"], [39, 39, 19, 19, "CID"], [64, 64, 19, 19, "CID"], [97, 97, 19, 19, "CID"], [52, 52, 50, 50, "CID"], [52, 52, 58, 58, "CID"], [57, 57, 50, 50, "CID"], [57, 57, 58, 58, "CID"]]], "clusters": [], "translated": "药物中毒时的 Alpha 和 Beta <3>昏迷</3>未并发<13>脑缺氧</13>。描述了四名因药物中毒而<4>昏迷</4>或<9>昏迷</9>但并未缺氧的患者。三名患者因<12>酒精</12><14>戒断症状</14>接受了高剂量的<0>氯甲噻唑</0>，一名服用 <10>自杀性</10><7>过量药物的硝西泮</7>。<8>硝西泮</8><11>过量</11>的患者和其中两名<1>氯甲噻唑</1>中毒患者符合“阿尔法<5>昏迷</5>”标准，在 EEG 中显示非反应性全身性或额叶主导的 alpha 活动。第4名患者在服用<2>氯美噻唑</2>后失去知觉，在慢β范围内表现出广泛的非反应活性。在停用致病药物后，所有四人都完全康复，没有<15>神经系统后遗症</15>。讨论了结构性损伤和脑干网状结构的药理学<16>抑制</16>效应之间的相似性。这表明，在这两种情况下，受干扰的网状-丘脑相互作用在 alpha<6>昏迷</6>的发病机制中很重要。得出的结论是，如果在药物中毒时出现这种脑电图和行为图，且没有明显的<17>低氧血症</17>，则可以预期会有良好的结果。", "revised": true}
{"doc_key": "10579464", "sentences": [["A", "selective", "dopamine", "D4", "receptor", "antagonist", ",", "NRA0160", ":", "a", "preclinical", "neuropharmacological", "profile", ".", "NRA0160", ",", "5", "-", "[", "2", "-", "(", "4", "-", "(", "3", "-", "fluorobenzylidene", ")", "piperidin", "-", "1", "-", "yl", ")", "ethyl", "]", "-", "4", "-", "(", "4", "-", "fluorophenyl", ")", "thiazole", "-", "2", "-", "carboxamide", ",", "has", "a", "high", "affinity", "for", "human", "cloned", "dopamine", "D4", ".", "2", ",", "D4", ".", "4", "and", "D4", ".", "7", "receptors", ",", "with", "Ki", "values", "of", "0", ".", "5", ",", "0", ".", "9", "and", "2", ".", "7", "nM", ",", "respectively", ".", "NRA0160", "is", "over", "20", ",", "000fold", "more", "potent", "at", "the", "dopamine", "D4", ".", "2", "receptor", "compared", "with", "the", "human", "cloned", "dopamine", "D2L", "receptor", ".", "NRA0160", "has", "negligible", "affinity", "for", "the", "human", "cloned", "dopamine", "D3", "receptor", "(", "Ki", "=", "39", "nM", ")", ",", "rat", "serotonin", "(", "5", "-", "HT", ")", "2A", "receptors", "(", "Ki", "=", "180", "nM", ")", "and", "rat", "alpha1", "adrenoceptor", "(", "Ki", "=", "237", "nM", ")", ".", "NRA0160", "and", "clozapine", "antagonized", "locomotor", "hyperactivity", "induced", "by", "methamphetamine", "(", "MAP", ")", "in", "mice", ".", "NRA0160", "and", "clozapine", "antagonized", "MAP", "-", "induced", "stereotyped", "behavior", "in", "mice", ",", "although", "their", "effects", "did", "not", "exceed", "50", "%", "inhibition", ",", "even", "at", "the", "highest", "dose", "given", ".", "NRA0160", "and", "clozapine", "significantly", "induced", "catalepsy", "in", "rats", ",", "although", "their", "effects", "did", "not", "exceed", "50", "%", "induction", "even", "at", "the", "highest", "dose", "given", ".", "NRA0160", "and", "clozapine", "significantly", "reversed", "the", "disruption", "of", "prepulse", "inhibition", "(", "PPI", ")", "in", "rats", "produced", "by", "apomorphine", ".", "NRA0160", "and", "clozapine", "significantly", "shortened", "the", "phencyclidine", "(", "PCP", ")", "-", "induced", "prolonged", "swimming", "latency", "in", "rats", "in", "a", "water", "maze", "task", ".", "These", "findings", "suggest", "that", "NRA0160", "may", "have", "unique", "antipsychotic", "activities", "without", "the", "liability", "of", "motor", "side", "effects", "typical", "of", "classical", "antipsychotics", "."]], "ner": [[[7, 7, "Chemical"], [14, 14, "Chemical"], [16, 49, "Chemical"], [91, 91, "Chemical"], [115, 115, "Chemical"], [159, 159, "Chemical"], [174, 174, "Chemical"], [203, 203, "Chemical"], [228, 228, "Chemical"], [247, 247, "Chemical"], [274, 274, "Chemical"], [208, 208, "Disease"], [161, 161, "Chemical"], [176, 176, "Chemical"], [205, 205, "Chemical"], [230, 230, "Chemical"], [249, 249, "Chemical"], [167, 167, "Chemical"], [169, 169, "Chemical"], [178, 178, "Chemical"], [164, 164, "Disease"], [2, 2, "Chemical"], [58, 58, "Chemical"], [101, 101, "Chemical"], [111, 111, "Chemical"], [123, 123, "Chemical"], [134, 134, "Chemical"], [136, 138, "Chemical"], [245, 245, "Chemical"], [253, 253, "Chemical"], [255, 255, "Chemical"]]], "relations": [[[7, 7, 208, 208, "CID"], [14, 14, 208, 208, "CID"], [16, 49, 208, 208, "CID"], [91, 91, 208, 208, "CID"], [115, 115, 208, 208, "CID"], [159, 159, 208, 208, "CID"], [174, 174, 208, 208, "CID"], [203, 203, 208, 208, "CID"], [228, 228, 208, 208, "CID"], [247, 247, 208, 208, "CID"], [274, 274, 208, 208, "CID"], [161, 161, 208, 208, "CID"], [176, 176, 208, 208, "CID"], [205, 205, 208, 208, "CID"], [230, 230, 208, 208, "CID"], [249, 249, 208, 208, "CID"], [167, 167, 164, 164, "CID"], [169, 169, 164, 164, "CID"], [178, 178, 164, 164, "CID"]]], "clusters": [], "translated": "选择性<21>多巴胺</21>D4受体拮抗剂，<0>NRA0160</0>：临床前神经药理学概况。<1>NRA0160</1>，<2>5-[2-(4-(3-氟亚苄基)哌啶-1-基)乙基]-4-(4-氟苯基)噻唑-2-甲酰胺</2>，对人类克隆的<22>多巴胺</22>D4具有高亲和力。2、D4.4和D4.7个受体，Ki值分别为0.5，0.9和2.7 nM。<3>NRA0160</3>对<23>多巴胺</23>D4的效力超过20,000倍，与人类克隆的<24>多巴胺</24>D2L受体相比。 <4>NRA0160</4>对人类克隆的<25>多巴胺</25>D3受体（Ki = 39 nM）、大鼠<26>血清素</26>(<27>5-HT</27>) 2A受体（Ki = 180 nM）和大鼠alpha1肾上腺素能受体（Ki = 237 nM)的亲和力极低。<5>NRA0160</5>和<12>氯氮平</12>拮抗<17>甲基苯丙胺</17>(<18>MAP</18>)引起的小鼠运动<20>多动</20>。<6>NRA0160</6>和<13>氯氮平</13>拮抗<19>MAP</19>诱导的小鼠刻板行为，尽管在最高剂量下也未超过50%。 <7>NRA0160</7>和<14>氯氮平</14>显着诱导大鼠<11>强直性昏厥</11>，尽管在最高剂量下也未超过50%。<8>NRA0160</8>和<15>氯氮平</15>显着逆转了由<28>阿朴吗啡</28>产生的大鼠体内前脉冲抑制(PPI)的破坏。<9>NRA0160</9>和<16>氯氮平</16>显着缩短了大鼠在水迷宫任务中<29>苯环利定</29>(<30>PCP</30>)诱导的游泳潜伏期的延长。这些发现表明，<10>NRA0160</10>可能具有独特的抗精神病活性，而不会产生经典抗精神病药物典型的运动副作用。", "revised": true}
{"doc_key": "3750012", "sentences": [["Myasthenia", "gravis", "caused", "by", "penicillamine", "and", "chloroquine", "therapy", "for", "rheumatoid", "arthritis", ".", "We", "have", "described", "a", "unique", "patient", "who", "had", "reversible", "and", "dose", "-", "related", "myasthenia", "gravis", "after", "penicillamine", "and", "chloroquine", "therapy", "for", "rheumatoid", "arthritis", ".", "Although", "acetylcholine", "receptor", "antibodies", "were", "not", "detectable", ",", "the", "time", "course", "was", "consistent", "with", "an", "autoimmune", "process", "."]], "ner": [[[4, 4, "Chemical"], [28, 28, "Chemical"], [0, 1, "Disease"], [25, 26, "Disease"], [6, 6, "Chemical"], [30, 30, "Chemical"], [37, 37, "Chemical"], [9, 10, "Disease"], [33, 34, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 25, 26, "CID"], [28, 28, 0, 1, "CID"], [28, 28, 25, 26, "CID"], [6, 6, 0, 1, "CID"], [6, 6, 25, 26, "CID"], [30, 30, 0, 1, "CID"], [30, 30, 25, 26, "CID"]]], "clusters": [], "translated": "<0>青霉胺</0>和<4>氯喹</4>治疗<7>类风湿性关节炎</7>引起的<2>重症肌无力</2>。我们描述了一位独特的患者，他在<1>青霉胺</1>和<5>氯喹</5>治疗<8>类风湿性关节炎</8>后出现了可逆的剂量相关性<3>重症肌无力</3>。虽然未检测到<6>乙酰胆碱</6>受体抗体，但时间过程与自身免疫过程一致。", "revised": true}
{"doc_key": "8643971", "sentences": [["A", "phase", "I", "/", "II", "study", "of", "paclitaxel", "plus", "cisplatin", "as", "first", "-", "line", "therapy", "for", "head", "and", "neck", "cancers", ":", "preliminary", "results", ".", "Improved", "outcomes", "among", "patients", "with", "head", "and", "neck", "carcinomas", "require", "investigations", "of", "new", "drugs", "for", "induction", "therapy", ".", "Preliminary", "results", "of", "an", "Eastern", "Cooperative", "Oncology", "Group", "study", "of", "single", "-", "agent", "paclitaxel", "(", "Taxol", ";", "Bristol", "-", "Myers", "Squibb", "Company", ",", "Princeton", ",", "NJ", ")", "reported", "a", "37", "%", "response", "rate", "in", "patients", "with", "head", "and", "neck", "cancer", ",", "and", "the", "paclitaxel", "/", "cisplatin", "combination", "has", "been", "used", "successfully", "and", "has", "significantly", "improved", "median", "response", "duration", "in", "ovarian", "cancer", "patients", ".", "We", "initiated", "a", "phase", "I", "/", "II", "trial", "to", "determine", "the", "response", "and", "toxicity", "of", "escalating", "paclitaxel", "doses", "combined", "with", "fixed", "-", "dose", "cisplatin", "with", "granulocyte", "colony", "-", "stimulating", "factor", "support", "in", "patients", "with", "untreated", "locally", "advanced", "inoperable", "head", "and", "neck", "carcinoma", ".", "To", "date", ",", "23", "men", "with", "a", "median", "age", "of", "50", "years", "and", "good", "performance", "status", "have", "entered", "the", "trial", ".", "Primary", "tumor", "sites", "were", "oropharynx", ",", "10", "patients", ";", "hypopharynx", ",", "four", ";", "larynx", ",", "two", ";", "oral", "cavity", ",", "three", ";", "unknown", "primary", ",", "two", ";", "and", "nasal", "cavity", "and", "parotid", "gland", ",", "one", "each", ".", "Of", "20", "patients", "evaluable", "for", "toxicity", ",", "four", "had", "stage", "III", "and", "16", "had", "stage", "IV", "disease", ".", "Treatment", ",", "given", "every", "21", "days", "for", "a", "maximum", "of", "three", "cycles", ",", "consisted", "of", "paclitaxel", "by", "3", "-", "hour", "infusion", "followed", "the", "next", "day", "by", "a", "fixed", "dose", "of", "cisplatin", "(", "75", "mg", "/", "m2", ")", ".", "The", "dose", "levels", "incorporate", "escalating", "paclitaxel", "doses", ",", "and", "intrapatient", "escalations", "within", "a", "given", "dose", "level", "are", "permitted", "if", "toxicity", "permits", ".", "At", "the", "time", "of", "this", "writing", ",", "dose", "level", "4", "(", "260", ",", "270", ",", "and", "280", "mg", "/", "m2", ")", "is", "being", "evaluated", ";", "three", "patients", "from", "this", "level", "are", "evaluable", ".", "With", "paclitaxel", "doses", "of", "200", "mg", "/", "m2", "and", "higher", ",", "granulocyte", "colony", "-", "stimulating", "factor", "5", "micrograms", "/", "kg", "/", "d", "is", "given", "(", "days", "4", "through", "12", ")", ".", "Of", "18", "patients", "evaluable", "for", "response", ",", "seven", "(", "39", "%", ")", "achieved", "a", "complete", "response", "and", "six", "(", "33", "%", ")", "achieved", "a", "partial", "response", ".", "Three", "patients", "had", "no", "change", "and", "disease", "progressed", "in", "two", ".", "The", "overall", "response", "rate", "is", "72", "%", ".", "Eleven", "responding", "patients", "had", "subsequent", "surgery", "/", "radiotherapy", "or", "radical", "radiotherapy", ".", "Two", "pathologic", "complete", "responses", "were", "observed", "in", "patients", "who", "had", "achieved", "clinical", "complete", "responses", ".", "Alopecia", ",", "paresthesias", ",", "and", "arthralgias", "/", "myalgias", "have", "occurred", "frequently", ",", "but", "with", "one", "exception", "(", "a", "grade", "3", "myalgia", ")", "they", "have", "been", "grade", "1", "or", "2", ".", "No", "dose", "-", "limiting", "hematologic", "toxicity", "has", "been", "seen", ".", "Paclitaxel", "/", "cisplatin", "is", "an", "effective", "first", "-", "line", "regimen", "for", "locoregionally", "advanced", "head", "and", "neck", "cancer", "and", "continued", "study", "is", "warranted", ".", "Results", "thus", "far", "suggest", "no", "dose", "-", "response", "effect", "for", "paclitaxel", "doses", "above", "200", "mg", "/", "m2", "."]], "ner": [[[7, 7, "Chemical"], [55, 55, "Chemical"], [57, 57, "Chemical"], [85, 85, "Chemical"], [121, 121, "Chemical"], [239, 239, "Chemical"], [267, 267, "Chemical"], [318, 318, "Chemical"], [461, 461, "Chemical"], [494, 494, "Chemical"], [421, 421, "Disease"], [423, 423, "Disease"], [426, 426, "Disease"], [9, 9, "Chemical"], [87, 87, "Chemical"], [128, 128, "Chemical"], [254, 254, "Chemical"], [463, 463, "Chemical"], [16, 19, "Disease"], [29, 32, "Disease"], [78, 81, "Disease"], [143, 146, "Disease"], [474, 477, "Disease"], [101, 102, "Disease"], [118, 118, "Disease"], [211, 211, "Disease"], [281, 281, "Disease"], [456, 456, "Disease"], [170, 170, "Disease"], [428, 428, "Disease"], [441, 441, "Disease"]]], "relations": [[[7, 7, 421, 421, "CID"], [55, 55, 421, 421, "CID"], [57, 57, 421, 421, "CID"], [85, 85, 421, 421, "CID"], [121, 121, 421, 421, "CID"], [239, 239, 421, 421, "CID"], [267, 267, 421, 421, "CID"], [318, 318, 421, 421, "CID"], [461, 461, 421, 421, "CID"], [494, 494, 421, 421, "CID"], [7, 7, 423, 423, "CID"], [55, 55, 423, 423, "CID"], [57, 57, 423, 423, "CID"], [85, 85, 423, 423, "CID"], [121, 121, 423, 423, "CID"], [239, 239, 423, 423, "CID"], [267, 267, 423, 423, "CID"], [318, 318, 423, 423, "CID"], [461, 461, 423, 423, "CID"], [494, 494, 423, 423, "CID"], [7, 7, 426, 426, "CID"], [55, 55, 426, 426, "CID"], [57, 57, 426, 426, "CID"], [85, 85, 426, 426, "CID"], [121, 121, 426, 426, "CID"], [239, 239, 426, 426, "CID"], [267, 267, 426, 426, "CID"], [318, 318, 426, 426, "CID"], [461, 461, 426, 426, "CID"], [494, 494, 426, 426, "CID"], [9, 9, 421, 421, "CID"], [87, 87, 421, 421, "CID"], [128, 128, 421, 421, "CID"], [254, 254, 421, 421, "CID"], [463, 463, 421, 421, "CID"], [9, 9, 423, 423, "CID"], [87, 87, 423, 423, "CID"], [128, 128, 423, 423, "CID"], [254, 254, 423, 423, "CID"], [463, 463, 423, 423, "CID"], [9, 9, 426, 426, "CID"], [87, 87, 426, 426, "CID"], [128, 128, 426, 426, "CID"], [254, 254, 426, 426, "CID"], [463, 463, 426, 426, "CID"]]], "clusters": [], "translated": "<0>紫杉醇</0>加<13>顺铂</13>一线治疗<18>头颈癌</18>的I/II期研究：初步结果。改善<19>头颈癌</19>患者的预后需要研究用于诱导治疗的新药。Eastern Cooperative Oncology Group对单药<1>紫杉醇</1>（<2>紫杉醇</2>；Bristol-Myers Squibb Company, Princeton, NJ）进行的一项研究的初步结果显示，患有<20>头颈癌</20>的患者的缓解率为37%，<3>紫杉醇</3>/<14>顺铂</14>组合已成功应用于<23>卵巢癌</23>患者。我们启动了一项I/II期试验，以确定递增<4>紫杉醇</4>剂量联合固定剂量的<15>顺铂</15>和粒细胞集落刺激的反应和<24>毒性</24>未经治疗的局部晚期不能手术的<21>头颈癌</21>患者的因素支持。迄今为止，已有23名中位年龄为50岁且身体状况良好的男性参加了试验。原发<28>肿瘤</28>部位为口咽部，10例； 喉咽，四个; 喉，两个; 口腔，三个；未知小学，二年级；鼻腔和腮腺各1个。在可评估<25>毒性</25>的20名患者中，4名患有III期疾病，16名患有IV期疾病。治疗，每21天一次，最多三个周期，包括输注<5>紫杉醇</5> 3小时，然后在第二天接受固定剂量的<16>顺铂</16>（75mg/m2）。剂量水平包含递增的<6>紫杉醇</6>剂量，如果<26>毒性</26>允许，允许在给定剂量水平内在患者体内递增剂量。在撰写本文时，正在评估剂量水平4（260、270和280mg/m2）; 这个级别的三名患者是可评估的。<7>紫杉醇</7>剂量为200mg/m2或更高时，给予粒细胞集落刺激因子5微克/公斤/天（第4 至12天）。在18名可评估反应的患者中，7名（39%）获得完全反应，6名（33%）获得部分反应。三名患者无变化，两名患者病情进展。总体响应率为72%。11名有反应的患者接受了后续手术 /放疗或根治性放疗。在达到临床完全缓解的患者中观察到两次病理完全缓解。<10>脱发</10>、<11>感觉异常</11>和<12>关节痛</12>/<29>肌痛</29>经常发生，但有一个例外（3级<30>肌痛</30>），它们已达到1级或2级。未见剂量限制性血液学<27>毒性</27>。<8>紫杉醇</8>/<17>顺铂</17>是局部晚期<22>头颈癌</22>的有效一线治疗方案，值得继续研究。迄今为止的结果表明，<9>紫杉醇</9>剂量超过200mg/m2时没有剂量反应效应。", "revised": true}
{"doc_key": "12589964", "sentences": [["Evaluation", "of", "cardiac", "troponin", "I", "and", "T", "levels", "as", "markers", "of", "myocardial", "damage", "in", "doxorubicin", "-", "induced", "cardiomyopathy", "rats", ",", "and", "their", "relationship", "with", "echocardiographic", "and", "histological", "findings", ".", "BACKGROUND", ":", "Cardiac", "troponins", "I", "(", "cTnI", ")", "and", "T", "(", "cTnT", ")", "have", "been", "shown", "to", "be", "highly", "sensitive", "and", "specific", "markers", "of", "myocardial", "cell", "injury", ".", "We", "investigated", "the", "diagnostic", "value", "of", "cTnI", "and", "cTnT", "for", "the", "diagnosis", "of", "myocardial", "damage", "in", "a", "rat", "model", "of", "doxorubicin", "(", "DOX", ")", "-", "induced", "cardiomyopathy", ",", "and", "we", "examined", "the", "relationship", "between", "serial", "cTnI", "and", "cTnT", "with", "the", "development", "of", "cardiac", "disorders", "monitored", "by", "echocardiography", "and", "histological", "examinations", "in", "this", "model", ".", "METHODS", ":", "Thirty", "-", "five", "Wistar", "rats", "were", "given", "1", ".", "5", "mg", "/", "kg", "DOX", ",", "i", ".", "v", ".", ",", "weekly", "for", "up", "to", "8", "weeks", "for", "a", "total", "cumulative", "dose", "of", "12", "mg", "/", "kg", "BW", ".", "Ten", "rats", "received", "saline", "as", "a", "control", "group", ".", "cTnI", "was", "measured", "with", "Access", "(", "R", ")", "(", "ng", "/", "ml", ")", "and", "a", "research", "immunoassay", "(", "pg", "/", "ml", ")", ",", "and", "compared", "with", "cTnT", ",", "CK", "-", "MB", "mass", "and", "CK", ".", "By", "using", "transthoracic", "echocardiography", ",", "anterior", "and", "posterior", "wall", "thickness", ",", "LV", "diameters", "and", "LV", "fractional", "shortening", "(", "FS", ")", "were", "measured", "in", "all", "rats", "before", "DOX", "or", "saline", ",", "and", "at", "weeks", "6", "and", "9", "after", "treatment", "in", "all", "surviving", "rats", ".", "Histology", "was", "performed", "in", "DOX", "-", "rats", "at", "6", "and", "9", "weeks", "after", "the", "last", "DOX", "dose", "and", "in", "all", "controls", ".", "RESULTS", ":", "Eighteen", "of", "the", "DOX", "rats", "died", "prematurely", "of", "general", "toxicity", "during", "the", "9", "-", "week", "period", ".", "End", "-", "diastolic", "(", "ED", ")", "and", "end", "-", "systolic", "(", "ES", ")", "LV", "diameters", "/", "BW", "significantly", "increased", ",", "whereas", "LV", "FS", "was", "decreased", "after", "9", "weeks", "in", "the", "DOX", "group", "(", "p", "<", "0", ".", "001", ")", ".", "These", "parameters", "remained", "unchanged", "in", "controls", ".", "Histological", "evaluation", "of", "hearts", "from", "all", "rats", "given", "DOX", "revealed", "significant", "slight", "degrees", "of", "perivascular", "and", "interstitial", "fibrosis", ".", "In", "7", "of", "the", "18", "rats", ",", "degeneration", "and", "myocyte", "vacuolisation", "were", "found", ".", "Only", "five", "of", "the", "controls", "exhibited", "evidence", "of", "very", "slight", "perivascular", "fibrosis", ".", "A", "significant", "rise", "in", "cTnT", "was", "found", "in", "DOX", "rats", "after", "cumulative", "doses", "of", "7", ".", "5", "and", "12", "mg", "/", "kg", "in", "comparison", "with", "baseline", "(", "p", "<", "0", ".", "05", ")", ".", "cTnT", "found", "in", "rats", "after", "12", "mg", "/", "kg", "were", "significantly", "greater", "than", "that", "found", "after", "7", ".", "5", "mg", "/", "kg", "DOX", ".", "Maximal", "cTnI", "(", "pg", "/", "ml", ")", "and", "cTnT", "levels", "were", "significantly", "increased", "in", "DOX", "rats", "compared", "with", "controls", "(", "p", "=", "0", ".", "006", ",", "0", ".", "007", ")", ".", "cTnI", "(", "ng", "/", "ml", ")", ",", "CK", "-", "MB", "mass", "and", "CK", "remained", "unchanged", "in", "DOX", "rats", "compared", "with", "controls", ".", "All", "markers", "remained", "stable", "in", "controls", ".", "Analysis", "of", "data", "revealed", "a", "significant", "correlation", "between", "maximal", "cTnT", "and", "ED", "and", "ES", "LV", "diameters", "/", "BW", "(", "r", "=", "0", ".", "81", "and", "0", ".", "65", ";", "p", "<", "0", ".", "0001", ")", ".", "A", "significant", "relationship", "was", "observed", "between", "maximal", "cTnT", "and", "the", "extent", "of", "myocardial", "morphological", "changes", ",", "and", "between", "LV", "diameters", "/", "BW", "and", "histological", "findings", ".", "CONCLUSIONS", ":", "Among", "markers", "of", "ischemic", "injury", "after", "DOX", "in", "rats", ",", "cTnT", "showed", "the", "greatest", "ability", "to", "detect", "myocardial", "damage", "assessed", "by", "echocardiographic", "detection", "and", "histological", "changes", ".", "Although", "there", "was", "a", "discrepancy", "between", "the", "amount", "of", "cTnI", "and", "cTnT", "after", "DOX", ",", "probably", "due", "to", "heterogeneity", "in", "cross", "-", "reactivities", "of", "mAbs", "to", "various", "cTnI", "and", "cTnT", "forms", ",", "it", "is", "likely", "that", "cTnT", "in", "rats", "after", "DOX", "indicates", "cell", "damage", "determined", "by", "the", "magnitude", "of", "injury", "induced", "and", "that", "cTnT", "should", "be", "a", "useful", "marker", "for", "the", "prediction", "of", "experimentally", "induced", "cardiotoxicity", "and", "possibly", "for", "cardioprotective", "experiments", "."]], "ner": [[[14, 14, "Chemical"], [77, 77, "Chemical"], [79, 79, "Chemical"], [126, 126, "Chemical"], [221, 221, "Chemical"], [242, 242, "Chemical"], [253, 253, "Chemical"], [265, 265, "Chemical"], [309, 309, "Chemical"], [334, 334, "Chemical"], [380, 380, "Chemical"], [428, 428, "Chemical"], [444, 444, "Chemical"], [477, 477, "Chemical"], [560, 560, "Chemical"], [594, 594, "Chemical"], [621, 621, "Chemical"], [11, 12, "Disease"], [17, 17, "Disease"], [53, 55, "Disease"], [70, 71, "Disease"], [83, 83, "Disease"], [571, 572, "Disease"], [99, 100, "Disease"], [271, 271, "Disease"], [343, 343, "Disease"], [370, 370, "Disease"], [557, 558, "Disease"], [646, 646, "Disease"]]], "relations": [[[14, 14, 11, 12, "CID"], [14, 14, 17, 17, "CID"], [14, 14, 53, 55, "CID"], [14, 14, 70, 71, "CID"], [14, 14, 83, 83, "CID"], [14, 14, 571, 572, "CID"], [77, 77, 11, 12, "CID"], [77, 77, 17, 17, "CID"], [77, 77, 53, 55, "CID"], [77, 77, 70, 71, "CID"], [77, 77, 83, 83, "CID"], [77, 77, 571, 572, "CID"], [79, 79, 11, 12, "CID"], [79, 79, 17, 17, "CID"], [79, 79, 53, 55, "CID"], [79, 79, 70, 71, "CID"], [79, 79, 83, 83, "CID"], [79, 79, 571, 572, "CID"], [126, 126, 11, 12, "CID"], [126, 126, 17, 17, "CID"], [126, 126, 53, 55, "CID"], [126, 126, 70, 71, "CID"], [126, 126, 83, 83, "CID"], [126, 126, 571, 572, "CID"], [221, 221, 11, 12, "CID"], [221, 221, 17, 17, "CID"], [221, 221, 53, 55, "CID"], [221, 221, 70, 71, "CID"], [221, 221, 83, 83, "CID"], [221, 221, 571, 572, "CID"], [242, 242, 11, 12, "CID"], [242, 242, 17, 17, "CID"], [242, 242, 53, 55, "CID"], [242, 242, 70, 71, "CID"], [242, 242, 83, 83, "CID"], [242, 242, 571, 572, "CID"], [253, 253, 11, 12, "CID"], [253, 253, 17, 17, "CID"], [253, 253, 53, 55, "CID"], [253, 253, 70, 71, "CID"], [253, 253, 83, 83, "CID"], [253, 253, 571, 572, "CID"], [265, 265, 11, 12, "CID"], [265, 265, 17, 17, "CID"], [265, 265, 53, 55, "CID"], [265, 265, 70, 71, "CID"], [265, 265, 83, 83, "CID"], [265, 265, 571, 572, "CID"], [309, 309, 11, 12, "CID"], [309, 309, 17, 17, "CID"], [309, 309, 53, 55, "CID"], [309, 309, 70, 71, "CID"], [309, 309, 83, 83, "CID"], [309, 309, 571, 572, "CID"], [334, 334, 11, 12, "CID"], [334, 334, 17, 17, "CID"], [334, 334, 53, 55, "CID"], [334, 334, 70, 71, "CID"], [334, 334, 83, 83, "CID"], [334, 334, 571, 572, "CID"], [380, 380, 11, 12, "CID"], [380, 380, 17, 17, "CID"], [380, 380, 53, 55, "CID"], [380, 380, 70, 71, "CID"], [380, 380, 83, 83, "CID"], [380, 380, 571, 572, "CID"], [428, 428, 11, 12, "CID"], [428, 428, 17, 17, "CID"], [428, 428, 53, 55, "CID"], [428, 428, 70, 71, "CID"], [428, 428, 83, 83, "CID"], [428, 428, 571, 572, "CID"], [444, 444, 11, 12, "CID"], [444, 444, 17, 17, "CID"], [444, 444, 53, 55, "CID"], [444, 444, 70, 71, "CID"], [444, 444, 83, 83, "CID"], [444, 444, 571, 572, "CID"], [477, 477, 11, 12, "CID"], [477, 477, 17, 17, "CID"], [477, 477, 53, 55, "CID"], [477, 477, 70, 71, "CID"], [477, 477, 83, 83, "CID"], [477, 477, 571, 572, "CID"], [560, 560, 11, 12, "CID"], [560, 560, 17, 17, "CID"], [560, 560, 53, 55, "CID"], [560, 560, 70, 71, "CID"], [560, 560, 83, 83, "CID"], [560, 560, 571, 572, "CID"], [594, 594, 11, 12, "CID"], [594, 594, 17, 17, "CID"], [594, 594, 53, 55, "CID"], [594, 594, 70, 71, "CID"], [594, 594, 83, 83, "CID"], [594, 594, 571, 572, "CID"], [621, 621, 11, 12, "CID"], [621, 621, 17, 17, "CID"], [621, 621, 53, 55, "CID"], [621, 621, 70, 71, "CID"], [621, 621, 83, 83, "CID"], [621, 621, 571, 572, "CID"]]], "clusters": [], "translated": "评估心肌肌钙蛋白 I 和 T 水平作为<0>多柔比星</0>诱导的<18>心肌病</18>大鼠<17>心肌损伤</17>的标志物，及其与超声心动图和组织学发现的关系。背景：心肌肌钙蛋白 I (cTnI) 和 T (cTnT) 已被证明是<19>心肌细胞损伤</19>的高度敏感和特异性标志物。我们研究了 cTnI 和 cTnT 在<1>阿霉素</1> (<2>DOX</2>)诱导的<21>心肌病</21>大鼠模型中诊断<20>心肌损伤</20>的诊断价值，并我们检查了连续的 cTnI 和 cTnT 与<23>心脏疾病</23>发展之间的关系，通过该模型中的超声心动图和组织学检查监测。方法：35只Wistar大鼠给予1.5毫克/千克<3>DOX</3>，i.v.，每周一次，最多8周，总累积剂量为12 mg/kg BW。10只大鼠接受生理盐水作为对照组。cTnI用Access(R)(ng/ml)和研究免疫测定法(pg/ml)测量，并与cTnT、CK-MB质量和CK进行比较。通过使用经胸超声心动图，在<4>DOX</4>或生理盐水处理前以及治疗后第6周和第9周，测量所有大鼠的前壁和后壁厚度、左室直径和左室缩短分数(FS)。在<5>DOX</5>大鼠和所有对照组中，在最后一次<6>DOX</6>给药后6周和9周进行了组织学检查。结果：在9周期间，<7>DOX</7>大鼠中有18只因一般<24>毒性</24>过早死亡。在<8>DOX</8>组中，舒张末期(ED)和收缩末期(ES) LV 直径/BW 显着增加，而 LV FS 降低(p < 0.001)。这些参数在对照中保持不变。对给予<9>DOX</9>的所有大鼠的心脏进行的组织学评估显示，血管周围和间质有显着轻微程度的<25>纤维化</25>。在18只大鼠中有7只出现变性和肌细胞空泡化。只有五个对照组表现出非常轻微的血管周围<26>纤维化</26>证据。在累积剂量为7后，<10>DOX</10>大鼠的 cTnT 显着升高。5和12 mg/kg与基线相比(p < 0.05)。12 mg/kg后在大鼠中发现的cTnT明显大于7.5毫克/千克<11>阿霉素</11>。与对照组相比，<12>DOX</12>大鼠的最大cTnI(pg/ml)和cTnT水平显着升高(p = 0.006, 0.007)。与对照组相比，<13>DOX</13>大鼠的cTnI(ng/ml)、CK-MB质量和CK保持不变。所有标记在对照中保持稳定。数据分析显示最大cTnT与ED和ES LV 直径/BW 之间存在显着相关性(r = 0.81和0.65；p < 0.0001)。观察到最大cTnT与心肌形态学变化程度之间以及LV直径/BW与组织学发现之间存在显着关系。结论：在大鼠<14>DOX</14>后<27>缺血性损伤</27>的标志物中，cTnT通过超声心动图检测和组织学改变检测<22>心肌损伤</22>的能力最强。尽管<15>DOX</15>后cTnI和cTnT的量存在差异，可能是由于mAb对各种cTnI和cTnT形式的交叉反应的异质性，<16>大鼠的cTnT很可能DOX</16>表明细胞损伤由诱导的损伤程度决定，cTnT应该是预测实验诱导的<28>心脏毒性</28>并可能用于心脏保护实验的有用标记。", "revised": true}
{"doc_key": "14596845", "sentences": [["A", "diet", "promoting", "sugar", "dependency", "causes", "behavioral", "cross", "-", "sensitization", "to", "a", "low", "dose", "of", "amphetamine", ".", "Previous", "research", "in", "this", "laboratory", "has", "shown", "that", "a", "diet", "of", "intermittent", "excessive", "sugar", "consumption", "produces", "a", "state", "with", "neurochemical", "and", "behavioral", "similarities", "to", "drug", "dependency", ".", "The", "present", "study", "examined", "whether", "female", "rats", "on", "various", "regimens", "of", "sugar", "access", "would", "show", "behavioral", "cross", "-", "sensitization", "to", "a", "low", "dose", "of", "amphetamine", ".", "After", "a", "30", "-", "min", "baseline", "measure", "of", "locomotor", "activity", "(", "day", "0", ")", ",", "animals", "were", "maintained", "on", "a", "cyclic", "diet", "of", "12", "-", "h", "deprivation", "followed", "by", "12", "-", "h", "access", "to", "10", "%", "sucrose", "solution", "and", "chow", "pellets", "(", "12", "h", "access", "starting", "4", "h", "after", "onset", "of", "the", "dark", "period", ")", "for", "21", "days", ".", "Locomotor", "activity", "was", "measured", "again", "for", "30", "min", "at", "the", "beginning", "of", "days", "1", "and", "21", "of", "sugar", "access", ".", "Beginning", "on", "day", "22", ",", "all", "rats", "were", "maintained", "on", "ad", "libitum", "chow", ".", "Nine", "days", "later", "locomotor", "activity", "was", "measured", "in", "response", "to", "a", "single", "low", "dose", "of", "amphetamine", "(", "0", ".", "5", "mg", "/", "kg", ")", ".", "The", "animals", "that", "had", "experienced", "cyclic", "sucrose", "and", "chow", "were", "hyperactive", "in", "response", "to", "amphetamine", "compared", "with", "four", "control", "groups", "(", "ad", "libitum", "10", "%", "sucrose", "and", "chow", "followed", "by", "amphetamine", "injection", ",", "cyclic", "chow", "followed", "by", "amphetamine", "injection", ",", "ad", "libitum", "chow", "with", "amphetamine", ",", "or", "cyclic", "10", "%", "sucrose", "and", "chow", "with", "a", "saline", "injection", ")", ".", "These", "results", "suggest", "that", "a", "diet", "comprised", "of", "alternating", "deprivation", "and", "access", "to", "a", "sugar", "solution", "and", "chow", "produces", "bingeing", "on", "sugar", "that", "leads", "to", "a", "long", "lasting", "state", "of", "increased", "sensitivity", "to", "amphetamine", ",", "possibly", "due", "to", "a", "lasting", "alteration", "in", "the", "dopamine", "system", "."]], "ner": [[[15, 15, "Chemical"], [68, 68, "Chemical"], [178, 178, "Chemical"], [202, 202, "Chemical"], [218, 218, "Chemical"], [225, 225, "Chemical"], [232, 232, "Chemical"], [280, 280, "Chemical"], [6, 9, "Disease"], [59, 62, "Disease"], [198, 198, "Disease"], [106, 106, "Chemical"], [194, 194, "Chemical"], [213, 213, "Chemical"], [238, 238, "Chemical"], [3, 4, "Disease"], [41, 42, "Disease"], [290, 290, "Chemical"]]], "relations": [[[15, 15, 6, 9, "CID"], [15, 15, 59, 62, "CID"], [15, 15, 198, 198, "CID"], [68, 68, 6, 9, "CID"], [68, 68, 59, 62, "CID"], [68, 68, 198, 198, "CID"], [178, 178, 6, 9, "CID"], [178, 178, 59, 62, "CID"], [178, 178, 198, 198, "CID"], [202, 202, 6, 9, "CID"], [202, 202, 59, 62, "CID"], [202, 202, 198, 198, "CID"], [218, 218, 6, 9, "CID"], [218, 218, 59, 62, "CID"], [218, 218, 198, 198, "CID"], [225, 225, 6, 9, "CID"], [225, 225, 59, 62, "CID"], [225, 225, 198, 198, "CID"], [232, 232, 6, 9, "CID"], [232, 232, 59, 62, "CID"], [232, 232, 198, 198, "CID"], [280, 280, 6, 9, "CID"], [280, 280, 59, 62, "CID"], [280, 280, 198, 198, "CID"], [106, 106, 6, 9, "CID"], [106, 106, 59, 62, "CID"], [106, 106, 198, 198, "CID"], [194, 194, 6, 9, "CID"], [194, 194, 59, 62, "CID"], [194, 194, 198, 198, "CID"], [213, 213, 6, 9, "CID"], [213, 213, 59, 62, "CID"], [213, 213, 198, 198, "CID"], [238, 238, 6, 9, "CID"], [238, 238, 59, 62, "CID"], [238, 238, 198, 198, "CID"]]], "clusters": [], "translated": "促进<15>糖依赖</15>的饮食导致<8>行为交叉过敏</8>对低剂量<0>苯丙胺</0>。该实验室之前的研究表明，间歇性过量摄入糖分的饮食会产生一种与<16>药物依赖</16>具有神经化学和行为相似性的状态。本研究检查了接受各种糖摄入方案的雌性大鼠是否会表现出对低剂量的<1>安非他明</1>的<9>行为交叉过敏</9>。在对运动活动进行30分钟基线测量后（第0天），动物维持12小时禁食的循环饮食，然后12小时获得10%<11>蔗糖</11>溶液和食物颗粒（12h在黑暗期开始后4小时开始访问），持续21天。在糖摄入的第1天和第21天开始时，再次测量运动活动30分钟。从第22天开始，所有大鼠都保持随意摄食。九天后，测量了对单一低剂量<2>安非他明</2>（0.5毫克/千克）的反应的运动活动。接受循环<12>蔗糖</12>和食物的动物对<3>苯丙胺</3>的反应较之四个对照组（随意10%<13>蔗糖</13>和食物后注射<4>苯丙胺</4>，循环食物后注射<5>苯丙胺</5>，随意喂食<6>苯丙胺</6>或循环10%<14>蔗糖</14>和用生理盐水注射的食物）表现出明显的<10>超活跃反应</10>。这些结果表明，由交替剥夺和接触糖溶液和食物组成的饮食会导致对糖的暴饮暴食，导致对<7>安非他明</7>的敏感性增加的长期持续状态，这可能是由于<17>多巴胺</17>系统的持久性改变。", "revised": true}
{"doc_key": "1549199", "sentences": [["Optimization", "of", "levodopa", "therapy", ".", "While", "there", "is", "no", "single", "correct", "starting", "dose", "for", "levodopa", "therapy", ",", "many", "individuals", "can", "be", "started", "on", "either", "the", "25", "/", "100", "or", "controlled", "-", "release", "formula", ",", "following", "the", "general", "rule", "not", "to", "attempt", "to", "titrate", "carbidopa", "-", "levodopa", "to", "the", "point", "of", "\"", "normality", ",", "\"", "which", "can", "lead", "to", "toxicity", ".", "The", "physician", "should", "also", "determine", "the", "proper", "use", "of", "any", "adjunctive", "medications", ";", "such", "combined", "therapy", "has", "become", "the", "standard", "approach", "to", "treatment", ".", "Following", "the", "initial", "period", "of", "therapy", ",", "emerging", "difficulties", "require", "a", "reassessment", "of", "therapeutic", "approaches", ",", "such", "as", "dosage", "adjustment", "or", "introduction", "of", "a", "dopamine", "agonist", ".", "Other", "possible", "adverse", "effects", "-", "-", "such", "as", "gastrointestinal", "disorders", ",", "orthostatic", "hypotension", ",", "levodopa", "-", "induced", "psychosis", ",", "sleep", "disturbances", "or", "parasomnias", ",", "or", "drug", "interactions", "-", "-", "also", "require", "carefully", "monitored", "individual", "treatment", ".", "Nonpharmacologic", "concerns", "can", "help", "the", "Parkinson", "'s", "disease", "patient", "achieve", "and", "maintain", "optimal", "functioning", ",", "including", "daily", "exercise", ",", "physical", "therapy", ",", "and", "involvement", "with", "support", "groups", "."]], "ner": [[[2, 2, "Chemical"], [14, 14, "Chemical"], [45, 45, "Chemical"], [125, 125, "Chemical"], [119, 120, "Disease"], [122, 123, "Disease"], [133, 133, "Disease"], [58, 58, "Disease"], [128, 128, "Disease"], [130, 131, "Disease"], [152, 154, "Disease"], [43, 43, "Chemical"], [108, 108, "Chemical"]]], "relations": [[[2, 2, 119, 120, "CID"], [14, 14, 119, 120, "CID"], [45, 45, 119, 120, "CID"], [125, 125, 119, 120, "CID"], [2, 2, 122, 123, "CID"], [14, 14, 122, 123, "CID"], [45, 45, 122, 123, "CID"], [125, 125, 122, 123, "CID"], [2, 2, 133, 133, "CID"], [14, 14, 133, 133, "CID"], [45, 45, 133, 133, "CID"], [125, 125, 133, 133, "CID"]]], "clusters": [], "translated": "<0>左旋多巴</0>疗法的优化。虽然 <1>左旋多巴</1>治疗没有单一正确的起始剂量，但许多人可以从25/100或控释配方开始，遵循一般规则不要尝试滴定 <11> 卡比多巴 </11> - <2> 左旋多巴 </2>到“正常”点，这会导致<7>毒性</7>。 医生还应确定任何辅助药物的正确使用；这种联合疗法已成为标准的治疗方法。在治疗的初始阶段之后，新出现的困难需要重新评估治疗方法，例如调整剂量或引入<12>多巴胺</12>激动剂。其他可能的不良反应——如<4>胃肠道疾病</4>、<5>直立性低血压</5>、<3>左旋多巴</3>诱发的<8>精神病</8>、<9>睡眠障碍</9>或<6>异态睡眠</6>，或药物相互作用——也需要仔细监测个体治疗。非药物方面的关注可以帮助<10>帕金森病</10>患者实现并保持最佳机能，包括日常锻炼、物理治疗和参与支持小组。", "revised": true}
{"doc_key": "17020434", "sentences": [["Optimising", "stroke", "prevention", "in", "non", "-", "valvular", "atrial", "fibrillation", ".", "Atrial", "fibrillation", "is", "associated", "with", "substantial", "morbidity", "and", "mortality", ".", "Pooled", "data", "from", "trials", "comparing", "antithrombotic", "treatment", "with", "placebo", "have", "shown", "that", "warfarin", "reduces", "the", "risk", "of", "stroke", "by", "62", "%", ",", "and", "that", "aspirin", "alone", "reduces", "the", "risk", "by", "22", "%", ".", "Overall", ",", "in", "high", "-", "risk", "patients", ",", "warfarin", "is", "superior", "to", "aspirin", "in", "preventing", "strokes", ",", "with", "a", "relative", "risk", "reduction", "of", "36", "%", ".", "Ximelagatran", ",", "an", "oral", "direct", "thrombin", "inhibitor", ",", "was", "found", "to", "be", "as", "efficient", "as", "vitamin", "K", "antagonist", "drugs", "in", "the", "prevention", "of", "embolic", "events", ",", "but", "has", "been", "recently", "withdrawn", "because", "of", "abnormal", "liver", "function", "tests", ".", "The", "ACTIVE", "-", "W", "(", "Atrial", "Fibrillation", "Clopidogrel", "Trial", "with", "Irbesartan", "for", "Prevention", "of", "Vascular", "Events", ")", "study", "has", "demonstrated", "that", "warfarin", "is", "superior", "to", "platelet", "therapy", "(", "clopidogrel", "plus", "aspirin", ")", "in", "the", "prevention", "af", "embolic", "events", ".", "Idraparinux", ",", "a", "Factor", "Xa", "inhibitor", ",", "is", "being", "evaluated", "in", "patients", "with", "atrial", "fibrillation", ".", "Angiotensin", "-", "converting", "enzyme", "inhibitors", "and", "angiotensin", "II", "receptor", "-", "blocking", "drugs", "hold", "promise", "in", "atrial", "fibrillation", "through", "cardiac", "remodelling", ".", "Preliminary", "studies", "suggest", "that", "statins", "could", "interfere", "with", "the", "risk", "of", "recurrence", "after", "electrical", "cardioversion", ".", "Finally", ",", "percutaneous", "methods", "for", "the", "exclusion", "of", "left", "atrial", "appendage", "are", "under", "investigation", "in", "high", "-", "risk", "patients", "."]], "ner": [[[79, 79, "Chemical"], [112, 114, "Disease"], [32, 32, "Chemical"], [61, 61, "Chemical"], [138, 138, "Chemical"], [1, 1, "Disease"], [37, 37, "Disease"], [68, 68, "Disease"], [44, 44, "Chemical"], [65, 65, "Chemical"], [147, 147, "Chemical"], [94, 95, "Chemical"], [124, 124, "Chemical"], [145, 145, "Chemical"], [127, 127, "Chemical"], [156, 156, "Chemical"], [172, 172, "Chemical"], [178, 179, "Chemical"], [197, 197, "Chemical"], [7, 8, "Disease"], [10, 11, "Disease"], [122, 123, "Disease"], [169, 170, "Disease"], [187, 188, "Disease"], [102, 103, "Disease"], [153, 154, "Disease"], [190, 191, "Disease"]]], "relations": [[[79, 79, 112, 114, "CID"]]], "clusters": [], "translated": "优化非瓣膜性<19>心房颤动</19>的<5>中风</5>预防。 <20>房颤</20>与高发病率和死亡率有关。来自比较抗血栓治疗和安慰剂的试验的汇总数据表明，<2>华法林</2>可将<6>中风</6>的风险降低62%，而单独使用<8>阿司匹林</8>可降低该风险减少22%。总体而言，在高危患者中，<3>华法林</3>在预防<7>中风</7>方面优于<9>阿司匹林</9>，相对风险降低36%。<0>Ximelagatran</0>是一种口服直接凝血酶抑制剂，被发现在预防<24>栓塞事件</24>方面与<11>维生素K</11>拮抗剂药物一样有效，但近期因<1>肝功能异常</1>检查退出。ACTIVE-W（<21>心房颤动</21><12>氯吡格雷</12>试验与<14>厄贝沙坦</14>预防血管事件）研究表明<4>华法林</4>在预防<25>栓塞事件</25>方面优于血小板疗法（<13>氯吡格雷</13>加<10>阿司匹林</10>）。<15>Idraparinux</15>是一种Xa因子抑制剂，目前正在对<22>心房颤动</22>患者进行评估。<16>血管紧张素</16>-转化酶抑制剂和<17>血管紧张素II</17>受体阻滞剂在<23>心房颤动</23>到<26>心脏重塑</26>中具有前景。初步研究表明，<18>他汀类药物</18>可能会干扰电复律后的复发风险。最后，正在对高危患者进行经皮切除左心耳的方法的研究。", "revised": true}
{"doc_key": "1130930", "sentences": [["Nephrotoxicity", "of", "combined", "cephalothin", "-", "gentamicin", "regimen", ".", "Two", "patients", "developed", "acute", "tubular", "necrosis", ",", "characterized", "clinically", "by", "acute", "oliguric", "renal", "failure", ",", "while", "they", "were", "receiving", "a", "combination", "of", "cephalothin", "sodium", "and", "gentamicin", "sulfate", "therapy", ".", "Patients", "who", "are", "given", "this", "drug", "regimen", "should", "be", "observed", "very", "carefully", "for", "early", "signs", "of", "nephrotoxicity", ".", "High", "doses", "of", "this", "antibiotic", "combination", "should", "be", "avoided", "especially", "in", "elderly", "patients", ".", "Patients", "with", "renal", "insufficiency", "should", "not", "be", "given", "this", "regimen", "."]], "ner": [[[3, 3, "Chemical"], [30, 31, "Chemical"], [11, 13, "Disease"], [19, 21, "Disease"], [5, 5, "Chemical"], [33, 34, "Chemical"], [0, 0, "Disease"], [53, 53, "Disease"], [71, 72, "Disease"]]], "relations": [[[3, 3, 11, 13, "CID"], [30, 31, 11, 13, "CID"], [3, 3, 19, 21, "CID"], [30, 31, 19, 21, "CID"], [5, 5, 11, 13, "CID"], [33, 34, 11, 13, "CID"], [5, 5, 19, 21, "CID"], [33, 34, 19, 21, "CID"]]], "clusters": [], "translated": "联合<0>头孢噻吩</0>-<4>庆大霉素硫酸</4>方案的<6>肾毒性</6>。两名患者发生<2>急性肾小管坏死</2>，临床特征为急性<3>少尿性肾功能衰竭</3>，同时接受<1>头孢噻吩钠</1>和<5>庆大霉素硫酸</5>联合治疗。接受这种药物治疗的患者应密切观察<7>肾毒性</7>的早期体征。应避免使用高剂量的这种抗生素组合，尤其是老年患者。<8>肾功能不全</8>的患者不应使用该方案。", "revised": true}
{"doc_key": "3076126", "sentences": [["HMG", "CoA", "reductase", "inhibitors", ".", "Current", "clinical", "experience", ".", "Lovastatin", "and", "simvastatin", "are", "the", "2", "best", "-", "known", "members", "of", "the", "class", "of", "hypolipidaemic", "agents", "known", "as", "HMG", "CoA", "reductase", "inhibitors", ".", "Clinical", "experience", "with", "lovastatin", "includes", "over", "5000", "patients", ",", "700", "of", "whom", "have", "been", "treated", "for", "2", "years", "or", "more", ",", "and", "experience", "with", "simvastatin", "includes", "over", "3500", "patients", ",", "of", "whom", "350", "have", "been", "treated", "for", "18", "months", "or", "more", ".", "Lovastatin", "has", "been", "marketed", "in", "the", "United", "States", "for", "over", "6", "months", ".", "Both", "agents", "show", "substantial", "clinical", "efficacy", ",", "with", "reductions", "in", "total", "cholesterol", "of", "over", "30", "%", "and", "in", "LDL", "-", "cholesterol", "of", "40", "%", "in", "clinical", "studies", ".", "Modest", "increases", "in", "HDL", "-", "cholesterol", "levels", "of", "about", "10", "%", "are", "also", "reported", ".", "Clinical", "tolerability", "of", "both", "agents", "has", "been", "good", ",", "with", "fewer", "than", "3", "%", "of", "patients", "withdrawn", "from", "treatment", "because", "of", "clinical", "adverse", "experiences", ".", "Ophthalmological", "examinations", "in", "over", "1100", "patients", "treated", "with", "one", "or", "the", "other", "agent", "have", "revealed", "no", "evidence", "of", "significant", "short", "term", "(", "up", "to", "2", "years", ")", "cataractogenic", "potential", ".", "One", "to", "2", "%", "of", "patients", "have", "elevations", "of", "serum", "transaminases", "to", "greater", "than", "3", "times", "the", "upper", "limit", "of", "normal", ".", "These", "episodes", "are", "asymptomatic", "and", "reversible", "when", "therapy", "is", "discontinued", ".", "Minor", "elevations", "of", "creatine", "kinase", "levels", "are", "reported", "in", "about", "5", "%", "of", "patients", ".", "Myopathy", ",", "associated", "in", "some", "cases", "with", "myoglobinuria", ",", "and", "in", "2", "cases", "with", "transient", "renal", "failure", ",", "has", "been", "rarely", "reported", "with", "lovastatin", ",", "especially", "in", "patients", "concomitantly", "treated", "with", "cyclosporin", ",", "gemfibrozil", "or", "niacin", ".", "Lovastatin", "and", "simvastatin", "are", "both", "effective", "and", "well", "-", "tolerated", "agents", "for", "lowering", "elevated", "levels", "of", "serum", "cholesterol", ".", "As", "wider", "use", "confirms", "their", "safety", "profile", ",", "they", "will", "gain", "increasing", "importance", "in", "the", "therapeutic", "approach", "to", "hypercholesterolaemia", "and", "its", "consequences", "."]], "ner": [[[9, 9, "Chemical"], [35, 35, "Chemical"], [74, 74, "Chemical"], [256, 256, "Chemical"], [270, 270, "Chemical"], [240, 240, "Disease"], [248, 249, "Disease"], [264, 264, "Chemical"], [233, 233, "Disease"], [266, 266, "Chemical"], [268, 268, "Chemical"], [307, 307, "Disease"], [11, 11, "Chemical"], [56, 56, "Chemical"], [272, 272, "Chemical"], [98, 98, "Chemical"], [107, 107, "Chemical"], [120, 120, "Chemical"], [287, 287, "Chemical"], [221, 221, "Chemical"]]], "relations": [[[9, 9, 240, 240, "CID"], [35, 35, 240, 240, "CID"], [74, 74, 240, 240, "CID"], [256, 256, 240, 240, "CID"], [270, 270, 240, 240, "CID"], [9, 9, 248, 249, "CID"], [35, 35, 248, 249, "CID"], [74, 74, 248, 249, "CID"], [256, 256, 248, 249, "CID"], [270, 270, 248, 249, "CID"], [264, 264, 233, 233, "CID"], [266, 266, 233, 233, "CID"], [268, 268, 233, 233, "CID"]]], "clusters": [], "translated": "HMG CoA 还原酶抑制剂。目前的临床经验。 <0>洛伐他汀</0> 和 <12>辛伐他汀</12> 是被称为 HMG CoA 还原酶抑制剂的降血脂药物类别中最著名的两个成员。 <1>洛伐他汀</1> 的临床经验包括超过 5000 名患者，其中 700 名已接受治疗 2 年或更长时间，<13>辛伐他汀</13> 的经验包括超过 3500 名患者，其中 350 名已接受治疗 18 个月或更长时间。 <2>洛伐他汀</2> 已在美国上市 6 个多月。这两种药物都显示出显着的临床疗效，在临床研究中总<15>胆固醇</15>和低密度脂蛋白-<16>胆固醇</16>降低了 30% 以上。还报道了 HDL-<17>胆固醇</17> 水平适度增加约 10%。这两种药物的临床耐受性都很好，只有不到 3% 的患者因为临床不良反应而退出治疗。对 1100 多名接受一种或另一种药物治疗的患者进行的眼科检查未发现有明显的短期（长达 2 年）潜在白内障的证据。1% 到 2% 的患者血清转氨酶升高至正常上限的 3 倍以上。这些发作是无症状的，并且在停止治疗时是可逆的。约 5% 的患者报告<19>肌酸激酶</19>水平轻微升高。 <8>肌病</8>，部分病例伴有<5>肌红蛋白尿</5>，2 例伴有短暂性<6>肾功能衰竭</6>，<3>洛伐他汀</3>，特别是同时接受<7>环孢菌素</7>、<9>吉非贝齐</9>或<10>烟酸</10>治疗的患者报告罕见。 <4>洛伐他汀</4> 和<14>辛伐他汀</14>都是有效且耐受性良好的药物，可降低升高的血清<18>胆固醇</18>水平。随着更广泛的使用证实了它们的安全性，它们在<11>高胆固醇血症</11>及其后果的治疗方法中将变得越来越重要。", "revised": true}
{"doc_key": "14976857", "sentences": [["Transient", "platypnea", "-", "orthodeoxia", "-", "like", "syndrome", "induced", "by", "propafenone", "overdose", "in", "a", "young", "woman", "with", "Ebstein", "'s", "anomaly", ".", "In", "this", "report", "we", "describe", "the", "case", "of", "a", "37", "-", "year", "-", "old", "white", "woman", "with", "Ebstein", "'s", "anomaly", ",", "who", "developed", "a", "rare", "syndrome", "called", "platypnea", "-", "orthodeoxia", ",", "characterized", "by", "massive", "right", "-", "to", "-", "left", "interatrial", "shunting", "with", "transient", "profound", "hypoxia", "and", "cyanosis", ".", "This", "shunt", "of", "blood", "via", "a", "patent", "foramen", "ovale", "occurred", "in", "the", "presence", "of", "a", "normal", "pulmonary", "artery", "pressure", ",", "and", "was", "probably", "precipitated", "by", "a", "propafenone", "overdose", ".", "This", "drug", "caused", "biventricular", "dysfunction", ",", "due", "to", "its", "negative", "inotropic", "effect", ",", "and", "hypotension", ",", "due", "to", "its", "peripheral", "vasodilatory", "effect", ".", "These", "effects", "gave", "rise", "to", "an", "increase", "in", "the", "right", "atrial", "pressure", "and", "a", "decrease", "in", "the", "left", "one", "with", "a", "consequent", "stretching", "of", "the", "foramen", "ovale", "and", "the", "creation", "of", "massive", "right", "-", "to", "-", "left", "shunting", ".", "In", "our", "case", "this", "interatrial", "shunt", "was", "very", "accurately", "detected", "at", "bubble", "contrast", "echocardiography", "."]], "ner": [[[9, 9, "Chemical"], [94, 94, "Chemical"], [64, 64, "Disease"], [66, 66, "Disease"], [100, 101, "Disease"], [10, 10, "Disease"], [95, 95, "Disease"], [16, 18, "Disease"], [37, 39, "Disease"], [74, 76, "Disease"], [111, 111, "Disease"]]], "relations": [[[9, 9, 64, 64, "CID"], [94, 94, 64, 64, "CID"], [9, 9, 66, 66, "CID"], [94, 94, 66, 66, "CID"], [9, 9, 100, 101, "CID"], [94, 94, 100, 101, "CID"]]], "clusters": [], "translated": "<0>普罗帕酮</0> <5>过量</5>：在一位患有<7>埃布斯坦氏畸形</7>的年轻女性中引发瞬时扁平呼吸-正畸样综合征。在这份报告中，我们描述了一名患有<8>埃布斯坦氏异常</8>的37岁白人女性的病例，她患上了一种罕见综合征称为扁平呼吸-正畸，其特征是大量的右向左心房分流、一过性的深度<2>缺氧</2>和<3>发绀</3>。这种血液通过<9>未闭的卵圆孔</9>进行分流，且在正常肺动脉压下发生，很可能是由于<1>普罗帕酮</1> <6>过量</6>引起的。该药物通过其负性肌力作用使得双心室功能<4>损害</4>，以及外周血管扩张作用导致<10>低血压</10>。这些影响引起右心房压力上升和左心房压力下降，从而导致了卵圆孔的拉伸和大量的右向左分流。在我们的案例中，这种心房分流被气泡造影超声心动图准确地检测到。", "revised": true}
{"doc_key": "12483326", "sentences": [["Severe", "ocular", "and", "orbital", "toxicity", "after", "intracarotid", "injection", "of", "carboplatin", "for", "recurrent", "glioblastomas", ".", "BACKGROUND", ":", "Glioblastoma", "is", "a", "malignant", "tumor", "that", "occurs", "in", "the", "cerebrum", "during", "adulthood", ".", "With", "current", "treatment", "regimens", "including", "combined", "surgery", ",", "radiation", "and", "chemotherapy", ",", "the", "average", "life", "expectancy", "of", "the", "patients", "is", "limited", "to", "approximately", "1", "year", ".", "Therefore", ",", "patients", "with", "glioblastoma", "sometimes", "have", "intracarotid", "injection", "of", "carcinostatics", "added", "to", "the", "treatment", "regimen", ".", "Generally", ",", "carboplatin", "is", "said", "to", "have", "milder", "side", "effects", "than", "cisplatin", ",", "whose", "ocular", "and", "orbital", "toxicity", "are", "well", "known", ".", "However", ",", "we", "experienced", "a", "case", "of", "severe", "ocular", "and", "orbital", "toxicity", "after", "intracarotid", "injection", "of", "carboplatin", ",", "which", "is", "infrequently", "reported", ".", "CASE", ":", "A", "58", "-", "year", "-", "old", "man", "received", "an", "intracarotid", "injection", "of", "carboplatin", "for", "recurrent", "glioblastomas", "in", "his", "left", "temporal", "lobe", ".", "He", "complained", "of", "pain", "and", "visual", "disturbance", "in", "the", "ipsilateral", "eye", "30", "h", "after", "the", "injection", ".", "Various", "ocular", "symptoms", "and", "findings", "caused", "by", "carboplatin", "toxicity", "were", "seen", ".", "RESULTS", ":", "He", "was", "treated", "with", "intravenous", "administration", "of", "corticosteroids", "and", "glycerin", "for", "6", "days", "after", "the", "injection", ".", "Although", "the", "intraocular", "pressure", "elevation", "caused", "by", "secondary", "acute", "angle", "-", "closure", "glaucoma", "decreased", "and", "ocular", "pain", "diminished", ",", "inexorable", "papilledema", "and", "exudative", "retinal", "detachment", "continued", "for", "3", "weeks", ".", "Finally", ",", "6", "weeks", "later", ",", "diffuse", "chorioretinal", "atrophy", "with", "optic", "atrophy", "occurred", "and", "the", "vision", "in", "his", "left", "eye", "was", "lost", ".", "CONCLUSION", ":", "When", "performing", "intracarotid", "injection", "of", "carboplatin", ",", "we", "must", "be", "aware", "of", "its", "potentially", "blinding", "ocular", "toxicity", ".", "It", "is", "recommended", "that", "further", "studies", "and", "investigations", "are", "undertaken", "in", "the", "effort", "to", "minimize", "such", "severe", "side", "effects", "."]], "ner": [[[9, 9, "Chemical"], [74, 74, "Chemical"], [110, 110, "Chemical"], [131, 131, "Chemical"], [165, 165, "Chemical"], [249, 249, "Chemical"], [1, 4, "Disease"], [86, 89, "Disease"], [102, 105, "Disease"], [144, 151, "Disease"], [204, 205, "Disease"], [209, 209, "Disease"], [212, 213, "Disease"], [229, 230, "Disease"], [259, 260, "Disease"], [83, 83, "Chemical"], [181, 181, "Chemical"], [12, 12, "Disease"], [16, 16, "Disease"], [59, 59, "Disease"], [134, 134, "Disease"], [19, 20, "Disease"], [166, 166, "Disease"], [201, 201, "Disease"], [226, 227, "Disease"]]], "relations": [[[9, 9, 1, 4, "CID"], [9, 9, 86, 89, "CID"], [9, 9, 102, 105, "CID"], [74, 74, 1, 4, "CID"], [74, 74, 86, 89, "CID"], [74, 74, 102, 105, "CID"], [110, 110, 1, 4, "CID"], [110, 110, 86, 89, "CID"], [110, 110, 102, 105, "CID"], [131, 131, 1, 4, "CID"], [131, 131, 86, 89, "CID"], [131, 131, 102, 105, "CID"], [165, 165, 1, 4, "CID"], [165, 165, 86, 89, "CID"], [165, 165, 102, 105, "CID"], [249, 249, 1, 4, "CID"], [249, 249, 86, 89, "CID"], [249, 249, 102, 105, "CID"], [9, 9, 144, 151, "CID"], [9, 9, 204, 205, "CID"], [74, 74, 144, 151, "CID"], [74, 74, 204, 205, "CID"], [110, 110, 144, 151, "CID"], [110, 110, 204, 205, "CID"], [131, 131, 144, 151, "CID"], [131, 131, 204, 205, "CID"], [165, 165, 144, 151, "CID"], [165, 165, 204, 205, "CID"], [249, 249, 144, 151, "CID"], [249, 249, 204, 205, "CID"], [9, 9, 209, 209, "CID"], [74, 74, 209, 209, "CID"], [110, 110, 209, 209, "CID"], [131, 131, 209, 209, "CID"], [165, 165, 209, 209, "CID"], [249, 249, 209, 209, "CID"], [9, 9, 212, 213, "CID"], [74, 74, 212, 213, "CID"], [110, 110, 212, 213, "CID"], [131, 131, 212, 213, "CID"], [165, 165, 212, 213, "CID"], [249, 249, 212, 213, "CID"], [9, 9, 229, 230, "CID"], [74, 74, 229, 230, "CID"], [110, 110, 229, 230, "CID"], [131, 131, 229, 230, "CID"], [165, 165, 229, 230, "CID"], [249, 249, 229, 230, "CID"]]], "clusters": [], "translated": "<0>卡铂</0> 复发性<17>胶质母细胞瘤</17>颈动脉内注射后严重<6>眼和眼眶毒性</6>。 背景： <18>胶质母细胞瘤</18>是一种发生于成年期大脑的<21>恶性肿瘤</21>。目前的治疗方案包括手术、放疗和化疗，患者的平均预期寿命被限制在大约1年。因此，<19>胶质母细胞瘤</19>患者有时会在治疗方案中加入颈动脉内注射抑癌剂。一般而言，据说<1>卡铂</1>的副作用比<15>顺铂</15>轻，后者的<7>眼和眼眶毒性</7>是众所周知的。然而，我们经历了一例在颈动脉内注射<2>卡铂</2>后出现严重<8>眼和眼眶毒性</8>的病例，这很少见报道。 案例：一名58岁的男性因左颞叶复发性<20>胶质母细胞瘤</20>接受了颈动脉内注射<3>卡铂</3>。注射后30小时，他诉同侧<9>眼疼痛和视力障碍</9>。可见<4>卡铂</4><22>毒性</22>引起的各种眼部症状和表现。 结果：注射后给予皮质类固醇和<16>甘油</16>静脉注射治疗6天。虽然继发性急性闭角型青光眼引起的眼压升高已经<23>下降</23>，<10>眼痛</10>减轻，但<11>视乳头水肿</11>和<12>渗出性视网膜脱离</12>持续了3周。最后6周后，弥漫性<24>脉络膜视网膜萎缩</24>伴有<13>视神经萎缩</13>，导致左眼失明。 结论：颈动脉内注射<5>卡铂</5>时，必须注意其潜在的<14>眼毒性</14>致盲。建议进行进一步的研究和调查，以尽量减少这种严重的副作用。", "revised": true}
{"doc_key": "3985451", "sentences": [["Warfarin", "-", "induced", "iliopsoas", "hemorrhage", "with", "subsequent", "femoral", "nerve", "palsy", ".", "We", "present", "the", "case", "of", "a", "28", "-", "year", "-", "old", "man", "on", "chronic", "warfarin", "therapy", "who", "sustained", "a", "minor", "muscle", "tear", "and", "developed", "increasing", "pain", "and", "a", "flexure", "contracture", "of", "the", "right", "hip", ".", "Surgical", "exploration", "revealed", "an", "iliopsoas", "hematoma", "and", "femoral", "nerve", "entrapment", ",", "resulting", "in", "a", "femoral", "nerve", "palsy", "and", "partial", "loss", "of", "quadriceps", "functions", ".", "Anticoagulant", "-", "induced", "femoral", "nerve", "palsy", "represents", "the", "most", "common", "form", "of", "warfarin", "-", "induced", "peripheral", "neuropathy", ";", "it", "is", "characterized", "by", "severe", "pain", "in", "the", "inguinal", "region", ",", "varying", "degrees", "of", "motor", "and", "sensory", "impairment", ",", "and", "flexure", "contracture", "of", "the", "involved", "extremity", "."]], "ner": [[[0, 0, "Chemical"], [25, 25, "Chemical"], [82, 82, "Chemical"], [7, 9, "Disease"], [60, 62, "Disease"], [73, 75, "Disease"], [31, 32, "Disease"], [64, 68, "Disease"], [51, 51, "Disease"], [54, 55, "Disease"], [4, 4, "Disease"], [36, 36, "Disease"], [93, 93, "Disease"], [40, 40, "Disease"], [109, 109, "Disease"], [85, 86, "Disease"], [102, 105, "Disease"]]], "relations": [[[0, 0, 7, 9, "CID"], [0, 0, 60, 62, "CID"], [0, 0, 73, 75, "CID"], [25, 25, 7, 9, "CID"], [25, 25, 60, 62, "CID"], [25, 25, 73, 75, "CID"], [82, 82, 7, 9, "CID"], [82, 82, 60, 62, "CID"], [82, 82, 73, 75, "CID"], [0, 0, 31, 32, "CID"], [0, 0, 64, 68, "CID"], [25, 25, 31, 32, "CID"], [25, 25, 64, 68, "CID"], [82, 82, 31, 32, "CID"], [82, 82, 64, 68, "CID"], [0, 0, 51, 51, "CID"], [25, 25, 51, 51, "CID"], [82, 82, 51, 51, "CID"], [0, 0, 54, 55, "CID"], [25, 25, 54, 55, "CID"], [82, 82, 54, 55, "CID"]]], "clusters": [], "translated": " <0>华法林</0> - 诱发髂腰肌<10>出血</10>，随后<3>股神经麻痹</3>。我们介绍了一名长期接受<1>华法林</1>治疗的 28 岁男性的案例，该患者持续轻微的<6>肌肉撕裂</6>并出现越来越严重的<11>疼痛</11>和屈曲<13>挛缩</13>右髋。手术探查发现髂腰肌<8>血肿</8>和股骨<9>神经卡压</9>，导致<4>股神经麻痹</4>和<7>股四头肌部分功能丧失</7>。抗凝剂引起的<5>股神经麻痹</5>是<2>华法林</2>引起的<15>周围神经病变</15>的最常见形式；以腹股沟区剧烈<12>疼痛</12>、不同程度<16>运动和感觉障碍</16>、受累肢体屈曲<14>挛缩</14>为特征。", "revised": true}
{"doc_key": "18544179", "sentences": [["Omitting", "fentanyl", "reduces", "nausea", "and", "vomiting", ",", "without", "increasing", "pain", ",", "after", "sevoflurane", "for", "day", "surgery", ".", "BACKGROUND", "AND", "OBJECTIVE", ":", "Despite", "advantages", "of", "induction", "and", "maintenance", "of", "anaesthesia", "with", "sevoflurane", ",", "postoperative", "nausea", "and", "vomiting", "occurs", "frequently", ".", "Fentanyl", "is", "a", "commonly", "used", "supplement", "that", "may", "contribute", "to", "this", ",", "although", "it", "may", "also", "improve", "analgesia", ".", "METHODS", ":", "This", "double", "-", "blind", "study", "examined", "the", "incidence", "and", "severity", "of", "postoperative", "nausea", "and", "vomiting", "and", "pain", "in", "the", "first", "24", "h", "after", "sevoflurane", "anaesthesia", "in", "216", "adult", "day", "surgery", "patients", ".", "Patients", "were", "randomly", "allocated", "to", "either", "receive", "or", "not", "receive", "1", "1", "fentanyl", ",", "while", "a", "third", "group", "received", "dexamethasone", "in", "addition", "to", "fentanyl", ".", "RESULTS", ":", "Omission", "of", "fentanyl", "did", "not", "reduce", "the", "overall", "incidence", "of", "postoperative", "nausea", "and", "vomiting", ",", "but", "did", "reduce", "the", "incidence", "of", "vomiting", "and", "/", "or", "moderate", "to", "severe", "nausea", "prior", "to", "discharge", "from", "20", "%", "and", "17", "%", "with", "fentanyl", "and", "fentanyl", "-", "dexamethasone", ",", "respectively", ",", "to", "5", "%", "(", "P", "=", "0", ".", "013", ")", ".", "Antiemetic", "requirements", "were", "reduced", "from", "24", "%", "and", "31", "%", "to", "7", "%", "(", "P", "=", "0", ".", "0012", ")", ".", "Dexamethasone", "had", "no", "significant", "effect", "on", "the", "incidence", "or", "severity", "of", "postoperative", "nausea", "and", "vomiting", ".", "Combining", "the", "two", "fentanyl", "groups", "revealed", "further", "significant", "benefits", "from", "the", "avoidance", "of", "opioids", ",", "reducing", "postoperative", "nausea", "and", "vomiting", "and", "nausea", "prior", "to", "discharge", "from", "35", "%", "and", "33", "%", "to", "22", "%", "and", "19", "%", "(", "P", "=", "0", ".", "049", "and", "P", "=", "0", ".", "035", ")", ",", "respectively", ",", "while", "nausea", "in", "the", "first", "24", "h", "was", "decreased", "from", "42", "%", "to", "27", "%", "(", "P", "=", "0", ".", "034", ")", ".", "Pain", "severity", "and", "analgesic", "requirements", "were", "unaffected", "by", "the", "omission", "of", "fentanyl", ".", "Fentanyl", "did", "reduce", "minor", "intraoperative", "movement", "but", "had", "no", "sevoflurane", "-", "sparing", "effect", "and", "increased", "respiratory", "depression", ",", "hypotension", "and", "bradycardia", ".", "CONCLUSION", ":", "As", "fentanyl", "exacerbated", "postoperative", "nausea", "and", "vomiting", "without", "an", "improvement", "in", "postoperative", "pain", "and", "also", "had", "adverse", "cardiorespiratory", "effects", ",", "it", "appears", "to", "be", "an", "unnecessary", "and", "possibly", "detrimental", "supplement", "to", "sevoflurane", "in", "day", "surgery", "."]], "ner": [[[1, 1, "Chemical"], [39, 39, "Chemical"], [104, 104, "Chemical"], [115, 115, "Chemical"], [121, 121, "Chemical"], [158, 158, "Chemical"], [160, 160, "Chemical"], [217, 217, "Chemical"], [301, 301, "Chemical"], [303, 303, "Chemical"], [328, 328, "Chemical"], [32, 35, "Disease"], [71, 74, "Disease"], [129, 132, "Disease"], [209, 212, "Disease"], [230, 233, "Disease"], [330, 333, "Disease"], [318, 319, "Disease"], [321, 321, "Disease"], [323, 323, "Disease"], [3, 3, "Disease"], [147, 147, "Disease"], [235, 235, "Disease"], [268, 268, "Disease"], [5, 5, "Disease"], [140, 140, "Disease"], [9, 9, "Disease"], [76, 76, "Disease"], [290, 290, "Disease"], [338, 339, "Disease"], [12, 12, "Chemical"], [30, 30, "Chemical"], [83, 83, "Chemical"], [312, 312, "Chemical"], [358, 358, "Chemical"], [111, 111, "Chemical"], [162, 162, "Chemical"], [198, 198, "Chemical"]]], "relations": [[[1, 1, 32, 35, "CID"], [1, 1, 71, 74, "CID"], [1, 1, 129, 132, "CID"], [1, 1, 209, 212, "CID"], [1, 1, 230, 233, "CID"], [1, 1, 330, 333, "CID"], [39, 39, 32, 35, "CID"], [39, 39, 71, 74, "CID"], [39, 39, 129, 132, "CID"], [39, 39, 209, 212, "CID"], [39, 39, 230, 233, "CID"], [39, 39, 330, 333, "CID"], [104, 104, 32, 35, "CID"], [104, 104, 71, 74, "CID"], [104, 104, 129, 132, "CID"], [104, 104, 209, 212, "CID"], [104, 104, 230, 233, "CID"], [104, 104, 330, 333, "CID"], [115, 115, 32, 35, "CID"], [115, 115, 71, 74, "CID"], [115, 115, 129, 132, "CID"], [115, 115, 209, 212, "CID"], [115, 115, 230, 233, "CID"], [115, 115, 330, 333, "CID"], [121, 121, 32, 35, "CID"], [121, 121, 71, 74, "CID"], [121, 121, 129, 132, "CID"], [121, 121, 209, 212, "CID"], [121, 121, 230, 233, "CID"], [121, 121, 330, 333, "CID"], [158, 158, 32, 35, "CID"], [158, 158, 71, 74, "CID"], [158, 158, 129, 132, "CID"], [158, 158, 209, 212, "CID"], [158, 158, 230, 233, "CID"], [158, 158, 330, 333, "CID"], [160, 160, 32, 35, "CID"], [160, 160, 71, 74, "CID"], [160, 160, 129, 132, "CID"], [160, 160, 209, 212, "CID"], [160, 160, 230, 233, "CID"], [160, 160, 330, 333, "CID"], [217, 217, 32, 35, "CID"], [217, 217, 71, 74, "CID"], [217, 217, 129, 132, "CID"], [217, 217, 209, 212, "CID"], [217, 217, 230, 233, "CID"], [217, 217, 330, 333, "CID"], [301, 301, 32, 35, "CID"], [301, 301, 71, 74, "CID"], [301, 301, 129, 132, "CID"], [301, 301, 209, 212, "CID"], [301, 301, 230, 233, "CID"], [301, 301, 330, 333, "CID"], [303, 303, 32, 35, "CID"], [303, 303, 71, 74, "CID"], [303, 303, 129, 132, "CID"], [303, 303, 209, 212, "CID"], [303, 303, 230, 233, "CID"], [303, 303, 330, 333, "CID"], [328, 328, 32, 35, "CID"], [328, 328, 71, 74, "CID"], [328, 328, 129, 132, "CID"], [328, 328, 209, 212, "CID"], [328, 328, 230, 233, "CID"], [328, 328, 330, 333, "CID"], [1, 1, 318, 319, "CID"], [39, 39, 318, 319, "CID"], [104, 104, 318, 319, "CID"], [115, 115, 318, 319, "CID"], [121, 121, 318, 319, "CID"], [158, 158, 318, 319, "CID"], [160, 160, 318, 319, "CID"], [217, 217, 318, 319, "CID"], [301, 301, 318, 319, "CID"], [303, 303, 318, 319, "CID"], [328, 328, 318, 319, "CID"], [1, 1, 321, 321, "CID"], [39, 39, 321, 321, "CID"], [104, 104, 321, 321, "CID"], [115, 115, 321, 321, "CID"], [121, 121, 321, 321, "CID"], [158, 158, 321, 321, "CID"], [160, 160, 321, 321, "CID"], [217, 217, 321, 321, "CID"], [301, 301, 321, 321, "CID"], [303, 303, 321, 321, "CID"], [328, 328, 321, 321, "CID"], [1, 1, 323, 323, "CID"], [39, 39, 323, 323, "CID"], [104, 104, 323, 323, "CID"], [115, 115, 323, 323, "CID"], [121, 121, 323, 323, "CID"], [158, 158, 323, 323, "CID"], [160, 160, 323, 323, "CID"], [217, 217, 323, 323, "CID"], [301, 301, 323, 323, "CID"], [303, 303, 323, 323, "CID"], [328, 328, 323, 323, "CID"]]], "clusters": [], "translated": "省略<0>芬太尼</0>减少<20>恶心</20>和<24>呕吐</24>，不增加<26>疼痛</26>，<30>七氟醚</30>天后外科手术。背景与目的：尽管<31>七氟烷</31>麻醉的诱导和维持具有优势，但<11>术后恶心呕吐</11>的发生率较高。<1>芬太尼</1>是一种常用的补充剂，可能有助于此，尽管它也可能改善镇痛。方法：这项双盲研究检查了216名成人日间手术患者，在<32>七氟醚</32>麻醉后第一个24小时内<12>术后恶心和呕吐</12>和<27>疼痛</27>的发生率和严重程度。患者被随机分配到接受或不接受<2>芬太尼</2>，而第三组除<3>芬太尼</3>外还接受<35>地塞米松</35>。结果：省略<4>芬太尼</4>并未降低<13>术后恶心和呕吐</13>的总体发生率，但确实降低了<25>呕吐</25>和/或中度至出院前严重<21>恶心</21>，分别从20%和17%使用<5>芬太尼</5>和<6>芬太尼</6>-<36>地塞米松</36>至5%(P=0.013)。止吐需求从24%和31%减少到7% (P=0.0012)。<37>地塞米松</37>对<14>术后恶心呕吐</14>的发生率或严重程度无显着影响。结合两个<7>芬太尼</7>组显示避免阿片类药物的进一步显着益处，减少<15>术后恶心和呕吐</15>和<22>恶心</22>出院前35%和33%至22%和19% (P=0.049和P=0.035)，而<23>恶心</23>在第一个24小时内从42%减少到27% (P=0.034)。<28>疼痛</28>严重程度和镇痛要求未受到<8>芬太尼</8>遗漏的影响。<9>芬太尼</9>确实减少了术中的轻微运动，但没有<33>七氟烷</33>-保护作用，并增加了<17>呼吸抑制</17>、<18>低血压</18>和<19>心动过缓</19>。结论：由于<10>芬太尼</10>加剧了<16>术后恶心和呕吐</16>，而<29>术后疼痛</29>没有改善，而且还具有不良的心肺作用，因此似乎是不必要的和日间手术中<34>七氟烷</34>的补充可能有害。", "revised": true}
{"doc_key": "16867021", "sentences": [["Antipsychotic", "-", "like", "profile", "of", "thioperamide", ",", "a", "selective", "H3", "-", "receptor", "antagonist", "in", "mice", ".", "Experimental", "and", "clinical", "evidence", "points", "to", "a", "role", "of", "central", "histaminergic", "system", "in", "the", "pathogenesis", "of", "schizophrenia", ".", "The", "present", "study", "was", "designed", "to", "study", "the", "effect", "of", "histamine", "H", "(", "3", ")", "-", "receptor", "ligands", "on", "neuroleptic", "-", "induced", "catalepsy", ",", "apomorphine", "-", "induced", "climbing", "behavior", "and", "amphetamine", "-", "induced", "locomotor", "activities", "in", "mice", ".", "Catalepsy", "was", "induced", "by", "haloperidol", "(", "2", "mg", "/", "kg", "p", ".", "o", ".", ")", ",", "while", "apomorphine", "(", "1", ".", "5", "mg", "/", "kg", "s", ".", "c", ".", ")", "and", "amphetamine", "(", "2", "mg", "/", "kg", "s", ".", "c", ".", ")", "were", "used", "for", "studying", "climbing", "behavior", "and", "locomotor", "activities", ",", "respectively", ".", "(", "R", ")", "-", "alpha", "-", "methylhistamine", "(", "RAMH", ")", "(", "5", "microg", "i", ".", "c", ".", "v", ".", ")", "and", "thioperamide", "(", "THP", ")", "(", "15", "mg", "/", "kg", "i", ".", "p", ".", ")", ",", "per", "se", "did", "not", "cause", "catalepsy", ".", "Administration", "of", "THP", "(", "3", ".", "75", ",", "7", ".", "5", "and", "15", "mg", "/", "kg", "i", ".", "p", ".", ")", "1", "h", "prior", "to", "haloperidol", "resulted", "in", "a", "dose", "-", "dependent", "increase", "in", "the", "catalepsy", "times", "(", "P", "<", "0", ".", "05", ")", ".", "However", ",", "pretreatment", "with", "RAMH", "significantly", "reversed", "such", "an", "effect", "of", "THP", "(", "15", "mg", "/", "kg", "i", ".", "p", ".", ")", ".", "RAMH", "per", "se", "showed", "significant", "reduction", "in", "locomotor", "time", ",", "distance", "traveled", "and", "average", "speed", "but", "THP", "(", "15", "mg", "/", "kg", "i", ".", "p", ".", ")", "per", "se", "had", "no", "effect", "on", "these", "parameters", ".", "On", "amphetamine", "-", "induced", "hyperactivity", ",", "THP", "(", "3", ".", "75", "and", "7", ".", "5", "mg", "/", "kg", "i", ".", "p", ".", ")", "reduced", "locomotor", "time", ",", "distance", "traveled", "and", "average", "speed", "(", "P", "<", "0", ".", "05", ")", ".", "Pretreatment", "with", "RAMH", "(", "5", "microg", "i", ".", "c", ".", "v", ".", ")", "could", "partially", "reverse", "such", "effects", "of", "THP", "(", "3", ".", "75", "mg", "/", "kg", "i", ".", "p", ".", ")", ".", "Climbing", "behavior", "induced", "by", "apomorphine", "was", "reduced", "in", "animals", "treated", "with", "THP", ".", "Such", "an", "effect", "was", ",", "however", ",", "reversed", "in", "presence", "of", "RAMH", ".", "THP", "exhibited", "an", "antipsychotic", "-", "like", "profile", "by", "potentiating", "haloperidol", "-", "induced", "catalepsy", ",", "reducing", "amphetamine", "-", "induced", "hyperactivity", "and", "reducing", "apomorphine", "-", "induced", "climbing", "in", "mice", ".", "Such", "effects", "of", "THP", "were", "reversed", "by", "RAMH", "indicating", "the", "involvement", "of", "histamine", "H", "(", "3", ")", "-", "receptors", ".", "Findings", "suggest", "a", "potential", "for", "H", "(", "3", ")", "-", "receptor", "antagonists", "in", "improving", "the", "refractory", "cases", "of", "schizophrenia", "."]], "ner": [[[5, 5, "Chemical"], [147, 147, "Chemical"], [149, 149, "Chemical"], [171, 171, "Chemical"], [225, 225, "Chemical"], [253, 253, "Chemical"], [279, 279, "Chemical"], [332, 332, "Chemical"], [357, 357, "Chemical"], [372, 372, "Chemical"], [403, 403, "Chemical"], [56, 56, "Disease"], [72, 72, "Disease"], [167, 167, "Disease"], [204, 204, "Disease"], [384, 384, "Disease"], [76, 76, "Chemical"], [194, 194, "Chemical"], [381, 381, "Chemical"], [64, 64, "Chemical"], [103, 103, "Chemical"], [274, 274, "Chemical"], [387, 387, "Chemical"], [277, 277, "Disease"], [390, 390, "Disease"], [32, 32, "Disease"], [438, 438, "Disease"], [44, 44, "Chemical"], [412, 412, "Chemical"], [58, 58, "Chemical"], [89, 89, "Chemical"], [350, 350, "Chemical"], [393, 393, "Chemical"], [126, 132, "Chemical"], [134, 134, "Chemical"], [218, 218, "Chemical"], [237, 237, "Chemical"], [315, 315, "Chemical"], [370, 370, "Chemical"], [407, 407, "Chemical"]]], "relations": [[[5, 5, 56, 56, "CID"], [5, 5, 72, 72, "CID"], [5, 5, 167, 167, "CID"], [5, 5, 204, 204, "CID"], [5, 5, 384, 384, "CID"], [147, 147, 56, 56, "CID"], [147, 147, 72, 72, "CID"], [147, 147, 167, 167, "CID"], [147, 147, 204, 204, "CID"], [147, 147, 384, 384, "CID"], [149, 149, 56, 56, "CID"], [149, 149, 72, 72, "CID"], [149, 149, 167, 167, "CID"], [149, 149, 204, 204, "CID"], [149, 149, 384, 384, "CID"], [171, 171, 56, 56, "CID"], [171, 171, 72, 72, "CID"], [171, 171, 167, 167, "CID"], [171, 171, 204, 204, "CID"], [171, 171, 384, 384, "CID"], [225, 225, 56, 56, "CID"], [225, 225, 72, 72, "CID"], [225, 225, 167, 167, "CID"], [225, 225, 204, 204, "CID"], [225, 225, 384, 384, "CID"], [253, 253, 56, 56, "CID"], [253, 253, 72, 72, "CID"], [253, 253, 167, 167, "CID"], [253, 253, 204, 204, "CID"], [253, 253, 384, 384, "CID"], [279, 279, 56, 56, "CID"], [279, 279, 72, 72, "CID"], [279, 279, 167, 167, "CID"], [279, 279, 204, 204, "CID"], [279, 279, 384, 384, "CID"], [332, 332, 56, 56, "CID"], [332, 332, 72, 72, "CID"], [332, 332, 167, 167, "CID"], [332, 332, 204, 204, "CID"], [332, 332, 384, 384, "CID"], [357, 357, 56, 56, "CID"], [357, 357, 72, 72, "CID"], [357, 357, 167, 167, "CID"], [357, 357, 204, 204, "CID"], [357, 357, 384, 384, "CID"], [372, 372, 56, 56, "CID"], [372, 372, 72, 72, "CID"], [372, 372, 167, 167, "CID"], [372, 372, 204, 204, "CID"], [372, 372, 384, 384, "CID"], [403, 403, 56, 56, "CID"], [403, 403, 72, 72, "CID"], [403, 403, 167, 167, "CID"], [403, 403, 204, 204, "CID"], [403, 403, 384, 384, "CID"], [76, 76, 56, 56, "CID"], [76, 76, 72, 72, "CID"], [76, 76, 167, 167, "CID"], [76, 76, 204, 204, "CID"], [76, 76, 384, 384, "CID"], [194, 194, 56, 56, "CID"], [194, 194, 72, 72, "CID"], [194, 194, 167, 167, "CID"], [194, 194, 204, 204, "CID"], [194, 194, 384, 384, "CID"], [381, 381, 56, 56, "CID"], [381, 381, 72, 72, "CID"], [381, 381, 167, 167, "CID"], [381, 381, 204, 204, "CID"], [381, 381, 384, 384, "CID"], [64, 64, 277, 277, "CID"], [64, 64, 390, 390, "CID"], [103, 103, 277, 277, "CID"], [103, 103, 390, 390, "CID"], [274, 274, 277, 277, "CID"], [274, 274, 390, 390, "CID"], [387, 387, 277, 277, "CID"], [387, 387, 390, 390, "CID"]]], "clusters": [], "translated": "<0>thioperamide</0> 的抗精神病药样特征，一种在小鼠中的选择性 H3 受体拮抗剂。实验和临床证据表明中枢组胺能系统在<25>精神分裂症</25>的发病机制中发挥作用。本研究旨在研究<27>组胺</27>H(3)-受体配体对神经安定药引起的<11>强直性昏厥</11>、<29>阿扑吗啡</29>引起的攀爬行为的影响和<19>苯丙胺</19> - 诱导小鼠的运动活动。<12>强直性昏厥</12>由<16>氟哌啶醇</16>（2 mg/kg p.o.）诱导，而<30>阿扑吗啡</30>（1.5 mg/kg s.c.）和<20>苯丙胺</20> (2 mg/kg s.c.)分别用于研究攀爬行为和运动活动。<33>(R)-α-甲基组胺</33>(<34>RAMH</34>) (5 μg i.c.v.)和<1>thioperamide</1>(<2>THP</2>) (15 mg/kg i.p.)，本身不会引起<13>强直性昏厥</13>。在<17>氟哌啶醇</17>前1小时给予<3>THP</3>（3.75、7.5和15 mg/kg i.p.）导致剂量依赖性增加<14>强直次</14> (P<0.05)。然而，用<35>RAMH</35>预处理显着逆转了<4>THP</4> (15 mg/kg i.p.)的这种作用。<36>RAMH</36>本身显示运动时间、行进距离和平均速度显着减少，但<5>THP</5>（15 mg/kg i.p.）本身对这些参数没有影响。在<21>苯丙胺</21>诱导的<23>多动性</23>，<6>THP</6>（3.75和7.5 mg/kg i.p.）减少运动时间，行进距离和平均速度（P<0.05）。用<37>RAMH</37> (5 μg i.c.v.)预处理可部分逆转<7>THP</7> (3.75 mg/kg i.p.)的这种作用。<8>THP</8>处理的动物中<31>阿扑吗啡</31>诱导的攀爬行为减少。然而，这种效果在<38>RAMH</38>的存在下被逆转。<9>THP</9>通过增强<18>氟哌啶醇</18>诱导的<15>强直性昏厥</15>，减少<22>苯丙胺</22>诱导的<24>多动症</24>，表现出类似抗精神病药的特征并减少<32>阿朴吗啡</32>诱导的小鼠攀爬。<10>THP</10>的这种作用被<39>RAMH</39>逆转，表明<28>组胺</28>H(3)-受体的参与。研究结果表明H(3)-受体拮抗剂在改善难治性<26>精神分裂症</26>方面具有潜力。", "revised": true}
{"doc_key": "19445921", "sentences": [["Cardioprotective", "effect", "of", "salvianolic", "acid", "A", "on", "isoproterenol", "-", "induced", "myocardial", "infarction", "in", "rats", ".", "The", "present", "study", "was", "designed", "to", "evaluate", "the", "cardioprotective", "potential", "of", "salvianolic", "acid", "A", "on", "isoproterenol", "-", "induced", "myocardial", "infarction", "in", "rats", ".", "Hemodynamic", "parameters", "and", "lead", "II", "electrocardiograph", "were", "monitored", "and", "recorded", "continuously", ".", "Cardiac", "marker", "enzymes", "and", "antioxidative", "parameters", "in", "serum", "and", "heart", "tissues", "were", "measured", ".", "Assay", "for", "mitochondrial", "respiratory", "function", "and", "histopathological", "examination", "of", "heart", "tissues", "were", "performed", ".", "Isoproterenol", "-", "treated", "rats", "showed", "significant", "increases", "in", "the", "levels", "of", "lactate", "dehydrogenase", ",", "aspartate", "transaminase", ",", "creatine", "kinase", "and", "malondialdehyde", "and", "significant", "decreases", "in", "the", "activities", "of", "superoxide", "dismutase", ",", "catalase", "and", "glutathione", "peroxidase", "in", "serum", "and", "heart", ".", "These", "rats", "also", "showed", "declines", "in", "left", "ventricular", "systolic", "pressure", ",", "maximum", "and", "minimum", "rate", "of", "developed", "left", "ventricular", "pressure", ",", "and", "elevation", "of", "left", "ventricular", "end", "-", "diastolic", "pressure", "and", "ST", "-", "segment", ".", "In", "addition", ",", "mitochondrial", "respiratory", "dysfunction", "characterized", "by", "decreased", "respiratory", "control", "ratio", "and", "ADP", "/", "O", "was", "observed", "in", "isoproterenol", "-", "treated", "rats", ".", "Administration", "of", "salvianolic", "acid", "A", "for", "a", "period", "of", "8", "days", "significantly", "attenuated", "isoproterenol", "-", "induced", "cardiac", "dysfunction", "and", "myocardial", "injury", "and", "improved", "mitochondrial", "respiratory", "function", ".", "The", "protective", "role", "of", "salvianolic", "acid", "A", "against", "isoproterenol", "-", "induced", "myocardial", "damage", "was", "further", "confirmed", "by", "histopathological", "examination", ".", "The", "results", "of", "our", "study", "suggest", "that", "salvianolic", "acid", "A", "possessing", "antioxidant", "activity", "has", "a", "significant", "protective", "effect", "against", "isoproterenol", "-", "induced", "myocardial", "infarction", "."]], "ner": [[[7, 7, "Chemical"], [30, 30, "Chemical"], [78, 78, "Chemical"], [172, 172, "Chemical"], [190, 190, "Chemical"], [212, 212, "Chemical"], [243, 243, "Chemical"], [10, 11, "Disease"], [33, 34, "Disease"], [246, 247, "Disease"], [3, 5, "Chemical"], [26, 28, "Chemical"], [179, 181, "Chemical"], [208, 210, "Chemical"], [231, 233, "Chemical"], [157, 158, "Disease"], [193, 194, "Disease"], [196, 197, "Disease"], [215, 216, "Disease"], [89, 89, "Chemical"], [92, 92, "Chemical"], [95, 95, "Chemical"], [98, 98, "Chemical"], [106, 106, "Chemical"], [111, 111, "Chemical"], [166, 166, "Chemical"]]], "relations": [[[7, 7, 10, 11, "CID"], [7, 7, 33, 34, "CID"], [7, 7, 246, 247, "CID"], [30, 30, 10, 11, "CID"], [30, 30, 33, 34, "CID"], [30, 30, 246, 247, "CID"], [78, 78, 10, 11, "CID"], [78, 78, 33, 34, "CID"], [78, 78, 246, 247, "CID"], [172, 172, 10, 11, "CID"], [172, 172, 33, 34, "CID"], [172, 172, 246, 247, "CID"], [190, 190, 10, 11, "CID"], [190, 190, 33, 34, "CID"], [190, 190, 246, 247, "CID"], [212, 212, 10, 11, "CID"], [212, 212, 33, 34, "CID"], [212, 212, 246, 247, "CID"], [243, 243, 10, 11, "CID"], [243, 243, 33, 34, "CID"], [243, 243, 246, 247, "CID"]]], "clusters": [], "translated": "<10>丹酚酸A</10> 对 <0>异丙肾上腺素</0> 所致大鼠<7>心肌梗死</7>的心脏保护作用。本研究旨在评估<11>丹酚酸A</11> 对<1>异丙肾上腺素</1> 诱导的大鼠<8>心肌梗死</8>的心脏保护作用。连续监测和记录血流动力学参数和导联 II 心电图。测量了血清和心脏组织中的心脏标记酶和抗氧化参数。进行了线粒体呼吸 功能测定和心脏组织的组织病理学检查。<2> 异丙肾上腺素 </2>-处理的大鼠显示显著升高血清和心脏<19>乳酸</19>脱氢酶、<20>天冬氨酸</20>转氨酶、<21>肌酸</21>激酶和<22>丙-2-醛</22>的水平，但血清和心脏<23>超氧化物</23>歧化酶、过氧化氢酶和<24>谷胱甘肽</24>过氧化物酶活性显著降低。这些大鼠还表现出左心室收缩压下降、左心室压力发展的最大和最小速率以及左心室舒张末期压力和 ST 段升高。此外，在<3>异丙肾上腺素</3>处理的大鼠中观察到以呼吸控制比和<25>ADP</25>/O降低为特征的线粒体<15>呼吸功能障碍</15>。给予 <12>丹酚酸A</12> 治疗8天可显著减轻<4>异丙肾上腺素</4>引起的<16>心功能不全</16>和<17>心肌损伤</17>，并改善线粒体呼吸功能。组织病理学检查进一步证实了<13>丹酚酸A</13>对<5>异丙肾上腺素</5>所致<18>心肌损伤</18>的保护作用。本研究结果表明，具有抗氧化活性的<14>丹酚酸A</14>对<6>异丙肾上腺素</6>诱导的<9>心肌梗死</9>具有显著的保护作用。", "revised": true}
{"doc_key": "12921865", "sentences": [["Protective", "efficacy", "of", "neuroactive", "steroids", "against", "cocaine", "kindled", "-", "seizures", "in", "mice", ".", "Neuroactive", "steroids", "demonstrate", "pharmacological", "actions", "that", "have", "relevance", "for", "a", "host", "of", "neurological", "and", "psychiatric", "disorders", ".", "They", "offer", "protection", "against", "seizures", "in", "a", "range", "of", "models", "and", "seem", "to", "inhibit", "certain", "stages", "of", "drug", "dependence", "in", "preclinical", "assessments", ".", "The", "present", "study", "was", "designed", "to", "evaluate", "two", "endogenous", "and", "one", "synthetic", "neuroactive", "steroid", "that", "positively", "modulate", "the", "gamma", "-", "aminobutyric", "acid", "(", "GABA", "(", "A", ")", ")", "receptor", "against", "the", "increase", "in", "sensitivity", "to", "the", "convulsant", "effects", "of", "cocaine", "engendered", "by", "repeated", "cocaine", "administration", "(", "seizure", "kindling", ")", ".", "Allopregnanolone", "(", "3alpha", "-", "hydroxy", "-", "5alpha", "-", "pregnan", "-", "20", "-", "one", ")", ",", "pregnanolone", "(", "3alpha", "-", "hydroxy", "-", "5beta", "-", "pregnan", "-", "20", "-", "one", ")", "and", "ganaxolone", "(", "a", "synthetic", "derivative", "of", "allopregnanolone", "3alpha", "-", "hydroxy", "-", "3beta", "-", "methyl", "-", "5alpha", "-", "pregnan", "-", "20", "-", "one", ")", "were", "tested", "for", "their", "ability", "to", "suppress", "the", "expression", "(", "anticonvulsant", "effect", ")", "and", "development", "(", "antiepileptogenic", "effect", ")", "of", "cocaine", "-", "kindled", "seizures", "in", "male", ",", "Swiss", "-", "Webster", "mice", ".", "Kindled", "seizures", "were", "induced", "by", "daily", "administration", "of", "60", "mg", "/", "kg", "cocaine", "for", "5", "days", ".", "All", "of", "these", "positive", "GABA", "(", "A", ")", "modulators", "suppressed", "the", "expression", "of", "kindled", "seizures", ",", "whereas", "only", "allopregnanolone", "and", "ganaxolone", "inhibited", "the", "development", "of", "kindling", ".", "Allopregnanolone", "and", "pregnanolone", ",", "but", "not", "ganaxolone", ",", "also", "reduced", "cumulative", "lethality", "associated", "with", "kindling", ".", "These", "findings", "demonstrate", "that", "some", "neuroactive", "steroids", "attenuate", "convulsant", "and", "sensitizing", "properties", "of", "cocaine", "and", "add", "to", "a", "growing", "literature", "on", "their", "potential", "use", "in", "the", "modulation", "of", "effects", "of", "drugs", "of", "abuse", "."]], "ner": [[[6, 6, "Chemical"], [92, 92, "Chemical"], [96, 96, "Chemical"], [176, 176, "Chemical"], [200, 200, "Chemical"], [261, 261, "Chemical"], [9, 9, "Disease"], [34, 34, "Disease"], [99, 99, "Disease"], [179, 179, "Disease"], [189, 189, "Disease"], [219, 219, "Disease"], [4, 4, "Chemical"], [14, 14, "Chemical"], [66, 66, "Chemical"], [254, 254, "Chemical"], [25, 28, "Disease"], [47, 48, "Disease"], [71, 74, "Chemical"], [76, 76, "Chemical"], [209, 209, "Chemical"], [103, 103, "Chemical"], [105, 115, "Chemical"], [118, 118, "Chemical"], [120, 130, "Chemical"], [139, 139, "Chemical"], [223, 223, "Chemical"], [232, 232, "Chemical"], [234, 234, "Chemical"], [133, 133, "Chemical"], [140, 154, "Chemical"], [225, 225, "Chemical"], [238, 238, "Chemical"]]], "relations": [[[6, 6, 9, 9, "CID"], [6, 6, 34, 34, "CID"], [6, 6, 99, 99, "CID"], [6, 6, 179, 179, "CID"], [6, 6, 189, 189, "CID"], [6, 6, 219, 219, "CID"], [92, 92, 9, 9, "CID"], [92, 92, 34, 34, "CID"], [92, 92, 99, 99, "CID"], [92, 92, 179, 179, "CID"], [92, 92, 189, 189, "CID"], [92, 92, 219, 219, "CID"], [96, 96, 9, 9, "CID"], [96, 96, 34, 34, "CID"], [96, 96, 99, 99, "CID"], [96, 96, 179, 179, "CID"], [96, 96, 189, 189, "CID"], [96, 96, 219, 219, "CID"], [176, 176, 9, 9, "CID"], [176, 176, 34, 34, "CID"], [176, 176, 99, 99, "CID"], [176, 176, 179, 179, "CID"], [176, 176, 189, 189, "CID"], [176, 176, 219, 219, "CID"], [200, 200, 9, 9, "CID"], [200, 200, 34, 34, "CID"], [200, 200, 99, 99, "CID"], [200, 200, 179, 179, "CID"], [200, 200, 189, 189, "CID"], [200, 200, 219, 219, "CID"], [261, 261, 9, 9, "CID"], [261, 261, 34, 34, "CID"], [261, 261, 99, 99, "CID"], [261, 261, 179, 179, "CID"], [261, 261, 189, 189, "CID"], [261, 261, 219, 219, "CID"]]], "clusters": [], "translated": "神经活性 <12> 类固醇 </12> 对小鼠 <0> 可卡因 </0> 诱发- <6>癫痫发作</6>的保护作用。具有神经活性的<13>类固醇</13>表现出与许多<16>神经和精神疾病</16>相关的药理作用。它们在一系列模型中提供针对<7>癫痫发作</7>的保护，并且在临床前评估中似乎抑制了<17>药物依赖</17>的某些阶段。本研究旨在评估两种内源性和一种合成神经活性<14>类固醇</14>，它们可正向调节<18>γ-氨基丁酸</18>（<19>GABA</19>(A)）受体对抗因重复<2>可卡因</2>给药而引起的<1>可卡因</1>惊厥作用的敏感性增加（<8>癫痫发作</8>点燃）。<21>Allopregnanolone</21>（<22>3alpha-hydroxy-5alpha-pregnan-20-one</22>）、<23>pregnanolone</23>（<24>3alpha-hydroxy-5beta-pregnan-20-one</24>）和<29>ganaxolone</29>（<25>四氢孕酮</25>的合成衍生物<30>3alpha-羟基-3beta-甲基-5alpha-孕酮-20-one</30>）在雄性Swiss-Webster小鼠中测试了它们抑制<3>可卡因</3>引起的<9>癫痫发作</9>的表达（抗惊厥作用）和发展（抗癫痫作用）的能力。每天给予60 mg/kg<4>可卡因</4> 5天，诱发<10>癫痫发作</10>。所有这些阳性<20>GABA</20>(A)调节剂都抑制了点燃的<11>癫痫发作</11>的表达，而只有<26>allopregnanolone</26>和<31>ganaxolone</31>抑制火种的发展。<27>Allopregnanolone</27>和<28>pregnanolone</28>，但不是<32>ganaxolone</32>，也降低了与点燃相关的累积致死率。这些发现表明，一些神经活性<15>类固醇</15>减弱了<5>可卡因</5>的惊厥和致敏特性，并增加了关于它们在调节滥用药物影响中的潜在用途的越来越多的文献。", "revised": true}
{"doc_key": "19356307", "sentences": [["Components", "of", "lemon", "essential", "oil", "attenuate", "dementia", "induced", "by", "scopolamine", ".", "The", "anti", "-", "dementia", "effects", "of", "s", "-", "limonene", "and", "s", "-", "perillyl", "alcohol", "were", "observed", "using", "the", "passive", "avoidance", "test", "(", "PA", ")", "and", "the", "open", "field", "habituation", "test", "(", "OFH", ")", ".", "These", "lemon", "essential", "oils", "showed", "strong", "ability", "to", "improve", "memory", "impaired", "by", "scopolamine", ";", "however", ",", "s", "-", "perillyl", "alcohol", "relieved", "the", "deficit", "of", "associative", "memory", "in", "PA", "only", ",", "and", "did", "not", "improve", "non", "-", "associative", "memory", "significantly", "in", "OFH", ".", "Analysis", "of", "neurotransmitter", "concentration", "in", "some", "brain", "regions", "on", "the", "test", "day", "showed", "that", "dopamine", "concentration", "of", "the", "vehicle", "/", "scopolamine", "group", "was", "significantly", "lower", "than", "that", "of", "the", "vehicle", "/", "vehicle", "group", ",", "but", "this", "phenomenon", "was", "reversed", "when", "s", "-", "limonene", "or", "s", "-", "perillyl", "alcohol", "were", "administered", "before", "the", "injection", "of", "scopolamine", ".", "Simultaneously", ",", "we", "found", "that", "these", "two", "lemon", "essential", "oil", "components", "could", "inhibit", "acetylcholinesterase", "activity", "in", "vitro", "using", "the", "Ellman", "method", "."]], "ner": [[[9, 9, "Chemical"], [57, 57, "Chemical"], [107, 107, "Chemical"], [141, 141, "Chemical"], [54, 55, "Disease"], [67, 70, "Disease"], [6, 6, "Disease"], [14, 14, "Disease"], [17, 19, "Chemical"], [127, 129, "Chemical"], [21, 24, "Chemical"], [61, 64, "Chemical"], [131, 134, "Chemical"], [101, 101, "Chemical"]]], "relations": [[[9, 9, 54, 55, "CID"], [9, 9, 67, 70, "CID"], [57, 57, 54, 55, "CID"], [57, 57, 67, 70, "CID"], [107, 107, 54, 55, "CID"], [107, 107, 67, 70, "CID"], [141, 141, 54, 55, "CID"], [141, 141, 67, 70, "CID"]]], "clusters": [], "translated": "柠檬精油成分可减轻<0>东莨菪碱</0>诱发的<6>痴呆</6>。采用被动回避试验(PA)和旷场习惯法观察<8>s-柠檬烯</8>和<10>s-紫苏醇</10>的抗<7>痴呆</7>作用。这些柠檬精油表现出很强的改善<1>东莨菪碱</1><4>记忆力受损</4>的能力；然而，<11>s-紫苏醇</11>仅缓解了<5>联想记忆缺陷</5>，并没有显着改善非联想记忆。测试当天部分脑区神经递质浓度分析显示，赋形剂/<2>东莨菪碱</2>组的<13>多巴胺</13>浓度明显低于赋形剂/赋形剂组，但这在<3>东莨菪碱</3>注射前给予<9>s-柠檬烯</9>或<12>s-紫苏醇</12>可逆转上述现象。同时，我们通过Ellman法发现这两种柠檬精油成分在体外可以抑制乙酰胆碱酯酶活性。", "revised": true}
{"doc_key": "15957009", "sentences": [["The", "selective", "5", "-", "HT6", "receptor", "antagonist", "Ro4368554", "restores", "memory", "performance", "in", "cholinergic", "and", "serotonergic", "models", "of", "memory", "deficiency", "in", "the", "rat", ".", "Antagonists", "at", "serotonin", "type", "6", "(", "5", "-", "HT", "(", "6", ")", ")", "receptors", "show", "activity", "in", "models", "of", "learning", "and", "memory", ".", "Although", "the", "underlying", "mechanism", "(", "s", ")", "are", "not", "well", "understood", ",", "these", "effects", "may", "involve", "an", "increase", "in", "acetylcholine", "(", "ACh", ")", "levels", ".", "The", "present", "study", "sought", "to", "characterize", "the", "cognitive", "-", "enhancing", "effects", "of", "the", "5", "-", "HT", "(", "6", ")", "antagonist", "Ro4368554", "(", "3", "-", "benzenesulfonyl", "-", "7", "-", "(", "4", "-", "methyl", "-", "piperazin", "-", "1", "-", "yl", ")", "1H", "-", "indole", ")", "in", "a", "rat", "object", "recognition", "task", "employing", "a", "cholinergic", "(", "scopolamine", "pretreatment", ")", "and", "a", "serotonergic", "-", "(", "tryptophan", "(", "TRP", ")", "depletion", ")", "deficient", "model", ",", "and", "compared", "its", "pattern", "of", "action", "with", "that", "of", "the", "acetylcholinesterase", "inhibitor", "metrifonate", ".", "Initial", "testing", "in", "a", "time", "-", "dependent", "forgetting", "task", "employing", "a", "24", "-", "h", "delay", "between", "training", "and", "testing", "showed", "that", "metrifonate", "improved", "object", "recognition", "(", "at", "10", "and", "30", "mg", "/", "kg", ",", "p", ".", "o", ".", ")", ",", "whereas", "Ro4368554", "was", "inactive", ".", "Both", ",", "Ro4368554", "(", "3", "and", "10", "mg", "/", "kg", ",", "intraperitoneally", "(", "i", ".", "p", ".", ")", ")", "and", "metrifonate", "(", "10", "mg", "/", "kg", ",", "p", ".", "o", ".", ",", "respectively", ")", "reversed", "memory", "deficits", "induced", "by", "scopolamine", "and", "TRP", "depletion", "(", "10", "mg", "/", "kg", ",", "i", ".", "p", ".", ",", "and", "3", "mg", "/", "kg", ",", "p", ".", "o", ".", ",", "respectively", ")", ".", "In", "conclusion", ",", "although", "Ro4368554", "did", "not", "improve", "a", "time", "-", "related", "retention", "deficit", ",", "it", "reversed", "a", "cholinergic", "and", "a", "serotonergic", "memory", "deficit", ",", "suggesting", "that", "both", "mechanisms", "may", "be", "involved", "in", "the", "facilitation", "of", "object", "memory", "by", "Ro4368554", "and", ",", "possibly", ",", "other", "5", "-", "HT", "(", "6", ")", "receptor", "antagonists", "."]], "ner": [[[124, 124, "Chemical"], [239, 239, "Chemical"], [17, 18, "Disease"], [235, 236, "Disease"], [290, 291, "Disease"], [7, 7, "Chemical"], [91, 91, "Chemical"], [93, 112, "Chemical"], [196, 196, "Chemical"], [202, 202, "Chemical"], [272, 272, "Chemical"], [307, 307, "Chemical"], [25, 25, "Chemical"], [29, 31, "Chemical"], [84, 86, "Chemical"], [313, 315, "Chemical"], [65, 65, "Chemical"], [67, 67, "Chemical"], [132, 132, "Chemical"], [134, 134, "Chemical"], [241, 241, "Chemical"], [153, 153, "Chemical"], [176, 176, "Chemical"], [220, 220, "Chemical"]]], "relations": [[[124, 124, 17, 18, "CID"], [124, 124, 235, 236, "CID"], [124, 124, 290, 291, "CID"], [239, 239, 17, 18, "CID"], [239, 239, 235, 236, "CID"], [239, 239, 290, 291, "CID"]]], "clusters": [], "translated": "选择性 5-HT6 受体拮抗剂 <5>Ro4368554</5> 可恢复大鼠 <2>记忆缺陷</2> 的胆碱能和血清素能模型的记忆性能。在学习和记忆模型中，<12>血清素</12> 6 型 (<13>5-HT</13>(6)) 受体的拮抗剂展现了作用。虽然潜在机制尚不清楚，但这些影响可能涉及<16>乙酰胆碱</16> (<17>ACh</17>)水平的增加。本研究旨在表征 <14>5-HT</14>(6) 拮抗剂 <6>Ro4368554</6> (<7>3-苯磺酰基-7-(4-甲基-哌嗪-1-yl)1H-吲哚</7>) 在大鼠物体识别任务中使用胆碱能（<0>东莨菪碱</0>预处理）和血清素能-（<18>色氨酸</18>（<19>TRP</19>)耗竭）的模型，并将其作用模式与乙酰胆碱酯酶抑制剂<21>甲磺酸</21>的作用模式进行比较。在训练和测试之间采用 24 小时延迟的时间依赖性遗忘任务的初步测试表明，<22>甲磺酸</22> 改善了物体识别（在10和30 mg/kg时，p.o.），而<8>Ro4368554</8>处于非活动状态。<9>Ro4368554</9>（3 和10mg/kg，腹膜内注射（i.p.））和<23>甲磺酸</23>（分别为10mg/kg，p.o.）逆转由<1>东莨菪碱</1>和<20>TRP</20> 耗竭（分别为10mg/kg，i.p.和3mg/kg，p.o.）引起的<3>记忆缺陷</3>。总之，尽管<10>Ro4368554</10>未改善与时间相关的保留缺陷，但它逆转了胆碱能和血清素能<4>记忆缺陷</4> ，这表明这两种机制都可能参与<11>Ro4368554</11>和其他可能的<15>5-HT</15>(6) 受体拮抗剂促进对象记忆的实现。", "revised": true}
{"doc_key": "18439803", "sentences": [["Acute", "effects", "of", "N", "-", "(", "2", "-", "propylpentanoyl", ")", "urea", "on", "hippocampal", "amino", "acid", "neurotransmitters", "in", "pilocarpine", "-", "induced", "seizure", "in", "rats", ".", "The", "present", "study", "aimed", "to", "investigate", "the", "anticonvulsant", "activity", "as", "well", "as", "the", "effects", "on", "the", "level", "of", "hippocampal", "amino", "acid", "neurotransmitters", "(", "glutamate", ",", "aspartate", ",", "glycine", "and", "GABA", ")", "of", "N", "-", "(", "2", "-", "propylpentanoyl", ")", "urea", "(", "VPU", ")", "in", "comparison", "to", "its", "parent", "compound", ",", "valproic", "acid", "(", "VPA", ")", ".", "VPU", "was", "more", "potent", "than", "VPA", ",", "exhibiting", "the", "median", "effective", "dose", "(", "ED", "(", "50", ")", ")", "of", "49", "mg", "/", "kg", "in", "protecting", "rats", "against", "pilocarpine", "-", "induced", "seizure", "whereas", "the", "corresponding", "value", "for", "VPA", "was", "322", "mg", "/", "kg", ".", "In", "vivo", "microdialysis", "demonstrated", "that", "an", "intraperitoneal", "administration", "of", "pilocarpine", "induced", "a", "pronounced", "increment", "of", "hippocampal", "glutamate", "and", "aspartate", "whereas", "no", "significant", "change", "was", "observed", "on", "the", "level", "of", "glycine", "and", "GABA", ".", "Pretreatment", "with", "either", "VPU", "(", "50", "and", "100", "mg", "/", "kg", ")", "or", "VPA", "(", "300", "and", "600", "mg", "/", "kg", ")", "completely", "abolished", "pilocarpine", "-", "evoked", "increases", "in", "extracellular", "glutamate", "and", "aspartate", ".", "In", "addition", ",", "a", "statistically", "significant", "reduction", "was", "also", "observed", "on", "the", "level", "of", "GABA", "and", "glycine", "but", "less", "than", "a", "drastic", "reduction", "of", "glutamate", "and", "aspartate", "level", ".", "Based", "on", "the", "finding", "that", "VPU", "and", "VPA", "could", "protect", "the", "animals", "against", "pilocarpine", "-", "induced", "seizure", "it", "is", "suggested", "that", "the", "reduction", "of", "inhibitory", "amino", "acid", "neurotransmitters", "was", "comparatively", "minor", "and", "offset", "by", "a", "pronounced", "reduction", "of", "glutamate", "and", "aspartate", ".", "Therefore", ",", "like", "VPA", ",", "the", "finding", "that", "VPU", "could", "drastically", "reduce", "pilocarpine", "-", "induced", "increases", "in", "glutamate", "and", "aspartate", "should", "account", ",", "at", "least", "partly", ",", "for", "its", "anticonvulsant", "activity", "observed", "in", "pilocarpine", "-", "induced", "seizure", "in", "experimental", "animals", ".", "Some", "other", "mechanism", "than", "those", "being", "reported", "herein", "should", "be", "further", "investigated", "."]], "ner": [[[17, 17, "Chemical"], [107, 107, "Chemical"], [132, 132, "Chemical"], [180, 180, "Chemical"], [232, 232, "Chemical"], [273, 273, "Chemical"], [294, 294, "Chemical"], [20, 20, "Disease"], [110, 110, "Disease"], [235, 235, "Disease"], [297, 297, "Disease"], [3, 10, "Chemical"], [56, 63, "Chemical"], [65, 65, "Chemical"], [80, 80, "Chemical"], [159, 159, "Chemical"], [224, 224, "Chemical"], [269, 269, "Chemical"], [13, 14, "Chemical"], [43, 44, "Chemical"], [244, 245, "Chemical"], [47, 47, "Chemical"], [139, 139, "Chemical"], [186, 186, "Chemical"], [214, 214, "Chemical"], [257, 257, "Chemical"], [278, 278, "Chemical"], [49, 49, "Chemical"], [141, 141, "Chemical"], [188, 188, "Chemical"], [216, 216, "Chemical"], [259, 259, "Chemical"], [280, 280, "Chemical"], [51, 51, "Chemical"], [152, 152, "Chemical"], [206, 206, "Chemical"], [53, 53, "Chemical"], [154, 154, "Chemical"], [204, 204, "Chemical"], [74, 75, "Chemical"], [77, 77, "Chemical"], [85, 85, "Chemical"], [116, 116, "Chemical"], [169, 169, "Chemical"], [226, 226, "Chemical"], [264, 264, "Chemical"]]], "relations": [[[17, 17, 20, 20, "CID"], [17, 17, 110, 110, "CID"], [17, 17, 235, 235, "CID"], [17, 17, 297, 297, "CID"], [107, 107, 20, 20, "CID"], [107, 107, 110, 110, "CID"], [107, 107, 235, 235, "CID"], [107, 107, 297, 297, "CID"], [132, 132, 20, 20, "CID"], [132, 132, 110, 110, "CID"], [132, 132, 235, 235, "CID"], [132, 132, 297, 297, "CID"], [180, 180, 20, 20, "CID"], [180, 180, 110, 110, "CID"], [180, 180, 235, 235, "CID"], [180, 180, 297, 297, "CID"], [232, 232, 20, 20, "CID"], [232, 232, 110, 110, "CID"], [232, 232, 235, 235, "CID"], [232, 232, 297, 297, "CID"], [273, 273, 20, 20, "CID"], [273, 273, 110, 110, "CID"], [273, 273, 235, 235, "CID"], [273, 273, 297, 297, "CID"], [294, 294, 20, 20, "CID"], [294, 294, 110, 110, "CID"], [294, 294, 235, 235, "CID"], [294, 294, 297, 297, "CID"]]], "clusters": [], "translated": "<11>N-(2-丙基戊酰基)脲</11> 对 <0>毛果芸香碱</0> 诱导的<7>癫痫发作</7>老鼠中海马<18>氨基酸</18>神经递质的急性作用。本研究旨在研究抗惊厥活性以及 <12> N-(2-丙基戊酰基)脲</12> ( <13>VPU</13> ) 对海马<19>氨基酸</19>神经递质（<21>谷氨酸</21>、<27>天冬氨酸</27>、<33>甘氨酸</33>和<36>GABA</36>）水平的影响，与其母体化合物 <39>丙戊酸</39> ( <40>VPA</40> ) 相比。 <14>VPU</14> 比<41> VPA </41> 更有效，在保护大鼠免受 <1>毛果芸香碱</1> - 诱发<8>癫痫发作</8>时表现出 49 mg/kg 的中位有效剂量 ( ED (50) )，而<42> VPA </42> 的相应值为 322 mg/kg。体内微透析表明，腹膜内注射 <2>毛果芸香碱</2> 会导致海马中 <22>谷氨酸</22> 和<28>天冬氨酸</28> 显着增加，而<34>甘氨酸</34>和<37> GABA </37>水平没有明显变化。用 <15>VPU</15> ( 50 和 100 mg/kg ) 或 <43> VPA </43> ( 300 和 600 mg/kg ) 预处理完全消除了<3>毛果芸香碱</3> - 诱发细胞外<23>谷氨酸</23>和<29>天冬氨酸</29>的增加。此外，<38>GABA</38> 和<35>甘氨酸</35> 的水平也有统计学意义的显着降低，但小于<24>谷氨酸</24>和 <30>天冬氨酸</30>级的显着降低。基于 <16>VPU</16> 和<44> VPA </44> 可以保护动物免受<4>毛果芸香碱</4> 诱导的<9>癫痫发作</9>的发现，建议抑制性<20>氨基酸</20>神经递质的减少相对较小，并被<25>谷氨酸</25>和<31>天冬氨酸</31>的显着减少所抵消。因此，与 <45> VPA </45> 一样，<17> VPU </17> 可以显着减少<5>毛果芸香碱</5> 诱导的<26>谷氨酸</26>和<32>天冬氨酸</32>的增加，应该至少部分地解释其在 <6>毛果芸香碱</6> - 诱导的实验动物<10>癫痫发作</10>中观察到的抗惊厥活性。需要进一步研究除此处所报告的机制之外的其他一些机制。", "revised": true}
{"doc_key": "10406016", "sentences": [["Effect", "of", "fucoidan", "treatment", "on", "collagenase", "-", "induced", "intracerebral", "hemorrhage", "in", "rats", ".", "Inflammatory", "cells", "are", "postulated", "to", "mediate", "some", "of", "the", "brain", "damage", "following", "ischemic", "stroke", ".", "Intracerebral", "hemorrhage", "is", "associated", "with", "more", "inflammation", "than", "ischemic", "stroke", ".", "We", "tested", "the", "sulfated", "polysaccharide", "fucoidan", ",", "which", "has", "been", "reported", "to", "reduce", "inflammatory", "brain", "damage", ",", "in", "a", "rat", "model", "of", "intracerebral", "hemorrhage", "induced", "by", "injection", "of", "bacterial", "collagenase", "into", "the", "caudate", "nucleus", ".", "Rats", "were", "treated", "with", "seven", "day", "intravenous", "infusion", "of", "fucoidan", "(", "30", "micrograms", "h", "-", "1", ")", "or", "vehicle", ".", "The", "hematoma", "was", "assessed", "in", "vivo", "by", "magnetic", "resonance", "imaging", ".", "Motor", "behavior", ",", "passive", "avoidance", ",", "and", "skilled", "forelimb", "function", "were", "tested", "repeatedly", "for", "six", "weeks", ".", "Fucoidan", "-", "treated", "rats", "exhibited", "evidence", "of", "impaired", "blood", "clotting", "and", "hemodilution", ",", "had", "larger", "hematomas", ",", "and", "tended", "to", "have", "less", "inflammation", "in", "the", "vicinity", "of", "the", "hematoma", "after", "three", "days", ".", "They", "showed", "significantly", "more", "rapid", "improvement", "of", "motor", "function", "in", "the", "first", "week", "following", "hemorrhage", "and", "better", "memory", "retention", "in", "the", "passive", "avoidance", "test", ".", "Acute", "white", "matter", "edema", "and", "eventual", "neuronal", "loss", "in", "the", "striatum", "adjacent", "to", "the", "hematoma", "did", "not", "differ", "between", "the", "two", "groups", ".", "Investigation", "of", "more", "specific", "anti", "-", "inflammatory", "agents", "and", "hemodiluting", "agents", "are", "warranted", "in", "intracerebral", "hemorrhage", "."]], "ner": [[[2, 2, "Chemical"], [44, 44, "Chemical"], [83, 83, "Chemical"], [122, 122, "Chemical"], [129, 131, "Disease"], [133, 133, "Disease"], [181, 183, "Disease"], [8, 9, "Disease"], [28, 29, "Disease"], [61, 62, "Disease"], [217, 218, "Disease"], [22, 23, "Disease"], [53, 54, "Disease"], [25, 26, "Disease"], [36, 37, "Disease"], [34, 34, "Disease"], [144, 144, "Disease"], [95, 95, "Disease"], [137, 137, "Disease"], [150, 150, "Disease"], [194, 194, "Disease"], [169, 169, "Disease"], [186, 187, "Disease"]]], "relations": [[[2, 2, 129, 131, "CID"], [2, 2, 133, 133, "CID"], [44, 44, 129, 131, "CID"], [44, 44, 133, 133, "CID"], [83, 83, 129, 131, "CID"], [83, 83, 133, 133, "CID"], [122, 122, 129, 131, "CID"], [122, 122, 133, 133, "CID"], [2, 2, 181, 183, "CID"], [44, 44, 181, 183, "CID"], [83, 83, 181, 183, "CID"], [122, 122, 181, 183, "CID"]]], "clusters": [], "translated": "<0>褐藻糖胶</0>对胶原酶诱导大鼠<7>脑出血</7>的影响。据推测，炎症细胞介导了<11>缺血性中风</11>后的一些<13>脑损伤</13>。 <8>脑出血</8>与<15>炎症</15>的相关性高于<14>缺血性中风</14>。我们在注射细菌引起的<9>脑出血</9>大鼠模型中测试了硫酸化多糖 <1> 岩藻依聚糖 </1>，据报道它可以减少炎症性<12>脑损伤</12>。对大鼠进行为期7天的<2>褐藻糖胶</2>（30微克h-1）或载体静脉输注治疗。<17>血肿</17>通过磁共振成像在体内进行评估。六周内反复测试运动行为、被动回避和熟练的前肢功能。<3>褐藻糖胶</3>-处理的大鼠表现出<4>血液凝固受损</4>和<5>血液稀释</5>的证据，有较大的<18>血肿</18>，并且倾向于较少<16>炎症</16>，三天后<19>血肿</19>附近。他们在<21>出血</21>后的第一周表现出运动功能明显更快的改善，并且在被动回避测试中记忆力保持得更好。急性<6>白质水肿</6>和最终在<20>血肿</20>附近的纹状体<22>神经元丢失</22>在两组之间没有差异。在<10>脑出血</10>中需要研究更特异的抗炎药和血液稀释剂。", "revised": true}
{"doc_key": "17919553", "sentences": [["Acute", "hepatitis", "attack", "after", "exposure", "to", "telithromycin", ".", "INTRODUCTION", ":", "Antibiotic", "-", "associated", "hepatotoxicity", "is", "rare", ".", "With", "widespread", "use", "of", "antimicrobial", "agents", ",", "however", ",", "hepatic", "injury", "occurs", "frequently", ",", "and", "among", "adverse", "drug", "reactions", ",", "idiosyncratic", "reactions", "are", "the", "most", "serious", ".", "CASE", "SUMMARY", ":", "A", "25", "-", "year", "-", "old", "male", "patient", ",", "with", "a", "height", "of", "175", "cm", "and", "weight", "of", "72", "kg", "presented", "to", "Marmara", "University", "Hospital", "Emergency", "Department", ",", "Istanbul", ",", "Turkey", ",", "with", "5", "days", "'", "history", "of", "jaundice", ",", "malaise", ",", "nausea", ",", "and", "vomiting", ".", "He", "had", "been", "prescribed", "telithromycin", "400", "mg", "/", "d", "PO", "to", "treat", "an", "upper", "respiratory", "tract", "infection", "7", "days", "prior", ".", "Admission", "laboratory", "tests", "were", "as", "follows", ":", "alanine", "aminotransferase", ",", "67", "U", "/", "L", "(", "reference", "range", ",", "10", "-", "37", "U", "/", "L", ")", ";", "aspartate", "aminotransferase", ",", "98", "U", "/", "L", "(", "10", "-", "40", "U", "/", "L", ")", ";", "alkaline", "phosphatase", ",", "513", "U", "/", "L", "(", "0", "-", "270", "U", "/", "L", ")", ";", "gamma", "-", "glutamyltransferase", ",", "32", "U", "/", "L", "(", "7", "-", "49", "U", "/", "L", ")", ";", "amylase", ",", "46", "U", "/", "L", "(", "0", "-", "220", "U", "/", "L", ")", ";", "total", "bilirubin", ",", "20", ".", "1", "mg", "/", "dL", "(", "0", ".", "2", "-", "1", ".", "0", "mg", "/", "dL", ")", ";", "direct", "bilirubin", ",", "14", ".", "8", "mg", "/", "dL", "(", "0", "-", "0", ".", "3", "mg", "/", "dL", ")", ";", "and", "albumin", ",", "4", ".", "7", "mg", "/", "dL", "(", "3", ".", "5", "-", "5", ".", "4", "mg", "/", "dL", ")", ".", "No", "toxin", ",", "alcohol", ",", "or", "other", "drugs", "were", "reported", ".", "The", "patient", "had", "suffered", "a", "previous", "episode", "of", "\"", "acute", "hepatitis", "of", "unknown", "origin", ",", "\"", "that", "occurred", "after", "telithromycin", "usage", ".", "Both", "incidents", "occurred", "within", "a", "year", ".", "DISCUSSION", ":", "Telithromycin", "is", "the", "first", "of", "the", "ketolide", "antibacterials", "to", "receive", "US", "Food", "and", "Drug", "Administration", "approval", "for", "clinical", "use", ".", "It", "has", "been", "associated", "with", "infrequent", "and", "usually", "reversible", "severe", "hepatic", "dysfunction", ".", "Based", "on", "a", "score", "of", "8", "on", "the", "Naranjo", "adverse", "drug", "reaction", "probability", "scale", ",", "telithromycin", "was", "the", "probable", "cause", "of", "acute", "hepatitis", "in", "this", "patient", ",", "and", "pathological", "findings", "suggested", "drug", "-", "induced", "toxic", "hepatitis", ".", "Recurrence", "of", "hepatitis", "attack", "might", "have", "been", "avoided", "if", "the", "initial", "incident", "had", "been", "communicated", "to", "the", "attending", "physician", "who", "prescribed", "telithromycin", "the", "second", "time", ".", "CONCLUSION", ":", "Here", "we", "report", "a", "case", "of", "acute", "hepatitis", "probably", "associated", "with", "the", "administration", "of", "telithromycin", "."]], "ner": [[[6, 6, "Chemical"], [98, 98, "Chemical"], [299, 299, "Chemical"], [311, 311, "Chemical"], [359, 359, "Chemical"], [402, 402, "Chemical"], [423, 423, "Chemical"], [1, 1, "Disease"], [13, 13, "Disease"], [26, 27, "Disease"], [290, 290, "Disease"], [366, 366, "Disease"], [378, 379, "Disease"], [383, 383, "Disease"], [416, 416, "Disease"], [122, 122, "Chemical"], [141, 141, "Chemical"], [206, 206, "Chemical"], [228, 228, "Chemical"], [272, 272, "Chemical"], [33, 35, "Disease"], [353, 355, "Disease"], [85, 85, "Disease"], [89, 89, "Disease"], [92, 92, "Disease"], [107, 110, "Disease"], [341, 342, "Disease"]]], "relations": [[[6, 6, 1, 1, "CID"], [6, 6, 13, 13, "CID"], [6, 6, 26, 27, "CID"], [6, 6, 290, 290, "CID"], [6, 6, 366, 366, "CID"], [6, 6, 378, 379, "CID"], [6, 6, 383, 383, "CID"], [6, 6, 416, 416, "CID"], [98, 98, 1, 1, "CID"], [98, 98, 13, 13, "CID"], [98, 98, 26, 27, "CID"], [98, 98, 290, 290, "CID"], [98, 98, 366, 366, "CID"], [98, 98, 378, 379, "CID"], [98, 98, 383, 383, "CID"], [98, 98, 416, 416, "CID"], [299, 299, 1, 1, "CID"], [299, 299, 13, 13, "CID"], [299, 299, 26, 27, "CID"], [299, 299, 290, 290, "CID"], [299, 299, 366, 366, "CID"], [299, 299, 378, 379, "CID"], [299, 299, 383, 383, "CID"], [299, 299, 416, 416, "CID"], [311, 311, 1, 1, "CID"], [311, 311, 13, 13, "CID"], [311, 311, 26, 27, "CID"], [311, 311, 290, 290, "CID"], [311, 311, 366, 366, "CID"], [311, 311, 378, 379, "CID"], [311, 311, 383, 383, "CID"], [311, 311, 416, 416, "CID"], [359, 359, 1, 1, "CID"], [359, 359, 13, 13, "CID"], [359, 359, 26, 27, "CID"], [359, 359, 290, 290, "CID"], [359, 359, 366, 366, "CID"], [359, 359, 378, 379, "CID"], [359, 359, 383, 383, "CID"], [359, 359, 416, 416, "CID"], [402, 402, 1, 1, "CID"], [402, 402, 13, 13, "CID"], [402, 402, 26, 27, "CID"], [402, 402, 290, 290, "CID"], [402, 402, 366, 366, "CID"], [402, 402, 378, 379, "CID"], [402, 402, 383, 383, "CID"], [402, 402, 416, 416, "CID"], [423, 423, 1, 1, "CID"], [423, 423, 13, 13, "CID"], [423, 423, 26, 27, "CID"], [423, 423, 290, 290, "CID"], [423, 423, 366, 366, "CID"], [423, 423, 378, 379, "CID"], [423, 423, 383, 383, "CID"], [423, 423, 416, 416, "CID"]]], "clusters": [], "translated": "接触<0>泰利霉素</0>后急性<7>肝炎</7>发作。简介：与抗生素相关的<8>肝毒性</8>很少见。然而，随着抗菌药物的广泛使用，<9>肝损伤</9>的发生频发，其中<20>药物不良反应</20>又以异质反应最为严重。病例概要：一名25岁男性患者，身高175厘米，体重72公斤，就诊于土耳其伊斯坦布尔马尔马拉大学医院急诊科，有5天的<22>黄疸病史</22>，不适、<23>恶心</23>和<24>呕吐</24>。7天前，他被处方<1>泰利霉素</1> 400 mg/d PO 治疗<25>上呼吸道感染</25> 。入院实验室检查如下：<15>丙氨酸</15>氨基转移酶，67 U/L（参考范围，10～37 U/L）；<16>天冬氨酸</16>氨基转移酶，98 U/L（10-40 U/L）；碱性磷酸酶，513 U/L（0-270 U/L）；γ-谷氨酰转移酶，32 U/L (7-49 U/L)；淀粉酶，46 U/L (0-220 U/L)；总<17>胆红素</17>，20.1毫克/分升 (0.2-1.0毫克/分升)；直接<18>胆红素</18>，14.8毫克/分升（0-0.3毫克/分升）；和白蛋白，4.7毫克/分升（3.5-5.4毫克/分升）。没有毒素、<19>酒精</19>或其他药物的报道。患者曾患过“不明原因的急性<10>肝炎</10>”，发生在使用<2>泰利霉素</2>后。这两起事件都发生在一年之内。讨论：<3>泰利霉素</3>是第一个获得美国食品和药物管理局批准用于临床的酮内酯类抗菌药物。它与罕见且通常可逆的严重<26>肝功能障碍</26>有关。根据 Naranjo <21>药物不良反应</21>概率量表的8分，<4>泰利霉素</4>是该患者急性<11>肝炎</11>的可能原因，并且病理学结果提示药物性<12>中毒性肝炎</12>。如果将初次事件告知给第二次开出<5>泰利霉素</5>处方的主治医师，则可以避免<13>肝炎</13>发作的复发。结论：我们在此报告一例可能与服用<6>泰利霉素</6>有关的急性<14>肝炎</14>。", "revised": true}
{"doc_key": "15899738", "sentences": [["Lone", "atrial", "fibrillation", "associated", "with", "creatine", "monohydrate", "supplementation", ".", "Atrial", "fibrillation", "in", "young", "patients", "without", "structural", "heart", "disease", "is", "rare", ".", "Therefore", ",", "when", "the", "arrhythmia", "is", "present", "in", "this", "population", ",", "reversible", "causes", "must", "be", "identified", "and", "resolved", ".", "Thyroid", "disorders", ",", "illicit", "drug", "or", "stimulant", "use", ",", "and", "acute", "alcohol", "intoxication", "are", "among", "these", "causes", ".", "We", "report", "the", "case", "of", "a", "30", "-", "year", "-", "old", "Caucasian", "man", "who", "came", "to", "the", "emergency", "department", "in", "atrial", "fibrillation", "with", "rapid", "ventricular", "response", ".", "His", "medical", "history", "was", "unremarkable", ",", "except", "for", "minor", "fractures", "of", "the", "fingers", "and", "foot", ".", "Thyroid", "-", "stimulating", "hormone", ",", "magnesium", ",", "and", "potassium", "levels", "were", "within", "normal", "limits", ",", "urine", "drug", "screen", "was", "negative", ",", "and", "alcohol", "use", "was", "denied", ".", "However", ",", "when", "the", "patient", "was", "questioned", "about", "use", "of", "herbal", "products", "and", "supplements", ",", "the", "use", "of", "creatine", "monohydrate", "was", "revealed", ".", "The", "patient", "was", "admitted", "to", "the", "hospital", ",", "anticoagulated", "with", "unfractionated", "heparin", ",", "and", "given", "intravenous", "diltiazem", "for", "rate", "control", "and", "intravenous", "amiodarone", "for", "rate", "and", "rhythm", "control", ".", "When", "discharged", "less", "than", "24", "hours", "later", ",", "he", "was", "receiving", "metoprolol", "and", "aspirin", ",", "with", "follow", "-", "up", "plans", "for", "echocardiography", "and", "nuclear", "imaging", "to", "assess", "perfusion", ".", "Exogenous", "creatine", "is", "used", "by", "athletes", "to", "theoretically", "improve", "exercise", "performance", ".", "Vegetarians", "may", "also", "take", "creatine", "to", "replace", "what", "they", "are", "not", "consuming", "from", "meat", ",", "fish", ",", "and", "other", "animal", "products", ".", "Previous", "anecdotal", "reports", "have", "linked", "creatine", "to", "the", "development", "of", "arrhythmia", ".", "Clinicians", "must", "be", "diligent", "when", "interviewing", "patients", "about", "their", "drug", "therapy", "histories", "and", "include", "questions", "about", "their", "use", "of", "herbal", "products", "and", "dietary", "supplements", ".", "In", "addition", ",", "it", "is", "important", "to", "report", "adverse", "effects", "associated", "with", "frequently", "consumed", "supplements", "and", "herbal", "products", "to", "the", "Food", "and", "Drug", "Administration", "and", "in", "the", "literature", "."]], "ner": [[[5, 5, "Chemical"], [146, 146, "Chemical"], [210, 210, "Chemical"], [225, 225, "Chemical"], [248, 248, "Chemical"], [1, 2, "Disease"], [9, 10, "Disease"], [78, 79, "Disease"], [106, 106, "Chemical"], [109, 109, "Chemical"], [123, 123, "Chemical"], [162, 162, "Chemical"], [167, 167, "Chemical"], [173, 173, "Chemical"], [191, 191, "Chemical"], [193, 193, "Chemical"], [16, 17, "Disease"], [25, 25, "Disease"], [253, 253, "Disease"], [40, 41, "Disease"], [50, 52, "Disease"], [94, 94, "Disease"]]], "relations": [[[5, 5, 1, 2, "CID"], [5, 5, 9, 10, "CID"], [5, 5, 78, 79, "CID"], [146, 146, 1, 2, "CID"], [146, 146, 9, 10, "CID"], [146, 146, 78, 79, "CID"], [210, 210, 1, 2, "CID"], [210, 210, 9, 10, "CID"], [210, 210, 78, 79, "CID"], [225, 225, 1, 2, "CID"], [225, 225, 9, 10, "CID"], [225, 225, 78, 79, "CID"], [248, 248, 1, 2, "CID"], [248, 248, 9, 10, "CID"], [248, 248, 78, 79, "CID"]]], "clusters": [], "translated": "孤立性<5>心房颤动</5>与<0>肌酸</0>一水合物补充剂相关。<6>心房颤动</6>在没有结构性<16>心脏病</16>的年轻患者中是罕见的。因此，当该人群中出现<17>心律失常</17>时，必须确定并解决可逆原因。<19>甲状腺疾病</19>、非法药物或兴奋剂的使用以及<20>急性酒精中毒</20>都是这些原因。我们报告了一名30岁的白人男子因<7>心房颤动</7>伴快速心室反应来到急诊室的病例。除了手指和脚的轻微<21>骨折</21>外，他的病史没有什么特别之处。促甲状腺激素、<8>镁</8>和<9>钾</9>水平在正常范围内，尿液药物筛查呈阴性，拒绝<10>饮酒</10>。然而，当询问患者是否使用草药产品和补充剂时，却透露使用了<1>肌酸</1>一水合物。患者入院，使用普通<11>肝素</11>抗凝，静脉注射<12>地尔硫卓</12>控制心率，静脉注射<13>胺碘酮</13>控制心率和节律。不到24小时后出院时，他正在服用<14>美托洛尔</14>和<15>阿司匹林</15>，并制定后续超声心动图和核成像评估灌注的计划。理论上，运动员利用外源性<2>肌酸</2>来提高运动成绩。素食者也可以服用<3>肌酸</3>来替代他们没有从肉类、鱼类和其他动物产品中摄取的物质。以前的轶事报道将<4>肌酸</4>与<18>心律失常</18>的发展联系起来。临床医生在询问患者的药物治疗史时必须勤勉，并包括有关他们使用草药产品和膳食补充剂的问题。此外，重要的是要向食品和药物管理局以及在文献中报告与经常食用的补充剂和草药产品相关的不良反应。", "revised": true}
{"doc_key": "19884587", "sentences": [["Antibacterial", "medication", "use", "during", "pregnancy", "and", "risk", "of", "birth", "defects", ":", "National", "Birth", "Defects", "Prevention", "Study", ".", "OBJECTIVE", ":", "To", "estimate", "the", "association", "between", "antibacterial", "medications", "and", "selected", "birth", "defects", ".", "DESIGN", ",", "SETTING", ",", "AND", "PARTICIPANTS", ":", "Population", "-", "based", ",", "multisite", ",", "case", "-", "control", "study", "of", "women", "who", "had", "pregnancies", "affected", "by", "1", "of", "more", "than", "30", "eligible", "major", "birth", "defects", "identified", "via", "birth", "defect", "surveillance", "programs", "in", "10", "states", "(", "n", "=", "13", "155", ")", "and", "control", "women", "randomly", "selected", "from", "the", "same", "geographical", "regions", "(", "n", "=", "4941", ")", ".", "MAIN", "EXPOSURE", ":", "Reported", "maternal", "use", "of", "antibacterials", "(", "1", "month", "before", "pregnancy", "through", "the", "end", "of", "the", "first", "trimester", ")", ".", "MAIN", "OUTCOME", "MEASURE", ":", "Odds", "ratios", "(", "ORs", ")", "measuring", "the", "association", "between", "antibacterial", "use", "and", "selected", "birth", "defects", "adjusted", "for", "potential", "confounders", ".", "RESULTS", ":", "The", "reported", "use", "of", "antibacterials", "increased", "during", "pregnancy", ",", "peaking", "during", "the", "third", "month", ".", "Sulfonamides", "were", "associated", "with", "anencephaly", "(", "adjusted", "OR", "[", "AOR", "]", "=", "3", ".", "4", ";", "95", "%", "confidence", "interval", "[", "CI", "]", ",", "1", ".", "3", "-", "8", ".", "8", ")", ",", "hypoplastic", "left", "heart", "syndrome", "(", "AOR", "=", "3", ".", "2", ";", "95", "%", "CI", ",", "1", ".", "3", "-", "7", ".", "6", ")", ",", "coarctation", "of", "the", "aorta", "(", "AOR", "=", "2", ".", "7", ";", "95", "%", "CI", ",", "1", ".", "3", "-", "5", ".", "6", ")", ",", "choanal", "atresia", "(", "AOR", "=", "8", ".", "0", ";", "95", "%", "CI", ",", "2", ".", "7", "-", "23", ".", "5", ")", ",", "transverse", "limb", "deficiency", "(", "AOR", "=", "2", ".", "5", ";", "95", "%", "CI", ",", "1", ".", "0", "-", "5", ".", "9", ")", ",", "and", "diaphragmatic", "hernia", "(", "AOR", "=", "2", ".", "4", ";", "95", "%", "CI", ",", "1", ".", "1", "-", "5", ".", "4", ")", ".", "Nitrofurantoins", "were", "associated", "with", "anophthalmia", "or", "microphthalmos", "(", "AOR", "=", "3", ".", "7", ";", "95", "%", "CI", ",", "1", ".", "1", "-", "12", ".", "2", ")", ",", "hypoplastic", "left", "heart", "syndrome", "(", "AOR", "=", "4", ".", "2", ";", "95", "%", "CI", ",", "1", ".", "9", "-", "9", ".", "1", ")", ",", "atrial", "septal", "defects", "(", "AOR", "=", "1", ".", "9", ";", "95", "%", "CI", ",", "1", ".", "1", "-", "3", ".", "4", ")", ",", "and", "cleft", "lip", "with", "cleft", "palate", "(", "AOR", "=", "2", ".", "1", ";", "95", "%", "CI", ",", "1", ".", "2", "-", "3", ".", "9", ")", ".", "Other", "antibacterial", "agents", "that", "showed", "associations", "included", "erythromycins", "(", "2", "defects", ")", ",", "penicillins", "(", "1", "defect", ")", ",", "cephalosporins", "(", "1", "defect", ")", ",", "and", "quinolones", "(", "1", "defect", ")", ".", "CONCLUSIONS", ":", "Reassuringly", ",", "penicillins", ",", "erythromycins", ",", "and", "cephalosporins", ",", "although", "used", "commonly", "by", "pregnant", "women", ",", "were", "not", "associated", "with", "many", "birth", "defects", ".", "Sulfonamides", "and", "nitrofurantoins", "were", "associated", "with", "several", "birth", "defects", ",", "indicating", "a", "need", "for", "additional", "scrutiny", "."]], "ner": [[[158, 158, "Chemical"], [465, 465, "Chemical"], [8, 9, "Disease"], [12, 13, "Disease"], [28, 29, "Disease"], [62, 63, "Disease"], [66, 67, "Disease"], [134, 135, "Disease"], [462, 463, "Disease"], [472, 473, "Disease"], [307, 307, "Chemical"], [467, 467, "Chemical"], [162, 162, "Disease"], [191, 194, "Disease"], [334, 337, "Disease"], [215, 218, "Disease"], [239, 240, "Disease"], [261, 263, "Disease"], [285, 286, "Disease"], [311, 311, "Disease"], [313, 313, "Disease"], [358, 360, "Disease"], [382, 383, "Disease"], [385, 386, "Disease"], [414, 414, "Chemical"], [445, 445, "Chemical"], [420, 420, "Chemical"], [443, 443, "Chemical"], [426, 426, "Chemical"], [448, 448, "Chemical"], [433, 433, "Chemical"]]], "relations": [[[158, 158, 8, 9, "CID"], [158, 158, 12, 13, "CID"], [158, 158, 28, 29, "CID"], [158, 158, 62, 63, "CID"], [158, 158, 66, 67, "CID"], [158, 158, 134, 135, "CID"], [158, 158, 462, 463, "CID"], [158, 158, 472, 473, "CID"], [465, 465, 8, 9, "CID"], [465, 465, 12, 13, "CID"], [465, 465, 28, 29, "CID"], [465, 465, 62, 63, "CID"], [465, 465, 66, 67, "CID"], [465, 465, 134, 135, "CID"], [465, 465, 462, 463, "CID"], [465, 465, 472, 473, "CID"], [307, 307, 8, 9, "CID"], [307, 307, 12, 13, "CID"], [307, 307, 28, 29, "CID"], [307, 307, 62, 63, "CID"], [307, 307, 66, 67, "CID"], [307, 307, 134, 135, "CID"], [307, 307, 462, 463, "CID"], [307, 307, 472, 473, "CID"], [467, 467, 8, 9, "CID"], [467, 467, 12, 13, "CID"], [467, 467, 28, 29, "CID"], [467, 467, 62, 63, "CID"], [467, 467, 66, 67, "CID"], [467, 467, 134, 135, "CID"], [467, 467, 462, 463, "CID"], [467, 467, 472, 473, "CID"], [158, 158, 162, 162, "CID"], [465, 465, 162, 162, "CID"], [158, 158, 191, 194, "CID"], [158, 158, 334, 337, "CID"], [465, 465, 191, 194, "CID"], [465, 465, 334, 337, "CID"], [158, 158, 215, 218, "CID"], [465, 465, 215, 218, "CID"], [158, 158, 239, 240, "CID"], [465, 465, 239, 240, "CID"], [158, 158, 261, 263, "CID"], [465, 465, 261, 263, "CID"], [158, 158, 285, 286, "CID"], [465, 465, 285, 286, "CID"], [307, 307, 191, 194, "CID"], [307, 307, 334, 337, "CID"], [467, 467, 191, 194, "CID"], [467, 467, 334, 337, "CID"], [307, 307, 311, 311, "CID"], [467, 467, 311, 311, "CID"], [307, 307, 313, 313, "CID"], [467, 467, 313, 313, "CID"], [307, 307, 358, 360, "CID"], [467, 467, 358, 360, "CID"], [307, 307, 382, 383, "CID"], [467, 467, 382, 383, "CID"], [307, 307, 385, 386, "CID"], [467, 467, 385, 386, "CID"]]], "clusters": [], "translated": "怀孕期间使用抗菌药物和<2>出生缺陷</2>的风险：国家<3>出生缺陷</3>预防研究。 目的：评估抗菌药物与选定的<4>出生缺陷</4>之间的关联。 设计、设置和参与者：来自10个州的> 30 个符合条件的>主要<5>出生缺陷</5>的妊娠受影响的妇女（n = 13 155），以及从相同地理区域随机选择的对照妇女（n = 4941），进行基于人群的、多中心、病例对照研究，并通过<6>出生缺陷</6>监测计划确定。 主要暴露：报告的母亲使用抗菌剂（从怀孕前 1 个月到妊娠早期结束）。 主要结果测量：比值比（ORs）衡量抗菌药物使用与选定的<7>出生缺陷</7>之间的关联，并针对潜在的混杂因素进行了调整。 结果：报告的抗生素使用在怀孕期间增加，在第三个月达到高峰。<0>磺胺类药物</0>与<12>无脑畸形</12>相关（调整后的OR [AOR]=3.4；95%置信区间[CI]，1.3-8.8），<13>左心发育不全综合征</13>（AOR=3.2；95%CI，1.3-7.6），<15>主动脉缩窄</15>（AOR=2.7；95%CI，1.3-5.6），<16>鼻后孔闭锁</16>（AOR=8.0；95%CI，2.7-23.5），通过<17>横向肢体缺陷</17> (AOR=2.5; 95% CI, 1.0-5.9) 和<18>膈疝</18> (AOR=2.4; 95% CI, 1.1-5.4)。 <10>呋喃妥因类药物</10>与<19>无眼症</19>或<20>小眼症</20>相关（AOR=3.7；95%CI，1.1-12.2），<14>左心发育不良综合征</14>（AOR=4.2；95%CI，1.9-9.1），<21>房间隔缺损</21>（AOR=1.9；95%CI，1.1-3.4），以及<22>唇裂</22>伴有<23>腭裂</23>（AOR=2.1；95%CI，1.2-3.9）。其他显示关联的抗菌剂包括<24>红霉素</24>（2个缺陷），<26>青霉素</26>（1个缺陷），<28>头孢菌素</28>（1个缺陷）和<30>喹诺酮类药物</30>（1个缺陷）。结论：令人欣慰的是，<27>青霉素</27>、<25>红霉素</25>和<29>头孢菌素</29>虽然被孕妇广泛使用，但与<8>许多出生缺陷</8>无关。 <1>磺胺类药物</1>和<11>呋喃妥因类药物</11>与多种<9>出生缺陷</9>有关，表明需要进行额外的检查。", "revised": true}
{"doc_key": "3403780", "sentences": [["Paracetamol", "-", "associated", "coma", ",", "metabolic", "acidosis", ",", "renal", "and", "hepatic", "failure", ".", "A", "case", "of", "metabolic", "acidosis", ",", "acute", "renal", "failure", "and", "hepatic", "failure", "following", "paracetamol", "ingestion", "is", "presented", ".", "The", "diagnostic", "difficulty", "at", "presentation", "is", "highlighted", ".", "Continuous", "arteriovenous", "haemofiltration", "proved", "a", "valuable", "means", "of", "maintaining", "fluid", "and", "electrolyte", "balance", ".", "The", "patient", "recovered", "."]], "ner": [[[0, 0, "Chemical"], [26, 26, "Chemical"], [5, 6, "Disease"], [16, 17, "Disease"], [8, 11, "Disease"], [19, 24, "Disease"], [3, 3, "Disease"]]], "relations": [[[0, 0, 5, 6, "CID"], [0, 0, 16, 17, "CID"], [26, 26, 5, 6, "CID"], [26, 26, 16, 17, "CID"], [0, 0, 8, 11, "CID"], [0, 0, 19, 24, "CID"], [26, 26, 8, 11, "CID"], [26, 26, 19, 24, "CID"]]], "clusters": [], "translated": "<0>扑热息痛</0> - 相关<6>昏迷</6>、<2>代谢性酸中毒</2>、<4>肾和肝功能衰竭</4>。一例<3>代谢性酸中毒</3>，<5>急性肾功能衰竭和肝功能衰竭</5>在<1>扑热息痛</1>摄入后出现。突出显示诊断困难。连续动静脉血液滤过被证明是维持体液和电解质平衡的一种有价值的方法。病人痊愈了。", "revised": true}
{"doc_key": "18186898", "sentences": [["Renal", "Fanconi", "syndrome", "and", "myopathy", "after", "liver", "transplantation", ":", "drug", "-", "related", "mitochondrial", "cytopathy", "?", "Advances", "in", "the", "field", "of", "transplantation", "provide", "a", "better", "quality", "of", "life", "and", "allow", "more", "favorable", "conditions", "for", "growth", "and", "development", "in", "children", ".", "However", ",", "combinations", "of", "different", "therapeutic", "regimens", "require", "consideration", "of", "potential", "adverse", "reactions", ".", "We", "describe", "a", "15", "-", "yr", "-", "old", "girl", "who", "had", "orthotopic", "liver", "transplantation", "because", "of", "Wilson", "'s", "disease", ".", "Tacrolimus", ",", "MMF", ",", "and", "steroids", "were", "given", "as", "immunosuppressant", ".", "Lamivudine", "was", "added", "because", "of", "de", "nova", "hepatitis", "B", "infection", "during", "her", "follow", "-", "up", ".", "Three", "yr", "after", "transplantation", "she", "developed", "renal", "Fanconi", "syndrome", "with", "severe", "metabolic", "acidosis", ",", "hypophosphatemia", ",", "glycosuria", ",", "and", "aminoaciduria", ".", "Although", "tacrolimus", "was", "suspected", "to", "be", "the", "cause", "of", "late", "post", "-", "transplant", "renal", "acidosis", "and", "was", "replaced", "by", "sirolimus", ",", "acidosis", ",", "and", "electrolyte", "imbalance", "got", "worse", ".", "Proximal", "muscle", "weakness", "has", "developed", "during", "her", "follow", "-", "up", ".", "Fanconi", "syndrome", ",", "as", "well", "as", "myopathy", ",", "is", "well", "recognized", "in", "patients", "with", "mitochondrial", "disorders", "and", "caused", "by", "depletion", "of", "mtDNA", ".", "We", "suggest", "that", "our", "patient", "'s", "tubular", "dysfunction", "and", "myopathy", "may", "have", "resulted", "from", "mitochondrial", "dysfunction", "which", "is", "triggered", "by", "tacrolimus", "and", "augmented", "by", "lamivudine", "."]], "ner": [[[73, 73, "Chemical"], [122, 122, "Chemical"], [204, 204, "Chemical"], [0, 2, "Disease"], [106, 108, "Disease"], [161, 162, "Disease"], [190, 191, "Disease"], [84, 84, "Chemical"], [208, 208, "Chemical"], [4, 4, "Disease"], [167, 167, "Disease"], [193, 193, "Disease"], [78, 78, "Chemical"], [140, 140, "Chemical"], [12, 13, "Disease"], [69, 71, "Disease"], [91, 93, "Disease"], [111, 112, "Disease"], [135, 135, "Disease"], [142, 142, "Disease"], [114, 114, "Disease"], [116, 116, "Disease"], [119, 119, "Disease"], [151, 152, "Disease"], [175, 176, "Disease"], [198, 199, "Disease"]]], "relations": [[[73, 73, 0, 2, "CID"], [73, 73, 106, 108, "CID"], [73, 73, 161, 162, "CID"], [73, 73, 190, 191, "CID"], [122, 122, 0, 2, "CID"], [122, 122, 106, 108, "CID"], [122, 122, 161, 162, "CID"], [122, 122, 190, 191, "CID"], [204, 204, 0, 2, "CID"], [204, 204, 106, 108, "CID"], [204, 204, 161, 162, "CID"], [204, 204, 190, 191, "CID"], [84, 84, 0, 2, "CID"], [84, 84, 106, 108, "CID"], [84, 84, 161, 162, "CID"], [84, 84, 190, 191, "CID"], [208, 208, 0, 2, "CID"], [208, 208, 106, 108, "CID"], [208, 208, 161, 162, "CID"], [208, 208, 190, 191, "CID"], [73, 73, 4, 4, "CID"], [73, 73, 167, 167, "CID"], [73, 73, 193, 193, "CID"], [122, 122, 4, 4, "CID"], [122, 122, 167, 167, "CID"], [122, 122, 193, 193, "CID"], [204, 204, 4, 4, "CID"], [204, 204, 167, 167, "CID"], [204, 204, 193, 193, "CID"], [84, 84, 4, 4, "CID"], [84, 84, 167, 167, "CID"], [84, 84, 193, 193, "CID"], [208, 208, 4, 4, "CID"], [208, 208, 167, 167, "CID"], [208, 208, 193, 193, "CID"]]], "clusters": [], "translated": "肝移植后<3>肾范可尼综合征</3>和<9>肌病</9>：与药物相关的<14>线粒体细胞病变</14>？移植领域的进步提供了更好的生活质量，并为儿童的生长发育创造了更有利的条件。然而，不同治疗方案的组合需要考虑潜在的不良反应。我们描述了一名 15 岁的女孩，她因<15>威尔逊氏病</15>而接受了原位肝移植。<0>他克莫司</0>、MMF和<12>类固醇</12>作为免疫抑制剂。<7>拉米夫定</7>，因随访期间新发<16>乙肝感染</16>加用。移植后三年，她出现了<4>肾范可尼综合征</4>，伴有严重的<17>代谢性酸中毒</17>、<20>低磷血症</20>、<21>糖尿</21>和<22>氨基酸尿</22>。虽然<1>他克莫司</1>被怀疑是移植后晚期肾性<18>酸中毒</18>的原因并被<13>西罗莫司</13>替代，但<19>酸中毒</19>、电解质失衡变得更糟。近端<23>肌肉无力</23>在随访期间出现。<5>Fanconi 综合征</5>，以及<10>肌病</10>，在患有<24>线粒体疾病</24>且由 mtDNA 耗竭引起的患者中得到广泛认可。我们认为我们患者的<6>肾小管功能障碍</6>和<11>肌病</11>可能是由<2>他克莫司</2>引发的<25>线粒体功能障碍</25>引起的并辅以<8>拉米夫定</8>。", "revised": true}
{"doc_key": "15632880", "sentences": [["Spironolactone", "-", "induced", "renal", "insufficiency", "and", "hyperkalemia", "in", "patients", "with", "heart", "failure", ".", "BACKGROUND", ":", "A", "previous", "randomized", "controlled", "trial", "evaluating", "the", "use", "of", "spironolactone", "in", "heart", "failure", "patients", "reported", "a", "low", "risk", "of", "hyperkalemia", "(", "2", "%", ")", "and", "renal", "insufficiency", "(", "0", "%", ")", ".", "Because", "treatments", "for", "heart", "failure", "have", "changed", "since", "the", "benefits", "of", "spironolactone", "were", "reported", ",", "the", "prevalence", "of", "these", "complications", "may", "differ", "in", "current", "clinical", "practice", ".", "We", "therefore", "sought", "to", "determine", "the", "prevalence", "and", "clinical", "associations", "of", "hyperkalemia", "and", "renal", "insufficiency", "in", "heart", "failure", "patients", "treated", "with", "spironolactone", ".", "METHODS", ":", "We", "performed", "a", "case", "control", "study", "of", "heart", "failure", "patients", "treated", "with", "spironolactone", "in", "our", "clinical", "practice", ".", "Cases", "were", "patients", "who", "developed", "hyperkalemia", "(", "K", "(", "+", ")", ">", "5", ".", "0", "mEq", "/", "L", ")", "or", "renal", "insufficiency", "(", "Cr", ">", "or", "=", "2", ".", "5", "mg", "/", "dL", ")", ",", "and", "they", "were", "compared", "to", "2", "randomly", "selected", "controls", "per", "case", ".", "Clinical", "characteristics", ",", "medications", ",", "and", "serum", "chemistries", "at", "baseline", "and", "follow", "-", "up", "time", "periods", "were", "compared", ".", "RESULTS", ":", "Sixty", "-", "seven", "of", "926", "patients", "(", "7", ".", "2", "%", ")", "required", "discontinuation", "of", "spironolactone", "due", "to", "hyperkalemia", "(", "n", "=", "33", ")", "or", "renal", "failure", "(", "n", "=", "34", ")", ".", "Patients", "who", "developed", "hyperkalemia", "were", "older", "and", "more", "likely", "to", "have", "diabetes", ",", "had", "higher", "baseline", "serum", "potassium", "levels", "and", "lower", "baseline", "potassium", "supplement", "doses", ",", "and", "were", "more", "likely", "to", "be", "treated", "with", "beta", "-", "blockers", "than", "controls", "(", "n", "=", "134", ")", ".", "Patients", "who", "developed", "renal", "insufficiency", "had", "lower", "baseline", "body", "weight", "and", "higher", "baseline", "serum", "creatinine", ",", "required", "higher", "doses", "of", "loop", "diuretics", ",", "and", "were", "more", "likely", "to", "be", "treated", "with", "thiazide", "diuretics", "than", "controls", ".", "CONCLUSIONS", ":", "Spironolactone", "-", "induced", "hyperkalemia", "and", "renal", "insufficiency", "are", "more", "common", "in", "our", "clinical", "experience", "than", "reported", "previously", ".", "This", "difference", "is", "explained", "by", "patient", "comorbidities", "and", "more", "frequent", "use", "of", "beta", "-", "blockers", "."]], "ner": [[[0, 0, "Chemical"], [24, 24, "Chemical"], [58, 58, "Chemical"], [95, 95, "Chemical"], [111, 111, "Chemical"], [200, 200, "Chemical"], [301, 301, "Chemical"], [3, 4, "Disease"], [40, 41, "Disease"], [87, 88, "Disease"], [137, 138, "Disease"], [210, 211, "Disease"], [266, 267, "Disease"], [306, 307, "Disease"], [6, 6, "Disease"], [34, 34, "Disease"], [85, 85, "Disease"], [122, 122, "Disease"], [203, 203, "Disease"], [221, 221, "Disease"], [304, 304, "Disease"], [10, 11, "Disease"], [26, 27, "Disease"], [50, 51, "Disease"], [90, 91, "Disease"], [106, 107, "Disease"], [229, 229, "Disease"], [124, 124, "Chemical"], [235, 235, "Chemical"], [240, 240, "Chemical"], [140, 140, "Chemical"], [277, 277, "Chemical"], [294, 294, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 40, 41, "CID"], [0, 0, 87, 88, "CID"], [0, 0, 137, 138, "CID"], [0, 0, 210, 211, "CID"], [0, 0, 266, 267, "CID"], [0, 0, 306, 307, "CID"], [24, 24, 3, 4, "CID"], [24, 24, 40, 41, "CID"], [24, 24, 87, 88, "CID"], [24, 24, 137, 138, "CID"], [24, 24, 210, 211, "CID"], [24, 24, 266, 267, "CID"], [24, 24, 306, 307, "CID"], [58, 58, 3, 4, "CID"], [58, 58, 40, 41, "CID"], [58, 58, 87, 88, "CID"], [58, 58, 137, 138, "CID"], [58, 58, 210, 211, "CID"], [58, 58, 266, 267, "CID"], [58, 58, 306, 307, "CID"], [95, 95, 3, 4, "CID"], [95, 95, 40, 41, "CID"], [95, 95, 87, 88, "CID"], [95, 95, 137, 138, "CID"], [95, 95, 210, 211, "CID"], [95, 95, 266, 267, "CID"], [95, 95, 306, 307, "CID"], [111, 111, 3, 4, "CID"], [111, 111, 40, 41, "CID"], [111, 111, 87, 88, "CID"], [111, 111, 137, 138, "CID"], [111, 111, 210, 211, "CID"], [111, 111, 266, 267, "CID"], [111, 111, 306, 307, "CID"], [200, 200, 3, 4, "CID"], [200, 200, 40, 41, "CID"], [200, 200, 87, 88, "CID"], [200, 200, 137, 138, "CID"], [200, 200, 210, 211, "CID"], [200, 200, 266, 267, "CID"], [200, 200, 306, 307, "CID"], [301, 301, 3, 4, "CID"], [301, 301, 40, 41, "CID"], [301, 301, 87, 88, "CID"], [301, 301, 137, 138, "CID"], [301, 301, 210, 211, "CID"], [301, 301, 266, 267, "CID"], [301, 301, 306, 307, "CID"], [0, 0, 6, 6, "CID"], [0, 0, 34, 34, "CID"], [0, 0, 85, 85, "CID"], [0, 0, 122, 122, "CID"], [0, 0, 203, 203, "CID"], [0, 0, 221, 221, "CID"], [0, 0, 304, 304, "CID"], [24, 24, 6, 6, "CID"], [24, 24, 34, 34, "CID"], [24, 24, 85, 85, "CID"], [24, 24, 122, 122, "CID"], [24, 24, 203, 203, "CID"], [24, 24, 221, 221, "CID"], [24, 24, 304, 304, "CID"], [58, 58, 6, 6, "CID"], [58, 58, 34, 34, "CID"], [58, 58, 85, 85, "CID"], [58, 58, 122, 122, "CID"], [58, 58, 203, 203, "CID"], [58, 58, 221, 221, "CID"], [58, 58, 304, 304, "CID"], [95, 95, 6, 6, "CID"], [95, 95, 34, 34, "CID"], [95, 95, 85, 85, "CID"], [95, 95, 122, 122, "CID"], [95, 95, 203, 203, "CID"], [95, 95, 221, 221, "CID"], [95, 95, 304, 304, "CID"], [111, 111, 6, 6, "CID"], [111, 111, 34, 34, "CID"], [111, 111, 85, 85, "CID"], [111, 111, 122, 122, "CID"], [111, 111, 203, 203, "CID"], [111, 111, 221, 221, "CID"], [111, 111, 304, 304, "CID"], [200, 200, 6, 6, "CID"], [200, 200, 34, 34, "CID"], [200, 200, 85, 85, "CID"], [200, 200, 122, 122, "CID"], [200, 200, 203, 203, "CID"], [200, 200, 221, 221, "CID"], [200, 200, 304, 304, "CID"], [301, 301, 6, 6, "CID"], [301, 301, 34, 34, "CID"], [301, 301, 85, 85, "CID"], [301, 301, 122, 122, "CID"], [301, 301, 203, 203, "CID"], [301, 301, 221, 221, "CID"], [301, 301, 304, 304, "CID"]]], "clusters": [], "translated": "<0>螺内酯</0>在<21>心力衰竭</21>患者中引起<7>肾功能不全</7>和<14>高钾血症</14>。背景：之前的一项随机对照试验评估了<1>螺内酯</1>在<22>心力衰竭</22>患者中的应用，报告了<15>高钾血症</15>（2%）和<8>肾功能不全</8>（0%）。自从报告了<2>螺内酯</2>的获益以来，<23>心力衰竭</23>的治疗方法发生了变化，因此这些并发症的发生率在目前的临床实践中可能有所不同。因此，我们试图确定接受<3>螺内酯</3>治疗的<24>心力衰竭</24>患者中<16>高钾血症</16>和<9>肾功能不全</9>的患病率和临床相关性。方法：我们对临床实践中使用<4>螺内酯</4>治疗的<25>心力衰竭</25>患者进行了病例对照研究。病例是发生<17>高钾血症</17>（<27>K</27>（+）>5.0 mEq/L）或<10>肾功能不全</10>（<30>Cr</30>>或=2.5 mg/dL），并且每个病例将它们与2个随机选择的对照进行比较。比较基线和随访时间段的临床特征、药物和血清化学。结果：926名患者中有67名（7.2%）由于<11>肾功能衰竭</11>（n = 34）或<18>高钾血症</18>（n = 33）需要停用<5>螺内酯</5>。出现<19>高钾血症</19>的患者年龄较大，更可能患有<26>糖尿病</26>，基线血清<28>钾</28>水平较高，基线<29>补充剂量低</29>，并更可能接受β受体阻滞剂治疗（n = 134）。出现<12>肾功能不全</12>的患者基线体重较低，基线血清<31>肌酐</31>较高，需要较高剂量的袢利尿剂，并且更有可能接受<32>噻嗪</32>利尿剂优于对照组。结论：<6>螺内酯</6>诱发的<20>高钾血症</20>和<13>肾功能不全</13>在我们的临床经验中比以前报道的更为常见。这种差异可以用患者的合并症和更频繁地使用β受体阻滞剂来解释。", "revised": true}
{"doc_key": "8437969", "sentences": [["Sinus", "arrest", "associated", "with", "continuous", "-", "infusion", "cimetidine", ".", "The", "administration", "of", "intermittent", "intravenous", "infusions", "of", "cimetidine", "is", "infrequently", "associated", "with", "the", "development", "of", "bradyarrhythmias", ".", "A", "40", "-", "year", "-", "old", "man", "with", "leukemia", "and", "no", "history", "of", "cardiac", "disease", "developed", "recurrent", ",", "brief", "episodes", "of", "apparent", "sinus", "arrest", "while", "receiving", "continuous", "-", "infusion", "cimetidine", "50", "mg", "/", "hour", ".", "The", "arrhythmias", "were", "temporally", "related", "to", "cimetidine", "administration", ",", "disappeared", "after", "dechallenge", ",", "and", "did", "not", "recur", "during", "ranitidine", "treatment", ".", "This", "is", "the", "first", "reported", "case", "of", "sinus", "arrest", "associated", "with", "continuous", "-", "infusion", "cimetidine", "."]], "ner": [[[7, 7, "Chemical"], [16, 16, "Chemical"], [55, 55, "Chemical"], [67, 67, "Chemical"], [96, 96, "Chemical"], [0, 1, "Disease"], [48, 49, "Disease"], [89, 90, "Disease"], [24, 24, "Disease"], [79, 79, "Chemical"], [34, 34, "Disease"], [39, 40, "Disease"], [62, 62, "Disease"]]], "relations": [[[7, 7, 0, 1, "CID"], [7, 7, 48, 49, "CID"], [7, 7, 89, 90, "CID"], [16, 16, 0, 1, "CID"], [16, 16, 48, 49, "CID"], [16, 16, 89, 90, "CID"], [55, 55, 0, 1, "CID"], [55, 55, 48, 49, "CID"], [55, 55, 89, 90, "CID"], [67, 67, 0, 1, "CID"], [67, 67, 48, 49, "CID"], [67, 67, 89, 90, "CID"], [96, 96, 0, 1, "CID"], [96, 96, 48, 49, "CID"], [96, 96, 89, 90, "CID"], [7, 7, 24, 24, "CID"], [16, 16, 24, 24, "CID"], [55, 55, 24, 24, "CID"], [67, 67, 24, 24, "CID"], [96, 96, 24, 24, "CID"]]], "clusters": [], "translated": "窦性停搏<5></5>与持续输注<0>西咪替丁</0>有关。间歇性静脉输注<1>西咪替丁</1>很少与<8>心动过缓</8>的发生有关。一名患有<10>白血病</10>并且没有<11>心脏病</11>病史的40岁男性在接受连续输液治疗时出现了反复发作的明显窦性停搏<6></6><2>西咪替丁</2>50毫克/小时。<12>心律失常</12>在时间上与<3>西咪替丁</3>给药有关，在去激发后消失，并且在<9>雷尼替丁</9>治疗期间没有复发。这是第一例与持续输注<4>西咪替丁</4>相关的窦性停搏<7></7>病例。", "revised": true}
{"doc_key": "20880751", "sentences": [["Levodopa", "-", "induced", "dyskinesias", "in", "patients", "with", "Parkinson", "'s", "disease", ":", "filling", "the", "bench", "-", "to", "-", "bedside", "gap", ".", "Levodopa", "is", "the", "most", "effective", "drug", "for", "the", "treatment", "of", "Parkinson", "'s", "disease", ".", "However", ",", "the", "long", "-", "term", "use", "of", "this", "dopamine", "precursor", "is", "complicated", "by", "highly", "disabling", "fluctuations", "and", "dyskinesias", ".", "Although", "preclinical", "and", "clinical", "findings", "suggest", "pulsatile", "stimulation", "of", "striatal", "postsynaptic", "receptors", "as", "a", "key", "mechanism", "underlying", "levodopa", "-", "induced", "dyskinesias", ",", "their", "pathogenesis", "is", "still", "unclear", ".", "In", "recent", "years", ",", "evidence", "from", "animal", "models", "of", "Parkinson", "'s", "disease", "has", "provided", "important", "information", "to", "understand", "the", "effect", "of", "specific", "receptor", "and", "post", "-", "receptor", "molecular", "mechanisms", "underlying", "the", "development", "of", "dyskinetic", "movements", ".", "Recent", "preclinical", "and", "clinical", "data", "from", "promising", "lines", "of", "research", "focus", "on", "the", "differential", "role", "of", "presynaptic", "versus", "postsynaptic", "mechanisms", ",", "dopamine", "receptor", "subtypes", ",", "ionotropic", "and", "metabotropic", "glutamate", "receptors", ",", "and", "non", "-", "dopaminergic", "neurotransmitter", "systems", "in", "the", "pathophysiology", "of", "levodopa", "-", "induced", "dyskinesias", "."]], "ner": [[[0, 0, "Chemical"], [20, 20, "Chemical"], [71, 71, "Chemical"], [159, 159, "Chemical"], [3, 3, "Disease"], [52, 52, "Disease"], [74, 74, "Disease"], [115, 116, "Disease"], [162, 162, "Disease"], [7, 9, "Disease"], [30, 32, "Disease"], [91, 93, "Disease"], [43, 43, "Chemical"], [139, 139, "Chemical"], [146, 146, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 52, 52, "CID"], [0, 0, 74, 74, "CID"], [0, 0, 115, 116, "CID"], [0, 0, 162, 162, "CID"], [20, 20, 3, 3, "CID"], [20, 20, 52, 52, "CID"], [20, 20, 74, 74, "CID"], [20, 20, 115, 116, "CID"], [20, 20, 162, 162, "CID"], [71, 71, 3, 3, "CID"], [71, 71, 52, 52, "CID"], [71, 71, 74, 74, "CID"], [71, 71, 115, 116, "CID"], [71, 71, 162, 162, "CID"], [159, 159, 3, 3, "CID"], [159, 159, 52, 52, "CID"], [159, 159, 74, 74, "CID"], [159, 159, 115, 116, "CID"], [159, 159, 162, 162, "CID"]]], "clusters": [], "translated": "<0>左旋多巴</0>诱发<4>运动障碍</4><9>帕金森氏病</9>患者：填补从工作台到床边的空白。<1>左旋多巴</1>是治疗<10>帕金森病</10>最有效的药物。然而，长期使用这种<12>多巴胺</12>前体会因高度致残的波动和<5>运动障碍</5>而变得复杂。尽管临床前和临床研究结果表明纹状体突触后受体的脉冲刺激是<2>左旋多巴</2>诱发<6>运动障碍</6>的关键机制，但其发病机制仍不清楚。近年来，来自<11>帕金森病</11>动物模型的证据提供了重要信息，以了解特定受体和其后受体分子机制在<7>运动障碍运动</7>的发展中发挥的作用。最新的临床前和临床研究数据来自有前途的研究领域，聚焦于突触前机制与突触后机制、<13>多巴胺</13>受体亚型、离子型和代谢型<14>谷氨酸</14>受体以及非多巴胺能神经递质系统在<3>左旋多巴</3>引起的<8>运动障碍</8>的病理生理机制中的不同作用。", "revised": true}
{"doc_key": "9245658", "sentences": [["The", "role", "of", "nicotine", "in", "smoking", "-", "related", "cardiovascular", "disease", ".", "Nicotine", "activates", "the", "sympathetic", "nervous", "system", "and", "in", "this", "way", "could", "contribute", "to", "cardiovascular", "disease", ".", "Animal", "studies", "and", "mechanistic", "studies", "indicate", "that", "nicotine", "could", "play", "a", "role", "in", "accelerating", "atherosclerosis", ",", "but", "evidence", "among", "humans", "is", "too", "inadequate", "to", "be", "definitive", "about", "such", "an", "effect", ".", "Almost", "certainly", ",", "nicotine", "via", "its", "hemodynamic", "effects", "contributes", "to", "acute", "cardiovascular", "events", ",", "although", "current", "evidence", "suggests", "that", "the", "effects", "of", "nicotine", "are", "much", "less", "important", "than", "are", "the", "prothrombotic", "effects", "of", "cigarette", "smoking", "or", "the", "effects", "of", "carbon", "monoxide", ".", "Nicotine", "does", "not", "appear", "to", "enhance", "thrombosis", "among", "humans", ".", "Clinical", "studies", "of", "pipe", "smokers", "and", "people", "using", "transdermal", "nicotine", "support", "the", "idea", "that", "toxins", "other", "than", "nicotine", "are", "the", "most", "important", "causes", "of", "acute", "cardiovascular", "events", ".", "Finally", ",", "the", "dose", "response", "for", "cardiovascular", "events", "of", "nicotine", "appears", "to", "be", "flat", ",", "suggesting", "that", "if", "nicotine", "is", "involved", ",", "adverse", "effects", "might", "be", "seen", "with", "relatively", "low", "-", "level", "cigarette", "exposures", "."]], "ner": [[[3, 3, "Chemical"], [11, 11, "Chemical"], [34, 34, "Chemical"], [61, 61, "Chemical"], [80, 80, "Chemical"], [100, 100, "Chemical"], [119, 119, "Chemical"], [127, 127, "Chemical"], [147, 147, "Chemical"], [156, 156, "Chemical"], [8, 9, "Disease"], [24, 25, "Disease"], [41, 41, "Disease"], [106, 106, "Disease"], [97, 98, "Chemical"]]], "relations": [[[3, 3, 8, 9, "CID"], [3, 3, 24, 25, "CID"], [11, 11, 8, 9, "CID"], [11, 11, 24, 25, "CID"], [34, 34, 8, 9, "CID"], [34, 34, 24, 25, "CID"], [61, 61, 8, 9, "CID"], [61, 61, 24, 25, "CID"], [80, 80, 8, 9, "CID"], [80, 80, 24, 25, "CID"], [100, 100, 8, 9, "CID"], [100, 100, 24, 25, "CID"], [119, 119, 8, 9, "CID"], [119, 119, 24, 25, "CID"], [127, 127, 8, 9, "CID"], [127, 127, 24, 25, "CID"], [147, 147, 8, 9, "CID"], [147, 147, 24, 25, "CID"], [156, 156, 8, 9, "CID"], [156, 156, 24, 25, "CID"], [3, 3, 41, 41, "CID"], [11, 11, 41, 41, "CID"], [34, 34, 41, 41, "CID"], [61, 61, 41, 41, "CID"], [80, 80, 41, 41, "CID"], [100, 100, 41, 41, "CID"], [119, 119, 41, 41, "CID"], [127, 127, 41, 41, "CID"], [147, 147, 41, 41, "CID"], [156, 156, 41, 41, "CID"]]], "clusters": [], "translated": " <0>尼古丁</0>在与吸烟有关的<10>心血管疾病</10>中的作用。<1>尼古丁</1>激活交感神经系统，从而可能导致<11>心血管疾病</11>。动物研究和机理研究表明，<2>尼古丁</2>可能在加速<12>动脉粥样硬化</12>中发挥作用，但人类证据太不足，无法确定这种影响。几乎可以肯定，<3>尼古丁</3>通过其血液动力学效应导致急性心血管事件，尽管目前的证据表明<4>尼古丁</4>的影响远不如吸烟或<14>一氧化碳</14>的影响。<5>尼古丁</5>似乎不会增强人类的<13>血栓形成</13>。对烟斗吸烟者和使用透皮<6>尼古丁</6>的人的临床研究支持这样的观点，即<7>尼古丁</7>以外的毒素是急性心血管事件的最重要原因。最后，<8>尼古丁</8>对心血管事件的剂量反应似乎是平缓的，这表明如果涉及<9>尼古丁</9>，相对低水平的香烟暴露可能会出现不良反应。", "revised": true}
{"doc_key": "9034419", "sentences": [["Seizure", "resulting", "from", "a", "venlafaxine", "overdose", ".", "OBJECTIVE", ":", "To", "report", "a", "case", "of", "venlafaxine", "overdose", ".", "CASE", "SUMMARY", ":", "A", "40", "-", "year", "-", "old", "woman", "with", "major", "depression", "took", "an", "overdose", "of", "venlafaxine", "in", "an", "apparent", "suicide", "attempt", ".", "After", "the", "ingestion", "of", "26", "venlafaxine", "50", "-", "mg", "tablets", ",", "the", "patient", "experienced", "a", "witnessed", "generalized", "seizure", ".", "She", "was", "admitted", "to", "the", "medical", "intensive", "care", "unit", ",", "venlafaxine", "was", "discontinued", ",", "and", "no", "further", "sequelae", "were", "seen", ".", "DISCUSSION", ":", "To", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "of", "venlafaxine", "overdose", "that", "resulted", "in", "a", "generalized", "seizure", ".", "Based", "on", "nonoverdose", "pharmacokinetics", "and", "pharmacodynamics", "of", "venlafaxine", "and", "the", "potential", "risks", "of", "available", "interventions", ",", "no", "emergent", "therapy", "was", "instituted", ".", "CONCLUSIONS", ":", "The", "venlafaxine", "overdose", "in", "our", "patient", "resulted", "in", "a", "single", "episode", "of", "generalized", "seizure", "but", "elicited", "no", "further", "sequelae", "."]], "ner": [[[4, 4, "Chemical"], [14, 14, "Chemical"], [34, 34, "Chemical"], [46, 46, "Chemical"], [70, 70, "Chemical"], [94, 94, "Chemical"], [110, 110, "Chemical"], [128, 128, "Chemical"], [0, 0, "Disease"], [58, 58, "Disease"], [101, 101, "Disease"], [140, 140, "Disease"], [5, 5, "Disease"], [15, 15, "Disease"], [32, 32, "Disease"], [95, 95, "Disease"], [129, 129, "Disease"], [28, 29, "Disease"]]], "relations": [[[4, 4, 0, 0, "CID"], [4, 4, 58, 58, "CID"], [4, 4, 101, 101, "CID"], [4, 4, 140, 140, "CID"], [14, 14, 0, 0, "CID"], [14, 14, 58, 58, "CID"], [14, 14, 101, 101, "CID"], [14, 14, 140, 140, "CID"], [34, 34, 0, 0, "CID"], [34, 34, 58, 58, "CID"], [34, 34, 101, 101, "CID"], [34, 34, 140, 140, "CID"], [46, 46, 0, 0, "CID"], [46, 46, 58, 58, "CID"], [46, 46, 101, 101, "CID"], [46, 46, 140, 140, "CID"], [70, 70, 0, 0, "CID"], [70, 70, 58, 58, "CID"], [70, 70, 101, 101, "CID"], [70, 70, 140, 140, "CID"], [94, 94, 0, 0, "CID"], [94, 94, 58, 58, "CID"], [94, 94, 101, 101, "CID"], [94, 94, 140, 140, "CID"], [110, 110, 0, 0, "CID"], [110, 110, 58, 58, "CID"], [110, 110, 101, 101, "CID"], [110, 110, 140, 140, "CID"], [128, 128, 0, 0, "CID"], [128, 128, 58, 58, "CID"], [128, 128, 101, 101, "CID"], [128, 128, 140, 140, "CID"], [4, 4, 5, 5, "CID"], [4, 4, 15, 15, "CID"], [4, 4, 32, 32, "CID"], [4, 4, 95, 95, "CID"], [4, 4, 129, 129, "CID"], [14, 14, 5, 5, "CID"], [14, 14, 15, 15, "CID"], [14, 14, 32, 32, "CID"], [14, 14, 95, 95, "CID"], [14, 14, 129, 129, "CID"], [34, 34, 5, 5, "CID"], [34, 34, 15, 15, "CID"], [34, 34, 32, 32, "CID"], [34, 34, 95, 95, "CID"], [34, 34, 129, 129, "CID"], [46, 46, 5, 5, "CID"], [46, 46, 15, 15, "CID"], [46, 46, 32, 32, "CID"], [46, 46, 95, 95, "CID"], [46, 46, 129, 129, "CID"], [70, 70, 5, 5, "CID"], [70, 70, 15, 15, "CID"], [70, 70, 32, 32, "CID"], [70, 70, 95, 95, "CID"], [70, 70, 129, 129, "CID"], [94, 94, 5, 5, "CID"], [94, 94, 15, 15, "CID"], [94, 94, 32, 32, "CID"], [94, 94, 95, 95, "CID"], [94, 94, 129, 129, "CID"], [110, 110, 5, 5, "CID"], [110, 110, 15, 15, "CID"], [110, 110, 32, 32, "CID"], [110, 110, 95, 95, "CID"], [110, 110, 129, 129, "CID"], [128, 128, 5, 5, "CID"], [128, 128, 15, 15, "CID"], [128, 128, 32, 32, "CID"], [128, 128, 95, 95, "CID"], [128, 128, 129, 129, "CID"]]], "clusters": [], "translated": "<8> 癫痫发作 </8> 由<0> 文拉法辛 </0><12>过量服用</12>引起。目的：报告一例<1>文拉法辛</1> <13>用药过量</13>。案例概要：一名患有<17>重度抑郁症</17>的40岁女性服用<14>过量</14><2>文拉法辛</2>，显然是企图自杀。在服用26片<3>文拉法辛</3> 50毫克药片后，患者经历了一次有目击的全身性<9>癫痫发作</9>。她被收入内科重症监护病房，<4>文拉法辛</4>停药，未见其他后遗症。讨论：据我们所知，这是第一例报告的<5>文拉法辛</5><15>过量服用</15>导致全身性<10>癫痫发作 </10>的病例。根据<6>文拉法辛</6>的非过量药代动力学和药效学以及现有干预措施的潜在风险，未制定紧急治疗。结论：本例患者<7>文拉法辛</7><16>过量服用</16>导致单次全身性<11>癫痫发作</11>，但未引起进一步的后遗症。", "revised": true}
{"doc_key": "8829025", "sentences": [["Effect", "of", "nifedipine", "on", "renal", "function", "in", "liver", "transplant", "recipients", "receiving", "tacrolimus", ".", "The", "effect", "of", "nifedipine", "on", "renal", "function", "in", "liver", "transplant", "recipients", "who", "were", "receiving", "tacrolimus", "was", "evaluated", "between", "January", "1992", "and", "January", "1996", ".", "Two", "groups", "of", "patients", "receiving", "tacrolimus", "were", "compared", "over", "a", "period", "of", "1", "year", ",", "one", "group", "comprising", "hypertensive", "patients", "who", "were", "receiving", "nifedipine", ",", "and", "the", "other", "comprising", "nonhypertensive", "patients", "not", "receiving", "nifedipine", ".", "The", "time", "from", "transplant", "to", "baseline", "was", "similar", "in", "all", "patients", ".", "Nifedipine", "significantly", "improved", "kidney", "function", "as", "indicated", "by", "a", "significant", "lowering", "of", "serum", "creatinine", "levels", "at", "6", "and", "12", "months", ".", "The", "observed", "positive", "impact", "of", "nifedipine", "on", "reducing", "the", "nephrotoxicity", "associated", "with", "tacrolimus", "in", "liver", "transplant", "recipients", "should", "be", "an", "important", "factor", "in", "selecting", "an", "agent", "to", "treat", "hypertension", "in", "this", "population", "."]], "ner": [[[11, 11, "Chemical"], [27, 27, "Chemical"], [42, 42, "Chemical"], [117, 117, "Chemical"], [55, 55, "Disease"], [133, 133, "Disease"], [2, 2, "Chemical"], [16, 16, "Chemical"], [60, 60, "Chemical"], [70, 70, "Chemical"], [84, 84, "Chemical"], [110, 110, "Chemical"], [114, 114, "Disease"], [97, 97, "Chemical"]]], "relations": [[[11, 11, 55, 55, "CID"], [11, 11, 133, 133, "CID"], [27, 27, 55, 55, "CID"], [27, 27, 133, 133, "CID"], [42, 42, 55, 55, "CID"], [42, 42, 133, 133, "CID"], [117, 117, 55, 55, "CID"], [117, 117, 133, 133, "CID"]]], "clusters": [], "translated": "<6>硝苯地平</6>对<0>他克莫司</0>肝移植受者肾功能的影响。1992年1月至1996年1月，评估了<7>硝苯地平</7>对接受<1>他克莫司</1>的肝移植受者肾功能的影响。对接受<2>他克莫司</2>治疗的两组患者进行为期1年的比较，其中一组包括接受<8>硝苯地平</8>的<4>高血压</4>患者，另一组包括未服用<9>硝苯地平</9>的非高血压患者。所有患者从移植到基线的时间相似。<10>硝苯地平</10>显着改善肾功能，表现为6个月和12个月时血清<13>肌酐</13>水平显着降低。观察到<11>硝苯地平</11>对降低<3>他克莫司</3>肝移植受者相关的<12>肾毒性</12>的积极影响应该是选择治疗药物的重要因素，在这个人群中<5>高血压</5>。", "revised": true}
{"doc_key": "11745184", "sentences": [["A", "Phase", "II", "trial", "of", "cisplatin", "plus", "WR", "-", "2721", "(", "amifostine", ")", "for", "metastatic", "breast", "carcinoma", ":", "an", "Eastern", "Cooperative", "Oncology", "Group", "Study", "(", "E8188", ")", ".", "BACKGROUND", ":", "Cisplatin", "has", "minimal", "antitumor", "activity", "when", "used", "as", "second", "-", "or", "third", "-", "line", "treatment", "of", "metastatic", "breast", "carcinoma", ".", "Older", "reports", "suggest", "an", "objective", "response", "rate", "of", "8", "%", "when", "60", "-", "120", "mg", "/", "m2", "of", "cisplatin", "is", "administered", "every", "3", "-", "4", "weeks", ".", "Although", "a", "dose", "-", "response", "effect", "has", "been", "observed", "with", "cisplatin", ",", "the", "dose", "-", "limiting", "toxicities", "associated", "with", "cisplatin", "(", "e", ".", "g", ".", ",", "nephrotoxicity", ",", "ototoxicity", ",", "and", "neurotoxicity", ")", "have", "limited", "its", "use", "as", "a", "treatment", "for", "breast", "carcinoma", ".", "WR", "-", "2721", "or", "amifostine", "initially", "was", "developed", "to", "protect", "military", "personnel", "in", "the", "event", "of", "nuclear", "war", ".", "Amifostine", "subsequently", "was", "shown", "to", "protect", "normal", "tissues", "from", "the", "toxic", "effects", "of", "alkylating", "agents", "and", "cisplatin", "without", "decreasing", "the", "antitumor", "effect", "of", "the", "chemotherapy", ".", "Early", "trials", "of", "cisplatin", "and", "amifostine", "also", "suggested", "that", "the", "incidence", "and", "severity", "of", "cisplatin", "-", "induced", "nephrotoxicity", ",", "ototoxicity", ",", "and", "neuropathy", "were", "reduced", ".", "METHODS", ":", "A", "Phase", "II", "study", "of", "the", "combination", "of", "cisplatin", "plus", "amifostine", "was", "conducted", "in", "patients", "with", "progressive", "metastatic", "breast", "carcinoma", "who", "had", "received", "one", ",", "but", "not", "more", "than", "one", ",", "chemotherapy", "regimen", "for", "metastatic", "disease", ".", "Patients", "received", "amifostine", ",", "910", "mg", "/", "m2", "intravenously", "over", "15", "minutes", ".", "After", "completion", "of", "the", "amifostine", "infusion", ",", "cisplatin", "120", "mg", "/", "m2", "was", "administered", "over", "30", "minutes", ".", "Intravenous", "hydration", "and", "mannitol", "was", "administered", "before", "and", "after", "cisplatin", ".", "Treatment", "was", "administered", "every", "3", "weeks", "until", "disease", "progression", ".", "RESULTS", ":", "Forty", "-", "four", "patients", "were", "enrolled", "in", "the", "study", "of", "which", "7", "(", "16", "%", ")", "were", "ineligible", ".", "A", "median", "of", "2", "cycles", "of", "therapy", "was", "administered", "to", "the", "37", "eligible", "patients", ".", "Six", "partial", "responses", "were", "observed", "for", "an", "overall", "response", "rate", "of", "16", "%", ".", "Most", "patients", "(", "57", "%", ")", "stopped", "treatment", "because", "of", "disease", "progression", ".", "Neurologic", "toxicity", "was", "reported", "in", "52", "%", "of", "patients", ".", "Seven", "different", "life", "-", "threatening", "toxicities", "were", "observed", "in", "patients", "while", "receiving", "treatment", ".", "CONCLUSIONS", ":", "The", "combination", "of", "cisplatin", "and", "amifostine", "in", "this", "study", "resulted", "in", "an", "overall", "response", "rate", "of", "16", "%", ".", "Neither", "a", "tumor", "-", "protective", "effect", "nor", "reduced", "toxicity", "to", "normal", "tissues", "was", "observed", "with", "the", "addition", "of", "amifostine", "to", "cisplatin", "in", "this", "trial", "."]], "ner": [[[5, 5, "Chemical"], [30, 30, "Chemical"], [68, 68, "Chemical"], [87, 87, "Chemical"], [96, 96, "Chemical"], [156, 156, "Chemical"], [169, 169, "Chemical"], [180, 180, "Chemical"], [202, 202, "Chemical"], [251, 251, "Chemical"], [271, 271, "Chemical"], [375, 375, "Chemical"], [411, 411, "Chemical"], [103, 103, "Disease"], [183, 183, "Disease"], [105, 105, "Disease"], [185, 185, "Disease"], [188, 188, "Disease"], [15, 16, "Disease"], [47, 48, "Disease"], [118, 119, "Disease"], [212, 213, "Disease"], [93, 93, "Disease"], [361, 361, "Disease"], [399, 399, "Disease"], [108, 108, "Disease"], [346, 347, "Disease"], [393, 393, "Disease"], [7, 9, "Chemical"], [11, 11, "Chemical"], [121, 123, "Chemical"], [125, 125, "Chemical"], [140, 140, "Chemical"], [171, 171, "Chemical"], [204, 204, "Chemical"], [233, 233, "Chemical"], [248, 248, "Chemical"], [377, 377, "Chemical"], [409, 409, "Chemical"], [153, 154, "Chemical"], [265, 265, "Chemical"]]], "relations": [[[5, 5, 103, 103, "CID"], [5, 5, 183, 183, "CID"], [30, 30, 103, 103, "CID"], [30, 30, 183, 183, "CID"], [68, 68, 103, 103, "CID"], [68, 68, 183, 183, "CID"], [87, 87, 103, 103, "CID"], [87, 87, 183, 183, "CID"], [96, 96, 103, 103, "CID"], [96, 96, 183, 183, "CID"], [156, 156, 103, 103, "CID"], [156, 156, 183, 183, "CID"], [169, 169, 103, 103, "CID"], [169, 169, 183, 183, "CID"], [180, 180, 103, 103, "CID"], [180, 180, 183, 183, "CID"], [202, 202, 103, 103, "CID"], [202, 202, 183, 183, "CID"], [251, 251, 103, 103, "CID"], [251, 251, 183, 183, "CID"], [271, 271, 103, 103, "CID"], [271, 271, 183, 183, "CID"], [375, 375, 103, 103, "CID"], [375, 375, 183, 183, "CID"], [411, 411, 103, 103, "CID"], [411, 411, 183, 183, "CID"], [5, 5, 105, 105, "CID"], [5, 5, 185, 185, "CID"], [30, 30, 105, 105, "CID"], [30, 30, 185, 185, "CID"], [68, 68, 105, 105, "CID"], [68, 68, 185, 185, "CID"], [87, 87, 105, 105, "CID"], [87, 87, 185, 185, "CID"], [96, 96, 105, 105, "CID"], [96, 96, 185, 185, "CID"], [156, 156, 105, 105, "CID"], [156, 156, 185, 185, "CID"], [169, 169, 105, 105, "CID"], [169, 169, 185, 185, "CID"], [180, 180, 105, 105, "CID"], [180, 180, 185, 185, "CID"], [202, 202, 105, 105, "CID"], [202, 202, 185, 185, "CID"], [251, 251, 105, 105, "CID"], [251, 251, 185, 185, "CID"], [271, 271, 105, 105, "CID"], [271, 271, 185, 185, "CID"], [375, 375, 105, 105, "CID"], [375, 375, 185, 185, "CID"], [411, 411, 105, 105, "CID"], [411, 411, 185, 185, "CID"], [5, 5, 188, 188, "CID"], [30, 30, 188, 188, "CID"], [68, 68, 188, 188, "CID"], [87, 87, 188, 188, "CID"], [96, 96, 188, 188, "CID"], [156, 156, 188, 188, "CID"], [169, 169, 188, 188, "CID"], [180, 180, 188, 188, "CID"], [202, 202, 188, 188, "CID"], [251, 251, 188, 188, "CID"], [271, 271, 188, 188, "CID"], [375, 375, 188, 188, "CID"], [411, 411, 188, 188, "CID"]]], "clusters": [], "translated": "<0>顺铂</0>加<28>WR-2721</28> (<29>氨磷汀</29>)治疗转移性<18>乳腺癌</18>的II期试验：东方合作肿瘤学小组学习 (E8188)。背景:<1>顺铂</1>作为转移性<19>乳腺癌</19>的二线或三线治疗时，抗肿瘤活性很小。较早的报告表明，当每3-4周服用60-120 mg/m2的<2>顺铂</2>时，客观缓解率为8%。尽管已观察到<3>顺铂</3>的剂量反应效应，但与<4>顺铂</4>相关的剂量限制性<22>毒性</22>（例如，<13>肾毒性</13>、<15>耳毒性</15>和<25>神经毒性</25>）限制了它作为<20>乳腺癌</20>治疗的用途。<30>WR-2721</30>或<31>氨磷汀</31>最初是为了在发生核战争时保护军事人员而开发的。<32>氨磷汀</32>随后被证明可以保护正常组织免受<39>烷化剂</39>和<5>顺铂</5>的毒性作用，而不会降低化疗的抗肿瘤作用。早期试验也表明，<6>顺铂</6>和<33>氨磷汀</33>可以减少<7>顺铂</7>引起的<14>肾毒性</14>、<16>耳毒性</16>以及<17>神经病变</17>的发生率和严重程度。方法：一项<8>顺铂</8>加<34>氨磷汀</34>联合用药的II期研究在进展性转移性<21>乳腺癌</21>患者中进行，这些患者曾接受过一种药物，但未接受过不止一，转移性疾病的化疗方案。患者在15分钟内接受了<35>氨磷汀</35>910 mg/m2静脉注射。<36>氨磷汀</36>输注完成后，在30分钟内给予<9>顺铂</9>120 mg/m2。在<10>顺铂</10>前后给予静脉水化和<40>甘露醇</40>。每3周进行一次治疗，直至疾病进展。结果：44名患者被纳入研究，其中7名(16%)不符合条件。37名符合条件的患者接受了平均2个周期的治疗。观察到6个部分反应，总反应率为16%。大多数患者(57%)因疾病进展而停止治疗。<26>神经毒性</26>在52%的患者中报告。在接受治疗的患者中观察到七种不同的危及生命的<23>毒性</23>。结论：在本研究中，<11>顺铂</11>和<37>氨磷汀</37>的组合导致总反应率为16%。在<12>顺铂</12>中添加<38>氨磷汀</38>既没有观察到<27>肿瘤</27>保护作用也没有降低<24>毒性</24>。", "revised": true}
{"doc_key": "9088814", "sentences": [["Combined", "effects", "of", "prolonged", "prostaglandin", "E1", "-", "induced", "hypotension", "and", "haemodilution", "on", "human", "hepatic", "function", ".", "Combined", "effects", "of", "prolonged", "prostaglandin", "E1", "(", "PGE1", ")", "-", "induced", "hypotension", "and", "haemodilution", "on", "hepatic", "function", "were", "studied", "in", "30", "patients", "undergoing", "hip", "surgery", ".", "The", "patients", "were", "randomly", "allocated", "to", "one", "of", "three", "groups", ";", "those", "in", "group", "A", "(", "n", "=", "10", ")", "were", "subjected", "to", "controlled", "hypotension", "alone", ",", "those", "in", "group", "B", "(", "n", "=", "10", ")", "to", "haemodilution", "alone", "and", "those", "in", "group", "C", "(", "n", "=", "10", ")", "to", "both", "controlled", "hypotension", "and", "haemodilution", ".", "Haemodilution", "in", "groups", "B", "and", "C", "was", "produced", "by", "withdrawing", "approximately", "1000", "mL", "of", "blood", "and", "replacing", "it", "with", "the", "same", "amount", "of", "dextran", "solution", ",", "and", "final", "haematocrit", "values", "were", "21", "or", "22", "%", ".", "Controlled", "hypotension", "in", "groups", "A", "and", "C", "was", "induced", "with", "PGE1", "to", "maintain", "mean", "arterial", "blood", "pressure", "at", "55", "mmHg", "for", "180", "min", ".", "Measurements", "included", "arterial", "ketone", "body", "ratio", "(", "AKBR", ",", "aceto", "-", "acetate", "/", "3", "-", "hydroxybutyrate", ")", "and", "clinical", "hepatic", "function", "parameters", ".", "AKBR", "and", "biological", "hepatic", "function", "tests", "showed", "no", "change", "throughout", "the", "time", "course", "in", "groups", "A", "and", "B", ".", "In", "group", "C", ",", "AKBR", "showed", "a", "significant", "decrease", "at", "120", "min", "(", "-", "40", "%", ")", "and", "at", "180", "min", "(", "-", "49", "%", ")", "after", "the", "start", "of", "hypotension", "and", "at", "60", "min", "(", "-", "32", "%", ")", "after", "recovery", "of", "normotension", ",", "and", "SGOT", ",", "SGPT", ",", "LDH", "and", "total", "bilirubin", "showed", "significant", "increases", "after", "operation", ".", "The", "results", "suggest", "that", "a", "prolonged", "combination", "of", "more", "than", "120", "min", "of", "PGE1", "-", "induced", "hypotension", "and", "moderate", "haemodilution", "would", "cause", "impairment", "of", "hepatic", "function", "."]], "ner": [[[4, 5, "Chemical"], [20, 21, "Chemical"], [23, 23, "Chemical"], [144, 144, "Chemical"], [273, 273, "Chemical"], [8, 8, "Disease"], [27, 27, "Disease"], [66, 66, "Disease"], [94, 94, "Disease"], [135, 135, "Disease"], [230, 230, "Disease"], [276, 276, "Disease"], [282, 285, "Disease"], [10, 10, "Disease"], [29, 29, "Disease"], [79, 79, "Disease"], [96, 96, "Disease"], [98, 98, "Disease"], [279, 279, "Disease"], [121, 121, "Chemical"], [167, 169, "Chemical"], [171, 173, "Chemical"], [253, 253, "Chemical"]]], "relations": [[[4, 5, 8, 8, "CID"], [4, 5, 27, 27, "CID"], [4, 5, 66, 66, "CID"], [4, 5, 94, 94, "CID"], [4, 5, 135, 135, "CID"], [4, 5, 230, 230, "CID"], [4, 5, 276, 276, "CID"], [20, 21, 8, 8, "CID"], [20, 21, 27, 27, "CID"], [20, 21, 66, 66, "CID"], [20, 21, 94, 94, "CID"], [20, 21, 135, 135, "CID"], [20, 21, 230, 230, "CID"], [20, 21, 276, 276, "CID"], [23, 23, 8, 8, "CID"], [23, 23, 27, 27, "CID"], [23, 23, 66, 66, "CID"], [23, 23, 94, 94, "CID"], [23, 23, 135, 135, "CID"], [23, 23, 230, 230, "CID"], [23, 23, 276, 276, "CID"], [144, 144, 8, 8, "CID"], [144, 144, 27, 27, "CID"], [144, 144, 66, 66, "CID"], [144, 144, 94, 94, "CID"], [144, 144, 135, 135, "CID"], [144, 144, 230, 230, "CID"], [144, 144, 276, 276, "CID"], [273, 273, 8, 8, "CID"], [273, 273, 27, 27, "CID"], [273, 273, 66, 66, "CID"], [273, 273, 94, 94, "CID"], [273, 273, 135, 135, "CID"], [273, 273, 230, 230, "CID"], [273, 273, 276, 276, "CID"], [4, 5, 282, 285, "CID"], [20, 21, 282, 285, "CID"], [23, 23, 282, 285, "CID"], [144, 144, 282, 285, "CID"], [273, 273, 282, 285, "CID"]]], "clusters": [], "translated": "长期<0>前列腺素E1</0>诱导的<5>低血压</5>和<13>血液稀释</13>对人体肝功能的综合影响。在30名正在接受髋关节手术的患者中，研究了长期<1>前列腺素E1</1>（<2>PGE1</2>）引起的<6>低血压</6>和<14>血液稀释</14>对肝功能的综合影响。患者被随机分配到三组中的一组；A组（n = 10）单独接受受控制性<7>降压</7>，B组（n = 10）单独进行<15>血液稀释</15>，而C组（n = 10）接受同时进行控制性<8>低血压</8>和<16>血液稀释</16>。B组和C组的<17>血液稀释</17>是通过抽取大约1000毫升的血液并使用相同量的<19>葡聚糖</19>溶液进行替换来产生的，最终血细胞比容值为21%或22%。A组和C组的<9>控制性低血压</9>通过使用<3>PGE1</3>维持平均动脉血压在55毫米汞柱180分钟。测量值包括动脉酮体比率（AKBR，<20>乙酰乙酸</20>/ <21>3-羟基丁酸</21>）和临床肝功能参数。AKBR和生物肝功能测试显示A组和B组在整个时间范围内没有变化。在C组中，AKBR显示出明显的下降，<10>低血压</10>开始后的120分钟（-40%）和180分钟（-49%），恢复到正常血压后的60分钟（-32%），术后的SGOT、SGPT、LDH和总<22>胆红素</22>显示出明显升高。结果表明，<4>PGE1</4>诱导的<11>低血压</11>和中度<18>血液稀释</18>超过120分钟的长时间组合会导致<12>肝功能损伤</12>。", "revised": true}
{"doc_key": "9523805", "sentences": [["Transient", "neurologic", "symptoms", "after", "spinal", "anesthesia", ":", "a", "lower", "incidence", "with", "prilocaine", "and", "bupivacaine", "than", "with", "lidocaine", ".", "BACKGROUND", ":", "Recent", "evidence", "suggests", "that", "transient", "neurologic", "symptoms", "(", "TNSs", ")", "frequently", "follow", "lidocaine", "spinal", "anesthesia", "but", "are", "infrequent", "with", "bupivacaine", ".", "However", ",", "identification", "of", "a", "short", "-", "acting", "local", "anesthetic", "to", "substitute", "for", "lidocaine", "for", "brief", "surgical", "procedures", "remains", "an", "important", "goal", ".", "Prilocaine", "is", "an", "amide", "local", "anesthetic", "with", "a", "duration", "of", "action", "similar", "to", "that", "of", "lidocaine", ".", "Accordingly", ",", "the", "present", ",", "prospective", "double", "-", "blind", "study", "compares", "prilocaine", "with", "lidocaine", "and", "bupivacaine", "with", "respect", "to", "duration", "of", "action", "and", "relative", "risk", "of", "TNSs", ".", "METHODS", ":", "Ninety", "patients", "classified", "as", "American", "Society", "of", "Anesthesiologists", "physical", "status", "I", "or", "II", "who", "were", "scheduled", "for", "short", "gynecologic", "procedures", "under", "spinal", "anesthesia", "were", "randomly", "allocated", "to", "receive", "2", ".", "5", "ml", "2", "%", "lidocaine", "in", "7", ".", "5", "%", "glucose", ",", "2", "%", "prilocaine", "in", "7", ".", "5", "%", "glucose", ",", "or", "0", ".", "5", "%", "bupivacaine", "in", "7", ".", "5", "%", "glucose", ".", "All", "solutions", "were", "provided", "in", "blinded", "vials", "by", "the", "hospital", "pharmacy", ".", "Details", "of", "spinal", "puncture", ",", "extension", "and", "regression", "of", "spinal", "block", ",", "and", "the", "times", "to", "reach", "discharge", "criteria", "were", "noted", ".", "In", "the", "evening", "of", "postoperative", "day", "1", ",", "patients", "were", "evaluated", "for", "TNSs", "by", "a", "physician", "unaware", "of", "the", "drug", "administered", "and", "the", "details", "of", "the", "anesthetic", "procedure", ".", "RESULTS", ":", "Nine", "of", "30", "patients", "receiving", "lidocaine", "experienced", "TNSs", ",", "1", "of", "30", "patients", "receiving", "prilocaine", "(", "P", "=", "0", ".", "03", ")", "had", "them", ",", "and", "none", "of", "30", "patients", "receiving", "bupivacaine", "had", "TNSs", ".", "Times", "to", "ambulate", "and", "to", "void", "were", "similar", "after", "lidocaine", "and", "prilocaine", "(", "150", "vs", ".", "165", "min", "and", "238", "vs", ".", "253", "min", ",", "respectively", ")", "but", "prolonged", "after", "bupivacaine", "(", "200", "and", "299", "min", ",", "respectively", ";", "P", "<", "0", ".", "05", ")", ".", "CONCLUSIONS", ":", "Prilocaine", "may", "be", "preferable", "to", "lidocaine", "for", "short", "surgical", "procedures", "because", "it", "has", "a", "similar", "duration", "of", "action", "but", "a", "lower", "incidence", "of", "TNSs", "."]], "ner": [[[11, 11, "Chemical"], [64, 64, "Chemical"], [92, 92, "Chemical"], [155, 155, "Chemical"], [255, 255, "Chemical"], [287, 287, "Chemical"], [324, 324, "Chemical"], [0, 2, "Disease"], [24, 26, "Disease"], [28, 28, "Disease"], [107, 107, "Disease"], [222, 222, "Disease"], [248, 248, "Disease"], [274, 274, "Disease"], [347, 347, "Disease"], [16, 16, "Chemical"], [32, 32, "Chemical"], [54, 54, "Chemical"], [79, 79, "Chemical"], [94, 94, "Chemical"], [145, 145, "Chemical"], [246, 246, "Chemical"], [285, 285, "Chemical"], [329, 329, "Chemical"], [13, 13, "Chemical"], [39, 39, "Chemical"], [96, 96, "Chemical"], [168, 168, "Chemical"], [272, 272, "Chemical"], [306, 306, "Chemical"], [151, 151, "Chemical"], [161, 161, "Chemical"], [174, 174, "Chemical"]]], "relations": [[[11, 11, 0, 2, "CID"], [11, 11, 24, 26, "CID"], [11, 11, 28, 28, "CID"], [11, 11, 107, 107, "CID"], [11, 11, 222, 222, "CID"], [11, 11, 248, 248, "CID"], [11, 11, 274, 274, "CID"], [11, 11, 347, 347, "CID"], [64, 64, 0, 2, "CID"], [64, 64, 24, 26, "CID"], [64, 64, 28, 28, "CID"], [64, 64, 107, 107, "CID"], [64, 64, 222, 222, "CID"], [64, 64, 248, 248, "CID"], [64, 64, 274, 274, "CID"], [64, 64, 347, 347, "CID"], [92, 92, 0, 2, "CID"], [92, 92, 24, 26, "CID"], [92, 92, 28, 28, "CID"], [92, 92, 107, 107, "CID"], [92, 92, 222, 222, "CID"], [92, 92, 248, 248, "CID"], [92, 92, 274, 274, "CID"], [92, 92, 347, 347, "CID"], [155, 155, 0, 2, "CID"], [155, 155, 24, 26, "CID"], [155, 155, 28, 28, "CID"], [155, 155, 107, 107, "CID"], [155, 155, 222, 222, "CID"], [155, 155, 248, 248, "CID"], [155, 155, 274, 274, "CID"], [155, 155, 347, 347, "CID"], [255, 255, 0, 2, "CID"], [255, 255, 24, 26, "CID"], [255, 255, 28, 28, "CID"], [255, 255, 107, 107, "CID"], [255, 255, 222, 222, "CID"], [255, 255, 248, 248, "CID"], [255, 255, 274, 274, "CID"], [255, 255, 347, 347, "CID"], [287, 287, 0, 2, "CID"], [287, 287, 24, 26, "CID"], [287, 287, 28, 28, "CID"], [287, 287, 107, 107, "CID"], [287, 287, 222, 222, "CID"], [287, 287, 248, 248, "CID"], [287, 287, 274, 274, "CID"], [287, 287, 347, 347, "CID"], [324, 324, 0, 2, "CID"], [324, 324, 24, 26, "CID"], [324, 324, 28, 28, "CID"], [324, 324, 107, 107, "CID"], [324, 324, 222, 222, "CID"], [324, 324, 248, 248, "CID"], [324, 324, 274, 274, "CID"], [324, 324, 347, 347, "CID"], [16, 16, 0, 2, "CID"], [16, 16, 24, 26, "CID"], [16, 16, 28, 28, "CID"], [16, 16, 107, 107, "CID"], [16, 16, 222, 222, "CID"], [16, 16, 248, 248, "CID"], [16, 16, 274, 274, "CID"], [16, 16, 347, 347, "CID"], [32, 32, 0, 2, "CID"], [32, 32, 24, 26, "CID"], [32, 32, 28, 28, "CID"], [32, 32, 107, 107, "CID"], [32, 32, 222, 222, "CID"], [32, 32, 248, 248, "CID"], [32, 32, 274, 274, "CID"], [32, 32, 347, 347, "CID"], [54, 54, 0, 2, "CID"], [54, 54, 24, 26, "CID"], [54, 54, 28, 28, "CID"], [54, 54, 107, 107, "CID"], [54, 54, 222, 222, "CID"], [54, 54, 248, 248, "CID"], [54, 54, 274, 274, "CID"], [54, 54, 347, 347, "CID"], [79, 79, 0, 2, "CID"], [79, 79, 24, 26, "CID"], [79, 79, 28, 28, "CID"], [79, 79, 107, 107, "CID"], [79, 79, 222, 222, "CID"], [79, 79, 248, 248, "CID"], [79, 79, 274, 274, "CID"], [79, 79, 347, 347, "CID"], [94, 94, 0, 2, "CID"], [94, 94, 24, 26, "CID"], [94, 94, 28, 28, "CID"], [94, 94, 107, 107, "CID"], [94, 94, 222, 222, "CID"], [94, 94, 248, 248, "CID"], [94, 94, 274, 274, "CID"], [94, 94, 347, 347, "CID"], [145, 145, 0, 2, "CID"], [145, 145, 24, 26, "CID"], [145, 145, 28, 28, "CID"], [145, 145, 107, 107, "CID"], [145, 145, 222, 222, "CID"], [145, 145, 248, 248, "CID"], [145, 145, 274, 274, "CID"], [145, 145, 347, 347, "CID"], [246, 246, 0, 2, "CID"], [246, 246, 24, 26, "CID"], [246, 246, 28, 28, "CID"], [246, 246, 107, 107, "CID"], [246, 246, 222, 222, "CID"], [246, 246, 248, 248, "CID"], [246, 246, 274, 274, "CID"], [246, 246, 347, 347, "CID"], [285, 285, 0, 2, "CID"], [285, 285, 24, 26, "CID"], [285, 285, 28, 28, "CID"], [285, 285, 107, 107, "CID"], [285, 285, 222, 222, "CID"], [285, 285, 248, 248, "CID"], [285, 285, 274, 274, "CID"], [285, 285, 347, 347, "CID"], [329, 329, 0, 2, "CID"], [329, 329, 24, 26, "CID"], [329, 329, 28, 28, "CID"], [329, 329, 107, 107, "CID"], [329, 329, 222, 222, "CID"], [329, 329, 248, 248, "CID"], [329, 329, 274, 274, "CID"], [329, 329, 347, 347, "CID"]]], "clusters": [], "translated": " <7>脊髓麻醉后的短暂性神经系统症状</7>： <0>丙胺卡因</0> 和<24>布比卡因</24> 的发生率低于<15>利多卡因</15>。背景：最近的证据表明<8>短暂性神经系统症状</8>（<9>TNSs</9>）在<16>利多卡因</16>脊髓麻醉后经常出现，但在<25>布比卡因</25>后很少见。然而，确定一种短效局部麻醉剂来替代<17>利多卡因</17>进行简短的外科手术仍然是一个重要的目标。<1>丙胺卡因</1>是一种酰胺类局部麻醉剂，其作用持续时间与<18>利多卡因</18>相似。因此，本前瞻性双盲研究比较了<2>丙胺卡因</2>与<19>利多卡因</19>和<26>布比卡因</26>的作用持续时间和<10>TNSs</10>的相对风险。方法：90名美国麻醉医师协会身体状况分级为I级或II级的计划在脊髓麻醉下进行短期妇科手术的患者被随机分配到 2.5毫升2%<20>利多卡因</20> 7.5%<30>葡萄糖</30>，2%<3>丙胺卡因</3>在7.5% <31>葡萄糖</31> 或0.5%<27>布比卡因</27>在7.5% <32>葡萄糖</32>。所有溶液均由医院药房在盲瓶中提供。记录脊柱穿刺细节、脊柱阻滞的伸展和消退 ，以及达到出院标准的时间。术后第1天晚上，医生对患者进行了<11>TNSs</11>评估，该医生不知道给药的药物和麻醉程序的细节。结果：接受<21>利多卡因</21>治疗的30名患者中有9名出现<12>TNSs</12> ，接受<4>丙胺卡因</4>治疗的30名患者中有1名出现<10>TNSs</10>（P=0.03），并且没有接受<28>布比卡因</28>治疗的30名患者中有<13>TNSs</13>。走动和排尿的时间在<22>利多卡因 </22>和<5>丙胺卡因</5>后相似（150对165分钟和238对253分钟），但在<29>布比卡因</29>后延长（分别为200和299分钟;P<0.05）。结论：<6>丙胺卡因</6>可能优于<23>利多卡因</23>用于短期手术，因为它具有相似的作用持续时间但<14>TNSs</14>的发生率较低。", "revised": true}
{"doc_key": "10835440", "sentences": [["Effect", "of", "intravenous", "nimodipine", "on", "blood", "pressure", "and", "outcome", "after", "acute", "stroke", ".", "BACKGROUND", "AND", "PURPOSE", ":", "The", "Intravenous", "Nimodipine", "West", "European", "Stroke", "Trial", "(", "INWEST", ")", "found", "a", "correlation", "between", "nimodipine", "-", "induced", "reduction", "in", "blood", "pressure", "(", "BP", ")", "and", "an", "unfavorable", "outcome", "in", "acute", "stroke", ".", "We", "sought", "to", "confirm", "this", "correlation", "with", "and", "without", "adjustment", "for", "prognostic", "variables", "and", "to", "investigate", "outcome", "in", "subgroups", "with", "increasing", "levels", "of", "BP", "reduction", ".", "METHODS", ":", "Patients", "with", "a", "clinical", "diagnosis", "of", "ischemic", "stroke", "(", "within", "24", "hours", ")", "were", "consecutively", "allocated", "to", "receive", "placebo", "(", "n", "=", "100", ")", ",", "1", "mg", "/", "h", "(", "low", "-", "dose", ")", "nimodipine", "(", "n", "=", "101", ")", ",", "or", "2", "mg", "/", "h", "(", "high", "-", "dose", ")", "nimodipine", "(", "n", "=", "94", ")", ".", "The", "correlation", "between", "average", "BP", "change", "during", "the", "first", "2", "days", "and", "the", "outcome", "at", "day", "21", "was", "analyzed", ".", "RESULTS", ":", "Two", "hundred", "sixty", "-", "five", "patients", "were", "included", "in", "this", "analysis", "(", "n", "=", "92", ",", "93", ",", "and", "80", "for", "placebo", ",", "low", "dose", ",", "and", "high", "dose", ",", "respectively", ")", ".", "Nimodipine", "treatment", "resulted", "in", "a", "statistically", "significant", "reduction", "in", "systolic", "BP", "(", "SBP", ")", "and", "diastolic", "BP", "(", "DBP", ")", "from", "baseline", "compared", "with", "placebo", "during", "the", "first", "few", "days", ".", "In", "multivariate", "analysis", ",", "a", "significant", "correlation", "between", "DBP", "reduction", "and", "worsening", "of", "the", "neurological", "score", "was", "found", "for", "the", "high", "-", "dose", "group", "(", "beta", "=", "0", ".", "49", ",", "P", "=", "0", ".", "048", ")", ".", "Patients", "with", "a", "DBP", "reduction", "of", ">", "or", "=", "20", "%", "in", "the", "high", "-", "dose", "group", "had", "a", "significantly", "increased", "adjusted", "OR", "for", "the", "compound", "outcome", "variable", "death", "or", "dependency", "(", "Barthel", "Index", "<", "60", ")", "(", "n", "/", "N", "=", "25", "/", "26", ",", "OR", "10", ".", "16", ",", "95", "%", "CI", "1", ".", "02", "to", "101", ".", "74", ")", "and", "death", "alone", "(", "n", "/", "N", "=", "9", "/", "26", ",", "OR", "4", ".", "336", ",", "95", "%", "CI", "1", ".", "131", "16", ".", "619", ")", "compared", "with", "all", "placebo", "patients", "(", "n", "/", "N", "=", "62", "/", "92", "and", "14", "/", "92", ",", "respectively", ")", ".", "There", "was", "no", "correlation", "between", "SBP", "change", "and", "outcome", ".", "CONCLUSIONS", ":", "DBP", ",", "but", "not", "SBP", ",", "reduction", "was", "associated", "with", "neurological", "worsening", "after", "the", "intravenous", "administration", "of", "high", "-", "dose", "nimodipine", "after", "acute", "stroke", ".", "For", "low", "-", "dose", "nimodipine", ",", "the", "results", "were", "not", "conclusive", ".", "These", "results", "do", "not", "confirm", "or", "exclude", "a", "neuroprotective", "property", "of", "nimodipine", "."]], "ner": [[[3, 3, "Chemical"], [19, 19, "Chemical"], [31, 31, "Chemical"], [111, 111, "Chemical"], [128, 128, "Chemical"], [190, 190, "Chemical"], [401, 401, "Chemical"], [410, 410, "Chemical"], [429, 429, "Chemical"], [34, 37, "Disease"], [72, 73, "Disease"], [197, 200, "Disease"], [229, 230, "Disease"], [262, 263, "Disease"], [10, 11, "Disease"], [22, 22, "Disease"], [46, 47, "Disease"], [403, 404, "Disease"], [83, 84, "Disease"], [287, 287, "Disease"], [322, 322, "Disease"]]], "relations": [[[3, 3, 34, 37, "CID"], [3, 3, 72, 73, "CID"], [3, 3, 197, 200, "CID"], [3, 3, 229, 230, "CID"], [3, 3, 262, 263, "CID"], [19, 19, 34, 37, "CID"], [19, 19, 72, 73, "CID"], [19, 19, 197, 200, "CID"], [19, 19, 229, 230, "CID"], [19, 19, 262, 263, "CID"], [31, 31, 34, 37, "CID"], [31, 31, 72, 73, "CID"], [31, 31, 197, 200, "CID"], [31, 31, 229, 230, "CID"], [31, 31, 262, 263, "CID"], [111, 111, 34, 37, "CID"], [111, 111, 72, 73, "CID"], [111, 111, 197, 200, "CID"], [111, 111, 229, 230, "CID"], [111, 111, 262, 263, "CID"], [128, 128, 34, 37, "CID"], [128, 128, 72, 73, "CID"], [128, 128, 197, 200, "CID"], [128, 128, 229, 230, "CID"], [128, 128, 262, 263, "CID"], [190, 190, 34, 37, "CID"], [190, 190, 72, 73, "CID"], [190, 190, 197, 200, "CID"], [190, 190, 229, 230, "CID"], [190, 190, 262, 263, "CID"], [401, 401, 34, 37, "CID"], [401, 401, 72, 73, "CID"], [401, 401, 197, 200, "CID"], [401, 401, 229, 230, "CID"], [401, 401, 262, 263, "CID"], [410, 410, 34, 37, "CID"], [410, 410, 72, 73, "CID"], [410, 410, 197, 200, "CID"], [410, 410, 229, 230, "CID"], [410, 410, 262, 263, "CID"], [429, 429, 34, 37, "CID"], [429, 429, 72, 73, "CID"], [429, 429, 197, 200, "CID"], [429, 429, 229, 230, "CID"], [429, 429, 262, 263, "CID"]]], "clusters": [], "translated": "静脉注射<0>尼莫地平</0>对<14>急性卒中</14>后血压和预后的影响。背景和目的：静脉注射<1>尼莫地平</1>西欧<15>中风</15>试验(INWEST)发现<2>尼莫地平</2>诱导的<9>血压降低</9>(BP)和<16>急性中风</16>的不利结果。我们试图在调整和不调整预后变量的情况下证实这种相关性，并研究<10>血压降低水平增加</10>的亚组的结果。方法：临床诊断为<18>缺血性卒中</18>（24小时内）的患者被连续分配接受安慰剂(n=100)、1 mg/h(低剂量)<3>尼莫地平</3>(n=101)，或2 mg/h(高剂量)<4>尼莫地平</4>(n=94)。分析了前2天平均血压变化与第21天结果之间的相关性。结果：265名患者被纳入该分析(安慰剂组、低剂量组和高剂量组分别为n=92、93和80)<5>尼莫地平</5>治疗导致在最初几天与安慰剂相比，收缩压(SBP)和舒张压(DBP)相对于基线有统计学意义的<11>降低</11>。在多变量分析中，在高剂量组中，<12>DBP降低</12>与神经学评分恶化之间存在显著相关性(beta=0.49，P=0.048)。高剂量组<13>DBP降低</13>>或=20%的患者复合结果变量<19>死亡</19>或依赖性的调整OR显着增加(Barthel指数<60) (n/N=25/26，OR 10.16，95% CI 1.02至101.74)和<20>死亡</20>(n/N=9/26，OR 4.336，95% CI 1.13116.619)与所有安慰剂患者相比(n/N分别为62/92和14/92)。SBP变化与结果之间没有相关性。结论：<17>急性卒中</17>后静脉注射高剂量<6>尼莫地平</6>后，DBP而非SBP降低与神经功能恶化相关。对于低剂量<7>尼莫地平</7>，结果尚无定论。这些结果并未证实或排除<8>尼莫地平</8>的神经保护特性。", "revised": true}
{"doc_key": "3101906", "sentences": [["Hepatic", "reactions", "associated", "with", "ketoconazole", "in", "the", "United", "Kingdom", ".", "Ketoconazole", "was", "introduced", "in", "the", "United", "Kingdom", "in", "1981", ".", "By", "November", "1984", "the", "Committee", "on", "Safety", "of", "Medicines", "had", "received", "82", "reports", "of", "possible", "hepatotoxicity", "associated", "with", "the", "drug", ",", "including", "five", "deaths", ".", "An", "analysis", "of", "the", "75", "cases", "that", "had", "been", "adequately", "followed", "up", "suggested", "that", "16", ",", "including", "three", "deaths", ",", "were", "probably", "related", "to", "treatment", "with", "the", "drug", ".", "Of", "the", "remainder", ",", "48", "were", "possibly", "related", "to", "treatment", ",", "five", "were", "unlikely", "to", "be", "so", ",", "and", "six", "were", "unclassifiable", ".", "The", "mean", "age", "of", "patients", "in", "the", "16", "probable", "cases", "was", "57", ".", "9", ",", "with", "hepatotoxicity", "being", "more", "common", "in", "women", ".", "The", "average", "duration", "of", "treatment", "before", "the", "onset", "of", "jaundice", "was", "61", "days", ".", "None", "of", "these", "well", "validated", "cases", "occurred", "within", "the", "first", "10", "days", "after", "treatment", ".", "The", "results", "of", "serum", "liver", "function", "tests", "suggested", "hepatocellular", "injury", "in", "10", "(", "63", "%", ")", ";", "the", "rest", "showed", "a", "mixed", "pattern", ".", "In", "contrast", ",", "the", "results", "of", "histological", "examination", "of", "the", "liver", "often", "showed", "evidence", "of", "cholestasis", ".", "The", "characteristics", "of", "the", "48", "patients", "in", "the", "possible", "cases", "were", "similar", ".", "Allergic", "manifestations", "such", "as", "rash", "and", "eosinophilia", "were", "rare", ".", "Hepatitis", "was", "usually", "reversible", "when", "treatment", "was", "stopped", ",", "with", "the", "results", "of", "liver", "function", "tests", "returning", "to", "normal", "after", "an", "average", "of", "3", ".", "1", "months", ".", "In", "two", "of", "the", "three", "deaths", "probably", "associated", "with", "ketoconazole", "treatment", "the", "drug", "had", "been", "continued", "after", "the", "onset", "of", "jaundice", "and", "other", "symptoms", "of", "hepatitis", ".", "Clinical", "and", "biochemical", "monitoring", "at", "regular", "intervals", "for", "evidence", "of", "hepatitis", "is", "advised", "during", "long", "term", "treatment", "with", "ketoconazole", "to", "prevent", "possible", "serious", "hepatic", "injury", "."]], "ner": [[[4, 4, "Chemical"], [10, 10, "Chemical"], [250, 250, "Chemical"], [286, 286, "Chemical"], [35, 35, "Disease"], [113, 113, "Disease"], [157, 158, "Disease"], [213, 213, "Disease"], [266, 266, "Disease"], [278, 278, "Disease"], [291, 292, "Disease"], [129, 129, "Disease"], [261, 261, "Disease"], [188, 188, "Disease"], [43, 43, "Disease"], [63, 63, "Disease"], [246, 246, "Disease"], [207, 207, "Disease"], [209, 209, "Disease"]]], "relations": [[[4, 4, 35, 35, "CID"], [4, 4, 113, 113, "CID"], [4, 4, 157, 158, "CID"], [4, 4, 213, 213, "CID"], [4, 4, 266, 266, "CID"], [4, 4, 278, 278, "CID"], [4, 4, 291, 292, "CID"], [10, 10, 35, 35, "CID"], [10, 10, 113, 113, "CID"], [10, 10, 157, 158, "CID"], [10, 10, 213, 213, "CID"], [10, 10, 266, 266, "CID"], [10, 10, 278, 278, "CID"], [10, 10, 291, 292, "CID"], [250, 250, 35, 35, "CID"], [250, 250, 113, 113, "CID"], [250, 250, 157, 158, "CID"], [250, 250, 213, 213, "CID"], [250, 250, 266, 266, "CID"], [250, 250, 278, 278, "CID"], [250, 250, 291, 292, "CID"], [286, 286, 35, 35, "CID"], [286, 286, 113, 113, "CID"], [286, 286, 157, 158, "CID"], [286, 286, 213, 213, "CID"], [286, 286, 266, 266, "CID"], [286, 286, 278, 278, "CID"], [286, 286, 291, 292, "CID"], [4, 4, 129, 129, "CID"], [4, 4, 261, 261, "CID"], [10, 10, 129, 129, "CID"], [10, 10, 261, 261, "CID"], [250, 250, 129, 129, "CID"], [250, 250, 261, 261, "CID"], [286, 286, 129, 129, "CID"], [286, 286, 261, 261, "CID"], [4, 4, 188, 188, "CID"], [10, 10, 188, 188, "CID"], [250, 250, 188, 188, "CID"], [286, 286, 188, 188, "CID"]]], "clusters": [], "translated": "在英国与<0>酮康唑</0>相关的肝脏反应。<1>酮康唑</1>于1981年在英国上市。到1984年11月，药物安全委员会已收到82份可能与该药物相关的<4>肝毒性</4>报告，其中包括5例<14>死亡</14>。对已充分随访的75例病例的分析表明，其中16例（包括3例<15>死亡</15>）可能与药物治疗有关。其余的48例可能与治疗有关，5例不太可能，6例无法分类。16例疑似病例患者的平均年龄为57.9，<5>肝毒性</5>在女性中更为常见。发生<11>黄疸</11>前的平均治疗时间为61天。这些经过充分验证的病例均未发生在治疗后的前10天内。血清肝功能检查结果提示<6>肝细胞损伤</6>的有10例（63%）；其余的则呈混合模式。相比之下，肝脏的组织学检查结果往往显示出<13>胆汁淤积</13>的证据。可能病例中的48例患者特征相似。<17>皮疹</17>和<18>嗜酸性粒细胞增多</18>等过敏表现罕见。<7>肝炎</7>通常在停止治疗后是可逆的，平均3.1个月后肝功能检查结果恢复正常。在可能与<2>酮康唑</2>治疗相关的三例<16>死亡</16>中，有两例在出现<12>黄疸</12>和其他<8>肝炎症状</8>后继续服用药物。在使用<3>酮康唑</3>进行长期治疗期间，建议定期进行临床和生化监测以发现<9>肝炎</9>的证据，以防止可能发生的严重<10>肝损伤</10>。", "revised": true}
{"doc_key": "3560096", "sentences": [["Hyperkalemia", "associated", "with", "sulindac", "therapy", ".", "Hyperkalemia", "has", "recently", "been", "recognized", "as", "a", "complication", "of", "nonsteroidal", "antiinflammatory", "agents", "(", "NSAID", ")", "such", "as", "indomethacin", ".", "Several", "recent", "studies", "have", "stressed", "the", "renal", "sparing", "features", "of", "sulindac", ",", "owing", "to", "its", "lack", "of", "interference", "with", "renal", "prostacyclin", "synthesis", ".", "We", "describe", "4", "patients", "in", "whom", "hyperkalemia", "ranging", "from", "6", ".", "1", "to", "6", ".", "9", "mEq", "/", "l", "developed", "within", "3", "to", "8", "days", "of", "sulindac", "administration", ".", "In", "all", "of", "them", "normal", "serum", "potassium", "levels", "reached", "within", "2", "to", "4", "days", "of", "stopping", "sulindac", ".", "As", "no", "other", "medications", "known", "to", "effect", "serum", "potassium", "had", "been", "given", "concomitantly", ",", "this", "course", "of", "events", "is", "suggestive", "of", "a", "cause", "-", "and", "-", "effect", "relationship", "between", "sulindac", "and", "hyperkalemia", ".", "These", "observations", "indicate", "that", "initial", "hopes", "that", "sulindac", "may", "not", "be", "associated", "with", "the", "adverse", "renal", "effects", "of", "other", "NSAID", "are", "probably", "not", "justified", "."]], "ner": [[[3, 3, "Chemical"], [35, 35, "Chemical"], [74, 74, "Chemical"], [93, 93, "Chemical"], [124, 124, "Chemical"], [135, 135, "Chemical"], [0, 0, "Disease"], [6, 6, "Disease"], [54, 54, "Disease"], [126, 126, "Disease"], [23, 23, "Chemical"], [45, 45, "Chemical"], [83, 83, "Chemical"], [103, 103, "Chemical"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 6, 6, "CID"], [3, 3, 54, 54, "CID"], [3, 3, 126, 126, "CID"], [35, 35, 0, 0, "CID"], [35, 35, 6, 6, "CID"], [35, 35, 54, 54, "CID"], [35, 35, 126, 126, "CID"], [74, 74, 0, 0, "CID"], [74, 74, 6, 6, "CID"], [74, 74, 54, 54, "CID"], [74, 74, 126, 126, "CID"], [93, 93, 0, 0, "CID"], [93, 93, 6, 6, "CID"], [93, 93, 54, 54, "CID"], [93, 93, 126, 126, "CID"], [124, 124, 0, 0, "CID"], [124, 124, 6, 6, "CID"], [124, 124, 54, 54, "CID"], [124, 124, 126, 126, "CID"], [135, 135, 0, 0, "CID"], [135, 135, 6, 6, "CID"], [135, 135, 54, 54, "CID"], [135, 135, 126, 126, "CID"], [23, 23, 0, 0, "CID"], [23, 23, 6, 6, "CID"], [23, 23, 54, 54, "CID"], [23, 23, 126, 126, "CID"]]], "clusters": [], "translated": "<6>高钾血症</6>与<0>舒林酸</0>治疗相关。<7>高钾血症</7>最近被认为是非甾体类抗炎药（NSAID）如<10>吲哚美辛</10>的并发症。最近的几项研究强调了<1>舒林酸</1>的肾脏保护特性，因为它不干扰肾脏<11>前列环素</11>的合成。我们描述了4名患者，在<2>舒林酸</2>给药后3至8天内出现范围为6.1到6.9mEq/l的<8>高钾血症</8>。在停止使用<3>舒林酸</3>后的2到4天内，所有这些患者的血清<12>钾</12>水平均达到正常水平。由于没有同时给予已知影响血清<13>钾</13>的其他药物，这一事件过程提示<4>舒林酸</4>和<9>高钾血症</9>之间存在因果关系。这些观察结果表明，最初希望<5>舒林酸</5>可能与其他NSAID的肾脏不良反应无关，这可能是不合理的。", "revised": true}
{"doc_key": "7468724", "sentences": [["Cardiovascular", "complications", "associated", "with", "terbutaline", "treatment", "for", "preterm", "labor", ".", "Severe", "cardiovascular", "complications", "occurred", "in", "eight", "of", "160", "patients", "treated", "with", "terbutaline", "for", "preterm", "labor", ".", "Associated", "corticosteroid", "therapy", "and", "twin", "gestations", "appear", "to", "be", "predisposing", "factors", ".", "Potential", "mechanisms", "of", "the", "pathophysiology", "are", "briefly", "discussed", "."]], "ner": [[[4, 4, "Chemical"], [21, 21, "Chemical"], [0, 1, "Disease"], [11, 12, "Disease"], [7, 8, "Disease"], [23, 24, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 11, 12, "CID"], [21, 21, 0, 1, "CID"], [21, 21, 11, 12, "CID"]]], "clusters": [], "translated": " \n<2>心血管并发症</2>与<0>特布他林</0>治疗<4>早产</4>相关。在160名<5>早产</5>患者治疗时，有8名出现<3>严重的心血管并发症</3>，并接受<1>特布他林</1>治疗。相关的皮质类固醇治疗和双胎妊娠似乎是诱发因素。简要讨论了病理生理学的潜在机制。", "revised": true}
{"doc_key": "12584269", "sentences": [["Kidney", "function", "and", "morphology", "after", "short", "-", "term", "combination", "therapy", "with", "cyclosporine", "A", ",", "tacrolimus", "and", "sirolimus", "in", "the", "rat", ".", "BACKGROUND", ":", "Sirolimus", "(", "SRL", ")", "may", "supplement", "calcineurin", "inhibitors", "in", "clinical", "organ", "transplantation", ".", "These", "are", "nephrotoxic", ",", "but", "SRL", "seems", "to", "act", "differently", "displaying", "only", "minor", "nephrotoxic", "effects", ",", "although", "this", "question", "is", "still", "open", ".", "In", "a", "number", "of", "treatment", "protocols", "where", "SRL", "was", "combined", "with", "a", "calcineurin", "inhibitor", "indications", "of", "a", "synergistic", "nephrotoxic", "effect", "were", "described", ".", "The", "aim", "of", "this", "study", "was", "to", "examine", "further", "the", "renal", "function", ",", "including", "morphological", "analysis", "of", "the", "kidneys", "of", "male", "Sprague", "-", "Dawley", "rats", "treated", "with", "either", "cyclosporine", "A", "(", "CsA", ")", ",", "tacrolimus", "(", "FK506", ")", "or", "SRL", "as", "monotherapies", "or", "in", "different", "combinations", ".", "METHODS", ":", "For", "a", "period", "of", "2", "weeks", ",", "CsA", "15", "mg", "/", "kg", "/", "day", "(", "given", "orally", ")", ",", "FK506", "3", ".", "0", "mg", "/", "kg", "/", "day", "(", "given", "orally", ")", "or", "SRL", "0", ".", "4", "mg", "/", "kg", "/", "day", "(", "given", "intraperitoneally", ")", "was", "administered", "once", "a", "day", "as", "these", "doses", "have", "earlier", "been", "found", "to", "achieve", "a", "significant", "immunosuppressive", "effect", "in", "Sprague", "-", "Dawley", "rats", ".", "In", "the", "'", "conscious", "catheterized", "rat", "'", "model", ",", "the", "glomerular", "filtration", "rate", "(", "GFR", ")", "was", "measured", "as", "the", "clearance", "of", "Cr", "(", "EDTA", ")", ".", "The", "morphological", "analysis", "of", "the", "kidneys", "included", "a", "semi", "-", "quantitative", "scoring", "system", "analysing", "the", "degree", "of", "striped", "fibrosis", ",", "subcapsular", "fibrosis", "and", "the", "number", "of", "basophilic", "tubules", ",", "plus", "an", "additional", "stereological", "analysis", "of", "the", "total", "grade", "of", "fibrosis", "in", "the", "cortex", "stained", "with", "Sirius", "Red", ".", "RESULTS", ":", "CsA", ",", "FK506", "and", "SRL", "all", "significantly", "decreased", "the", "GFR", ".", "A", "further", "deterioration", "was", "seen", "when", "CsA", "was", "combined", "with", "either", "FK506", "or", "SRL", ",", "whereas", "the", "GFR", "remained", "unchanged", "in", "the", "group", "treated", "with", "FK506", "plus", "SRL", "when", "compared", "with", "treatment", "with", "any", "of", "the", "single", "substances", ".", "The", "morphological", "changes", "presented", "a", "similar", "pattern", ".", "The", "semi", "-", "quantitative", "scoring", "was", "significantly", "worst", "in", "the", "group", "treated", "with", "CsA", "plus", "SRL", "(", "P", "<", "0", ".", "001", "compared", "with", "controls", ")", "and", "the", "analysis", "of", "the", "total", "grade", "of", "fibrosis", "also", "showed", "the", "highest", "proportion", "in", "the", "same", "group", "and", "was", "significantly", "different", "from", "controls", "(", "P", "<", "0", ".", "02", ")", ".", "The", "FK506", "plus", "SRL", "combination", "showed", "only", "a", "marginally", "higher", "degree", "of", "fibrosis", "as", "compared", "with", "controls", "(", "P", "=", "0", ".", "05", ")", ".", "CONCLUSION", ":", "This", "rat", "study", "demonstrated", "a", "synergistic", "nephrotoxic", "effect", "of", "CsA", "plus", "SRL", ",", "whereas", "FK506", "plus", "SRL", "was", "better", "tolerated", "."]], "ner": [[[11, 12, "Chemical"], [110, 111, "Chemical"], [113, 113, "Chemical"], [138, 138, "Chemical"], [278, 278, "Chemical"], [295, 295, "Chemical"], [349, 349, "Chemical"], [430, 430, "Chemical"], [38, 38, "Disease"], [49, 49, "Disease"], [77, 77, "Disease"], [427, 427, "Disease"], [14, 14, "Chemical"], [116, 116, "Chemical"], [118, 118, "Chemical"], [150, 150, "Chemical"], [280, 280, "Chemical"], [300, 300, "Chemical"], [314, 314, "Chemical"], [395, 395, "Chemical"], [435, 435, "Chemical"], [16, 16, "Chemical"], [23, 23, "Chemical"], [25, 25, "Chemical"], [41, 41, "Chemical"], [66, 66, "Chemical"], [121, 121, "Chemical"], [164, 164, "Chemical"], [282, 282, "Chemical"], [302, 302, "Chemical"], [316, 316, "Chemical"], [351, 351, "Chemical"], [397, 397, "Chemical"], [432, 432, "Chemical"], [437, 437, "Chemical"], [246, 246, "Disease"], [249, 249, "Disease"], [267, 267, "Disease"], [370, 370, "Disease"], [406, 406, "Disease"]]], "relations": [[[11, 12, 38, 38, "CID"], [11, 12, 49, 49, "CID"], [11, 12, 77, 77, "CID"], [11, 12, 427, 427, "CID"], [110, 111, 38, 38, "CID"], [110, 111, 49, 49, "CID"], [110, 111, 77, 77, "CID"], [110, 111, 427, 427, "CID"], [113, 113, 38, 38, "CID"], [113, 113, 49, 49, "CID"], [113, 113, 77, 77, "CID"], [113, 113, 427, 427, "CID"], [138, 138, 38, 38, "CID"], [138, 138, 49, 49, "CID"], [138, 138, 77, 77, "CID"], [138, 138, 427, 427, "CID"], [278, 278, 38, 38, "CID"], [278, 278, 49, 49, "CID"], [278, 278, 77, 77, "CID"], [278, 278, 427, 427, "CID"], [295, 295, 38, 38, "CID"], [295, 295, 49, 49, "CID"], [295, 295, 77, 77, "CID"], [295, 295, 427, 427, "CID"], [349, 349, 38, 38, "CID"], [349, 349, 49, 49, "CID"], [349, 349, 77, 77, "CID"], [349, 349, 427, 427, "CID"], [430, 430, 38, 38, "CID"], [430, 430, 49, 49, "CID"], [430, 430, 77, 77, "CID"], [430, 430, 427, 427, "CID"], [14, 14, 38, 38, "CID"], [14, 14, 49, 49, "CID"], [14, 14, 77, 77, "CID"], [14, 14, 427, 427, "CID"], [116, 116, 38, 38, "CID"], [116, 116, 49, 49, "CID"], [116, 116, 77, 77, "CID"], [116, 116, 427, 427, "CID"], [118, 118, 38, 38, "CID"], [118, 118, 49, 49, "CID"], [118, 118, 77, 77, "CID"], [118, 118, 427, 427, "CID"], [150, 150, 38, 38, "CID"], [150, 150, 49, 49, "CID"], [150, 150, 77, 77, "CID"], [150, 150, 427, 427, "CID"], [280, 280, 38, 38, "CID"], [280, 280, 49, 49, "CID"], [280, 280, 77, 77, "CID"], [280, 280, 427, 427, "CID"], [300, 300, 38, 38, "CID"], [300, 300, 49, 49, "CID"], [300, 300, 77, 77, "CID"], [300, 300, 427, 427, "CID"], [314, 314, 38, 38, "CID"], [314, 314, 49, 49, "CID"], [314, 314, 77, 77, "CID"], [314, 314, 427, 427, "CID"], [395, 395, 38, 38, "CID"], [395, 395, 49, 49, "CID"], [395, 395, 77, 77, "CID"], [395, 395, 427, 427, "CID"], [435, 435, 38, 38, "CID"], [435, 435, 49, 49, "CID"], [435, 435, 77, 77, "CID"], [435, 435, 427, 427, "CID"], [16, 16, 38, 38, "CID"], [16, 16, 49, 49, "CID"], [16, 16, 77, 77, "CID"], [16, 16, 427, 427, "CID"], [23, 23, 38, 38, "CID"], [23, 23, 49, 49, "CID"], [23, 23, 77, 77, "CID"], [23, 23, 427, 427, "CID"], [25, 25, 38, 38, "CID"], [25, 25, 49, 49, "CID"], [25, 25, 77, 77, "CID"], [25, 25, 427, 427, "CID"], [41, 41, 38, 38, "CID"], [41, 41, 49, 49, "CID"], [41, 41, 77, 77, "CID"], [41, 41, 427, 427, "CID"], [66, 66, 38, 38, "CID"], [66, 66, 49, 49, "CID"], [66, 66, 77, 77, "CID"], [66, 66, 427, 427, "CID"], [121, 121, 38, 38, "CID"], [121, 121, 49, 49, "CID"], [121, 121, 77, 77, "CID"], [121, 121, 427, 427, "CID"], [164, 164, 38, 38, "CID"], [164, 164, 49, 49, "CID"], [164, 164, 77, 77, "CID"], [164, 164, 427, 427, "CID"], [282, 282, 38, 38, "CID"], [282, 282, 49, 49, "CID"], [282, 282, 77, 77, "CID"], [282, 282, 427, 427, "CID"], [302, 302, 38, 38, "CID"], [302, 302, 49, 49, "CID"], [302, 302, 77, 77, "CID"], [302, 302, 427, 427, "CID"], [316, 316, 38, 38, "CID"], [316, 316, 49, 49, "CID"], [316, 316, 77, 77, "CID"], [316, 316, 427, 427, "CID"], [351, 351, 38, 38, "CID"], [351, 351, 49, 49, "CID"], [351, 351, 77, 77, "CID"], [351, 351, 427, 427, "CID"], [397, 397, 38, 38, "CID"], [397, 397, 49, 49, "CID"], [397, 397, 77, 77, "CID"], [397, 397, 427, 427, "CID"], [432, 432, 38, 38, "CID"], [432, 432, 49, 49, "CID"], [432, 432, 77, 77, "CID"], [432, 432, 427, 427, "CID"], [437, 437, 38, 38, "CID"], [437, 437, 49, 49, "CID"], [437, 437, 77, 77, "CID"], [437, 437, 427, 427, "CID"]]], "clusters": [], "translated": "<0>环孢菌素A</0>、<12>他克莫司</12>和<21>西罗莫司</21>短期联合治疗大鼠肾功能和形态。背景：<22>西罗莫司</22>（<23>SRL</23>）可在临床器官移植中补充钙调磷酸酶抑制剂。这些是<8>肾毒性</8>，但<24>SRL</24>似乎表现出不同的作用，仅显示轻微的<9>肾毒性</9>作用，尽管这个问题仍然悬而未决。在许多将<25>SRL</25>与钙调神经磷酸酶抑制剂联合使用的治疗方案中，描述了协同<10>肾毒性</10>作用的指征。本研究的目的是进一步检查肾功能，包括用<1>环孢素A</1>（<2>CsA</2>），<13>他克莫司</13>（<14>FK506</14>）或<26>SRL</26>作为单一疗法或不同的组合中处理的雄性Sprague-Dawley大鼠的肾脏形态。方法：为期2周，<3>CsA</3>15毫克/千克/天（口服），<15>FK506</15>3.0毫克/千克/天（口服）或<27>SRL</27>0.4毫克/千克/天（腹膜内给药），每天给药一次，因为早先发现这些剂量对Sprague-Dawley大鼠具有显着的免疫抑制作用。在“清醒导管大鼠”模型中，肾小球滤过率（GFR）被测量为Cr（EDTA）的清除率。肾脏的形态学分析包括一个半定量评分系统，用于分析条纹<35>纤维化</35>、包膜下<36>纤维化</36>和嗜碱性小管的数量，以及额外的体视学分析用天狼星红染色的皮质<37>纤维化</37>总等级。结果：<4>CsA</4>、<16>FK506</16>和<28>SRL</28>均显着降低GFR。当<5>CsA</5>与<17>FK506</17>或<29>SRL</29>联合使用时，病情进一步恶化，而<18>FK506</18>加上<30>SRL</30>与任何单一物质的治疗相比，GFR保持不变。形态变化呈现出相似的规律。<6>CsA</6>加<31>SRL</31>组的半定量评分显着最差（与对照组相比P < 0.001），总分分析<38>纤维化</38>在同组中所占比例也最高，并且与对照组有显着差异（P < 0.02）。与对照组相比，<19>FK506</19>加<32>SRL</32>组合仅显示略高程度的<39>纤维化</39>（P = 0.05）。结论：这项大鼠研究证明了<7>CsA</7>加<33>SRL</33>的协同<11>肾毒性</11>作用，而<20>FK506</20>加<34>SRL</34>的耐受性更好。", "revised": true}
{"doc_key": "1085609", "sentences": [["Neonatal", "pyridoxine", "responsive", "convulsions", "due", "to", "isoniazid", "therapy", ".", "A", "17", "-", "day", "-", "old", "infant", "on", "isoniazid", "therapy", "13", "mg", "/", "kg", "daily", "from", "birth", "because", "of", "maternal", "tuberculosis", "was", "admitted", "after", "4", "days", "of", "clonic", "fits", ".", "No", "underlying", "infective", "or", "biochemical", "cause", "could", "be", "found", ".", "The", "fits", "ceased", "within", "4", "hours", "of", "administering", "intramuscular", "pyridoxine", ",", "suggesting", "an", "aetiology", "of", "pyridoxine", "deficiency", "secondary", "to", "isoniazid", "medication", "."]], "ner": [[[6, 6, "Chemical"], [17, 17, "Chemical"], [68, 68, "Chemical"], [3, 3, "Disease"], [36, 37, "Disease"], [50, 50, "Disease"], [1, 1, "Chemical"], [58, 58, "Chemical"], [64, 64, "Chemical"], [29, 29, "Disease"]]], "relations": [[[6, 6, 3, 3, "CID"], [6, 6, 36, 37, "CID"], [6, 6, 50, 50, "CID"], [17, 17, 3, 3, "CID"], [17, 17, 36, 37, "CID"], [17, 17, 50, 50, "CID"], [68, 68, 3, 3, "CID"], [68, 68, 36, 37, "CID"], [68, 68, 50, 50, "CID"]]], "clusters": [], "translated": "新生儿 <6>吡哆醇</6> 反应性<3>惊厥</3>由于<0>异烟肼</0>治疗。一名17日龄婴儿因母亲<9>肺结核</9>出生后每天接受<1>异烟肼</1>治疗13 mg/kg，在<4>阵挛发作</4>4天后入院。没有发现潜在的感染或生化原因。<5>发作</5>在肌内注射<7>吡哆醇</7>后4小时内停止，提示<8>吡哆醇</8>缺乏继发于<2>异烟肼</2>药物治疗。", "revised": true}
{"doc_key": "6640832", "sentences": [["Early", "adjuvant", "adriamycin", "in", "superficial", "bladder", "carcinoma", ".", "A", "multicenter", "study", "was", "performed", "in", "110", "patients", "with", "superficial", "transitional", "cell", "carcinoma", "of", "the", "bladder", ".", "Adriamycin", "(", "50", "mg", "/", "50", "ml", ")", "was", "administered", "intravesically", "within", "24", "h", "after", "transurethral", "resection", "of", "TA", "-", "T1", "(", "O", "-", "A", ")", "bladder", "tumors", ".", "Instillation", "was", "repeated", "twice", "during", "the", "first", "week", ",", "then", "weekly", "during", "the", "first", "month", "and", "afterwards", "monthly", "for", "1", "year", ".", "The", "tolerance", "was", "evaluated", "in", "these", "110", "patients", ",", "and", "29", "patients", "presented", "with", "local", "side", "-", "effects", ".", "In", "24", "of", "these", "patients", "chemical", "cystitis", "was", "severe", "enough", "for", "them", "to", "drop", "out", "of", "the", "study", ".", "No", "systemic", "side", "-", "effects", "were", "observed", ".", "Recurrence", "was", "studied", "in", "82", "evaluable", "patients", "after", "1", "year", "of", "follow", "-", "up", "and", "in", "72", "patients", "followed", "for", "2", "-", "3", "years", "(", "mean", "32", "months", ")", ".", "Of", "the", "82", "patients", "studied", "after", "1", "year", ",", "23", "had", "primary", "and", "59", "recurrent", "disease", ".", "Of", "the", "82", "evaluable", "patients", ",", "50", "did", "not", "show", "any", "recurrence", "after", "1", "year", "(", "61", "%", ")", ",", "while", "32", "presented", "with", "one", "or", "more", "recurrences", "(", "39", "%", ")", ".", "Of", "these", "recurrences", ",", "27", "were", "T1", "tumors", "while", "five", "progressed", "to", "more", "highly", "invasive", "lesions", ".", "In", "patients", "that", "were", "free", "of", "recurrence", "during", "the", "first", "year", ",", "80", "%", "remained", "tumor", "-", "free", "during", "the", "2", "-", "to", "3", "-", "year", "follow", "-", "up", "period", ".", "Of", "the", "patients", "developing", "one", "or", "more", "recurrences", "during", "the", "first", "year", ",", "only", "50", "%", "presented", "with", "further", "recurrence", "once", "the", "instillations", "were", "stopped", ".", "The", "beneficial", "effect", "of", "Adriamycin", "appears", "obvious", "and", "might", "be", "related", "to", "the", "drug", "itself", ",", "the", "early", "and", "repeated", "instillations", "after", "TUR", ",", "or", "both", "."]], "ner": [[[2, 2, "Chemical"], [25, 25, "Chemical"], [280, 280, "Chemical"], [101, 101, "Disease"], [5, 6, "Disease"], [20, 23, "Disease"], [51, 52, "Disease"], [209, 209, "Disease"], [234, 234, "Disease"]]], "relations": [[[2, 2, 101, 101, "CID"], [25, 25, 101, 101, "CID"], [280, 280, 101, 101, "CID"]]], "clusters": [], "translated": "浅表性<4>膀胱癌</4>早期辅助<0>阿霉素</0>。对110名患有<5>浅表性膀胱移行细胞癌</5>的患者进行了一项多中心研究。 <1>阿霉素</1> (50mg/50ml) 被经尿道切除TA-T1(O-A)<6>膀胱肿瘤</6>后24小时内膀胱内给予。第一周内反复滴注两次，然后在第一个月内每周反复滴注一次，之后每月滴注一次，持续1年。这项研究对这110名患者的耐受性进行了评估，其中29名患者出现局部副作用。其中24名患者由于化学性<3>膀胱炎</3>严重而不得不退出研究。没有观察到全身性副作用。在1年随访后对82名可评估患者和随访2-3年(平均32个月)的72名患者的复发情况进行了研究。在82名随访1年后的患者中，23名患有原发性疾病，59名患有复发性疾病。在82名可评估的患者中，50名没有任何复发(61%)，而32名患者出现一次或多次复发(39%)。在这些复发中，27例为T1<7>肿瘤</7>，而5例进展到更具侵袭性的病变。在第一年无复发的患者中，80%仍然没有<8>肿瘤</8>在2-3年的随访期间。在第一年出现一次或多次复发的患者中，只有50%的患者在停止滴注后再次复发。 <2>阿霉素</2>的有益作用似乎很明显，可能与药物本身、TUR后的早期和/或重复滴注有关。", "revised": true}
{"doc_key": "19843802", "sentences": [["When", "drugs", "disappear", "from", "the", "patient", ":", "elimination", "of", "intravenous", "medication", "by", "hemodiafiltration", ".", "Twenty", "-", "three", "hours", "after", "heart", "transplantation", ",", "life", "-", "threatening", "acute", "right", "heart", "failure", "was", "diagnosed", "in", "a", "patient", "requiring", "continuous", "venovenous", "hemodiafiltration", "(", "CVVHDF", ")", ".", "Increasing", "doses", "of", "catecholamines", ",", "sedatives", ",", "and", "muscle", "relaxants", "administered", "through", "a", "central", "venous", "catheter", "were", "ineffective", ".", "However", ",", "a", "bolus", "of", "epinephrine", "injected", "through", "an", "alternative", "catheter", "provoked", "a", "hypertensive", "crisis", ".", "Thus", ",", "interference", "with", "the", "central", "venous", "infusion", "by", "the", "dialysis", "catheter", "was", "suspected", ".", "The", "catheters", "were", "changed", ",", "and", "hemodynamics", "stabilized", "at", "lower", "catecholamine", "doses", ".", "When", "the", "effects", "of", "IV", "drugs", "are", "inadequate", "in", "patients", "receiving", "CVVHDF", ",", "interference", "with", "adjacent", "catheters", "resulting", "in", "elimination", "of", "the", "drug", "by", "CVVHDF", "should", "be", "suspected", "."]], "ner": [[[66, 66, "Chemical"], [74, 74, "Disease"], [45, 45, "Chemical"], [102, 102, "Chemical"], [26, 28, "Disease"]]], "relations": [[[66, 66, 74, 74, "CID"]]], "clusters": [], "translated": "当药物从患者体内消失时：通过血液透析滤过消除静脉药物。心脏移植后 23 小时，一位需要持续静脉血液透析滤过 (CVVHDF) 的患者被诊断出危及生命的急性<4>右心衰竭</4>。通过中心静脉导管增加剂量的<2>儿茶酚胺</2>、镇静剂和肌肉松弛剂无效。然而，通过备用导管注射的<0>肾上腺素</0>团剂引发了<1>高血压</1>危象。因此，怀疑透析导管干扰中心静脉输液。更换了导管，血流动力学稳定在较低的<3>儿茶酚胺</3>剂量。当 IV 药物对接受 CVVHDF 的患者效果不佳时，应怀疑干扰相邻导管导致药物被 CVVHDF 消除。", "revised": true}
{"doc_key": "20080419", "sentences": [["Prevention", "of", "seizures", "and", "reorganization", "of", "hippocampal", "functions", "by", "transplantation", "of", "bone", "marrow", "cells", "in", "the", "acute", "phase", "of", "experimental", "epilepsy", ".", "In", "this", "study", ",", "we", "investigated", "the", "therapeutic", "potential", "of", "bone", "marrow", "mononuclear", "cells", "(", "BMCs", ")", "in", "a", "model", "of", "epilepsy", "induced", "by", "pilocarpine", "in", "rats", ".", "BMCs", "obtained", "from", "green", "fluorescent", "protein", "(", "GFP", ")", "transgenic", "mice", "or", "rats", "were", "transplanted", "intravenously", "after", "induction", "of", "status", "epilepticus", "(", "SE", ")", ".", "Spontaneous", "recurrent", "seizures", "(", "SRS", ")", "were", "monitored", "using", "Racine", "'s", "seizure", "severity", "scale", ".", "All", "of", "the", "rats", "in", "the", "saline", "-", "treated", "epileptic", "control", "group", "developed", "SRS", ",", "whereas", "none", "of", "the", "BMC", "-", "treated", "epileptic", "animals", "had", "seizures", "in", "the", "short", "term", "(", "15", "days", "after", "transplantation", ")", ",", "regardless", "of", "the", "BMC", "source", ".", "Over", "the", "long", "-", "term", "chronic", "phase", "(", "120", "days", "after", "transplantation", ")", ",", "only", "25", "%", "of", "BMC", "-", "treated", "epileptic", "animals", "had", "seizures", ",", "but", "with", "a", "lower", "frequency", "and", "duration", "compared", "to", "the", "epileptic", "control", "group", ".", "The", "density", "of", "hippocampal", "neurons", "in", "the", "brains", "of", "animals", "treated", "with", "BMCs", "was", "markedly", "preserved", ".", "At", "hippocampal", "Schaeffer", "collateral", "-", "CA1", "synapses", ",", "long", "-", "term", "potentiation", "was", "preserved", "in", "BMC", "-", "transplanted", "rats", "compared", "to", "epileptic", "controls", ".", "The", "donor", "-", "derived", "GFP", "(", "+", ")", "cells", "were", "rarely", "found", "in", "the", "brains", "of", "transplanted", "epileptic", "rats", ".", "In", "conclusion", ",", "treatment", "with", "BMCs", "can", "prevent", "the", "development", "of", "chronic", "seizures", ",", "reduce", "neuronal", "loss", ",", "and", "influence", "the", "reorganization", "of", "the", "hippocampal", "neuronal", "network", "."]], "ner": [[[46, 46, "Chemical"], [20, 20, "Disease"], [43, 43, "Disease"], [99, 99, "Disease"], [112, 112, "Disease"], [154, 154, "Disease"], [169, 169, "Disease"], [211, 211, "Disease"], [231, 231, "Disease"], [69, 70, "Disease"], [72, 72, "Disease"], [2, 2, "Disease"], [86, 86, "Disease"], [115, 115, "Disease"], [157, 157, "Disease"], [246, 246, "Disease"], [249, 250, "Disease"]]], "relations": [[[46, 46, 20, 20, "CID"], [46, 46, 43, 43, "CID"], [46, 46, 99, 99, "CID"], [46, 46, 112, 112, "CID"], [46, 46, 154, 154, "CID"], [46, 46, 169, 169, "CID"], [46, 46, 211, 211, "CID"], [46, 46, 231, 231, "CID"], [46, 46, 69, 70, "CID"], [46, 46, 72, 72, "CID"]]], "clusters": [], "translated": "在实验性<1>癫痫</1>的急性期通过移植骨髓细胞预防<11>癫痫发作</11>和重组海马功能。在这项研究中，我们研究了骨髓单个核细胞(BMCs)在<0>毛果芸香碱</0>诱导的大鼠<2>癫痫</2>模型中的治疗潜力。将绿色荧光蛋白(GFP)转基因小鼠或大鼠的BMCs诱导<9>癫痫持续状态</9>(<10>SE</10>)后静脉移植。使用Racine的<12>癫痫发作</12>严重程度量表监测自发性复发性癫痫发作(SRS)。盐水处理的<3>癫痫</3>对照组中的所有大鼠都出现了SRS，而BMC处理的<4>癫痫</4>动物在短期内没有<13>癫痫发作</13>（移植后15天），与BMC来源无关。在长期慢性期（移植后120天），只有25%经BMC治疗的<5>癫痫</5>动物有<14>癫痫发作</14>，但与<6>癫痫</6>对照组相比，仅仅有一些动物发生癫痫发作，并且发作的频率和持续时间较短。用BMCs处理的动物大脑中海马神经元的密度得到了显著保留。在海马Schaeffer侧支-CA1突触中，与<7>癫痫</7>对照组相比，BMC移植大鼠的长时程增强得到了保留。在移植的<8>癫痫</8>大鼠脑中，很少发现供体来源的GFP(+ )细胞。总之，BMCs治疗可以预防慢性<15>癫痫发作</15>的发展，减少<16>神经元丢失</16>，并影响海马神经元网络的重组。", "revised": true}
{"doc_key": "2265898", "sentences": [["Serial", "epilepsy", "caused", "by", "levodopa", "/", "carbidopa", "administration", "in", "two", "patients", "on", "hemodialysis", ".", "Two", "patients", "with", "similar", "clinical", "features", "are", "presented", ":", "both", "patients", "had", "chronic", "renal", "failure", ",", "on", "hemodialysis", "for", "many", "years", "but", "recently", "begun", "on", "a", "high", "-", "flux", "dialyzer", ";", "both", "had", "been", "receiving", "a", "carbidopa", "/", "levodopa", "preparation", ";", "and", "both", "had", "the", "onset", "of", "hallucinosis", "and", "recurrent", "seizures", ",", "which", "were", "refractory", "to", "anticonvulsants", ".", "The", "first", "patient", "died", "without", "a", "diagnosis", ";", "the", "second", "patient", "had", "a", "dramatic", "recovery", "following", "the", "administration", "of", "vitamin", "B6", ".", "Neither", "patient", "was", "considered", "to", "have", "a", "renal", "state", "sufficiently", "severe", "enough", "to", "explain", "their", "presentation", "."]], "ner": [[[4, 6, "Chemical"], [50, 52, "Chemical"], [1, 1, "Disease"], [91, 92, "Chemical"], [26, 28, "Disease"], [61, 61, "Disease"], [64, 64, "Disease"]]], "relations": [[[4, 6, 1, 1, "CID"], [50, 52, 1, 1, "CID"]]], "clusters": [], "translated": "连续<2>癫痫</2>由<0>左旋多巴/卡比多巴</0>给药引起的两名血液透析患者。介绍了具有相似临床特征的两名患者：两名患者均患有<4>慢性肾功能衰竭</4>，多年进行血液透析，但最近开始使用高通量透析器；两者均已接受<1>卡比多巴/左旋多巴</1>制剂；并且两人都出现了<5>幻觉</5>和反复发作的<6>癫痫发作</6>，这些都是抗惊厥药难以治愈的。第一个病人在没有诊断的情况下死亡；第二位患者在使用<3>维生素 B6</3>后有了显着的恢复。两名患者均未被认为有足够严重的肾病来解释他们的表现。", "revised": true}
{"doc_key": "2375138", "sentences": [["Possible", "intramuscular", "midazolam", "-", "associated", "cardiorespiratory", "arrest", "and", "death", ".", "Midazolam", "hydrochloride", "is", "commonly", "used", "for", "dental", "or", "endoscopic", "procedures", ".", "Although", "generally", "consisted", "safe", "when", "given", "intramuscularly", ",", "intravenous", "administration", "is", "known", "to", "cause", "respiratory", "and", "cardiovascular", "depression", ".", "This", "report", "describes", "the", "first", "published", "case", "of", "cardiorespiratory", "arrest", "and", "death", "associated", "with", "intramuscular", "administration", "of", "midazolam", ".", "Information", "regarding", "midazolam", "use", "is", "reviewed", "to", "provide", "recommendation", "for", "safe", "administration", "."]], "ner": [[[2, 2, "Chemical"], [10, 11, "Chemical"], [57, 57, "Chemical"], [61, 61, "Chemical"], [5, 6, "Disease"], [48, 49, "Disease"], [35, 38, "Disease"], [8, 8, "Disease"], [51, 51, "Disease"]]], "relations": [[[2, 2, 5, 6, "CID"], [2, 2, 48, 49, "CID"], [10, 11, 5, 6, "CID"], [10, 11, 48, 49, "CID"], [57, 57, 5, 6, "CID"], [57, 57, 48, 49, "CID"], [61, 61, 5, 6, "CID"], [61, 61, 48, 49, "CID"], [2, 2, 35, 38, "CID"], [10, 11, 35, 38, "CID"], [57, 57, 35, 38, "CID"], [61, 61, 35, 38, "CID"]]], "clusters": [], "translated": "可能的<0>肌肉注射咪达唑仑</0>-相关的<4>心肺骤停</4>和<7>死亡</7>。 <1>盐酸咪达唑仑</1>常用于牙科或内窥镜手术。虽然肌肉注射通常是安全的，但已知静脉注射会引起<6>呼吸和心血管抑制</6>。本报告描述了第一例与<2>咪达唑仑</2>肌肉注射相关的<5>心跳呼吸骤停</5>和<8>死亡</8>病例。审查有关<3>咪达唑仑</3>使用的信息，以提供安全给药的建议。", "revised": true}
{"doc_key": "3358181", "sentences": [["Ventricular", "tachyarrhythmias", "during", "cesarean", "section", "after", "ritodrine", "therapy", ":", "interaction", "with", "anesthetics", ".", "This", "case", "illustrates", "that", "patients", "receiving", "ritodrine", "for", "preterm", "labor", "may", "risk", "interactions", "between", "the", "residual", "betamimetic", "effects", "of", "ritodrine", "and", "the", "effects", "of", "anesthetics", "during", "cesarean", "section", ".", "Such", "interactions", "may", "result", "in", "serious", "cardiovascular", "complications", "even", "after", "cessation", "of", "an", "infusion", "of", "ritodrine", ".", "Preoperative", "assessment", "should", "focus", "on", "cardiovascular", "status", "and", "serum", "potassium", "level", ".", "Delaying", "induction", "of", "anesthesia", "should", "be", "considered", "whenever", "possible", ".", "Careful", "fluid", "administration", "and", "cautious", "use", "of", "titrated", "doses", "of", "ephedrine", "are", "advised", ".", "After", "delivery", "of", "the", "infant", ",", "there", "should", "be", "no", "contraindication", "to", "the", "use", "of", "an", "alpha", "-", "adrenergic", "vasopressor", "such", "as", "phenylephrine", "to", "treat", "hypotensive", "patients", "with", "tachycardia", "."]], "ner": [[[6, 6, "Chemical"], [19, 19, "Chemical"], [32, 32, "Chemical"], [57, 57, "Chemical"], [0, 1, "Disease"], [68, 68, "Chemical"], [91, 91, "Chemical"], [117, 117, "Chemical"], [21, 22, "Disease"], [48, 49, "Disease"], [120, 120, "Disease"], [123, 123, "Disease"]]], "relations": [[[6, 6, 0, 1, "CID"], [19, 19, 0, 1, "CID"], [32, 32, 0, 1, "CID"], [57, 57, 0, 1, "CID"]]], "clusters": [], "translated": "<0>利托君</0>治疗后剖宫产期间的<4>室性心动过速</4>：与麻醉剂的相互作用。该病例说明接受<1>利托君</1>治疗<8>早产</8>的患者可能存在<2>利托君</2>的残余 β-受体作用与剖宫产期间麻醉剂作用之间相互作用的风险。这种相互作用可能导致严重的<9>心血管并发症</9>，即使在停止输注<3>利托君</3>后也是如此。术前评估应重点关注心血管状况和血清<5>钾</5>水平。应尽可能考虑延迟麻醉诱导。建议谨慎输液并谨慎使用滴定剂量的<6>麻黄碱</6>。婴儿分娩后，使用α-肾上腺素能血管加压药如<7>去氧肾上腺素</7>治疗<10>低血压</10>、<11>心动过速</11>患者应该没有禁忌症。", "revised": true}
{"doc_key": "7199841", "sentences": [["Neurologic", "effects", "of", "subarachnoid", "administration", "of", "2", "-", "chloroprocaine", "-", "CE", ",", "bupivacaine", ",", "and", "low", "pH", "normal", "saline", "in", "dogs", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "neurologic", "consequences", "of", "deliberate", "subarachnoid", "injection", "of", "large", "volumes", "of", "2", "-", "chloroprocaine", "-", "CE", "in", "experimental", "animals", ".", "The", "possible", "role", "of", "low", "pH", "as", "well", "as", "total", "volume", "as", "potential", "factors", "in", "causing", "neurotoxicity", "was", "evaluated", ".", "The", "65", "dogs", "in", "the", "study", "received", "injections", "in", "the", "subarachnoid", "space", "as", "follows", ":", "6", "to", "8", "ml", "of", "bupivacaine", "(", "N", "=", "15", ")", ",", "2", "-", "chloroprocaine", "-", "CE", "(", "N", "=", "20", ")", ",", "low", "pH", "normal", "saline", "(", "pH", "3", ".", "0", ")", "(", "N", "=", "20", ")", ",", "or", "normal", "saline", "(", "N", "=", "10", ")", ".", "Of", "the", "20", "animals", "that", "received", "subarachnoid", "injection", "of", "2", "-", "chloroprocaine", "-", "CE", "seven", "(", "35", "%", ")", "developed", "hind", "-", "limb", "paralysis", ".", "None", "of", "the", "animals", "that", "received", "bupivacaine", ",", "normal", "saline", ",", "or", "normal", "saline", "titrated", "to", "a", "pH", "3", ".", "0", "developed", "hind", "-", "limb", "paralysis", ".", "Of", "the", "15", "spinal", "cords", "of", "the", "animals", "that", "received", "2", "-", "chloroprocaine", "-", "CE", ",", "13", "showed", "subpial", "necrosis", ";", "the", "nerve", "roots", "and", "subarachnoid", "vessels", "were", "normal", ".", "The", "spinal", "cords", "of", "the", "animals", "that", "received", "bupivacaine", ",", "low", "pH", "normal", "saline", "(", "pH", "3", ".", "0", ")", ",", "or", "normal", "saline", "did", "not", "show", "abnormal", "findings", "."]], "ner": [[[6, 10, "Chemical"], [41, 45, "Chemical"], [97, 101, "Chemical"], [142, 146, "Chemical"], [195, 199, "Chemical"], [156, 156, "Disease"], [183, 183, "Disease"], [203, 204, "Disease"], [66, 66, "Disease"], [12, 12, "Chemical"], [90, 90, "Chemical"], [164, 164, "Chemical"], [223, 223, "Chemical"]]], "relations": [[[6, 10, 156, 156, "CID"], [6, 10, 183, 183, "CID"], [41, 45, 156, 156, "CID"], [41, 45, 183, 183, "CID"], [97, 101, 156, 156, "CID"], [97, 101, 183, 183, "CID"], [142, 146, 156, 156, "CID"], [142, 146, 183, 183, "CID"], [195, 199, 156, 156, "CID"], [195, 199, 183, 183, "CID"], [6, 10, 203, 204, "CID"], [41, 45, 203, 204, "CID"], [97, 101, 203, 204, "CID"], [142, 146, 203, 204, "CID"], [195, 199, 203, 204, "CID"]]], "clusters": [], "translated": "<0>2-氯普鲁卡因-CE</0>、<9>布比卡因</9> 和低 pH 生理盐水对狗脊髓蛛网膜下腔注射的神经学影响。本研究的目的是评估故意在实验动物脊髓蛛网膜下腔注射大量 <1>2-氯普鲁卡因-CE</1> 的神经后果。评估低 pH 值和总体积作为潜在因素引起<8>神经毒性</8>。研究中的65只狗在脊髓蛛网膜下腔中接受以下注射：6-8毫升<10>布比卡因</10>（N=15），<2>2-氯普鲁卡因-CE</2>（N=20），低 pH 生理盐水（pH 3.0）（N=20）或生理盐水（N=10）。在接受<3>2-氯普鲁卡因-CE</3>蛛网膜下腔注射的20只动物中，有7只（35％）出现后肢<5>麻痹</5>。接受<11>布比卡因</11>、生理盐水或生理盐水调节至 pH 3.0 的动物没有出现后肢<6>瘫痪</6>。在接受<4>2-氯普鲁卡因-CE</4>注射的15只动物的脊髓中，13只出现了<7>局灶性坏死</7>，神经根和蛛网膜下腔血管正常。接受<12>布比卡因</12>、低 pH 生理盐水（pH 3.0）或生理盐水的动物脊髓未发现异常。", "revised": true}
{"doc_key": "19211690", "sentences": [["Testosterone", "-", "dependent", "hypertension", "and", "upregulation", "of", "intrarenal", "angiotensinogen", "in", "Dahl", "salt", "-", "sensitive", "rats", ".", "Blood", "pressure", "(", "BP", ")", "is", "more", "salt", "sensitive", "in", "men", "than", "in", "premenopausal", "women", ".", "In", "Dahl", "salt", "-", "sensitive", "rats", "(", "DS", ")", ",", "high", "-", "salt", "(", "HS", ")", "diet", "increases", "BP", "more", "in", "males", "than", "females", ".", "In", "contrast", "to", "the", "systemic", "renin", "-", "angiotensin", "system", ",", "which", "is", "suppressed", "in", "response", "to", "HS", "in", "male", "DS", ",", "intrarenal", "angiotensinogen", "expression", "is", "increased", ",", "and", "intrarenal", "levels", "of", "ANG", "II", "are", "not", "suppressed", ".", "In", "this", "study", ",", "the", "hypothesis", "was", "tested", "that", "there", "is", "a", "sexual", "dimorphism", "in", "HS", "-", "induced", "upregulation", "of", "intrarenal", "angiotensinogen", "mediated", "by", "testosterone", "that", "also", "causes", "increases", "in", "BP", "and", "renal", "injury", ".", "On", "a", "low", "-", "salt", "(", "LS", ")", "diet", ",", "male", "DS", "had", "higher", "levels", "of", "intrarenal", "angiotensinogen", "mRNA", "than", "females", ".", "HS", "diet", "for", "4", "wk", "increased", "renal", "cortical", "angiotensinogen", "mRNA", "and", "protein", "only", "in", "male", "DS", ",", "which", "was", "prevented", "by", "castration", ".", "Ovariectomy", "of", "female", "DS", "had", "no", "effect", "on", "intrarenal", "angiotensinogen", "expression", "on", "either", "diet", ".", "Radiotelemetric", "BP", "was", "similar", "between", "males", "and", "castrated", "rats", "on", "LS", "diet", ".", "HS", "diet", "for", "4", "wk", "caused", "a", "progressive", "increase", "in", "BP", ",", "protein", "and", "albumin", "excretion", ",", "and", "glomerular", "sclerosis", "in", "male", "DS", "rats", ",", "which", "were", "attenuated", "by", "castration", ".", "Testosterone", "replacement", "in", "castrated", "DS", "rats", "increased", "BP", ",", "renal", "injury", ",", "and", "upregulation", "of", "renal", "angiotensinogen", "associated", "with", "HS", "diet", ".", "Testosterone", "contributes", "to", "the", "development", "of", "hypertension", "and", "renal", "injury", "in", "male", "DS", "rats", "on", "HS", "diet", "possibly", "through", "upregulation", "of", "the", "intrarenal", "renin", "-", "angiotensin", "system", "."]], "ner": [[[11, 11, "Chemical"], [23, 23, "Chemical"], [34, 34, "Chemical"], [44, 44, "Chemical"], [133, 133, "Chemical"], [126, 127, "Disease"], [220, 221, "Disease"], [242, 243, "Disease"], [263, 264, "Disease"], [0, 0, "Chemical"], [118, 118, "Chemical"], [233, 233, "Chemical"], [255, 255, "Chemical"], [3, 3, "Disease"], [261, 261, "Disease"], [64, 64, "Chemical"], [280, 280, "Chemical"]]], "relations": [[[11, 11, 126, 127, "CID"], [11, 11, 220, 221, "CID"], [11, 11, 242, 243, "CID"], [11, 11, 263, 264, "CID"], [23, 23, 126, 127, "CID"], [23, 23, 220, 221, "CID"], [23, 23, 242, 243, "CID"], [23, 23, 263, 264, "CID"], [34, 34, 126, 127, "CID"], [34, 34, 220, 221, "CID"], [34, 34, 242, 243, "CID"], [34, 34, 263, 264, "CID"], [44, 44, 126, 127, "CID"], [44, 44, 220, 221, "CID"], [44, 44, 242, 243, "CID"], [44, 44, 263, 264, "CID"], [133, 133, 126, 127, "CID"], [133, 133, 220, 221, "CID"], [133, 133, 242, 243, "CID"], [133, 133, 263, 264, "CID"]]], "clusters": [], "translated": " <9>睾酮</9>依赖性<13>高血压</13>和Dahl<0>盐</0>敏感大鼠肾内血管紧张素原上调。与绝经前女性相比，男性的血压 (BP) 对<1>盐</1>更敏感。在 Dahl<2>盐</2>敏感大鼠 (DS) 中，高<3>盐</3> (HS) 饮食使雄性血压升高的程度高于雌性。与全身性肾素-<15>血管紧张素</15>系统相比，男性 DS 对 HS 的反应受到抑制，肾内血管紧张素原表达增加，肾内 ANG II 水平未受到抑制。在这项研究中，假设在 HS 诱导的肾内血管紧张素原上调中存在性别二态性，该上调由<10>睾酮</10>介导，这也导致血压升高和<5>肾损伤</5>。在低<4>盐</4> (LS) 饮食中，男性 DS 的肾内血管紧张素原 mRNA 水平高于女性。 HS 饮食4周仅在男性 DS 中增加肾皮质血管紧张素原 mRNA 和蛋白质，这是通过去势阻止的。女性 DS 的卵巢切除术对两种饮食的肾内血管紧张素原表达均无影响。 LS 饮食的雄性和去势大鼠的无线电遥测血压相似。 HS 饮食4周引起雄性 DS 大鼠血压、蛋白质和白蛋白排泄的进行性增加和<6>肾小球硬化</6>，通过去势减轻。<11>睾酮</11>替代去势 DS 大鼠的血压升高、<7>肾损伤</7>，以及与 HS 饮食相关的肾血管紧张素原上调。<12>睾酮</12>可能通过上调肾内肾素-<16>血管紧张素</16>系统促进 HS 饮食雄性 DS 大鼠<14>高血压</14>和<8>肾损伤</8>的发展。", "revised": true}
{"doc_key": "11773892", "sentences": [["End", "-", "stage", "renal", "disease", "(", "ESRD", ")", "after", "orthotopic", "liver", "transplantation", "(", "OLTX", ")", "using", "calcineurin", "-", "based", "immunotherapy", ":", "risk", "of", "development", "and", "treatment", ".", "BACKGROUND", ":", "The", "calcineurin", "inhibitors", "cyclosporine", "and", "tacrolimus", "are", "both", "known", "to", "be", "nephrotoxic", ".", "Their", "use", "in", "orthotopic", "liver", "transplantation", "(", "OLTX", ")", "has", "dramatically", "improved", "success", "rates", ".", "Recently", ",", "however", ",", "we", "have", "had", "an", "increase", "of", "patients", "who", "are", "presenting", "after", "OLTX", "with", "end", "-", "stage", "renal", "disease", "(", "ESRD", ")", ".", "This", "retrospective", "study", "examines", "the", "incidence", "and", "treatment", "of", "ESRD", "and", "chronic", "renal", "failure", "(", "CRF", ")", "in", "OLTX", "patients", ".", "METHODS", ":", "Patients", "receiving", "an", "OLTX", "only", "from", "June", "1985", "through", "December", "of", "1994", "who", "survived", "6", "months", "postoperatively", "were", "studied", "(", "n", "=", "834", ")", ".", "Our", "prospectively", "collected", "database", "was", "the", "source", "of", "information", ".", "Patients", "were", "divided", "into", "three", "groups", ":", "Controls", ",", "no", "CRF", "or", "ESRD", ",", "n", "=", "748", ";", "CRF", ",", "sustained", "serum", "creatinine", ">", "2", ".", "5", "mg", "/", "dl", ",", "n", "=", "41", ";", "and", "ESRD", ",", "n", "=", "45", ".", "Groups", "were", "compared", "for", "preoperative", "laboratory", "variables", ",", "diagnosis", ",", "postoperative", "variables", ",", "survival", ",", "type", "of", "ESRD", "therapy", ",", "and", "survival", "from", "onset", "of", "ESRD", ".", "RESULTS", ":", "At", "13", "years", "after", "OLTX", ",", "the", "incidence", "of", "severe", "renal", "dysfunction", "was", "18", ".", "1", "%", "(", "CRF", "8", ".", "6", "%", "and", "ESRD", "9", ".", "5", "%", ")", ".", "Compared", "with", "control", "patients", ",", "CRF", "and", "ESRD", "patients", "had", "higher", "preoperative", "serum", "creatinine", "levels", ",", "a", "greater", "percentage", "of", "patients", "with", "hepatorenal", "syndrome", ",", "higher", "percentage", "requirement", "for", "dialysis", "in", "the", "first", "3", "months", "postoperatively", ",", "and", "a", "higher", "1", "-", "year", "serum", "creatinine", ".", "Multivariate", "stepwise", "logistic", "regression", "analysis", "using", "preoperative", "and", "postoperative", "variables", "identified", "that", "an", "increase", "of", "serum", "creatinine", "compared", "with", "average", "at", "1", "year", ",", "3", "months", ",", "and", "4", "weeks", "postoperatively", "were", "independent", "risk", "factors", "for", "the", "development", "of", "CRF", "or", "ESRD", "with", "odds", "ratios", "of", "2", ".", "6", ",", "2", ".", "2", ",", "and", "1", ".", "6", ",", "respectively", ".", "Overall", "survival", "from", "the", "time", "of", "OLTX", "was", "not", "significantly", "different", "among", "groups", ",", "but", "by", "year", "13", ",", "the", "survival", "of", "the", "patients", "who", "had", "ESRD", "was", "only", "28", ".", "2", "%", "compared", "with", "54", ".", "6", "%", "in", "the", "control", "group", ".", "Patients", "developing", "ESRD", "had", "a", "6", "-", "year", "survival", "after", "onset", "of", "ESRD", "of", "27", "%", "for", "the", "patients", "receiving", "hemodialysis", "versus", "71", ".", "4", "%", "for", "the", "patients", "developing", "ESRD", "who", "subsequently", "received", "kidney", "transplants", ".", "CONCLUSIONS", ":", "Patients", "who", "are", "more", "than", "10", "years", "post", "-", "OLTX", "have", "CRF", "and", "ESRD", "at", "a", "high", "rate", ".", "The", "development", "of", "ESRD", "decreases", "survival", ",", "particularly", "in", "those", "patients", "treated", "with", "dialysis", "only", ".", "Patients", "who", "develop", "ESRD", "have", "a", "higher", "preoperative", "and", "1", "-", "year", "serum", "creatinine", "and", "are", "more", "likely", "to", "have", "hepatorenal", "syndrome", ".", "However", ",", "an", "increase", "of", "serum", "creatinine", "at", "various", "times", "postoperatively", "is", "more", "predictive", "of", "the", "development", "of", "CRF", "or", "ESRD", ".", "New", "strategies", "for", "long", "-", "term", "immunosuppression", "may", "be", "needed", "to", "decrease", "this", "complication", "."]], "ner": [[[32, 32, "Chemical"], [40, 40, "Disease"], [222, 223, "Disease"], [34, 34, "Chemical"], [0, 4, "Disease"], [6, 6, "Disease"], [74, 78, "Disease"], [80, 80, "Disease"], [92, 92, "Disease"], [94, 96, "Disease"], [98, 98, "Disease"], [151, 151, "Disease"], [153, 153, "Disease"], [159, 159, "Disease"], [177, 177, "Disease"], [200, 200, "Disease"], [208, 208, "Disease"], [230, 230, "Disease"], [236, 236, "Disease"], [248, 248, "Disease"], [250, 250, "Disease"], [328, 328, "Disease"], [330, 330, "Disease"], [376, 376, "Disease"], [396, 396, "Disease"], [406, 406, "Disease"], [424, 424, "Disease"], [444, 444, "Disease"], [446, 446, "Disease"], [455, 455, "Disease"], [471, 471, "Disease"], [509, 509, "Disease"], [511, 511, "Disease"], [163, 163, "Chemical"], [256, 256, "Chemical"], [287, 287, "Chemical"], [305, 305, "Chemical"], [481, 481, "Chemical"], [497, 497, "Chemical"], [265, 266, "Disease"], [488, 489, "Disease"]]], "relations": [[[32, 32, 40, 40, "CID"], [32, 32, 222, 223, "CID"], [34, 34, 40, 40, "CID"], [34, 34, 222, 223, "CID"]]], "clusters": [], "translated": "<4>终末期肾病</4> (<5>ESRD</5>) 原位肝移植 (OLTX) 后使用基于神经钙蛋白的免疫疗法：发展和治疗的风险。背景：已知钙调神经磷酸酶抑制剂<0>环孢菌素</0>和<3>他克莫司</3>均具有<1>肾毒性</1>。它们在原位肝移植 (OLTX)中的应用显着提高了成功率。然而，最近我们发现接受 OLTX 后出现<6>终末期肾病</6> (<7>ESRD</7>)的患者有所增加。本回顾性研究检查了 OLTX 患者中<8>ESRD</8>和<9>慢性肾功能衰竭</9> (<10>CRF</10>)的发生率和治疗。方法：对1985年6月至1994年12月期间仅接受 OLTX 且术后存活 6 个月的患者进行了研究 (n=834)。我们前瞻性收集的数据库是信息的来源。患者分为三组：对照组，无<11>CRF</11>或<12>ESRD</12>，n=748；<13>CRF</13>，持续血清<33>肌酐</33>>2.5毫克/分升，n=41；和<14>终末期肾病</14>，n=45。比较各组的术前实验室变量、诊断、术后变量、生存率、<15>ESRD</15>治疗类型以及<16>ESRD</16>发作后的生存率。结果：OLTX治疗后13年，严重<2>肾功能不全</2>的发生率为18.1%（<17>CRF</17>8.6%和<18>ESRD</18>9.5%）。与对照组相比，<19>CRF</19>和<20>ESRD</20>患者术前血清<34>肌酐</34>水平较高，<39>肝肾综合征</39>的患者比例更高，术后前3个月透析需求百分比较高，1年血清<35>肌酐</35>较高。使用术前和术后变量的多变量逐步逻辑回归分析确定血清<36>肌酐</36>与术后1年、3个月和4周的平均值相比增加是<21>CRF发展的独立危险因素</21>或<22>ESRD</22>的优势比为2.6、2.2和1.6，分别。从 OLTX 开始的总生存率在各组之间没有显着差异，但到第13年，<23>ESRD</23>患者的生存率仅为28.2%，比对照组的54.6%低。发生<24>ESRD</24>的患者在发生<25>ESRD</25>后的6年生存率在接受血液透析的患者中为27%，而接受肾移植的患者为71.4%。对于随后接受肾移植的<26>终末期肾病</26>患者，这一比例为4%。结论：OLTX后10年以上的患者<27>CRF</27>和<28>ESRD</28>发生率高。发生<29>终末期肾病</29>会降低生存率，尤其是那些仅接受透析治疗的患者。发生<30>ESRD</30>的患者术前和1年血清<37>肌酐</37>较高，并且更可能患有<40>肝肾综合征</40>。然而，术后不同时间血清<38>肌酐</38>的升高更能预测<31>CRF</31>或<32>ESRD</32>的发展。可能需要新的长期免疫抑制策略来减少这种并发症。", "revised": true}
{"doc_key": "2425813", "sentences": [["On", "two", "paradoxical", "side", "-", "effects", "of", "prednisolone", "in", "rats", ",", "ribosomal", "RNA", "biosyntheses", ",", "and", "a", "mechanism", "of", "action", ".", "Liver", "enlargement", "and", "muscle", "wastage", "occurred", "in", "Wistar", "rats", "following", "the", "subcutaneous", "administration", "of", "prednisolone", ".", "In", "the", "liver", "both", "the", "content", "of", "RNA", "and", "the", "biosynthesis", "of", "ribosomal", "RNA", "increased", "while", "both", "the", "RNA", "content", "and", "ribosomal", "RNA", "biosynthesis", "were", "reduced", "in", "the", "gastrocnemius", "muscle", ".", "It", "is", "suggested", "that", "the", "drug", "acted", "in", "a", "selective", "and", "tissue", "-", "specific", "manner", "to", "enhance", "ribosomal", "RNA", "synthesis", "in", "the", "liver", "and", "depress", "such", "synthesis", "in", "the", "muscle", ".", "This", "view", "supports", "the", "contention", "that", "the", "liver", "and", "muscle", "are", "independent", "sites", "of", "prednisolone", "action", "."]], "ner": [[[7, 7, "Chemical"], [35, 35, "Chemical"], [113, 113, "Chemical"], [21, 22, "Disease"], [24, 25, "Disease"]]], "relations": [[[7, 7, 21, 22, "CID"], [35, 35, 21, 22, "CID"], [113, 113, 21, 22, "CID"], [7, 7, 24, 25, "CID"], [35, 35, 24, 25, "CID"], [113, 113, 24, 25, "CID"]]], "clusters": [], "translated": "关于 <0>泼尼松龙</0> 在大鼠中的两个反常副作用、核糖体 RNA 生物合成和作用机制。皮下注射<1>泼尼松龙</1>后，Wistar大鼠出现<3>肝脏增大</3>和<4>肌肉萎缩</4>。肝脏中 RNA 含量和核糖体 RNA 生物合成均增加，而腓肠肌中RNA含量和核糖体 RNA 生物合成均降低。提示该药物以选择性和组织特异性方式作用于增强肝脏中核糖体 RNA 的合成并抑制肌肉中的这种合成。这一观点支持<2> 泼尼松龙 </2>作用的独立部位的论点。", "revised": true}
{"doc_key": "15188772", "sentences": [["Severe", "reversible", "left", "ventricular", "systolic", "and", "diastolic", "dysfunction", "due", "to", "accidental", "iatrogenic", "epinephrine", "overdose", ".", "Catecholamine", "-", "induced", "cardiomyopathy", "due", "to", "chronic", "excess", "of", "endogenous", "catecholamines", "has", "been", "recognized", "for", "decades", "as", "a", "clinical", "phenomenon", ".", "In", "contrast", ",", "reports", "of", "myocardial", "dysfunction", "due", "to", "acute", "iatrogenic", "overdose", "are", "rare", ".", "A", "35", "-", "year", "-", "old", "woman", "whose", "cervix", "uteri", "was", "inadvertently", "injected", "with", "8", "mg", "of", "epinephrine", "developed", "myocardial", "stunning", "that", "was", "characterized", "by", "severe", "hemodynamic", "compromise", ",", "profound", ",", "albeit", "transient", ",", "left", "ventricular", "systolic", "and", "diastolic", "dysfunction", ",", "and", "only", "modestly", "elevated", "biochemical", "markers", "of", "myocardial", "necrosis", ".", "Our", "case", "illustrates", "the", "serious", "consequences", "of", "medical", "errors", "that", "can", "be", "avoided", "through", "improved", "medication", "labeling", "and", "staff", "supervision", "."]], "ner": [[[12, 12, "Chemical"], [68, 68, "Chemical"], [70, 71, "Disease"], [2, 7, "Disease"], [85, 90, "Disease"], [15, 15, "Chemical"], [25, 25, "Chemical"], [13, 13, "Disease"], [47, 47, "Disease"], [18, 18, "Disease"], [41, 42, "Disease"], [99, 100, "Disease"]]], "relations": [[[12, 12, 70, 71, "CID"], [68, 68, 70, 71, "CID"]]], "clusters": [], "translated": "由于意外的医源性<0>肾上腺素</0> <7>过量</7>导致的严重可逆性<3>左心室收缩和舒张功能障碍</3>。 <5>儿茶酚胺</5>诱导的<9>心肌病</9>，由于内源性<6>儿茶酚胺</6>的长期过量，几十年来一直被认为是一种临床现象。相比之下，由于急性医源性<8>药物过量</8>引起的<10>心肌功能障碍</10>的报道很少见。一位35岁的女性，她的子宫颈被无意中注射了8mg的<1>肾上腺素</1>，发生了<2>心肌顿抑</2>，其特征是严重的血液动力学受损，虽然是短暂的，但很严重，<4>左心室收缩和舒张功能障碍</4>，<11>心肌坏死</11>的生化标志物仅轻度升高。我们的案例说明了可以通过改进药物标签和员工监督来避免医疗错误的严重后果。", "revised": true}
{"doc_key": "15859940", "sentences": [["Causes", "of", "acute", "thrombotic", "microangiopathy", "in", "patients", "receiving", "kidney", "transplantation", ".", "OBJECTIVES", ":", "Thrombotic", "microangiopathy", "is", "a", "well", "-", "known", "problem", "in", "patients", "following", "renal", "transplantation", ".", "In", "postrenal", "transplantation", ",", "thrombotic", "microangiopathy", "is", "often", "a", "reflection", "of", "hemolytic", "uremic", "syndrome", ".", "We", "aimed", "to", "determine", "the", "causes", "of", "thrombotic", "microangiopathy", "in", "a", "population", "of", "renal", "transplantation", "recipients", "and", "discuss", "the", "literature", ".", "MATERIALS", "AND", "METHODS", ":", "We", "investigated", "the", "causes", "of", "thrombotic", "microangiopathy", "during", "a", "1", "-", "year", "period", ",", "from", "June", "2003", "to", "June", "2004", ",", "at", "the", "King", "Fahad", "National", "Guard", "Hospital", "in", "Riyadh", ",", "Saudi", "Arabia", ",", "by", "reviewing", "the", "slides", "of", "all", "transplant", "biopsies", "(", "n", "=", "25", ")", "performed", "during", "this", "interval", ".", "Pre", "-", "and", "posttransplant", "crossmatching", "was", "done", "when", "possible", ".", "RESULTS", ":", "Five", "cases", "of", "thrombotic", "microangiopathy", "were", "found", ".", "Three", "of", "these", "cases", "were", "from", "the", "25", "transplantations", "performed", "at", "King", "Fahad", "National", "Guard", "Hospital", ",", "while", "the", "other", "2", "transplantations", "had", "been", "performed", "abroad", "and", "were", "referred", "to", "us", "for", "follow", "-", "up", ".", "Three", "cases", "were", "related", "to", "cyclosporine", ",", "and", "1", "case", "was", "secondary", "to", "both", "cyclosporine", "and", "tacrolimus", ".", "The", "fifth", "case", "had", "features", "of", "thrombotic", "microangiopathy", "related", "to", "an", "antiphospholipid", "syndrome", "in", "a", "patient", "with", "systemic", "lupus", "erythematosus", ".", "CONCLUSIONS", ":", "In", "the", "literature", ",", "the", "most", "-", "frequent", "cause", "of", "hemolytic", "uremic", "syndrome", "in", "patients", "following", "renal", "transplantation", "is", "recurrence", "of", "the", "hemolytic", "uremic", "syndrome", ".", "Other", "causes", "include", "drug", "-", "related", "(", "cyclosporine", ",", "tacrolimus", ")", "toxicity", ",", "procoagulant", "status", ",", "and", "antibody", "-", "mediated", "rejection", ".", "We", "found", "that", "the", "most", "-", "frequent", "cause", "of", "thrombotic", "microangiopathy", "was", "drug", "related", ",", "secondary", "mainly", "to", "cyclosporine", ".", "In", "the", "current", "study", ",", "the", "frequency", "of", "thrombotic", "microangiopathy", "was", "similar", "to", "the", "percentage", "reported", "in", "the", "literature", "(", "20", "%", ")", "."]], "ner": [[[180, 180, "Chemical"], [189, 189, "Chemical"], [249, 249, "Chemical"], [282, 282, "Chemical"], [3, 4, "Disease"], [13, 14, "Disease"], [31, 32, "Disease"], [49, 50, "Disease"], [72, 73, "Disease"], [134, 135, "Disease"], [199, 200, "Disease"], [273, 274, "Disease"], [292, 293, "Disease"], [191, 191, "Chemical"], [251, 251, "Chemical"], [38, 40, "Disease"], [226, 228, "Disease"], [238, 240, "Disease"], [204, 205, "Disease"], [210, 212, "Disease"], [253, 253, "Disease"]]], "relations": [[[180, 180, 3, 4, "CID"], [180, 180, 13, 14, "CID"], [180, 180, 31, 32, "CID"], [180, 180, 49, 50, "CID"], [180, 180, 72, 73, "CID"], [180, 180, 134, 135, "CID"], [180, 180, 199, 200, "CID"], [180, 180, 273, 274, "CID"], [180, 180, 292, 293, "CID"], [189, 189, 3, 4, "CID"], [189, 189, 13, 14, "CID"], [189, 189, 31, 32, "CID"], [189, 189, 49, 50, "CID"], [189, 189, 72, 73, "CID"], [189, 189, 134, 135, "CID"], [189, 189, 199, 200, "CID"], [189, 189, 273, 274, "CID"], [189, 189, 292, 293, "CID"], [249, 249, 3, 4, "CID"], [249, 249, 13, 14, "CID"], [249, 249, 31, 32, "CID"], [249, 249, 49, 50, "CID"], [249, 249, 72, 73, "CID"], [249, 249, 134, 135, "CID"], [249, 249, 199, 200, "CID"], [249, 249, 273, 274, "CID"], [249, 249, 292, 293, "CID"], [282, 282, 3, 4, "CID"], [282, 282, 13, 14, "CID"], [282, 282, 31, 32, "CID"], [282, 282, 49, 50, "CID"], [282, 282, 72, 73, "CID"], [282, 282, 134, 135, "CID"], [282, 282, 199, 200, "CID"], [282, 282, 273, 274, "CID"], [282, 282, 292, 293, "CID"]]], "clusters": [], "translated": "肾移植患者急性<4>血栓性微血管病</4>的病因。目的：<5>血栓性微血管病</5>是肾移植术后患者的一个众所周知的问题。在肾后移植中，<6>血栓性微血管病</6>常是<15>溶血性尿毒症综合征</15>的反映。我们旨在确定肾移植受者群体中<7>血栓性微血管病</7>的原因并讨论文献。材料和方法：我们调查了2003年6月至2004年6月在沙特阿拉伯利雅得的法赫德国王国民警卫队医院1年期间<8>血栓性微血管病</8>的原因，方法是回顾所有移植活检(n=25)均在此期间进行。尽可能进行移植前后的交叉配血。结果：共检出5例<9>血栓性微血管病</9>。其中3例来自法赫德国王国民警卫队医院进行的25例移植，另外2例移植是在国外进行的，转诊至我们进行随访。3例与<0>环孢素</0>有关，1例继发于<1>环孢素</1>和<13>他克莫司</13>。第5例具有<10>血栓性微血管病</10>的特征，该特征与<18>抗磷脂综合征</18>相关，患者为<19>系统性红斑狼疮</19>。结论：在文献中，肾移植后患者<16>溶血性尿毒症综合征</16>的最常见原因是复发的<17>溶血性尿毒症综合征</17>。其他原因包括药物相关(<2>环孢菌素</2>、<14>他克莫司</14>)<20>毒性</20>、促凝状态和抗体介导的排斥反应。我们发现<11>血栓性微血管病</11>最常见的原因与药物有关，主要继发于<3>环孢菌素</3>。在当前的研究中，<12>血栓性微血管病</12>的发生率与文献报道的百分比(20%)相似。", "revised": true}
{"doc_key": "2440413", "sentences": [["Differential", "effects", "of", "gamma", "-", "hexachlorocyclohexane", "(", "lindane", ")", "on", "pharmacologically", "-", "induced", "seizures", ".", "Gamma", "-", "hexachlorocyclohexane", "(", "gamma", "-", "HCH", ")", ",", "the", "active", "ingredient", "of", "the", "insecticide", "lindane", ",", "has", "been", "shown", "to", "decrease", "seizure", "threshold", "to", "pentylenetrazol", "(", "PTZ", ")", "3", "h", "after", "exposure", "to", "gamma", "-", "HCH", "and", "conversely", "increase", "threshold", "to", "PTZ", "-", "induced", "seizures", "24", "h", "after", "exposure", "to", "gamma", "-", "HCH", "(", "Vohland", "et", "al", ".", "1981", ")", ".", "In", "this", "study", ",", "the", "severity", "of", "response", "to", "other", "seizure", "-", "inducing", "agents", "was", "tested", "in", "mice", "1", "and", "24", "h", "after", "intraperitoneal", "administration", "of", "80", "mg", "/", "kg", "gamma", "-", "HCH", ".", "One", "hour", "after", "the", "administration", "of", "gamma", "-", "HCH", ",", "the", "activity", "of", "seizure", "-", "inducing", "agents", "was", "increased", ",", "regardless", "of", "their", "mechanism", ",", "while", "24", "h", "after", "gamma", "-", "HCH", "a", "differential", "response", "was", "observed", ".", "Seizure", "activity", "due", "to", "PTZ", "and", "picrotoxin", "(", "PTX", ")", "was", "significantly", "decreased", ";", "however", ",", "seizure", "activity", "due", "to", "3", "-", "mercaptopropionic", "acid", "(", "MPA", ")", ",", "bicuculline", "(", "BCC", ")", ",", "methyl", "6", ",", "7", "-", "dimethoxy", "-", "4", "-", "ethyl", "-", "B", "-", "carboline", "-", "3", "-", "carboxylate", "(", "DMCM", ")", ",", "or", "strychnine", "(", "STR", ")", "was", "not", "different", "from", "control", ".", "In", "vitro", ",", "gamma", "-", "HCH", ",", "pentylenetetrazol", "and", "picrotoxin", "were", "shown", "to", "inhibit", "3H", "-", "TBOB", "binding", "in", "mouse", "whole", "brain", ",", "with", "IC50", "values", "of", "4", ".", "6", ",", "404", "and", "9", ".", "4", "microM", ",", "respectively", ".", "MPA", ",", "BCC", ",", "DMCM", ",", "and", "STR", "showed", "no", "inhibition", "of", "3H", "-", "TBOB", "(", "t", "-", "butyl", "bicyclo", "-", "orthobenzoate", ")", "binding", "at", "concentrations", "of", "100", "micron", ".", "The", "pharmacological", "challenge", "data", "suggest", "that", "tolerance", "may", "occur", "to", "seizure", "activity", "induced", "by", "PTZ", "and", "PTX", "24", "h", "after", "gamma", "-", "HCH", ",", "since", "the", "response", "to", "only", "these", "two", "seizure", "-", "inducing", "agents", "is", "decreased", ".", "The", "in", "vitro", "data", "suggest", "that", "the", "site", "responsible", "for", "the", "decrease", "in", "seizure", "activity", "24", "h", "after", "gamma", "-", "HCH", "may", "be", "the", "GABA", "-", "A", "receptor", "-", "linked", "chloride", "channel", "."]], "ner": [[[42, 42, "Chemical"], [57, 57, "Chemical"], [153, 153, "Chemical"], [222, 222, "Chemical"], [299, 299, "Chemical"], [13, 13, "Disease"], [37, 37, "Disease"], [60, 60, "Disease"], [87, 87, "Disease"], [124, 124, "Disease"], [149, 149, "Disease"], [165, 165, "Disease"], [295, 295, "Disease"], [316, 316, "Disease"], [336, 336, "Disease"], [155, 155, "Chemical"], [157, 157, "Chemical"], [224, 224, "Chemical"], [301, 301, "Chemical"], [169, 172, "Chemical"], [174, 174, "Chemical"], [255, 255, "Chemical"], [177, 177, "Chemical"], [179, 179, "Chemical"], [257, 257, "Chemical"], [182, 199, "Chemical"], [201, 201, "Chemical"], [259, 259, "Chemical"], [205, 205, "Chemical"], [207, 207, "Chemical"], [262, 262, "Chemical"], [3, 5, "Chemical"], [7, 7, "Chemical"], [15, 17, "Chemical"], [19, 21, "Chemical"], [30, 30, "Chemical"], [49, 51, "Chemical"], [66, 68, "Chemical"], [107, 109, "Chemical"], [117, 119, "Chemical"], [140, 142, "Chemical"], [218, 220, "Chemical"], [305, 307, "Chemical"], [341, 343, "Chemical"], [229, 231, "Chemical"], [267, 269, "Chemical"], [271, 276, "Chemical"], [347, 347, "Chemical"]]], "relations": [[[42, 42, 13, 13, "CID"], [42, 42, 37, 37, "CID"], [42, 42, 60, 60, "CID"], [42, 42, 87, 87, "CID"], [42, 42, 124, 124, "CID"], [42, 42, 149, 149, "CID"], [42, 42, 165, 165, "CID"], [42, 42, 295, 295, "CID"], [42, 42, 316, 316, "CID"], [42, 42, 336, 336, "CID"], [57, 57, 13, 13, "CID"], [57, 57, 37, 37, "CID"], [57, 57, 60, 60, "CID"], [57, 57, 87, 87, "CID"], [57, 57, 124, 124, "CID"], [57, 57, 149, 149, "CID"], [57, 57, 165, 165, "CID"], [57, 57, 295, 295, "CID"], [57, 57, 316, 316, "CID"], [57, 57, 336, 336, "CID"], [153, 153, 13, 13, "CID"], [153, 153, 37, 37, "CID"], [153, 153, 60, 60, "CID"], [153, 153, 87, 87, "CID"], [153, 153, 124, 124, "CID"], [153, 153, 149, 149, "CID"], [153, 153, 165, 165, "CID"], [153, 153, 295, 295, "CID"], [153, 153, 316, 316, "CID"], [153, 153, 336, 336, "CID"], [222, 222, 13, 13, "CID"], [222, 222, 37, 37, "CID"], [222, 222, 60, 60, "CID"], [222, 222, 87, 87, "CID"], [222, 222, 124, 124, "CID"], [222, 222, 149, 149, "CID"], [222, 222, 165, 165, "CID"], [222, 222, 295, 295, "CID"], [222, 222, 316, 316, "CID"], [222, 222, 336, 336, "CID"], [299, 299, 13, 13, "CID"], [299, 299, 37, 37, "CID"], [299, 299, 60, 60, "CID"], [299, 299, 87, 87, "CID"], [299, 299, 124, 124, "CID"], [299, 299, 149, 149, "CID"], [299, 299, 165, 165, "CID"], [299, 299, 295, 295, "CID"], [299, 299, 316, 316, "CID"], [299, 299, 336, 336, "CID"], [155, 155, 13, 13, "CID"], [155, 155, 37, 37, "CID"], [155, 155, 60, 60, "CID"], [155, 155, 87, 87, "CID"], [155, 155, 124, 124, "CID"], [155, 155, 149, 149, "CID"], [155, 155, 165, 165, "CID"], [155, 155, 295, 295, "CID"], [155, 155, 316, 316, "CID"], [155, 155, 336, 336, "CID"], [157, 157, 13, 13, "CID"], [157, 157, 37, 37, "CID"], [157, 157, 60, 60, "CID"], [157, 157, 87, 87, "CID"], [157, 157, 124, 124, "CID"], [157, 157, 149, 149, "CID"], [157, 157, 165, 165, "CID"], [157, 157, 295, 295, "CID"], [157, 157, 316, 316, "CID"], [157, 157, 336, 336, "CID"], [224, 224, 13, 13, "CID"], [224, 224, 37, 37, "CID"], [224, 224, 60, 60, "CID"], [224, 224, 87, 87, "CID"], [224, 224, 124, 124, "CID"], [224, 224, 149, 149, "CID"], [224, 224, 165, 165, "CID"], [224, 224, 295, 295, "CID"], [224, 224, 316, 316, "CID"], [224, 224, 336, 336, "CID"], [301, 301, 13, 13, "CID"], [301, 301, 37, 37, "CID"], [301, 301, 60, 60, "CID"], [301, 301, 87, 87, "CID"], [301, 301, 124, 124, "CID"], [301, 301, 149, 149, "CID"], [301, 301, 165, 165, "CID"], [301, 301, 295, 295, "CID"], [301, 301, 316, 316, "CID"], [301, 301, 336, 336, "CID"], [169, 172, 13, 13, "CID"], [169, 172, 37, 37, "CID"], [169, 172, 60, 60, "CID"], [169, 172, 87, 87, "CID"], [169, 172, 124, 124, "CID"], [169, 172, 149, 149, "CID"], [169, 172, 165, 165, "CID"], [169, 172, 295, 295, "CID"], [169, 172, 316, 316, "CID"], [169, 172, 336, 336, "CID"], [174, 174, 13, 13, "CID"], [174, 174, 37, 37, "CID"], [174, 174, 60, 60, "CID"], [174, 174, 87, 87, "CID"], [174, 174, 124, 124, "CID"], [174, 174, 149, 149, "CID"], [174, 174, 165, 165, "CID"], [174, 174, 295, 295, "CID"], [174, 174, 316, 316, "CID"], [174, 174, 336, 336, "CID"], [255, 255, 13, 13, "CID"], [255, 255, 37, 37, "CID"], [255, 255, 60, 60, "CID"], [255, 255, 87, 87, "CID"], [255, 255, 124, 124, "CID"], [255, 255, 149, 149, "CID"], [255, 255, 165, 165, "CID"], [255, 255, 295, 295, "CID"], [255, 255, 316, 316, "CID"], [255, 255, 336, 336, "CID"], [177, 177, 13, 13, "CID"], [177, 177, 37, 37, "CID"], [177, 177, 60, 60, "CID"], [177, 177, 87, 87, "CID"], [177, 177, 124, 124, "CID"], [177, 177, 149, 149, "CID"], [177, 177, 165, 165, "CID"], [177, 177, 295, 295, "CID"], [177, 177, 316, 316, "CID"], [177, 177, 336, 336, "CID"], [179, 179, 13, 13, "CID"], [179, 179, 37, 37, "CID"], [179, 179, 60, 60, "CID"], [179, 179, 87, 87, "CID"], [179, 179, 124, 124, "CID"], [179, 179, 149, 149, "CID"], [179, 179, 165, 165, "CID"], [179, 179, 295, 295, "CID"], [179, 179, 316, 316, "CID"], [179, 179, 336, 336, "CID"], [257, 257, 13, 13, "CID"], [257, 257, 37, 37, "CID"], [257, 257, 60, 60, "CID"], [257, 257, 87, 87, "CID"], [257, 257, 124, 124, "CID"], [257, 257, 149, 149, "CID"], [257, 257, 165, 165, "CID"], [257, 257, 295, 295, "CID"], [257, 257, 316, 316, "CID"], [257, 257, 336, 336, "CID"], [182, 199, 13, 13, "CID"], [182, 199, 37, 37, "CID"], [182, 199, 60, 60, "CID"], [182, 199, 87, 87, "CID"], [182, 199, 124, 124, "CID"], [182, 199, 149, 149, "CID"], [182, 199, 165, 165, "CID"], [182, 199, 295, 295, "CID"], [182, 199, 316, 316, "CID"], [182, 199, 336, 336, "CID"], [201, 201, 13, 13, "CID"], [201, 201, 37, 37, "CID"], [201, 201, 60, 60, "CID"], [201, 201, 87, 87, "CID"], [201, 201, 124, 124, "CID"], [201, 201, 149, 149, "CID"], [201, 201, 165, 165, "CID"], [201, 201, 295, 295, "CID"], [201, 201, 316, 316, "CID"], [201, 201, 336, 336, "CID"], [259, 259, 13, 13, "CID"], [259, 259, 37, 37, "CID"], [259, 259, 60, 60, "CID"], [259, 259, 87, 87, "CID"], [259, 259, 124, 124, "CID"], [259, 259, 149, 149, "CID"], [259, 259, 165, 165, "CID"], [259, 259, 295, 295, "CID"], [259, 259, 316, 316, "CID"], [259, 259, 336, 336, "CID"], [205, 205, 13, 13, "CID"], [205, 205, 37, 37, "CID"], [205, 205, 60, 60, "CID"], [205, 205, 87, 87, "CID"], [205, 205, 124, 124, "CID"], [205, 205, 149, 149, "CID"], [205, 205, 165, 165, "CID"], [205, 205, 295, 295, "CID"], [205, 205, 316, 316, "CID"], [205, 205, 336, 336, "CID"], [207, 207, 13, 13, "CID"], [207, 207, 37, 37, "CID"], [207, 207, 60, 60, "CID"], [207, 207, 87, 87, "CID"], [207, 207, 124, 124, "CID"], [207, 207, 149, 149, "CID"], [207, 207, 165, 165, "CID"], [207, 207, 295, 295, "CID"], [207, 207, 316, 316, "CID"], [207, 207, 336, 336, "CID"], [262, 262, 13, 13, "CID"], [262, 262, 37, 37, "CID"], [262, 262, 60, 60, "CID"], [262, 262, 87, 87, "CID"], [262, 262, 124, 124, "CID"], [262, 262, 149, 149, "CID"], [262, 262, 165, 165, "CID"], [262, 262, 295, 295, "CID"], [262, 262, 316, 316, "CID"], [262, 262, 336, 336, "CID"]]], "clusters": [], "translated": " <31>γ-六氯环己烷</31>（<32>林丹</32>）对药物引起的<5>癫痫发作</5>的不同影响。<33>γ-六氯环己烷</33>（<34>γ-HCH</34>）是杀虫剂<35>林丹</35>的活性成分，已被证明可以减少<6>癫痫发作</6>阈值，3小时后暴露于<36>γ-HCH</36>时对戊四唑(<0>PTZ</0>)的反应然而24小时后接触<37>γ-HCH</37>时会相反增加阈值至<1>PTZ</1>-诱发<7>癫痫发作</7>（Vohland 等人，1981 年）。在这项研究中，给小鼠腹腔注射 80 mg/kg <38>γ-HCH</38> 后 1 小时和 24 小时测试了对其他<8>癫痫发作</8>诱导剂的反应严重程度。<39>γ-HCH</39>给药后 1 小时，<9>癫痫发作</9>诱导剂的活性增加，无论其机制如何，而24小时后<40>γ-HCH</40>给药则观察到不同的反应。<2>PTZ</2>和<15>印防己毒素</15>（<16>PTX</16>）引起的<10>癫痫发作</10>活性显著降低；然而，<19> 3-巯基丙酸</19>（<20>MPA</20>）、<22>荷包牡丹碱</22>（<23>BCC</23>）、<25>6,7-二甲氧基-4-乙基-B-咔啉-3-羧酸甲酯</25>（<26>DMCM</26>）、或<28>士的宁</28>（<29>STR</29>）的<11>癫痫发作</11>活性与对照相同。体外实验中，<41>γ-HCH</41>、<3>戊四氮</3>和<17>印防己毒素</17>显示可抑制小鼠全脑中的<44>3H-TBOB</44>结合，分别的 IC50 值为4.6、404和9.4 微米。<21>MPA</21>、<24>BCC</24>、<27>DMCM</27>和<30>STR</30>的100微米浓度下未显示对<45>3H-TBOB</45>（<46>t-Butyl Bicyclo-Orthobenzoate</46>）结合的抑制作用。药理学挑战数据表明，<42>γ-HCH</42>后 24 小时，<4>PTZ</4> 和<18>PTX</18>诱导的<12>癫痫发作</12>活性可能发生耐受性，因为只有这两种<13>癫痫发作</13>的反应减少了。体外数据表明，<43>γ-HCH</43>后24小时，可能是<47>GABA</47>-A受体-联系氯离子通道的部位对<14>癫痫发作</14>活动减少作用。", "revised": true}
{"doc_key": "16337777", "sentences": [["Investigation", "of", "mitochondrial", "involvement", "in", "the", "experimental", "model", "of", "epilepsy", "induced", "by", "pilocarpine", ".", "Mitochondrial", "abnormalities", "have", "been", "associated", "with", "several", "aspects", "of", "epileptogenesis", ",", "such", "as", "energy", "generation", ",", "control", "of", "cell", "death", ",", "neurotransmitter", "synthesis", ",", "and", "free", "radical", "(", "FR", ")", "production", ".", "Increased", "production", "of", "FRs", "may", "cause", "mtDNA", "damage", "leading", "to", "decreased", "activities", "of", "oxidative", "phosphorylation", "complexes", "containing", "mtDNA", "-", "encoded", "subunits", ".", "In", "this", "study", ",", "we", "investigated", "whether", "increased", "generation", "of", "FR", "during", "status", "epilepticus", "would", "be", "sufficient", "to", "provoke", "abnormalities", "in", "mtDNA", "and", "in", "the", "expression", "and", "activity", "of", "cytochrome", "c", "oxidase", "(", "CCO", ")", ",", "complex", "IV", "of", "the", "respiratory", "chain", ",", "in", "the", "chronic", "phase", "of", "the", "pilocarpine", "model", "of", "temporal", "lobe", "epilepsy", ".", "DNA", "analysis", "revealed", "low", "amounts", "of", "a", "4", ".", "8", "kb", "mtDNA", "deletion", "but", "with", "no", "differences", "in", "frequency", "or", "quantity", "in", "the", "control", "and", "experimental", "groups", ".", "We", "did", "not", "find", "abnormalities", "in", "the", "expression", "and", "distribution", "of", "an", "mtDNA", "-", "encoded", "subunit", "of", "CCO", "(", "CCO", "-", "I", ")", "or", "a", "relative", "decrease", "in", "CCO", "-", "I", "when", "compared", "with", "nuclear", "-", "encoded", "subunits", "(", "CCO", "-", "IV", "and", "SDH", "-", "fp", ")", ".", "No", "abnormality", "in", "CCO", "activity", "was", "observed", "through", "histochemistry", ".", "Although", "evidences", "of", "mitochondrial", "abnormalities", "were", "found", "in", "previously", "published", "studies", ",", "our", "results", "do", "not", "suggest", "that", "the", "FRs", ",", "generated", "during", "the", "acute", "phase", ",", "determined", "important", "abnormalities", "in", "mtDNA", ",", "in", "expression", "of", "CCO", "-", "I", ",", "and", "in", "CCO", "activity", "."]], "ner": [[[12, 12, "Chemical"], [117, 117, "Chemical"], [120, 122, "Disease"], [9, 9, "Disease"], [14, 15, "Disease"], [213, 214, "Disease"], [33, 33, "Disease"], [80, 81, "Disease"]]], "relations": [[[12, 12, 120, 122, "CID"], [117, 117, 120, 122, "CID"]]], "clusters": [], "translated": "线粒体参与<0>毛果芸香碱</0>致<3>癫痫</3>实验模型的研究。<4>线粒体异常</4>与癫痫发生的几个方面有关，例如能量产生、细胞<6>死亡</6>的控制、神经递质合成和自由基 (FR) 的产生。增加的FRs可能导致mtDNA损伤，导致逆转录过程中进行基因表达所必需的mtDNA编码的各种蛋白质亚基的丢失，从而引起包含细胞色素c氧化酶 (CCO) 的氧化磷酸化复合物的活性降低。在这项研究中，我们研究了在<7>癫痫持续状态</7>期间，FR的生成增加是否足以在<1>毛果芸香碱</1><2>颞叶癫痫</2>模型慢性期内引起mtDNA和CCO的表达和活性异常。DNA分析显示在对照组和实验组中4.8kb的mtDNA缺失量没有差异。我们没有发现CCO I亚基的(mtDNA编码亚基)表达和分布异常，也没有看到CCO活性的相对降低。虽然之前的研究发现了<5>线粒体异常</5>的证据，但我们的结果并未表明在急性期FR的增产决定了mtDNA、CCO-I表达以及CCO活性的重大异常。", "revised": true}
{"doc_key": "2887062", "sentences": [["Immunohistochemical", ",", "electron", "microscopic", "and", "morphometric", "studies", "of", "estrogen", "-", "induced", "rat", "prolactinomas", "after", "bromocriptine", "treatment", ".", "To", "clarify", "the", "effects", "of", "bromocriptine", "on", "prolactinoma", "cells", "in", "vivo", ",", "immunohistochemical", ",", "ultrastructural", "and", "morphometrical", "analyses", "were", "applied", "to", "estrogen", "-", "induced", "rat", "prolactinoma", "cells", "1", "h", "and", "6", "h", "after", "injection", "of", "bromocriptine", "(", "3", "mg", "/", "kg", "of", "body", "weight", ")", ".", "One", "h", "after", "treatment", ",", "serum", "prolactin", "levels", "decreased", "markedly", ".", "Electron", "microscopy", "disclosed", "many", "secretory", "granules", ",", "slightly", "distorted", "rough", "endoplasmic", "reticulum", ",", "and", "partially", "dilated", "Golgi", "cisternae", "in", "the", "prolactinoma", "cells", ".", "Morphometric", "analysis", "revealed", "that", "the", "volume", "density", "of", "secretory", "granules", "increased", ",", "while", "the", "volume", "density", "of", "cytoplasmic", "microtubules", "decreased", ".", "These", "findings", "suggest", "that", "lowered", "serum", "prolactin", "levels", "in", "the", "early", "phase", "of", "bromocriptine", "treatment", "may", "result", "from", "an", "impaired", "secretion", "of", "prolactin", "due", "to", "decreasing", "numbers", "of", "cytoplasmic", "microtubules", ".", "At", "6", "h", "after", "injection", ",", "serum", "prolactin", "levels", "were", "still", "considerably", "lower", "than", "in", "controls", ".", "The", "prolactinoma", "cells", "at", "this", "time", "were", "well", "granulated", ",", "with", "vesiculated", "rough", "endoplasmic", "reticulum", "and", "markedly", "dilated", "Golgi", "cisternae", ".", "Electron", "microscopical", "immunohistochemistry", "revealed", "positive", "reaction", "products", "noted", "on", "the", "secretory", "granules", ",", "Golgi", "cisternae", ",", "and", "endoplasmic", "reticulum", "of", "the", "untreated", "rat", "prolactinoma", "cells", ".", "However", ",", "only", "secretory", "granules", "showed", "the", "positive", "reaction", "products", "for", "prolactin", "6", "h", "after", "bromocriptine", "treatment", "of", "the", "adenoma", "cells", ".", "An", "increase", "in", "the", "volume", "density", "of", "secretory", "granules", "and", "a", "decrease", "in", "the", "volume", "densities", "of", "rough", "endoplasmic", "reticulum", "and", "microtubules", "was", "determined", "by", "morphometric", "analysis", ",", "suggesting", "that", "bromocriptine", "inhibits", "protein", "synthesis", "as", "well", "as", "bringing", "about", "a", "disturbance", "of", "the", "prolactin", "secretion", "."]], "ner": [[[8, 8, "Chemical"], [38, 38, "Chemical"], [12, 12, "Disease"], [24, 24, "Disease"], [42, 42, "Disease"], [94, 94, "Disease"], [167, 167, "Disease"], [210, 210, "Disease"], [232, 232, "Disease"], [14, 14, "Chemical"], [22, 22, "Chemical"], [52, 52, "Chemical"], [131, 131, "Chemical"], [228, 228, "Chemical"], [265, 265, "Chemical"]]], "relations": [[[8, 8, 12, 12, "CID"], [8, 8, 24, 24, "CID"], [8, 8, 42, 42, "CID"], [8, 8, 94, 94, "CID"], [8, 8, 167, 167, "CID"], [8, 8, 210, 210, "CID"], [38, 38, 12, 12, "CID"], [38, 38, 24, 24, "CID"], [38, 38, 42, 42, "CID"], [38, 38, 94, 94, "CID"], [38, 38, 167, 167, "CID"], [38, 38, 210, 210, "CID"]]], "clusters": [], "translated": "<9>溴隐亭</9>治疗后<0>雌激素</0>诱导的大鼠<2>催乳素瘤</2>的免疫组织化学、电镜和形态学研究。为阐明<10>溴隐亭</10>对体内<3>泌乳素瘤</3>细胞的影响，对<1>雌激素</1>诱导的大鼠<4>泌乳素瘤</4>进行了免疫组化、超微结构和形态学分析。细胞在注射<11>溴隐亭</11>（3 mg/kg体重）后1小时和6小时。治疗1小时后，血清催乳素水平明显下降。电镜显示<5>泌乳素瘤</5>细胞内有许多分泌颗粒，粗面内质网略微变形，高尔基体池部分扩张。形态分析显示分泌颗粒的体积密度增加，而细胞质微管的体积密度降低。这些发现表明，<12>溴隐亭</12>治疗早期血清催乳素水平降低可能是由于细胞质微管数量减少导致催乳素分泌受损所致。注射后6小时，血清催乳素水平仍显着低于对照组。此时的<6>泌乳素瘤</6>细胞呈颗粒状，粗面内质网呈空泡状，高尔基体池明显扩张。电镜免疫组织化学显示未治疗的大鼠<7>泌乳素瘤</7>细胞的分泌颗粒、高尔基体池和内质网中有阳性反应产物。而在<13>溴隐亭</13>处理<8>腺瘤</8>细胞后6小时，只有分泌颗粒出现催乳素阳性反应产物。形态学分析表明，分泌颗粒体积密度增加，粗面内质网和微管体积密度降低，表明<14>溴隐亭</14>抑制蛋白质合成，并引起细胞内分泌紊乱和催乳素分泌障碍。", "revised": true}
{"doc_key": "11166519", "sentences": [["Acute", "cocaine", "-", "induced", "seizures", ":", "differential", "sensitivity", "of", "six", "inbred", "mouse", "strains", ".", "Mature", "male", "and", "female", "mice", "from", "six", "inbred", "stains", "were", "tested", "for", "susceptibility", "to", "behavioral", "seizures", "induced", "by", "a", "single", "injection", "of", "cocaine", ".", "Cocaine", "was", "injected", "ip", "over", "a", "range", "of", "doses", "(", "50", "-", "100", "mg", "/", "kg", ")", "and", "behavior", "was", "monitored", "for", "20", "minutes", ".", "Seizure", "end", "points", "included", "latency", "to", "forelimb", "or", "hindlimb", "clonus", ",", "latency", "to", "clonic", "running", "seizure", "and", "latency", "to", "jumping", "bouncing", "seizure", ".", "A", "range", "of", "strain", "specific", "sensitivities", "was", "documented", "with", "A", "/", "J", "and", "SJL", "mice", "being", "most", "sensitive", "and", "C57BL", "/", "6J", "most", "resistant", ".", "DBA", "/", "2J", ",", "BALB", "/", "cByJ", "and", "NZW", "/", "LacJ", "strains", "exhibited", "intermediate", "sensitivity", ".", "EEG", "recordings", "were", "made", "in", "SJL", ",", "A", "/", "J", "and", "C57BL", "/", "6J", "mice", "revealing", "a", "close", "correspondence", "between", "electrical", "activity", "and", "behavior", ".", "Additionally", ",", "levels", "of", "cocaine", "determined", "in", "hippocampus", "and", "cortex", "were", "not", "different", "between", "sensitive", "and", "resistant", "strains", ".", "Additional", "studies", "of", "these", "murine", "strains", "may", "be", "useful", "for", "investigating", "genetic", "influences", "on", "cocaine", "-", "induced", "seizures", "."]], "ner": [[[1, 1, "Chemical"], [36, 36, "Chemical"], [38, 38, "Chemical"], [156, 156, "Chemical"], [185, 185, "Chemical"], [4, 4, "Disease"], [29, 29, "Disease"], [63, 63, "Disease"], [78, 78, "Disease"], [84, 84, "Disease"], [188, 188, "Disease"]]], "relations": [[[1, 1, 4, 4, "CID"], [1, 1, 29, 29, "CID"], [1, 1, 63, 63, "CID"], [1, 1, 78, 78, "CID"], [1, 1, 84, 84, "CID"], [1, 1, 188, 188, "CID"], [36, 36, 4, 4, "CID"], [36, 36, 29, 29, "CID"], [36, 36, 63, 63, "CID"], [36, 36, 78, 78, "CID"], [36, 36, 84, 84, "CID"], [36, 36, 188, 188, "CID"], [38, 38, 4, 4, "CID"], [38, 38, 29, 29, "CID"], [38, 38, 63, 63, "CID"], [38, 38, 78, 78, "CID"], [38, 38, 84, 84, "CID"], [38, 38, 188, 188, "CID"], [156, 156, 4, 4, "CID"], [156, 156, 29, 29, "CID"], [156, 156, 63, 63, "CID"], [156, 156, 78, 78, "CID"], [156, 156, 84, 84, "CID"], [156, 156, 188, 188, "CID"], [185, 185, 4, 4, "CID"], [185, 185, 29, 29, "CID"], [185, 185, 63, 63, "CID"], [185, 185, 78, 78, "CID"], [185, 185, 84, 84, "CID"], [185, 185, 188, 188, "CID"]]], "clusters": [], "translated": "急性<0>可卡因</0>诱发的<5>癫痫发作</5>：六种近交小鼠品系的不同敏感性。测试来自六个近交系的成熟雄性和雌性小鼠对单次注射<1>可卡因</1>诱导的行为<6>癫痫发作</6>的易感性。<2>可卡因</2>以一定剂量范围(50-100 mg/kg)进行腹膜内注射，并监测行为20分钟。<7>发作</7>终点包括前肢或后肢阵挛的潜伏期、阵挛性奔跑的潜伏期<8>发作</8>和跳跃跳跃的潜伏期<9>发作</9>。记录了一系列品系特异性敏感性，其中A/J和SJL小鼠最为敏感，而C57BL/6J小鼠最具抵抗力。DBA/2J、BALB/cByJ和NZW/LacJ菌株表现出中等敏感性。脑电图记录在SJL、A/J和C57BL/6J小鼠身上进行，揭示了电活动和行为之间的密切对应。此外，在海马体和皮层中测定的<3>可卡因</3>水平在敏感菌株和耐药菌株之间没有差异。对这些小鼠品系的其他研究可能有助于研究遗传对<4>可卡因</4>诱导的<10>癫痫发作</10>的影响。", "revised": true}
{"doc_key": "2071257", "sentences": [["Effect", "of", "L", "-", "alpha", "-", "glyceryl", "-", "phosphorylcholine", "on", "amnesia", "caused", "by", "scopolamine", ".", "The", "present", "study", "was", "carried", "out", "to", "test", "the", "effects", "of", "L", "-", "alpha", "-", "glycerylphosphorylcholine", "(", "L", "-", "alpha", "-", "GFC", ")", "on", "memory", "impairment", "induced", "by", "scopolamine", "in", "man", ".", "Thirty", "-", "two", "healthy", "young", "volunteers", "were", "randomly", "allocated", "to", "four", "different", "groups", ".", "They", "were", "given", "a", "ten", "day", "pretreatment", "with", "either", "L", "-", "alpha", "-", "GFC", "or", "placebo", ",", "p", ".", "o", ".", ",", "and", "on", "the", "eleventh", "day", "either", "scopolamine", "or", "placebo", ",", "i", ".", "m", ".", "Before", "and", "0", ".", "5", ",", "1", ",", "2", ",", "3", ",", "and", "6", "h", "after", "injection", "the", "subjects", "were", "given", "attention", "and", "mnemonic", "tests", ".", "The", "findings", "of", "this", "study", "indicate", "that", "the", "drug", "is", "able", "to", "antagonize", "impairment", "of", "attention", "and", "memory", "induced", "by", "scopolamine", "."]], "ner": [[[13, 13, "Chemical"], [43, 43, "Chemical"], [89, 89, "Chemical"], [143, 143, "Chemical"], [39, 40, "Disease"], [136, 140, "Disease"], [2, 8, "Chemical"], [26, 30, "Chemical"], [32, 36, "Chemical"], [70, 74, "Chemical"], [10, 10, "Disease"]]], "relations": [[[13, 13, 39, 40, "CID"], [13, 13, 136, 140, "CID"], [43, 43, 39, 40, "CID"], [43, 43, 136, 140, "CID"], [89, 89, 39, 40, "CID"], [89, 89, 136, 140, "CID"], [143, 143, 39, 40, "CID"], [143, 143, 136, 140, "CID"]]], "clusters": [], "translated": "<6>L-α-甘油基磷酸胆碱</6>对<0>东莨菪碱</0>所致<10>失忆</10>的影响。本研究旨在测试<7>L-α-甘油磷酰胆碱</7>（<8>L-α-GFC</8>）对<4>记忆障碍</4>的影响，<1>东莨菪碱</1>在人身上。三十二名健康青年志愿者被随机分配到四个不同的组。他们用<9>L-α-GFC</9>或安慰剂进行为期10天的预处理，p.o.，并在第十一天，<2>东莨菪碱</2>或安慰剂，i.m.在注射后0.5、1、2、3和6小时，对受试者进行了注意力和记忆测试。本研究结果表明，该药可拮抗<5>注意力和记忆力的损害</5>，具有对抗<3>东莨菪碱</3>所致的作用。", "revised": true}
{"doc_key": "20621845", "sentences": [["Elevation", "of", "ADAM10", ",", "ADAM17", ",", "MMP", "-", "2", "and", "MMP", "-", "9", "expression", "with", "media", "degeneration", "features", "CaCl2", "-", "induced", "thoracic", "aortic", "aneurysm", "in", "a", "rat", "model", ".", "PURPOSE", ":", "This", "study", "was", "designed", "to", "establish", "a", "rat", "model", "of", "thoracic", "aortic", "aneurysm", "(", "TAA", ")", "by", "calcium", "chloride", "(", "CaCl", "(", "2", ")", ")", "-", "induced", "arterial", "injury", "and", "to", "explore", "the", "potential", "role", "of", "a", "disintegrin", "and", "metalloproteinase", "(", "ADAM", ")", ",", "matrix", "metalloproteinases", "(", "MMPs", ")", "and", "their", "endogenous", "inhibitors", "(", "TIMPs", ")", "in", "TAA", "formation", ".", "METHODS", ":", "Thoracic", "aorta", "of", "male", "Sprague", "-", "Dawley", "rats", "was", "exposed", "to", "0", ".", "5M", "CaCl", "(", "2", ")", "or", "normal", "saline", "(", "NaCl", ")", ".", "After", "12weeks", ",", "animals", "were", "euthanized", ",", "and", "CaCl", "(", "2", ")", "-", "treated", ",", "CaCl", "(", "2", ")", "-", "untreated", "(", "n", "=", "12", ")", "and", "NaCl", "-", "treated", "aortic", "segments", "(", "n", "=", "12", ")", "were", "collected", "for", "histological", "and", "molecular", "assessments", ".", "MMP", "-", "TIMP", "and", "ADAM", "mRNAs", "were", "semi", "-", "quantitatively", "analyzed", "and", "protein", "expressions", "were", "determined", "by", "immunohistochemistry", ".", "RESULTS", ":", "Despite", "similar", "external", "diameters", "among", "CaCl", "(", "2", ")", "-", "treated", ",", "non", "-", "CaCl", "(", "2", ")", "-", "treated", "and", "NaCl", "-", "treated", "segments", ",", "aneurymal", "alteration", "(", "n", "=", "6", ",", "50", "%", ")", ",", "media", "degeneration", "with", "regional", "disruption", ",", "fragmentation", "of", "elastic", "fiber", ",", "and", "increased", "collagen", "deposition", "(", "n", "=", "12", ",", "100", "%", ")", "were", "demonstrated", "in", "CaCl", "(", "2", ")", "-", "treated", "segments", ".", "MMP", "-", "2", ",", "MMP", "-", "9", ",", "ADAM", "-", "10", "and", "ADAM", "-", "17", "mRNA", "levels", "were", "increased", "in", "CaCl", "(", "2", ")", "-", "treated", "segments", "(", "all", "p", "<", "0", ".", "01", ")", ",", "with", "trends", "of", "elevation", "in", "CaCl", "(", "2", ")", "-", "untreated", "segments", ",", "as", "compared", "with", "NaCl", "-", "treated", "segments", ".", "Immunohistochemistry", "displayed", "significantly", "increased", "expressions", "of", "MMP", "-", "2", ",", "MMP", "-", "9", ",", "ADAM", "-", "10", "and", "ADAM", "-", "17", "(", "all", "p", "<", "0", ".", "01", ")", "in", "intima", "and", "media", "for", "CaCl", "(", "2", ")", "-", "treated", "segments", ".", "TIMP", "mRNA", "and", "tissue", "levels", "did", "not", "differ", "obviously", "among", "the", "three", "aortic", "segments", ".", "CONCLUSION", ":", "This", "study", "establishes", "a", "TAA", "model", "by", "periarterial", "CaCl", "(", "2", ")", "exposure", "in", "rats", ",", "and", "demonstrates", "a", "significant", "elevation", "of", "expression", "of", "MMP", "-", "2", ",", "MMP", "-", "9", ",", "ADAM10", "and", "ADAM17", "in", "the", "pathogenesis", "of", "vascular", "remodeling", "."]], "ner": [[[18, 18, "Chemical"], [48, 49, "Chemical"], [51, 54, "Chemical"], [107, 110, "Chemical"], [126, 129, "Chemical"], [133, 136, "Chemical"], [189, 192, "Chemical"], [198, 201, "Chemical"], [247, 250, "Chemical"], [275, 278, "Chemical"], [296, 299, "Chemical"], [346, 349, "Chemical"], [379, 382, "Chemical"], [21, 23, "Disease"], [41, 43, "Disease"], [45, 45, "Disease"], [88, 88, "Disease"], [375, 375, "Disease"], [58, 59, "Disease"], [115, 115, "Chemical"], [145, 145, "Chemical"], [205, 205, "Chemical"], [307, 307, "Chemical"]]], "relations": [[[18, 18, 21, 23, "CID"], [18, 18, 41, 43, "CID"], [18, 18, 45, 45, "CID"], [18, 18, 88, 88, "CID"], [18, 18, 375, 375, "CID"], [48, 49, 21, 23, "CID"], [48, 49, 41, 43, "CID"], [48, 49, 45, 45, "CID"], [48, 49, 88, 88, "CID"], [48, 49, 375, 375, "CID"], [51, 54, 21, 23, "CID"], [51, 54, 41, 43, "CID"], [51, 54, 45, 45, "CID"], [51, 54, 88, 88, "CID"], [51, 54, 375, 375, "CID"], [107, 110, 21, 23, "CID"], [107, 110, 41, 43, "CID"], [107, 110, 45, 45, "CID"], [107, 110, 88, 88, "CID"], [107, 110, 375, 375, "CID"], [126, 129, 21, 23, "CID"], [126, 129, 41, 43, "CID"], [126, 129, 45, 45, "CID"], [126, 129, 88, 88, "CID"], [126, 129, 375, 375, "CID"], [133, 136, 21, 23, "CID"], [133, 136, 41, 43, "CID"], [133, 136, 45, 45, "CID"], [133, 136, 88, 88, "CID"], [133, 136, 375, 375, "CID"], [189, 192, 21, 23, "CID"], [189, 192, 41, 43, "CID"], [189, 192, 45, 45, "CID"], [189, 192, 88, 88, "CID"], [189, 192, 375, 375, "CID"], [198, 201, 21, 23, "CID"], [198, 201, 41, 43, "CID"], [198, 201, 45, 45, "CID"], [198, 201, 88, 88, "CID"], [198, 201, 375, 375, "CID"], [247, 250, 21, 23, "CID"], [247, 250, 41, 43, "CID"], [247, 250, 45, 45, "CID"], [247, 250, 88, 88, "CID"], [247, 250, 375, 375, "CID"], [275, 278, 21, 23, "CID"], [275, 278, 41, 43, "CID"], [275, 278, 45, 45, "CID"], [275, 278, 88, 88, "CID"], [275, 278, 375, 375, "CID"], [296, 299, 21, 23, "CID"], [296, 299, 41, 43, "CID"], [296, 299, 45, 45, "CID"], [296, 299, 88, 88, "CID"], [296, 299, 375, 375, "CID"], [346, 349, 21, 23, "CID"], [346, 349, 41, 43, "CID"], [346, 349, 45, 45, "CID"], [346, 349, 88, 88, "CID"], [346, 349, 375, 375, "CID"], [379, 382, 21, 23, "CID"], [379, 382, 41, 43, "CID"], [379, 382, 45, 45, "CID"], [379, 382, 88, 88, "CID"], [379, 382, 375, 375, "CID"]]], "clusters": [], "translated": "ADAM10、ADAM17、MMP-2 和 MMP-9 表达升高与介质变性特征<0>CaCl2</0>- 在大鼠模型中诱导<13>胸主动脉瘤</13>。目的：本研究旨在通过<1>氯化钙</1>（<2>CaCl ( 2 ) </2>）建立<14>胸主动脉瘤</14>（<15>TAA</15>）大鼠模型，诱导<18>动脉损伤</18>，并探讨解联素和金属蛋白酶(ADAM)、基质金属蛋白酶(MMPs)及其内源性抑制剂(TIMPs)在<16>TAA</16>编队。方法：雄性Sprague-Dawley大鼠的胸主动脉暴露于0.5M <3>CaCl(2)</3>或生理盐水(<19>NaCl</19>)。12周后，动物被安乐死，收集经<4>CaCl ( 2 )</4>-处理、<5>CaCl(2)</5>-未处理 (n=12)和<20>NaCl</20>-处理的主动脉节段(n=12)进行组织学和分子学评估。对MMP-TIMP和ADAM mRNAs进行半定量分析，并通过免疫组织化学方法测定蛋白表达。结果：尽管<6>CaCl(2)</6>处理、非<7>CaCl(2)</7>处理和<21>NaCl</21>处理的动脉瘤节段具有相似的外径，但<8>CaCl(2)</8>处理的节段出现改变 (n=6, 50%)、介质退化伴局部破坏、弹性纤维碎裂和胶原蛋白沉积增加 (n=12, 100%)。MMP-2、MMP-9、ADAM-10和ADAM-17 mRNA水平在<9>CaCl(2)</9>处理的节段中增加（所有p<0.01），在<10>CaCl(2)</10>-未处理的片段，与<22>NaCl</22>-处理的片段相比，具有升高趋势。免疫组织化学显示，<11>CaCl(2)</11>处理的节段内膜和中膜中MMP-2、MMP-9、ADAM-10和ADAM-17的表达显着增加(所有p<0.01)。三个主动脉节段的TIMP mRNA和组织水平无明显差异。结论：本研究建立了大鼠动脉周围<12> CaCl(2)</12> 暴露的<17>TAA</17>模型，并显示MMP-2、MMP-9、ADAM10和ADAM17在血管重塑的发病机制中的作用。", "revised": true}
{"doc_key": "15130900", "sentences": [["Urinary", "bladder", "cancer", "in", "Wegener", "'s", "granulomatosis", ":", "risks", "and", "relation", "to", "cyclophosphamide", ".", "OBJECTIVE", ":", "To", "assess", "and", "characterise", "the", "risk", "of", "bladder", "cancer", ",", "and", "its", "relation", "to", "cyclophosphamide", ",", "in", "patients", "with", "Wegener", "'s", "granulomatosis", ".", "METHODS", ":", "In", "the", "population", "based", ",", "nationwide", "Swedish", "Inpatient", "Register", "a", "cohort", "of", "1065", "patients", "with", "Wegener", "'s", "granulomatosis", ",", "1969", "-", "95", ",", "was", "identified", ".", "Through", "linkage", "with", "the", "Swedish", "Cancer", "Register", ",", "all", "subjects", "in", "this", "cohort", "diagnosed", "with", "bladder", "cancer", "were", "identified", ".", "Nested", "within", "the", "cohort", ",", "a", "matched", "case", "-", "control", "study", "was", "performed", "to", "estimate", "the", "association", "between", "cyclophosphamide", "and", "bladder", "cancer", "using", "odds", "ratios", "(", "ORs", ")", "as", "relative", "risk", ".", "In", "the", "cohort", "the", "cumulative", "risk", "of", "bladder", "cancer", "after", "Wegener", "'s", "granulomatosis", ",", "and", "the", "relative", "prevalence", "of", "a", "history", "of", "bladder", "cancer", "at", "the", "time", "of", "diagnosis", "of", "Wegener", "'s", "granulomatosis", ",", "were", "also", "estimated", ".", "RESULTS", ":", "The", "median", "cumulative", "doses", "of", "cyclophosphamide", "among", "cases", "(", "n", "=", "11", ")", "and", "controls", "(", "n", "=", "25", ")", "were", "113", "g", "and", "25", "g", ",", "respectively", ".", "The", "risk", "of", "bladder", "cancer", "doubled", "for", "every", "10", "g", "increment", "in", "cyclophosphamide", "(", "OR", "=", "2", ".", "0", ",", "95", "%", "confidence", "interval", "(", "CI", ")", "0", ".", "8", "to", "4", ".", "9", ")", ".", "Treatment", "duration", "longer", "than", "1", "year", "was", "associated", "with", "an", "eightfold", "increased", "risk", "(", "OR", "=", "7", ".", "7", ",", "95", "%", "CI", "0", ".", "9", "to", "69", ")", ".", "The", "absolute", "risk", "for", "bladder", "cancer", "in", "the", "cohort", "reached", "10", "%", "16", "years", "after", "diagnosis", "of", "Wegener", "'s", "granulomatosis", ",", "and", "a", "history", "of", "bladder", "cancer", "was", "(", "non", "-", "significantly", ")", "twice", "as", "common", "as", "expected", "at", "the", "time", "of", "diagnosis", "of", "Wegener", "'s", "granulomatosis", ".", "CONCLUSION", ":", "The", "results", "indicate", "a", "dose", "-", "response", "relationship", "between", "cyclophosphamide", "and", "the", "risk", "of", "bladder", "cancer", ",", "high", "cumulative", "risks", "in", "the", "entire", "cohort", ",", "and", "also", "the", "possibility", "of", "risk", "factors", "operating", "even", "before", "Wegener", "'s", "granulomatosis", "."]], "ner": [[[12, 12, "Chemical"], [30, 30, "Chemical"], [105, 105, "Chemical"], [164, 164, "Chemical"], [200, 200, "Chemical"], [313, 313, "Chemical"], [0, 2, "Disease"], [23, 24, "Disease"], [82, 83, "Disease"], [107, 108, "Disease"], [126, 127, "Disease"], [141, 142, "Disease"], [191, 192, "Disease"], [258, 259, "Disease"], [279, 280, "Disease"], [318, 319, "Disease"], [4, 6, "Disease"], [35, 37, "Disease"], [56, 58, "Disease"], [129, 131, "Disease"], [149, 151, "Disease"], [271, 273, "Disease"], [298, 300, "Disease"], [339, 341, "Disease"], [72, 72, "Disease"]]], "relations": [[[12, 12, 0, 2, "CID"], [12, 12, 23, 24, "CID"], [12, 12, 82, 83, "CID"], [12, 12, 107, 108, "CID"], [12, 12, 126, 127, "CID"], [12, 12, 141, 142, "CID"], [12, 12, 191, 192, "CID"], [12, 12, 258, 259, "CID"], [12, 12, 279, 280, "CID"], [12, 12, 318, 319, "CID"], [30, 30, 0, 2, "CID"], [30, 30, 23, 24, "CID"], [30, 30, 82, 83, "CID"], [30, 30, 107, 108, "CID"], [30, 30, 126, 127, "CID"], [30, 30, 141, 142, "CID"], [30, 30, 191, 192, "CID"], [30, 30, 258, 259, "CID"], [30, 30, 279, 280, "CID"], [30, 30, 318, 319, "CID"], [105, 105, 0, 2, "CID"], [105, 105, 23, 24, "CID"], [105, 105, 82, 83, "CID"], [105, 105, 107, 108, "CID"], [105, 105, 126, 127, "CID"], [105, 105, 141, 142, "CID"], [105, 105, 191, 192, "CID"], [105, 105, 258, 259, "CID"], [105, 105, 279, 280, "CID"], [105, 105, 318, 319, "CID"], [164, 164, 0, 2, "CID"], [164, 164, 23, 24, "CID"], [164, 164, 82, 83, "CID"], [164, 164, 107, 108, "CID"], [164, 164, 126, 127, "CID"], [164, 164, 141, 142, "CID"], [164, 164, 191, 192, "CID"], [164, 164, 258, 259, "CID"], [164, 164, 279, 280, "CID"], [164, 164, 318, 319, "CID"], [200, 200, 0, 2, "CID"], [200, 200, 23, 24, "CID"], [200, 200, 82, 83, "CID"], [200, 200, 107, 108, "CID"], [200, 200, 126, 127, "CID"], [200, 200, 141, 142, "CID"], [200, 200, 191, 192, "CID"], [200, 200, 258, 259, "CID"], [200, 200, 279, 280, "CID"], [200, 200, 318, 319, "CID"], [313, 313, 0, 2, "CID"], [313, 313, 23, 24, "CID"], [313, 313, 82, 83, "CID"], [313, 313, 107, 108, "CID"], [313, 313, 126, 127, "CID"], [313, 313, 141, 142, "CID"], [313, 313, 191, 192, "CID"], [313, 313, 258, 259, "CID"], [313, 313, 279, 280, "CID"], [313, 313, 318, 319, "CID"]]], "clusters": [], "translated": "<16>韦格纳肉芽肿</16>中的<6>膀胱癌</6>：风险和与<0>环磷酰胺</0>的关系。目的：评估和描述<17>韦格纳肉芽肿</17>患者<7>膀胱癌</7>的风险及其与<1>环磷酰胺</1>的关系。方法：在基于人群的瑞典全国住院患者登记系统中，确定了1065名1969年至95年间患有<18>韦格纳肉芽肿病</18>的患者队列。通过与瑞典<24>癌症</24>登记册的联系，确定了该队列中诊断出患有<8>膀胱癌</8>的所有受试者。嵌套在队列中，进行了一项匹配的病例对照研究，以使用比值比 (OR) 作为相对风险来估计<2>环磷酰胺</2>和<9>膀胱癌</9>之间的关联。在队列中，估计了<19>韦格纳肉芽肿</19>后<10>膀胱癌</10>的累积风险，以及<20>韦格纳肉芽肿</20>诊断时患<11>膀胱癌</11>病史的相对患病率。结果：病例(n=11)和对照组(n=25)中<3>环磷酰胺</3>的中位累积剂量分别为113g和25g。<4>环磷酰胺</4>每增加10克，患<12>膀胱癌</12>的风险增加一倍（OR=2.0，95%置信区间（CI）0.8至4.9）。治疗时间超过1年与八倍风险增加有关（OR=7.7，95% CI 0.9至69）。在诊断出<21>韦格纳肉芽肿</21>时，加上患<14>膀胱癌</14>病史后16年，队列中<13>膀胱癌</13>的绝对风险达到10%（不显著）是诊断<22>韦格纳肉芽肿病</22>时预期的两倍。结论：结果表明<5>环磷酰胺</5>与<15>膀胱癌</15>风险之间存在剂量反应关系，整个队列的累积风险较高，而且风险因素甚至可能在患<23>韦格纳肉芽肿病</23>之前就存在。", "revised": true}
{"doc_key": "17437408", "sentences": [["Upregulation", "of", "brain", "expression", "of", "P", "-", "glycoprotein", "in", "MRP2", "-", "deficient", "TR", "(", "-", ")", "rats", "resembles", "seizure", "-", "induced", "up", "-", "regulation", "of", "this", "drug", "efflux", "transporter", "in", "normal", "rats", ".", "PURPOSE", ":", "The", "multidrug", "resistance", "protein", "2", "(", "MRP2", ")", "is", "a", "drug", "efflux", "transporter", "that", "is", "expressed", "predominantly", "at", "the", "apical", "domain", "of", "hepatocytes", "but", "seems", "also", "to", "be", "expressed", "at", "the", "apical", "membrane", "of", "brain", "capillary", "endothelial", "cells", "that", "form", "the", "blood", "-", "brain", "barrier", "(", "BBB", ")", ".", "MRP2", "is", "absent", "in", "the", "transport", "-", "deficient", "(", "TR", "(", "-", ")", ")", "Wistar", "rat", "mutant", ",", "so", "that", "this", "rat", "strain", "was", "very", "helpful", "in", "defining", "substrates", "of", "MRP2", "by", "comparing", "tissue", "concentrations", "or", "functional", "activities", "of", "compounds", "in", "MRP2", "-", "deficient", "rats", "with", "those", "in", "transport", "-", "competent", "Wistar", "rats", ".", "By", "using", "this", "strategy", "to", "study", "the", "involvement", "of", "MRP2", "in", "brain", "access", "of", "antiepileptic", "drugs", "(", "AEDs", ")", ",", "we", "recently", "reported", "that", "phenytoin", "is", "a", "substrate", "for", "MRP2", "in", "the", "BBB", ".", "However", ",", "one", "drawback", "of", "such", "studies", "in", "genetically", "deficient", "rats", "is", "the", "fact", "that", "compensatory", "changes", "with", "upregulation", "of", "other", "transporters", "can", "occur", ".", "This", "prompted", "us", "to", "study", "the", "brain", "expression", "of", "P", "-", "glycoprotein", "(", "Pgp", ")", ",", "a", "major", "drug", "efflux", "transporter", "in", "many", "tissues", ",", "including", "the", "BBB", ",", "in", "TR", "(", "-", ")", "rats", "compared", "with", "nonmutant", "(", "wild", "-", "type", ")", "Wistar", "rats", ".", "METHODS", ":", "The", "expression", "of", "MRP2", "and", "Pgp", "in", "brain", "and", "liver", "sections", "of", "TR", "(", "-", ")", "rats", "and", "normal", "Wistar", "rats", "was", "determined", "with", "immunohistochemistry", ",", "by", "using", "a", "novel", ",", "highly", "selective", "monoclonal", "MRP2", "antibody", "and", "the", "monoclonal", "Pgp", "antibody", "C219", ",", "respectively", ".", "RESULTS", ":", "Immunofluorescence", "staining", "with", "the", "MRP2", "antibody", "was", "found", "to", "label", "a", "high", "number", "of", "microvessels", "throughout", "the", "brain", "in", "normal", "Wistar", "rats", ",", "whereas", "such", "labeling", "was", "absent", "in", "TR", "(", "-", ")", "rats", ".", "TR", "(", "-", ")", "rats", "exhibited", "a", "significant", "up", "-", "regulation", "of", "Pgp", "in", "brain", "capillary", "endothelial", "cells", "compared", "with", "wild", "-", "type", "controls", ".", "No", "such", "obvious", "upregulation", "of", "Pgp", "was", "observed", "in", "liver", "sections", ".", "A", "comparable", "overexpression", "of", "Pgp", "in", "the", "BBB", "was", "obtained", "after", "pilocarpine", "-", "induced", "seizures", "in", "wild", "-", "type", "Wistar", "rats", ".", "Experiments", "with", "systemic", "administration", "of", "the", "Pgp", "substrate", "phenobarbital", "and", "the", "selective", "Pgp", "inhibitor", "tariquidar", "in", "TR", "(", "-", ")", "rats", "substantiated", "that", "Pgp", "is", "functional", "and", "compensates", "for", "the", "lack", "of", "MRP2", "in", "the", "BBB", ".", "CONCLUSIONS", ":", "The", "data", "on", "TR", "(", "-", ")", "rats", "indicate", "that", "Pgp", "plays", "an", "important", "role", "in", "the", "compensation", "of", "MRP2", "deficiency", "in", "the", "BBB", ".", "Because", "such", "a", "compensatory", "mechanism", "most", "likely", "occurs", "to", "reduce", "injury", "to", "the", "brain", "from", "cytotoxic", "compounds", ",", "the", "present", "data", "substantiate", "the", "concept", "that", "MRP2", "performs", "a", "protective", "role", "in", "the", "BBB", ".", "Furthermore", ",", "our", "data", "suggest", "that", "TR", "(", "-", ")", "rats", "are", "an", "interesting", "tool", "to", "study", "consequences", "of", "overexpression", "of", "Pgp", "in", "the", "BBB", "on", "access", "of", "drugs", "in", "the", "brain", ",", "without", "the", "need", "of", "inducing", "seizures", "or", "other", "Pgp", "-", "enhancing", "events", "for", "this", "purpose", "."]], "ner": [[[375, 375, "Chemical"], [18, 18, "Disease"], [378, 378, "Disease"], [522, 522, "Disease"], [162, 162, "Chemical"], [394, 394, "Chemical"], [400, 400, "Chemical"], [460, 463, "Disease"]]], "relations": [[[375, 375, 18, 18, "CID"], [375, 375, 378, 378, "CID"], [375, 375, 522, 522, "CID"]]], "clusters": [], "translated": "MRP2缺陷型 TR(-) 大鼠大脑中 P-糖蛋白表达的上调类似于<1>癫痫发作</1>诱导的正常大鼠这种药物外排转运蛋白的上调。目的：多药耐药蛋白 2 (MRP2) 是一种药物外排转运蛋白，主要在肝细胞的顶端区域表达，但似乎也在形成血脑屏障（BBB）的脑毛细血管内皮细胞的顶膜表达。MRP2在运输缺陷型（TR(-)）Wistar大鼠突变体中不存在，因此该大鼠品系通过比较MRP2缺陷型大鼠和运输型大鼠的组织浓度或化合物的功能活性，非常有助于确定MRP2的底物，称职的Wistar大鼠。通过使用该策略研究MRP2参与抗癫痫药物（AED）的脑通路，我们最近报道了<4>苯妥英</4>是BBB中MRP2的底物。然而，此类针对遗传缺陷大鼠的研究的一个缺点是随着其他转运蛋白的上调，可能会发生代偿性变化。这促使我们研究P-糖蛋白（Pgp）的大脑表达，P-糖蛋白是许多组织（包括BBB）中的一种主要药物外排转运体。与非突变（野生型）Wistar大鼠相比，TR(-)大鼠。方法：采用免疫组织化学方法分别采用新型高选择性MRP2单克隆抗体和Pgp单克隆抗体C219检测TR(-)大鼠和正常Wistar大鼠的脑切片和肝切片中MRP2和Pgp的表达。结果：发现用MRP2抗体进行的免疫荧光染色在正常Wistar大鼠的大脑中标记了大量微血管，而在TR(-)大鼠中则没有这种标记。与野生型对照组相比，TR(-)大鼠脑毛细血管内皮细胞Pgp显着上调。在肝切片中没有观察到这种明显的Pgp上调。在<0>毛果芸香碱</0>诱导野生型Wistar大鼠<2>癫痫发作</2>后，血脑屏障中Pgp的过表达相当。在TR(-)大鼠中全身施用Pgp底物<5>苯巴比妥</5>和选择性Pgp抑制剂<6>tariquidar</6>的实验证实Pgp具有功能并补偿BBB中MRP2的缺乏。结论：TR(-)大鼠的数据表明Pgp在血脑屏障MRP2缺陷的代偿中起重要作用。因为这种补偿机制很可能是为了减少细胞毒性化合物对大脑的<7>损伤</7>，所以目前的数据证实了MRP2在BBB中发挥保护作用的概念。此外，我们的数据表明，TR(-)大鼠是研究BBB中Pgp过度表达对大脑药物通路影响的有趣工具，无需诱导<3>癫痫发作</3>或其他Pgp-为此目的增强事件。", "revised": true}
{"doc_key": "12695819", "sentences": [["MR", "imaging", "with", "quantitative", "diffusion", "mapping", "of", "tacrolimus", "-", "induced", "neurotoxicity", "in", "organ", "transplant", "patients", ".", "Our", "objective", "was", "to", "investigate", "brain", "MR", "imaging", "findings", "and", "the", "utility", "of", "diffusion", "-", "weighted", "(", "DW", ")", "imaging", "in", "organ", "transplant", "patients", "who", "developed", "neurologic", "symptoms", "during", "tacrolimus", "therapy", ".", "Brain", "MR", "studies", ",", "including", "DW", "imaging", ",", "were", "prospectively", "performed", "in", "14", "organ", "transplant", "patients", "receiving", "tacrolimus", "who", "developed", "neurologic", "complications", ".", "In", "each", "patient", "who", "had", "abnormalities", "on", "the", "initial", "MR", "study", ",", "a", "follow", "-", "up", "MR", "study", "was", "performed", "1", "month", "later", ".", "Apparent", "diffusion", "coefficient", "(", "ADC", ")", "values", "on", "the", "initial", "MR", "study", "were", "correlated", "with", "reversibility", "of", "the", "lesions", ".", "Of", "the", "14", "patients", ",", "5", "(", "35", ".", "7", "%", ")", "had", "white", "matter", "abnormalities", ",", "1", "(", "7", ".", "1", "%", ")", "had", "putaminal", "hemorrhage", ",", "and", "8", "(", "57", ".", "1", "%", ")", "had", "normal", "findings", "on", "initial", "MR", "images", ".", "Among", "the", "5", "patients", "with", "white", "matter", "abnormalities", ",", "4", "patients", "(", "80", ".", "0", "%", ")", "showed", "higher", "than", "normal", "ADC", "values", "on", "initial", "MR", "images", ",", "and", "all", "showed", "complete", "resolution", "on", "follow", "-", "up", "images", ".", "The", "remaining", "1", "patient", "(", "20", ".", "0", "%", ")", "showed", "lower", "than", "normal", "ADC", "value", "and", "showed", "incomplete", "resolution", "with", "cortical", "laminar", "necrosis", ".", "Diffusion", "-", "weighted", "imaging", "may", "be", "useful", "in", "predicting", "the", "outcomes", "of", "the", "lesions", "of", "tacrolimus", "-", "induced", "neurotoxicity", "."]], "ner": [[[7, 7, "Chemical"], [45, 45, "Chemical"], [65, 65, "Chemical"], [238, 238, "Chemical"], [128, 130, "Disease"], [164, 166, "Disease"], [10, 10, "Disease"], [241, 241, "Disease"], [68, 69, "Disease"], [140, 141, "Disease"], [219, 221, "Disease"]]], "relations": [[[7, 7, 128, 130, "CID"], [7, 7, 164, 166, "CID"], [45, 45, 128, 130, "CID"], [45, 45, 164, 166, "CID"], [65, 65, 128, 130, "CID"], [65, 65, 164, 166, "CID"], [238, 238, 128, 130, "CID"], [238, 238, 164, 166, "CID"]]], "clusters": [], "translated": "MR 成像与<0>他克莫司</0>诱导的<6>神经毒性</6>在器官移植患者中的定量扩散映射。我们的目的是调查大脑 MR 成像结果和弥散加权（DW）成像在<1>他克莫司</1>治疗期间出现神经系统症状的器官移植患者中的效用。前瞻性地对14名接受<2>他克莫司</2>并出现<8>神经系统并发症</8>的器官移植患者进行了脑部 MR 研究，包括 DW 成像。在初始 MR 检查中出现异常的每位患者中，1 个月后进行了随访 MR 检查。初始 MR 研究的表观扩散系数（ADC）值与病变的可逆性相关。14例患者中，5例（35.7%）有<4>白质异常</4>，1例（7.1%）有<9>壳核出血</9>，8例（57.1%）在最初的 MR 图像上有正常的发现。在<5>白质异常</5>的5例患者中，4例（80.0%）在初始 MR 图像上显示 ADC 值高于正常值，并且在后续图像上均显示完全消退。其余1例患者（20.0%）显示低于正常 ADC 值，显示不完全消退，<10>皮质层状坏死</10>。弥散加权成像可能有助于预测<3>他克莫司</3>引起的<7>神经毒性</7>损伤的结果。", "revised": true}
{"doc_key": "1592014", "sentences": [["Seizures", "induced", "by", "the", "cocaine", "metabolite", "benzoylecgonine", "in", "rats", ".", "The", "half", "-", "life", "(", "t1", "/", "2", ")", "of", "cocaine", "is", "relatively", "short", ",", "but", "some", "of", "the", "consequences", "of", "its", "use", ",", "such", "as", "seizures", "and", "strokes", ",", "can", "occur", "hours", "after", "exposure", ".", "This", "led", "us", "to", "hypothesize", "that", "a", "metabolite", "of", "cocaine", "may", "be", "responsible", "for", "some", "of", "those", "delayed", "sequelae", ".", "We", "evaluated", "the", "potential", "of", "the", "major", "metabolite", "of", "cocaine", ",", "benzoylecgonine", "(", "BE", ")", ",", "to", "cause", "seizures", ".", "Two", "separate", "equimolar", "doses", "(", "0", ".", "2", "and", "0", ".", "4", "mumol", ")", "of", "either", "cocaine", "or", "BE", "were", "injected", "ventricularly", "in", "unanesthetized", "juvenile", "rats", ".", "Treated", "rats", "were", "then", "evaluated", "for", "incidence", ",", "latency", ",", "and", "seizure", "pattern", "or", "for", "locomotor", "activity", "in", "animals", "without", "seizures", ".", "BE", "-", "Induced", "seizures", "occurred", "more", "frequently", "and", "had", "significantly", "longer", "latencies", "than", "those", "induced", "by", "equimolar", "amounts", "of", "cocaine", ".", "Whereas", "cocaine", "-", "induced", "seizures", "were", "best", "characterized", "as", "brief", ",", "generalized", ",", "and", "tonic", "and", "resulted", "in", "death", ",", "those", "induced", "by", "BE", "were", "prolonged", ",", "often", "multiple", "and", "mixed", "in", "type", ",", "and", "rarely", "resulted", "in", "death", ".", "Electrical", "recordings", "from", "the", "hippocampus", "showed", "a", "rhythmic", "progression", "in", "EEG", "frequency", "and", "voltage", "with", "clinical", "seizure", "expression", ".", "BE", "-", "Injected", "rats", "that", "did", "not", "have", "seizures", "had", "significantly", "more", "locomotor", "activity", "than", "cocaine", "-", "injected", "animals", "without", "seizures", ".", "The", "finding", "that", "cocaine", "-", "and", "BE", "-", "induced", "seizures", "differ", "in", "several", "respects", "suggests", "more", "than", "one", "mechanism", "for", "cocaine", "-", "induced", "seizures", "and", "emphasizes", "the", "importance", "of", "a", "cocaine", "metabolite", ",", "BE", "."]], "ner": [[[4, 4, "Chemical"], [20, 20, "Chemical"], [55, 55, "Chemical"], [75, 75, "Chemical"], [102, 102, "Chemical"], [154, 154, "Chemical"], [157, 157, "Chemical"], [230, 230, "Chemical"], [240, 240, "Chemical"], [257, 257, "Chemical"], [267, 267, "Chemical"], [0, 0, "Disease"], [36, 36, "Disease"], [84, 84, "Disease"], [124, 124, "Disease"], [133, 133, "Disease"], [138, 138, "Disease"], [160, 160, "Disease"], [212, 212, "Disease"], [223, 223, "Disease"], [235, 235, "Disease"], [246, 246, "Disease"], [260, 260, "Disease"], [6, 6, "Chemical"], [77, 77, "Chemical"], [79, 79, "Chemical"], [104, 104, "Chemical"], [135, 135, "Chemical"], [179, 179, "Chemical"], [215, 215, "Chemical"], [243, 243, "Chemical"], [270, 270, "Chemical"], [38, 38, "Disease"], [174, 174, "Disease"], [194, 194, "Disease"]]], "relations": [[[4, 4, 0, 0, "CID"], [4, 4, 36, 36, "CID"], [4, 4, 84, 84, "CID"], [4, 4, 124, 124, "CID"], [4, 4, 133, 133, "CID"], [4, 4, 138, 138, "CID"], [4, 4, 160, 160, "CID"], [4, 4, 212, 212, "CID"], [4, 4, 223, 223, "CID"], [4, 4, 235, 235, "CID"], [4, 4, 246, 246, "CID"], [4, 4, 260, 260, "CID"], [20, 20, 0, 0, "CID"], [20, 20, 36, 36, "CID"], [20, 20, 84, 84, "CID"], [20, 20, 124, 124, "CID"], [20, 20, 133, 133, "CID"], [20, 20, 138, 138, "CID"], [20, 20, 160, 160, "CID"], [20, 20, 212, 212, "CID"], [20, 20, 223, 223, "CID"], [20, 20, 235, 235, "CID"], [20, 20, 246, 246, "CID"], [20, 20, 260, 260, "CID"], [55, 55, 0, 0, "CID"], [55, 55, 36, 36, "CID"], [55, 55, 84, 84, "CID"], [55, 55, 124, 124, "CID"], [55, 55, 133, 133, "CID"], [55, 55, 138, 138, "CID"], [55, 55, 160, 160, "CID"], [55, 55, 212, 212, "CID"], [55, 55, 223, 223, "CID"], [55, 55, 235, 235, "CID"], [55, 55, 246, 246, "CID"], [55, 55, 260, 260, "CID"], [75, 75, 0, 0, "CID"], [75, 75, 36, 36, "CID"], [75, 75, 84, 84, "CID"], [75, 75, 124, 124, "CID"], [75, 75, 133, 133, "CID"], [75, 75, 138, 138, "CID"], [75, 75, 160, 160, "CID"], [75, 75, 212, 212, "CID"], [75, 75, 223, 223, "CID"], [75, 75, 235, 235, "CID"], [75, 75, 246, 246, "CID"], [75, 75, 260, 260, "CID"], [102, 102, 0, 0, "CID"], [102, 102, 36, 36, "CID"], [102, 102, 84, 84, "CID"], [102, 102, 124, 124, "CID"], [102, 102, 133, 133, "CID"], [102, 102, 138, 138, "CID"], [102, 102, 160, 160, "CID"], [102, 102, 212, 212, "CID"], [102, 102, 223, 223, "CID"], [102, 102, 235, 235, "CID"], [102, 102, 246, 246, "CID"], [102, 102, 260, 260, "CID"], [154, 154, 0, 0, "CID"], [154, 154, 36, 36, "CID"], [154, 154, 84, 84, "CID"], [154, 154, 124, 124, "CID"], [154, 154, 133, 133, "CID"], [154, 154, 138, 138, "CID"], [154, 154, 160, 160, "CID"], [154, 154, 212, 212, "CID"], [154, 154, 223, 223, "CID"], [154, 154, 235, 235, "CID"], [154, 154, 246, 246, "CID"], [154, 154, 260, 260, "CID"], [157, 157, 0, 0, "CID"], [157, 157, 36, 36, "CID"], [157, 157, 84, 84, "CID"], [157, 157, 124, 124, "CID"], [157, 157, 133, 133, "CID"], [157, 157, 138, 138, "CID"], [157, 157, 160, 160, "CID"], [157, 157, 212, 212, "CID"], [157, 157, 223, 223, "CID"], [157, 157, 235, 235, "CID"], [157, 157, 246, 246, "CID"], [157, 157, 260, 260, "CID"], [230, 230, 0, 0, "CID"], [230, 230, 36, 36, "CID"], [230, 230, 84, 84, "CID"], [230, 230, 124, 124, "CID"], [230, 230, 133, 133, "CID"], [230, 230, 138, 138, "CID"], [230, 230, 160, 160, "CID"], [230, 230, 212, 212, "CID"], [230, 230, 223, 223, "CID"], [230, 230, 235, 235, "CID"], [230, 230, 246, 246, "CID"], [230, 230, 260, 260, "CID"], [240, 240, 0, 0, "CID"], [240, 240, 36, 36, "CID"], [240, 240, 84, 84, "CID"], [240, 240, 124, 124, "CID"], [240, 240, 133, 133, "CID"], [240, 240, 138, 138, "CID"], [240, 240, 160, 160, "CID"], [240, 240, 212, 212, "CID"], [240, 240, 223, 223, "CID"], [240, 240, 235, 235, "CID"], [240, 240, 246, 246, "CID"], [240, 240, 260, 260, "CID"], [257, 257, 0, 0, "CID"], [257, 257, 36, 36, "CID"], [257, 257, 84, 84, "CID"], [257, 257, 124, 124, "CID"], [257, 257, 133, 133, "CID"], [257, 257, 138, 138, "CID"], [257, 257, 160, 160, "CID"], [257, 257, 212, 212, "CID"], [257, 257, 223, 223, "CID"], [257, 257, 235, 235, "CID"], [257, 257, 246, 246, "CID"], [257, 257, 260, 260, "CID"], [267, 267, 0, 0, "CID"], [267, 267, 36, 36, "CID"], [267, 267, 84, 84, "CID"], [267, 267, 124, 124, "CID"], [267, 267, 133, 133, "CID"], [267, 267, 138, 138, "CID"], [267, 267, 160, 160, "CID"], [267, 267, 212, 212, "CID"], [267, 267, 223, 223, "CID"], [267, 267, 235, 235, "CID"], [267, 267, 246, 246, "CID"], [267, 267, 260, 260, "CID"], [6, 6, 0, 0, "CID"], [6, 6, 36, 36, "CID"], [6, 6, 84, 84, "CID"], [6, 6, 124, 124, "CID"], [6, 6, 133, 133, "CID"], [6, 6, 138, 138, "CID"], [6, 6, 160, 160, "CID"], [6, 6, 212, 212, "CID"], [6, 6, 223, 223, "CID"], [6, 6, 235, 235, "CID"], [6, 6, 246, 246, "CID"], [6, 6, 260, 260, "CID"], [77, 77, 0, 0, "CID"], [77, 77, 36, 36, "CID"], [77, 77, 84, 84, "CID"], [77, 77, 124, 124, "CID"], [77, 77, 133, 133, "CID"], [77, 77, 138, 138, "CID"], [77, 77, 160, 160, "CID"], [77, 77, 212, 212, "CID"], [77, 77, 223, 223, "CID"], [77, 77, 235, 235, "CID"], [77, 77, 246, 246, "CID"], [77, 77, 260, 260, "CID"], [79, 79, 0, 0, "CID"], [79, 79, 36, 36, "CID"], [79, 79, 84, 84, "CID"], [79, 79, 124, 124, "CID"], [79, 79, 133, 133, "CID"], [79, 79, 138, 138, "CID"], [79, 79, 160, 160, "CID"], [79, 79, 212, 212, "CID"], [79, 79, 223, 223, "CID"], [79, 79, 235, 235, "CID"], [79, 79, 246, 246, "CID"], [79, 79, 260, 260, "CID"], [104, 104, 0, 0, "CID"], [104, 104, 36, 36, "CID"], [104, 104, 84, 84, "CID"], [104, 104, 124, 124, "CID"], [104, 104, 133, 133, "CID"], [104, 104, 138, 138, "CID"], [104, 104, 160, 160, "CID"], [104, 104, 212, 212, "CID"], [104, 104, 223, 223, "CID"], [104, 104, 235, 235, "CID"], [104, 104, 246, 246, "CID"], [104, 104, 260, 260, "CID"], [135, 135, 0, 0, "CID"], [135, 135, 36, 36, "CID"], [135, 135, 84, 84, "CID"], [135, 135, 124, 124, "CID"], [135, 135, 133, 133, "CID"], [135, 135, 138, 138, "CID"], [135, 135, 160, 160, "CID"], [135, 135, 212, 212, "CID"], [135, 135, 223, 223, "CID"], [135, 135, 235, 235, "CID"], [135, 135, 246, 246, "CID"], [135, 135, 260, 260, "CID"], [179, 179, 0, 0, "CID"], [179, 179, 36, 36, "CID"], [179, 179, 84, 84, "CID"], [179, 179, 124, 124, "CID"], [179, 179, 133, 133, "CID"], [179, 179, 138, 138, "CID"], [179, 179, 160, 160, "CID"], [179, 179, 212, 212, "CID"], [179, 179, 223, 223, "CID"], [179, 179, 235, 235, "CID"], [179, 179, 246, 246, "CID"], [179, 179, 260, 260, "CID"], [215, 215, 0, 0, "CID"], [215, 215, 36, 36, "CID"], [215, 215, 84, 84, "CID"], [215, 215, 124, 124, "CID"], [215, 215, 133, 133, "CID"], [215, 215, 138, 138, "CID"], [215, 215, 160, 160, "CID"], [215, 215, 212, 212, "CID"], [215, 215, 223, 223, "CID"], [215, 215, 235, 235, "CID"], [215, 215, 246, 246, "CID"], [215, 215, 260, 260, "CID"], [243, 243, 0, 0, "CID"], [243, 243, 36, 36, "CID"], [243, 243, 84, 84, "CID"], [243, 243, 124, 124, "CID"], [243, 243, 133, 133, "CID"], [243, 243, 138, 138, "CID"], [243, 243, 160, 160, "CID"], [243, 243, 212, 212, "CID"], [243, 243, 223, 223, "CID"], [243, 243, 235, 235, "CID"], [243, 243, 246, 246, "CID"], [243, 243, 260, 260, "CID"], [270, 270, 0, 0, "CID"], [270, 270, 36, 36, "CID"], [270, 270, 84, 84, "CID"], [270, 270, 124, 124, "CID"], [270, 270, 133, 133, "CID"], [270, 270, 138, 138, "CID"], [270, 270, 160, 160, "CID"], [270, 270, 212, 212, "CID"], [270, 270, 223, 223, "CID"], [270, 270, 235, 235, "CID"], [270, 270, 246, 246, "CID"], [270, 270, 260, 260, "CID"]]], "clusters": [], "translated": "<11>癫痫发作</11>由<0>可卡因</0>代谢物<23>苯甲酰爱康宁</23>在大鼠中诱发。 <1>可卡因</1>的半衰期 ( t1 / 2 ) 相对较短，但其使用的一些后果，例如<12>癫痫发作</12>和<32>中风</32>，可在接触数小时后发生。这使我们假设<2>可卡因</2>的代谢物可能是造成某些延迟后遗症的原因。我们评估了<3>可卡因</3>的主要代谢物<24>苯甲酰爱康宁</24> (<25>BE</25>)引起<13>癫痫发作</13>的可能性。将<4>可卡因</4>或<26>BE</26>两种不同的等摩尔剂量 (0.2和0.4 μmol)注射到未麻醉的幼年大鼠心室。然后评估治疗大鼠的发病率、潜伏期和<14>癫痫发作</14>模式，或评估没有<15>癫痫发作</15>的动物的运动活动。<27>BE</27>诱导的<16>癫痫发作</16>发生频率更高，潜伏期明显更长，而且与等摩尔量的 <5>可卡因</5> 相比更严重。<6>可卡因</6>诱发的<17>癫痫发作</17>的最佳特征是短暂的、全面的和强直的，并导致<33>死亡</33>，而<28>BE</28>持续时间长，常为多发性和混合型，很少导致<34>死亡</34>。来自海马体的电记录显示 EEG 频率和电压随临床<18>发作</18>表达呈节律性进展。<29>BE</29> - 没有<19>癫痫发作</19>的注射大鼠比 <7>可卡因</7> - 没有<20>癫痫发作</20> 的注射动物有明显更多的运动活动。发现<8>可卡因</8>和<30>BE</30>诱导的<21>癫痫发作</21>在几个方面不同的表现，可以看出，引起<9>可卡因</9>诱发<22>癫痫发作</22>的机制不止一种，并且强调了<10>可卡因</10>代谢物<31>BE</31>的重要性。", "revised": true}
{"doc_key": "12596116", "sentences": [["Octreotide", "-", "induced", "hypoxemia", "and", "pulmonary", "hypertension", "in", "premature", "neonates", ".", "The", "authors", "report", "2", "cases", "of", "premature", "neonates", "who", "had", "enterocutaneous", "fistula", "complicating", "necrotizing", "enterocolitis", ".", "Pulmonary", "hypertension", "developed", "after", "administration", "of", "a", "somatostatin", "analogue", ",", "octreotide", ",", "to", "enhance", "resolution", "of", "the", "fistula", ".", "The", "authors", "discuss", "the", "mechanism", "of", "the", "occurrence", "of", "this", "complication", "and", "recommend", "caution", "of", "its", "use", "in", "high", "-", "risk", "premature", "neonates", "."]], "ner": [[[0, 0, "Chemical"], [37, 37, "Chemical"], [5, 6, "Disease"], [27, 28, "Disease"], [3, 3, "Disease"], [22, 22, "Disease"], [44, 44, "Disease"], [24, 25, "Disease"]]], "relations": [[[0, 0, 5, 6, "CID"], [0, 0, 27, 28, "CID"], [37, 37, 5, 6, "CID"], [37, 37, 27, 28, "CID"]]], "clusters": [], "translated": "<0>奥曲肽</0>引起的早产儿<4>低氧血症</4>和<2>肺动脉高压</2>。作者报道2例早产儿因<5>肠皮瘘</5>并发<7>坏死性小肠结肠炎</7>。 <3>肺动脉高压</3>在服用生长抑素类似物<1>奥曲肽</1>以促进<6>瘘管</6>消退后发生。作者讨论了该并发症发生的机制，并建议谨慎用于高危早产儿。", "revised": true}
{"doc_key": "18703024", "sentences": [["Prenatal", "protein", "deprivation", "alters", "dopamine", "-", "mediated", "behaviors", "and", "dopaminergic", "and", "glutamatergic", "receptor", "binding", ".", "Epidemiological", "evidence", "indicates", "that", "prenatal", "nutritional", "deprivation", "may", "increase", "the", "risk", "of", "schizophrenia", ".", "The", "goal", "of", "these", "studies", "was", "to", "use", "an", "animal", "model", "to", "examine", "the", "effects", "of", "prenatal", "protein", "deprivation", "on", "behaviors", "and", "receptor", "binding", "with", "relevance", "to", "schizophrenia", ".", "We", "report", "that", "prenatally", "protein", "deprived", "(", "PD", ")", "female", "rats", "showed", "an", "increased", "stereotypic", "response", "to", "apomorphine", "and", "an", "increased", "locomotor", "response", "to", "amphetamine", "in", "adulthood", ".", "These", "differences", "were", "not", "observed", "during", "puberty", ".", "No", "changes", "in", "haloperidol", "-", "induced", "catalepsy", "or", "MK", "-", "801", "-", "induced", "locomotion", "were", "seen", "following", "PD", ".", "In", "addition", ",", "PD", "female", "rats", "showed", "increased", "(", "3", ")", "H", "-", "MK", "-", "801", "binding", "in", "the", "striatum", "and", "hippocampus", ",", "but", "not", "in", "the", "cortex", ".", "PD", "female", "rats", "also", "showed", "increased", "(", "3", ")", "H", "-", "haloperidol", "binding", "and", "decreased", "dopamine", "transporter", "binding", "in", "striatum", ".", "No", "statistically", "significant", "changes", "in", "behavior", "or", "receptor", "binding", "were", "found", "in", "PD", "males", "with", "the", "exception", "of", "increased", "(", "3", ")", "H", "-", "MK", "-", "801", "binding", "in", "cortex", ".", "This", "animal", "model", "may", "be", "useful", "to", "explore", "the", "mechanisms", "by", "which", "prenatal", "nutritional", "deficiency", "enhances", "risk", "for", "schizophrenia", "in", "humans", "and", "may", "also", "have", "implications", "for", "developmental", "processes", "leading", "to", "differential", "sensitivity", "to", "drugs", "of", "abuse", "."]], "ner": [[[97, 97, "Chemical"], [153, 153, "Chemical"], [100, 100, "Disease"], [4, 4, "Chemical"], [157, 157, "Chemical"], [27, 27, "Disease"], [56, 56, "Disease"], [212, 212, "Disease"], [207, 208, "Disease"], [75, 75, "Chemical"], [82, 82, "Chemical"], [102, 104, "Chemical"], [126, 128, "Chemical"], [187, 189, "Chemical"], [124, 124, "Chemical"], [151, 151, "Chemical"], [185, 185, "Chemical"]]], "relations": [[[97, 97, 100, 100, "CID"], [153, 153, 100, 100, "CID"]]], "clusters": [], "translated": "产前蛋白质剥夺会改变<3>多巴胺</3>介导的行为以及多巴胺能和谷氨酸能受体结合。流行病学证据表明，产前营养剥夺可能会增加<5>精神分裂症</5>的风险。这些研究的目的是使用动物模型来检查产前蛋白质剥夺对与<6>精神分裂症</6>相关的行为和受体结合的影响。我们报告说，产前蛋白质剥夺（PD）雌性大鼠对<9>阿扑吗啡</9>的刻板反应增加，成年后对<10>安非他明</10>的运动反应增加。这些差异在青春期没有观察到。PD后<0>氟哌啶醇</0>诱导的<2>强直性昏厥</2>或<11>MK-801</11>诱导的运动没有变化。此外，PD雌性大鼠在纹状体和海马体中的(3)<14>H</14>-<12>MK-801</12>结合增加，但在皮质中没有。PD雌性大鼠也表现出纹状体中(3)<15>H</15>-<1>氟哌啶醇</1>结合增加和<4>多巴胺</4>转运蛋白结合减少。除了在皮层中(3)<16>H</16>-<13>MK-801</13>结合增加外，在PD男性中未发现行为或受体结合发生统计学上的显着变化。这种动物模型可能有助于探索产前<8>营养缺乏</8>增加人类<7>精神分裂症</7>风险的机制，也可能对导致对药物的不同敏感性的发育过程产生影响。", "revised": true}
{"doc_key": "19473225", "sentences": [["Long", "-", "term", "glutamate", "supplementation", "failed", "to", "protect", "against", "peripheral", "neurotoxicity", "of", "paclitaxel", ".", "Toxic", "peripheral", "neuropathy", "is", "still", "a", "significant", "limiting", "factor", "for", "chemotherapy", "with", "paclitaxel", "(", "PAC", ")", ",", "although", "glutamate", "and", "its", "closely", "related", "amino", "acid", "glutamine", "were", "claimed", "to", "ameliorate", "PAC", "neurotoxicity", ".", "This", "pilot", "trial", "aimed", "to", "evaluate", "the", "role", "of", "glutamate", "supplementation", "for", "preventing", "PAC", "-", "induced", "peripheral", "neuropathy", "in", "a", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blinded", "clinical", "and", "electro", "-", "diagnostic", "study", ".", "Forty", "-", "three", "ovarian", "cancer", "patients", "were", "available", "for", "analysis", "following", "six", "cycles", "of", "the", "same", "PAC", "-", "containing", "regimen", ":", "23", "had", "been", "supplemented", "by", "glutamate", "all", "along", "the", "treatment", "period", ",", "at", "a", "daily", "dose", "of", "three", "times", "500", "mg", "(", "group", "G", ")", ",", "and", "20", "had", "received", "a", "placebo", "(", "group", "P", ")", ".", "Patients", "were", "evaluated", "by", "neurological", "examinations", ",", "questionnaires", "and", "sensory", "-", "motor", "nerve", "conduction", "studies", ".", "There", "was", "no", "significant", "difference", "in", "the", "frequency", "of", "signs", "or", "symptoms", "between", "the", "two", "groups", "although", "neurotoxicity", "symptoms", "presented", "mostly", "with", "lower", "scores", "of", "severity", "in", "group", "G", ".", "However", ",", "this", "difference", "reached", "statistical", "significance", "only", "with", "regard", "to", "reported", "pain", "sensation", "(", "P", "=", "0", ".", "011", ")", ".", "Also", "the", "frequency", "of", "abnormal", "electro", "-", "diagnostic", "findings", "showed", "similarity", "between", "the", "two", "groups", "(", "G", ":", "7", "/", "23", "=", "30", ".", "4", "%", ";", "P", ":", "6", "/", "20", "=", "30", "%", ")", ".", "This", "pilot", "study", "leads", "to", "the", "conclusion", "that", "glutamate", "supplementation", "at", "the", "chosen", "regimen", "fails", "to", "protect", "against", "peripheral", "neurotoxicity", "of", "PAC", "."]], "ner": [[[12, 12, "Chemical"], [26, 26, "Chemical"], [28, 28, "Chemical"], [44, 44, "Chemical"], [60, 60, "Chemical"], [99, 99, "Chemical"], [267, 267, "Chemical"], [9, 10, "Disease"], [15, 16, "Disease"], [63, 64, "Disease"], [264, 265, "Disease"], [3, 3, "Chemical"], [32, 32, "Chemical"], [39, 39, "Chemical"], [56, 56, "Chemical"], [109, 109, "Chemical"], [254, 254, "Chemical"], [45, 45, "Disease"], [174, 174, "Disease"], [86, 87, "Disease"], [199, 199, "Disease"], [37, 38, "Chemical"]]], "relations": [[[12, 12, 9, 10, "CID"], [12, 12, 15, 16, "CID"], [12, 12, 63, 64, "CID"], [12, 12, 264, 265, "CID"], [26, 26, 9, 10, "CID"], [26, 26, 15, 16, "CID"], [26, 26, 63, 64, "CID"], [26, 26, 264, 265, "CID"], [28, 28, 9, 10, "CID"], [28, 28, 15, 16, "CID"], [28, 28, 63, 64, "CID"], [28, 28, 264, 265, "CID"], [44, 44, 9, 10, "CID"], [44, 44, 15, 16, "CID"], [44, 44, 63, 64, "CID"], [44, 44, 264, 265, "CID"], [60, 60, 9, 10, "CID"], [60, 60, 15, 16, "CID"], [60, 60, 63, 64, "CID"], [60, 60, 264, 265, "CID"], [99, 99, 9, 10, "CID"], [99, 99, 15, 16, "CID"], [99, 99, 63, 64, "CID"], [99, 99, 264, 265, "CID"], [267, 267, 9, 10, "CID"], [267, 267, 15, 16, "CID"], [267, 267, 63, 64, "CID"], [267, 267, 264, 265, "CID"]]], "clusters": [], "translated": "长期<11>谷氨酸</11>补充剂未能防止<0>紫杉醇</0>的<7>外周神经毒性</7>。中毒性<8>周围神经病变</8>仍然是<1>紫杉醇</1>（<2>PAC</2>）化疗的重要限制因素，尽管<12>谷氨酸</12>及其密切相关<21>氨基酸</21><13>谷氨酰胺</13>据称可改善<3>PAC</3>引起的<17>神经毒性</17>。该试验性试验旨在评估补充<14>谷氨酸</14>在预防<4>PAC</4>-引起的<9>周围神经病变</9>方面的作用，这是一项随机、安慰剂对照、双盲的试验临床和电子诊断研究。43名<19>卵巢癌</19>患者在相同的<5>PAC</5>治疗方案的六个周期后可用于分析：23名患者一直补充了<15>谷氨酸</15>治疗期间，每日剂量为3次500毫克（<0>G</0> 组），而20人曾接受过安慰剂（<1>P</1>组）。通过神经学检查、问卷调查和感觉运动神经传导研究对患者进行评估。尽管<18>神经毒性</18>症状在<0>G</0>组中严重程度得分较低，但两组之间的体征或症状频率没有显着差异。然而，这种差异仅在报告的<20>疼痛</20>感觉方面具有统计学意义 (P = 0.011) 。异常电诊断结果的频率也显示出两组之间的相似性（<0>G</0>：7/23 = 30.4%；<1>P</1>：6/20 = 30%）。该试点研究得出的结论是，在所选方案中补充<16>谷氨酸</16>无法防止<6>PAC</6>的<10>周围神经毒性</10>。", "revised": true}
{"doc_key": "809711", "sentences": [["Reversal", "by", "phenylephrine", "of", "the", "beneficial", "effects", "of", "intravenous", "nitroglycerin", "in", "patients", "with", "acute", "myocardial", "infarction", ".", "Nitroglycerin", "has", "been", "shown", "to", "reduce", "ST", "-", "segment", "elevation", "during", "acute", "myocardial", "infarction", ",", "an", "effect", "potentiated", "in", "the", "dog", "by", "agents", "that", "reverse", "nitroglycerin", "-", "induced", "hypotension", ".", "Our", "study", "was", "designed", "to", "determine", "the", "effects", "of", "combined", "nitroglycerin", "and", "phenylephrine", "therapy", ".", "Ten", "patients", "with", "acute", "transmural", "myocardial", "infarctions", "received", "intravenous", "nitroglycerin", ",", "sufficient", "to", "reduce", "mean", "arterial", "pressure", "from", "107", "+", "/", "-", "6", "to", "85", "+", "/", "-", "6", "mm", "Hg", "(", "P", "less", "than", "0", ".", "001", ")", ",", "for", "60", "minutes", ".", "Left", "ventricular", "filling", "pressure", "decreased", "from", "19", "+", "/", "-", "2", "to", "11", "+", "/", "-", "2", "mm", "Hg", "(", "P", "less", "than", "0", ".", "001", ")", ".", "SigmaST", ",", "the", "sum", "of", "ST", "-", "segment", "elevations", "in", "16", "precordial", "leads", ",", "decreased", "(", "P", "less", "than", "0", ".", "02", ")", "with", "intravenous", "nitroglycerin", ".", "Subsequent", "addition", "of", "phenylephrine", "infusion", ",", "sufficient", "to", "re", "-", "elevate", "mean", "arterial", "pressure", "to", "106", "+", "/", "-", "4", "mm", "Hg", "(", "P", "less", "than", "0", ".", "001", ")", "for", "30", "minutes", ",", "increased", "left", "ventricular", "filling", "pressure", "to", "17", "+", "/", "-", "2", "mm", "Hg", "(", "P", "less", "than", "0", ".", "05", ")", "and", "also", "significantly", "increased", "sigmaST", "(", "P", "less", "than", "0", ".", "05", ")", ".", "Our", "results", "suggest", "that", "addition", "of", "phenylephrine", "to", "nitroglycerin", "is", "not", "beneficial", "in", "the", "treatment", "of", "patients", "with", "acute", "myocardial", "infarction", "."]], "ner": [[[9, 9, "Chemical"], [17, 17, "Chemical"], [42, 42, "Chemical"], [57, 57, "Chemical"], [71, 71, "Chemical"], [159, 159, "Chemical"], [238, 238, "Chemical"], [45, 45, "Disease"], [2, 2, "Chemical"], [59, 59, "Chemical"], [164, 164, "Chemical"], [236, 236, "Chemical"], [13, 15, "Disease"], [28, 30, "Disease"], [67, 68, "Disease"], [248, 250, "Disease"]]], "relations": [[[9, 9, 45, 45, "CID"], [17, 17, 45, 45, "CID"], [42, 42, 45, 45, "CID"], [57, 57, 45, 45, "CID"], [71, 71, 45, 45, "CID"], [159, 159, 45, 45, "CID"], [238, 238, 45, 45, "CID"]]], "clusters": [], "translated": "<8>去氧肾上腺素</8> 逆转静脉注射 <0>硝酸甘油</0> 对 <12>急性心肌梗死</12> 患者的有益作用。 <1>硝酸甘油</1> 已被证明可降低 <13>急性心肌梗死</13> 期间的 ST 段抬高，这种作用在犬中被逆转 <2>硝酸甘油</2>诱导的<7>低血压</7> 。我们的研究旨在确定<3>硝酸甘油</3>和<9>去氧肾上腺素</9>联合治疗的效果。 10 名急性透壁性<14>心肌梗死</14>患者接受了静脉注射 <4>硝酸甘油</4>，足以将平均动脉压从 107 +/- 6 降低至 85 +/- 6 mm Hg（P 小于 0.001) ，持续 60 分钟。左心室充盈压从 19 +/- 2 降低到 11 +/- 2 mm Hg （P 小于 0.001） 。SigmaST，即 16 个胸前导联 ST 段升高的总和，在静脉注射 <5>硝酸甘油</5> 后下降（P 小于 0.02）。随后加入 <10>去氧肾上腺素</10> 输注，足以将平均动脉压重新升高至 106 + / - 4 mm Hg（P 小于 0.001） 30 分钟，左心室充盈压增加至 17 + / - 2 毫米汞柱（P 小于 0.05）并且 SigmaST 也显着增加（P 小于0.05）。我们的结果表明，<6>硝酸甘油</6>中加入<11>去氧肾上腺素</11>对<15>急性心肌梗死</15> 患者的治疗无益处。", "revised": true}
{"doc_key": "19387625", "sentences": [["Attentional", "modulation", "of", "perceived", "pain", "intensity", "in", "capsaicin", "-", "induced", "secondary", "hyperalgesia", ".", "Perceived", "pain", "intensity", "is", "modulated", "by", "attention", ".", "However", ",", "it", "is", "not", "known", "that", "how", "pain", "intensity", "ratings", "are", "affected", "by", "attention", "in", "capsaicin", "-", "induced", "secondary", "hyperalgesia", ".", "Here", "we", "show", "that", "perceived", "pain", "intensity", "in", "secondary", "hyperalgesia", "is", "decreased", "when", "attention", "is", "distracted", "away", "from", "the", "painful", "pinprick", "stimulus", "with", "a", "visual", "task", ".", "Furthermore", ",", "it", "was", "found", "that", "the", "magnitude", "of", "attentional", "modulation", "in", "secondary", "hyperalgesia", "is", "very", "similar", "to", "that", "of", "capsaicin", "-", "untreated", ",", "control", "condition", ".", "Our", "findings", ",", "showing", "no", "interaction", "between", "capsaicin", "treatment", "and", "attentional", "modulation", "suggest", "that", "capsaicin", "-", "induced", "secondary", "hyperalgesia", "and", "attention", "might", "affect", "mechanical", "pain", "through", "independent", "mechanisms", "."]], "ner": [[[7, 7, "Chemical"], [37, 37, "Chemical"], [90, 90, "Chemical"], [104, 104, "Chemical"], [111, 111, "Chemical"], [11, 11, "Disease"], [41, 41, "Disease"], [52, 52, "Disease"], [83, 83, "Disease"], [115, 115, "Disease"], [4, 4, "Disease"], [14, 14, "Disease"], [29, 29, "Disease"], [48, 48, "Disease"], [121, 121, "Disease"]]], "relations": [[[7, 7, 11, 11, "CID"], [7, 7, 41, 41, "CID"], [7, 7, 52, 52, "CID"], [7, 7, 83, 83, "CID"], [7, 7, 115, 115, "CID"], [37, 37, 11, 11, "CID"], [37, 37, 41, 41, "CID"], [37, 37, 52, 52, "CID"], [37, 37, 83, 83, "CID"], [37, 37, 115, 115, "CID"], [90, 90, 11, 11, "CID"], [90, 90, 41, 41, "CID"], [90, 90, 52, 52, "CID"], [90, 90, 83, 83, "CID"], [90, 90, 115, 115, "CID"], [104, 104, 11, 11, "CID"], [104, 104, 41, 41, "CID"], [104, 104, 52, 52, "CID"], [104, 104, 83, 83, "CID"], [104, 104, 115, 115, "CID"], [111, 111, 11, 11, "CID"], [111, 111, 41, 41, "CID"], [111, 111, 52, 52, "CID"], [111, 111, 83, 83, "CID"], [111, 111, 115, 115, "CID"]]], "clusters": [], "translated": "<0>辣椒素</0>诱导的继发性<5>痛觉过敏</5>中感知<10>疼痛</10>强度的注意力调节。感知到的<11>疼痛</11>强度受注意力调节。然而，在<1>辣椒素</1>诱发的继发性<6>痛觉过敏</6>中，注意力如何影响<12>疼痛</12>强度等级尚不清楚。在这里，我们表明当注意力从疼痛针刺刺激转移开时，继发性<7>痛觉过敏</7>中感知到的<13>疼痛</13>强度会降低。此外，还发现<2>辣椒素</2>未处理的对照条件下，继发性<8>痛觉过敏</8>的注意力调节幅度非常相似。我们的研究结果表明，<3>辣椒素</3>治疗与注意力调节之间没有相互作用，这表明<4>辣椒素</4>诱导的继发性<9>痛觉过敏</9>和注意力可能通过独立机制影响机械性<14>疼痛</14>。", "revised": true}
{"doc_key": "17242861", "sentences": [["Use", "of", "chromosome", "substitution", "strains", "to", "identify", "seizure", "susceptibility", "loci", "in", "mice", ".", "Seizure", "susceptibility", "varies", "among", "inbred", "mouse", "strains", ".", "Chromosome", "substitution", "strains", "(", "CSS", ")", ",", "in", "which", "a", "single", "chromosome", "from", "one", "inbred", "strain", "(", "donor", ")", "has", "been", "transferred", "onto", "a", "second", "strain", "(", "host", ")", "by", "repeated", "backcrossing", ",", "may", "be", "used", "to", "identify", "quantitative", "trait", "loci", "(", "QTLs", ")", "that", "contribute", "to", "seizure", "susceptibility", ".", "QTLs", "for", "susceptibility", "to", "pilocarpine", "-", "induced", "seizures", ",", "a", "model", "of", "temporal", "lobe", "epilepsy", ",", "have", "not", "been", "reported", ",", "and", "CSS", "have", "not", "previously", "been", "used", "to", "localize", "seizure", "susceptibility", "genes", ".", "We", "report", "QTLs", "identified", "using", "a", "B6", "(", "host", ")", "x", "A", "/", "J", "(", "donor", ")", "CSS", "panel", "to", "localize", "genes", "involved", "in", "susceptibility", "to", "pilocarpine", "-", "induced", "seizures", ".", "Three", "hundred", "fifty", "-", "five", "adult", "male", "CSS", "mice", ",", "58", "B6", ",", "and", "39", "A", "/", "J", "were", "tested", "for", "susceptibility", "to", "pilocarpine", "-", "induced", "seizures", ".", "Highest", "stage", "reached", "and", "latency", "to", "each", "stage", "were", "recorded", "for", "all", "mice", ".", "B6", "mice", "were", "resistant", "to", "seizures", "and", "slower", "to", "reach", "stages", "compared", "to", "A", "/", "J", "mice", ".", "The", "CSS", "for", "Chromosomes", "10", "and", "18", "progressed", "to", "the", "most", "severe", "stages", ",", "diverging", "dramatically", "from", "the", "B6", "phenotype", ".", "Latencies", "to", "stages", "were", "also", "significantly", "shorter", "for", "CSS10", "and", "CSS18", "mice", ".", "CSS", "mapping", "suggests", "seizure", "susceptibility", "loci", "on", "mouse", "Chromosomes", "10", "and", "18", ".", "This", "approach", "provides", "a", "framework", "for", "identifying", "potentially", "novel", "homologous", "candidate", "genes", "for", "human", "temporal", "lobe", "epilepsy", "."]], "ner": [[[75, 75, "Chemical"], [131, 131, "Chemical"], [159, 159, "Chemical"], [83, 85, "Disease"], [257, 259, "Disease"], [7, 7, "Disease"], [13, 13, "Disease"], [68, 68, "Disease"], [78, 78, "Disease"], [101, 101, "Disease"], [134, 134, "Disease"], [162, 162, "Disease"], [183, 183, "Disease"], [233, 233, "Disease"]]], "relations": [[[75, 75, 83, 85, "CID"], [75, 75, 257, 259, "CID"], [131, 131, 83, 85, "CID"], [131, 131, 257, 259, "CID"], [159, 159, 83, 85, "CID"], [159, 159, 257, 259, "CID"]]], "clusters": [], "translated": "使用染色体替代品系鉴定小鼠<5>癫痫发作</5>易感位点。<6>癫痫发作</6>易感性因近交系小鼠品系而异。染色体替代品系(CSS)，其中一个近交品系(供体)的单个染色体通过重复回交转移到第二个品系(宿主)，可用于鉴定有助于<7>癫痫发作</7>易感性的数量性状位点(QTL)。对<0>毛果芸香碱</0>诱导的<8>癫痫发作</8>(<3>颞叶癫痫</3>模型)易感性的QTL尚未见报道，并且CSS以前也未用于定位<9>癫痫发作</9>易感基因。我们报告了使用B6(宿主)x A/J(供体) CSS panel鉴定的QTL，以定位参与对<1>毛果芸香碱</1>诱导的<10>癫痫发作</10>易感性的基因。测试了355只成年雄性CSS小鼠、58只B6和39只A/J对<2>毛果芸香碱</2>诱导的<11>癫痫发作</11>的敏感性。记录所有小鼠除到达的最高阶段和每个阶段的潜伏期。与A/J小鼠相比，B6小鼠对<12>癫痫发作有抵抗力</12>，并且达到阶段的速度较慢。10号和18号染色体的CSS发展到最严重的阶段，与B6表型显着不同。CSS10和CSS18小鼠的阶段延迟也显著缩短。CSS映射表明小鼠10号和18号染色体上的<13>癫痫发作</13>易感位点。这种方法提供了一个框架，用于识别人类<4>颞叶癫痫</4>的潜在新型同源候选基因。", "revised": true}
{"doc_key": "18162529", "sentences": [["Hypothalamic", "prolactin", "receptor", "messenger", "ribonucleic", "acid", "levels", ",", "prolactin", "signaling", ",", "and", "hyperprolactinemic", "inhibition", "of", "pulsatile", "luteinizing", "hormone", "secretion", "are", "dependent", "on", "estradiol", ".", "Hyperprolactinemia", "can", "reduce", "fertility", "and", "libido", ".", "Although", "central", "prolactin", "actions", "are", "thought", "to", "contribute", "to", "this", ",", "the", "mechanisms", "are", "poorly", "understood", ".", "We", "first", "tested", "whether", "chronic", "hyperprolactinemia", "inhibited", "two", "neuroendocrine", "parameters", "necessary", "for", "female", "fertility", ":", "pulsatile", "LH", "secretion", "and", "the", "estrogen", "-", "induced", "LH", "surge", ".", "Chronic", "hyperprolactinemia", "induced", "by", "the", "dopamine", "antagonist", "sulpiride", "caused", "a", "40", "%", "reduction", "LH", "pulse", "frequency", "in", "ovariectomized", "rats", ",", "but", "only", "in", "the", "presence", "of", "chronic", "low", "levels", "of", "estradiol", ".", "Sulpiride", "did", "not", "affect", "the", "magnitude", "of", "a", "steroid", "-", "induced", "LH", "surge", "or", "the", "percentage", "of", "GnRH", "neurons", "activated", "during", "the", "surge", ".", "Estradiol", "is", "known", "to", "influence", "expression", "of", "the", "long", "form", "of", "prolactin", "receptors", "(", "PRL", "-", "R", ")", "and", "components", "of", "prolactin", "'s", "signaling", "pathway", ".", "To", "test", "the", "hypothesis", "that", "estrogen", "increases", "PRL", "-", "R", "expression", "and", "sensitivity", "to", "prolactin", ",", "we", "next", "demonstrated", "that", "estradiol", "greatly", "augments", "prolactin", "-", "induced", "STAT5", "activation", ".", "Lastly", ",", "we", "measured", "PRL", "-", "R", "and", "suppressor", "of", "cytokine", "signaling", "(", "SOCS", "-", "1", "and", "-", "3", "and", "CIS", ",", "which", "reflect", "the", "level", "of", "prolactin", "signaling", ")", "mRNAs", "in", "response", "to", "sulpiride", "and", "estradiol", ".", "Sulpiride", "induced", "only", "SOCS", "-", "1", "in", "the", "medial", "preoptic", "area", ",", "where", "GnRH", "neurons", "are", "regulated", ",", "but", "in", "the", "arcuate", "nucleus", "and", "choroid", "plexus", ",", "PRL", "-", "R", ",", "SOCS", "-", "3", ",", "and", "CIS", "mRNA", "levels", "were", "also", "induced", ".", "Estradiol", "enhanced", "these", "effects", "on", "SOCS", "-", "3", "and", "CIS", ".", "Interestingly", ",", "estradiol", "also", "induced", "PRL", "-", "R", ",", "SOCS", "-", "3", ",", "and", "CIS", "mRNA", "levels", "independently", ".", "These", "data", "show", "that", "GnRH", "pulse", "frequency", "is", "inhibited", "by", "chronic", "hyperprolactinemia", "in", "a", "steroid", "-", "dependent", "manner", ".", "They", "also", "provide", "evidence", "for", "estradiol", "-", "dependent", "and", "brain", "region", "-", "specific", "regulation", "of", "PRL", "-", "R", "expression", "and", "signaling", "responses", "by", "prolactin", "."]], "ner": [[[81, 81, "Chemical"], [106, 106, "Chemical"], [219, 219, "Chemical"], [223, 223, "Chemical"], [12, 12, "Disease"], [24, 24, "Disease"], [53, 53, "Disease"], [75, 75, "Disease"], [307, 307, "Disease"], [4, 5, "Chemical"], [22, 22, "Chemical"], [104, 104, "Chemical"], [130, 130, "Chemical"], [176, 176, "Chemical"], [221, 221, "Chemical"], [266, 266, "Chemical"], [279, 279, "Chemical"], [320, 320, "Chemical"], [68, 68, "Chemical"], [161, 161, "Chemical"], [79, 79, "Chemical"], [114, 114, "Chemical"], [310, 310, "Chemical"]]], "relations": [[[81, 81, 12, 12, "CID"], [81, 81, 24, 24, "CID"], [81, 81, 53, 53, "CID"], [81, 81, 75, 75, "CID"], [81, 81, 307, 307, "CID"], [106, 106, 12, 12, "CID"], [106, 106, 24, 24, "CID"], [106, 106, 53, 53, "CID"], [106, 106, 75, 75, "CID"], [106, 106, 307, 307, "CID"], [219, 219, 12, 12, "CID"], [219, 219, 24, 24, "CID"], [219, 219, 53, 53, "CID"], [219, 219, 75, 75, "CID"], [219, 219, 307, 307, "CID"], [223, 223, 12, 12, "CID"], [223, 223, 24, 24, "CID"], [223, 223, 53, 53, "CID"], [223, 223, 75, 75, "CID"], [223, 223, 307, 307, "CID"]]], "clusters": [], "translated": "下丘脑催乳素受体信使<9>核糖核酸</9>水平、催乳素信号和<4>高催乳素血症</4>抑制脉动性黄体生成素分泌均依赖于<10>雌二醇</10>。<5>高催乳素血症</5>可降低生育能力和性欲。虽然中枢催乳激素作用被认为对此有贡献，但其机制却知之甚少。我们首先测试了慢性<6>高泌乳素血症</6>是否会抑制女性生育所必需的两个神经内分泌参数：脉动性LH分泌和<18>雌激素</18>诱导的LH激增。由<20>多巴胺</20>拮抗剂<0>舒必利</0>诱导的慢性<7>高泌乳素血症</7>导致去卵巢大鼠的LH脉冲频率降低40%，但仅在慢性低水平<11>雌二醇</11>存在时。 <1>舒必利</1>不影响<21>类固醇</21>诱导的LH激增的幅度或激增期间激活的GnRH神经元的百分比 。<12>雌二醇</12>已知会影响长型催乳素受体(PRL-R)和催乳素信号通路成分的表达。为了验证<19>雌激素</19>增加PRL-R表达和对催乳素敏感性的假设，我们接下来证明<13>雌二醇</13>大大增强了催乳素诱导的STAT5激活。最后，我们测量了响应<2>舒必利</2>和<14>雌二醇</14>的PRL-R和细胞因子信号转导抑制因子(SOCS-1和-3和CIS，反映催乳素信号转导水平)mRNAs。 <3>舒必利</3>仅在受GnRH神经元调节的内侧视前区诱导SOCS-1，但在弓状核和脉络丛中也诱导PRL-R、SOCS-3和CIS mRNA水平 。<15>雌二醇</15>增强了对<16>雌二醇</16>诱导PRL-R、SOCS-3和CIS mRNA水平的这些影响 。这些数据表明，慢性<8>高催乳素血症</8>以<22>类固醇</22>依赖性方式抑制GnRH脉冲频率。它们还为催乳素对PRL-R表达和信号反应的<17>雌二醇</17>依赖性和脑区特异性调节提供了证据。", "revised": true}
{"doc_key": "7890216", "sentences": [["Composition", "of", "gall", "bladder", "stones", "associated", "with", "octreotide", ":", "response", "to", "oral", "ursodeoxycholic", "acid", ".", "Octreotide", ",", "an", "effective", "treatment", "for", "acromegaly", ",", "induces", "gall", "bladder", "stones", "in", "13", "-", "60", "%", "of", "patients", ".", "Because", "knowledge", "of", "stone", "composition", "is", "essential", "for", "studies", "of", "their", "pathogenesis", ",", "treatment", ",", "and", "prevention", ",", "this", "was", "investigated", "by", "direct", "and", "indirect", "methods", "in", "14", "octreotide", "treated", "acromegalic", "patients", "with", "gall", "stones", ".", "Chemical", "analysis", "of", "gall", "stones", "retrieved", "at", "cholecystectomy", "from", "two", "patients", ",", "showed", "that", "they", "contained", "71", "%", "and", "87", "%", "cholesterol", "by", "weight", ".", "In", "the", "remaining", "12", "patients", ",", "localised", "computed", "tomography", "of", "the", "gall", "bladder", "showed", "that", "eight", "had", "stones", "with", "maximum", "attenuation", "scores", "of", "<", "100", "Hounsfield", "units", "(", "values", "of", "<", "100", "HU", "predict", "cholesterol", "rich", ",", "dissolvable", "stones", ")", ".", "Gall", "bladder", "bile", "was", "obtained", "by", "ultrasound", "guided", ",", "fine", "needle", "puncture", "from", "six", "patients", ".", "All", "six", "patients", "had", "supersaturated", "bile", "(", "mean", "(", "SEM", ")", "cholesterol", "saturation", "index", "of", "1", ".", "19", "(", "0", ".", "08", ")", "(", "range", "1", ".", "01", "-", "1", ".", "53", ")", ")", "and", "all", "had", "abnormally", "rapid", "cholesterol", "microcrystal", "nucleation", "times", "(", "<", "4", "days", "(", "range", "1", "-", "4", ")", ")", ",", "whilst", "in", "four", ",", "the", "bile", "contained", "cholesterol", "microcrystals", "immediately", "after", "sampling", ".", "Of", "the", "12", "patients", "considered", "for", "oral", "ursodeoxycholic", "acid", "(", "UDCA", ")", "treatment", ",", "two", "had", "a", "blocked", "cystic", "duct", "and", "were", "not", "started", "on", "UDCA", "while", "one", "was", "lost", "to", "follow", "up", ".", "After", "one", "year", "of", "treatment", ",", "five", "of", "the", "remaining", "nine", "patients", "showed", "either", "partial", "(", "n", "=", "3", ")", "or", "complete", "(", "n", "=", "2", ")", "gall", "stone", "dissolution", ",", "suggesting", "that", "their", "stones", "were", "cholesterol", "rich", ".", "This", "corresponds", ",", "by", "actuarial", "(", "life", "table", ")", "analysis", ",", "to", "a", "combined", "gall", "stone", "dissolution", "rate", "of", "58", ".", "3", "(", "15", ".", "9", "%", ")", ".", "In", "conclusion", ",", "octreotide", "induced", "gall", "stones", "are", "generally", "small", ",", "multiple", ",", "and", "cholesterol", "rich", "although", ",", "in", "common", "with", "spontaneous", "gall", "stone", "disease", ",", "at", "presentation", "some", "patients", "will", "have", "a", "blocked", "cystic", "duct", "and", "some", "gall", "stones", "containing", "calcium", "."]], "ner": [[[7, 7, "Chemical"], [15, 15, "Chemical"], [63, 63, "Chemical"], [326, 326, "Chemical"], [2, 4, "Disease"], [24, 26, "Disease"], [68, 69, "Disease"], [74, 75, "Disease"], [282, 283, "Disease"], [308, 309, "Disease"], [328, 329, "Disease"], [345, 347, "Disease"], [361, 362, "Disease"], [12, 13, "Chemical"], [228, 229, "Chemical"], [231, 231, "Chemical"], [246, 246, "Chemical"], [92, 92, "Chemical"], [130, 130, "Chemical"], [164, 164, "Chemical"], [192, 192, "Chemical"], [215, 215, "Chemical"], [291, 291, "Chemical"], [337, 337, "Chemical"], [364, 364, "Chemical"], [21, 21, "Disease"], [65, 65, "Disease"]]], "relations": [[[7, 7, 2, 4, "CID"], [7, 7, 24, 26, "CID"], [7, 7, 68, 69, "CID"], [7, 7, 74, 75, "CID"], [7, 7, 282, 283, "CID"], [7, 7, 308, 309, "CID"], [7, 7, 328, 329, "CID"], [7, 7, 345, 347, "CID"], [7, 7, 361, 362, "CID"], [15, 15, 2, 4, "CID"], [15, 15, 24, 26, "CID"], [15, 15, 68, 69, "CID"], [15, 15, 74, 75, "CID"], [15, 15, 282, 283, "CID"], [15, 15, 308, 309, "CID"], [15, 15, 328, 329, "CID"], [15, 15, 345, 347, "CID"], [15, 15, 361, 362, "CID"], [63, 63, 2, 4, "CID"], [63, 63, 24, 26, "CID"], [63, 63, 68, 69, "CID"], [63, 63, 74, 75, "CID"], [63, 63, 282, 283, "CID"], [63, 63, 308, 309, "CID"], [63, 63, 328, 329, "CID"], [63, 63, 345, 347, "CID"], [63, 63, 361, 362, "CID"], [326, 326, 2, 4, "CID"], [326, 326, 24, 26, "CID"], [326, 326, 68, 69, "CID"], [326, 326, 74, 75, "CID"], [326, 326, 282, 283, "CID"], [326, 326, 308, 309, "CID"], [326, 326, 328, 329, "CID"], [326, 326, 345, 347, "CID"], [326, 326, 361, 362, "CID"]]], "clusters": [], "translated": "与<0>奥曲肽</0>相关的<4>胆囊结石</4>的组成：对口服<13>熊去氧胆酸</13>的反应。 <1>奥曲肽</1>是<25>肢端肥大症</25>的有效治疗方法，可在 13-60% 的患者中诱发<5>胆囊结石</5>。由于结石成分的知识对于研究其发病机制、治疗和预防至关重要，因此通过直接和间接方法对 14 名<2>奥曲肽</2> 治疗<26>肢端肥大症</26>患者进行了调查<6>胆结石</6>。对在胆囊切除术中从两名患者身上取出的<7>胆结石</7>进行的化学分析表明，按重量计，它们含有 71%和87%的<17>胆固醇</17>。在其余 12 名患者中，胆囊的局部计算机断层扫描显示有 8 名患者的结石的最大衰减值小于 100 亨斯菲尔德单位（小于 100 HU 的值预示着富含<18>胆固醇</18>的可溶性结石）。胆囊胆汁是通过超声引导下的细针穿刺从六名患者身上获得的。所有六名患者的胆汁都过饱和（平均 (SEM)<19>胆固醇</19>饱和指数为 1.19(0.08)（范围 1.01-1.53））,并且所有患者的<20>胆固醇微晶成核时间异常快速</20>（<4 天（范围 1-4））,而在四个样品中，胆汁在取样后立即含有<21>胆固醇</21>微晶。在考虑口服<14>熊去氧胆酸</14>（<15>UDCA</15>）治疗的 12 名患者中，2 名患有胆囊管阻塞，未开始接受<16>UDCA</16>，而 1 名是失去了跟进。经过一年的治疗，其余九名患者中有五名表现出部分(n=3)或完全(n=2)<8>胆结石</8>溶解，表明他们的结石是<22>胆固醇</22>丰富。根据精算（生命表）分析，这对应于 58.3(15.9%)的综合<9>胆结石</9>溶解率。总之，<3>奥曲肽</3>诱发的<10>胆结石</10>通常体积小、多发且富含<23>胆固醇</23>，但与自发性<11>胆结石病</11>不同，在就诊时，一些患者会出现胆囊管阻塞和一些<12>胆结石</12>，其中含有<24>钙</24>。", "revised": true}
{"doc_key": "7292072", "sentences": [["Variant", "ventricular", "tachycardia", "in", "desipramine", "toxicity", ".", "We", "report", "a", "case", "of", "variant", "ventricular", "tachycardia", "induced", "by", "desipramine", "toxicity", ".", "Unusual", "features", "of", "the", "arrhythmia", "are", "repetitive", "group", "beating", ",", "progressive", "shortening", "of", "the", "R", "-", "R", "interval", ",", "progressive", "widening", "of", "the", "QRS", "complex", "with", "eventual", "failure", "of", "intraventricular", "conduction", ",", "and", "changes", "in", "direction", "of", "the", "QRS", "axis", ".", "Recognition", "of", "variant", "ventricular", "tachycardia", "is", "important", "because", "therapy", "differs", "from", "that", "of", "classic", "ventricular", "tachycardia", "."]], "ner": [[[4, 4, "Chemical"], [17, 17, "Chemical"], [1, 2, "Disease"], [13, 14, "Disease"], [64, 65, "Disease"], [75, 76, "Disease"], [5, 5, "Disease"], [18, 18, "Disease"], [24, 24, "Disease"]]], "relations": [[[4, 4, 1, 2, "CID"], [4, 4, 13, 14, "CID"], [4, 4, 64, 65, "CID"], [4, 4, 75, 76, "CID"], [17, 17, 1, 2, "CID"], [17, 17, 13, 14, "CID"], [17, 17, 64, 65, "CID"], [17, 17, 75, 76, "CID"]]], "clusters": [], "translated": "<0>地昔帕明</0><6>毒性</6>中的变异<2>室性心动过速</2>。我们报告了一例由<1>地昔帕明</1><7>毒性</7>引起的变异型<3>室性心动过速</3>。<8>心律失常</8>的不寻常特征是重复性群搏动，R-R间期进行性缩短，QRS波群进行性加宽并最终导致心室内传导失败，以及QRS轴方向改变。识别变异型<4>室性心动过速</4>很重要，因为治疗不同于经典<5>室性心动过速</5>。", "revised": true}
{"doc_key": "4027862", "sentences": [["Desipramine", "-", "induced", "delirium", "at", "\"", "subtherapeutic", "\"", "concentrations", ":", "a", "case", "report", ".", "An", "elderly", "patient", "treated", "with", "low", "dose", "Desipramine", "developed", "a", "delirium", "while", "her", "plasma", "level", "was", "in", "the", "\"", "subtherapeutic", "\"", "range", ".", "Delirium", ",", "which", "may", "be", "induced", "by", "tricyclic", "drug", "therapy", "in", "the", "elderly", ",", "can", "be", "caused", "by", "tricyclics", "with", "low", "anticholinergic", "potency", ".", "Therapeutic", "ranges", "for", "antidepressants", "that", "have", "been", "derived", "from", "general", "adult", "population", "studies", "may", "not", "be", "appropriate", "for", "the", "elderly", ".", "Further", "studies", "of", "specifically", "elderly", "patients", "are", "now", "required", "to", "establish", "safer", "and", "more", "appropriate", "guidelines", "for", "drug", "therapy", "."]], "ner": [[[0, 0, "Chemical"], [21, 21, "Chemical"], [3, 3, "Disease"], [24, 24, "Disease"], [37, 37, "Disease"], [64, 64, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 24, 24, "CID"], [0, 0, 37, 37, "CID"], [21, 21, 3, 3, "CID"], [21, 21, 24, 24, "CID"], [21, 21, 37, 37, "CID"]]], "clusters": [], "translated": " <0>地昔帕明</0> - 在“亚治疗”浓度下诱发<2>谵妄</2>：病例报告。一名接受低剂量<1>地昔帕明</1>治疗的老年患者出现了<3>谵妄</3>，而她的血浆水平处于“亚治疗”范围内。<4>谵妄</4>，可能由三环类药物治疗在老年人中诱发，可由抗胆碱能作用低的三环类药物引起。从一般成人人群研究中得出的<5>抗抑郁药</5>的治疗范围可能不适合老年人，现在需要对特定的老年患者进行进一步研究，以建立更安全、更合适的药物治疗指南。", "revised": true}
{"doc_key": "11875660", "sentences": [["Sequential", "observations", "of", "exencephaly", "and", "subsequent", "morphological", "changes", "by", "mouse", "exo", "utero", "development", "system", ":", "analysis", "of", "the", "mechanism", "of", "transformation", "from", "exencephaly", "to", "anencephaly", ".", "Anencephaly", "has", "been", "suggested", "to", "develop", "from", "exencephaly", ";", "however", ",", "there", "is", "little", "direct", "experimental", "evidence", "to", "support", "this", ",", "and", "the", "mechanism", "of", "transformation", "remains", "unclear", ".", "We", "examined", "this", "theory", "using", "the", "exo", "utero", "development", "system", "that", "allows", "direct", "and", "sequential", "observations", "of", "mid", "-", "to", "late", "-", "gestation", "mouse", "embryos", ".", "We", "observed", "the", "exencephaly", "induced", "by", "5", "-", "azacytidine", "at", "embryonic", "day", "13", ".", "5", "(", "E13", ".", "5", ")", ",", "let", "the", "embryos", "develop", "exo", "utero", "until", "E18", ".", "5", ",", "and", "re", "-", "observed", "the", "same", "embryos", "at", "E18", ".", "5", ".", "We", "confirmed", "several", "cases", "of", "transformation", "from", "exencephaly", "to", "anencephaly", ".", "However", ",", "in", "many", "cases", ",", "the", "exencephalic", "brain", "tissue", "was", "preserved", "with", "more", "or", "less", "reduction", "during", "this", "period", ".", "To", "analyze", "the", "transformation", "patterns", ",", "we", "classified", "the", "exencephaly", "by", "size", "and", "shape", "of", "the", "exencephalic", "tissue", "into", "several", "types", "at", "E13", ".", "5", "and", "E18", ".", "5", ".", "It", "was", "found", "that", "the", "transformation", "of", "exencephalic", "tissue", "was", "not", "simply", "size", "-", "dependent", ",", "and", "all", "cases", "of", "anencephaly", "at", "E18", ".", "5", "resulted", "from", "embryos", "with", "a", "large", "amount", "of", "exencephalic", "tissue", "at", "E13", ".", "5", ".", "Microscopic", "observation", "showed", "the", "configuration", "of", "exencephaly", "at", "E13", ".", "5", ",", "frequent", "hemorrhaging", "and", "detachment", "of", "the", "neural", "plate", "from", "surface", "ectoderm", "in", "the", "exencephalic", "head", "at", "E15", ".", "5", ",", "and", "multiple", "modes", "of", "reduction", "in", "the", "exencephalic", "tissue", "at", "E18", ".", "5", ".", "From", "observations", "of", "the", "vasculature", ",", "altered", "distribution", "patterns", "of", "vessels", "were", "identified", "in", "the", "exencephalic", "head", ".", "These", "findings", "suggest", "that", "overgrowth", "of", "the", "exencephalic", "neural", "tissue", "causes", "the", "altered", "distribution", "patterns", "of", "vessels", ",", "subsequent", "peripheral", "circulatory", "failure", "and", "/", "or", "hemorrhaging", "in", "various", "parts", "of", "the", "exencephalic", "head", ",", "leading", "to", "the", "multiple", "modes", "of", "tissue", "reduction", "during", "transformation", "from", "exencephaly", "to", "anencephaly", "."]], "ner": [[[87, 89, "Chemical"], [24, 24, "Disease"], [26, 26, "Disease"], [134, 134, "Disease"], [207, 207, "Disease"], [338, 338, "Disease"], [3, 3, "Disease"], [22, 22, "Disease"], [33, 33, "Disease"], [84, 84, "Disease"], [132, 132, "Disease"], [143, 143, "Disease"], [166, 166, "Disease"], [173, 173, "Disease"], [194, 194, "Disease"], [220, 220, "Disease"], [233, 233, "Disease"], [252, 252, "Disease"], [266, 266, "Disease"], [288, 288, "Disease"], [298, 298, "Disease"], [322, 322, "Disease"], [336, 336, "Disease"], [240, 240, "Disease"], [316, 316, "Disease"], [311, 312, "Disease"]]], "relations": [[[87, 89, 24, 24, "CID"], [87, 89, 26, 26, "CID"], [87, 89, 134, 134, "CID"], [87, 89, 207, 207, "CID"], [87, 89, 338, 338, "CID"]]], "clusters": [], "translated": "小鼠宫外发育系统<6>露脑</6>及后续形态学变化的连续观察：<7>露脑</7>向<1>无脑</1>转化机制分析。 <2>无脑</2>被认为是从<8>露脑</8>发展而来的；然而，几乎没有直接的实验证据支持这一点，转化机制仍不清楚。我们使用子宫外发育系统检验了这一理论，该系统允许对妊娠中期至晚期的小鼠胚胎进行直接和连续观察。我们在胚胎第13天观察到由<0>5-氮杂胞苷</0>诱导的<9>露脑</9>。在将胚胎培育到子宫外至E18.5并重新观察相同胚胎后，我们确认了几例<10>露脑</10>向<3>无脑畸形</3>的转化。但在很多情况下，<11>露脑</11>脑组织在此期间或多或少地有所减少。为了分析转化模式，我们在E13.5和E18.5分别根据 <13>露脑</13> 组织的大小和形状将<12>露脑</12>分为几种类型。结果发现，<14>露脑</14>组织的转化并非简单的大小依赖性，所有E18.5下的<4>无脑畸形</4>均来源于E13.5中<15>露脑</15>组织丰富的胚胎。显微镜观察显示E13.5下的<16>露脑</16>形态，E15.5下<17>露脑</17>头部神经板频繁<23>出血</23>和表层外胚层脱离，E18.5下的<18>露脑</18>组织多种减少模式。通过对脉管系统的观察，在<19>露脑</19>头部发现了改变的血管分布模式。这些发现表明，<20>露脑</20>神经组织的过度生长会导致血管分布模式改变，随后在各个部位出现外周<25>循环衰竭</25>和/或<24>出血</24>，从而导致<21>无脑畸形</21>头部在<22>露脑畸形</22>到<5>无脑畸形</5>转化过程中呈现多种组织减少模式。", "revised": true}
{"doc_key": "8701950", "sentences": [["Microangiopathic", "hemolytic", "anemia", "complicating", "FK506", "(", "tacrolimus", ")", "therapy", ".", "We", "describe", "3", "episodes", "of", "microangiopathic", "hemolytic", "anemia", "(", "MAHA", ")", "in", "2", "solid", "organ", "recipients", "under", "FK506", "(", "tacrolimus", ")", "therapy", ".", "In", "both", "cases", ",", "discontinuation", "of", "FK506", "and", "treatment", "with", "plasma", "exchange", ",", "fresh", "frozen", "plasma", "replacement", ",", "corticosteroids", ",", "aspirin", ",", "and", "dipyridamole", "led", "to", "resolution", "of", "MAHA", ".", "In", "one", "patient", ",", "reintroduction", "of", "FK506", "led", "to", "rapid", "recurrence", "of", "MAHA", ".", "FK506", "-", "associated", "MAHA", "is", "probably", "rare", "but", "physicians", "must", "be", "aware", "of", "this", "severe", "complication", ".", "In", "our", "experience", "and", "according", "to", "the", "literature", ",", "FK506", "does", "not", "seem", "to", "cross", "-", "react", "with", "cyclosporin", "A", "(", "CyA", ")", ",", "an", "immuno", "-", "suppressive", "drug", "already", "known", "to", "induce", "MAHA", "."]], "ner": [[[4, 4, "Chemical"], [6, 6, "Chemical"], [27, 27, "Chemical"], [29, 29, "Chemical"], [39, 39, "Chemical"], [69, 69, "Chemical"], [77, 77, "Chemical"], [103, 103, "Chemical"], [0, 2, "Disease"], [15, 17, "Disease"], [19, 19, "Disease"], [61, 61, "Disease"], [75, 75, "Disease"], [80, 80, "Disease"], [127, 127, "Disease"], [51, 51, "Chemical"], [53, 53, "Chemical"], [56, 56, "Chemical"], [112, 113, "Chemical"], [115, 115, "Chemical"]]], "relations": [[[4, 4, 0, 2, "CID"], [4, 4, 15, 17, "CID"], [4, 4, 19, 19, "CID"], [4, 4, 61, 61, "CID"], [4, 4, 75, 75, "CID"], [4, 4, 80, 80, "CID"], [4, 4, 127, 127, "CID"], [6, 6, 0, 2, "CID"], [6, 6, 15, 17, "CID"], [6, 6, 19, 19, "CID"], [6, 6, 61, 61, "CID"], [6, 6, 75, 75, "CID"], [6, 6, 80, 80, "CID"], [6, 6, 127, 127, "CID"], [27, 27, 0, 2, "CID"], [27, 27, 15, 17, "CID"], [27, 27, 19, 19, "CID"], [27, 27, 61, 61, "CID"], [27, 27, 75, 75, "CID"], [27, 27, 80, 80, "CID"], [27, 27, 127, 127, "CID"], [29, 29, 0, 2, "CID"], [29, 29, 15, 17, "CID"], [29, 29, 19, 19, "CID"], [29, 29, 61, 61, "CID"], [29, 29, 75, 75, "CID"], [29, 29, 80, 80, "CID"], [29, 29, 127, 127, "CID"], [39, 39, 0, 2, "CID"], [39, 39, 15, 17, "CID"], [39, 39, 19, 19, "CID"], [39, 39, 61, 61, "CID"], [39, 39, 75, 75, "CID"], [39, 39, 80, 80, "CID"], [39, 39, 127, 127, "CID"], [69, 69, 0, 2, "CID"], [69, 69, 15, 17, "CID"], [69, 69, 19, 19, "CID"], [69, 69, 61, 61, "CID"], [69, 69, 75, 75, "CID"], [69, 69, 80, 80, "CID"], [69, 69, 127, 127, "CID"], [77, 77, 0, 2, "CID"], [77, 77, 15, 17, "CID"], [77, 77, 19, 19, "CID"], [77, 77, 61, 61, "CID"], [77, 77, 75, 75, "CID"], [77, 77, 80, 80, "CID"], [77, 77, 127, 127, "CID"], [103, 103, 0, 2, "CID"], [103, 103, 15, 17, "CID"], [103, 103, 19, 19, "CID"], [103, 103, 61, 61, "CID"], [103, 103, 75, 75, "CID"], [103, 103, 80, 80, "CID"], [103, 103, 127, 127, "CID"]]], "clusters": [], "translated": "<8>微血管病性溶血性贫血</8>使<0>FK506</0>（<1>他克莫司</1>）治疗复杂化。我们描述了2名实体器官受者在<2> FK506 </2> ( <3> 他克莫司 </3> )治疗下发生的3次<9>微血管病性溶血性贫血</9> (<10>MAHA</10>)。在这两种情况下，停止使用<4>FK506</4>并进行血浆置换、新鲜冰冻血浆替代、<15>皮质类固醇</15>、<16>阿司匹林</16>和<17>双嘧达莫</17>导致了<11>MAHA</11>的决解。在一名患者中，重新引入<5>FK506</5>导致<12>MAHA</12>快速复发。<6> FK506 </6>相关的<13>MAHA </13>可能很少见，但医生必须意识到这种严重的并发症。根据我们的经验和文献，<7> FK506 </7> 似乎不会与<18>环孢菌素A</18> (<19>CyA</19>)发生交叉反应，后者是一种已知会引发<14>MAHA</14>的免疫抑制药物。", "revised": true}
{"doc_key": "17879945", "sentences": [["Estrogen", "prevents", "cholesteryl", "ester", "accumulation", "in", "macrophages", "induced", "by", "the", "HIV", "protease", "inhibitor", "ritonavir", ".", "Individuals", "with", "HIV", "can", "now", "live", "long", "lives", "with", "drug", "therapy", "that", "often", "includes", "protease", "inhibitors", "such", "as", "ritonavir", ".", "Many", "patients", ",", "however", ",", "develop", "negative", "long", "-", "term", "side", "effects", "such", "as", "premature", "atherosclerosis", ".", "We", "have", "previously", "demonstrated", "that", "ritonavir", "treatment", "increases", "atherosclerotic", "lesion", "formation", "in", "male", "mice", "to", "a", "greater", "extent", "than", "in", "female", "mice", ".", "Furthermore", ",", "peripheral", "blood", "monocytes", "isolated", "from", "ritonavir", "-", "treated", "females", "had", "less", "cholesteryl", "ester", "accumulation", ".", "In", "the", "present", "study", ",", "we", "have", "investigated", "the", "molecular", "mechanisms", "by", "which", "female", "hormones", "influence", "cholesterol", "metabolism", "in", "macrophages", "in", "response", "to", "the", "HIV", "protease", "inhibitor", "ritonavir", ".", "We", "have", "utilized", "the", "human", "monocyte", "cell", "line", ",", "THP", "-", "1", "as", "a", "model", "to", "address", "this", "question", ".", "Briefly", ",", "cells", "were", "differentiated", "for", "72", "h", "with", "100", "nM", "PMA", "to", "obtain", "a", "macrophage", "-", "like", "phenotype", "in", "the", "presence", "or", "absence", "of", "1", "nM", "17beta", "-", "estradiol", "(", "E2", ")", ",", "100", "nM", "progesterone", "or", "vehicle", "(", "0", ".", "01", "%", "ethanol", ")", ".", "Cells", "were", "then", "treated", "with", "30", "ng", "/", "ml", "ritonavir", "or", "vehicle", "in", "the", "presence", "of", "aggregated", "LDL", "for", "24", "h", ".", "Cell", "extracts", "were", "harvested", ",", "and", "lipid", "or", "total", "RNA", "was", "isolated", ".", "E2", "decreased", "the", "accumulation", "of", "cholesteryl", "esters", "in", "macrophages", "following", "ritonavir", "treatment", ".", "Ritonavir", "increased", "the", "expression", "of", "the", "scavenger", "receptor", ",", "CD36", "mRNA", ",", "responsible", "for", "the", "uptake", "of", "LDL", ".", "Additionally", ",", "ritonavir", "treatment", "selectively", "increased", "the", "relative", "levels", "of", "PPARgamma", "mRNA", ",", "a", "transcription", "factor", "responsible", "for", "the", "regulation", "of", "CD36", "mRNA", "expression", ".", "Treatment", "with", "E2", ",", "however", ",", "failed", "to", "prevent", "these", "increases", "at", "the", "mRNA", "level", ".", "E2", "did", ",", "however", ",", "significantly", "suppress", "CD36", "protein", "levels", "as", "measured", "by", "fluorescent", "immunocytochemistry", ".", "This", "data", "suggests", "that", "E2", "modifies", "the", "expression", "of", "CD36", "at", "the", "level", "of", "protein", "expression", "in", "monocyte", "-", "derived", "macrophages", "resulting", "in", "reduced", "cholesteryl", "ester", "accumulation", "following", "ritonavir", "treatment", "."]], "ner": [[[13, 13, "Chemical"], [33, 33, "Chemical"], [57, 57, "Chemical"], [82, 82, "Chemical"], [119, 119, "Chemical"], [197, 197, "Chemical"], [233, 233, "Chemical"], [236, 236, "Chemical"], [257, 257, "Chemical"], [340, 340, "Chemical"], [49, 50, "Disease"], [60, 61, "Disease"], [2, 3, "Chemical"], [88, 89, "Chemical"], [228, 229, "Chemical"], [336, 337, "Chemical"], [108, 108, "Chemical"], [168, 170, "Chemical"], [172, 172, "Chemical"], [223, 223, "Chemical"], [282, 282, "Chemical"], [296, 296, "Chemical"], [316, 316, "Chemical"], [177, 177, "Chemical"], [185, 185, "Chemical"]]], "relations": [[[13, 13, 49, 50, "CID"], [13, 13, 60, 61, "CID"], [33, 33, 49, 50, "CID"], [33, 33, 60, 61, "CID"], [57, 57, 49, 50, "CID"], [57, 57, 60, 61, "CID"], [82, 82, 49, 50, "CID"], [82, 82, 60, 61, "CID"], [119, 119, 49, 50, "CID"], [119, 119, 60, 61, "CID"], [197, 197, 49, 50, "CID"], [197, 197, 60, 61, "CID"], [233, 233, 49, 50, "CID"], [233, 233, 60, 61, "CID"], [236, 236, 49, 50, "CID"], [236, 236, 60, 61, "CID"], [257, 257, 49, 50, "CID"], [257, 257, 60, 61, "CID"], [340, 340, 49, 50, "CID"], [340, 340, 60, 61, "CID"]]], "clusters": [], "translated": "雌激素可防止 HIV 蛋白酶抑制剂<0>利托那韦</0>诱导的巨噬细胞中<12>胆固醇酯</12>积累。HIV感染者现在可以通过通常包括蛋白酶抑制剂（例如<1>利托那韦</1>）的药物疗法延长寿命。然而，许多患者会出现长期的负面副作用，例如<10>早发性动脉粥样硬化</10>。我们之前已经证明，<2>利托那韦</2>治疗在雄性小鼠中增加了<11>动脉粥样硬化病变</11>的形成，相比之下，雌性小鼠中增加较少。此外，从<3>利托那韦</3>治疗的女性中分离出的外周血单核细胞中，<13>胆固醇酯</13>积累更少。在本研究中，我们研究了女性荷尔蒙如何影响巨噬细胞响应HIV蛋白酶抑制剂<4>利托那韦</4>的<16>胆固醇</16>代谢的分子机制。我们利用人类单核细胞系 THP-1作为模型来解决这个问题。简言之，细胞在100 nM PMA 存在或不存在的情况下分化72小时，以获得类似于巨噬细胞的表型，并且在 1 nM<17>17beta-雌二醇</17>(<18>E2</18>)、100 nM<23>孕酮</23>或者载体（0.01%<24>乙醇</24>）的存在下处理。随后，在聚集的 LDL 存在下，用 30 ng/ml<5>利托那韦</5>或者载体处理细胞 24小时。接着，收集细胞提取物，分离脂质或者RNA。在<6>利托那韦</6>处理后，<19>E2</19>降低了巨噬细胞中<14>胆固醇酯</14>的积累。此外，<7>利托那韦</7>增加了清道夫受体CD36 mRNA的表达，负责摄取低密度脂蛋白。另外，<8>利托那韦</8>治疗选择性地增加了 PPARgamma mRNA 的相对水平，PPARgamma mRNA 是一种负责调节 CD36 mRNA 表达的转录因子。然而，<20>E2</20>处理未能阻止 mRNA 水平的这些增加。然而，<21>E2</21> 确实显着抑制了 CD36 蛋白水平，如荧光免疫细胞化学所测量的。该数据表明，<22>E2</22>通过降低蛋白质表达水平上修饰 CD36 的表达，在单核细胞来源的巨噬细胞中减少了<9>利托那韦</9>后 <15>胆固醇酯</15>的积累。", "revised": true}
{"doc_key": "2008831", "sentences": [["Effect", "of", "direct", "intracoronary", "administration", "of", "methylergonovine", "in", "patients", "with", "and", "without", "variant", "angina", ".", "The", "effects", "of", "intracoronary", "administration", "of", "methylergonovine", "were", "studied", "in", "21", "patients", "with", "variant", "angina", "and", "22", "patients", "with", "atypical", "chest", "pain", "and", "in", "others", "without", "angina", "pectoris", "(", "control", "group", ")", ".", "Methylergonovine", "was", "administered", "continuously", "at", "a", "rate", "of", "10", "micrograms", "/", "min", "up", "to", "50", "micrograms", ".", "In", "all", "patients", "with", "variant", "angina", ",", "coronary", "spasm", "was", "provoked", "at", "a", "mean", "dose", "of", "28", "+", "/", "-", "13", "micrograms", "(", "mean", "+", "/", "-", "SD", ")", ".", "In", "the", "control", "group", "neither", "ischemic", "ST", "change", "nor", "localized", "spasm", "occurred", ".", "The", "basal", "tone", "of", "the", "right", "coronary", "artery", "was", "significantly", "lower", "than", "that", "of", "the", "left", "coronary", "artery", ".", "The", "percentage", "of", "vasoconstriction", "of", "the", "right", "coronary", "artery", "was", "significantly", "higher", "than", "that", "of", "the", "left", "coronary", "artery", ".", "These", "results", "suggest", "that", "spasm", "provocation", "tests", ",", "which", "use", "an", "intracoronary", "injection", "of", "a", "relatively", "low", "dose", "of", "methylergonovine", ",", "have", "a", "high", "sensitivity", "in", "variant", "angina", "and", "the", "vasoreactivity", "of", "the", "right", "coronary", "artery", "may", "be", "greater", "than", "that", "of", "the", "other", "coronary", "arteries", "."]], "ner": [[[6, 6, "Chemical"], [21, 21, "Chemical"], [48, 48, "Chemical"], [166, 166, "Chemical"], [72, 73, "Disease"], [12, 13, "Disease"], [28, 29, "Disease"], [69, 70, "Disease"], [173, 174, "Disease"], [35, 36, "Disease"], [41, 42, "Disease"], [105, 105, "Disease"], [151, 151, "Disease"]]], "relations": [[[6, 6, 72, 73, "CID"], [21, 21, 72, 73, "CID"], [48, 48, 72, 73, "CID"], [166, 166, 72, 73, "CID"]]], "clusters": [], "translated": "<0>甲基麦角新碱</0> 对伴有和不伴有<5>变异型心绞痛</5>的患者的直接冠状动脉内给药的影响。在21名<6>变异性心绞痛</6>患者和22名非典型<9>胸痛</9>患者以及其他无<10>心绞痛</10>的患者中研究了<1>甲基麦角新碱</1>冠状动脉内给药的效果（对照组）。<2>甲基麦角新碱</2>以10微克/分钟的速度连续给药，直至50微克。在所有患有<7>变异性心绞痛</7>的患者中，<4>冠状动脉痉挛</4>是在平均剂量为28+/-13微克（平均+/-标准差）时引起的。对照组既没有出现缺血性ST段改变，也没有出现局部<11>痉挛</11>。右冠状动脉基音明显低于左冠状动脉。右冠状动脉血管收缩百分比明显高于左冠状动脉。这些结果表明，<12>痉挛</12>激发试验使用相对低剂量的<3>甲基麦角新碱</3>冠状动脉内注射，对<8>变异型心绞痛</8>和右冠状动脉的血管反应性可能大于其他冠状动脉。", "revised": true}
{"doc_key": "9746003", "sentences": [["Inappropriate", "use", "of", "carbamazepine", "and", "vigabatrin", "in", "typical", "absence", "seizures", ".", "Carbamazepine", "and", "vigabatrin", "are", "contraindicated", "in", "typical", "absence", "seizures", ".", "Of", "18", "consecutive", "referrals", "of", "children", "with", "resistant", "typical", "absences", "only", ",", "eight", "were", "erroneously", "treated", "with", "carbamazepine", "either", "as", "monotherapy", "or", "as", "an", "add", "-", "on", ".", "Vigabatrin", "was", "also", "used", "in", "the", "treatment", "of", "two", "children", ".", "Frequency", "of", "absences", "increased", "in", "four", "children", "treated", "with", "carbamazepine", "and", "two", "of", "these", "developed", "myoclonic", "jerks", ",", "which", "resolved", "on", "withdrawal", "of", "carbamazepine", ".", "Absences", "were", "aggravated", "in", "both", "cases", "where", "vigabatrin", "was", "added", "on", "to", "concurrent", "treatment", ".", "Optimal", "control", "of", "the", "absences", "was", "achieved", "with", "sodium", "valproate", ",", "lamotrigine", ",", "or", "ethosuximide", "alone", "or", "in", "combination", "."]], "ner": [[[3, 3, "Chemical"], [11, 11, "Chemical"], [38, 38, "Chemical"], [69, 69, "Chemical"], [83, 83, "Chemical"], [8, 9, "Disease"], [18, 19, "Disease"], [75, 76, "Disease"], [5, 5, "Chemical"], [13, 13, "Chemical"], [49, 49, "Chemical"], [92, 92, "Chemical"], [108, 109, "Chemical"], [111, 111, "Chemical"], [114, 114, "Chemical"]]], "relations": [[[3, 3, 8, 9, "CID"], [3, 3, 18, 19, "CID"], [11, 11, 8, 9, "CID"], [11, 11, 18, 19, "CID"], [38, 38, 8, 9, "CID"], [38, 38, 18, 19, "CID"], [69, 69, 8, 9, "CID"], [69, 69, 18, 19, "CID"], [83, 83, 8, 9, "CID"], [83, 83, 18, 19, "CID"], [3, 3, 75, 76, "CID"], [11, 11, 75, 76, "CID"], [38, 38, 75, 76, "CID"], [69, 69, 75, 76, "CID"], [83, 83, 75, 76, "CID"], [5, 5, 8, 9, "CID"], [5, 5, 18, 19, "CID"], [13, 13, 8, 9, "CID"], [13, 13, 18, 19, "CID"], [49, 49, 8, 9, "CID"], [49, 49, 18, 19, "CID"], [92, 92, 8, 9, "CID"], [92, 92, 18, 19, "CID"]]], "clusters": [], "translated": "在典型的<5>失神发作</5>中不恰当地使用<0>卡马西平</0>和<8>氨己烯酸</8>。<1>卡马西平</1>和<9>氨己烯酸</9>禁用于典型的<6>失神发作</6>。在连续转诊的18名仅具有顽固性典型失神的儿童中，有8名被错误地用<2>卡马西平</2>作为单一疗法或附加疗法进行治疗。<10>氨己烯酸</10>也被用于治疗两名儿童。接受<3>卡马西平</3>治疗的4名儿童缺席频率增加，其中2名出现<7>肌阵挛性抽搐</7>，在停用<4>卡马西平</4>后缓解。在将<11>氨己烯酸</11>添加到同步治疗中的两种情况下，缺席情况都加重了。单独或联合使用<12>丙戊酸钠</12>、<13>拉莫三嗪</13>或<14>乙琥胺</14>可实现对缺失的最佳控制。", "revised": true}
{"doc_key": "6203452", "sentences": [["Thrombotic", "microangiopathy", "and", "renal", "failure", "associated", "with", "antineoplastic", "chemotherapy", ".", "Five", "patients", "with", "carcinoma", "developed", "thrombotic", "microangiopathy", "(", "characterized", "by", "renal", "insufficiency", ",", "microangiopathic", "hemolytic", "anemia", ",", "and", "usually", "thrombocytopenia", ")", "after", "treatment", "with", "cisplatin", ",", "bleomycin", ",", "and", "a", "vinca", "alkaloid", ".", "One", "patient", "had", "thrombotic", "thrombocytopenic", "purpura", ",", "three", "the", "hemolytic", "-", "uremic", "syndrome", ",", "and", "one", "an", "apparent", "forme", "fruste", "of", "one", "of", "these", "disorders", ".", "Histologic", "examination", "of", "the", "renal", "tissue", "showed", "evidence", "of", "intravascular", "coagulation", ",", "primarily", "affecting", "the", "small", "arteries", ",", "arterioles", ",", "and", "glomeruli", ".", "Because", "each", "patient", "was", "tumor", "-", "free", "or", "had", "only", "a", "small", "tumor", "at", "the", "onset", "of", "this", "syndrome", ",", "the", "thrombotic", "microangiopathy", "may", "have", "been", "induced", "by", "chemotherapy", ".", "Diagnosis", "of", "this", "potentially", "fatal", "complication", "may", "be", "delayed", "or", "missed", "if", "renal", "tissue", "or", "the", "peripheral", "blood", "smear", "is", "not", "examined", ",", "because", "renal", "failure", "may", "be", "ascribed", "to", "cisplatin", "nephrotoxicity", "and", "the", "anemia", "and", "thrombocytopenia", "to", "drug", "-", "induced", "bone", "marrow", "suppression", "."]], "ner": [[[34, 34, "Chemical"], [152, 152, "Chemical"], [46, 48, "Disease"], [52, 55, "Disease"], [153, 153, "Disease"], [36, 36, "Chemical"], [40, 41, "Chemical"], [0, 1, "Disease"], [15, 16, "Disease"], [113, 114, "Disease"], [3, 4, "Disease"], [20, 21, "Disease"], [146, 147, "Disease"], [13, 13, "Disease"], [23, 25, "Disease"], [29, 29, "Disease"], [158, 158, "Disease"], [78, 79, "Disease"], [96, 96, "Disease"], [104, 104, "Disease"], [156, 156, "Disease"], [163, 165, "Disease"]]], "relations": [[[34, 34, 46, 48, "CID"], [152, 152, 46, 48, "CID"], [34, 34, 52, 55, "CID"], [152, 152, 52, 55, "CID"], [34, 34, 153, 153, "CID"], [152, 152, 153, 153, "CID"], [36, 36, 46, 48, "CID"], [36, 36, 52, 55, "CID"], [36, 36, 153, 153, "CID"], [40, 41, 46, 48, "CID"], [40, 41, 52, 55, "CID"], [40, 41, 153, 153, "CID"]]], "clusters": [], "translated": "<7>血栓性微血管病</7>和<10>肾功能衰竭</10>与抗肿瘤化疗有关。5例<13>癌症</13>患者发生了<8>血栓性微血管病</8>（其特征是<11> 肾功能不全</11>，<14>微血管病性溶血性贫血</14>，通常由<0>顺铂</0>、<5>博来霉素</5>和<6>长春花生物碱</6>治疗后<15>血小板减少症</15>）。一名患者患有<2>血栓性血小板减少性紫癜</2>，三名患者患有<3>溶血性尿毒症综合征</3>，一名患者患有其中一种疾病的明显变异形式。肾组织的组织学检查显示<17>血管内凝血</17>的证据，主要影响小动脉、小动脉和肾小球。因为每位患者在该综合征发作时都<18>没有肿瘤</18>或只有一个小的<19>肿瘤</19>，<9>血栓性微血管病</9>可能是由化疗引起的。如果不检查肾组织或外周血涂片，可能会延迟或漏诊这种潜在致命并发症的诊断，因为<12>肾功能衰竭</12>可能归因于<1>顺铂</1><4>肾毒性</4>，而<20>贫血</20>和<16>血小板减少</16>可能是由药物引起的<21>骨髓抑制</21>。", "revised": true}
{"doc_key": "2484011", "sentences": [["Mouse", "strain", "-", "dependent", "effect", "of", "amantadine", "on", "motility", "and", "brain", "biogenic", "amines", ".", "The", "effect", "of", "amantadine", "hydrochloride", ",", "injected", "i", ".", "p", ".", "in", "6", "increments", "of", "100", "mg", "/", "kg", "each", "over", "30", "hr", ",", "on", "mouse", "motility", "and", "whole", "brain", "content", "of", "selected", "biogenic", "amines", "and", "major", "metabolites", "was", "studied", "in", "4", "strains", "of", "mice", ".", "These", "were", "the", "albino", "Sprague", "-", "Dawley", "ICR", "and", "BALB", "/", "C", ",", "the", "black", "C57BL", "/", "6", "and", "the", "brown", "CDF", "-", "I", "mouse", "strains", ".", "Amantadine", "treatment", "produced", "a", "biphasic", "effect", "on", "mouse", "motility", ".", "The", "initial", "dose", "of", "amantadine", "depressed", "locomotor", "activity", "in", "all", "mouse", "strains", "studied", "with", "the", "BALB", "/", "C", "mice", "being", "the", "most", "sensitive", ".", "Subsequent", "amantadine", "treatments", "produced", "enhancement", "of", "motility", "from", "corresponding", "control", "in", "all", "mouse", "strains", "with", "the", "BALB", "/", "C", "mice", "being", "the", "least", "sensitive", ".", "The", "locomotor", "activity", "was", "decreased", "from", "corresponding", "controls", "in", "all", "strains", "studied", ",", "except", "for", "the", "ICR", "mice", ",", "during", "an", "overnight", "drug", "-", "free", "period", "following", "the", "fourth", "amantadine", "treatment", ".", "Readministration", "of", "amantadine", ",", "after", "a", "drug", "-", "free", "overnight", "period", ",", "increased", "motility", "from", "respective", "saline", "control", "in", "all", "strains", "with", "exception", "of", "the", "BALB", "/", "C", "mice", "where", "suppression", "of", "motility", "occurred", ".", "Treatment", "with", "amantadine", "did", "not", "alter", "whole", "brain", "dopamine", "levels", "but", "decreased", "the", "amounts", "of", "3", ",", "4", "-", "dihydroxyphenylacetic", "acid", "in", "the", "BALB", "/", "C", "mice", "compared", "to", "saline", "control", ".", "Conversely", ",", "brain", "normetanephrine", "concentration", "was", "increased", "from", "saline", "control", "by", "amantadine", "in", "the", "BALB", "/", "C", "mice", ".", "The", "results", "suggest", "a", "strain", "-", "dependent", "effect", "of", "amantadine", "on", "motility", "and", "indicate", "a", "differential", "response", "to", "the", "acute", "and", "multiple", "dose", "regimens", "used", ".", "The", "BALB", "/", "C", "mouse", "was", "the", "most", "sensitive", "strain", "and", "could", "serve", "as", "the", "strain", "of", "choice", "for", "evaluating", "the", "side", "effects", "of", "amantadine", ".", "The", "biochemical", "results", "of", "brain", "biogenic", "amines", "of", "BALB", "/", "C", "mouse", "strain", "suggest", "a", "probable", "decrease", "of", "catecholamine", "turnover", "rate", "and", "/", "or", "metabolism", "by", "monoamine", "oxidase", "and", "a", "resulting", "increase", "in", "O", "-", "methylation", "of", "norepinephrine", "which", "may", "account", "for", "a", "behavioral", "depression", "caused", "by", "amantadine", "in", "the", "BALB", "/", "C", "mice", "."]], "ner": [[[6, 6, "Chemical"], [17, 18, "Chemical"], [87, 87, "Chemical"], [101, 101, "Chemical"], [122, 122, "Chemical"], [175, 175, "Chemical"], [180, 180, "Chemical"], [215, 215, "Chemical"], [256, 256, "Chemical"], [273, 273, "Chemical"], [314, 314, "Chemical"], [363, 363, "Chemical"], [208, 210, "Disease"], [359, 360, "Disease"], [102, 102, "Disease"], [12, 12, "Chemical"], [48, 48, "Chemical"], [322, 322, "Chemical"], [221, 221, "Chemical"], [228, 233, "Chemical"], [248, 248, "Chemical"], [334, 334, "Chemical"], [353, 353, "Chemical"]]], "relations": [[[6, 6, 208, 210, "CID"], [6, 6, 359, 360, "CID"], [17, 18, 208, 210, "CID"], [17, 18, 359, 360, "CID"], [87, 87, 208, 210, "CID"], [87, 87, 359, 360, "CID"], [101, 101, 208, 210, "CID"], [101, 101, 359, 360, "CID"], [122, 122, 208, 210, "CID"], [122, 122, 359, 360, "CID"], [175, 175, 208, 210, "CID"], [175, 175, 359, 360, "CID"], [180, 180, 208, 210, "CID"], [180, 180, 359, 360, "CID"], [215, 215, 208, 210, "CID"], [215, 215, 359, 360, "CID"], [256, 256, 208, 210, "CID"], [256, 256, 359, 360, "CID"], [273, 273, 208, 210, "CID"], [273, 273, 359, 360, "CID"], [314, 314, 208, 210, "CID"], [314, 314, 359, 360, "CID"], [363, 363, 208, 210, "CID"], [363, 363, 359, 360, "CID"]]], "clusters": [], "translated": "<0>金刚烷胺</0> 对运动性和脑生物源性<15>胺</15>的小鼠品系依赖性影响。 <1>盐酸金刚烷胺</1>，i.p.在30小时内以6次100mg/kg的增量注射液的作用，研究了4种小鼠品系对小鼠运动性和全脑含量的选定生物<16>胺</16>和主要代谢物的影响。这些品系包括白化Sprague-Dawley ICR和BALB/C，黑色C57BL/6和棕色CDF-I小鼠。<2>金刚烷胺</2>处理对小鼠运动产生双相效应。初始剂量<3>金刚烷胺</3> <14>抑制</14>了所研究的所有小鼠品系的自发活动，其中BALB/C小鼠最为敏感。随后的<4>金刚烷胺</4>处理在所有小鼠品系中产生了相应对照的运动增强，其中BALB/C小鼠最不敏感。在第4次<5>金刚烷胺</5>治疗后的整夜无药期间，研究的所有品系的相应对照的运动活性均降低，ICR小鼠除外。经过一夜无药期后重新给药<6>金刚烷胺</6>，除BALB/C小鼠外，所有品系的相应盐水对照均增强了运动性，其中<12>抑制运动性</12>在BALB/C小鼠中发生。用<7>金刚烷胺</7>处理不会改变全脑<18>多巴胺</18>水平，但会减少BALB/C小鼠中<19> 3,4-二羟基苯乙酸 </19> 的含量。 BALB/C小鼠脑部<20>去甲肾上腺素</20>浓度在生理盐水控制下被<8>金刚烷胺</8>增加。结果表明<9>金刚烷胺</9>对运动的效应存在品系依赖性，并且表明对使用的急性和多剂量方案的反应不同。 BALB/C小鼠是最敏感的品系，并可作为评估<10>金刚烷胺</10>副作用的首选品系。 BALB/C小鼠品系脑部生物<17>胺</17> 的生化结果表明<21>儿茶酚胺</21>周转率和/或通过单胺氧化酶代谢可能降低，并导致<22>去甲肾上腺素</22>的O-甲基化增加，这可能是 BALB/C 小鼠中<11>金刚烷胺</11>引起的<13>行为抑郁</13>的原因。", "revised": true}
{"doc_key": "12707296", "sentences": [["L", "-", "arginine", "transport", "in", "humans", "with", "cortisol", "-", "induced", "hypertension", ".", "A", "deficient", "L", "-", "arginine", "-", "nitric", "oxide", "system", "is", "implicated", "in", "cortisol", "-", "induced", "hypertension", ".", "We", "investigate", "whether", "abnormalities", "in", "L", "-", "arginine", "uptake", "contribute", "to", "this", "deficiency", ".", "Eight", "healthy", "men", "were", "recruited", ".", "Hydrocortisone", "acetate", "(", "50", "mg", ")", "was", "given", "orally", "every", "6", "hours", "for", "24", "hours", "after", "a", "5", "-", "day", "fixed", "-", "salt", "diet", "(", "150", "mmol", "/", "d", ")", ".", "Crossover", "studies", "were", "performed", "2", "weeks", "apart", ".", "Thirty", "milliliters", "of", "blood", "was", "obtained", "for", "isolation", "of", "peripheral", "blood", "mononuclear", "cells", "after", "each", "treatment", "period", ".", "L", "-", "arginine", "uptake", "was", "assessed", "in", "mononuclear", "cells", "incubated", "with", "L", "-", "arginine", "(", "1", "to", "300", "micromol", "/", "L", ")", ",", "incorporating", "100", "nmol", "/", "L", "[", "3H", "]", "-", "l", "-", "arginine", "for", "a", "period", "of", "5", "minutes", "at", "37", "degrees", "C", ".", "Forearm", "[", "3H", "]", "-", "L", "-", "arginine", "extraction", "was", "calculated", "after", "infusion", "of", "[", "3H", "]", "-", "L", "-", "arginine", "into", "the", "brachial", "artery", "at", "a", "rate", "of", "100", "nCi", "/", "min", "for", "80", "minutes", ".", "Deep", "forearm", "venous", "samples", "were", "collected", "for", "determination", "of", "L", "-", "arginine", "extraction", ".", "Plasma", "cortisol", "concentrations", "were", "significantly", "raised", "during", "the", "active", "phase", "(", "323", "+", "/", "-", "43", "to", "1082", "+", "/", "-", "245", "mmol", "/", "L", ",", "P", "<", "0", ".", "05", ")", ".", "Systolic", "blood", "pressure", "was", "elevated", "by", "an", "average", "of", "7", "mm", "Hg", ".", "Neither", "L", "-", "arginine", "transport", "into", "mononuclear", "cells", "(", "placebo", "vs", "active", ",", "26", ".", "3", "+", "/", "-", "3", ".", "6", "vs", "29", ".", "0", "+", "/", "-", "2", ".", "1", "pmol", "/", "10", "000", "cells", "per", "5", "minutes", ",", "respectively", ",", "at", "an", "l", "-", "arginine", "concentration", "of", "300", "micromol", "/", "L", ")", "nor", "L", "-", "arginine", "extraction", "in", "the", "forearm", "(", "at", "80", "minutes", ",", "placebo", "vs", "active", ",", "1", "868", "904", "+", "/", "-", "434", "962", "vs", "2", "013", "910", "+", "/", "-", "770", "619", "disintegrations", "per", "minute", ")", "was", "affected", "by", "cortisol", "treatment", ";", "ie", ",", "that", "L", "-", "arginine", "uptake", "is", "not", "affected", "by", "short", "-", "term", "cortisol", "treatment", ".", "We", "conclude", "that", "cortisol", "-", "induced", "increases", "in", "blood", "pressure", "are", "not", "associated", "with", "abnormalities", "in", "the", "l", "-", "arginine", "transport", "system", "."]], "ner": [[[49, 50, "Chemical"], [10, 10, "Disease"], [27, 27, "Disease"], [371, 374, "Disease"], [0, 2, "Chemical"], [14, 16, "Chemical"], [34, 36, "Chemical"], [106, 108, "Chemical"], [117, 119, "Chemical"], [134, 140, "Chemical"], [153, 159, "Chemical"], [166, 172, "Chemical"], [198, 200, "Chemical"], [250, 252, "Chemical"], [294, 296, "Chemical"], [305, 307, "Chemical"], [351, 353, "Chemical"], [382, 384, "Chemical"], [7, 7, "Chemical"], [24, 24, "Chemical"], [204, 204, "Chemical"], [345, 345, "Chemical"], [362, 362, "Chemical"], [368, 368, "Chemical"], [18, 19, "Chemical"]]], "relations": [[[49, 50, 10, 10, "CID"], [49, 50, 27, 27, "CID"], [49, 50, 371, 374, "CID"]]], "clusters": [], "translated": " <4>L-精氨酸</4>在人体中的转运与<18>皮质醇</18>诱导的<1>高血压</1>。缺陷的<L-精氨酸<5></5>-<24>一氧化氮</24>系统与<19>皮质醇</19>诱发的<2>高血压</2>有关。我们调查了<6>L-精氨酸</6>摄取异常是否导致了这种缺陷。招募了八名健康男性。<0>醋酸氢化可的松</0>(50 mg)在5天固定盐饮食(150 mmol/d)后每6小时口服一次，持续24小时。交叉研究间隔2周进行。每个治疗期后取30毫升血液分离外周血单个核细胞。<7>L-精氨酸</7>吸收在与<8>L-精氨酸</8>（1至300微摩尔/升）共孵育的单核细胞中进行评估，并掺入100 nmol/L <9>[3H]-L-精氨酸</9>在37摄氏度下保持5分钟。前臂<10>[3H]-L-精氨酸</10>提取是在将<11>[3H]-L-精氨酸</11>以100 nCi/分钟的速率输注到肱动脉中80分钟后计算的。收集前臂深静脉样本用于测定<12>L-精氨酸</12>提取。活动期血浆<20>皮质醇</20>浓度显着升高（323±43～1082±245mmol/L，P<0.05）。收缩压平均升高了7毫米汞柱。<13>L-精氨酸</13>均未转运至单核细胞（安慰剂与活性药物，分别为26.3+/-3.6与29.0+/-2.1 pmol/10000个细胞每5分钟，在<14>L-精氨酸</14>浓度为300微摩尔/L时）或<15>L-精氨酸</15>在前臂中提取（在80分钟时，安慰剂与活性剂，1868904+/-434962对比2013910+/-770619崩解/分钟）受到 <21> 皮质醇 </21> 治疗的影响；也就是说，<16>L-精氨酸</16>的摄取不受短期<22>皮质醇</22>治疗的影响。我们得出结论，<23>皮质醇</23>诱导的<3>血压升高</3>与<17>L-精氨酸</17>转运系统异常无关。", "revised": true}
{"doc_key": "1468485", "sentences": [["Hyperbaric", "oxygen", "therapy", "for", "control", "of", "intractable", "cyclophosphamide", "-", "induced", "hemorrhagic", "cystitis", ".", "We", "report", "a", "case", "of", "intractable", "hemorrhagic", "cystitis", "due", "to", "cyclophosphamide", "therapy", "for", "Wegener", "'s", "granulomatosis", ".", "Conservative", "treatment", ",", "including", "bladder", "irrigation", "with", "physiological", "saline", "and", "instillation", "of", "prostaglandin", "F2", "alpha", ",", "failed", "to", "totally", "control", "hemorrhage", ".", "We", "then", "used", "hyperbaric", "oxygen", "at", "an", "absolute", "pressure", "of", "2", "atm", ",", "5", "days", "a", "week", "for", "8", "consecutive", "weeks", ".", "The", "bleeding", "ceased", "completely", "by", "the", "end", "of", "treatment", "and", "the", "patient", "remained", "free", "of", "hematuria", "thereafter", ".", "No", "side", "effect", "was", "noted", "during", "the", "course", "of", "therapy", ".", "In", "future", ",", "this", "form", "of", "therapy", "can", "offer", "a", "safe", "alternative", "in", "the", "treatment", "of", "cyclophosphamide", "-", "induced", "hemorrhagic", "cystitis", "."]], "ner": [[[7, 7, "Chemical"], [23, 23, "Chemical"], [119, 119, "Chemical"], [10, 11, "Disease"], [19, 20, "Disease"], [50, 50, "Disease"], [75, 75, "Disease"], [122, 123, "Disease"], [89, 89, "Disease"], [1, 1, "Chemical"], [56, 56, "Chemical"], [26, 28, "Disease"], [42, 44, "Chemical"]]], "relations": [[[7, 7, 10, 11, "CID"], [7, 7, 19, 20, "CID"], [7, 7, 50, 50, "CID"], [7, 7, 75, 75, "CID"], [7, 7, 122, 123, "CID"], [23, 23, 10, 11, "CID"], [23, 23, 19, 20, "CID"], [23, 23, 50, 50, "CID"], [23, 23, 75, 75, "CID"], [23, 23, 122, 123, "CID"], [119, 119, 10, 11, "CID"], [119, 119, 19, 20, "CID"], [119, 119, 50, 50, "CID"], [119, 119, 75, 75, "CID"], [119, 119, 122, 123, "CID"], [7, 7, 89, 89, "CID"], [23, 23, 89, 89, "CID"], [119, 119, 89, 89, "CID"]]], "clusters": [], "translated": "高压<9>氧气</9>治疗控制难治性<0>环磷酰胺</0>引起的<3>出血性膀胱炎</3>。我们报告了一例难治性<4>出血性膀胱炎</4>，由于<1>环磷酰胺</1>治疗<11>韦格纳肉芽肿</11>。保守治疗，包括生理盐水膀胱冲洗和滴注<12>前列腺素 F2α</12>，未能完全控制<5>出血</5>。然后，我们在 2 个大气压的绝对压力下使用高压<10>氧气</10>，每周 5 天，连续 8 周。<6>出血</6>在治疗结束时完全停止，此后患者一直没有<8>血尿</8>。治疗过程中未见副作用。将来，这种疗法可以为<2>环磷酰胺</2>诱发的<7>出血性膀胱炎</7>提供一种安全的替代疗法。", "revised": true}
{"doc_key": "1732369", "sentences": [["Dobutamine", "stress", "echocardiography", ":", "a", "sensitive", "indicator", "of", "diminished", "myocardial", "function", "in", "asymptomatic", "doxorubicin", "-", "treated", "long", "-", "term", "survivors", "of", "childhood", "cancer", ".", "Doxorubicin", "is", "an", "effective", "anticancer", "chemotherapeutic", "agent", "known", "to", "cause", "acute", "and", "chronic", "cardiomyopathy", ".", "To", "develop", "a", "more", "sensitive", "echocardiographic", "screening", "test", "for", "cardiac", "damage", "due", "to", "doxorubicin", ",", "a", "cohort", "study", "was", "performed", "using", "dobutamine", "infusion", "to", "differentiate", "asymptomatic", "long", "-", "term", "survivors", "of", "childhood", "cancer", "treated", "with", "doxorubicin", "from", "healthy", "control", "subjects", ".", "Echocardiographic", "data", "from", "the", "experimental", "group", "of", "21", "patients", "(", "mean", "age", "16", "+", "/", "-", "5", "years", ")", "treated", "from", "1", ".", "6", "to", "14", ".", "3", "years", "(", "median", "5", ".", "3", ")", "before", "this", "study", "with", "27", "to", "532", "mg", "/", "m2", "of", "doxorubicin", "(", "mean", "196", ")", "were", "compared", "with", "echocardiographic", "data", "from", "12", "normal", "age", "-", "matched", "control", "subjects", ".", "Graded", "dobutamine", "infusions", "of", "0", ".", "5", ",", "2", ".", "5", ",", "5", "and", "10", "micrograms", "/", "kg", "per", "min", "were", "administered", ".", "Echocardiographic", "Doppler", "studies", "were", "performed", "before", "infusion", "and", "after", "15", "min", "of", "infusion", "at", "each", "rate", ".", "Dobutamine", "infusion", "at", "10", "micrograms", "/", "kg", "per", "min", "was", "discontinued", "after", "six", "studies", "secondary", "to", "a", "50", "%", "incidence", "rate", "of", "adverse", "symptoms", ".", "The", "most", "important", "findings", "were", "that", "compared", "with", "values", "in", "control", "subjects", ",", "end", "-", "systolic", "left", "ventricular", "posterior", "wall", "dimension", "and", "percent", "of", "left", "ventricular", "posterior", "wall", "thickening", "in", "doxorubicin", "-", "treated", "patients", "were", "decreased", "at", "baseline", "study", "and", "these", "findings", "were", "more", "clearly", "delineated", "with", "dobutamine", "stimulation", ".", "End", "-", "systolic", "left", "ventricular", "posterior", "wall", "dimension", "at", "baseline", "for", "the", "doxorubicin", "-", "treated", "group", "was", "11", "+", "/", "-", "1", ".", "9", "mm", "versus", "13", ".", "1", "+", "/", "-", "1", ".", "5", "mm", "for", "control", "subjects", "(", "p", "less", "than", "0", ".", "01", ")", ".", "End", "-", "systolic", "left", "ventricular", "posterior", "wall", "dimension", "at", "the", "5", "-", "micrograms", "/", "kg", "per", "min", "dobutamine", "infusion", "for", "the", "doxorubicin", "-", "treated", "group", "was", "14", ".", "1", "+", "/", "-", "2", ".", "4", "mm", "versus", "19", ".", "3", "+", "/", "-", "2", ".", "6", "mm", "for", "control", "subjects", "(", "p", "less", "than", "0", ".", "01", ")", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[13, 13, "Chemical"], [24, 24, "Chemical"], [52, 52, "Chemical"], [74, 74, "Chemical"], [126, 126, "Chemical"], [240, 240, "Chemical"], [272, 272, "Chemical"], [329, 329, "Chemical"], [37, 37, "Disease"], [0, 0, "Chemical"], [60, 60, "Chemical"], [146, 146, "Chemical"], [185, 185, "Chemical"], [257, 257, "Chemical"], [325, 325, "Chemical"], [22, 22, "Disease"], [71, 71, "Disease"], [48, 49, "Disease"]]], "relations": [[[13, 13, 37, 37, "CID"], [24, 24, 37, 37, "CID"], [52, 52, 37, 37, "CID"], [74, 74, 37, 37, "CID"], [126, 126, 37, 37, "CID"], [240, 240, 37, 37, "CID"], [272, 272, 37, 37, "CID"], [329, 329, 37, 37, "CID"]]], "clusters": [], "translated": "<9>多巴酚丁胺</9>负荷超声心动图：无症状<0>多柔比星</0>治疗的儿童<15>癌症</15>长期幸存者心肌功能下降的敏感指标。 <1>阿霉素</1>是一种有效的抗癌化疗药物，已知可引起急性和慢性<8>心肌病</8>。为了针对<2>阿霉素</2>引起的<17>心脏损伤</17>开发更灵敏的超声心动图筛查试验，使用<10>多巴酚丁胺</10>输液进行队列研究以区分无症状长期儿童<16>癌症</16>的幸存者接受了来自健康对照受试者的<3>阿霉素</3>治疗。超声心动图数据来自实验组的 21 名患者（平均年龄 16+/- 5 岁），接受 1.6至14.3年（中位数 5.3）使用27至532毫克/平方米的<4>多柔比星</4>（平均196）与来自12名年龄匹配的正常对照受试者的超声心动图数据进行了比较。分级<11>多巴酚丁胺</11>输注 0.5、2.5、5和10微克/千克每分钟，输注前和输注15分钟后在每种速率进行超声心动图多普勒研究。<12>多巴酚丁胺</12>输注在每分钟 10 微克/千克的速度，6项研究后因不良症状发生率为 50% 而停止。最重要的发现是，与对照受试者的值相比，<5>多柔比星</5>治疗患者的收缩末期左心室后壁尺寸和左心室后壁增厚百分比在基线研究中有所降低，这些发现是用<13>多巴酚丁胺</13>刺激更清楚地描绘。<6>多柔比星</6>治疗组的基线收缩末期左心室后壁尺寸为11+/-1.9毫米，控制对象的为13.1+/-1.5毫米，(P小于0.01)。<7>多柔比星</7>治疗组在每分钟 5 微克/千克<14>多巴酚丁胺</14>输注时的收缩末期左心室后壁尺寸为 14.1+/-2.4毫米，控制对象为19.3+/-2.6毫米，(P小于0.01)。 （摘要被截断为 250 个单词）", "revised": true}
{"doc_key": "1992636", "sentences": [["Hemolytic", "anemia", "associated", "with", "the", "use", "of", "omeprazole", ".", "Omeprazole", "is", "the", "first", "drug", "designed", "to", "block", "the", "final", "step", "in", "the", "acid", "secretory", "process", "within", "the", "parietal", "cell", ".", "It", "has", "been", "shown", "to", "be", "extremely", "effective", "in", "the", "treatment", "of", "peptic", "ulcer", "disease", ",", "reflux", "esophagitis", ",", "and", "the", "Zollinger", "-", "Ellison", "syndrome", ".", "Although", "clinical", "experience", "with", "omeprazole", "is", "still", "limited", ",", "many", "controlled", "studies", "have", "established", "the", "short", "-", "term", "safety", "of", "this", "drug", ".", "We", "report", "the", "first", "case", "of", "a", "serious", "short", "-", "term", "adverse", "reaction", "with", "the", "use", "of", "omeprazole", ":", "hemolytic", "anemia", ".", "The", "patient", "developed", "weakness", ",", "lethargy", ",", "and", "shortness", "of", "breath", "2", "days", "after", "starting", "therapy", "with", "omeprazole", ".", "Two", "weeks", "after", "the", "initiation", "of", "therapy", ",", "her", "hematocrit", "had", "decreased", "from", "44", ".", "1", "%", "to", "20", ".", "4", "%", ",", "and", "she", "had", "a", "positive", "direct", "Coombs", "antiglobulin", "test", "and", "an", "elevated", "indirect", "bilirubin", ".", "After", "she", "discontinued", "the", "omeprazole", ",", "her", "hemoglobin", "and", "hematocrit", "gradually", "returned", "to", "normal", ".", "The", "mechanism", "by", "which", "omeprazole", "caused", "the", "patient", "'s", "hemolytic", "anemia", "is", "uncertain", ",", "but", "physicians", "should", "be", "alerted", "to", "this", "possible", "adverse", "effect", "."]], "ner": [[[7, 7, "Chemical"], [9, 9, "Chemical"], [60, 60, "Chemical"], [96, 96, "Chemical"], [118, 118, "Chemical"], [162, 162, "Chemical"], [177, 177, "Chemical"], [0, 1, "Disease"], [98, 99, "Disease"], [182, 183, "Disease"], [106, 106, "Disease"], [109, 111, "Disease"], [156, 156, "Chemical"], [42, 44, "Disease"], [46, 47, "Disease"], [51, 54, "Disease"]]], "relations": [[[7, 7, 0, 1, "CID"], [7, 7, 98, 99, "CID"], [7, 7, 182, 183, "CID"], [9, 9, 0, 1, "CID"], [9, 9, 98, 99, "CID"], [9, 9, 182, 183, "CID"], [60, 60, 0, 1, "CID"], [60, 60, 98, 99, "CID"], [60, 60, 182, 183, "CID"], [96, 96, 0, 1, "CID"], [96, 96, 98, 99, "CID"], [96, 96, 182, 183, "CID"], [118, 118, 0, 1, "CID"], [118, 118, 98, 99, "CID"], [118, 118, 182, 183, "CID"], [162, 162, 0, 1, "CID"], [162, 162, 98, 99, "CID"], [162, 162, 182, 183, "CID"], [177, 177, 0, 1, "CID"], [177, 177, 98, 99, "CID"], [177, 177, 182, 183, "CID"], [7, 7, 106, 106, "CID"], [9, 9, 106, 106, "CID"], [60, 60, 106, 106, "CID"], [96, 96, 106, 106, "CID"], [118, 118, 106, 106, "CID"], [162, 162, 106, 106, "CID"], [177, 177, 106, 106, "CID"], [7, 7, 109, 111, "CID"], [9, 9, 109, 111, "CID"], [60, 60, 109, 111, "CID"], [96, 96, 109, 111, "CID"], [118, 118, 109, 111, "CID"], [162, 162, 109, 111, "CID"], [177, 177, 109, 111, "CID"]]], "clusters": [], "translated": "<7>溶血性贫血</7>与使用<0>奥美拉唑</0>有关。 <1>奥美拉唑</1>是第一种旨在阻断壁细胞内酸分泌过程最后一步的药物。它已被证明在治疗<13>消化性溃疡病</13>、<14>反流性食管炎</14>和<15>佐林格-埃里森综合征</15>方面极为有效。虽然<2>奥美拉唑</2>的临床经验仍然有限，但许多对照研究已经确定了该药物的短期安全性。我们报告了第一例使用<3>奥美拉唑</3>引起的严重短期不良反应：<8>溶血性贫血</8>。开始用<4>奥美拉唑</4>治疗后2天，患者出现虚弱、<10>嗜睡</10>和<11>呼吸急促</11>。开始治疗两周后，她的血细胞比容从44.1%到20.4%，她的直接Coombs抗球蛋白试验呈阳性，间接<12>胆红素</12>升高。停用<5>奥美拉唑</5>后，她的血红蛋白和血细胞比容逐渐恢复正常。<6>奥美拉唑</6>引起患者<9>溶血性贫血</9>的机制尚不明确，但医生应警惕这种可能的不良反应。", "revised": true}
{"doc_key": "2396046", "sentences": [["No", "enhancement", "by", "phenobarbital", "of", "the", "hepatocarcinogenicity", "of", "a", "choline", "-", "devoid", "diet", "in", "the", "rat", ".", "An", "experiment", "was", "performed", "to", "test", "whether", "inclusion", "of", "phenobarbital", "in", "a", "choline", "-", "devoid", "diet", "would", "increase", "the", "hepatocarcinogenicity", "of", "the", "diet", ".", "Groups", "of", "5", "-", "week", "old", "male", "Fischer", "-", "344", "rats", "were", "fed", "for", "7", "-", "25", "months", "semipurified", "choline", "-", "devoid", "or", "choline", "-", "supplemented", "diets", ",", "containing", "or", "not", "0", ".", "06", "%", "phenobarbital", ".", "No", "hepatic", "preneoplastic", "nodules", "or", "hepatocellular", "carcinomas", "developed", "in", "rats", "fed", "the", "plain", "choline", "-", "supplemented", "diet", ",", "while", "one", "preneoplastic", "nodule", "and", "one", "hepatocellular", "carcinoma", "developed", "in", "two", "rats", "fed", "the", "same", "diet", "containing", "phenobarbital", ".", "The", "incidence", "of", "preneoplastic", "nodules", "and", "of", "hepatocellular", "carcinomas", "was", "10", "%", "and", "37", "%", ",", "respectively", ",", "in", "rats", "fed", "the", "plain", "choline", "-", "devoid", "diet", ",", "and", "17", "%", "and", "30", "%", ",", "in", "rats", "fed", "the", "phenobarbital", "-", "containing", "choline", "-", "devoid", "diet", ".", "The", "results", "evinced", "no", "enhancement", "of", "the", "hepatocarcinogenicity", "of", "the", "choline", "-", "devoid", "diet", "by", "phenobarbital", ".", "Sporadic", "neoplastic", "lesions", "were", "observed", "in", "organs", "other", "than", "the", "liver", "of", "some", "of", "the", "animals", ",", "irrespective", "of", "the", "diet", "fed", "."]], "ner": [[[9, 9, "Chemical"], [29, 29, "Chemical"], [60, 60, "Chemical"], [64, 64, "Chemical"], [91, 91, "Chemical"], [138, 138, "Chemical"], [157, 157, "Chemical"], [172, 172, "Chemical"], [83, 84, "Disease"], [102, 103, "Disease"], [122, 123, "Disease"], [3, 3, "Chemical"], [26, 26, "Chemical"], [76, 76, "Chemical"], [113, 113, "Chemical"], [154, 154, "Chemical"], [177, 177, "Chemical"]]], "relations": [[[9, 9, 83, 84, "CID"], [9, 9, 102, 103, "CID"], [9, 9, 122, 123, "CID"], [29, 29, 83, 84, "CID"], [29, 29, 102, 103, "CID"], [29, 29, 122, 123, "CID"], [60, 60, 83, 84, "CID"], [60, 60, 102, 103, "CID"], [60, 60, 122, 123, "CID"], [64, 64, 83, 84, "CID"], [64, 64, 102, 103, "CID"], [64, 64, 122, 123, "CID"], [91, 91, 83, 84, "CID"], [91, 91, 102, 103, "CID"], [91, 91, 122, 123, "CID"], [138, 138, 83, 84, "CID"], [138, 138, 102, 103, "CID"], [138, 138, 122, 123, "CID"], [157, 157, 83, 84, "CID"], [157, 157, 102, 103, "CID"], [157, 157, 122, 123, "CID"], [172, 172, 83, 84, "CID"], [172, 172, 102, 103, "CID"], [172, 172, 122, 123, "CID"]]], "clusters": [], "translated": "<11>苯巴比妥</11> 没有增强<0>胆碱</0>饮食对大鼠的肝癌性。进行了一项实验来测试在缺乏<1>胆碱</1>的饮食中加入<12>苯巴比妥</12>是否会增加饮食的肝癌性。将5周大的雄性Fisher-344大鼠各组喂食半纯化<2>胆碱</2>或<3>胆碱</3>补充饮食7-25个月，其中含有或不含0.06%<13>苯巴比妥</13>。喂食普通<4>胆碱</4>-补充饮食的大鼠没有发生肝癌前结节或<8>肝细胞癌</8>，而在喂食相同饮食含有<14>苯巴比妥</14>的两组实验中却发生了1例癌前结节和1例<9>肝细胞癌</9>。在喂食<6>缺乏胆碱</6>和含有<15>苯巴比妥</15>-不含<6>胆碱</6>的饮食的大鼠中，分别有10%和37%的癌前结节和<10>肝细胞癌</10>的发生率；而在喂食普通<5>胆碱</5>补充饮食的大鼠中，这些疾病都没有发生。结果表明，在<7>缺乏胆碱</7>饮食中加入<16>苯巴比妥</16>并没有增加饮食的肝癌性。无论喂养何种饮食，一些动物的肝脏以外的器官中都观察到散发性肿瘤病变。", "revised": true}
{"doc_key": "20528871", "sentences": [["Salvage", "therapy", "with", "nelarabine", ",", "etoposide", ",", "and", "cyclophosphamide", "in", "relapsed", "/", "refractory", "paediatric", "T", "-", "cell", "lymphoblastic", "leukaemia", "and", "lymphoma", ".", "A", "combination", "of", "5", "d", "of", "nelarabine", "(", "AraG", ")", "with", "5", "d", "of", "etoposide", "(", "VP", ")", "and", "cyclophosphamide", "(", "CPM", ")", "and", "prophylactic", "intrathecal", "chemotherapy", "was", "used", "as", "salvage", "therapy", "in", "seven", "children", "with", "refractory", "or", "relapsed", "T", "-", "cell", "leukaemia", "or", "lymphoma", ".", "The", "most", "common", "side", "effects", "attributable", "to", "the", "AraG", "included", "Grade", "2", "and", "3", "sensory", "and", "motor", "neuropathy", "and", "musculoskeletal", "pain", ".", "Haematological", "toxicity", "was", "greater", "for", "the", "combination", "than", "AraG", "alone", ",", "although", "median", "time", "to", "neutrophil", "and", "platelet", "recovery", "was", "consistent", "with", "other", "salvage", "therapies", ".", "All", "patients", "had", "some", "response", "to", "the", "combined", "therapy", "and", "five", "of", "the", "seven", "went", "into", "complete", "remission", "after", "one", "or", "two", "courses", "of", "AraG", "/", "VP", "/", "CPM", ".", "Our", "experience", "supports", "the", "safety", "of", "giving", "AraG", "as", "salvage", "therapy", "in", "synchrony", "with", "etoposide", "and", "cyclophosphamide", ",", "although", "neurological", "toxicity", "must", "be", "closely", "monitored", "."]], "ner": [[[3, 3, "Chemical"], [28, 28, "Chemical"], [30, 30, "Chemical"], [76, 76, "Chemical"], [98, 98, "Chemical"], [140, 140, "Chemical"], [153, 153, "Chemical"], [85, 85, "Disease"], [165, 166, "Disease"], [87, 88, "Disease"], [90, 91, "Disease"], [14, 20, "Disease"], [61, 66, "Disease"], [5, 5, "Chemical"], [36, 36, "Chemical"], [38, 38, "Chemical"], [142, 142, "Chemical"], [160, 160, "Chemical"], [8, 8, "Chemical"], [41, 41, "Chemical"], [43, 43, "Chemical"], [144, 144, "Chemical"], [162, 162, "Chemical"]]], "relations": [[[3, 3, 85, 85, "CID"], [3, 3, 165, 166, "CID"], [28, 28, 85, 85, "CID"], [28, 28, 165, 166, "CID"], [30, 30, 85, 85, "CID"], [30, 30, 165, 166, "CID"], [76, 76, 85, 85, "CID"], [76, 76, 165, 166, "CID"], [98, 98, 85, 85, "CID"], [98, 98, 165, 166, "CID"], [140, 140, 85, 85, "CID"], [140, 140, 165, 166, "CID"], [153, 153, 85, 85, "CID"], [153, 153, 165, 166, "CID"], [3, 3, 87, 88, "CID"], [28, 28, 87, 88, "CID"], [30, 30, 87, 88, "CID"], [76, 76, 87, 88, "CID"], [98, 98, 87, 88, "CID"], [140, 140, 87, 88, "CID"], [153, 153, 87, 88, "CID"], [3, 3, 90, 91, "CID"], [28, 28, 90, 91, "CID"], [30, 30, 90, 91, "CID"], [76, 76, 90, 91, "CID"], [98, 98, 90, 91, "CID"], [140, 140, 90, 91, "CID"], [153, 153, 90, 91, "CID"]]], "clusters": [], "translated": "<0>奈拉滨</0>、<13>依托泊苷</13>和<18>环磷酰胺</18>对复发/难治性儿科<11>T细胞淋巴细胞白血病和淋巴瘤</11>的挽救治疗。5天的<1>奈拉滨</1>（<2>AraG</2>）与5天的<14>依托泊苷</14>（<15>VP</15>）和<19>环磷酰胺</19>（<20>CPM</20>）的组合，并使用预防性鞘内化疗，作为难治性或复发的<12>T细胞白血病或淋巴瘤</12>的7位患儿的挽救治疗。最常见的<3>AraG</3>副作用包括二级和三级感觉和运动<7>神经病变</7>和<9>肌骨疼痛</9>。<10>血液学毒性</10>比<4>AraG</4>单独使用时更大，虽然中性粒细胞和血小板恢复的中位时间与其他补救疗法一致。所有患者对联合治疗均有一定反应，7名患者中有5名在<5>AraG</5>/<16>VP</16>/<21>CPM</21>一两个疗程后完全缓解。我们的经验支持与<17>依托泊苷</17>和<22>环磷酰胺</22>同步给予<6>AraG</6>作为补救治疗的安全性，尽管<8>神经毒性</8>必须受到严密监控。", "revised": true}
{"doc_key": "15325671", "sentences": [["Cardiac", "toxicity", "observed", "in", "association", "with", "high", "-", "dose", "cyclophosphamide", "-", "based", "chemotherapy", "for", "metastatic", "breast", "cancer", ".", "INTRODUCTION", ":", "Cyclophosphamide", "is", "an", "alkylating", "agent", "given", "frequently", "as", "a", "component", "of", "many", "conditioning", "regimens", ".", "In", "high", "doses", ",", "its", "nonhematological", "dose", "-", "limiting", "toxicity", "is", "cardiomyopathy", ".", "STUDY", "DESIGN", ":", "We", "combined", "paclitaxel", ",", "melphalan", "and", "high", "-", "dose", "cyclophosphamide", ",", "thiotepa", ",", "and", "carboplatin", "in", "a", "triple", "sequential", "high", "-", "dose", "regimen", "for", "patients", "with", "metastatic", "breast", "cancer", ".", "Analysis", "was", "performed", "on", "61", "women", "with", "chemotherapy", "-", "responsive", "metastatic", "breast", "cancer", "receiving", "96", "-", "h", "infusional", "cyclophosphamide", "as", "part", "of", "a", "triple", "sequential", "high", "-", "dose", "regimen", "to", "assess", "association", "between", "presence", "of", "peritransplant", "congestive", "heart", "failure", "(", "CHF", ")", "and", "the", "following", "pretreatment", "characteristics", ":", "presence", "of", "electrocardiogram", "(", "EKG", ")", "abnormalities", ",", "age", ",", "hypertension", ",", "prior", "cardiac", "history", ",", "smoking", ",", "diabetes", "mellitus", ",", "prior", "use", "of", "anthracyclines", ",", "and", "left", "-", "sided", "chest", "irradiation", ".", "RESULTS", ":", "Six", "of", "61", "women", "(", "10", "%", ")", "developed", "clinically", "reversible", "grade", "3", "CHF", "following", "infusional", "cyclophosphamide", "with", "a", "median", "percent", "decline", "in", "ejection", "fraction", "of", "31", "%", ".", "Incidence", "of", "transient", "cyclophosphamide", "-", "related", "cardiac", "toxicity", "(", "10", "%", ")", "is", "comparable", "to", "previous", "recorded", "literature", ".", "Older", "age", "was", "significantly", "correlated", "with", "the", "CHF", "development", ";", "with", "median", "ages", "for", "the", "entire", "group", "and", "for", "patients", "developing", "CHF", "of", "45", "and", "59", ",", "respectively", ".", "No", "association", "was", "found", "with", "other", "pretreatment", "characteristics", ".", "CONCLUSIONS", ":", "As", "a", "result", "of", "these", "findings", ",", "oncologists", "should", "carefully", "monitor", "fluid", "balance", "in", "older", "patients", ".", "Routine", "EKG", "monitoring", "during", "infusional", "cyclophosphamide", "did", "not", "predict", "CHF", "development", "."]], "ner": [[[9, 9, "Chemical"], [20, 20, "Chemical"], [60, 60, "Chemical"], [99, 99, "Chemical"], [180, 180, "Chemical"], [196, 196, "Chemical"], [274, 274, "Chemical"], [117, 119, "Disease"], [121, 121, "Disease"], [177, 177, "Disease"], [219, 219, "Disease"], [233, 233, "Disease"], [278, 278, "Disease"], [0, 1, "Disease"], [199, 200, "Disease"], [53, 53, "Chemical"], [55, 55, "Chemical"], [62, 62, "Chemical"], [65, 65, "Chemical"], [153, 153, "Chemical"], [15, 16, "Disease"], [78, 79, "Disease"], [92, 93, "Disease"], [44, 44, "Disease"], [46, 46, "Disease"], [139, 139, "Disease"], [147, 148, "Disease"]]], "relations": [[[9, 9, 117, 119, "CID"], [9, 9, 121, 121, "CID"], [9, 9, 177, 177, "CID"], [9, 9, 219, 219, "CID"], [9, 9, 233, 233, "CID"], [9, 9, 278, 278, "CID"], [20, 20, 117, 119, "CID"], [20, 20, 121, 121, "CID"], [20, 20, 177, 177, "CID"], [20, 20, 219, 219, "CID"], [20, 20, 233, 233, "CID"], [20, 20, 278, 278, "CID"], [60, 60, 117, 119, "CID"], [60, 60, 121, 121, "CID"], [60, 60, 177, 177, "CID"], [60, 60, 219, 219, "CID"], [60, 60, 233, 233, "CID"], [60, 60, 278, 278, "CID"], [99, 99, 117, 119, "CID"], [99, 99, 121, 121, "CID"], [99, 99, 177, 177, "CID"], [99, 99, 219, 219, "CID"], [99, 99, 233, 233, "CID"], [99, 99, 278, 278, "CID"], [180, 180, 117, 119, "CID"], [180, 180, 121, 121, "CID"], [180, 180, 177, 177, "CID"], [180, 180, 219, 219, "CID"], [180, 180, 233, 233, "CID"], [180, 180, 278, 278, "CID"], [196, 196, 117, 119, "CID"], [196, 196, 121, 121, "CID"], [196, 196, 177, 177, "CID"], [196, 196, 219, 219, "CID"], [196, 196, 233, 233, "CID"], [196, 196, 278, 278, "CID"], [274, 274, 117, 119, "CID"], [274, 274, 121, 121, "CID"], [274, 274, 177, 177, "CID"], [274, 274, 219, 219, "CID"], [274, 274, 233, 233, "CID"], [274, 274, 278, 278, "CID"]]], "clusters": [], "translated": "<13>观察到心脏毒性</13>与高剂量<0>环磷酰胺</0>为基础的转移性<20>乳腺癌</20>化疗有关。简介：<1>环磷酰胺</1>是一种烷化剂，经常作为许多预处理方案的组成部分使用。在高剂量下，其非血液学剂量限制性<23>毒性</23>是<24>心肌病</24>。研究设计：我们将<15>紫杉醇</15>、<16>马法兰</16>和高剂量<2>环磷酰胺</2>、<17>噻替哌</17>和<18>卡铂</18>在转移性<21>乳腺癌</21>患者的三重序贯高剂量方案中。对61名化疗敏感的转移性<22>乳腺癌</22>女性进行了分析，这些女性接受96小时输注<3>环磷酰胺</3>作为三重顺序高剂量方案的一部分，以评估存在围移植期<7>充血性心力衰竭</7> (<8>CHF</8>)的关联和以下治疗前特征：存在心电图 (EKG) 异常、年龄、<25>高血压</25>、既往心脏病史、吸烟、<26>糖尿病</26>、之前使用过<19>蒽环类药物</19>和左侧胸部照射。结果：61名女性中有6名 (10%)在输注<4>环磷酰胺</4>后发展为临床可逆的3级<9>CHF</9>，射血分数下降百分比中位数为31%。短暂性<5>环磷酰胺</5>相关的<14>心脏毒性</14>的发生率 (10%)与先前记录的文献相当。高龄与<10>CHF</10>的发生显着相关；整个组和发生<11>CHF</11>的患者的中位年龄分别为45岁和59岁。未发现与其他治疗前特征相关。结论：由于这些发现，肿瘤学家应该仔细监测老年患者的体液平衡。输注<6>环磷酰胺</6>期间的常规心电图监测不能预测<12>CHF</12>的发展。", "revised": true}
{"doc_key": "8387218", "sentences": [["The", "use", "and", "toxicity", "of", "didanosine", "(", "ddI", ")", "in", "HIV", "antibody", "-", "positive", "individuals", "intolerant", "to", "zidovudine", "(", "AZT", ")", "One", "hundred", "and", "fifty", "-", "one", "patients", "intolerant", "to", "zidovudine", "(", "AZT", ")", "received", "didanosine", "(", "ddI", ")", "to", "a", "maximum", "dose", "of", "12", ".", "5", "mg", "/", "kg", "/", "day", ".", "Patient", "response", "was", "assessed", "using", "changes", "in", "CD4", "+", "lymphocyte", "subset", "count", ",", "HIV", "p24", "antigen", ",", "weight", ",", "and", "quality", "of", "life", ".", "Seventy", "patients", "developed", "major", "opportunistic", "infections", "whilst", "on", "therapy", ";", "this", "was", "the", "first", "AIDS", "diagnosis", "in", "17", ".", "Only", "minor", "changes", "in", "CD4", "+", "lymphocyte", "subset", "count", "were", "observed", "in", "AIDS", "patients", ",", "although", "a", "more", "significant", "rise", "occurred", "in", "those", "with", "earlier", "stages", "of", "disease", ".", "Of", "those", "positive", "for", "p24", "antigen", "at", "the", "commencement", "of", "the", "study", "67", "%", "showed", "a", "positive", "response", ",", "and", "this", "was", "most", "likely", "in", "those", "with", "CD4", "+", "lymphocyte", "subset", "counts", "above", "100", "mm3", ".", "A", "positive", "weight", "response", "was", "seen", "in", "16", "%", "of", "patients", ".", "Most", "patients", "showed", "improvement", "in", "individual", "parameters", "and", "global", "score", "of", "quality", "of", "life", ".", "Adverse", "reactions", "possibly", "attributable", "to", "didanosine", "were", "common", ".", "The", "most", "common", "side", "-", "effect", "was", "diarrhoea", ",", "which", "resulted", "in", "cessation", "of", "therapy", "in", "19", "individuals", ".", "Peripheral", "neuropathy", "occurred", "in", "12", "patients", "and", "pancreatitis", "in", "six", ".", "Thirteen", "patients", "developed", "a", "raised", "serum", "amylase", "without", "abdominal", "pain", ".", "Seven", "patients", "developed", "glucose", "tolerance", "curves", "characteristic", "of", "diabetes", "but", "these", "were", "mild", ",", "did", "not", "require", "treatment", "and", "returned", "to", "normal", "on", "ceasing", "didanosine", "."]], "ner": [[[5, 5, "Chemical"], [7, 7, "Chemical"], [35, 35, "Chemical"], [37, 37, "Chemical"], [193, 193, "Chemical"], [262, 262, "Chemical"], [204, 204, "Disease"], [216, 217, "Disease"], [223, 223, "Disease"], [241, 243, "Disease"], [3, 3, "Disease"], [17, 17, "Chemical"], [19, 19, "Chemical"], [30, 30, "Chemical"], [32, 32, "Chemical"], [10, 13, "Disease"], [81, 82, "Disease"], [91, 91, "Disease"], [108, 108, "Disease"], [235, 236, "Disease"], [246, 246, "Disease"]]], "relations": [[[5, 5, 204, 204, "CID"], [7, 7, 204, 204, "CID"], [35, 35, 204, 204, "CID"], [37, 37, 204, 204, "CID"], [193, 193, 204, 204, "CID"], [262, 262, 204, 204, "CID"], [5, 5, 216, 217, "CID"], [7, 7, 216, 217, "CID"], [35, 35, 216, 217, "CID"], [37, 37, 216, 217, "CID"], [193, 193, 216, 217, "CID"], [262, 262, 216, 217, "CID"], [5, 5, 223, 223, "CID"], [7, 7, 223, 223, "CID"], [35, 35, 223, 223, "CID"], [37, 37, 223, 223, "CID"], [193, 193, 223, 223, "CID"], [262, 262, 223, 223, "CID"], [5, 5, 241, 243, "CID"], [7, 7, 241, 243, "CID"], [35, 35, 241, 243, "CID"], [37, 37, 241, 243, "CID"], [193, 193, 241, 243, "CID"], [262, 262, 241, 243, "CID"]]], "clusters": [], "translated": "<0>去羟肌苷</0> (<1>ddI</1>) 在<15>抗HIV体</15>对<11>齐多夫定</11> (<12>AZT</12>) 不耐受的个体中使用和<10>毒性</10>：<13>齐多夫定</13> (<14>AZT</14>) 不耐受的 151 例病患接受了剂量最高达 12.5 毫克/千克/天的<2>去羟肌苷</2> (<3>ddI</3>)。使用 CD4+ 淋巴细胞亚群计数、HIV p24 抗原、体重和生命质量的变化来评估患者反应。70 名患者在治疗期间发生了严重的<16>机会性感染</16>，这是在 17 个患者中第一个被诊断为<17>艾滋病</17>的病例。在<18>AIDS</18>患者中，CD4+ 淋巴细胞亚群计数只有轻微变化，但在疾病早期阶段的患者中有更明显的提高。在研究开始时 p24 抗原阳性的患者中，67% 显示出阳性反应，这种反应最有可能发生在 CD4+ 淋巴细胞亚群计数高于 100 mm3 的患者中。16% 的患者的体重出现积极反应。大多数患者的个体参数和生命质量的整体评分都有所改善。与<4>去羟肌苷</4>有关的不良反应很常见。最常见的副作用是<6>腹泻</6>，导致 19 人停止治疗。12 名患者发生<7>周围神经病变</7>，6 名患者发生<8>胰腺炎</8>。13 名患者出现血清淀粉酶升高，但没有<19>腹痛</19>。7 名患者出现了<9>葡萄糖耐量曲线</9>特征性的<20>糖尿病</20>曲线，但这些曲线轻微，不需要治疗，在停止<5>去羟肌苷</5>后恢复正常。", "revised": true}
{"doc_key": "7977601", "sentences": [["Survey", "of", "complications", "of", "indocyanine", "green", "angiography", "in", "Japan", ".", "PURPOSE", ":", "We", "evaluated", "the", "safety", "of", "indocyanine", "green", "for", "use", "in", "fundus", "angiography", ".", "METHODS", ":", "We", "sent", "a", "questionnaire", "concerning", "complications", "of", "indocyanine", "green", "to", "32", "institutions", "in", "Japan", ",", "which", "were", "selected", "on", "the", "basis", "of", "the", "client", "list", "from", "the", "Topcon", "Company", ",", "which", "manufactures", "the", "indocyanine", "green", "fundus", "camera", ".", "RESULTS", ":", "Ophthalmologists", "at", "15", "institutions", "responded", ",", "reporting", "a", "total", "of", "3", ",", "774", "indocyanine", "green", "angiograms", "performed", "on", "2", ",", "820", "patients", "between", "June", "1984", "and", "September", "1992", ".", "Before", "angiography", ",", "intradermal", "or", "intravenous", "indocyanine", "green", "testing", ",", "or", "both", "was", "performed", "at", "13", "of", "15", "institutions", ".", "For", "three", "patients", ",", "the", "decision", "was", "made", "not", "to", "proceed", "with", "angiography", "after", "positive", "preangiographic", "testing", ".", "The", "dosage", "of", "indocyanine", "green", "used", "for", "angiography", "varied", "from", "25", "to", "75", "mg", ",", "depending", "upon", "the", "institution", ".", "There", "were", "13", "cases", "of", "adverse", "reactions", "(", "0", ".", "34", "%", ")", ",", "ten", "of", "which", "were", "mild", "reactions", "such", "as", "nausea", ",", "exanthema", ",", "urtication", ",", "itchiness", ",", "and", "urgency", "to", "defecate", ",", "and", "did", "not", "require", "treatment", ".", "Also", "recorded", "were", "one", "case", "of", "pain", "of", "the", "vein", ",", "which", "required", "treatment", ",", "and", "two", "cases", "of", "hypotension", ".", "The", "two", "hypotensive", "patients", "required", "treatment", "for", "shock", ".", "CONCLUSIONS", ":", "A", "comparison", "of", "frequency", "of", "adverse", "reactions", "to", "indocyanine", "green", "with", "the", "previously", "reported", "frequency", "of", "such", "reactions", "to", "fluorescein", "sodium", "indicated", "that", "indocyanine", "green", "is", "a", "safe", "as", "fluorescein", "for", "use", "in", "angiography", "."]], "ner": [[[4, 5, "Chemical"], [17, 18, "Chemical"], [34, 35, "Chemical"], [60, 61, "Chemical"], [80, 81, "Chemical"], [102, 103, "Chemical"], [137, 138, "Chemical"], [235, 236, "Chemical"], [250, 251, "Chemical"], [176, 176, "Disease"], [178, 178, "Disease"], [180, 180, "Disease"], [182, 182, "Disease"], [201, 201, "Disease"], [214, 214, "Disease"], [218, 218, "Disease"], [223, 223, "Disease"], [246, 247, "Chemical"], [256, 256, "Chemical"]]], "relations": [[[4, 5, 176, 176, "CID"], [17, 18, 176, 176, "CID"], [34, 35, 176, 176, "CID"], [60, 61, 176, 176, "CID"], [80, 81, 176, 176, "CID"], [102, 103, 176, 176, "CID"], [137, 138, 176, 176, "CID"], [235, 236, 176, 176, "CID"], [250, 251, 176, 176, "CID"], [4, 5, 178, 178, "CID"], [17, 18, 178, 178, "CID"], [34, 35, 178, 178, "CID"], [60, 61, 178, 178, "CID"], [80, 81, 178, 178, "CID"], [102, 103, 178, 178, "CID"], [137, 138, 178, 178, "CID"], [235, 236, 178, 178, "CID"], [250, 251, 178, 178, "CID"], [4, 5, 180, 180, "CID"], [17, 18, 180, 180, "CID"], [34, 35, 180, 180, "CID"], [60, 61, 180, 180, "CID"], [80, 81, 180, 180, "CID"], [102, 103, 180, 180, "CID"], [137, 138, 180, 180, "CID"], [235, 236, 180, 180, "CID"], [250, 251, 180, 180, "CID"], [4, 5, 182, 182, "CID"], [17, 18, 182, 182, "CID"], [34, 35, 182, 182, "CID"], [60, 61, 182, 182, "CID"], [80, 81, 182, 182, "CID"], [102, 103, 182, 182, "CID"], [137, 138, 182, 182, "CID"], [235, 236, 182, 182, "CID"], [250, 251, 182, 182, "CID"], [4, 5, 201, 201, "CID"], [17, 18, 201, 201, "CID"], [34, 35, 201, 201, "CID"], [60, 61, 201, 201, "CID"], [80, 81, 201, 201, "CID"], [102, 103, 201, 201, "CID"], [137, 138, 201, 201, "CID"], [235, 236, 201, 201, "CID"], [250, 251, 201, 201, "CID"], [4, 5, 214, 214, "CID"], [4, 5, 218, 218, "CID"], [17, 18, 214, 214, "CID"], [17, 18, 218, 218, "CID"], [34, 35, 214, 214, "CID"], [34, 35, 218, 218, "CID"], [60, 61, 214, 214, "CID"], [60, 61, 218, 218, "CID"], [80, 81, 214, 214, "CID"], [80, 81, 218, 218, "CID"], [102, 103, 214, 214, "CID"], [102, 103, 218, 218, "CID"], [137, 138, 214, 214, "CID"], [137, 138, 218, 218, "CID"], [235, 236, 214, 214, "CID"], [235, 236, 218, 218, "CID"], [250, 251, 214, 214, "CID"], [250, 251, 218, 218, "CID"], [4, 5, 223, 223, "CID"], [17, 18, 223, 223, "CID"], [34, 35, 223, 223, "CID"], [60, 61, 223, 223, "CID"], [80, 81, 223, 223, "CID"], [102, 103, 223, 223, "CID"], [137, 138, 223, 223, "CID"], [235, 236, 223, 223, "CID"], [250, 251, 223, 223, "CID"]]], "clusters": [], "translated": "日本<0>吲哚菁绿</0>血管造影并发症的调查。目的：我们评估了<1>吲哚菁绿</1>用于眼底血管造影的安全性。方法：我们向日本的32家机构发送了关于<2>吲哚菁绿</2>并发症的问卷调查，这些机构是根据生产<3>吲哚菁绿</3>的Topcon公司的客户名单选出的眼底照相机。结果：15个机构的眼科医师作出回应，报告在1984年6月至1992年9月期间对2820名患者进行了3774次<4>吲哚菁绿</4><0>血管造影</0>。在血管造影之前，15家机构中的13家进行了皮内或静脉内<5>吲哚菁绿</5>检测，或两者同时进行。对于3名患者，在血管造影前检测呈阳性后决定不进行血管造影。用于血管造影的<6>吲哚菁绿</6>剂量从25到75毫克不等，具体取决于机构。不良反应13例（0.34%），其中10例为轻度反应，如<9>恶心</9>、<10>皮疹</10>、<11>荨麻疹</11>、<12>痒</12>，还有便急，没必要治疗。还记录了1例需要治疗的<13>静脉疼痛</13>和2例<14>低血压</14>。两名<15>低血压</15>患者因<16>休克</16>需要治疗。结论：<7>吲哚菁绿</7>不良反应频率与先前报道的<17>荧光素钠</17>不良反应频率的比较表明，<8>吲哚菁绿</8>是一种与<18>荧光素</18>一样安全，可用于血管造影。", "revised": true}
{"doc_key": "16740173", "sentences": [["Case", "report", ":", "acute", "unintentional", "carbachol", "intoxication", ".", "INTRODUCTION", ":", "Intoxications", "with", "carbachol", ",", "a", "muscarinic", "cholinergic", "receptor", "agonist", "are", "rare", ".", "We", "report", "an", "interesting", "case", "investigating", "a", "(", "near", ")", "fatal", "poisoning", ".", "METHODS", ":", "The", "son", "of", "an", "84", "-", "year", "-", "old", "male", "discovered", "a", "newspaper", "report", "stating", "clinical", "success", "with", "plant", "extracts", "in", "Alzheimer", "'s", "disease", ".", "The", "mode", "of", "action", "was", "said", "to", "be", "comparable", "to", "that", "of", "the", "synthetic", "compound", "'", "carbamylcholin", "'", ";", "that", "is", ",", "carbachol", ".", "He", "bought", "25", "g", "of", "carbachol", "as", "pure", "substance", "in", "a", "pharmacy", ",", "and", "the", "father", "was", "administered", "400", "to", "500", "mg", ".", "Carbachol", "concentrations", "in", "serum", "and", "urine", "on", "day", "1", "and", "2", "of", "hospital", "admission", "were", "analysed", "by", "HPLC", "-", "mass", "spectrometry", ".", "RESULTS", ":", "Minutes", "after", "oral", "administration", ",", "the", "patient", "developed", "nausea", ",", "sweating", "and", "hypotension", ",", "and", "finally", "collapsed", ".", "Bradycardia", ",", "cholinergic", "symptoms", "and", "asystole", "occurred", ".", "Initial", "cardiopulmonary", "resuscitation", "and", "immediate", "treatment", "with", "adrenaline", "(", "epinephrine", ")", ",", "atropine", "and", "furosemide", "was", "successful", ".", "On", "hospital", "admission", ",", "blood", "pressure", "of", "the", "intubated", ",", "bradyarrhythmic", "patient", "was", "100", "/", "65", "mmHg", ".", "Further", "signs", "were", "hyperhidrosis", ",", "hypersalivation", ",", "bronchorrhoea", ",", "and", "severe", "miosis", ";", "the", "electrocardiographic", "finding", "was", "atrio", "-", "ventricular", "dissociation", ".", "High", "doses", "of", "atropine", "(", "up", "to", "50", "mg", "per", "24", "hours", ")", ",", "adrenaline", "and", "dopamine", "were", "necessary", ".", "The", "patient", "was", "extubated", "1", "week", "later", ".", "However", ",", "increased", "dyspnoea", "and", "bronchospasm", "necessitated", "reintubation", ".", "Respiratory", "insufficiency", "was", "further", "worsened", "by", "Proteus", "mirabilis", "infection", "and", "severe", "bronchoconstriction", ".", "One", "week", "later", ",", "the", "patient", "was", "again", "extubated", "and", "3", "days", "later", "was", "transferred", "to", "a", "peripheral", "ward", ".", "On", "the", "next", "day", "he", "died", ",", "probably", "as", "a", "result", "of", "heart", "failure", ".", "Serum", "samples", "from", "the", "first", "and", "second", "days", "contained", "3", ".", "6", "and", "1", ".", "9", "mg", "/", "l", "carbachol", ",", "respectively", ".", "The", "corresponding", "urine", "concentrations", "amounted", "to", "374", "and", "554", "mg", "/", "l", ".", "CONCLUSION", ":", "This", "case", "started", "with", "a", "media", "report", "in", "a", "popular", "newspaper", ",", "initiated", "by", "published", ",", "peer", "-", "reviewed", "research", "on", "herbals", ",", "and", "involved", "human", "failure", "in", "a", "case", "history", ",", "medical", "examination", "and", "clinical", "treatment", ".", "For", "the", "first", "time", ",", "an", "analytical", "method", "for", "the", "determination", "of", "carbachol", "in", "plasma", "and", "urine", "has", "been", "developed", ".", "The", "analysed", "carbachol", "concentration", "exceeded", "the", "supposed", "serum", "level", "resulting", "from", "a", "therapeutic", "dose", "by", "a", "factor", "of", "130", "to", "260", ".", "Especially", "in", "old", "patients", ",", "intensivists", "should", "consider", "intoxications", "(", "with", "cholinergics", ")", "as", "a", "cause", "of", "acute", "cardiovascular", "failure", "."]], "ner": [[[5, 5, "Chemical"], [12, 12, "Chemical"], [78, 78, "Chemical"], [84, 84, "Chemical"], [91, 91, "Chemical"], [109, 109, "Chemical"], [321, 321, "Chemical"], [390, 390, "Chemical"], [401, 401, "Chemical"], [141, 141, "Disease"], [145, 145, "Disease"], [151, 151, "Disease"], [156, 156, "Disease"], [198, 198, "Disease"], [200, 200, "Disease"], [206, 206, "Disease"], [299, 300, "Disease"], [33, 33, "Disease"], [58, 60, "Disease"], [212, 215, "Disease"], [248, 248, "Disease"], [250, 250, "Disease"], [254, 255, "Disease"], [260, 262, "Disease"], [438, 440, "Disease"], [166, 166, "Chemical"], [168, 168, "Chemical"], [231, 231, "Chemical"], [171, 171, "Chemical"], [220, 220, "Chemical"], [173, 173, "Chemical"], [233, 233, "Chemical"]]], "relations": [[[5, 5, 141, 141, "CID"], [12, 12, 141, 141, "CID"], [78, 78, 141, 141, "CID"], [84, 84, 141, 141, "CID"], [91, 91, 141, 141, "CID"], [109, 109, 141, 141, "CID"], [321, 321, 141, 141, "CID"], [390, 390, 141, 141, "CID"], [401, 401, 141, 141, "CID"], [5, 5, 145, 145, "CID"], [12, 12, 145, 145, "CID"], [78, 78, 145, 145, "CID"], [84, 84, 145, 145, "CID"], [91, 91, 145, 145, "CID"], [109, 109, 145, 145, "CID"], [321, 321, 145, 145, "CID"], [390, 390, 145, 145, "CID"], [401, 401, 145, 145, "CID"], [5, 5, 151, 151, "CID"], [12, 12, 151, 151, "CID"], [78, 78, 151, 151, "CID"], [84, 84, 151, 151, "CID"], [91, 91, 151, 151, "CID"], [109, 109, 151, 151, "CID"], [321, 321, 151, 151, "CID"], [390, 390, 151, 151, "CID"], [401, 401, 151, 151, "CID"], [5, 5, 156, 156, "CID"], [12, 12, 156, 156, "CID"], [78, 78, 156, 156, "CID"], [84, 84, 156, 156, "CID"], [91, 91, 156, 156, "CID"], [109, 109, 156, 156, "CID"], [321, 321, 156, 156, "CID"], [390, 390, 156, 156, "CID"], [401, 401, 156, 156, "CID"], [5, 5, 198, 198, "CID"], [12, 12, 198, 198, "CID"], [78, 78, 198, 198, "CID"], [84, 84, 198, 198, "CID"], [91, 91, 198, 198, "CID"], [109, 109, 198, 198, "CID"], [321, 321, 198, 198, "CID"], [390, 390, 198, 198, "CID"], [401, 401, 198, 198, "CID"], [5, 5, 200, 200, "CID"], [12, 12, 200, 200, "CID"], [78, 78, 200, 200, "CID"], [84, 84, 200, 200, "CID"], [91, 91, 200, 200, "CID"], [109, 109, 200, 200, "CID"], [321, 321, 200, 200, "CID"], [390, 390, 200, 200, "CID"], [401, 401, 200, 200, "CID"], [5, 5, 206, 206, "CID"], [12, 12, 206, 206, "CID"], [78, 78, 206, 206, "CID"], [84, 84, 206, 206, "CID"], [91, 91, 206, 206, "CID"], [109, 109, 206, 206, "CID"], [321, 321, 206, 206, "CID"], [390, 390, 206, 206, "CID"], [401, 401, 206, 206, "CID"], [5, 5, 299, 300, "CID"], [12, 12, 299, 300, "CID"], [78, 78, 299, 300, "CID"], [84, 84, 299, 300, "CID"], [91, 91, 299, 300, "CID"], [109, 109, 299, 300, "CID"], [321, 321, 299, 300, "CID"], [390, 390, 299, 300, "CID"], [401, 401, 299, 300, "CID"]]], "clusters": [], "translated": "病例报告：急性无意<0>卡巴胆碱</0>中毒。简介：<1>卡巴胆碱</1>（一种毒蕈碱性胆碱能受体激动剂）引起的中毒很少见。我们报告了一个调查（接近）致命<17>中毒</17>的有趣案例。方法：一位 84 岁男性的儿子发现了一份报纸报道，该报道称植物提取物在<18>阿尔茨海默氏病</18>中取得了临床成功。据说其作用方式与合成化合物“<2>氨甲酰胆碱</2>”相当；即<3>卡巴胆碱</3>。他在药房买了 25 克纯净的<4>卡巴胆碱</4>，给父亲服用了 400 到 500 毫克。入院第 1 天和第 2 天血清和尿液中的<5>卡巴胆碱</5>浓度采用高效液相色谱-质谱法进行分析。结果：口服后数分钟，患者出现<9>恶心</9>、出汗和<10>低血压</10>，最后昏倒。<11>心动过缓</11>、胆碱能症状和<12>心搏停止</12>发生。初步心肺复苏和立即用<25>肾上腺素</25>（<26>肾上腺素</26>）、<28>阿托品</28>和<30>速尿</30>治疗是成功的。入院时，插管的缓慢性心律失常患者的血压为 100/65 毫米汞柱。进一步的体征是<13>多汗症</13>、<14>唾液分泌过多</14>、支气管分泌物增多和严重的<15>瞳孔缩小</15>；心电图检查结果为<19>房室分离</19>。需要高剂量的<29>阿托品</29>（高达每 24 小时 50 毫克）、<27>肾上腺素</27>和<31>多巴胺</31>。患者 1 周后拔管。然而，<20>呼吸困难</20>和<21>支气管痉挛</21>的加重需要重新插管。<22>呼吸功能不全</22>因<23>奇异变形杆菌感染</23>和严重的支气管收缩而进一步恶化。1 周后再次拔管，3 天后转入外周病房。第二天他就死了，可能是因为<16>心力衰竭</16>。第一天和第二天的血清样本含有 3.6 和 1.9 毫克/升<6>卡巴胆碱</6>，相应的尿浓度为 374 和 554 毫克/升。结论：该病例始于一份大众报纸上的媒体报道，由发表的、经过同行评审的草药研究发起，并涉及病史、医学检查和临床治疗中的人为失败。首次建立了测定血浆和尿液中<7>卡巴胆碱</7>的分析方法。分析的<8>卡巴胆碱</8>浓度超过治疗剂量产生的假定血清水平 130 至 260 倍。特别是对于老年患者，重症监护医师应将中毒（使用胆碱能药物）视为<24>急性心血管衰竭</24>的原因。", "revised": true}
{"doc_key": "19300402", "sentences": [["Bradykinin", "receptors", "antagonists", "and", "nitric", "oxide", "synthase", "inhibitors", "in", "vincristine", "and", "streptozotocin", "induced", "hyperalgesia", "in", "chemotherapy", "and", "diabetic", "neuropathy", "rat", "model", ".", "PURPOSE", ":", "The", "influence", "of", "an", "irreversible", "inhibitor", "of", "constitutive", "NO", "synthase", "(", "L", "-", "NOArg", ";", "1", ".", "0", "mg", "/", "kg", "ip", ")", ",", "a", "relatively", "selective", "inhibitor", "of", "inducible", "NO", "synthase", "(", "L", "-", "NIL", ";", "1", ".", "0", "mg", "/", "kg", "ip", ")", "and", "a", "relatively", "specific", "inhibitor", "of", "neuronal", "NO", "synthase", "(", "7", "-", "NI", ";", "0", ".", "1", "mg", "/", "kg", "ip", ")", ",", "on", "antihyperalgesic", "action", "of", "selective", "antagonists", "of", "B2", "and", "B1", "receptors", ":", "D", "-", "Arg", "-", "[", "Hyp3", ",", "Thi5", ",", "D", "-", "Tic7", ",", "Oic8", "]", "bradykinin", "(", "HOE", "140", ";", "70", "nmol", "/", "kg", "ip", ")", "or", "des", "Arg10", "HOE", "140", "(", "70", "nmol", "/", "kg", "ip", ")", "respectively", ",", "in", "model", "of", "diabetic", "(", "streptozotocin", "-", "induced", ")", "and", "toxic", "(", "vincristine", "-", "induced", ")", "neuropathy", "was", "investigated", ".", "METHODS", ":", "The", "changes", "in", "pain", "thresholds", "were", "determined", "using", "mechanical", "stimuli", "-", "-", "the", "modification", "of", "the", "classic", "paw", "withdrawal", "test", "described", "by", "Randall", "-", "Selitto", ".", "RESULTS", ":", "The", "results", "of", "this", "paper", "confirm", "that", "inhibition", "of", "bradykinin", "receptors", "and", "inducible", "NO", "synthase", "but", "not", "neuronal", "NO", "synthase", "activity", "reduces", "diabetic", "hyperalgesia", ".", "Pretreatment", "with", "L", "-", "NOArg", "and", "L", "-", "NIL", "but", "not", "7", "-", "NI", ",", "significantly", "increases", "antihyperalgesic", "activity", "both", "HOE", "140", "and", "des", "Arg10", "HOE", "140", ".", "It", "was", "also", "shown", "that", "both", "products", "of", "inducible", "NO", "synthase", "and", "neuronal", "NO", "synthase", "activation", "as", "well", "as", "bradykinin", "are", "involved", "in", "hyperalgesia", "produced", "by", "vincristine", ".", "Moreover", ",", "L", "-", "NOArg", "and", "7", "-", "NI", "but", "not", "L", "-", "NIL", "intensify", "antihyperalgesic", "activity", "of", "HOE", "140", "or", "des", "-", "Arg10HOE", "140", "in", "toxic", "neuropathy", ".", "CONCLUSIONS", ":", "Results", "of", "these", "studies", "suggest", "that", "B1", "and", "B2", "receptors", "are", "engaged", "in", "transmission", "of", "nociceptive", "stimuli", "in", "both", "diabetic", "and", "toxic", "neuropathy", ".", "In", "streptozotocin", "-", "induced", "hyperalgesia", ",", "inducible", "NO", "synthase", "participates", "in", "pronociceptive", "activity", "of", "bradykinin", ",", "whereas", "in", "vincristine", "-", "induced", "hyperalgesia", "bradykinin", "seemed", "to", "activate", "neuronal", "NO", "synthase", "pathway", ".", "Therefore", ",", "concomitant", "administration", "of", "small", "doses", "of", "bradykinin", "receptor", "antagonists", "and", "NO", "synthase", "inhibitors", "can", "be", "effective", "in", "alleviation", "of", "neuropathic", "pain", ",", "even", "in", "hospital", "care", "."]], "ner": [[[9, 9, "Chemical"], [273, 273, "Chemical"], [348, 348, "Chemical"], [13, 13, "Disease"], [216, 217, "Disease"], [270, 270, "Disease"], [334, 334, "Disease"], [351, 351, "Disease"], [147, 160, "Disease"], [301, 302, "Disease"], [325, 328, "Disease"], [11, 11, "Chemical"], [331, 331, "Chemical"], [17, 18, "Disease"], [0, 0, "Chemical"], [119, 119, "Chemical"], [203, 203, "Chemical"], [266, 266, "Chemical"], [344, 344, "Chemical"], [352, 352, "Chemical"], [369, 369, "Chemical"], [169, 169, "Disease"], [382, 383, "Disease"], [4, 5, "Chemical"], [32, 32, "Chemical"], [54, 54, "Chemical"], [76, 76, "Chemical"], [207, 207, "Chemical"], [212, 212, "Chemical"], [256, 256, "Chemical"], [260, 260, "Chemical"], [337, 337, "Chemical"], [357, 357, "Chemical"], [373, 373, "Chemical"], [121, 122, "Chemical"], [239, 240, "Chemical"], [293, 294, "Chemical"], [131, 134, "Chemical"], [242, 245, "Chemical"], [296, 299, "Chemical"]]], "relations": [[[9, 9, 13, 13, "CID"], [9, 9, 216, 217, "CID"], [9, 9, 270, 270, "CID"], [9, 9, 334, 334, "CID"], [9, 9, 351, 351, "CID"], [273, 273, 13, 13, "CID"], [273, 273, 216, 217, "CID"], [273, 273, 270, 270, "CID"], [273, 273, 334, 334, "CID"], [273, 273, 351, 351, "CID"], [348, 348, 13, 13, "CID"], [348, 348, 216, 217, "CID"], [348, 348, 270, 270, "CID"], [348, 348, 334, 334, "CID"], [348, 348, 351, 351, "CID"], [9, 9, 147, 160, "CID"], [9, 9, 301, 302, "CID"], [9, 9, 325, 328, "CID"], [273, 273, 147, 160, "CID"], [273, 273, 301, 302, "CID"], [273, 273, 325, 328, "CID"], [348, 348, 147, 160, "CID"], [348, 348, 301, 302, "CID"], [348, 348, 325, 328, "CID"], [11, 11, 13, 13, "CID"], [11, 11, 216, 217, "CID"], [11, 11, 270, 270, "CID"], [11, 11, 334, 334, "CID"], [11, 11, 351, 351, "CID"], [331, 331, 13, 13, "CID"], [331, 331, 216, 217, "CID"], [331, 331, 270, 270, "CID"], [331, 331, 334, 334, "CID"], [331, 331, 351, 351, "CID"], [11, 11, 17, 18, "CID"], [11, 11, 147, 160, "CID"], [11, 11, 325, 328, "CID"], [331, 331, 17, 18, "CID"], [331, 331, 147, 160, "CID"], [331, 331, 325, 328, "CID"]]], "clusters": [], "translated": " <14>缓激肽</14>受体拮抗剂和<23>一氧化氮</23>合酶抑制剂在<0>长春新碱</0>和<11>链脲佐菌素</11>诱导的<3>痛觉过敏</3>化疗和<13>糖尿病神经病变</13>大鼠模型中。目的：不可逆组成型<24>NO</24>合酶抑制剂 (L-NOArg; 1.0 mg/kg ip)，一种相对选择性的诱导型<25>NO</25>合酶抑制剂 (L-NIL; 1.0 mg/kg ip)和一种相对特异性的神经元<26>NO</26>合酶抑制剂(7-NI; 0.1 mg/kg ip)，对B2和B1的选择性拮抗剂的抗痛觉过敏作用：<15>D-Arg-[Hyp3、Thi5、D-Tic7、Oic8]</15><15>缓激肽</15>（<34>HOE 140</34>; 70 nmol/kg ip）或<37>des Arg10 HOE 140</37> (70 nmol/kg ip)。分别在<8>糖尿病（链脲佐菌素诱导）和中毒性（长春新碱诱导）神经病变</8>模型中研究。方法：使用机械刺激确定<21>疼痛</21>阈值的变化 -由Randall-Selitto描述的经典缩爪试验的改进版。结果：本文的结果证实，抑制<16>缓激肽</16>受体和诱导型<27>NO</27>合酶而非神经元<28>NO</28>合酶活性可降低<4>糖尿病痛觉过敏</4>。用L-NOArg和L-NIL但不是7-NI预处理显着增加了<35>HOE 140</35>和<38>des Arg10 HOE 140</38> 的抗痛觉过敏活性。还表明，诱导型<29>NO</29>合酶和神经元<30>NO</30>合酶激活的产物以及<17>缓激肽</17>都参与了<5>痛觉过敏</5>由<1>长春新碱</1>产生。此外，L-NOArg和7-NI而不是L-NIL可增强<36>HOE 140</36>或<39>des-Arg10HOE 140</39>在<9>中毒性神经病</9>中的抗痛觉过敏活性。结论：这些研究的结果表明，B1和B2受体参与了<10>糖尿病和中毒性神经病</10>中伤害性刺激的传递。在<12>链脲佐菌素</12>诱导的<6>痛觉过敏 </6>中，可诱导的<31>NO</31>合酶参与<18>缓激肽</18>的伤害感受活性，而在<2>长春新碱</2>-诱导的<7>痛觉过敏</7>中<19>缓激肽 </19>似乎激活了神经元<32>NO</32>合酶途径。因此，同时服用小剂量的<20>缓激肽</20>受体拮抗剂和<33>NO</33>合酶抑制剂可有效缓解<22>神经性疼痛</22>，即使在住院治疗中也是如此。", "revised": true}
{"doc_key": "11928786", "sentences": [["Bupropion", "(", "Zyban", ")", "toxicity", ".", "Bupropion", "is", "a", "monocyclic", "antidepressant", "structurally", "related", "to", "amphetamine", ".", "Zyban", ",", "a", "sustained", "-", "release", "formulation", "of", "bupropion", "hydrochloride", ",", "was", "recently", "released", "in", "Ireland", ",", "as", "a", "smoking", "cessation", "aid", ".", "In", "the", "initial", "6", "months", "since", "it", "'s", "introduction", ",", "12", "overdose", "cases", "have", "been", "reported", "to", "The", "National", "Poisons", "Information", "Centre", ".", "8", "patients", "developed", "symptoms", "of", "toxicity", ".", "Common", "features", "included", "tachycardia", ",", "drowsiness", ",", "hallucinations", "and", "convulsions", ".", "Two", "patients", "developed", "severe", "cardiac", "arrhythmias", ",", "including", "one", "patient", "who", "was", "resuscitated", "following", "a", "cardiac", "arrest", ".", "All", "patients", "recovered", "without", "sequelae", ".", "We", "report", "a", "case", "of", "a", "31", "year", "old", "female", "who", "required", "admission", "to", "the", "Intensive", "Care", "Unit", "for", "ventilation", "and", "full", "supportive", "therapy", ",", "following", "ingestion", "of", "13", ".", "5g", "bupropion", ".", "Recurrent", "seizures", "were", "treated", "with", "diazepam", "and", "broad", "complex", "tachycardia", "was", "successfully", "treated", "with", "adenosine", ".", "Zyban", "caused", "significant", "neurological", "and", "cardiovascular", "toxicity", "in", "overdose", ".", "The", "potential", "toxic", "effects", "should", "be", "considered", "when", "prescribing", "it", "as", "a", "smoking", "cessation", "aid", "."]], "ner": [[[0, 0, "Chemical"], [2, 2, "Chemical"], [6, 6, "Chemical"], [16, 16, "Chemical"], [24, 25, "Chemical"], [135, 135, "Chemical"], [153, 153, "Chemical"], [72, 72, "Disease"], [146, 146, "Disease"], [76, 76, "Disease"], [78, 78, "Disease"], [138, 138, "Disease"], [84, 85, "Disease"], [95, 96, "Disease"], [4, 4, "Disease"], [67, 67, "Disease"], [50, 50, "Disease"], [161, 161, "Disease"], [156, 159, "Disease"], [10, 10, "Chemical"], [14, 14, "Chemical"], [142, 142, "Chemical"], [151, 151, "Chemical"]]], "relations": [[[0, 0, 72, 72, "CID"], [0, 0, 146, 146, "CID"], [2, 2, 72, 72, "CID"], [2, 2, 146, 146, "CID"], [6, 6, 72, 72, "CID"], [6, 6, 146, 146, "CID"], [16, 16, 72, 72, "CID"], [16, 16, 146, 146, "CID"], [24, 25, 72, 72, "CID"], [24, 25, 146, 146, "CID"], [135, 135, 72, 72, "CID"], [135, 135, 146, 146, "CID"], [153, 153, 72, 72, "CID"], [153, 153, 146, 146, "CID"], [0, 0, 76, 76, "CID"], [2, 2, 76, 76, "CID"], [6, 6, 76, 76, "CID"], [16, 16, 76, 76, "CID"], [24, 25, 76, 76, "CID"], [135, 135, 76, 76, "CID"], [153, 153, 76, 76, "CID"], [0, 0, 78, 78, "CID"], [0, 0, 138, 138, "CID"], [2, 2, 78, 78, "CID"], [2, 2, 138, 138, "CID"], [6, 6, 78, 78, "CID"], [6, 6, 138, 138, "CID"], [16, 16, 78, 78, "CID"], [16, 16, 138, 138, "CID"], [24, 25, 78, 78, "CID"], [24, 25, 138, 138, "CID"], [135, 135, 78, 78, "CID"], [135, 135, 138, 138, "CID"], [153, 153, 78, 78, "CID"], [153, 153, 138, 138, "CID"], [0, 0, 84, 85, "CID"], [2, 2, 84, 85, "CID"], [6, 6, 84, 85, "CID"], [16, 16, 84, 85, "CID"], [24, 25, 84, 85, "CID"], [135, 135, 84, 85, "CID"], [153, 153, 84, 85, "CID"], [0, 0, 95, 96, "CID"], [2, 2, 95, 96, "CID"], [6, 6, 95, 96, "CID"], [16, 16, 95, 96, "CID"], [24, 25, 95, 96, "CID"], [135, 135, 95, 96, "CID"], [153, 153, 95, 96, "CID"]]], "clusters": [], "translated": " <0>安非他酮</0>（<1>Zyban</1>）<14>毒性</14>。<2>安非他酮</2>是一种单环<19>抗抑郁药</19>，与<20>苯丙胺</20>结构上相关。<3>Zyban</3>是一种<4>氢氯酸安非他酮</4>的缓释制剂，最近在爱尔兰上市，用作戒烟辅助剂。在其推出后的最初6个月内，已向国家毒物信息中心报告了12起<16>过量</16>病例。8名患者出现<15>毒性</15>症状。常见特征包括<7>心动过速</7>、嗜睡、<9>幻觉</9>和<10>抽搐</10>。两名患者出现严重的<12>心律失常</12>，其中一名患者在<13>心脏骤停</13>后复苏。全部痊愈，无后遗症。我们报告了一名31岁女性的病例，她摄入了13.5克<5>安非他酮</5>，需要进入重症监护病房进行通气和全面支持治疗。复发性<11>癫痫发作</11>使用<21>地西泮</21>治疗，宽波QRS<8>心动过速</8>使用<22>腺苷</22>成功治疗。<6>Zyban</6>在<17>过量</17>中引起显着的<18>神经和心血管毒性</18>。将其用作戒烟辅助剂时，应考虑潜在的毒性作用。", "revised": true}
{"doc_key": "1009330", "sentences": [["Further", "studies", "on", "effects", "of", "irrigation", "solutions", "on", "rat", "bladders", ".", "Further", "studies", "on", "the", "effects", "of", "certain", "irrigating", "fluids", "on", "the", "rat", "bladder", "for", "18", "hours", "are", "reported", ".", "The", "results", "have", "shown", "that", "the", "degradation", "product", "p", "-", "choloroaniline", "is", "not", "a", "significant", "factor", "in", "chlorhexidine", "-", "digluconate", "associated", "erosive", "cystitis", ".", "A", "high", "percentage", "of", "kanamycin", "-", "colistin", "and", "povidone", "-", "iodine", "irrigations", "were", "associated", "with", "erosive", "cystitis", "and", "suggested", "a", "possible", "complication", "with", "human", "usage", ".", "Picloxydine", "irrigations", "appeared", "to", "have", "a", "lower", "incidence", "of", "erosive", "cystitis", "but", "further", "studies", "would", "have", "to", "be", "performed", "before", "it", "could", "be", "recommended", "for", "use", "in", "urological", "procedures", "."]], "ner": [[[47, 49, "Chemical"], [52, 52, "Disease"], [70, 70, "Disease"], [90, 90, "Disease"], [58, 58, "Chemical"], [60, 60, "Chemical"], [62, 64, "Chemical"], [38, 40, "Chemical"], [80, 80, "Chemical"]]], "relations": [[[47, 49, 52, 52, "CID"], [47, 49, 70, 70, "CID"], [47, 49, 90, 90, "CID"], [58, 58, 52, 52, "CID"], [58, 58, 70, 70, "CID"], [58, 58, 90, 90, "CID"], [60, 60, 52, 52, "CID"], [60, 60, 70, 70, "CID"], [60, 60, 90, 90, "CID"], [62, 64, 52, 52, "CID"], [62, 64, 70, 70, "CID"], [62, 64, 90, 90, "CID"]]], "clusters": [], "translated": "进一步研究冲洗液对大鼠膀胱的影响。进一步研究了某些冲洗液对大鼠膀胱 18 小时的影响。结果表明，降解产物<7>对氯苯胺</7>不是<0>氯己定-二葡萄糖酸盐</0>相关糜烂性<1>膀胱炎</1>的重要因素。高比例的<4>卡那霉素</4> - <5>粘菌素</5> 和<6>聚维酮-碘</6> 冲洗与糜烂性<2>膀胱炎</2>相关，提示可能存在并发症。 <8>Picloxydine</8> 冲洗似乎具有较低的<3>糜烂性膀胱炎</3>发生率，但在推荐用于泌尿外科手术之前必须进行进一步的研究。", "revised": true}
{"doc_key": "1436384", "sentences": [["Protection", "against", "amphetamine", "-", "induced", "neurotoxicity", "toward", "striatal", "dopamine", "neurons", "in", "rodents", "by", "LY274614", ",", "an", "excitatory", "amino", "acid", "antagonist", ".", "LY274614", ",", "3SR", ",", "4aRS", ",", "6SR", ",", "8aRS", "-", "6", "-", "[", "phosphonomethyl", "]", "decahydr", "oisoquinoline", "-", "3", "-", "carboxylic", "acid", ",", "has", "been", "described", "as", "a", "potent", "antagonist", "of", "the", "N", "-", "methyl", "-", "D", "-", "aspartate", "(", "NMDA", ")", "subtype", "of", "glutamate", "receptor", ".", "Here", "its", "ability", "to", "antagonize", "the", "prolonged", "depletion", "of", "dopamine", "in", "the", "striatum", "by", "amphetamine", "in", "iprindole", "-", "treated", "rats", "is", "reported", ".", "A", "single", "18", ".", "4", "mg", "/", "kg", "(", "i", ".", "p", ".", ")", "dose", "of", "(", "+", "/", "-", ")", "-", "amphetamine", "hemisulfate", ",", "given", "to", "rats", "pretreated", "with", "iprindole", ",", "resulted", "in", "persistent", "depletion", "of", "dopamine", "in", "the", "striatum", "1", "week", "later", ".", "This", "prolonged", "depletion", "of", "dopamine", "in", "the", "striatum", "was", "antagonized", "by", "dizocilpine", "(", "MK", "-", "801", ",", "a", "non", "-", "competitive", "antagonist", "of", "NMDA", "receptors", ")", "or", "by", "LY274614", "(", "a", "competitive", "antagonist", "of", "NMDA", "receptors", ")", ".", "The", "protective", "effect", "of", "LY274614", "was", "dose", "-", "dependent", ",", "being", "maximum", "at", "10", "-", "40", "mgkg", "(", "i", ".", "p", ".", ")", ".", "A", "10", "mg", "/", "kg", "dose", "of", "LY274614", "was", "effective", "in", "antagonizing", "the", "depletion", "of", "dopamine", "in", "the", "striatum", ",", "when", "given", "as", "long", "as", "8", "hr", "prior", "to", "amphetamine", "but", "not", "when", "given", "24", "hr", "prior", "to", "amphetamine", ".", "Depletion", "of", "dopamine", "in", "the", "striatum", "was", "also", "antagonized", "when", "LY274614", "was", "given", "after", "the", "injection", "of", "amphetamine", ";", "LY274614", "protected", "when", "given", "up", "to", "4", "hr", "after", "but", "not", "when", "given", "8", "or", "24", "hr", "after", "amphetamine", ".", "The", "prolonged", "depletion", "of", "dopamine", "in", "the", "striatum", "in", "mice", ",", "given", "multiple", "injections", "of", "methamphetamine", ",", "was", "also", "antagonized", "dose", "-", "dependently", "and", "completely", "by", "LY274614", ".", "The", "data", "strengthen", "the", "evidence", "that", "the", "neurotoxic", "effect", "of", "amphetamine", "and", "related", "compounds", "toward", "nigrostriatal", "dopamine", "neurons", "involves", "NMDA", "receptors", "and", "that", "LY274614", "is", "an", "NMDA", "receptor", "antagonist", "with", "long", "-", "lasting", "in", "vivo", "effects", "in", "rats", "."]], "ner": [[[2, 2, "Chemical"], [82, 82, "Chemical"], [113, 113, "Chemical"], [227, 227, "Chemical"], [236, 236, "Chemical"], [255, 255, "Chemical"], [275, 275, "Chemical"], [315, 315, "Chemical"], [5, 5, "Disease"], [312, 312, "Disease"], [8, 8, "Chemical"], [77, 77, "Chemical"], [128, 128, "Chemical"], [140, 140, "Chemical"], [213, 213, "Chemical"], [240, 240, "Chemical"], [281, 281, "Chemical"], [321, 321, "Chemical"], [13, 13, "Chemical"], [21, 21, "Chemical"], [23, 42, "Chemical"], [164, 164, "Chemical"], [178, 178, "Chemical"], [205, 205, "Chemical"], [248, 248, "Chemical"], [257, 257, "Chemical"], [303, 303, "Chemical"], [328, 328, "Chemical"], [17, 18, "Chemical"], [53, 59, "Chemical"], [61, 61, "Chemical"], [159, 159, "Chemical"], [170, 170, "Chemical"], [324, 324, "Chemical"], [331, 331, "Chemical"], [65, 65, "Chemical"], [84, 84, "Chemical"], [121, 121, "Chemical"], [147, 147, "Chemical"], [149, 151, "Chemical"], [292, 292, "Chemical"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 312, 312, "CID"], [82, 82, 5, 5, "CID"], [82, 82, 312, 312, "CID"], [113, 113, 5, 5, "CID"], [113, 113, 312, 312, "CID"], [227, 227, 5, 5, "CID"], [227, 227, 312, 312, "CID"], [236, 236, 5, 5, "CID"], [236, 236, 312, 312, "CID"], [255, 255, 5, 5, "CID"], [255, 255, 312, 312, "CID"], [275, 275, 5, 5, "CID"], [275, 275, 312, 312, "CID"], [315, 315, 5, 5, "CID"], [315, 315, 312, 312, "CID"]]], "clusters": [], "translated": "通过<18>LY274614</18>一种兴奋性<28>氨基酸</28>，防止<0>苯丙胺</0>对啮齿类动物纹状体<10>多巴胺</10>神经元引起的<8>神经毒性</8>拮抗剂。 <19>LY274614</19>，<20>3SR，4aRS，6SR，8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3-carboxylic acid</20>，已被描述为<29>N-甲基-D-天冬氨酸</29>（<30>NMDA</30>）<35>谷氨酸</35>受体的亚型。此处报道了在<36>伊普吲多</36>治疗的大鼠中，它能够拮抗<1>苯丙胺</1>对纹状体中<11>多巴胺</11>的长期消耗。一个18.4 mg/kg (i.p.)剂量的(+/-)-<2>安非他明</2>半硫酸盐，给予用<37>伊普吲多</37> 预处理的大鼠，导致<12>持续耗竭1周后纹状体中的多巴胺</12>。纹状体中<13>多巴胺</13>的这种长期消耗被<38> 地佐西平</38>(<39>MK-801</39>，一种<31>NMDA</31>受体)或通过<21>LY274614</21>（<32>NMDA</32>受体的竞争性拮抗剂）。<22>LY274614</22>的保护作用是剂量依赖性的，在10-40 mg/kg (i.p.)时最大。10 mg/kg 剂量的<23>LY274614</23>可有效拮抗纹状体中<14>多巴胺</14>的消耗，只要在<3>安非他明</3>之前给予8小时，但不是在<4>苯丙胺</4>之前24小时给予。当在注射<5>安非他明</5>后给予<24>LY274614</24>时，纹状体中<15>多巴胺</15>的消耗也被拮抗；<25>LY274614</25>在4小时后给予保护，但在<6>安非他明</6>后8或24小时给予时不受保护。多次注射<40>甲基苯丙胺</40>后，小鼠纹状体中<16>多巴胺</16>的长期消耗也被<26>LY274614</26>剂量依赖性地完全拮抗。这些数据进一步证明了<7>苯丙胺</7>和相关化合物对黑质纹状体<17>多巴胺</17>神经元的<9>神经毒性</9>作用涉及<33>NMDA</33>受体和<27>LY274614</27>是一种<34>NMDA</34>受体拮抗剂，在大鼠体内具有持久的体内作用。", "revised": true}
{"doc_key": "20698227", "sentences": [["Can", "angiogenesis", "be", "a", "target", "of", "treatment", "for", "ribavirin", "associated", "hemolytic", "anemia", "?", "BACKGROUND", "/", "AIMS", ":", "Recently", "ribavirin", "has", "been", "found", "to", "inhibit", "angiogenesis", "and", "a", "number", "of", "angiogenesis", "inhibitors", "such", "as", "sunitinib", "and", "sorafenib", "have", "been", "found", "to", "cause", "acute", "hemolysis", ".", "We", "aimed", "to", "investigate", "whether", "there", "is", "a", "relation", "between", "hemoglobin", ",", "haptoglobin", "and", "angiogenesis", "soluble", "markers", "which", "are", "modifiable", "and", "can", "help", "in", "developing", "strategies", "against", "anemia", ".", "METHODS", ":", "Fourteen", "patients", "chronically", "infected", "with", "hepatitis", "C", "virus", "were", "treated", "by", "pegylated", "interferon", "alpha", "2a", "and", "ribavirin", ".", "Serum", "hemoglobin", ",", "haptoglobin", "and", "angiogenesis", "markers", "of", "vascular", "endothelial", "growth", "factor", "and", "angiopoetin", "-", "2", "were", "investigated", "before", "and", "after", "therapy", ".", "RESULTS", ":", "We", "observed", "a", "significant", "decrease", "in", "haptoglobin", "levels", "at", "the", "end", "of", "the", "treatment", "period", ".", "Hemoglobin", "levels", "also", "decreased", "but", "insignificantly", "by", "treatment", ".", "In", "contrast", "with", "the", "literature", ",", "serum", "levels", "of", "angiogenesis", "factors", "did", "not", "change", "significantly", "by", "pegylated", "interferon", "and", "ribavirin", "therapy", ".", "We", "found", "no", "correlation", "of", "angiogenesis", "soluble", "markers", "with", "either", "hemoglobin", "or", "haptoglobin", ".", "CONCLUSION", ":", "This", "is", "the", "first", "study", "in", "the", "literature", "investigating", "a", "link", "between", "angiogenesis", "soluble", "markers", "and", "ribavirin", "induced", "anemia", "in", "patients", "with", "hepatitis", "C", "and", "we", "could", "not", "find", "any", "relation", ".", "Future", "research", "with", "larger", "number", "of", "patients", "is", "needed", "to", "find", "out", "modifiable", "factors", "that", "will", "improve", "the", "safety", "of", "ribavirin", "therapy", "."]], "ner": [[[33, 33, "Chemical"], [42, 42, "Disease"], [35, 35, "Chemical"], [8, 8, "Chemical"], [18, 18, "Chemical"], [91, 91, "Chemical"], [162, 162, "Chemical"], [197, 197, "Chemical"], [233, 233, "Chemical"], [10, 11, "Disease"], [71, 71, "Disease"], [199, 199, "Disease"], [77, 82, "Disease"], [203, 204, "Disease"], [86, 89, "Chemical"], [159, 160, "Chemical"]]], "relations": [[[33, 33, 42, 42, "CID"], [35, 35, 42, 42, "CID"]]], "clusters": [], "translated": "血管生成能否成为<3>利巴韦林</3><0>相关</0><9>溶血性贫血</9>的治疗靶点？背景/目的：最近<4>利巴韦林</4>被发现抑制血管生成，许多血管生成抑制剂如<0>舒尼替尼</0>和<2>索拉非尼</2>被发现可引起急性<1>溶血</1>。我们的目的是调查血红蛋白、触珠蛋白和血管生成可溶性标记物之间是否存在关系，这些标记物是可改变的，可以帮助制定针对<10>贫血</10>的策略。方法：14例<12>慢性丙型肝炎病毒感染</12>患者采用<14>聚乙二醇干扰素α2a</14>和<5>利巴韦林</5>治疗。治疗前后检测血清血红蛋白、触珠蛋白和血管生成标志物血管内皮生长因子和血管生成素-2。结果：我们观察到治疗期结束时触珠蛋白水平显着下降。治疗后血红蛋白水平也有所下降，但并不显着。与文献相反，<15>聚乙二醇干扰素α2a</15>和<6>利巴韦林</6>治疗后血管生成因子的血清水平没有明显变化。我们发现血管生成可溶性标志物与血红蛋白或触珠蛋白没有相关性。结论：这是文献中第一项调查血管生成可溶性标志物与<7>利巴韦林</7>诱导的<13>丙型肝炎</13>患者<11>贫血</11>之间联系的研究，我们找不到任何关系。未来需要对更多患者进行研究，以找出可提高<8>利巴韦林</8>治疗安全性的可改变因素。", "revised": true}
{"doc_key": "347884", "sentences": [["Clinical", "experiences", "in", "an", "open", "and", "a", "double", "-", "blind", "trial", ".", "A", "total", "of", "sixty", "patients", "were", "trated", "with", "bromperidol", "first", "in", "open", "conditions", "(", "20", "patients", ")", ",", "then", "on", "a", "double", "blind", "basis", "(", "40", "patients", ")", "with", "haloperidol", "as", "the", "reference", "substance", ".", "The", "open", "study", "lasted", "for", "four", "weeks", ";", "the", "drug", "was", "administrated", "in", "the", "form", "of", "1", "mg", "tablets", ".", "The", "daily", "dose", "(", "initial", "dose", ":", "1", "mg", ";", "mean", "dose", "at", "the", "end", "of", "the", "trial", ":", "4", ".", "47", "mg", ")", "was", "always", "administered", "in", "one", "single", "dose", ".", "Nineteen", "patients", "finished", "the", "trial", ",", "and", "in", "18", "cases", "the", "therapeutic", "result", "was", "considered", "very", "good", "to", "good", ".", "These", "results", "were", "confirmed", "by", "statistical", "analysis", ".", "Nine", "patients", "exhibited", "mild", "to", "moderate", "extrapyramidal", "concomitant", "symptoms", ";", "no", "other", "side", "effects", "were", "observed", ".", "The", "results", "of", "detailed", "laboratory", "tests", "and", "evaluations", "of", "various", "quantitative", "and", "qualitative", "tolerability", "parameters", "were", "not", "indicative", "of", "toxic", "effects", ".", "In", "the", "double", "blind", "study", "with", "haloperidol", ",", "both", "substances", "were", "found", "to", "be", "highly", "effective", "in", "the", "treatment", "of", "psychotic", "syndromes", "belonging", "predominantly", "to", "the", "schizophrenia", "group", ".", "Certain", "clues", ",", "including", "the", "onset", "of", "action", ",", "seem", "to", "be", "indicative", "of", "the", "superiority", "of", "bromperidol", ".", "No", "differences", "were", "observed", "with", "respect", "to", "side", "effects", "and", "general", "tolerability", "."]], "ner": [[[20, 20, "Chemical"], [212, 212, "Chemical"], [133, 135, "Disease"], [41, 41, "Chemical"], [172, 172, "Chemical"], [186, 193, "Disease"]]], "relations": [[[20, 20, 133, 135, "CID"], [212, 212, 133, 135, "CID"], [41, 41, 133, 135, "CID"], [172, 172, 133, 135, "CID"]]], "clusters": [], "translated": "开放和双盲试验的临床经验。共有60名患者接受<0>溴哌立多</0>治疗，首先在开放条件下（20名患者），然后在双盲基础上（40名患者）使用<3>氟哌啶醇</3>作为参考物质。公开研究持续了四个星期；该药物以1毫克片剂的形式给药。每日剂量（初始剂量：1毫克；试验结束时的平均剂量：4.47毫克）始终以单次剂量给药。19名患者完成试验，18名患者的治疗结果被认为非常好。这些结果经统计分析证实。9名患者表现出轻度至中度<2>锥体外系伴随症状</2>；没有观察到其他副作用。各种定量和定性耐受性参数的详细实验室测试和评估结果并未表明毒性作用。<4>氟哌啶醇</4>的双盲研究中，这两种物质在治疗主要属于精神分裂症组的<5>精神病性综合征</5>方面均表现出良好的疗效。某些线索，包括起效，似乎表明<1>溴哌立多</1>具有优越性。在副作用和一般耐受性方面没有观察到差异。", "revised": true}
{"doc_key": "19767176", "sentences": [["Pyrrolidine", "dithiocarbamate", "protects", "the", "piriform", "cortex", "in", "the", "pilocarpine", "status", "epilepticus", "model", ".", "Pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", "has", "a", "dual", "mechanism", "of", "action", "as", "an", "antioxidant", "and", "an", "inhibitor", "of", "the", "transcription", "factor", "kappa", "-", "beta", ".", "Both", ",", "production", "of", "reactive", "oxygen", "species", "as", "well", "as", "activation", "of", "NF", "-", "kappaB", "have", "been", "implicated", "in", "severe", "neuronal", "damage", "in", "different", "sub", "-", "regions", "of", "the", "hippocampus", "as", "well", "as", "in", "the", "surrounding", "cortices", ".", "The", "effect", "of", "PDTC", "on", "status", "epilepticus", "-", "associated", "cell", "loss", "in", "the", "hippocampus", "and", "piriform", "cortex", "was", "evaluated", "in", "the", "rat", "fractionated", "pilocarpine", "model", ".", "Treatment", "with", "150", "mg", "/", "kg", "PDTC", "before", "and", "following", "status", "epilepticus", "significantly", "increased", "the", "mortality", "rate", "to", "100", "%", ".", "Administration", "of", "50", "mg", "/", "kg", "PDTC", "(", "low", "-", "dose", ")", "did", "not", "exert", "major", "effects", "on", "the", "development", "of", "a", "status", "epilepticus", "or", "the", "mortality", "rate", ".", "In", "vehicle", "-", "treated", "rats", ",", "status", "epilepticus", "caused", "pronounced", "neuronal", "damage", "in", "the", "piriform", "cortex", "comprising", "both", "pyramidal", "cells", "and", "interneurons", ".", "Low", "-", "dose", "PDTC", "treatment", "almost", "completely", "protected", "from", "lesions", "in", "the", "piriform", "cortex", ".", "A", "significant", "decrease", "in", "neuronal", "density", "of", "the", "hippocampal", "hilar", "formation", "was", "identified", "in", "vehicle", "-", "and", "PDTC", "-", "treated", "rats", "following", "status", "epilepticus", ".", "In", "conclusion", ",", "the", "NF", "-", "kappaB", "inhibitor", "and", "antioxidant", "PDTC", "protected", "the", "piriform", "cortex", ",", "whereas", "it", "did", "not", "affect", "hilar", "neuronal", "loss", ".", "These", "data", "might", "indicate", "that", "the", "generation", "of", "reactive", "oxygen", "species", "and", "activation", "of", "NF", "-", "kappaB", "plays", "a", "more", "central", "role", "in", "seizure", "-", "associated", "neuronal", "damage", "in", "the", "temporal", "cortex", "as", "compared", "to", "the", "hippocampal", "hilus", ".", "However", ",", "future", "investigations", "are", "necessary", "to", "exactly", "analyze", "the", "biochemical", "mechanisms", "by", "which", "PDTC", "exerted", "its", "beneficial", "effects", "in", "the", "piriform", "cortex", "."]], "ner": [[[8, 8, "Chemical"], [99, 99, "Chemical"], [9, 10, "Disease"], [81, 82, "Disease"], [112, 113, "Disease"], [145, 146, "Disease"], [158, 159, "Disease"], [212, 213, "Disease"], [58, 59, "Disease"], [162, 163, "Disease"], [237, 238, "Disease"], [266, 267, "Disease"], [0, 1, "Chemical"], [13, 14, "Chemical"], [16, 16, "Chemical"], [79, 79, "Chemical"], [108, 108, "Chemical"], [129, 129, "Chemical"], [178, 178, "Chemical"], [207, 207, "Chemical"], [225, 225, "Chemical"], [293, 293, "Chemical"], [263, 263, "Disease"], [43, 43, "Chemical"], [249, 249, "Chemical"]]], "relations": [[[8, 8, 9, 10, "CID"], [8, 8, 81, 82, "CID"], [8, 8, 112, 113, "CID"], [8, 8, 145, 146, "CID"], [8, 8, 158, 159, "CID"], [8, 8, 212, 213, "CID"], [99, 99, 9, 10, "CID"], [99, 99, 81, 82, "CID"], [99, 99, 112, 113, "CID"], [99, 99, 145, 146, "CID"], [99, 99, 158, 159, "CID"], [99, 99, 212, 213, "CID"], [8, 8, 58, 59, "CID"], [8, 8, 162, 163, "CID"], [8, 8, 237, 238, "CID"], [8, 8, 266, 267, "CID"], [99, 99, 58, 59, "CID"], [99, 99, 162, 163, "CID"], [99, 99, 237, 238, "CID"], [99, 99, 266, 267, "CID"]]], "clusters": [], "translated": "<12>吡咯烷二硫代氨基甲酸酯</12>在<0>毛果芸香碱</0><2>癫痫持续状态</2>模型中保护梨状皮质。<13>吡咯烷二硫代氨基甲酸酯</13> (<14>PDTC</14>)具有双重作用机制，作为抗氧化剂和转录因子kappa-beta的抑制剂。在海马体不同亚区以及周围皮质中，产生的活性<23>氧</23>物质以及NF-kappaB的活化都与严重的<8>神经元损伤</8>有关。在大鼠分级<1>毛果芸香碱</1>模型中评估<15>PDTC</15>对<3>癫痫持续状态</3>相关的海马和梨状皮质细胞丢失的影响。在<4>癫痫持续状态</4>前后用150 mg/kg <16>PDTC</16>治疗可显着增加死亡率至100%。施用50 mg/kg<17>PDTC</17>（低剂量）对<5>癫痫持续状态</5>的发展或死亡率没有产生重大影响。在载体处理的大鼠中，<6>癫痫持续状态</6>在包括梨状皮质的锥体细胞和中间神经元中引起明显的<9>神经元损伤</9>。低剂量<18>PDTC</18>治疗几乎完全保护梨状皮质免受损伤。在<7>癫痫持续状态</7>后，载体-和<19>PDTC</19> - 处理的大鼠中发现海马门形成的神经元密度显着降低。总之，NF-kappaB抑制剂和抗氧化剂<20>PDTC</20>保护梨状皮质，但不影响海马门的<10>神经元丧失</10>。这些数据可能表明活性<24>氧</24>物质的产生和NF-kappaB的活化在<22>癫痫发作</22>-相关的<11>神经元损伤</11>中起着更重要的作用与海马门相比，颞叶皮层。然而，未来的研究有必要准确分析<21>PDTC</21>在梨状皮质中发挥有益作用的生化机制。", "revised": true}
{"doc_key": "9495837", "sentences": [["Antinociceptive", "and", "antiamnesic", "properties", "of", "the", "presynaptic", "cholinergic", "amplifier", "PG", "-", "9", ".", "The", "antinociceptive", "effect", "of", "3", "alpha", "-", "tropyl", "2", "-", "(", "p", "-", "bromophenyl", ")", "propionate", "[", "(", "+", "/", "-", ")", "-", "PG", "-", "9", "]", "(", "10", "-", "40", "mg", "kg", "-", "1", "s", ".", "c", ".", ";", "30", "-", "60", "mg", "kg", "-", "1", "p", ".", "o", ".", ";", "10", "-", "30", "mg", "kg", "-", "1", "i", ".", "v", ".", ";", "10", "-", "30", "micrograms", "/", "mouse", "i", ".", "c", ".", "v", ".", ")", "was", "examined", "in", "mice", ",", "rats", "and", "guinea", "pigs", "by", "use", "of", "the", "hot", "-", "plate", ",", "abdominal", "-", "constriction", ",", "tail", "-", "flick", "and", "paw", "-", "pressure", "tests", ".", "(", "+", "/", "-", ")", "-", "PG", "-", "9", "antinociception", "peaked", "15", "min", "after", "injection", "and", "then", "slowly", "diminished", ".", "The", "antinociception", "produced", "by", "(", "+", "/", "-", ")", "-", "PG", "-", "9", "was", "prevented", "by", "the", "unselective", "muscarinic", "antagonist", "atropine", ",", "the", "M1", "-", "selective", "antagonists", "pirenzepine", "and", "dicyclomine", "and", "the", "acetylcholine", "depletor", "hemicholinium", "-", "3", ",", "but", "not", "by", "the", "opioid", "antagonist", "naloxone", ",", "the", "gamma", "-", "aminobutyric", "acidB", "antagonist", "3", "-", "aminopropyl", "-", "diethoxy", "-", "methyl", "-", "phosphinic", "acid", ",", "the", "H3", "agonist", "R", "-", "(", "alpha", ")", "-", "methylhistamine", ",", "the", "D2", "antagonist", "quinpirole", ",", "the", "5", "-", "hydroxytryptamine4", "antagonist", "2", "-", "methoxy", "-", "4", "-", "amino", "-", "5", "-", "chlorobenzoic", "acid", "2", "-", "(", "diethylamino", ")", "ethyl", "ester", "hydrochloride", ",", "the", "5", "-", "hydroxytryptamin1A", "antagonist", "1", "-", "(", "2", "-", "methoxyphenyl", ")", "-", "4", "-", "[", "4", "-", "(", "2", "-", "phthalimido", ")", "butyl", "]", "piperazine", "hydrobromide", "and", "the", "polyamines", "depletor", "reserpine", ".", "Based", "on", "these", "data", ",", "it", "can", "be", "postulated", "that", "(", "+", "/", "-", ")", "-", "PG", "-", "9", "exerted", "an", "antinociceptive", "effect", "mediated", "by", "a", "central", "potentiation", "of", "cholinergic", "transmission", ".", "(", "+", "/", "-", ")", "-", "PG", "-", "9", "(", "10", "-", "40", "mg", "kg", "-", "1", "i", ".", "p", ".", ")", "was", "able", "to", "prevent", "amnesia", "induced", "by", "scopolamine", "(", "1", "mg", "kg", "-", "1", "i", ".", "p", ".", ")", "and", "dicyclomine", "(", "2", "mg", "kg", "-", "1", "i", ".", "p", ".", ")", "in", "the", "mouse", "passive", "-", "avoidance", "test", ".", "Affinity", "profiles", "of", "(", "+", "/", "-", ")", "-", "PG", "-", "9", "for", "muscarinic", "receptor", "subtypes", ",", "determined", "by", "functional", "studies", "(", "rabbit", "vas", "deferens", "for", "M1", ",", "guinea", "pig", "atrium", "for", "M2", ",", "guinea", "pig", "ileum", "for", "M3", "and", "immature", "guinea", "pig", "uterus", "for", "putative", "M4", ")", ",", "have", "shown", "an", "M4", "/", "M1", "selectivity", "ratio", "of", "10", ".", "2", "that", "might", "be", "responsible", "for", "the", "antinociception", "and", "the", "anti", "-", "amnesic", "effect", "induced", "by", "(", "+", "/", "-", ")", "-", "PG", "-", "9", "through", "an", "increase", "in", "acetylcholine", "extracellular", "levels", ".", "In", "the", "antinociceptive", "and", "antiamnesic", "dose", "range", ",", "(", "+", "/", "-", ")", "-", "PG", "-", "9", "did", "not", "impair", "mouse", "performance", "evaluated", "by", "the", "rota", "-", "rod", "test", "and", "Animex", "apparatus", "."]], "ner": [[[169, 169, "Chemical"], [352, 352, "Chemical"], [336, 336, "Disease"], [444, 444, "Disease"], [339, 339, "Chemical"], [9, 11, "Chemical"], [17, 28, "Chemical"], [36, 38, "Chemical"], [126, 128, "Chemical"], [150, 152, "Chemical"], [294, 296, "Chemical"], [316, 318, "Chemical"], [381, 383, "Chemical"], [454, 456, "Chemical"], [479, 481, "Chemical"], [160, 160, "Chemical"], [167, 167, "Chemical"], [172, 172, "Chemical"], [461, 461, "Chemical"], [174, 176, "Chemical"], [184, 184, "Chemical"], [187, 190, "Chemical"], [192, 201, "Chemical"], [206, 212, "Chemical"], [217, 217, "Chemical"], [220, 222, "Chemical"], [246, 248, "Chemical"], [224, 242, "Chemical"], [250, 270, "Chemical"], [276, 276, "Chemical"]]], "relations": [[[169, 169, 336, 336, "CID"], [169, 169, 444, 444, "CID"], [352, 352, 336, 336, "CID"], [352, 352, 444, 444, "CID"], [339, 339, 336, 336, "CID"], [339, 339, 444, 444, "CID"]]], "clusters": [], "translated": "突触前胆碱能放大器<5>PG-9</5>的镇痛和抗遗忘特性。<6>3α-托品2-(对-溴苯基)丙酸酯</6>[(+/-)<7>PG-9</7>](10-40mg·kg-1s.c.; 30-60mgkg-1p.o.; 10-30mgkg-1i.v.; 10-30微克/小鼠i.c.v.)在小鼠、大鼠和豚鼠中进行了检测，通过使用热板、腹部收缩、甩尾和爪压测试。(+/-)<8>PG-9</8>抗伤害作用在注射后15分钟达到峰值，然后缓慢减弱。非选择性毒蕈碱拮抗剂<15>阿托品</15>、M1-选择性拮抗剂<16>哌仑西平</16>和(+/-)<9>PG-9</9>产生的镇痛作用被阻止<0> 双环胺 </0>和<17>乙酰胆碱</17>消耗剂<19>半胆碱-3</19>，但不是阿片类拮抗剂<20>纳洛酮</20>，<21>γ-氨基丁酸B</21>拮抗剂<22> 3-氨基丙基-二乙氧基-甲基-次膦酸</22>，H3激动剂<23>R-(α)-甲基组胺</23>，D2拮抗剂<24>喹吡罗</24>，<25>5-羟色胺4</25>拮抗剂<27>2-甲氧基-4-氨基-5-氯苯甲酸2-(二乙氨基)乙酯</27>盐酸盐，<26>5-羟色胺1A</26>拮抗剂<28>1-(2-甲氧基苯基)-4-[4-(2-邻苯二甲酰亚胺基)丁基]哌嗪</28>氢溴酸盐和多胺消耗剂<29>利血平</29>。基于这些数据，可以假设(+/-)<10>PG-9</10>发挥了由胆碱能传递的中枢增强作用介导的镇痛作用。(+/-)<11>PG-9</11>(10-40mgkg-1i.p.)能够预防<2>遗忘</2>引起的<4>东莨菪碱</4>(1mgkg-1i.p.)和<1>双环胺</1>(2mgkg-1i.p.)在小鼠被动回避测试中。(+/-)<12>PG-9</12>对毒蕈碱受体亚型的亲和力分布，由功能研究确定（兔输精管M1、豚鼠心房M2、豚鼠回肠M3和未成熟豚鼠子宫用于推定的 M4)，显示M4/M1的选择性比率为10.2，可能与(+/-)<13>PG-9</13>通过增加<18>乙酰胆碱</18>诱导的抗伤害作用和抗-<3>遗忘</3>作用有关>细胞外水平。在镇痛剂和抗遗忘剂剂量范围内，(+/-)<14>PG-9</14>不会损害通过旋转杆试验和Animex仪器评估的小鼠性能。", "revised": true}
{"doc_key": "11250767", "sentences": [["Propylthiouracil", "-", "induced", "perinuclear", "-", "staining", "antineutrophil", "cytoplasmic", "autoantibody", "-", "positive", "vasculitis", "in", "conjunction", "with", "pericarditis", ".", "OBJECTIVE", ":", "To", "describe", "a", "case", "of", "propylthiouracil", "-", "induced", "vasculitis", "manifesting", "with", "pericarditis", ".", "METHODS", ":", "We", "present", "the", "first", "case", "report", "of", "a", "woman", "with", "hyperthyroidism", "treated", "with", "propylthiouracil", "in", "whom", "a", "syndrome", "of", "pericarditis", ",", "fever", ",", "and", "glomerulonephritis", "developed", ".", "Serologic", "testing", "and", "immunologic", "studies", "were", "done", ",", "and", "a", "pericardial", "biopsy", "was", "performed", ".", "RESULTS", ":", "A", "25", "-", "year", "-", "old", "woman", "with", "Graves", "'", "disease", "had", "a", "febrile", "illness", "and", "evidence", "of", "pericarditis", ",", "which", "was", "confirmed", "by", "biopsy", ".", "Serologic", "evaluation", "revealed", "the", "presence", "of", "perinuclear", "-", "staining", "antineutrophil", "cytoplasmic", "autoantibodies", "(", "pANCA", ")", "against", "myeloperoxidase", "(", "MPO", ")", ".", "Propylthiouracil", "therapy", "was", "withdrawn", ",", "and", "she", "was", "treated", "with", "a", "1", "-", "month", "course", "of", "prednisone", ",", "which", "alleviated", "her", "symptoms", ".", "A", "literature", "review", "revealed", "no", "prior", "reports", "of", "pericarditis", "in", "anti", "-", "MPO", "pANCA", "-", "positive", "vasculitis", "associated", "with", "propylthio", "-", "uracil", "therapy", ".", "CONCLUSION", ":", "Pericarditis", "may", "be", "the", "initial", "manifestation", "of", "drug", "-", "induced", "vasculitis", "attributable", "to", "propylthio", "-", "uracil", "therapy", "."]], "ner": [[[0, 0, "Chemical"], [24, 24, "Chemical"], [47, 47, "Chemical"], [125, 125, "Chemical"], [167, 169, "Chemical"], [187, 189, "Chemical"], [15, 15, "Disease"], [30, 30, "Disease"], [53, 53, "Disease"], [96, 96, "Disease"], [156, 156, "Disease"], [174, 174, "Disease"], [55, 55, "Disease"], [91, 92, "Disease"], [58, 58, "Disease"], [11, 11, "Disease"], [27, 27, "Disease"], [164, 164, "Disease"], [184, 184, "Disease"], [44, 44, "Disease"], [86, 88, "Disease"], [141, 141, "Chemical"]]], "relations": [[[0, 0, 15, 15, "CID"], [0, 0, 30, 30, "CID"], [0, 0, 53, 53, "CID"], [0, 0, 96, 96, "CID"], [0, 0, 156, 156, "CID"], [0, 0, 174, 174, "CID"], [24, 24, 15, 15, "CID"], [24, 24, 30, 30, "CID"], [24, 24, 53, 53, "CID"], [24, 24, 96, 96, "CID"], [24, 24, 156, 156, "CID"], [24, 24, 174, 174, "CID"], [47, 47, 15, 15, "CID"], [47, 47, 30, 30, "CID"], [47, 47, 53, 53, "CID"], [47, 47, 96, 96, "CID"], [47, 47, 156, 156, "CID"], [47, 47, 174, 174, "CID"], [125, 125, 15, 15, "CID"], [125, 125, 30, 30, "CID"], [125, 125, 53, 53, "CID"], [125, 125, 96, 96, "CID"], [125, 125, 156, 156, "CID"], [125, 125, 174, 174, "CID"], [167, 169, 15, 15, "CID"], [167, 169, 30, 30, "CID"], [167, 169, 53, 53, "CID"], [167, 169, 96, 96, "CID"], [167, 169, 156, 156, "CID"], [167, 169, 174, 174, "CID"], [187, 189, 15, 15, "CID"], [187, 189, 30, 30, "CID"], [187, 189, 53, 53, "CID"], [187, 189, 96, 96, "CID"], [187, 189, 156, 156, "CID"], [187, 189, 174, 174, "CID"], [0, 0, 55, 55, "CID"], [0, 0, 91, 92, "CID"], [24, 24, 55, 55, "CID"], [24, 24, 91, 92, "CID"], [47, 47, 55, 55, "CID"], [47, 47, 91, 92, "CID"], [125, 125, 55, 55, "CID"], [125, 125, 91, 92, "CID"], [167, 169, 55, 55, "CID"], [167, 169, 91, 92, "CID"], [187, 189, 55, 55, "CID"], [187, 189, 91, 92, "CID"], [0, 0, 58, 58, "CID"], [24, 24, 58, 58, "CID"], [47, 47, 58, 58, "CID"], [125, 125, 58, 58, "CID"], [167, 169, 58, 58, "CID"], [187, 189, 58, 58, "CID"]]], "clusters": [], "translated": " <0>丙基硫氧嘧啶</0>诱导的核周染色抗中性粒细胞胞质自身抗体阳性<15>血管炎</15>并伴有<6>心包炎</6> 。目的：描述一例<1>丙基硫氧嘧啶</1>诱发<16>血管炎</16>并伴有<7>心包炎</7>的病例。方法：我们报道第一例使用<2>丙基硫氧嘧啶</2>治疗<19>甲状腺功能亢进</19>的女性，出现了<8>心包炎</8>、<12>发热</12>和<14>肾小球肾炎</14>。进行了血清学检测和免疫学研究，并进行了心包活检。结果：一名患有<20>格雷夫斯病</20>的25岁女性有<13>发热性疾病</13>和<9>心包炎</9>的证据，经活检证实。血清学评估显示存在针对髓过氧化物酶(MPO)的核周染色抗中性粒细胞胞质自身抗体(pANCA)。 <3>丙基硫氧嘧啶</3>治疗停止，给予<21>泼尼松</21>1个月的疗程，症状缓解。一项文献回顾显示，在抗MPO pANCA阳性 <17>血管炎</17>与<4>丙硫基尿嘧啶</4>治疗相关的情况下，之前没有关于<10>心包炎</10>的报道。结论：<11>心包炎</11>可能是<5>丙硫基尿嘧啶</5>治疗所致药物性<18>血管炎</18>的首发表现。", "revised": true}
{"doc_key": "20667451", "sentences": [["Curcumin", "ameliorates", "cognitive", "dysfunction", "and", "oxidative", "damage", "in", "phenobarbitone", "and", "carbamazepine", "administered", "rats", ".", "The", "antiepileptic", "drugs", ",", "phenobarbitone", "and", "carbamazepine", "are", "well", "known", "to", "cause", "cognitive", "impairment", "on", "chronic", "use", ".", "The", "increase", "in", "free", "radical", "generation", "has", "been", "implicated", "as", "one", "of", "the", "important", "mechanisms", "of", "cognitive", "impairment", "by", "antiepileptic", "drugs", ".", "Curcumin", "has", "shown", "antioxidant", ",", "anti", "-", "inflammatory", "and", "neuro", "-", "protective", "properties", ".", "Therefore", ",", "the", "present", "study", "was", "carried", "out", "to", "investigate", "the", "effect", "of", "chronic", "curcumin", "administration", "on", "phenobarbitone", "-", "and", "carbamazepine", "-", "induced", "cognitive", "impairment", "and", "oxidative", "stress", "in", "rats", ".", "Pharmacokinetic", "interactions", "of", "curcumin", "with", "phenobarbitone", "and", "carbamazepine", "were", "also", "studied", ".", "Vehicle", "/", "drugs", "were", "administered", "daily", "for", "21days", "to", "male", "Wistar", "rats", ".", "Passive", "avoidance", "paradigm", "and", "elevated", "plus", "maze", "test", "were", "used", "to", "assess", "cognitive", "function", ".", "At", "the", "end", "of", "study", "period", ",", "serum", "phenobarbitone", "and", "carbamazepine", ",", "whole", "brain", "malondialdehyde", "and", "reduced", "glutathione", "levels", "were", "estimated", ".", "The", "administration", "of", "phenobarbitone", "and", "carbamazepine", "for", "21days", "caused", "a", "significant", "impairment", "of", "learning", "and", "memory", "as", "well", "as", "an", "increased", "oxidative", "stress", ".", "Concomitant", "curcumin", "administration", "prevented", "the", "cognitive", "impairment", "and", "decreased", "the", "increased", "oxidative", "stress", "induced", "by", "these", "antiepileptic", "drugs", ".", "Curcumin", "co", "-", "administration", "did", "not", "cause", "any", "significant", "alteration", "in", "the", "serum", "concentrations", "of", "both", "phenobarbitone", "as", "well", "as", "carbamazepine", ".", "These", "results", "show", "that", "curcumin", "has", "beneficial", "effect", "in", "mitigating", "the", "deterioration", "of", "cognitive", "functions", "and", "oxidative", "damage", "in", "rats", "treated", "with", "phenobarbitone", "and", "carbamazepine", "without", "significantly", "altering", "their", "serum", "concentrations", ".", "The", "findings", "suggest", "that", "curcumin", "can", "be", "considered", "as", "a", "potential", "safe", "and", "effective", "adjuvant", "to", "phenobarbitone", "and", "carbamazepine", "therapy", "in", "preventing", "cognitive", "impairment", "associated", "with", "these", "drugs", "."]], "ner": [[[8, 8, "Chemical"], [18, 18, "Chemical"], [85, 85, "Chemical"], [104, 104, "Chemical"], [147, 147, "Chemical"], [164, 164, "Chemical"], [220, 220, "Chemical"], [248, 248, "Chemical"], [274, 274, "Chemical"], [2, 3, "Disease"], [26, 27, "Disease"], [48, 49, "Disease"], [91, 92, "Disease"], [172, 176, "Disease"], [190, 191, "Disease"], [237, 240, "Disease"], [280, 281, "Disease"], [10, 10, "Chemical"], [20, 20, "Chemical"], [88, 88, "Chemical"], [106, 106, "Chemical"], [149, 149, "Chemical"], [166, 166, "Chemical"], [224, 224, "Chemical"], [250, 250, "Chemical"], [276, 276, "Chemical"], [0, 0, "Chemical"], [54, 54, "Chemical"], [82, 82, "Chemical"], [102, 102, "Chemical"], [186, 186, "Chemical"], [204, 204, "Chemical"], [230, 230, "Chemical"], [262, 262, "Chemical"], [153, 153, "Chemical"], [156, 156, "Chemical"]]], "relations": [[[8, 8, 2, 3, "CID"], [8, 8, 26, 27, "CID"], [8, 8, 48, 49, "CID"], [8, 8, 91, 92, "CID"], [8, 8, 172, 176, "CID"], [8, 8, 190, 191, "CID"], [8, 8, 237, 240, "CID"], [8, 8, 280, 281, "CID"], [18, 18, 2, 3, "CID"], [18, 18, 26, 27, "CID"], [18, 18, 48, 49, "CID"], [18, 18, 91, 92, "CID"], [18, 18, 172, 176, "CID"], [18, 18, 190, 191, "CID"], [18, 18, 237, 240, "CID"], [18, 18, 280, 281, "CID"], [85, 85, 2, 3, "CID"], [85, 85, 26, 27, "CID"], [85, 85, 48, 49, "CID"], [85, 85, 91, 92, "CID"], [85, 85, 172, 176, "CID"], [85, 85, 190, 191, "CID"], [85, 85, 237, 240, "CID"], [85, 85, 280, 281, "CID"], [104, 104, 2, 3, "CID"], [104, 104, 26, 27, "CID"], [104, 104, 48, 49, "CID"], [104, 104, 91, 92, "CID"], [104, 104, 172, 176, "CID"], [104, 104, 190, 191, "CID"], [104, 104, 237, 240, "CID"], [104, 104, 280, 281, "CID"], [147, 147, 2, 3, "CID"], [147, 147, 26, 27, "CID"], [147, 147, 48, 49, "CID"], [147, 147, 91, 92, "CID"], [147, 147, 172, 176, "CID"], [147, 147, 190, 191, "CID"], [147, 147, 237, 240, "CID"], [147, 147, 280, 281, "CID"], [164, 164, 2, 3, "CID"], [164, 164, 26, 27, "CID"], [164, 164, 48, 49, "CID"], [164, 164, 91, 92, "CID"], [164, 164, 172, 176, "CID"], [164, 164, 190, 191, "CID"], [164, 164, 237, 240, "CID"], [164, 164, 280, 281, "CID"], [220, 220, 2, 3, "CID"], [220, 220, 26, 27, "CID"], [220, 220, 48, 49, "CID"], [220, 220, 91, 92, "CID"], [220, 220, 172, 176, "CID"], [220, 220, 190, 191, "CID"], [220, 220, 237, 240, "CID"], [220, 220, 280, 281, "CID"], [248, 248, 2, 3, "CID"], [248, 248, 26, 27, "CID"], [248, 248, 48, 49, "CID"], [248, 248, 91, 92, "CID"], [248, 248, 172, 176, "CID"], [248, 248, 190, 191, "CID"], [248, 248, 237, 240, "CID"], [248, 248, 280, 281, "CID"], [274, 274, 2, 3, "CID"], [274, 274, 26, 27, "CID"], [274, 274, 48, 49, "CID"], [274, 274, 91, 92, "CID"], [274, 274, 172, 176, "CID"], [274, 274, 190, 191, "CID"], [274, 274, 237, 240, "CID"], [274, 274, 280, 281, "CID"], [10, 10, 2, 3, "CID"], [10, 10, 26, 27, "CID"], [10, 10, 48, 49, "CID"], [10, 10, 91, 92, "CID"], [10, 10, 172, 176, "CID"], [10, 10, 190, 191, "CID"], [10, 10, 237, 240, "CID"], [10, 10, 280, 281, "CID"], [20, 20, 2, 3, "CID"], [20, 20, 26, 27, "CID"], [20, 20, 48, 49, "CID"], [20, 20, 91, 92, "CID"], [20, 20, 172, 176, "CID"], [20, 20, 190, 191, "CID"], [20, 20, 237, 240, "CID"], [20, 20, 280, 281, "CID"], [88, 88, 2, 3, "CID"], [88, 88, 26, 27, "CID"], [88, 88, 48, 49, "CID"], [88, 88, 91, 92, "CID"], [88, 88, 172, 176, "CID"], [88, 88, 190, 191, "CID"], [88, 88, 237, 240, "CID"], [88, 88, 280, 281, "CID"], [106, 106, 2, 3, "CID"], [106, 106, 26, 27, "CID"], [106, 106, 48, 49, "CID"], [106, 106, 91, 92, "CID"], [106, 106, 172, 176, "CID"], [106, 106, 190, 191, "CID"], [106, 106, 237, 240, "CID"], [106, 106, 280, 281, "CID"], [149, 149, 2, 3, "CID"], [149, 149, 26, 27, "CID"], [149, 149, 48, 49, "CID"], [149, 149, 91, 92, "CID"], [149, 149, 172, 176, "CID"], [149, 149, 190, 191, "CID"], [149, 149, 237, 240, "CID"], [149, 149, 280, 281, "CID"], [166, 166, 2, 3, "CID"], [166, 166, 26, 27, "CID"], [166, 166, 48, 49, "CID"], [166, 166, 91, 92, "CID"], [166, 166, 172, 176, "CID"], [166, 166, 190, 191, "CID"], [166, 166, 237, 240, "CID"], [166, 166, 280, 281, "CID"], [224, 224, 2, 3, "CID"], [224, 224, 26, 27, "CID"], [224, 224, 48, 49, "CID"], [224, 224, 91, 92, "CID"], [224, 224, 172, 176, "CID"], [224, 224, 190, 191, "CID"], [224, 224, 237, 240, "CID"], [224, 224, 280, 281, "CID"], [250, 250, 2, 3, "CID"], [250, 250, 26, 27, "CID"], [250, 250, 48, 49, "CID"], [250, 250, 91, 92, "CID"], [250, 250, 172, 176, "CID"], [250, 250, 190, 191, "CID"], [250, 250, 237, 240, "CID"], [250, 250, 280, 281, "CID"], [276, 276, 2, 3, "CID"], [276, 276, 26, 27, "CID"], [276, 276, 48, 49, "CID"], [276, 276, 91, 92, "CID"], [276, 276, 172, 176, "CID"], [276, 276, 190, 191, "CID"], [276, 276, 237, 240, "CID"], [276, 276, 280, 281, "CID"]]], "clusters": [], "translated": "<26>姜黄素</26> 改善 <9>认知功能障碍</9> 和 <0>苯巴比妥</0> 和 <17>卡马西平</17> 给药大鼠的氧化损伤。众所周知，抗癫痫药 <1>苯巴比妥</1> 和 <18>卡马西平</18> 长期使用会导致 <10>认知障碍</10>。自由基生成的增加被认为是抗癫痫药物引起 <11>认知障碍</11> 的重要机制之一。 <27>姜黄素</27> 具有抗氧化、抗炎和神经保护作用。因此，本研究旨在探讨长期服用 <28>姜黄素</28> 对 <2>苯巴比妥</2> 和 <19>卡马西平</19> 引起的 <12>认知障碍</12> 和大鼠的氧化应激。还研究了 <29>姜黄素</29> 与 <3>苯巴比妥</3> 和 <20>卡马西平</20> 的药代动力学相互作用。对雄性 Wistar 大鼠每天给药载体/药物，持续 21 天。被动回避范式和高架十字迷宫测试用于评估认知功能。在研究期结束时，估计了血清 <4>苯巴比妥</4> 和 <21>卡马西平</21>、全脑 <34>丙二醛</34> 和还原型 <35>谷胱甘肽</35> 水平。 <5>苯巴比妥</5> 和 <22>卡马西平</22> 给药 21 天导致显着 <13>学习和记忆障碍</13> 以及氧化应激增加。同时使用 <30>姜黄素</30> 可以预防 <14>认知障碍</14> 并减少由这些抗癫痫药物引起的氧化应激增加。 <31>姜黄素</31> 联合给药不会导致 <6>苯巴比妥</6> 和 <23>卡马西平</23> 的血清浓度发生任何显着变化。这些结果表明，<32>姜黄素</32> 在减轻 <7>苯巴比妥</7> 和 <24>卡马西平</24> 引起的 <15>认知功能退化</15> 和氧化损伤方面具有有益作用，而不会显着改变其血清浓度。研究结果表明，<33>姜黄素</33> 可被视为 <8>苯巴比妥</8> 和 <25>卡马西平</25> 疗法预防 <16>认知障碍</16> 的潜在安全有效的辅助药物与这些药物有关。", "revised": true}
{"doc_key": "15863244", "sentences": [["Comparison", "of", "developmental", "toxicity", "of", "selective", "and", "non", "-", "selective", "cyclooxygenase", "-", "2", "inhibitors", "in", "CRL", ":", "(", "WI", ")", "WUBR", "Wistar", "rats", "-", "-", "DFU", "and", "piroxicam", "study", ".", "BACKGROUND", ":", "Cyclooxygenase", "(", "COX", ")", "inhibitors", "are", "one", "of", "the", "most", "often", "ingested", "drugs", "during", "pregnancy", ".", "Unlike", "general", "toxicity", "data", ",", "their", "prenatal", "toxic", "effects", "were", "not", "extensively", "studied", "before", ".", "The", "aim", "of", "the", "experiment", "was", "to", "evaluate", "the", "developmental", "toxicity", "of", "the", "non", "-", "selective", "(", "piroxicam", ")", "and", "selective", "(", "DFU", ";", "5", ",", "5", "-", "dimethyl", "-", "3", "-", "(", "3", "-", "fluorophenyl", ")", "-", "4", "-", "(", "4", "-", "methylsulphonyl", ")", "phenyl", "-", "2", "(", "5H", ")", "-", "furanon", ")", "COX", "-", "2", "inhibitors", ".", "METHODS", ":", "Drugs", "were", "separately", ",", "orally", "once", "daily", "dosed", "to", "pregnant", "rats", "from", "day", "8", "to", "21", "(", "GD1", "=", "plug", "day", ")", ".", "Doses", "were", "set", "at", "0", ".", "3", ",", "3", ".", "0", "and", "30", ".", "0mg", "/", "kg", "for", "piroxicam", "and", "0", ".", "2", ",", "2", ".", "0", "and", "20", ".", "0mg", "/", "kg", "for", "DFU", ".", "Fetuses", "were", "delivered", "on", "GD", "21", "and", "routinely", "examined", ".", "Comprehensive", "clinical", "and", "developmental", "measurements", "were", "done", ".", "The", "pooled", "statistical", "analysis", "for", "ventricular", "septal", "(", "VSD", ")", "and", "midline", "(", "MD", ")", "defects", "was", "performed", "for", "rat", "fetuses", "exposed", "to", "piroxicam", ",", "selective", "and", "non", "-", "selective", "COX", "-", "2", "inhibitor", "based", "on", "present", "and", "historic", "data", ".", "RESULTS", ":", "Maternal", "toxicity", ",", "intrauterine", "growth", "retardation", ",", "and", "increase", "of", "external", "and", "skeletal", "variations", "were", "found", "in", "rats", "treated", "with", "the", "highest", "dose", "of", "piroxicam", ".", "Decrease", "of", "fetal", "length", "was", "the", "only", "signs", "of", "the", "DFU", "developmental", "toxicity", "observed", "in", "pups", "exposed", "to", "the", "highest", "compound", "dose", ".", "Lack", "of", "teratogenicity", "was", "found", "in", "piroxicam", "and", "DFU", "-", "exposed", "groups", ".", "Prenatal", "exposure", "to", "non", "-", "selective", "COX", "inhibitors", "increases", "the", "risk", "of", "VSD", "and", "MD", "when", "compared", "to", "historic", "control", "but", "not", "with", "selective", "COX", "-", "2", "inhibitors", ".", "CONCLUSION", ":", "Both", "selective", "and", "non", "-", "selective", "COX", "-", "2", "inhibitors", "were", "toxic", "for", "rats", "fetuses", "when", "administered", "in", "the", "highest", "dose", ".", "Unlike", "DFU", ",", "piroxicam", "was", "also", "highly", "toxic", "to", "the", "dams", ".", "Prenatal", "exposure", "to", "selective", "COX", "-", "2", "inhibitors", "does", "not", "increase", "the", "risk", "of", "ventricular", "septal", "and", "midline", "defects", "in", "rat", "when", "compared", "to", "non", "-", "selective", "drugs", "and", "historic", "control", "."]], "ner": [[[25, 25, "Chemical"], [85, 85, "Chemical"], [87, 115, "Chemical"], [181, 181, "Chemical"], [280, 280, "Chemical"], [301, 301, "Chemical"], [360, 360, "Chemical"], [247, 249, "Disease"], [27, 27, "Chemical"], [80, 80, "Chemical"], [165, 165, "Chemical"], [224, 224, "Chemical"], [268, 268, "Chemical"], [299, 299, "Chemical"], [362, 362, "Chemical"], [252, 257, "Disease"], [3, 3, "Disease"], [50, 50, "Disease"], [73, 73, "Disease"], [245, 245, "Disease"], [282, 282, "Disease"], [206, 216, "Disease"], [385, 389, "Disease"]]], "relations": [[[25, 25, 247, 249, "CID"], [85, 85, 247, 249, "CID"], [87, 115, 247, 249, "CID"], [181, 181, 247, 249, "CID"], [280, 280, 247, 249, "CID"], [301, 301, 247, 249, "CID"], [360, 360, 247, 249, "CID"], [27, 27, 247, 249, "CID"], [80, 80, 247, 249, "CID"], [165, 165, 247, 249, "CID"], [224, 224, 247, 249, "CID"], [268, 268, 247, 249, "CID"], [299, 299, 247, 249, "CID"], [362, 362, 247, 249, "CID"], [27, 27, 252, 257, "CID"], [80, 80, 252, 257, "CID"], [165, 165, 252, 257, "CID"], [224, 224, 252, 257, "CID"], [268, 268, 252, 257, "CID"], [299, 299, 252, 257, "CID"], [362, 362, 252, 257, "CID"]]], "clusters": [], "translated": "选择性和非选择性环氧合酶-2抑制剂在CRL中的发育<16>毒性</16>比较：（WI）WUBR Wistar大鼠--<0>DFU</0>和<8>吡罗昔康</8>研究。背景：环氧合酶（COX）抑制剂是孕期最常用的药物之一。与一般<17>毒性</17>数据不同，它们的产前毒性作用之前没有得到广泛研究。实验的目的是评估非选择性（<9>吡罗昔康</9>），和选择性（<1>DFU</1>；<2>5,5-二甲基-3-(3-氟苯基)-4-(4-甲基磺酰基)苯基-2(5H)-呋喃</2>）COX-2抑制剂的发育<18>毒性</18>。方法：从第8天到第21天（GD1=plug day），分别给孕鼠口服药物，每日一次。剂量设定为0.3、3.0和30.0 mg/kg的<10>吡罗昔康</10>，以及0.2、2.0和20.0 mg/kg的<3>DFU</3>。胎儿于GD 21分娩并进行常规检查。进行了全面的临床和发育测量。对暴露于<11>吡罗昔康</11>、选择性和非选择性COX-2抑制剂的大鼠胎儿进行了<21>室间隔（VSD）和中线（MD）缺陷</21>的汇总统计分析，基于现有和历史数据。结果：在用最高剂量<12>吡罗昔康</12>治疗的大鼠中，发现母体<19>毒性</19>、<7>宫内生长迟缓</7>和<15>外部和骨骼变异增加</15>。观察到的<4>DFU</4>发育<20>毒性</20>的唯一迹象是胎儿身长缩短。暴露于<13>吡罗昔康</13>和<5>DFU</5>的组无致畸性。与历史对照相比，产前接触非选择性COX抑制剂会增加VSD和MD的风险，但不会增加选择性COX-2抑制剂的风险。结论：给予最高剂量时，选择性和非选择性COX-2抑制剂对大鼠胎儿都有毒性。与<6>DFU</6>不同，<14>吡罗昔康</14>对母鼠也具有高毒性。与非选择性药物和历史对照相比，产前接触选择性COX-2抑制剂不会增加大鼠<22>室间隔和中线缺陷</22>的风险。", "revised": true}
{"doc_key": "8595686", "sentences": [["Thiopentone", "pretreatment", "for", "propofol", "injection", "pain", "in", "ambulatory", "patients", ".", "This", "study", "investigated", "propofol", "injection", "pain", "in", "patients", "undergoing", "ambulatory", "anaesthesia", ".", "In", "a", "randomized", ",", "double", "-", "blind", "trial", ",", "90", "women", "were", "allocated", "to", "receive", "one", "of", "three", "treatments", "prior", "to", "induction", "of", "anaesthesia", "with", "propofol", ".", "Patients", "in", "Group", "C", "received", "2", "ml", "normal", "saline", ",", "Group", "L", ",", "2", "ml", ",", "lidocaine", "2", "%", "(", "40", "mg", ")", "and", "Group", "T", ",", "2", "ml", "thiopentone", "2", ".", "5", "%", "(", "50", "mg", ")", ".", "Venous", "discomfort", "was", "assessed", "with", "a", "visual", "analogue", "scale", "(", "VAS", ")", "5", "-", "15", "sec", "after", "commencing", "propofol", "administration", "using", "an", "infusion", "pump", "(", "rate", "1000", "micrograms", ".", "kg", "-", "1", ".", "min", "-", "1", ")", ".", "Loss", "of", "consciousness", "occurred", "in", "60", "-", "90", "sec", ".", "Visual", "analogue", "scores", "(", "mean", "+", "/", "-", "SD", ")", "during", "induction", "were", "lower", "in", "Groups", "L", "(", "3", ".", "3", "+", "/", "-", "2", ".", "5", ")", "and", "T", "(", "4", ".", "1", "+", "/", "-", "2", ".", "7", ")", "than", "in", "Group", "C", "(", "5", ".", "6", "+", "/", "-", "2", ".", "3", ")", ";", "P", "=", "0", ".", "0031", ".", "The", "incidence", "of", "venous", "discomfort", "was", "lower", "in", "Group", "L", "(", "76", ".", "6", "%", ";", "P", "<", "0", ".", "05", ")", "than", "in", "Group", "C", "(", "100", "%", ")", "but", "not", "different", "from", "Group", "T", "(", "90", "%", ")", ".", "The", "VAS", "scores", "for", "recall", "of", "pain", "in", "the", "recovery", "room", "were", "correlated", "with", "the", "VAS", "scores", "during", "induction", "(", "r", "=", "0", ".", "7045", ";", "P", "<", "0", ".", "0001", ")", ".", "Recovery", "room", "discharge", "times", "were", "similar", ":", "C", "(", "75", ".", "9", "+", "/", "-", "19", ".", "4", "min", ")", ";", "L", "73", ".", "6", "+", "/", "-", "21", ".", "6", "min", ")", ";", "T", "(", "77", ".", "1", "+", "/", "-", "18", ".", "9", "min", ")", ".", "Assessing", "their", "overall", "satisfaction", ",", "89", ".", "7", "%", "would", "choose", "propofol", "anaesthesia", "again", ".", "We", "conclude", "that", "lidocaine", "reduces", "the", "incidence", "and", "severity", "of", "propofol", "injection", "pain", "in", "ambulatory", "patients", "whereas", "thiopentone", "only", "reduces", "its", "severity", "."]], "ner": [[[3, 3, "Chemical"], [13, 13, "Chemical"], [47, 47, "Chemical"], [106, 106, "Chemical"], [332, 332, "Chemical"], [346, 346, "Chemical"], [5, 5, "Disease"], [15, 15, "Disease"], [246, 246, "Disease"], [348, 348, "Disease"], [0, 0, "Chemical"], [78, 78, "Chemical"], [353, 353, "Chemical"], [126, 128, "Disease"], [65, 65, "Chemical"], [339, 339, "Chemical"]]], "relations": [[[3, 3, 5, 5, "CID"], [3, 3, 15, 15, "CID"], [3, 3, 246, 246, "CID"], [3, 3, 348, 348, "CID"], [13, 13, 5, 5, "CID"], [13, 13, 15, 15, "CID"], [13, 13, 246, 246, "CID"], [13, 13, 348, 348, "CID"], [47, 47, 5, 5, "CID"], [47, 47, 15, 15, "CID"], [47, 47, 246, 246, "CID"], [47, 47, 348, 348, "CID"], [106, 106, 5, 5, "CID"], [106, 106, 15, 15, "CID"], [106, 106, 246, 246, "CID"], [106, 106, 348, 348, "CID"], [332, 332, 5, 5, "CID"], [332, 332, 15, 15, "CID"], [332, 332, 246, 246, "CID"], [332, 332, 348, 348, "CID"], [346, 346, 5, 5, "CID"], [346, 346, 15, 15, "CID"], [346, 346, 246, 246, "CID"], [346, 346, 348, 348, "CID"]]], "clusters": [], "translated": " <10>硫喷妥钠</10>预处理<0>异丙酚</0>注射液<6>疼痛</6>门诊患者。本研究调查了接受门诊麻醉的患者<1>异丙酚</1>注射<7>疼痛</7>。在一项随机、双盲试验中，90名女性被分配到接受 <2>异丙酚</2>麻醉诱导前的三种治疗中的一种。C组患者给予生理盐水2 ml，L组给予2 ml <14>利多卡因</14> 2%（40 mg），T组给予2 ml<11>硫喷妥钠</11> 2.5%（50毫克）。在使用输液泵（速率1000微克.kg-1.min-1）开始<3>异丙酚</3>给药后5-15秒，使用视觉模拟量表(VAS)评估静脉不适。<13>意识丧失</13>发生在60-90秒内。L组(3.3+/-2.5)和T组(4.1+/-2.7)组在诱导期间的视觉模拟评分（平均值+/-SD）低于C组（5.6+/-2.3）；P=0.0031。L组的静脉不适发生率(76.6%; P<0.05)低于C组(100%)，但与T组(90%)无差异。恢复室<8>疼痛</8>的VAS评分与诱导期间的VAS评分相关(r=0.7045；P<0.0001)。恢复室出院时间相似：C（75.9+/-19.4分钟）；L（73.6+/-21.6分钟）；T（77.1+/-18.9分钟）。评估他们的总体满意度，89.7%会再次选择<4>异丙酚</4>麻醉。我们得出结论，<15>利多卡因</15>可降低门诊患者<5>丙泊酚</5>注射<9>疼痛</9>的发生率和严重程度，而<12>硫喷妥钠</12>仅降低其严重程度。", "revised": true}
{"doc_key": "1527456", "sentences": [["Treatment", "of", "tinnitus", "by", "intratympanic", "instillation", "of", "lignocaine", "(", "lidocaine", ")", "2", "per", "cent", "through", "ventilation", "tubes", ".", "Idiopathic", "subjective", "tinnitus", "(", "IST", ")", "is", "one", "of", "the", "most", "obscure", "otological", "pathologies", ".", "This", "paper", "presents", "the", "results", "of", "treating", "IST", "by", "intratympanic", "instillation", "of", "lignocaine", "(", "lidocaine", ")", "2", "per", "cent", "through", "a", "grommet", ",", "for", "five", "weekly", "courses", ".", "Fifty", "-", "two", "patients", "suffering", "from", "intractable", "tinnitus", "entered", "this", "therapeutic", "trial", ",", "but", "only", "nine", "finished", "all", "five", "courses", ".", "In", "one", "patient", ",", "the", "tinnitus", "was", "almost", "completely", "abolished", ",", "but", "in", "all", "the", "nine", "patients", "the", "decompensated", "tinnitus", "changed", "to", "a", "compensated", "one", ".", "We", "suggest", "this", "mode", "of", "treatment", "for", "patients", "that", "were", "previously", "treated", "by", "drugs", ",", "acupuncture", "and", "biofeedback", ",", "with", "disappointing", "results", ".", "Patients", "should", "be", "warned", "about", "the", "side", "effects", "of", "vertigo", "and", "vomiting", ",", "which", "subsides", "gradually", "with", "every", "new", "instillation", ",", "and", "that", "the", "tinnitus", "may", "not", "disappear", "but", "will", "be", "alleviated", ",", "enabling", "them", "to", "cope", "more", "easily", "with", "the", "disease", "and", "lead", "a", "more", "normal", "life", "."]], "ner": [[[7, 7, "Chemical"], [9, 9, "Chemical"], [45, 45, "Chemical"], [47, 47, "Chemical"], [140, 140, "Disease"], [142, 142, "Disease"], [2, 2, "Disease"], [18, 20, "Disease"], [22, 22, "Disease"], [40, 40, "Disease"], [68, 68, "Disease"], [87, 87, "Disease"], [101, 101, "Disease"], [155, 155, "Disease"]]], "relations": [[[7, 7, 140, 140, "CID"], [9, 9, 140, 140, "CID"], [45, 45, 140, 140, "CID"], [47, 47, 140, 140, "CID"], [7, 7, 142, 142, "CID"], [9, 9, 142, 142, "CID"], [45, 45, 142, 142, "CID"], [47, 47, 142, 142, "CID"]]], "clusters": [], "translated": "通过通气管鼓室内滴注 2% 的<0>利多卡因</0>（<1>利多卡因</1>）治疗<6>耳鸣</6>。 <7>特发性主观性耳鸣</7>（<8>IST</8>）是最隐蔽的耳科疾病之一。本文介绍了治疗<9>IST</9>的结果，方法是通过鼓膜内滴注2%的<2>利多卡因</2>（<3>利多卡因</3>），每周疗程为5个疗程。52名患有顽固性<10>耳鸣</10>的患者参加了这项治疗试验，但只有九名患者完成了全部五个疗程。在一名患者中，<11>耳鸣</11>几乎完全消失，但在所有九名患者中，失代偿性<12>耳鸣</12>都变成了代偿性<12>耳鸣</12>。对于之前采用药物、针灸和生物反馈治疗效果不佳的患者，我们建议采用这种治疗方式。应警告患者<4>眩晕</4>和<5>呕吐</5>的副作用，随着每次新的滴注逐渐消退，并且<13>耳鸣</13>可能不会消失但将得到缓解，使他们能够更轻松地应对疾病并过上更正常的生活。", "revised": true}
{"doc_key": "234669", "sentences": [["Effects", "of", "aminophylline", "on", "the", "threshold", "for", "initiating", "ventricular", "fibrillation", "during", "respiratory", "failure", ".", "Cardiac", "arrhythmias", "have", "frequently", "been", "reported", "in", "association", "with", "respiratory", "failure", ".", "The", "possible", "additive", "role", "of", "pharmacologic", "agents", "in", "precipitating", "cardiac", "disturbances", "in", "patients", "with", "respiratory", "failure", "has", "only", "recently", "been", "emphasized", ".", "The", "effects", "of", "aminophylline", "on", "the", "ventricular", "fibrillation", "threshold", "during", "normal", "acid", "-", "base", "conditions", "and", "during", "respiratory", "failure", "were", "studied", "in", "anesthetized", "open", "chest", "dogs", ".", "The", "ventricular", "fibrillation", "threshold", "was", "measured", "by", "passing", "a", "gated", "train", "of", "12", "constant", "current", "pulses", "through", "the", "ventricular", "myocardium", "during", "the", "vulnerable", "period", "of", "the", "cardiac", "cycle", ".", "During", "the", "infusion", "of", "aminophylline", ",", "the", "ventricular", "fibrillation", "threshold", "was", "reduced", "by", "30", "to", "40", "percent", "of", "the", "control", "when", "pH", "and", "partial", "pressures", "of", "oxygen", "(", "PO2", ")", "and", "carbon", "dioxide", "(", "CO2", ")", "were", "kept", "within", "normal", "limits", ".", "When", "respiratory", "failure", "was", "produced", "by", "hypoventilation", "(", "pH", "7", ".", "05", "to", "7", ".", "25", ";", "PC02", "70", "to", "100", "mm", "Hg", ":", "P02", "20", "to", "40", "mm", "Hg", ")", ",", "infusion", "of", "aminophylline", "resulted", "in", "an", "even", "greater", "decrease", "in", "ventricular", "fibrillation", "threshold", "to", "60", "percent", "of", "the", "control", "level", ".", "These", "experiments", "suggest", "that", "although", "many", "factors", "may", "contribute", "to", "the", "increased", "incidence", "of", "ventricular", "arrhythmias", "in", "respiratory", "failure", ",", "pharmacologic", "agents", ",", "particularly", "aminophylline", ",", "may", "play", "a", "significant", "role", "."]], "ner": [[[2, 2, "Chemical"], [51, 51, "Chemical"], [108, 108, "Chemical"], [180, 180, "Chemical"], [223, 223, "Chemical"], [8, 9, "Disease"], [54, 55, "Disease"], [76, 77, "Disease"], [111, 112, "Disease"], [188, 189, "Disease"], [11, 12, "Disease"], [23, 24, "Disease"], [40, 41, "Disease"], [65, 66, "Disease"], [147, 148, "Disease"], [216, 217, "Disease"], [14, 15, "Disease"], [213, 214, "Disease"], [35, 36, "Disease"], [152, 152, "Disease"], [130, 130, "Chemical"], [132, 132, "Chemical"], [135, 136, "Chemical"], [138, 138, "Chemical"]]], "relations": [[[2, 2, 8, 9, "CID"], [2, 2, 54, 55, "CID"], [2, 2, 76, 77, "CID"], [2, 2, 111, 112, "CID"], [2, 2, 188, 189, "CID"], [51, 51, 8, 9, "CID"], [51, 51, 54, 55, "CID"], [51, 51, 76, 77, "CID"], [51, 51, 111, 112, "CID"], [51, 51, 188, 189, "CID"], [108, 108, 8, 9, "CID"], [108, 108, 54, 55, "CID"], [108, 108, 76, 77, "CID"], [108, 108, 111, 112, "CID"], [108, 108, 188, 189, "CID"], [180, 180, 8, 9, "CID"], [180, 180, 54, 55, "CID"], [180, 180, 76, 77, "CID"], [180, 180, 111, 112, "CID"], [180, 180, 188, 189, "CID"], [223, 223, 8, 9, "CID"], [223, 223, 54, 55, "CID"], [223, 223, 76, 77, "CID"], [223, 223, 111, 112, "CID"], [223, 223, 188, 189, "CID"]]], "clusters": [], "translated": "<0>氨茶碱</0>对<10>呼吸衰竭</10>期间<5>心室颤动</5>起始阈值的影响。<16>心律失常</16>经常与<11>呼吸衰竭</11>有关。药物在诱发<12>呼吸衰竭</12>患者中的<18>心脏不适</18>方面可能起到附加作用，而这一点近来受到了强调。在麻醉下开胸犬中研究了<1>氨茶碱</1>在正常酸碱条件下和<13>呼吸衰竭</13>期间对<6>心室颤动</6>出发阈值的影响。通过在心脏周期中易感时期通过心室心肌传递门控恒流脉冲序列来测量<7>心室颤动</7>起始阈值。在输注<2>氨茶碱</2>期间，当pH值、<20>氧分压</20>（<21>PO2</21>）和<22>二氧化碳</22>（<23>CO2</23>）处于正常范围内时，<8>心室颤动</8>起始阈值降低了30%到40%的对照水平。当通过<19>通气不足</19>（pH 7.05 至7.25; PCO2 70 至100 毫米汞柱：PO2 20 至40 毫米汞柱）导致<14>呼吸衰竭</14>时，输注<3>氨茶碱</3>导致<9>心室颤动</9>起始阈值进一步降至对照水平的60%。这些实验结果表明，尽管许多因素都可能导致<15>呼吸衰竭</15>患者发生<17>室性心律失常</17>的发生率增加，但药物，特别是<4>氨茶碱</4>，可能会起到显着作用。", "revised": true}
{"doc_key": "2870085", "sentences": [["Flestolol", ":", "an", "ultra", "-", "short", "-", "acting", "beta", "-", "adrenergic", "blocking", "agent", ".", "Flestolol", "(", "ACC", "-", "9089", ")", "is", "a", "nonselective", ",", "competitive", ",", "ultra", "-", "short", "-", "acting", "beta", "-", "adrenergic", "blocking", "agent", ",", "without", "any", "intrinsic", "sympathomimetic", "activity", ".", "Flestolol", "is", "metabolized", "by", "plasma", "esterases", "and", "has", "an", "elimination", "half", "-", "life", "of", "approximately", "6", ".", "5", "minutes", ".", "This", "agent", "was", "well", "tolerated", "in", "healthy", "volunteers", "at", "doses", "up", "to", "100", "micrograms", "/", "kg", "/", "min", ".", "In", "long", "-", "term", "infusion", "studies", ",", "flestolol", "was", "well", "tolerated", "at", "the", "effective", "beta", "-", "blocking", "dose", "(", "5", "micrograms", "/", "kg", "/", "min", ")", "for", "up", "to", "seven", "days", ".", "Flestolol", "blood", "concentrations", "increased", "linearly", "with", "increasing", "dose", "and", "good", "correlation", "exists", "between", "blood", "concentrations", "of", "flestolol", "and", "beta", "-", "adrenergic", "blockade", ".", "Flestolol", "produced", "a", "dose", "-", "dependent", "attenuation", "of", "isoproterenol", "-", "induced", "tachycardia", ".", "Electrophysiologic", "and", "hemodynamic", "effects", "of", "flestolol", "are", "similar", "to", "those", "of", "other", "beta", "blockers", ".", "In", "contrast", "with", "other", "beta", "blockers", ",", "flestolol", "-", "induced", "effects", "reverse", "rapidly", "(", "within", "30", "minutes", ")", "following", "discontinuation", "because", "of", "its", "short", "half", "-", "life", ".", "Flestolol", "effectively", "reduced", "heart", "rate", "in", "patients", "with", "supraventricular", "tachyarrhythmia", ".", "In", "patients", "with", "unstable", "angina", ",", "flestolol", "infusion", "was", "found", "to", "be", "safe", "and", "effective", "in", "controlling", "chest", "pain", ".", "It", "is", "concluded", "that", "flestolol", "is", "a", "potent", ",", "well", "-", "tolerated", ",", "ultra", "-", "short", "-", "acting", "beta", "-", "adrenergic", "blocking", "agent", ".", "Use", "of", "flestolol", "in", "the", "critical", "care", "setting", "is", "currently", "undergoing", "investigation", "."]], "ner": [[[145, 145, "Chemical"], [148, 148, "Disease"], [0, 0, "Chemical"], [14, 14, "Chemical"], [16, 18, "Chemical"], [43, 43, "Chemical"], [89, 89, "Chemical"], [114, 114, "Chemical"], [130, 130, "Chemical"], [137, 137, "Chemical"], [155, 155, "Chemical"], [172, 172, "Chemical"], [193, 193, "Chemical"], [210, 210, "Chemical"], [228, 228, "Chemical"], [250, 250, "Chemical"], [201, 202, "Disease"], [207, 208, "Disease"], [221, 222, "Disease"]]], "relations": [[[145, 145, 148, 148, "CID"]]], "clusters": [], "translated": "<2>氟来洛尔</2>：一种超短效<14>β-肾上腺素阻滞剂</14>。 <3>氟来洛尔</3> (<4>ACC-9089</4>) 是一种<13>非选择性、竞争性、超短效的β-肾上腺素阻断剂</13>，没有任何内在的拟交感活性。 <5>氟来洛尔</5> 由<9>血浆酯酶</9>代谢，消除半衰期约为<6>6.5分钟</6>。该药物在健康志愿者中耐受性良好，剂量高达<7>100微克/公斤/分钟</7>。在长期输注研究中，<6>氟来洛尔</6>在有效的<14>β受体阻滞剂</14>量（<7>5微克/公斤/分钟</7>）下长达<8>7天</8>的耐受性良好。 <7>氟来洛尔</7>的血药浓度随剂量增加呈线性增加，<8>氟来洛尔</8>的血药浓度与<14>β-肾上腺素能阻滞剂</14>之间存在良好的相关性。 <9><14>氟来洛尔</14></9>对<0>异丙肾上腺素</0>诱导的<1>心动过速</1>产生剂量依赖性衰减。 <10>氟来洛尔</10>的<14>电生理和血液动力学</14>效应与其他<14>β受体阻滞剂</14>相似。与其他<14>β受体阻滞剂</14>相比，<11><14>氟来洛尔</14></11>诱导的作用在停药后迅速逆转（<6>30分钟内</6>），因为它的半衰期短。 <12><14>氟来洛尔</14></12>可有效降低<16>室上性心动过速</16> 患者的心率。在<17>不稳定型心绞痛</17>患者中，发现<13>氟来洛尔</13>输注可安全有效地控制<18>胸痛</18>。结论是<14>氟来洛尔</14>是一种强效、耐受性良好的<14>超短效β-肾上腺素阻滞剂</14>。使用<15>氟来洛尔</15>在重症监护环境中的目前正在进行调查。", "revised": true}
{"doc_key": "9334596", "sentences": [["Endocrine", "screening", "in", "1", ",", "022", "men", "with", "erectile", "dysfunction", ":", "clinical", "significance", "and", "cost", "-", "effective", "strategy", ".", "PURPOSE", ":", "We", "reviewed", "the", "results", "of", "serum", "testosterone", "and", "prolactin", "determination", "in", "1", ",", "022", "patients", "referred", "because", "of", "erectile", "dysfunction", "and", "compared", "the", "data", "with", "history", ",", "results", "of", "physical", "examination", ",", "other", "etiological", "investigations", "and", "effects", "of", "endocrine", "therapy", "to", "refine", "the", "rules", "of", "cost", "-", "effective", "endocrine", "screening", "and", "to", "pinpoint", "actual", "responsibility", "for", "hormonal", "abnormalities", ".", "MATERIALS", "AND", "METHODS", ":", "Testosterone", "and", "prolactin", "were", "determined", "by", "radioimmunoassay", ".", "Every", "patient", "was", "screened", "for", "testosterone", "and", "451", "were", "screened", "for", "prolactin", "on", "the", "basis", "of", "low", "sexual", "desire", ",", "gynecomastia", "or", "testosterone", "less", "than", "4", "ng", ".", "/", "ml", ".", "Determination", "was", "repeated", "in", "case", "of", "abnormal", "first", "results", ".", "Prolactin", "results", "were", "compared", "with", "those", "of", "a", "previous", "personal", "cohort", "of", "1", ",", "340", "patients", "with", "erectile", "dysfunction", "and", "systematic", "prolactin", "determination", ".", "Main", "clinical", "criteria", "tested", "regarding", "efficiency", "in", "hormone", "determination", "were", "low", "sexual", "desire", ",", "small", "testes", "and", "gynecomastia", ".", "Endocrine", "therapy", "consisted", "of", "testosterone", "heptylate", "or", "human", "chorionic", "gonadotropin", "for", "hypogonadism", "and", "bromocriptine", "for", "hyperprolactinemia", ".", "RESULTS", ":", "Testosterone", "was", "less", "than", "3", "ng", ".", "/", "ml", ".", "in", "107", "patients", "but", "normal", "in", "40", "%", "at", "repeat", "determination", ".", "The", "prevalence", "of", "repeatedly", "low", "testosterone", "increased", "with", "age", "(", "4", "%", "before", "age", "50", "years", "and", "9", "%", "50", "years", "or", "older", ")", ".", "Two", "pituitary", "tumors", "were", "discovered", "after", "testosterone", "determination", ".", "Most", "of", "the", "other", "low", "testosterone", "levels", "seemed", "to", "result", "from", "nonorganic", "hypothalamic", "dysfunction", "because", "of", "normal", "serum", "luteinizing", "hormone", "and", "prolactin", "and", "to", "have", "only", "a", "small", "role", "in", "erectile", "dysfunction", "(", "definite", "improvement", "in", "only", "16", "of", "44", "[", "36", "%", "]", "after", "androgen", "therapy", ",", "normal", "morning", "or", "nocturnal", "erections", "in", "30", "%", "and", "definite", "vasculogenic", "contributions", "in", "42", "%", ")", ".", "Determining", "testosterone", "only", "in", "cases", "of", "low", "sexual", "desire", "or", "abnormal", "physical", "examination", "would", "have", "missed", "40", "%", "of", "the", "cases", "with", "low", "testosterone", ",", "including", "37", "%", "of", "those", "subsequently", "improved", "by", "androgen", "therapy", ".", "Prolactin", "exceeded", "20", "ng", ".", "/", "ml", ".", "in", "5", "men", "and", "was", "normal", "in", "2", "at", "repeat", "determination", ".", "Only", "1", "prolactinoma", "was", "discovered", ".", "These", "data", "are", "lower", "than", "those", "we", "found", "during", "the", "last", "2", "decades", "(", "overall", "prolactin", "greater", "than", "20", "ng", ".", "/", "ml", ".", "in", "1", ".", "86", "%", "of", "1", ",", "821", "patients", ",", "prolactinomas", "in", "7", ",", "0", ".", "38", "%", ")", ".", "Bromocriptine", "was", "definitely", "effective", "in", "cases", "with", "prolactin", "greater", "than", "35", "ng", ".", "/", "ml", ".", "(", "8", "of", "12", "compared", "to", "only", "9", "of", "22", "cases", "with", "prolactin", "between", "20", "and", "35", "ng", ".", "/", "ml", ".", ")", ".", "Testosterone", "was", "low", "in", "less", "than", "50", "%", "of", "cases", "with", "prolactin", "greater", "than", "35", "ng", ".", "/", "ml", ".", "CONCLUSIONS", ":", "Low", "prevalences", "and", "effects", "of", "low", "testosterone", "and", "high", "prolactin", "in", "erectile", "dysfunction", "can", "not", "justify", "their", "routine", "determination", ".", "However", ",", "cost", "-", "effective", "screening", "strategies", "recommended", "so", "far", "missed", "40", "to", "50", "%", "of", "cases", "improved", "with", "endocrine", "therapy", "and", "the", "pituitary", "tumors", ".", "We", "now", "advocate", "that", "before", "age", "50", "years", "testosterone", "be", "determined", "only", "in", "cases", "of", "low", "sexual", "desire", "and", "abnormal", "physical", "examination", "but", "that", "it", "be", "measured", "in", "all", "men", "older", "than", "50", "years", ".", "Prolactin", "should", "be", "determined", "only", "in", "cases", "of", "low", "sexual", "desire", ",", "gynecomastia", "and", "/", "or", "testosterone", "less", "than", "4", "ng", ".", "/", "ml", "."]], "ner": [[[27, 27, "Chemical"], [84, 84, "Chemical"], [97, 97, "Chemical"], [114, 114, "Chemical"], [195, 195, "Chemical"], [222, 222, "Chemical"], [248, 248, "Chemical"], [256, 256, "Chemical"], [317, 317, "Chemical"], [339, 339, "Chemical"], [463, 463, "Chemical"], [491, 491, "Chemical"], [539, 539, "Chemical"], [582, 582, "Chemical"], [108, 110, "Disease"], [167, 169, "Disease"], [322, 324, "Disease"], [546, 548, "Disease"], [574, 576, "Disease"], [8, 9, "Disease"], [39, 40, "Disease"], [150, 151, "Disease"], [281, 282, "Disease"], [496, 497, "Disease"], [180, 181, "Chemical"], [189, 189, "Chemical"], [423, 423, "Chemical"], [112, 112, "Disease"], [174, 174, "Disease"], [578, 578, "Disease"], [187, 187, "Disease"], [191, 191, "Disease"], [243, 244, "Disease"], [528, 529, "Disease"], [263, 264, "Disease"], [374, 374, "Disease"], [413, 413, "Disease"]]], "relations": [[[27, 27, 108, 110, "CID"], [27, 27, 167, 169, "CID"], [27, 27, 322, 324, "CID"], [27, 27, 546, 548, "CID"], [27, 27, 574, 576, "CID"], [84, 84, 108, 110, "CID"], [84, 84, 167, 169, "CID"], [84, 84, 322, 324, "CID"], [84, 84, 546, 548, "CID"], [84, 84, 574, 576, "CID"], [97, 97, 108, 110, "CID"], [97, 97, 167, 169, "CID"], [97, 97, 322, 324, "CID"], [97, 97, 546, 548, "CID"], [97, 97, 574, 576, "CID"], [114, 114, 108, 110, "CID"], [114, 114, 167, 169, "CID"], [114, 114, 322, 324, "CID"], [114, 114, 546, 548, "CID"], [114, 114, 574, 576, "CID"], [195, 195, 108, 110, "CID"], [195, 195, 167, 169, "CID"], [195, 195, 322, 324, "CID"], [195, 195, 546, 548, "CID"], [195, 195, 574, 576, "CID"], [222, 222, 108, 110, "CID"], [222, 222, 167, 169, "CID"], [222, 222, 322, 324, "CID"], [222, 222, 546, 548, "CID"], [222, 222, 574, 576, "CID"], [248, 248, 108, 110, "CID"], [248, 248, 167, 169, "CID"], [248, 248, 322, 324, "CID"], [248, 248, 546, 548, "CID"], [248, 248, 574, 576, "CID"], [256, 256, 108, 110, "CID"], [256, 256, 167, 169, "CID"], [256, 256, 322, 324, "CID"], [256, 256, 546, 548, "CID"], [256, 256, 574, 576, "CID"], [317, 317, 108, 110, "CID"], [317, 317, 167, 169, "CID"], [317, 317, 322, 324, "CID"], [317, 317, 546, 548, "CID"], [317, 317, 574, 576, "CID"], [339, 339, 108, 110, "CID"], [339, 339, 167, 169, "CID"], [339, 339, 322, 324, "CID"], [339, 339, 546, 548, "CID"], [339, 339, 574, 576, "CID"], [463, 463, 108, 110, "CID"], [463, 463, 167, 169, "CID"], [463, 463, 322, 324, "CID"], [463, 463, 546, 548, "CID"], [463, 463, 574, 576, "CID"], [491, 491, 108, 110, "CID"], [491, 491, 167, 169, "CID"], [491, 491, 322, 324, "CID"], [491, 491, 546, 548, "CID"], [491, 491, 574, 576, "CID"], [539, 539, 108, 110, "CID"], [539, 539, 167, 169, "CID"], [539, 539, 322, 324, "CID"], [539, 539, 546, 548, "CID"], [539, 539, 574, 576, "CID"], [582, 582, 108, 110, "CID"], [582, 582, 167, 169, "CID"], [582, 582, 322, 324, "CID"], [582, 582, 546, 548, "CID"], [582, 582, 574, 576, "CID"]]], "clusters": [], "translated": "1,022例<19>勃起功能障碍</19>男性的内分泌筛查：临床意义及成本效益策略。目的：我们回顾了因<20>勃起功能障碍</20>转诊的1,022例患者的血清<0>睾酮</0>和催乳素测定结果，并将这些数据与病史、体格检查结果、其他病因进行比较，以完善具有成本效益的内分泌筛查规则，并查明荷尔蒙异常的实际责任。材料与方法：<1>睾酮</1>和催乳素采用放射免疫法测定。根据<14>性欲低下</14>、<27>男性乳房发育</27>或<3>睾酮</3>，每位患者都接受了<2>睾酮</2>筛查，451例患者接受了催乳素筛查，基于小于4纳克/毫升。如果第一次结果异常，则重复测定。将催乳素结果与之前的1,340名<21>勃起功能障碍</21>患者队列和系统催乳素测定结果进行了比较。关于激素测定效率的主要临床标准是<15>性欲低下</15>、小睾丸和<28>男性乳房发育</28>。内分泌治疗包括<24>庚酸睾酮</24>或人绒毛膜促性腺激素用于<30>性腺机能减退</30>和<25>溴隐亭</25>用于<31>高泌乳素血症</31>。结果：<4>睾酮</4>小于3纳克/毫升在107名患者中，但40%在重复测定时正常。反复低<5>睾酮</5>的患病率随年龄增长而增加（50岁前为4% ，50岁或以上为9%）。<6>睾酮</6>测定后发现两例<32>垂体瘤</32>。大多数其他低<7>睾酮</7>水平似乎是由非器质性<34>下丘脑功能障碍</34>引起的，因为血清黄体生成素和催乳素正常，并且在<22>勃起功能障碍</22>（雄激素治疗后44人中只有16人[36%]明显改善，30%的人早晨或夜间正常勃起，42%的人血管生成明显改善）。仅在<16>性欲低下</16>或体检异常的情况下测定<8>睾酮</8>会漏掉40%的<9>睾酮</9>低的病例，包括37%的那些随后通过雄激素治疗得到改善。催乳素超过20纳克/毫升的患者有5名，2名在重复测定时正常。仅发现1例<35>催乳素瘤</35>。这些数据低于我们在过去2十年中发现的数据（总催乳素大于20 ng./ml.在1.86%的1,821名患者中，<36>催乳素瘤</36>在7.0.38%）。<26>溴隐亭</26>对催乳素大于35 ng./毫升.的病例肯定有效（12人中有8人与22人中只有9人相比，催乳素水平在20和35 ng./ml之间）。<10>睾酮</10>在催乳素大于35 ng./毫升.的情况下低于50%。结论：<11>睾酮</11>低和催乳素高在<23>勃起功能障碍</23>中的患病率和影响不能证明他们的常规测定是合理的。然而，迄今为止推荐的具有成本效益的筛查策略遗漏了40%到50%的内分泌治疗改善的病例和<33>垂体瘤</33>。我们现在提倡在50岁之前<12>睾丸激素</12>仅在<17>性欲低下</17>和体检异常的情况下进行测定，但对所有50岁以上的男性进行测定。只有在<18>性欲低下</18>、<29>男性乳房发育</29>和/或<13>睾酮</13>低于4纳克/毫升的情况下才应测定催乳素。", "revised": true}
{"doc_key": "16330293", "sentences": [["Safety", "profile", "of", "a", "nicotine", "lozenge", "compared", "with", "that", "of", "nicotine", "gum", "in", "adult", "smokers", "with", "underlying", "medical", "conditions", ":", "a", "12", "-", "week", ",", "randomized", ",", "open", "-", "label", "study", ".", "BACKGROUND", ":", "Nicotine", "polacrilex", "lozenges", "deliver", "25", "%", "to", "27", "%", "more", "nicotine", "compared", "with", "equivalent", "doses", "of", "nicotine", "polacrilex", "gum", ".", "The", "increased", "nicotine", "exposure", "from", "the", "lozenge", "has", "raised", "questions", "about", "the", "relative", "safety", "of", "the", "lozenge", "and", "gum", ".", "OBJECTIVE", ":", "The", "objective", "of", "this", "study", "was", "to", "compare", "the", "safety", "profiles", "of", "the", "4", "-", "mg", "nicotine", "lozenge", "and", "4", "-", "mg", "nicotine", "gum", "in", "smokers", "with", "selected", "label", "-", "restricted", "diseases", ".", "METHODS", ":", "This", "was", "a", "multicenter", ",", "randomized", ",", "open", "-", "label", "study", "in", "adult", "smokers", "with", "heart", "disease", ",", "hypertension", "not", "controlled", "by", "medication", ",", "and", "/", "or", "diabetes", "mellitus", ".", "Patients", "were", "randomized", "in", "a", "1", ":", "1", "ratio", "to", "receive", "the", "4", "-", "mg", "nicotine", "lozenge", "or", "4", "-", "mg", "nicotine", "gum", ".", "Safety", "assessments", "were", "made", "at", "baseline", "and", "at", "2", ",", "4", ",", "6", ",", "and", "12", "weeks", "after", "the", "start", "of", "product", "use", ".", "RESULTS", ":", "Nine", "hundred", "one", "patients", "were", "randomized", "to", "treatment", ",", "447", "who", "received", "the", "lozenge", "and", "454", "who", "received", "the", "gum", "(", "safety", "population", ")", ".", "The", "majority", "were", "women", "(", "52", ".", "7", "%", ")", ".", "Patients", "'", "mean", "age", "was", "53", ".", "9", "years", ",", "their", "mean", "weight", "was", "193", ".", "9", "pounds", ",", "and", "they", "smoked", "a", "mean", "of", "25", ".", "2", "cigarettes", "per", "day", "at", "baseline", ".", "Five", "hundred", "fifty", "-", "three", "patients", ",", "264", "taking", "the", "lozenge", "and", "289", "taking", "the", "gum", ",", "used", "the", "study", "product", "for", ">", "or", "=", "4", "days", "per", "week", "during", "the", "first", "2", "weeks", "(", "evaluable", "population", ")", ".", "The", "nicotine", "lozenge", "and", "nicotine", "gum", "were", "equally", "well", "tolerated", ",", "despite", "increased", "nicotine", "exposure", "from", "the", "lozenge", ".", "The", "incidence", "of", "adverse", "events", "in", "the", "2", "groups", "was", "similar", "during", "the", "first", "2", "weeks", "of", "product", "use", "(", "evaluation", "population", ":", "55", ".", "3", "%", "lozenge", ",", "54", ".", "7", "%", "gum", ")", ",", "as", "well", "as", "during", "the", "entire", "study", "(", "safety", "population", ":", "63", ".", "8", "%", "and", "58", ".", "6", "%", ",", "respectively", ")", ".", "Stratification", "of", "patients", "by", "sex", ",", "age", ",", "extent", "of", "concurrent", "smoking", ",", "extent", "of", "product", "use", ",", "and", "severity", "of", "adverse", "events", "revealed", "no", "clinically", "significant", "differences", "between", "the", "lozenge", "and", "gum", ".", "The", "most", "common", "adverse", "events", "were", "nausea", "(", "17", ".", "2", "%", "and", "16", ".", "1", "%", ";", "95", "%", "CI", ",", "-", "3", ".", "7", "to", "6", ".", "0", ")", ",", "hiccups", "(", "10", ".", "7", "%", "and", "6", ".", "6", "%", ";", "95", "%", "CI", ",", "0", ".", "5", "to", "7", ".", "8", ")", ",", "and", "headache", "(", "8", ".", "7", "%", "and", "9", ".", "9", "%", ";", "95", "%", "Cl", ",", "-", "5", ".", "0", "to", "2", ".", "6", ")", ".", "Serious", "adverse", "events", "were", "reported", "in", "11", "and", "13", "patients", "in", "the", "respective", "groups", ".", "Fewer", "than", "6", "%", "of", "patients", "in", "either", "group", "were", "considered", "by", "the", "investigator", "to", "have", "a", "worsening", "of", "their", "overall", "disease", "condition", "during", "the", "study", ".", "The", "majority", "of", "patients", "(", ">", "60", "%", ")", "experienced", "no", "change", "in", "their", "disease", "status", "from", "baseline", ".", "CONCLUSION", ":", "The", "4", "-", "mg", "nicotine", "lozenge", "and", "4", "-", "mg", "nicotine", "gum", "had", "comparable", "safety", "profiles", "in", "these", "patients", "with", "label", "-", "restricted", "medical", "conditions", "."]], "ner": [[[4, 4, "Chemical"], [10, 10, "Chemical"], [34, 34, "Chemical"], [44, 44, "Chemical"], [50, 50, "Chemical"], [56, 56, "Chemical"], [92, 92, "Chemical"], [98, 98, "Chemical"], [156, 156, "Chemical"], [162, 162, "Chemical"], [301, 301, "Chemical"], [304, 304, "Chemical"], [313, 313, "Chemical"], [564, 564, "Chemical"], [570, 570, "Chemical"], [419, 419, "Disease"], [445, 445, "Disease"], [471, 471, "Disease"], [126, 127, "Disease"], [129, 129, "Disease"], [138, 139, "Disease"]]], "relations": [[[4, 4, 419, 419, "CID"], [10, 10, 419, 419, "CID"], [34, 34, 419, 419, "CID"], [44, 44, 419, 419, "CID"], [50, 50, 419, 419, "CID"], [56, 56, 419, 419, "CID"], [92, 92, 419, 419, "CID"], [98, 98, 419, 419, "CID"], [156, 156, 419, 419, "CID"], [162, 162, 419, 419, "CID"], [301, 301, 419, 419, "CID"], [304, 304, 419, 419, "CID"], [313, 313, 419, 419, "CID"], [564, 564, 419, 419, "CID"], [570, 570, 419, 419, "CID"], [4, 4, 445, 445, "CID"], [10, 10, 445, 445, "CID"], [34, 34, 445, 445, "CID"], [44, 44, 445, 445, "CID"], [50, 50, 445, 445, "CID"], [56, 56, 445, 445, "CID"], [92, 92, 445, 445, "CID"], [98, 98, 445, 445, "CID"], [156, 156, 445, 445, "CID"], [162, 162, 445, 445, "CID"], [301, 301, 445, 445, "CID"], [304, 304, 445, 445, "CID"], [313, 313, 445, 445, "CID"], [564, 564, 445, 445, "CID"], [570, 570, 445, 445, "CID"], [4, 4, 471, 471, "CID"], [10, 10, 471, 471, "CID"], [34, 34, 471, 471, "CID"], [44, 44, 471, 471, "CID"], [50, 50, 471, 471, "CID"], [56, 56, 471, 471, "CID"], [92, 92, 471, 471, "CID"], [98, 98, 471, 471, "CID"], [156, 156, 471, 471, "CID"], [162, 162, 471, 471, "CID"], [301, 301, 471, 471, "CID"], [304, 304, 471, 471, "CID"], [313, 313, 471, 471, "CID"], [564, 564, 471, 471, "CID"], [570, 570, 471, 471, "CID"]]], "clusters": [], "translated": " <0>尼古丁</0> 锭剂与 <1>尼古丁</1> 口香糖在有基础疾病的成年吸烟者中的安全性比较：一项为期 12 周的随机、开放标签研究。背景：与同等剂量的 <4>尼古丁</4> polacrilex口香糖相比，<2>尼古丁</2> polacrilex 锭剂释放的 <3>尼古丁</3> 多25%至27%。从锭剂中增加的 <5>尼古丁</5> 暴露引起了人们对锭剂和口香糖的相对安全性的质疑。目的：本研究的目的是比较 4 毫克 <6> 尼古丁 </6> 锭剂和 4 毫克 <7> 尼古丁 </7> 口香糖在患有特定标签限制疾病的吸烟者中的安全性。方法：这是一项针对患有 <18>心脏病</18>、<19>高血压</19>且药物无法控制和/或<20>糖尿病</20>的多中心、随机、开放标签研究。患者以1:1的比例随机接受4毫克 <8>尼古丁</8> 锭剂或4毫克 <9>尼古丁</9> 口香糖。在基线以及产品使用开始后的2、4、6和12周时进行了安全性评估。结果：901名患者被随机分配接受治疗，447名接受锭剂，454名接受口香糖（安全人群）。大多数是女性(52. 7%)。患者的平均年龄为53岁，平均体重为193.9磅，此前平均吸了25.2支香烟。五百五十三名患者，其中264名服用锭剂，289名服用口香糖，在前2周内每周使用研究产品≥4天（可评估人群）。 <10>尼古丁</10> 锭剂和 <11>尼古丁</11> 口香糖的耐受性同样好，尽管 锭剂中的<12>尼古丁</12> 暴露增加。在产品使用的前2周（评估人群：55.3%锭剂，54.7%口香糖）以及整个研究期间（安全人群：63.8%和58.6%分别），两组的不良事件发生率相似。按性别、年龄、同时吸烟的程度、产品使用的程度和不良事件的严重程度对患者进行分层显示，锭剂和口香糖之间没有临床显着差异。最常见的不良事件是<15>恶心</15>(17.2%和16.1%；95% CI，-3.7至6.0)，<16>打嗝</16>(10.7%和6.6%；95% CI，0.5至7.8)和<17>头痛</17> (8.7%和9.9%；95% Cl，-5.0至2.6)。各组分别有11名和13名患者报告了严重不良事件。研究者认为两组中只有不到6%的患者在研究期间整体疾病状况恶化。大多数患者(>60%)的疾病状态与基线相比没有变化。结论：4毫克<13>尼古丁</13>锭剂和4毫克<14>尼古丁</14>口香糖在这些有标签限制医疗条件的患者中具有相当的安全性。", "revised": true}
{"doc_key": "15649445", "sentences": [["Acute", "reserpine", "and", "subchronic", "haloperidol", "treatments", "change", "synaptosomal", "brain", "glutamate", "uptake", "and", "elicit", "orofacial", "dyskinesia", "in", "rats", ".", "Reserpine", "-", "and", "haloperidol", "-", "induced", "orofacial", "dyskinesia", "are", "putative", "animal", "models", "of", "tardive", "dyskinesia", "(", "TD", ")", "whose", "pathophysiology", "has", "been", "related", "to", "free", "radical", "generation", "and", "oxidative", "stress", ".", "In", "the", "present", "study", ",", "the", "authors", "induced", "orofacial", "dyskinesia", "by", "acute", "reserpine", "and", "subchronic", "haloperidol", "administration", "to", "rats", ".", "Reserpine", "injection", "(", "one", "dose", "of", "1", "mg", "/", "kg", "s", ".", "c", ".", ")", "every", "other", "day", "for", "3", "days", "caused", "a", "significant", "increase", "in", "vacuous", "chewing", ",", "tongue", "protrusion", "and", "duration", "of", "facial", "twitching", ",", "compared", "to", "the", "control", ".", "Haloperidol", "administration", "(", "one", "dose", "of", "12", "mg", "/", "kg", "once", "a", "week", "s", ".", "c", ".", ")", "for", "4", "weeks", "caused", "an", "increase", "in", "vacuous", "chewing", ",", "tongue", "protrusion", "and", "duration", "of", "facial", "twitching", "observed", "in", "four", "weekly", "evaluations", ".", "After", "the", "treatments", "and", "behavioral", "observation", ",", "glutamate", "uptake", "by", "segments", "of", "the", "brain", "was", "analyzed", ".", "A", "decreased", "glutamate", "uptake", "was", "observed", "in", "the", "subcortical", "parts", "of", "animals", "treated", "with", "reserpine", "and", "haloperidol", ",", "compared", "to", "the", "control", ".", "Importantly", ",", "a", "decrease", "in", "glutamate", "uptake", "correlates", "negatively", "with", "an", "increase", "in", "the", "incidence", "of", "orofacial", "diskinesia", ".", "These", "results", "indicate", "that", "early", "changes", "in", "glutamate", "transport", "may", "be", "related", "to", "the", "development", "of", "vacuous", "chewing", "movements", "in", "rats", "."]], "ner": [[[1, 1, "Chemical"], [18, 18, "Chemical"], [61, 61, "Chemical"], [69, 69, "Chemical"], [183, 183, "Chemical"], [13, 14, "Disease"], [24, 25, "Disease"], [31, 32, "Disease"], [34, 34, "Disease"], [57, 58, "Disease"], [208, 209, "Disease"], [4, 4, "Chemical"], [21, 21, "Chemical"], [64, 64, "Chemical"], [111, 111, "Chemical"], [185, 185, "Chemical"], [9, 9, "Chemical"], [159, 159, "Chemical"], [171, 171, "Chemical"], [197, 197, "Chemical"], [218, 218, "Chemical"]]], "relations": [[[1, 1, 13, 14, "CID"], [1, 1, 24, 25, "CID"], [1, 1, 31, 32, "CID"], [1, 1, 34, 34, "CID"], [1, 1, 57, 58, "CID"], [1, 1, 208, 209, "CID"], [18, 18, 13, 14, "CID"], [18, 18, 24, 25, "CID"], [18, 18, 31, 32, "CID"], [18, 18, 34, 34, "CID"], [18, 18, 57, 58, "CID"], [18, 18, 208, 209, "CID"], [61, 61, 13, 14, "CID"], [61, 61, 24, 25, "CID"], [61, 61, 31, 32, "CID"], [61, 61, 34, 34, "CID"], [61, 61, 57, 58, "CID"], [61, 61, 208, 209, "CID"], [69, 69, 13, 14, "CID"], [69, 69, 24, 25, "CID"], [69, 69, 31, 32, "CID"], [69, 69, 34, 34, "CID"], [69, 69, 57, 58, "CID"], [69, 69, 208, 209, "CID"], [183, 183, 13, 14, "CID"], [183, 183, 24, 25, "CID"], [183, 183, 31, 32, "CID"], [183, 183, 34, 34, "CID"], [183, 183, 57, 58, "CID"], [183, 183, 208, 209, "CID"], [4, 4, 13, 14, "CID"], [4, 4, 24, 25, "CID"], [4, 4, 31, 32, "CID"], [4, 4, 34, 34, "CID"], [4, 4, 57, 58, "CID"], [4, 4, 208, 209, "CID"], [21, 21, 13, 14, "CID"], [21, 21, 24, 25, "CID"], [21, 21, 31, 32, "CID"], [21, 21, 34, 34, "CID"], [21, 21, 57, 58, "CID"], [21, 21, 208, 209, "CID"], [64, 64, 13, 14, "CID"], [64, 64, 24, 25, "CID"], [64, 64, 31, 32, "CID"], [64, 64, 34, 34, "CID"], [64, 64, 57, 58, "CID"], [64, 64, 208, 209, "CID"], [111, 111, 13, 14, "CID"], [111, 111, 24, 25, "CID"], [111, 111, 31, 32, "CID"], [111, 111, 34, 34, "CID"], [111, 111, 57, 58, "CID"], [111, 111, 208, 209, "CID"], [185, 185, 13, 14, "CID"], [185, 185, 24, 25, "CID"], [185, 185, 31, 32, "CID"], [185, 185, 34, 34, "CID"], [185, 185, 57, 58, "CID"], [185, 185, 208, 209, "CID"]]], "clusters": [], "translated": "急性<0>利血平</0>和亚慢性<11>氟哌啶醇</11>治疗改变大鼠突触体脑部<16>谷氨酸</16>摄取并引发<5>口面部运动障碍</5>。<1>利血平</1>和<12>氟哌啶醇</12>诱导的<6>口面部运动障碍</6>是<7>迟发性运动障碍</7>的推定动物模型（<8>TD</8>），其病理生理学与自由基生成和氧化应激有关。在本研究中，作者通过对大鼠急性<2>利血平</2>和亚慢性<13>氟哌啶醇</13>给药诱导了<9>口面部运动障碍</9>。<3>利血平</3>注射液（一剂1mg/kg s.c.）每隔一天注射一次，持续3天。与对照组相比，咀嚼无力、舌头伸出和面部抽搐持续时间显着增加。<14>氟哌啶醇</14>给药（一次剂量为12mg/kg，每周一次，皮下注射）持续4周导致咀嚼无力、舌头突出和面部抽搐持续时间增加，在四周评估中观察到。在治疗和行为观察之后，分析了大脑部分对<17>谷氨酸</17>的摄取，与对照组相比，用<4>利血平</4>和<15>氟哌啶醇</15>处理的动物皮层下部分观察到<18>谷氨酸</18>摄取减少。重要的是，<19>谷氨酸</19>摄取的减少与<10>口面部运动障碍</10>发病率的增加呈负相关。这些结果表明，<20>谷氨酸</20>转运的早期变化可能与大鼠空洞咀嚼运动的发展有关。", "revised": true}
{"doc_key": "18308784", "sentences": [["Ginsenoside", "Rg1", "restores", "the", "impairment", "of", "learning", "induced", "by", "chronic", "morphine", "administration", "in", "rats", ".", "Rg1", ",", "as", "a", "ginsenoside", "extracted", "from", "Panax", "ginseng", ",", "could", "ameliorate", "spatial", "learning", "impairment", ".", "Previous", "studies", "have", "demonstrated", "that", "Rg1", "might", "be", "a", "useful", "agent", "for", "the", "prevention", "and", "treatment", "of", "the", "adverse", "effects", "of", "morphine", ".", "The", "aim", "of", "this", "study", "was", "to", "investigate", "the", "effect", "of", "Rg1", "on", "learning", "impairment", "by", "chronic", "morphine", "administration", "and", "the", "mechanism", "responsible", "for", "this", "effect", ".", "Male", "rats", "were", "subcutaneously", "injected", "with", "morphine", "(", "10", "mg", "/", "kg", ")", "twice", "a", "day", "at", "12", "hour", "intervals", "for", "10", "days", ",", "and", "Rg1", "(", "30", "mg", "/", "kg", ")", "was", "intraperitoneally", "injected", "2", "hours", "after", "the", "second", "injection", "of", "morphine", "once", "a", "day", "for", "10", "days", ".", "Spatial", "learning", "capacity", "was", "assessed", "in", "the", "Morris", "water", "maze", ".", "The", "results", "showed", "that", "rats", "treated", "with", "Morphine", "/", "Rg1", "decreased", "escape", "latency", "and", "increased", "the", "time", "spent", "in", "platform", "quadrant", "and", "entering", "frequency", ".", "By", "implantation", "of", "electrodes", "and", "electrophysiological", "recording", "in", "vivo", ",", "the", "results", "showed", "that", "Rg1", "restored", "the", "long", "-", "term", "potentiation", "(", "LTP", ")", "impaired", "by", "morphine", "in", "both", "freely", "moving", "and", "anaesthetised", "rats", ".", "The", "electrophysiological", "recording", "in", "vitro", "showed", "that", "Rg1", "restored", "the", "LTP", "in", "slices", "from", "the", "rats", "treated", "with", "morphine", ",", "but", "not", "changed", "LTP", "in", "the", "slices", "from", "normal", "saline", "-", "or", "morphine", "/", "Rg1", "-", "treated", "rats", ";", "this", "restoration", "could", "be", "inhibited", "by", "N", "-", "methyl", "-", "D", "-", "aspartate", "(", "NMDA", ")", "receptor", "antagonist", "MK801", ".", "We", "conclude", "that", "Rg1", "may", "significantly", "improve", "the", "spatial", "learning", "capacity", "impaired", "by", "chonic", "morphine", "administration", "and", "restore", "the", "morphine", "-", "inhibited", "LTP", ".", "This", "effect", "is", "NMDA", "receptor", "dependent", "."]], "ner": [[[10, 10, "Chemical"], [52, 52, "Chemical"], [71, 71, "Chemical"], [87, 87, "Chemical"], [123, 123, "Chemical"], [149, 149, "Chemical"], [193, 193, "Chemical"], [220, 220, "Chemical"], [234, 234, "Chemical"], [275, 275, "Chemical"], [280, 280, "Chemical"], [4, 6, "Disease"], [28, 29, "Disease"], [67, 68, "Disease"], [0, 1, "Chemical"], [15, 15, "Chemical"], [36, 36, "Chemical"], [65, 65, "Chemical"], [106, 106, "Chemical"], [151, 151, "Chemical"], [181, 181, "Chemical"], [209, 209, "Chemical"], [236, 236, "Chemical"], [264, 264, "Chemical"], [19, 19, "Chemical"], [247, 253, "Chemical"], [255, 255, "Chemical"], [288, 288, "Chemical"], [259, 259, "Chemical"]]], "relations": [[[10, 10, 4, 6, "CID"], [10, 10, 28, 29, "CID"], [10, 10, 67, 68, "CID"], [52, 52, 4, 6, "CID"], [52, 52, 28, 29, "CID"], [52, 52, 67, 68, "CID"], [71, 71, 4, 6, "CID"], [71, 71, 28, 29, "CID"], [71, 71, 67, 68, "CID"], [87, 87, 4, 6, "CID"], [87, 87, 28, 29, "CID"], [87, 87, 67, 68, "CID"], [123, 123, 4, 6, "CID"], [123, 123, 28, 29, "CID"], [123, 123, 67, 68, "CID"], [149, 149, 4, 6, "CID"], [149, 149, 28, 29, "CID"], [149, 149, 67, 68, "CID"], [193, 193, 4, 6, "CID"], [193, 193, 28, 29, "CID"], [193, 193, 67, 68, "CID"], [220, 220, 4, 6, "CID"], [220, 220, 28, 29, "CID"], [220, 220, 67, 68, "CID"], [234, 234, 4, 6, "CID"], [234, 234, 28, 29, "CID"], [234, 234, 67, 68, "CID"], [275, 275, 4, 6, "CID"], [275, 275, 28, 29, "CID"], [275, 275, 67, 68, "CID"], [280, 280, 4, 6, "CID"], [280, 280, 28, 29, "CID"], [280, 280, 67, 68, "CID"]]], "clusters": [], "translated": "<14>人参皂甙Rg1</14>恢复大鼠慢性<0>吗啡</0>给药引起的<11>学习障碍</11>。 <15>Rg1</15>作为从<24>人参</24>中提取的<24>人参皂苷</24>，可改善空间<12>学习障碍</12>。以往的研究表明，<16>Rg1</16>可能是预防和治疗<1>吗啡</1>不良反应的有效药物。本研究的目的是研究<17>Rg1</17>对慢性<2>吗啡</2>给药引起的<13>学习障碍</13>的影响以及造成这种影响的机制。雄性大鼠皮下注射<3>吗啡</3>（10 mg/kg），每天2次，间隔12小时，连续10天，腹腔注射<18>Rg1</18>（30 mg/kg）2小时后第二次注射<4>吗啡</4>，每天一次，连续10天。在Morris水迷宫中评估空间学习能力。结果表明，用<5>吗啡</5>/<19>Rg1</19>处理的大鼠逃避潜伏期减少，平台象限时间和进入频率增加。通过电极植入和体内电生理记录，结果表明<20>Rg1</20>可恢复自由活动和麻醉大鼠因<6>吗啡</6>受损的长时程增强（LTP）。体外电生理记录显示，<21>Rg1</21>可恢复<7>吗啡</7>大鼠切片的LTP，但生理盐水或<8>吗啡</8>/<22>Rg1</22>处理过的大鼠LTP无变化；这种恢复可被<25>N-甲基-D-天冬氨酸</25>（<26>NMDA</26>）受体拮抗剂<28>MK801</28>抑制。我们得出结论，<23>Rg1</23>可能会显著提高因慢性<9>吗啡</9>给药而受损的空间学习能力，并恢复<10>吗啡</10>抑制的LTP。这种作用是<27>NMDA</27>受体依赖性的。", "revised": true}
{"doc_key": "20633755", "sentences": [["Suxamethonium", "induced", "prolonged", "apnea", "in", "a", "patient", "receiving", "electroconvulsive", "therapy", ".", "Suxamethonium", "causes", "prolonged", "apnea", "in", "patients", "in", "whom", "pseudocholinesterase", "enzyme", "gets", "deactivated", "by", "organophosphorus", "(", "OP", ")", "poisons", ".", "Here", ",", "we", "present", "a", "similar", "incident", "in", "a", "severely", "depressed", "patient", "who", "received", "electroconvulsive", "therapy", "(", "ECT", ")", ".", "Prolonged", "apnea", "in", "our", "case", "ensued", "because", "the", "information", "about", "suicidal", "attempt", "by", "OP", "compound", "was", "concealed", "from", "the", "treating", "team", "."]], "ner": [[[0, 0, "Chemical"], [11, 11, "Chemical"], [3, 3, "Disease"], [14, 14, "Disease"], [51, 51, "Disease"], [24, 28, "Chemical"], [63, 64, "Chemical"], [40, 40, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 14, 14, "CID"], [0, 0, 51, 51, "CID"], [11, 11, 3, 3, "CID"], [11, 11, 14, 14, "CID"], [11, 11, 51, 51, "CID"], [24, 28, 3, 3, "CID"], [24, 28, 14, 14, "CID"], [24, 28, 51, 51, "CID"], [63, 64, 3, 3, "CID"], [63, 64, 14, 14, "CID"], [63, 64, 51, 51, "CID"]]], "clusters": [], "translated": " <0>琥珀胆碱</0>在接受电休克疗法的患者中引起了长时间的<2>呼吸暂停</2>。 <1>琥珀胆碱</1>会导致假胆碱酯酶因<5>有机磷 (OP) 毒物</5>而失活的患者长时间<3>呼吸暂停</3>。在这里，我们介绍了一名严重<7>抑郁</7>患者接受电休克疗法 (ECT) 的类似事件。在我们的案例中，<4>呼吸暂停</4>持续时间延长是因为自杀未遂的<6>OP化合物</6>信息被治疗团队隐瞒了。", "revised": true}
{"doc_key": "18631865", "sentences": [["mToR", "inhibitors", "-", "induced", "proteinuria", ":", "mechanisms", ",", "significance", ",", "and", "management", ".", "Massive", "urinary", "protein", "excretion", "has", "been", "observed", "after", "conversion", "from", "calcineurin", "inhibitors", "to", "mammalian", "target", "of", "rapamycin", "(", "mToR", ")", "inhibitors", ",", "especially", "sirolimus", ",", "in", "renal", "transplant", "recipients", "with", "chronic", "allograft", "nephropathy", ".", "Because", "proteinuria", "is", "a", "major", "predictive", "factor", "of", "poor", "transplantation", "outcome", ",", "many", "studies", "focused", "on", "this", "adverse", "event", "during", "the", "past", "years", ".", "Whether", "proteinuria", "was", "due", "to", "sirolimus", "or", "only", "a", "consequence", "of", "calcineurin", "inhibitors", "withdrawal", "remained", "unsolved", "until", "high", "range", "proteinuria", "has", "been", "observed", "during", "sirolimus", "therapy", "in", "islet", "transplantation", "and", "in", "patients", "who", "received", "sirolimus", "de", "novo", ".", "Podocyte", "injury", "and", "focal", "segmental", "glomerulosclerosis", "have", "been", "related", "to", "mToR", "inhibition", "in", "some", "patients", ",", "but", "the", "pathways", "underlying", "these", "lesions", "remain", "hypothetic", ".", "We", "discuss", "herein", "the", "possible", "mechanisms", "and", "the", "significance", "of", "mToR", "blockade", "-", "induced", "proteinuria", "."]], "ner": [[[29, 29, "Chemical"], [36, 36, "Chemical"], [76, 76, "Chemical"], [95, 95, "Chemical"], [105, 105, "Chemical"], [4, 4, "Disease"], [48, 48, "Disease"], [72, 72, "Disease"], [90, 90, "Disease"], [148, 148, "Disease"], [43, 45, "Disease"], [114, 114, "Disease"]]], "relations": [[[29, 29, 4, 4, "CID"], [29, 29, 48, 48, "CID"], [29, 29, 72, 72, "CID"], [29, 29, 90, 90, "CID"], [29, 29, 148, 148, "CID"], [36, 36, 4, 4, "CID"], [36, 36, 48, 48, "CID"], [36, 36, 72, 72, "CID"], [36, 36, 90, 90, "CID"], [36, 36, 148, 148, "CID"], [76, 76, 4, 4, "CID"], [76, 76, 48, 48, "CID"], [76, 76, 72, 72, "CID"], [76, 76, 90, 90, "CID"], [76, 76, 148, 148, "CID"], [95, 95, 4, 4, "CID"], [95, 95, 48, 48, "CID"], [95, 95, 72, 72, "CID"], [95, 95, 90, 90, "CID"], [95, 95, 148, 148, "CID"], [105, 105, 4, 4, "CID"], [105, 105, 48, 48, "CID"], [105, 105, 72, 72, "CID"], [105, 105, 90, 90, "CID"], [105, 105, 148, 148, "CID"]]], "clusters": [], "translated": "mToR 抑制剂诱导的<5>蛋白尿</5>：机制、意义和管理。在患有<10>慢性同种异体移植物肾病</10>的肾移植受者中，在从钙调神经磷酸酶抑制剂转化为哺乳动物<0>雷帕霉素</0> ( mToR ) 抑制剂，尤其是<1>西罗莫司</1>后，观察到大量尿蛋白排泄。由于<6>蛋白尿</6>是移植结果不佳的主要预测因素，因此在过去几年中许多研究都集中在这一不良事件上。<7>蛋白尿</7>是由于<2>西罗莫司</2>还是仅是钙调神经磷酸酶抑制剂停用的结果仍未解决，直到在胰岛移植中使用<3>西罗莫司</3>和de novo接受<4>西罗莫司</4>的患者观察到高范围的<8>蛋白尿</8>。足细胞损伤和局灶节段性<11>肾小球硬化</11>与某些患者的mToR抑制有关，但这些病变背后的通路仍然是假设的。我们在此讨论了mToR阻断引起的<9>蛋白尿</9>的可能机制和意义。", "revised": true}
{"doc_key": "20477932", "sentences": [["Cocaine", "causes", "memory", "and", "learning", "impairments", "in", "rats", ":", "involvement", "of", "nuclear", "factor", "kappa", "B", "and", "oxidative", "stress", ",", "and", "prevention", "by", "topiramate", ".", "Different", "mechanisms", "have", "been", "suggested", "for", "cocaine", "toxicity", "including", "an", "increase", "in", "oxidative", "stress", "but", "the", "association", "between", "oxidative", "status", "in", "the", "brain", "and", "cocaine", "induced", "-", "behaviour", "is", "poorly", "understood", ".", "Nuclear", "factor", "kappa", "B", "(", "NFkappaB", ")", "is", "a", "sensor", "of", "oxidative", "stress", "and", "participates", "in", "memory", "formation", "that", "could", "be", "involved", "in", "drug", "toxicity", "and", "addiction", "mechanisms", ".", "Therefore", "NFkappaB", "activity", ",", "oxidative", "stress", ",", "neuronal", "nitric", "oxide", "synthase", "(", "nNOS", ")", "activity", ",", "spatial", "learning", "and", "memory", "as", "well", "as", "the", "effect", "of", "topiramate", ",", "a", "previously", "proposed", "therapy", "for", "cocaine", "addiction", ",", "were", "evaluated", "in", "an", "experimental", "model", "of", "cocaine", "administration", "in", "rats", ".", "NFkappaB", "activity", "was", "decreased", "in", "the", "frontal", "cortex", "of", "cocaine", "treated", "rats", ",", "as", "well", "as", "GSH", "concentration", "and", "glutathione", "peroxidase", "activity", "in", "the", "hippocampus", ",", "whereas", "nNOS", "activity", "in", "the", "hippocampus", "was", "increased", ".", "Memory", "retrieval", "of", "experiences", "acquired", "prior", "to", "cocaine", "administration", "was", "impaired", "and", "negatively", "correlated", "with", "NFkappaB", "activity", "in", "the", "frontal", "cortex", ".", "In", "contrast", ",", "learning", "of", "new", "tasks", "was", "enhanced", "and", "correlated", "with", "the", "increase", "of", "nNOS", "activity", "and", "the", "decrease", "of", "glutathione", "peroxidase", ".", "These", "results", "provide", "evidence", "for", "a", "possible", "mechanistic", "role", "of", "oxidative", "and", "nitrosative", "stress", "and", "NFkappaB", "in", "the", "alterations", "induced", "by", "cocaine", ".", "Topiramate", "prevented", "all", "the", "alterations", "observed", ",", "showing", "novel", "neuroprotective", "properties", "."]], "ner": [[[0, 0, "Chemical"], [30, 30, "Chemical"], [48, 48, "Chemical"], [128, 128, "Chemical"], [142, 142, "Chemical"], [175, 175, "Chemical"], [235, 235, "Chemical"], [2, 5, "Disease"], [31, 31, "Disease"], [80, 80, "Disease"], [118, 119, "Disease"], [22, 22, "Chemical"], [111, 111, "Chemical"], [237, 237, "Chemical"], [93, 94, "Chemical"], [149, 149, "Chemical"], [152, 152, "Chemical"], [211, 211, "Chemical"]]], "relations": [[[0, 0, 2, 5, "CID"], [30, 30, 2, 5, "CID"], [48, 48, 2, 5, "CID"], [128, 128, 2, 5, "CID"], [142, 142, 2, 5, "CID"], [175, 175, 2, 5, "CID"], [235, 235, 2, 5, "CID"]]], "clusters": [], "translated": "<0>可卡因</0>导致大鼠<7>记忆和学习障碍</7>：核因子κB和氧化应激的参与，以及<11>托吡酯</11>的预防。不同机制已被提出来解释<1>可卡因</1> <8>毒性</8>，包括氧化应激的增加，但是大脑中氧化状态和<2>可卡因</2>引起的行为之间的关联还不清楚。核因子 κB (NFkappaB)是氧化应激传感器，参与记忆形成，可能参与药物<9>毒性</9>和成瘾机制。因此对于实验模型中<3>可卡因</3>给药，评估了在额叶皮质中的NFkappaB活性、氧化应激、神经元 <14>一氧化氮</14> 合酶（nNOS）活性、空间学习和记忆，以及一种先前提出的<12>托吡酯</12>治疗<10>可卡因成瘾</10>方法的作用。发现<4>可卡因</4>治疗的大鼠额叶皮质中的NFkappaB活性下降，海马中的<15>GSH</15>浓度和<16>谷胱甘肽</16>过氧化物酶活性降低，而在海马中nNOS活性却增加。对于在服用<5>可卡因</5>前获得的经验记忆检索进行了评估，结果表明检索功能受到损害，并且与额叶皮质中NFkappaB活性呈负相关。相应地，对于新任务的学习，nNOS活性的增加和<17>谷胱甘肽</17>过氧化物酶活性的降低与之相关联。这些结果提供了氧化应激和亚硝化应激以及NFkappaB在<6>可卡因</6>引起的改变中可能发挥的部分机制作用的证据。<13>托吡酯</13>阻止了观察到的所有改变，显示了新的神经保护特性。", "revised": true}
{"doc_key": "137340", "sentences": [["Effect", "of", "humoral", "modulators", "of", "morphine", "-", "induced", "increase", "in", "locomotor", "activity", "of", "mice", ".", "The", "effect", "of", "humoral", "modulators", "on", "the", "morphine", "-", "induced", "increase", "in", "locomotor", "activity", "of", "mice", "was", "studied", ".", "The", "subcutaneous", "administration", "of", "10", "mg", "/", "kg", "of", "morphine", "-", "HC1", "produced", "a", "marked", "increase", "in", "locomotor", "activity", "in", "mice", ".", "The", "morphine", "-", "induced", "hyperactivity", "was", "potentiated", "by", "scopolamine", "and", "attenuated", "by", "physostigmine", ".", "In", "contrast", ",", "both", "methscopolamine", "and", "neostigmine", ",", "which", "do", "not", "penetrate", "the", "blood", "-", "brain", "barrier", ",", "had", "no", "effect", "on", "the", "hyperactivity", "produced", "by", "morphine", ".", "Pretreatment", "of", "mice", "with", "alpha", "-", "methyltyrosine", "(", "20", "mg", "/", "kg", "i", ".", "p", ".", ",", "one", "hour", ")", ",", "an", "inhibitor", "of", "tyrosine", "hydroxylase", ",", "significantly", "decreased", "the", "activity", "-", "increasing", "effects", "of", "morphine", ".", "On", "the", "other", "hand", ",", "pretreatment", "with", "p", "-", "chlorophenylalamine", "(", "3", "X", "320", "mg", "/", "kg", "i", ".", "p", ".", ",", "24", "hr", ")", ",", "a", "serotonin", "depletor", ",", "caused", "no", "significant", "change", "in", "the", "hyperactivity", ".", "The", "study", "suggests", "that", "the", "activity", "-", "increasing", "effects", "of", "morphine", "are", "mediated", "by", "the", "release", "of", "catecholamines", "from", "adrenergic", "neurons", "in", "the", "brain", ".", "And", "the", "results", "are", "consistent", "with", "the", "hypothesis", "that", "morphine", "acts", "by", "retarding", "the", "release", "of", "acetylcholine", "at", "some", "central", "cholinergic", "synapses", ".", "It", "is", "also", "suggested", "from", "collected", "evidence", "that", "the", "activity", "-", "increasing", "effects", "of", "morphine", "in", "mice", "are", "mediated", "by", "mechanisms", "different", "from", "those", "which", "mediate", "the", "activity", "-", "increasing", "effects", "of", "morphine", "in", "rats", "."]], "ner": [[[5, 5, "Chemical"], [22, 22, "Chemical"], [43, 43, "Chemical"], [57, 57, "Chemical"], [96, 96, "Chemical"], [133, 133, "Chemical"], [183, 183, "Chemical"], [207, 207, "Chemical"], [235, 235, "Chemical"], [253, 253, "Chemical"], [8, 11, "Disease"], [25, 28, "Disease"], [49, 52, "Disease"], [60, 60, "Disease"], [93, 93, "Disease"], [171, 171, "Disease"], [64, 64, "Chemical"], [68, 68, "Chemical"], [74, 74, "Chemical"], [76, 76, "Chemical"], [102, 104, "Chemical"], [122, 122, "Chemical"], [142, 144, "Chemical"], [162, 162, "Chemical"], [190, 190, "Chemical"], [214, 214, "Chemical"]]], "relations": [[[5, 5, 8, 11, "CID"], [5, 5, 25, 28, "CID"], [5, 5, 49, 52, "CID"], [5, 5, 60, 60, "CID"], [5, 5, 93, 93, "CID"], [5, 5, 171, 171, "CID"], [22, 22, 8, 11, "CID"], [22, 22, 25, 28, "CID"], [22, 22, 49, 52, "CID"], [22, 22, 60, 60, "CID"], [22, 22, 93, 93, "CID"], [22, 22, 171, 171, "CID"], [43, 43, 8, 11, "CID"], [43, 43, 25, 28, "CID"], [43, 43, 49, 52, "CID"], [43, 43, 60, 60, "CID"], [43, 43, 93, 93, "CID"], [43, 43, 171, 171, "CID"], [57, 57, 8, 11, "CID"], [57, 57, 25, 28, "CID"], [57, 57, 49, 52, "CID"], [57, 57, 60, 60, "CID"], [57, 57, 93, 93, "CID"], [57, 57, 171, 171, "CID"], [96, 96, 8, 11, "CID"], [96, 96, 25, 28, "CID"], [96, 96, 49, 52, "CID"], [96, 96, 60, 60, "CID"], [96, 96, 93, 93, "CID"], [96, 96, 171, 171, "CID"], [133, 133, 8, 11, "CID"], [133, 133, 25, 28, "CID"], [133, 133, 49, 52, "CID"], [133, 133, 60, 60, "CID"], [133, 133, 93, 93, "CID"], [133, 133, 171, 171, "CID"], [183, 183, 8, 11, "CID"], [183, 183, 25, 28, "CID"], [183, 183, 49, 52, "CID"], [183, 183, 60, 60, "CID"], [183, 183, 93, 93, "CID"], [183, 183, 171, 171, "CID"], [207, 207, 8, 11, "CID"], [207, 207, 25, 28, "CID"], [207, 207, 49, 52, "CID"], [207, 207, 60, 60, "CID"], [207, 207, 93, 93, "CID"], [207, 207, 171, 171, "CID"], [235, 235, 8, 11, "CID"], [235, 235, 25, 28, "CID"], [235, 235, 49, 52, "CID"], [235, 235, 60, 60, "CID"], [235, 235, 93, 93, "CID"], [235, 235, 171, 171, "CID"], [253, 253, 8, 11, "CID"], [253, 253, 25, 28, "CID"], [253, 253, 49, 52, "CID"], [253, 253, 60, 60, "CID"], [253, 253, 93, 93, "CID"], [253, 253, 171, 171, "CID"], [64, 64, 8, 11, "CID"], [64, 64, 25, 28, "CID"], [64, 64, 49, 52, "CID"], [64, 64, 60, 60, "CID"], [64, 64, 93, 93, "CID"], [64, 64, 171, 171, "CID"]]], "clusters": [], "translated": "<0>吗啡</0><0>体液调节剂</0>对小鼠<10>运动活动增加</10>的影响。研究了<0>体液调节剂</0>对<1>吗啡</1>诱导的小鼠<11>运动活动增加</11>的影响。皮下注射10 mg/kg的<2>吗啡</2>-HC1可使小鼠的运动活动显着<12>增加</12>。<3>吗啡</3>诱导的<13>多动症</13>被<16>东莨菪碱</16>增强，被<17>毒扁豆碱</17>减弱。相比之下，不穿透血脑屏障的<18>甲基东莨菪碱</18>和<19>新斯的明</19>对<4>吗啡</4>引起的<14>多动症</14>没有影响。用<20>α-甲基酪氨酸</20>预处理小鼠（20 mg/kg i. p.,一小时），一种<21>酪氨酸</21>羟化酶抑制剂，可显著降低<5>吗啡</5>的活性增加作用。另一方面，用<22>对氯苯丙胺</22> （3 X 320 mg/kg i. p., 24小时），一种<23>血清素</23>消耗剂预处理，没有引起显著变化的<15>多动症</15>。该研究表明，<6>吗啡</6>的活性增加作用是由大脑中肾上腺素能神经元释放的<24>儿茶酚胺</24>介导的。并且结果与<7>吗啡</7>通过延迟某些中枢胆碱能突触中<25>乙酰胆碱</25>的释放起作用的假设一致。收集到的证据还表明，<8>吗啡</8>在小鼠中的活动增加作用是由不同于在大鼠中介导<9>吗啡</9>活动增加作用的机制介导的。", "revised": true}
{"doc_key": "6466532", "sentences": [["Comparison", "of", "i", ".", "v", ".", "glycopyrrolate", "and", "atropine", "in", "the", "prevention", "of", "bradycardia", "and", "arrhythmias", "following", "repeated", "doses", "of", "suxamethonium", "in", "children", ".", "The", "effectiveness", "of", "administration", "of", "glycopyrrolate", "5", "and", "10", "micrograms", "kg", "-", "1", "and", "atropine", "10", "and", "20", "micrograms", "kg", "-", "1", "i", ".", "v", ".", "immediately", "before", "the", "induction", "of", "anaesthesia", ",", "to", "prevent", "arrhythmia", "and", "bradycardia", "following", "repeated", "doses", "of", "suxamethonium", "in", "children", ",", "was", "studied", ".", "A", "control", "group", "was", "included", "for", "comparison", "with", "the", "lower", "dose", "range", "of", "glycopyrrolate", "and", "atropine", ".", "A", "frequency", "of", "bradycardia", "of", "50", "%", "was", "noted", "in", "the", "control", "group", ",", "but", "this", "was", "not", "significantly", "different", "from", "the", "frequency", "with", "the", "active", "drugs", ".", "Bradycardia", "(", "defined", "as", "a", "decrease", "in", "heart", "rate", "to", "less", "than", "50", "beat", "min", "-", "1", ")", "was", "prevented", "when", "the", "larger", "dose", "of", "either", "active", "drug", "was", "used", ".", "It", "is", "recommended", "that", "either", "glycopyrrolate", "10", "micrograms", "kg", "-", "1", "or", "atropine", "20", "micrograms", "kg", "-", "1", "i", ".", "v", ".", "should", "immediately", "precede", "induction", "of", "anaesthesia", ",", "in", "children", ",", "if", "the", "repeated", "administration", "of", "suxamethonium", "is", "anticipated", "."]], "ner": [[[20, 20, "Chemical"], [66, 66, "Chemical"], [186, 186, "Chemical"], [13, 13, "Disease"], [61, 61, "Disease"], [93, 93, "Disease"], [118, 118, "Disease"], [6, 6, "Chemical"], [29, 29, "Chemical"], [86, 86, "Chemical"], [154, 154, "Chemical"], [15, 15, "Disease"], [59, 59, "Disease"], [8, 8, "Chemical"], [38, 38, "Chemical"], [88, 88, "Chemical"], [161, 161, "Chemical"]]], "relations": [[[20, 20, 13, 13, "CID"], [20, 20, 61, 61, "CID"], [20, 20, 93, 93, "CID"], [20, 20, 118, 118, "CID"], [66, 66, 13, 13, "CID"], [66, 66, 61, 61, "CID"], [66, 66, 93, 93, "CID"], [66, 66, 118, 118, "CID"], [186, 186, 13, 13, "CID"], [186, 186, 61, 61, "CID"], [186, 186, 93, 93, "CID"], [186, 186, 118, 118, "CID"]]], "clusters": [], "translated": "我的比较研究了在麻醉诱导前即刻预防儿童重复服用<1>琥珀胆碱</1>后的<3>心动过缓</3>和<11>心律失常</11>的<7>静脉注射格隆溴铵</7>和<13>阿托品</13>的效果。研究了<8>格隆溴铵</8> 5 和 10 微克/公斤和<14>阿托品</14> 10 和 20 微克/公斤静脉注射在麻醉诱导前即刻预防儿童重复使用<2>琥珀胆碱</2>后出现<12>心律失常</12>和<4>心动过缓</4>的情况。为了与<9>格隆溴铵</9>和<15>阿托品</15>的较低剂量范围进行比较，还设置了一个对照组。注意到对照组出现<5>心动过缓</5>的频率为50％，但这与使用活性药物的频率没有显著差异。当使用较大剂量的任一活性药物时，均可预防<6>心动过缓</6>（定义为心率降低至低于50次/分）。建议在儿童麻醉诱导前立即使用<10>格隆溴铵</10>10微克/公斤或<16>阿托品</16>20微克/公斤静脉注射，如果预计需要重复给予<0>琥珀胆碱</0>。", "revised": true}
{"doc_key": "11027905", "sentences": [["Analgesic", "effect", "of", "intravenous", "ketamine", "in", "cancer", "patients", "on", "morphine", "therapy", ":", "a", "randomized", ",", "controlled", ",", "double", "-", "blind", ",", "crossover", ",", "double", "-", "dose", "study", ".", "Pain", "not", "responsive", "to", "morphine", "is", "often", "problematic", ".", "Animal", "and", "clinical", "studies", "have", "suggested", "that", "N", "-", "methyl", "-", "D", "-", "aspartate", "(", "NMDA", ")", "antagonists", ",", "such", "as", "ketamine", ",", "may", "be", "effective", "in", "improving", "opioid", "analgesia", "in", "difficult", "pain", "syndromes", ",", "such", "as", "neuropathic", "pain", ".", "A", "slow", "bolus", "of", "subhypnotic", "doses", "of", "ketamine", "(", "0", ".", "25", "mg", "/", "kg", "or", "0", ".", "50", "mg", "/", "kg", ")", "was", "given", "to", "10", "cancer", "patients", "whose", "pain", "was", "unrelieved", "by", "morphine", "in", "a", "randomized", ",", "double", "-", "blind", ",", "crossover", ",", "double", "-", "dose", "study", ".", "Pain", "intensity", "on", "a", "0", "to", "10", "numerical", "scale", ";", "nausea", "and", "vomiting", ",", "drowsiness", ",", "confusion", ",", "and", "dry", "mouth", ",", "using", "a", "scale", "from", "0", "to", "3", "(", "not", "at", "all", ",", "slight", ",", "a", "lot", ",", "awful", ")", ";", "Mini", "-", "Mental", "State", "Examination", "(", "MMSE", ")", "(", "0", "-", "30", ")", ";", "and", "arterial", "pressure", "were", "recorded", "before", "administration", "of", "drugs", "(", "T0", ")", "and", "after", "30", "minutes", "(", "T30", ")", ",", "60", "minutes", "(", "T60", ")", ",", "120", "minutes", "(", "T120", ")", ",", "and", "180", "minutes", "(", "T180", ")", ".", "Ketamine", ",", "but", "not", "saline", "solution", ",", "significantly", "reduced", "the", "pain", "intensity", "in", "almost", "all", "the", "patients", "at", "both", "doses", ".", "This", "effect", "was", "more", "relevant", "in", "patients", "treated", "with", "higher", "doses", ".", "Hallucinations", "occurred", "in", "4", "patients", ",", "and", "an", "unpleasant", "sensation", "(", "\"", "empty", "head", "\"", ")", "was", "also", "reported", "by", "2", "patients", ".", "These", "episodes", "reversed", "after", "the", "administration", "of", "diazepam", "1", "mg", "intravenously", ".", "Significant", "increases", "in", "drowsiness", "were", "reported", "in", "patients", "treated", "with", "ketamine", "in", "both", "groups", "and", "were", "more", "marked", "with", "ketamine", "0", ".", "50", "mg", "/", "kg", ".", "A", "significant", "difference", "in", "MMSE", "was", "observed", "at", "T30", "in", "patients", "who", "received", "0", ".", "50", "mg", "/", "kg", "of", "ketamine", ".", "Ketamine", "can", "improve", "morphine", "analgesia", "in", "difficult", "pain", "syndromes", ",", "such", "as", "neuropathic", "pain", ".", "However", ",", "the", "occurrence", "of", "central", "adverse", "effects", "should", "be", "taken", "into", "account", ",", "especially", "when", "using", "higher", "doses", ".", "This", "observation", "should", "be", "tested", "in", "studies", "of", "prolonged", "ketamine", "administration", "."]], "ner": [[[4, 4, "Chemical"], [58, 58, "Chemical"], [84, 84, "Chemical"], [222, 222, "Chemical"], [300, 300, "Chemical"], [309, 309, "Chemical"], [337, 337, "Chemical"], [339, 339, "Chemical"], [383, 383, "Chemical"], [255, 255, "Disease"], [6, 6, "Disease"], [104, 104, "Disease"], [28, 28, "Disease"], [69, 69, "Disease"], [107, 107, "Disease"], [127, 127, "Disease"], [232, 232, "Disease"], [346, 346, "Disease"], [74, 75, "Disease"], [351, 352, "Disease"], [137, 137, "Disease"], [139, 139, "Disease"], [143, 143, "Disease"], [146, 147, "Disease"], [9, 9, "Chemical"], [32, 32, "Chemical"], [111, 111, "Chemical"], [342, 342, "Chemical"], [44, 50, "Chemical"], [52, 52, "Chemical"], [285, 285, "Chemical"]]], "relations": [[[4, 4, 255, 255, "CID"], [58, 58, 255, 255, "CID"], [84, 84, 255, 255, "CID"], [222, 222, 255, 255, "CID"], [300, 300, 255, 255, "CID"], [309, 309, 255, 255, "CID"], [337, 337, 255, 255, "CID"], [339, 339, 255, 255, "CID"], [383, 383, 255, 255, "CID"]]], "clusters": [], "translated": "静脉注射<0>氯胺酮</0>对接受<24>吗啡</24>治疗的<10>癌症</10>患者的镇痛效果：一项随机、对照、双盲、交叉、双剂量研究。<12>疼痛</12>对<25>吗啡</25>没有反应通常是有问题的。动物和临床研究表明，<28>N-甲基-D-天冬氨酸</28>( <29>NMDA</29> )拮抗剂，例如<1>氯胺酮</1>，可能有效改善阿片类药物困难<13>疼痛</13>综合征的镇痛，如<18>神经性疼痛</18>。向10名<11>癌症</11>患者的<14>疼痛</14>未被<26>吗啡</26>缓解是一项随机、双盲、交叉、双剂量研究。<15>疼痛</15>强度在0到10数字范围内；<20>恶心</20>和<21>呕吐</21>，嗜睡，<22>意识模糊</22>和<23>口干</23>，使用0到3的量表（没有，轻微，很多，糟糕）；使用 Mini-Mental State Examination (MMSE) (0-30)评估认知功能；记录给药前(T0)、给药30分钟(T30)、60分钟(T60)、120分钟(T120)、180分钟(T180)后的血压和动脉压。向10名<11>癌症</11>患者分别小剂量和大剂量予以缓慢 bolus 的 <2>氯胺酮</2> (0.25mg/kg或0.5mg/kg)治疗，这些患者的<14>疼痛</14>未被<26>吗啡</26>缓解，在一项随机、双盲、交叉、双剂量的研究中进行观察。几乎在所有患者中，<3>氯胺酮</3>但非生理盐水，显着减轻了<16>疼痛</16>强度。这种效应在接受更高剂量治疗的患者中更为相关。在 4 名患者中出现了<9>幻觉</9>，并且2名患者也报告出现了不愉快的感觉（“空头”）。这些发作在静脉注射<30>地西泮</30>1mg后得到逆转。在两组接受<4>氯胺酮</4>治疗的患者中，嗜睡均显着增加，并且在接受0.5mg/kg的<5>氯胺酮</5>治疗的患者中更为明显。在接受0.5mg/kg的<6>氯胺酮</6>的患者在T30时观察到了显著的MMSE差异。<7>氯胺酮</7>能够提高<27>吗啡</27>对困难<17>疼痛</17>综合征，如<19>神经性疼痛</19>的镇痛作用。然而，在使用较高剂量时，应考虑到中枢不良反应的发生。这些观察结果应在延长<8>氯胺酮</8>给药的研究中进行检验。", "revised": true}
{"doc_key": "11961407", "sentences": [["GLEPP1", "receptor", "tyrosine", "phosphatase", "(", "Ptpro", ")", "in", "rat", "PAN", "nephrosis", ".", "A", "marker", "of", "acute", "podocyte", "injury", ".", "Glomerular", "epithelial", "protein", "1", "(", "GLEPP1", ")", "is", "a", "podocyte", "receptor", "membrane", "protein", "tyrosine", "phosphatase", "located", "on", "the", "apical", "cell", "membrane", "of", "visceral", "glomerular", "epithelial", "cell", "and", "foot", "processes", ".", "This", "receptor", "plays", "a", "role", "in", "regulating", "the", "structure", "and", "function", "of", "podocyte", "foot", "process", ".", "To", "better", "understand", "the", "utility", "of", "GLEPP1", "as", "a", "marker", "of", "glomerular", "injury", ",", "the", "amount", "and", "distribution", "of", "GLEPP1", "protein", "and", "mRNA", "were", "examined", "by", "immunohistochemistry", ",", "Western", "blot", "and", "RNase", "protection", "assay", "in", "a", "model", "of", "podocyte", "injury", "in", "the", "rat", ".", "Puromycin", "aminonucleoside", "nephrosis", "was", "induced", "by", "single", "intraperitoneal", "injection", "of", "puromycin", "aminonucleoside", "(", "PAN", ",", "20", "mg", "/", "100g", "BW", ")", ".", "Tissues", "were", "analyzed", "at", "0", ",", "5", ",", "7", ",", "11", ",", "21", ",", "45", ",", "80", "and", "126", "days", "after", "PAN", "injection", "so", "as", "to", "include", "both", "the", "acute", "phase", "of", "proteinuria", "associated", "with", "foot", "process", "effacement", "(", "days", "5", "-", "11", ")", "and", "the", "chronic", "phase", "of", "proteinuria", "associated", "with", "glomerulosclerosis", "(", "days", "45", "-", "126", ")", ".", "At", "day", "5", ",", "GLEPP1", "protein", "and", "mRNA", "were", "reduced", "from", "the", "normal", "range", "(", "265", ".", "2", "+", "/", "-", "79", ".", "6", "x", "10", "(", "6", ")", "moles", "/", "glomerulus", "and", "100", "%", ")", "to", "15", "%", "of", "normal", "(", "41", ".", "8", "+", "/", "-", "4", ".", "8", "x", "10", "(", "6", ")", "moles", "/", "glomerulus", ",", "p", "<", "0", ".", "005", ")", ".", "This", "occurred", "in", "association", "with", "an", "increase", "in", "urinary", "protein", "content", "from", "1", ".", "8", "+", "/", "-", "1", "to", "99", ".", "0", "+", "/", "-", "61", "mg", "/", "day", "(", "p", "<", "0", ".", "001", ")", ".", "In", "contrast", ",", "podocalyxin", "did", "not", "change", "significantly", "at", "this", "time", ".", "By", "day", "11", ",", "GLEPP1", "protein", "and", "mRNA", "had", "begun", "to", "return", "towards", "baseline", ".", "By", "day", "45", "-", "126", ",", "at", "a", "time", "when", "glomerular", "scarring", "was", "present", ",", "GLEPP1", "was", "absent", "from", "glomerulosclerotic", "areas", "although", "the", "total", "glomerular", "content", "of", "GLEPP1", "was", "not", "different", "from", "normal", ".", "We", "conclude", "that", "GLEPP1", "expression", ",", "unlike", "podocalyxin", ",", "reflects", "podocyte", "injury", "induced", "by", "PAN", ".", "GLEPP1", "expression", "may", "be", "a", "useful", "marker", "of", "podocyte", "injury", "."]], "ner": [[[9, 9, "Chemical"], [109, 110, "Chemical"], [119, 120, "Chemical"], [122, 122, "Chemical"], [152, 152, "Chemical"], [371, 371, "Chemical"], [10, 10, "Disease"], [111, 111, "Disease"], [163, 163, "Disease"], [180, 180, "Disease"], [2, 2, "Chemical"], [32, 32, "Chemical"], [76, 77, "Disease"], [183, 183, "Disease"]]], "relations": [[[9, 9, 10, 10, "CID"], [9, 9, 111, 111, "CID"], [109, 110, 10, 10, "CID"], [109, 110, 111, 111, "CID"], [119, 120, 10, 10, "CID"], [119, 120, 111, 111, "CID"], [122, 122, 10, 10, "CID"], [122, 122, 111, 111, "CID"], [152, 152, 10, 10, "CID"], [152, 152, 111, 111, "CID"], [371, 371, 10, 10, "CID"], [371, 371, 111, 111, "CID"], [9, 9, 163, 163, "CID"], [9, 9, 180, 180, "CID"], [109, 110, 163, 163, "CID"], [109, 110, 180, 180, "CID"], [119, 120, 163, 163, "CID"], [119, 120, 180, 180, "CID"], [122, 122, 163, 163, "CID"], [122, 122, 180, 180, "CID"], [152, 152, 163, 163, "CID"], [152, 152, 180, 180, "CID"], [371, 371, 163, 163, "CID"], [371, 371, 180, 180, "CID"]]], "clusters": [], "translated": "GLEPP1受体<10>酪氨酸</10>磷酸酶(Ptpro)在大鼠<0>PAN</0><6>肾病</6>中的作用。急性足细胞损伤的标志物。肾小球上皮蛋白1(GLEPP1)是一种足细胞受体膜蛋白<11>酪氨酸</11>磷酸酶，位于内脏肾小球上皮细胞和足突的顶端细胞膜上。该受体对足细胞足突的结构和功能具有调节作用。为了更好地理解GLEPP1作为<12>肾小球损伤</12>标志物的效用，在大鼠足细胞损伤模型中，通过免疫组织化学、蛋白质印迹和RNase保护试验检测了GLEPP1蛋白和mRNA的数量和分布。 <1>嘌呤霉素氨基核苷</1><7>肾病</7>采用单次腹腔注射<2>嘌呤霉素氨基核苷</2>(<3>PAN</3>，20 mg/100g BW)诱导。在<4>PAN</4>注射后第0、5、7、11、21、45、80和126天对组织进行分析，以包括与足部相关的<8>蛋白尿</8>急性期过程消失（第5-11天）和与<13>肾小球硬化</13>相关的<9>蛋白尿</9>慢性期（第45-126天）。在第5天，GLEPP1蛋白和mRNA从正常范围（265.2+/-79.6x10(6)摩尔/肾小球和100%）减少到正常范围的15%（41.8+/-4.8x10(6)摩尔/肾小球，p<0.005）。这与尿蛋白含量从1.8+/-1至99.0+/-61毫克/天（p<0.001）。相比之下，此时podocalyxin没有明显变化。到第11天，GLEPP1蛋白和mRNA开始恢复到基线水平。到第45-126天时，即肾小球瘢痕形成时，GLEPP1已从肾小球硬化区域消失，尽管GLEPP1的总肾小球含量与正常无异。我们得出的结论是，GLEPP1的表达与podocalyxin不同，反映了<5>PAN</5>诱导的足细胞损伤。GLEPP1表达可能是足细胞损伤的有用标志物。", "revised": true}
{"doc_key": "1639466", "sentences": [["Adverse", "effect", "of", "the", "calcium", "channel", "blocker", "nitrendipine", "on", "nephrosclerosis", "in", "rats", "with", "renovascular", "hypertension", ".", "The", "effect", "of", "a", "6", "-", "week", "treatment", "with", "the", "calcium", "channel", "blocker", "nitrendipine", "or", "the", "angiotensin", "converting", "enzyme", "inhibitor", "enalapril", "on", "blood", "pressure", ",", "albuminuria", ",", "renal", "hemodynamics", ",", "and", "morphology", "of", "the", "nonclipped", "kidney", "was", "studied", "in", "rats", "with", "two", "-", "kidney", ",", "one", "clip", "renovascular", "hypertension", ".", "Six", "weeks", "after", "clipping", "of", "one", "renal", "artery", ",", "hypertensive", "rats", "(", "178", "+", "/", "-", "4", "mm", "Hg", ")", "were", "randomly", "assigned", "to", "three", "groups", ":", "untreated", "hypertensive", "controls", "(", "n", "=", "8", ")", ",", "enalapril", "-", "treated", "(", "n", "=", "8", ")", ",", "or", "nitrendipine", "-", "treated", "(", "n", "=", "10", ")", ".", "Sham", "-", "operated", "rats", "served", "as", "normotensive", "controls", "(", "128", "+", "/", "-", "3", "mm", "Hg", ",", "n", "=", "8", ")", ".", "After", "6", "weeks", "of", "treatment", ",", "renal", "hemodynamics", "(", "glomerular", "filtration", "rate", "and", "renal", "plasma", "flow", ")", "were", "measured", "in", "the", "anesthetized", "rats", ".", "Renal", "tissue", "was", "obtained", "for", "determination", "of", "glomerular", "size", "and", "sclerosis", ".", "Enalapril", "but", "not", "nitrendipine", "reduced", "blood", "pressure", "significantly", ".", "After", "6", "weeks", "of", "therapy", ",", "glomerular", "filtration", "rate", "was", "not", "different", "among", "the", "studied", "groups", ".", "Renal", "plasma", "flow", "increased", ",", "but", "albumin", "excretion", "and", "glomerulosclerosis", "did", "not", "change", "after", "enalapril", "treatment", ".", "In", "contrast", ",", "in", "the", "nitrendipine", "-", "treated", "group", "albuminuria", "increased", "from", "12", ".", "8", "+", "/", "-", "2", "progressively", "to", "163", "+", "/", "-", "55", "compared", "with", "19", ".", "2", "+", "/", "-", "9", "mg", "/", "24", "hr", "in", "the", "hypertensive", "controls", ".", "Furthermore", ",", "glomerulosclerosis", "index", "was", "significantly", "increased", "in", "the", "nitrendipine", "-", "treated", "group", "compared", "with", "the", "hypertensive", "controls", "(", "0", ".", "38", "+", "/", "-", "0", ".", "1", "versus", "0", ".", "13", "+", "/", "-", "0", ".", "04", ")", ".", "In", "addition", ",", "glomerular", "size", "was", "higher", "in", "the", "nitrendipine", "-", "treated", "group", "(", "14", ".", "9", "+", "/", "-", "0", ".", "17", "10", "(", "-", "3", ")", "mm2", ")", "but", "lower", "in", "the", "enalapril", "-", "treated", "group", "(", "11", ".", "5", "+", "/", "-", "0", ".", "15", "10", "(", "-", "3", ")", "mm2", ")", "compared", "with", "the", "hypertensive", "controls", "(", "12", ".", "1", "+", "/", "-", "0", ".", "17", "10", "(", "-", "3", ")", "mm2", ")", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[7, 7, "Chemical"], [29, 29, "Chemical"], [112, 112, "Chemical"], [182, 182, "Chemical"], [227, 227, "Chemical"], [275, 275, "Chemical"], [315, 315, "Chemical"], [9, 9, "Disease"], [41, 41, "Disease"], [231, 231, "Disease"], [4, 4, "Chemical"], [26, 26, "Chemical"], [13, 14, "Disease"], [63, 64, "Disease"], [75, 75, "Disease"], [94, 94, "Disease"], [263, 263, "Disease"], [282, 282, "Disease"], [364, 364, "Disease"], [214, 214, "Disease"], [268, 268, "Disease"], [32, 32, "Chemical"], [36, 36, "Chemical"], [102, 102, "Chemical"], [179, 179, "Chemical"], [219, 219, "Chemical"], [340, 340, "Chemical"]]], "relations": [[[7, 7, 9, 9, "CID"], [29, 29, 9, 9, "CID"], [112, 112, 9, 9, "CID"], [182, 182, 9, 9, "CID"], [227, 227, 9, 9, "CID"], [275, 275, 9, 9, "CID"], [315, 315, 9, 9, "CID"], [7, 7, 41, 41, "CID"], [7, 7, 231, 231, "CID"], [29, 29, 41, 41, "CID"], [29, 29, 231, 231, "CID"], [112, 112, 41, 41, "CID"], [112, 112, 231, 231, "CID"], [182, 182, 41, 41, "CID"], [182, 182, 231, 231, "CID"], [227, 227, 41, 41, "CID"], [227, 227, 231, 231, "CID"], [275, 275, 41, 41, "CID"], [275, 275, 231, 231, "CID"], [315, 315, 41, 41, "CID"], [315, 315, 231, 231, "CID"]]], "clusters": [], "translated": "<10>钙</10>通道阻滞剂<0>尼群地平</0>对<12>肾血管性高血压</12>大鼠<7>肾硬化</7>的不良影响。6周治疗<11>钙</11>通道阻滞剂<1>尼群地平</1>或<21>血管紧张素</21>转化酶抑制剂<22>依那普利</22>后，双肾单夹<13>肾血管性高血压</13>大鼠比较血压、<8>蛋白尿</8>、肾血流动力学和非夹肾形态的变化。一根肾动脉夹闭后6周，<14>高血压</14>大鼠（178 + /- 4 mmHg）随机分配到3组：未治疗<15>高血压</15>对照组（n = 8），<23>依那普利</23>-治疗组（n = 8）或<2>尼群地平</2>-治疗组（n = 10）。假手术大鼠作为血压正常的对照组（128 +/- 3 mmHg，n = 8）。治疗6周后，麻醉大鼠的肾血流动力学（肾小球滤过率和肾血浆流量）测量。获得肾组织用于测定肾小球大小和硬化程度。<24>依那普利</24>显著降低血压，而<3>尼群地平</3>没有显著降压。治疗6周后，研究各组肾小球滤过率没有明显差异。治疗<25>依那普利</25>后，肾血浆流量增加，然而白蛋白排泄和<19>肾小球硬化</19>没有改变；相反，在<4>尼群地平</4>-治疗组中，<9>蛋白尿</9>逐渐从12.8 + /- 2增加至163 + /- 55，并且明显高于<16>高血压</16>对照组的19.2 + /- 9毫克/24小时。此外，<5>尼群地平</5>-治疗组的<20>肾小球硬化</20>指数相比于<17>高血压</17>对照组显著增加（0.38 + /- 0. 1对0.13 + /- 0.04）。另外，<6>尼群地平</6>-治疗组比起<18>高血压</18>对照组肾小球尺寸更大（14.9 + / - 0.17×10（-3）mm2对12.1 + / - 0.17×10（-3）mm2），而<26>依那普利</26>-治疗组则更小（11.5 + / - 0.15×10（-3）mm2）。 （摘要截至250字）", "revised": true}
{"doc_key": "9401499", "sentences": [["Ticlopidine", "-", "induced", "aplastic", "anemia", ":", "report", "of", "three", "Chinese", "patients", "and", "review", "of", "the", "literature", ".", "In", "this", "study", ",", "three", "Chinese", "patients", "with", "ticlopidine", "-", "induced", "aplastic", "anemia", "were", "reported", "and", "another", "13", "patients", "in", "the", "English", "literature", "were", "reviewed", ".", "We", "attempted", "to", "find", "underlying", "similarities", ",", "evaluate", "the", "risk", "factors", ",", "and", "identify", "appropriate", "treatment", "for", "this", "complication", ".", "All", "but", "one", "of", "the", "patients", "were", "over", "60", "years", "old", ",", "and", "the", "6", "who", "died", "were", "all", "older", "than", "65", ".", "Therefore", ",", "old", "age", "may", "be", "a", "risk", "factor", "for", "developing", "this", "complication", ".", "Agranulocytosis", "occurred", "3", "-", "20", "weeks", "after", "initiation", "of", "ticlopidine", ",", "so", "frequent", "examination", "of", "white", "cell", "count", "during", "treatment", "is", "recommended", ".", "There", "seemed", "to", "be", "no", "direct", "correlation", "between", "the", "dose", "or", "duration", "used", "and", "the", "severity", "of", "bone", "marrow", "suppression", ".", "Treatment", "for", "ticlopidine", "-", "induced", "aplastic", "anemia", "with", "colony", "-", "stimulating", "factors", "seemed", "to", "have", "little", "effect", ".", "The", "fact", "that", "5", "of", "the", "6", "patients", "who", "received", "concurrent", "calcium", "channel", "blockers", "died", ",", "should", "alert", "clinicians", "to", "be", "more", "cautious", "when", "using", "these", "two", "drugs", "simultaneously", "."]], "ner": [[[0, 0, "Chemical"], [25, 25, "Chemical"], [109, 109, "Chemical"], [146, 146, "Chemical"], [3, 4, "Disease"], [28, 29, "Disease"], [149, 150, "Disease"], [100, 100, "Disease"], [140, 142, "Disease"], [173, 173, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 28, 29, "CID"], [0, 0, 149, 150, "CID"], [25, 25, 3, 4, "CID"], [25, 25, 28, 29, "CID"], [25, 25, 149, 150, "CID"], [109, 109, 3, 4, "CID"], [109, 109, 28, 29, "CID"], [109, 109, 149, 150, "CID"], [146, 146, 3, 4, "CID"], [146, 146, 28, 29, "CID"], [146, 146, 149, 150, "CID"], [0, 0, 100, 100, "CID"], [25, 25, 100, 100, "CID"], [109, 109, 100, 100, "CID"], [146, 146, 100, 100, "CID"]]], "clusters": [], "translated": " <0>噻氯匹定</0>致<4>再生障碍性贫血</4>：三例中国患者报告及文献复习。在这项研究中，报道了三例<1>噻氯匹定</1>诱发的<5>再生障碍性贫血</5>的中国患者，并对另外13例英文文献进行了回顾。我们试图找到潜在的相似之处，评估风险因素，并确定适合这种并发症的治疗方法。除一名患者外，其他患者均超过60岁，死亡的6名患者均超过65岁。因此，高龄可能是发生这种并发症的危险因素。<7> 粒细胞缺乏症 </7>发生在<2> 噻氯匹定 </2>开始后3-20周，因此建议在治疗期间经常检查白细胞计数。使用的剂量或持续时间与<8> 骨髓抑制 </8>的严重程度之间似乎没有直接相关性。用集落刺激因子治疗<3> 噻氯匹定 </3>诱发的<6> 再生障碍性贫血 </6>似乎收效甚微。6例同时接受<9> 钙 </9>通道阻滞剂治疗的患者中有5例死亡，这一事实提醒临床医生在同时使用这两种药物时要更加谨慎。", "revised": true}
{"doc_key": "2273650", "sentences": [["Facilitation", "of", "memory", "retrieval", "by", "pre", "-", "test", "morphine", "and", "its", "state", "dependency", "in", "the", "step", "-", "through", "type", "passive", "avoidance", "learning", "test", "in", "mice", ".", "Amnesia", "produced", "by", "scopolamine", "and", "cycloheximide", "were", "reversed", "by", "morphine", "given", "30", "min", "before", "the", "test", "trial", "(", "pre", "-", "test", ")", ",", "and", "pre", "-", "test", "morphine", "also", "facilitated", "the", "memory", "retrieval", "in", "the", "animals", "administered", "naloxone", "during", "the", "training", "trial", ".", "Similarly", ",", "pre", "-", "test", "scopolamine", "partially", "reversed", "the", "scopolamine", "-", "induced", "amnesia", ",", "but", "not", "significantly", ";", "and", "pre", "-", "test", "cycloheximide", "failed", "to", "reverse", "the", "cycloheximide", "-", "induced", "amnesia", ".", "These", "results", "suggest", "that", "the", "facilitation", "of", "memory", "retrieval", "by", "pre", "-", "test", "morphine", "might", "be", "the", "direct", "action", "of", "morphine", "rather", "than", "a", "state", "dependent", "effect", "."]], "ner": [[[29, 29, "Chemical"], [74, 74, "Chemical"], [78, 78, "Chemical"], [26, 26, "Disease"], [81, 81, "Disease"], [99, 99, "Disease"], [31, 31, "Chemical"], [91, 91, "Chemical"], [96, 96, "Chemical"], [8, 8, "Chemical"], [35, 35, "Chemical"], [53, 53, "Chemical"], [114, 114, "Chemical"], [121, 121, "Chemical"], [63, 63, "Chemical"]]], "relations": [[[29, 29, 26, 26, "CID"], [29, 29, 81, 81, "CID"], [29, 29, 99, 99, "CID"], [74, 74, 26, 26, "CID"], [74, 74, 81, 81, "CID"], [74, 74, 99, 99, "CID"], [78, 78, 26, 26, "CID"], [78, 78, 81, 81, "CID"], [78, 78, 99, 99, "CID"], [31, 31, 26, 26, "CID"], [31, 31, 81, 81, "CID"], [31, 31, 99, 99, "CID"], [91, 91, 26, 26, "CID"], [91, 91, 81, 81, "CID"], [91, 91, 99, 99, "CID"], [96, 96, 26, 26, "CID"], [96, 96, 81, 81, "CID"], [96, 96, 99, 99, "CID"]]], "clusters": [], "translated": "前测<9>吗啡</9>对小鼠记忆提取的促进作用及其在小鼠步进型被动回避学习试验中的状态依赖性。<3>失忆症</3>由<0>东莨菪碱</0>和<6>环己酰亚胺</6>产生，被<10>吗啡</10>在试验前30分钟给予逆转（试验前）和前测<11>吗啡</11>也促进了在训练试验期间给予<14>纳洛酮</14>的动物的记忆检索。同样，前测<1>东莨菪碱</1>部分逆转了<2>东莨菪碱</2>诱发的<4>失忆症</4>，但不显着；并且前测<7>环己酰亚胺</7>未能逆转<8>环己酰亚胺</8>诱导的<5>失忆症</5>。这些结果表明，前测<12>吗啡</12>促进记忆检索可能是<13>吗啡</13>的直接作用，而不是状态依赖效应。", "revised": true}
{"doc_key": "220563", "sentences": [["Perhexiline", "maleate", "and", "peripheral", "neuropathy", ".", "Peripheral", "neuropathy", "has", "been", "noted", "as", "a", "complication", "of", "therapy", "with", "perhexiline", "maleate", ",", "a", "drug", "widely", "used", "in", "France", "(", "and", "in", "clinical", "trials", "in", "the", "United", "States", ")", "for", "the", "prophylactic", "treatment", "of", "angina", "pectoris", ".", "In", "24", "patients", "with", "this", "complication", ",", "the", "marked", "slowing", "of", "motor", "nerve", "conduction", "velocity", "and", "the", "electromyographic", "changes", "imply", "mainly", "a", "demyelinating", "disorder", ".", "Improvement", "was", "noted", "with", "cessation", "of", "therapy", ".", "In", "a", "few", "cases", "the", "presence", "of", "active", "denervation", "signified", "a", "poor", "prognosis", ",", "with", "only", "slight", "improvement", ".", "The", "underlying", "mechanism", "causing", "the", "neuropathy", "is", "not", "yet", "fully", "known", ",", "although", "some", "evidence", "indicates", "that", "it", "may", "be", "a", "lipid", "storage", "process", "."]], "ner": [[[0, 1, "Chemical"], [17, 18, "Chemical"], [3, 4, "Disease"], [6, 7, "Disease"], [66, 67, "Disease"], [41, 42, "Disease"], [101, 101, "Disease"]]], "relations": [[[0, 1, 3, 4, "CID"], [0, 1, 6, 7, "CID"], [17, 18, 3, 4, "CID"], [17, 18, 6, 7, "CID"], [0, 1, 66, 67, "CID"], [17, 18, 66, 67, "CID"]]], "clusters": [], "translated": "<0>马来酸哌可昔林</0>和<2>周围神经病变</2>。 <3>周围神经病变</3>已被注意到是<1>马来酸哌可昔林</1>治疗的并发症，该药物在法国（以及在美国的临床试验中）广泛用于预防性治疗<5>心绞痛</5>。24例出现该并发症的患者，运动神经传导速度明显减慢，肌电图改变提示主要为<4>脱髓鞘疾病</4>。停止治疗后出现改善。在少数情况下，主动去神经支配的存在预示着预后不良，只有轻微的改善。导致<6>神经病变</6>的潜在机制尚不完全清楚，尽管一些证据表明它可能是脂质储存过程。", "revised": true}
{"doc_key": "12464714", "sentences": [["Crossover", "comparison", "of", "efficacy", "and", "preference", "for", "rizatriptan", "10", "mg", "versus", "ergotamine", "/", "caffeine", "in", "migraine", ".", "Rizatriptan", "is", "a", "selective", "5", "-", "HT", "(", "1B", "/", "1D", ")", "receptor", "agonist", "with", "rapid", "oral", "absorption", "and", "early", "onset", "of", "action", "in", "the", "acute", "treatment", "of", "migraine", ".", "This", "randomized", "double", "-", "blind", "crossover", "outpatient", "study", "assessed", "the", "preference", "for", "1", "rizatriptan", "10", "mg", "tablet", "to", "2", "ergotamine", "1", "mg", "/", "caffeine", "100", "mg", "tablets", "in", "439", "patients", "treating", "a", "single", "migraine", "attack", "with", "each", "therapy", ".", "Of", "patients", "expressing", "a", "preference", "(", "89", ".", "1", "%", ")", ",", "more", "than", "twice", "as", "many", "preferred", "rizatriptan", "to", "ergotamine", "/", "caffeine", "(", "69", ".", "9", "vs", ".", "30", ".", "1", "%", ",", "p", "<", "or", "=", "0", ".", "001", ")", ".", "Faster", "relief", "of", "headache", "was", "the", "most", "important", "reason", "for", "preference", ",", "cited", "by", "67", ".", "3", "%", "of", "patients", "preferring", "rizatriptan", "and", "54", ".", "2", "%", "of", "patients", "who", "preferred", "ergotamine", "/", "caffeine", ".", "The", "co", "-", "primary", "endpoint", "of", "being", "pain", "free", "at", "2", "h", "was", "also", "in", "favor", "of", "rizatriptan", ".", "Forty", "-", "nine", "percent", "of", "patients", "were", "pain", "free", "2", "h", "after", "rizatriptan", ",", "compared", "with", "24", ".", "3", "%", "treated", "with", "ergotamine", "/", "caffeine", "(", "p", "<", "or", "=", "0", ".", "001", ")", ",", "rizatriptan", "being", "superior", "within", "1", "h", "of", "treatment", ".", "Headache", "relief", "at", "2", "h", "was", "75", ".", "9", "%", "for", "rizatriptan", "and", "47", ".", "3", "%", "for", "ergotamine", "/", "caffeine", "(", "p", "<", "or", "=", "0", ".", "001", ")", ",", "with", "rizatriptan", "being", "superior", "to", "ergotamine", "/", "caffeine", "within", "30", "min", "of", "dosing", ".", "Almost", "36", "%", "of", "patients", "taking", "rizatriptan", "were", "pain", "free", "at", "2", "h", "and", "had", "no", "recurrence", "or", "need", "for", "additional", "medication", "within", "24", "h", ",", "compared", "to", "20", "%", "of", "patients", "on", "ergotamine", "/", "caffeine", "(", "p", "<", "or", "=", "0", ".", "001", ")", ".", "Rizatriptan", "was", "also", "superior", "to", "ergotamine", "/", "caffeine", "in", "the", "proportions", "of", "patients", "with", "no", "nausea", ",", "vomiting", ",", "phonophobia", "or", "photophobia", "and", "for", "patients", "with", "normal", "function", "2", "h", "after", "drug", "intake", "(", "p", "<", "or", "=", "0", ".", "001", ")", ".", "More", "patients", "were", "(", "completely", ",", "very", "or", "somewhat", ")", "satisfied", "2", "h", "after", "treatment", "with", "rizatriptan", "(", "69", ".", "8", "%", ")", "than", "at", "2", "h", "after", "treatment", "with", "ergotamine", "/", "caffeine", "(", "38", ".", "6", "%", ",", "p", "<", "or", "=", "0", ".", "001", ")", ".", "Recurrence", "rates", "were", "31", ".", "4", "%", "with", "rizatriptan", "and", "15", ".", "3", "%", "with", "ergotamine", "/", "caffeine", ".", "Both", "active", "treatments", "were", "well", "tolerated", ".", "The", "most", "common", "adverse", "events", "(", "incidence", ">", "or", "=", "5", "%", "in", "one", "group", ")", "after", "rizatriptan", "and", "ergotamine", "/", "caffeine", ",", "respectively", ",", "were", "dizziness", "(", "6", ".", "7", "and", "5", ".", "3", "%", ")", ",", "nausea", "(", "4", ".", "2", "and", "8", ".", "5", "%", ")", "and", "somnolence", "(", "5", ".", "5", "and", "2", ".", "3", "%", ")", "."]], "ner": [[[7, 7, "Chemical"], [17, 17, "Chemical"], [60, 60, "Chemical"], [104, 104, "Chemical"], [150, 150, "Chemical"], [181, 181, "Chemical"], [195, 195, "Chemical"], [218, 218, "Chemical"], [238, 238, "Chemical"], [259, 259, "Chemical"], [278, 278, "Chemical"], [318, 318, "Chemical"], [377, 377, "Chemical"], [417, 417, "Chemical"], [452, 452, "Chemical"], [333, 333, "Disease"], [473, 473, "Disease"], [461, 461, "Disease"], [15, 15, "Disease"], [45, 45, "Disease"], [80, 80, "Disease"], [132, 132, "Disease"], [227, 227, "Disease"], [171, 171, "Disease"], [190, 190, "Disease"], [280, 280, "Disease"], [335, 335, "Disease"], [337, 337, "Disease"], [339, 339, "Disease"], [485, 485, "Disease"], [11, 11, "Chemical"], [66, 66, "Chemical"], [106, 106, "Chemical"], [160, 160, "Chemical"], [205, 205, "Chemical"], [245, 245, "Chemical"], [263, 263, "Chemical"], [305, 305, "Chemical"], [323, 323, "Chemical"], [391, 391, "Chemical"], [424, 424, "Chemical"], [454, 454, "Chemical"], [13, 13, "Chemical"], [70, 70, "Chemical"], [108, 108, "Chemical"], [162, 162, "Chemical"], [207, 207, "Chemical"], [247, 247, "Chemical"], [265, 265, "Chemical"], [307, 307, "Chemical"], [325, 325, "Chemical"], [393, 393, "Chemical"], [426, 426, "Chemical"], [456, 456, "Chemical"], [21, 23, "Chemical"]]], "relations": [[[7, 7, 333, 333, "CID"], [7, 7, 473, 473, "CID"], [17, 17, 333, 333, "CID"], [17, 17, 473, 473, "CID"], [60, 60, 333, 333, "CID"], [60, 60, 473, 473, "CID"], [104, 104, 333, 333, "CID"], [104, 104, 473, 473, "CID"], [150, 150, 333, 333, "CID"], [150, 150, 473, 473, "CID"], [181, 181, 333, 333, "CID"], [181, 181, 473, 473, "CID"], [195, 195, 333, 333, "CID"], [195, 195, 473, 473, "CID"], [218, 218, 333, 333, "CID"], [218, 218, 473, 473, "CID"], [238, 238, 333, 333, "CID"], [238, 238, 473, 473, "CID"], [259, 259, 333, 333, "CID"], [259, 259, 473, 473, "CID"], [278, 278, 333, 333, "CID"], [278, 278, 473, 473, "CID"], [318, 318, 333, 333, "CID"], [318, 318, 473, 473, "CID"], [377, 377, 333, 333, "CID"], [377, 377, 473, 473, "CID"], [417, 417, 333, 333, "CID"], [417, 417, 473, 473, "CID"], [452, 452, 333, 333, "CID"], [452, 452, 473, 473, "CID"], [7, 7, 461, 461, "CID"], [17, 17, 461, 461, "CID"], [60, 60, 461, 461, "CID"], [104, 104, 461, 461, "CID"], [150, 150, 461, 461, "CID"], [181, 181, 461, 461, "CID"], [195, 195, 461, 461, "CID"], [218, 218, 461, 461, "CID"], [238, 238, 461, 461, "CID"], [259, 259, 461, 461, "CID"], [278, 278, 461, 461, "CID"], [318, 318, 461, 461, "CID"], [377, 377, 461, 461, "CID"], [417, 417, 461, 461, "CID"], [452, 452, 461, 461, "CID"]]], "clusters": [], "translated": " <0>利扎曲坦</0> 10 mg 与 <30>麦角胺</30>/<42>咖啡因</42> 在<18>偏头痛</18>中的疗效和偏好的交叉比较。<1> Rizatriptan </1>是一种选择性<54>5-HT</54> (1B/1D) 受体激动剂，口服吸收迅速，起效早，可用于急性治疗<19>偏头痛</19>。这项随机双盲交叉门诊研究评估了439名患者对1<2>利扎曲坦</2> 10 mg片剂与2<31>麦角胺</31>1 mg/<43>咖啡因</43>100 mg片剂的偏好，每次治疗一次<20>偏头痛</20>发作的患者 。在表示偏好的患者（89.1%）中，偏好<3>利扎曲坦</3>的患者是<32>麦角胺</32>/<44>咖啡因</44>的两倍多（69.9比30.1%, p<或=0.001）。更快地缓解<21>头痛</21>是首选的最重要原因，67.3%的患者 preferring <4>利扎曲坦</4>，54.2%的患者 preferring <33>麦角胺</33>/<45>咖啡因</45>。2小时后<23>无痛</23>的共同主要终点也支持<5>利扎曲坦</5>。49%的患者在<6>利扎曲坦</6>后2小时<24>疼痛</24>消失，相比之下，这一比例为24.3%接受<34>麦角胺</34>/<46>咖啡因</46> (p<或=0.001)，<7>利扎曲坦</7>在治疗后1小时内效果更好。 <22>头痛</22>在2小时时的缓解率为75.9%，<8>利扎曲坦</8>与<35>麦角胺</35>/<47>咖啡因</47>为47.3%（p<或=0.001），其中<9>利扎曲坦</9>优于<36>麦角胺</36>/<48>咖啡因</48>给药后30分钟内。服用<10>利扎曲坦</10>的患者中有近36%在2小时内<25>疼痛</25>消失，并且在24小时内没有复发或需要额外的药物治疗，而服用<37>麦角胺</37>/<49>咖啡因</49>的患者中这一比例为20% (p<或=0.001)。 <11>利扎曲坦</11>在无<15>恶心</15>、<26>呕吐</26>、<27>畏声</27>或<28>畏光</28>以及服药2小时后功能正常的患者比例方面也优于<38>麦角胺</38>/<50>咖啡因</50> （p<或=0.001）。与<39>麦角胺</39>/<51>咖啡因</51>治疗后2小时相比，<12>利扎曲坦</12>治疗后2小时（69.8%）有更多患者 (完全、非常或有些) 满意，而<38>麦角胺</38>/<50>咖啡因</50>之后为38.6% (p<或=0.001)。复发率为31.4%与<13>利扎曲坦</13>和15.3%含<40>麦角胺</40>/<52>咖啡因</52>。两种积极的治疗都具有良好的耐受性。在服用<14>利扎曲坦</14>和<41>麦角胺</41>/<53>咖啡因</53>后最常见的不良事件（发生率在一组中>或=5%）分别是<17>头晕</17>（6.7和5.3%），<16>恶心</16>（4.2和8.5%）和<29>嗜睡</29>（5.5和2.3%）。", "revised": true}
{"doc_key": "9931093", "sentences": [["Mechanisms", "of", "FK", "506", "-", "induced", "hypertension", "in", "the", "rat", ".", "-", "Tacrolimus", "(", "FK", "506", ")", "is", "a", "powerful", ",", "widely", "used", "immunosuppressant", ".", "The", "clinical", "utility", "of", "FK", "506", "is", "complicated", "by", "substantial", "hypertension", "and", "nephrotoxicity", ".", "To", "clarify", "the", "mechanisms", "of", "FK", "506", "-", "induced", "hypertension", ",", "we", "studied", "the", "chronic", "effects", "of", "FK", "506", "on", "the", "synthesis", "of", "endothelin", "-", "1", "(", "ET", "-", "1", ")", ",", "the", "expression", "of", "mRNA", "of", "ET", "-", "1", "and", "endothelin", "-", "converting", "enzyme", "-", "1", "(", "ECE", "-", "1", ")", ",", "the", "endothelial", "nitric", "oxide", "synthase", "(", "eNOS", ")", "activity", ",", "and", "the", "expression", "of", "mRNA", "of", "eNOS", "and", "C", "-", "type", "natriuretic", "peptide", "(", "CNP", ")", "in", "rat", "blood", "vessels", ".", "In", "addition", ",", "the", "effect", "of", "the", "specific", "endothelin", "type", "A", "receptor", "antagonist", "FR", "139317", "on", "FK", "506", "-", "induced", "hypertension", "in", "rats", "was", "studied", ".", "FK", "506", ",", "5", "mg", ".", "kg", "-", "1", ".", "d", "-", "1", "given", "for", "4", "weeks", ",", "elevated", "blood", "pressure", "from", "102", "+", "/", "-", "13", "to", "152", "+", "/", "-", "15", "mm", "Hg", "and", "increased", "the", "synthesis", "of", "ET", "-", "1", "and", "the", "levels", "of", "ET", "-", "1", "mRNA", "in", "the", "mesenteric", "artery", "(", "240", "%", "and", "230", "%", ",", "respectively", ")", ".", "Little", "change", "was", "observed", "in", "the", "expression", "of", "ECE", "-", "1", "mRNA", "and", "CNP", "mRNA", ".", "FK", "506", "decreased", "eNOS", "activity", "and", "the", "levels", "of", "eNOS", "mRNA", "in", "the", "aorta", "(", "48", "%", "and", "55", "%", ",", "respectively", ")", ".", "The", "administration", "of", "FR", "139317", "(", "10", "mg", ".", "kg", "-", "1", ".", "d", "-", "1", ")", "prevented", "FK", "506", "-", "induced", "hypertension", "in", "rats", ".", "These", "results", "indicate", "that", "FK", "506", "may", "increase", "blood", "pressure", "not", "only", "by", "increasing", "ET", "-", "1", "production", "but", "also", "by", "decreasing", "NO", "synthesis", "in", "the", "vasculature", "."]], "ner": [[[2, 3, "Chemical"], [12, 12, "Chemical"], [14, 15, "Chemical"], [29, 30, "Chemical"], [44, 45, "Chemical"], [56, 57, "Chemical"], [139, 140, "Chemical"], [149, 150, "Chemical"], [230, 231, "Chemical"], [272, 273, "Chemical"], [284, 285, "Chemical"], [6, 6, "Disease"], [35, 35, "Disease"], [48, 48, "Disease"], [143, 143, "Disease"], [276, 276, "Disease"], [37, 37, "Disease"], [94, 95, "Chemical"], [302, 302, "Chemical"], [136, 137, "Chemical"], [257, 258, "Chemical"]]], "relations": [[[2, 3, 6, 6, "CID"], [2, 3, 35, 35, "CID"], [2, 3, 48, 48, "CID"], [2, 3, 143, 143, "CID"], [2, 3, 276, 276, "CID"], [12, 12, 6, 6, "CID"], [12, 12, 35, 35, "CID"], [12, 12, 48, 48, "CID"], [12, 12, 143, 143, "CID"], [12, 12, 276, 276, "CID"], [14, 15, 6, 6, "CID"], [14, 15, 35, 35, "CID"], [14, 15, 48, 48, "CID"], [14, 15, 143, 143, "CID"], [14, 15, 276, 276, "CID"], [29, 30, 6, 6, "CID"], [29, 30, 35, 35, "CID"], [29, 30, 48, 48, "CID"], [29, 30, 143, 143, "CID"], [29, 30, 276, 276, "CID"], [44, 45, 6, 6, "CID"], [44, 45, 35, 35, "CID"], [44, 45, 48, 48, "CID"], [44, 45, 143, 143, "CID"], [44, 45, 276, 276, "CID"], [56, 57, 6, 6, "CID"], [56, 57, 35, 35, "CID"], [56, 57, 48, 48, "CID"], [56, 57, 143, 143, "CID"], [56, 57, 276, 276, "CID"], [139, 140, 6, 6, "CID"], [139, 140, 35, 35, "CID"], [139, 140, 48, 48, "CID"], [139, 140, 143, 143, "CID"], [139, 140, 276, 276, "CID"], [149, 150, 6, 6, "CID"], [149, 150, 35, 35, "CID"], [149, 150, 48, 48, "CID"], [149, 150, 143, 143, "CID"], [149, 150, 276, 276, "CID"], [230, 231, 6, 6, "CID"], [230, 231, 35, 35, "CID"], [230, 231, 48, 48, "CID"], [230, 231, 143, 143, "CID"], [230, 231, 276, 276, "CID"], [272, 273, 6, 6, "CID"], [272, 273, 35, 35, "CID"], [272, 273, 48, 48, "CID"], [272, 273, 143, 143, "CID"], [272, 273, 276, 276, "CID"], [284, 285, 6, 6, "CID"], [284, 285, 35, 35, "CID"], [284, 285, 48, 48, "CID"], [284, 285, 143, 143, "CID"], [284, 285, 276, 276, "CID"]]], "clusters": [], "translated": "<0>FK 506</0>诱导大鼠<11>高血压</11>的机制。-<1>他克莫司</1>(<2>FK 506</2>)是一种广泛使用的强效免疫抑制剂。<3>FK 506 </3>的临床应用因严重的<12>高血压</12>和<16>肾毒性</16>而复杂化。为了阐明<4>FK 506</4>-诱发<13>高血压</13>的机制，我们研究了<5>FK 506</5>对内皮素-1(ET-1)、内皮素转化酶-1(ECE-1)mRNA表达、内皮<17>一氧化氮</17>合酶(eNOS)活性、eNOS和CNP mRNA表达在大鼠血管中的作用。此外，还研究了特异性内皮素A型受体拮抗剂<19>FR 139317</19>对<6>FK 506</6>诱导的大鼠<14>高血压</14>的影响。<7>FK 506</7>，5毫克。公斤-1。d-1给药4周，血压从102 +/- 13升至152 +/- 15 mm Hg，并增加 ET-1的合成和肠系膜动脉中ET-1 mRNA的水平（240%和230％，分别）。ECE-1 mRNA和CNP mRNA的表达变化不大。<8>FK 506</8>降低主动脉中的eNOS活性和eNOS mRNA水平（分别为48％和55％）。<20>FR 139317</20>(10毫克。公斤-1。d-1)的给药可预防大鼠<9>FK 506</9>诱导的<15>高血压</15>。这些结果表明，<10>FK 506</10>不仅可以通过增加ET-1的产生而且还可以通过减少脉管系统中的<18>NO</18>合成来增加血压。", "revised": true}
{"doc_key": "10683478", "sentences": [["Test", "conditions", "influence", "the", "response", "to", "a", "drug", "challenge", "in", "rodents", ".", "These", "studies", "were", "conducted", "to", "examine", "the", "differential", "response", "to", "a", "drug", "challenge", "under", "varied", "experimental", "test", "conditions", "routinely", "employed", "to", "study", "drug", "-", "induced", "behavioral", "and", "neurophysiological", "responses", "in", "rodents", ".", "Apomorphine", ",", "a", "nonselective", "dopamine", "agonist", ",", "was", "selected", "due", "to", "its", "biphasic", "behavioral", "effects", ",", "its", "ability", "to", "induce", "hypothermia", ",", "and", "to", "produce", "distinct", "changes", "to", "dopamine", "turnover", "in", "the", "rodent", "brain", ".", "From", "such", "experiments", "there", "is", "evidence", "that", "characterization", "and", "detection", "of", "apomorphine", "-", "induced", "activity", "in", "rodents", "critically", "depends", "upon", "the", "test", "conditions", "employed", ".", "In", "rats", ",", "detection", "of", "apomorphine", "-", "induced", "hyperactivity", "was", "facilitated", "by", "a", "period", "of", "acclimatization", "to", "the", "test", "conditions", ".", "Moreover", ",", "test", "conditions", "can", "impact", "upon", "other", "physiological", "responses", "to", "apomorphine", "such", "as", "drug", "-", "induced", "hypothermia", ".", "In", "mice", ",", "apomorphine", "produced", "qualitatively", "different", "responses", "under", "novel", "conditions", "when", "compared", "to", "those", "behaviors", "elicited", "in", "the", "home", "test", "cage", ".", "Drug", "-", "induced", "gross", "activity", "counts", "were", "increased", "in", "the", "novel", "exploratory", "box", "only", ",", "while", "measures", "of", "stereotypic", "behavior", "were", "similar", "in", "both", ".", "By", "contrast", ",", "apomorphine", "-", "induced", "locomotion", "was", "more", "prominent", "in", "the", "novel", "exploratory", "box", ".", "Dopamine", "turnover", "ratios", "(", "DOPAC", ":", "DA", "and", "HVA", ":", "DA", ")", "were", "found", "to", "be", "lower", "in", "those", "animals", "exposed", "to", "the", "exploratory", "box", "when", "compared", "to", "their", "home", "cage", "counterparts", ".", "However", ",", "apomorphine", "-", "induced", "reductions", "in", "striatal", "dopamine", "turnover", "were", "detected", "in", "both", "novel", "and", "home", "cage", "environments", ".", "The", "implications", "of", "these", "findings", "are", "discussed", "with", "particular", "emphasis", "upon", "conducting", "psychopharmacological", "challenge", "tests", "in", "rodents", "."]], "ner": [[[44, 44, "Chemical"], [90, 90, "Chemical"], [109, 109, "Chemical"], [136, 136, "Chemical"], [147, 147, "Chemical"], [195, 195, "Chemical"], [243, 243, "Chemical"], [64, 64, "Disease"], [142, 142, "Disease"], [112, 112, "Disease"], [48, 49, "Chemical"], [214, 214, "Chemical"], [218, 218, "Chemical"], [72, 72, "Chemical"], [208, 208, "Chemical"], [249, 249, "Chemical"], [212, 212, "Chemical"], [216, 216, "Chemical"]]], "relations": [[[44, 44, 64, 64, "CID"], [44, 44, 142, 142, "CID"], [90, 90, 64, 64, "CID"], [90, 90, 142, 142, "CID"], [109, 109, 64, 64, "CID"], [109, 109, 142, 142, "CID"], [136, 136, 64, 64, "CID"], [136, 136, 142, 142, "CID"], [147, 147, 64, 64, "CID"], [147, 147, 142, 142, "CID"], [195, 195, 64, 64, "CID"], [195, 195, 142, 142, "CID"], [243, 243, 64, 64, "CID"], [243, 243, 142, 142, "CID"], [44, 44, 112, 112, "CID"], [90, 90, 112, 112, "CID"], [109, 109, 112, 112, "CID"], [136, 136, 112, 112, "CID"], [147, 147, 112, 112, "CID"], [195, 195, 112, 112, "CID"], [243, 243, 112, 112, "CID"]]], "clusters": [], "translated": "测试条件会影响啮齿动物对药物挑战的反应。进行这些研究是为了检查在不同的实验测试条件下对药物挑战的不同反应，这些测试条件通常用于研究啮齿动物的药物诱导的行为和神经生理学反应。 <0>阿扑吗啡</0> 是一种非选择性<10>多巴胺激动剂</10>，由于其双相行为效应、诱导<7>体温过低</7>以及对<13>多巴胺</13>在啮齿动物大脑中的转换产生明显变化的能力而被选中。从此类实验中可以看出，表征和检测啮齿类动物中<1>阿扑吗啡</1>诱导的活性关键取决于所采用的测试条件。在大鼠中，需要在试验条件下的适应期之后才能检测出<2>阿扑吗啡</2>诱导的<9>过度活动</9>。此外，测试条件还会影响到对<3>阿扑吗啡</3>的其他生理反应，例如药物引发的<8>体温降低</8>。在小鼠中，<4>阿扑吗啡</4>在新条件下引发的反应与在家庭测试笼中引发的行为相比有质的不同。药物引发的总体活动计数只有在新的探索盒中增加，而坐着的行为在两者中相似。相比之下，<5>阿扑吗啡</5>诱发的运动在新探索盒中更为显著。 <14>多巴胺</14>周转率(<16>DOPAC</16>：<11>DA</11>和<17>HVA</17>：<12>DA</12>)在暴露于探索箱的动物中较家庭笼环境中的动物更低。然而，在新笼环境和家庭笼环境中均检测到了<6>阿扑吗啡</6>引起的纹状体<15>多巴胺</15>转换减少的情况。讨论了这些发现的含义，特别强调在啮齿动物中进行精神药理学挑战测试的重要性。", "revised": true}
{"doc_key": "17931375", "sentences": [["A", "study", "on", "the", "effect", "of", "the", "duration", "of", "subcutaneous", "heparin", "injection", "on", "bruising", "and", "pain", ".", "AIM", ":", "This", "study", "was", "carried", "out", "to", "determine", "the", "effect", "of", "injection", "duration", "on", "bruising", "and", "pain", "following", "the", "administration", "of", "the", "subcutaneous", "injection", "of", "heparin", ".", "BACKGROUND", ":", "Although", "different", "methods", "to", "prevent", "bruising", "and", "pain", "following", "the", "subcutaneous", "injection", "of", "heparin", "have", "been", "widely", "studied", "and", "described", ",", "the", "effect", "of", "injection", "duration", "on", "the", "occurrence", "of", "bruising", "and", "pain", "is", "little", "documented", ".", "DESIGN", ":", "This", "study", "was", "designed", "as", "within", "-", "subject", ",", "quasi", "-", "experimental", "research", ".", "METHOD", ":", "The", "sample", "for", "the", "study", "consisted", "of", "50", "patients", "to", "whom", "subcutaneous", "heparin", "was", "administered", ".", "Heparin", "was", "injected", "over", "10", "seconds", "on", "the", "right", "abdominal", "site", "and", "30", "seconds", "on", "the", "left", "abdominal", "site", ".", "Injections", "areas", "were", "assessed", "for", "the", "presence", "of", "bruising", "at", "48", "and", "72", "hours", "after", "each", "injection", ".", "Dimensions", "of", "the", "bruising", "on", "the", "heparin", "applied", "areas", "were", "measured", "using", "transparent", "millimetric", "measuring", "paper", ".", "The", "visual", "analog", "scale", "(", "VAS", ")", "was", "used", "to", "measure", "pain", "intensity", "and", "a", "stop", "-", "watch", "was", "used", "to", "time", "the", "pain", "period", ".", "Data", "were", "analysed", "using", "chi", "-", "square", "test", ",", "Mann", "-", "Whitney", "U", ",", "Wilcoxon", "signed", "ranks", "tests", "and", "correlation", ".", "RESULTS", ":", "The", "percentage", "of", "bruising", "occurrence", "was", "64", "%", "with", "the", "injection", "of", "10", "seconds", "duration", "and", "42", "%", "in", "the", "30", "-", "second", "injection", ".", "It", "was", "determined", "that", "the", "size", "of", "the", "bruising", "was", "smaller", "in", "the", "30", "-", "second", "injection", ".", "Pain", "intensity", "and", "pain", "period", "were", "statistically", "significantly", "lower", "for", "the", "30", "-", "second", "injection", "than", "for", "the", "10", "-", "second", "injection", ".", "CONCLUSIONS", ":", "It", "was", "determined", "that", "injection", "duration", "had", "an", "effect", "on", "bruising", "and", "pain", "following", "the", "subcutaneous", "administration", "of", "heparin", ".", "This", "study", "should", "be", "repeated", "on", "a", "larger", "sample", ".", "RELEVANCE", "TO", "CLINICAL", "PRACTICE", ":", "When", "administering", "subcutaneous", "heparin", "injections", ",", "it", "is", "important", "to", "extend", "the", "duration", "of", "the", "injection", "."]], "ner": [[[10, 10, "Chemical"], [43, 43, "Chemical"], [60, 60, "Chemical"], [114, 114, "Chemical"], [118, 118, "Chemical"], [162, 162, "Chemical"], [308, 308, "Chemical"], [328, 328, "Chemical"], [13, 13, "Disease"], [32, 32, "Disease"], [52, 52, "Disease"], [77, 77, "Disease"], [146, 146, "Disease"], [159, 159, "Disease"], [225, 225, "Disease"], [255, 255, "Disease"], [300, 300, "Disease"], [15, 15, "Disease"], [34, 34, "Disease"], [54, 54, "Disease"], [79, 79, "Disease"], [184, 184, "Disease"], [196, 196, "Disease"], [265, 265, "Disease"], [268, 268, "Disease"], [302, 302, "Disease"]]], "relations": [[[10, 10, 13, 13, "CID"], [10, 10, 32, 32, "CID"], [10, 10, 52, 52, "CID"], [10, 10, 77, 77, "CID"], [10, 10, 146, 146, "CID"], [10, 10, 159, 159, "CID"], [10, 10, 225, 225, "CID"], [10, 10, 255, 255, "CID"], [10, 10, 300, 300, "CID"], [43, 43, 13, 13, "CID"], [43, 43, 32, 32, "CID"], [43, 43, 52, 52, "CID"], [43, 43, 77, 77, "CID"], [43, 43, 146, 146, "CID"], [43, 43, 159, 159, "CID"], [43, 43, 225, 225, "CID"], [43, 43, 255, 255, "CID"], [43, 43, 300, 300, "CID"], [60, 60, 13, 13, "CID"], [60, 60, 32, 32, "CID"], [60, 60, 52, 52, "CID"], [60, 60, 77, 77, "CID"], [60, 60, 146, 146, "CID"], [60, 60, 159, 159, "CID"], [60, 60, 225, 225, "CID"], [60, 60, 255, 255, "CID"], [60, 60, 300, 300, "CID"], [114, 114, 13, 13, "CID"], [114, 114, 32, 32, "CID"], [114, 114, 52, 52, "CID"], [114, 114, 77, 77, "CID"], [114, 114, 146, 146, "CID"], [114, 114, 159, 159, "CID"], [114, 114, 225, 225, "CID"], [114, 114, 255, 255, "CID"], [114, 114, 300, 300, "CID"], [118, 118, 13, 13, "CID"], [118, 118, 32, 32, "CID"], [118, 118, 52, 52, "CID"], [118, 118, 77, 77, "CID"], [118, 118, 146, 146, "CID"], [118, 118, 159, 159, "CID"], [118, 118, 225, 225, "CID"], [118, 118, 255, 255, "CID"], [118, 118, 300, 300, "CID"], [162, 162, 13, 13, "CID"], [162, 162, 32, 32, "CID"], [162, 162, 52, 52, "CID"], [162, 162, 77, 77, "CID"], [162, 162, 146, 146, "CID"], [162, 162, 159, 159, "CID"], [162, 162, 225, 225, "CID"], [162, 162, 255, 255, "CID"], [162, 162, 300, 300, "CID"], [308, 308, 13, 13, "CID"], [308, 308, 32, 32, "CID"], [308, 308, 52, 52, "CID"], [308, 308, 77, 77, "CID"], [308, 308, 146, 146, "CID"], [308, 308, 159, 159, "CID"], [308, 308, 225, 225, "CID"], [308, 308, 255, 255, "CID"], [308, 308, 300, 300, "CID"], [328, 328, 13, 13, "CID"], [328, 328, 32, 32, "CID"], [328, 328, 52, 52, "CID"], [328, 328, 77, 77, "CID"], [328, 328, 146, 146, "CID"], [328, 328, 159, 159, "CID"], [328, 328, 225, 225, "CID"], [328, 328, 255, 255, "CID"], [328, 328, 300, 300, "CID"], [10, 10, 15, 15, "CID"], [10, 10, 34, 34, "CID"], [10, 10, 54, 54, "CID"], [10, 10, 79, 79, "CID"], [10, 10, 184, 184, "CID"], [10, 10, 196, 196, "CID"], [10, 10, 265, 265, "CID"], [10, 10, 268, 268, "CID"], [10, 10, 302, 302, "CID"], [43, 43, 15, 15, "CID"], [43, 43, 34, 34, "CID"], [43, 43, 54, 54, "CID"], [43, 43, 79, 79, "CID"], [43, 43, 184, 184, "CID"], [43, 43, 196, 196, "CID"], [43, 43, 265, 265, "CID"], [43, 43, 268, 268, "CID"], [43, 43, 302, 302, "CID"], [60, 60, 15, 15, "CID"], [60, 60, 34, 34, "CID"], [60, 60, 54, 54, "CID"], [60, 60, 79, 79, "CID"], [60, 60, 184, 184, "CID"], [60, 60, 196, 196, "CID"], [60, 60, 265, 265, "CID"], [60, 60, 268, 268, "CID"], [60, 60, 302, 302, "CID"], [114, 114, 15, 15, "CID"], [114, 114, 34, 34, "CID"], [114, 114, 54, 54, "CID"], [114, 114, 79, 79, "CID"], [114, 114, 184, 184, "CID"], [114, 114, 196, 196, "CID"], [114, 114, 265, 265, "CID"], [114, 114, 268, 268, "CID"], [114, 114, 302, 302, "CID"], [118, 118, 15, 15, "CID"], [118, 118, 34, 34, "CID"], [118, 118, 54, 54, "CID"], [118, 118, 79, 79, "CID"], [118, 118, 184, 184, "CID"], [118, 118, 196, 196, "CID"], [118, 118, 265, 265, "CID"], [118, 118, 268, 268, "CID"], [118, 118, 302, 302, "CID"], [162, 162, 15, 15, "CID"], [162, 162, 34, 34, "CID"], [162, 162, 54, 54, "CID"], [162, 162, 79, 79, "CID"], [162, 162, 184, 184, "CID"], [162, 162, 196, 196, "CID"], [162, 162, 265, 265, "CID"], [162, 162, 268, 268, "CID"], [162, 162, 302, 302, "CID"], [308, 308, 15, 15, "CID"], [308, 308, 34, 34, "CID"], [308, 308, 54, 54, "CID"], [308, 308, 79, 79, "CID"], [308, 308, 184, 184, "CID"], [308, 308, 196, 196, "CID"], [308, 308, 265, 265, "CID"], [308, 308, 268, 268, "CID"], [308, 308, 302, 302, "CID"], [328, 328, 15, 15, "CID"], [328, 328, 34, 34, "CID"], [328, 328, 54, 54, "CID"], [328, 328, 79, 79, "CID"], [328, 328, 184, 184, "CID"], [328, 328, 196, 196, "CID"], [328, 328, 265, 265, "CID"], [328, 328, 268, 268, "CID"], [328, 328, 302, 302, "CID"]]], "clusters": [], "translated": "皮下<0>肝素</0>注射持续时间对<8>瘀伤</8>和<17>疼痛</17>影响的研究。目的：本研究旨在确定皮下注射<1>肝素</1>后注射持续时间对<9>瘀伤</9>和<18>疼痛</18>的影响。背景：虽然在皮下注射<2>肝素</2>后预防<10>瘀伤</10>和<19>疼痛</19>的不同方法已得到广泛研究和描述，但注射持续时间对<11>瘀伤</11>和<20>疼痛</20>的发生很少有记载。设计：本研究被设计为受试者内、准实验研究。方法：研究样本包括50名皮下注射<3>肝素</3>的患者。<4>肝素</4>在右腹部注射了10秒，在左腹部注射了30秒。在每次注射后48和72小时评估注射区域是否存在<12>瘀伤</12>。使用透明毫米测量纸测量<5>肝素</5>应用区域<13>瘀伤</13>的尺寸。使用视觉模拟量表(VAS)测量<21>疼痛</21>强度，并使用秒表为<22>疼痛</22>时间段计时。使用卡方检验、Mann-Whitney U、Wilcoxon符号秩检验和相关分析数据。结果：<14>瘀伤</14>的发生率在注射10秒时为64%，在注射30秒时为42%。经确定，<15>瘀伤</15>的大小在30秒注射时较小。30秒注射的<23>疼痛</23>强度和<24>疼痛</24>时间在统计学上显着低于10秒注射。结论：已确定注射持续时间对<6>肝素</6>皮下给药后的<16>瘀伤</16>和<25>疼痛</25>有影响。这项研究应该在更大的样本上重复进行。与临床实践的相关性：皮下注射<7>肝素</7>时，延长注射时间很重要。", "revised": true}
{"doc_key": "14698717", "sentences": [["Acute", "psychosis", "due", "to", "treatment", "with", "phenytoin", "in", "a", "nonepileptic", "patient", ".", "The", "development", "of", "psychosis", "related", "to", "antiepileptic", "drug", "treatment", "is", "usually", "attributed", "to", "the", "interaction", "between", "the", "epileptic", "brain", "substratum", "and", "the", "antiepileptic", "drugs", ".", "The", "case", "of", "a", "nonepileptic", "patient", "who", "developed", "psychosis", "following", "phenytoin", "treatment", "for", "trigeminal", "neuralgia", "is", "described", ".", "This", "case", "suggests", "that", "the", "psychotic", "symptoms", "that", "occur", "following", "phenytoin", "treatment", "in", "some", "epileptic", "patients", "may", "be", "the", "direct", "result", "of", "medication", ",", "unrelated", "to", "seizures", "."]], "ner": [[[6, 6, "Chemical"], [47, 47, "Chemical"], [65, 65, "Chemical"], [0, 1, "Disease"], [15, 15, "Disease"], [45, 45, "Disease"], [60, 61, "Disease"], [29, 29, "Disease"], [69, 69, "Disease"], [50, 51, "Disease"], [81, 81, "Disease"]]], "relations": [[[6, 6, 0, 1, "CID"], [6, 6, 15, 15, "CID"], [6, 6, 45, 45, "CID"], [6, 6, 60, 61, "CID"], [47, 47, 0, 1, "CID"], [47, 47, 15, 15, "CID"], [47, 47, 45, 45, "CID"], [47, 47, 60, 61, "CID"], [65, 65, 0, 1, "CID"], [65, 65, 15, 15, "CID"], [65, 65, 45, 45, "CID"], [65, 65, 60, 61, "CID"]]], "clusters": [], "translated": "<3>急性精神病</3> 由于非癫痫患者<0>苯妥英</0>治疗。与抗癫痫药物治疗相关的<4>精神病</4>的发生通常归因于<7>癫痫</7>脑基质和抗癫痫药物之间的相互作用。描述了一名非癫痫患者在治疗<9>三叉神经痛</9>时接受<1>苯妥英</1>后出现<5>精神病</5>的案例。本病例表明，<8>癫痫</8>患者中有些人在接受<2>苯妥英</2>治疗后出现的<6>精神症状</6>可能是由于药物直接作用，而与<10>癫痫发作</10>无关。", "revised": true}
{"doc_key": "20067456", "sentences": [["The", "effects", "of", "the", "adjunctive", "bupropion", "on", "male", "sexual", "dysfunction", "induced", "by", "a", "selective", "serotonin", "reuptake", "inhibitor", ":", "a", "double", "-", "blind", "placebo", "-", "controlled", "and", "randomized", "study", ".", "OBJECTIVE", ":", "To", "determine", "the", "safety", "and", "efficacy", "of", "adjunctive", "bupropion", "sustained", "-", "release", "(", "SR", ")", "on", "male", "sexual", "dysfunction", "(", "SD", ")", "induced", "by", "a", "selective", "serotonin", "reuptake", "inhibitor", "(", "SSRI", ")", ",", "as", "SD", "is", "a", "common", "side", "-", "effect", "of", "SSRIs", "and", "the", "most", "effective", "treatments", "have", "yet", "to", "be", "determined", ".", "PATIENTS", "AND", "METHODS", ":", "The", "randomized", "sample", "consisted", "of", "234", "euthymic", "men", "who", "were", "receiving", "some", "type", "of", "SSRI", ".", "The", "men", "were", "randomly", "assigned", "to", "bupropion", "SR", "(", "150", "mg", "twice", "daily", ",", "117", ")", "or", "placebo", "(", "twice", "daily", ",", "117", ")", "for", "12", "weeks", ".", "Efficacy", "was", "evaluated", "using", "the", "Clinical", "Global", "Impression", "-", "Sexual", "Function", "(", "CGI", "-", "SF", ";", "the", "primary", "outcome", "measure", ")", ",", "the", "International", "Index", "of", "Erectile", "Function", "(", "IIEF", ")", ",", "Arizona", "Sexual", "Experience", "Scale", "(", "ASEX", ")", ",", "and", "Erectile", "Dysfunction", "Inventory", "of", "Treatment", "Satisfaction", "(", "EDITS", ")", "(", "secondary", "outcome", "measures", ")", ".", "Participants", "were", "followed", "biweekly", "during", "study", "period", ".", "RESULTS", ":", "After", "12", "weeks", "of", "treatment", ",", "the", "mean", "(", "sd", ")", "scores", "for", "CGI", "-", "SF", "were", "significantly", "lower", ",", "i", ".", "e", ".", "better", ",", "in", "patients", "on", "bupropion", "SR", ",", "at", "2", ".", "4", "(", "1", ".", "2", ")", ",", "than", "in", "the", "placebo", "group", ",", "at", "3", ".", "9", "(", "1", ".", "1", ")", "(", "P", "=", "0", ".", "01", ")", ".", "Men", "who", "received", "bupropion", "had", "a", "significant", "increase", "in", "the", "total", "IIEF", "score", "(", "54", ".", "4", "%", "vs", "1", ".", "2", "%", ";", "P", "=", "0", ".", "003", ")", ",", "and", "in", "the", "five", "different", "domains", "of", "the", "IIEF", ".", "Total", "ASEX", "scores", "were", "significantly", "lower", ",", "i", ".", "e", ".", "better", ",", "among", "men", "who", "received", "bupropion", "than", "placebo", ",", "at", "15", ".", "5", "(", "4", ".", "3", ")", "vs", "21", ".", "5", "(", "4", ".", "7", ")", "(", "P", "=", "0", ".", "002", ")", ".", "The", "EDITS", "scores", "were", "67", ".", "4", "(", "10", ".", "2", ")", "for", "the", "bupropion", "and", "36", ".", "3", "(", "11", ".", "7", ")", "for", "the", "placebo", "group", "(", "P", "=", "0", ".", "001", ")", ".", "The", "ASEX", "score", "and", "CGI", "-", "SF", "score", "were", "correlated", "(", "P", "=", "0", ".", "003", ")", ".", "In", "linear", "regression", "analyses", "the", "CGI", "-", "SF", "score", "was", "not", "affected", "significantly", "by", "the", "duration", "of", "SD", ",", "type", "of", "SSRI", "used", "and", "age", ".", "CONCLUSIONS", ":", "Bupropion", "is", "an", "effective", "treatment", "for", "male", "SD", "induced", "by", "SSRIs", ".", "These", "results", "provide", "empirical", "support", "for", "conducting", "a", "further", "study", "of", "bupropion", "."]], "ner": [[[13, 16, "Chemical"], [56, 59, "Chemical"], [61, 61, "Chemical"], [73, 73, "Chemical"], [103, 103, "Chemical"], [427, 427, "Chemical"], [444, 444, "Chemical"], [174, 175, "Disease"], [5, 5, "Chemical"], [39, 39, "Chemical"], [111, 111, "Chemical"], [228, 228, "Chemical"], [267, 267, "Chemical"], [322, 322, "Chemical"], [366, 366, "Chemical"], [434, 434, "Chemical"], [457, 457, "Chemical"], [8, 9, "Disease"], [48, 49, "Disease"], [51, 51, "Disease"], [65, 65, "Disease"], [423, 423, "Disease"], [441, 441, "Disease"]]], "relations": [[[13, 16, 174, 175, "CID"], [56, 59, 174, 175, "CID"], [61, 61, 174, 175, "CID"], [73, 73, 174, 175, "CID"], [103, 103, 174, 175, "CID"], [427, 427, 174, 175, "CID"], [444, 444, 174, 175, "CID"]]], "clusters": [], "translated": "辅助药物<8>安非他酮</8> 对<0>选择性5-羟色胺再摄取抑制剂</0> 引起的男性<17>性功能障碍</17>的影响：双盲安慰剂对照和随机研究。目的: 确定辅助性<9>安非他酮</9>缓释(SR)对<18>性功能障碍</18>(<19>SD</19>)的安全性和有效性<1>选择性5-羟色胺再摄取抑制剂</1>(<2>SSRI</2>)，因为<20>SD</20>是<3>SSRIs</3>的常见副作用，最有效的治疗方法尚未确定。患者和方法：随机抽样由234名接受某种类型的<4>SSRI</4>的正常男性组成。这些男性被随机分配到<10>安非他酮</10> SR(150毫克，每天两次，117人)或安慰剂(每天两次，117人)组，持续12周。使用临床总体印象-性功能(CGI-SF；主要结果测量)、国际勃起功能指数(IIEF)、亚利桑那性体验量表(ASEX)和<7>勃起功能障碍</7>评估疗效，治疗满意度清单(EDITS)（次要结果测量）。在研究期间，每两周跟踪一次参与者。结果：治疗12周后，CGI-SF的平均(sd)分数显着降低，即更好，服用<11>安非他酮</11> SR的患者，为2.4(1.2)，比安慰剂组高3.9(1.1)(P = 0.01)。服用<12>安非他酮</12>的男性在IIEF总分（54.4 %对1.2 %；P = 0.003）以及IIEF的五个不同领域都有显着增加。总ASEX分数显着降低，在接受<13>安非他酮</13>治疗的男性中，比接受安慰剂的男性表现更好，为15.5(4.3)与21.5(4.7)(P = 0.002)。EDITS得分为67.4(10.2)为<14>安非他酮</14>和36.3(11.7)为安慰剂组(P = 0.001)。ASEX评分和CGI-SF评分相关(P = 0.003)。在线性回归分析中，CGI-SF评分不受<21>SD</21>持续时间、使用的<5>SSRI</5>类型和年龄的显着影响。结论：<15>安非他酮</15>是治疗<6>SSRIs</6>所致男性<22>SD</22>的有效药物。这些结果为进一步研究<16>安非他酮</16>提供了实证支持。", "revised": true}
{"doc_key": "12523465", "sentences": [["Visual", "hallucinations", "associated", "with", "zonisamide", ".", "Zonisamide", "is", "a", "broad", "-", "spectrum", "antiepileptic", "drug", "used", "to", "treat", "various", "types", "of", "seizures", ".", "Although", "visual", "hallucinations", "have", "not", "been", "reported", "as", "an", "adverse", "effect", "of", "this", "agent", ",", "we", "describe", "three", "patients", "who", "experienced", "complex", "visual", "hallucinations", "and", "altered", "mental", "status", "after", "zonisamide", "treatment", "was", "begun", "or", "its", "dosage", "increased", ".", "All", "three", "had", "been", "diagnosed", "earlier", "with", "epilepsy", ",", "and", "their", "electroencephalogram", "(", "EEG", ")", "findings", "were", "abnormal", ".", "During", "monitoring", ",", "visual", "hallucinations", "did", "not", "correlate", "with", "EEG", "readings", ",", "nor", "did", "video", "recording", "capture", "any", "of", "the", "described", "events", ".", "None", "of", "the", "patients", "had", "experienced", "visual", "hallucinations", "before", "this", "event", ".", "The", "only", "recent", "change", "in", "their", "treatment", "was", "the", "introduction", "or", "increased", "dosage", "of", "zonisamide", ".", "With", "either", "discontinuation", "or", "decreased", "dosage", "of", "the", "drug", "the", "symptoms", "disappeared", "and", "did", "not", "recur", ".", "Further", "observations", "and", "reports", "will", "help", "clarify", "this", "adverse", "effect", ".", "Until", "then", ",", "clinicians", "need", "to", "be", "aware", "of", "this", "possible", "complication", "associated", "with", "zonisamide", "."]], "ner": [[[4, 4, "Chemical"], [6, 6, "Chemical"], [51, 51, "Chemical"], [128, 128, "Chemical"], [172, 172, "Chemical"], [0, 1, "Disease"], [23, 24, "Disease"], [44, 45, "Disease"], [82, 83, "Disease"], [108, 109, "Disease"], [20, 20, "Disease"], [67, 67, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 23, 24, "CID"], [4, 4, 44, 45, "CID"], [4, 4, 82, 83, "CID"], [4, 4, 108, 109, "CID"], [6, 6, 0, 1, "CID"], [6, 6, 23, 24, "CID"], [6, 6, 44, 45, "CID"], [6, 6, 82, 83, "CID"], [6, 6, 108, 109, "CID"], [51, 51, 0, 1, "CID"], [51, 51, 23, 24, "CID"], [51, 51, 44, 45, "CID"], [51, 51, 82, 83, "CID"], [51, 51, 108, 109, "CID"], [128, 128, 0, 1, "CID"], [128, 128, 23, 24, "CID"], [128, 128, 44, 45, "CID"], [128, 128, 82, 83, "CID"], [128, 128, 108, 109, "CID"], [172, 172, 0, 1, "CID"], [172, 172, 23, 24, "CID"], [172, 172, 44, 45, "CID"], [172, 172, 82, 83, "CID"], [172, 172, 108, 109, "CID"]]], "clusters": [], "translated": "<5>视觉幻觉</5>与<0>唑尼沙胺</0> 相关。<1>唑尼沙胺</1>是一种广谱抗癫痫药，用于治疗各种类型的<10>癫痫发作</10>。虽然<6>视觉幻觉</6>尚未报告为该药物的不良反应，但我们描述了三名在<2>唑尼沙胺</2>开始治疗或增加剂量后经历复杂的<7>视觉幻觉</7>和精神状态改变的患者。这三人早前都被诊断出患有<11>癫痫</11>，他们的脑电图 (EEG) 结果均异常。在监测期间，<8>视觉幻觉</8>与脑电图读数无关，视频记录也没有捕捉到任何描述的事件。在此事件之前，没有患者经历过<9>视觉幻觉</9>。他们的治疗最近发生的唯一变化是引入或增加了<3>唑尼沙胺</3>的剂量。随着药物的停药或剂量的减少，症状消失并且没有复发。进一步的观察和报告将有助于澄清这种不良影响。在此之前，临床医生需要了解这种可能与<4>唑尼沙胺</4>相关的并发症。", "revised": true}
{"doc_key": "11206082", "sentences": [["Two", "mouse", "lines", "selected", "for", "differential", "sensitivities", "to", "beta", "-", "carboline", "-", "induced", "seizures", "are", "also", "differentially", "sensitive", "to", "various", "pharmacological", "effects", "of", "other", "GABA", "(", "A", ")", "receptor", "ligands", ".", "Two", "mouse", "lines", "were", "selectively", "bred", "according", "to", "their", "sensitivity", "(", "BS", "line", ")", "or", "resistance", "(", "BR", "line", ")", "to", "seizures", "induced", "by", "a", "single", "i", ".", "p", ".", "injection", "of", "methyl", "beta", "-", "carboline", "-", "3", "-", "carboxylate", "(", "beta", "-", "CCM", ")", ",", "an", "inverse", "agonist", "of", "the", "GABA", "(", "A", ")", "receptor", "benzodiazepine", "site", ".", "Our", "aim", "was", "to", "characterize", "both", "lines", "'", "sensitivities", "to", "various", "physiological", "effects", "of", "other", "ligands", "of", "the", "GABA", "(", "A", ")", "receptor", ".", "We", "measured", "diazepam", "-", "induced", "anxiolysis", "with", "the", "elevated", "plus", "-", "maze", "test", ",", "diazepam", "-", "induced", "sedation", "by", "recording", "the", "vigilance", "states", ",", "and", "picrotoxin", "-", "and", "pentylenetetrazol", "-", "induced", "seizures", "after", "i", ".", "p", ".", "injections", ".", "Results", "presented", "here", "show", "that", "the", "differential", "sensitivities", "of", "BS", "and", "BR", "lines", "to", "beta", "-", "CCM", "can", "be", "extended", "to", "diazepam", ",", "picrotoxin", ",", "and", "pentylenetetrazol", ",", "suggesting", "a", "genetic", "selection", "of", "a", "general", "sensitivity", "and", "resistance", "to", "several", "ligands", "of", "the", "GABA", "(", "A", ")", "receptor", "."]], "ner": [[[8, 10, "Chemical"], [63, 70, "Chemical"], [72, 74, "Chemical"], [167, 169, "Chemical"], [13, 13, "Disease"], [52, 52, "Disease"], [145, 145, "Disease"], [139, 139, "Chemical"], [176, 176, "Chemical"], [142, 142, "Chemical"], [179, 179, "Chemical"], [24, 24, "Chemical"], [82, 82, "Chemical"], [108, 108, "Chemical"], [196, 196, "Chemical"], [87, 87, "Chemical"], [116, 116, "Chemical"], [128, 128, "Chemical"], [174, 174, "Chemical"]]], "relations": [[[8, 10, 13, 13, "CID"], [8, 10, 52, 52, "CID"], [8, 10, 145, 145, "CID"], [63, 70, 13, 13, "CID"], [63, 70, 52, 52, "CID"], [63, 70, 145, 145, "CID"], [72, 74, 13, 13, "CID"], [72, 74, 52, 52, "CID"], [72, 74, 145, 145, "CID"], [167, 169, 13, 13, "CID"], [167, 169, 52, 52, "CID"], [167, 169, 145, 145, "CID"], [139, 139, 13, 13, "CID"], [139, 139, 52, 52, "CID"], [139, 139, 145, 145, "CID"], [176, 176, 13, 13, "CID"], [176, 176, 52, 52, "CID"], [176, 176, 145, 145, "CID"], [142, 142, 13, 13, "CID"], [142, 142, 52, 52, "CID"], [142, 142, 145, 145, "CID"], [179, 179, 13, 13, "CID"], [179, 179, 52, 52, "CID"], [179, 179, 145, 145, "CID"]]], "clusters": [], "translated": "选择对<0>β-咔啉</0>诱导的<4>癫痫发作</4>的不同敏感性的两个小鼠品系对其他<11>GABA</11>（A）受体的各种药理作用也不同敏感配体。根据它们对单个i.p.注射<1>甲基β-咔啉-3-羧酸盐</1>（<2>β-CCM</2>），<12>GABA</12>（A）受体<15>苯二氮卓</15>位点的反向激动剂的<5>癫痫发作</5>的敏感性（BS线）或抵抗力（BR线），有选择地培育了两个小鼠系。我们的目的是表征这两条线对<13>GABA</13>（A）受体其他配体的各种生理效应的敏感性。我们测量了<16>安定</16>（<a>地西泮</a>）-通过高架十字迷宫试验引起的抗焦虑，<17>安定</17>（<a>地西泮</a>）-通过记录警觉状态引起的镇静，以及i.p.注射后，<7>印防己毒素</7>和<9>戊四氮</9>诱导的<6>癫痫发作</6>。此处显示的结果表明，BS和BR线对<3>β-CCM</3>的差异敏感性可以扩展到<18>安定</18>（<a>地西泮</a>）、<8>印防己毒素</8>和<10>戊四唑</10>，表明对<14>GABA</14>（A）受体的几种配体具有普遍敏感性和抗性的遗传选择。", "revised": true}
{"doc_key": "18464113", "sentences": [["Lamivudine", "for", "the", "prevention", "of", "hepatitis", "B", "virus", "reactivation", "in", "hepatitis", "-", "B", "surface", "antigen", "(", "HBSAG", ")", "seropositive", "cancer", "patients", "undergoing", "cytotoxic", "chemotherapy", ".", "Hepatitis", "B", "virus", "(", "HBV", ")", "is", "one", "of", "the", "major", "causes", "of", "chronic", "liver", "disease", "worldwide", ".", "Cancer", "patients", "who", "are", "chronic", "carriers", "of", "HBV", "have", "a", "higher", "hepatic", "complication", "rate", "while", "receiving", "cytotoxic", "chemotherapy", "(", "CT", ")", "and", "this", "has", "mainly", "been", "attributed", "to", "HBV", "reactivation", ".", "In", "this", "study", ",", "cancer", "patients", "who", "have", "solid", "and", "hematological", "malignancies", "with", "chronic", "HBV", "infection", "received", "the", "antiviral", "agent", "lamivudine", "prior", "and", "during", "CT", "compared", "with", "historical", "control", "group", "who", "did", "not", "receive", "lamivudine", ".", "The", "objectives", "were", "to", "assess", "the", "efficacy", "of", "lamivudine", "in", "reducing", "the", "incidence", "of", "HBV", "reactivation", ",", "and", "diminishing", "morbidity", "and", "mortality", "during", "CT", ".", "Two", "groups", "were", "compared", "in", "this", "study", ".", "The", "prophylactic", "lamivudin", "group", "consisted", "of", "37", "patients", "who", "received", "prophylactic", "lamivudine", "treatment", ".", "The", "historical", "controls", "consisted", "of", "50", "consecutive", "patients", "who", "underwent", "CT", "without", "prophylactic", "lamivudine", ".", "They", "were", "followed", "up", "during", "and", "for", "8", "weeks", "after", "CT", ".", "The", "outcomes", "were", "compared", "for", "both", "groups", ".", "Of", "our", "control", "group", "(", "n", "=", "50", ")", ",", "21", "patients", "(", "42", "%", ")", "were", "established", "hepatitis", ".", "Twelve", "(", "24", "%", ")", "of", "them", "were", "evaluated", "as", "severe", "hepatitis", ".", "In", "the", "prophylactic", "lamivudine", "group", "severe", "hepatitis", "were", "observed", "only", "in", "1", "patient", "(", "2", ".", "7", "%", ")", "of", "37", "patients", "(", "p", "<", "0", ".", "006", ")", ".", "Comparison", "of", "the", "mean", "ALT", "values", "revealed", "significantly", "higher", "mean", "alanine", "aminotransferase", "(", "ALT", ")", "values", "in", "the", "control", "group", "than", "the", "prophylactic", "lamivudine", "group", ";", "154", ":", "64", "(", "p", "<", "0", ".", "32", ")", ".", "Our", "study", "suggests", "that", "prophylactic", "lamivudine", "significantly", "decreases", "the", "incidence", "of", "HBV", "reactivation", "and", "overall", "morbidity", "in", "cancer", "patients", "during", "and", "after", "immunosuppressive", "therapy", ".", "Further", "studies", "are", "needed", "to", "determine", "the", "most", "appropriate", "nucleoside", "or", "nucleotide", "analogue", "for", "antiviral", "prophylaxis", "during", "CT", "and", "the", "optimal", "duration", "of", "administration", "after", "completion", "of", "CT", "."]], "ner": [[[10, 14, "Chemical"], [16, 16, "Chemical"], [5, 6, "Disease"], [25, 26, "Disease"], [88, 89, "Disease"], [0, 0, "Chemical"], [94, 94, "Chemical"], [108, 108, "Chemical"], [118, 118, "Chemical"], [145, 145, "Chemical"], [154, 154, "Chemical"], [170, 170, "Chemical"], [228, 228, "Chemical"], [278, 278, "Chemical"], [297, 297, "Chemical"], [19, 19, "Disease"], [43, 43, "Disease"], [78, 78, "Disease"], [309, 309, "Disease"], [39, 40, "Disease"], [54, 55, "Disease"], [84, 85, "Disease"], [210, 210, "Disease"], [223, 223, "Disease"], [231, 231, "Disease"], [265, 265, "Chemical"], [326, 326, "Chemical"], [328, 328, "Chemical"]]], "relations": [[[10, 14, 5, 6, "CID"], [10, 14, 25, 26, "CID"], [10, 14, 88, 89, "CID"], [16, 16, 5, 6, "CID"], [16, 16, 25, 26, "CID"], [16, 16, 88, 89, "CID"]]], "clusters": [], "translated": "<5>拉米夫定</5>用于预防<0>乙型肝炎表面抗原</0>（<1>HBSAG</1>）血清反应阳性<2>乙型肝炎</2>病毒再激活，接受细胞毒性化疗的<15>癌症</15>患者。 <3>乙型肝炎</3>病毒（HBV）是全世界慢性<19>肝病</19>的主要原因之一。在接受细胞毒性化疗（CT）的<16>癌症</16>患者中，慢性HBV携带者发生<20>肝脏并发症</20>的概率更高，这主要归因于HBV再激活。本研究中，<17>实体瘤</17>患者和<21>血液系统恶性肿瘤</21>患者，患慢性<4>HBV感染</4>，在接受细胞毒性化疗之前和期间使用抗病毒药物<6>拉米夫定</6>，并与未接受<7>拉米夫定</7>的历史对照组进行比较。本研究目的是评估<8>拉米夫定</8>在降低HBV再激活发生率和在CT期间减少发病率和死亡率方面的疗效。本研究比较了两组。预防性<9>拉米夫定</9>组包括接受预防性<10>拉米夫定</10>治疗的37名患者。历史对照组包括50名连续接受CT但未接受预防性<11>拉米夫定</11>的患者。在CT期间和之后进行了8周的随访。比较两组的结果。在对照组（n = 50）中，有21名患者（42%）确诊为<22>肝炎</22>，其中12人（24%）被评估为重度<23>肝炎</23>。在预防性<12>拉米夫定</12>组中，37名患者中只有1名患者（2.7%）出现严重的<24>肝炎</24>（p < 0.006）。平均ALT值的比较表明，对照组的平均<25>丙氨酸</25>转氨酶（ALT）值显着高于预防性<13>拉米夫定</13>组；154 : 64（p < 0.32）。我们的研究表明，预防性<14>拉米夫定</14>显著降低<18>癌症</18>患者在免疫抑制治疗期间和之后的HBV再激活发生率和总体发病率。需要进一步的研究来确定最适用于在CT期间进行抗病毒预防的<26>核苷</26>或<27>核苷酸</27>类似物及其在CT结束后的优化给药持续时间。", "revised": true}
{"doc_key": "6308277", "sentences": [["Reduction", "in", "caffeine", "toxicity", "by", "acetaminophen", ".", "A", "patient", "who", "allegedly", "consumed", "100", "tablets", "of", "an", "over", "-", "the", "-", "counter", "analgesic", "containing", "sodium", "acetylsalicylate", ",", "caffeine", ",", "and", "acetaminophen", "displayed", "no", "significant", "CNS", "stimulation", "despite", "the", "presence", "of", "175", "micrograms", "of", "caffeine", "per", "mL", "of", "serum", ".", "Because", "salicylates", "have", "been", "reported", "to", "augment", "the", "stimulatory", "effects", "of", "caffeine", "on", "the", "CNS", ",", "attention", "was", "focused", "on", "the", "possibility", "that", "the", "presence", "of", "acetaminophen", "(", "52", "micrograms", "/", "mL", ")", "reduced", "the", "CNS", "toxicity", "of", "caffeine", ".", "Studies", "in", "DBA", "/", "2J", "mice", "showed", "that", ":", "1", ")", "pretreatment", "with", "acetaminophen", "(", "100", "mg", "/", "kg", ")", "increased", "the", "interval", "between", "the", "administration", "of", "caffeine", "(", "300", "to", "450", "mg", "/", "kg", "IP", ")", "and", "the", "onset", "of", "fatal", "convulsions", "by", "a", "factor", "of", "about", "two", ";", "and", "2", ")", "pretreatment", "with", "acetaminophen", "(", "75", "mg", "/", "kg", ")", "reduced", "the", "incidence", "of", "audiogenic", "seizures", "produced", "in", "the", "presence", "of", "caffeine", "(", "12", ".", "5", "to", "75", "mg", "/", "kg", "IP", ")", ".", "The", "frequency", "of", "sound", "-", "induced", "seizures", "after", "12", ".", "5", "or", "25", "mg", "/", "kg", "caffeine", "was", "reduced", "from", "50", "to", "5", "%", "by", "acetaminophen", ".", "In", "the", "absence", "of", "caffeine", ",", "acetaminophen", "(", "up", "to", "300", "mg", "/", "kg", ")", "did", "not", "modify", "the", "seizures", "induced", "by", "maximal", "electroshock", "and", "did", "not", "alter", "the", "convulsant", "dose", "of", "pentylenetetrezol", "in", "mice", "(", "tests", "performed", "by", "the", "Anticonvulsant", "Screening", "Project", "of", "NINCDS", ")", ".", "Acetaminophen", "(", "up", "to", "150", "micrograms", "/", "mL", ")", "did", "not", "retard", "the", "incorporation", "of", "radioactive", "adenosine", "into", "ATP", "in", "slices", "of", "rat", "cerebral", "cortex", ".", "Thus", "the", "mechanism", "by", "which", "acetaminophen", "antagonizes", "the", "actions", "of", "caffeine", "in", "the", "CNS", "remains", "unknown", "."]], "ner": [[[2, 2, "Chemical"], [26, 26, "Chemical"], [42, 42, "Chemical"], [59, 59, "Chemical"], [86, 86, "Chemical"], [115, 115, "Chemical"], [161, 161, "Chemical"], [190, 190, "Chemical"], [205, 205, "Chemical"], [284, 284, "Chemical"], [130, 130, "Disease"], [155, 155, "Disease"], [180, 180, "Disease"], [220, 220, "Disease"], [233, 233, "Chemical"], [3, 3, "Disease"], [84, 84, "Disease"], [5, 5, "Chemical"], [29, 29, "Chemical"], [74, 74, "Chemical"], [101, 101, "Chemical"], [143, 143, "Chemical"], [199, 199, "Chemical"], [207, 207, "Chemical"], [248, 248, "Chemical"], [279, 279, "Chemical"], [264, 264, "Chemical"], [266, 266, "Chemical"]]], "relations": [[[2, 2, 130, 130, "CID"], [2, 2, 155, 155, "CID"], [2, 2, 180, 180, "CID"], [2, 2, 220, 220, "CID"], [26, 26, 130, 130, "CID"], [26, 26, 155, 155, "CID"], [26, 26, 180, 180, "CID"], [26, 26, 220, 220, "CID"], [42, 42, 130, 130, "CID"], [42, 42, 155, 155, "CID"], [42, 42, 180, 180, "CID"], [42, 42, 220, 220, "CID"], [59, 59, 130, 130, "CID"], [59, 59, 155, 155, "CID"], [59, 59, 180, 180, "CID"], [59, 59, 220, 220, "CID"], [86, 86, 130, 130, "CID"], [86, 86, 155, 155, "CID"], [86, 86, 180, 180, "CID"], [86, 86, 220, 220, "CID"], [115, 115, 130, 130, "CID"], [115, 115, 155, 155, "CID"], [115, 115, 180, 180, "CID"], [115, 115, 220, 220, "CID"], [161, 161, 130, 130, "CID"], [161, 161, 155, 155, "CID"], [161, 161, 180, 180, "CID"], [161, 161, 220, 220, "CID"], [190, 190, 130, 130, "CID"], [190, 190, 155, 155, "CID"], [190, 190, 180, 180, "CID"], [190, 190, 220, 220, "CID"], [205, 205, 130, 130, "CID"], [205, 205, 155, 155, "CID"], [205, 205, 180, 180, "CID"], [205, 205, 220, 220, "CID"], [284, 284, 130, 130, "CID"], [284, 284, 155, 155, "CID"], [284, 284, 180, 180, "CID"], [284, 284, 220, 220, "CID"], [233, 233, 130, 130, "CID"], [233, 233, 155, 155, "CID"], [233, 233, 180, 180, "CID"], [233, 233, 220, 220, "CID"]]], "clusters": [], "translated": "通过 <17>对乙酰氨基酚</17> 降低 <0>咖啡因</0> <15>毒性</15>。据称一名患者服用了100片含有乙酰水杨酸钠、<1>咖啡因</1>和<18>对乙酰氨基酚</18> 的非处方止痛药，尽管血清中存在每毫升175微克的 <2>咖啡因</2>。因为据报道水杨酸盐会增强 <3>咖啡因</3> 对中枢神经系统的刺激作用，所以人们关注的是 <19>对乙酰氨基酚</19> （ 52 微克/毫升）的存在会降低 <4>咖啡因的</4><16>毒性</16> 的可能性。在 DBA/2J小鼠中的研究表明: 1) 用 <20> 对乙酰氨基酚</20> ( 100mg/kg) 预处理增加了 <5>咖啡因 </5>(300至450mg/kg IP给药之间的间隔)和致命的<10>抽搐</10>的发生率约为两倍；和2) 用 <21> 对乙酰氨基酚</21> (75mg/kg) 预处理降低了在<6>咖啡因 </6>(12.5至75毫克/千克IP) 后声音诱发<11>癫痫</11>的发作。当采用12.5或25mg/kg<7>咖啡因</7>时，声音诱发的<12>癫痫</12>的发生率从50%减少到5%的<22>对乙酰氨基酚 </22>。在没有<8>咖啡因</8>的情况下，<23>对乙酰氨基酚 </23> (高达300mg/kg) 不会改变最大电击引起的<13>癫痫发作</13>，也不会改变<14>戊四唑 </14>在小鼠中的惊厥剂量 (由NINCDS的抗惊厥筛选项目进行的测试)。 <24> 对乙酰氨基酚</24> (高达150微克/毫升) 不会阻碍放射性<26>腺苷</26>进入大鼠大脑皮层切片中的<27> ATP </27>。因此，<25> 对乙酰氨基酚 </25>拮抗中枢神经系统中<9>咖啡因</9>作用的机制仍然未知。", "revised": true}
{"doc_key": "14568327", "sentences": [["Development", "of", "levodopa", "-", "induced", "dyskinesias", "in", "parkinsonian", "monkeys", "may", "depend", "upon", "rate", "of", "symptom", "onset", "and", "/", "or", "duration", "of", "symptoms", ".", "Levodopa", "-", "induced", "dyskinesias", "(", "LIDs", ")", "present", "a", "major", "problem", "for", "the", "long", "-", "term", "management", "of", "Parkinson", "'s", "disease", "(", "PD", ")", "patients", ".", "Due", "to", "the", "interdependence", "of", "risk", "factors", "in", "clinical", "populations", ",", "it", "is", "difficult", "to", "independently", "examine", "factors", "that", "may", "influence", "the", "development", "of", "LIDs", ".", "Using", "macaque", "monkeys", "with", "different", "types", "of", "MPTP", "-", "induced", "parkinsonism", ",", "the", "current", "study", "evaluated", "the", "degree", "to", "which", "rate", "of", "symptom", "progression", ",", "symptom", "severity", ",", "and", "response", "to", "and", "duration", "of", "levodopa", "therapy", "may", "be", "involved", "in", "the", "development", "of", "LIDs", ".", "Monkeys", "with", "acute", "(", "short", "-", "term", ")", "MPTP", "exposure", ",", "rapid", "symptom", "onset", "and", "short", "symptom", "duration", "prior", "to", "initiation", "of", "levodopa", "therapy", "developed", "dyskinesia", "between", "11", "and", "24", "days", "of", "daily", "levodopa", "administration", ".", "In", "contrast", ",", "monkeys", "with", "long", "-", "term", "MPTP", "exposure", ",", "slow", "symptom", "progression", "and", "/", "or", "long", "symptom", "duration", "prior", "to", "initiation", "of", "levodopa", "therapy", "were", "more", "resistant", "to", "developing", "LIDs", "(", "e", ".", "g", ".", ",", "dyskinesia", "developed", "no", "sooner", "than", "146", "days", "of", "chronic", "levodopa", "administration", ")", ".", "All", "animals", "were", "similarly", "symptomatic", "at", "the", "start", "of", "levodopa", "treatment", "and", "had", "similar", "therapeutic", "responses", "to", "the", "drug", ".", "These", "data", "suggest", "distinct", "differences", "in", "the", "propensity", "to", "develop", "LIDs", "in", "monkeys", "with", "different", "rates", "of", "symptom", "progression", "or", "symptom", "durations", "prior", "to", "levodopa", "and", "demonstrate", "the", "value", "of", "these", "models", "for", "further", "studying", "the", "pathophysiology", "of", "LIDs", "."]], "ner": [[[2, 2, "Chemical"], [23, 23, "Chemical"], [109, 109, "Chemical"], [142, 142, "Chemical"], [153, 153, "Chemical"], [180, 180, "Chemical"], [203, 203, "Chemical"], [216, 216, "Chemical"], [251, 251, "Chemical"], [5, 5, "Disease"], [26, 26, "Disease"], [28, 28, "Disease"], [73, 73, "Disease"], [118, 118, "Disease"], [145, 145, "Disease"], [187, 187, "Disease"], [194, 194, "Disease"], [237, 237, "Disease"], [265, 265, "Disease"], [82, 82, "Chemical"], [128, 128, "Chemical"], [164, 164, "Chemical"], [85, 85, "Disease"], [7, 7, "Disease"], [41, 43, "Disease"], [45, 45, "Disease"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 26, 26, "CID"], [2, 2, 28, 28, "CID"], [2, 2, 73, 73, "CID"], [2, 2, 118, 118, "CID"], [2, 2, 145, 145, "CID"], [2, 2, 187, 187, "CID"], [2, 2, 194, 194, "CID"], [2, 2, 237, 237, "CID"], [2, 2, 265, 265, "CID"], [23, 23, 5, 5, "CID"], [23, 23, 26, 26, "CID"], [23, 23, 28, 28, "CID"], [23, 23, 73, 73, "CID"], [23, 23, 118, 118, "CID"], [23, 23, 145, 145, "CID"], [23, 23, 187, 187, "CID"], [23, 23, 194, 194, "CID"], [23, 23, 237, 237, "CID"], [23, 23, 265, 265, "CID"], [109, 109, 5, 5, "CID"], [109, 109, 26, 26, "CID"], [109, 109, 28, 28, "CID"], [109, 109, 73, 73, "CID"], [109, 109, 118, 118, "CID"], [109, 109, 145, 145, "CID"], [109, 109, 187, 187, "CID"], [109, 109, 194, 194, "CID"], [109, 109, 237, 237, "CID"], [109, 109, 265, 265, "CID"], [142, 142, 5, 5, "CID"], [142, 142, 26, 26, "CID"], [142, 142, 28, 28, "CID"], [142, 142, 73, 73, "CID"], [142, 142, 118, 118, "CID"], [142, 142, 145, 145, "CID"], [142, 142, 187, 187, "CID"], [142, 142, 194, 194, "CID"], [142, 142, 237, 237, "CID"], [142, 142, 265, 265, "CID"], [153, 153, 5, 5, "CID"], [153, 153, 26, 26, "CID"], [153, 153, 28, 28, "CID"], [153, 153, 73, 73, "CID"], [153, 153, 118, 118, "CID"], [153, 153, 145, 145, "CID"], [153, 153, 187, 187, "CID"], [153, 153, 194, 194, "CID"], [153, 153, 237, 237, "CID"], [153, 153, 265, 265, "CID"], [180, 180, 5, 5, "CID"], [180, 180, 26, 26, "CID"], [180, 180, 28, 28, "CID"], [180, 180, 73, 73, "CID"], [180, 180, 118, 118, "CID"], [180, 180, 145, 145, "CID"], [180, 180, 187, 187, "CID"], [180, 180, 194, 194, "CID"], [180, 180, 237, 237, "CID"], [180, 180, 265, 265, "CID"], [203, 203, 5, 5, "CID"], [203, 203, 26, 26, "CID"], [203, 203, 28, 28, "CID"], [203, 203, 73, 73, "CID"], [203, 203, 118, 118, "CID"], [203, 203, 145, 145, "CID"], [203, 203, 187, 187, "CID"], [203, 203, 194, 194, "CID"], [203, 203, 237, 237, "CID"], [203, 203, 265, 265, "CID"], [216, 216, 5, 5, "CID"], [216, 216, 26, 26, "CID"], [216, 216, 28, 28, "CID"], [216, 216, 73, 73, "CID"], [216, 216, 118, 118, "CID"], [216, 216, 145, 145, "CID"], [216, 216, 187, 187, "CID"], [216, 216, 194, 194, "CID"], [216, 216, 237, 237, "CID"], [216, 216, 265, 265, "CID"], [251, 251, 5, 5, "CID"], [251, 251, 26, 26, "CID"], [251, 251, 28, 28, "CID"], [251, 251, 73, 73, "CID"], [251, 251, 118, 118, "CID"], [251, 251, 145, 145, "CID"], [251, 251, 187, 187, "CID"], [251, 251, 194, 194, "CID"], [251, 251, 237, 237, "CID"], [251, 251, 265, 265, "CID"], [82, 82, 85, 85, "CID"], [128, 128, 85, 85, "CID"], [164, 164, 85, 85, "CID"]]], "clusters": [], "translated": " <0>左旋多巴</0> - 诱发的<10>运动障碍</10>（<11>LIDs</11>）是<24>帕金森病</24>长期管理的主要问题（<25>PD</25>）患者。<1>左旋多巴</1>诱发的<9>运动障碍</9>在<23>帕金森病</23>猴子中的发展可能取决于症状发作的速度和/或症状的持续时间。由于临床人群中危险因素的相互依赖性，很难独立检查可能影响<12>LIDs</12>发展的因素。使用患有不同类型<19>MPTP</19>诱发的<22>帕金森病</22>的猕猴，当前的研究评估了症状进展的速度、症状的严重程度以及对<2>左旋多巴</2>治疗的反应和持续时间可能与<13>LIDs</13>的发生有关。在<3>左旋多巴</3>治疗开始前，急性（短期）<20>MPTP</20>暴露、症状发作迅速且症状持续时间短的猴子在11至24天的每日<4>左旋多巴</4>给药后发展<14>运动障碍</14>。相比之下，在<21>MPTP</21>暴露长期、症状进展缓慢和/或症状持续时间长的猴子在<5>左旋多巴</5>治疗开始前更耐受发生<15>LIDs</15>（例如，<16>运动障碍</16>在长期<6>左旋多巴</6>给药后出现的时间不早于146天）。所有动物在<7>左旋多巴</7>治疗开始时都有相似的症状，并且对药物有相似的治疗反应。这些数据表明，在<8>左旋多巴</8>治疗之前，具有不同症状进展率或症状持续时间的猴子发生<17>LIDs</17>的倾向存在明显差异，并证明了这些模型对于进一步研究<18>LIDs</18>的病理生理学的价值。", "revised": true}
{"doc_key": "3714122", "sentences": [["The", "correlation", "between", "neurotoxic", "esterase", "inhibition", "and", "mipafox", "-", "induced", "neuropathic", "damage", "in", "rats", ".", "The", "correlation", "between", "neuropathic", "damage", "and", "inhibition", "of", "neurotoxic", "esterase", "or", "neuropathy", "target", "enzyme", "(", "NTE", ")", "was", "examined", "in", "rats", "acutely", "exposed", "to", "Mipafox", "(", "N", ",", "N", "'", "-", "diisopropylphosphorodiamidofluoridate", ")", ",", "a", "neurotoxic", "organophosphate", ".", "Brain", "and", "spinal", "cord", "NTE", "activities", "were", "measured", "in", "Long", "-", "Evans", "male", "rats", "1", "hr", "post", "-", "exposure", "to", "various", "dosages", "of", "Mipafox", "(", "ip", ",", "1", "-", "15", "mg", "/", "kg", ")", ".", "These", "data", "were", "correlated", "with", "histologically", "scored", "cervical", "cord", "damage", "in", "a", "separate", "group", "of", "similarly", "dosed", "rats", "sampled", "14", "-", "21", "days", "post", "-", "exposure", ".", "Those", "dosages", "(", "greater", "than", "or", "equal", "to", "10", "mg", "/", "kg", ")", "that", "inhibited", "mean", "NTE", "activity", "in", "the", "spinal", "cord", "greater", "than", "or", "equal", "to", "73", "%", "and", "brain", "greater", "than", "or", "equal", "to", "67", "%", "of", "control", "values", "produced", "severe", "(", "greater", "than", "or", "equal", "to", "3", ")", "cervical", "cord", "pathology", "in", "85", "%", "of", "the", "rats", ".", "In", "contrast", ",", "dosages", "of", "Mipafox", "(", "less", "than", "or", "equal", "to", "5", "mg", "/", "kg", ")", "which", "inhibited", "mean", "NTE", "activity", "in", "spinal", "cord", "less", "than", "or", "equal", "to", "61", "%", "and", "brain", "less", "than", "or", "equal", "to", "60", "%", "produced", "this", "degree", "of", "cord", "damage", "in", "only", "9", "%", "of", "the", "animals", ".", "These", "data", "indicate", "that", "a", "critical", "percentage", "of", "NTE", "inhibition", "in", "brain", "and", "spinal", "cord", "sampled", "shortly", "after", "Mipafox", "exposure", "can", "predict", "neuropathic", "damage", "in", "rats", "several", "weeks", "later", "."]], "ner": [[[7, 7, "Chemical"], [39, 39, "Chemical"], [41, 46, "Chemical"], [76, 76, "Chemical"], [181, 181, "Chemical"], [249, 249, "Chemical"], [96, 97, "Disease"], [221, 222, "Disease"], [3, 3, "Disease"], [23, 23, "Disease"], [50, 50, "Disease"], [51, 51, "Chemical"], [10, 11, "Disease"], [18, 19, "Disease"], [26, 26, "Disease"], [253, 254, "Disease"]]], "relations": [[[7, 7, 96, 97, "CID"], [7, 7, 221, 222, "CID"], [39, 39, 96, 97, "CID"], [39, 39, 221, 222, "CID"], [41, 46, 96, 97, "CID"], [41, 46, 221, 222, "CID"], [76, 76, 96, 97, "CID"], [76, 76, 221, 222, "CID"], [181, 181, 96, 97, "CID"], [181, 181, 221, 222, "CID"], [249, 249, 96, 97, "CID"], [249, 249, 221, 222, "CID"]]], "clusters": [], "translated": "在大鼠中，<8>神经毒性</8>酯酶抑制与<0>mipafox</0>诱导的<12>神经性损伤</12>之间的相关性。在急性暴露于<1>米帕福克斯</1>的大鼠中检测了<13>神经性损害</13>与<9>神经毒性</9>酯酶或<14>神经病变</14>靶酶（NTE）抑制之间的相关性（<2>N，N'-二异丙基氟磷酸二酰胺</2>），一种<10>神经毒性</10><11>有机磷</11>。在 Long-Evans 雄性大鼠接触不同剂量的 <3> Mipafox</3>（腹腔注射，1-15 mg/kg）后 1 小时，测量大脑和脊髓 NTE 活动。这些数据与在暴露后 14-21 天取样的另一组类似剂量的大鼠中组织学评分的颈部 <6> 脊髓损伤 </6> 相关。抑制脊髓中 NTE 活性大于或等于 73 % 和大脑大于或等于对照值 67 % 的那些剂量（大于或等于 10 mg / kg ）产生严重（大于或等于 3 ) 85% 的大鼠有颈髓病变。相比之下，<4> Mipafox </4> 剂量（小于或等于 5 mg/kg ）抑制脊髓中的平均 NTE 活性小于或等于 61 % 和大脑小于或等于 60 % 产生了这个<7>脊髓损伤</7>的程度只有9%的动物。这些数据表明，在 <5> Mipafox </5> 暴露后不久取样的脑和脊髓中 NTE 抑制的临界百分比可以预测大鼠数周后的 <15> 神经性损伤 </15>。", "revised": true}
{"doc_key": "18791946", "sentences": [["Severe", "thrombocytopenia", "and", "haemolytic", "anaemia", "associated", "with", "ciprofloxacin", ":", "a", "case", "report", "with", "fatal", "outcome", ".", "Haematological", "adverse", "reactions", "associated", "with", "fatal", "outcome", "are", "rare", "during", "treatment", "with", "ciprofloxacin", ".", "A", "30", "-", "year", "old", "Caucasian", "man", "reported", "with", "abdominal", "pain", "and", "jaundice", "after", "3", "-", "day", "administration", "of", "oral", "ciprofloxacin", "for", "a", "suspect", "of", "urinary", "tract", "infection", ".", "Clinical", "evaluations", "suggested", "an", "initial", "diagnosis", "of", "severe", "thrombocytopenia", "and", "haemolysis", ".", "The", "patient", "progressively", "developed", "petechiae", "and", "purpura", "on", "thorax", "and", "lower", "limbs", ".", "Despite", "pharmacological", "and", "supportive", "interventions", ",", "laboratory", "parameters", "worsened", "and", "the", "patient", "died", "17", "hours", "after", "admission", ".", "An", "accurate", "autopsy", "revealed", "most", "organs", "with", "diffuse", "petechial", "haemorrhages", ".", "No", "signs", "of", "bone", "marrow", "depression", "were", "found", ".", "No", "thrombi", "or", "signs", "of", "microangiopathies", "were", "observed", "in", "arterial", "vessels", ".", "Blood", "and", "urine", "cultures", "did", "not", "show", "any", "bacterial", "growth", ".", "This", "case", "report", "shows", "that", "ciprofloxacin", "may", "precipitate", "life", "-", "threatening", "thrombocytopenia", "and", "haemolytic", "anaemia", ",", "even", "in", "the", "early", "phases", "of", "treatment", "and", "without", "apparent", "previous", "exposures", "."]], "ner": [[[7, 7, "Chemical"], [28, 28, "Chemical"], [50, 50, "Chemical"], [150, 150, "Chemical"], [1, 1, "Disease"], [67, 67, "Disease"], [156, 156, "Disease"], [3, 4, "Disease"], [158, 159, "Disease"], [39, 40, "Disease"], [42, 42, "Disease"], [75, 75, "Disease"], [77, 77, "Disease"], [55, 57, "Disease"], [69, 69, "Disease"], [111, 111, "Disease"], [116, 118, "Disease"], [123, 123, "Disease"], [127, 127, "Disease"]]], "relations": [[[7, 7, 1, 1, "CID"], [7, 7, 67, 67, "CID"], [7, 7, 156, 156, "CID"], [28, 28, 1, 1, "CID"], [28, 28, 67, 67, "CID"], [28, 28, 156, 156, "CID"], [50, 50, 1, 1, "CID"], [50, 50, 67, 67, "CID"], [50, 50, 156, 156, "CID"], [150, 150, 1, 1, "CID"], [150, 150, 67, 67, "CID"], [150, 150, 156, 156, "CID"], [7, 7, 3, 4, "CID"], [7, 7, 158, 159, "CID"], [28, 28, 3, 4, "CID"], [28, 28, 158, 159, "CID"], [50, 50, 3, 4, "CID"], [50, 50, 158, 159, "CID"], [150, 150, 3, 4, "CID"], [150, 150, 158, 159, "CID"], [7, 7, 39, 40, "CID"], [28, 28, 39, 40, "CID"], [50, 50, 39, 40, "CID"], [150, 150, 39, 40, "CID"], [7, 7, 42, 42, "CID"], [28, 28, 42, 42, "CID"], [50, 50, 42, 42, "CID"], [150, 150, 42, 42, "CID"], [7, 7, 75, 75, "CID"], [7, 7, 77, 77, "CID"], [28, 28, 75, 75, "CID"], [28, 28, 77, 77, "CID"], [50, 50, 75, 75, "CID"], [50, 50, 77, 77, "CID"], [150, 150, 75, 75, "CID"], [150, 150, 77, 77, "CID"]]], "clusters": [], "translated": "与 <0> 环丙沙星 </0> 相关的严重 <4> 血小板减少症 </4> 和 <7> 溶血性贫血 </7> ：具有致命结果的病例报告。在使用 <1> 环丙沙星 </1> 治疗期间，与致命结果相关的血液学不良反应很少见。一名 30 岁的白人男子因疑似 <13> 尿路感染</13>而口服 <2> 环丙沙星 </2> 3 天后报告出现 <9> 腹痛 </9> 和 <10> 黄疸 </10>呼吸道感染</13> .临床评估表明初步诊断为严重<5>血小板减少症</5>和<14>溶血</14>。患者进行性出现胸、下肢<11>瘀点</11>和<12>紫癜</12>。尽管进行了药物和支持性干预，但实验室参数恶化，患者在入院 17 小时后死亡。准确的尸检显示大部分器官都有弥漫性瘀斑 <15> 出血 </15> 。未发现<16>骨髓抑制</16>的迹象。在动脉血管中未观察到<17>血栓</17>或<18>微血管病</18>迹象。血液和尿液培养未见任何细菌生长。该病例报告显示，即使在治疗的早期阶段并且既往没有明显的暴露史，<3>环丙沙星</3>也可能引发危及生命的<6>血小板减少症</6>和<8>溶血性贫血</8>。", "revised": true}
{"doc_key": "11672959", "sentences": [["The", "3", "-", "week", "sulphasalazine", "syndrome", "strikes", "again", ".", "A", "34", "-", "year", "-", "old", "lady", "developed", "a", "constellation", "of", "dermatitis", ",", "fever", ",", "lymphadenopathy", "and", "hepatitis", ",", "beginning", "on", "the", "17th", "day", "of", "a", "course", "of", "oral", "sulphasalazine", "for", "sero", "-", "negative", "rheumatoid", "arthritis", ".", "Cervical", "and", "inguinal", "lymph", "node", "biopsies", "showed", "the", "features", "of", "severe", "necrotising", "lymphadenitis", ",", "associated", "with", "erythrophagocytosis", "and", "prominent", "eosinophilic", "infiltrates", ",", "without", "viral", "inclusion", "bodies", ",", "suggestive", "of", "an", "adverse", "drug", "reaction", ".", "A", "week", "later", ",", "fulminant", "drug", "-", "induced", "hepatitis", ",", "associated", "with", "the", "presence", "of", "anti", "-", "nuclear", "autoantibodies", "(", "but", "not", "with", "other", "markers", "of", "autoimmunity", ")", ",", "and", "accompanied", "by", "multi", "-", "organ", "failure", "and", "sepsis", ",", "supervened", ".", "She", "subsequently", "died", "some", "5", "weeks", "after", "the", "commencement", "of", "her", "drug", "therapy", ".", "Post", "-", "mortem", "examination", "showed", "evidence", "of", "massive", "hepatocellular", "necrosis", ",", "acute", "hypersensitivity", "myocarditis", ",", "focal", "acute", "tubulo", "-", "interstitial", "nephritis", "and", "extensive", "bone", "marrow", "necrosis", ",", "with", "no", "evidence", "of", "malignancy", ".", "It", "is", "thought", "that", "the", "clinico", "-", "pathological", "features", "and", "chronology", "of", "this", "case", "bore", "the", "hallmarks", "of", "the", "so", "-", "called", "\"", "3", "-", "week", "sulphasalazine", "syndrome", "\"", ",", "a", "rare", ",", "but", "often", "fatal", ",", "immunoallergic", "reaction", "to", "sulphasalazine", "."]], "ner": [[[4, 4, "Chemical"], [38, 38, "Chemical"], [194, 194, "Chemical"], [208, 208, "Chemical"], [20, 20, "Disease"], [22, 22, "Disease"], [24, 24, "Disease"], [26, 26, "Disease"], [85, 88, "Disease"], [117, 117, "Disease"], [148, 148, "Disease"], [155, 155, "Disease"], [43, 44, "Disease"], [58, 58, "Disease"], [76, 78, "Disease"], [106, 106, "Disease"], [112, 115, "Disease"], [142, 144, "Disease"], [158, 160, "Disease"], [166, 166, "Disease"]]], "relations": [[[4, 4, 20, 20, "CID"], [38, 38, 20, 20, "CID"], [194, 194, 20, 20, "CID"], [208, 208, 20, 20, "CID"], [4, 4, 22, 22, "CID"], [38, 38, 22, 22, "CID"], [194, 194, 22, 22, "CID"], [208, 208, 22, 22, "CID"], [4, 4, 24, 24, "CID"], [38, 38, 24, 24, "CID"], [194, 194, 24, 24, "CID"], [208, 208, 24, 24, "CID"], [4, 4, 26, 26, "CID"], [4, 4, 85, 88, "CID"], [38, 38, 26, 26, "CID"], [38, 38, 85, 88, "CID"], [194, 194, 26, 26, "CID"], [194, 194, 85, 88, "CID"], [208, 208, 26, 26, "CID"], [208, 208, 85, 88, "CID"], [4, 4, 117, 117, "CID"], [38, 38, 117, 117, "CID"], [194, 194, 117, 117, "CID"], [208, 208, 117, 117, "CID"], [4, 4, 148, 148, "CID"], [38, 38, 148, 148, "CID"], [194, 194, 148, 148, "CID"], [208, 208, 148, 148, "CID"], [4, 4, 155, 155, "CID"], [38, 38, 155, 155, "CID"], [194, 194, 155, 155, "CID"], [208, 208, 155, 155, "CID"]]], "clusters": [], "translated": "为期 3 周的 <0> 柳氮磺胺吡啶 </0> 综合症再次发作。一位34岁的女士在口服<1>硫柳氮嗪</1>治疗血清阴性的<12>类风湿性关节炎</12>的第17天开始，出现了一系列<4>皮炎</4>、<5>发烧</5>、<6>淋巴结病</6>和<7>肝炎</7>。颈部和腹股沟淋巴结活检显示严重坏死性 <13> 淋巴结炎 </13> 的特征，伴有红细胞吞噬作用和显着的嗜酸性粒细胞浸润，无病毒包涵体，提示 <14> 药物不良反应 </14>。一周后，爆发性 <8> 药物性肝炎 </8> ，与抗核自身抗体的存在相关（但与 <15> 自身免疫的其他标记 </15> 无关） ，并伴有 <16> 多发性肝炎- 器官衰竭 </16> 和 <9> 脓毒症 </9>，伴随而来。她随后在开始药物治疗后约 5 周后死亡。尸检显示<17>大量肝细胞坏死</17>、急性超敏反应<10>心肌炎</10>、局灶性急性肾小管-间质性<11>肾炎</11>和广泛<18>骨髓坏死的证据</18> ，没有 <19> 恶性肿瘤 </19> 的证据。据认为，该病例的临床病理特征和时间顺序具有所谓的“3 周 <2> 柳氮磺胺吡啶 </2> 综合征” 的特征，这是一种罕见但通常致命的对 <3> 的免疫过敏反应。柳氮磺胺吡啶</3> .", "revised": true}
{"doc_key": "12617329", "sentences": [["The", "effect", "of", "treatment", "with", "gum", "Arabic", "on", "gentamicin", "nephrotoxicity", "in", "rats", ":", "a", "preliminary", "study", ".", "In", "the", "present", "work", "we", "assessed", "the", "effect", "of", "treatment", "of", "rats", "with", "gum", "Arabic", "on", "acute", "renal", "failure", "induced", "by", "gentamicin", "(", "GM", ")", "nephrotoxicity", ".", "Rats", "were", "treated", "with", "the", "vehicle", "(", "2", "mL", "/", "kg", "of", "distilled", "water", "and", "5", "%", "w", "/", "v", "cellulose", ",", "10", "days", ")", ",", "gum", "Arabic", "(", "2", "mL", "/", "kg", "of", "a", "10", "%", "w", "/", "v", "aqueous", "suspension", "of", "gum", "Arabic", "powder", ",", "orally", "for", "10", "days", ")", ",", "or", "gum", "Arabic", "concomitantly", "with", "GM", "(", "80mg", "/", "kg", "/", "day", "intramuscularly", ",", "during", "the", "last", "six", "days", "of", "the", "treatment", "period", ")", ".", "Nephrotoxicity", "was", "assessed", "by", "measuring", "the", "concentrations", "of", "creatinine", "and", "urea", "in", "the", "plasma", "and", "reduced", "glutathione", "(", "GSH", ")", "in", "the", "kidney", "cortex", ",", "and", "by", "light", "microscopic", "examination", "of", "kidney", "sections", ".", "The", "results", "indicated", "that", "concomitant", "treatment", "with", "gum", "Arabic", "and", "GM", "significantly", "increased", "creatinine", "and", "urea", "by", "about", "183", "and", "239", "%", ",", "respectively", "(", "compared", "to", "432", "and", "346", "%", ",", "respectively", ",", "in", "rats", "treated", "with", "cellulose", "and", "GM", ")", ",", "and", "decreased", "that", "of", "cortical", "GSH", "by", "21", "%", "(", "compared", "to", "27", "%", "in", "the", "cellulose", "plus", "GM", "group", ")", "The", "GM", "-", "induced", "proximal", "tubular", "necrosis", "appeared", "to", "be", "slightly", "less", "severe", "in", "rats", "given", "GM", "together", "with", "gum", "Arabic", "than", "in", "those", "given", "GM", "and", "cellulose", ".", "It", "could", "be", "inferred", "that", "gum", "Arabic", "treatment", "has", "induced", "a", "modest", "amelioration", "of", "some", "of", "the", "histological", "and", "biochemical", "indices", "of", "GM", "nephrotoxicity", ".", "Further", "work", "is", "warranted", "on", "the", "effect", "of", "the", "treatments", "on", "renal", "functional", "aspects", "in", "models", "of", "chronic", "renal", "failure", ",", "and", "on", "the", "mechanism", "(", "s", ")", "involved", "."]], "ner": [[[5, 6, "Chemical"], [30, 31, "Chemical"], [70, 71, "Chemical"], [87, 88, "Chemical"], [98, 99, "Chemical"], [163, 164, "Chemical"], [239, 240, "Chemical"], [254, 255, "Chemical"], [33, 35, "Disease"], [8, 8, "Chemical"], [38, 38, "Chemical"], [40, 40, "Chemical"], [102, 102, "Chemical"], [166, 166, "Chemical"], [196, 196, "Chemical"], [217, 217, "Chemical"], [221, 221, "Chemical"], [236, 236, "Chemical"], [245, 245, "Chemical"], [271, 271, "Chemical"], [9, 9, "Disease"], [42, 42, "Disease"], [122, 122, "Disease"], [272, 272, "Disease"], [225, 226, "Disease"], [291, 293, "Disease"], [130, 130, "Chemical"], [169, 169, "Chemical"], [132, 132, "Chemical"], [171, 171, "Chemical"], [138, 138, "Chemical"], [140, 140, "Chemical"], [204, 204, "Chemical"]]], "relations": [[[5, 6, 33, 35, "CID"], [30, 31, 33, 35, "CID"], [70, 71, 33, 35, "CID"], [87, 88, 33, 35, "CID"], [98, 99, 33, 35, "CID"], [163, 164, 33, 35, "CID"], [239, 240, 33, 35, "CID"], [254, 255, 33, 35, "CID"], [8, 8, 33, 35, "CID"], [38, 38, 33, 35, "CID"], [40, 40, 33, 35, "CID"], [102, 102, 33, 35, "CID"], [166, 166, 33, 35, "CID"], [196, 196, 33, 35, "CID"], [217, 217, 33, 35, "CID"], [221, 221, 33, 35, "CID"], [236, 236, 33, 35, "CID"], [245, 245, 33, 35, "CID"], [271, 271, 33, 35, "CID"]]], "clusters": [], "translated": "用<0>阿拉伯胶</0>治疗大鼠<9>庆大霉素</9><20>肾毒性</20>的影响：一项初步研究。在目前的工作中，我们评估了用<1>阿拉伯胶</1>治疗大鼠对<10>庆大霉素</10>（<11>GM</11>）<21>肾毒性</21>引起的<8>急性肾功能衰竭</8>的影响。大鼠用赋形剂（2 mL/kg蒸馏水和5%w/v纤维素，10天）、<2>阿拉伯树胶</2>（2 mL/kg<3>阿拉伯树脂</3>粉末的10%w/v水悬浮液，口服10天）或<4>阿拉伯树油</4>同时用<12>GM</12>治疗（在治疗期的最后六天，肌肉注射80mg/kg/天）通过测量血浆中<26>肌酸酐</26>和<28>尿素</28>的浓度以及肾皮质中减少的<30>谷胱甘肽</30>（<31>谷胱甘肽</31>）的浓度以及肾脏切片的光镜检查来评估<22>肾毒性</22>。结果表明，用<5>阿拉伯树胶</5>和<13>GM</13>联合治疗使<27>肌酸酐</27>和<29>尿素</29>分别显著增加约183%和239%（相比之下，用纤维素和<14>GM</14>治疗的大鼠分别为432和346%），并将皮质<32>GSH</32>的含量降低21%（相比之下，纤维素加<15>GM</15>组为27%）。与给予<18>GM</18>和纤维素的大鼠相比，给予<17>GM</17>和<6>阿拉伯树胶</6>的大鼠，<16>GM</16>诱导的近端<24>肾小管坏死</24>的严重程度似乎略轻。可以推断，<7>阿拉伯树胶</7>治疗诱导了<19>GM</19><23>肾毒性</23>的一些组织学和生化指标的适度改善。需要进一步研究<25>慢性肾功能衰竭</25>模型中治疗对肾功能方面的影响，以及相关机制。", "revised": true}
{"doc_key": "11334364", "sentences": [["In", "vivo", "protection", "of", "dna", "damage", "associated", "apoptotic", "and", "necrotic", "cell", "deaths", "during", "acetaminophen", "-", "induced", "nephrotoxicity", ",", "amiodarone", "-", "induced", "lung", "toxicity", "and", "doxorubicin", "-", "induced", "cardiotoxicity", "by", "a", "novel", "IH636", "grape", "seed", "proanthocyanidin", "extract", ".", "Grape", "seed", "extract", ",", "primarily", "a", "mixture", "of", "proanthocyanidins", ",", "has", "been", "shown", "to", "modulate", "a", "wide", "-", "range", "of", "biological", ",", "pharmacological", "and", "toxicological", "effects", "which", "are", "mainly", "cytoprotective", ".", "This", "study", "assessed", "the", "ability", "of", "IH636", "grape", "seed", "proanthocyanidin", "extract", "(", "GSPE", ")", "to", "prevent", "acetaminophen", "(", "AAP", ")", "-", "induced", "nephrotoxicity", ",", "amiodarone", "(", "AMI", ")", "-", "induced", "lung", "toxicity", ",", "and", "doxorubicin", "(", "DOX", ")", "-", "induced", "cardiotoxicity", "in", "mice", ".", "Experimental", "design", "consisted", "of", "four", "groups", ":", "control", "(", "vehicle", "alone", ")", ",", "GSPE", "alone", ",", "drug", "alone", "and", "GSPE", "+", "drug", ".", "For", "the", "cytoprotection", "study", ",", "animals", "were", "orally", "gavaged", "100", "mg", "/", "Kg", "GSPE", "for", "7", "-", "10", "days", "followed", "by", "i", ".", "p", ".", "injections", "of", "organ", "specific", "three", "drugs", "(", "AAP", ":", "500", "mg", "/", "Kg", "for", "24", "h", ";", "AMI", ":", "50", "mg", "/", "Kg", "/", "day", "for", "four", "days", ";", "DOX", ":", "20", "mg", "/", "Kg", "for", "48", "h", ")", ".", "Parameters", "of", "study", "included", "analysis", "of", "serum", "chemistry", "(", "ALT", ",", "BUN", "and", "CPK", ")", ",", "and", "orderly", "fragmentation", "of", "genomic", "DNA", "(", "both", "endonuclease", "-", "dependent", "and", "independent", ")", "in", "addition", "to", "microscopic", "evaluation", "of", "damage", "and", "/", "or", "protection", "in", "corresponding", "PAS", "stained", "tissues", ".", "Results", "indicate", "that", "GSPE", "preexposure", "prior", "to", "AAP", ",", "AMI", "and", "DOX", ",", "provided", "near", "complete", "protection", "in", "terms", "of", "serum", "chemistry", "changes", "(", "ALT", ",", "BUN", "and", "CPK", ")", ",", "and", "significantly", "reduced", "DNA", "fragmentation", ".", "Histopathological", "examination", "of", "kidney", ",", "heart", "and", "lung", "sections", "revealed", "moderate", "to", "massive", "tissue", "damage", "with", "a", "variety", "of", "morphological", "aberrations", "by", "all", "the", "three", "drugs", "in", "the", "absence", "of", "GSPE", "preexposure", "than", "in", "its", "presence", ".", "GSPE", "+", "drug", "exposed", "tissues", "exhibited", "minor", "residual", "damage", "or", "near", "total", "recovery", ".", "Additionally", ",", "histopathological", "alterations", "mirrored", "both", "serum", "chemistry", "changes", "and", "the", "pattern", "of", "DNA", "fragmentation", ".", "Interestingly", ",", "all", "the", "drugs", ",", "such", "as", ",", "AAP", ",", "AMI", "and", "DOX", "induced", "apoptotic", "death", "in", "addition", "to", "necrosis", "in", "the", "respective", "organs", "which", "was", "very", "effectively", "blocked", "by", "GSPE", ".", "Since", "AAP", ",", "AMI", "and", "DOX", "undergo", "biotransformation", "and", "are", "known", "to", "produce", "damaging", "radicals", "in", "vivo", ",", "the", "protection", "by", "GSPE", "may", "be", "linked", "to", "both", "inhibition", "of", "metabolism", "and", "/", "or", "detoxification", "of", "cytotoxic", "radicals", ".", "In", "addition", ",", "its", "'", "presumed", "contribution", "to", "DNA", "repair", "may", "be", "another", "important", "attribute", ",", "which", "played", "a", "role", "in", "the", "chemoprevention", "process", ".", "Additionally", ",", "this", "may", "have", "been", "the", "first", "report", "on", "AMI", "-", "induced", "apoptotic", "death", "in", "the", "lung", "tissue", ".", "Taken", "together", ",", "these", "events", "undoubtedly", "establish", "GSPE", "'s", "abundant", "bioavailability", ",", "and", "the", "power", "to", "defend", "multiple", "target", "organs", "from", "toxic", "assaults", "induced", "by", "structurally", "diverse", "and", "functionally", "different", "entities", "in", "vivo", "."]], "ner": [[[13, 13, "Chemical"], [84, 84, "Chemical"], [86, 86, "Chemical"], [167, 167, "Chemical"], [254, 254, "Chemical"], [360, 360, "Chemical"], [385, 385, "Chemical"], [9, 9, "Disease"], [371, 371, "Disease"], [18, 18, "Chemical"], [92, 92, "Chemical"], [94, 94, "Chemical"], [177, 177, "Chemical"], [256, 256, "Chemical"], [362, 362, "Chemical"], [387, 387, "Chemical"], [457, 457, "Chemical"], [24, 24, "Chemical"], [102, 102, "Chemical"], [104, 104, "Chemical"], [189, 189, "Chemical"], [258, 258, "Chemical"], [364, 364, "Chemical"], [389, 389, "Chemical"], [16, 16, "Disease"], [90, 90, "Disease"], [21, 22, "Disease"], [98, 99, "Disease"], [27, 27, "Disease"], [108, 108, "Disease"], [31, 35, "Chemical"], [37, 39, "Chemical"], [74, 78, "Chemical"], [80, 80, "Chemical"], [125, 125, "Chemical"], [131, 131, "Chemical"], [148, 148, "Chemical"], [250, 250, "Chemical"], [314, 314, "Chemical"], [321, 321, "Chemical"], [382, 382, "Chemical"], [405, 405, "Chemical"], [474, 474, "Chemical"], [45, 45, "Chemical"], [297, 298, "Disease"]]], "relations": [[[13, 13, 9, 9, "CID"], [13, 13, 371, 371, "CID"], [84, 84, 9, 9, "CID"], [84, 84, 371, 371, "CID"], [86, 86, 9, 9, "CID"], [86, 86, 371, 371, "CID"], [167, 167, 9, 9, "CID"], [167, 167, 371, 371, "CID"], [254, 254, 9, 9, "CID"], [254, 254, 371, 371, "CID"], [360, 360, 9, 9, "CID"], [360, 360, 371, 371, "CID"], [385, 385, 9, 9, "CID"], [385, 385, 371, 371, "CID"], [18, 18, 9, 9, "CID"], [18, 18, 371, 371, "CID"], [92, 92, 9, 9, "CID"], [92, 92, 371, 371, "CID"], [94, 94, 9, 9, "CID"], [94, 94, 371, 371, "CID"], [177, 177, 9, 9, "CID"], [177, 177, 371, 371, "CID"], [256, 256, 9, 9, "CID"], [256, 256, 371, 371, "CID"], [362, 362, 9, 9, "CID"], [362, 362, 371, 371, "CID"], [387, 387, 9, 9, "CID"], [387, 387, 371, 371, "CID"], [457, 457, 9, 9, "CID"], [457, 457, 371, 371, "CID"], [24, 24, 9, 9, "CID"], [24, 24, 371, 371, "CID"], [102, 102, 9, 9, "CID"], [102, 102, 371, 371, "CID"], [104, 104, 9, 9, "CID"], [104, 104, 371, 371, "CID"], [189, 189, 9, 9, "CID"], [189, 189, 371, 371, "CID"], [258, 258, 9, 9, "CID"], [258, 258, 371, 371, "CID"], [364, 364, 9, 9, "CID"], [364, 364, 371, 371, "CID"], [389, 389, 9, 9, "CID"], [389, 389, 371, 371, "CID"], [13, 13, 16, 16, "CID"], [13, 13, 90, 90, "CID"], [84, 84, 16, 16, "CID"], [84, 84, 90, 90, "CID"], [86, 86, 16, 16, "CID"], [86, 86, 90, 90, "CID"], [167, 167, 16, 16, "CID"], [167, 167, 90, 90, "CID"], [254, 254, 16, 16, "CID"], [254, 254, 90, 90, "CID"], [360, 360, 16, 16, "CID"], [360, 360, 90, 90, "CID"], [385, 385, 16, 16, "CID"], [385, 385, 90, 90, "CID"], [18, 18, 21, 22, "CID"], [18, 18, 98, 99, "CID"], [92, 92, 21, 22, "CID"], [92, 92, 98, 99, "CID"], [94, 94, 21, 22, "CID"], [94, 94, 98, 99, "CID"], [177, 177, 21, 22, "CID"], [177, 177, 98, 99, "CID"], [256, 256, 21, 22, "CID"], [256, 256, 98, 99, "CID"], [362, 362, 21, 22, "CID"], [362, 362, 98, 99, "CID"], [387, 387, 21, 22, "CID"], [387, 387, 98, 99, "CID"], [457, 457, 21, 22, "CID"], [457, 457, 98, 99, "CID"], [24, 24, 27, 27, "CID"], [24, 24, 108, 108, "CID"], [102, 102, 27, 27, "CID"], [102, 102, 108, 108, "CID"], [104, 104, 27, 27, "CID"], [104, 104, 108, 108, "CID"], [189, 189, 27, 27, "CID"], [189, 189, 108, 108, "CID"], [258, 258, 27, 27, "CID"], [258, 258, 108, 108, "CID"], [364, 364, 27, 27, "CID"], [364, 364, 108, 108, "CID"], [389, 389, 27, 27, "CID"], [389, 389, 108, 108, "CID"]]], "clusters": [], "translated": "新型<30>IH636葡萄籽原花青素提取物</30>对<0>对乙酰氨基酚</0>诱导的<24>肾毒性</24>、<9>胺碘酮</9>诱导的<26>肺毒性</26>和<17>阿霉素</17>诱导的<28>心脏毒性</28>期间与dna损伤相关的凋亡和<7>坏死</7>细胞死亡的体内保护。 <31>葡萄籽提取物</31>，主要是<43>原花青素</43>的混合物，已被证明可以调节广泛的生物学、药理学和毒理学作用，主要是细胞保护作用。本研究评估了 <32> IH636 葡萄籽原花青素提取物 </32> ( <33> GSPE </33> ) 预防 <1> 对乙酰氨基酚 </1> ( <2> AAP </2> ) 诱导的能力<25> 肾毒性</25> 、<10> 胺碘酮</10> ( <11> AMI </11> ) 引起的<27> 肺毒性</27> 和<18> 阿霉素</18> ( <19> DOX </19> )-诱导小鼠<29>心脏毒性</29>。实验设计包括四组：对照组（单独的载体）、单独的<34>GSPE</34>、单独的药物和<35>GSPE</35>+药物。对于细胞保护研究，动物口服强饲 100 mg/Kg <36> GSPE </36> 7-10 天，然后 i. p.器官特异性三药注射（<3>AAP</3>：500mg/Kg，24小时；<12>AMI</12>：50mg/Kg/天，4天；<20>DOX</20>: 20 mg/Kg 持续 48 小时)。研究参数包括血清化学分析（ALT、BUN 和 CPK）和基因组 DNA 的有序片段化（核酸内切酶依赖性和非依赖性），以及相应 PAS 染色组织中损伤和/或保护的显微镜评估。结果表明，<4> AAP </4>、<13> AMI </13> 和 <21> DOX </21> 之前的 <37> GSPE </37> 预暴露在血清化学方面提供了近乎完全的保护变化（ALT、BUN 和 CPK），并显着减少 DNA 碎片。肾脏、心脏和肺切片的组织病理学检查显示，在没有 <38> GSPE </38> 暴露前的情况下，所有三种药物都有中度到大量的 <44> 组织损伤 </44> ，并伴有各种形态学异常. <39>GSPE</39>+ 药物暴露组织表现出轻微的残余损伤或接近完全恢复。此外，组织病理学改变反映了血清化学变化和 DNA 片段化模式。有趣的是，<5> AAP </5> 、 <14> AMI </14> 和<22> DOX </22> 等所有药物在<8> 坏死</8> 之外均诱导细胞凋亡。 <40> GSPE </40> 非常有效地阻断了各个器官。由于 <6> AAP </6> 、<15> AMI </15> 和 <23> DOX </23> 进行生物转化并已知在体内产生破坏性自由基，<41> GSPE </41> 的保护可能与抑制新陈代谢和/或细胞毒性自由基的解毒有关。此外，它对 DNA 修复的推测贡献可能是另一个重要属性，它在化学预防过程中发挥了作用。此外，这可能是关于 <16>AMI</16> 诱导的肺组织细胞凋亡的第一份报告。综上所述，这些事件无疑证实了 <42>GSPE</42> 丰富的生物利用度，以及保护多个靶器官免受体内结构多样和功能不同的实体引起的毒性攻击的能力。", "revised": true}
